PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Fujiwara, T; Okuyama, M; Miyasaka, M				Fujiwara, Takeo; Okuyama, Makiko; Miyasaka, Mikiko			Characteristics that distinguish abusive from nonabusive head trauma among young children who underwent head computed tomography in Japan	PEDIATRICS			English	Article						child abuse; shaken baby syndrome; craniocerebral trauma; abusive head trauma; traumatic brain injury	SHAKEN-BABY-SYNDROME; AGE-RELATED INCIDENCE; BRAIN-INJURY; SUBDURAL HEMORRHAGES; POPULATION; INFANTS; BED; MECHANISMS; HEMATOMAS; CHILDHOOD	OBJECTIVE. Distinguishing abusive head trauma in young children from other diseases by symptoms is difficult in practice. Comparisons between abusive and nonabusive head trauma in young children in Japan, where computed tomography is widely and easily available, might contribute to identifying markers of abusive head trauma that differ from that in Western countries. The objective of this study was to compare the characteristics of abusive and nonabusive head trauma in young children in Japan. METHODS. A comparative case series study involving a retrospective medical chart and social work record review of children who were aged 0 to 2 years, visited the National Center for Child Health and Development (Tokyo, Japan) from March 1, 2002, to December 31, 2005, and underwent computed tomography scanning because of suspected intracranial injury was performed. Patients (N = 260) were identified and classified as having either abusive or nonabusive head trauma on the basis of the published definition. Demographic and perinatal characteristics, injury history, clinical presentation, and outcomes were compared by using chi(2) and Fisher's exact tests. RESULTS. Patients with abusive head trauma were significantly younger than patients with nonabusive head trauma and had a peak at similar to 2 to 4 and 7 to 9 months. Patients with abusive head trauma more likely presented no injury history by the caregiver, neurologic symptoms (unconsciousness, seizure, paralysis), subdural hemorrhage, and retinal hemorrhages. Although patients with abusive head trauma had severe clinical outcomes, only 32% of them were separated from the caregiver by social welfare services. CONCLUSIONS. This study highlights the several clinical markers to detect abusive head trauma at a medical visit, including an absence of injury history, neurologic symptoms, subdural hemorrhage, and retinal hemorrhage. These markers can be used to detect abusive head trauma cases by physicians and social welfare workers to protect children from additional abuse.	[Fujiwara, Takeo] Natl Inst Publ Hlth, Sect Behav Sci, Dept Hlth Promot & Res, Saitama 3510197, Japan; [Fujiwara, Takeo] Univ British Columbia, Dept Pediat, Ctr Community Child Hlth Res, Child & Family Res Inst, Vancouver, BC V6T 1W5, Canada; [Fujiwara, Takeo; Okuyama, Makiko] Natl Ctr Child Hlth & Dev, Dept Psychol Med, Tokyo, Japan; [Miyasaka, Mikiko] Natl Ctr Child Hlth & Dev, Dept Radiol, Tokyo, Japan	Fujiwara, T (corresponding author), Natl Inst Publ Hlth, Sect Behav Sci, Dept Hlth Promot & Res, 2-3-6 Wako Shi, Saitama 3510197, Japan.	tfujiwara@niph.go.jp			Research on Prevention, Intervention, and Care for Maltreated Children; Research on Children and Families; Ministry of Health, Labor, and Welfare and Empirical Research on Diagnosis, Cure, and Prevention of Traumatic Brain Injury in Developmental Period and Establishment of Its Guideline; Ministry of Health, Labor, and WelfareMinistry of Health, Labour and Welfare, Japan	This research is supported by Research on Prevention, Intervention, and Care for Maltreated Children, in Research on Children and Families, Health and Labor Sciences Research grants from Ministry of Health, Labor, and Welfare (principal investigator: Dr Okuyama) and Empirical Research on Diagnosis, Cure, and Prevention of Traumatic Brain Injury in Developmental Period and Establishment of Its Guideline, Commission Grant for Mental and Neurological Diseases from Ministry of Health, Labor, and Welfare (principal investigator: Dr Masanori Tamura).; We thank Dr Ronald G. Barr, who helped with interpretation of results.	Alexander RC, 2001, CHILD ABUSE MED DIAG, P47; AOKI N, 1986, NEUROSURGERY, V18, P475, DOI 10.1227/00006123-198604000-00017; AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; BARR RG, 2008, RUDOLPHS PE IN PRESS; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; BERGER RP, 2002, PEDIATRICS, V109; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Datta S, 2005, ARCH DIS CHILD, V90, P947, DOI 10.1136/adc.2002.021154; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Feldman KW, 2001, PEDIATRICS, V108, P636, DOI 10.1542/peds.108.3.636; Fujiwara T, 2007, PUBLIC HEALTH, V121, P485, DOI 10.1016/j.puhe.2006.09.013; Fukumizu M, 2005, PEDIATRICS, V115, P217, DOI 10.1542/peds.2004-0815C; Green MA, 1996, BRIT J OPHTHALMOL, V80, P282, DOI 10.1136/bjo.80.4.282; HELFER RE, 1977, PEDIATRICS, V60, P533; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Jaspan T, 2003, CLIN RADIOL, V58, P44, DOI 10.1053/crad.2002.1094; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; King WJ, 2003, CAN MED ASSOC J, V168, P155; KIVLIN JD, 2001, SHAKEN BABY SYNDROME, P137; Latz S, 1999, ARCH PEDIAT ADOL MED, V153, P339; Lee C, 2007, J DEV BEHAV PEDIATR, V28, P288, DOI 10.1097/DBP.0b013e3180327b55; LEVENE S, 1991, ARCH DIS CHILD, V66, P1047, DOI 10.1136/adc.66.9.1047; LYONS TJ, 1993, PEDIATRICS, V92, P125; Maehashi N, 2006, RES PREVENTION INTER, P375; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; Organization for Economic Cooperation and Development, HLTH GLANC OECD IND; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; ROSE P, 1962, AM J NURS, V62, P94, DOI 10.2307/3452159; Tung GA, 2006, PEDIATRICS, V118, P626, DOI 10.1542/peds.2006-0130; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; YANAI Y, 2001, PEDIAT PSYCHIAT NEUR, V41, P373; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	45	34	35	0	8	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	OCT	2008	122	4					E841	E847		10.1542/peds.2008-0387			7	Pediatrics	Pediatrics	356YD	WOS:000259812600050	18762487				2021-06-18	
J	Williams, TM; Sadjadi, J; Harken, AH; Victorino, GP				Williams, Trevor M.; Sadjadi, Javid; Harken, Alden H.; Victorino, Gregory P.			The Necessity to Assess Anticoagulation Status in Elderly Injured Patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Anticoagulation; Warfarin; Elderly; Trauma; Mortality or outcome	PREINJURY WARFARIN USE; TRAUMA PATIENTS; IMPACT; MANAGEMENT; REHABILITATION; ADULTS	Background: The trauma literature is inconsistent in its conclusions and recommendations concerning the influence of oral anticoagulation on outcomes after injury. Some report worse outcomes, whereas others showed no effect. We approached this problem by using the patients' admission international normalized ratio (INR) values to document anticoagulation and hypothesized that warfarin anticoagulation is associated with increased mortality after trauma in the elderly. We further questioned the cost-effectiveness of admission INR testing. MethodS: We conducted a retrospective review of 3,242 trauma patients aged 50 and older. INR data were used as a surrogate for warfarin anticoagulation and was related to age, sex, and Injury Severity Scale score (ISS) to analyze effects on mortality. Logistic regression was used to perform multivariate analyses. INR costs were summed from all laboratory department costs. Results: Of the 3,242 elderly injured patients, admission INR was obtained in 1,251 patients. One hundred and two patients had an "elevated" JNR of >1.5. Mortality for those with an INR >1.5 was 22.6%, versus 8.2% for those with an INR <1.5 (p < 0.0001). The logistic regression gave an age and ISS adjusted odds of death of 30% for a one unit increase in INR (OR 1.3, 95% CI 1.1-1.5; p value 0.002). This correlates to an age and injury score adjusted odds of death of 2.5 for an INR > 1.5 (95% Cl 1.2-4.2; p value 0.014). INR cost was estimated at $5 per blood draw. Conclusion: After adjusting for age, gender, and ISS, anticoagulation was associated with increased overall mortality. Elderly patients are commonly anticoagulated and anticoagulation is a therapeutically reversible risk factor. Considering the increasing number of indications for and prevalence of anticoagulation, the low cost of an INR and the potential reduction in costs associated with traumatic brain injury, these data support the recommendation to assess a coagulation profile in elderly trauma patients to identify earlier those in need of closer monitoring and a more aggressive reversal of their anticoagulation.	[Williams, Trevor M.; Sadjadi, Javid; Harken, Alden H.; Victorino, Gregory P.] UCSF E Bay, Dept Surg, Alameda Cty Med Ctr, Oakland, CA 94602 USA	Victorino, GP (corresponding author), UCSF E Bay, Dept Surg, Alameda Cty Med Ctr, 1411 E 31st St, Oakland, CA 94602 USA.	victorinog@surgery.ucsf.edu					Chu UB, 1996, AM J SURG, V172, P558, DOI 10.1016/S0002-9610(96)00234-6; CHU UB, 1996, AM J SURG, V172, P562; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Go AS, 2001, JAMA-J AM MED ASSOC, V285, P2370, DOI 10.1001/jama.285.18.2370; Heit JA, 2001, J THROMB THROMBOLYS, V12, P81, DOI 10.1023/A:1012746729537; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sachdev GP, 1999, AM J HEALTH-SYST PH, V56, P1505, DOI 10.1093/ajhp/56.15.1505; SCALEA TM, 1990, J TRAUMA, V30, P129, DOI 10.1097/00005373-199002000-00001; Scalea TM, 1990, J TRAUMA, V30, P134; STEIN J, 1995, ARCH PHYS MED REHAB, V76, P840, DOI 10.1016/S0003-9993(95)80549-4; *US BUR CENS, 2000, INT PROJ; Wahl WL, 2001, J TRAUMA, V51, P1151; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	17	34	35	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2008	65	4					772	777		10.1097/TA.0b013e3181877ff7			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	361JS	WOS:000260124500006	18849789				2021-06-18	
J	Chen, XR; Besson, VC; Beziaud, T; Plotkine, M; Marchand-Leroux, C				Chen, Xiao Ru; Besson, Valerie C.; Beziaud, Tiphaine; Plotkine, Michel; Marchand-Leroux, Catherine			Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, on experimental traumatic brain injury	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							PPAR-ALPHA; COMBINED HYPERLIPIDEMIA; NEURONAL SURVIVAL; CEREBRAL EDEMA; ATORVASTATIN; STATINS; EXPRESSION; FIBRATE; RATS; CYCLOOXYGENASE-2	We and others have demonstrated that fibrates [peroxisome proliferator-activated receptor (PPAR)alpha agonists] and statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) exerted neuroprotective and pleiotropic effects in experimental models of traumatic brain injury (TBI). Because the combination of statins and fibrates synergistically enhanced PPAR alpha activation, we hypothesized that the combination of both drugs may exert more important and/or prolonged beneficial effects in TBI than each alone. In this study, we examined the combination of fenofibrate with simvastatin, administered 1 and 6 h after injury, on the consequences of TBI. First, our dose-effect study demonstrated that the most efficient dose of simvastatin (37.5 mg/kg) reduced post-traumatic neurological deficits and brain edema. Then, the effects of the combination of fenofibrate (50 mg/kg) and simvastatin (37.5 mg/kg), given p. o. at 1 and 6 h after TBI, were evaluated on the TBI consequences in the early and late phase after injury. The combination exerted more sustained neurological recovery-promoting and antiedematous effects than monotherapies, and it synergistically decreased the post-traumatic brain lesion. Furthermore, a delayed treatment given p. o. at 3 and 8 h after TBI with the combination was still efficient on neurological deficits induced by TBI, but it failed to reduce the brain edema at 48 h. The present data represent the first demonstration that the combination of fenofibrate and simvastatin exerts prolonged and synergistic neuroprotective effects than each drug alone. Thus, these results may have important therapeutic significance for the treatment of TBI.	[Chen, Xiao Ru; Besson, Valerie C.; Beziaud, Tiphaine; Plotkine, Michel; Marchand-Leroux, Catherine] Univ Paris 05, Fac Sci Pharmaceut & Biol, Equipe Rech Pharmacol Circulat Cerebrale EA 2510, F-75006 Paris, France	Besson, VC (corresponding author), Univ Paris 05, Pharmacol Lab, EA 2510, 4 Ave Observ, F-75006 Paris, France.	valerie.besson@univ-paris5.fr	BESSON, VALERIE/AAZ-9989-2020; MARCHAND-LEROUX, Catherine/L-7453-2017; besson, valerie C/L-7388-2017	BESSON, VALERIE/0000-0002-1491-2380; MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; besson, valerie C/0000-0002-1491-2380			Athyros VG, 2002, DIABETES CARE, V25, P1198, DOI 10.2337/diacare.25.7.1198; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Besson VC, 2005, NEUROSCI LETT, V388, P7, DOI 10.1016/j.neulet.2005.06.019; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Charney DS, 2004, AM J PSYCHIAT, V161, P1, DOI 10.1176/appi.ajp.161.1.1; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216; Davidson MH, 2007, AM J CARDIOL, V99, p3C, DOI 10.1016/j.amjcard.2006.11.016; Fruchart JC, 1999, CURR OPIN LIPIDOL, V10, P245, DOI 10.1097/00041433-199906000-00007; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Greenwood J, 2007, TRENDS IMMUNOL, V28, P88, DOI 10.1016/j.it.2006.12.003; Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9; Inoue I, 2002, BIOCHEM BIOPH RES CO, V290, P131, DOI 10.1006/bbrc.2001.6141; Koh KK, 2005, J AM COLL CARDIOL, V45, P1649, DOI 10.1016/j.jacc.2005.02.052; Koh KK, 2004, INT J CARDIOL, V97, P239, DOI 10.1016/j.ijcard.2003.09.007; Koh KK, 2008, INT J CARDIOL, V124, P149, DOI 10.1016/j.ijcard.2007.04.080; Landrier JF, 2004, J BIOL CHEM, V279, P45512, DOI 10.1074/jbc.M407461200; Law M, 2006, AM J CARDIOL, V97, p52C, DOI 10.1016/j.amjcard.2005.12.010; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Millerot-Serrurot E, 2007, NEUROCHEM INT, V50, P328, DOI 10.1016/j.neuint.2006.08.016; Moinard C, 2005, INTENS CARE MED, V31, P281, DOI 10.1007/s00134-004-2489-9; Musial J, 2001, INT J CARDIOL, V77, P247, DOI 10.1016/S0167-5273(00)00439-3; Pannu R, 2005, J NEUROSCI RES, V79, P340, DOI 10.1002/jnr.20345; Paumelle R, 2006, CIRC RES, V98, P361, DOI 10.1161/01.RES.0000202706.70992.95; Penn R, 2006, CLIN THER, V28, P45, DOI 10.1016/j.clinthera.2005.12.004; Qu CS, 2005, J NEUROSURG, V103, P695, DOI 10.3171/jns.2005.103.4.0695; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Shabanzadeh AP, 2005, BRAIN RES, V1042, P1, DOI 10.1016/j.brainres.2005.01.105; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Stepien K, 2005, PHARMACOL REP, V57, P561; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vega GL, 2003, AM J CARDIOL, V91, P956, DOI 10.1016/S0002-9149(03)00111-5; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Yano M, 2007, CIRC RES, V100, P1442, DOI 10.1161/01.RES.0000268411.49545.9c; Zapolska-Downar D, 2004, LIFE SCI, V75, P1287, DOI 10.1016/j.lfs.2004.03.005	41	34	35	0	0	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	SEP	2008	326	3					966	974		10.1124/jpet.108.140368			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	338RB	WOS:000258524400033	18562561				2021-06-18	
J	Fleming, J; Riley, L; Gill, H; Gullo, MJ; Strong, J; Shum, D				Fleming, Jennifer; Riley, Lee; Gill, Hannah; Gullo, Matthew J.; Strong, Jenny; Shum, David			Predictors of prospective memory in adults with traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						memory deficits; intention; neuropsychological tests; chronic brain injury; rehabilitation; outpatients	CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; SELF-AWARENESS; NORMATIVE DATA; PERFORMANCE; REHABILITATION; DEFICITS; REMEDIATION; RELIABILITY; PROGRAM	Previous studies have established that prospective memory is commonly affected following traumatic brain injury (TBI). This study examines whether demographic factors, injury severity and site, executive function, and metacognitive factors predict prospective memory performance in adults with TBI, using a cross-sectional multivariate correlational model. Prospective memory of 44 adults (mean age = 30 years) with severe TBI was measured by the Cambridge Prospective Memory Test (CAMPROMPT) time-based and event-based scores. Using stepwise multiple regression, the time-based score was predicted by the Controlled Oral Word Association Test (COWAT) Animals subtest score, length of post-traumatic amnesia (PTA) and use of note-taking on the CAMPROMPT. The event-based score was predicted by length of PTA and COWAT Animals score. Therefore, patients with longer periods of PTA and executive function impairment may be expected to display poorer prospective memory. Note-taking was associated with improved performance on time-based prospective memory tasks.	[Fleming, Jennifer; Riley, Lee; Gill, Hannah; Strong, Jenny] Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Gill, Hannah; Gullo, Matthew J.; Shum, David] Griffith Univ, Appl Cognit Neurosci Res Ctr, Brisbane, Qld 4111, Australia; [Gullo, Matthew J.; Shum, David] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia	Fleming, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia.	j.fleming@uq.edu.au	Shum, David/A-3914-2008; Gullo, Hannah/C-5011-2008; Gullo, Matthew/C-3850-2008; Strong, Jenny/F-1211-2010; Fleming, Jennifer M/B-4436-2011	Shum, David/0000-0002-4810-9262; Gullo, Matthew/0000-0003-3657-5191; Strong, Jenny/0000-0002-9367-8755; GULLO, Hannah/0000-0003-4238-4033	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [288002]	This research was funded by a National Health and Medical Research Council (NHMRC) Project grant (ID No. 288002).	Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Chau LT, 2007, NEUROPSYCHOL REHABIL, V17, P707, DOI 10.1080/09602010600923926; COCKBURN J, 1995, CORTEX, V31, P87, DOI 10.1016/S0010-9452(13)80107-4; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; Geffen G., 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, P23; Levine B., 2002, PRINCIPLES FRONTAL L, P51; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Otani H, 1997, MEMORY, V5, P343, DOI 10.1080/741941393; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Palmer HM, 2000, BRAIN COGNITION, V44, P103; PRIGATANO GP, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P381; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D., 2002, BRAIN IMPAIR, V3, DOI [https://doi.org/10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Simons JS, 2006, NEUROPSYCHOLOGIA, V44, P1388, DOI 10.1016/j.neuropsychologia.2006.01.005; Spreen O., 1998, COMPENDIUM NEUROPSYC; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Tabachnick BG, 2007, USING MULTIVARIATE S; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Wechsler D., 2011, WECHLSER ABBREVIATED; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; Wilson B., 2005, CAMBRIDGE PROSPECTIV	46	34	36	0	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2008	14	5					823	831		10.1017/S1355617708080971			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	354DZ	WOS:000259620400012	18764977	Green Published, Bronze			2021-06-18	
J	Chiaretti, A; Antonelli, A; Genovese, O; Pezzotti, P; Di Rocco, C; Viola, L; Riccardi, R				Chiaretti, Antonio; Antonelli, Alessia; Genovese, Orazio; Pezzotti, Patrizio; Di Rocco, Concezio; Viola, Luigi; Riccardi, Riccardo			Nerve growth factor and doublecortin expression correlates with improved outcome in children with severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						doublecortin; nerve growth factor; neuroprotection; traumatic brain injury	NEURAL STEM-CELLS; NEURONAL DEATH; ADULT BRAIN; CEREBROSPINAL-FLUID; NEUROTROPHIC FACTOR; PROLIFERATION; DEFICITS; NEUROGENESIS; INCREASES; INFUSION	Background. In the adult brain, migrating neuroblasts can replace damaged neurons after severe traumatic brain injury (TBI). Little is known about which factors determine the magnitude and amplification of neurogenesis after TBI, but there are some evidences that the nerve growth factor (NGF) and the doublecortin (DCX) can influence neurogenesis and neuronal repair. Methods: This study investigates the NGF and DCX levels in the cerebrospinal fluid of 12 children with severe TBI and 12 matched controls, to determine the correlation between the expression of both these factors and the patients outcome. We collected cerebrospinal fluid samples 2 hours (Time T1) and 48 hours (Time T2) after brain injury. NGF levels were measured using a two-site immunoenzymatic assay, whereas the DCX expression by a Western blot analysis. Results: At time T1 and T2, children with the best outcomes had higher levels of NGF than children with poor outcomes. Evaluating the change of NGF levels from time T1 to time T2, we found that the NGF up-regulation in the early time after injury was significantly associated with good outcomes of patients. Concomitantly, the expression of DCX increased only in patients with NGF up-regulation from time T1 to time T2. In others patients and in controls the expression of DCX remained unchanged. Conclusion: Based on these results, we hypothesize that NGF and DCX contribute to the mechanisms of neuroprotection and neuronal connection reorganization after TBI, playing a key role in the outcome of these patients.	[Chiaretti, Antonio; Antonelli, Alessia; Genovese, Orazio; Viola, Luigi] Univ Cattolica Sacro Cuore, Sch Med, Pediatr Intens Care Unit, Policlin A Gemelli Largo Gemelli, I-00168 Rome, Italy; [Pezzotti, Patrizio] Univ Cattolica Sacro Cuore, Sch Med, Agcy Publ Hlth Lazio Reg, I-00168 Rome, Italy	Antonelli, A (corresponding author), Univ Cattolica Sacro Cuore, Sch Med, Pediatr Intens Care Unit, Policlin A Gemelli Largo Gemelli, I-00168 Rome, Italy.	antonelliales@yahoo.it		RICCARDI, RICCARDO/0000-0001-7515-6622; GENOVESE, Orazio/0000-0002-1989-1363			Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Barde Y. A., 1994, PROG CLIN BIOL RES, V390, P1855; Calza L, 2003, P NATL ACAD SCI USA, V100, P7325, DOI 10.1073/pnas.1132092100; Chiaretti A, 2005, NEUROL RES, V27, P741, DOI 10.1179/016164105X35611; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Collin T, 2005, EXP NEUROL, V195, P71, DOI 10.1016/j.expneurol.2005.03.017; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Gu Q, 1995, REV NEUROSCIENCE, V6, P329; Gustafsson E, 2003, EUR J NEUROSCI, V17, P2667, DOI 10.1046/j.1460-9568.2003.02713.x; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Karl C, 2005, J NEUROCHEM, V92, P264, DOI 10.1111/j.1471-4159.2004.02879.x; Krenz NR, 2000, J NEUROCHEM, V74, P730, DOI 10.1046/j.1471-4159.2000.740730.x; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; Marzesco AM, 2005, J CELL SCI, V118, P2849, DOI 10.1242/jcs.02439; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; Ong J, 2005, PEDIATR RES, V58, P600, DOI 10.1203/01.PDR.0000179381.86809.02; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Wilde GJC, 2000, EUR J NEUROSCI, V12, P3863, DOI 10.1046/j.1460-9568.2000.00273.x; Zhou Zheng, 2003, Journal of Basic and Clinical Physiology and Pharmacology, V14, P217; Zigova T, 1998, MOL CELL NEUROSCI, V11, P234, DOI 10.1006/mcne.1998.0684	30	34	35	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2008	65	1					80	85		10.1097/TA.0b013e31805f7036			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	327ZP	WOS:000257767300014	18580535				2021-06-18	
J	Newsome, MR; Scheibel, RS; Troyanskaya, M; Hanten, G; Lin, X; Vasquez, C; Li, X; Wilde, EA; Levin, HS; Steinberg, JL; Chu, Z; Lu, H; Lane, S; Hunter, JV; Zientz, J				Newsome, Mary R.; Scheibel, Randall S.; Troyanskaya, Maya; Hanten, Gerri; Lin, Xiaodi; Vasquez, Carmen; Li, Xiaoqi; Wilde, Elisabeth A.; Levin, Harvey S.; Steinberg, Joel L.; Chu, Z.; Lu, Hanzhang; Lane, Summer; Hunter, Jill V.; Zientz, Jennifer			Effects of traumatic brain injury on working memory-related brain activation in adolescents	NEUROPSYCHOLOGY			English	Article						fMRI; traumatic brain injury; adolescents; working memory	PREFRONTAL CORTEX; FUNCTIONAL MRI; FMRI; MAINTENANCE; RETRIEVAL; CHILDREN; CHILDHOOD; REVEALS	Eight adolescents (ages 13-18 years) who sustained traumatic brain injury (TBI) and eight gender- and age-matched typically developing (TD) adolescents underwent event-related functional MRI (fMRI) while performing a Sternberg letter recognition task. Encoding, maintenance, and retrieval were examined with memory loads of one or four items during imaging. Both groups performed above a 70% accuracy criterion and did not differ in performance. TD, adolescents showed greater increase in frontal and parietal activation during high-load relative to low-load maintenance than the TBI group. The TBI patients showed greater increase in activation during high-load relative to low-load encoding and retrieval than the TD group. Results from this preliminary study suggest that the capability to differentially allocate neural resources according to memory load is disrupted by TBI for the maintenance subcomponent of working memory. The overrecruitment of frontal and extrafrontal regions during encoding and retrieval following TBI may represent a compensatory process.	[Newsome, Mary R.; Scheibel, Randall S.; Troyanskaya, Maya; Hanten, Gerri; Lin, Xiaodi; Vasquez, Carmen; Li, Xiaoqi; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Steinberg, Joel L.] Univ Texas Houston, Sch Med, Dept Psychiat & Behav Sci, Houston, TX USA; [Chu, Z.; Hunter, Jill V.] Texas Childrens Hosp, Baylor Coll Med & Diagnost Imaging, Houston, TX 77030 USA; [Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Lane, Summer; Zientz, Jennifer] Univ Texas Dallas, Ctr Brain Hlth, Dallas, TX 75230 USA	Newsome, MR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 725, Houston, TX 77030 USA.	mnewsome@bcm.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042772, NS021889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889, R01NS042772] Funding Source: NIH RePORTER		Baddeley A. D., 1986, WORKING MEMORY; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Cabeza R, 2002, NEUROIMAGE, V16, P317, DOI 10.1006/nimg.2002.1063; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; D'Esposito M, 2007, PHILOS T R SOC B, V362, P761, DOI 10.1098/rstb.2007.2086; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gazzaley Adam, 2004, Cognitive Affective & Behavioral Neuroscience, V4, P580, DOI 10.3758/CABN.4.4.580; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Karlsgodt KH, 2005, NEUROIMAGE, V25, P1224, DOI 10.1016/j.neuroimage.2005.01.038; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; MILLER, 2001, ANN REV NEUROSCIENCE, V24, P167; Narayanan NS, 2005, NEUROPSYCHOLOGY, V19, P223, DOI 10.1037/0894-4105.19.2.223; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Olesen PJ, 2003, COGNITIVE BRAIN RES, V18, P48, DOI 10.1016/j.cogbrainres.2003.09.003; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Swanson HL, 1999, J EXP CHILD PSYCHOL, V72, P1, DOI 10.1006/jecp.1998.2477; TEASDALE G, 1974, LANCET, V2, P81; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Veltman DJ, 2003, NEUROIMAGE, V18, P247, DOI 10.1016/S1053-8119(02)00049-6; Weisskoff RM, 1996, MAGNET RESON MED, V36, P643, DOI 10.1002/mrm.1910360422; Woodward TS, 2006, NEUROSCIENCE, V139, P317, DOI 10.1016/j.neuroscience.2005.05.043	30	34	35	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	2008	22	4					419	425		10.1037/0894-4105.22.4.419			7	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	319NS	WOS:000257171300001	18590353				2021-06-18	
J	Chen, G; Shi, JX; Qi, M; Wang, HX; Hang, CH				Chen, Gang; Shi, Ji-Xin; Qi, Meng; Wang, Hu-Xu; Hang, Chun-Hua			Effects of progesterone on intestinal inflammatory response, mucosa structure alterations, and apoptosis following traumatic brain injury in male rats	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; intestine; inflammation; apoptosis; progesterone	ENDOTHELIAL-CELLS; EXPRESSION; INTERLEUKIN-6; ALLOPREGNANOLONE; PROLIFERATION; ESTROGEN; FAILURE; CORTEX; ALPHA; GUT	Background. Traumatic brain injury (TBI) can induce a persistent inflammatory response, histopathological changes, and apoptosis in the gut. Progesterone given after TBI has been shown to reduce the cerebral inflammation and neuronal apoptosis in the brain. However, the effects of progesterone on the inflammatory response, structure alterations, and apoptosis in the intestinal mucosa following TBI has not been investigated. Materials and methods. Right parietal cortical contusion in male rats was made by using the weight-dropping method. Rats were given 0 or 16 mg/kg injections of progesterone at postinjury at 1 and 6 hours and on days 1, 2, 3, 4, and 5. Gut samples were extracted at 5 days after trauma. We measured the concentrations of interleukin-1 beta (IL-1 beta), tumor necrosis factor-alpha, and interleukin-6 (IL-6) by enzyme-linked immunosorbent assay; intercellular adhesion molecule-1 expression by immunohistochemistry; intestinal mucosal morphological changes by histopathological study and electron microscopy; and apoptosis by terminal deoxynucleotidyl transferase. mediated dUTP nick end-labeling staining. Results. Administration of progesterone following TBI could decrease the intestinal concentrations of IL-1 beta and tumor necrosis factor-alpha, but not IL-6. The level of intercellular adhesion molecule-1 expression in the gut was down-regulated by progesterone. TBI-induced damages of gut structure and apoptosis were attenuated after progesterone injections. Conclusions. The results of the present study suggest that post-TBI progesterone administration could suppress the intestinal inflammation, protect the intestinal mucosal structure, and reduce the mucosa apoptosis. (C) 2008 Elsevier Inc. All rights reserved.	[Chen, Gang; Shi, Ji-Xin; Qi, Meng; Wang, Hu-Xu; Hang, Chun-Hua] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210002, Jiangsu Prov, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	nju_neurosurgery@163.com	QI, Meng/F-2802-2012	Chen, Gang/0000-0002-0758-1907			Bese T, 2006, INT J GYNECOL CANCER, V16, P809, DOI 10.1111/j.1525-1438.2006.00533.x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Gotkin JL, 2006, AM J OBSTET GYNECOL, V195, P1015, DOI 10.1016/j.ajog.2006.07.002; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; Hang CH, 2005, WORLD J GASTROENTERO, V11, P1149, DOI 10.3748/wjg.v11.i8.1149; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Keck C, 1998, EXP CLIN ENDOCR DIAB, V106, P334, DOI 10.1055/s-0029-1211994; Kurachi O, 2001, J CLIN ENDOCR METAB, V86, P2275, DOI 10.1210/jc.86.5.2275; Lan L, 1999, MOL CELL ENDOCRINOL, V155, P123, DOI 10.1016/S0303-7207(99)00066-0; Okuda K, 2004, BIOL REPROD, V71, P2065, DOI 10.1095/biolreprod.104.028076; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Piercy KT, 2002, J SURG RES, V105, P215, DOI 10.1006/jsre.2002.6405; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Shields AD, 2005, AM J OBSTET GYNECOL, V193, P1144, DOI 10.1016/j.ajog.2005.05.046; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Telleria CM, 1998, ENDOCRINOLOGY, V139, P3597, DOI 10.1210/en.139.8.3597; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656	26	34	40	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUN 1	2008	147	1					92	98		10.1016/j.jss.2007.05.029			7	Surgery	Surgery	298EF	WOS:000255668500014	17868700				2021-06-18	
J	Sosnoff, JJ; Broglio, SP; Ferrara, MS				Sosnoff, Jacob J.; Broglio, Steven P.; Ferrara, Michael S.			Cognitive and motor function are associated following mild traumatic brain injury	EXPERIMENTAL BRAIN RESEARCH			English	Article						post-concussion; postural control; reaction time	COLLEGIATE FOOTBALL PLAYERS; POSTURAL STABILITY; CONCUSSION; ATTENTION; RECOVERY; DEFICITS; GAIT; SENSORIMOTOR; PERFORMANCE; SYMPTOMS	Mild traumatic brain injury (mTBI) causes deficits in motor and cognitive function. There is a dearth of research examining the association between these deficits. The purpose of this investigation was to examine the effect of mTBI on the association between cognitive and motor function. Thirty-six individuals completed a neurocognitive test battery and postural control assessment at baseline and were retested 24-h post mTBI. Reaction time and accuracy to various cognitive tasks was assessed. Postural control was indexed with the somatosenory organization test. This test allows for the decomposition of postural control resulting from the integration of visual, somatosensory and vestibular information. The association between cognitive and motor function was assessed with correlational analyses. Overall, it was found that mTBI resulted in increased simple and choice reaction time as well as deficits in verbal and visual memory. mTBI was also found to reduce overall postural control, especially when visual information was utilized. Prior to injury there was no association between cognitive and motor function-indicating minimal association between cognitive and motor function. After injury there were significant positive correlations between cognitive and motor function. The findings suggest that transient neural insults resulting from mTBI lead to increased cognitive-motor association. It is speculated that a shared neural process, such as visuospatial attention is damaged resulting in similar deficits in cognitive and motor function.	[Sosnoff, Jacob J.; Broglio, Steven P.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Sosnoff, Jacob J.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Ferrara, Michael S.] Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA	Sosnoff, JJ (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 Goodwin Ave, Urbana, IL 61801 USA.	jsosnoff@uiuc.edu	Sosnoff, Jacob/P-3397-2019	Sosnoff, Jacob/0000-0002-0286-9207			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bowen A, 2001, AGE AGEING, V30, P319, DOI 10.1093/ageing/30.4.319; BROGLIO SP, 2007, J ATHL TRAINING, V42, P502; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; ERLANGER DM, 2002, HEADMINDER CONCUSSIO; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hausdorff JM, 2006, EXP AGING RES, V32, P411, DOI 10.1080/03610730600875817; Holtzer R, 2006, NEUROPSYCHOLOGY, V20, P215, DOI 10.1037/0894-4105.20.2.215; Holtzer R, 2007, NEUROPSYCHOLOGY, V21, P540, DOI 10.1037/0894-4105.21.5.540; Kahneman D., 1973, ATTENTION EFFORT; Kelly JP, 1997, NEUROLOGY, V48, P581; KERR B, 1985, J EXP PSYCHOL HUMAN, V11, P617, DOI 10.1037/0096-1523.11.5.617; Konczak J, 2007, NEUROSCI BIOBEHAV R, V31, P1101, DOI 10.1016/j.neubiorev.2007.04.014; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Li SC, 2001, GERONTOLOGY, V47, P100, DOI 10.1159/000052782; LOVELL MR, 2005, IMPACT 2005 4 0 CLIN; Maylor EA, 1996, J GERONTOL B-PSYCHOL, V51, pP143, DOI 10.1093/geronb/51B.3.P143; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Nashner LM., 1997, HDB BALANCE FUNCTION, P280; Nesselroade JR, 2004, J GERONTOL B-PSYCHOL, V59, pP49, DOI 10.1093/geronb/59.2.P49; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Pugh KG, 2002, NEUROBIOL AGING, V23, P421, DOI 10.1016/S0197-4580(01)00319-0; Rosenbaum DA, 2005, AM PSYCHOL, V60, P308, DOI 10.1037/0003-066X.60.4.308; Serrien DJ, 2007, PROG NEUROBIOL, V82, P95, DOI 10.1016/j.pneurobio.2007.02.003; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sosnoff JJ, 2007, NEUROPSYCHOLOGY, V21, P796, DOI 10.1037/0894-4105.21.6.796; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; Woollacott M, 2002, GAIT POSTURE, V16, P1, DOI 10.1016/S0966-6362(01)00156-4	49	34	34	1	18	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0014-4819	1432-1106		EXP BRAIN RES	Exp. Brain Res.	JUN	2008	187	4					563	571		10.1007/s00221-008-1324-x			9	Neurosciences	Neurosciences & Neurology	304BM	WOS:000256085000006	18301883				2021-06-18	
J	Ashman, TA; Cantor, JB; Gordon, WA; Sacks, A; Spielman, L; Egan, M; Hibbard, MR				Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Sacks, Amanda; Spielman, Lisa; Egan, Matthew; Hibbard, Mary R.			A comparison of cognitive functioning in older adults with and without traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aging; APOE epsilon 4; cognitive functioning; older adult; traumatic brain injury	HEAD-INJURY; ALZHEIMERS-DISEASE; MODERATE; MILD; REHABILITATION; ASSOCIATION; DECLINE; RISK; AGE; EPIDEMIOLOGY	Objective: Cognitive impairments are common sequelae of traumatic brain injury (TBI) and are often associated with the natural process of aging. Few studies have examined the effect of both age and TBI on cognitive functioning. The purpose of this study was to compare cognitive functioning between older adults who sustained a TBI to an age-matched group of individuals without a brain injury and to determine whether the presence or absence of a genetic marker apolipoprotein 8 (APOE epsilon 4 allele) accounts for additional cognitive decline in both groups examined. Methods and procedures: Cognitive performance was measured by 11 neuropsychological tests, in 54 adults with TBI aged 55 and older and 40 age-matched control participants. All participants were reexamined 2 to 5 years later. Setting: Community volunteer-based sample examined at a large, urban medical center. Main outcome measure(s): California Verbal Learning Test; Wechsler Memory Scale-III (Logical Memory I & II; Visual Reproduction I & II); Grooved Pegboard; Woodcock-Johnson Test of Cognitive Ability (Visual Matching and Cross-out); Wisconsin Card Sorting Test; Trail Making Test A & B; Conners' Continuous Performance Task; Wechsler Adult Intelligence Scale-III (Vocabulary); Controlled Oral Word Association Test; and Boston Naming Test. Results: Participants with TBI had lower scores on tests of attention and verbal memory than did participants with no disability. Neither group exhibited a significant decline in cognitive function over time. The presence of the APOE epsilon 4 allele did not account for additional decline in cognitive function in either group. Conclusion(s): The findings suggest that older adults with TBI may not be at increased risk for cognitive decline over short time periods (2 to 5 years) even if they are carriers of the APOE epsilon 4 allele.	[Ashman, Teresa A.; Cantor, Joshua B.; Gordon, Wayne A.; Sacks, Amanda; Spielman, Lisa; Egan, Matthew; Hibbard, Mary R.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Ashman, TA (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.	teresa.ashman@mssm.edu	Ashman, Teresa/B-1621-2013				ADEKOYA N, 1998, MMWR SURVEILL SUMM, V51, P1; AharonPeretz J, 1997, BRAIN INJURY, V11, P871; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Benton A, 1989, MULTILINGUAL APHASIA; Blacker D, 2007, ARCH NEUROL-CHICAGO, V64, P862, DOI 10.1001/archneur.64.6.862; Bowie CR, 2006, NAT PROTOC, V1, P2277, DOI 10.1038/nprot.2006.390; Centers for Disease Control and Prevention, 2002, CDC INJ RES AG; Chai Chen K, 2007, Am J Alzheimers Dis Other Demen, V22, P37, DOI 10.1177/1533317506295655; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; CHIANG MF, 1949, ACTA NEUROCHIR WIEN, V145, P653; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; CORKIN S, 1989, J NEUROSCI, V9, P3876; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; CROSSON B, 1988, J CLIN EXP NEUROPSYC, V10, P754, DOI 10.1080/01688638808402812; CROSSON B, 1993, NEUROPSYCHOLOGY, V7, P193, DOI DOI 10.1037/0894-4105.7.2.193; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; Delis DC, 2000, CALIFORNIA VERBAL LE; Flanagan JL, 1997, J COMMUN DISORD, V30, P33, DOI 10.1016/S0021-9924(96)00039-1; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Frankel JE, 2006, ARCH PHYS MED REHAB, V87, P57, DOI 10.1016/j.apmr.2005.07.309; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Goodglass H, 1998, BRAIN LANG, V64, P1, DOI 10.1006/brln.1998.1950; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; HAUT MC, 1992, NEUROPSYCHOLOGY, P51; HEATON RK, 1993, CARD SORTING TEST WC; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Isoniemi H, 2006, J NEUROTRAUM, V23, P1600, DOI 10.1089/neu.2006.23.1600; Iverson GL, 1999, CLIN NEUROPSYCHOL, V13, P437, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT437; Jacobs ML, 2007, ARCH CLIN NEUROPSYCH, V22, P143, DOI 10.1016/j.acn.2006.12.002; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Katzman R, 1996, NEUROLOGY, V46, P889; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KERR C, 1995, BRAIN INJURY, V9, P777, DOI 10.3109/02699059509008234; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KLOVE H, 1963, MED CLIN N AM, V47, P1647, DOI 10.1016/S0025-7125(16)33515-5; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LANGLOIS JA, 1997, MMWR-MORBID MORTAL W, V52, P1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Luukinen H, 2005, EUR J NEUROL, V12, P86, DOI 10.1111/j.1468-1331.2004.00953.x; Mauri M, 2006, FUNCT NEUROL, V21, P223; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McArdle JJ, 2002, DEV PSYCHOL, V38, P115, DOI 10.1037//0012-1649.38.1.115; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; MILLIS SR, 1995, BRAIN INJURY, V9, P509, DOI 10.3109/02699059509008210; Millis SR, 2003, AM J PHYS MED REHAB, V82, pS32, DOI 10.1097/01.PHM.0000087007.19214.32; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rasmusson DX, 1996, BRAIN COGNITION, V31, P133, DOI 10.1006/brcg.1996.0038; Reitan RM., 1985, HALSTEAD REITAN NEUR; *RES TRAIN CTR COM, 1998, BRAIN INJ QUEST; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Starkstein SE, 2005, INT PSYCHOGERIATR, V17, pS93, DOI 10.1017/S1041610205001973; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Swan GE, 2005, J GERIATR PSYCH NEUR, V18, P196, DOI 10.1177/0891988705281864; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tulsky D., 1997, WAIS 3 WMS 3 TECHNIC; TULSKY DS, 1997, WMS 3 ADM SCORING MA; TUPPER DE, 1990, J LEARN DISABIL, V23, P306, DOI 10.1177/002221949002300510; U.S. Census Bureau, 2005, INT STAT POP PROJ; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; vanDuijn CM, 1996, J NEUROL NEUROSUR PS, V60, P478, DOI 10.1136/jnnp.60.5.478; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; Walker A E, 1972, Scand J Rehabil Med, V4, P5; Wechsler D, 1997, WAIS 3 WMS 3 TECHN M; WOODCOCK RW, 2001, W JOHNSON 3 TEST COG; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	81	34	37	2	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2008	23	3					139	148		10.1097/01.HTR.0000319930.69343.64			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	309XN	WOS:000256493600002	18520426				2021-06-18	
J	Mayer, NH; Whyte, J; Wannstedt, G; Ellis, CA				Mayer, Nathaniel H.; Whyte, John; Wannstedt, Gunillia; Ellis, Colin A.			Comparative impact of 2 botulinum toxin injection techniques for elbow flexor hypertonia	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						botulinum toxins; brain injuries; injections; muscle hypertonia; rehabilitation	UPPER-LIMB SPASTICITY; DOUBLE-BLIND; HEMIPLEGIC PATIENTS; MUSCLE SPASTICITY; ASHWORTH SCALE; MOTOR CONTROL; BRAIN-INJURY; STROKE; EFFICACY; TRIAL	Objective: To compare 2 techniques of botulinum toxin injection for elbow flexor hypertonia. Design: Parallel-group, randomized, controlled trial with blinded outcome assessment. Setting: Laboratory, tertiary rehabilitation hospital. Participants: Adults (N=31) with acquired brain injury (21 with traumatic brain injury, 8 with stroke, 2 with hypoxic encephalopathy) provided 36 sets of elbow flexors with Ash-worth Scale scores equal to 3. Intervention: Botulinum toxin type A (BTX-A) was injected with a motor point or a multisite injection technique after obtaining 2 baseline evaluations of the main outcome measures. Motor point technique involved decremental electric stimulation with delivery of 60U of BTX-A (Botox) in 2.4mL or 30U BTX-A in 1.2mL of preservative-free saline at single biceps and brachioradialis motor points, respectively. Distributed injection was performed using, electromyographic feedback. Fifteen units in 0.6mL were delivered to each of 4 biceps sites and 2 brachioradialis sites. Total dose (90U) and total injection volume (3.6mL) were identical across groups. Only sites and injection techniques varied. The brachialis was not injected in either group. Main Outcome Measures: Ashworth Scale, Tardieu Catch angle, and root mean square surface electromyographic activity of the biceps, brachialis, and brachioradialis. Results: Postintervention testing at 3 weeks showed no significant differences between groups (P range, 3 1-82 across 3 outcome measures). However, within each group, significant treatment effects were observed on all outcome measures (all P <.01). For the uninjected brachialis muscle, electromyographic reduction was greater for the distributed group. Conclusions: In 31 adults with acquired brain injury, single motor point and multisite distributed injections of low-dose. high-volume BTX-A had similar impact. Findings suggest that low-dose, high-volume strategies may have a potential role in reducing drug cost and helping clinicians stay within accepted limits for total body dose in patients With upper motoneuron syndrome requiring many injections.	[Mayer, Nathaniel H.] Temple Univ, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19122 USA; [Mayer, Nathaniel H.; Whyte, John; Ellis, Colin A.] Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA USA; [Whyte, John] Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA; [Mayer, Nathaniel H.; Wannstedt, Gunillia] MossRehab, Motor Control Anal Lab, Elkins Pk, PA 19027 USA	Mayer, NH (corresponding author), MossRehab, Motor Control Anal Lab, 60 E Township Line Rd, Elkins Pk, PA 19027 USA.	nmayer@einstein.edu		Whyte, John/0000-0002-4381-1474	National Institute on Disability and Rehabilitation Research [H133AO20505]	Supported in part by the National Institute on Disability and Rehabilitation Research (grant no. H133AO20505) and an educational grant front Allergan Inc.	Abbruzzese G, 2006, NEUROTOX RES, V9, P109, DOI 10.1007/BF03033927; AQUILONIUS SM, 1984, MUSCLE NERVE, V7, P287, DOI 10.1002/mus.880070406; ASHWORTH B, 1964, PRACTITIONER, V192, P540; Bakheit AMO, 2003, J NEUROL NEUROSUR PS, V74, P646, DOI 10.1136/jnnp.74.5.646; Bakheit AMO, 2001, EUR J NEUROL, V8, P559, DOI 10.1046/j.1468-1331.2001.00277.x; Banks RW, 2006, J ANAT, V208, P753, DOI 10.1111/j.1469-7580.2006.00558.x; Bergfeldt U, 2006, J REHABIL MED, V38, P166, DOI 10.1080/16501970500415348; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; BORODIC GE, 1990, HEAD NECK-J SCI SPEC, V12, P392, DOI 10.1002/hed.2880120504; Boyd RN, 1999, EUR J NEUROL, V6, pS23, DOI 10.1111/j.1468-1331.1999.tb00031.x; BOYD RN, 1998, DEV MED CHILD NEUROL, V40, P7; Brashear A, 2002, NEW ENGL J MED, V347, P395, DOI 10.1056/NEJMoa011892; Brin M F, 1997, Muscle Nerve Suppl, V6, pS208; Childers MK, 1996, AM J PHYS MED REHAB, V75, P462, DOI 10.1097/00002060-199611000-00013; Childers MK, 2004, ARCH PHYS MED REHAB, V85, P1063, DOI 10.1016/j.apmr.2003.10.015; Childers MK, 1998, MUSCLE NERVE, V21, P653, DOI 10.1002/(SICI)1097-4598(199805)21:5<653::AID-MUS15>3.0.CO;2-W; COERS C, 1959, Am J Phys Med, V38, P166; Coers C., 1959, INNERVATION MUSCLE B; De Luca C. J., 2002, SURFACE ELECTROMYOGR; Deshpande S, 2006, NEUROTOX RES, V9, P115, DOI 10.1007/BF03033928; Francisco GE, 2002, AM J PHYS MED REHAB, V81, P355, DOI 10.1097/00002060-200205000-00007; GLENN MB, 1990, PRACTICAL MANAGEMENT, P227; Gracies JM, 2002, ANN NEUROL, V52, pS87; Gracies JM, 2001, NEUROLOGY, V56, pA3; Gracies JM, 2000, ARCH PHYS MED REHAB, V81, P1547, DOI 10.1053/apmr.2000.16346; KATZ RT, 1989, ARCH PHYS MED REHAB, V70, P144; Kokkorogiannis T, 2004, J THEOR BIOL, V229, P263, DOI 10.1016/j.jtbi.2004.03.019; Leslie GC, 1992, CLIN REHABIL, V6, P41; LEVIN MF, 1994, BRAIN RES, V657, P23, DOI 10.1016/0006-8993(94)90949-0; Levin MF, 2000, BRAIN RES, V853, P352, DOI 10.1016/S0006-8993(99)02298-2; Mayer NH, 2004, J HEAD TRAUMA REHAB, V19, P119, DOI 10.1097/00001199-200403000-00005; Mayer NH, 2002, SPASTICITY ETIOLOGY, P154; Pandyan AD, 2002, CLIN REHABIL, V16, P654, DOI 10.1191/0269215502cr536oa; Rousseaux M, 2002, J NEUROL, V249, P76, DOI 10.1007/PL00007851; Sanger TD, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e89; SHAARI CM, 1991, LARYNGOSCOPE, V101, P960; SHAARI CM, 1993, MUSCLE NERVE, V16, P964, DOI 10.1002/mus.880160913; Simpson DM, 1996, NEUROLOGY, V46, P1306, DOI 10.1212/WNL.46.5.1306; Smith SJ, 2000, CLIN REHABIL, V14, P5, DOI 10.1191/026921500666642221; Warfel J, 1985, EXTREMITIES MUSCLES	40	34	34	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					982	987		10.1016/j.apmr.2007.10.022			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900026	18452749				2021-06-18	
J	Tata, DA; Yamamoto, BK				Tata, Despina A.; Yamamoto, Bryan K.			Chronic stress enhances methamphetamine-induced extracellular glutamate and excitotoxicity in the rat striatum	SYNAPSE			English	Article						spectrin proteolysis; glucocorticoids; metyrapone; dopamine transporter; serotonin transporter	EXCITATORY AMINO-ACIDS; COCAINE-INDUCED LOCOMOTION; NUCLEUS-ACCUMBENS SHELL; TRAUMATIC BRAIN-INJURY; CHRONIC MILD STRESS; ALPHA-II-SPECTRIN; LONG-TERM; INDUCED NEUROTOXICITY; CORTICOSTERONE SYNTHESIS; MONOAMINE DEPLETIONS	Striking parallels exist between the neurochemical and toxic effects of stress and methamphetamine. Despite these similarities, no studies have examined how stress may promote the toxic effects of methamphetamine (METH). The current study tested the hypothesis that chronic stress enhances METH toxicity by augmenting glutamate (GLU) release and excitotoxicity in response to METH administration. Adult male Sprague-Dawley rats were exposed to 10 days of unpredictable stress and then received either saline or METH (7.5 mg/kg, i.p., once every 2 h x four injections). Prior exposure to unpredictable stress acutely enhanced the striatal extracellular GLU concentrations in response to METH, and eventually caused proteolysis of the cytoskeleton protein spectrin. Administration of the corticosterone synthesis inhibitor, metyrapone (25 mg/kg, i.p., prior to each stressor), during unpredictable stress attenuated the enhanced striatal GLU release in response to METH, blocked spectrin proteolysis, and attenuated METH-associated toxicity measured by long-term depletions in the dopamine and serotonin tissue content as well as depletions in dopamine and serotonin transporter immunoreactivity of the striatum. In summary, prior exposure to unpredictable stress enhances METH-induced elevations of GLU in the striatum, resulting in long-term excitotoxic damage and an augmentation of damage to dopamine and serotonin terminals. These studies provide a neurochemical basis for how stress contributes to the deleterious effects of METH abuse.	[Tata, Despina A.; Yamamoto, Bryan K.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Neurochem Lab, Boston, MA 02118 USA	Yamamoto, BK (corresponding author), Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Neurochem Lab, L-613,715 Albany St, Boston, MA 02118 USA.	bkyam@bu.edu	Tata, Despina A./AAH-5300-2020; Yamamoto, Bryan/Z-1050-2019	Tata, Despina A./0000-0001-5563-4017; 	NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA007606, R01DA016866] Funding Source: NIH RePORTER; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA007606, DA16866, DA07606, R01 DA016866] Funding Source: Medline		ABEKAWA T, 1994, BRAIN RES, V643, P276, DOI 10.1016/0006-8993(94)90033-7; Araujo APN, 2003, BEHAV BRAIN RES, V139, P75, DOI 10.1016/S0166-4328(02)00088-8; ARMANINI MP, 1990, BRAIN RES, V532, P7, DOI 10.1016/0006-8993(90)91734-X; BAKHIT C, 1981, NEUROSCI LETT, V23, P99, DOI 10.1016/0304-3940(81)90194-4; Bielajew C, 2002, BEHAV BRAIN RES, V136, P583, DOI 10.1016/S0166-4328(02)00222-X; BIRON D, 1992, NEUROENDOCRINOLOGY, V55, P468, DOI 10.1159/000126158; Broom SL, 2005, PSYCHOPHARMACOLOGY, V181, P467, DOI 10.1007/s00213-005-0007-6; Brown PJ, 1998, J SUBST ABUSE TREAT, V15, P445, DOI 10.1016/S0740-5472(97)00286-9; Burrows KB, 1999, NEUROSCIENCE, V90, P833, DOI 10.1016/S0306-4522(98)00506-5; Calvo N, 1998, BRAIN RES, V800, P227, DOI 10.1016/S0006-8993(98)00515-0; Clemens KJ, 2005, NEUROPHARMACOLOGY, V49, P195, DOI 10.1016/j.neuropharm.2005.03.002; Cordero MI, 2002, STRESS, V5, P71, DOI 10.1080/102538902900124404; Czyrak A, 1997, NEUROSCIENCE, V79, P489, DOI 10.1016/S0306-4522(96)00649-5; Daberkow DP, 2005, PHARMACOL BIOCHEM BE, V81, P198, DOI 10.1016/j.pbb.2005.03.010; Dal-Zotto S, 2003, PSYCHONEUROENDOCRINO, V28, P992, DOI 10.1016/S0306-4530(02)00120-8; Davidson C, 2001, BRAIN RES REV, V36, P1, DOI 10.1016/S0165-0173(01)00054-6; Deng XL, 2007, BIOL PSYCHIAT, V61, P1235, DOI 10.1016/j.biopsych.2006.09.010; Deng XL, 2002, NEUROPHARMACOLOGY, V42, P837, DOI 10.1016/S0028-3908(02)00034-5; Der-Avakian A, 2006, PSYCHONEUROENDOCRINO, V31, P653, DOI 10.1016/j.psyneuen.2006.02.004; Dziedzicka-Wasylewska M, 1997, BEHAV PHARMACOL, V8, P607, DOI 10.1097/00008877-199711000-00017; Eyerman DJ, 2005, J PHARMACOL EXP THER, V312, P160, DOI 10.1124/jpet.104.072264; Friedman SD, 1998, PHARMACOL BIOCHEM BE, V61, P35, DOI 10.1016/S0091-3057(98)00066-5; HERMAN JP, 1995, NEUROENDOCRINOLOGY, V61, P180, DOI 10.1159/000126839; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; Kita T, 2003, J PHARMACOL SCI, V92, P178; Liu L, 1999, BRAIN RES, V821, P134, DOI 10.1016/S0006-8993(99)01085-9; LOWY MT, 1993, J NEUROCHEM, V61, P1957, DOI 10.1111/j.1471-4159.1993.tb09839.x; LOWY MT, 1995, J NEUROCHEM, V65, P268; MAGARINOS AM, 1995, NEUROSCIENCE, V69, P89, DOI 10.1016/0306-4522(95)00259-L; Marinelli M, 1996, BRAIN RES, V724, P251, DOI 10.1016/0006-8993(96)00309-5; Mark KA, 2004, J NEUROSCI, V24, P11449, DOI 10.1523/JNEUROSCI.3597-04.2004; Matuszewich L, 2004, NEUROSCIENCE, V124, P637, DOI 10.1016/j.neuroscience.2003.12.007; MOGHADDAM B, 1994, BRAIN RES, V655, P251, DOI 10.1016/0006-8993(94)91622-5; MOGHADDAM B, 1993, J NEUROCHEM, V60, P1650, DOI 10.1111/j.1471-4159.1993.tb13387.x; NASH JF, 1992, BRAIN RES, V581, P237, DOI 10.1016/0006-8993(92)90713-J; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PIAZZA PV, 1994, BRAIN RES, V658, P259, DOI 10.1016/S0006-8993(09)90034-8; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Quinton MS, 2006, AAPS J, V8, pE337, DOI 10.1208/aapsj080238; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; SAMANTARAY S, 2006, ANN NY ACAD SCI, V74, P349; SIMAN R, 1989, J NEUROSCI, V9, P1579; Sinha R, 2001, PSYCHOPHARMACOLOGY, V158, P343, DOI 10.1007/s002130100917; Soderpalm A, 2003, PSYCHOPHARMACOLOGY, V170, P188, DOI 10.1007/s00213-003-1536-5; SONINO N, 1982, HORMONE ANTAGONISTS, P419; Sonsalla PK, 1996, BRAIN RES, V738, P172, DOI 10.1016/0006-8993(96)00995-X; SONSALLA PK, 1989, SCIENCE, V243, P398, DOI 10.1126/science.2563176; Staszewski RD, 2006, J NEUROCHEM, V96, P1267, DOI 10.1111/j.1471-4159.2005.03618.x; STEINBEHRENS B, 1994, J NEUROSCI, V14, P5373; STEINBEHRENS BA, 1994, J NEUROCHEM, V63, P596; STEINBEHRENS BA, 1992, J NEUROCHEM, V58, P1730, DOI 10.1111/j.1471-4159.1992.tb10047.x; STEPHANS SE, 1994, SYNAPSE, V17, P203, DOI 10.1002/syn.890170310; Straiko MMW, 2007, NEUROSCIENCE, V144, P223, DOI 10.1016/j.neuroscience.2006.08.073; TATA DA, 2005, CHRONIS STRESS ENHAN; Thiriet N, 2005, J NEUROSCI, V25, P5273, DOI 10.1523/JNEUROSCI.4893-04.2005; Venero C, 1999, EUR J NEUROSCI, V11, P2465, DOI 10.1046/j.1460-9568.1999.00668.x; WAGNER GC, 1980, BRAIN RES, V181, P151, DOI 10.1016/0006-8993(80)91265-2; Wallace TL, 2001, SYNAPSE, V39, P1, DOI 10.1002/1098-2396(20010101)39:1<1::AID-SYN1>3.0.CO;2-7; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; YAMAMOTO BK, 1990, BRAIN RES, V506, P236, DOI 10.1016/0006-8993(90)91256-G; Yu J, 2004, BRAIN RES, V1007, P124, DOI 10.1016/j.brainres.2004.01.077; Zhu JPQ, 2006, NEUROSCIENCE, V140, P607, DOI 10.1016/j.neuroscience.2006.02.055	65	34	37	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0887-4476	1098-2396		SYNAPSE	Synapse	MAY	2008	62	5					325	336		10.1002/syn.20497			12	Neurosciences	Neurosciences & Neurology	284CA	WOS:000254681600002	18288648	Green Accepted			2021-06-18	
J	Carey, JC; Wade, SL; Wolfe, CR				Carey, Joanne C.; Wade, Shari L.; Wolfe, Christopher R.			Lessons learned: The effect of prior technology use on web-based interventions	CYBERPSYCHOLOGY & BEHAVIOR			English	Article							TRAUMATIC BRAIN-INJURY; PROBLEM-SOLVING INTERVENTION; COMPUTER ANXIETY; EFFICACY BELIEFS; CHILDREN; FAMILIES	This study examined the role of regular prior technology use in treatment response to an online family problem-solving (OFPS) intervention and an Internet resource intervention (IRI) for pediatric traumatic brain injury (TBI). Participants were 150 individuals in 40 families of children with TBI randomly assigned to OFPS intervention or an IRI. All families received free computers and Internet access to TBI resources. OFPS families received Web-based sessions and therapist-guided synchronous videoconferences focusing on problem solving, communication skills, and behavior management. All participants completed measures of depression, anxiety, and computer usage. OFPS participants rated treatment satisfaction, therapeutic alliance, and Web site and technology comfort. With the OFPS intervention, depression and anxiety improved significantly more among technology using parents (n = 14) than nontechnology users (n = 6). Technology users reported increasing comfort with technology over time, and this change was predictive of depression at followup. Satisfaction and ease-of-use ratings did not differ by technology usage. Lack of regular prior home computer usage and nonadherence were predictive of anxiety at followup. The IRI was not globally effective. However, controlling for prior depression, age, and technology at work, there was a significant effect of technology at home for depression. Families with technology experience at home (n = 11) reported significantly greater improvements in depression than families without prior technology experience at home (n = 8). Although Web-based OFPS was effective in improving caregiver functioning, individuals with limited computer experience may benefit less from an online intervention due to increased nonadherence.	[Carey, Joanne C.; Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat Rehabiliatat, Cincinnati, OH 45229 USA; [Wolfe, Christopher R.] Miami Univ, Sch Interdisciplinary Studies, Oxford, OH 45056 USA	Wade, SL (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Dept Pediat Rehabiliatat, 3333 Burnett Ave,MLC 4009, Cincinnati, OH 45229 USA.	Shari.Wade@cchmc.org			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD040942] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40942-02, R21 HD040942] Funding Source: Medline		A Henry Suzanne Ball Ruth M Williams Lucy, 1998, J Ment Health, V7, P411, DOI 10.1080/09638239818012; Agnew-Davies R, 1998, BRIT J CLIN PSYCHOL, V37, P155, DOI 10.1111/j.2044-8260.1998.tb01291.x; Brodie M, 2000, HEALTH AFFAIR, V19, P255, DOI 10.1377/hlthaff.19.6.255; Chua SL, 1999, COMPUT HUM BEHAV, V15, P609, DOI 10.1016/S0747-5632(99)00039-4; GLUECKAUF RL, 1997, AUDIOVISUAL EQUIPMEN; Hauser RM, 1997, SOCIOL METHODOL, V27, P177, DOI 10.1111/1467-9531.271028; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Hufford BJ, 1999, REHABIL PSYCHOL, V44, P176, DOI 10.1037/0090-5550.44.2.176; Potosky D, 2002, COMPUT HUM BEHAV, V18, P241, DOI 10.1016/S0747-5632(01)00050-4; Radloff LS, 1977, J APPL PSYCHOL MEASU, V1, P385, DOI DOI 10.1177/014662167700100306; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Speilberger C.D., 1983, STATE TRAIT ANXIETY; Stepankova O, 2006, METHOD INFORM MED, V45, P300; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2005, J PEDIATR PSYCHOL, V30, P437, DOI 10.1093/jpepsy/jsi067; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Wade SL, 2004, BEHAV RES METH INS C, V36, P261, DOI 10.3758/BF03195572; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wade SL, 2006, J CONSULT CLIN PSYCH, V51, P178; Wilfong JD, 2006, COMPUT HUM BEHAV, V22, P1001, DOI 10.1016/j.chb.2004.03.020	20	34	36	0	18	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1094-9313			CYBERPSYCHOL BEHAV	CyberPsychol. Behav.	APR	2008	11	2					188	195		10.1089/cpb.2007.0025			8	Communication; Psychology, Applied	Communication; Psychology	294SH	WOS:000255425300010	18422412	Green Accepted			2021-06-18	
J	Hu, X; Xu, P; Lee, DJ; Vespa, P; Baldwin, K; Bergsneider, M				Hu, Xiao; Xu, Peng; Lee, Darrin J.; Vespa, Paul; Baldwin, Kevin; Bergsneider, Marvin			An algorithm for extracting intracranial pressure latency relative to electrocardiogram R wave	PHYSIOLOGICAL MEASUREMENT			English	Article						intracranial pressure; pulse wave velocity; cerebrovascular resistance; cerebral blood flow autoregulation	ARTERIAL STIFFNESS; VELOCITY; DISEASE; ECG	Intracranial pressure ( ICP) latency is defined as the time interval between the peak of the QRS complex of the electrocardiogram ( ECG) and the corresponding onset of intracranial pressure ( ICP) pulse. Due to its inherent relationship with arterial pulse wave velocity, ICP latency may allow continuous monitoring of pathophysiological changes in the cerebrovasculature. The objective of the present work was to develop and validate a computerized algorithm for extracting ICP latency in a beat-by-beat fashion. The proposed ICP latency extraction algorithm exploits the mature technique of ECG QRS detection and includes a new adaptive peak detection methodology. The results were validated by comparing the performance of two human observers versus the algorithm in terms of locating the onset points of ICP pulses for 59 recordings extracted from 25 adult patients. The average ICP latency was 72.6 +/- 19.5 ms ( range 40.0-159.8). The ICP pulse detection algorithm demonstrated a baseline sensitivity of 0.97 and a positive predictivity of 0.88. No difference was found in the mean location errors from comparing the results obtained by the two observers and those from comparing the results from the algorithm to those from the two observers. Further investigation is needed to demonstrate the role of ICP latency in characterizing dynamic cerebral vascular pathophysiological changes in clinical states such as subarachnoid hemorrhage and traumatic brain injury.	[Hu, Xiao; Xu, Peng; Lee, Darrin J.; Vespa, Paul; Baldwin, Kevin; Bergsneider, Marvin] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Neural Syst & Dynam Lab, Los Angeles, CA 90095 USA; [Hu, Xiao; Bergsneider, Marvin] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Biomed Engn Grad Program, Los Angeles, CA USA; [Xu, Peng] Univ Elect Sci & Technol China, Sch Life Sci & Technol, Chengdu 610054, Peoples R China	Hu, X (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Neural Syst & Dynam Lab, Los Angeles, CA 90095 USA.	mbergsneider@mednet.ucla.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS055045, R01NS054881, R21NS055998, R21NS059797] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS055045, R21 NS059797, R01 NS054881-02, R01 NS054881, R21 NS055045-02, R21-NS055045, R21 NS059797-01A1, R21-NS055998, R21 NS055998, R21-NS054881, R21 NS055998-02] Funding Source: Medline		Aboy M, 2005, IEEE T BIO-MED ENG, V52, P1662, DOI 10.1109/TBME.2005.855725; Afonso VX, 1999, IEEE T BIO-MED ENG, V46, P192, DOI 10.1109/10.740882; Chang HK, 2006, ANN RHEUM DIS, V65, P415, DOI 10.1136/ard.2005.043430; CHIU YC, 1991, AM HEART J, V121, P1460, DOI 10.1016/0002-8703(91)90153-9; DALEY ML, 1982, NEUROSURGERY, V11, P617, DOI 10.1227/00006123-198211000-00005; Davies JI, 2003, J HYPERTENS, V21, P463, DOI 10.1097/00004872-200303000-00004; de Isla LP, 2006, J AM SOC ECHOCARDIOG, V19, P1338, DOI 10.1016/j.echo.2006.05.015; GILLER CA, 1994, ULTRASOUND MED BIOL, V20, P101, DOI 10.1016/0301-5629(94)90074-4; Hansen TW, 2006, CIRCULATION, V113, P664, DOI 10.1161/CIRCULATIONAHA.105.579342; Harrod CG, 2005, NEUROSURGERY, V56, P633, DOI 10.1227/01.NEU.0000156644.45384.92; Jadhav Uday M, 2005, Indian Heart J, V57, P226; Kohler BU, 2002, IEEE ENG MED BIOL, V21, P42, DOI 10.1109/51.993193; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; Nichols W. W., 2005, MCDONALDS BLOOD FLOW; Nichols WW, 2002, CURR OPIN CARDIOL, V17, P543, DOI 10.1097/00001573-200209000-00016; NYGARDS ME, 1983, MED BIOL ENG COMPUT, V21, P538, DOI 10.1007/BF02442378; Sutton-Tyrrell K, 2005, CIRCULATION, V111, P3384, DOI 10.1161/CIRCULATIONAHA.104.483628	18	34	34	0	1	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0967-3334	1361-6579		PHYSIOL MEAS	Physiol. Meas.	APR	2008	29	4					459	471		10.1088/0967-3334/29/4/004			13	Biophysics; Engineering, Biomedical; Physiology	Biophysics; Engineering; Physiology	285VJ	WOS:000254804000004	18354246	Green Accepted			2021-06-18	
J	Wang, HC; Chang, WN; Chang, HW; Ho, JT; Yang, TM; Lin, WC; Chuang, YC; Lu, CH				Wang, Hung-Chen; Chang, Wen-Neng; Chang, Hsueh-Wen; Ho, Jih-Tsun; Yang, Tzu-Ming; Lin, Wei-Che; Chuang, Yao-Chung; Lu, Cheng-Hsien			Factors predictive of outcome in posttraumatic seizures	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							EPILEPSY; PHENYTOIN; INJURY; PREVENTION; TRAUMA; AGENTS; DRUGS; RISK	Background: Seizures are important neurologic complications of traumatic brain injury (TBI). There is a need for better delineation of potential prognostic factors and outcomes in patients with posttraumatic seizures (PTS) who could receive treatment when brought to the hospital. Methods: In this 10-year retrospective study, 170 adult patients with PTS were enrolled in this study. The degree of seizure control was analyzed using a Seizure Frequency Scoring System, which classified them into excellent and nonexcellent outcomes. Results: There were 170 patients with acute symptomatic seizure enrolled in this study, 106 of whom had early PTS, whereas 64 had late PTS. Of the 106 early PTS, 58% (61 of 106) occurred within 24 hours of trauma. Risk factors for developing nonexcellent outcome included patients who undergo surgical intervention and presence of late-provoked seizures during the acute phase of TBI. Conclusion: Seizures are an important neurologic complication of TBI. Regarding the potentially side effects of antiepileptic drugs, antiepileptic therapy should be carefully administrated in those nonexcellent outcome patients.	[Chang, Wen-Neng; Chuang, Yao-Chung; Lu, Cheng-Hsien] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Neurol, Kaohsiung, Hsien, Taiwan; [Wang, Hung-Chen; Ho, Jih-Tsun; Yang, Tzu-Ming] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Neurosurg, Kaohsiung, Hsien, Taiwan; [Lin, Wei-Che] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Radiol, Kaohsiung, Hsien, Taiwan; [Chang, Hsueh-Wen] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung 80424, Taiwan	Lu, CH (corresponding author), Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Kaohsiung Med Ctr,Dept Neurol, 123,Ta Pei Rd,Niao Sung Hsiang, Kaohsiung, Hsien, Taiwan.	chlu99@ms44.url.com.tw		WANG, HUNG-CHEN/0000-0003-3962-1958			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; CALLAGHAN N, 1988, NEW ENGL J MED, V318, P942, DOI 10.1056/NEJM198804143181502; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; RAPP RP, 1983, NEUROSURGERY, V13, P272, DOI 10.1227/00006123-198309000-00010; Rasmussen T.B., 1993, SURG TREATMENT EPILE, P609; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; SHINNAR S, 1985, NEW ENGL J MED, V313, P976, DOI 10.1056/NEJM198510173131603; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594	26	34	37	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2008	64	4					883	888		10.1097/TA.0b013e31804a7fa4			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	287UN	WOS:000254942100007	18404052				2021-06-18	
J	Willemse-Van Son, AHP; Ribbers, GM; Hop, WCJ; van Duijn, CM; Stam, HJ				Willemse-van Son, A. H. P.; Ribbers, G. M.; Hop, W. C. J.; van Duijn, C. M.; Stam, H. J.			Association between apolipoprotein-epsilon 4 and long-term outcome after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY; SHORT GENERIC VERSION; E POLYMORPHISM; GENOTYPE PREDICTS; APOE GENOTYPE; E EPSILON-4; NEUROGENESIS; GUIDELINES; RECOVERY; E4	Objectives: To investigate the effect of carrying the apolipoprotein epsilon 4 (APOE-epsilon 4) allele on global functional outcome, on activity limitations and participation restrictions, and on community integration at 3, 6, 12, 18, 24 and 36 months after traumatic brain injury. Method: The Glasgow Outcome Scale (GOS), the Sickness Impact Profile-68 (SIP-68) and the Community Integration Questionnaire (CIQ) were assessed in 79 moderate and severe traumatic brain injury patients at 3, 6, 12, 18, 24 and 36 months post injury. Repeated measures analyses of variance were performed with APOE-epsilon 4 status and time of measurement as independent variables and the GOS, SIP-68 and CIQ as dependent variables. Analyses were adjusted for baseline age, gender and Glasgow Coma Scale. Results: Patients with the APOE-epsilon 4 allele had a significantly better global functional outcome on the GOS than patients without the APOE-epsilon 4 allele. No significant associations were found between APOE-epsilon 4 status and the SIP-68 and CIQ. Discussion: In contrast to other studies, we found that carrying the APOE-epsilon 4 allele had a protective influence on outcome. Multiple mechanisms, and in some cases competitive mechanisms, may explain the variable relation between the APOE-epsilon 4 allele and outcome after traumatic brain injury.	[Willemse-van Son, A. H. P.; Ribbers, G. M.; Stam, H. J.] Erasmus MC, Dept Rehabil Med, Rotterdam, Netherlands; [Ribbers, G. M.] Rijndam Rehabil Ctr, Rotterdam, Netherlands; [Hop, W. C. J.; van Duijn, C. M.] Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands	Willemse-Van Son, AHP (corresponding author), Erasmus MC, Dept Rehabil Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.vanson-willemse@erasmusmc.nl	Ribbers, Gerard M/C-1454-2014; Ribbers, Gerard/N-3623-2019	Ribbers, Gerard M/0000-0002-6114-349X; 			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Chiang MF, 2003, ACTA NEUROCHIR WIEN, V145, P53; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P863, DOI 10.1016/0895-4356(94)90189-9; DEBRUIN AF, 1994, J CLIN EPIDEMIOL, V47, P407, DOI 10.1016/0895-4356(94)90162-7; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dyker AG, 1997, BMJ-BRIT MED J, V314, P1584, DOI 10.1136/bmj.314.7094.1584; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levi O, 2007, J NEUROCHEM, V100, P202, DOI 10.1111/j.1471-4159.2006.04189.x; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Oria RB, 2005, PEDIATR RES, V57, P310, DOI 10.1203/01.PDR.0000148719.82468.CA; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; SING CF, 1985, AM J HUM GENET, V37, P268; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organization, 2002, INT CLASS FUNCT DIS; Wright RO, 2003, PEDIATR RES, V54, P819, DOI 10.1203/01.PDR.0000090927.53818.DE	45	34	35	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2008	79	4					426	430		10.1136/jnnp.2007.129460			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	275AP	WOS:000254044600018	17971433				2021-06-18	
J	Byrne, RW; Bagan, BT; Slavin, KV; Curry, D; Koski, TR; Origitano, TC				Byrne, Richard W.; Bagan, Bradley T.; Slavin, Konstantin V.; Curry, Daniel; Koski, Tyler R.; Origitano, Thomas C.			Neurosurgical emergency transfers to academic centers in Cook County: A prospective multicenter study	NEUROSURGERY			English	Article						Cook County; Emergency Medical Treatment and Active Labor Act; emergency room coverage; neurosurgical transfers	TRAUMATIC BRAIN-INJURY; ACUTE-CARE SURGERY; SYSTEM; TRANSPORT; MORTALITY	OBJECTIVE: The absence of surgical subspecialty emergency care in the United States is a growing public health concern. Neurosurgery is a field lacking coverage ill many areas of the country; however, this is generally thought to be of greater concern in rural areas. Because of decreasing numbers of neurosurgeons, medical malpractice, and liability concerns, neurosurgery coverage is becoming a public health crisis in urban areas. Our objective was to quantify neurosurgical emergency transfers to academic medical centers in Cook County, IL, including patient demographics, reasons for transfer, time lapse in transfer, and effects on patient condition. METHODS: Data on neurosurgery emergency transfers was gathered prospectively by all five of the academic neurosurgery departments in Cook County, IL, over a 2-month period. Patient demographics devoid of identifiers, diagnosis, transfer origin, time lapse of transfer, and patient condition at the time of transfer and at the receiving hospital were recorded. RESULTS: Two-hundred thirty emergent neurosurgical transfers occurred during the study period. The most common diagnoses were parenchymal intracerebral hemorrhage (33%) and subarachnoid hemorrhage (28%). Sixty-six percent of neurosurgical transfers to academic medical facilities originated at hospitals without full-time neurosurgery coverage. The mean time to transfer for all patients was 5 hours 10 minutes (standard deviation, 3 h 42 min; range, 1-20 h 12 min). A decline in Glasgow Coma Scale score was seen in 29 patients. A shortage of neurosurgical intensive care unit beds occurred on 55% of the days in the study. Only 19% of the emergency cases were related to cranial trauma, and only 3% of transfers came from Level 1 trauma centers. CONCLUSION: A combination of factors has led to decreases in availability of neurosurgical coverage in Cook County community hospital emergency departments. This has placed an increased burden on neurosurgical departments at academic centers, and, in some cases, delays led to a decline in patient condition. Eighty-one percent of the cases were not related to cranial trauma; thus, acute care trauma surgeons would be of little use. Coordinated efforts among local governments, medical centers, and emergency medical services to regionalize subspecialty services will be necessary to manage this problem.	[Byrne, Richard W.; Bagan, Bradley T.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA; [Curry, Daniel] Univ Illinois, Dept Surg, Div Neurosurg, Chicago, IL 60680 USA; [Koski, Tyler R.] Northwestern Univ, Dept Neurosurg, Chicago, IL 60611 USA; [Origitano, Thomas C.] Loyola Univ, Dept Neurosurg, Chicago, IL 60611 USA	Byrne, RW (corresponding author), Rush Univ, Med Ctr, Dept Neurosurg, 1725 W Harrison,Suite 1115, Chicago, IL 60612 USA.	rbyrne37@aol.com	Slavin, Konstantin/H-3269-2019; Byrne, Richard/Q-9644-2019	Slavin, Konstantin/0000-0002-7946-8639; 			*AM ASS NEUR SURG, 2001, EM ROOM COV WHAT EV; *AM COLL EM PHYS, 2004, ON CALL SPEC COV US; *AM MED ASS, 2006, PHYS CHAR DISTR US 2; ANSELL DA, 1987, JAMA-J AM MED ASSOC, V257, P1500, DOI 10.1001/jama.257.11.1500; BYRNE R, 2004, AANS B, V13, P14; Dunn LT, 1997, INJURY, V28, P427, DOI 10.1016/S0020-1383(97)00051-X; ELJAMEL MS, 1992, BRIT J NEUROSURG, V6, P559, DOI 10.3109/02688699209002373; *GEN ACC OFF, 2003, GAO03836; GENTLEMAN D, 1992, INJURY, V23, P471, DOI 10.1016/0020-1383(92)90066-2; Harrington DT, 2005, ANN SURG, V241, P961, DOI 10.1097/01.sla.0000164178.62726.f1; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Holmen CD, 2002, J TRAUMA, V53, P345, DOI 10.1097/00005373-200208000-00026; *I MED, 2006, FUT EM CAR KEY FIND; Lind CRP, 2005, ANZ J SURG, V75, P858, DOI 10.1111/j.1445-2197.2005.03574.x; Moore EE, 2006, J AM COLL SURGEONS, V202, P698, DOI 10.1016/j.jamcollsurg.2005.12.007; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; SEAVER M, 2006, AANS B, V15, P8; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Sklar D, 2002, ANN EMERG MED, V39, P456, DOI 10.1067/mem.2002.122782; VALADKA AB, 2004, AM ASS NEUROLOGICAL, V13, P6; Valadka AB, 2007, SURGERY, V141, P321, DOI 10.1016/j.surg.2007.01.009; Valadka AB, 2006, J AM COLL SURGEONS, V203, P962, DOI 10.1016/j.jamcollsurg.2006.08.014; Williams JM, 2001, ANN EMERG MED, V38, P323, DOI 10.1067/mem.2001.115217; Wyatt SM, 1997, ACAD MED, V72, P922	24	34	34	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAR	2008	62	3					709	715		10.1227/01.neu.0000317320.79106.7e			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	292LV	WOS:000255268500037	18425017				2021-06-18	
J	Samah, B; Porcheray, F; Gras, G				Samah, B.; Porcheray, F.; Gras, G.			Neurotrophins modulate monocyte chemotaxis without affecting macrophage function	CLINICAL AND EXPERIMENTAL IMMUNOLOGY			English	Article						chemotaxis; macrophage; monocyte; neurotrophin; SDF-1	NERVE GROWTH-FACTOR; MESSENGER-RNA EXPRESSION; CHEMOKINE RECEPTOR CXCR4; TRAUMATIC BRAIN-INJURY; CELL-DERIVED FACTOR-1-ALPHA; TRK PROTOONCOGENE; RAT HIPPOCAMPUS; ALPHA-CHEMOKINE; IN-VITRO; GLUCOCORTICOIDS MODULATE	Neurotrophins nerve growth factor (NGF), brain-derived growth factor (BDNF), neurotrophin-3 (NT-3) and neurotrophin-4 (NT-4) and their high-affinity tyrosine protein kinase receptor (Trk) family, TrkA, TrkB, TrkC, and low-affinity p75(NTR) receptor, are key molecules implicated in the development of the central nervous system. Increasing evidence suggests that they also have physiological and pathological roles outside the nervous system. In this study we examined the expression of neurotrophins and their receptors in human activated macrophages and to what extent neurotrophins themselves modulate macrophage activation, in a model of primary adult monocyte-derived macrophage. Our data indicate that macrophages express neurotrophin and neurotrophin receptor genes differentially, and respond to cell stimulation by specific inductions. Neurotrophins did not modify the antigen-presenting capacities of macrophages or their production of proinflammatory cytokines, but somehow skewed their activation phenotype. In contrast, NGF clearly increased CXCR-4 expression in macrophage and their chemotactic response to low CXCL-12 concentration. The differential effect of specific macrophage stimuli on neurotrophin expression, in particular NGF and NT-3, and the specific enhancement of CXCR-4 expression suggest that neurotrophins might participate in tissue-healing mechanisms that should be investigated further in vivo.	[Samah, B.; Porcheray, F.; Gras, G.] Univ Paris Sud, Serv Immunovirol, IFR13 Inst Paris Cytokines, CEA,DSV,iMETI,SIV,UMR E 01, F-92265 Fontenay Aux Roses, France	Gras, G (corresponding author), Univ Paris Sud, Serv Immunovirol, IFR13 Inst Paris Cytokines, CEA,DSV,iMETI,SIV,UMR E 01, 18 Route Panorama, F-92265 Fontenay Aux Roses, France.	gabriel.gras@cea.fr					Arnold L, 2007, J EXP MED, V204, P1057, DOI 10.1084/jem.20070075; Asami T, 2006, BIOCHEM BIOPH RES CO, V344, P941, DOI 10.1016/j.bbrc.2006.03.228; Badr G, 2005, INT IMMUNOL, V17, P459, DOI 10.1093/intimm/dxh227; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Barouch R, 2001, J LEUKOCYTE BIOL, V69, P1019; Barouch R, 2001, J NEUROIMMUNOL, V112, P72, DOI 10.1016/S0165-5728(00)00408-2; Belliveau DJ, 1997, J CELL BIOL, V136, P375, DOI 10.1083/jcb.136.2.375; Bonini P, 2001, JOP, V2, P105; BOTHWELL M, 1995, ANNU REV NEUROSCI, V18, P223, DOI 10.1146/annurev.neuro.18.1.223; BRODIE C, 1992, J IMMUNOL, V148, P3492; Caroleo MC, 2001, J NEUROIMMUNOL, V113, P193, DOI 10.1016/S0165-5728(00)00441-0; Carter BD, 1997, NEURON, V18, P187, DOI 10.1016/S0896-6273(00)80259-7; Chang CN, 2005, J CLIN NEUROSCI, V12, P680, DOI 10.1016/j.jocn.2005.05.004; Chen S, 2005, IMMUNOLOGY, V114, P565, DOI 10.1111/j.1365-2567.2004.02110.x; De Simone R, 2004, MOL NEUROBIOL, V29, P197, DOI 10.1385/MN:29:2:197; EHRHARD PB, 1993, P NATL ACAD SCI USA, V90, P5423, DOI 10.1073/pnas.90.12.5423; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Felszeghy K, 2004, NEUROIMMUNOMODULAT, V11, P404, DOI 10.1159/000080151; FIGDOR CG, 1983, CELL BIOPHYS, V5, P105, DOI 10.1007/BF02796137; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Garaci E, 1999, P NATL ACAD SCI USA, V96, P14013, DOI 10.1073/pnas.96.24.14013; Garcia-Suarez O, 1998, IMMUNOLOGY, V94, P235, DOI 10.1046/j.1365-2567.1998.00505.x; Goerdt S, 1999, PATHOBIOLOGY, V67, P222, DOI 10.1159/000028096; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grundy PL, 2000, NEUROREPORT, V11, P3381, DOI 10.1097/00001756-200010200-00023; Grundy PL, 2001, BRAIN RES, V892, P386, DOI 10.1016/S0006-8993(00)03258-3; Hattori K, 2003, LEUKEMIA LYMPHOMA, V44, P575, DOI 10.1080/1042819021000037985; Hess DC, 2004, EXP NEUROL, V186, P134, DOI 10.1016/j.expneurol.2003.11.005; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; HOLLOWELL JP, 1990, EXP NEUROL, V110, P45, DOI 10.1016/0014-4886(90)90050-3; JOHNSON JE, 1986, J NEUROSCI, V6, P3031; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; Kayali AG, 2003, J CELL BIOL, V163, P859, DOI 10.1083/jcb.200304153; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; Kobayashi H, 2001, NEUROSCI LETT, V305, P157, DOI 10.1016/S0304-3940(01)01854-7; Kristiansen M, 2001, NATURE, V409, P198, DOI 10.1038/35051594; la Sala A, 2000, J LEUKOCYTE BIOL, V68, P104; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LAURENZI MA, 1994, EUR J BIOCHEM, V223, P733, DOI 10.1111/j.1432-1033.1994.tb19047.x; Lazarini F, 2003, GLIA, V42, P139, DOI 10.1002/glia.10139; LEVIMONTALCINI R, 1960, P NATL ACAD SCI USA, V46, P384, DOI 10.1073/pnas.46.3.384; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; LINDSAY RM, 1989, NATURE, V337, P362, DOI 10.1038/337362a0; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Montaner LJ, 1999, J IMMUNOL, V162, P4606; Morrissette Naomi, 1999, Trends in Cell Biology, V9, P199, DOI 10.1016/S0962-8924(99)01540-8; MUES B, 1989, IMMUNOLOGY, V67, P303; Nakajima K, 1998, GLIA, V24, P272, DOI 10.1002/(SICI)1098-1136(199811)24:3<272::AID-GLIA2>3.0.CO;2-4; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; Perez-Perez M, 1999, CELL TISSUE RES, V298, P75, DOI 10.1007/s004419900089; Porcheray F, 2005, CLIN EXP IMMUNOL, V142, P481, DOI 10.1111/j.1365-2249.2005.02934.x; Porcheray F, 2006, AM J PHYSIOL-CELL PH, V291, pC618, DOI 10.1152/ajpcell.00021.2006; Porcheray F, 2006, VIROLOGY, V349, P112, DOI 10.1016/j.virol.2006.02.031; Ricci A, 2004, AM J RESP CELL MOL, V30, P12, DOI 10.1165/rcmb.2002-0110OC; Rozen S, 2000, Methods Mol Biol, V132, P365; Schebesch C, 1997, IMMUNOLOGY, V92, P478, DOI 10.1046/j.1365-2567.1997.00371.x; Shamovsky IL, 1999, PROTEIN SCI, V8, P2223; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Susaki Y, 1996, BLOOD, V88, P4630, DOI 10.1182/blood.V88.12.4630.bloodjournal88124630; Tham TN, 2001, EUR J NEUROSCI, V13, P845, DOI 10.1046/j.0953-816x.2000.01451.x; THORPE LW, 1987, J NEUROSCI RES, V18, P134, DOI 10.1002/jnr.490180120; UNANUE ER, 1987, HOSP PRACT, V22, P87, DOI 10.1080/21548331.1987.11707695; UNANUE ER, 1987, HOSP PRACT OFF, V22, P102; Vega JA, 2003, J ANAT, V203, P1, DOI 10.1046/j.1469-7580.2003.00203.x; Yang JT, 2005, EXP NEUROL, V192, P437, DOI 10.1016/j.expneurol.2004.12.023; Yang JT, 1998, NEUROREPORT, V9, P3477, DOI 10.1097/00001756-199810260-00026; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	75	34	35	0	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0009-9104			CLIN EXP IMMUNOL	Clin. Exp. Immunol.	MAR	2008	151	3					476	486		10.1111/j.1365-2249.2007.03578.x			11	Immunology	Immunology	256EW	WOS:000252711500014	18190610	Green Published			2021-06-18	
J	Brown, R; Thompson, HJ; Imran, SA; Ur, E; Wilkinson, M				Brown, Russell; Thompson, Hilaire J.; Imran, Syed A.; Ur, Ehud; Wilkinson, Michael			Traumatic brain injury induces adipokine gene expression in rat brain	NEUROSCIENCE LETTERS			English	Article						leptin resistin; fasting-induced adipose factor (FIAF); inflammation; lipopolysaccharide (LPS); hypothalamus; cortex	FLUID-PERCUSSION; IN-VITRO; EXPERIMENTAL-MODELS; LEPTIN; ISCHEMIA; CELLS; ANGIOGENESIS; RESISTIN; MOUSE; VIVO	Traumatic brain injury (TBI) induces cachexia and neuroinflammation which profoundly impact patient recovery. Adipokine genes such as leptin (ob), resistin (rstn) and fasting-induced adipose factor (fiaf) are implicated in energy metabolism and body weight control and are also associated with chronic low grade inflammation. Since central rstn and fiaf expression was increased following hypoxic/ischemic brain injury, we hypothesized that these genes would also be induced in the rat brain following TB1. Realtime RT-PCR detected a 2-2.5-fold increase in ob mRNA in the ipsilateral cortex and thalamus 12h following lateral fluid percussion (FP)-induced brain injury. Fiaf mRNA was elevated 5-7.5-fold in cortex, hippocampus and thalamus, and modest increases were also detectable in the contralateral brain. Remarkably, rstn mRNA was elevated in ipsilateral (150-fold) and in contralateral (50-fold) hippocampus. To test whether these changes were part of an inflammatory response to TBI we also examined the effects of an intracerebral injection of lipopolysaccharide (LPS). We determined that central injection of LPS produced some, but not all, of the changes seen after TBI. For example, in contrast to the stimulatory influence of TBI, LPS had no effect on ob expression in any brain region, though fiaf and rstn mRNA levels were significantly elevated in both ipsi- and contralateral cortex. In conclusion: (a) brain-derived adipokines could be involved in the acute pathology of traumatic brain injury partly through modulation of central inflammatory responses, but also via leptin-mediated neuroprotective effects and (b) TBI-induced brain adipokines may induce the metabolic changes observed following neurotrauma. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Brown, Russell; Imran, Syed A.; Ur, Ehud; Wilkinson, Michael] Dalhousie Univ, Dept Obstet & Gynaecol, IWK Hlth Ctr, Halifax, NS B3K 6R8, Canada; [Brown, Russell; Wilkinson, Michael] Dalhousie Univ, Dept Physiol & Biophys, Halifax, NS, Canada; [Imran, Syed A.; Ur, Ehud; Wilkinson, Michael] Dalhousie Univ, Fac Med, Div Endocrinol & Metab, Halifax, NS, Canada; [Thompson, Hilaire J.] Univ Washington, Dept Biobehav Nursing & Hlth Syst, Seattle, WA 98195 USA	Wilkinson, M (corresponding author), Dalhousie Univ, Dept Obstet & Gynaecol, IWK Hlth Ctr, Univ Ave,POB 9700, Halifax, NS B3K 6R8, Canada.	mwilk@dal.ca			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR007694, T32NR007106] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [L30 DC008284-01, L30 DC008284] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32 NS043126, T32 NS043126-01A1, T32-NS043126] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31 NR007694, T32-NR007106, T32 NR007106, T32 NR007106-07] Funding Source: Medline		Ahima RS, 2006, PROG BRAIN RES, V153, P155, DOI 10.1016/S0079-6123(06)53009-2; Ahima RS, 1999, ENDOCRINOLOGY, V140, P2755, DOI 10.1210/en.140.6.2755; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Bond BC, 2002, MOL BRAIN RES, V106, P101, DOI 10.1016/S0169-328X(02)00417-5; Brown R, 2005, MOL BRAIN RES, V139, P357, DOI 10.1016/j.molbrainres.2005.05.009; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Dicou E, 2001, NEUROREPORT, V12, P3947, DOI 10.1097/00001756-200112210-00019; Emery DL, 2000, J COMP NEUROL, V424, P521; Grosfeld A, 2002, J BIOL CHEM, V277, P42953, DOI 10.1074/jbc.M206775200; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Koster A, 2005, ENDOCRINOLOGY, V146, P4943, DOI 10.1210/en.2005-0476; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Lu SC, 2002, FEBS LETT, V530, P158, DOI 10.1016/S0014-5793(02)03450-6; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moinard C, 2005, INTENS CARE MED, V31, P281, DOI 10.1007/s00134-004-2489-9; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Nag S, 2002, TRENDS MOL MED, V8, P38, DOI 10.1016/S1471-4914(01)02221-3; Paradis E, 2003, J BIOL CHEM, V278, P9698, DOI 10.1074/jbc.M208452200; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Russo VC, 2004, ENDOCRINOLOGY, V145, P4103, DOI 10.1210/en.2003-1767; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; Wiesner G, 2006, NEUROREPORT, V17, P1195, DOI 10.1097/01.wnr.0000224776.12647.ba; Wilkinson M, 2007, NEUROENDOCRINOLOGY, V86, P191, DOI 10.1159/000108635; ZHANG F, 2006, NEUR M PLANN ATL GA	29	34	41	0	4	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 13	2008	432	1					73	78		10.1016/j.neulet.2007.12.008			6	Neurosciences	Neurosciences & Neurology	271RY	WOS:000253807600015	18178314	Green Accepted			2021-06-18	
J	Butt, MF; Dhar, SA; ul Gani, N; Farooq, M; Mir, MR; Halwai, MA; Kangu, KA; Mir, BA; Kawoosa, AA				Butt, Mohammad Farooq; Dhar, Shabir A.; ul Gani, Naseem; Farooq, Munir; Mir, M. R.; Halwai, M. A.; Kangu, K. A.; Mir, B. A.; Kawoosa, A. A.			Delayed fixation of displaced femoral neck fractures in younger adults	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						fracture neck of femur; delayed fixation; avascular necrosis; non-union	INTERNAL-FIXATION; INTRACAPSULAR FRACTURES; HEAD; NECROSIS; REDUCTION; FEMUR; AGES; HIP	We report the results of 52 patients aged 20-55 years with displaced femoral neck fractures, in whom delayed closed reduction and internal fixation was performed. Seven patients developed avascular necrosis (AVN) and non-union was seen in five patients. Whereas most patients with non-union were subjected to repeat procedures, none of the patients with AVN required surgery. The follow-up averaged 40 months (range 22-64 months). Three patients were lost to follow-up. Functional outcome was defined by Judet's system. Good to excellent functional outcome was achieved in 45 cases. The study demonstrated that delayed closed reduction and internal fixation of displaced fractures in young adults which, we believe, is the prevalent form of treatment of these injuries in the developing world results in high rate of fracture union and good functional outcome. The rate of AVN, however, may be a concern if the patients are followed for a longer period. (c) 2007 Elsevier Ltd. All rights reserved.	[Butt, Mohammad Farooq; Dhar, Shabir A.; ul Gani, Naseem; Farooq, Munir; Mir, M. R.; Halwai, M. A.; Kangu, K. A.; Mir, B. A.; Kawoosa, A. A.] Govt Hosp Bone & Joint Surg, Srinagar 190005, Jammu & Kashmir, India	Butt, MF (corresponding author), Govt Hosp Bone & Joint Surg, Srinagar 190005, Jammu & Kashmir, India.	mfbutt72@yahoo.co.in		Ahmad Kawoosa, Altaf/0000-0002-1092-9775			ARNOLDI CC, 1972, CLIN ORTHOP RELAT R, P116; ARNOLDI CC, 1977, CLIN ORTHOP RELAT R, P217; ASNIS SE, 1994, J BONE JOINT SURG AM, V76A, P1793, DOI 10.2106/00004623-199412000-00005; BRAY TJ, 1988, CLIN ORTHOP RELAT R, P127; CLAFFEY TJ, 1960, J BONE JOINT SURG BR, V42, P802; DRAKE JK, 1984, CLIN ORTHOP RELAT R, P172; FICAT RP, 1985, J BONE JOINT SURG BR, V67, P3; GARDEN R S, 1971, Journal of Bone and Joint Surgery British Volume, V53, P183; Haidukewych GJ, 2004, J BONE JOINT SURG AM, V86A, P1711, DOI 10.2106/00004623-200408000-00015; Jain R, 2002, J BONE JOINT SURG AM, V84A, P1605, DOI 10.2106/00004623-200209000-00013; Jakob M, 1999, Swiss Surg, V5, P257, DOI 10.1024/1023-9332.5.6.257; LINDEQUIST S, 1995, J ORTHOP TRAUMA, V9, P215, DOI 10.1097/00005131-199506000-00006; LUYAO GL, 1994, J BONE JOINT SURG AM, V76A, P15, DOI 10.2106/00004623-199401000-00003; MANNINGER J, 1989, INJURY, V20, P101, DOI 10.1016/0020-1383(89)90152-6; PARKER MJ, 1992, J BONE JOINT SURG BR, V74, P203; PROTZMAN RR, 1976, J BONE JOINT SURG AM, V58, P689, DOI 10.2106/00004623-197658050-00020; STINCHFIELD FE, 1957, J BONE JOINT SURG AM, V39, P1043, DOI 10.2106/00004623-195739050-00005; SWIONTKOWSKI MF, 1994, J BONE JOINT SURG AM, V76A, P129, DOI 10.2106/00004623-199401000-00019; SWIONTKOWSKI MF, 1987, J ORTHOPAED RES, V5, P433, DOI 10.1002/jor.1100050316; SWIONTKOWSKI MF, 1984, J BONE JOINT SURG AM, V66A, P837, DOI 10.2106/00004623-198466060-00003; SWIONTKOWSKI MF, 1993, ACTA ORTHOP SCAND, V64, P196, DOI 10.3109/17453679308994570; Upadhyay A, 2004, J BONE JOINT SURG BR, V86B, P1035, DOI 10.1302/0301-620X.86B7.15047; Whitman R., 1933, AM J SURG, V21, P335; ZETTERBERG CH, 1982, ACTA ORTHOP SCAND, V53, P427, DOI 10.3109/17453678208992237	24	34	39	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	FEB	2008	39	2					238	243		10.1016/j.injury.2007.09.002			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	268UV	WOS:000253606200015	18241865				2021-06-18	
J	Chang, PFJ; Ostir, GV; Kuo, YF; Granger, CV; Ottenbacher, KJ				Chang, Pei-Fen J.; Ostir, Glenn V.; Kuo, Yong-Fang; Granger, Carl V.; Ottenbacher, Kenneth J.			Ethnic differences in discharge destination among older patients with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						elderly; ethnic groups; head injuries; rehabilitation	FUNCTIONAL INDEPENDENCE MEASURE; REHABILITATION OUTCOMES; RELIABILITY; IMPACT	Objective: To estimate the association between ethnicity and discharge destination in older patients with traumatic brain injury (TBI). Design: A retrospective analysis. Setting: Nationally representative sample of older patients from the Uniform Data System for Medical Rehabilitation in 2002 and 2003. Participants: Patients (N=9240) aged 65 years or older who received inpatient rehabilitation services for TBI. Interventions: Not applicable. Main Outcome Measures: Discharge destination (home, assisted living facility, institution) and ethnicity (white, black, Hispanic). Results: Multinomial logit models showed that older Hispanics (odds ratio [OR]=2.24; 95% confidence interval [CI], 1.66-3.02) and older blacks (OR=2; 95% CI, 1.55-2.59) with TBI were significantly more likely to be discharged. home than older whites with TBI, after adjusting for relevant risk factors. Older blacks were also 78% less likely (OR=.22; 95% CI, .08-.60) to be discharged to an assisted living facility than whites after adjusting for relevant risk factors. Conclusions: Our findings indicate that older minority patients with TBI were significantly more likely to be discharged home than white patients with TBI. Studies are needed to investigate underlying factors associated with this ethnic difference.	[Chang, Pei-Fen J.; Ottenbacher, Kenneth J.] Univ Texas Galveston, Med Branch, Div Rehabil Sci, Galveston, TX 77555 USA; [Ostir, Glenn V.; Kuo, Yong-Fang] Univ Texas Galveston, Med Branch, Sealy Ctr Aging, Galveston, TX 77555 USA; [Ostir, Glenn V.] Univ Texas Galveston, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Granger, Carl V.] SUNY Buffalo, Dept Rehabil Med, Buffalo, NY USA	Chang, PFJ (corresponding author), Univ Texas Galveston, Med Branch, Div Rehabil Sci, 301 Univ Blvd, Galveston, TX 77555 USA.	pjchang@utmb.edu		Ottenbacher, Kenneth/0000-0001-5990-3982	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG024806-04, R01-AG024806, R01 AG031178, R01 AG031178-02, K02-AG019736, K02 AG019736-05, K02 AG019736, R01 AG024806] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01 HD046682, K01 HD046682-04, K01-HD046682] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD046682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031178, K02AG019736, R01AG024806] Funding Source: NIH RePORTER		*AM ASS RET PERS, PROTR OLD MIN; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Bottemiller KL, 2006, REHABIL NURS, V31, P22, DOI 10.1002/j.2048-7940.2006.tb00006.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; CARTER GM, 1997, PROSPECTIVE PAYMENT; Center for Disease Control and Prevention, NAT CTR INJ PREV CON; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Cruise CM, 2006, CLIN GERIATR MED, V22, P257, DOI 10.1016/j.cger.2005.12.015; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Flanagan SR, 2006, CLIN GERIATR MED, V22, P449, DOI 10.1016/j.cger.2005.12.011; Foster M, 2000, BRAIN INJURY, V14, P1035; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lutz Barbara J, 2004, Rehabil Nurs, V29, P154; Mauthe RW, 1996, ARCH PHYS MED REHAB, V77, P10, DOI 10.1016/S0003-9993(96)90212-9; Neufeld Stewart W, 2004, Home Health Care Serv Q, V23, P29, DOI 10.1300/J027v23n04_03; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PAZ JJ, 1993, SUPPORT HISPANIC ELD, P177; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Roush C V, 2000, Home Healthc Nurse, V18, P388, DOI 10.1097/00004045-200006000-00015; Swenson M M, 1998, Health Care Women Int, V19, P381; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Unsworth C, 1996, AM J OCCUP THER, V50, P207, DOI 10.5014/ajot.50.3.207; van Boxel YJ, 1996, J REHABIL SCI, V9, P11; Williams A, 2003, HEALTH ECON, V12, P65, DOI 10.1002/hec.778; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	34	34	34	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2008	89	2					231	236		10.1016/j.apmr.2007.08.143			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	260OD	WOS:000253018700005	18226645	Green Accepted			2021-06-18	
J	Matsuoka, Y; Nishi, D; Nakajima, S; Kim, Y; Homma, M; Otomo, Y				Matsuoka, Yutaka; Nishi, Daisuke; Nakajima, Satomi; Kim, Yoshiharu; Homma, Masato; Otomo, Yasuhiro			Incidence and prediction of psychiatric morbidity after a motor vehicle accident in Japan: The Tachikawa Cohort of Motor Vehicle Accident Study	CRITICAL CARE MEDICINE			English	Article						accidents; injury; critical care; depression; post-traumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; TRAUMATIC BRAIN-INJURY; HEART-RATE; FOLLOW-UP; EMERGENCY-DEPARTMENT; MAJOR TRAUMA; RISK-FACTORS; VICTIMS; SCALE	Objectives: To assess both the incidence of new-onset psychiatric illness after involvement in a motor vehicle accident in Japan for comparison with Western data and the predictors of psychiatric morbidity and posttraumatic stress disorder (PTSD) evaluated immediately after the accident. Design, Prospective cohort study of injured patients assessed immediately and 4-6 wks after involvement in a motor vehicle accident. Setting. Intensive care unit in a teaching hospital in Tokyo, Japan. Patients. Total of 100 consecutive patients with motor vehicle accident-related injuries (mean Injury Severity Score, 11.2; mean Glasgow Coma Scale, 14.5; age, 18-69 yrs) admitted to the intensive care unit. Patients with traumatic brain injury, suicidality, current psychiatric or neurologic illness, or cognitive impairment were excluded. Measurements. An extensive clinical interview and evaluation of vital signs, sociodemographic variables, previous traumatic events, family history of psychopathology, Impact of Event Scale-Revised, Hospital Anxiety and Depression Scale, Clinician-Administered PTSD Scale, and Mini-International Neuropsychiatric Interview. Results: A total of 31 patients showed some form of new-onset psychiatric illness at the 4- to 1 follow-up. The majority of illnesses consisted of depression (major depression, n = 16; minor depression, n = 7) and PTSD (full PTSD, n = 8; partial PTSD, n 16). Other illnesses included alcohol dependence (n 3), obsessive-compulsive disorder (n = 2), agoraphobia (n = 2), and social phobia (n = 1). Both psychiatric morbidity and PTSD were predicted by a sense of life threat (odds ratio, 4.2 and 6.2, respectively), elevated heart rate (odds ratio, 1.6 and 1.7), and higher Impact of Event Scale-Revised intrusion subscale score (odds ratio, 1.1 and 1.1). Conclusion: This study showed that psychopathology and PTSD after a motor vehicle accident in Japan is common and that the incidence is within the range of that in Western countries. A combination of a sense of life threat, heart rate, and Impact of Event Scale-Revised intrusion subscale allowed for significant prediction of psychiatric morbidity and PTSD.	[Matsuoka, Yutaka; Nishi, Daisuke; Nakajima, Satomi; Kim, Yoshiharu] NIMH, Div Adult Mental Hlth, Natl Ctr Neurol & Psychiat, Tokyo, Japan; [Homma, Masato] Natl Disaster Med Ctr, Dept Crit Care & Traumatol, Tokyo, Japan; [Otomo, Yasuhiro] Tokyo Med & Dent Univ, Dept Acute Crit Care & Disaster Med, Tokyo, Japan	Matsuoka, Y (corresponding author), NIMH, Div Adult Mental Hlth, Natl Ctr Neurol & Psychiat, Tokyo, Japan.	yutaka@ncnp.go.jp	Matsuoka, Yutaka/D-1171-2011; Nishi, Daisuke/AAH-7211-2019; Matsuoka, Yutaka/N-1588-2019	Nishi, Daisuke/0000-0001-9349-3294; Matsuoka, Yutaka/0000-0002-8690-8129			American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Asukai N, 2002, J NERV MENT DIS, V190, P175, DOI 10.1097/00005053-200203000-00006; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 2004, PSYCHOSOM MED, V66, P760, DOI 10.1097/01.psy.0000138121.13198.84; Bryant RA, 2006, ANN NY ACAD SCI, V1071, P19, DOI 10.1196/annals.1364.002; Buckley B, 2004, J TRAUMA STRESS, V17, P317, DOI 10.1023/B:JOTS.0000038480.87290.4a; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Kassam-Adams N, 2005, ARCH GEN PSYCHIAT, V62, P335, DOI 10.1001/archpsyc.62.3.335; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Koren D, 1999, AM J PSYCHIAT, V156, P367; KRAEMER B, 2007, J PSYCHIAT RES; Kugaya A, 1998, JPN J CLIN ONCOL, V28, P333, DOI 10.1093/jjco/28.5.333; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mason S, 2002, EMERG MED J, V19, P400, DOI 10.1136/emj.19.5.400; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; Mayou R, 2001, AM J PSYCHIAT, V158, P1231, DOI 10.1176/appi.ajp.158.8.1231; MAYOU R, 1991, INJURY, V22, P365, DOI 10.1016/0020-1383(91)90095-V; Mellman TA, 2001, DEPRESS ANXIETY, V14, P226, DOI 10.1002/da.1071; Mori E., 1985, JPN J NEUROPSYCHOL, V1, P82; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nishi D, 2006, EMERG MED J, V23, P468, DOI 10.1136/emj.2005.029769; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Otsubo T, 2005, PSYCHIAT CLIN NEUROS, V59, P517, DOI 10.1111/j.1440-1819.2005.01408.x; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Schnyder U, 2000, CRIT CARE MED, V28, P86, DOI 10.1097/00003246-200001000-00014; Schnyder U, 2003, AM J PSYCHIAT, V160, P2025, DOI 10.1176/appi.ajp.160.11.2025; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Schnyder U, 2001, AM J RESP CRIT CARE, V164, P653, DOI 10.1164/ajrccm.164.4.2008087; SCHNYDER U, 2007, IN PRESS PSYCHOTHER; Seekamp A, 1996, INJURY, V27, P133, DOI 10.1016/0020-1383(95)00178-6; Shalev AY, 2005, AM J PSYCHIAT, V162, P1188, DOI 10.1176/appi.ajp.162.6.1188; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Simon GE, 2002, PSYCHOL MED, V32, P585, DOI 10.1017/S0033291702005457; STRAIN JJ, 1991, AM J PSYCHIAT, V148, P1044; TEASDALE G, 1974, LANCET, V2, P81; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Vaiva G, 2004, BIOL PSYCHIAT, V55, P250, DOI 10.1016/j.biopsych.2003.08.009; Vaiva G, 2003, BIOL PSYCHIAT, V54, P947, DOI 10.1016/S0006-3223(03)00412-8; Weiss Daniel S., 1997, P399; Wu KK, 2006, J TRAUMA STRESS, V19, P923, DOI 10.1002/jts.20178; Zatzick DF, 2005, BIOL PSYCHIAT, V57, P91, DOI 10.1016/j.biopsych.2004.10.005; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	57	34	36	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JAN	2008	36	1					74	80		10.1097/01.CCM.0000291650.70816.D6			7	Critical Care Medicine	General & Internal Medicine	291YA	WOS:000255232100010	18090377				2021-06-18	
J	Pekkala, S; Albert, ML; Spiro, A; Erkinjuntti, T				Pekkala, S.; Albert, M. L.; Spiro, A., III; Erkinjuntti, T.			Perseveration in Alzheimer's disease	DEMENTIA AND GERIATRIC COGNITIVE DISORDERS			English	Article						recurrent perseveration; stuck-in-set perseveration; continuous perseveration; semantic verbal fluency task; Alzheimer's disease	TRAUMATIC BRAIN INJURY; HUNTINGTONS-DISEASE; VASCULAR DEMENTIA; CATEGORY FLUENCY; WORKING-MEMORY; VERBAL FLUENCY; FRONTAL LOBES; APHASIA; VARIETIES; RETRIEVAL	Background/Aims and Methods: Perseveration is common in Alzheimer's disease (AD). We document the type and quantitative burden of perseveration as cognitive decline progresses from normal aging (n = 30) through mild AD (n = 20) to moderate AD (n = 20) by administering a semantic verbal fluency task. Results: We found perseveration to increase significantly with increasing severity of AD and different types of perseveration that distinguish the subject groups in a statistically significant manner. Recurrent and continuous perseverations appear early in AD. As the disease progresses in severity into moderate stage, the number of recurrent and continuous perseverations increases, and stuck-in-set perseverations emerge. Conclusion: The different types of perseveration are likely to reflect the progressive deterioration of different brain regions in AD. Copyright (C) 2007 S. Karger AG, Basel.	[Pekkala, S.; Albert, M. L.] VA Boston Healthcare Syst, Language Aging Brain Lab, Med Res Serv, Boston, MA 02130 USA; [Pekkala, S.] Univ Helsinki, Dept Speech Sci, Helsinki, Finland; [Erkinjuntti, T.] Univ Helsinki, Dept Neurol, Helsinki, Finland; [Spiro, A., III] VA Boston Healthcare Syst, Normat Aging Study, Boston, MA 02130 USA; [Albert, M. L.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Spiro, A., III] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA	Pekkala, S (corresponding author), VA Boston Healthcare Syst, Language Aging Brain Lab, Med Res Serv, 12D,Room 91,150 S Huntington Ave, Boston, MA 02130 USA.	seija.pekkala@helsinki.fi		Spiro III, Avron/0000-0003-4080-8621; Pekkala, Seija/0000-0003-2849-974X	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG 14345] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG014345] Funding Source: NIH RePORTER		ALBERT ML, 1986, CORTEX, V22, P103, DOI 10.1016/S0010-9452(86)80035-1; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; Azuma T, 2004, NEUROPSYCHOLOGY, V18, P69, DOI 10.1037/0894-4105.18.1.69; BARR WB, 1989, J COMMUN DISORD, V22, P327, DOI 10.1016/0021-9924(89)90009-9; BAYLES KA, 1993, J CLIN EXP NEUROPSYC, V15, P547, DOI 10.1080/01688639308402578; Beatty WW, 1997, AGING NEUROPSYCHOL C, V4, P273, DOI 10.1080/13825589708256652; BUCKINGHAM HW, 1979, STUDIES NEUROLINGUIS, V4, P329; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Demery JA, 2002, J CLIN EXP NEUROPSYC, V24, P818, DOI 10.1076/jcen.24.6.818.8400; Foldi NS, 2003, AGING NEUROPSYCHOL C, V10, P268, DOI 10.1076/anec.10.4.268.28970; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLDBERG E, 1986, J CLIN EXP NEUROPSYC, V8, P710, DOI 10.1080/01688638608405191; Goldberg E, 2001, EXECUTIVE BRAIN FRON; GOLDBERG E, 1978, J CLIN NEUROPSYCHOL, V4, P273; HELMESTABROOKS N, 1994, BRAIN LANG, V47, P457; HOTZ G, 1995, BRAIN INJURY, V9, P151, DOI 10.3109/02699059509008188; HUDSON AJ, 1968, BRAIN, V91, P571, DOI 10.1093/brain/91.3.571; Lamar M, 1997, NEUROPSYCHOLOGY, V11, P523, DOI 10.1037/0894-4105.11.4.523; LURIA AR, 1965, BRAIN, V88, P1, DOI 10.1093/brain/88.1.1; Marczinski CA, 2006, BRAIN LANG, V97, P258, DOI 10.1016/j.bandl.2005.11.001; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Paulesu E, 1997, NEUROREPORT, V8, P2011, DOI 10.1097/00001756-199705260-00042; Possin KL, 2005, J CLIN EXP NEUROPSYC, V27, P953, DOI 10.1080/13803390490919092; Ramage A, 1999, BRAIN LANG, V66, P329, DOI 10.1006/brln.1999.2032; REISBERG B, 1982, AM J PSYCHIAT, V139, P1136; Rosen VM, 1997, J EXP PSYCHOL GEN, V126, P211, DOI 10.1037/0096-3445.126.3.211; ROSSER A, 1994, J NEUROL NEUROSUR PS, V57, P1389, DOI 10.1136/jnnp.57.11.1389; SANDSON J, 1984, NEUROPSYCHOLOGIA, V22, P715, DOI 10.1016/0028-3932(84)90098-8; SANDSON J, 1987, NEUROLOGY, V37, P1736, DOI 10.1212/WNL.37.11.1736; SHINDLER AG, 1984, BRAIN LANG, V23, P148, DOI 10.1016/0093-934X(84)90013-0; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Suhr JA, 1998, ARCH CLIN NEUROPSYCH, V13, P447, DOI 10.1016/S0887-6177(97)00040-1; Traykov L, 2005, J NEUROL SCI, V229, P75, DOI 10.1016/j.jns.2004.11.006; TROSTER AI, 1989, BRAIN LANG, V37, P500, DOI 10.1016/0093-934X(89)90032-1; VILKKI J, 1989, BRAIN LANG, V36, P543, DOI 10.1016/0093-934X(89)90085-0; Ylikoski R, 2000, RELATIONSHIP NEUROPS	37	34	34	0	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1420-8008	1421-9824		DEMENT GERIATR COGN	Dement. Geriatr. Cogn. Disord.		2008	25	2					109	114		10.1159/000112476			6	Geriatrics & Gerontology; Clinical Neurology; Psychiatry	Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry	254MW	WOS:000252591700003	18075249				2021-06-18	
J	Shintani, A; Nakao, N; Kakishita, K; Itakura, T				Shintani, Aki; Nakao, Naoyuki; Kakishita, Koji; Itakura, Toru			Protection of dopamine neurons by bone marrow stromal cells	BRAIN RESEARCH			English	Article						neurotrophic factor; dopamine neuron; cell therapy	TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVAL; PARKINSONS-DISEASE; RAT MODEL; NEUROTROPHIC FACTOR; MESENCEPHALIC TISSUE; FUNCTIONAL RECOVERY; LAZAROIDS IMPROVE; STEM-CELLS; ADULT RATS	Transplantation of bone marrow stromal cells (BMSC) has recently been demonstrated to provide neuroprotection in animal models of brain injuries such as ischemia and trauma. The present study was undertaken to explore whether BMSC can promote the survival of dopamine (DA) neurons in neuronal insult models in vitro. We also examined whether BMSC can increase the survival rate of embryonic DA neurons grafted into the striatum of a rat model of Parkinson's disease (PD). Treatment with conditioned media derived from BMSC cultures was found to significantly prevent the death of DA neurons in in vitro cell injury models such as serum deprivation and exposure to the neurotoxin 6-OHDA. In a transplantation study, we also found that the survival of grafted DA cells was significantly enhanced by treating donor cells with the conditioned media at the steps of both cell dissociation and implantation. The results suggest that BMSC may secrete diffusible factors able to protect DA neurons against neuronal injuries. Indeed, BMSC expressed mRNA encoding brain-derived neurotrophic factor, fibroblast growth factor-2 and glial cell line-derived neurotrophic factor, all of which have previously been shown to exhibit potent neurotrophic effects on DA cells. Enzyme-linked immunosorbent assay revealed that the cells release these growth factors into culture media. The present data indicate that BMSC may be a potential donor source of cell-based regenerative therapy for PD where the progressive loss of the midbrain DA neurons takes place. (c) 2007 Elsevier B.V. All rights reserved.	[Shintani, Aki; Nakao, Naoyuki; Kakishita, Koji; Itakura, Toru] Wakayama Med Univ, Dept Neurol Surg, Wakayama 6410012, Japan	Nakao, N (corresponding author), Wakayama Med Univ, Dept Neurol Surg, Wakayama 6410012, Japan.	nnakao@wakayama-med.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [19591697] Funding Source: KAKEN		ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Bjorklund A, 1997, NEUROBIOL DIS, V4, P186, DOI 10.1006/nbdi.1997.0151; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Brundin P, 2000, BRAIN, V123, P1380, DOI 10.1093/brain/123.7.1380; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2002, J NEUROL SCI, V199, P17, DOI 10.1016/S0022-510X(02)00075-8; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FREEMAN TB, 1995, ANN NEUROL, V38, P379, DOI 10.1002/ana.410380307; FRODL EM, 1994, NEUROREPORT, V5, P2393, DOI 10.1097/00001756-199411000-00045; Hagell P, 1999, BRAIN, V122, P1121, DOI 10.1093/brain/122.6.1121; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Horwitz EM, 2002, P NATL ACAD SCI USA, V99, P8932, DOI 10.1073/pnas.132252399; Horwitz EM, 2001, BLOOD, V97, P1227, DOI 10.1182/blood.V97.5.1227; HYMAN C, 1994, J NEUROSCI, V14, P335; HYMAN C, 1991, NATURE, V350, P230, DOI 10.1038/350230a0; Kakishita K, 2003, BRAIN RES, V980, P48, DOI 10.1016/S0006-8993(03)02875-0; Kinnaird T, 2004, CIRC RES, V95, P354, DOI 10.1161/01.RES.0000137878.26174.66; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Kordower JH, 1996, J COMP NEUROL, V370, P203; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; LINDVALL O, 1994, ANN NEUROL, V35, P172, DOI 10.1002/ana.410350208; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; MAYER E, 1993, NEUROSCIENCE, V56, P379, DOI 10.1016/0306-4522(93)90339-H; McKay BS, 2006, EXP NEUROL, V201, P234, DOI 10.1016/j.expneurol.2006.04.016; Nakao N, 1998, J NEUROSCI, V18, P1806; Nakao N, 2004, EXP NEUROL, V188, P65, DOI 10.1016/j.expneurol.2004.03.004; NAKAO N, 1995, NAT MED, V1, P226, DOI 10.1038/nm0395-226; Nakao N, 1997, BRAIN RES, V777, P202, DOI 10.1016/S0006-8993(97)01116-5; Nakao N, 2000, J NEUROSURG, V92, P659, DOI 10.3171/jns.2000.92.4.0659; NAKAO N, 1994, P NATL ACAD SCI USA, V91, P12408, DOI 10.1073/pnas.91.26.12408; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; OTTO D, 1993, J NEUROSCI RES, V34, P382, DOI 10.1002/jnr.490340403; PESCHANSKI M, 1994, BRAIN, V117, P487, DOI 10.1093/brain/117.3.487; Pittenger MF, 2004, CIRC RES, V95, P9, DOI 10.1161/01.RES.0000135902.99383.6f; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Rosenzweig A, 2006, NEW ENGL J MED, V355, P1274, DOI 10.1056/NEJMe068172; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Toledo-Aral JJ, 2003, J NEUROSCI, V23, P141; UNGERSTEDT U, 1970, BRAIN RES, V24, P486; Villadiego J, 2005, J NEUROSCI, V25, P4091, DOI 10.1523/JNEUROSCI.4312-04.2005; Wenning GK, 1997, ANN NEUROL, V42, P95, DOI 10.1002/ana.410420115; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587	55	34	36	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 19	2007	1186						48	55		10.1016/j.brainres.2007.09.086			8	Neurosciences	Neurosciences & Neurology	249BJ	WOS:000252201500006	17996227				2021-06-18	
J	Allen, MD; Bigler, ED; Larsen, J; Goodrich-Hunsaker, NJ; Hopkins, RO				Allen, Mark D.; Bigler, Erin D.; Larsen, James; Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.			Functional neuroimaging evidence for high cognitive effort on the Word Memory Test in the absence of external incentives	BRAIN INJURY			English	Article						fMRI; word memory test; neuropsychological assessment; symptom validity testing; malingering	TRAUMATIC BRAIN-INJURY; INVOLVEMENT; RETRIEVAL; ATTENTION; ANTERIOR; TBI	Primary objective: This study presents data from a functional neuroimaging experiment which brings into question whether poor performance on the Word Memory Test (WMT) can be construed as straightforward evidence for 'poor effort' in the context of cognitive assessment, as asserted in a recent report in this journal. Methods and procedures: Functional magnetic resonance image (fMRI) data were acquired from four participants without brain injury who engaged in the delayed recognition (DR) portion of Green's WMT protocol. Outcomes and results: Compared to a simple perceptual identification control task, this study found a highly reliable activation pattern across all participants which was restricted almost exclusively to cortical areas most commonly associated with task difficulty, memory load, concentration and other forms of cognitive effort These areas include dorsolateral prefrontal cortex, anterior insula, superior parietal cortex and the dorsal anterior cingulate. Conclusions: These findings demonstrate that the WMT activates numerous cortical regions that are critical for cognitive effort. Given the extensive neural network necessary to perform the WMT, this study raises important questions about what WMT 'failure' truly means in patients with traumatic brain injury, who have increased likelihood of disruption within this neural network of vision, language, attention, effort and working memory.	[Allen, Mark D.; Bigler, Erin D.; Larsen, James; Hopkins, Ramona O.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Allen, Mark D.; Bigler, Erin D.; Goodrich-Hunsaker, Naomi J.; Hopkins, Ramona O.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Hopkins, Ramona O.] LDS Hosp, Dept Med, Div Pulm & Crit Care, Salt Lake City, UT USA	Allen, MD (corresponding author), Brigham Young Univ, Dept Psychol, 1022 SWKT, Provo, UT 84602 USA.	m_allen@byu.edu					Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Buckner RL, 1998, NEUROIMAGE, V7, P151, DOI 10.1006/nimg.1998.0327; Cowell RA, 2006, J NEUROSCI, V26, P12186, DOI 10.1523/JNEUROSCI.2818-06.2006; Dockree PM, 2006, BRAIN, V129, P128, DOI 10.1093/brain/awh664; Dockree PM, 2006, EXP BRAIN RES, V168, P218, DOI 10.1007/s00221-005-0079-x; Donders J, 2007, BRAIN INJURY, V21, P319, DOI 10.1080/02699050701253129; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Frederick RI, 2007, ASSESSMENT, V14, P3, DOI 10.1177/1073191106292009; Gorissen M, 2005, SCHIZOPHR RES, V78, P199, DOI 10.1016/j.schres.2005.02.016; GREEN P, 2003, MANUAL WORLD MEMORY; Green Paul, 2007, Phys Med Rehabil Clin N Am, V18, P43, DOI 10.1016/j.pmr.2006.11.002; Herrmann M, 2001, HUM BRAIN MAPP, V13, P94, DOI 10.1002/hbm.1027; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; OKEEFE FM, 2006, J INT NEUROPSYCH SOC, V13, P38; Ranganath C, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0005.2000; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sarter M, 2006, BRAIN RES REV, V51, P145, DOI 10.1016/j.brainresrev.2005.11.002; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245	21	34	34	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2007	21	13-14					1425	1428		10.1080/02699050701769819			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	253AA	WOS:000252488200011	18066945				2021-06-18	
J	Ballweg, JA; Wernovsky, G; Ittenbach, RF; Bernbaum, J; Gerdes, M; Gallagher, PR; Dominguez, TE; Zackai, E; Clancy, RR; Nicolson, SC; Spray, TL; Gaynor, JW				Ballweg, Jean A.; Wernovsky, Gil; Ittenbach, Richard F.; Bernbaum, Judy; Gerdes, Marsha; Gallagher, Paul R.; Dominguez, Troy E.; Zackai, Elaine; Clancy, Robert R.; Nicolson, Susan C.; Spray, Thomas L.; Gaynor, J. William			Hyperglycemia after infant cardiac surgery does not adversely impact neurodevelopmental outcome	ANNALS OF THORACIC SURGERY			English	Article; Proceedings Paper	43rd Annual Meeting of the Society-of-Thoracic-Surgeons	JAN 29-31, 2007	San Diego, CA	Soc Thorac Surg			ACUTE MYOCARDIAL-INFARCTION; HYPOTHERMIC CARDIOPULMONARY BYPASS; CIRCULATORY ARREST; HEART-SURGERY; STRESS HYPERGLYCEMIA; DIABETIC-PATIENTS; BLOOD-GLUCOSE; MORTALITY; CHILDREN; FLOW	Background. Hyperglycemia has been associated with worse outcome after traumatic brain injury and cardiac surgery in adults. It is not known whether postoperative hyperglycemia results in worse neurodevelopmental outcome after infant cardiac surgery. Methods. Secondary analysis of postoperative glucose levels was performed in infants younger than 6 months of age enrolled in a prospective study of genetic polymorphisms and neurodevelopmental outcomes who were undergoing repair of two- ventricle cardiac defects. Neurodevelopmental outcomes at 1 year of age were assessed with the Bayley Scales of Infant Development-II, yielding two indices: Mental Developmental Index and Psychomotor Developmental Index. Results. Surgical repair was performed in 247 infants with 1 in-hospital and 3 late deaths. Neurodevelopmental evaluation was performed in 188 of 243 (77%) survivors. Glucose levels at cardiac intensive care unit admission and during the first 48 postoperative hours were available for 180 of 188 patients. Mean admission glucose was 328 +/- 106 mg/ dL; maximum glucose was 340 +/- 109 mg/dL. At least one glucose was greater than 200 mg/dL in 160 of 180 patients, and 49 of 180 patients (27%) had a glucose greater than 400 mg/dL. Only 1 patient had a glucose less than 50 mg/dL. Female sex (p = 0.02), but no other patient or operative variable, was associated with higher glucose levels. Mean Mental Developmental Index and Psychomotor Developmental Index were 90.6 +/- 14.9 and 81.6 +/- 17.2, respectively. Hyperglycemia was not associated with lower Mental Developmental Index and Psychomotor Developmental Index scores for the entire cohort or for neonates alone. Conclusions. Hyperglycemia is common early after infant cardiac surgery, but is not associated with worse neurodevelopmental outcome at 1 year of age.	Childrens Hosp, Div Pediat Cardiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Gen Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Psychol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Genet, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Cardiothorac Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Cardiothorac Surg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Cardiac Ctr, Div Biostat & Data Management Core, Philadelphia, PA 19104 USA	Ballweg, JA (corresponding author), Childrens Hosp, Div Pediat Cardiol, 34th & Civic Ctr Blvd,Suite 6121, Philadelphia, PA 19104 USA.	ballweg@email.chop.edu	Carvalho, Lidiane/P-8446-2019; Ittenbach, Richard F/Q-1806-2015; gaynor, J william/E-5194-2013	Carvalho, Lidiane/0000-0002-2290-329X; gaynor, J william/0000-0001-7955-5604	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL071834] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL071834-05, R01 HL071834-04, HL071834, R01 HL071834-01A1, R01 HL071834, R01 HL071834-02, R01 HL071834-03] Funding Source: Medline		Aouifi A, 1997, J CARDIOTHOR VASC AN, V11, P411, DOI 10.1016/S1053-0770(97)90046-X; Bellinger DC, 1999, CIRCULATION, V100, P526, DOI 10.1161/01.CIR.100.5.526; Bellinger DC, 2003, J THORAC CARDIOV SUR, V126, P1385, DOI 10.1016/S0022-5223(03)00711-6; BELLINGER DC, 1995, NEW ENGL J MED, V332, P549, DOI 10.1056/NEJM199503023320901; Bellinger DC, 2001, J THORAC CARDIOV SUR, V121, P374, DOI 10.1067/mtc.2001.111206; CALLAHAN DJ, 1990, PEDIATR RES, V27, P186, DOI 10.1203/00006450-199002000-00020; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; de Ferranti S, 2004, ANESTHESIOLOGY, V100, P1345, DOI 10.1097/00000542-200406000-00005; Doenst T, 2005, J THORAC CARDIOV SUR, V130, P1144, DOI 10.1016/j.jtcvs.2005.05.049; Faustino EV, 2005, J PEDIATR-US, V146, P30, DOI 10.1016/j.jpeds.2004.08.076; Foo K, 2003, HEART, V89, P512, DOI 10.1136/heart.89.5.512; Galli KK, 2004, J THORAC CARDIOV SUR, V127, P692, DOI 10.1016/j.jtcvs.2003.09.053; Gaynor JW, 2003, J THORAC CARDIOV SUR, V126, P1736, DOI 10.1016/S0022-5223(03)01188-7; GAYNOR JW, 2007, IN PRESS J THORAC CA; Guvener M, 2002, ENDOCR J, V49, P531, DOI 10.1507/endocrj.49.531; HATTORI H, 1990, ANN NEUROL, V28, P122, DOI 10.1002/ana.410280203; HOLLINGSHEAD A, 1975, FACTOR INDEX SOCIAL; Jonas RA, 2003, J THORAC CARDIOV SUR, V126, P1765, DOI 10.1016/j.jtcvs.2003.04.003; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; Licht DJ, 2004, J THORAC CARDIOV SUR, V128, P841, DOI 10.1016/j.jtcvs.2004.07.022; Malmberg K, 1999, CIRCULATION, V99, P2626, DOI 10.1161/01.CIR.99.20.2626; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; Newburger JW, 2003, J PEDIATR-US, V143, P67, DOI 10.1016/S0022-3476(03)00183-5; Nicolson S C, 1992, J Cardiothorac Vasc Anesth, V6, P316, DOI 10.1016/1053-0770(92)90148-Z; Ouattara A, 2005, ANESTHESIOLOGY, V103, P687, DOI 10.1097/00000542-200510000-00006; Quinn DW, 2006, J THORAC CARDIOV SUR, V131, P34, DOI 10.1016/j.jtcvs.2005.05.057; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; SCHURR A, 1987, BRAIN RES, V421, P135, DOI 10.1016/0006-8993(87)91283-2; SIEBER FE, 1992, CRIT CARE MED, V20, P104, DOI 10.1097/00003246-199201000-00022; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANNUCCI RC, 1992, BIOL NEONATE, V62, P215; Wahab NN, 2002, J AM COLL CARDIOL, V40, P1748, DOI 10.1016/S0735-1097(02)02483-X; Williams LS, 2002, NEUROLOGY, V59, P67, DOI 10.1212/WNL.59.1.67; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; Yates AR, 2006, PEDIATR CRIT CARE ME, V7, P351, DOI 10.1097/01.PCC.0000227755.96700.98	37	34	36	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0003-4975	1552-6259		ANN THORAC SURG	Ann. Thorac. Surg.	DEC	2007	84	6					2052	2058		10.1016/j.athoracsur.2007.06.099			7	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	234PP	WOS:000251176300035	18036934				2021-06-18	
J	Mathias, JL; Bowden, SC; Bigler, ED; Rosenfeld, JV				Mathias, J. L.; Bowden, S. C.; Bigler, E. D.; Rosenfeld, J. V.			Is performance on the Wechsler test of adult reading affected by traumatic brain injury?	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							PREMORBID INTELLIGENCE; VALIDITY	Objectives. The validity of the National Adult Reading Test (NART) as a predictor of premorbid IQ when used with patients who have sustained a traumatic brain injury (TBI) has been questioned in recent years. This study examined whether performance on the Wechsler Test of Adult Reading (WTAR) is similarly affected by TBI in the first year after an injury. Design and Method. The WTAR scores of participants who had sustained a mild TBI (N = 82), moderate TBI (N = 73), severe TBI (N = 61) or an orthopaedic injury (N = 95) were compared (cross-sectional study). A subset of 21 mild TBI, 31 moderate TBI, 26 severe TBI and 21 control group participants were additionally reassessed 6 months later to assess the impact of recovery on WTAR scores (longitudinal study). Results. The severe TBI group had significantly lower scores on the WTAR than the mild TBI, moderate TBI and control groups in the cross-sectional study, despite being matched demographically. The findings from the longitudinal study revealed a significant group difference and a small improvement in performance over time but the interaction between group and time was not significant, suggesting that the improvements in WTAR performance over time were not restricted to more severely injured individuals whose performance was temporarily suppressed. Conclusions. These findings suggest that reading performance may be affected by severe TBI and that the WTAR may underestimate premorbid IQ when used in this context, which may cause clinicians to underestimate the cognitive deficits experienced by these patients.	Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia; Univ Melbourne, Sch Behav Sci, Dept Psychol, Melbourne, Vic, Australia; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Mathias, J L/L-6295-2013; Rosenfeld, Jeffrey V/B-7249-2011	Mathias, Jane/0000-0001-8957-8594			Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; CRAWFORD JR, 1988, BRIT J PSYCHIAT, V153, P178, DOI 10.1192/bjp.153.2.178; CRAWFORD JR, 1990, BRIT J CLIN PSYCHOL, V29, P435, DOI 10.1111/j.2044-8260.1990.tb00908.x; Franzen MD, 1997, ARCH CLIN NEUROPSYCH, V12, P711, DOI 10.1016/S0887-6177(97)00046-2; Freeman J, 2000, BRIT J CLIN PSYCHOL, V39, P95, DOI 10.1348/014466500163130; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Morris PG, 2005, BRIT J CLIN PSYCHOL, V44, P209, DOI 10.1348/014466505X34174; Riley GA, 2003, BRIT J CLIN PSYCHOL, V42, P319, DOI 10.1348/01446650360703410; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 1981, WECHSLER INTELLIGENC, V3rd; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLSHIRE D, 1991, J CLIN EXP NEUROPSYC, V13, P204, DOI 10.1080/01688639108401038; Wilson, 1991, NATL ADULT READING T	20	34	34	0	4	BRITISH PSYCHOLOGICAL SOC	LEICESTER	ST ANDREWS HOUSE, 48 PRINCESS RD EAST, LEICESTER LE1 7DR, LEICS, ENGLAND	0144-6657			BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	NOV	2007	46		4				457	466		10.1348/014466507X190197			10	Psychology, Clinical	Psychology	234KS	WOS:000251163600007	17535531				2021-06-18	
J	Bell, JD; Ai, JL; Chen, YH; Baker, AJ				Bell, Joshua D.; Ai, Jinglu; Chen, Yonghong; Baker, Andrew J.			Mild in vitro trauma induces rapid Glur2 endocytosis, robustly augments calcium permeability and enhances susceptibility to secondary excitotoxic insult in cultured Purkinje cells	BRAIN			English	Article						GluR2; AMPA; stretch; traumatic brain injury; cerebellum; Purkinje cells; calcium; endocytosis	GLUTAMATE-OPERATED CHANNELS; OXYGEN-GLUCOSE DEPRIVATION; EXCITATORY AMINO-ACIDS; AMPA-RECEPTOR CHANNELS; STRETCH-INDUCED INJURY; BRAIN-INJURY; MECHANICAL STRETCH; DEPENDENT NEURODEGENERATION; QUANTITATIVE-DETERMINATION; MOLECULAR-MECHANISMS	Mild brain trauma results in a wide range of neurological symptoms that are not easily explained by the primary pathology. Purkinje neurons of the cerebellum are selectively vulnerable to brain trauma, including indirect remote trauma to the forebrain. This vulnerability manifests itself as a selective and delayed cell loss, for which the underlying mechanisms are poorly understood. Alterations to the surface expression of calcium impermeable AMPA receptors (GluR2-containing) may mediate post-traumatic calcium overload, and initiate biochemical cascades that ultimately cause progressive cell death. Our current study examined this hypothesis using an in vitro model of mild Purkinje trauma, delivered by an elastic stretch at 2.5-2.9 pounds per square inch (psi). This mild trauma alone did not increase cell loss as measured by propidium iodide (PI) uptake (at 20 h) compared to uninjured controls. However, there was a marked increase in cell loss, when cells following mild trauma, were exposed to 10 mu M AMPA for 1 h compared to either mild trauma or AMPA exposure alone. Mild injury rendered Purkinje neurons significantly more permeable to AMPA-stimulated (4 mu M) calcium influx at 15 min post-injury, including a sustained calcium plateau. This effect was eliminated by inhibiting protein kinase C-dependent GluR2 endocytosis with 2 mu M Go6976 or blocking the calcium pore of GluR1/3 containing AMPARs with 500 nM 1-naphthylacetyl spermine (Naspm). Nifedipine (2 mM) eliminated the calcium plateau following mild injury but not the initial spike of Ca2+ increase. These results suggest that mild injuries resulted in a rapid AMPA receptor subtype switch (GluR2 was replaced by GluR1/3), which in turn resulted in an enhanced Ca2+ permeability. We further confirmed this by immunocytochemistry. Dendritic GluR2 co-localization with the pre-synaptic marker synaptophysin was markedly down-regulated at 15 min following mild stretch (P < 0.01), indicative of a rapid decrease in the synaptic expression of receptors containing this subunit. Carboxyfluorescence (CBF) assays revealed that mild stretch did not alter membrane integrity. Finally, we demonstrated that the combination of 500 nM Naspm and 5 nM Go6976 conferred a powerful neuroprotective effect on Purkinje cells by effectively eliminating the effects of mild stretch combined with AMPA in 95% of cells. These results represent a newly described mechanism rendering neurons susceptible to secondary injuries following trauma. Prevention of GluR2 endocytosis may be critical in the development of pharmacotherapies aimed at mild, seemingly inconsequential trauma, to avoid ensuing secondary damage.	Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res, Traumat Brain Injury Lab, Toronto, ON M5B 1W8, Canada; St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON, Canada	Baker, AJ (corresponding author), Univ Toronto, St Michaels Hosp, Cara Phelan Ctr Trauma Res, Traumat Brain Injury Lab, 100 Coll St, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca		AI, JINGLU/0000-0001-7414-0207			Ai JL, 2007, EXP BRAIN RES, V177, P95, DOI 10.1007/s00221-006-0654-9; Ai JL, 2006, EXP BRAIN RES, V169, P126, DOI 10.1007/s00221-005-0314-5; Amar AP, 1999, NEUROSURGERY, V44, P1027, DOI 10.1097/00006123-199905000-00052; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; AUDINAT E, 1990, J PHYSIOL-LONDON, V430, P297, DOI 10.1113/jphysiol.1990.sp018292; BARTOLETTI DC, 1989, FEBS LETT, V256, P4, DOI 10.1016/0014-5793(89)81707-7; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; BRORSON JR, 1994, J NEUROSCI, V14, P187; BRORSON JR, 1992, MOL PHARMACOL, V41, P603; BRORSON JR, 1995, J NEUROSCI, V15, P4515; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; David JC, 1996, J NEUROSCI, V16, P200; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2001, J BIOMECH ENG-T ASME, V123, P247, DOI 10.1115/1.1374201; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gift EA, 2000, CYTOMETRY, V39, P243; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Greger IH, 2002, NEURON, V34, P759, DOI 10.1016/S0896-6273(02)00693-1; Groc L, 2006, CELL TISSUE RES, V326, P423, DOI 10.1007/s00441-006-0254-9; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; JOELS M, 1989, P NATL ACAD SCI USA, V86, P3404, DOI 10.1073/pnas.86.9.3404; Joyal CC, 1996, BRAIN RES, V739, P1, DOI 10.1016/S0006-8993(96)00333-2; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lalonde R, 2003, CEREBELLUM, V2, P300, DOI 10.1080/14734220310017456; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Leggio MG, 2000, P NATL ACAD SCI USA, V97, P2320, DOI 10.1073/pnas.040554297; LINDEN DJ, 1993, NEURON, V11, P1093, DOI 10.1016/0896-6273(93)90222-D; Liu BS, 2006, J NEUROSCI, V26, P5309, DOI 10.1523/JNEUROSCI.0567-06.2006; Liu SQJ, 2000, NATURE, V405, P454; LLANO I, 1988, P NATL ACAD SCI USA, V85, P3221, DOI 10.1073/pnas.85.9.3221; LUCHTER S, 1995, J NEUROTRAUM, V12, P517, DOI 10.1089/neu.1995.12.517; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; Manni E, 2004, NAT REV NEUROSCI, V5, P241, DOI 10.1038/nrn1347; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Middleton FA, 2000, BRAIN RES REV, V31, P236, DOI 10.1016/S0165-0173(99)00040-5; Middleton FA, 1998, TRENDS NEUROSCI, V21, P367, DOI 10.1016/S0166-2236(98)01330-7; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; Momiyama A, 2003, J PHYSIOL-LONDON, V549, P75, DOI 10.1113/jphysiol.2002.033472; Momiyama A, 1996, J PHYSIOL-LONDON, V494, P479, DOI 10.1113/jphysiol.1996.sp021507; MONYER H, 1991, NEURON, V6, P799, DOI 10.1016/0896-6273(91)90176-Z; Ogoshi F, 2003, J NEUROSCI, V23, P10521; Park E, 2006, J NEUROPATH EXP NEUR, V65, P226, DOI 10.1097/01.jnen.0000202888.29705.93; Petrosini L, 1998, PROG NEUROBIOL, V56, P191, DOI 10.1016/S0301-0082(98)00036-7; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; SORIMACHI M, 1993, J NEUROCHEM, V60, P1236, DOI 10.1111/j.1471-4159.1993.tb03282.x; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Tanaka J, 2005, J NEUROSCI, V25, P799, DOI 10.1523/JNEUROSCI.4256-04.2005; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; Tempia F, 1996, J NEUROSCI, V16, P456; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Weiss JH, 2000, TRENDS NEUROSCI, V23, P365, DOI 10.1016/S0166-2236(00)01610-6; Yuzaki M, 1996, J NEUROSCI, V16, P4651; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhao XR, 2000, J CEREBR BLOOD F MET, V20, P550, DOI 10.1097/00004647-200003000-00014	76	34	39	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2007	130		10				2528	2542		10.1093/brain/awm164			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	218UC	WOS:000250039500007	17664176	Bronze			2021-06-18	
J	Marklund, N; Bayre, FM; Royo, NC; Thompson, HJ; Mir, AK; Grady, MS; Schwab, ME; McIntosh, TK				Marklund, Niklas; Bayre, Florence M.; Royo, Nicolas C.; Thompson, Hilaire J.; Mir, Anis K.; Grady, M. Sean; Schwab, Martin E.; McIntosh, Tracy K.			Cognitive outcome following brain injury and treatment with an inhibitor of Nogo-A in association with an attenuated downregulation of hippocampal growth-associated protein-43 expression	JOURNAL OF NEUROSURGERY			English	Article						cognition; GAP-43; neurological motor deficits; Nogo-A; regeneration; traumatic brain injury	MONOCLONAL-ANTIBODY IN-1; CENTRAL-NERVOUS-SYSTEM; MYELIN-ASSOCIATED GLYCOPROTEIN; SPINAL-CORD REPAIR; NEURITE GROWTH; FUNCTIONAL RECOVERY; AXONAL REGENERATION; ADULT-RAT; CORTICAL LESION; HEAD-INJURY	Object. Central nervous system axons regenerate poorly after traumatic brain injury (TBI), partly due to inhibitors such as the protein Nogo-A present in myelin. The authors evaluated the efficacy of anti-Nogo-A monoclonal antibody (mAb) 7B 12 administration on the neurobehavioral and cognitive outcome of rats following lateral fluid-percussion brain injury, characterized the penetration of the 7B 12 or control antibodies into target brain regions, and evaluated the effects of Nogo-A inhibition on hemispheric tissue loss and sprouting of uninjured motor tracts in the cervical cord. To elucidate a potential molecular response to Nogo-A inhibition, we evaluated the effects of 7B 12 on hippocampal GAP-43 expression. Methods. Beginning 24 hours after lateral fluid-percussion brain injury or sham injury in rats, the mAb 7B 12 or control antibody was infused intracerebroventricularly over 14 days, and behavior was assessed over 4 weeks. Results. Immunoreactivity for 7B 12 or immunoglobulin G was detected in widespread brain regions at 1 and 3 weeks postinjury. The brain-injured animals treated with 7B 12 showed improvement in cognitive function (p < 0.05) at 4 weeks but no improvement in neurological motor function from 1 to 4 weeks postinjury compared with brain-injured, vehicle-treated controls. The enhanced cognitive function following inhibition of Nogo-A was correlated with an attenuated postinjury downregulation of hippocampal GAP-43 expression (p < 0.05). Conclusions. Increased GAP-43 expression may be a novel molecular mechanism of the enhanced cognitive recovery mediated by Nogo-A inhibition after TBI in rats.	Univ Uppsala Hosp, Dept Neurosurg, SE-75185 Uppsala, Sweden; Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Zurich, Brain Res Inst, Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, Zurich, Switzerland; Novartis Inst Biomed Res, Basel, Switzerland	Marklund, N (corresponding author), Univ Uppsala Hosp, Dept Neurosurg, SE-75185 Uppsala, Sweden.	niklas.marklund@neurokir.uu.se	Schwab, Martin E/B-6818-2016	Marklund, Niklas/0000-0002-9797-5626	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [L30 DC008284, L30 DC008284-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS008803-27, NS P50-08803, R01 NS040978-04, NS R01-40978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER		Acevedo L, 2004, NAT MED, V10, P382, DOI 10.1038/nm1020; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Bareyre FM, 2002, J NEUROSCI, V22, P7097; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bomze HM, 2001, NAT NEUROSCI, V4, P38; Buchli AD, 2005, ANN MED, V37, P556, DOI 10.1080/07853890500407520; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; David S, 2003, ANNU REV NEUROSCI, V26, P411, DOI 10.1146/annurev.neuro.26.043002.094946; Dergham P, 2002, J NEUROSCI, V22, P6570; Emerick AJ, 2003, J NEUROSCI, V23, P4826; Emery DL, 2000, J COMP NEUROL, V424, P521; Emery DL, 2003, J NEUROTRAUM, V20, P1271, DOI 10.1089/089771503322686085; Fiedler M, 2002, PROTEIN ENG, V15, P931, DOI 10.1093/protein/15.11.931; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Fouad K, 2004, EUR J NEUROSCI, V20, P2479, DOI 10.1111/j.1460-9568.2004.03716.x; Fournier AE, 2002, PROG BRAIN RES, V137, P361; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Freund P, 2006, NAT MED, V12, P790, DOI 10.1038/nm1436; Gianola S, 2004, EUR J NEUROSCI, V19, P819, DOI 10.1111/j.0953-816X.2004.03190.x; Grados-Munro EM, 2003, J NEUROSCI RES, V74, P479, DOI 10.1002/jnr.10803; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Hoover RC, 2004, J NEUROTRAUM, V21, P501, DOI 10.1089/089771504774129847; Hulo S, 2002, EUR J NEUROSCI, V15, P1976, DOI 10.1046/j.1460-9568.2002.02026.x; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Kartje GL, 1999, ANN NEUROL, V45, P778, DOI 10.1002/1531-8249(199906)45:6<778::AID-ANA12>3.0.CO;2-B; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Marklund N, 2005, RESTOR NEUROL NEUROS, V23, P31; MASLIAH E, 1991, EXP NEUROL, V113, P131, DOI 10.1016/0014-4886(91)90169-D; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meier S, 2003, FASEB J, V17, P1153, DOI 10.1096/fj.02-0453fje; Mingorance A, 2004, MOL CELL NEUROSCI, V26, P34, DOI 10.1016/j.mcn.2004.01.001; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; *NAT RES COUNC, 1996, GUID CAR US LAB; Oertle T, 2003, J NEUROSCI, V23, P5393; Oudega M, 2000, NEUROSCIENCE, V100, P873, DOI 10.1016/S0306-4522(00)00350-X; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; PAXIOS G, 1986, RAT BRAIN STEREOTAXI; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rekart JL, 2005, HIPPOCAMPUS, V15, P1, DOI 10.1002/hipo.20045; Riedel G, 2001, PROG NEURO-PSYCHOPH, V25, P835, DOI 10.1016/S0278-5846(01)00153-1; Routtenberg A, 2000, P NATL ACAD SCI USA, V97, P7657, DOI 10.1073/pnas.97.13.7657; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; SchmidtKastner R, 1997, CELL TISSUE RES, V288, P225, DOI 10.1007/s004410050808; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Weinmann O, 2006, MOL CELL NEUROSCI, V32, P161, DOI 10.1016/j.mcn.2006.03.007; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	66	34	34	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2007	107	4					844	853		10.3171/JNS-07/10/0844			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	214NY	WOS:000249746500021	17937233	Green Accepted			2021-06-18	
J	Soustiel, JF; Sviri, GE				Soustiel, Jean F.; Sviri, Gill E.			Monitoring of cerebral metabolism: non-ischemic impairment of oxidative metabolism following severe traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; cerebral blood flow; cerebral metabolism	SEVERE HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; BLOOD-FLOW; GLUCOSE-UTILIZATION; PREDICTOR; OXYGEN; CONSCIOUSNESS; DYSFUNCTION; ASTROCYTES; PRESSURE	Objective: To investigate and compare the respective dynamics of cerebral blood flow (CBF) and metabolism in response to changes in neurological condition and intracranial pressure (ICP) in severe traumatic brain injury (TBI). Methods: Eight-four patients with severe TBI were prospectively enrolled in this study. CBF was measured daily and global cerebral metabolic rates of oxygen (CMRO2), glucose (CMRGlc) and lactate (CMRLct) were calculated using arterial jugular differences. In addition, 33 patients had a second evaluation shortly after a significant change (>5 mmHg) in their ICP. Results: Eight hundred and ninety-four evaluations were collected during a period ranging between 1 and 12 days (mean: 5.1 +/- 2.6 days). CBF was moderately but significantly decreased. Oppositely, CMRO2 was profoundly reduced with evidence for critical metabolic failure (<1.2 ml/100 g/min) in 30.5% whereas only 8.5% of CBF measurements were lower than 20 ml/100 g/min. Furthermore, in 78 instances of a dynamic assessment performed following ICP increase (n = 20) or decrease (n = 58), CMRO2 but not CBF proved to be significantly and inversely affected by ICP fluctuations. Finally, CMRO2 and CMRLct correlated with GCS score in contrast with CBF. Both CBF and metabolic indices, however, correlated with neurological outcome. Conclusion: This study shows that cerebral metabolic failure following TBI is a common finding that is not of ischemic origin in most instances. Unlike frequently assumed, cerebral metabolism is not constrained within the narrow range of a static depression sustained for weeks but rather subject to significant variations in response to changes in ICP or neurological condition.	Technion Israel Inst Technol, Fac Med, Rambam Med Ctr, Dept Neurosurg, IL-31096 Haifa, Israel	Soustiel, JF (corresponding author), Rambam Med Ctr, Dept Neurosurg, PO Box 9602, IL-31096 Haifa, Israel.	lj_soustiel@rambam.health.gov.il					Ames A, 2000, BRAIN RES REV, V34, P42, DOI 10.1016/S0165-0173(00)00038-2; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Soustiel JF, 2003, STROKE, V34, P1876, DOI 10.1161/01.STR.0000080942.32331.39; Soustiel JF, 2002, J ULTRAS MED, V21, P1405, DOI 10.7863/jum.2002.21.12.1405; TEASDALE G, 1974, LANCET, V2, P81; VALADKA B, 2000, NEUROSURG FOCUS, V9, pE3; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WALZ W, 1988, NEUROSCI LETT, V86, P296, DOI 10.1016/0304-3940(88)90499-5; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	29	34	35	1	4	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	OCT	2007	29	7					654	660		10.1179/016164107X240017			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	234MJ	WOS:000251167900004	18173902				2021-06-18	
J	Hickey, RW; Adelson, PD; Johnnides, MJ; Davis, DS; Yu, Z; Rose, ME; Chang, YF; Graham, SH				Hickey, Robert W.; Adelson, P. David; Johnnides, Michael J.; Davis, Dwight S.; Yu, Zhisheng; Rose, Marie E.; Chang, Yue-Fang; Graham, Steven H.			Cyclooxygenase-2 activity following traumatic brain injury in the developing rat	PEDIATRIC RESEARCH			English	Article							NITRIC-OXIDE SYNTHASE; NEURONAL CELL-DEATH; CEREBRAL-ISCHEMIA; INHIBITION; EXPRESSION; APOPTOSIS; MODEL; NEUROTOXICITY; INFLAMMATION; METABOLISM	Cyclooxygenase (COX) is the rate-limiting enzyme in the production of prostaglandins. COX-2, the predominant COX isoform in brain, is induced by synaptic activity. COX-2-generated prostaglandins are important regulators for a range of activities under physiologic conditions. However, under pathologic conditions, COX-2 activity can produce reactive oxygen species and toxic prostaglandin metabolites that can exacerbate brain injury. In this study, we examine the developmental production of COX-2 and test the ability of a COX-2 inhibitor, SC58125, to attenuate traumatic brain injury in developing rats. We show that constitutive COX-2 concentration is low (0.5-fold adult concentration) during the first postnatal week and then increases to 3-fold of adult levels between days 14-60. Controlled cortical impact (CCI) at postnatal day (PND) 17, but not PND 7, caused an additional 3-fold increase in COX-2 content and was associated with an increase in the COX-2 product PGE(2). Treatment with the COX-2 inhibitor SC58125 in PND17 rats exposed to CCI attenuated the rise in PGE, but did not attenuate lesion volume or improve performance in the Morris water	Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; VA Pittsburg Healthcare Syst, Ctr Clin, Pittsburgh, PA 15206 USA	Hickey, RW (corresponding author), Childrens Hosp Pittsburgh, Div Pediat, 3705 5th Ave, Pittsburgh, PA 15213 USA.	robert.hickely@chp.edu	Adelson, David/W-2083-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037459, R01NS042298] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08 HD040848, KO8 HD40848] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS42298, R01 NS037459-08, R01 NS037459] Funding Source: Medline		Andreasson KI, 2001, J NEUROSCI, V21, P8198; Bezzi P, 1998, NATURE, V391, P281; CEMAK I, 2001, CLIN EXP PHARM PHYSL, V28, P922; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Graham SH, 2003, ARCH NEUROL-CHICAGO, V60, P628, DOI 10.1001/archneur.60.4.628; Jiang JF, 2004, J NEUROCHEM, V90, P1036, DOI 10.1111/j.1471-4159.2004.02577.x; Kaufmann WE, 1997, BRAIN DEV-JPN, V19, P25, DOI 10.1016/S0387-7604(96)00047-2; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kim EJ, 2002, J NEUROSCI RES, V70, P97, DOI 10.1002/jnr.10373; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Koyfman L, 2000, J NEUROSURG ANESTH, V12, P44, DOI 10.1097/00008506-200001000-00009; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Li ZM, 2004, BIOCHEM BIOPH RES CO, V319, P1171, DOI 10.1016/j.bbrc.2004.05.098; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Moochhala SM, 2005, J TRAUMA, V59, P448, DOI 10.1097/01.ta.0000174858.79847.6d; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; Schwab JM, 2001, J NEUROTRAUM, V18, P881, DOI 10.1089/089771501750451802; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; Takamatsu H, 2002, BRAIN RES, V925, P176, DOI 10.1016/S0006-8993(01)03280-2; Teather LA, 2002, LEARN MEMORY, V9, P41, DOI 10.1101/lm.43602; Tocco G, 1997, EXP NEUROL, V144, P339, DOI 10.1006/exnr.1997.6429; Towfighi J, 1997, DEV BRAIN RES, V100, P149, DOI 10.1016/S0165-3806(97)00036-9; UENO R, 1985, J NEUROCHEM, V45, P483, DOI 10.1111/j.1471-4159.1985.tb04014.x; Yagami T, 2002, J NEUROCHEM, V81, P449, DOI 10.1046/j.1471-4159.2002.00800.x	30	34	34	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0031-3998	1530-0447		PEDIATR RES	Pediatr. Res.	SEP	2007	62	3					271	276		10.1203/PDR.0b013e3180db2902			6	Pediatrics	Pediatrics	203KJ	WOS:000248973200008	17622965	Bronze			2021-06-18	
J	Rothman, MS; Arciniegas, DB; Filley, CM; Wierman, ME				Rothman, Micol S.; Arciniegas, David B.; Filley, Christopher M.; Wierman, Margaret E.			The neuroendocrine effects of traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							GROWTH-HORMONE DEFICIENCY; COGNITIVE FUNCTION; TESTOSTERONE REPLACEMENT; SUBARACHNOID HEMORRHAGE; PITUITARY DYSFUNCTION; CRITICAL ILLNESS; HYPOGONADAL MEN; SEPTIC SHOCK; SEX-HORMONES; HEAD TRAUMA	Neuroendocrine dysfunction after traumatic brain injury (TBI) is under-diagnosed, under-treated, and may adversely affect the rate of recovery. Single or multiple pituitary-target hormone disruption occurs in up to two-thirds of persons with TBI, most commonly affecting the gonadal and growth hormone axes. The time course of decline in and recovery of pituitary function in relation to cognitive dysfunction and rehabilitation progress are not well described. This article reviews the clinical spectrum Of neuroendocrine deficits after TBI and their underlying mechanisms. Future studies of the effects of hormonal replacement on recovery are recommended.	Univ Colorado, Dept Med, Denver, CO USA; Ctr Hlth Sci, Aurora, CO USA; Univ Colorado, Dept Psychiat & Neurol, Denver, CO USA; Univ Colorado, Dept Med, Denver, CO USA; Vet Affairs Med Ctr, Res Serv, Denver, CO USA; Healthone Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA	Wierman, ME (corresponding author), VAMC, 111H Endocrinol, 1055 Clermont St, Denver, CO 80220 USA.	margaret.wierman@uchsc.edu	Arciniegas, David/A-3792-2009				Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Azad N, 2003, J CLIN ENDOCR METAB, V88, P3064, DOI 10.1210/jc.2002-020632; Azcoitia I, 2003, ANN NY ACAD SCI, V1007, P298, DOI 10.1196/annals.1286.028; BECKER RA, 1982, CRIT CARE MED, V10, P870, DOI 10.1097/00003246-198212000-00014; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bhasin S, 1998, J CLIN ENDOCR METAB, V83, P3155, DOI 10.1210/jc.83.9.3155; Bhasin S, 1997, J CLIN ENDOCR METAB, V82, P407, DOI 10.1210/jc.82.2.407; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BRENT GA, 1986, J CLIN ENDOCR METAB, V63, P1; Butler TL, 2003, BRAIN RES BULL, V59, P339, DOI 10.1016/S0361-9230(02)00926-7; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Casanueva FF, 2004, J ENDOCRINOL INVEST, V27, P793, DOI 10.1007/BF03347526; Cernak I, 1999, BRAIN INJURY, V13, P1005; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; Chinga-Alayo E, 2005, INTENS CARE MED, V31, P1356, DOI 10.1007/s00134-005-2719-9; CLARK JDA, 1992, CLIN ENDOCRINOL, V36, P481, DOI 10.1111/j.1365-2265.1992.tb02249.x; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; Ferrando AA, 2001, CRIT CARE MED, V29, P1936, DOI 10.1097/00003246-200110000-00015; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GREENSPAN FS, 2004, BASIC CLIN ENDOCRINO; Grinspoon S, 2000, ANN INTERN MED, V133, P348, DOI 10.7326/0003-4819-133-5-200009050-00010; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; JIANG ZM, 1989, ANN SURG, V210, P513, DOI 10.1097/00000658-198910000-00012; JORGENSEN JOL, 1989, LANCET, V1, P1221; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Knox JB, 1996, AM J SURG, V171, P576, DOI 10.1016/S0002-9610(96)00033-5; Ko YH, 2006, NEUROPSYCHOBIOLOGY, V53, P169, DOI 10.1159/000093780; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Marik PE, 2003, CRIT CARE MED, V31, P141, DOI 10.1097/00003246-200301000-00022; Maruff P, 2005, HORM RES, V64, P100, DOI 10.1159/000089325; MAY ME, 1985, AM J MED, V79, P679, DOI 10.1016/0002-9343(85)90517-0; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McEwen BS, 1999, J CLIN ENDOCR METAB, V84, P1790, DOI 10.1210/jc.84.6.1790; Mechanick JI, 2006, CRIT CARE CLIN, V22, P87, DOI 10.1016/j.ccc.2005.08.005; Moffat SD, 2002, J CLIN ENDOCR METAB, V87, P5001, DOI 10.1210/jc.2002-020419; Nierman DM, 1999, CRIT CARE MED, V27, P2418, DOI 10.1097/00003246-199911000-00016; O'Connor DB, 2001, NEUROPSYCHOLOGIA, V39, P1385, DOI 10.1016/S0028-3932(01)00067-7; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rasmuson S, 1996, CLIN ENDOCRINOL, V44, P151, DOI 10.1046/j.1365-2265.1996.600482.x; REICHLIN S, 1992, NEUROENDOCRINOLOGY W, P174; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; SPRATT DI, 1993, J CLIN ENDOCR METAB, V76, P1548, DOI 10.1210/jc.76.6.1548; SPRATT DI, 1992, J CLIN ENDOCR METAB, V75, P1562, DOI 10.1210/jc.75.6.1562; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; WHITEHEAD HM, 1992, CLIN ENDOCRINOL, V36, P45, DOI 10.1111/j.1365-2265.1992.tb02901.x; Wolf OT, 2002, HORM BEHAV, V41, P259, DOI 10.1006/hbeh.2002.1770; WOOLF PD, 1985, J CLIN ENDOCR METAB, V60, P444, DOI 10.1210/jcem-60-3-444; Yaffe K, 2002, J AM GERIATR SOC, V50, P707, DOI 10.1046/j.1532-5415.2002.50166.x; Yaffe K, 2000, LANCET, V356, P708, DOI 10.1016/S0140-6736(00)02628-3	71	34	38	0	6	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2007	19	4					363	372		10.1176/appi.neuropsych.19.4.363			10	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	235EQ	WOS:000251216700002	18070838				2021-06-18	
J	Yilmaz, N; Dulger, H; Kiymaz, N; Yilmaz, C; Gudu, BO; Demir, I				Yilmaz, Nebi; Dulger, Haluk; Kiymaz, Nejmi; Yilmaz, Cahide; Gudu, Burhan O.; Demir, Ismail			Activity of mannitol and hypertonic saline therapy on the oxidant and antioxidant system during the acute term after traumatic brain injury in the rats	BRAIN RESEARCH			English	Article						mannitol; hypertonic saline; malondialdehyde; antioxidant enzyme; brain injury	ELEVATED INTRACRANIAL-PRESSURE; ACID-REACTIVE SUBSTANCES; CATALASE ACTIVITY; MODEL; PATHOPHYSIOLOGY; DEXTRAN-70; INCREASES; SERUM	In this study, our objective is to investigate the effects of mannitol and 7.5% hypertonic saline (HS) therapy on the levels of malondialdehyde (MDA), catalase and glutathione peroxidase (GSH-Px) in the early stages of experimental head traumas in rats. Rats included in the study were divided into four groups: Group I Control, Group II Trauma, Group III Mannitol, and Group IV 7.5% Hypertonic Saline. Rats in Group 11 were subject to head trauma only. Mannitol was injected intraperitoneally to rats in Group III after head trauma and 7.5% HS was injected intraperitoneally to rats in Group IV after head trauma. Rats were sacrificed 4 h after administration of mannitol. or 7.5% HS, and the levels of MDA catalase and GSH-Px in brain tissues extracted from rats were determined. MDA levels in the trauma group were significantly increased compared with the control group (p<0.01), whereas there was a reduction in catalase and GSH-Px levels, although these differences were not significant. By contrast, in the mannitol group, MDA, catalase and GSH-Px levels were lower than the levels in the trauma group, and these reductions were statistically significant (p<0.05). The MDA, catalase and GSH-Px levels of the 7.5% HS group were lower than those of the trauma group; however, this reduction was not statistically significant. It was concluded that mannitol and 7.5% HS therapies that are used to reduce intracranial pressure and to increase the use of catalase, an antioxidant enzyme, and GSH-Px, are likely to reduce cellular damage by reducing the formation of MDA, the levels of which are known to be indicative of cellular level oxidant damage. (c) 2007 Elsevier B.V. All rights reserved.	Yuzuncu Yil Univ, Sch Med, Dept Neurosurg, Van, Turkey; Yuzuncu Yil Univ, Sch Med, Dept Biochem, Van, Turkey; Yuzuncu Yil Univ, Sch Med, Dept Pediat Neurol, Van, Turkey	Yilmaz, N (corresponding author), Yuzuncu Yil Univ, Sch Med, Dept Neurosurg, Van, Turkey.	yilmaznebi@yahoo.com					Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; CAO LZ, 2000, HUNAN YIKE DAXUE XUE, V28, P109; Choi SH, 2006, EMERG MED J, V23, P119, DOI 10.1136/emj.2004.020651; Farooqui AA, 1998, CELL MOL NEUROBIOL, V18, P599, DOI 10.1023/A:1020261600498; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GOTH L, 1991, CLIN CHIM ACTA, V196, P143, DOI 10.1016/0009-8981(91)90067-M; HALL ED, 1993, RES P ARNMD, V71, P81; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Orlic T, 2002, AM J PHYSIOL-CELL PH, V282, pC1261, DOI 10.1152/ajpcell.00479.2001; PLEBAN PA, 1982, CLIN CHEM, V28, P311; Povlishock J T, 1992, Hum Cell, V5, P345; Santos A, 2005, NEUROCHEM RES, V30, P625, DOI 10.1007/s11064-005-2750-9; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; Toung TJK, 2005, CRIT CARE MED, V33, P203, DOI 10.1097/01.CCM.0000150659.15558.23; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WASOWICZ W, 1993, CLIN CHEM, V39, P2522	22	34	36	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 20	2007	1164						132	135		10.1016/j.brainres.2007.06.017			4	Neurosciences	Neurosciences & Neurology	208LX	WOS:000249321900014	17651707				2021-06-18	
J	Bouras, T; Stranjalis, G; Korfias, S; Andrianakis, I; Pitaridis, M; Sakas, DE				Bouras, Triantafyllos; Stranjalis, George; Korfias, Stefanos; Andrianakis, Ilias; Pitaridis, Marianos; Sakas, Damianos E.			Head injury mortality in a geriatric population: Differentiating an "Edge" age group with better potential for benefit than older poor-prognosis patients	JOURNAL OF NEUROTRAUMA			English	Article						age; geriatric population; head injury; mortality; outcome; traumatic brain injury	TRAUMATIC BRAIN INJURY; GLASGOW COMA SCALE; PREDICTION; FUTURE; WORSE; SCORE	A comparison of outcomes between different modes of head-injury treatment in the elderly has important bearing on questions of cost-effectiveness and medical ethics. Here, we have examined rates of mortality in elderly head-trauma victims to determine whether it is valid to differentiate an "edge" age group of younger elderly patients, 65 -74 years of age, from older elderly patients, considering possible benefit from intensive treatment and surgical intervention. We collected data from 1926 cases of head trauma and separated them into three age groups: 14-64 years, 65 -74 years, and 75 years or older. We then compared these groups with respect to cause of injury, severity of injury, and whether or not treatment included either admission to an Intensive Care Unit (ICU) or surgical intervention. We found that road traffic accidents were the major cause of head injury in the younger age group, whereas in the elderly falls predominated. Mortality was higher in the elderly in all the head injury severity subgroups. Young subjects with a Glasgow Coma Scale (GCS) score of less than or equal to 8 tended to benefit from ICU treatment whereas patients 75 and over did not, regardless of their severity of injury. For these patients who were in the 65-74 age group, the data suggested that some benefit was likely. Patients 75 and older were significantly less likely to survive surgical intervention than younger patients. We conclude that it is valid to treat patients in the age group 65-74 years as a separate group from those patients 75 and older. Patients in this younger subset of the elderly may benefit from ICU treatment or surgical intervention. However, the patients in our older subset of elderly patients clearly did not, and they had a significantly higher risk of surgical mortality.	Univ Athens, Evangelismos Hosp, Dept Neurosurg, Athens, Greece; Univ Athens, Evangelismos Hosp, Intens Care Unit, Athens, Greece	Bouras, T (corresponding author), Univ Athens, Evangelismos Hosp, Dept Neurosurg, Athens, Greece.	trbouras@yahoo.gr					AMACHER AL, 1987, NEUROSURGERY, V20, P954; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Demetriades D, 2004, J AM COLL SURGEONS, V199, P216, DOI 10.1016/j.jamcollsurg.2004.02.030; Demetriades D, 2001, J TRAUMA, V51, P754, DOI 10.1097/00005373-200110000-00022; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Grant PT, 2000, INJURY, V31, P519, DOI 10.1016/S0020-1383(00)00038-3; Helling TS, 1999, J TRAUMA, V46, P453, DOI 10.1097/00005373-199903000-00019; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; Maurice-Williams RS, 1999, BRIT J NEUROSURG, V13, P5, DOI 10.1080/02688699944104; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nagurney J T, 1998, J Emerg Med, V16, P709, DOI 10.1016/S0736-4679(98)00083-3; STRANG I, 1978, INJURY, V10, P154; Stranjalis G, 1998, J NEUROSURG, V88, P782, DOI 10.3171/jns.1998.88.4.0782; STRANJALIS G, 2000, J RESTOR NEUROSCI NE, V6, P24; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Taylor MD, 2002, J TRAUMA, V53, P407, DOI 10.1097/00005373-200209000-00001; Udekwu P, 2004, J TRAUMA, V56, P1084, DOI 10.1097/01.TA.0000124283.02605.A5; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456; ZWIMPFER TJ, 1993, CRIT CARE CLIN, V9, P727	25	34	39	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1355	1361		10.1089/neu.2005.370			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500007	17711397				2021-06-18	
J	Gallagher, CN; Hutchinson, PJ; Pickard, JD				Gallagher, Clare N.; Hutchinson, Peter J.; Pickard, John D.			Neuroimaging in trauma	CURRENT OPINION IN NEUROLOGY			English	Article						computed tomography; imaging; MRI; PET; trauma	DIFFUSE AXONAL INJURY; CEREBRAL-BLOOD-FLOW; CT HEAD RULE; NEW-ORLEANS CRITERIA; BRAIN-INJURY; CORPUS-CALLOSUM; FIBER TRACKING; ISCHEMIA; DAMAGE; STEM	Purpose of review Developments in imaging following traumatic brain injury are outlined. Numerous techniques have evolved over the past several years giving us more information about the injury and prognosis for recovery. Some of these techniques are in clinical use while others are used primarily in research but have the potential to become clinically useful. Recent findings Computed tomography (CT) scanning is the primary imaging technique for acute brain injury, giving rapid information and being part of a general trauma work up in the emergency situation. It has supplanted plain films in the immediate management of brain injury. Following stabilization, MRI is the method of choice for evaluating the full extent of brain injury. Information on diffuse axonal injury is obtained by several MRI sequences. Diffusion tensor imaging is able to show long tract damage and relates to prognosis. There are several techniques which are best suited to research in brain injury, including single photon emission CT, PET and xenon CT. Summary CT and MRI are now the imaging techniques for acute and subacute brain injury, respectively. Diffusion tensor imaging is being developed to provide more information on structural damage in brain injury. There are several research techniques available for brain injury, particularly relating to cerebral blood flow and metabolism.	Univ Cambridge, Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge, England; Univ Calgary, Calgary, AB, Canada	Gallagher, CN (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Acad Neurosurg, Hills Rd, Cambridge, England.	galclare@gmail.com			Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G0001237, G0601025, G9439390] Funding Source: Medline		Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Bradley PG, 2004, CLINICAL MR NEUROIMAGING: DIFFUSION, PERFUSION AND SPECTROSCOPY, P626, DOI 10.1017/CBO9780511544958.040; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cunningham AS, 2005, BRAIN, V128, P1931, DOI 10.1093/brain/awh536; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486; Gean A, 1994, IMAGING HEAD TRAUMA; Giugni E, 2005, AM J NEURORADIOL, V26, P1140; Gowda NK, 2006, AM J NEURORADIOL, V27, P447; Hassan Z, 2005, EMERG MED J, V22, P845, DOI 10.1136/emj.2004.021717; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; Lee Bruce, 2005, NeuroRx, V2, P372; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Menon DK, 2006, CURR OPIN CRIT CARE, V12, P85, DOI 10.1097/01.ccx.0000216572.19062.8f; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Pickard JD, 2005, ACT NEUR S, V95, P459; Poon WS, 2005, ACT NEUR S, V95, P9; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Shin YB, 2006, BRAIN INJURY, V20, P661, DOI 10.1080/02699050600677071; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sultan HY, 2004, EMERG MED J, V21, P420, DOI 10.1136/emj.2003.011353; Teasdale E, 2005, HEAD INJURY PATHOPHY, P169; Toyama Yoshihiro, 2005, Radiat Med, V23, P309; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu HM, 2004, J NEUROTRAUM, V21, P149, DOI 10.1089/089771504322778613; Yen K, 2006, AM J NEURORADIOL, V27, P70	46	34	36	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	AUG	2007	20	4					403	409		10.1097/WCO.0b013e32821b987b			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	195NL	WOS:000248418800005	17620874				2021-06-18	
J	Wagner, AK; Postal, BA; Darrah, SD; Chen, X; Khan, AS				Wagner, Amy K.; Postal, Brett A.; Darrah, Shaun D.; Chen, Xiangbai; Khan, Amina S.			Deficits in novelty exploration after controlled cortical impact	JOURNAL OF NEUROTRAUMA			English	Article						exploratory behavior; novelty; open field; traumatic brain injury; Y-maze	TRAUMATIC BRAIN-INJURY; WATER MAZE PERFORMANCE; CHRONIC METHYLPHENIDATE TREATMENT; SENSATION-SEEKING TRAIT; ENVIRONMENTAL ENRICHMENT; MODERATE HYPOTHERMIA; NUCLEUS-ACCUMBENS; MOTIVATIONAL DEFICITS; COGNITIVE DEFICITS; PREFRONTAL CORTEX	Experimental models of traumatic brain injury (TBI) have been utilized to characterize the behavioral derangements associated with brain trauma. Several studies exist characterizing motor function in the controlled cortical impact (CCI) injury model of TBI, but less research has focused on how CCI affects exploratory behavior. The goal of this study was to characterize deficits in three novelty exploration tasks after the CCI. Under anesthesia, 37 adult male Sprague Dawley rats received CCI (2.7 mm and 2.9 mm; 4 m/sec) over the right parietal cortex or sham surgery. For days 1-6 post-surgery, the beam balance and beam walking tasks were used to assess motor deficits. The Open Field, Y-Maze, and Free Choice Novelty (FCN) tasks were used to measure exploratory deficits from days 7-14 post-surgery. Injured rats displayed a significant, but transient, deficit on each motor task (p < 0.0001). Open Field results showed that injured rats had lower activity levels than shams (p < 0.0001), displayed less habituation to the task, and had more anxiety related behaviors ( thigmotaxis) across days (p < 0.0001). Y-maze results suggest that injured rats spent less time in the novel arm versus the familiar arms when compared to shams (p < 0.0001). For FCN, injured rats were less active (p < 0.05) and spent less time and had fewer interactions with objects in the novel environment compared to shams (p < 0.05). These results suggest that several ethological factors contribute to exploratory deficits after CCI and can be effectively characterized with the behavioral tasks described. Future work will utilize these tasks to evaluate the neural substrates underlying exploratory deficits after TBI.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15260 USA.	wagnerak@upmc.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER		Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Cannon CM, 2004, PHYSIOL BEHAV, V81, P741, DOI 10.1016/j.physbeh.2004.04.020; Chen Q, 2006, P NATL ACAD SCI USA, V103, P3881, DOI 10.1073/pnas.0505407103; Choleris E, 2001, NEUROSCI BIOBEHAV R, V25, P235, DOI 10.1016/S0149-7634(01)00011-2; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; Daenen EWPM, 2001, BRAIN RES, V918, P153, DOI 10.1016/S0006-8993(01)02987-0; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; De Leonibus E, 2003, EUR J NEUROSCI, V18, P2365, DOI 10.1046/j.1460-9568.2003.02939.x; DELLU F, 1993, PERS INDIV DIFFER, V15, P411, DOI 10.1016/0191-8869(93)90069-F; Dellu F, 1997, NEUROBIOL LEARN MEM, V67, P112, DOI 10.1006/nlme.1997.3746; Dellu F, 1996, NEUROPSYCHOBIOLOGY, V34, P136, DOI 10.1159/000119305; Dellu F, 2000, NEUROBIOL LEARN MEM, V73, P31, DOI 10.1006/nlme.1999.3919; Dishman RK, 2000, BRAIN RES BULL, V52, P337, DOI 10.1016/S0361-9230(00)00271-9; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fromm L, 2004, J AM COLL NUTR, V23, p529S, DOI 10.1080/07315724.2004.10719396; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hart T, 2006, J HEAD TRAUMA REHAB, V21, P142, DOI 10.1097/00001199-200603000-00007; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Hughes RN, 1997, BEHAV PROCESS, V41, P213, DOI 10.1016/S0376-6357(97)00055-7; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2002, BRAIN RES, V937, P22, DOI 10.1016/S0006-8993(02)02458-7; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maurer N, 2001, EXPERT OPIN BIOL TH, V1, P923, DOI 10.1517/14712598.1.6.923; Maurice T, 2001, BRAIN RES, V898, P113, DOI 10.1016/S0006-8993(01)02152-7; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; Mele A, 2004, BEHAV PHARMACOL, V15, P423, DOI 10.1097/00008877-200409000-00017; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; OADES R, 1985, PSYCHOPHARMACOLOGY, V85, P123, DOI 10.1007/BF00427335; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pogorelov VM, 2005, NEUROPSYCHOPHARMACOL, V30, P1818, DOI 10.1038/sj.npp.1300724; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rebec GV, 1997, NEUROSCIENCE, V76, P707, DOI 10.1016/S0306-4522(96)00382-X; REBEC GV, 1984, NEUROSCI BIOBEHAV R, V8, P153, DOI 10.1016/0149-7634(84)90030-7; Robbins TW, 1996, CURR OPIN NEUROBIOL, V6, P228, DOI 10.1016/S0959-4388(96)80077-8; Rossetti ZL, 2005, J NEUROSCI, V25, P2322, DOI 10.1523/JNEUROSCI.3038-04.2005; Roy V, 2004, BEHAV BRAIN RES, V154, P439, DOI 10.1016/j.bbr.2004.03.010; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schultz W, 2002, NEURON, V36, P241, DOI 10.1016/S0896-6273(02)00967-4; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Sutcliffe JS, 2007, BEHAV BRAIN RES, V177, P117, DOI 10.1016/j.bbr.2006.10.029; TIPPER SP, 1989, J EXP CHILD PSYCHOL, V48, P353, DOI 10.1016/0022-0965(89)90047-7; Vallee M, 1997, J NEUROSCI, V17, P2626; van der Meulen JAJ, 2007, CEREB CORTEX, V17, P1444, DOI 10.1093/cercor/bhl057; Viggiano D, 2003, NEUROSCI BIOBEHAV R, V27, P683, DOI 10.1016/j.neubiorev.2003.08.011; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Wagner AK, 2002, NEUROSCI LETT, V334, P165, DOI 10.1016/S0304-3940(02)01103-5; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wang H, 2005, NEUROSCI BIOBEHAV R, V29, P1361, DOI 10.1016/j.neubiorev.2005.05.008; Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Zhuang XX, 2001, P NATL ACAD SCI USA, V98, P1982, DOI 10.1073/pnas.98.4.1982	78	34	34	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1308	1320		10.1089/neu.2007.0274			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500002	17711392				2021-06-18	
J	Bhang, SH; Lee, YE; Cho, SW; Shim, JW; Lee, SH; Choi, CY; Chang, JW; Kim, BS				Bhang, Suk Ho; Lee, Young Eun; Cho, Seung-Woo; Shim, Jae-Won; Lee, Sang-Hun; Choi, Cha Yong; Chang, Jin Woo; Kim, Byung-Soo			Basic fibroblast growth factor promotes bone marrow stromal cell transplantation-mediated neural regeneration in traumatic brain injury	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						basic fibroblast growth factors; bone marrow stromal cell; brain trauma injury; fibrin gel	RAT MODEL; ISCHEMIA; MICE; NEUROGENESIS; RELEASE; HEPARIN	The current study was designed to evaluate the effects of basic fibroblast growth factor (bFGF) on human BMSC (hBMSC) transplantation-mediated neural regeneration in traumatic brain injury (TBI). Fibrin gel was used as a delivery vehicle to release bFGF locally in the TBI sites in a controlled manner. To test this hypothesis, hBMSCs suspended in fibrin gel containing bFGF were transplanted to rat TBI sites. Transplantation of hBMSCs suspended in fibrin gel without bFGF served as a control. hBMSC transplantation and bFGF treatment showed enhanced neural tissue regeneration than that of the control. The infarction volume and apoptotic activity of the transplanted hBMSCs were significantly decreased, and functional outcomes were significantly improved in the hBMSC transplantation and bFGF treatment group than in the control group. This study demonstrates that bFGF significantly enhances histological and functional recovery when used in hBMSC transplantation therapy in TBI. (C) 2007 Elsevier Inc. All rights reserved.	Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea; Seoul Natl Univ, Sch Chem & Biol Engn, Seoul 151742, South Korea; Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Neurosurg, Seoul 120752, South Korea; Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 133791, South Korea; Hanyang Univ, Inst Mental Hlth, Seoul 133791, South Korea	Chang, JW (corresponding author), Hanyang Univ, Dept Bioengn, Seoul 133791, South Korea.	jchang@yumc.yonsei.ac.kr; bskim@hanyang.ac.kr	lee, sang hun/Q-4650-2019; Kim, Byung-Soo/O-2352-2013	lee, sang hun/0000-0002-9005-5966; Chang, Jin Woo/0000-0002-2717-0101			Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Brundin P, 2000, CELL TRANSPLANT, V9, P179, DOI 10.1177/096368970000900205; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Hile DD, 2000, J CONTROL RELEASE, V66, P177, DOI 10.1016/S0168-3659(99)00268-0; Jeon O, 2005, J CONTROL RELEASE, V105, P249, DOI 10.1016/j.jconrel.2005.03.023; Kilic E, 2002, ANN NEUROL, V52, P617, DOI 10.1002/ana.10356; Kilic E, 2004, NEUROSCIENCE, V128, P359, DOI 10.1016/j.neuroscience.2004.06.064; Li Q, 2002, EXP NEUROL, V177, P531, DOI 10.1006/exnr.2002.7994; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; OLSSON M, 1995, J NEUROSCI, V15, P3863; Ourednik J, 2004, CELL TRANSPLANT, V13, P307, DOI 10.3727/000000004783983963; Ramirez JJ, 1999, NEUROREPORT, V10, P1201, DOI 10.1097/00001756-199904260-00008; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Rozas G, 1997, BRAIN RES PROTOC, V2, P75, DOI 10.1016/S1385-299X(97)00034-2; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V65, P389, DOI 10.1016/S0168-3659(99)00221-7; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Tabata Y, 1998, BIOMATERIALS, V19, P807, DOI 10.1016/S0142-9612(98)00233-6; Wagner JP, 1999, J NEUROSCI, V19, P6006, DOI 10.1523/JNEUROSCI.19-14-06006.1999; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yulug B, 2004, BRAIN RES, V996, P76, DOI 10.1016/j.brainres.2003.10.012	31	34	51	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X	1090-2104		BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	JUL 20	2007	359	1					40	45		10.1016/j.bbrc.2007.05.046			6	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	178YZ	WOS:000247257600007	17531197				2021-06-18	
J	Henry, JD; Phillips, LH; Crawford, JR; Kliegel, M; Theodorou, G; Summers, F				Henry, Julie D.; Phillips, Louise H.; Crawford, John R.; Kliegel, Matthias; Theodorou, Georgia; Summers, Fiona			Traumatic brain injury and prospective memory: Influence of task complexity	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							VERBAL FLUENCY PERFORMANCE; EVENT; INTENTIONS; DEFICITS; AGE	A quantitative review indicated that prospective memory impairment is a consistent feature of traumatic brain injury (TBI). However, evidence also suggests that manipulations that increase demands on controlled attentional processes moderate the magnitude of observed deficits. A total of 16 TBI participants were compared with 15 matched controls on a task in which the number of prospective target events was manipulated. This manipulation was of interest because two competing models make different predictions as to its effect on controlled attentional processes. In the context of Smith and Bayen's (2004) preparatory attentional processes and memory processes (PAM) model increasing the number of target events should increase requirements for controlled attentional processing. In contrast, McDaniel and Einstein's (2000) multiprocess framework assumes that distinct target events presented in focal awareness of the processing activities required for the ongoing task are likely to depend on automatic processes. This latter model therefore leads to the prediction that increasing the number of target events should not increase demands upon controlled attentional processes. Consistent with McDaniel and Einstein's (2000) multiprocess framework, TBI patients were significantly and comparably impaired on the one- and the four-target-event conditions relative to controls. Further, TBI deficits could not be attributed to increased difficulty with the retrospective component of the prospective memory task. The practical and theoretical implications of these results are discussed.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Aberdeen, Dept Neurosurg, Aberdeen, Scotland; Univ Zurich, Zurich, Switzerland	Henry, JD (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	julie.henry@unsw.edu.au	Phillips, Louise H/A-7952-2008; Crawford, John R/A-4165-2008	Phillips, Louise H/0000-0003-1005-8567; Crawford, John R/0000-0003-3403-3428; Henry, Julie/0000-0002-2081-3717; Kliegel, Matthias/0000-0002-2001-2522; Phillips, Louise/0000-0002-0988-3028			Carlesimo GA, 2004, J INT NEUROPSYCH SOC, V10, P679, DOI 10.1017/S1355617704105079; Cherry KE, 2001, MEMORY, V9, P177, DOI 10.1080/09658210143000092; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Craik F.I.M., 1986, HUMAN MEMORY COGNITI, P409; Crawford J.R, 2005, EFFECTIVENESS REHABI, P233, DOI DOI 10.1093/ACPROF:OSO/9780198526544.003.0019; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; EINSTEIN GO, 1992, PSYCHOL AGING, V7, P471, DOI 10.1037/0882-7974.7.3.471; Einstein GO, 2000, PSYCHOL AGING, V15, P671, DOI 10.1037//0882-7974.15.4.671; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Kinch J., 2001, BRAIN IMPAIR, V2, P119, DOI [10.1375/brim.2.2.119, DOI 10.1375/BRIM.2.2.119]; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kliegel M, 2004, BRAIN COGNITION, V56, P43, DOI 10.1016/j.bandc.2004.05.005; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVIN HS, 1991, HDB NEUROPSYCOLOGY, V6, P183; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; Maujean A., 2003, BRAIN IMPAIR, V4, P135, DOI DOI 10.1375/BRIM.4.2.135.27024; McDaniel MA, 2004, J EXP PSYCHOL LEARN, V30, P605, DOI 10.1037/0278-7393.30.3.605; McDaniel MA, 2000, APPL COGNITIVE PSYCH, V14, pS127, DOI 10.1002/acp.775; Nelson HE, 1982, NATL ADULT READING T; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D., 2002, BRAIN IMPAIR, V3, DOI [https://doi.org/10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Smith RE, 2004, J EXP PSYCHOL LEARN, V30, P756, DOI 10.1037/0278-7393.30.4.756; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; TEASDALE G, 1974, LANCET, V2, P81	32	34	35	1	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUL	2007	29	5					457	466		10.1080/13803390600762717			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	185RJ	WOS:000247727800001	17564911				2021-06-18	
J	Dore-Duffy, P; Wang, XQ; Mehedi, A; Kreipke, CW; Rafols, JA				Dore-Duffy, Paula; Wang, Xueqain; Mehedi, Afroza; Kreipke, Christian W.; Rafols, Jose A.			Differential expression of capillary VEGF isoforms following traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						brain trauma; angiogenesis; pericytes	ENDOTHELIAL GROWTH-FACTOR; VESSEL FORMATION; TUMOR-GROWTH; ANGIOGENESIS; HEPARIN; RECEPTORS; VEGF(121); BINDING; CELLS; PERICYTES	Objectives: While it is known that angiogenesis occurs after trauma, we sought to characterize the expression of vascular endothelial growth factor (VEGF) subtypes, vascular endothelial growth factor receptor 2 (VEGFR2) and angiopoietin within capillaries of animals subjected to traumatic brain injury (TBI). Further, we sought to characterize pericyte cell death in isolated capillaries. Methods: We used Marmarou's acceleration impact model to induce head trauma and measured VEGF, VEGFR2 and angiopoietin levels in isolated capillaries. TUNEL was used to determine pericyte cell death. Results: The VEGF response was restricted to the VEGF120 isoform. No increase in transcripts for VEGF164 and VEGF188 was observed. VEGFR2 was marginally increased and angiopoietin was increased. A subset of pericytes were TUNEL-positive. Discussion: These results show a distinct expression pattern of angiogenic factors following injury and suggest that pericyte involvement in adaptive angiogenesis may be altered following TBI.	Wayne State Univ, Sch Med, Div Neuroimmunol, Dept Neurol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA	Dore-Duffy, P (corresponding author), Wayne State Univ, Sch Med, Div Neuroimmunol, Dept Neurol, 540 E Canfield, Detroit, MI 48201 USA.	pdduffy@med.wayne.edu					Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7; Ashikari- Hada S, 2005, J BIOL CHEM, V280, P31508, DOI 10.1074/jbc.M414581200; BALLAUN C, 1995, J INVEST DERMATOL, V104, P7, DOI 10.1111/1523-1747.ep12613450; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bates DO, 2002, CANCER RES, V62, P4123; Beckman JD, 2006, ENDOCRINE, V29, P467, DOI 10.1385/ENDO:29:3:467; Benelli R, 2006, CURR PHARM DESIGN, V12, P3101, DOI 10.2174/138161206777947461; Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232; BREIER G, 1992, DEVELOPMENT, V114, P521; Brkovic A, 2007, J CELL BIOCHEM, V100, P727, DOI 10.1002/jcb.21124; Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x; Cheung CY, 1999, J SOC GYNECOL INVEST, V6, P179, DOI 10.1016/S1071-5576(99)00016-7; Cheung CY, 1998, GROWTH FACTORS, V16, P11, DOI 10.3109/08977199809017488; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; COHEN T, 1995, J BIOL CHEM, V270, P11322, DOI 10.1074/jbc.270.19.11322; DIAZFLORES L, 1994, ANAT REC, V238, P68, DOI 10.1002/ar.1092380109; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Dore-Duffy P, 2006, J CEREBR BLOOD F MET, V26, P613, DOI 10.1038/sj.jcbfm.9600272; Dore-Duffy Paula, 2003, Methods Mol Med, V89, P375; DOREDUFFY P, 1994, J CEREBR BLOOD F MET, V14, P837, DOI 10.1038/jcbfm.1994.105; Ehrbar M, 2004, CIRC RES, V94, P1124, DOI 10.1161/01.RES.0000126411.29641.08; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Galambos C, 2002, AM J RESP CELL MOL, V27, P194, DOI 10.1165/ajrcmb.27.2.4703; GitayGoren H, 1996, J BIOL CHEM, V271, P5519, DOI 10.1074/jbc.271.10.5519; Goerges AL, 2003, J BIOL CHEM, V278, P19518, DOI 10.1074/jbc.M211208200; Gowdak LHW, 2000, CIRCULATION, V102, P565; Hamik A, 2006, ARTERIOSCL THROM VAS, V26, P1936, DOI 10.1161/01.ATV.0000232542.42968.e3; HAVASHI T, 2006, CURR NEUROVASC RES, V3, P119; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; LaManna JC, 2004, J EXP BIOL, V207, P3163, DOI 10.1242/jeb.00976; Lim M, 2006, CURR NEUROVASC RES, V3, P237, DOI 10.2174/156720206778018730; LOBB RR, 1985, INT J CANCER, V36, P473, DOI 10.1002/ijc.2910360410; Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925-4773(01)00601-3; MAJONE TE, 1995, J BIOL CHEM, V270, P15059; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mattot V, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000013925.19218.7B; Mohamedali KA, 2006, CANCER RES, V66, P10919, DOI 10.1158/0008-5472.CAN-06-0459; MOHANRAJ D, 1995, BIOCHEM BIOPH RES CO, V215, P750, DOI 10.1006/bbrc.1995.2527; Ng YS, 2001, DEV DYNAM, V220, P112, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1093>3.0.CO;2-D; PARK JE, 1993, MOL BIOL CELL, V4, P1317; Pichiule P, 2003, ADV EXP MED BIOL, V530, P611; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Ramsauer M, 2002, FASEB J, V16, P1274, DOI 10.1096/fj.01-0814fje; Rosenthal RA, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011010; Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x; Sakurai S, 2002, INVEST OPHTH VIS SCI, V43, P2774; SEIP WF, 1980, J CLIN MICROBIOL, V11, P226, DOI 10.1128/JCM.11.3.226-233.1980; Shimizu T, 2007, J REPROD DEVELOP, V53, P105, DOI 10.1262/jrd.18088; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; SOBEL AT, 1977, J IMMUNOL, V119, P1230; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; TESSLER S, 1994, J BIOL CHEM, V269, P12456; Tian Xuejun, 1999, Zhonghua Zhongliu Zazhi, V21, P93; Tober KL, 1998, BIOCHEM BIOPH RES CO, V247, P644, DOI 10.1006/bbrc.1998.8787; Wakui S, 2006, LAB INVEST, V86, P1172, DOI 10.1038/labinvest.3700476; Wiley SR, 2003, CYTOKINE GROWTH F R, V14, P241, DOI 10.1016/S1359-6101(03)00019-4; Zhang HT, 2000, BRIT J CANCER, V83, P63	59	34	34	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2007	29	4					395	403		10.1179/016164107X204729			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	192PM	WOS:000248214200010	17626736				2021-06-18	
J	Rodgers, ML; Strode, AD; Norell, DM; Short, RA; Dyck, DG; Becker, B				Rodgers, Martina L.; Strode, Anne D.; Norell, Diane M.; Short, Robert A.; Dyck, Dennis G.; Becker, Bruce			Adapting multiple-family group treatment for brain and spinal cord injury intervention development and preliminary outcomes	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						family psychoeducation; family support program; traumatic brain injury; spinal cord injury	QUALITY-OF-LIFE; CAREGIVER BURDEN; SCHIZOPHRENIA; IMPACT; SATISFACTION; MANAGEMENT; SURVIVORS; PATIENT; TBI	Objective: There is a need for interventions that assist in managing the multiple adjustments of persons with spinal cord and brain injuries and their families. The purpose of the present field-initiated development project was to adapt a family psychoeducation model, multiple-family group treatment (MFGT), for persons with brain and spinal cord injury and their families. Design: The experiences of survivors and caregivers in MFGT were evaluated using quantitative and qualitative methods. Twenty-seven survivors and 28 caregivers participated in MFGT for 12-18 mos. Reliable and valid quantitative measures were used to assess a variety of target outcomes. Additionally, semistructured interviews and focus groups were conducted with participants. Results: Survivors reported a decrease in depressive symptoms and anger expression toward others as well as an Increase in life satisfaction. Caregivers reported a significant reduction in burden. The themes derived from the qualitative analysis addressed the normalization of the caregiving experience, importance of socialization, improvement in a variety of coping skills, and education about the injuries. Conclusions: The findings support the adaptation of MFGT for brain and spinal cord injuries.	Washington State Univ, Washington Inst Mental Illness Res & Training, Spokane, WA 99210 USA; Washington State Univ, Dept Psychol, Spokane, WA 99210 USA; St Lukes Rehabil Inst, Spokane, WA USA	Dyck, DG (corresponding author), Washington State Univ, Washington Inst Mental Illness Res & Training, POB 1495, Spokane, WA 99210 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [H133G RR 020006] Funding Source: Medline		ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dyck DG, 1999, PSYCHOSOM MED, V61, P411, DOI 10.1097/00006842-199907000-00001; Dyck DG, 2000, PSYCHIAT SERV, V51, P513, DOI 10.1176/appi.ps.51.4.513; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Folzer SM, 2001, AM J ORTHOPSYCHIAT, V71, P245, DOI 10.1037/0002-9432.71.2.245; Gonzalez S, 2002, MULTIFAMILY GROUPS T, P315; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; LEHMAN AF, 1988, EVAL PROGRAM PLANN, V11, P51, DOI 10.1016/0149-7189(88)90033-X; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCDONELL MG, 2006, FAM PROCESS, V33, P147; MCFARLANE W, 1991, MULTIPLE FAMILY PSYC; McFarlane WR, 1996, PSYCHIAT SERV, V47, P744; McFarlane WR, 2003, J MARITAL FAM THER, V29, P223, DOI 10.1111/j.1752-0606.2003.tb01202.x; MCFARLANE WR, 1995, FAM PROCESS, V34, P127, DOI 10.1111/j.1545-5300.1995.00127.x; MCFARLANE WR, 1994, NEW DIRECTIONS MENTA, V62, P13, DOI DOI 10.1002/YD.23319946204; NEUGARTEN BL, 1961, J GERONTOL, V16, P134, DOI 10.1093/geronj/16.2.134; NOVAK M, 1989, GERONTOLOGIST, V29, P798, DOI 10.1093/geront/29.6.798; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Prigatano GP, 2003, INT REV PSYCHIATR, V15, P371, DOI 10.1080/09540260310001606755; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROHRER K, 1980, ARCH PHYS MED REHAB, V61, P225; Rotondi AJ, 2005, J HEAD TRAUMA REHAB, V20, P173, DOI 10.1097/00001199-200503000-00005; Sarason, 1985, SOCIAL SUPPORT THEOR, P73, DOI DOI 10.1007/978-94-009-5115-0_5; SATIN W, 1989, J PEDIATR PSYCHOL, V14, P259, DOI 10.1093/jpepsy/14.2.259; Silverman D, 2004, QUALITATIVE RES PRAC; Smith Michele S, 2002, Rehabil Nurs, V27, P209; SPIELBERGER CD, 1985, ANGER HOSTILITY CARD, P6; Strauss A., 1998, BASICS QUALITATIVE R; Sullivan J, 1990, Crit Care Nurs Clin North Am, V2, P407; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; *US CDCP, 2000, EP TRAUM BRAIN INJ U; VITALIANO PP, 1985, MULTIVAR BEHAV RES, V20, P3, DOI 10.1207/s15327906mbr2001_1; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; Weitzenkamp DA, 1997, ARCH PHYS MED REHAB, V78, P822, DOI 10.1016/S0003-9993(97)90194-5; WELLER DJ, 1977, SOC WORK HEALTH CARE, V3, P7, DOI 10.1300/J010v03n01_02; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	49	34	34	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	2007	86	6					482	492		10.1097/PHM.0b013e31805c00a1			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	172UJ	WOS:000246829600009	17515688				2021-06-18	
J	Stalnacke, BM; Elgh, E; Sojka, P				Stalnacke, Britt-Marie; Elgh, Eva; Sojka, Peter			One-year follow-up of mild traumatic brain injury: Cognition, disability and life satisfaction of patients seeking consultation	JOURNAL OF REHABILITATION MEDICINE			English	Article						traumatic brain injury; head trauma; brain concussion; post-concussion symptoms; life satisfaction; neuropsychological tests	POST-CONCUSSION SYMPTOMS; NEURON-SPECIFIC ENOLASE; HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; WESTERN SWEDEN; SERUM-LEVELS; CHRONIC PAIN; ACUTE-PHASE; TASK; QUESTIONNAIRE	Objective: To investigate cognitive function, symptoms, disabilities and life satisfaction of patients with mild traumatic brain injury who accepted consultation one year post-trauma. Design: Prospective study. Patients: Sixty-nine patients (16 accepted the consultation offered, 53 declined). Methods: At follow-up, the patients answered questionnaires about symptoms, disabilities (RHFUQ) and life satisfaction (LiSat-11). The patients who underwent consultation and their healthy control subjects were administered a neuropsychological evaluation. Results: In the group undergoing consultation, the number of cognitive tests with outcomes below cut-off limits (-1.5 SD) was statistically significantly higher compared with a control group (21 tests in 11 patients vs 8 tests in 7 control subjects; p = 0.025). The number of patients with one or more disability was statistically significantly higher among patients with consultation than without (94% and 34%, respectively; p < 0.001). Total RHFUQ score was statistically significantly higher for the group with consultation than without (5.9 +/- 3.7 and 1.1 +/- 2.3, respectively p < 0.001). The group with consultation exhibited a lower level of life satisfaction (41.5 +/- 10.4 vs 45.8 +/- 13.8 for the non-consulting group; p = 0.057). Conclusion: The high frequency of occurrence of disabilities and lower cognitive functioning, together with the lower level of life satisfaction, appear to characterize patients choosing consultation 1 year post-injury. This highlights the importance of offering consultation for persons suffering mild head injuries.	Dept Community Med & Rehabil, Umea, Sweden; Dept Rehabil Med, Umea, Sweden; Dept Geriatr, Umea, Sweden	Sojka, P (corresponding author), Umea Univ Hosp, Dept Community Med & Rehabil Rehabil Med, Bldg 9A, SE-90185 Umea, Sweden.	peter.sojka@clinphys.umu.se					Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Fugl-Meyer A. R., 1991, CLIN REHABIL, V5, DOI [10.1177/026921559100500105, DOI 10.1177/026921559100500105, 10.1177/026921559100500105.]; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Levander S., 1988, AUTOMATED PSYCHOL TE; Lezak M, 2004, NEUROPSYCHOLOGICAL A, P158; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; REITAN RM, 1992, J CLIN PSYCHOL, V48, P521, DOI 10.1002/1097-4679(199207)48:4<521::AID-JCLP2270480414>3.0.CO;2-C; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Skell RL, 2000, BRAIN INJURY, V14, P705; SMITH JR, 1986, MANUAL CWT SERIAL CO; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207	33	34	34	0	3	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2007	39	5					405	411		10.2340/16501977-0057			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	174SF	WOS:000246962400011	17549333	DOAJ Gold			2021-06-18	
J	Ko, K; Segan, S				Ko, Kathryn; Segan, Scott			In situ hinge craniectomy	NEUROSURGERY			English	Article						brain injury; craniectomy; hinge	DECOMPRESSIVE CRANIECTOMY	OBJECTIVE: To describe an optional method for performing decompressive craniectomy using in situ hinge craniectomy technique in patients with traumatic brain injury and stroke. METHODS: Sixteen patients underwent surgery for treatment of presenting pathology followed by the placement of hinge craniectomy. The technique is detailed. RESULTS: Six patients with traumatic head injury and 10 with stroke underwent treatment of their primary pathologies with subsequent hinge craniectomy. Of these patients, more than half underwent refixation of the hinge in a minor procedure after recovery. No patient had complications related to this technique and none required further cranial decompression. In patients with intracranial pressure monitoring, all displayed values in the normal range. CONCLUSION: In this limited study, in situ hinge craniectomy proved useful in the treatment of patients experiencing stroke or traumatic brain injury. This procedure has the potential to eliminate the additional second incision to explant the bone flap or the refrigeration storage of the bone flap. Also, the second operation to restore the cranial contour by reimplanting the bone flap or by the creation of a cranioplasty with artificial material would not be necessary.	Cornell Univ, Weill Med Coll, Dept Neurosurg, New York, NY 10021 USA; St Barnabas Hosp, Stroke Ctr, Div Neurol, Bronx, NY USA	Ko, K (corresponding author), Cherokee Stn, POB 20398, New York, NY 10021 USA.	k@gyrus.cc					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005; Raposio E, 1998, ANN PLAS SURG, V41, P17, DOI 10.1097/00000637-199807000-00004; Traxler H, 2002, CLIN ANAT, V15, P173, DOI 10.1002/ca.10022; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110	6	34	34	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2007	60	4		S			255	258		10.1227/01.NEU.0000255380.64969.81			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	155VR	WOS:000245607100015	17415161				2021-06-18	
J	Tranel, D; Hathaway-Nepple, J; Anderson, SW				Tranel, Daniel; Hathaway-Nepple, Julie; Anderson, Steven W.			Impaired behavior on real-world tasks following damage to the ventromedial prefrontal cortex	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							SORTING TEST-PERFORMANCE; TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE DAMAGE; STRATEGY APPLICATION; ECOLOGICAL VALIDITY; EXECUTIVE FUNCTION; SIMPLIFIED VERSION; GOAL MANAGEMENT; DEFICITS; LESIONS	Patients with damage to the ventromedial prefrontal cortices (VMPC) commonly manifest blatant behavioral navigation defects in the real world, but it has been difficult to measure these impairments in the clinic or laboratory. Using a set of "strategy application" tasks, which were designed by Shallice and Burgess (1991) to be ecologically valid for detecting executive dysfunction, we investigated the hypothesis that VMPC damage would be associated with defective performance on such tasks, whereas damage outside the VMPC region would not. A group of 9 patients with bilateral VMPC damage was contrasted with comparison groups of participants with (a) prefrontal brain damage outside the VMPC region (n = 8); (b) nonprefrontal brain damage (n = 17); and (c) no brain damage (n=20). We found support for the hypothesis: VMPC patients had more impaired performances on the strategy application tasks, especially on a Multiple Errands Test that required patients to execute a series of unstructured tasks in a real-world setting (shopping mall). The results are consistent with the notion that efficacious behavioral navigation is dependent on the VMPC region. However, the strategy application tasks were relatively time consuming and effortful, and their diagnostic yield over and above conventional executive functioning tests may not be sufficient to warrant their inclusion in standard clinical assessment.	Univ Iowa, Coll Med, Dept Neurol, Div Cognit Neurosci, Iowa City, IA 52242 USA	Tranel, D (corresponding author), Univ Iowa Hosp & Clin, Dept Neurol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	daniel-tranel@uiowa.edu		Anderson, Steven/0000-0002-7364-1680; Tranel, Daniel/0000-0002-1338-1389	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA022549, R01 DA022549-02] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS019632, P01 NS19632, NS19632] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS019632, P01NS019632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA022549] Funding Source: NIH RePORTER		Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; ANDERSON SW, 2002, HDB NEUROPSYCHOLOGY, V7, P145; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Damasio A., 1994, DESCARTESERROR EMOTI; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; Damasio H, 2004, COGNITION, V92, P179, DOI 10.1016/j.cognition.2002.07.001; Damasio H, 2000, HDB NEUROPSYCHOLOGY, P77; Denburg NL, 2005, NEUROPSYCHOLOGIA, V43, P1099, DOI 10.1016/j.neuropsychologia.2004.09.012; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fellows LK, 2005, CEREB CORTEX, V15, P58, DOI 10.1093/cercor/bhh108; Frank RJ, 1997, NEUROIMAGE, V5, P13, DOI 10.1006/nimg.1996.0250; Goel V, 2000, COGN NEUROPSYCHOL, V17, P415, DOI 10.1080/026432900410775; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; GRAFMAN J, 1990, PERCEPT MOTOR SKILL, V71, P1120, DOI 10.2466/PMS.71.8.1120-1122; Jelicic M, 2001, INT J NEUROSCI, V110, P73, DOI 10.3109/00207450108994222; Kafer K L, 1997, J Int Neuropsychol Soc, V3, P108; Kliegel M, 2000, MEM COGNITION, V28, P1041, DOI 10.3758/BF03209352; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; LEVINE B, IN PRESS J CLIN EXPT; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shuren JE, 2002, ARCH NEUROL-CHICAGO, V59, P916, DOI 10.1001/archneur.59.6.916; Stout JC, 2004, PSYCHON B REV, V11, P742, DOI 10.3758/BF03196629; Stuss DT, 2000, NEUROPSYCHOLOGIA, V38, P388, DOI 10.1016/S0028-3932(99)00093-7; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Tranel D, 2005, BRAIN, V128, P2872, DOI 10.1093/brain/awh643; TRANEL D, IN PRESS HDB CLIN NE; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Yechiam E, 2005, PSYCHOL SCI, V16, P973, DOI 10.1111/j.1467-9280.2005.01646.x	49	34	34	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	2007	29	3					319	332		10.1080/13803390600701376			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	165XG	WOS:000246340000009	17454352	Green Accepted			2021-06-18	
J	Berger, C; Xia, F; Kohrmann, M; Schwab, S				Berger, Christian; Xia, Feng; Koehrmann, Martin; Schwab, Stefan			Hypothermia in acute stroke - Slow versus fast rewarming - An experimental study in rats	EXPERIMENTAL NEUROLOGY			English	Article						hypothermia; glutamate; middle cerebral artery; stroke; brain edema; inflammation	CEREBRAL-ARTERY OCCLUSION; EXCITATORY AMINO-ACIDS; TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; FOREBRAIN ISCHEMIA; THERAPEUTIC HYPOTHERMIA; NEURONAL DAMAGE; CYCLOSPORINE-A; FOCAL MODEL	The rewarming phase after therapeutic hypothermia in cerebral ischemia appears crucial as rapid rewarming may lead to rebound phenomena and enhance deleterious ischemic effects. We hypothesized that slow and controlled rewarming after moderate hypothermia is superior to fast rewarming in rats subjected to 90 min temporary middle cerebral artery occlusion (tMCAO). Two experiments were designed: (i) 34 rats were randomly assigned to either normothermic treatment, to hypothermia (33 degrees C) with rapid rewarming within 20 min, or to hypothermia with slow rewarming within 2 h after 4 h of hypothermia starting 2 h after tMCAO. Infarct size, neuroscore, myeloperoxidase and aquaporin 4 (AQP4) positive cells were assessed on day 5 after tMCAO. (ii) In 15 rats, striatal cerebral microdialysis was performed from 1.5 h before until 8 h after tMCAO. Total infarct volume was largest in the normothermic group (89.9 +/- 16.9 mm(3)) followed by the fast rewarming group (69.2 +/- 12.6 mm(3)), and a significantly smaller infarct volume in the slow rewarming group (41.1 +/- 6.6 mm(3), p < 0.05). Neurological functions improved in both hypothermia groups at day 5 after tMCAO (Neuroscore median 2.5 in normothermia vs. 1.5 in both hypothermia groups) though without any difference between slowly and fast rewarmed animals. Periinfarct expression of AQP4 was less prominent in slowly rewarmed animals as was the count of MPO-positive cells in subcortical regions. Glutamate release was significantly higher at 4 distinct time points in the control group. Slow rewarming after a period of hypothermia is superior to fast rewarming. It may blunt deleterious rebound effects such as overexpression of AQP4, sustain anti-inflammatory mechanisms and thereby preserve the neuroprotection delivered by hypothermia. (c) 2006 Elsevier Inc. All rights reserved.	Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany	Berger, C (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	christian.berger@urz.uni-heidelberg.de					Aoki A, 2002, NEUROL RES, V24, P271, DOI 10.1179/016164102101199909; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Berger C, 2002, STROKE, V33, P519, DOI 10.1161/hs0102.100878; BLAIR E, 1956, CIRCULATION, V13, P909, DOI 10.1161/01.CIR.13.6.909; Boris-Moller F, 1998, EXP BRAIN RES, V121, P277, DOI 10.1007/s002210050461; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; Colbourne F, 1999, J CEREBR BLOOD F MET, V19, P742, DOI 10.1097/00004647-199907000-00003; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Fujisawa H, 1999, J NEUROTRAUM, V16, P1083, DOI 10.1089/neu.1999.16.1083; Inamasu J, 2001, NEUROL RES, V23, P105, DOI 10.1179/016164101101198217; Ishikawa M, 1999, STROKE, V30, P1679, DOI 10.1161/01.STR.30.8.1679; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982; Kloss CUA, 2002, NEUROL RES, V24, P713, DOI 10.1179/016164102101200636; Kollmar R, 2002, STROKE, V33, P1899, DOI 10.1161/01.STR.0000019603.29818.9C; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Maier CM, 2001, J NEUROSURG, V94, P90, DOI 10.3171/jns.2001.94.1.0090; MARSH DC, 1991, HEPATOLOGY, V13, P500, DOI 10.1002/hep.1840130318; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; MENZIES SA, 1992, NEUROSURGERY, V31, P100, DOI 10.1227/00006123-199207000-00014; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Ooboshi H, 2000, BRAIN RES, V884, P23, DOI 10.1016/S0006-8993(00)02861-4; POPOVIC V, 1959, ANN NY ACAD SCI, V80, P320, DOI 10.1111/j.1749-6632.1959.tb49212.x; Schabitz WR, 2001, STROKE, V32, P1226, DOI 10.1161/01.STR.32.5.1226; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1998, ACT NEUR S, V71, P131; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; STEEN PA, 1979, STROKE, V10, P522, DOI 10.1161/01.STR.10.5.522; Steiner T, 2001, STROKE, V32, P2833, DOI 10.1161/hs1201.99511; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Wakiyama S, 1997, BRIT J SURG, V84, P459; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; ZHANG RL, 1995, BRAIN RES, V682, P182, DOI 10.1016/0006-8993(95)00346-R	45	34	36	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2007	204	1					131	137		10.1016/j.expneurol.2006.10.002			7	Neurosciences	Neurosciences & Neurology	148PC	WOS:000245086100014	17112513				2021-06-18	
J	Rusnak, M; Janciak, I; Majdan, M; Wilbacher, I; Mauritz, W				Rusnak, Martin; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Mauritz, Walter		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria I: Introduction to the study	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; treatment; guidelines; epidemiology	GLASGOW OUTCOME SCALE; CLINICAL-TRIALS; CARE; GUIDELINES	OBJECTIVES: The goals of the Austrian Severe Traumatic Brain Injury Study were to investigate the current management of patients with severe traumatic brain injury in Austria and to assess the effects of introducing guidelines for the management of severe traumatic brain injury upon the outcome of these patients. The purpose of this paper is to give a detailed description of the goals, methods, and overall results of the study, and to provide an introduction to a series of papers where the results of the study will be presented and discussed. STUDY DESIGN: The study included patients with severe traumatic brain injury from five centers in Austria. Data on accident, pre-hospital treatment, hospital treatment, and patient status were collected prospectively. Patient data was entered daily for the first 10 days in hospital and then up to a year after discharge from intensive care. All data was entered into an internet-based database. The data was evaluated to describe epidemiology, pre-hospital treatment, medical management, and surgical management; the evaluation also assessed the effects of guideline-based management on traumatic brain injury patients. RESULTS: The data set comprises a total of 492 patient records from the 5 participating hospitals; this data was collected over a 3-year period. Data quality is considered good; the number of missing data items is low. ICU mortality was 31.6%. Final outcome: 23% of the patients had a good recovery, 10% had moderate disabilities, 8% had severe disabilities, 6% were persistent vegetative, and 38% died. Final outcome was unknown in 16% of patients. CONCLUSIONS: This study proved that an internetbased database may be a valuable tool for prospective multicenter studies if many variables have to be collected for a high number of patients. The results of our study provide enough evidence to initiate further research on many aspects of the management of traumatic brain injury patients.	INRO, Med Advisory Board, A-1080 Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anaesthesia & Crit Care Med, Vienna, Austria	Mauritz, W (corresponding author), INRO, Med Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Rusnak, Martin/K-9349-2016; Majdan, Marek/K-5017-2012	Rusnak, Martin/0000-0003-3321-1042; Majdan, Marek/0000-0001-8037-742X; Mauritz, Walter/0000-0001-9043-3712			*ADD INC, XLSTAT VERS; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Drobetz H, 2000, ANASTH INTENSIV NOTF, V35, P630, DOI 10.1055/s-2000-7365; Erly WK, 2002, AM J NEURORADIOL, V23, P103; Eysenbach G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.2.e13; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Lallas CD, 2004, J UROLOGY, V171, P1880, DOI 10.1097/01.ju.0000120221.39184.3c; Laupland KB, 2004, CRIT CARE, V8, pR431, DOI 10.1186/cc2947; Marks RG, 2004, CONTROL CLIN TRIALS, V25, P437, DOI 10.1016/j.cct.2004.07.001; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Mauritz W, 2003, CLIN RES REGUL AFF, V20, P81, DOI 10.1081/CRP-120018744; Nathanson AT, 1999, WILD ENVIRON MED, V10, P218, DOI 10.1580/1080-6032(1999)010[0218:WIROAP]2.3.CO;2; *OST STAT ZENTR, 2000, KAPITEL, V3, P11; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; *US DEP HHS CDCP N, 1999, TRAUM BRAIN INJ US R; Wade D T, 1987, Int Rehabil Med, V8, P129; Wei SJ, 2004, J CLIN ONCOL, V22, P4730, DOI 10.1200/JCO.2004.07.103; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wyatt JC, 2000, J AM MED INFORM ASSN, V7, P426, DOI 10.1136/jamia.2000.0070426	22	34	34	0	8	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					23	28		10.1007/s00508-006-0760-5			6	Medicine, General & Internal	General & Internal Medicine	142GQ	WOS:000244637800007	17318747				2021-06-18	
J	Francisco, GE; Walker, WC; Zasler, ND; Bouffard, MH				Francisco, Gerard E.; Walker, William C.; Zasler, Nathan D.; Bouffard, Mark H.			Pharmacological management of neurobehavioural sequelae of traumatic brain injury: A survey of current physiatric practice	BRAIN INJURY			English	Article						brain injuries; drug therapy; survey	AGITATION; MEMORY	Objective: To describe pharmacological preference for the treatment of neurobehavioural sequela of traumatic brain injury (TBI). Design: Survey. Participants: TBI physiatrists were divided into specialists ( completed a TBI fellowship or commit > 70% of clinical practice time to TBI) and non-specialists. Outcome measures: Participants were asked to list the drugs most frequently prescribed for each of 15 neurobehavioural symptoms commonly encountered during TBI rehabilitation and enumerate neurobehavioural symptom for which they prescribed each listed drug or drug class. Results: There was no clear consensus on drug of choice for each target symptom. There were differences in drug choice patterns between specialists and non-specialists, especially for agitation. Conclusion: There is limited uniformity in drug selection for various TBI neurobehavioural sequela. Potential explanations include the availability of various medications with similar clinical effect, the variability of clinical presentation and severity of neurobehavioural symptoms and the lack of clinical practice guidelines.	Inst Rehabil & Res, Houston, TX 77030 USA; Univ Texas, Baylor Coll Med, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Houston, TX USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Concuss Care Ctr Virginia, Glen Allen, VA USA	Francisco, GE (corresponding author), Inst Rehabil & Res, 1333 Moursund St, Houston, TX 77030 USA.	gerard.e.francisco@uth.tmc.edu	Walker, William C/N-3162-2014				Beers SR, 2005, J HEAD TRAUMA REHAB, V20, P450, DOI 10.1097/00001199-200509000-00006; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P917; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; FLEMINGER S, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003299; Fugate LP, 1997, ARCH PHYS MED REHAB, V78, P924, DOI 10.1016/S0003-9993(97)90051-4; Giacino JT, 2003, J HEAD TRAUMA REHAB, V18, P4, DOI 10.1097/00001199-200301000-00003; Levy M, 2005, NEUROREHABILITATION, V20, P279; MALKMUS D, 1980, REHAPILITATION HEAD; MEYTHELER JM, 2006, HEAD TRAUMA REHABILI, V21, P416; MEYTHELER JM, 1992, ARCH PHYS MED REHAB, V10, P917; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ripley DL, 2006, J HEAD TRAUMA REHAB, V21, P85, DOI 10.1097/00001199-200601000-00010; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; SPEECH TJ, 2003, J HEAD TRAUMA REHAB, V18, P4; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	15	34	34	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	10					1007	1014		10.1080/02699050701559558			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600002	17891562				2021-06-18	
S	Sharma, HS; Patnaik, R; Patnaik, S; Mohanty, S; Sharma, A; Vannemreddy, P		Slikker, W; Andrew, RJ; Trembly, B		Sharma, H. S.; Patnaik, R.; Patnaik, S.; Mohanty, S.; Sharma, A.; Vannemreddy, P.			Antibodies to serotonin attenuate closed head injury induced blood-brain barrier disruption and brain pathology	NEUROPROTECTIVE AGENTS: EIGHTH INTERNATIONAL NEUROPROTECTION SOCIETY MEETING	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	8th International Conference on Neuroprotective Agents	SEP 18-20, 2006	Mackinac Isl, MI	Int Neuroprotect Soc		closed head injury; serotonin; brain edema; blood-brain barrier; brain damage; antibodies to serotonin; neuroprotection	RAT SPINAL-CORD; TERM IMMOBILIZATION STRESS; EXPERIMENTAL ANIMAL-MODELS; INDUCED EDEMA FORMATION; TOPICAL APPLICATION; NITRIC-OXIDE; CELL CHANGES; MICROVASCULAR PERMEABILITY; YOUNG-RATS; TRAUMA	Closed head injury (CHI) often results in profound brain swelling and instant death of the victims due to compression of the vital centers. However, the neurochemical basis of edema formation in CHI is still obscure. Previous studies from our laboratory show that blockade of serotonin synthesis prior to CHI in a rat model attenuates brain edema, indicating a prominent role for serotonin in head injury. Thus, neutralization of endogenous serotonin activity and/or blocking of its receptors will induce neuroprotection in CHI. Since serotonin has more than 14 receptors and selective serotonin antagonists are still not available, we used serotonin antiserum to neutralize its in vivo effects before or after CHI in a rat model. CHI was produced by an impact of 0.224 N on the right parietal skull bone under Equithesin anesthesia by dropping a weight of 114.6g from a height of 20 cm through a guide tube. This concussive brain injury resulted in blood-brain barrier (131313) disruption, brain edema formation, and volume swelling at 5 h that were most pronounced in the contralateral cerebral hemisphere. The plasma and brain serotonin levels were increased several-fold at this time. Intracere-broventricular administration of serotonin antiserum (1:20, monoclonal) into the left lateral cerebral ventricle (30 mu L in PBS) 30 min before or 30 min (but not 60 min) after CHI significantly attenuated BBB disruption, brain edema formation, volume swelling, and brain pathology. The plasma and brain serotonin levels continued to remain high. These observations are the first to suggest that antiserum to serotonin when administered into the CSF during the early phase of CHI are capable of inducing neuroprotection.	[Sharma, H. S.; Sharma, A.; Vannemreddy, P.] Uppsala Univ, Univ Hosp, Dept Surg Sci Anaesthesiol & Intens Care, Uppsala, Sweden; [Patnaik, R.] Banaras Hindu Univ, Dept Biomed Engn, Varanasi 221005, Uttar Pradesh, India; [Patnaik, S.] Banaras Hindu Univ, Dept Pharm, Inst Technol, Varanasi 221005, Uttar Pradesh, India; [Mohanty, S.] Banaras Hindu Univ, Inst Med Sci, Dept Neurosurg, Varanasi 221005, Uttar Pradesh, India	Sharma, HS (corresponding author), Frodingsgatan 12 28, SE-75421 Uppsala, Sweden.	Sharma@surgsci.uu.se	Patnaik, Ranjana/AAZ-4440-2020; Sharma, Aruna/D-4430-2011; Patnaik, Ranjana/D-1469-2017	Patnaik, Ranjana/0000-0002-8131-177X; Patnaik, Ranjana/0000-0002-8131-177X			Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; DEY P K, 1984, Indian Journal of Physiology and Pharmacology, V28, P177; DEY PK, 1983, INDIAN J MED RES, V77, P554; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; Gong Y, 2006, ACTA NEUROCHIR SUPPL, V96, P232; Kroesen BJ, 1998, ADV DRUG DELIVER REV, V31, P105, DOI 10.1016/S0169-409X(97)00096-3; Lesch KP, 2005, HANDB EXP PHARM, V169, P71; MILLER T, 1994, CSN INJURY DATA CHIL; MOHANTY S, 1985, BRAIN OEDEMA, P25; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; RAPOPORT SI, 1976, BLOOD BRAIN BARRIER, P1; RUAN JS, 1994, THESIS WAYNE STATE U, P1; SALZMAN SK, 1994, J PHARMACOL EXP THER, V269, P322; SALZMAN SK, 1991, ANN NEUROL, V30, P533, DOI 10.1002/ana.410300405; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P309; Sharma H. S., 2000, CURRENT DRUGS, P28; Sharma H. S., 1982, THESIS BANARAS HINDU, P1; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Sharma HS, 2007, PROG BRAIN RES, V162, P173, DOI 10.1016/S0079-6123(06)62010-4; Sharma HS, 1996, ADV BEHAV BIOL, V46, P117; SHARMA HS, 1993, NEUROSCIENCE, V57, P443, DOI 10.1016/0306-4522(93)90076-R; SHARMA HS, 1990, BRAIN RES, V517, P215, DOI 10.1016/0006-8993(90)91029-G; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2003, ACT NEUR S, V86, P407; Sharma HS, 2002, AMINO ACIDS, V23, P261, DOI 10.1007/s00726-001-0137-z; Sharma HS, 1995, PROG BRAIN RES, V104, P401; SHARMA HS, 1989, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1988, P317; SHARMA HS, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P147; Sharma HS, 1995, NEW CONCEPTS OF A BLOOD-BRAIN BARRIER, P75; Sharma HS, 1997, ACT NEUR S, V70, P155; Sharma HS, 2000, ACT NEUR S, V76, P91; Sharma HS, 1996, NEUROSCI RES, V24, P373, DOI 10.1016/0168-0102(95)01015-7; SHARMA HS, 1991, J NEUROL SCI, V102, P150, DOI 10.1016/0022-510X(91)90063-D; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1994, ACTA NEUROCHIR, P65; SHARMA HS, 1988, NEUROSCI RES, V5, P224, DOI 10.1016/0168-0102(88)90051-X; Sharma HS, 1996, BEHAV BRAIN RES, V72, P189; Sharma HS, 2004, BLOOD SPINAL CORD BR, P117; Sharma HS, 1999, ACTA U UPSAL, V830, P1; SHARMA HS, 2005, SOLICITED CONTRIBU S, V23, P1; SHATTIL SJ, 1992, IMMUNOMETHODS, V1, P53; TAUB R, 1989, J BIOL CHEM, V264, P259; TEITLER M, 1994, CRIT REV NEUROBIOL, V8, P175; THURMAN DJ, 1994, TRAUMATIC BRAIN INJU; Vannemreddy P, 2006, ACTA NEUROCHIR SUPPL, V96, P151; WALDMANN TA, 1991, SCIENCE, V252, P1657, DOI 10.1126/science.2047874	50	34	36	0	11	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-685-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2007	1122						295	312		10.1196/annals.1403.022			18	Multidisciplinary Sciences; Neurosciences; Pharmacology & Pharmacy	Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BHD20	WOS:000252267100022	18077582				2021-06-18	
J	Stapleton, S; Adams, M; Atterton, L				Stapleton, Sally; Adams, Malcolm; Atterton, Linda			A mobile phone as a memory aid for individuals with traumatic brain injury: A preliminary investigation	BRAIN INJURY			English	Article						memory aid; memory rehabilitation; cognitive rehabilitation; traumatic brain injury; single case series	COGNITIVE REHABILITATION; PAGING SYSTEM	Primary objective: To investigate the use of a 'reminders' function on a mobile phone as a compensatory memory aid for five individuals with traumatic brain injury ( TBI). Research design: A series of five single case ABAB reversal design. Methods and procedure: A mobile phone was given to each participant during two intervention phases. Target behaviours were recorded for the length of the study. Experimental intervention: The phone was programmed to prompt a number of identified target behaviours. Main outcomes and results: For two participants, there was an increase in the target behaviours achieved when the phone was used, with percentages rising from 51% to 95% for Participant 1 ( P1) and 58% to 88% for Participant 5 ( P5). The percentage of target behaviours achieved did not return to initial baseline levels when the phone was removed, indicating that the intervention may have facilitated P1 and, in particular, P5 in the learning of their routines. The participants who did not benefit from the mobile phone differed from P1 and P5 as they fell in the category of 'severe memory impairment' on the RBMT, were significantly impaired on an assessment of executive functioning ( Tower Test) and required 24- hour care. Conclusions: The preliminary investigation with five participants suggests that this system may be of best use with individuals who do not require 24- hour care and do not experience severe memory and executive functioning difficulties. However, further research with a larger sample is highly recommended.	Julian Hosp, So Team, Norwich NR2 3TD, Norfolk, England; Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; Colman Hosp, Colman Ctr Specialist Rehabil, Dept Psychol, Norwich, Norfolk, England	Stapleton, S (corresponding author), Julian Hosp, So Team, Bowthorpe Rd, Norwich NR2 3TD, Norfolk, England.	sally.stapleton@nwmhp.nhs.uk					BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Baddeley A.D., 1992, SPEED CAPACITY LANGU; Barlow D.H., 1984, SINGLE CASE EXPT DES; Cappa SF, 2005, EUR J NEUROL, V12, P665; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DELIS DC, 2001, DKEFS EXECUTIVE FUNC; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Evans JJ, 2006, J NEUROL, V253, P520, DOI 10.1007/s00415-006-0014-5; Huitema B. E., 2004, Understanding Statistics, V3, P27, DOI 10.1207/s15328031us0301_2; Hunkin NM, 1998, NEUROPSYCHOLOGIA, V36, P25, DOI 10.1016/S0028-3932(97)00106-1; Mathias JL, 2005, BRAIN INJURY, V19, P271, DOI 10.1080/02699050400005028; MORLEY S, 1991, BRIT J CLIN PSYCHOL, V30, P97, DOI 10.1111/j.2044-8260.1991.tb00926.x; MORLEY S, 1989, BRIT J CLIN PSYCHOL, V28, P1, DOI 10.1111/j.2044-8260.1989.tb00807.x; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson B.A., 1991, NEUROPSYCHOL REHABIL, V1, P117, DOI [https://doi.org/10.1080/09602019108401386, DOI 10.1080/09602019108401386]; Wilson BA, 2005, BRAIN INJURY, V19, P891, DOI 10.1080/02699050400002363; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; World Health Organization, 2001, INT CLASS FUNCT DIS	24	34	34	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	4					401	411		10.1080/02699050701252030			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600006	17487638				2021-06-18	
J	Durham, SR; Liu, KC; Selden, NR				Durham, Susan R.; Liu, Kenneth C.; Selden, Nathan R.			Utility of serial computed tomography imaging in pediatric patients with head trauma	JOURNAL OF NEUROSURGERY			English	Article						brain injury; trauma; computed tomography; pediatric neurosurgery	BRAIN-INJURY; CT; CHILDREN; SCAN	Object. The purpose of this study was to evaluate the risk of progression of traumatic intracranial lesions in children by comparing initial and subsequent computed tomography (CT) scans. Reserving repeated CT imaging for patients who harbor higher-risk lesions may reduce overall radiation exposure, the need for sedative agents, and cost. Methods. The authors performed a retrospective cohort study in 268 patients younger than 18 years of age who underwent repeated CT scanning within 24 hours of their initial CT scanning procedure. The risk of progression between the initial and repeated CT scanning sessions and the need for delayed neurosurgical intervention were, determined for each lesion type. In 54 patients (20.1%) the normal findings on the initial CT study did not change on subsequent imaging. In 61 (28.5%) of the 214 patients in whom abnormal findings were present on the initial scan, progression was demonstrated. Patients with epidural hematoma (EDH; odds ratio [OR] 12.29), subdural hematoma (SDH; OR 3.18), cerebral edema (OR 9.34), and intraparenchymal hemorrhage (IPH; OR 18.3) were found to be at a significantly increased risk for progression and to require delayed neurosurgical intervention (OR 11.91). No significantly increased risk was found for patients with subarachnoid hemorrhage (SAH), intraventricular hemorrhage (IVH), diffuse axonal injury (DAI), or skull fracture. Conclusions. Repeated CT imaging in children with high-risk lesions such as EDH, SDH, cerebral edema, and IPH is recommended. However, in children with low-risk lesions, such as SAH, IVH, DAI, and isolated skull fractures but no sign of clinical deterioration, repeated imaging may be less likely to alter the clinical management scheme. The limited benefits of undertaking repeated imaging in these patients should be weighed against the risks of radiation exposure, sedation, intrahospital transportation, and patient monitoring.	Oregon Hlth & Sci Univ, Doernbecher Childrens HOsp, Div Pediat Neurosurg, Dept Neurol Surg, Portland, OR 97201 USA; Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Dept Surg Pediat Neurosurg, Lebanon, NH USA	Durham, SR (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03766 USA.	srd@hitchcock.org		Selden, Nathan/0000-0001-6108-9721			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS5; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; Dharap SB, 2005, INJURY, V36, P412, DOI 10.1016/j.injury.2004.06.020; Donnelly LF, 2001, PEDIATR RADIOL, V31, P388, DOI 10.1007/s002470100479; ELSNER H, 1990, J NEUROSURG, V72, P813, DOI 10.3171/jns.1990.72.5.0813; Figg RE, 2003, J TRAUMA, V55, P1061, DOI 10.1097/01.TA.0000096712.90133.5C; HURST JM, 1992, J TRAUMA, V33, P582, DOI 10.1097/00005373-199210000-00015; JAIMOVICH R, 1992, PEDIATR NEUROSURG, V17, P25, DOI 10.1159/000120562; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; Paterson A, 2001, AM J ROENTGENOL, V176, P297, DOI 10.2214/ajr.176.2.1760297; POON WS, 1992, NEUROSURGERY, V30, P681; Schuster R, 2005, AM SURGEON, V71, P701; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Sifri ZC, 2004, AM J SURG, V187, P338, DOI 10.1016/j.amjsurg.2003.12.015; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Tabori U, 2000, CRIT CARE MED, V28, P840, DOI 10.1097/00003246-200003000-00038; VANE DW, 1995, J TRAUMA, V38, P867, DOI 10.1097/00005373-199506000-00006	19	34	34	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2006	105	5		S			365	369		10.3171/ped.2006.105.5.365			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	102HC	WOS:000241800600007	17328259				2021-06-18	
J	Pickelsimer, EE; Selassie, AW; Gu, JK; Langlois, JA				Pickelsimer, E. Elisabeth; Selassie, Anbesaw W.; Gu, Ja Kook; Langlois, Jean A.			A population-based outcomes study of persons hospitalized with traumatic brain injury - Operations of the South Carolina traumatic brain injury follow-up registry	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						follow-up registry methods; outcomes study; population surveillance; traumatic brain injury	QUALITY-OF-LIFE; HEAD-INJURY; SF-36; NEEDS; QUESTIONNAIRE; HANDICAP; VALIDITY; PROXIES; DESIGN; IMPACT	Objective: To describe the design and operations of the South Carolina Traumatic Brain Injury (TBI) Follow-up Registry. Design: Statewide prospective cohort study. Setting: State of South Carolina. Participants: 2118 persons discharged from acute care hospitals after experiencing TBI. Intervention: Telephone interviews. Main Outcome Measures: Service needs, alcohol and drug use, psychosocial health, health-related quality of life, functional status, symptoms of TBI, employment, global life satisfaction, and death. Results: Selected initial and 1-year follow-up findings concerning demographic, insurance status, income, and employment factors. Conclusions: Population-based outcome studies that describe longer term problems associated with TBI, the need for services, and estimated disability could be useful to inform public policy.	Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; Ctr Dis Control & Prevent, Div Injury Response, Natl Ctr Injury Prevent & Control, Atlanta, GA USA	Pickelsimer, EE (corresponding author), Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, POB 250835,135 Cannon St,Suite 303, Charleston, SC 29425 USA.	pickelse@musc.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [U17/CCU421926] Funding Source: Medline		Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BARRERA M, 1983, AM J COMMUN PSYCHOL, V11, P133; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; *CDCP, 1999, REP REC TRAUM BRAIN; *CDCP, 1998, GRANT M MAY 4 ATL; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; CHESNUT RM, 1999, 2 AG HLTH CAR POL RE; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P205, DOI 10.1097/00001199-200405000-00002; *CTR INJ RES POL J, 1997, ICMAP 90 SOFTW; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; DAVIS K, 1995, INQUIRY-J HEALTH CAR, V32, P196; DEROGATIS LR, 1974, BEHAV SCI, V19, P1, DOI 10.1002/bs.3830190102; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; *DIV INJ VIOL PREV, 1999, TBI SURV SYST DAT EV; Feldhaus KM, 1997, JAMA-J AM MED ASSOC, V277, P1357, DOI 10.1001/jama.277.17.1357; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GERBER WD, 1995, FUNCT NEUROL, V10, P27; GFROERER J, 1992, BRIT J ADDICT, V87, P1345; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann AW, 2002, ARCH PHYS MED REHAB, V83, P1052, DOI 10.1053/apmr.2002.34283; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199508000-00007; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Jones M L, 1992, J Insur Med, V24, P186; KATZ D, 1995, ARCH NEUROL-CHICAGO, V51, P661; *L HARR ASS INC, 1994, HARR POLL DIS AM, P101; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LAWRENCE RH, 1995, J AGING HEALTH, V7, P74, DOI 10.1177/089826439500700104; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; MACKENZIE EJ, 1993, J ORTHOP TRAUMA, V7, P393, DOI 10.1097/00005131-199310000-00001; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; MCDOWELL AJ, 1971, HEALTH SERV REP, V86, P592, DOI 10.2307/4594235; *NAT CTR HLTH STAT, 1995, VIT HLTH STAT SE 193, V193; National Center for Health Statistics, INT CLASS DIS; National Center for Injury Prevention and Control, 2001, INJ FACT BOOK 2001 2; Novack TA, 2000, BRAIN INJURY, V14, P987; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; ROTHMAN ML, 1991, MED CARE, V29, P115, DOI 10.1097/00005650-199102000-00004; *S CAR DEP HLTH EN, 2003 BRFSS ALC CONS; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; SELASSIE AW, 2006, S CAROLINA TRAUMATIC, P236; SZKLO M, 2000, EPIDEMIOLOGY BASICS, P343; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Thurman DJ., 1995, GUIDELINES SURVEILLA; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VICKREY BG, 1992, MED CARE, V30, P299, DOI 10.1097/00005650-199204000-00002; VOGLESBURG R, 1990, VOCATIONAL REHABILIT; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WIEDERHOLT WC, 1989, NEUROLOGY, V39, P96, DOI 10.1212/WNL.39.1.96; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103	64	34	34	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2006	21	6					491	504		10.1097/00001199-200611000-00004			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	109UC	WOS:000242333400004	17122680				2021-06-18	
J	Ates, O; Cayli, S; Gurses, I; Yucel, N; Iraz, M; Altinoz, E; Kocak, A; Yologlu, S				Ates, Ozkan; Cayli, Suleyman; Gurses, Iclal; Yucel, Neslihan; Iraz, Mustafa; Altinoz, Eyup; Kocak, Ayhan; Yologlu, Saim			Effect of pinealectomy and. melatonin replacement on morphological and biochemical recovery after traumatic brain injury	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						antioxidant; melatonin; oxidative stress; pinealectomy; traumatic brain injury	XANTHINE-OXIDASE ACTIVITY; CENTRAL-NERVOUS-SYSTEM; OXIDATIVE STRESS; FREE-RADICALS; NITRIC-OXIDE; RAT-BRAIN; NEUROHORMONE MELATONIN; LIPID-PEROXIDATION; MOLECULAR DAMAGE; HEAD TRAUMA	Numerous studies showed that melatonin, a free radical scavenger, is neuroprotective. In this study, we investigated the effect of pinealectomy and administration of exogenous melatonin on oxidative stress and morphological changes after experimental brain injury. The animals were divided into six groups, each having 12 rats. Group I underwent craniotomy alone. Group 2 underwent craniotomy followed by brain trauma and received no medication. Group 3 underwent craniotomy followed by brain trauma and received melatonin. Group 4 underwent pinealectomy and craniotomy alone. Group 5 underwent pinealectomy and craniotomy followed by brain injury and received no medication. Group 6 underwent pinealectomy and craniotomy followed by brain trauma and received melatonin. Melatonin (100 mg/kg) was given intraperitoneally immediately after trauma to the rats in Groups 3 and 6. Pinealectomy caused a significant increase in the malondialdehyde (MDA), nitric oxide (NO), glutathione (GSH), and xanthine oxidase (XO) levels, and a decrease in GSH levels as compared to the control group. Trauma to pinealectomized rats causes significantly higher oxidative stress. Exogeneous melatonin administration significantly reduced MDA, XO and NO levels, increased GSH levels, and attenuated tissue lesion area. These findings suggest that reduction in endogenous melatonin after pinealectomy makes the rats more vulnerable to trauma, and exogenous melatonin administration has an important neuroprotective effect. (c) 2006 ISDN. Published by Elsevier Ltd. All rights reserved.	Inonu Univ, Dept Neurosurg, Sch Med, Turgut Ozal Med Ctr, TR-44069 Malatya, Turkey; Inonu Univ, Dept Pathol, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Dept Emergency Med, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Dept Pharmacol, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Dept Biochem, Sch Med, TR-44069 Malatya, Turkey; Inonu Univ, Dept Biostat, Sch Med, TR-44069 Malatya, Turkey	Ates, O (corresponding author), Inonu Univ, Dept Neurosurg, Sch Med, Turgut Ozal Med Ctr, TR-44069 Malatya, Turkey.	atesozkan@hotmail.com	Yucel, Neslihan/ABI-3412-2020; Yologlu, Saim/ABI-8014-2020; Gurses, Iclal/AAH-8552-2021	Yucel, Neslihan/0000-0001-5845-2614; Yologlu, Saim/0000-0002-9619-3462; Altinoz, Eyup/0000-0002-3991-9773			ANDERSON D K, 1985, Journal of Free Radicals in Biology and Medicine, V1, P59, DOI 10.1016/0748-5514(85)90030-3; Antolin I, 1996, FASEB J, V10, P882; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bettahi I, 1996, J PINEAL RES, V20, P205, DOI 10.1111/j.1600-079X.1996.tb00260.x; Bonnefont-Rousselot D, 2000, DIABETES METAB, V26, P163; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; De Butte M, 2002, NEUROBIOL AGING, V23, P309, DOI 10.1016/S0197-4580(01)00277-9; DELLACOR.E, 1972, BIOCHEM J, V126, P739, DOI 10.1042/bj1260739; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; Dundar K, 2005, CLIN EXP PHARMACOL P, V32, P926, DOI 10.1111/j.1440-1681.2005.04286.x; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Ercan M, 2001, NEUROSURG REV, V24, P127, DOI 10.1007/PL00012396; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HARDELAND R, 1995, J PINEAL RES, V18, P104, DOI 10.1111/j.1600-079X.1995.tb00147.x; HOFFMAN RA, 1965, ANAT REC, V153, P19, DOI 10.1002/ar.1091530103; Horakova L, 2000, GEN PHYSIOL BIOPHYS, V19, P195; IKEDA Y, 1990, NEUROSURGERY, V27, P1; ITOH T, 1986, STROKE, V17, P1284, DOI 10.1161/01.STR.17.6.1284; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; KANEMITSU H, 1989, BRAIN RES, V499, P367, DOI 10.1016/0006-8993(89)90786-5; Kerman M, 2005, EXP BRAIN RES, V163, P406, DOI 10.1007/s00221-005-2338-2; Marklund N., 1997, NEUROREPORT, V717, P109; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Noda Y, 1999, J PINEAL RES, V27, P159, DOI 10.1111/j.1600-079X.1999.tb00611.x; Ozbek E, 2000, EUR UROL, V37, P172, DOI 10.1159/000020135; PANG SF, 1990, J PINEAL RES, V8, P179, DOI 10.1111/j.1600-079X.1990.tb00678.x; PEUNOVA N, 1993, NATURE, V364, P450, DOI 10.1038/364450a0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; PRAJDA N, 1975, FEBS LETT, V59, P245, DOI 10.1016/0014-5793(75)80385-1; REITER RJ, 1993, BRAZ J MED BIOL RES, V26, P1141; Reiter RJ, 1998, ANN NY ACAD SCI, V854, P410, DOI 10.1111/j.1749-6632.1998.tb09920.x; Reiter RJ, 1998, NUTRITION, V14, P691, DOI 10.1016/S0899-9007(98)00064-1; Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200; REITER RJ, 1995, FASEB J, V9, P526; Ressmeyer AR, 2003, REDOX REP, V8, P205, DOI 10.1179/135100003225002709; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; SKENE DJ, 1990, BRAIN RES, V528, P170, DOI 10.1016/0006-8993(90)90214-V; Sofic E, 2005, J NEURAL TRANSM, V112, P349, DOI 10.1007/s00702-004-0270-4; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Tan DX, 2001, FASEB J, V15, P2294; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; Vural H, 2001, J PINEAL RES, V31, P193, DOI 10.1034/j.1600-079X.2001.310301.x; Yakovlev Alexander G, 2004, NeuroRx, V1, P5, DOI 10.1007/BF03206563; Yeleswaram K, 1997, J PINEAL RES, V22, P45, DOI 10.1111/j.1600-079X.1997.tb00302.x; ZANG LY, 1998, BIOCHIM BIOPHYS ACTA, V27, P469; Zhou JN, 2003, J PINEAL RES, V35, P125, DOI 10.1034/j.1600-079X.2003.00065.x	51	34	36	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	OCT	2006	24	6					357	363		10.1016/j.ijdevneu.2006.08.003			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	092ZZ	WOS:000241138200002	16959465				2021-06-18	
J	Bigler, ED; Ryser, DK; Gandhi, P; Kimball, J; Wilde, EA				Bigler, Erin D.; Ryser, David K.; Gandhi, Partha; Kimball, Jordan; Wilde, Elisabeth A.			Day-of-injury computerized tomography, rehabilitation status, and development of cerebral atrophy in persons with traumatic brain injury	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						traumatic brain injury; computerized tomography; magnetic resonance imaging; disability rating scale; FIM; rehabilitation outcome	SEVERE HEAD-INJURY; PROGNOSTIC VALUE; AXONAL INJURY; STEM LESIONS; COMA; MRI; CT; CLASSIFICATION; PREDICTION; SCAN	Objective: To compare day-of-injury (DOI) computerized tomography (CT) findings with acute injury severity markers, disability at acute hospital admission and discharge from inpatient rehabilitation, injury severity markers, and degree of postacute cerebral atrophy on magnetic resonance imaging (MRI). Design: Retrospective chart review of 240 consecutive traumatic brain injury (TBI) admissions (mean age 31.7 +/- 15.8 yrs) with moderate-to-severe initial brain injury. All DOI CT abnormalities were qualitatively rated. Disability was assessed using the Disability Rating Scale (DRS) and the FIM measure. In a representative subset, cerebral atrophy was determined by the ventricle-to-brain ratio (VBR) method and quantified from MRI scans 25 or more days postinjury. Results: CT classification resulted in nonsignificant differences in DRS and FIM ratings at the time of discharge from the rehabilitation unit, except in brainstem injury subjects who had significantly higher DRS and lower FIM scores at rehabilitation discharge. At 25 or more days postinjury, presence of any DOI CT abnormality was associated with larger VBR. Increased VBR, as an index of cerebral atrophy, was associated with worse rehabilitation discharge DRS and FIM ratings. Conclusions: Other than brainstem injury, DOI CT findings relate poorly to rehabilitation outcome. Presence of DOI CT abnormalities were associated with the development of cerebral atrophy, which was associated with poorer rehabilitation discharge DRS and FIM scores.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; LDS Hosp, Neuro Specialty Rehabil Unit, Salt Lake City, UT USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Psychiat, Salt Lake City, UT 84112 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 Spencer W Kimball Tower, Provo, UT 84602 USA.						Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P442, DOI 10.1017/S1355617704103111; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; BIGLER ED, 1994, BRAIN INJURY, V8, P231, DOI 10.3109/02699059409150975; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2000, AM J NEURORADIOL, V21, P1857; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BOWEN JM, 1997, DEV MED CHILD NEUROL, P39; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; DUNCAN PW, 1990, REHABILITATION ADULT; Englander J, 2003, ARCH PHYS MED REHAB, V84, P214, DOI 10.1053/apmr.2003.50094; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; *FIM, 1990, UN DAT SET MED REHB; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gean A, 1994, IMAGING HEAD TRAUMA; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hamilton B., 1987, REHABILITATION OUTCO; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Herzog T, 1996, RES METHODS SOCIAL S; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kaups KL, 2004, J TRAUMA, V56, P475, DOI 10.1097/01.TA.0000114304.56006.D4; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN JR, 1989, AM STATISTICIAN, V43; LIPPER MH, 1985, AM J ROENTGENOL, V144, P483, DOI 10.2214/ajr.144.3.483; Lubillo S, 1999, J NEUROSURG, V91, P581, DOI 10.3171/jns.1999.91.4.0581; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; Ryser DK, 2005, ARCH PHYS MED REHAB, V86, P1108, DOI 10.1016/j.apmr.2004.11.041; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Temkin NR, 2003, J NEUROTRAUM, V20, P229, DOI 10.1089/089771503321532815; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Wedekind C, 2002, MUSCLE NERVE, V26, P270, DOI 10.1002/mus.10187; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	61	34	34	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	OCT	2006	85	10					793	806		10.1097/01.phm.0000237873.26250.e1			14	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	089JD	WOS:000240875700002	16998426				2021-06-18	
J	Isoniemi, H; Kurki, T; Tenovuo, O; Kairisto, V; Portin, R				Isoniemi, H.; Kurki, T.; Tenovuo, O.; Kairisto, V.; Portin, R.			Hippocampal volume, brain atrophy, and APOE genotype after traumatic brain injury	NEUROLOGY			English	Article							APOLIPOPROTEIN-E POLYMORPHISM; HEAD-INJURY; ALZHEIMERS-DISEASE; PSYCHIATRIC-DISORDERS; E DEFICIENCY; RISK; ASSOCIATION; POPULATION; PREDICTS; MUTATION	Objective: To examine the association between hippocampal volumes, general brain atrophy, and apolipoprotein E (APOE) polymorphism in patients with a remote traumatic brain injury (TBI). Methods: MRI-based volumetric analyses of the hippocampus and lateral ventricles were performed in 58 patients with TBI of varying severity on average 31.3 years after the trauma. The APOE genotype was determined using standard methods and correlated with the MRI volumetric measurements. Results: Hippocampal or lateral ventricle volumes did not differ significantly in those patients with the APOE-epsilon 4 allele (APOE4) vs those without this allele. Conclusions: The APOE-epsilon 4 allele was not associated with the development of hippocampal or ventricular atrophy after traumatic brain injury. If the APOE-epsilon 4 allele is associated with an unfavorable outcome after traumatic brain injury as proposed, this association may involve mechanisms other than those responsible for the development of brain atrophy.	Turku Univ, Cent Hosp, Dept Radiol, Turku, Finland; Turku Univ, Cent Hosp, Dept Clin Chem, Turku, Finland; Turku Univ, Cent Hosp, Dept Neurol, Turku, Finland	Tenovuo, O (corresponding author), Turku Univ, Dept Neurol, Kiinamyllynkatu 4-8, Turku 20520, Finland.	olli.tenovuo@tyks.fi		Kurki, Timo/0000-0001-5532-3534			Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Champagne D, 2005, EXP NEUROL, V194, P31, DOI 10.1016/j.expneurol.2005.01.016; DELEON MJ, 1993, AM J NEURORADIOL, V14, P897; den Heijer T, 2002, NEUROLOGY, V59, P746, DOI 10.1212/WNL.59.5.746; Donohoe GG, 2000, CLIN CHEM, V46, P1540; Donohoe GG, 1999, CLIN CHEM, V45, P143; EHNHOLM C, 1986, J LIPID RES, V27, P227; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GREENWOOD R, 2002, J NEUROL NEUROSUR PS, V73, P8; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; Groswasser Z, 2002, BRAIN INJURY, V16, P681, DOI 10.1080/02699050110119835; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kleifeld O, 1998, INT J DEV NEUROSCI, V16, P755, DOI 10.1016/S0736-5748(98)00084-7; Koponen S, 2004, NEUROLOGY, V63, P749, DOI 10.1212/01.WNL.0000134603.57107.2F; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Newcombe F, 1996, J CLIN EXP NEUROPSYC, V18, P1, DOI 10.1080/01688639608408258; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PASQUALIN A, 1991, NEUROSURGERY, V28, P370, DOI 10.1227/00006123-199103000-00006; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L	33	34	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	SEP 12	2006	67	5					756	760		10.1212/01.wnl.0000234140.64954.12			5	Clinical Neurology	Neurosciences & Neurology	083EC	WOS:000240437700006	16966535				2021-06-18	
J	Hessen, E; Nestvold, K; Sundet, K				Hessen, Erik; Nestvold, Knut; Sundet, Kjetil			Neuropsychological function in a group of patients 25 years after sustaining minor head injuries as children and adolescents	SCANDINAVIAN JOURNAL OF PSYCHOLOGY			English	Article						mild head injury; cognitive deficits; neuropsychological impairment	TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; MILD; CHILDHOOD	Previous studies suggest that neuropsychological impairment following mild to moderate pediatric head injury may become persistent and interrupt the normal course of intellectual development. In this study 45 subjects were assessed with a standardized neuropsychological test battery 25 years after sustaining mild to moderate head injury as children. Although the group scores in the normal range, significant relations between head injury severity and current neuropsychological function were found. The most important predictor of poor outcome was length of PTA at injury, EEG pathology, and loss of consciousness at injury. No significant influence of pre- and post-injury risk factors on current neuropsychological function was evident. The findings support the view that complicated mild and moderate paediatric head injury may heighten the risk of developing subtle neuropsychological problems later in life.	Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway; Univ Oslo, Inst Psychol, Oslo, Norway	Hessen, E (corresponding author), Akershus Univ Hosp, Dept Neurol, N-1478 Lorenskog, Norway.	erik.hessen@nevropsykologi.no					Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2000, BRAIN INJURY, V14, P679; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; BOLL TJ, 1983, PSYCHIAT DEV, V1, P263; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; *BRIT SOC REH MED, 1998, REH TRAUM BRAIN INJ; ENGVIK H, 1978, WECHSLER ADULT INTEL; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; GIMSE R, 1995, WECHSLER MEMORY SCAL; GULDBRANDSEN GB, 1984, J CLIN NEUROPSYCHOLO, V6, P257; Halstead WC, 1985, HALSTEAD REITAN NEUR; Heaton R.K., 1991, COMPREHENSIVE NORMS; Horowitz I, 1983, Int Rehabil Med, V5, P32; *HOUS COMM SEL COM, 2001, 3 REP HEAD INJ REH; JENNETT B, 1975, LANCET, V1, P480; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1989, PSYCHIAT MED, V7, P11; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MASSAGLI TL, 1996, ARCH PHYS MED REHAB, V77, P25; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, P134; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; *STAT NORW, 2001, LEV ED PERS 16 YEARS; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL; Winogron H W, 1984, J Clin Neuropsychol, V6, P267; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	37	34	34	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0036-5564			SCAND J PSYCHOL	Scand. J. Psychol.	AUG	2006	47	4					245	251		10.1111/j.1467-9450.2006.00514.x			7	Psychology, Multidisciplinary	Psychology	061SU	WOS:000238893700002	16869857				2021-06-18	
J	Tate, RL; Pfaff, A; Baguley, IJ; Marosszeky, JE; Gurka, JA; Hodgkinson, AE; King, C; T Lane-Brown, A; Hanna, J				Tate, R. L.; Pfaff, A.; Baguley, I. J.; Marosszeky, J. E.; Gurka, J. A.; Hodgkinson, A. E.; King, C.; T Lane-Brown, A.; Hanna, J.			A multicentre, randomised trial examining the effect of test procedures measuring emergence from post-traumatic amnesia	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; TRAUMATIC BRAIN-INJURY; GALVESTON ORIENTATION; RECOVERY; MEMORY; SCALE; RETENTION; DURATION; STATE; PTA	Background: Post-traumatic amnesia (PTA) tests that record different PTA durations in the same patient, thereby raising measurement accuracy issues, have been reported previously. A major problem lies in determining the end point of PTA. Aims: To delineate areas of discrepancy in PTA tests and to provide independent verification for a criterion signalling emergence from PTA. Methods: In a randomised design, two related PTA procedures were compared, one purportedly more difficult (Westmead PTA Scale, WPTAS) than the other (Modified Oxford PTA Scale, MOPTAS). Eighty two patients in the early stages of PTA were examined daily until emergence, by using the Galveston Orientation and Amnesia Test (GOAT) and the WPTAS/MOPTAS. A short battery of cognitive and behavioural measurements was made on three occasions: at the early stage of PTA (time 1), towards the end of PTA when the maximum score (12/12) was first obtained (time 2) and at the traditional criterion for emergence (scoring 12/12 for 3 consecutive days; time 3). Results: No significant difference was recorded in PTA duration between the MOPTAS and WPTAS. Both scales recorded longer PTA durations than the GOAT. By using Kaplan-Meier survival analyses, the WPTAS was found to show a more protracted pattern of emergence at the end stage of PTA than the MOPTAS. A time lag of >= 1 week in the resolution of disorientation as compared with amnesia was observed in 59% cases. Significant improvements occurred on all independent measurements between time 1 and time 2, but on only 2 of 5 cognitive measurements between time 2 and time 3. Conclusions: Although no significant differences in the duration of PTA on the MOPTAS/WPTAS were recorded, emergence from the late stages of PTA occurred more promptly with the MOPTAS. The need for inclusion of both orientation and memory items in PTA tests is highlighted by the frequency of disorientation-amnesia dissociations. The patterns of results on the independent measures suggest that patients who are in PTA for. 4 weeks have probably emerged from PTA when they first score 12/12 on the MOPTAS/WPTAS, and this criterion can replace the traditional criterion.	Univ Sydney, Fac Med, Rehabil Studies Unit, No Clin Sch, Sydney, NSW 2006, Australia; Liverpool Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia; Westmead Hosp, Brain Injury Rehabil Serv, Sydney, NSW, Australia; Royal Rehabil Ctr, Brain Injury Rehabil Serv, Sydney, NSW, Australia	Tate, RL (corresponding author), Rehabil Studies Unit, POB 6, Ryde, NSW, Australia.	rtate@med.usyd.edu.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; 			Ahmed S, 2000, BRAIN INJURY, V14, P765; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Borgdorff MW, 2001, LANCET, V357, P1532, DOI 10.1016/S0140-6736(00)04690-0; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; HUNKIN NM, 1993, CORTEX, V29, P485, DOI 10.1016/S0010-9452(13)80255-9; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Kennedy RE, 2003, PSYCHOSOMATICS, V44, P283, DOI 10.1176/appi.psy.44.4.283; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Marosszeky NEV, 1998, PTA PROTOCOL GUIDELI; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Miller E. N., 1990, CALIFORNIA COMPUTERI; Mysiw WJ., 1990, J HEAD TRAUMA REHAB, V5, P65; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; PARKIN AJ, 1990, CORTEX, V26, P373, DOI 10.1016/S0010-9452(13)80087-1; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Reynolds C.R., 1994, TEST MEMORY LEARNING; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Schwartz ML, 1998, CAN J NEUROL SCI, V25, P108, DOI 10.1017/S0317167100033709; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Strub R.L., 2000, MENTAL STATUS EXAMIN; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Tate RL, 2001, J HEAD TRAUMA REHAB, V16, P525, DOI 10.1097/00001199-200112000-00002; Tate RL, 2000, J NEUROL NEUROSUR PS, V68, P178, DOI 10.1136/jnnp.68.2.178; Tate RL., 2000, BRAIN IMPAIR, V1, P116; THORNDIKE EI, 1944, TEACHERS WORLD BOOK; Wilson B.A., 1992, NEUROPSYCHOL REHABIL, V2, P231, DOI [10.1080/09602019208401410, DOI 10.1080/09602019208401410]; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412	35	34	36	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2006	77	7							841	10.1136/jnnp.2005.074989			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	054ZL	WOS:000238417900011	16574735	Green Published			2021-06-18	
J	Lin, HW; Basu, A; Druckman, C; Cicchese, M; Krady, JK; Levison, SW				Lin, Hsiao-Wen; Basu, Anirban; Druckman, Charles; Cicchese, Michael; Krady, J. Kyle; Levison, Steven W.			Astrogliosis is delayed in type 1 interleukin-1 receptor-null mice following a penetrating brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article							CHONDROITIN-SULFATE PROTEOGLYCAN; CENTRAL-NERVOUS-SYSTEM; FACTOR MESSENGER-RNA; GROWTH-FACTOR; CONVERTING-ENZYME; RAT-BRAIN; ACTIVATED RECEPTOR-1; CYTOKINE REGULATION; CEREBRAL-ISCHEMIA; GENE-EXPRESSION	The cytokines IL-1 alpha and IL-1 beta are induced rapidly after insults to the CNS, and their subsequent signaling through the type 1 IL-1 receptor (IL-1R1) has been regarded as essential for a normal astroglial and microglial/macrophage response. To determine whether abrogating signaling through the IL-1R1 will alter the cardinal astrocytic responses to injury, we analyzed molecules characteristic of activated astrocytes in response to a penetrating stab wound in wild type mice and mice with a targeted deletion of IL-1R1. Here we show that after a stab wound injury, glial fibrillary acidic protein (GFAP) induction on a per cell basis is delayed in the IL-1R1-null mice compared to wild type counterparts. However, the induction of chondroitin sulfate proteoglycans, tenascin, S-100B as well as glutamate transporter proteins, GLAST and GLT-1, and glutamine synthetase are independent of IL-1R1 signaling. Cumulatively, our studies on gliosis in the IL-1R1-null mice indicate that abrogating IL-1R1 signaling delays some responses of astroglial activation; however, many of the important neuroprotective adaptations of astrocytes to brain trauma are preserved. These data recommend the continued development of therapeutics to abrogate IL-1R1 signaling to treat traumatic brain injuries. However, astroglial scar related proteins were induced irrespective of blocking IL-1R1 signaling and thus, other therapeutic strategies will be required to inhibit glial scarring.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07103 USA; Natl Brain Res Ctr, Gurgaon 122050, India; Penn State Univ, Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA	Levison, SW (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, 185 S Orange Ave, Newark, NJ 07103 USA.	linh3@umdnj.edu; anirban@nbrc.res.in; chuckdruck@hotmail.com; michael_cicchese@yahoo.com; jkk7@psu.edu; steve.levison@umdnj.edu	BASU, ANIRBAN/C-1166-2009; Levison, Steven W./Q-6903-2019	Levison, Steven W./0000-0002-1264-7309; Basu, Anirban/0000-0002-5200-2054			Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Albrecht PJ, 2002, EXP NEUROL, V173, P46, DOI 10.1006/exnr.2001.7834; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; ALOISI F, 1992, J IMMUNOL, V149, P2358; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; Basu A, 2005, J CEREBR BLOOD F MET, V25, P17, DOI 10.1038/sj.jcbfm.9600002; Basu A, 2002, GLIA, V40, P109, DOI 10.1002/glia.10118; Basu A, 2002, J NEUROSCI, V22, P6071; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; BAUER J, 1993, J NEUROIMMUNOL, V48, P13, DOI 10.1016/0165-5728(93)90053-2; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; Boutin H, 2001, J NEUROSCI, V21, P5528; Boven LA, 2003, J IMMUNOL, V170, P2638, DOI 10.4049/jimmunol.170.5.2638; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Colognato R, 2003, BLOOD, V102, P2645, DOI 10.1182/blood-2002-08-2497; DACUNHA A, 1992, J NEUROIMMUNOL, V36, P157; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; DECKERTSCHLUTER M, 1992, J NEUROL SCI, V113, P50, DOI 10.1016/0022-510X(92)90264-L; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; DOU CL, 1994, J NEUROSCI, V14, P7616; Eng DL, 1997, BRAIN RES, V778, P215, DOI 10.1016/S0006-8993(97)01093-7; Engel U, 1996, GLIA, V16, P16, DOI 10.1002/(SICI)1098-1136(199601)16:1<16::AID-GLIA3>3.3.CO;2-I; ERIKSSON A, 2001, INT J STRUCT STAB DY, V1, P1; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friedman WJ, 1996, J BIOL CHEM, V271, P31115, DOI 10.1074/jbc.271.49.31115; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; HARTUNG HP, 1989, BRAIN RES, V489, P113, DOI 10.1016/0006-8993(89)90013-9; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; HENDERSON CE, 1994, NEURAL CELL CULTURE; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; HOFMAN FM, 1986, J IMMUNOL, V136, P3239; Krum JM, 2002, EXP NEUROL, V174, P137, DOI 10.1006/exnr.2002.7867; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; Lazovic J, 2005, STROKE, V36, P2226, DOI 10.1161/01.STR.0000182255.08162.6a; Lee KR, 1996, J NEUROSURG, V84, P91, DOI 10.3171/jns.1996.84.1.0091; Lee MT, 1996, AM J HEMATOL, V51, P307, DOI 10.1002/(SICI)1096-8652(199604)51:4<307::AID-AJH10>3.0.CO;2-B; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levison SW, 1996, EXP NEUROL, V141, P256, DOI 10.1006/exnr.1996.0160; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MAEDA N, 1995, NEUROSCIENCE, V67, P23, DOI 10.1016/0306-4522(94)00069-H; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; Mason JL, 2001, J NEUROSCI, V21, P7046, DOI 10.1523/JNEUROSCI.21-18-07046.2001; McGuinness MC, 1997, J NEUROIMMUNOL, V75, P174, DOI 10.1016/S0165-5728(97)00020-9; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MeyerPuttlitz B, 1996, J COMP NEUROL, V366, P44, DOI 10.1002/(SICI)1096-9861(19960226)366:1<44::AID-CNE4>3.0.CO;2-K; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; Nawashiro H, 2000, J CEREBR BLOOD F MET, V20, P1040, DOI 10.1097/00004647-200007000-00003; Nicole O, 2005, J NEUROSCI, V25, P4319, DOI 10.1523/JNEUROSCI.5200-04.2005; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; Nishiyama A, 2002, J NEUROCYTOL, V31, P437, DOI 10.1023/A:1025783412651; NORRIS JG, 1994, J IMMUNOL, V152, P841; OCALLAGHAN JP, 1991, NEUROTOXICOL TERATOL, V13, P275, DOI 10.1016/0892-0362(91)90073-6; OOHIRA A, 1994, NEUROSCIENCE, V60, P145, DOI 10.1016/0306-4522(94)90210-0; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Shinohara T, 2002, CYTOKINE, V19, P66, DOI 10.1006/cyto.2002.1946; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; SPARACIO SM, 1992, J NEUROIMMUNOL, V39, P231, DOI 10.1016/0165-5728(92)90257-L; STALLCUP WB, 1981, DEV BIOL, V83, P154, DOI 10.1016/S0012-1606(81)80018-8; Striggow F, 2000, P NATL ACAD SCI USA, V97, P2264, DOI 10.1073/pnas.040552897; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; VAUGHAN PJ, 1995, J NEUROSCI, V15, P5389; WINNINGHAMMAJOR F, 1989, J CELL BIOL, V109, P3063, DOI 10.1083/jcb.109.6.3063; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; YAMADA T, 1994, BRAIN RES, V637, P308, DOI 10.1016/0006-8993(94)91250-5; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676	79	34	35	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUN 30	2006	3								15	10.1186/1742-2094-3-15			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	174UV	WOS:000246969200001	16808851	DOAJ Gold, Green Published			2021-06-18	
J	Akca, O				Akca, Ozan			Optimizing the intraoperative management of carbon dioxide concentration	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						carbon dioxide; cardiac output; hypercapnia; hypocapnia; ischemia; oxygen; perfusion; reperfusion; tissue oxygenation		Purpose of review This review assesses whether there is a carbon dioxide concentration range that provides optimum benefit to the patient intraoperatively. It includes the physiological effects of carbon dioxide on various organ systems in awake and anesthetized individuals and its clinical effects in the ischemia/reperfusion setting. This review will present views on end-tidal or arterial carbon dioxide tension management in the perioperative period. Recent findings Hypocapnia reduces intracranial pressure and is used by clinicians during acute traumatic brain injury, acute intracranial hemorrhage, and acutely growing brain tumors. There is mounting evidence, however, that hypercapnia improves tissue perfusion and oxygenation. Therefore, clinicians may want to induce mild-to-moderate hypercapnia during reperfusion states such as major vascular surgery, organ transplantation, tissue-graft surgery, and cases managed with low mean arterial pressures to control bleeding. As hypercapnia preserves cerebral blood flow even under relatively low perfusion pressures, it may be beneficial during global reperfusion scenarios. This hypothesis needs to be tested extensively before being considered for clinical applications. From a different perspective, current American Heart Association Guidelines recommend 12-15 breaths/min during cardiopulmonary resuscitation and stress the potential negative role of inadvertent hyperventilation on survival outcome. The importance of this concept is discussed briefly. Summary Overall, the benefits of managing carbon dioxide concentration intraoperatively for the maintenance of cardiac output, tissue oxygenation, perfusion, intracranial pressure, and cerebrovascular reactivity are well defined.	[Akca, Ozan] Univ Louisville, Dept Anesthesiol & Perioperat Med, Outcomes Res Inst, Louisville, KY 40292 USA; [Akca, Ozan] Univ Louisville, Neurosci & Anesthesia Intens Care Unit, Louisville, KY 40292 USA	Akca, O (corresponding author), 501 East Broadway,Suite 210, Louisville, KY 40202 USA.	ozan.akca@louisville.edu	Akca, Ozan/I-8856-2019	Akca, Ozan/0000-0002-7275-1060	NIH (Bethesda, MD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [GM 61655, DE 14879-01A1]; Joseph Drown Foundation (Los Angeles, CA); Gheens Foundation (Louisville, KY); Commonwealth of Kentucky Research Challenge Trust Fund (Louisville, KY); Foundation for Anesthesia Education and Research; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM061655] Funding Source: NIH RePORTER	This work was supported by NIH Grants GM 61655 and DE 14879-01A1 (Bethesda, MD), the Joseph Drown Foundation (Los Angeles, CA), the Gheens Foundation (Louisville, KY), and the Commonwealth of Kentucky Research Challenge Trust Fund (Louisville, KY). Dr Akca is the recipient of a Research Training Grant from the Foundation for Anesthesia Education and Research. The author appreciates the editorial assistance of Nancy Alsip, PhD.	Akca O, 2003, ANAESTHESIA, V58, P536, DOI 10.1046/j.1365-2044.2003.03193.x; Akca O, 1999, LANCET, V354, P41, DOI 10.1016/S0140-6736(99)00874-0; Akca O, 2002, ANESTHESIOLOGY, V97, P801, DOI 10.1097/00000542-200210000-00009; Akca O, 2004, AMERICAN SOCIETY OF; ALBERTI E, 1975, BRIT J ANAESTH, V47, P941, DOI 10.1093/bja/47.9.941; Ali S, 2003, AMERICAN SOCIETY OF, pA; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; ANDERSEN MN, 1966, ANN SURG, V163, P161, DOI 10.1097/00000658-196602000-00001; [Anonymous], 2000, CIRCULATION SUPPL, V102, pI1; Aufderheide Tom P, 2004, Crit Care Med, V32, pS345, DOI 10.1097/01.CCM.0000134335.46859.09; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; BLACKBURN JP, 1970, BRIT J ANAESTH, V42, P559; BLACKBURN JP, 1972, ANESTHESIOLOGY, V37, P268, DOI 10.1097/00000542-197209000-00002; BOIX JH, 1994, REV ESP FISIOL, V50, P19; BONIFACE KJ, 1953, AM J PHYSIOL, V172, P752; Cottrell J., 2004, AM SOC ANESTHESIOLOG, V2004, P145; CULLEN DJ, 1969, ANESTHESIOLOGY, V31, P407; Duong TQ, 2001, MAGN RESON MED, V45, P61, DOI 10.1002/1522-2594(200101)45:1<61::AID-MRM1010>3.0.CO;2-8; Gelb A, 2004, AM SOC ANESTHESIOLOG, V2004, P377; GLEASON CA, 1989, J PEDIATR-US, V115, P309, DOI 10.1016/S0022-3476(89)80091-5; GOSAIN A, 1991, SURGERY, V109, P523; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HICKLING KG, 1995, ACTA ANAESTH SCAND, V39, P201, DOI 10.1111/j.1399-6576.1995.tb04359.x; Huttunen J, 1999, EXP BRAIN RES, V125, P248, DOI 10.1007/s002210050680; Ikeda T, 1998, AM J SURG, V175, P33, DOI 10.1016/S0002-9610(97)00237-7; Kaisti KK, 2003, ANESTHESIOLOGY, V99, P603, DOI 10.1097/00000542-200309000-00015; Karsli C, 2004, ANESTH ANALG, V99, P1049, DOI 10.1213/01.ane.0000132778.84943.8d; Karsli C, 2003, PAEDIATR ANAESTH, V13, P26, DOI 10.1046/j.1460-9592.2003.01017.x; Karsli C, 2003, ANESTH ANALG, V97, P694, DOI 10.1213/01.ANE.0000074235.81165.AF; KONTOS HA, 1977, STROKE, V8, P358, DOI 10.1161/01.STR.8.3.358; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P2287, DOI 10.1164/ajrccm.162.6.2003066; Laffey JG, 2000, AM J RESP CRIT CARE, V162, P399, DOI 10.1164/ajrccm.162.2.9911026; Laffey JG, 2000, INTENS CARE MED, V26, P133, DOI 10.1007/s001340050027; Laffey JG, 1999, LANCET, V354, P1283, DOI 10.1016/S0140-6736(99)02388-0; LEON JE, 1991, CAN J ANAESTH, V38, P817, DOI 10.1007/BF03036954; MANLEY ES, 1964, AM J PHYSIOL, V207, P634; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Mas A, 2000, CRIT CARE MED, V28, P360, DOI 10.1097/00003246-200002000-00012; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; MATTA BF, 1995, ANESTHESIOLOGY, V83, P980, DOI 10.1097/00000542-199511000-00011; Mirzai H, 2004, J NEUROSURG ANESTH, V16, P1, DOI 10.1097/00008506-200401000-00001; MONROE RG, 1960, AM J PHYSIOL, V199, P1121; Nagase K, 2001, J CLIN ANESTH, V13, P551, DOI 10.1016/S0952-8180(01)00328-2; NG ML, 1967, AM J PHYSIOL, V213, P115; Nishiyama T, 1999, ANESTH ANALG, V89, P1437, DOI 10.1097/00000539-199912000-00021; NOBLE MIM, 1967, J APPL PHYSIOL, V22, P147; NOBLE WH, 1981, CAN ANAESTH SOC J, V28, P422, DOI 10.1007/BF03010350; NOMURA F, 1994, CIRCULATION, V90, P321; Plattner O, 2000, ARCH SURG-CHICAGO, V135, P818, DOI 10.1001/archsurg.135.7.818; Ragheb J, 2004, BRIT J ANAESTH, V92, P464, DOI 10.1093/bja/aeh090; RICHARDSON DW, 1972, AM J PHYSIOL, V223, P1308; Rosenblum WI, 2001, EUR J PHARMACOL, V417, P203, DOI 10.1016/S0014-2999(01)00899-8; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Shibata K, 1998, AM J RESP CRIT CARE, V158, P1578, DOI 10.1164/ajrccm.158.5.9804039; SHOEMAKER WC, 1991, CRIT CARE MED, V19, P672, DOI 10.1097/00003246-199105000-00014; STREBEL S, 1993, BRIT J ANAESTH, V71, P272, DOI 10.1093/bja/71.2.272; Vannucci RC, 1997, PEDIATR RES, V42, P24, DOI 10.1203/00006450-199707000-00005; Weckesser M, 1999, MAGN RESON MED, V41, P213, DOI 10.1002/(SICI)1522-2594(199901)41:1<213::AID-MRM31>3.0.CO;2-S; Wei EP, 1999, STROKE, V30, P851, DOI 10.1161/01.STR.30.4.851; Wilson-Smith E, 2003, BRIT J ANAESTH, V91, P190, DOI 10.1093/bja/aeg171; Wolley K, 1990, CIRC RES, V100, P102; YOUNG WL, 1991, ANESTH ANALG, V73, P416	63	34	40	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	FEB	2006	19	1					19	25					7	Anesthesiology	Anesthesiology	V42RV	WOS:000209631800004	16547429				2021-06-18	
J	Jankowitz, BT; Adelson, PD				Jankowitz, Brian T.; Adelson, P. David			Pediatric traumatic brain injury: Past, present and future	DEVELOPMENTAL NEUROSCIENCE			English	Article						pediatric traumatic brain injury; treatment guidelines	SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; YOUNG-CHILDREN; DEXAMETHASONE THERAPY; INTRACRANIAL-PRESSURE; QUINOLINIC ACID; COMA SCALE; INFANTS; SEVERITY; SURVIVAL	Traumatic brain injury (TBI) is the leading cause of death and disability in children. Evidence-based guidelines for the management of this population are available; however, the data highlight significant deficiencies with few treatment standards or guidelines. Considering the limited availability of resources, it is necessary to define realistic goals. Attention should be given to injury prevention, developing standardized pediatric admission and outcome evaluations, increasing the utility and spectrum of physiological and biochemical testing, and defining the evolving role of imaging in TBI. Copyright (c) 2006 S. Karger AG, Basel.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA	Adelson, PD (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurosurg, 3705 5th Ave, Pittsburgh, PA 15213 USA.	David.Adelson@chp.edu	Adelson, David/W-2083-2019				Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; ARJAMAA O, 1992, ACTA PHYSIOL SCAND, V144, P113, DOI 10.1111/j.1748-1716.1992.tb09275.x; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger RP, 2004, J NEUROTRAUM, V21, P1123; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bullock RM, 2000, J NEUROTRAUM, V17, P449; *CDCP NAT CTR INJ, 2003, REP C MILD TRAUM BRA; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; DORSCH MM, 1987, ACCIDENT ANAL PREV, V19, P183, DOI 10.1016/0001-4575(87)90002-9; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Falk AC, 2005, CHILD NERV SYST, V21, P430, DOI 10.1007/s00381-005-1142-4; FANCONI S, 1988, INTENS CARE MED, V14, P163; FEIG PU, 1977, NEW ENGL J MED, V297, P1444, DOI 10.1056/NEJM197712292972608; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Hall JR, 1996, J PEDIATR SURG, V31, P72, DOI 10.1016/S0022-3468(96)90322-X; Han Yong Y, 2003, Pediatr Crit Care Med, V4, P21, DOI 10.1097/00130478-200301000-00004; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; Hulka F, 1997, J TRAUMA, V42, P514, DOI 10.1097/00005373-199703000-00020; *IMPACT, BEST APPR CONC MAN; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1996, PEDIATR NEUROSURG, V25, P309, DOI 10.1159/000121145; KASSELL NF, 1980, NEUROSURGERY, V7, P598, DOI 10.1227/00006123-198012000-00011; Kim PK, 2005, WORLD J SURG, V29, P1557, DOI 10.1007/s00268-005-0106-x; KLOTI J, 1987, CHILD NERV SYST, V3, P103, DOI 10.1007/BF00271134; KRAUS JF, 1987, AM J PUBLIC HEALTH, V77, P76, DOI 10.2105/AJPH.77.1.76; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsubara Kosuke, 2005, Nihon Hoshasen Gijutsu Gakkai Zasshi, V61, P1581; McManus ML, 1998, ANESTHESIOLOGY, V88, P1586, DOI 10.1097/00000542-199806000-00023; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MOSS GS, 1988, AM J SURG, V155, P425, DOI 10.1016/S0002-9610(88)80106-5; Msall ME, 1993, PHYS MED REHAB CLIN, V4, P517; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PHILLIPS R, 1987, J NEUROSURG, V67, P846, DOI 10.3171/jns.1987.67.6.0846; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; REILLY PL, 1988, CHILD NERV SYST, V4, P30; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Robertson CL, 2001, CRIT CARE MED, V29, P2287, DOI 10.1097/00003246-200112000-00009; RODGERS GB, 1993, BICYCLE BICYCLE HELM; ROEBER DE, 2002, COMMUNICATION   0305; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEPAS JJ, 1989, J PEDIATR SURG, V24, P156, DOI 10.1016/S0022-3468(89)80237-4; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WASSERMAN RC, 1988, AM J PUBLIC HEALTH, V78, P1220, DOI 10.2105/AJPH.78.9.1220; WASSERMAN RC, 1990, AM J SPORT MED, V18, P96, DOI 10.1177/036354659001800116; Westbrook A, 1997, Nurs Crit Care, V2, P72; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; YOUNG B, 1983, CHILD BRAIN, V10, P185; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91, DOI 10.1080/J006v21n02_08; ZUCCARELLO M, 1985, CHILD NERV SYST, V1, P158, DOI 10.1007/BF00735731	69	34	35	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					264	275		10.1159/000094153			12	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600004	16943650				2021-06-18	
J	Shields, BJ; Smith, GA				Shields, BJ; Smith, GA			Cheerleading-related injuries to children 5 to 18 years of age: United States, 1990-2002	PEDIATRICS			English	Article							HIGH-SCHOOL; FREQUENCY	OBJECTIVE. To describe the epidemiology of cheerleading-related injuries among children in the United States. DESIGN. A retrospective analysis of data for children 5 to 18 years old from the National Electronic Injury Surveillance System (NEISS) of the US Consumer Product Safety Commission, 1990-2002. METHODS. Sample weights provided by the NEISS were used to make national estimates of cheerleading-related injuries. Injury rates were calculated for the most frequently occurring types of injury using cheerleading participation data. RESULTS. An estimated 208 800 children (95% confidence interval [CI]: 166 620 250 980) 5 to 18 years of age were treated in US hospital emergency departments for cheerleading-related injuries during the 13-year period of 1990-2002. The number of injuries increased by 110% from 10 900 in 1990 to 22 900 in 2002, with an average of 16 100 (95% CI: 12 848-19 352) injuries per year (P < .01). The average age of injured children was 14.4 years (median: 15.0 years); 97% were female; and 85% of injuries occurred to children 12 to 17 years old. The number of injuries per 1000 participants per year was greater for 12- to 17-year-olds (8.1) than for 6- to 11-year-olds (1.2) for all cheerleading-related injuries combined (P <. 01; relative risk [RR]: 6.49; 95% CI: 6.40-6.58), as well as for injuries grouped by body part injured and type of injury. The body parts injured were lower extremity (37.2%), upper extremity (26.4%), head/neck (18.8%), trunk (16.8%), and other (0.8%). Injury diagnoses were strains/sprains (52.4%), soft tissue injuries (18.4%), fractures/dislocations (16.4%), lacerations/avulsions (3.8%), concussions/closed head injuries (3.5%), and other (5.5%). Children in the 12- to 18-year age group were more likely to sustain strains or sprains to the lower extremity than 5- to 11-year-olds (P < .01; RR: 1.62; 95% CI: 1.50-1.88). The majority of patients with cheerleading-related injuries was treated and released from the emergency department (98.7%). Patients sustaining fractures or dislocations were more likely to be admitted to the hospital than those sustaining other types of injury ( P < .01; RR: 5.30; 95% CI: 3.29-6.43). CONCLUSIONS. To our knowledge, this study is the first to report numbers, rates, and trends of cheerleading-related injuries to children using a nationally representative sample. Cheerleading is an important source of injury to girls. The number of cheerleading-related injuries more than doubled during the 13-year study period. A set of uniform rules and regulations directed at increasing the safety of cheerleading, that are universally enforced, should be implemented. Mandatory completion of a safety training and certification program should be required of all cheerleading coaches. Establishment of a national database for cheerleading-related injuries would facilitate the development and evaluation of injury-prevention strategies based on epidemiologic evidence.	Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Pediat, Columbus, OH 43210 USA	Shields, BJ (corresponding author), Childrens Hosp, Columbus Childrens Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	shieldsb@pediatrics.ohio-state.edu					*AM ASS CHEERL COA, AM ASS CHEERL COACHE; American Sports Data Inc, 2004, SUP SPORTS PART, VII; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Axe M J, 1991, Del Med J, V63, P359; Boden BP, 2003, AM J SPORT MED, V31, P881, DOI 10.1177/03635465030310062501; CANTU RC, 1994, CLIN J SPORT MED, V4, P75; *CHIC IL, 2003, SPSS WIND COMP PROGR; Davis Y, 1996, J SAFETY RES, V27, P83, DOI 10.1016/0022-4375(96)00002-3; Fort GG, 1999, AM J EMERG MED, V17, P432, DOI 10.1016/S0735-6757(99)90107-9; Hage P, 1981, Phys Sportsmed, V9, P140, DOI 10.1080/00913847.1981.11711019; HAGE P, 1983, PHYSICIAN SPORTSMED, V11, P25; HOPKINS RS, 1989, AM J PREV MED, V5, P104; Hutchinson MR, 1997, PHYSICIAN SPORTSMED, V25, P83, DOI 10.3810/psm.1997.09.1508; Jacobson BH, 2005, BRIT J SPORT MED, V39, P237, DOI 10.1136/bjsm.2004.014605; Jacobson BH, 2004, J ORTHOP SPORT PHYS, V34, P261, DOI 10.2519/jospt.2004.34.5.261; KESSLER E, 1999, NEIS SAMPLE DESIGN I; *LUCK, 2002, PEDIATR CLIN N AM, V49, P753; Luckstead EF, 2002, PEDIATR CLIN N AM, V49, P753, DOI 10.1016/S0031-3955(02)00017-2; Luckstead EF, 2002, PEDIATR CLIN N AM, V49, P581, DOI 10.1016/S0031-3955(02)00006-8; McDonald A K, 1996, Inj Prev, V2, P77, DOI 10.1136/ip.2.1.77; McGeehan J, 2004, PEDIATRICS, V114, P124, DOI 10.1542/peds.114.1.124; MCNEILL AM, 1995, ANN EMERG MED, V26, P187, DOI 10.1016/S0196-0644(95)70150-8; Mueller FO, 2001, J ATHL TRAINING, V36, P312; MUELLER FO, 2003, SPECIAL SECTIONS CHE; NINEMIRE V, 2005, HUSKERS CHEERLEADERS; Ortega HW, 2004, CLIN PEDIATR, V43, P251, DOI 10.1177/000992280404300306; ROENIGK A, 2002, AM CHEERLEADER, V8, P159; ROENIGK A, 2002, AM CHEERLEADER, V8, P46; Schroeder T., 2001, NEISS SAMPLE DESIGN; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; SHIELDS RW, 1986, ARCH PHYS MED REHAB, V67, P824; Simon TD, 2004, ACAD EMERG MED, V11, P1042, DOI 10.1197/j.aem.2004.04.013; Sinha AK, 1999, CLIN J SPORT MED, V9, P199, DOI 10.1097/00042752-199910000-00003; Smith GA, 1998, PEDIATRICS, V101, P406, DOI 10.1542/peds.101.3.406; Smith GA, 1998, ARCH PEDIAT ADOL MED, V152, P694; Weiss H B, 1996, Inj Prev, V2, P166, DOI 10.1136/ip.2.2.166; Weiss H B, 1996, Inj Prev, V2, P61, DOI 10.1136/ip.2.1.61; *WORLD CHEERL ASS, OP CHALL SER DIV 200; Xiang HY, 2005, J TRAUMA, V58, P112, DOI 10.1097/01.TA.0000151270.26634.DD; UNL RIGHTS ALLOW STU	40	34	35	1	19	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2006	117	1					122	129		10.1542/peds.2005-1139			8	Pediatrics	Pediatrics	999QV	WOS:000234406100017	16396869	Bronze			2021-06-18	
J	Sumpter, RE; McMillan, TM				Sumpter, RE; McMillan, TM			Errors in self-report of post-traumatic stress disorder after severe traumatic brain injury	BRAIN INJURY			English	Article						PTSD; brain injury; self-report; assessment	SCALE	Assessing PTSD by questionnaire can lead to false positive diagnosis after severe traumatic brain injury. Sumpter and McMillan, reported quantitative data on 34 people with severe TBI; 59% were PTSD 'cases' by questionnaire assessment, but only 3% using a structured interview. The present paper describes ways in which these individuals made errors on questionnaires. Some did not follow questionnaire instructions because of inattention and concrete thinking or instead reported effects of brain injury. Symptom overlap between TBI and PTSD, including insomnia, irritability and impaired concentration can cause errors. Brain injury can also provoke curiosity about loss of memory (during coma, retrograde and post-traumatic amnesia), decreased participation, social withdrawal and difficulty adjusting to injury that may be mistaken for fear-associated PTSD symptoms. Assessment of PTSD by questionnaire can lead to erroneous conclusions and factors related to brain injury must be carefully considered when investigating PTSD.	Univ Glasgow, Fac Med, Gartnavel Royal Hosp, Glasgow G12 OXH, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Fac Med, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 OXH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050150209110; NELSON HE, 1991, NATL ADULT READINT T; ODDY M, 2003, NEUROLOGICAL REHABIL, P453; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	17	34	34	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					93	99		10.1080/02699050500394090			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000010	16403704				2021-06-18	
J	Tasker, RC				Tasker, Robert C.			Changes in white matter late after severe traumatic brain injury in childhood	DEVELOPMENTAL NEUROSCIENCE			English	Article						magnetic resonance imaging; traumatic axonal injury; traumatic brain injury; white matter	CLOSED-HEAD-INJURY; CORPUS-CALLOSUM GROWTH; HIPPOCAMPAL PATHOLOGY; INTRACRANIAL-PRESSURE; QUANTITATIVE-ANALYSIS; CLINICAL-FEATURES; VASCULAR PATTERN; CHILDREN; ATROPHY; MRI	Severe traumatic brain injury in childhood, particularly that complicated by raised intracranial pressure, has significant long-term effects on the brain. Since magnetic resonance imaging provides a means of visualizing neuroanatomic structure in exquisite detail, the scope of this review is to revisit the pathology of traumatic brain injury described in recent clinical imaging studies. Acute imaging provides insight into the acute mechanism of focal and diffuse injury. There is some reduction in threshold for white matter pathology in the hemisphere ipsilateral to injury. After injury, there may be long-term effects on white matter architecture and the potential for brain growth. In this context, the pattern of hippocampal rather than parahippocampal gyrus tissue loss provides insight into the likely cause of white matter injury being cerebral hypoperfusion. Copyright (c) 2006 S. Karger AG, Basel.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Paediat, Cambridge CB2 2QQ, England	Tasker, RC (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Dept Paediat, Cambridge CB2 2QQ, England.	rct31@cam.ac.uk	Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113			ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1996, NEUROPSYCHOLOGY, V10, P333, DOI 10.1037/0894-4105.10.3.333; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; DEREUCK J, 1971, EUR NEUROL, V5, P321; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GENARELLI TA, 1982, ANN NEUROL, V12, P564; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giedd JN, 1996, DEV BRAIN RES, V91, P274; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Graham D.I., 1992, GREENFIELDS NEUROPAT, P153; Henry-Feugeas MC, 2000, BRAIN INJURY, V14, P597; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JOHNSON SC, 1994, NEUROPSYCHOLOGY, V8, P1; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; KOTAPKA MJ, 1993, NEUROPATH APPL NEURO, V19, P128, DOI 10.1111/j.1365-2990.1993.tb00417.x; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LINDENBERG R, 1955, AM J PATHOL, V31, P297; Lo T Y M, 2003, Pediatr Rehabil, V6, P47, DOI 10.1080/1363849031000109516; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; MOODY DM, 1990, AM J NEURORADIOL, V11, P431; Nakagawa H, 1998, AM J NEURORADIOL, V19, P1129; NG T, 1989, ACTA NEUROPATHOL, V78, P438, DOI 10.1007/BF00688181; ONUMA T, 1995, J NEUROSURG, V82, P995, DOI 10.3171/jns.1995.82.6.0995; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; PRAYER L, 1993, ACTA RADIOL, V34, P593; PUJOL J, 1993, ANN NEUROL, V34, P71, DOI 10.1002/ana.410340113; Rajapakse JC, 1996, BRAIN DEV-JPN, V18, P379, DOI 10.1016/0387-7604(96)00034-4; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TASKER RC, 2001, DEV MED CHILD NEUROL, V86, pS6; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomita H, 1990, Adv Neurol, V52, P553; VANDENBE.R, 1969, ANGIOLOGY, V20, P88, DOI 10.1177/000331976902000205; VANHOESEN GW, 1982, TRENDS NEUROSCI, V5, P345, DOI 10.1016/0166-2236(82)90201-6; Verger K, 2001, BRAIN INJURY, V15, P211; Vinjamuri S, 2000, NUCL MED COMMUN, V21, P645, DOI 10.1097/00006231-200007000-00008; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333	63	34	34	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0378-5866	1421-9859		DEV NEUROSCI-BASEL	Dev. Neurosci.		2006	28	4-5					302	308		10.1159/000094156			7	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	080ZS	WOS:000240287600007	16943653				2021-06-18	
J	Whyte, J; Grieb-Neff, P; Gantz, C; Polansky, M				Whyte, John; Grieb-Neff, Patricia; Gantz, Christopher; Polansky, Marcia			Measuring sustained attention after traumatic brain injury: Differences in key findings from the sustained attention to response task (SART)	NEUROPSYCHOLOGIA			English	Article						brain injuries; attention; vigilance; sustained attention to response task (SART)	HEAD-INJURY; METHYLPHENIDATE; DEFICITS; FAILURES; MOOD	Clinical reports after traumatic brain injury (TBI) suggest frequent difficulties with sustained attention, but their objective measurement has proved difficult. In 1997, Robertson and colleagues reported on a new sustained attention assessment tool, the sustained attention to response task (SART). Individuals with TBI were reported to produce more errors of commission on the SART than control participants, and both groups showed a relationship between SART errors and everyday lapses of attention as measured by the cognitive failures questionnaire (CFQ). Although few direct replications of these findings have been reported, the SART has been used widely as a measure of sustained attention in TBI, in normal controls, and in various other clinical samples. As part of a program of research on attention in TBI, we administered the SART and the CFQ to a sample of 34 survivors of moderate to severe TBI and to 35 control participants. CFQ scores reported by significant others showed clear group differences in everyday lapses of attention. Despite this, group differences in SART errors of commission were small and non-significant, and the correlations between SART errors and CFQ scores were small within both groups. Further analyses excluding participants with invalid score profiles, or restricting the analysis to the first performance of the SART failed to alter the results. These findings suggest that more research is needed to establish the validity of the SART as a measure of sustained attention after TBI, and to determine under what circumstances the original findings hold. (c) 2006 Elsevier Ltd. All rights reserved.	Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Dept Rehabil Med, Philadelphia, PA 19107 USA; Drexel Univ, Dept Biostat, Philadelphia, PA 19104 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor St,Suite 213, Philadelphia, PA 19141 USA.	jwhyte@einstein.edu		Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline		Alban JP, 2004, AM J PHYS MED REHAB, V83, P131, DOI 10.1097/01.phm.0000112308.68586.1d; Bellgrove MA, 2005, NEUROPSYCHOLOGIA, V43, P1847, DOI 10.1016/j.neuropsychologia.2005.03.011; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Broun T., 1910, Bulletin of the New Zealand Institute Wellington, V1; BUCHTEL HA, 1987, ATTENTION VIGILANCE; Challman TD, 2000, MAYO CLIN PROC, V75, P711; Chan RCK, 2003, BRAIN INJURY, V17, P131, DOI 10.1080/0269905021000010168; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Chan RCK, 2001, BRAIN INJURY, V15, P819, DOI 10.1080/02699050119721; Cohen J., 1988, T TEST MEANS; Dale MT, 2003, BRIT J ANAESTH, V90, p824P; David AS, 2002, PSYCHOL MED, V32, P1357, DOI 10.1017/S0033291702006359; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; Hull L, 2003, PERS INDIV DIFFER, V35, P1211, DOI 10.1016/S0191-8869(02)00329-X; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Manly T, 1999, NEUROPSYCHOLOGIA, V37, P661, DOI 10.1016/S0028-3932(98)00127-4; Manly T, 2003, NEUROCASE, V9, P340, DOI 10.1076/neur.9.4.340.15553; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P1, DOI 10.1016/S0028-3932(01)00086-0; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MELAMED S, 1985, SCAND J REHABIL MED, P16; PARASURAMAN R, 1984, SUSTAINED ATTENTION; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Thompson JP, 2002, EUR J ANAESTH, V19, P585, DOI 10.1017/S0265021502000947; Wallace JC, 2003, J BUS PSYCHOL, V17, P503, DOI 10.1023/A:1023452218225; WALLACE JC, 2001, N AM J PSYCHOL, V3, P481; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3	29	34	34	0	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	10					2007	2014		10.1016/j.neuropsychologia.2006.02.012			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	068VS	WOS:000239403200039	16682059				2021-06-18	
J	Karhunen, H; Jolkkonen, J; Sivenius, J; Pitkanen, A				Karhunen, H; Jolkkonen, J; Sivenius, J; Pitkanen, A			Epileptogenesis after experimental focal cerebral ischemia	NEUROCHEMICAL RESEARCH			English	Article						animal models; brain ischemia; epilepsy; seizures	QUALITY-OF-LIFE; ARTERY OCCLUSION; BLOOD-FLOW; NONCONVULSIVE SEIZURES; STATUS EPILEPTICUS; BRAIN INFARCTION; GENE-EXPRESSION; TIME-COURSE; RAT MODEL; STROKE	Cerebrovascular diseases are one of the most common causes of epilepsy in adults, and the incidence of stroke-induced epileptogenesis is increasing as the population ages. The mechanisms that lead to stroke-induced epileptogenesis in a subpopulation of patients, however, are still poorly understood. Recent advances in inducing epileptogenesis in rodent focal ischemia models have provided tools that can be used to identify the risk factors and neurobiologic changes leading to development of epilepsy after stroke. Here we summarize data from models in which epileptogenesis has been studied after focal ischemia; photothrombosis, middle cerebral artery (MCA) occlusion with filament, and endothelin-1-induced MCA occlusion. Analysis of the data indicates that neurobiologic changes occurring during stroke-induced epileptogenesis share some similarities to those induced by status epilepticus or traumatic brain injury.	Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Neurosci & Neurol, FIN-70211 Kuopio, Finland; Brain Res & Rehabil Ctr Neuron, Kuopio, Finland; Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitka-nen@uku.fi					ARMON C, 1991, CLIN NEUROPHARMACOL, V14, P17, DOI 10.1097/00002826-199102000-00002; Aronowski J, 1997, J CEREBR BLOOD F MET, V17, P1048, DOI 10.1097/00004647-199710000-00006; Bernard C, 2004, SCIENCE, V305, P532, DOI 10.1126/science.1097065; BEZVENYUK Z, 2003, 3 SOC NEUR; Bidmon HJ, 1998, NEUROSCIENCE, V82, P397; Biernaskie J, 2001, MAGNET RESON MED, V46, P827, DOI 10.1002/mrm.1263; Bladin CF, 2000, ARCH NEUROL-CHICAGO, V57, P1617, DOI 10.1001/archneur.57.11.1617; Bogaert L, 2000, BRAIN RES, V887, P266, DOI 10.1016/S0006-8993(00)02959-0; BOGOUSSLAVSKY J, 1992, ARCH NEUROL-CHICAGO, V49, P385, DOI 10.1001/archneur.1992.00530280073025; Brewster AL, 2005, NEUROBIOL DIS, V19, P200, DOI 10.1016/j.nbd.2004.12.015; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; BuchkremerRatzmann I, 1996, STROKE, V27, P1105, DOI 10.1161/01.STR.27.6.1105; BuchkremerRatzmann I, 1997, NEUROREPORT, V8, P519, DOI 10.1097/00001756-199701200-00028; Burn J, 1997, BRIT MED J, V315, P1582, DOI 10.1136/bmj.315.7122.1582; Cheung CM, 2003, J NEUROL, V250, P839, DOI 10.1007/s00415-003-1091-3; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P184, DOI 10.1038/jcbfm.1986.31; Dihne M, 2002, STROKE, V33, P3006, DOI 10.1161/01.STR.0000039406.64644.CB; Dittmar M, 2003, STROKE, V34, P2252, DOI 10.1161/01.STR.0000083625.54851.9A; Ellerkmann RK, 2003, NEUROSCIENCE, V119, P323, DOI 10.1016/S0306-4522(03)00168-4; Engel J, 2001, EPILEPSIA, V42, P3, DOI 10.1046/j.1528-1157.2001.0420s6003.x; Frahm C, 2004, NEUROSCIENCE, V127, P341, DOI 10.1016/j.neuroscience.2004.05.027; Frontczak-Baniewicz M, 2001, NEUROENDOCRINOL LETT, V22, P87; Fuxe K, 1997, NEUROREPORT, V8, P2623, DOI 10.1097/00001756-199707280-00040; Gartshore G, 1996, NEUROSCI LETT, V202, P209, DOI 10.1016/0304-3940(95)12236-2; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Gregersen R, 2001, EXP BRAIN RES, V138, P384, DOI 10.1007/s002210100715; GROME JJ, 1988, J CEREBR BLOOD F MET, V8, P89, DOI 10.1038/jcbfm.1988.11; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; Hartings JA, 2003, EXP NEUROL, V179, P139, DOI 10.1016/S0014-4886(02)00013-4; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HUNTER AJ, 1995, TRENDS PHARMACOL SCI, V16, P123, DOI 10.1016/S0165-6147(00)88999-3; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Jolkkonen J, 2003, BEHAV BRAIN RES, V138, P187, DOI 10.1016/S0166-4328(02)00241-3; Jonkman EJ, 1998, ACTA NEUROL SCAND, V98, P169, DOI 10.1111/j.1600-0404.1998.tb07289.x; Jutila L, 2002, ADV TECH STAND NEUR, V27, P3; Karhunen H, 2003, EPILEPSY RES, V54, P1, DOI 10.1016/S0920-1211(03)00034-2; Kelly KM, 2001, EPILEPSY RES, V47, P189, DOI 10.1016/S0920-1211(01)00294-7; KELLY KM, IN PRESS ANIMAL MODE; Kharlamov EA, 2003, EPILEPSY RES, V56, P185, DOI 10.1016/j.eplepsyres.2003.09.005; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; KOTILA M, 1992, EPILEPSIA, V33, P495, DOI 10.1111/j.1528-1157.1992.tb01698.x; KUDO M, 1982, STROKE, V13, P505, DOI 10.1161/01.STR.13.4.505; KUGE Y, 1995, STROKE, V26, P1655, DOI 10.1161/01.STR.26.9.1655; Labovitz DL, 2001, NEUROLOGY, V57, P200, DOI 10.1212/WNL.57.2.200; Leidy NK, 1999, NEUROLOGY, V53, P162, DOI 10.1212/WNL.53.1.162; Li GL, 2000, APMIS, V108, P98; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Liu JP, 2002, EPILEPSY RES, V52, P85, DOI 10.1016/S0920-1211(02)00194-8; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu XCM, 2001, NEUROPATH APPL NEURO, V27, P481, DOI 10.1046/j.1365-2990.2001.00357.x; Lukasiuk K, 2004, NEUROCHEM RES, V29, P1169, DOI 10.1023/B:NERE.0000023604.91584.6c; MACRAE IM, 1993, J CEREBR BLOOD F MET, V13, P276, DOI 10.1038/jcbfm.1993.34; Miyake K, 2002, BRAIN RES, V935, P24, DOI 10.1016/S0006-8993(02)02420-4; Moyanova S, 1998, ARCH PHYSIOL BIOCHEM, V106, P384, DOI 10.1076/apab.106.5.384.4362; MULLER TB, 1995, STROKE, V26, P1453, DOI 10.1161/01.STR.26.8.1453; Neumann-Haefelin T, 1998, NEUROSCIENCE, V87, P871, DOI 10.1016/S0306-4522(98)00124-9; Nilsson T, 1997, NEUROSURGERY, V40, P346, DOI 10.1097/00006123-199702000-00023; Paolucci S, 1997, EPILEPSIA, V38, P266, DOI 10.1111/j.1528-1157.1997.tb01115.x; PITKANEN A, IN PRESS ANIMAL MODE; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Reith J, 1997, STROKE, V28, P1585, DOI 10.1161/01.STR.28.8.1585; ROBINSON MJ, 1991, J CARDIOVASC PHARM, V17, pS354, DOI 10.1097/00005344-199100177-00101; RYGLEWICZ D, 1990, ACTA NEUROL SCAND, V81, P488; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Schroeter M, 1999, NEUROSCIENCE, V89, P1367, DOI 10.1016/S0306-4522(98)00398-4; Schwartz-Bloom RD, 2001, J NEUROCHEM, V77, P353, DOI 10.1046/j.1471-4159.2001.00274.x; SHARKEY J, 1995, J NEUROSCI METH, V60, P125, DOI 10.1016/0165-0270(95)00003-D; SHARKEY J, 1993, J CEREBR BLOOD F MET, V13, P865, DOI 10.1038/jcbfm.1993.108; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; Silverman IE, 2002, ARCH NEUROL-CHICAGO, V59, P195, DOI 10.1001/archneur.59.2.195; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; STROEMER RP, 1995, STROKE, V26, P2135, DOI 10.1161/01.STR.26.11.2135; STROEMER RP, 1993, NEUROSCI LETT, V162, P51, DOI 10.1016/0304-3940(93)90557-2; Su H, 2002, J NEUROSCI, V22, P3645; Sutula TP, 2004, EPILEPSY RES, V60, P161, DOI 10.1016/j.eplepsyres.2004.07.001; Vernino S, 2003, STROKE, V34, P1828, DOI 10.1161/01.STR.0000080534.98416.A0; Wang CX, 2001, J NEUROSCI METH, V109, P147, DOI 10.1016/S0165-0270(01)00408-3; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Williams AJ, 2002, BRAIN RES, V932, P45, DOI 10.1016/S0006-8993(02)02275-8; Williams AJ, 2001, J PHARMACOL EXP THER, V299, P48; Williams AJ, 2004, J PHARMACOL EXP THER, V311, P220, DOI 10.1124/jpet.104.069146; Witte O W, 1999, Adv Neurol, V81, P25; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	83	34	37	0	7	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	DEC	2005	30	12					1529	1542		10.1007/s11064-005-8831-y			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	994TN	WOS:000234054200009	16362772				2021-06-18	
J	Marin-Caballos, A; Murillo-Cabezas, F; Cayuela-Dominguez, A; Dominguez-Roldan, JM; Rincon-Ferrari, MD; Valencia-Anguita, J; Flores-Cordero, JM; Munoz-Sanchez, MA				Marin-Caballos, A; Murillo-Cabezas, F; Cayuela-Dominguez, A; Dominguez-Roldan, JM; Rincon-Ferrari, MD; Valencia-Anguita, J; Flores-Cordero, JM; Munoz-Sanchez, MA			Cerebral perfusion pressure and risk of brain hypoxia in severe head injury: a prospective observational study	CRITICAL CARE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; INTRACRANIAL HYPERTENSION; MODERATE HYPOTHERMIA; TISSUE OXYGEN; NOREPINEPHRINE; AUGMENTATION; DOPAMINE; TENSION; BLOOD; PO2	Introduction Higher and lower cerebral perfusion pressure (CPP) thresholds have been proposed to improve brain tissue oxygen pressure (PtiO(2)) and outcome. We study the distribution of hypoxic PtiO(2) samples at different CPP thresholds, using prospective multimodality monitoring in patients with severe traumatic brain injury. Methods This is a prospective observational study of 22 severely head injured patients admitted to a neurosurgical critical care unit from whom multimodality data was collected during standard management directed at improving intracranial pressure, CPP and PtiO(2). Local PtiO(2) was continuously measured in uninjured areas and snapshot samples were collected hourly and analyzed in relation to simultaneous CPP. Other variables that influence tissue oxygen availability, mainly arterial oxygen saturation, end tidal carbon dioxide, body temperature and effective hemoglobin, were also monitored to keep them stable in order to avoid non-ischemic hypoxia. Results Our main results indicate that half of PtiO(2) samples were at risk of hypoxia ( defined by a PtiO(2) equal to or less than 15 mmHg) when CPP was below 60 mmHg, and that this percentage decreased to 25% and 10% when CPP was between 60 and 70 mmHg and above 70 mmHg, respectively ( p < 0.01). Conclusion Our study indicates that the risk of brain tissue hypoxia in severely head injured patients could be really high when CPP is below the normally recommended threshold of 60 mmHg, is still elevated when CPP is slightly over it, but decreases at CPP values above it.	Hosp Univ Virgen Rocio, Serv Cuidados Crit & Urgencias, Seville 41013, Spain; Hosp Univ Virgen Rocio, Unidad Apoyo Invest, Seville 41013, Spain; Hosp Univ Virgen Rocio, Serv Neurocirugia, Seville 41013, Spain	Marin-Caballos, A (corresponding author), Hosp Univ Virgen Rocio, Serv Cuidados Crit & Urgencias, Avda Manuel Siurot S-N, Seville 41013, Spain.	antmarin@terra.es	IBIS, NEUROCRITICOS/C-1805-2016; Dominguez-Roldan, Jose-Maria/M-1728-2016; Murillo-Cabezas, Francisco/AAO-3348-2021	Dominguez-Roldan, Jose-Maria/0000-0003-1933-1478; 			BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Bruzzone P, 1998, ACT NEUR S, V71, P111; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; DEARDEN NM, 1993, ACTA NEUROCHIR, P91; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Sahuquillo J, 2000, ACT NEUR S, V76, P457; Schneider GH, 1998, ACT NEUR S, V71, P62; SIGGAARDANDERSEN O, 1995, CRIT CARE MED, V23, P1284, DOI 10.1097/00003246-199507000-00020; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Stocchetti N, 1998, ACT NEUR S, V71, P162; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; UPDATE NOTICE GUIDEL; MANAGEMENT PROGNOS 1	27	34	36	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	DEC	2005	9	6					R670	R676		10.1186/cc3822			7	Critical Care Medicine	General & Internal Medicine	014XR	WOS:000235514400014	16356218	DOAJ Gold, Green Published			2021-06-18	
J	Marmarou, A; Guy, M; Murphey, L; Roy, F; Layani, L; Combal, JP; Marquer, C				Marmarou, A; Guy, M; Murphey, L; Roy, F; Layani, L; Combal, JP; Marquer, C		Amer Brain Injury Consortium	A single dose, three-arm, placebo-controlled, phase I study of the bradykinin B-2 receptor antagonist anatibant (LF16-0687Ms) in patients with severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						anatibant; bradykinin; clinical trial; LF16-0687 Ms; pharmacokinetics	KALLIKREIN-KININ SYSTEM; HEAD-INJURY; CLINICAL-TRIALS; LF 16-0687MS; EDEMA; PLASMA; MEDIATOR; INHIBITION; METABOLITE; HUMANS	Traumatic brain injury (TBI) mortality and morbidity remains a public health challenge. Because experimental studies support an important role of bradykinin (BK) in the neurological deterioration that follows TBI, a double-blind, randomized, placebo-controlled study of Anatibant (LF16-0687Ms), a selective and potent antagonist of the BK B-2 receptor, was conducted in severe (Glasgow Coma Scale [GCS] < 8) TBI patients (n = 25) at six sites in the United States. At 8-12 h after injury (9.9 +/- 2.8 h), patients received a single subcutaneous injection of Anatibant (3.75 mg or 22.5 mg, n = 10 each) or placebo (n = 5). The primary objective was to investigate the pharmacokinetics of Anatibant; general safety, local tolerability, levels of the bradykinin metabolite BK1-5 in plasma and cerebrospinal fluid (CSF), intracranial pressure (ICP), and cerebral perfusion pressure were also assessed. We observed a dose-proportionality of the pharmacokinetics, C-max, and AUC of Anatibant. V-d/F, Cl/F, and t(1/2) were independent on the dose and protein binding was > 97.7%. Anatibant, administered as single subcutaneous injections of 3.75 g and 22.5 mg, was well tolerated in severe TBI patients with no unexpected clinical adverse events or biological abnormalities observed. Interestingly, plasma and CSF levels of BK1-5 were significantly and markedly increased after trauma (e.g., 34,700 +/- 35,300 fmol/mL in plasma vs. 34.9 +/- 5.6 fmol/mL previously reported for normal volunteers), supporting the use of Anatibant as a treatment of secondary brain damage. To address this issue, a dose-response trial that would investigate the effects of Anatibant on the incidence of raised ICP and on functional outcome in severe TBI patients is needed.	Labs Fournier SA, F-21121 Daix, France; ABIC Tech Ctr, Richmond, VA USA; Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37212 USA	Guy, M (corresponding author), Labs Fournier SA, 50 Rue Dijon, F-21121 Daix, France.	m.guy@fr.fournierpharma.com					BETZ AL, 1992, NEUROSURGERY SCI BAS, P353; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Cold G E, 1990, Acta Neurochir Suppl (Wien), V49, P1; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; FESSLER RD, 1993, ANN EMERG MED, V22, P998, DOI 10.1016/S0196-0644(05)82741-6; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; HELLAL F, 2003, NSS 2003 BIL; Kaplan R P, 1987, Adv Dermatol, V2, P19; KASUYA H, 1988, ACTA NEUROCHIR, V91, P120, DOI 10.1007/BF01424566; Kenworthy KE, 1999, BRIT J CLIN PHARMACO, V48, P716; LOWENSTEIN CJ, 1994, ANN INTERN MED, V120, P227, DOI 10.7326/0003-4819-120-3-199402010-00009; Maas AIR, 2004, ACT NEUR S, V89, P113; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Murphey LJ, 2000, J PHARMACOL EXP THER, V294, P263; Murphey LJ, 2004, J PHARMACOL EXP THER, V308, P1046, DOI 10.1124/jpet.103.059337; Murphey LJ, 2001, ANAL BIOCHEM, V292, P87, DOI 10.1006/abio.2001.5073; MURR R, 1993, ACTA NEUROCHIR, P11; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Narotam PK, 1998, ACTA NEUROCHIR, V140, P793, DOI 10.1007/s007010050181; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PITTS LH, 1990, HDB CLIN NEUROLOGY, V13, P65; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; Pretorius M, 2004, CLIN PHARMACOL THER, V76, P379, DOI 10.1016/j.clpt.2004.06.004; Pruneau D, 1999, J NEUROTRAUM, V16, P1057, DOI 10.1089/neu.1999.16.1057; Pruneau D, 1999, IMMUNOPHARMACOLOGY, V43, P187, DOI 10.1016/S0162-3109(99)00128-9; Ray SK, 2002, HISTOL HISTOPATHOL, V17, P1137, DOI 10.14670/HH-17.1137; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Schilling L, 1997, KIDNEY INT, pS69; Schulz J, 2000, ACT NEUR S, V76, P137; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Stover JF, 2000, J NEUROSURG, V92, P853, DOI 10.3171/jns.2000.92.5.0853; SUGIMOTO K, AM J PHYSL, V274, pR1556; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WAHL M, 1983, J CEREBR BLOOD F MET, V3, P231, DOI 10.1038/jcbfm.1983.31; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; Wahl M, 1996, IMMUNOPHARMACOLOGY, V33, P257, DOI 10.1016/0162-3109(96)00068-9; Wahl M., 1993, REGULATION CEREBRAL, P315; XU J, 1991, J NEUROCHEM, V57, P975, DOI 10.1111/j.1471-4159.1991.tb08246.x; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505; 2002, CDC REPORT, V51, P1	47	34	35	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1444	1455		10.1089/neu.2005.22.1444			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500007	16379582				2021-06-18	
J	Fonseca, AH; Ochsner, MG; Bromberg, WJ; Gantt, D				Fonseca, AH; Ochsner, MG; Bromberg, WJ; Gantt, D			All-terrain vehicle injuries: Are they dangerous? A 6-year experience at a level I trauma center after legislative regulations expired	AMERICAN SURGEON			English	Article; Proceedings Paper	Annual Meeting of the Southeastern-Surgical-Congress	FEB 11-15, 2005	New Orleans, LA	SE Surg Congress			CHILDREN	All-terrain vehicles (ATVs) have increased in popularity and sales since 1971. This rise in popularity led to an increase in injuries resulting in voluntary industry rider safety regulations in 1988, which expired without renewal in 1998. Our purpose was twofold, to determine the incidence and severity of ATV injuries in our patient population and what, if any impact the safety regulations had. To further characterize the risk of ATV use, we compared them to a vehicle generally recognized as dangerous, the motorcycle (MC). Our trauma registry was reviewed from January 1998 through August 2004 for ATV or MC injured. Data collected included age, gender, mortality, Injury Severity Score (ISS), helmet use, and injury distribution. These were compared to our data from the decade of regulation. There were 352 MC and 221 ATV patients. ATV injured demonstrated a higher proportion of pediatric and female patients (P < 0.001 and P < 0.01, respectively), a decrease in helmet use (8.6% vs 64.7%, P < 0.001), and increased closed head injuries (CHI) (54.2% vs 44.9%, P < 0.05) compared with MC injured. ISS and mortality were similar. The average number of patients from 1988 to 1998 was 6.9/yr compared to 31.6/yr (P < 0.001) during 1998-2004 with equal ISS. Our data show that there has been a dramatic and progressive increase in the number of ATV crashes since expiration of industry regulations. ATVs are as dangerous as MCs based on patient ISS and mortality. There are significantly more children and women injured on ATVs. The lower rate of helmet use in ATVs may account for the significantly greater incidence of CHI. These data mandate the need for injury prevention efforts for ATV riders, in particular children, through increased public awareness and new legislation.	Mem Hlth Univ Med Ctr, Dept Surg Educ, Savannah, GA USA	Fonseca, AH (corresponding author), 1105 E 50th St, Savannah, GA 31404 USA.						Acosta JA, 2003, J TRAUMA, V55, P282, DOI 10.1097/01.TA.0000080525.77566.ED; Branas CC, 2001, ACCIDENT ANAL PREV, V33, P641, DOI 10.1016/S0001-4575(00)00078-6; Brown RL, 2002, J PEDIATR SURG, V37, P375, DOI 10.1053/jpsu.2002.30826; HARGARTEN SW, 1991, AM J EMERG MED, V9, P149, DOI 10.1016/0735-6757(91)90178-M; KYLE SB, 1998, REPORT 1997 INJURY S; Lynch JM, 1998, J PEDIATR SURG, V33, P329, DOI 10.1016/S0022-3468(98)90456-0; Moore MJ, 1997, INT REV LAW ECON, V17, P379, DOI 10.1016/S0144-8188(97)00022-7; Murphy N, 2004, J TRAUMA, V56, P1185, DOI 10.1097/01.TA.0000123038.94864.E2; RODGERS GB, 1990, ACCIDENT ANAL PREV, V22, P47, DOI 10.1016/0001-4575(90)90006-7; Rodgers GB, 1999, ACCIDENT ANAL PREV, V31, P409, DOI 10.1016/S0001-4575(98)00080-3; Ross RT, 1999, AM SURGEON, V65, P870; Upperman JS, 2003, J PEDIATR SURG, V38, P1284, DOI 10.1016/S0022-3468(03)00383-X; *US CONS PROD SAF, 1998, ALLT VEH EXP INJ DEA; *US CONS PROD SAF, 2002, ANN REP ATV DEATH IN	14	34	34	0	0	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	NOV	2005	71	11					937	940					4	Surgery	Surgery	985SH	WOS:000233398200013	16372612				2021-06-18	
J	Pegg, PO; Auerbach, SM; Seel, RT; Buenaver, LF; Kiesler, DJ; Plybon, LE				Pegg, PO; Auerbach, SM; Seel, RT; Buenaver, LF; Kiesler, DJ; Plybon, LE			The impact of patient-centered information on patients' treatment satisfaction and outcomes in traumatic brain injury rehabilitation	REHABILITATION PSYCHOLOGY			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; OWN HEALTH-CARE; DECISION-MAKING; INTERPERSONAL IMPACTS; STRESS MANAGEMENT; RESEARCH ISSUES; INTERVENTIONS; CIRCUMPLEX; ADJUSTMENT; MEDICINE	Objective: To evaluate the effects on patients with traumatic brain injury (TBI) of detailed, personalized information about their injuries, acute care treatment, and rehabilitation progress. Participants: Twenty-eight former or present military personnel (mean age = 30 years) with moderate to severe TBI (mean of 29 days spent in intensive care before admission to TBI unit). Design: Two (personalized information vs. general information) X 2 (high- vs. low-patient preference for health care information) factorial design. Interpersonal behavior of patients, information providers, and health care staff were measured by the Impact Message Inventory. Outcome Measures: Rehabilitation Intensity of Therapy Scale, Functional Independence Measure, Treatment Satisfaction Questionnaire. Results: Patients given personalized information exerted greater effort in physical therapy, made greater improvement in functional independence, and were more satisfied with rehabilitation treatment. Patient preference for information and ratings of interpersonal behavior were largely unrelated to patient outcomes. Conclusion: Cognitively impaired TBI patients can benefit from interventions designed to enhance their sense of control and personal involvement in their own care.	Western Kentucky Univ, Dept Psychol, Bowling Green, KY 42101 USA; Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; Hunter Holmes McGuire Vet Adm Med Ctr, Richmond, VA USA	Pegg, PO (corresponding author), Western Kentucky Univ, Dept Psychol, 1 Big Red Way, Bowling Green, KY 42101 USA.	phil.pegg@wku.edu					AUERBACH SM, 1983, J PERS SOC PSYCHOL, V44, P1284, DOI 10.1037/0022-3514.44.6.1284; Auerbach SM, 2004, J BEHAV MED, V27, P11, DOI 10.1023/B:JOBM.0000013641.64651.16; AUERBACH SM, 1989, J CONSULT CLIN PSYCH, V57, P388, DOI 10.1037/0022-006X.57.3.388; Auerbach SM, 2002, J HEALTH PSYCHOL, V7, P393, DOI 10.1177/1359105302007004328; Auerbach SM, 2002, J BEHAV MED, V25, P17, DOI 10.1023/A:1013585617303; Auerbach SM, 2001, J HEALTH PSYCHOL, V6, P191, DOI 10.1177/135910530100600208; Auerbach SM, 2000, ANN BEHAV MED, V22, P246, DOI 10.1007/BF02895120; AVERILL JR, 1973, PSYCHOL BULL, V80, P286, DOI 10.1037/h0034845; BALTES MM, 1986, PSYCHOL CONTROL AGIN; Braddock CH, 1999, JAMA-J AM MED ASSOC, V282, P2313, DOI 10.1001/jama.282.24.2313; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; CROMWELL RL, 1977, ACUTE MYOCARDIAL INF; DERENZI E, 1978, CORTEX, V14, P41, DOI 10.1016/S0010-9452(78)80006-9; Elliott TR, 2002, REHABIL PSYCHOL, V47, P131, DOI 10.1037//0090-5550.47.2.131; Ford S, 1995, EUR J CANCER, V31A, P2264, DOI 10.1016/0959-8049(95)00336-3; Hagen C, 1984, LANGUAGE DISORDERS A, P245; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hogbin B., 1992, PSYCHO-ONCOLOGY, V1, P147, DOI [10.1002/pon.2960010304, DOI 10.1002/PON.2960010304]; Kaplan RM, 1999, ANN BEHAV MED, V21, P3, DOI 10.1007/BF02895027; Kiesler D., 1993, IMPACT MESSAGE INVEN; Kiesler DJ, 2003, SOC SCI MED, V57, P1707, DOI 10.1016/S0277-9536(02)00558-0; KIESLER DJ, 1983, PSYCHOL REV, V90, P185, DOI 10.1037/0033-295X.90.3.185; Kiesler DJ, 1996, CONT INTERPERSONAL T; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; Laine C, 1996, JAMA-J AM MED ASSOC, V275, P152, DOI 10.1001/jama.275.2.152; Lazure L L, 1995, Am J Crit Care, V4, P157; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARTELLI MF, 1987, J CONSULT CLIN PSYCH, V55, P201, DOI 10.1037/0022-006X.55.2.201; Mead N, 2000, SOC SCI MED, V51, P1087, DOI 10.1016/S0277-9536(00)00098-8; MERZ JF, 1990, J LEGAL MED, V11, P321, DOI 10.1080/01947649009510831; MEYER TJ, 1995, HEALTH PSYCHOL, V14, P101, DOI 10.1037/0278-6133.14.2.101; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PEGG PO, 2001, TREATMENT SATISFACTI; Quill TE, 1996, ANN INTERN MED, V125, P763, DOI 10.7326/0003-4819-125-9-199611010-00010; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Schmidt JA, 1999, J COUNS PSYCHOL, V46, P325, DOI 10.1037/0022-0167.46.3.325; Seel R. T., 2001, REHABILITATION INTEN; SIMINOFF L A, 1989, Annals of Behavioral Medicine, V11, P108, DOI 10.1207/s15324796abm1103_3; Stewart M, 1989, COMMUNICATING MED PA; SULS J, 1989, J CONSULT CLIN PSYCH, V57, P372, DOI 10.1037/0022-006X.57.3.372; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *UN DAT SYST MED R, 1997, FIM INSTR	42	34	34	0	6	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2005	50	4					366	374		10.1037/0090-5550.50.4.366			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	990KL	WOS:000233741700006					2021-06-18	
J	Sawchyn, JM; Mateer, CA; Suffield, JB				Sawchyn, JM; Mateer, CA; Suffield, JB			Awareness, emotional adjustment, and injury severity in postacute brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness; emotional adjustment; severity; traumatic brain injury	CLOSED-HEAD-INJURY; COMPETENCE RATING-SCALE; SELF-AWARENESS; IMPAIRED AWARENESS; SOCIAL-BEHAVIOR; DEFICITS; INDIVIDUALS; LIMITATIONS; ANOSOGNOSIA; DISABILITY	Objective: Relationships among awareness of deficits, injury severity, and emotional adjustment in patients with traumatic brain injury were explored. Participants: One hundred sixty-six individuals were referred for postacute neurocognitive assessment. Design: Retrospective file analysis identified injury severity, and data from the Patient Competency Rating Scale and Katz Adjustment Scale-Revised, utilizing self-ratings and significant others' ratings, were gathered. Results: Significant others described emotional adjustment difficulties, regardless of the severity of injury. A positive association was noted between patients' acknowledgment of neurobehavioral problems and ratings of their emotional adjustment. Conclusions: Severity of TBI appeared less important than emotional adjustment in the awareness of deficit; mildly injured patients were more likely to report neurobehavioral deficits than were moderately and severely injured patients, relative to the reports of significant others.	AT Malcolm & Associates, Victoria, BC V8R 1T2, Canada; Univ Victoria, Dept Psychol, Victoria, BC V8R 1T2, Canada; Columbia Rehabil Ctr, Calgary, AB, Canada	Sawchyn, JM (corresponding author), AT Malcolm & Associates, 216-284 Helmcken Rd, Victoria, BC V8R 1T2, Canada.	jsawchyn@island.net					ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Baker KA, 1998, REHABIL PSYCHOL, V43, P30, DOI 10.1037/0090-5550.43.1.30; BENYISHAY Y, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P194; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Coetzer BR, 2001, J COGN REHABIL, V19, P8; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GORAN DA, 1993, BRAIN INJURY, V7, P219, DOI 10.3109/02699059309029674; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Kortte KB, 2003, REHABIL PSYCHOL, V48, P131, DOI 10.1037/0090-5550.48.3.131; Lanham RA, 2000, J HEAD TRAUMA REHAB, V15, P1123, DOI 10.1097/00001199-200010000-00006; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P799; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigozhin L, 1996, FREE BOUNDARY PROBLE, V10, P2; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Ryan LM, 1998, ARCH CLIN NEUROPSYCH, V13, P147; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Stuss D.T., 1986, FRONTAL LOBES; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wallace CA, 2000, BRAIN INJURY, V14, P549	45	34	34	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2005	20	4					301	314		10.1097/00001199-200507000-00003			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941MV	WOS:000230219800003	16030438				2021-06-18	
J	Kaplan, S; Gokyar, A; Unal, B; Tunc, AT; Bahadir, A; Aslan, H				Kaplan, S; Gokyar, A; Unal, B; Tunc, AT; Bahadir, A; Aslan, H			A simple technique for localizing consecutive fields for disector pairs in light microscopy: Application to neuron counting in rabbit spinal cord following spinal cord injury	JOURNAL OF NEUROSCIENCE METHODS			English	Article						physical fractionator; stereology; injury; spinal cord; hypothermia; methylprednisolone	TRAUMATIC BRAIN-INJURY; METHYLPREDNISOLONE TREATMENT; ARBITRARY PARTICLES; UNBIASED ESTIMATION; ISCHEMIC-STROKE; CYCLOSPORINE-A; STEREOLOGY; RAT; HYPOTHERMIA; NUMBER	Locating the same microscopic fields in consecutive sections is important in stereological analysis. The tools for achieving this requirement have limited number in practice. This paper presents a simple and inexpensive technique for localizing the same fields on disector pairs in conventional light microscopes equipped with widely available dial indicators. It is partly a modification of equipment previously described. The presented procedure requires two light microscopes equipped with dial indicators and modified slide clips. An application of the present system was shown in a model of spinal cord injury (SCI). A midthoracic laminectomy was performed leaving the dura intact. A contusion was done at the level of midthoracic spinal cord segments (T7-T8) by dropping a 10-g mass from a height of 30cm. The subjects were randomly divided into three groups (10 animals in each): hypothermia group, methylprednisolone group, and traumatic spinal cord injury alone group. Present result show that treatment with hypothermia after spinal cord trauma has a neuroprotective effect on cell damage but not in the methylprednisolone treatment group. (c) 2005 Elsevier B.V. All rights reserved.	Ondokuz Mayis Univ, Sch Med, Dept Histol & Embryol, TR-55139 Kurupelit, Turkey; Hosp Social Insurance Fdn, Neurosurg Clin, TR-55305 Samsun, Turkey; Ataturk Univ, Sch Med, Dept Histol & Embryol, TR-25100 Erzurum, Turkey; Gaziosmanpasa Univ, Sch Med, Dept Histol & Embryol, TR-60100 Tokat, Turkey	Kaplan, S (corresponding author), Ondokuz Mayis Univ, Sch Med, Dept Histol & Embryol, TR-55139 Kurupelit, Turkey.	skaplan@omu.edu.tr	Kaplan, Suleyman/A-5396-2008; Gokyar, Ahmet/N-9877-2018; Aslan, Huseyin/K-4602-2012	Kaplan, Suleyman/0000-0003-1477-5002; Gokyar, Ahmet/0000-0003-1942-587X; 			Battiston B, 2000, MICROSURG, V20, P37, DOI 10.1002/(SICI)1098-2752(2000)20:1<37::AID-MICR7>3.0.CO;2-5; Borlongan CV, 2005, LIFE SCI, V76, P1503, DOI 10.1016/j.lfs.2004.09.022; BRADBURY S, 1990, MICROSC ANAL, V17, P7; BRAENDGAARD H, 1986, J NEUROSCI METH, V18, P39, DOI 10.1016/0165-0270(86)90112-3; DELATTRE JY, 1989, J NEUROSURG, V70, P920, DOI 10.3171/jns.1989.70.6.0920; Glaser JR, 2000, J CHEM NEUROANAT, V20, P115, DOI 10.1016/S0891-0618(00)00073-9; Gok A, 2002, ACTA NEUROCHIR, V144, P817, DOI 10.1007/s00701-002-0964-z; Gong QY, 1999, BRIT J RADIOL, V72, P1177, DOI 10.1259/bjr.72.864.10703475; Graves MJ, 2000, BRIT J RADIOL, V73, P825, DOI 10.1259/bjr.73.872.11026856; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Gunnarsson T, 2003, CURR OPIN NEUROL, V16, P717, DOI 10.1097/00019052-200312000-00012; GUNTINASLICHIUS O, 1993, J MICROSC-OXFORD, V172, P177, DOI 10.1111/j.1365-2818.1993.tb03409.x; Hof PR, 2001, TRENDS NEUROSCI, V24, P377, DOI 10.1016/S0166-2236(00)01834-8; HOWARD CV, 1998, 3 DIMENSIONAL MEASUR, P187; Inamasu J, 2003, J NEUROL SCI, V209, P55, DOI 10.1016/S0022-510X(02)00463-X; Kaplan S, 2001, J MICROSC-OXFORD, V203, P321, DOI 10.1046/j.1365-2818.2001.00931.x; KIM D, 2002, SPINE J S, V2, P34; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; Larsen JO, 1998, J NEUROSCI METH, V85, P107, DOI 10.1016/S0165-0270(98)00129-0; Mackay CE, 1999, ACTA STEREOL, V18, P149; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McCutcheon EP, 2004, J TRAUMA, V56, P1076, DOI 10.1097/01.TA.0000082312.71894.D4; MEANS ED, 1981, J NEUROSURG, V55, P200, DOI 10.3171/jns.1981.55.2.0200; Merola A, 2002, J ORTHOP TRAUMA, V16, P155, DOI 10.1097/00005131-200203000-00003; MOLLER A, 1990, J MICROSC-OXFORD, V159, P61, DOI 10.1111/j.1365-2818.1990.tb03019.x; Ohm TG, 1997, NEUROBIOL AGING, V18, P393, DOI 10.1016/S0197-4580(97)00034-1; POVER CM, 1991, ANAT REC, V231, P573, DOI 10.1002/ar.1092310419; Sharma Alok, 2004, Indian Journal of Experimental Biology, V42, P476; Sonmez OF, 2002, ACTA NEUROCHIR, V144, P921, DOI 10.1007/s00701-002-0971-0; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Taoka Y, 1998, PROG NEUROBIOL, V56, P341, DOI 10.1016/S0301-0082(98)00049-5; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Tos P, 2000, MICROSURG, V20, P65, DOI 10.1002/(SICI)1098-2752(2000)20:2<65::AID-MICR4>3.0.CO;2-4; TUCKER JH, 1994, J MICROSC-OXFORD, V176, P75, DOI 10.1111/j.1365-2818.1994.tb03501.x; VANICKY I, 1993, J NEUROSURG, V79, P736, DOI 10.3171/jns.1993.79.5.0736; WEIRICH SD, 1990, SPINE, V15, P630, DOI 10.1097/00007632-199007000-00004; White RJ, 2001, J NEUROSURG, V94, P183; Yu GL, 2004, BRAIN RES, V1018, P32, DOI 10.1016/j.brainres.2004.05.056; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206; Zeidman SM, 1996, J SPINAL DISORD, V9, P367	44	34	37	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	JUN 30	2005	145	1-2					277	284		10.1016/j.jneumeth.2005.02.012			8	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	936OY	WOS:000229866500024	15922043				2021-06-18	
J	Jones, C; Harvey, AG; Brewin, CR				Jones, C; Harvey, AG; Brewin, CR			Traumatic brain injury, dissociation, and posttraumatic stress disorder in road traffic accident survivors	JOURNAL OF TRAUMATIC STRESS			English	Article							MOTOR-VEHICLE ACCIDENTS; CLOSED HEAD-INJURY; SYMPTOMS; MEMORY; PTSD	This study investigated the symptom profiles of acute stress disorder (ASD) and posttraumatic stress disorder (PTSD) in participants who did and did not sustain traumatic brain injury (TBI), following a road traffic accident. The participants were assessed at three time points: as soon as possible posttrauma as well as at 6 weeks and 3 months posttrauma. At the first assessment, fewer participants from the TBI group recalled feeling fear and helplessness at the time of the trauma, fewer TBI participants reported recurrent intrusive thoughts and images, and more TBI participants reported dissociation since the trauma, relative to the non-TBI group. At the second assessment, fewer participants from the TBI group recalled feeling intense helplessness at the time of the trauma. Fewer TBI participants also reported reliving and physiological reactions on trauma reminders relative to the non-TBI group. At 3 months posttrauma, there was no difference in PTSD symptom profile between non-TBI and TBI groups. Our findings indicate that the presence of TBI is likely to influence the distribution of certain symptoms, but need not be a significant barrier to diagnosing ASD and PTSD.	Univ Calif Berkeley, Dept Psychol, Berkeley, CA 94720 USA; Univ Oxford, Dept Expt Psychol, Oxford OX1 2JD, England; UCL, Subdept Clin Hlth Psychol, London, England	Harvey, AG (corresponding author), Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall 1650, Berkeley, CA 94720 USA.	aharvey@berkeley.edu	Brewin, Chris R/C-4566-2008	Brewin, Chris R/0000-0002-7462-4460			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, J NERV MENT DIS, V180, P183; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; BREWIN CR, 2003, POSTTRAUMATICAL STRE; Bryant R.A., 2000, ACUTE STRESS DISORDE; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Creamer M, 2004, BEHAV RES THER, V42, P315, DOI 10.1016/S0005-7967(03)00141-4; DAVIDOFF DA, 1988, COGNITIVE REHABI MAR, P8; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Halligan SL, 2003, J CONSULT CLIN PSYCH, V71, P419, DOI 10.1037/0022-006X.71.3.419; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Harvey AG, 2000, J NERV MENT DIS, V188, P602, DOI 10.1097/00005053-200009000-00007; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hyman IE, 1998, CLIN PSYCHOL REV, V18, P933, DOI 10.1016/S0272-7358(98)00041-5; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kato H, 1996, ACTA PSYCHIAT SCAND, V93, P477, DOI 10.1111/j.1600-0447.1996.tb10680.x; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MARMAR CR, 1997, ASSESSING PSYCHOL TR; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Middelboe T., 1992, European Psychiatry, V7, P183; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; Panasetis P, 2003, J TRAUMA STRESS, V16, P563, DOI 10.1023/B:JOTS.0000004079.74606.ba; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Symonds CP, 1943, LANCET, V1, P7; Ursano RJ, 1999, AM J PSYCHIAT, V156, P1808; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018	45	34	35	0	9	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0894-9867			J TRAUMA STRESS	J. Trauma Stress	JUN	2005	18	3					181	191		10.1002/jts.20031			11	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	986JQ	WOS:000233446300001	16281212				2021-06-18	
J	Hellmich, HL; Capra, B; Eidson, K; Garcia, J; Kennedy, D; Uchida, T; Parsley, M; Cowart, J; DeWitt, DS; Prough, DS				Hellmich, HL; Capra, B; Eidson, K; Garcia, J; Kennedy, D; Uchida, T; Parsley, M; Cowart, J; DeWitt, DS; Prough, DS			Dose-dependent neuronal injury after traumatic brain injury	BRAIN RESEARCH			English	Article						Fluoro-Jade; laser capture microdissection; injured neuron; gene expression	LATERAL FLUID PERCUSSION; FLUORO-JADE; CLINICAL-TRIALS; CELL-DEATH; NEUROPROTECTION; DEFICITS; HIPPOCAMPUS; MECHANISMS; EXPRESSION; ISCHEMIA	The Fluoro-Jade (FJ) stain reliably identifies degenerating neurons after multiple mechanisms of brain injury. We modified the FJ staining protocol to quickly stain frozen hippocampal rat brain sections and to permit systematic counts of stained, injured neurons at 4 and 24 h after mild, moderate or severe fluid percussion traumatic brain injury (TBI). In adjacent sections, laser capture microdissection was used to collect uninjured (FJ negative) CA3 hippocampal neurons to assess the effect of injury severity on mRNA levels of selected genes. Rats were anesthetized, intubated, mechanically ventilated and randomized to sham, mild (1.2 atm), moderate (2.0 atm) or severe (2.3 atm) TBI. Four or 24 h post-TBI, ten frozen sections (10 mu m thick, every 15th section) were collected from the hippocampus of each rat, stained with FJ and counterstained with cresyl violet. Fluoro-Jade-positive neurons were counted in hippocampal subfields CA1, CA3 and the dentate gyrus/ dentate hilus. At both 4 and 24 h post-TBI, numbers of FJ-positive neurons in all hippocampal regions increased dose-dependently in mildly and moderately injured rats but were not significantly more numerous after severe injury. Although analysis of variance demonstrated no overall difference in expression of mRNA levels for heat shock protein 70, bcl-2, caspase 3, caspase 9 and interleukin-1 beta in uninjured CA3 neurons at all injury levels, post hoc analysis suggested that TBI induces increases in neuroprotective gene expression that offset concomitant increases in deleterious gene expression. (c) 2005 Elsevier B.V. All rights reserved.	Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Hellmich, HL (corresponding author), Univ Texas, Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	hhellmic@utmb.edu; bacapra@utmb.edu; caeidson@utmb.edu; jmgarcia@utmb.edu; drkenned@utmb.edu; tuchida@utmb.edu; maparsle@utmb.edu; jccowart@utmb.edu; ddewitt@utmb.edu; dsprough@utmb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS042849-01A1] Funding Source: Medline		Amano T, 2002, NEUROL RES, V24, P809, DOI 10.1179/016164102101200771; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bota M, 2003, NAT NEUROSCI, V6, P795, DOI 10.1038/nn1096; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Butler TL, 2003, BRAIN RES BULL, V59, P339, DOI 10.1016/S0361-9230(02)00926-7; Carlson NG, 1999, J IMMUNOL, V163, P3963; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.3.CO;2-H; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hagan M, 2003, NEUROSCI LETT, V351, P149, DOI 10.1016/j.neulet.2003.07.021; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HEILMICH HL, 2005, IN PRESS ANESTHESIOL; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Lee JS, 2004, J NEUROTRAUM, V21, P549, DOI 10.1089/089771504774129883; Leung CHW, 2003, BRAIN RES, V984, P182, DOI 10.1016/S0006-8993(03)03129-9; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McLaughlin B, 2003, P NATL ACAD SCI USA, V100, P715, DOI 10.1073/pnas.0232966100; Myhrer T, 2003, BRAIN RES, V967, P293, DOI 10.1016/S0006-8993(03)02232-7; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; SAS Institute Inc, 1999, SAS STAT US GUID VER; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Shimamura M, 2004, MOL BRAIN RES, V122, P47, DOI 10.1016/j.molbrainres.2003.11.015; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; Ye XM, 2001, BRAIN RES PROTOC, V8, P104, DOI 10.1016/S1385-299X(01)00086-1; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496; ZENG YC, 1995, MECH AGEING DEV, V79, P169, DOI 10.1016/0047-6374(94)01559-5	50	34	34	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 24	2005	1044	2					144	154		10.1016/j.brainres.2005.02.054			11	Neurosciences	Neurosciences & Neurology	931CH	WOS:000229462900002	15885213				2021-06-18	
J	Besson, VC; Zsengeller, Z; Plotkine, M; Szabo, C; Marchand-Verrecchia, C				Besson, VC; Zsengeller, Z; Plotkine, M; Szabo, C; Marchand-Verrecchia, C			Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat	BRAIN RESEARCH			English	Article						inhibitors; neurological deficit; neuroprotection; poly(ADP-ribose) polymerase; rat; traumatic brain injury	ADP-RIBOSE POLYMERASE; DNA STRAND BREAKS; POTENT INHIBITOR; CEREBRAL-ISCHEMIA; NITRIC-OXIDE; CELL-DEATH; SYNTHETASE; ACTIVATION; IMPROVES; PARP	Traumatic brain injury produces peroxynitrite, a powerful oxidant which triggers DNA strand breaks, leading to the activation of poly(ADP-ribose)polymerase-1 (PARP-1). We previously demonstrated that 3-aminobenzamide, a PARP inhibitor, is neuroprotective in a model of traumatic brain injury induced by fluid percussion in rat, suggesting that PARP-1 could be a therapeutic target. In order to confirm this hypothesis, we investigated the effects of PJ34 and INO-1001, two PARP inhibitors from structural classes other than benzamide, on the post-traumatic consequences. Pre- and post-treatments with PJ34 (30 mg/kg/day) and INO-1001 (10 mg/kg/day) decrease the neurological deficit at 3 days post-injury and this deficit is still reduced at 7 days. These neurological recovery-promoting effects are associated with the inhibition of PARP-1 activation caused by trauma, as demonstrated by abolishment of immunostaining of poly(ADP-ribose). Thus, the present work strengthens strongly the concept that PARP-1 inhibition may be a suitable approach for the treatment of brain trauma. (c) 2005 Elsevier B.V. All rights reserved.	Univ Paris 05, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, F-75006 Paris, France; Inotek Pharmaceut Corp, Beverly, MA 01915 USA	Marchand-Verrecchia, C (corresponding author), Univ Paris 05, Lab Pharmacol Circulat Cerebrale, UPRES EA 2510, 4 Ave Observ, F-75006 Paris, France.	catherine.marchand@univ-paris5.fr	MARCHAND-LEROUX, Catherine/L-7453-2017; Szabo, Csaba/D-1882-2013; BESSON, VALERIE/AAZ-9989-2020; besson, valerie C/L-7388-2017	MARCHAND-LEROUX, Catherine/0000-0003-0113-5348; BESSON, VALERIE/0000-0002-1491-2380; besson, valerie C/0000-0002-1491-2380; Zsengeller, Zsuzsanna/0000-0002-4540-5728	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS037985] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R44NS037985] Funding Source: Medline		Abdelkarim GE, 2001, INT J MOL MED, V7, P255; ARNE JC, 1999, J BIOL CHEM, V274, P17860; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Besson VC, 2003, FREE RADICAL RES, V37, P1201, DOI 10.1080/10715760310001612568; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Faro R, 2002, ANN THORAC SURG, V73, P575, DOI 10.1016/S0003-4975(01)03329-X; GOLANOV EV, 1995, J CEREBR BLOOD F MET, V15, P172, DOI 10.1038/jcbfm.1995.19; Goldfarb RD, 2002, CRIT CARE MED, V30, P974, DOI 10.1097/00003246-200205000-00004; Ha HC, 2000, NEUROBIOL DIS, V7, P225, DOI 10.1006/nbdi.2000.0324; Ivanyi Z, 2003, SHOCK, V19, P415, DOI 10.1097/01.shk.0000048904.46342.22; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; Kaminker PG, 2001, J BIOL CHEM, V276, P35891, DOI 10.1074/jbc.M105968200; Khan TA, 2003, J AM COLL SURGEONS, V197, P270, DOI 10.1016/S1072-7515(03)00538-6; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Komjati K, 2004, INT J MOL MED, V13, P373; Lacza Z, 2003, INT J MOL MED, V12, P153; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Mabley JG, 2001, INFLAMM RES, V50, P561, DOI 10.1007/PL00000234; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mesenge C, 1999, J CEREB BLOOD FLOW M, V19, pS390; Pacher P, 2002, BIOCHEM PHARMACOL, V64, P1785, DOI 10.1016/S0006-2952(02)01421-1; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pieper AA, 2000, P NATL ACAD SCI USA, V97, P1845, DOI 10.1073/pnas.97.4.1845; Sallmann FR, 2000, J BIOL CHEM, V275, P15504, DOI 10.1074/jbc.275.20.15504; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Scott GS, 2001, J NEUROIMMUNOL, V117, P78, DOI 10.1016/S0165-5728(01)00329-0; Shimoda K, 2003, AM J PHYSIOL-LUNG C, V285, pL240, DOI 10.1152/ajplung.00319.2002; Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484; Soriano FG, 2001, NAT MED, V7, P108; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Szabo C, 1997, J EXP MED, V186, P1041, DOI 10.1084/jem.186.7.1041; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002	43	34	36	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 18	2005	1041	2					149	156		10.1016/j.brainres.2005.01.096			8	Neurosciences	Neurosciences & Neurology	921UM	WOS:000228790800005	15829224				2021-06-18	
J	Lozada, A; Maegele, M; Stark, H; Neugebauer, EMA; Panula, P				Lozada, A; Maegele, M; Stark, H; Neugebauer, EMA; Panula, P			Traumatic brain injury results in mast cell increase and changes in regulation of central histamine receptors	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article; Proceedings Paper	32nd Meeting of the European-Histamine-Research-Society	MAY 07-11, 2003	Univ Amsterdam, Amsterdam, NETHERLANDS	European Histamine Res Soc	Univ Amsterdam	binding densities; degranulation; gene expression; mast cell tryptase; neuronal cell death; oxidative stress	MANGANESE-SUPEROXIDE-DISMUTASE; RAT-BRAIN; MESSENGER-RNA; HISTIDINE-DECARBOXYLASE; NEURON SYSTEM; TUBEROMAMMILLARY NUCLEUS; INFERIOR COLLICULUS; DOWN-REGULATION; NERVOUS-SYSTEM; H-3 RECEPTORS	Experimental fluid-percussion models produce brain injury by rapidly injecting saline into the closed cranium of rats. In this study our purpose was to determine how the central histaminergic system, which controls excitability and neurotransmitter release through G-protein coupled receptors, is affected by the pathophysiology of traumatic brain injury. We found that mast cell infiltration, as a result of the trauma, occurred primarily in the injured cortex and did not proceed beyond the fimbria of the hippocampus. In comparing injured animals with controls we found that H-3 receptor binding densities are significantly decreased bilaterally in the cortex but are significantly increased bilaterally in the thalamus. H-3 receptor binding densities may well be affected by mast cell secretion of mediators (i.e. histamine, heparin, leukotrienes), evidenced by detection of a cosecreted enzyme (mast cell tryptase) in the extracellular region. Moreover, we detected significant decreases in H-1 and H-3 receptor mRNA as well as Cu/Zn-dependent superoxide dismutase (SOD) mRNA in the thalamic region closest to the trauma. These significant decreases delineate the extent of cellular damage because of trauma and may underlie sustained cognitive and motor deficits displayed by these animals.	Abo Akad Univ, Dept Biol, FIN-20520 Turku, Finland; Univ Cologne, Biochem & Expt Div, Cologne, Germany; Univ Cologne, Surg Clin, Dept Surg 2, Cologne, Germany; Goethe Univ Frankfurt, Inst Pharmazeut Chem, Biozentrum, D-6000 Frankfurt, Germany; Univ Helsinki, Ctr Neurosci, Helsinki, Finland; Univ Helsinki, Inst Biomed Anat, Helsinki, Finland	Panula, P (corresponding author), Abo Akad Univ, Dept Biol, Biocity 2nd Floor,Artillerigatan 6A, FIN-20520 Turku, Finland.	pertti.panula@abo.fi	Stark, Holger/A-4235-2009	Stark, Holger/0000-0003-3336-1710; Panula, Pertti/0000-0002-1189-5132			Abraham WM, 2002, AM J PHYSIOL-LUNG C, V282, pL193, DOI 10.1152/ajplung.00429.2001; ARRANG JM, 1983, NATURE, V302, P832, DOI 10.1038/302832a0; BARRETT KE, 1991, HDB EXP PHARM, V97, P93; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beil WJ, 2002, PATHOBIOLOGY, V70, P303, DOI 10.1159/000071270; Brown RE, 2001, PROG NEUROBIOL, V63, P637, DOI 10.1016/S0301-0082(00)00039-3; Brown RE, 1999, J PHYSIOL-LONDON, V515, P777, DOI 10.1111/j.1469-7793.1999.777ab.x; CALINGASAN NY, 1995, EXP NEUROL, V134, P64, DOI 10.1006/exnr.1995.1037; CASTREN E, 1990, NEUROSCI LETT, V120, P113, DOI 10.1016/0304-3940(90)90181-8; CHEN Z, 1993, J HISTOCHEM CYTOCHEM, V41, P961, DOI 10.1177/41.7.7685789; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Drutel G, 2001, MOL PHARMACOL, V59, P1; DUX E, 1982, EXP BRAIN RES, V47, P252; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; GALLI SJ, 1993, MAST CELL HLTH DIS, P109; Ghadge GD, 1997, J NEUROSCI, V17, P8756; GOLDSCHMIDT RC, 1984, BRAIN RES, V323, P209, DOI 10.1016/0006-8993(84)90291-9; Gonzalez-Zulueta M, 1998, J NEUROSCI, V18, P2040; Haas H, 2003, NAT REV NEUROSCI, V4, P121, DOI 10.1038/nrn1034; Hill SJ, 1997, PHARMACOL REV, V49, P253; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Igaz P, 2001, INFLAMM RES, V50, P123, DOI 10.1007/s000110050735; INAGAKI N, 1990, EXP BRAIN RES, V80, P374; INAGAKI N, 1988, J COMP NEUROL, V273, P283, DOI 10.1002/cne.902730302; Karlstedt K, 1999, J CEREBR BLOOD F MET, V19, P321, DOI 10.1097/00004647-199903000-00010; KITAMURA Y, 1993, AM J MED SCI, V306, P185, DOI 10.1097/00000441-199309000-00011; Kunikowska G, 2001, BRAIN RES, V922, P51, DOI 10.1016/S0006-8993(01)03149-3; LAGUNOFF D, 1991, ARCH BIOCHEM BIOPHYS, V291, P52, DOI 10.1016/0003-9861(91)90104-Q; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; LIGNEAU X, 1994, J PHARMACOL EXP THER, V271, P452; Lintunen M, 1998, EUR J NEUROSCI, V10, P2287, DOI 10.1046/j.1460-9568.1998.00240.x; Liu CL, 2001, MOL PHARMACOL, V59, P420; MACKAY GA, 1982, AGENTS ACTIONS, V24, pC315; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCCORD JM, 1993, CLIN BIOCHEM, V26, P351, DOI 10.1016/0009-9120(93)90111-I; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McRee RC, 2000, BRAIN RES, V858, P227, DOI 10.1016/S0006-8993(99)02309-4; Meng JS, 2003, NEUROPATHOLOGY, V23, P25, DOI 10.1046/j.1440-1789.2003.00481.x; Michaloudi H, 2003, DEV BRAIN RES, V140, P269, DOI 10.1016/S0165-3806(02)00613-2; MOHANTY S, 1989, J NEUROL SCI, V90, P87, DOI 10.1016/0022-510X(89)90048-8; ONODERA K, 1994, PROG NEUROBIOL, V42, P685, DOI 10.1016/0301-0082(94)90017-5; PALACIOS JM, 1981, NEUROSCIENCE, V6, P15, DOI 10.1016/0306-4522(81)90240-2; PANULA P, 1984, P NATL ACAD SCI-BIOL, V81, P2572, DOI 10.1073/pnas.81.8.2572; PANULA P, 1989, NEUROSCIENCE, V28, P585, DOI 10.1016/0306-4522(89)90007-9; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pillot C, 2002, NEUROSCIENCE, V114, P173, DOI 10.1016/S0306-4522(02)00135-5; POLLARD H, 1993, NEUROSCIENCE, V52, P169, DOI 10.1016/0306-4522(93)90191-H; RUAT M, 1990, P NATL ACAD SCI USA, V87, P1658, DOI 10.1073/pnas.87.5.1658; SCHLICKER E, 1994, FUND CLIN PHARMACOL, V8, P128, DOI 10.1111/j.1472-8206.1994.tb00789.x; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwartz J-C, 2002, NEUROPSYCHOPHARMACOL, P179, DOI Lippincott Williams & Wilkins; Shelton MK, 2000, J NEUROCHEM, V74, P555, DOI 10.1046/j.1471-4159.2000.740555.x; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; Takeshita Y, 1998, NEUROSCIENCE, V87, P797, DOI 10.1016/S0306-4522(98)00152-3; Takeuchi A, 2000, J NEUROBIOL, V45, P39, DOI 10.1002/1097-4695(200010)45:1<39::AID-NEU4>3.0.CO;2-A; Tashiro M, 2002, LIFE SCI, V72, P409, DOI 10.1016/S0024-3205(02)02276-2; Toyota H, 2002, MOL PHARMACOL, V62, P389, DOI 10.1124/mol.62.2.389; Troy CM, 1996, J NEUROSCI, V16, P253; Trudgett A, 2003, INT IMMUNOPHARMACOL, V3, P775, DOI 10.1016/S1567-5769(03)00079-1; Van der Werf YD, 2002, BRAIN RES REV, V39, P107, DOI 10.1016/S0165-0173(02)00181-9; WADA H, 1991, TRENDS NEUROSCI, V14, P415, DOI 10.1016/0166-2236(91)90034-R; WATANABE T, 1984, BRAIN RES, V295, P13, DOI 10.1016/0006-8993(84)90811-4	63	34	34	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	APR	2005	31	2					150	162		10.1111/j.1365-2990.2004.00622.x			13	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	905VA	WOS:000227597500005	15771708				2021-06-18	
J	Ozsuer, H; Gorgulu, A; Kiris, T; Cobanoglu, S				Ozsuer, H; Gorgulu, A; Kiris, T; Cobanoglu, S			The effects of memantine on lipid peroxidation following closed-head trauma in rats	NEUROSURGICAL REVIEW			English	Article						closed head trauma; excitatory aminoacid; lipid peroxidation; memantine	RECEPTOR-MEDIATED NEUROTOXICITY; CONCUSSIVE BRAIN-INJURY; AMINO-ACID RELEASE; NMDA RECEPTOR; NONCOMPETITIVE ANTAGONIST; NERVOUS-SYSTEM; FREE-RADICALS; GLUTAMATE; DAMAGE; EDEMA	Memantine is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. Unlike other NMDA antagonists, it has been used clinically for years for the treatment of Parkinson's disease, spasticity, and dementia without serious side effects. We aimed to investigate the therapeutic efficacy of memantine on a closed head trauma model. A total of 132 adult male Sprague-Dawley rats were randomly divided into four groups: sham-operated, control (closed head trauma), sham-vehicle (closed head trauma + saline), treatment (closed head trauma + memantine, 10 mg/kg, i.p.). A cranial impact was delivered to the skull, just in front of the coronal suture, over the left hemisphere, from the height of 7 cm. Saline or memantine were applied 15 min after trauma. Rats were euthanased 0.5, 1, 2, 6, 24, 48 h after trauma. Brain tissue samples were taken 5 mm away from the left frontal pole and also from the corresponding point of the contralateral hemispheres. Malondialdehyde activity (MDA) was considered to reflect the degree of lipid peroxidation. The MDA levels continued to increase for the first 2 h after the injury, then started to decrease gradually. Memantine treatment significantly reduced lipid peroxidation levels in the treatment group compared with other groups (P < 0.01). The findings of the present study indicate that memantine provides beneficial effects after closed head trauma in rats.	Ataturk State Hosp, Dept Neurosurg, TR-35360 Izmir, Turkey; Univ Suleyman Demirel, Sch Med, Dept Neurosurg, TR-32260 Isparta, Turkey; Istanbul Univ, Sch Med, Dept Neurosurg, TR-34390 Istanbul, Turkey; Trakya Univ, Sch Med, Dept Neurosurg, TR-22030 Edirne, Turkey	Gorgulu, A (corresponding author), Suleyman Demirel Bulvari 101 Cadde 73,Sener Apt A, TR-32100 Isparta, Turkey.	askingorgulu@hotmail.com	Kiris, Talat/AAP-4665-2020	Kiris, Talat/0000-0002-2985-3758			BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BLANDPIED TA, 1992, J NEUROPHYSIOL, V77, P309; Block F, 1996, NEUROSCI LETT, V208, P41, DOI 10.1016/0304-3940(96)12545-3; BORMANN J, 1989, EUR J PHARMACOL, V166, P591, DOI 10.1016/0014-2999(89)90385-3; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gorgulu A, 1999, ACTA NEUROCHIR, V141, P93, DOI 10.1007/s007010050271; Gorgulu A, 2000, ACTA NEUROCHIR, V142, P1287, DOI 10.1007/s007010070027; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; IKEDA Y, 1990, NEUROSURGERY, V27, P1; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; Kaplanski J, 2003, RESUSCITATION, V56, P207, DOI 10.1016/S0300-9572(02)00371-4; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KOEK W, 1988, J PHARMACOL EXP THER, V245, P969; Koura SS, 1998, ACT NEUR S, V71, P244; KUCHIWAKI H, 1994, ACTA NEUROCHIR, P62; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; NASR MS, 1990, EUR J PHARMACOL, V185, P19; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Orgogozo JM, 2002, STROKE, V33, P1834, DOI 10.1161/01.STR.0000020094.08790.49; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; PELLEGRINI JW, 1993, ANN NEUROL, V33, P403, DOI 10.1002/ana.410330414; Rao VLR, 2001, BRAIN RES, V911, P96; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Sang CN, 2002, ANESTHESIOLOGY, V96, P1053, DOI 10.1097/00000542-200205000-00005; SCATTON B, 1991, CEREBROVASC DIS, V1, P121, DOI 10.1159/000108829; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SOFFEL M, 1997, ACTA NEUROCHIR WIEN, V70, P91; TANAKA H, 1994, ACTA NEUROCHIR, P524; Uchida K, 2001, EUR J ANAESTH, V18, P295, DOI 10.1046/j.0265-0215.2000.00825.x; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; WELLER M, 1993, BRAIN RES, V613, P143, DOI 10.1016/0006-8993(93)90464-X	45	34	36	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5607	1437-2320		NEUROSURG REV	Neurosurg. Rev.	APR	2005	28	2					143	147		10.1007/s10143-004-0374-1			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	910NZ	WOS:000227939900012	15789251				2021-06-18	
J	Sinnakaruppan, I; Downey, B; Morrison, S				Sinnakaruppan, I; Downey, B; Morrison, S			Head injury and family carers: A pilot study to investigate an innovative community-based educational programme for family carers and patients	BRAIN INJURY			English	Article						head-injury; needs; carers; community; family	TRAUMATIC BRAIN-INJURY; BEHAVIOR MANAGEMENT; CAREGIVER BURDEN; DISTRESS; INDIVIDUALS; RELATIVES; SURVIVORS	Primary objective: The incidence of head injury is increasing among younger people with more family members undertaking their life-long care. Many research studies have highlighted the emotional well-being of such family carers and their unmet needs, however only a few consider the formal help provided for carers. Using a longitudinal, mixed variable, within and between-subject design, this pilot study evaluated the impact of an educational programme for family carers and their head-injured relatives in reducing carer and patient psychological distress and improving their coping ability. Main outcomes and results: The study comprised experimental and control samples each with carer and patient groups. The experimental sample had eight sessions of educational input. All groups were assessed pre- and post-intervention and at 3 months follow-up. The patient sample was further assessed using cognitive measures. There was evidence of reduction in psychological distress in the experimental carer group following the educational input, but these results were not statistically significant. However, the experimental patient population at follow-up assessment showed statistically significant improvements. Conclusions: A larger scale multi-centre study with a longer follow-up period of assessment is required for the generalization of findings. The pilot study identifies points for consideration in a potential main study.	Ayrshire Cent Hosp, Douglas Grant Rehabil Ctr, Dept Psychol, Irvine KA12 8SS, Ayr, Scotland	Sinnakaruppan, I (corresponding author), Ayrshire Cent Hosp, Douglas Grant Rehabil Ctr, Dept Psychol, Irvine KA12 8SS, Ayr, Scotland.	lesley.mcdermott@aaaht.scot.nhs.uk					ACORN S, 1993, J ADV NURS, V18, P39, DOI 10.1046/j.1365-2648.1993.18010039.x; ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; Bowen A, 2001, BRAIN INJURY, V15, P29, DOI 10.1080/02699050150209101; BROOKS WP, 1986, LETT APPL MICROBIOL, V2, P1, DOI 10.1111/j.1472-765X.1986.tb01502.x; Campbell C H, 1988, Rehabil Nurs, V13, P320; Carnevale GJ, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199602000-00005; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; DeJong G., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Flanagan DAJ, 1998, BRIT J CLIN PSYCHOL, V37, P431, DOI 10.1111/j.2044-8260.1998.tb01400.x; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Goldberg D., 1978, MANUAL GEN HLTH QUES; Granger C. V., 1984, FUNCTIONAL ASSESSMEN; HICKEY AM, 1992, IRISH MED J, V4, P109; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; KREUTZER JS, 1994, BRAIN INJURY, V8, P222; Kubler-Ross E., 1969, DEATH DYING; Liamaki G, 2003, CLIN PSYCHOL, V26, P28; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Pace GM, 1999, BRAIN INJURY, V13, P535; ROSE FD, 1996, BRAIN INJURY IMPROVE; Rosenberg M., 1989, SOC ADOLESCENT SELF; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; WECSHLER D, 1997, ADULT INTELLIGENCE S; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; Wilson B. A., 1991, RIVERMEAD BEHAV MEMO; Wilson BA, 1996, BEHAV ASSESSMENT DYS; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	34	34	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					283	308		10.1080/02699050400003924			26	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400006	15832874				2021-06-18	
J	David, AS; Prince, M				David, AS; Prince, M			Psychosis following head injury: A critical review	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; RISK-FACTORS; SCHIZOPHRENIA; BIRTH	Schizophrenia is the most common form of psychotic mental disorder, with a point prevalence generally estimated to lie between 0.6-1.0%. Genetically informative studies have indicated a multifactorial aetiology, with an important heritable (genetic) component, but with environmental exposures also undoubtedly relevant. The "neurodevelopmental hypothesis" has informed a body of research that fairly consistently identifies birth complications as a risk factor for the later onset of schizophrenia.(1 2) Injury to the head or brain after birth and beyond has been posited as a risk factor for psychosis for many decades but has enjoyed little systematic research (see Lishman,(3) van Reckurn et al,(4) and Fujii and Ahmed(5) for reviews). The purpose of this article is to review this information systematically. Computerised databases including Medline and Psychinfo were searched using head/brain injury and psychosis or schizophrenia as search terms, covering the period from 1966 to end 2003. Citations from published reviews were also retrieved and yielded important articles and monographs, sonic published more than two decades ago, not included in these databases. Four types of study design have been used to assess the relation between head injury and schizophrenia: the case report; the long term follow up of series of head injured persons; the cross sectional survey; and the case-control study.	Inst Psychiat, Sect Cognit Neuropsychiat, London SE5 8AF, England; Inst Psychiat, Epidemiol Sect, London, England	David, AS (corresponding author), Inst Psychiat, Sect Cognit Neuropsychiat, POB 68,De Crespigny Pk, London SE5 8AF, England.	a.david@iop.kcl.ac.uk	David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011; Prince, Martin J/A-9170-2010	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Prince, Martin J/0000-0003-1379-7146			AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; ANTHONY JC, 1985, ARCH GEN PSYCHIAT, V42, P667; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; Corcoran C, 2001, INT J MENT HLTH, V30, P17; Dalman C, 2001, BRIT J PSYCHIAT, V179, P403, DOI 10.1192/bjp.179.5.403; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; De Mol J, 1987, J ARCH PSYCHOL NEURO, V48, P336; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii Daryl, 2002, Cogn Neuropsychiatry, V7, P41, DOI 10.1080/135468000143000131; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; LIBERMAN JJ, 1964, ZH NEVROPATOL PSIKH, V64, P1369; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; OCALLAGHAN E, 1988, BRIT J PSYCHIAT, V153, P394, DOI 10.1192/bjp.153.3.394; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	24	34	35	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2005	76			1			I53	I60		10.1136/jnnp.2004.060475			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	902CV	WOS:000227329900009	15718223	Green Published, Bronze			2021-06-18	
J	Hang, CH; Shi, JX; Li, JS; Li, WQ; Yin, HX				Hang, Chun-Hua; Shi, Ji-Xin; Li, Jie-Shou; Li, Wei-Qin; Yin, Hong-Xia			Up-regulation of intestinal nuclear factor kappa B and intercellular adhesion molecule-1 following traumatic brain injury in rats	WORLD JOURNAL OF GASTROENTEROLOGY			English	Article						Traumatic brain injury; Intestine; Nuclear factor kappa B; Intercellular adhesion molecule-1; Inflammatory response	PLATELET-ACTIVATING-FACTOR; IN-VIVO; TRANSCRIPTIONAL REGULATION; HEMORRHAGIC-SHOCK; LUNG INJURY; TNF-ALPHA; PERMEABILITY; EXPRESSION; GUT; CELLS	AIM: Nuclear factor kappa B (NF-kappa B) regulates a large number of genes involved in the inflammatory response to critical illnesses, but it is not known if and how NF-kappa B is activated and intercellular adhesion molecule-1 (ICAM-1) expressed in the gut following traumatic brain injury (TBI). The aim of current study was to investigate the temporal pattern of intestinal NF-kappa B activation and ICAM-1 expression following TBI. METHODS: Male Wistar rats were randomly divided into six groups (6 rats in each group) including controls with sham operation and TBI groups at hours 3, 12, 24, and 72, and on d 7. Parietal brain contusion was adopted using weight-dropping method. All rats were decapitated at corresponding time point and mid-jejunum samples were taken. NF-kappa B binding activity in jejunal tissue was measured using EMSA. Immunohistochemistry was used for detection of ICAM-1 expression in jejunal samples. RESULTS: There was a very low NF-kappa B binding activity and little ICAM-1 expression in the gut of control rats after sham surgery. NF-kappa B binding activity in jejunum significantly increased by 160% at 3 h following TBI (P<0.05 vs control), peaked at 72 h (500% increase) and remained elevated on d 7 post-injury by 390% increase. Compared to controls, ICAM-1 was significantly up-regulated on the endothelia of microvessels in villous interstitium and lamina propria by 24 h following TBI and maximally expressed at 72 h post-injury (P<0.001). The endothelial ICAM-1 immunoreactivity in jejunal mucosa still remained strong on d 7 post-injury. The peak of NF-kappa B activation and endothelial ICAM-1 expression coincided in time with the period during which secondary mucosal injury of the gut was also at their culmination following TBI. CONCLUSION: TBI could induce an immediate and persistent up-regulation of NF-kappa B activity and subsequent up-regulation of ICAM-1 expression in the intestine. Inflammatory response mediated by increased NF-kappa B activation and ICAM-1 expression may play an important role in the pathogenesis of acute gut mucosal injury following TBI. (C) 2005 The WJG Press and Elsevier Inc. All rights reserved.	[Hang, Chun-Hua; Shi, Ji-Xin; Yin, Hong-Xia] Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Clin Med, Nanjing 210002, Jiangsu Provinc, Peoples R China; [Li, Jie-Shou; Li, Wei-Qin] Nanjing Univ, Res Inst Gen Surg, Jinling Hosp, Sch Clin Med, Nanjing 210002, Jiangsu Provinc, Peoples R China	Hang, CH (corresponding author), Nanjing Univ, Dept Neurosurg, Jinling Hosp, Sch Clin Med, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Provinc, Peoples R China.	hang1965@public1.ptt.js.cn	Yin, Hong/AAC-5784-2020		Scientific Research Foundation of the Chinese PLA [01Z011]	Supported by Scientific Research Foundation of the Chinese PLA Key Medical Programs During the 10th Five-Year Plan Period, No. 01Z011	Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BLACKWELL TS, 1994, AM J RESP CELL MOL, V11, P464, DOI 10.1165/ajrcmb.11.4.7917314; CHEN CC, 1995, AGENT ACTION SUPPL, V47, P135; De Plaen IG, 1998, BBA-LIPID LIPID MET, V1392, P185, DOI 10.1016/S0005-2760(98)00024-1; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; Essani NA, 1997, SHOCK, V7, P90, DOI 10.1097/00024382-199702000-00003; Faries PL, 1998, J TRAUMA, V44, P1031, DOI 10.1097/00005373-199806000-00016; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fiocchi C, 1997, AM J PHYSIOL-GASTR L, V273, pG769; Frossard JL, 1999, GASTROENTEROLOGY, V116, P694, DOI 10.1016/S0016-5085(99)70192-7; Grotz MRW, 1999, ANN SURG, V229, P478, DOI 10.1097/00000658-199904000-00005; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; HOU JZ, 1994, P NATL ACAD SCI USA, V91, P11641, DOI 10.1073/pnas.91.24.11641; HUANG L, 1994, IMMUNOLOGY, V83, P65; LANGKAMPHENKEN B, 1995, CRIT CARE MED, V23, P660, DOI 10.1097/00003246-199504000-00013; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Liu SF, 1997, J IMMUNOL, V159, P3976; Lush CW, 2003, GASTROENTEROLOGY, V124, P118, DOI 10.1053/gast.2003.50001; Magnotti LJ, 1998, ANN SURG, V228, P518, DOI 10.1097/00000658-199810000-00008; MEYER TA, 1995, SURGERY, V118, P336, DOI 10.1016/S0039-6060(05)80342-3; Molla M, 2003, INT J RADIAT ONCOL, V57, P264, DOI 10.1016/S0360-3016(03)00523-6; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Neurath MF, 1997, IMMUNOBIOLOGY, V198, P91, DOI 10.1016/S0171-2985(97)80030-7; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Partrick DA, 1997, J TRAUMA, V43, P297, DOI 10.1097/00005373-199708000-00015; Pritts TA, 2000, ARCH SURG-CHICAGO, V135, P860, DOI 10.1001/archsurg.135.7.860; Schottelius AJG, 1999, INT J COLORECTAL DIS, V14, P18, DOI 10.1007/s003840050178; Shenkar R, 1996, AM J PHYSIOL-LUNG C, V270, pL729; Shimada T, 1999, J PHARMACOL EXP THER, V291, P345; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Spies M, 2002, AM J PHYSIOL-GASTR L, V283, pG703, DOI 10.1152/ajpgi.00149.2001; Swank GM, 1996, WORLD J SURG, V20, P411, DOI 10.1007/s002689900065; Wang P, 1998, J SURG RES, V74, P141, DOI 10.1006/jsre.1997.5246; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yin MJ, 1998, NATURE, V396, P77	36	34	38	0	1	BAISHIDENG PUBL GRP CO LTD	BEIJING	RM 903, BLDG D, OCEAN INTERNATIONAL CTR, NO 62 DONGSIHUAN ZHONGLU, BEIJING, CHAOYANG DISTRICT 100025, PEOPLES R CHINA	1007-9327			WORLD J GASTROENTERO	World J. Gastroenterol.	FEB 28	2005	11	8					1149	1154		10.3748/wjg.v11.i8.1149			6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	V19VX	WOS:000208101000009	15754395	Green Published, Other Gold			2021-06-18	
J	Thompson, HJ; Hoover, RC; Tkacs, NC; Saatman, KE; McIntosh, TK				Thompson, HJ; Hoover, RC; Tkacs, NC; Saatman, KE; McIntosh, TK			Development of posttraumatic hyperthermia after traumatic brain injury in rats is associated with increased periventricular inflammation	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						circadian rhythm; head injury; inflammatory response; model development; thermoregulation	CLOSED-HEAD INJURY; FLUID-PERCUSSION INJURY; NEURONAL CELL-DEATH; ADULT-RAT; MODERATE HYPOTHERMIA; MESSENGER-RNA; FEVER; TEMPERATURE; PROTEIN; EXPRESSION	Posttraumatic hyperthermia (PTH) is a noninfectious elevation in body temperature that negatively influences outcome after traumatic brain injury (TBI). We sought to (1) characterize a clinically relevant model and (2) investigate potential cellular mechanisms of PTH. In study 1, body temperature patterns were analyzed for 1 week in male rats after severe lateral fluid percussion (FP) brain injury (n = 75) or sham injury (n = 17). After injury, 27% of surviving animals experienced PTH, while 69% experienced acute hypothermia with a slow return to baseline. A profound blunting or loss of circadian rhythmicity (CR) that persisted up to 5 days after injury was experienced by 75% of brain-injured animals. At 2 and 7 days after injury, patterns of cell loss and inflammation were assessed in selected brain thermoregulatory and circadian centers. Significant cell loss was not observed, but PTH was associated with inflammatory changes in the hypothalamic paraventricular nucleus (PVN) by one week after injury. In brain-injured animals with altered CR, reactive astrocytes were bilaterally localized in the suprachiasmatic nucleus (SCN) and the PVN. Occasional IL-1beta+/ED-1 + macrophages/microglia were observed in the PVN and SCN exclusively in brain-injured animals developing PTH. In animals with PTH there was a significant positive correlation (r = 0.788, P < 0.01) between the degree of postinjury hyperthermia and the total number of cells positive for inflammatory markers within selected thermoregulatory and circadian nuclei. In study 11, a separate group of animals underwent the same injury and temperature monitoring paradigm as in study 1, but had additional physiologic data obtained, including vital signs, arterial blood gases, white blood cell counts, and C-reactive protein levels. All parameters remained within normal ranges after injury. These data suggest that PTH and the alteration in CR of temperature may be due, in part, to acute reactive astrocytosis and inflammation in hypothalamic centers responsible for both thermoregulation and CR.	Univ Penn, Traumat Brain Injury Lab, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; VA Med Ctr, Philadelphia, PA USA	McIntosh, TK (corresponding author), 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	tkm53@comcast.net			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS043126, P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [F31NR007694] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 043126, NS 08803] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [NR 07694, F31 NR007694] Funding Source: Medline		AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Armstrong William E., 1995, P377; Behr R, 1997, ANN NY ACAD SCI, V813, P722, DOI 10.1111/j.1749-6632.1997.tb51774.x; BENEDEK G, 1987, CAN J NEUROL SCI, V14, P145; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Cermakian N, 2003, BRAIN RES REV, V42, P204, DOI 10.1016/S0165-0173(03)00171-1; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHILDERS MK, 1994, BRAIN INJURY, V8, P335, DOI 10.3109/02699059409150984; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORBETT DR, 2002, 32 ANN M SOC NEUR; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CUNHA BA, 1988, HEART LUNG, V17, P608; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1992, J NEUROTRAUMA, V9, P475; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Elmquist JK, 1996, J COMP NEUROL, V371, P85, DOI 10.1002/(SICI)1096-9861(19960715)371:1<85::AID-CNE5>3.0.CO;2-H; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GUILIAN D, 1988, J NEUROSCI, V8, P2485; GUILIAN D, 1985, SCIENCE, V228, P497; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HORN LJ, 1988, J HEAD TRAUMA REHAB, V3, P87; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kinoshita K, 2002, J NEUROSURG, V97, P945, DOI 10.3171/jns.2002.97.4.0945; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kozak W, 1998, ANN NY ACAD SCI, V856, P33, DOI 10.1111/j.1749-6632.1998.tb08310.x; Lausberg G, 1971, Cah Anesthesiol, V19, P315; LITTLE RA, 1985, BRIT MED BULL, V41, P226, DOI 10.1093/oxfordjournals.bmb.a072055; LITTLE RA, 1981, BRIT J SURG, V68, P221, DOI 10.1002/bjs.1800680402; LOESCH A, 1983, AUST J EXP BIOL MED, V61, P545, DOI 10.1038/icb.1983.52; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; PAXINOS G, 1990, STEREOTACTIC ATLAS R; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Powers JH, 1996, INFECT DIS CLIN N AM, V10, P45, DOI 10.1016/S0891-5520(05)70285-3; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REFINETTI R, 1999, CIRCADIAN PHYSL; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; RUDY TA, 1977, J PHYSIOL-LONDON, V272, P721, DOI 10.1113/jphysiol.1977.sp012069; RUDY TA, 1980, THERMOREGULATORY MEC, P75; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; Saper CB, 1998, ANN NY ACAD SCI, V856, P90, DOI 10.1111/j.1749-6632.1998.tb08317.x; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; Segatore M, 1992, J Neurosci Nurs, V24, P104; Simerly Richard B., 1995, P353; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Thompson HJ, 2003, J NEUROL NEUROSUR PS, V74, P614, DOI 10.1136/jnnp.74.5.614; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; WHYTE J, 1993, AM J PHYS MED REHAB, V72, P281, DOI 10.1097/00002060-199310000-00006; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2	74	34	36	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2005	25	2					163	176		10.1038/sj.jcbfm.9600008			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	893SS	WOS:000226740100003	15647747	Bronze			2021-06-18	
J	Yi, JH; Hazell, AS				Yi, JH; Hazell, AS			N-acetylcysteine attenuates early induction of heme oxygenase-1 following traumatic brain injury	BRAIN RESEARCH			English	Article						heme oxygenase; traumatic brain injury; astrocyte; oxidative stress; fluid percussion; antioxidant	OXIDATIVE STRESS; RAT; EXPRESSION; HO-1; CYSTEINE; HYPOXIA; VOLUME; GENE; GLIA	Traumatic brain injury (TBI) results in a cascade of events that includes the production of reactive oxygen species. Heme oxygenase-1 (HO-1) is induced in glial cells following head trauma, suggestive of oxidative stress. We have studied the temporal and spatial effects of the antioxidant N-acetylcysteine (NAC) on HO-1 levels following lateral fluid-percussion injury by immunoblotting and immunohistochemistry. In the injured cerebral cortex, maximal HO-1 induction was seen 6 h post-TBI and was maintained for up to 24 h following the insult, while the ipsilateral hippocampus and thalamus showed marked induction at 24 h postinjury. In all three brain regions, little or no HO-1 immunoreactivity was observed on the contralateral side. Astrocytes exhibited positive immunoreactivity for HO-1 in the injured cerebral cortex, hippocampus, and thalamus, while some neurons and microglia were also immunoreactive in the injured cortex. The administration of NAC 5 min following TBI resulted in a marked reduction in this widespread induction of HO-1, concomitant with a decrease in the volume of injury in all three brain regions. Together, these findings indicate that HO-1 induction is related to both oxidative and injury characteristics of the affected tissue, suggesting that protein expression of this gene is a credible marker of oxidative damage in this model of TBI. (C) 2004 Elsevier B.V All rights reserved.	Univ Montreal, Dept Med, Hop St Luc, CHUM, Montreal, PQ H2X 3J4, Canada	Hazell, AS (corresponding author), Univ Montreal, Dept Med, Hop St Luc, CHUM, 1058 St Denis St, Montreal, PQ H2X 3J4, Canada.	alan.stewart.hazell@umontreal.ca					ABRAHAM NG, 1995, P NATL ACAD SCI USA, V92, P6798, DOI 10.1073/pnas.92.15.6798; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Bergeron M, 1997, J CEREBR BLOOD F MET, V17, P647; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Garnier P, 2001, BRAIN RES, V893, P301, DOI 10.1016/S0006-8993(01)02009-1; Hazell AS, 2001, J NEUROCHEM, V78, P560, DOI 10.1046/j.1471-4159.2001.00436.x; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kelly G S, 1998, Altern Med Rev, V3, P114; Kweon MH, 2004, FREE RADICAL BIO MED, V36, P40, DOI 10.1016/j.freeradbiomed.2003.09.023; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; RATAN RR, 1994, J NEUROSCI, V14, P4385; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Scapagnini G, 2002, BRAIN RES, V954, P51, DOI 10.1016/S0006-8993(02)03338-3; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; SHAN Y, 2004, IN PRESS J BIOL CHEM; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; VINCENT SR, 1994, NEUROSCIENCE, V63, P223, DOI 10.1016/0306-4522(94)90018-3; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067	28	34	35	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 1	2005	1033	1					13	19		10.1016/j.brainres.2004.10.055			7	Neurosciences	Neurosciences & Neurology	899GZ	WOS:000227134200002	15680334				2021-06-18	
J	Farkas, O; Tamas, A; Zsombok, A; Reglodi, D; Pal, J; Buki, A; Lengvari, I; Povlishock, JT; Doczi, T				Farkas, O; Tamas, A; Zsombok, A; Reglodi, D; Pal, J; Buki, A; Lengvari, I; Povlishock, JT; Doczi, T			Effects of pituitary adenylate cyclase activating polypeptide in a rat model of traumatic brain injury	REGULATORY PEPTIDES			English	Article; Proceedings Paper	6th International Symposium on VIP/PACAP	SEP 01-04, 2003	Hakone, JAPAN			neuroprotection; traumatic brain injury; beta-amyloid precursor protein; corticospinal tract; traumatic axonal injury	VASOACTIVE-INTESTINAL-PEPTIDE; CEREBELLAR GRANULE NEURONS; CEREBRAL-ARTERY OCCLUSION; AXONAL INJURY; NEUROTROPHIC FACTOR; INDUCED NEUROTOXICITY; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; NERVOUS-SYSTEM; CELL-DEATH	Pituitary adenylate cyclase activating polypeptide (PACAP) is a,widely distributed neuropeptide that has numerous different actions. Recent studies have shown that PACAP exerts neuroprotective effects not only in vitro but also in vivo, in animal models of global and focal cerebral ischemia, Parkinson's disease and axonal injuries. Traumatic brain injury has an increasing mortality and morbidity and it evokes diffuse axonal injury which further contributes to its damaging effects. The aim of the present study was to examine the possible neuroprotective effect of PACAP in a rat model of diffuse axonal injury induced by impact acceleration. Axonal damage was assessed by immunohistochemistry using an antiserum against beta-amyloid precursor protein, a marker of altered axoplasmic transport considered as key feature in axonal injury. In these experiments, we have established the dose response curves for PACAP administration in traumatic axonal injury, demonstrating that a single post-injury intracerebroventricular injection of 100 mug PACAP significantly reduced the density of damaged, beta-amyloid precursor protein-immunoreactive axons in the corticospinal tract. (C) 2004 Elsevier B.V All rights reserved.	Univ Pecs, Hungarian Acad Sci, Neurohumoral Regulat Res Grp, Dept Anat,Med Fac, H-7624 Pecs, Hungary; Univ Pecs, Fac Med, Dept Cent Lab Anim Res, H-7624 Pecs, Hungary; Univ Pecs, Fac Med, Dept Neurosurg, H-7624 Pecs, Hungary; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA	Tamas, A (corresponding author), Univ Pecs, Hungarian Acad Sci, Neurohumoral Regulat Res Grp, Dept Anat,Med Fac, Szigeti 12, H-7624 Pecs, Hungary.	andrea.tamas@aok.pte.hu	Doczi, Tamas/C-5750-2009; Pal, Jozsef/I-3416-2013; Pal, Jozsef/C-4073-2009; Buki, Andras/B-1960-2010	Pal, Jozsef/0000-0001-6468-6409			Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; ARIMURA A, 1994, ANN NY ACAD SCI, V739, P228, DOI 10.1111/j.1749-6632.1994.tb19825.x; Arimura Akira, 2003, Regulatory Peptides, V115, P40; BANKS WA, 1993, J PHARMACOL EXP THER, V267, P690; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; DEUTSCH PJ, 1992, J BIOL CHEM, V267, P5108; Dibbern DA, 1997, J CLIN INVEST, V99, P2837, DOI 10.1172/JCI119476; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frechilla D, 2001, NEUROREPORT, V12, P919, DOI 10.1097/00001756-200104170-00011; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gozes I, 1999, P NATL ACAD SCI USA, V96, P4143, DOI 10.1073/pnas.96.7.4143; Gozes I, 2003, J MOL NEUROSCI, V20, P315, DOI 10.1385/JMN:20:3:315; Gozes I, 2001, TRENDS NEUROSCI, V24, P700, DOI 10.1016/S0166-2236(00)01931-7; Katahira M., 2003, Regulatory Peptides, V115, P49; Kim WK, 2000, J NEUROSCI, V20, P3622; Kimura H, 2003, LARYNGOSCOPE, V113, P1000, DOI 10.1097/00005537-200306000-00016; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Nonaka N, 2002, PEPTIDES, V23, P2197, DOI 10.1016/S0196-9781(02)00248-6; Ohtaki H., 2003, Regulatory Peptides, V115, P53; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Onoue S, 2002, PEPTIDES, V23, P1471, DOI 10.1016/S0196-9781(02)00085-2; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; SEKI T, 2003, REGUL PEPTIDES, V115, P55; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2000, REGUL PEPTIDES, V91, P89, DOI 10.1016/S0167-0115(00)00123-3; Somogyvari-Vigh A, 1998, ANN NY ACAD SCI, V865, P595, DOI 10.1111/j.1749-6632.1998.tb11243.x; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505; Tams JW, 1999, BIOCHEM J, V341, P271, DOI 10.1042/0264-6021:3410271; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/S0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x; Vaudry D, 2002, P NATL ACAD SCI USA, V99, P6398, DOI 10.1073/pnas.082112699; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; ZAMBONI L, 1967, J CELL BIOL, V35, P148; Zhou CJ, 2002, CURR PROTEIN PEPT SC, V3, P423, DOI 10.2174/1389203023380576	51	34	37	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-0115	1873-1686		REGUL PEPTIDES	Regul. Pept.	DEC 15	2004	123	1-3					69	75		10.1016/j.regpep.2004.05.014			7	Endocrinology & Metabolism; Physiology	Endocrinology & Metabolism; Physiology	871ST	WOS:000225154400011	15518895				2021-06-18	
J	Moon, C; Ahn, M; Kim, S; Jin, JK; Sim, KB; Kim, HM; Lee, MY; Shin, T				Moon, C; Ahn, M; Kim, S; Jin, JK; Sim, KB; Kim, HM; Lee, MY; Shin, T			Temporal patterns of the embryonic intermediate filaments nestin and vimentin expression in the cerebral cortex of adult rats after cryoinjury	BRAIN RESEARCH			English	Article						brain injury; cryoinjury; nestin; vimentin; regeneration	TRAUMATIC BRAIN-INJURY; FIBRILLARY ACIDIC PROTEIN; SPINAL-CORD; ASTROCYTES; CELLS; ENCEPHALOMYELITIS; DIFFERENTIATION; MACROPHAGES	The expression of two embryonic intermediate filaments, nestin and vimentin, in the rat brain at days 0 (control), 1, 4, 7 and 14 post-cryoinjury was studied to elucidate their roles in brain injury. Western blot analysis showed that both nestin and vimentin expressions in the ipsilateral cerebral cortex were significantly increased at 4 and 7 days post-cryoinjury, and were decreased at day 14 after cryoinjury. Immumohistochemistry showed that there were few nestin- and vimentin-positive cells in the cerebral cortex in normal controls. On days 4 and 7 post-injury, abundant glial cells in the periphery of the lesion were immunostained for nestin and/or vimentin; only vimentin was detected in the majority of inflammatory cells in the core lesion. These findings suggest that nestin and vimentin contribute to the repair of brain injury through the migration of activated cells and the formation of a glial sear. (C) 2004 Elsevier B.V. All rights reserved.	Jeju Natl Univ, Dept Vet Med, Cheju 690756, South Korea; Hallym Univ, Ilsong Inst Life Sci, Anyang 431060, South Korea; Jeju Natl Univ, Dept Neurosurg, Coll Med, Cheju 690756, South Korea; Kyung Hee Univ, Dept Pharmacol, Coll Oriental Med, Seoul 130701, South Korea; Catholic Univ Korea, Dept Anat, Coll Med, Seoul 137701, South Korea	Shin, T (corresponding author), Jeju Natl Univ, Dept Vet Med, Cheju 690756, South Korea.	shint@cheju.ac.kr		SHIN, Taekyun/0000-0002-9851-4354			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Baldwin SA, 1996, GLIA, V16, P266; CAIN H, 1983, VIRCHOWS ARCH B, V42, P65, DOI 10.1007/BF02890371; CALVO JL, 1991, BRAIN RES, V566, P333, DOI 10.1016/0006-8993(91)91720-L; Calza L, 2002, P NATL ACAD SCI USA, V99, P3258, DOI 10.1073/pnas.052704499; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Moon C, 2000, NEUROSCI LETT, V289, P41, DOI 10.1016/S0304-3940(00)01253-2; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shin Tae-kyun, 2003, J Vet Sci, V4, P9; Soares HD, 1995, J NEUROSCI, V15, P8223; Sun D, 2000, J NEUROPATH EXP NEUR, V59, P1031, DOI 10.1093/jnen/59.12.1031; TSURU A, 1990, J CELL BIOL, V110, P1655, DOI 10.1083/jcb.110.5.1655; Wei LC, 2002, DEV BRAIN RES, V139, P9, DOI 10.1016/S0165-3806(02)00509-6	18	34	35	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 3	2004	1028	2					238	242		10.1016/j.brainres.2004.09.022			5	Neurosciences	Neurosciences & Neurology	872LS	WOS:000225209300014	15527750				2021-06-18	
J	Koh, JO; Watkinson, EJ; Yoon, YJ				Koh, JO; Watkinson, EJ; Yoon, YJ			Video analysis of head blows leading to concussion in competition Taekwondo	BRAIN INJURY			English	Article							KICKS	Primary objectives: To analyse the situational and contextual factors surrounding concussions and head blows in Taekwondo. Methods and procedures: Prospective design. Direct observation, subject inter-view and videotape recording used. A total of 2328 competitors participated in the 2001 tournament, South Korea. All matches were recorded on videotape. All recipients of head blows were interviewed by athletic therapists and the researcher immediately after the match. The videotapes of concussions and head blows were analysed. Results: A total of 1009 head blows including concussions were analysed. Head blows and concussions were most evident when the attacker was situated in a closed stance and received a single roundhouse kick. The most frequent anatomical site of the head impact was the temporal region. Conclusions: The frequency of head blows and concussions is high in Taekwondo. Development of blocking skills, safety education, rigorous enforcement of the competition rules and improvement of head-gear are recommended.	Yonsei Univ, Dept Sports & Leisure Studies, Seoul 120749, South Korea; Univ Alberta, Fac Phys Educ & Recreat, Edmonton, AB, Canada	Koh, JO (corresponding author), Yonsei Univ, Dept Sports & Leisure Studies, 134 Shinchon Dong, Seoul 120749, South Korea.	kohjaeok@hotmail.com		Koh, Jae Ok/0000-0002-3639-0739			CHUANG TY, 1992, J BIOMECH ENG-T ASME, V114, P346, DOI 10.1115/1.2891394; Giza CC, 2001, J ATHL TRAINING, V36, P228; GORDIS L, 2000, EPIDEMIOLOGY, P77; Koh JO, 2002, J SPORT MED PHYS FIT, V42, P348; Koh JO, 2001, INT J APPL SPORTS SC, V13, P33; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Pieter W, 1998, J ROY SOC HEALTH, V118, P272, DOI 10.1177/146642409811800512; Pieter W, 1999, J SPORT MED PHYS FIT, V39, P147; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; SERINA ER, 1991, J BIOMECH, V24, P951, DOI 10.1016/0021-9290(91)90173-K; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; ZEMPER ED, 1994, AM SOC TEST MATER, V1229, P116, DOI 10.1520/STP12808S	12	34	34	1	7	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2004	18	12					1287	1296		10.1080/02699050410001719907			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	871BW	WOS:000225105300009	15666571				2021-06-18	
J	Ownsworth, T; McFarland, K				Ownsworth, T; McFarland, K			Investigation of psychological and neuropsychological factors associated with clinical outcome following a group rehabilitation programme	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; IMPAIRED SELF-AWARENESS; HEAD-INJURY; DEFICITS; SCALE; PSYCHOTHERAPY; UNAWARENESS; DISABILITY; DEPRESSION; SYMPTOMS	The present study investigated neuropsychological and psychological factors associated with successful treatment outcome following a group intervention for individuals with acquired brain injury (ABI). Participants were classified into two groups ("Clinically Improved" and "Not Improved") based upon the findings of a previous study (Ownsworth, McFarland, & Young, 2000a). A discriminant analysis was used to predict group membership on three outcome measures (Awareness and Strategy Behaviour indices of the Self-Regulation Skills Interview and the Psychosocial Dimension of the Sickness Impact Profile) between pre-assessment and post-assessment, and between pre-assessment and 6 months follow-up. Neuropsychological factors involved measures of executive functioning and psychological factors were assessed using measures of personality-related denial and coping-related denial. Overall, the results indicated that individuals with impaired executive functioning were most likely to be classified as Clinically Improved on measures of awareness, strategy behaviour and psychosocial functioning. Individuals who deny or minimise their ABI symptoms were less likely to improve their psychosocial functioning following the group intervention. Future research needs to evaluate interventions for enhancing self-regulation skills and improving psychosocial functioning for individuals who employ denial as a main strategy for coping following ABI.	Univ Queensland, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, St Lucia, Qld 4072, Australia	Ownsworth, T (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Dept Occupat Therapy, St Lucia, Qld 4072, Australia.	t.ownsworth@shrs.uq.edu.au		Ownsworth, Tamara/0000-0003-1835-7094			Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Barco P.P., 1991, COGNITIVE REHABILITA, P129; BAYLESS JD, 1989, J CLIN EXP NEUROPSYC, V11, P913, DOI 10.1080/01688638908400944; Bennett T L, 1997, Appl Neuropsychol, V4, P55, DOI 10.1207/s15324826an0401_7; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; CICERONE KD, 2000, TRAUMATIC BRAIN INJU, P95; Cramer P, 1998, J PERS, V66, P919, DOI 10.1111/1467-6494.00037; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; CRONBACH LJ, 1959, J EDUC PSYCHOL, V50, P230, DOI 10.1037/h0042848; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; DEATON AV, 1991, COGNITIVE REHABILITA, P191; Delmonico RL, 1998, J HEAD TRAUMA REHAB, V13, P10, DOI 10.1097/00001199-199812000-00004; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; EVANS RG, 1982, J PERS ASSESS, V46, P415, DOI 10.1207/s15327752jpa4604_14; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Feinberg TE, 1997, NEUROCASE, V3, P73, DOI 10.1093/neucas/3.1.73; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fleming JM, 1997, J HEAD TRAUMA REHAB, V12, P27, DOI 10.1097/00001199-199706000-00004; Fleminger S, 2003, NEUROPSYCHOL REHABIL, V13, P65, DOI 10.1080/09602010244000354; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; Geffen L., 1998, OXFORD HDB SPORTS ME, P152; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; Hageman WJJM, 1999, BEHAV RES THER, V37, P1169; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kelly AE, 1998, J COUNS PSYCHOL, V45, P50, DOI 10.1037/0022-0167.45.1.50; KENDALL E, 1998, THESIS U QUEENSLAND; Kolb B., 1999, COGNITIVE NEUROREHAB, P9; LANE RD, 1990, AM J PSYCHIAT, V147, P573; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; LEZAK MD, 1993, J HEAD TRAUMA REHAB, V8, P24, DOI DOI 10.1097/00001199-199303000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Loeb P. A., 1996, INDEPENDENT LIVING S; MALCOLM CD, 1993, LEZAKS TINKER TOY TE; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MILLS V M, 1992, Brain Injury, V6, P219, DOI 10.3109/02699059209029663; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; OWNSWORTH TL, 2002, 25 ANN C AUSTR SOC S; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; SHAW RE, 1985, PSYCHOSOM MED, V47, P262, DOI 10.1097/00006842-198505000-00004; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Smith H.E., 1992, CLIN REHABIL, V6, P31; Sohlberg MM, 1998, J HEAD TRAUMA REHAB, V13, P62, DOI 10.1097/00001199-199810000-00008; Stuss D. T., 1999, COGNITIVE NEUROREHAB, P188; Stuss D.T., 1986, FRONTAL LOBES; Tabachnick BG, 2013, USING MULTIVARIATE S; TUPPER DE, 1989, ANN M NAT AC NEUR WA; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; Williams WH, 1999, NEUROPSYCHOL REHABIL, V9, P421, DOI 10.1080/096020199389482; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wood RL, 1999, BRAIN INJURY, V13, P69, DOI 10.1080/026990599121746	67	34	34	0	14	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	DEC	2004	14	5					535	562		10.1080/09602010343000538			28	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	863AY	WOS:000224533800004					2021-06-18	
J	Stiefel, MF; Heuer, GG; Abrahams, JM; Bloom, S; Smith, MJ; Maloney-Wilensky, E; Grady, MS; LeRoux, PD				Stiefel, MF; Heuer, GG; Abrahams, JM; Bloom, S; Smith, MJ; Maloney-Wilensky, E; Grady, MS; LeRoux, PD			The effect of nimodipine on cerebral oxygenation in patients with poor-grade subarachnoid hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; cerebral oxygenation; nimodipine	PLACEBO-CONTROLLED TRIAL; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; BLOOD-FLOW; COOPERATIVE ANEURYSM; CALCIUM-ANTAGONISTS; CHANNEL BLOCKERS; RANDOMIZED TRIAL; ARTERIAL SPASM; TISSUE OXYGEN	Object. Nimodipine has been shown to improve neurological outcome after subarachnoid hemorrhage (SAH); the mechanism of this improvement, however, is uncertain. In addition, adverse systemic effects such as hypotension have been described. The authors investigated the effect of nimodipine on brain tissue PO2. Methods. Patients in whom Hunt and Hess Grade IV or V SAH had occurred who underwent aneurysm occlusion and had stable blood pressure were prospectively evaluated using continuous brain tissue PO, monitoring. Nimodipine (60 mg) was delivered through a nasogastric or Dobhoff tube every 4 hours. Data were obtained from 11 patients and measurements of brain tissue PO2, intracranial pressure (ICP), mean arterial blood pressure (MABP), and cerebral perfusion pressure (CPP) were recorded every 15 minutes. Nimodipine resulted in a significant reduction in brain tissue PO2 in seven (64%) of 11 patients. The baseline PO2 before nimodipine administration was 38.4 +/- 10.9 mm Ha. The baseline MABP and CPP were 90 +/- 20 and 84 +/- 19 mm Hg, respectively. The greatest reduction in brain tissue PO2 occurred 15 minutes after administration, when the mean pressure was 26.9 +/- 7.7 mm Hg (p < 0.05). The PO2 remained suppressed at 30 minutes (27.5 +/- 7.7 min Hg [p < 0.05]) and at 60 minutes (29.7 +/- 11.1 min Hg [p < 0.05]) after nimodipine administration but returned to baseline levels 2 hours later. In the seven patients in whom brain tissue PO2 decreased, other physiological variables such as arterial saturation, end-tidal CO2 heart rate, MABP, ICP, and CPP did not demonstrate any association with the nimodipine-induced reduction in PO2. In four patients PO2 remained stable and none of these patients had a significant increase in brain tissue PO2. Conclusions. Although nimodipine use is associated with improved outcome following SAH, in some patients it can temporarily reduce brain tissue PO2.	Univ Penn, Dept Neurosurg, Sch Med, Philadelphia, PA 19107 USA	LeRoux, PD (corresponding author), Univ Penn, Dept Neurosurg, Sch Med, 330 S 9th St, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu					ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; AUER LM, 1986, ACTA NEUROCHIR, V82, P7, DOI 10.1007/BF01456313; Barker FG, 1996, J NEUROSURG, V84, P405, DOI 10.3171/jns.1996.84.3.0405; Charbel FT, 2000, SURG NEUROL, V54, P432, DOI 10.1016/S0090-3019(00)00340-2; Dearden NM, 1998, CLIN NEUROPATHOL, V17, P221; Devlin JW, 2000, NEUROSURGERY, V47, P1243, DOI 10.1097/00006123-200011000-00048; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Dorsch Nicholas W C, 2002, Curr Opin Crit Care, V8, P128; DORSCH NWC, 1995, BRIT J NEUROSURG, V9, P403, DOI 10.1080/02688699550041403; Dreier JP, 2002, NEUROSURGERY, V51, P1457, DOI 10.1097/00006123-200212000-00017; EDVINSSON L, 1979, SURG NEUROL, V11, P327; Feigin VL, 1998, NEUROLOGY, V50, P876, DOI 10.1212/WNL.50.4.876; FORSMAN M, 1989, ANESTH ANALG, V68, P436; GAAB MR, 1985, BRIT J CLIN PHARMACO, V20, pS67, DOI 10.1111/j.1365-2125.1985.tb05145.x; GELMERS HJ, 1985, AM J CARDIOL, V55, pB144, DOI 10.1016/0002-9149(85)90623-X; HALEY EC, 1993, J NEUROSURG, V78, P537, DOI 10.3171/jns.1993.78.4.0537; HALEY EC, 1994, J NEUROSURG, V80, P788, DOI 10.3171/jns.1994.80.5.0788; HALEY EC, 1993, J NEUROSURG, V78, P548, DOI 10.3171/jns.1993.78.4.0548; HANDA J, 1975, SURG NEUROL, V3, P195; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; Horn J, 2001, STROKE, V32, P2433, DOI 10.1161/hs1001.096009; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JUVELA S, 1990, STROKE, V21, P1283, DOI 10.1161/01.STR.21.9.1283; KASSELL NF, 1990, J NEUROSURG, V73, P18, DOI 10.3171/jns.1990.73.1.0018; KASSELL NF, 1990, J NEUROSURG, V73, P37, DOI 10.3171/jns.1990.73.1.0037; KAZDA S, 1982, ACTA NEUROCHIR, V63, P259, DOI 10.1007/BF01728880; Kett-White R, 2002, ACT NEUR S, V81, P363; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; LANGLEY MS, 1989, DRUGS, V37, P669, DOI 10.2165/00003495-198937050-00004; LeRoux PD, 1997, J NEUROSURG, V87, P1, DOI 10.3171/jns.1997.87.1.0001; Macmillan CSA, 2001, J NEUROL NEUROSUR PS, V70, P101, DOI 10.1136/jnnp.70.1.101; MAYBERG MR, 1994, CIRCULATION, V90, P2592, DOI 10.1161/01.CIR.90.5.2592; McKhann GM, 2004, MANAGEMENT CEREBRAL, P431; MEE E, 1988, NEUROSURGERY, V22, P484, DOI 10.1227/00006123-198803000-00006; MOHAMED AA, 1984, J CEREBR BLOOD F MET, V4, P206, DOI 10.1038/jcbfm.1984.29; MULLERSCHWEINITZER E, 1983, J CEREBR BLOOD F MET, V3, P354; MURPHY JJ, 1990, LANCET, V336, P1205; NOSKO M, 1986, J NEUROSURG, V65, P376, DOI 10.3171/jns.1986.65.3.0376; OHMAN J, 1988, J NEUROSURG, V69, P683, DOI 10.3171/jns.1988.69.5.0683; PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505; PHILIPPON J, 1986, ACTA NEUROCHIR, V82, P110, DOI 10.1007/BF01456369; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; Pisani A, 1998, STROKE, V29, P196, DOI 10.1161/01.STR.29.1.196; PORCHET F, 1995, ACTA NEUROCHIR, V137, P62, DOI 10.1007/BF02188783; Radhakrishnan D, 1997, ANAESTHESIA, V52, P489, DOI 10.1111/j.1365-2044.1997.112-az0105.x; Rasmussen G, 1999, ACTA NEUROL SCAND, V99, P182, DOI 10.1111/j.1600-0404.1999.tb07341.x; Roos Y, 2000, NEUROLOGY, V54, P77, DOI 10.1212/WNL.54.1.77; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; Vath A, 2001, NEUROL RES, V23, P315, DOI 10.1179/016164101101198677; Weir B, 1993, Clin Neurosurg, V40, P40; Zumkeller M, 1997, NEUROSURG REV, V20, P259, DOI 10.1007/BF01105897; ZYGMUNT SC, 1995, ACTA NEUROCHIR, V135, P179, DOI 10.1007/BF02187765	53	34	38	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2004	101	4					594	599		10.3171/jns.2004.101.4.0594			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	865MP	WOS:000224707500009	15481712				2021-06-18	
J	Holmgren, EP; Dierks, EJ; Homer, LD; Potter, BE				Holmgren, EP; Dierks, EJ; Homer, LD; Potter, BE			Facial computed tomography use in trauma patients who require a head computed tomogram	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article							FRACTURES; INJURIES; DIAGNOSIS	Purpose: Head-injured patients admitted to a trauma center may or may not have associated facial fractures. Most head-injured patients undergo head computed tomography (CT) scan early in their evaluation. The question of adding a facial CT at the time of the head CT can be unclear. The aims of our study are 1) to analyze how the facial CT is used in conjunction with the head CT in facial fracture trauma patients, 2) to recognize unique identifiers that would aid the surgeon's decision-making process to order a facial CT in continuity with a head CT, and 3) to examine what is characteristic of head trauma patients who receive a facial CT separately, at some point after the head CT. Materials and Methods: Data were retrospectively reviewed for a 5-year period at a level 1 trauma center in which all patients who present with craniomaxillofacial trauma are managed by the oral and maxillofacial surgery (OMFS) service. included patients must have obtained a head CT during initial resuscitation and be diagnosed with a facial fracture during the same hospital stay. These patients were divided into 3 groups: those who had a 1) head CT only, 2) head CT and facial CT at the same time, and 3) head CT with the facial CT performed at a later time. Results: A total of 9,871 patients were admitted to the trauma service during a 5-year period and 4,926 patients (49.9%) had head CT performed. Of this group, 12% had facial fractures, and the most common associated injury in this group was facial lacerations and concussions. The nasal fracture followed by the orbital fracture was the most common fracture type. Eighty-four percent of the time, the facial CT was used to help diagnose facial fractures in this patient population. The 3 different groups showed unique trends. Conclusion: Six points were identified in our study that can augment the physical examination in patients who require head CT. The following points can help prompt the clinician to order a combination head and facial CT: 1) 12% of trauma patients who require a head CT will have a facial fracture, whereas half of these patients will have multiple facial fractures. 2) Orbital fractures are commonly missed in this group and often require a secondary scan such as coronal views for accurate diagnosis. 3) Facial lacerations correlate with ordering a combination head and facial CT. 4) The most common facial fracture identified among patients receiving a trauma head CT is the nasal fracture. 5) The use of the facial CT in more severely injured patients tended to be delayed and was related to increased hospital and intensive care unit days. 6) Only 16% of facial fracture patients who had received an initial trauma head CT did not require further facial CT scanning. (C) 2004 American Association of Oral and Maxillofacial Surgeons.	Oregon Hlth & Sci Univ, Dept Oral & Maxillofacial Surg, Portland, OR 97203 USA; Legacy Hosp Syst, Portland, OR 97203 USA	Holmgren, EP (corresponding author), Oregon Hlth & Sci Univ, Dept Oral & Maxillofacial Surg, 7416 N Olin Ave, Portland, OR 97203 USA.	holmgren@ohsu.edu					ABUBAKER AO, 2001, ORAL MAXILLOFACIAL S, P203; Alvi A, 2003, LARYNGOSCOPE, V113, P102, DOI 10.1097/00005537-200301000-00019; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BOOTH PW, 1999, MAXILLOFACIAL SURG, P21; Carroll SM, 1996, IRISH MED J, V89, P188; ENDERSON BL, 1991, SURG CLIN N AM, V71, P399; GAUTAM V, 1994, INJURY, V25, P47, DOI 10.1016/0020-1383(94)90184-8; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; McAuley Clyde E., 1992, Journal of Trauma, V33, P948; PRESS BH, 2000, INJURY, V31, P677; REHM CG, 1995, J ORAL MAXIL SURG, V53, P522, DOI 10.1016/0278-2391(95)90063-2; SINCLAIR D, 1988, Journal of Emergency Medicine, V6, P109, DOI 10.1016/0736-4679(88)90148-5; WHITAKER LA, 1990, ANN PLAS SURG, V25, P440, DOI 10.1097/00000637-199012000-00003	13	34	43	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	AUG	2004	62	8					913	918		10.1016/j.joms.2003.12.026			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	842RS	WOS:000223022300002	15278853				2021-06-18	
J	Meyers, JE; Rohling, ML				Meyers, JE; Rohling, ML			Validation of the Meyers Short Battery on mild TBI patients	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						neuropsychology; validity; reliability; short battery	HEAD-INJURY; WAIS-R; INDEX	This manuscript reports the results of two studies focusing on patients with mild Traumatic Brain Injury (TBI). The first assesses the validity of the Meyers Short Battery (MSB) of neuropsychological tests. The second study reports on the reliability of the MSB. The groups consisted of normal controls, depressed, chronic pain patients, and patients with mild TBI. Validity was assessed using a discriminant function analysis comparing the non-TBI participants with the TBI participants, which showed a 96.1% correct classification rate. When patients were assessed at least 6 months post-injury and re-assessment 12-14 months later, an overall reliability of r = .86 was obtained. This indicates that the MSB has adequate psychometric properties for clinical use. The results are consistent with previous published research indicating, that the MSB is sensitive not only to the presence of mild TBI but also to the degree of cognitive impairment based on loss of consciousness. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Ctr Neurosci Orthoped & Spine, Dakota Dunes, SD USA; Univ S Alabama, Moville, AL USA	Meyers, JE (corresponding author), Ctr Neurosci Orthoped & Spine, Dakota Dunes, SD USA.	jmeyers@mstar.net					BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Benton A.L., 1983, CONTRIBUTIONS NEUROP; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; Meyer-Abich KM, 2000, FORSCH KOMP KLAS NAT, V7, P154, DOI 10.1159/000021332; Meyers J., 1995, REY COMPLEX FIGURE T; Meyers J E, 2001, Appl Neuropsychol, V8, P234, DOI 10.1207/S15324826AN0804_6; Meyers J E, 1999, Appl Neuropsychol, V6, P208, DOI 10.1207/s15324826an0604_3; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P79, DOI 10.1016/S0887-6177(00)00105-0; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; Meyers JE, 1998, APPL NEUROPSYCHOL, V5, P120, DOI 10.1207/s15324826an0503_2; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; Reitan RM, 1997, NEUROPSYCHOL REV, V7, P3, DOI 10.1007/BF02876970; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Spreen O., 1998, COMPENDIUM NEUROPSYC; Spreen O., 1991, COMPENDIUM NEUROPSYC; Tabachnick B.G., 1989, USING MULTIVARIATE S; Volbrecht ME, 2000, ARCH CLIN NEUROPSYCH, V15, P251, DOI 10.1016/S0887-6177(99)00016-5; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M	22	34	34	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2004	19	5					637	651		10.1016/j.acn.2003.08.007			15	Psychology, Clinical; Psychology	Psychology	845PT	WOS:000223257500003	15271408	Bronze			2021-06-18	
J	Goforth, PB; Ellis, EF; Satin, LS				Goforth, PB; Ellis, EF; Satin, LS			Mechanical injury modulates AMPA receptor kinetics via an NMDA receptor-dependent pathway	JOURNAL OF NEUROTRAUMA			English	Article						AMPA; CaMKII; desensitization; glutamate; NMDA; traumatic brain injury	PROTEIN-KINASE-II; TRAUMATIC BRAIN-INJURY; STRETCH-INDUCED INJURY; GLUTAMATE RECEPTORS; HIPPOCAMPAL-NEURONS; SILENT SYNAPSES; CALCIUM; RAT; DESENSITIZATION; ACTIVATION	Alterations in glutamatergic transmission are thought to contribute to secondary neuronal damage following traumatic brain injury. Using an in vitro cell injury model, we previously demonstrated an apparent reduction in AMPA receptor desensitization and resultant potentiation of AMPA-evoked currents after stretch injury of cultured neonatal rat cortical neurons. In the present study, we sought to further characterize injury-induced enhancement of AMPA current and elucidate the mechanisms responsible for this pathological process. Using the patch-clamp technique, agonist-activated currents were recorded from control and injured neurons. Potentiation of AMPA-mediated currents occurred quickly, within 15-30 min following injury, and persisted for at least 24 h. Stretch-injury slowed the activation and desensitization of AMPA mediated currents recorded from excised outside-out patches. The co-application of 100 muM AMPA and 20 AM thiocyanate enhanced AMPA receptor desensitization in control neurons and restored desensitization in injured neurons. The potentiation of AMPA-elicited current was prevented by the NMDA receptor antagonist D-APV (20 muM) or the CaMKII inhibitor KN93 (10 muM). These results suggest that mechanical injury initiates a biochemical cascade that involves NMDA receptor and CaMKII activation and produces a long-lasting reduction of AMPA receptor desensitization, which may contribute to the pathophysiology of traumatic brain injury.	Virginia Commonwealth Univ, Ctr Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Med, Dept Physiol & Med Endocrinol, Richmond, VA 23298 USA	Satin, LS (corresponding author), Virginia Commonwealth Univ, Ctr Med, Dept Pharmacol & Toxicol, POB 980524, Richmond, VA 23298 USA.	lsatin@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 T32 NS 07288-13, NS 27214] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214, T32NS007288] Funding Source: NIH RePORTER		Aguayo LG, 1998, PFLUG ARCH EUR J PHY, V435, P382, DOI 10.1007/s004240050527; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; ARAI A, 1995, NEUROSCIENCE, V66, P815, DOI 10.1016/0306-4522(94)00616-D; ARMSTRONG D, 1988, CALCIUM ION CHANNEL, P220; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BOWIE D, 1993, BRIT J PHARMACOL, V109, P779, DOI 10.1111/j.1476-5381.1993.tb13642.x; BULLOCK R, 1997, HEAD INJURY PATHOPHY, P120; Churn SB, 1995, ADV NEUROIMMUNOL, V5, P241, DOI 10.1016/0960-5428(95)00016-U; COLBRAN RJ, 1989, J BIOL CHEM, V264, P4800; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; DAVIES GM, 1982, CURR PSYCHOL RES REV, V2, P235, DOI DOI 10.1007/BF02684516; Derkach V, 1999, P NATL ACAD SCI USA, V96, P3269, DOI 10.1073/pnas.96.6.3269; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; EVANS RH, 1982, BRIT J PHARMACOL, V75, P65, DOI 10.1111/j.1476-5381.1982.tb08758.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FUKUNAGA K, 1992, J BIOL CHEM, V267, P22527; FUKUNAGA K, 1989, J BIOL CHEM, V264, P21830; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; HAJIMOHAMMADREZA I, 1995, J NEUROSCI, V15, P4093; HALL RA, 1993, BRAIN RES, V628, P345, DOI 10.1016/0006-8993(93)90978-V; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY PT, 1991, MOL NEUROBIOL, V5, P153, DOI 10.1007/BF02935544; KELLY PT, 1987, METHOD ENZYMOL, V139, P690; KESSLER M, 1986, MOL PHARM, V49, P123; KISKIN NI, 1986, NEUROSCI LETT, V63, P225, DOI 10.1016/0304-3940(86)90360-5; LIAO D, 2000, NATURE, V405, P955; Liao DH, 1999, NAT NEUROSCI, V2, P37; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; NIELSEN EO, 1988, EUR J PHARMACOL, V157, P197, DOI 10.1016/0014-2999(88)90383-4; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OBENOVITCH TP, 1997, J NEUROTRAUM, V14, P677; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OLSEN RW, 1987, BRAIN RES, V402, P243, DOI 10.1016/0006-8993(87)90030-8; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Partin KM, 1996, J NEUROSCI, V16, P6634, DOI 10.1523/jneurosci.16-21-06634.1996; PATNEAU DK, 1991, NEURON, V6, P785, DOI 10.1016/0896-6273(91)90175-Y; Pickard L, 2001, NEUROPHARMACOLOGY, V41, P700, DOI 10.1016/S0028-3908(01)00127-7; Rammes G, 1999, PFLUG ARCH EUR J PHY, V437, P191, DOI 10.1007/s004240050768; RZIGALINSKI BA, 1996, J NEUROTRAUM, V13, P609; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Soderling TR, 1996, NEUROCHEM INT, V28, P359, DOI 10.1016/0197-0186(95)00098-4; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TANG CM, 1989, SCIENCE, V243, P1474, DOI 10.1126/science.2467378; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; TRUSSELL LO, 1988, P NATL ACAD SCI USA, V85, P4562, DOI 10.1073/pnas.85.12.4562-a; TRUSSELL LO, 1989, NEURON, V3, P209, DOI 10.1016/0896-6273(89)90034-2; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; WANG LY, 1994, J PHYSIOL-LONDON, V475, P431, DOI 10.1113/jphysiol.1994.sp020083; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; WYLLIE DJA, 1994, NEURON, V13, P635, DOI 10.1016/0896-6273(94)90031-0; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; Zauner A, 1996, ACT NEUR S, V67, P40; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	72	34	36	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					719	732		10.1089/0897715041269704			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600008	15253800				2021-06-18	
J	Raabe, A; Kopetsch, O; Woszczyk, A; Lang, J; Gerlach, R; Zimmermann, M; Seifert, V				Raabe, A; Kopetsch, O; Woszczyk, A; Lang, J; Gerlach, R; Zimmermann, M; Seifert, V			S-100B protein as a serum marker of secondary neurological complications in neurocritical care patients	NEUROLOGICAL RESEARCH			English	Article						S-100 protein; severe head injury; subarachnoid hemorrhage; neurocritical care; secondary brain damage	SEVERE HEAD-INJURY; NEURON-SPECIFIC ENOLASE; TRAUMATIC BRAIN-INJURY; ACUTE STROKE; NEUROBIOCHEMICAL MARKERS; SUBARACHNOID HEMORRHAGE; CEREBROSPINAL-FLUID; CARDIAC-SURGERY; S100B PROTEIN; SERIAL S-100	There is growing evidence that S-100B protein measured by a simple blood test can be used as a novel biochemical marker of brain cell damage. The objective of our study was to investigate the potential of S-100B measurements to diagnose an acute neurological complication in the analgo-sedated and intubated intensive care patient and the impact on patient management. Serum S-100B levels were serially investigated in 246 neurocritical care patients. Venous blood samples for S-100B determination were obtained as soon as possible after admission and every 24 hours thereafter, for the duration of the stay at the neurocritical care unit. Blood samples were taken every morning as part of the routine laboratory investigation for analysis of S-100B using the immunoluminometric assay (AB Sangtec Medical, Bromma, Sweden) and a fully automated LIAISON(R) system (Byk-Sangtec-Diagnostica, Dietzenbach, Germany) with a short time to result. The primary endpoint of our study was the occurrence of a severe neurological complication. Patients were admitted to the neurosurgical intensive care unit after routine major intracranial surgery in 116 cases (47%) and after a neurological or neurosurgical emergency in 130 cases (53%). Of the latter group, 79 patients (.32%) underwent emergency surgery for evacuation or decompression of a space-occupying lesion before ICU admission. A severe neurological complication was defined as a new infarction, new hemorrhage or a newly developed progressive disease despite maximum therapy with a radiologically confirmed increase of mass lesion and midline shift. In 33 patients (13%) a complication with neurological deterioration occurred. All patients showed pathologically increased serum S-100B values (mean 2.00 mug/l, standard deviation 2.67 mug/l, range 0.31-9.66 mug/l). Twenty-eight of these patients (85%) showed S-100B increases >0.5 mug/l. In five cases (16 %), the increase in S-100B was the first sign of neurological complication and prompted emergency computed tomography scanning. In another two ;cases, increasing S-100B values changed management decision towards a surgical intervention. The major finding of our study was the influence of serial S-100B measurement on actual management of the patient in 27% of cases with neurological complications.	Univ Frankfurt, Dept Neurosurg, Neuroctr, D-60528 Frankfurt, Germany	Raabe, A (corresponding author), Univ Frankfurt, Dept Neurosurg, Neuroctr, Schleusenweg 2-16, D-60528 Frankfurt, Germany.	A.Raabe@em.uni-frankfurt.de					Abraha HD, 1997, ANN CLIN BIOCHEM, V34, P546, DOI 10.1177/000456329703400510; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Bertsch T, 2001, CLIN CHEM LAB MED, V39, P319, DOI 10.1515/CCLM.2001.050; Bottiger BW, 2001, CIRCULATION, V103, P2694; Buttner T, 1997, STROKE, V28, P1961, DOI 10.1161/01.STR.28.10.1961; DONATO R, 1986, CELL CALCIUM, V7, P123, DOI 10.1016/0143-4160(86)90017-5; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Grasso G, 2002, J NEUROSURG, V96, P565, DOI 10.3171/jns.2002.96.3.0565; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 2001, ANN THORAC SURG, V71, P1433, DOI 10.1016/S0003-4975(00)02612-6; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; McKeating EG, 1998, ACT NEUR S, V71, P117; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1998, J NEUROL NEUROSUR PS, V65, P930, DOI 10.1136/jnnp.65.6.930; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	37	34	34	0	0	MANEY PUBLISHING	LEEDS	HUDSON RD, LEEDS LS9 7DL, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	JUN	2004	26	4					440	445		10.1179/016164104225015958			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	829CP	WOS:000222021400015	15198874				2021-06-18	
J	Prabhakaran, P; Reddy, AT; Oakes, WJ; King, WD; Winkler, MK; Givens, TG				Prabhakaran, P; Reddy, AT; Oakes, WJ; King, WD; Winkler, MK; Givens, TG			A pilot trial comparing cerebral perfusion pressure-targeted therapy to intracranial pressure-targeted therapy in children with severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain injury; trauma; cerebral edema; Glasgow Coma Scale; Glasgow Outcome Scale; intracranial pressure; cerebral perfusion pressure	SEVERE HEAD-INJURY; COMA DATA-BANK; BLOOD-FLOW; PRACTICAL SCALE; HYPERTENSION; HYPOTENSION; MANAGEMENT; INSULTS; ADULT	Object. The authors sought to compare cerebral perfusion pressure (CPP)- with intracranial pressure (ICP)-targeted therapy in children with severe traumatic brain injury (TBI). Methods. A randomized controlled trial was developed to assess CPP and ICP therapies in 17 children (range 15 months-15 years of age) with poststabilization Glasgow Coma Scale (GCS) scores of less than or equal to 8 who were admitted to a pediatric intensive care unit at a Level I trauma center. Goals in the ICP group were to maintain ICP lower than 20 mm Hg and CPP higher than 50 mm Hg. In the CPP group, goals were to maintain CPP higher than 70 mm Hg for patients at least 2 years old and higher than 60 mm Hg for patients younger than 2 years of age. The study outcomes were death or functional outcome at 1 year postinjury. The median GCS scores in the CPP group (12 patients) and the ICP group (five patients) were 6 and 7, respectively. In the CPP group, two patients died, one was lost to follow up, four were unimpaired, and five had mild impairment. In the ICP group, all patients survived one was lost to follow up, two had mild impairment, and two had hemiparesis and moderate impairment. There were four unimpaired survivors in the CPP arm compared with none in the ICP arm (p = 0.08). Conclusions. The CPP method appears to be safe, although this feasibility study does not establish that the CPP therapy is superior to ICP therapy.	Univ Alabama, Dept Pediat, Birmingham, AL USA; Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA	Reddy, AT (corresponding author), 1600 7th Ave S,ACC 512, Birmingham, AL 35233 USA.	areddy@peds.uab.edu					ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BOREL CO, 1987, AM J PHYSIOL, V253, pH1342; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; DAVIS RJ, 1992, TXB PEDIAT INTENSIVE, P805; DEWEY RC, 1974, J NEUROSURG, V41, P597, DOI 10.3171/jns.1974.41.5.0597; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; ELADAWY Y, 1989, INTRACRANIAL PRESSUR, V7, P829; FEIN JM, 1983, J NEUROSURG, V59, P51, DOI 10.3171/jns.1983.59.1.0051; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; JENNETT B, 1975, LANCET, V1, P480; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; KONTOS HA, 1978, AM J PHYSIOL, V234, P371; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rosner M., 1986, INTRACRANIAL PRESSUR, P137, DOI [10.1007/978-3-642-70971-5_25, DOI 10.1007/978-3-642-70971-5_25]; Rosner M., 1987, CEREBRAL BLOOD FLOW, P425; Rosner Michael J., 1993, P57; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1995, NEUROSURG CLIN N AM, V6, P761; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1993, INTRACRANIAL PRESSUR, V8, P414; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; TEASDALE G, 1974, LANCET, V2, P81; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; 2000, J NEUROTRAUMA, V17, P513	39	34	35	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2004	100	5		S			454	459		10.3171/ped.2004.100.5.0454			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	819MT	WOS:000221319700010	15287454				2021-06-18	
J	Scheff, SW; Dhillon, HS				Scheff, SW; Dhillon, HS			Creatine-enhanced diet alters levels of lactate and free fatty acids after experimental brain injury	NEUROCHEMICAL RESEARCH			English	Article						brain damage; excitotoxicity; lactic acid; neuroprotection; trauma	SIGNAL-TRANSDUCTION PATHWAY; EVANS BLUE EXTRAVASATION; PHOSPHATIDYLINOSITOL BISPHOSPHATE; CORTICAL CONTUSION; REGIONAL LEVELS; AMINO-ACIDS; MOUSE MODEL; RAT; ACCUMULATION; SUPPLEMENTATION	Free fatty acids (FFA) and lactic acid are markers of secondary cellular injury following traumatic brain injury (TBI). We previously showed that animals fed a creatine (Cr)-enriched diet are afforded neuroprotection following TBI. To further characterize the neuroprotective Cr diet, we studied neurochemical changes in cortex and hippocampus following a moderate injury. Adult rats were fed either a control or Cr-supplemented diet (0.5%, 1%) for 2 weeks before TBI. At 30 min or 6 h after injury, tissue was processed for quantitative analysis of neurochemical changes. Both lactate and FFA were significantly increased in all tissues ipsilateral to the injury. Cr-fed animals had significantly lower levels, although the levels were elevated compared to sham controls. Animals fed a 1% Cr-diet were afforded greater neuroprotection than animals fed a 0.5% Cr diet. These results support the idea that a Cr-enriched diet can provide substantial neuroprotection in part by suppressing secondary brain injury.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown, Lexington, KY 40536 USA.	sscheff@email.uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG021981] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828] Funding Source: Medline		Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Balestrino M, 1999, BRAIN RES, V816, P124, DOI 10.1016/S0006-8993(98)01131-7; BALLY PR, 1960, J BIOL CHEM, V235, P333; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brewer GJ, 2000, J NEUROCHEM, V74, P1968, DOI 10.1046/j.1471-4159.2000.0741968.x; Brustovetsky N, 2001, J NEUROCHEM, V76, P425, DOI 10.1046/j.1471-4159.2001.00052.x; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; Dhillon HS, 1999, J NEUROTRAUM, V16, P455, DOI 10.1089/neu.1999.16.455; Dhillon HS, 1998, BRAIN RES, V804, P231, DOI 10.1016/S0006-8993(98)00639-8; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Dhillon HS, 1995, J NEUROTRAUM, V12, P1035, DOI 10.1089/neu.1995.12.1035; Dhillon HS, 1999, BRAIN RES, V832, P7, DOI 10.1016/S0006-8993(99)01437-7; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferrante RJ, 2000, J NEUROSCI, V20, P4389, DOI 10.1523/JNEUROSCI.20-12-04389.2000; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GORMAN LK, 1994, NEUROSCI LETT, V166, P199, DOI 10.1016/0304-3940(94)90485-5; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; Hausmann ON, 2002, SPINAL CORD, V40, P449, DOI 10.1038/sj.sc.3101330; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Holtzman D, 1998, PEDIATR RES, V44, P410, DOI 10.1203/00006450-199809000-00024; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; Ipsiroglu OS, 2001, LIFE SCI, V69, P1805, DOI 10.1016/S0024-3205(01)01268-1; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; Matthews RT, 1998, J NEUROSCI, V18, P156; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PONTEN U, 1973, J NEUROCHEM, V21, P1127, DOI 10.1111/j.1471-4159.1973.tb07567.x; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Prasad RM, 1997, J NEUROTRAUM, V14, P919, DOI 10.1089/neu.1997.14.919; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SHAPIRO B, 1955, BIOCHEM PROBL, P347; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TZIGARET C, 1993, J NEUROCHEM, V60, P827, DOI 10.1111/j.1471-4159.1993.tb03226.x; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wilken B, 1998, PEDIATR RES, V43, P8, DOI 10.1203/00006450-199801000-00002; Zhang WH, 2003, ANN NEUROL, V53, P267, DOI 10.1002/ana.10476	58	34	37	0	1	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	FEB	2004	29	2					469	479		10.1023/B:NERE.0000013753.22615.59			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	769CZ	WOS:000188610000019	15002746				2021-06-18	
J	Vezzani, A; Moneta, D; Richichi, C; Perego, C; De Simoni, MG				Vezzani, A; Moneta, D; Richichi, C; Perego, C; De Simoni, MG			Functional role of proinflammatory and anti-inflammatory cytokines in seizures	RECENT ADVANCES IN EPILEPSY RESEARCH	ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY		English	Article							CENTRAL-NERVOUS-SYSTEM; LONG-TERM POTENTIATION; TUMOR-NECROSIS-FACTOR; INTERLEUKIN-1 RECEPTOR ANTAGONIST; TEMPORAL-LOBE EPILEPSY; GYRUS IN-VITRO; RAT-BRAIN; KAINIC ACID; CEREBROSPINAL-FLUID; FEBRILE SEIZURES	Recent evidence has shown that proinflammatory and anti-inflammatory molecules are synthesized during epileptic activity in glial cells in CNS regions where seizures initiate and spread. These molecules are released and interact with specific receptors on neurons. Since various cytokines have been shown to affect neuronal excitability, this led to the hypothesis that they may have a role in altering synaptic transmission in epileptic conditions. Indeed, intracerebral application of IL-1beta enhances epileptic activity in experimental models while its naturally occurring receptor antagonist (IL-1Ra) mediates anticonvulsant actions. Transgenic mice overexpressing IL-1Ra in astrocytes are less susceptible to seizures, indicating that endogenous IL-1 has proconvulsant activity. Several studies indicate a central role of IL-1beta for the exacerbation of brain damage after ischemic, traumatic or excitotoxic insults, suggesting that it may also contribute to neuronal cell injury associated with seizures. Finally, a functional polymorphism in the IL-1beta gene promoter, possibly associated with enhanced ability to produce this cytokine, has been specifically found in temporal lobe epilepsy patients with hippocampal sclerosis and in children with febrile seizures. Thus, the IL-1 system may represent a novel target for controlling seizure activity and/or the associated long-term sequelae. Furthermore, these studies suggest that other inflammatory and anti-inflammatory molecules produced in the CNS may have a role in the pathophysiology of seizure disorders.	Mario Negri Inst Pharmacol Res, Dept Neurosci, I-20157 Milan, Italy	Vezzani, A (corresponding author), Mario Negri Inst Pharmacol Res, Dept Neurosci, Via Eritrea 62, I-20157 Milan, Italy.		Vezzani, Annamaria/AAB-1882-2020; De Simoni, Maria Grazia/I-6021-2012	Vezzani, Annamaria/0000-0003-0573-6175; De Simoni, Maria Grazia/0000-0001-6695-5297; Perego, Carlo/0000-0002-0259-0003			Akassoglou K, 1997, J IMMUNOL, V158, P438; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; BAN E, 1991, NEUROSCIENCE, V43, P21, DOI 10.1016/0306-4522(91)90412-H; BARRES BA, 1991, J NEUROSCI, V11, P3685; BARTFAI T, 1993, NEUROCHEM INT, V22, P435, DOI 10.1016/0197-0186(93)90038-7; BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BENVENISTE EN, 1992, AM J PHYSIOL, V263, pC1; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Coogan A, 1997, NEUROREPORT, V8, P2107, DOI 10.1097/00001756-199707070-00004; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; DArcangelo G, 1997, NEUROREPORT, V8, P2079, DOI 10.1097/00001756-199705260-00053; De Simoni MG, 2000, EUR J NEUROSCI, V12, P2623, DOI 10.1046/j.1460-9568.2000.00140.x; De Simoni MG, 1998, BIOL SIGNAL RECEPT, V7, P33; DEBOCK F, 1996, NEUROREPORT, V7, P1126; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; Gahring LC, 1997, NEUROBIOL DIS, V3, P263, DOI 10.1006/nbdi.1996.0123; Hopkinson M, 2001, PRINT Q, V18, P83; Ichiyama T, 1998, NEUROLOGY, V50, P407, DOI 10.1212/WNL.50.2.407; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; KAMIKAWA H, 1998, AM J PHYSIOL, V274, pR806; Kanemoto K, 2000, ANN NEUROL, V47, P571, DOI 10.1002/1531-8249(200005)47:5<571::AID-ANA3>3.0.CO;2-A; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Lahat E, 1997, PEDIATR NEUROL, V17, P34, DOI 10.1016/S0887-8994(97)00034-9; LAPCHAK PA, 1993, NEUROREPORT, V4, P303, DOI 10.1097/00001756-199303000-00019; Luk WP, 1999, J NEUROSCI, V19, P4238; MILLER LG, 1991, MOL PHARMACOL, V39, P105; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; MonteroMenei CN, 1996, BRAIN RES, V724, P55, DOI 10.1016/0006-8993(96)00268-5; Nishiyori A, 1997, MOL BRAIN RES, V50, P237, DOI 10.1016/S0169-328X(97)00195-2; NITSCH C, 1986, ADV EXPT MED BIOL, P175; Peltola J, 2000, EPILEPSY RES, V41, P205, DOI 10.1016/S0920-1211(00)00140-6; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; PLATASALAMAN CR, 1992, BRAIN RES BULL, V29, P221, DOI 10.1016/0361-9230(92)90029-W; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SCARBOROUGH DE, 1989, ENDOCRINOLOGY, V124, P549, DOI 10.1210/endo-124-1-549; SCHOBITZ B, 1994, PROG NEUROBIOL, V44, P397, DOI 10.1016/0301-0082(94)90034-5; SHENG JG, 1994, J NEUROCHEM, V63, P1872; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; TAKAO T, 1990, ENDOCRINOLOGY, V127, P3070, DOI 10.1210/endo-127-6-3070; Vezzani A, 1999, J NEUROSCI, V19, P5054; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; VEZZANI A, 2001, 31 ANN M SOC NEUR NO, V557, P18; Virta N, 2002, PEDIATR NEUROL, V26, P192, DOI 10.1016/S0887-8994(01)00380-0; Wang S, 2000, J PHARMACOL EXP THER, V292, P497; YABUUCHI K, 1993, MOL BRAIN RES, V20, P153, DOI 10.1016/0169-328X(93)90121-5; YE ZC, 1996, NEUROREPORT, V72, P181; Zeise ML, 1997, BRAIN RES, V768, P341, DOI 10.1016/S0006-8993(97)00787-7; Zhao BY, 1998, J NEUROSCI RES, V52, P7, DOI 10.1002/(SICI)1097-4547(19980401)52:1<7::AID-JNR2>3.0.CO;2-I	50	34	34	0	1	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598			ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2004	548						123	133					11	Medicine, Research & Experimental	Research & Experimental Medicine	BAV10	WOS:000223703200010	15250591				2021-06-18	
J	Gerhart, KA; Mellick, DC; Weintraub, AH				Gerhart, KA; Mellick, DC; Weintraub, AH			Violence-related traumatic brain injury: A population-based study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						violence; traumatic brain injury; outcomes	SPINAL-CORD-INJURY; SICKNESS IMPACT PROFILE; GUNSHOT WOUNDS; SEVERITY SCORE; HEAD-INJURY; EXPERIENCE; ASSAULT; TRENDS	Background. Most studies of traumatic brain injury (TBI) and violence are small, focus on one violent mechanism only, and are nonrepresentative. This large, population-based effort examines characteristics, circumstances of injury, treatment pathways, and outcomes of persons with TBI as a result of all types of violence, compares them with other TBI survivors, identifies a risk profile, and examines how a violent cause impacts later outcomes. Methods. This study involved medical record abstraction and telephone survey at I year postinjury of a weighted sample of 2,771 Coloradans hospitalized with TBI between January 1, 1996, and June 30, 1999. Results. People with violently incurred TBI are more likely to be young, male, members of minority groups, single, and premorbid alcohol abusers than other TBI survivors. At I year postinjury, they report less community integration and more headaches, confusion, and sensory and attentional disturbances. Predictors of these outcomes included age, gender, injury severity, and employment status. Conclusion. it appears that essentially the same factors that increase risk of sustaining a violent TBI negatively impact later outcomes as well.	Craig Hosp Res, Rocky Mt Reg Brain Injury Syst, Englewood, CO 80110 USA	Gerhart, KA (corresponding author), Craig Hosp Res, Rocky Mt Reg Brain Injury Syst, 3425 S Clarkson St, Englewood, CO 80110 USA.	kgerhart@craighospital.org			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A980020] Funding Source: Medline; ODCDC CDC HHS [U17/CCU812447] Funding Source: Medline		BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BROOKS WB, 1990, MED CARE, V28, P793, DOI 10.1097/00005650-199009000-00009; *CDCP, EP TRAUM BRAIN INJ U; *COL TRAUM BRAIN I, 2001, DAT FIL DOC COL TRAU; Cook PJ, 1999, JAMA-J AM MED ASSOC, V282, P447, DOI 10.1001/jama.282.5.447; *CRAIG HOSP RES DE, 2000, CRAIG HAND ASS REP T; Damiano AM, 1996, SICKNESS IMPACT PROF; *DEP HLTH HUM SERV, 1989, INT HEAD INJ TASK FO; DEYO RA, 1986, SPINE, V11, P951, DOI 10.1097/00007632-198611000-00017; DEYO RA, 1983, SPINE, V8, P635, DOI 10.1097/00007632-198309000-00009; DIKERS M, 1991, J AM PARAPLEGIA SOC, V14, P85; DODGE GG, 1994, AM SURGEON, V60, P401; GOBNER JA, 2002, PHYS MED REHABIL, V82, P571; GROLEAU GA, 1993, J TRAUMA, V34, P366, DOI 10.1097/00005373-199303000-00010; HAHN YS, 1983, CHILD BRAIN, V10, P229; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hartzell KN, 1996, OPHTHALMOLOGY, V103, P953, DOI 10.1016/S0161-6420(96)30580-0; *J HOPK U, 1993, INJ SEV SCOR ICDM SC; KANE T, 1991, J SPINAL DISORD, V4, P306, DOI 10.1097/00002517-199109000-00007; KHELLA L, 1977, AM J PHYS MED REHAB, V56, P21; KRIEGER MD, 1995, NEUROSURG CLIN N AM, V6, P605; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX M, 1993, HLTH AFF, V12, P171; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P102, DOI 10.1097/00002060-199903000-00002; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Nobunaga AI, 1999, ARCH PHYS MED REHAB, V80, P1372, DOI 10.1016/S0003-9993(99)90247-2; Ochs HA, 1996, J AM DENT ASSOC, V127, P757, DOI 10.14219/jada.archive.1996.0311; ROSENBERG ML, 1991, VIOLENCE AM PUBL HLT; SHEPHERD JP, 1990, J ROY SOC MED, V83, P75, DOI 10.1177/014107689008300206; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; *SPSS INC, 1999, SPSS WIND VERS 10 0; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; *US DEP HHS, 1989, INT CLASS DIS; WATERS RL, 1992, PARAPLEGIA, V267, P14; WHITENECK G, 2002, COLORADO TRAUMATIC B; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1990, NEUROBEHAVIORAL SEQU; World Health Organization, 2001, INT CLASS FUNCT DIS; Zafonte R, 1993, J AM PARAPLEGIA SOC, V16, P94; Zafonte RD, 1997, BRAIN INJURY, V11, P403; Zafonte RD, 2001, ARCH PHYS MED REHAB, V82, P306, DOI 10.1053/apmr.2001.18226; ZAFONTE RD, 1999, TOP SPINAL CORD INJ, V93, P36	48	34	38	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1045	1053		10.1097/01.TA.0000044353.69681.96			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	758TL	WOS:000187666200008	14676649				2021-06-18	
J	Grossman, R; Shohami, E; Alexandrovich, A; Yatsiv, I; Kloog, Y; Biegon, A				Grossman, R; Shohami, E; Alexandrovich, A; Yatsiv, I; Kloog, Y; Biegon, A			Increase in peripheral benzodiazepine receptors and loss of glutamate NMDA receptors in a mouse model of closed head injury: a quantitative autoradiographic study	NEUROIMAGE			English	Article							TRANS-FARNESYLTHIOSALICYLIC ACID; TRAUMATIC BRAIN-INJURY; BINDING-SITES; RAT-BRAIN; NITRIC-OXIDE; IN-VIVO; MICROGLIAL ACTIVATION; CULTURED ASTROCYTES; INCREASED DENSITIES; MULTIPLE-SCLEROSIS	Increases in peripheral type benzodiazepine receptors (PTBR) have been utilized for the detection of neuroinflammation and neurotoxicity in the brain. We have investigated the relationship between PTBR and NMDA receptor binding density in mice with closed head injury (CHI) using quantitative autoradiography. CHI was induced by a weight drop in nine mice, four of which received a single injection of the rat sarcoma (Ras) inhibitor famesyl thiosalicylate (FTS) 1 h after the insult. Sham controls received anesthesia but no contusion. The neurological status of the mice was evaluated at 1 h, and hence up to 7 days using a neurological severity score (NSS). Animals were killed 7 days after CHI and consecutive brain sections were incubated with [H-3]PK11195, a PTBR antagonist, or [H-3]MK801, an n-methyl-d-aspartate receptor (NMDAR) use-dependent antagonist. CHI produced large (two- to threefold), widespread increases in PK11195 binding in the traumatized hemisphere and a significant decrease (20%-40%) in NMDAR binding limited to regions at close proximity to the lesion. Histologically, these regions were characterized by glial proliferation and neuronal loss. Significant increases in PTBR binding, but no concomitant decrease in NMDAR, were identified in several regions remote from the lesion, including the contralateral ventrolateral striatum and the ipsilateral ventral thalamus. Drug treatment significantly improved the neurological deficits but had only a marginal effect on PTBR. These results support a complex role for glial activation and PTBR increases in the context of CHI. (C) 2003 Elsevier Inc. All rights reserved.	Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Funct Imaging, Berkeley, CA 94720 USA; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hadassah Med Ctr, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Dept Neurobiochem, IL-69978 Tel Aviv, Israel	Biegon, A (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Dept Funct Imaging, 1 Cyclotron Rd, Berkeley, CA 94720 USA.	abiegon@lbl.gov					Bal-Price A, 2001, J NEUROSCI, V21, P6480; Banati RB, 1999, NEUROLOGY, V53, P2199, DOI 10.1212/WNL.53.9.2199; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Banati RB, 1997, J NEUROCYTOL, V26, P77, DOI 10.1023/A:1018567510105; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; BARON JC, 1991, CEREBROVASC DIS, V1, P22, DOI 10.1159/000108877; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bhat NR, 1998, J NEUROSCI, V18, P1633; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; BOWERY NG, 1988, BRIT J PHARMACOL, V93, P944, DOI 10.1111/j.1476-5381.1988.tb11484.x; Cagnin A, 2001, LANCET, V358, P461, DOI 10.1016/S0140-6736(01)05625-2; Castellano C, 2001, CURR DRUG TARGETS, V2, P273, DOI 10.2174/1389450013348515; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; DOBKIN JA, 1989, ARCH NEUROL-CHICAGO, V46, P1333, DOI 10.1001/archneur.1989.00520480077023; DUBOIS A, 1988, BRAIN RES, V445, P77, DOI 10.1016/0006-8993(88)91076-1; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; Friedman LK, 2001, MOL BRAIN RES, V86, P34, DOI 10.1016/S0169-328X(00)00252-7; Gagliardi RJ, 2000, ARQ NEURO-PSIQUIAT, V58, P583, DOI 10.1590/S0004-282X2000000300030; Gavish M, 1997, CLIN NEUROPHARMACOL, V20, P473, DOI 10.1097/00002826-199712000-00001; Gibbs AR, 2002, J LABELLED COMPD RAD, V45, P395, DOI 10.1002/jlcr.561; Giraldez L, 1998, NEUROCHEM RES, V23, P1327, DOI 10.1023/A:1020708603495; GIULIAN D, 1993, J NEUROSCI, V13, P29; GUILARTE TR, 1995, NEUROTOXICOLOGY, V16, P441; Hu SX, 1996, CLIN IMMUNOL IMMUNOP, V78, P93, DOI 10.1006/clin.1996.0015; ITZHAK Y, 1993, GLIA, V9, P211, DOI 10.1002/glia.440090306; Karussis D, 2001, J NEUROIMMUNOL, V120, P1; Krueger KE, 1995, BBA-REV BIOMEMBRANES, V1241, P453, DOI 10.1016/0304-4157(95)00016-X; LAGREZE HL, 1987, STROKE, V18, P882, DOI 10.1161/01.STR.18.5.882; LAVOIE J, 1990, HEPATOLOGY, V11, P874, DOI 10.1002/hep.1840110524; LEONG DK, 1994, J CEREBR BLOOD F MET, V14, P100, DOI 10.1038/jcbfm.1994.14; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Lipton SA, 1998, PROG BRAIN RES, V118, P73; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Miyazawa N, 1995, ACTA NEUROCHIR, V137, P207, DOI 10.1007/BF02187195; MYERS R, 1991, NEUROSCI LETT, V133, P20, DOI 10.1016/0304-3940(91)90047-W; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Papadopoulos V, 1998, P SOC EXP BIOL MED, V217, P130; Pappata S, 2000, NEUROLOGY, V55, P1052, DOI 10.1212/WNL.55.7.1052; PAXINOS G, MOUSE BRAIN STEROTOX; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Rao VLR, 2000, EXP NEUROL, V161, P102, DOI 10.1006/exnr.1999.7269; Shohami E, 2003, J CEREBR BLOOD F MET, V23, P728, DOI 10.1097/01.WCB.0000067704.86573.83; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STEPHENSON DT, 1995, J NEUROSCI, V15, P5263; Von Monakow C, 1895, ARCH PSYCHIAT NERVEN, V27, P1; VONMONAKOW C, 1914, LOKALISATION GROSSHI, P26; Vowinckel E, 1997, J NEUROSCI RES, V50, P345, DOI 10.1002/(SICI)1097-4547(19971015)50:2<345::AID-JNR22>3.0.CO;2-5; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Willard LB, 2000, EXP BRAIN RES, V134, P58, DOI 10.1007/s002210000446; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69	59	34	35	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	DEC	2003	20	4					1971	1981		10.1016/j.neuroimage.2003.06.003			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	756CM	WOS:000187448300008	14683703				2021-06-18	
J	Mather, FJ; Tate, RL; Hannan, TJ				Mather, FJ; Tate, RL; Hannan, TJ			Post-traumatic stress disorder in children following road traffic accidents: a comparison of those with and without mild traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; CONSEQUENCES	Background: It is now recognized that post-traumatic stress disorder ( PTSD) can occur following road traffic accidents, but controversy exists about the possibility of PTSD in people sustaining traumatic brain injury (TBI). The present investigation examined the frequency, course and comorbidity of PTSD in children with and without mild TBI after traffic accidents. Method: Interviews were conducted with 43 children and their parents 6 weeks after a traffic accident, assessing PTSD and associated symptomatology. Fourteen children sustained mild TBI and 29 had no TBI. A sub-set (n = 32) was re-interviewed 7 weeks later. Results: Children both with and without TBI reported PTSD symptomatology, but no significant group differences were found. At initial assessment, 74% of children were classified as having clinically significant PTSD symptomatology (86% and 69% in groups with and without TBI, respectively), which was strongly associated with report of general anxiety. At follow-up, PTSD symptomatology decreased, but 44% remained symptomatic (38% and 46% for those with and without TBI, respectively). Child and parental report of PTSD symptomatology were not significantly correlated. Conclusions: Presence of mild TBI did not influence the likelihood of experiencing PTSD symptomatology following a traffic accident. Given that PTSD symptomatology is a common consequence of traffic accidents in children, there is a clear need for provision of systematic assessment and, where appropriate, the implementation of intervention strategies to treat children.	Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia; Univ Sydney, Dept Med, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia; New Childrens Hosp, Dept Rehabil, Sydney, NSW, Australia	Tate, RL (corresponding author), Univ Sydney, Royal Rehabil Ctr, Rehabil Studies Unit, Dept Med, POB 6, Ryde, NSW 1680, Australia.	rtate@med.usyd.edu.au					Achenbach TM., 1991, INTEGRATIVE GUIDE 19; Albano AM, 1996, ANXIETY DISORDERS IN; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Boake C, 1996, J HEAD TRAUMA REHAB, V11, P98; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Cohen JA, 1998, J AM ACAD CHILD PSY, V37, p4S, DOI 10.1097/00004583-199810001-00002; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; FOA EB, 1995, CURR DIR PSYCHOL SCI, V4, P61, DOI 10.1111/1467-8721.ep10771786; FREDERICK C, 1992, CHILDHOOD PTS REACTI; HANDFORD HA, 1986, J AM ACAD CHILD PSY, V25, P409, DOI 10.1016/S0002-7138(09)60264-8; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Kovacs M., 1977, DEPRESSION CHILDHOOD, P1; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCGRATH B, 1997, THESIS U SYDNEY; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 2001, BRAIN INJURY, V15, P39, DOI 10.1080/02699050150209110; McNally R. J., 1991, PSYCHOL ASSESSMENT, V3, P531, DOI [DOI 10.1037/1040-3590.3.4.531, 10.1037/1040-3590.3.4.531]; Mirza KAH, 1998, BRIT J PSYCHIAT, V172, P443, DOI 10.1192/bjp.172.5.443; NADER KO, 1996, ASSESSING PSYCHOL TR, P291; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Pfefferbaum B, 1997, J AM ACAD CHILD PSY, V36, P1503, DOI 10.1016/S0890-8567(09)66558-8; Pfefferbaum B, 1998, CHILD ADOL PSYCH CL, V7, P183, DOI 10.1016/S1056-4993(18)30267-0; REYNOLDS CR, 1978, J ABNORM CHILD PSYCH, V6, P271, DOI 10.1007/BF00919131; SACK WH, 1986, J AM ACAD CHILD PSY, V25, P377, DOI 10.1016/S0002-7138(09)60260-0; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Stallard P, 1998, BRIT MED J, V317, P1619, DOI 10.1136/bmj.317.7173.1619; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; TEASDALE G, 1974, LANCET, V2, P81; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334	32	34	34	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2003	17	12					1077	1087		10.1080/0269905031000114045			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	731WR	WOS:000185909900006	14555366				2021-06-18	
J	Porter, MD				Porter, MD			A 9-year controlled prospective neuropsychologic assessment of amateur boxing	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						amateur boxing; prospective; neuropsychology; chronic traumatic encephalopathy	SPINAL-CORD INJURIES; CHRONIC BRAIN-DAMAGE; MINOR HEAD-INJURY; PROFESSIONAL BOXERS; FOOTBALLERS	Objective: To test the hypothesis that there is an association between amateur boxing and chronic traumatic encephalopathy using neuropsychologic assessments. Design: A prospective, controlled, blinded, observational, neuropsychologic study. Setting: Amateur boxing clubs in Dublin, Ireland, March 1992 to April 2001. Participants: Twenty randomly selected, actively competing, male amateur boxers and 20 age-matched, socioeconomic controls. Interventions: The boxers participated in amateur competition and sparring. Main Outcome Measures: Raw scores and changes in scores over time were recorded in the following neuropsychologic tests: Trail Making Tests A and B, Digit Symbol, Finger Tapping (dominant and nondominant hands), modified versions of the Finger Tapping Tests, Paired-Associate Learning, Digit Span, Re-Osterrieth Complex Figure Tests A and B, and Serial Addition. Raw scores and changes in scores for the two groups were compared, and a regression analysis was performed to detect any association between these values and exposure to boxing. Results: The boxers showed superior performance in the Trail Making Tests A and B at all time points and an inferior performance in both standard Finger Tapping Tests at all time points except baseline for the dominant hand. This inferior performance was not found in the modified versions of the tests. The controls showed significant deterioration in their performance in the Rey-Osterrieth Complex Figure Tests A and B. Conclusions: In this small controlled, prospective study of competitive amateur boxers, there was no evidence of neuropsychologic deterioration over 9 years. The amateur boxers demonstrated relative preservation and/or improvement of some neuropsychologic skills relative to the socioeconomic controls.	Sports Med Ctr, Oconnor, ACT 2602, Australia	Porter, MD (corresponding author), Sports Med Ctr, 190 Dryandra St, Oconnor, ACT 2602, Australia.						Boden BP, 2001, AM J SPORT MED, V29, P50, DOI 10.1177/03635465010290011301; BRAND D, 1998, AUSTR MED ASS   1008; BRENNAN TNN, 1968, BRIT J IND MED, V25, P326; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUSSE EW, 1952, JAMA-J AM MED ASSOC, V149, P1522, DOI 10.1001/jama.1952.02930340006003; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; Caulfield TA, 1999, GENET TEST, V3, P107, DOI 10.1089/gte.1999.3.107; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; *COUNC SCI AFF, 1983, JAMA-J AM MED ASSOC, V249, P254; Cripps R, 1998, AUSTR INJURY PREVENT, V18, P1; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; CRUIKSHANK JK, 1980, LANCET, V1, P626; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; ESTWANIK J J, 1984, Physician and Sportsmedicine, V12, P123; GEFFEN S, 1999, J SCI MED SPORT S, V2, P7; GONZALES TA, 1951, JAMA-J AM MED ASSOC, V46, P1506; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; HEILBRONNER RL, 1991, AM J SPORT MED, V19, P376, DOI 10.1177/036354659101900409; INGLIS J, 1959, BRAIN, P440; JOHNSON J, 1969, BRIT J PSYCHIAT, V115, P45, DOI 10.1192/bjp.115.518.45; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; KAPLAN HA, 1954, JAMA-J AM MED ASSOC, V156, P1138, DOI 10.1001/jama.1954.02950120012004; KASTE M, 1982, LANCET, V2, P1186; LAMPERT PW, 1984, JAMA-J AM MED ASSOC, V251, P2676, DOI 10.1001/jama.251.20.2676; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V67, P657, DOI 10.3171/jns.1987.67.5.0657; Lewis RF., 1979, MANUAL REPEATABLE CO; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MAWDSLEY C, 1963, LANCET, V2, P795; McCrory PR, 2000, MED J AUSTRALIA, V172, P217, DOI 10.5694/j.1326-5377.2000.tb123912.x; McCunny RJ, 1984, PHYSICIAN SPORTSMED, V12, P53; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; *NAT SAF COUNC, 1980, SPORTING NEWS   0801, P8; NEUBUERGER KT, 1959, ARCH NEURO PSYCHIATR, V81, P403, DOI 10.1001/archneurpsyc.1959.02340160001001; PARKINSON D, 1987, CLIN NEUROSURG, V20, P131; Porter MD, 1996, CLIN J SPORT MED, V6, P90, DOI 10.1097/00042752-199604000-00005; REFSHAUGE JGH, 1996, MED J AUSTRALIA, V1, P611; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Ross J, 2000, HAEMOPHILIA, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Rotem TR, 1998, MED J AUSTRALIA, V168, P379, DOI 10.5694/j.1326-5377.1998.tb138989.x; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; Ryan AJ, 1998, CLIN SPORT MED, V17, P155, DOI 10.1016/S0278-5919(05)70070-3; SCHIRRING L, 2001, PHYSICIAN SPORTSMED, V29, P11; SERCL M, 1962, WORLD NEUROL, V3, P350; Sironi V A, 1982, J Neurosurg Sci, V26, P165; SPILLANE J D, 1962, Br Med J, V2, P1205; Spreen O., 1991, COMPENDIUM NEUROPSYC; STEWART WF, 1994, AM J EPIDEMIOL, V139, P573, DOI 10.1093/oxfordjournals.aje.a117047; TAYLOR TKF, 1987, MED J AUSTRALIA, V147, P112, DOI 10.5694/j.1326-5377.1987.tb133298.x; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; Wechsler D., 1971, MANUAL WECHSLER ADUL; 1976, LANCET, V1, P401	58	34	35	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2003	13	6					339	352		10.1097/00042752-200311000-00002			14	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	746JL	WOS:000186743200002	14608222				2021-06-18	
J	Wu, KLH; Chan, SHH; Chao, YM; Chan, JYH				Wu, KLH; Chan, SHH; Chao, YM; Chan, JYH			Expression of pro-inflammatory cytokine and caspase genes promotes neuronal apoptosis in pontine reticular formation after spinal cord transection	NEUROBIOLOGY OF DISEASE			English	Article						apoptosis; proinflammatory genes; cytokines; caspases; pontine reticular formation; spinal cord injury	INTERLEUKIN-1-BETA CONVERTING-ENZYME; NUCLEUS-TRACTUS-SOLITARII; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA; POLY(ADP-RIBOSE) POLYMERASE; IL-1-BETA-CONVERTING ENZYME; ICE/CED-3 PROTEASE; TRAUMATIC INJURY; MICE DEFICIENT	We identified apoptotic neurons in pontine reticular formation (PRF), the origin of pontine reticulospinal fibers, in adult Sprague-Dawley rats after complete spinal cord transection (SCT) at T8 level. SCT also increased the expression in PRF of tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1beta, IL-6, caspase-1, or caspase-3 mRNA. This was followed by an augmented expression of activated caspase-3 protein, an increase in caspase-3 activity, and expression of a cleaved fragment of poly(ADP-ribose) polymerase (PARP), a proteolytic substrate of the activated caspase-3. Microinjection bilaterally into the PRF of an antiserum against TNF-a attenuated the expression of IL-6 mRNA and up-regulation of caspase-3 mRNA, and a caspase-3 inhibitor, DEVD-CHO, suppressed the augmentation in activated caspase-3 or cleaved PARP expression after SCT. Both treatments also reduced the number of SCT-induced apoptotic PRF neurons. We conclude that PRF neurons in adult mammalian brain may actively degrade themselves after SCT through apoptosis, via signaling processes that involve activation of proinflammatory cytokine genes and the intracellular caspase-3 pathway. (C) 2003 Elsevier Science (USA). All rights reserved.	Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan; Natl Sun Yat Sen Univ, Ctr Neurosci, Kaohsiung 804, Taiwan	Chan, JYH (corresponding author), Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 813, Taiwan.		Chan, Julie/X-5253-2019				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Armstrong RC, 1997, J NEUROSCI, V17, P553; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Binder C, 1999, ANTICANCER RES, V19, P1715; Chan JYH, 2000, NEUROSCIENCE, V95, P155; Chen J, 1998, J NEUROSCI, V18, P4914; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Friesen VJ, 1996, IEEE NETWORK, V10, P10, DOI 10.1109/65.539856; Geloso MC, 2002, EXP NEUROL, V175, P152, DOI 10.1006/exnr.2002.7866; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Juan TSC, 1996, ONCOGENE, V13, P749; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KEANE KM, 1995, CYTOKINE, V7, P105, DOI 10.1006/cyto.1995.1014; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MAJNO G, 1995, AM J PATHOL, V146, P3; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; Park IC, 2000, INT J ONCOL, V16, P1243; Patel T, 1996, FASEB J, V10, P587; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; PEITSCH MC, 1993, EMBO J, V12, P371, DOI 10.1002/j.1460-2075.1993.tb05666.x; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rathmell JC, 1999, ANNU REV IMMUNOL, V17, P781, DOI 10.1146/annurev.immunol.17.1.781; ROBBINS A, 1992, EXP BRAIN RES, V92, P46; Ruemmele FM, 1999, BIOCHEM BIOPH RES CO, V260, P159, DOI 10.1006/bbrc.1999.0734; Samali A, 1999, EMBO J, V18, P2040, DOI 10.1093/emboj/18.8.2040; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, P16; SAWADA M, 1992, BRAIN RES, V583, P296, DOI 10.1016/S0006-8993(10)80037-X; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; Takahashi K, 1999, J COMP NEUROL, V404, P159, DOI 10.1002/(SICI)1096-9861(19990208)404:2<159::AID-CNE2>3.0.CO;2-E; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TETZLAFF W, 1994, PROG BRAIN RES, V103, P271; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Wang CX, 1997, BRAIN RES, V759, P190, DOI 10.1016/S0006-8993(97)00254-0; Wang CX, 1996, J NEUROIMMUNOL, V69, P151; Wang LL, 2001, NEUROSCIENCE, V103, P143, DOI 10.1016/S0306-4522(00)00543-1; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739	58	34	39	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961			NEUROBIOL DIS	Neurobiol. Dis.	OCT	2003	14	1					19	31		10.1016/S0969-9961(03)00078-0			13	Neurosciences	Neurosciences & Neurology	723NP	WOS:000185438700003	13678663				2021-06-18	
J	Feeney, CJ; Pennefather, PS; Gyulkhandanyan, AV				Feeney, CJ; Pennefather, PS; Gyulkhandanyan, AV			A cuvette-based fluorometric analysis of mitochondrial membrane potential measured in cultured astrocyte monolayers	JOURNAL OF NEUROSCIENCE METHODS			English	Article						astrocyte; mitochondrial membrane potential (Delta psi(M)); plasma membrane potential; potentiometric fluorescent dyes JC-1, Rh123, TMRM; protonophore FCCP; azide; hydrogen peroxide	DEPOLARIZATION; NEURONS; INJURY; CELLS	Mitochondrial membrane potential (Deltapsi(M)) plays a key role in coordinating mitochondrial function and cell biology in general. In astrocytes, Deltapsi(M) is an important indicator of the health of these brain cells and their response to traumatic and hypoxic injury. We have shown previously how fluorescent signals can be measured from cells attached to a coverslip in a standard cuvette with a fluorometer and modulated using a cuvette perfusion system (Pflugers Arch-Eur. J. Physiol. 421 (1992) 400). Here we report on how this method can be employed to characterize the actions of a number of potentiometric fluorescent cationic dyes, including JC-1, Rh123 and TMRM, for their ability to monitor Deltapsi(M) in primary cultures of intact astrocytes. All dyes detected the reversible depolarization produced by brief exposure to the mitochondrial uncoupler protonophore FCCP, which short circuits and dissipates Deltapsi(M). Qualitatively similar responses were measured after treatment with either azide, an inhibitor of complex IV in the mitochondrial respiratory chain, or the oxidant H2O2, Cell depolarization with high potassium modified the responses to FCCP. The time courses of these responses differed in a manner dependent on the particular dye used and in a way that correlated with expected permeation rate. The merits and pitfalls of these different potentiometric dyes for monitoring Deltapsi(M) are discussed. (C) 2003 Elsevier Science B.V. All rights reserved.	Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Fac Pharm, Dept Pharmaceut Sci, Toronto, ON M5S 2S2, Canada	Pennefather, PS (corresponding author), Univ Toronto, Inst Med Sci, 100 Coll St, Toronto, ON M5S 1A8, Canada.	p.pennefather@utoronto.ca					BUNTING JR, 1992, BIOPHYS CHEM, V42, P163, DOI 10.1016/0301-4622(92)85006-P; Chinopoulos C, 1999, J NEUROCHEM, V73, P220, DOI 10.1046/j.1471-4159.1999.0730220.x; EHRENBERG B, 1988, BIOPHYS J, V53, P785, DOI 10.1016/S0006-3495(88)83158-8; Fontaine E, 1999, J BIOENERG BIOMEMBR, V31, P335, DOI 10.1023/A:1005475802350; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; LLORIS J, 1998, P NATL ACAD SCI USA, V95, P6803; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Petit PX, 1997, MOL CELL BIOCHEM, V174, P185, DOI 10.1023/A:1006848205880; Reers M, 1995, METHOD ENZYMOL, V260, P406, DOI 10.1016/0076-6879(95)60154-6; REERS M, 1991, BIOCHEMISTRY-US, V30, P4480, DOI 10.1021/bi00232a015; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0; Scanlon JM, 1998, J NEUROCHEM, V71, P2392; SCHLICHTER LC, 1992, PFLUG ARCH EUR J PHY, V421, P400, DOI 10.1007/BF00374232; Toescu EC, 2000, PFLUG ARCH EUR J PHY, V440, P941, DOI 10.1007/s004240000390; Ward MW, 2000, J NEUROSCI, V20, P7208; White RJ, 1996, J NEUROSCI, V16, P5688; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	23	34	34	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAY 30	2003	125	1-2					13	25		10.1016/S0165-0270(03)00027-X			13	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	687EJ	WOS:000183362900003	12763226				2021-06-18	
J	Kushimoto, S; Shibata, Y; Yamamoto, Y				Kushimoto, S; Shibata, Y; Yamamoto, Y			Implications of fibrinogenolysis in patients with closed head injury	JOURNAL OF NEUROTRAUMA			English	Article						alpha(2)-plasmin inhibitor; fibrinogenolysis; fibrinolysis; head injury; intravascular coagulation; plasmin	DISSEMINATED INTRAVASCULAR COAGULATION; ALPHA-2-PLASMIN INHIBITOR DEFICIENCY; FIBRIN DEGRADATION PRODUCTS; ENZYME-IMMUNOASSAY; BRAIN INJURY; SYSTEMIC FIBRINOGENOLYSIS; ALPHA2-PLASMIN INHIBITOR; MONOCLONAL-ANTIBODY; PLASMA; ABNORMALITIES	The objective of this study was to determine the clinical significance of fibrinogenolysis in patients with isolated closed head injury. We correlated indices of fibrinolytic activity, fibrinogen degradation products (FgDP), and fibrin degradation products (FbDP) with outcome in order to accomplish this. This study consisted of 40 patients with isolated closed head trauma in whom blood sampling could be initiated within 3 h after injury. Patients were divided into two groups according to Glasgow Outcome Scale status at 3 months after injury, characterized as good recovery or moderate disability (group 1, n = 21); and severe disability, vegetative, or death (group 2, n = 19). The plasma fibrinogen concentration correlated with the Glasgow Coma Scale score on admission (r(2) = 0.201, p < 0.01), and plasma fibrinogen concentrations in group 2 were lower than in group 1 (p < 0.05). Plasma concentrations of fibrin/fibrinogen degradation products (FDP) and plasmin-alpha(2)-plasmin inhibitor complex (PIC), molecular markers of activation of fibrinolysis, were higher in group 2 than in group 1 (p < 0.001), and both FgDP and FbDP concentrations in group 2 also were higher than in group 1 (p < 0.001). Both the FgDP and FbDP concentrations correlated with the PIC concentration. Moreover, the plasma FgDP concentrations correlated inversely with alpha(2)-plasmin inhibitor activity, a potent inhibitor of the fibrinolytic system, as did the FbDP concentration. This study reveals that both fibrinolysis and fibrinogenolysis are involved in the coagulopathy that develops during the acute phase of head injury and correlate with fibrinolytic activity. Decreased activity of alpha(2)-plasmin inhibitor may contribute to fibrinogenolysis.	Nippon Med Coll, Dept Emergency & Crit Care Med, Bunkyo Ku, Tokyo 1138603, Japan	Kushimoto, S (corresponding author), Nippon Med Coll, Dept Emergency & Crit Care Med, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.						AOKI N, 1984, SEMIN THROMB HEMOST, V10, P24, DOI 10.1055/s-2007-1004405; ASTRUP T, 1965, THROMB DIATH HAEMOST, V14, P401; BLANKENSTEIJN JD, 1992, TRANSPLANT INT, V5, P43, DOI 10.1007/BF00337189; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; CRONE KR, 1987, NEUROSURGERY, V21, P532, DOI 10.1227/00006123-198710000-00015; FRADE LJG, 1992, ACTA HAEMATOL-BASEL, V88, P7; FRANCIS CW, 1994, HEMOSTASIS THROMBOSI, P1076; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; HANTGAN RR, 1994, HEMOSTASIS THROMBOSI, P277; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; ISOGAI N, 1993, JPN J CLIN PATHOL, V41, P1349; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KEIMOWITZ RM, 1973, J NEUROSURG, V39, P178, DOI 10.3171/jns.1973.39.2.0178; KOOPMAN J, 1987, J LAB CLIN MED, V109, P75; KOPPERT PW, 1988, THROMB HAEMOSTASIS, V59, P310; KOPPERT PW, 1987, THROMB HAEMOSTASIS, V57, P25; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; KUSHIMOTO S, 2001, J JPN BIOMED FORUM, V11, P19; MARDER VJ, 1990, HEMATOLOGY, P1522; MAZZI G, 1994, HAEMATOLOGICA, V79, P283; MIMURO J, 1987, BLOOD, V69, P446; MOROI M, 1977, THROMB RES, V10, P851, DOI 10.1016/0049-3848(77)90142-6; OKAJIMA K, 1992, THROMB RES, V66, P717, DOI 10.1016/0049-3848(92)90047-E; OKAJIMA K, 1994, AM J HEMATOL, V45, P16, DOI 10.1002/ajh.2830450104; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; SAKATA Y, 1980, J CLIN INVEST, V65, P290, DOI 10.1172/JCI109671; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; SCHWARTZ BS, 1986, ANN INTERN MED, V105, P873, DOI 10.7326/0003-4819-105-6-873; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; TAKAHASHI H, 1990, THROMB HAEMOSTASIS, V63, P340; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1978, J NEUROSURG, V49, P357, DOI 10.3171/jns.1978.49.3.0357; von Sommoggy S, 1991, Eur J Vasc Surg, V5, P247	35	34	37	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					357	363		10.1089/089771503765172318			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900005	12866815				2021-06-18	
J	Johnstone, B; Price, T; Bounds, T; Schopp, LH; Schootman, M; Schumate, D				Johnstone, B; Price, T; Bounds, T; Schopp, LH; Schootman, M; Schumate, D			Rural/urban differences in vocational outcomes for state vocational rehabilitation clients with TBI	NEUROREHABILITATION			English	Article						traumatic brain injury; vocational rehabilitation; rural		Objective: To evaluate differences in demographics, injury severity, and vocational outcomes for persons with TBI based on rural vs. urban residency. Participants: 78 individuals with TBI (28 from rural counties, 50 from urban counties) who requested services from the Missouri Division of Vocational Rehabilitation (VR) over a two year period. Measures: Demographics (i.e., age, race, education), injury severity (i.e., loss of consciousness, post traumatic amnesia, length of hospitalization, neuropsychological test scores), VR services provided (e.g., transportation, maintenance, on-the-job training, etc.), and VR outcomes (successfully vs. unsuccessfully employed; cost per case). Procedure: All participants completed a standard neuropsychological evaluation and completed VR services (i.e., were followed from enrollment to case closure). Rural and urban residency was determined using U.S Office of Management and Budget definitions of metropolitan and non-metropolitan areas. Analyses: Chi-squares, Fisher's Exact tests, Wilcoxon Rank Sums test, and MANOVAs. Results: Few if any differences were found between the groups in demographics (i.e., more African Americans in urban areas), injury severity (i.e., more rural residents with multiple TBIs), or neuropsychological test scores. However, individuals from urban areas received significantly more maintenance funds (46% vs. 21 %), transportation services (36% vs. 11%), and on-the-job training (28% vs. 7%), and had more spent on them ($1,816 vs $1,242). Although statistically non-significant (p < 0.15), 24% of individuals from urban areas were successfully employed at VR case closure, compared to only 7% of individuals from rural areas. Conclusions: Individuals with TBI from rural and urban settings have generally similar demographic, injury severity, and neuropsychological abilities, although they appear to differ in terms of vocational outcomes and number of VR services received, possibly related to limited availability of resources in rural areas.	Univ Missouri, Columbia, MO USA; Inst Rehabil, Kansas City, MO USA; Washington Univ, St Louis, MO USA; Div Vocat Rehabil, Columbia, MO USA	Johnstone, B (corresponding author), Dept Hlth Psychol, DC046-46, Columbia, MO 65212 USA.	john-stoneg@health.missouri.edu	Schootman, Mario/AAF-3941-2019	Schootman, Mario/0000-0003-1162-8824; Johnstone, Brick/0000-0001-8845-9649			BOUNDS T, IN PRESS NEUROREHAB; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; DEFILIPPIS NA, 1991, MANUAL BOOKLET CATEG; GOODALL P, 1994, J HEAD TRAUMA REHAB, V9, P61; Halstead WC, 1985, HALSTEAD REITAN NEUR; HURT GD, 2000, NEUROPSYCHOLOGICAL M; INNES B, 2000, J DISABIL POLICY STU, V10, P207; Johnstone B, 2002, J RURAL HEALTH, V18, P109, DOI 10.1111/j.1748-0361.2002.tb00882.x; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; *KESSL MED REH RES, 2001, TRAUM BRAIN INJ FACT; KlOve H, 1963, MED CLIN N AM; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; PRICKEL D, 1989, COGNITIVE REHABILITA, V7, P22; Reitan R. M., 1992, TRAIL MAKING TEST MA; *RUR POL RES I, 1999, METR NONM COUNT DEF; Sample PL, 1998, BRAIN INJURY, V12, P855, DOI 10.1080/026990598122089; Schneider M J, 1986, Annu Rev Rehabil, V5, P217; Schootman M, 2000, BRAIN INJURY, V14, P373; Schootman M, 1999, BRAIN INJURY, V13, P995; Schootman M, 1998, BIOM HLTH R, V21, P73; SKEEL RL, IN PRESS REHAB PSYCH; *US BUR CENS, 2000, STAT COUNT QUICK FAC; *US BUR CENS, 1998, ANN TIM SER; WECHSLER D, 1997, WMS, V3; Wechsler D, 1997, WAIS, VIII; WOODCOCK RW, 1989, WOODCOCKJOHNSON TEST; HLTH US 2001 URBAN R	27	34	34	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2003	18	3					197	203					7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	733ZZ	WOS:000186031900003	14530584				2021-06-18	
J	Ravdin, LD; Barr, WB; Jordan, B; Lathan, WE; Relkin, NR				Ravdin, LD; Barr, WB; Jordan, B; Lathan, WE; Relkin, NR			Assessment of cognitive head recovery following sports related trauma in boxers	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sports related head injury; neuropsychology; baseline assessment; return-to-play decisions	PROFESSIONAL BOXERS; BRAIN INJURY; REACTION-TIME; WEIGHT-LOSS; PERFORMANCE; CONSISTENCY; CONCUSSION; WRESTLERS; PLAYERS; BATTERY	Objective: To prospectively examine recovery of cognitive function within one month following subconcussive sports related head trauma. Design: A prospective study of New York State licensed professional boxers,who underwent testing of cognitive functioning before and after (within days, one week, and one month) a professional bout. Setting: Male professional athletes recruited from the New York State Athletic Commission and local boxing gyms. Participants: Twenty-six licensed professional boxers were enrolled in the protocol. Data is presented on the 18 participants who completed testing on at least three of the four time points. Interventions: Serial neuropsychological assessment before and after the athletes engaged in competition. Main Outcome Measures: Neuropsychological measures of cognitive functioning, including new learning and memory, information processing speed, and mental flexibility. Results: A series of repeated. measures MANOVAS revealed significant within subject differences across testing on complex information processing and verbal fluency. Post hoc analyses indicated significant differences between time 1 (baseline) and time 4 (one month post), with scores one month following the bout indicating significantly improved performance. Memory scores did not change significantly across testing; however, prior boxing exposure measured by total number of professional bouts was associated with poorer memory performance. Conclusions: Cognitive testing one month following participation in a professional boxing bout yielded scores suggestive of recovery to a level above the baseline. We conclude that baseline assessment taken during periods of intense training are likely confounded by other pre-bout conditions (i.e., sparring, rapid weight loss, pre-bout anxiety) and do not represent true baseline abilities. Instability of performance associated with mild head injury may complicate the interpretation of post-injury assessments. Practice effects may also confound the interpretation of serial assessments, leading to underestimation of the effects of sports related head trauma. Poorer cognitive performance was evident during the presumed recovery period in boxers with greater exposure to the sport (>12 professional bouts). This finding is consistent with reports of a cumulative effect of repetitive head trauma and the subsequent development of chronic traumatic brain injury. These data have implications for assessing recovery of function following head injury in players of other contact sports as well as determination of return-to-play following an injury.	Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York Presbyterian Hosp, New York, NY 10021 USA; NYU, Sch Med, New York, NY USA; Burke Rehabil Hosp, New York, NY USA	Ravdin, LD (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York Presbyterian Hosp, 525 E 68 St,Suite F 610, New York, NY 10021 USA.			Barr, William/0000-0001-7711-7758	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR00047] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08-NS02016] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS002016] Funding Source: NIH RePORTER		ALVES W, 1991, ATHLETIC INJURIES HE, P28; Barth JT., 1989, MILD HEAD INJURY, P257; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CASSON IR, 1982, J NEUROL NEUROSUR PS, V45, P170, DOI 10.1136/jnnp.45.2.170; Choma CW, 1998, MED SCI SPORT EXER, V30, P746, DOI 10.1097/00005768-199805000-00016; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dicker G, 1993, Aust Fam Physician, V22, P750; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; DREW RH, 1986, J CLIN PSYCHOL, V42, P520, DOI 10.1002/1097-4679(198605)42:3<520::AID-JCLP2270420319>3.0.CO;2-6; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; Houston M E, 1981, Phys Sportsmed, V9, P73, DOI 10.1080/00913847.1981.11711208; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JORDAN B, 1997, JAMA-J AM MED ASSOC, V276, P136; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; KASTE M, 1982, LANCET, V2, P1186; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCaffrey RJ, 1995, NEUROPSYCHOL REV, V5, P203, DOI 10.1007/BF02214762; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; MITRUSHINA M, 1991, J CLIN PSYCHOL, V47, P790, DOI 10.1002/1097-4679(199111)47:6<790::AID-JCLP2270470610>3.0.CO;2-C; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; Segalowitz S J, 1997, J Int Neuropsychol Soc, V3, P95; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; WEBSTER S, 1990, MED SCI SPORT EXER, V22, P229; Wechsler D., 1987, WECHSLER MEMORY SCAL; YOUNGJOHN JR, 1992, CLIN NEUROPSYCHOL, V0006, P00276, DOI DOI 10.1080/13854049208404129	37	34	39	1	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2003	13	1					21	27		10.1097/00042752-200301000-00005			7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	639MG	WOS:000180632500005	12544160				2021-06-18	
J	Verbois, SL; Hopkins, DM; Scheff, SW; Pauly, JR				Verbois, SL; Hopkins, DM; Scheff, SW; Pauly, JR			Chronic intermittent nicotine administration attenuates traumatic brain injury-induced cognitive dysfunction	NEUROSCIENCE			English	Article						alpha 7(star) nicotinic receptor; neurotrauma; autoradiography; bungarotoxin; epibatidine; Morris water maze	MORRIS WATER MAZE; UP-REGULATION; BINDING-SITES; RECEPTOR SUBTYPES; RAT-BRAIN; HIPPOCAMPAL ALPHA-7; CONTINUOUS-INFUSION; CHRONIC EXPOSURE; HEAD-INJURY; AGED RATS	Traumatic brain injury (TBI) initiates immediate and secondary neuropathological cascades that can result in persistent neurological dysfunction. Previous studies from our laboratory have shown that experimental rat brain injury causes a rapid and persistent decrease in CNS alpha7* nicotinic cholinergic receptor (nAChr) expression. The purpose of this study was to investigate whether intermittent nicotine injections could improve cognitive performance in the Morris water maze (MWM) following experimental brain injury. Adult male rats were anesthetized and subjected to a 1.5 mm controlled cortical impact (CCI) injury of the somatosensory cortex. Animals received twice daily i.p. nicotine injections for 11 days prior to CCI, 11 days following CCI or during both pre- and post-surgical intervals. MWM training was initiated 12 days post-injury. In the training phase of cognitive testing, twice-daily nicotine treatment following injury attenuated trauma-induced deficits in the distance traveled to reach the escape platform. This group of animals also had improvements in several measures of the probe test, including time spent, distance traveled and total entries into the target quadrant. TBI caused significant deficits in alpha7* nAChr expression in several regions of the hippocampus and cerebral cortex, which were largely unaffected by intermittent nicotine treatment. However, nicotine treatment up-regulated [3H]-epibatidine binding to non-alpha7* nAChrs, attenuating TBI-induced deficits in receptor expression in several brain regions evaluated. These results suggest that nicotine is efficacious at attenuating CCl-induced cognitive deficits in a manner independent of changes in alpha7* nAChr expression, perhaps via up-regulation of non-alpha7* nAChrs. (C) 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA	Pauly, JR (corresponding author), Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS42196] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039828, R01NS042196] Funding Source: NIH RePORTER		ABDULLA FA, 1993, PSYCHOPHARMACOLOGY, V111, P508, DOI 10.1007/BF02253544; Abdulla FA, 1996, PSYCHOPHARMACOLOGY, V124, P323, DOI 10.1007/BF02247437; Attaway CM, 1999, PHYSIOL BEHAV, V67, P421, DOI 10.1016/S0031-9384(99)00081-5; BARRANTES GE, 1995, BRAIN RES, V672, P228, DOI 10.1016/0006-8993(94)01386-V; Brown RW, 2000, PHARMACOL BIOCHEM BE, V67, P473, DOI 10.1016/S0091-3057(00)00398-1; Buisson B, 2001, J NEUROSCI, V21, P1819, DOI 10.1523/JNEUROSCI.21-06-01819.2001; Collins AC, 1996, DRUG DEVELOP RES, V38, P231, DOI 10.1002/(SICI)1098-2299(199607/08)38:3/4<231::AID-DDR12>3.0.CO;2-1; D'Hooge R, 2001, BRAIN RES REV, V36, P60, DOI 10.1016/S0165-0173(01)00067-4; Dani JA, 2001, BIOL PSYCHIAT, V49, P166, DOI 10.1016/S0006-3223(00)01011-8; Decker MW, 1997, J PHARMACOL EXP THER, V283, P247; DECKER MW, 1994, EUR J PHARMACOL, V261, P217, DOI 10.1016/0014-2999(94)90323-9; Delbono O, 1997, J PHARMACOL EXP THER, V280, P428; Fenster CP, 1999, J NEUROSCI, V19, P4804; Flores CM, 1997, J NEUROCHEM, V69, P2216; Gerlai R, 2001, BEHAV BRAIN RES, V125, P269, DOI 10.1016/S0166-4328(01)00296-0; Granholm ACE, 2000, EXP NEUROL, V161, P647, DOI 10.1006/exnr.1999.7289; HODGES H, 1995, PSYCHOPHARMACOLOGY, V117, P318, DOI 10.1007/BF02246107; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kawai H, 2001, J NEUROCHEM, V78, P1367, DOI 10.1046/j.1471-4159.2001.00526.x; Ke L, 1998, J PHARMACOL EXP THER, V286, P825; Levin ED, 2002, NEUROSCIENCE, V109, P757, DOI 10.1016/S0306-4522(01)00538-3; LEVIN ED, 1992, BEHAV NEURAL BIOL, V58, P152, DOI 10.1016/0163-1047(92)90399-O; Levin ED, 2000, EUR J PHARMACOL, V393, P141, DOI 10.1016/S0014-2999(99)00885-7; Levin ED, 1998, PSYCHOPHARMACOLOGY, V140, P135, DOI 10.1007/s002130050750; MARKS MJ, 1987, PHARMACOL BIOCHEM BE, V27, P505, DOI 10.1016/0091-3057(87)90355-8; MARKS MJ, 1993, J PHARMACOL EXP THER, V266, P1268; MARKS MJ, 1992, J NEUROSCI, V12, P2765; McCallum SE, 2000, PSYCHOPHARMACOLOGY, V150, P1, DOI 10.1007/s002130000401; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; Meyer EM, 1997, BRAIN RES, V768, P49, DOI 10.1016/S0006-8993(97)00536-2; Molinari EJ, 1998, EUR J PHARMACOL, V347, P131, DOI 10.1016/S0014-2999(98)00084-3; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olale F, 1997, J PHARMACOL EXP THER, V283, P675; PAULY JR, 1991, J PHARMACOL EXP THER, V258, P1127; Pauly JR, 1996, J PHARMACOL EXP THER, V278, P361; Perry DC, 2002, J NEUROCHEM, V82, P468, DOI 10.1046/j.1471-4159.2002.00951.x; PERRY DC, 1995, J PHARMACOL EXP THER, V275, P1030; Perry EK, 2001, ALCOHOL, V24, P63, DOI 10.1016/S0741-8329(01)00130-6; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Riekkinen M, 1997, NEUROREPORT, V8, P699, DOI 10.1097/00001756-199702100-00024; Rusted JM, 2000, BEHAV BRAIN RES, V113, P121, DOI 10.1016/S0166-4328(00)00207-2; SANDERSON EM, 1993, BRAIN RES, V617, P349, DOI 10.1016/0006-8993(93)91104-Z; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Simosky JK, 2001, BIOL PSYCHIAT, V50, P493, DOI 10.1016/S0006-3223(01)01093-9; SOCCI DJ, 1995, NEUROBIOL AGING, V16, P857, DOI 10.1016/0197-4580(95)00091-R; Sparks JA, 1999, PSYCHOPHARMACOLOGY, V141, P145, DOI 10.1007/s002130050818; Taverni JP, 1998, BRAIN INJURY, V12, P77; Ulrich YM, 1997, NEUROPHARMACOLOGY, V36, P1119, DOI 10.1016/S0028-3908(97)00107-X; Verbois SL, 2000, J NEUROTRAUM, V17, P1001, DOI 10.1089/neu.2000.17.1001; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Verbois SL, 2003, NEUROPHARMACOLOGY, V44, P224, DOI 10.1016/S0028-3908(02)00366-0; WELZL H, 1988, PSYCHOPHARMACOLOGY, V96, P317, DOI 10.1007/BF00216057; Whiteaker P, 2002, J NEUROSCI, V22, P2522, DOI 10.1523/JNEUROSCI.22-07-02522.2002; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X	57	34	35	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2003	119	4					1199	1208		10.1016/S0306-4522(03)00206-9			10	Neurosciences	Neurosciences & Neurology	700HT	WOS:000184107100023	12831873				2021-06-18	
J	Hauber, RP; Jones, ML				Hauber, RP; Jones, ML			Telerehabilitation support for families at home caring for individuals in prolonged states of reduced consciousness	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						family caregiver; severe brain injury; telerehabilitation	TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; COMA DATA-BANK; VEGETATIVE STATE; NEEDS; IMPACT	Objective: To investigate the use of telerehabilitation to support families caring at home for individuals with prolonged states of reduced consciousness. Design: A comparison group approach. Participants: Participants were recruited from a special program that is part of a Model Systems brain injury program located in the Southeast. Five patients, ranging from Rancho I to Rancho 3 were discharged home with family members as the primary caregivers. Procedures: Participant families were followed for 4 to 8 weeks via videophone. Follow-up telephone surveys were conducted with a family member 6 to 9 months after discharge and compared with a similar group that had not received the videophone follow-up. Main Outcome Measures: Present living status, number of emergency room visits, number of hospitalizations, the caregivers' perceptions of functional status and care needs, readmission for rehabilitation and perceived family needs as measured by the Family Needs Questionnaire (FNQ). Results: More patients in the videoconferencing group were still living at home and had returned for rehabilitation. On the FNQ, families in the videophone group reported more of their needs met than families in the comparison group. Conclusions: The use of videoconferencing to bridge the transition to home for families caring for a family member at the Rancho I to Rancho 3 level may assist families in successfully caring for the individual in the home and reducing the number of perceived family needs.	Univ Tampa, Dept Nursing, Tampa, FL 33606 USA; Shepherd Ctr, Crawford Res Inst, Atlanta, GA USA	Hauber, RP (corresponding author), Shepherd Ctr, TeleRehabil Program, 2020 Peachtree Rd, Atlanta, GA 30309 USA.						ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; CHILDS NL, 1993, NEUROLOGY, V43, P1464; FIELD MJ, 1996, TELEMEDICINE GUIDE A; GIACINO JT, 1995, J HEAD TRAUMA REHAB, V10, P40; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; Hauber R P, 2000, J Neurosci Nurs, V32, P22; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; Jones ML, 1998, TOPICS SPINAL CORD I, V3, P61; KAUFMANN MA, 1992, RESUSCITATION, V23, P199, DOI 10.1016/0300-9572(92)90003-U; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer J. S., 1988, FAMILY NEEDS QUESTIO; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; Phillips VL, 2001, PUBLIC HEALTH REP, V116, P94, DOI 10.1093/phr/116.S1.94; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Vesmarovich S, 1999, Adv Wound Care, V12, P264; Walker WC, 1996, BRAIN INJURY, V10, P65	22	34	36	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2002	17	6					535	541		10.1097/00001199-200212000-00005			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	617NN	WOS:000179367900005	12802244				2021-06-18	
J	Williams, WH; Evans, JJ; Needham, P; Wilson, BA				Williams, WH; Evans, JJ; Needham, P; Wilson, BA			Neurological, cognitive and attributional predictors of posttraumatic stress symptoms after traumatic brain injury	JOURNAL OF TRAUMATIC STRESS			English	Article						PTSD; brain injury; predictors; insight and attributions	EVENT SCALE; DISORDER; IMPACT; MEMORY	We investigated the relationship between the reporting of symptoms of posttraumatic stress disorder (PTSD) in a community sample of 66 survivors of severe traumatic brain injury (TBI) and measures of injury severity, memory, insight, and index-event attributions. Correlational analyses revealed that reporting of PTSD symptoms was related to level of insight and not associated with the severity of survivors' injury, educational background, premorbid or current IQ, or memory impairment. The severity of PTSD symptoms was also associated with external attributions to others of causality for the event.	Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter EX4 4QG, Devon, England; Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, England; Cognit & Brain Sci Unit, Cambridge, England	Williams, WH (corresponding author), Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter EX4 4QG, Devon, England.			williams, huw/0000-0003-0670-2620			Baddeley A.D., 1992, SPEED CAPACITY LANGU; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; BREWIN CR, 1984, J SOC CLIN PSYCHOL, V2, P156, DOI DOI 10.1521/JSCP.1984.2.2.156; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cummings J. L., 1995, NEUROPSYCHIATRY BEHA; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; KING NS, 1997, J NEUROL NEUROSUR PS, V62, P8; KUSHER MG, 1992, BEHAV RES THER, V31, P105; Lishman WA, 1998, ORGANIC PSYCHIAT; Markowitsch HJ, 1998, NEUROCASE, V4, P429, DOI 10.1080/13554799808410636; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; Raven J.C., 1947, RAVENS PROGR MATRICE; RICHARDSON JTE, 1990, CLIN NEUROPSYCHOLOGI; Robertson I. H., 1994, TEST EVERYDAY ATTENT; Rothbaum B, 2000, J TRAUMA STRESS, V13, P558; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Warrington E., 1983, GRADED NAMING TEST; Williams WH, 1998, NEUROPSYCHOL REHABIL, V8, P43, DOI 10.1080/713755551; Wilson, 1991, NATL ADULT READING T; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1996, BEHAV ASSESSMENT DYS	26	34	34	0	6	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0894-9867			J TRAUMA STRESS	J. Trauma Stress	OCT	2002	15	5					397	400	UNSP 0894-9867/02/1000-0397/1	10.1023/A:1020185325026			4	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	593AK	WOS:000177968900007	12392227				2021-06-18	
J	Niess, C; Grauel, U; Toennes, SW; Bratzke, H				Niess, C; Grauel, U; Toennes, SW; Bratzke, H			Incidence of axonal injury in human brain tissue	ACTA NEUROPATHOLOGICA			English	Article						diffuse axonal injury; beta-amyloid precursor protein; drug intoxication; traumatic brain	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; NERVE-FIBERS; DAMAGE; NEUROPATHOLOGY; DIAGNOSIS; DISEASE; TRAUMA; MILD	Diffuse axonal injury (DAI) is considered to be the morphological correlate of traumatic brain injury as seen in acceleration/deceleration trauma and is believed to be the main cause for a poor clinical outcome in the absence of detectable intracranial lesions. To estimate the overall incidence of DAI, and since most changes are only seen microscopically to rule out whether there is a high number of undetected cases, 450 non-selected human brains were examined. Samples from two brain areas (pons and cerebrum) were immunostained for P-amyloidprecursor-protein (PAPP), and axonal damage was assessed microscopically. Axonal injury was detected in 12% of all cases, but only one third had a history of traumatic brain injury. The majority of the positive cases were associated with drug intoxication, chiefly due to opiates. PAPP staining was positive in both pons and cerebrum to a much higher extent in intoxication than in trauma cases; the latter showing axonal damage mainly in the pons area. This may reflect a more generalized pathomechanism in the intoxication group as compared to more biomechanical mechanisms in the trauma group. The findings also show that various causes may produce diffuse axonal injury and suggest that traumatic brain injury is not the only and probably not even the main cause of the observed neuropathological changes. A correlation between axonal damage and age-related processes could not be shown.	Goethe Univ Frankfurt, Zentrum Rechtsmed, D-60596 Frankfurt, Germany	Niess, C (corresponding author), Goethe Univ Frankfurt, Zentrum Rechtsmed, Kennedyallee 104, D-60596 Frankfurt, Germany.	niess@em.uni-frankfurt.de					Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GRAHAM DI, 1992, J CLIN PATHOL, V45, P840, DOI 10.1136/jcp.45.9.840; Imajo T, 1996, AM J FOREN MED PATH, V17, P324, DOI 10.1097/00000433-199612000-00010; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; OBREJA C, 2000, NEUROBIOL AGING, V2, P148; Oehmichen M, 1999, INT J LEGAL MED, V112, P261, DOI 10.1007/s004140050246; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Oehmichen M, 1996, ACTA NEUROPATHOL, V91, P642, DOI 10.1007/s004010050478; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Walter GF, 1999, CRIT REV NEUROSURG, V9, P367, DOI 10.1007/s003290050157	33	34	37	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUL	2002	104	1					79	84		10.1007/s00401-002-0525-9			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	569AP	WOS:000176577400012	12070668				2021-06-18	
J	Bergemalm, PO; Borg, E				Bergemalm, PO; Borg, E			Long-term objective and subjective audiologic consequences of closed head injury	ACTA OTO-LARYNGOLOGICA			English	Article						closed head injury; hearing loss; progressive hearing loss; quality of life	HEARING-LOSS	During a period of 5 years, a total of 47 patients, 16-60 years of age, with major closed head injury (CHI) were admitted to 2 Swedish medical centres. Seven to 11 years after injury, 25 of them (mean age 40.8 years; range 25 59 years) were evaluated using peripheral and central auditory tests, and most of them also completed 2 questionnaires concerning self-assessed hearing ability and quality of life. Twenty-two patients did not participate in the long-term follow-up tests: 15 were excluded for medical reasons and 4 did not wish to participate; an additional 2 were impossible to trace and I had died. As many as 68% of patients (17/25) demonstrated abnormalities on 1 or more of the audiometric tests, 14 on pure-tone audiometry (p < 0.02) and/or central audiometric tests (3 on central tests only and 2 on pure-tone audiometry only). Four out of six patients with available early post-traumatic audiograms showed a significant progressive deterioration. As a group, their assessments of hearing ability and quality of life were equal to or better than those of the controls. These results may indicate that a higher priority should be given to obtaining an early audiologic evaluation of every CHI patient than is the rule today. The impact of post-traumatic progress and central lesions on social hearing at an advanced age is highlighted.	Orebro Med Ctr Hosp, Ahlsen Res Inst, SE-70185 Orebro, Sweden; Lindesberg Cty Hosp, ENT Dept, Lindesberg, Sweden	Bergemalm, PO (corresponding author), Orebro Med Ctr Hosp, Ahlsen Res Inst, SE-70185 Orebro, Sweden.						Borg E, 2000, ACTA OTO-LARYNGOL, V120, P234, DOI 10.1080/000164800750001008; BROWNING GG, 1982, ARCH OTOLARYNGOL, V108, P474; Chiappa KH, 1989, EVOKED POTENTIALS CL, P173; COCKRELL J L, 1992, Brain Injury, V6, P261, DOI 10.3109/02699059209029667; DAVIES A, 1995, HEARING ADULTS; ELWANY S, 1988, J LARYNGOL OTOL, V102, P755, DOI 10.1017/S0022215100106383; FELDMANN H, 1987, ACTA OTO-LARYNGOL, V103, P379; GRIFFITH MV, 1979, J LARYNGOL OTOL, V93, P252; GROVE WE, 1947, ANN OTO RHINOL LARYN, V56, P264; Hugosson S, 1997, INT J PEDIATR OTORHI, V42, P149, DOI 10.1016/S0165-5876(97)00129-8; KAJANDI M, 1992, SOCIALMEDICINSK TIDS, V1, P21; Korsan-Bengtsen M, 1973, Acta Otolaryngol Suppl, V310, P1; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P176; MAKISHIMA K, 1976, LARYNGOSCOPE, V86, P1303, DOI 10.1288/00005537-197609000-00002; MAKISHIMA K, 1975, LARYNGOSCOPE, V85, P1947, DOI 10.1288/00005537-197512000-00001; Mellergard P, 1998, BASIC NEUROSURGERY, P189; Musiek FE, 1995, EAR HEARING, V16, P631, DOI 10.1097/00003446-199512000-00009; PAULSEN K, 1971, Z LARYNGOL RHINO, V5, P297; Ringdahl A, 1998, BRIT J AUDIOL, V32, P375, DOI 10.3109/03005364000000089; RONNBERG J, 1989, J SPEECH HEAR RES, V32, P725, DOI 10.1044/jshr.3204.725; ROSENHALL U, 1985, SCAND AUDIOL, V14, P187, DOI 10.3109/01050398509045940; SCHWETZ F, 1987, HNO, V35, P416; Tos M., 1971, J LARYNGOL OTOL, V85, P147; Wennmo C, 1989, Acta Otolaryngol Suppl, V468, P379	25	34	36	0	1	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0001-6489			ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	SEP	2001	121	6					724	734		10.1080/00016480152583674			11	Otorhinolaryngology	Otorhinolaryngology	481ZG	WOS:000171549900010	11678172				2021-06-18	
J	Peek-Asa, C; McArthur, D; Hovda, D; Kraus, J				Peek-Asa, C; McArthur, D; Hovda, D; Kraus, J			Early predictors of mortality in penetrating compared with closed brain injury	BRAIN INJURY			English	Article							GLASGOW-COMA-SCALE; GUNSHOT WOUNDS; HEAD-INJURY; CRANIOCEREBRAL INJURY; EMERGENCY; PROGNOSIS; CIVILIANS; SEVERITY; SCORE-3; DEATH	Introduction: Although brain injury incidence rates have been decreasing, the proportion of these injuries which are penetrating has been increasing. This study compares mortality amongst persons with penetrating and closed brain injuries and explores the relationship of early predictors of mortality. Methods: The study included 795 moderately or severely brain injured individuals identified through the UCLA Brain Injury Research Centre. Logistic regression was used to predict mortality by GCS level and brain injury type, controlling for age, gender, and presence of multiple trauma. Results: Of the 795 individuals, 110 had penetrating and 685 had closed brain injury. Case fatality rates were higher for penetrating than closed injuries for all GCS, gender, age, and cause of injury categories. When controlling for GCS level at admission, age, gender, and multiple trauma, those with penetrating injuries were 6.6 (95% CI = 3.9-11.1) times more likely to die. Conclusions: As the pool of information about survival and recovery from penetrating injuries grows, decisions regarding clinical care and prevention activities can be more appropriately focused.	Univ Calif Los Angeles, Sch Publ Hlth, SCIPR, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90024 USA	Peek-Asa, C (corresponding author), Univ Calif Los Angeles, Sch Publ Hlth, SCIPR, Dept Epidemiol, 10911 Weybum Ave,Suite 200, Los Angeles, CA 90024 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; BANDAK FA, 1995, J NEUROTRAUM, V12, P645; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Fingerhut LA., 1997, INJURY CHARTBOOK HLT; Gennarelli T.A., 1996, NEUROSURGERY, P2611; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HYMEL KP, 1998, CHILD MALTREATMENT, V3, P116, DOI DOI 10.1177/1077559598003002006; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KAUFMAN HH, 1991, SURG NEUROL, V36, P370, DOI 10.1016/0090-3019(91)90026-6; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1985, NEUROSURGERY, V16, P754, DOI 10.1227/00006123-198506000-00002; KAUFMAN HH, 1995, NEUROSURG CLIN N AM, V6, P701, DOI 10.1016/s1042-3680(18)30426-1; KENNEDY F, 1993, J TRAUMA, V35, P75, DOI 10.1097/00005373-199307000-00013; KORDESTANI RK, 1995, NEUROSURG CLIN N AM, V6, P657; Kraus J, 2000, HEAD INJURY, P1; Kraus JF, 1993, HEAD INJURY, P1; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; Marion D W, 1999, Clin Neurosurg, V45, P184; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; POLIN RS, 1995, NEUROSURG CLIN N AM, V6, P689; REYES D, 1999, MISSILE WOUNDS HEAD, V2, P257; *SAS I INC, 1997, SAS VERS 6 12; SELDEN BS, 1988, ANN EMERG MED, V17, P247, DOI 10.1016/S0196-0644(88)80117-3; SHAFFREY ME, 1992, J NEUROTRAUM, V9, pS279; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SIEGEL JH, 1995, J NEUROTRAUM, V12, P579, DOI 10.1089/neu.1995.12.579; Snyder HN, 1999, JUVENILE OFFENDERS V; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Zafonte RD, 1997, BRAIN INJURY, V11, P403	32	34	35	0	0	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2001	15	9					801	810		10.1080/02699050010025768			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	462ZM	WOS:000170452400005	11516348				2021-06-18	
J	Thatcher, RW; Biver, C; Gomez, JF; North, D; Curtin, R; Walker, RA; Salazar, A				Thatcher, RW; Biver, C; Gomez, JF; North, D; Curtin, R; Walker, RA; Salazar, A			Estimation of the EEG power spectrum using MRI T-2 relaxation time in traumatic brain injury	CLINICAL NEUROPHYSIOLOGY			English	Article						traumatic brain injury; magnetic resonance imaging T-2 relaxation time; entropy; qEEG	CLOSED-HEAD INJURY; BIOPHYSICAL LINKAGE; ALZHEIMERS-DISEASE; TISSUE; MECHANISMS; MILD; SEGMENTATION; CONCUSSION; FREQUENCY; SEQUENCES	Objectives: To study the relationship between magnetic resonance imaging (MRI) T-2 relaxation time and the power spectrum of the electroencephalogram (EEG) in long-term follow up of traumatic brain injury. Methods: Nineteen channel quantitative electroencephalograms or qEEG, tests of cognitive function and quantitative MRI T-2 relaxation times (qMRI) were measured in 18 mild to severe closed head injured outpatients 2 months to 4.6 years after injury and 11 normal controls. MRI T-2 and the Laplacian of T-2 were then correlated with the power spectrum of the scalp electrical potentials and current source densities of the qEEG. Results: qEEG and qMRI T-2 were related by a frequency tuning with maxima in the alpha (8-12 Hz) and the lower EEG frequencies (0.5-5 Hz), which varied as a function of spatial location. The Laplacian of T2 acted like a spatial-temporal 'lens' by increasing the spatial-temporal resolution of correlation between 3-dimensional T-2 and the ear referenced alert but resting spontaneous qEEG. Conclusions: The severity of traumatic brain injury can be modeled by a linear transfer function that relates the molecular qMRI to qEEG resonant frequencies. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Bay Pines Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33744 USA; Univ S Florida, Coll Med, Dept Neurol, Tampa, FL USA; Univ S Florida, Coll Med, Dept Radiol, Tampa, FL USA; Def & Vet Head Injury Program, Washington, DC 20307 USA	Thatcher, RW (corresponding author), Bay Pines Vet Adm Med Ctr, Res & Dev Serv 151, Bldg 23,Room 117, Bay Pines, FL 33744 USA.						ADVANI SH, 1982, HUMAN BODY DYNAMICS, P3; BARTH J, 1983, NEUROSURGERY, V13, P520; Bendat J.S., 1980, ENG APPL CORRELATION; BENSAID AM, 1994, P SPIE MED IMAGING, P454; BEZDEK JC, 1993, MED PHYS, V20, P1033, DOI 10.1118/1.597000; BLOCH F, 1946, PHYS REV, V70, P460, DOI 10.1103/PhysRev.70.460; BOTTOMLEY PA, 1984, MED PHYS, V11, P425, DOI 10.1118/1.595535; CHAITIN GJ, 1987, ALGORITHMIC INFORMAT; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; CRONWALL D, 1980, LANCET, V11, P605; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DARWIN RH, 1986, RADIOLOGY, V160, P375, DOI 10.1148/radiology.160.2.3726116; DASILVA FHL, 1995, DYNAMICS ELECT ACTIV; DASILVA FL, 1987, ELECTROENCEPHALOGRAP; DAWANT BM, 1993, IEEE T MED IMAGING, V12, P770, DOI 10.1109/42.251128; DECERTAINES JD, 1993, MAGN RESON IMAGING, V11, P841, DOI 10.1016/0730-725X(93)90201-N; DIXON RL, 1982, MED PHYS, V9, P807, DOI 10.1118/1.595189; FEYNMAN RP, 1963, FEYNMAN LECT PHYSICS, V1; FEYNMAN RP, 1963, FEYNMAN LECT PHYSICS, V2; Freeman WJ, 1975, MASS ACTION NERVOUS; FULLERTON GD, 1992, MAGNETIC RESONANCE I, P88; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; HICKEY DS, 1986, BRIT J RADIOL, V59, P565, DOI 10.1259/0007-1285-59-702-565; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; KIRSCH SJ, 1992, NEUROSCI LETT, V134, P187, DOI 10.1016/0304-3940(92)90513-7; KJOS BO, 1985, AM J ROENTGENOL, V144, P1165, DOI 10.2214/ajr.144.6.1165; KOENIG SH, 1991, MAGNET RESON MED, V20, P285, DOI 10.1002/mrm.1910200210; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Laakso MP, 1996, NEUROBIOL AGING, V17, P535, DOI 10.1016/0197-4580(96)00036-X; LEE Y-C, 1970, Mathematical Biosciences, V6, P473, DOI 10.1016/0025-5564(70)90080-5; Makeig S, 1996, ADV NEUR IN, V8, P145; Malmivuo J., 1995, BIOELECTROMAGNETISM; MAS F, 1993, CLIN ELECTROENCEPHAL, V24, P118, DOI 10.1177/155005949302400309; MILLS CM, 1984, RADIOLOGY, V150, P87, DOI 10.1148/radiology.150.1.6689792; MiotNoirault E, 1997, J NEUROSCI METH, V72, P5, DOI 10.1016/S0165-0270(96)00148-3; NARAYANA PA, 1988, MAGN RESON IMAGING, V6, P271, DOI 10.1016/0730-725X(88)90401-8; Nicholis G., 1989, EXPLORING COMPLEXITY; Nunez P., 1981, ELECT FIELDS BRAIN; Nunez P. L., 1995, NEOCORTICAL DYNAMICS; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; Ommaya AK, 1968, J BIOMECH; Otnes R. K., 1972, DIGITAL TIME SERIES; PASCUALMARQUI RD, 1988, INT J NEUROSCI, V43, P237, DOI 10.3109/00207458808986175; PASCUALMARQUI RD, 1999, NEUROIMAGE, V9, pS204; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; Press WH., 1994, NUMERICAL RECIPES C; PURPURA DP, 1959, INT REV NEUROBIOLOGY, V1; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; THATCHER RW, 2000, NEUROIMAGE, V9, pS110; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; TILLMAN S, 1997, PSYCHIAT RES-NEUROIM, V75, P173; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Egren L., 1996, CLIN ELECTROENCEPHAL, V27, P164; VANROTTERDAM A, 1982, B MATH BIOL, V44, P283, DOI 10.1016/S0092-8240(82)80070-0; von Bierbrauer A., 1993, EEG EMG Z ELEKTROENZ, V23, P151; Wehrli F. W, 1992, MAGNETIC RESONANCE I, P3; Whittall KP, 1997, MAGNET RESON MED, V37, P34, DOI 10.1002/mrm.1910370107	70	34	34	0	5	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1388-2457			CLIN NEUROPHYSIOL	Clin. Neurophysiol.	SEP	2001	112	9					1729	1745		10.1016/S1388-2457(01)00609-5			17	Clinical Neurology; Neurosciences	Neurosciences & Neurology	466ZQ	WOS:000170676400019	11514257				2021-06-18	
J	Kincaid, EH; Chang, MC; Letton, RW; Chen, JG; Meredith, JW				Kincaid, EH; Chang, MC; Letton, RW; Chen, JG; Meredith, JW			Admission base deficit in pediatric trauma: A study using the National Trauma Data Bank	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						base deficit; trauma; pediatric; shock; acidosis; children	ABDOMINAL INJURY; PREDICTORS; SEVERITY; MORTALITY; SHOCK; RISK	Background. The base deficit, an important indicator of physiologic derangement after severe injury in adults, has not been specifically examined in the pediatric trauma population. The purpose of this study was to assess the ability of the admission base deficit to predict injury severity and outcome in the pediatric trauma population. Methods. The study group included all patients in the National Trauma Data Bank over a 2-year period aged 0 to 12 years with a base deficit (0 to -30 mEq/L) recorded from the emergency depart-ment. Age, presence of a severe closed head injury, and base deficit were analyzed with respect to mortality and other indicators of injury severity. Results. A total of 515 patients constituted the study group. Base deficit less than -4 mEq/L (p < 0.001) and the presence of a closed head injury (odds ratio, 3.8; p < 0.05) were predictors of mortality. For the group, an admission base deficit of -8 mEq/L, corresponded to a probability of mortality of 25%. Significant correlations were found between base deficit and emergency department systolic blood pressure, Injury Severity Score, and Revised Trauma Score. There was no relationship between age and mortality. Conclusion In injured children, the admission base deficit reflects injury severity and predicts mortality. The probability of mortality increases precipitously in children with a base deficit less than -8 mEq/L, and should alert the clinician to the presence of potentially lethal injuries or uncompensated shock.	Wake Forest Univ, Sch Med, Med Ctr, Dept Gen Surg, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Med Ctr, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA	Chang, MC (corresponding author), Wake Forest Univ, Sch Med, Med Ctr, Dept Gen Surg, Med Ctr Blvd, Winston Salem, NC 27157 USA.						Botha AJ, 1997, INTENS CARE MED, V23, P504, DOI 10.1007/s001340050365; DAVIS JW, 1988, J TRAUMA, V28, P1464, DOI 10.1097/00005373-198810000-00010; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; DAVIS JW, 1991, ANN EMERG MED, V20, P842, DOI 10.1016/S0196-0644(05)81423-4; DUNHAM CM, 1991, CRIT CARE MED, V19, P231, DOI 10.1097/00003246-199102000-00020; Eichelberger M, 1993, PEDIAT TRAUMA PREVEN; Kincaid EH, 1998, J AM COLL SURGEONS, V187, P384, DOI 10.1016/S1072-7515(98)00202-6; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; MACKERSIE RC, 1989, ARCH SURG-CHICAGO, V124, P809; Rating the severity of tissue damage. I, 1971, JAMA-J AM MED ASSOC, V215, P277; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39; SHOEMAKER WC, 1971, SURG GYNECOL OBSTETR, V132, P1033; SIEGEL JH, 1990, ARCH SURG-CHICAGO, V125, P498; SIGGAARD.O, 1971, SCAND J CLIN LAB INV, V27, P239, DOI 10.3109/00365517109080214	15	34	35	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2001	51	2					332	335		10.1097/00005373-200108000-00018			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	463DW	WOS:000170462400017	11493795				2021-06-18	
J	Armstead, WM				Armstead, WM			Vasopressin-induced protein kinase C-dependent superoxide generation contributes to ATP-sensitive potassium channel but not calcium-sensitive potassium channel function impairment after brain injury	STROKE			English	Article						brain injuries; cerebral circulation; free radicals; newborn; potassium channels; vasopressin	CEREBRAL BLOOD-FLOW; GENE-RELATED PEPTIDE; MISSILE HEAD-INJURY; BASILAR ARTERY; SMOOTH-MUSCLE; NEWBORN PIGS; NITRIC-OXIDE; K+ CHANNELS; RESPONSES; ACTIVATION	Background and Purpose-Pial artery dilation in response to activators of the ATP-sensitive Kt (KATP) and calcium-sensitive K+ (K-Ca) channels is impaired after fluid percussion brain injury (FPI). Vasopressin, when coadministered with the K-ATP and K-Ca channel agonists cromakalim and NS1619 in a concentration approximating that observed in cerebrospinal fluid (CSF) after FPI, blunted K-ATP and K-Ca channel-mediated vasodilation. Vasopressin also contributes to impaired K-ATP and Kc, channel vasodilation after FPI. In addition, protein kinase C (PKC) activation generates superoxide anion (O-2(-)), which in turn contributes to K-ATP channel impairment after FPI. We tested whether vasopressin generates O-2(-) in a protein kinase C (PKC)-dependent manner, which could link vasopressin release to impaired KATP and K-Ca channel-induced pial artery dilation after FPI. Methods-injury of moderate severity (1.9 to 2.1 atm) was produced with the lateral FPI technique in anesthetized newborn pigs equipped with a closed cranial window. Superoxide dismutase-inhibitable nitroblue tetrazolium (NBT) reduction was determined as an index of O-2(-) generation. Results-Under sham injury conditions, topical vasopressin (40 pg/mL, the concentration present in CSF after FPI) increased superoxide dismutase-inhibitable NET reduction from 1 +/-1 to 23 +/-4 pmol/mm(2). Chelerythrine (10(-7) mol/L, a PKC inhibitor) blunted such NET reduction (1 +/-1 to 9 +/-2 pmol/mm(2)), whereas the vasopressin antagonist 1-(beta -mercapto-beta,beta -cyclopentamethylene propionic acid)2-(o-methyl) -Tyr-arginine vasopressin (MEAVP) blocked NET reduction. Chelerythrine and MEAVP also blunted the NET reduction observed after FPI (1 +/-1 to 15 +/-1, 1 +/-1 to 4 +/-1, and 1 +/-1 to 5 +/-1 pmol/mm(2) for sham-, chelerythrine-, and MEAVP-treated animals, respectively). Under sham injury conditions, vasopressin (40 pg/mL) coadministered with cromakalim or NS1619 blunted dilation in response to these K+ channel agonists, whereas chelerythrine partially restored such impaired vasodilation for cromakalim but not NS1619. Cromakalim- and NS1619-induced pial artery dilation also was blunted after FPI. MEAVP partially protected dilation to both Kt channel agonists after FPI, whereas chelerythrine did so for only cromakalim responses (for cromakalim at 10(-8) and 10(-6) mol/L, 13 +/-1% and 23 +/-1%, 2 +/-1% and 5 +/-1%, 9 +/-1% and 15 +/-2%, and 9 +/-1% and 16 +/-2% for sham-, FPI-, FPI-MEAVP-, and FPI-chelerythrine-pretreated animals, respectively). Conclusions-These data show that vasopressin, in concentrations present in CSF after FPI, increased O-2(-) production in a PKC-dependent manner and contributes to such production after FPI. These data show that vasopressin contributes to K-ATP but not K-Ca channel function impairment in a PKC-dependent manner after FPI and suggest that vasopressin contributes to K-Ca, channel function impairment after FPI via a mechanism independent of PKC activation.	Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA	Armstead, WM (corresponding author), Univ Penn, Dept Anesthesia, 3400 Spruce St, Philadelphia, PA 19104 USA.	armsteaw@mail.med.upenn.edu					ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANDERSON DK, 1994, NEUROBIOLOGY CENTRAL, P131; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH1272; Armstead WM, 1996, J NEUROTRAUM, V13, P115, DOI 10.1089/neu.1996.13.115; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Armstead WM, 1999, STROKE, V30, P153, DOI 10.1161/01.STR.30.1.153; Armstead WM, 1997, BRAIN RES, V747, P252, DOI 10.1016/S0006-8993(96)01284-X; ARMSTEAD WM, 1990, AM J PHYSIOL, V258, pH408; ARMSTEAD WM, 1989, CIRC RES, V64, P136, DOI 10.1161/01.RES.64.1.136; Armstead WM, 1997, BRAIN RES, V768, P177, DOI 10.1016/S0006-8993(97)00641-0; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1996, AM J PHYSIOL-HEART C, V270, pH423; ARMSTEAD WM, 1992, J PHARMACOL EXP THER, V260, P1107; Armstead WM, 2000, AM J PHYSIOL-HEART C, V279, pH2678; Bari F, 1996, STROKE, V27, P1874, DOI 10.1161/01.STR.27.10.1874; BECKMAN JS, 1994, ANN NY ACAD SCI, V738, P69; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faraci FM, 1998, PHYSIOL REV, V78, P53; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Holland M, 1996, BRIT J PHARMACOL, V117, P119, DOI 10.1111/j.1476-5381.1996.tb15163.x; Kasemsri T, 1997, STROKE, V28, P190, DOI 10.1161/01.STR.28.1.190; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KITAZONO T, 1993, HYPERTENSION, V22, P677, DOI 10.1161/01.HYP.22.5.677; KITAZONO T, 1993, AM J PHYSIOL, V265, pH581; Kulkarni M, 2000, STROKE, V31, P1990, DOI 10.1161/01.STR.31.8.1990; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MAYHAN WG, 1993, AM J PHYSIOL, V265, pH152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NELSON MT, 1990, AM J PHYSIOL, V259, pC3; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P625, DOI 10.1001/archpedi.1990.02150300019014; SAITO A, 1989, J PHARMACOL EXP THER, V248, P455; Salvucci A, 2000, BRAIN RES, V887, P406, DOI 10.1016/S0006-8993(00)03079-1; SHANKAR V, 1995, AM J PHYSIOL-HEART C, V269, pH997; Tepas J J 3rd, 1995, Semin Pediatr Surg, V4, P120; VINK R, 1994, J NEUROTRAUM, V11, P265, DOI 10.1089/neu.1994.11.265; WAKATSUKI T, 1992, AM J PHYSIOL, V263, pH491; WATSON BD, 1984, J NEUROCHEM, V42, P268, DOI 10.1111/j.1471-4159.1984.tb09728.x; WEI EP, 1985, AM J PHYSIOL, V248, pH157; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	45	34	37	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUN	2001	32	6					1408	1414		10.1161/01.STR.32.6.1408			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	440PZ	WOS:000169184600034	11387506	Bronze			2021-06-18	
J	Dunn, LT; Stewart, E; Murray, GD; Nicoll, JAR; Teasdale, GM				Dunn, LT; Stewart, E; Murray, GD; Nicoll, JAR; Teasdale, GM			The influence of apolipoprotein E genotype on outcome after spontaneous subarachnoid hemorrhage: A preliminary study	NEUROSURGERY			English	Article						apolipoproteins; outcome; subarachnoid hemorrhage	CEREBRAL AMYLOID ANGIOPATHY; E EPSILON-2 ALLELE; HIGH-FREQUENCY; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; CEREBROVASCULAR-DISEASE; E POLYMORPHISM; APOE GENOTYPE; SCALE; STROKE	OBJECTIVE: Possession of an apolipoprotein E (APOE)epsilon4 allele has been shown to be associated with a poor outcome after closed head injury and spontaneous intracerebral hemorrhage but not after ischemic stroke. This study assessed the influence of the APOE genotype on outcome in patients admitted to a neurosurgical unit with spontaneous subarachnoid hemorrhage. METHODS: A total of 100 patients with spontaneous subarachnoid hemorrhage were studied. Four patients were excluded because the diagnosis of subarachnoid hemorrhage was not confirmed. The incidence of rehemorrhage and delayed ischemia and the outcome at 6 months were determined using the Glasgow Outcome Scale. APOE genotypes were determined by polymerase chain reaction and restriction enzyme digestion. RESULTS: Allele frequencies in this patient group were 0.04 for epsilon2, 0.86 for epsilon3, and 0.1 for epsilon4. Of 96 patients, 72 had an aneurysmal hemorrhage and 1 had a hemorrhage from an arteriovenous malformation. In 14 patients, the results of angiography were negative, and in 9, no angiogram was performed. Of the 96 patients, 20 had one or more epsilon4 allele. Outcome at 6 months was no worse in patients with one or more epsilon4 allele than in those with no epsilon4 allele (odds ratio, 0.98; 95% confidence interval, 0.35-2.74). None of the 12 patients who experienced delayed ischemic deterioration had an epsilon4 allele. Of the 20 patients with an epsilon4 allele, 3 had a rehemorrhage, as compared with 6 of 76 patients without an epsilon4 allele. CONCLUSION: There was underrepresentation of the epsilon4 allele in this group when compared with previously studied cases of subarachnoid hemorrhage with a fatal outcome and with the general population. This suggests that patients with the epsilon4 allele who have a subarachnoid hemorrhage are less likely to be admitted to a neurosurgical unit. This study does not support an association between possession of an epsilon4 allele and poor outcome in patients admitted to a neurosurgical unit with spontaneous subarachnoid hemorrhage, although the wide confidence interval does not preclude a clinically relevant association between APOE genotype and outcome. The findings indicate that an association between genotype and the development of delayed ischemic complications after subarachnoid hemorrhage may be possible.	Univ Glasgow, Dept Neurosurg, Glasgow, Lanark, Scotland; Univ Glasgow, Dept Neuropathol, Glasgow, Lanark, Scotland; Univ Edinburgh, Dept Community Hlth Sci, Edinburgh, Midlothian, Scotland	Dunn, LT (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.		; Nicoll, James/I-9253-2017	Murray, Gordon/0000-0001-9866-4734; Nicoll, James/0000-0002-9444-7246; Dunn, Laurence/0000-0002-8990-4334			ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Basun H, 1996, STROKE, V27, P1310, DOI 10.1161/01.STR.27.8.1310; Corder EH, 1996, ARCH NEUROL-CHICAGO, V53, P418, DOI 10.1001/archneur.1996.00550050048022; CUMMING AM, 1984, CLIN GENET, V25, P310; DRAKE CG, 1988, J NEUROSURG, V68, P985; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GREENBERG SM, 1995, ANN NEUROL, V38, P254, DOI 10.1002/ana.410380219; Greenberg SM, 1996, STROKE, V27, P1333, DOI 10.1161/01.STR.27.8.1333; JENNETT B, 1975, LANCET, V1, P480; Laskowitz DT, 1998, J CEREBR BLOOD F MET, V18, P465, DOI 10.1097/00004647-199805000-00001; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; McCarron MO, 2000, ARCH NEUROL-CHICAGO, V57, P1480, DOI 10.1001/archneur.57.10.1480; McCarron MO, 1998, STROKE, V29, P1882, DOI 10.1161/01.STR.29.9.1882; McCarron MO, 1998, NEUROSCI LETT, V247, P45, DOI 10.1016/S0304-3940(98)00286-9; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; Nicoll JAR, 1996, ANN NEUROL, V39, P682, DOI 10.1002/ana.410390521; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	27	34	36	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	2001	48	5					1006	1010		10.1097/00006123-200105000-00007			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	424GB	WOS:000168223000017	11334266				2021-06-18	
J	Soto-Ares, G; Vinchon, M; Delmaire, C; Abecidan, E; Dhellemes, P; Pruvo, JP				Soto-Ares, G; Vinchon, M; Delmaire, C; Abecidan, E; Dhellemes, P; Pruvo, JP			Cerebellar atrophy after severe traumatic head injury in children	CHILDS NERVOUS SYSTEM			English	Article						traumatic brain injury; children; cerebellar atrophy; cerebellum; magnetic resonance imaging	BRAIN INJURY; MRI; ACTIVATION; TOMOGRAPHY; COGNITION; DEFICITS; LESIONS; SYSTEM; SCALE; MILD	Objects: The purpose of this study was to describe late neuropathological MRI findings in pediatric severe head injury and to explore the relationship between these lesions and cognitive sequelae. Methods: Thirteen infants with severe head trauma (Glasgow 6) were included in this investigation. Clinical examination, a battery of tests designed to assess neurophysiological status, and MRI investigations of the brain were obtained in periods ranging between 8 and 20 months after the accident. Hemosiderin deposits, encephalomalacia, and cerebellar atrophy were the most frequent traumatic sequelae. The lesions were located in frontal lobes, the basal ganglia, and the cerebellum. Six patients had cerebellar atrophy associated with frontal or temporal postraumatic lesions. Cerebellar clinical dysfunction was observed in only 3 of these patients. Performance on tests evaluating frontal lobe functions was depressed in 5 of them. Conclusions: Late MRI after severe head trauma in our pediatric population showed unexpected cerebellar atrophy. Its correlation with prefrontal dysfunction is difficult to confirm because of its association with other parenchymal post-traumatic lesions. Further research involving a larger sample of patients with brain injury of varying severity is in progress, to investigate whether cerebellar atrophy could be a consequence of severe head trauma.	CHRU Lille, Hop Roger Salengro, Dept Neuroradiol, F-59037 Lille, France; CHRU Lille, Hop Roger Salengro, Dept Pediat Neurosurg, F-59037 Lille, France	Soto-Ares, G (corresponding author), CHRU Lille, Hop Roger Salengro, Dept Neuroradiol, F-59037 Lille, France.			Vinchon, Matthieu/0000-0002-9122-6165			Alavi A, 1997, J NUCL MED, V38, P1717; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Ciesielski KT, 1997, NEUROPSYCHOLOGIA, V35, P643, DOI 10.1016/S0028-3932(96)00119-4; DAUM I, 1997, INT REV NEUROBIOL, V41, P445; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GUPTA N, 1994, AM J ROENTGENOL, V163, P750, DOI 10.2214/ajr.163.3.8079896; Holshouser BA, 1997, RADIOLOGY, V202, P487, DOI 10.1148/radiology.202.2.9015079; HUSSEIN M, 1998, CLIN NUCL MED, V28, P309; Ito H, 1997, Ann Nucl Med, V11, P167; Ivry R B, 1992, Curr Opin Neurobiol, V2, P212, DOI 10.1016/0959-4388(92)90015-D; Jancke L, 1999, NEUROIMAGE, V9, P497, DOI 10.1006/nimg.1998.0426; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KRAUSS JK, 1995, NEUROL RES, V17, P409, DOI 10.1080/01616412.1995.11740353; LEINER HC, 1991, BEHAV BRAIN RES, V44, P113, DOI 10.1016/S0166-4328(05)80016-6; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PARADISO S, 1998, NEUROPSYCHIATRY NEUR, V10, P1; Parsons LM, 1997, LEARN MEMORY, V4, P49, DOI 10.1101/lm.4.1.49; Pasquier F, 1996, EUR NEUROL, V36, P268, DOI 10.1159/000117270; Peeters RR, 1999, EUR J NEUROSCI, V11, P2720, DOI 10.1046/j.1460-9568.1999.00687.x; Rollins NK, 1995, PEDIATR RADIOL, V25, pS20; Tamada T, 1999, NEUROREPORT, V10, P325, DOI 10.1097/00001756-199902050-00022; TEASDALE G, 1974, LANCET, V2, P81; Townsend J, 1999, J NEUROSCI, V19, P5632; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VERTICHEL P, 1993, REV NEUROL, V149, P8; VERTICHEL P, 1993, REV NEUROL, V149, P491; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	35	34	34	0	6	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0256-7040			CHILD NERV SYST	Childs Nerv. Syst.	APR	2001	17	4-5					263	269		10.1007/s003810000411			7	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	434AX	WOS:000168793900013	11398947				2021-06-18	
J	Kotchoubey, B; Lang, S; Baales, R; Herb, E; Maurer, P; Mezger, G; Schmalohr, D; Bostanov, V; Birbaumer, N				Kotchoubey, B; Lang, S; Baales, R; Herb, E; Maurer, P; Mezger, G; Schmalohr, D; Bostanov, V; Birbaumer, N			Brain potentials in human patients with extremely severe diffuse brain damage	NEUROSCIENCE LETTERS			English	Article						apallic syndrome; stimulus complexity; event-related potentials; P3	PERSISTENT VEGETATIVE STATE; COMPLEX TONES; PITCH; DIAGNOSIS	To test higher cortical functions of neurological patients, oddball tasks are often used in which a frequent and a rare stimulus are randomly presented and a P3 brain wave is recorded to the rare stimulus. We examined 33 patients with extremely severe brain injury. Three oddball conditions were used: with two sine tones IST), with two complex tones (CT) and with vowels 'o' and 'i'. Across all patients, CT elicited P3 more often than ST, and the occurrence of the P3 after vowels was intermediate. However, among patients who showed a distinct P3 wave, its amplitude in the subgroup with traumatic brain injury was larger to vowels than to CT. In patients with non-traumatic etiology, CT and vowels elicited a P3 of a nearly equal amplitude. Stimuli of sufficient complexity should be used when the P3 technique is applied for assessment of cortical functions in severely impaired patients. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.	Univ Tubingen, Inst Med Psychol & Behav Neurobiol, D-72074 Tubingen, Germany; Rehabil Ctr Godeshohe, Bonn, Germany; Clin Karlsbad Langensteinbach, Karlsbad, Germany; Hosp Neurorehabil, Neresheim, Germany; Rehabil Clin Wangen in Allgau, Wangen In Allgau, Germany; Hagau Jugendwerk, Gailingen, Germany; Univ Padua, Dept Gen Psychol, Padua, Italy	Kotchoubey, B (corresponding author), Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Gartenstr 29, D-72074 Tubingen, Germany.	boris.kotchoubey@uni-tuebingen.de		Birbaumer, Niels/0000-0002-6786-5127; Bostanov, Vladimir/0000-0002-2946-0786			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Cariani PA, 1996, J NEUROPHYSIOL, V76, P1717; Celesia GG, 1997, THEOR MED, V18, P221, DOI 10.1023/A:1005709410296; Childs NL, 1996, NEW ENGL J MED, V334, P24, DOI 10.1056/NEJM199601043340105; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; COLES MGH, 1990, TUTORIALS PSYCHOPHYS, P413; DALLEORE G, 1987, APALLIC SYNDROME; Donchin E, 1986, PSYCHOPHYSIOLOGY SYS, P244; Fishman YI, 1998, BRAIN RES, V786, P18, DOI 10.1016/S0006-8993(97)01423-6; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Jones SJ, 2000, BRAIN, V123, P1007, DOI 10.1093/brain/123.5.1007; KENNARD C, 1995, J NEUROL NEUROSUR PS, V59, P347, DOI 10.1136/jnnp.59.4.347; MAROSI M, 1993, LANCET, V341, P1473, DOI 10.1016/0140-6736(93)90914-3; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Tervaniemi M, 2000, NEUROSCI LETT, V279, P29, DOI 10.1016/S0304-3940(99)00941-6; Tervaniemi M, 2000, NEUROSCI LETT, V290, P66, DOI 10.1016/S0304-3940(00)01290-8; Vihla M, 2000, P NATL ACAD SCI USA, V97, P10590, DOI 10.1073/pnas.180317297; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; WLTZKE W, 1996, NEUROL REHAB, V2, P68	19	34	36	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 23	2001	301	1					37	40		10.1016/S0304-3940(01)01600-7			4	Neurosciences	Neurosciences & Neurology	411NB	WOS:000167505200010	11239711				2021-06-18	
J	Zafonte, RD; Lexell, J; Cullen, N				Zafonte, RD; Lexell, J; Cullen, N			Possible applications for dopaminergic agents following traumatic brain injury: Part 2	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							EARLY PARKINSONS-DISEASE; DOUBLE-BLIND; PRAMIPEXOLE; AGONIST; AMANTADINE; PLACEBO; ROPINIROLE; TOLCAPONE; THERAPY; STATE		Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; UPMC Hlth Syst, Pittsburgh, PA USA; Lund Univ, Brain Injury Unit, Lund, Sweden; Univ Toronto, Toronto, ON, Canada; Toronto Rehabil Inst, Toronto, ON, Canada	Zafonte, RD (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Lillian Kaufmann Bldg,3471 5th Ave,Suite 901, Pittsburgh, PA 15213 USA.			Lexell, Jan/0000-0001-5294-3332; Cullen, Nora/0000-0001-6359-9418			ACTON G, 1989, BRIT J CLIN PHARMACO, V28, P435, DOI 10.1111/j.1365-2125.1989.tb03524.x; Adler CH, 1997, NEUROLOGY, V49, P393, DOI 10.1212/WNL.49.2.393; ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; Becker PM, 1998, NEUROLOGY, V51, P1221, DOI 10.1212/WNL.51.4.1221; CHANDLER M, 1988, BRAIN INJURY, V4, P309; Corrigan MH, 2000, DEPRESS ANXIETY, V11, P58, DOI 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; Jungerman T, 1999, J CLIN PSYCHOPHARM, V19, P522, DOI 10.1097/00004714-199912000-00006; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; Kunig G, 1999, CLIN NEUROPHARMACOL, V22, P301; Kuzel MD, 1999, AM J HEALTH-SYST PH, V56, P217, DOI 10.1093/ajhp/56.3.217; Larsen JP, 1999, EUR J NEUROL, V6, P539, DOI 10.1046/j.1468-1331.1999.650539.x; Ling ZD, 1999, J PHARMACOL EXP THER, V289, P202; Maj J, 1997, J NEURAL TRANSM, V104, P525, DOI 10.1007/BF01277669; Olanow CW, 2000, ARCH NEUROL-CHICAGO, V57, P263, DOI 10.1001/archneur.57.2.263; Rajput AH, 1997, NEUROLOGY, V49, P1066, DOI 10.1212/WNL.49.4.1066; Rinne UK, 1998, NEUROLOGY, V51, P1309, DOI 10.1212/WNL.51.5.1309; Schneider WN, 1999, BRAIN INJURY, V13, P863; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; Sporn J, 2000, Ann Clin Psychiatry, V12, P137; WELLER M, 1992, MED HYPOTHESES, V38, P329, DOI 10.1016/0306-9877(92)90027-A; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zou LL, 2000, NEUROSCI LETT, V281, P167, DOI 10.1016/S0304-3940(00)00853-3	23	34	35	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2001	16	1					112	116		10.1097/00001199-200102000-00014			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403ZC	WOS:000167072100016	11277855				2021-06-18	
J	Kroppenstedt, SN; Stover, JF; Unterberg, AW				Kroppenstedt, SN; Stover, JF; Unterberg, AW			Effects of dopamine on posttraumatic cerebral blood flow, brain edema, and cerebrospinal fluid glutamate and hypoxanthine concentrations	CRITICAL CARE MEDICINE			English	Article						blood pressure elevation; brain edema; cerebral blood flow; cerebrospinal fluid; controlled cortical impact; dopamine; excitotoxicity; laser-Doppler; traumatic brain injury	CONTROLLED CORTICAL IMPACT; HEAD-INJURED PATIENTS; AMINO-ACIDS; INTRAVENOUS-INFUSION; L-ARGININE; RATS; RELEASE; AUTOREGULATION; ISOFLURANE; PERFUSION	Objectives: Dopamine is often used in the treatment of traumatic brain injury to maintain cerebral perfusion pressure. However, it remains unclear whether dopamine contributes to secondary brain injury caused by vasoconstriction and resulting diminished cerebral perfusion. The present study investigated the effects of dopamine in different concentrations on posttraumatic cortical cerebral blood flow (CBF), brain edema formation, and cerebrospinal fluid concentrations of glutamate and hypoxanthine. Design: Randomized, placebo-controlled trial. Setting: Animal laboratory. Subjects: Eighteen male Sprague-Dawley rats subjected to a focal cortical brain injury. Interventions: Four hours after controlled cortical impact, rats were randomized to receive physiologic saline solution (n = 6), 10-42 mug/kg/min dopamine (n = 6), or 40-50 mug/kg/min dopamine (n = 6), for 3 hrs. Cortical GBF was measured over both hemispheres by using laser-Doppler flowmetry before trauma and before, during, and after the infusion period. At 8 hrs after trauma, brains were removed to determine hemispheric swelling and water content. Cisternal cerebrospinal fluid was sampled to measure glutamate and hypoxanthine. Measurements and Main Results: After trauma, cortical CBF was significantly decreased by 46% within the vicinity of the cortical contusion in all rats. Infusion of saline and 10-12 mug/kg/min dopamine did not change mean arterial blood pressure (MABP) or cortical CBF. However, infusion of 40-50 mug/kg/min dopamine, which elevated MABP from 89 to 120 mm Hg, significantly increased posttraumatic CBF within and around the contusion by 35%. Over the nontraumatized hemisphere, CBF remained unchanged. Hemispheric swelling, water content, cerebrospinal fluid glutamate, and hypoxanthine levels were not affected by dopamine in the given dosages. Conclusions: Under the present study design, there was no evidence for a dopamine-mediated vasoconstriction, because posttraumatic cortical GBF was increased by dopamine-induced elevation of MABP, However, the increase in CBF did not significantly affect edema formation or cerebrospinal fluid glutamate and hypoxanthine levels.	Humboldt Univ, Dept Neurosurg, Charite Virchow Med Ctr, D-13353 Berlin, Germany	Kroppenstedt, SN (corresponding author), Humboldt Univ, Dept Neurosurg, Charite Virchow Med Ctr, Augustenburger Pl 1, D-13353 Berlin, Germany.						ALTURA BM, 1980, BRIT J PHARMACOL, V69, P543, DOI 10.1111/j.1476-5381.1980.tb07900.x; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P103, DOI 10.1111/j.1399-6576.1995.tb04285.x; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt D S, 1995, New Horiz, V3, P376; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; GARNETT ES, 1980, AM J PHYSIOL, V238, pR318; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; GRANDE PO, 1998, PATHOPHYSIOLOGICAL P, P123; HAGBERG H, 1987, J NEUROCHEM, V49, P227, DOI 10.1111/j.1471-4159.1987.tb03419.x; HARKNESS RA, 1988, J CHROMATOGR-BIOMED, V429, P255, DOI 10.1016/S0378-4347(00)83873-6; HEIMANN A, 1994, J CEREBR BLOOD F MET, V14, P1100, DOI 10.1038/jcbfm.1994.144; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HOFFMAN WE, 1991, ANESTH ANALG, V73, P753; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KEMPSKI O, 1995, INT J MICROCIRC, V15, P37, DOI 10.1159/000178947; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kroppenstedt SN, 1999, J NEUROTRAUM, V16, P629, DOI 10.1089/neu.1999.16.629; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Maeda T, 1997, ACT NEUR S, V70, P102; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MUELLER RA, 1988, CELL MOL NEUROBIOL, V8, P235, DOI 10.1007/BF00711249; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Noh JS, 1999, EXP NEUROL, V159, P217, DOI 10.1006/exnr.1999.7144; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; RAMANI R, 1991, J CEREBR BLOOD F MET, V11, P388, DOI 10.1038/jcbfm.1991.79; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; SHIMADA N, 1993, J NEUROCHEM, V60, P66, DOI 10.1111/j.1471-4159.1993.tb05823.x; Stover JF, 1999, CRIT CARE MED, V27, P1351, DOI 10.1097/00003246-199907000-00028; Talmor D, 1998, ANESTH ANALG, V87, P574, DOI 10.1097/00000539-199809000-00014; UNGERSBOCK K, 1993, STROKE, V24, P563, DOI 10.1161/01.STR.24.4.563; VONESSEN C, 1981, STROKE, V12, P331, DOI 10.1161/01.STR.12.3.331; VONESSEN C, 1980, SURG NEUROL, V13, P181; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Zauner A, 1996, ACT NEUR S, V67, P40	53	34	35	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2000	28	12					3792	3798		10.1097/00003246-200012000-00004			7	Critical Care Medicine	General & Internal Medicine	388NB	WOS:000166186200003	11153616				2021-06-18	
J	Klonoff, PS; Lamb, DG; Henderson, SW				Klonoff, PS; Lamb, DG; Henderson, SW			Milieu-based neurorehabilitation in patients with traumatic brain injury: Outcome at up to 11 years postdischarge	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	18th Annual Meeting of the National-Academy-of-Neuropsychology	NOV, 1998	WASHTINGTON, D.C.	Natl Acad Neuropsychol		brain injuries; rehabilitation; employment; treatment outcome	FOLLOW-UP; REHABILITATION; STABILITY	Objective: To examine the rate of productivity and competitive activity in participants with traumatic brain injury (TBI) at a milieu-based day treatment neurorehabilitation program. Design: Follow-up data in a cross-sectional design sought from all admissions from May 1986 to May 1998 at 3 months and at year 1, 3, 5, 7, 9, and 11. Setting: Outpatient milieu-based interdisciplinary day treatment program. Patients: One hundred twelve participants with TBI, representing 78.9% of TBI patients successfully discharged from the program. Interventions: Milieu-based interdisciplinary neurorehabilitation (mean length of treatment, 6.2mo). Main Outcome Measures: Productivity, defined as gainful employment, school, and/or volunteer work, and competitive activity, defined as work for pay or enrollment in school. Results: 88.4% of patients were productive up to 11 years after discharge, with 76.8% engaged in competitive activity and with no decline in productivity seen over time from discharge. Conclusions: A large majority of patients suffering from TBI are able to return to work or a productive life situation after milieu-based neurorehabilitation. Level of outcome did not significantly decline over an 11 year follow-up interval.	Barrow Neurol Inst, Catholic Healthcare W, Phoenix, AZ 85013 USA; Adult Day Hosp Neurol Rehabil, Phoenix, AZ USA	Klonoff, PS (corresponding author), Barrow Neurol Inst, St Josephs Hosp & Med Ctr, ADHNR, 222 W Thomas Rd,Ste 115, Phoenix, AZ 85013 USA.						Ashley MJ, 1997, BRAIN INJURY, V11, P677; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EAMES P, 1995, BRAIN INJURY, V10, P631; Evans RW, 1997, ARCH PHYS MED REHAB, V78, pS17, DOI 10.1016/S0003-9993(97)90151-9; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, BRAIN INJURY, V13, P417; HARRICK L, 1994, BRAIN INJURY, V8, P439, DOI 10.3109/02699059409150995; Hillier SL, 1997, BRAIN INJURY, V11, P661; Klonoff P S, 1997, Appl Neuropsychol, V4, P107, DOI 10.1207/s15324826an0402_3; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; KLONOFF PS, 1997, CLIN NEUROPSYCHOLOGY, P219; Klonoff PS, 2000, INT HDB NEUROPSYCHOL, P195; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; SCHALEN W, 1994, BRAIN INJURY, V8, P37, DOI 10.3109/02699059409150957; Wall JR, 1998, BRAIN INJURY, V12, P215	18	34	35	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2000	81	11					1535	1537		10.1053/apmr.2000.9177			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	369YT	WOS:000165095900016	11083362				2021-06-18	
J	Grundy, PL; Patel, N; Harbuz, MS; Lightman, SL; Sharples, PM				Grundy, PL; Patel, N; Harbuz, MS; Lightman, SL; Sharples, PM			Glucocorticoids modulate BDNF mRNA expression in the rat hippocampus after traumatic brain injury	NEUROREPORT			English	Article						adrenalectomy; BDNF; fluid percussion; glucocorticoids; hippocampus; traumatic brain injury	NEUROTROPHIC FACTOR EXPRESSION; FLUID-PERCUSSION MODEL; MESSENGER-RNAS; HEAD-INJURY; STRESS; CORTICOSTERONE; ISCHEMIA; NEURONS; DEATH	Brain-derived neurotrophic factor (BDNF) expression in rat hippocampus is increased after experimental traumatic brain injury (TBI) and may be neuroprotective. Glucocorticoids are important regulators of brain neurotrophin levels and are often prescribed following TBI. The effect of adrenalectomy (ADX) on the expression of BDNF mRNA in the hippocampus after TBI has not been investigated to date. We used fluid percussion injury (FPI) and in situ hybridization to evaluate the expression of BDNF mRNA in the hippocampus 4 h after TBI in adrenal-intact or adrenalectomized rats (with or without corticosterone replacement). FPI and ADX independently increased expression of BDNF mRNA. In animals undergoing FPI, prior ADX caused further elevation of BDNF mRNA and this upregulation was prevented by corticosterone replacement in ADX rats. These findings suggest that glucocorticoids are involved in the modulation of the BDNF mRNA response to TBI. NeuroReport 11:3381-3384 (C) 2000 Lippincott Williams & Wilkins.	Frenchay Hosp, Dept Neurosurg, Acad Ctr, Bristol BS16 1LE, Avon, England; Univ Bristol, Div Child Hlth, Bristol BS2 8HW, Avon, England; Univ Bristol, Res Ctr Neuroendocrinol, Bristol BS2 8HW, Avon, England	Grundy, PL (corresponding author), Frenchay Hosp, Dept Neurosurg, Acad Ctr, Room 1, Bristol BS16 1LE, Avon, England.			Lightman, Stafford/0000-0002-8546-9646			Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BENGZON J, 1993, NEUROSCIENCE, V53, P433, DOI 10.1016/0306-4522(93)90207-V; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Chao HM, 1998, ENDOCRINOLOGY, V139, P3112, DOI 10.1210/en.139.7.3112; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; HARBUZ MS, 1989, J ENDOCRINOL, V122, P705, DOI 10.1677/joe.0.1220705; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; JACOBSON L, 1989, ENDOCRINOLOGY, V124, P2144, DOI 10.1210/endo-124-5-2144; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LAUTERBORN J, 1995, NEUROSCIENCE, V68, P363, DOI 10.1016/0306-4522(95)00150-H; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McEwen BS, 1995, VITAM HORM, V51, P371, DOI 10.1016/S0083-6729(08)61045-6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Pringle AK, 1996, NEUROSCI LETT, V211, P203, DOI 10.1016/0304-3940(96)12745-2; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; SHARPLES PM, 1990, BRIT MED J, V300, P87, DOI 10.1136/bmj.300.6717.87; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; SMITH MA, 1995, J NEUROSCI, V15, P1768; WHITELEY T, 1999, THESIS U NEWCASTLE U	24	34	40	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	OCT 20	2000	11	15					3381	3384		10.1097/00001756-200010200-00023			4	Neurosciences	Neurosciences & Neurology	366MY	WOS:000090010200018	11059906				2021-06-18	
J	Dolinak, D; Smith, C; Graham, DI				Dolinak, D; Smith, C; Graham, DI			Hypoglycaemia is a cause of axonal injury	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						axonal injury; human hypoglycaemia; raised intracranial pressure	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; INTRACRANIAL-PRESSURE; VEGETATIVE STATE; BRAIN-DAMAGE; BETA-APP; NEUROPATHOLOGY; HYPOGLYCEMIA; DIAGNOSIS	Axonal injury as demonstrated immunohistochemically is increasingly being recognized at post-mortem in patients who have been unconscious, and in some cases the cause of the coma may not be immediately apparent. Considerations include microscopical diffuse traumatic axonal injury and axonal injury associated with a range of metabolic encephalopathies. In this study, extensive neurohistological examination was undertaken in 13 patients in whom coma was attributed to hypoglycaemia and in whom neurohistological examination had revealed varying degrees of widely distributed neuronal necrosis: in five of these cases there was also evidence that the intracranial pressure had been high with internal hernation. It is concluded that a significant amount of axonal injury found in these 13 cases can be attributed to hypoglycaemia per se although the amount and distribution of the axonal damage is altered in the presence of raised intracranial pressure. However, in some cases axonal damage is seen in the absence of an elevated intracranial pressure and in one case its distribution closely mimicked that seen in microscopical diffuse traumatic axonal injury. This further demonstrates that not all axonal pathology is traumatic, and that adequate sampling and care in interpretation of A beta-PP staining is required in forensic practice.	Univ Glasgow, S Glasgow Univ Hosp NHS Trust, Dept Neuropathol, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland	Graham, DI (corresponding author), Univ Glasgow, S Glasgow Univ Hosp NHS Trust, Dept Neuropathol, Inst Neurol Sci, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.						ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1985, MED SCI LAW, V25, P265, DOI 10.1177/002580248502500407; AUER RN, 1989, CLIN NEUROPATHOL, V8, P63; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; AUER RN, 1997, GREENFIELDS NEUROPAT, P263; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brierley JB, 1984, GREENFIELDS NEUROPAT, P125; DOLINAK D, 2000, IN PRESS ACTA NEUROP; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GRAHAM DI, 1987, NEUROPATH APPL NEURO, V13, P209, DOI 10.1111/j.1365-2990.1987.tb00184.x; Kaur B, 1999, J CLIN PATHOL, V52, P203, DOI 10.1136/jcp.52.3.203; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; PILZ P, 1994, BRAIN PATHOL, V4, P485; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433	23	34	36	1	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0305-1846			NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	OCT	2000	26	5					448	453		10.1046/j.1365-2990.2000.00273.x			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	361RB	WOS:000089735900007	11054185				2021-06-18	
J	Kesler, SR; Adams, HF; Bigler, ED				Kesler, SR; Adams, HF; Bigler, ED			SPECT, MR and quantitative MR imaging: correlates with neuropsychological and psychological outcome in traumatic brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; TECHNETIUM-99M-HMPAO SPECT; MILD	This study examined the relative effectiveness of magnetic resonance (MR) imaging, single photon emission tomography (SPECT) and quantitative magnetic resonance (QMR) imaging in detecting brain abnormalities in 52 traumatically brain injured patients. The relationship between brain abnormalities and neuropsychological and psychological testing results was also investigated. Sixty-two per cent of patients had abnormal clinical MR findings, 57% had abnormal SPECT and 51% had abnormal QMR. Each neuroimaging modality detected brain abnormalities that the other two did not. Neuropsychological and psychological testing indicated significant memory impairments and subjective emotional distress even several years post-injury. Memory and intellectual impairments modestly but significantly correlated with the number of brain abnormalities indicated by all three imaging studies combined, as well as those detected individually by QMR and MR. SPECT abnormalities alone were not correlated with intellectual and memory outcome. Psychological distress was also related to the number of MR abnormalities, with most brain abnormalities being in the frontal areas.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 SWKT, Provo, UT 84602 USA.						ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; BIGLER ED, 1992, BRAIN RES BULL, V28, P651, DOI 10.1016/0361-9230(92)90119-I; BIGLER ED, 1996, NEUROIMAGING, V2, P261; *BIOM IM RES, 1993, AN 6 0; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; DEROGATIS LR, 1994, S CHECKL 90 ADM SCOR; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 1999, BRAIN INJURY, V13, P229, DOI 10.1080/026990599121601; Gean A, 1994, IMAGING HEAD TRAUMA; GRAY BG, 1992, J NUCL MED, V33, P52; Hopkins RO, 1997, NEUROPSYCHOL REV, V7, P87, DOI 10.1023/B:NERV.0000005946.46506.a9; ICHISE M, 1994, J NUCL MED, V35, P217; JACOBS A, 1994, J NUCL MED, V35, P942; JONES RD, 1996, HEAD INJURY POSTCONC; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Laatsch L, 1997, BRAIN INJURY, V11, P851; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 1989, MILD HEAD INJURY; MASDEU J, 1992, J NEUROIMAGING, V4, P177; Orrison William W. Jr., 1996, P71; Primus EA, 1997, BRAIN INJURY, V11, P577; PRITCHARD D, 1992, FORENSIC REPORTS, V5, P287; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Reynolds C.R., 1994, TEST MEMORY LEARNING; RIZZO M, 1996, HEAD INJURY POSTCONC; ROSENTHAL M, 1993, H133A2001693 NAT I D; Septien L., 1993, Encephale, V19, P249; Umile EM, 1998, BRAIN INJURY, V12, P577; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D., 1991, WECHSLER INTELLIGENC; WILSON J T L, 1990, Brain Injury, V4, P349	35	34	35	0	4	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2000	14	10					851	857					7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	364QG	WOS:000089902900001	11076132				2021-06-18	
J	Angstwurm, K; Reuss, S; Freyer, D; Arnold, G; Dirnagl, U; Schumann, RR; Weber, JR				Angstwurm, K; Reuss, S; Freyer, D; Arnold, G; Dirnagl, U; Schumann, RR; Weber, JR			Induced hypothermia in experimental pneumococcal meningitis	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain edema; cerebral blood flow; intracranial hypertension; laser Doppler flowmetry	ACUTE BACTERIAL-MENINGITIS; CONTROLLED CORTICAL IMPACT; TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; CARDIOPULMONARY BYPASS; MILD HYPOTHERMIA; NITRIC-OXIDE; BLOOD-FLOW; RAT; RABBITS	Pneumococcal meningitis resulting from Streptococcus pneumoniae has a death rate of 28% in adults. In severe bead injury and stroke, inflammatory changes and intracranial hypertension are improved by induced hypothermia, which also is neuroprotective. We hypothesized that moderate hypother- mia ameliorates inflammatory changes in experimental pneumococcal meningitis. Wistar rats were cooled systemically, and meningitis was induced by pneumococcal cell wall components. The increase of regional cerebral blood flow in the meningitis animals was blocked by hypothermia at 6 hours. The reduction of intracranial pressure correlated with temperature. The influx of leukocytes into the cerebrospinal fluid and levels of tumor necrosis factor alpha in the cerebrospinal fluid were decreased. Cooling the animals 2 hours after meningitis induction to 30.5 degrees C was also protective. We conclude that hypothermia is a new adjuvant approach to reduce meningitis-induced changes, in particular intracranial pressure, in the early phase of the disease.	Humboldt Univ, Klinikum Charite, Dept Neurol, D-10098 Berlin, Germany; Humboldt Univ, Klinikum Charite, Inst Microbiol & Hyg, D-10098 Berlin, Germany	Weber, JR (corresponding author), Humboldt Univ, Klinikum Charite, Dept Neurol, Clara Zetkin Str 94, D-10098 Berlin, Germany.			Dirnagl, Ulrich/0000-0003-0755-6119			BALCH HH, 1955, SURGERY, V38, P1036; BOHR V, 1984, ARCH NEUROL-CHICAGO, V41, P1045, DOI 10.1001/archneur.1984.04050210043012; Braun JS, 1999, NAT MED, V5, P298, DOI 10.1038/6514; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CROUGHWELL N, 1992, J THORAC CARDIOV SUR, V103, P549; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DURAND ML, 1993, NEW ENGL J MED, V328, P21, DOI 10.1056/NEJM199301073280104; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GREELEY WJ, 1993, ANN THORAC SURG, V56, P1464, DOI 10.1016/0003-4975(93)90731-V; Haddix TL, 1996, J SURG RES, V64, P176, DOI 10.1006/jsre.1996.0325; Irazuzta JE, 1999, BRAIN RES, V847, P143, DOI 10.1016/S0006-8993(99)02120-4; KOEDEL U, 1995, ANN NEUROL, V37, P313, DOI 10.1002/ana.410370307; LEDEIST F, 1995, CIRCULATION, V92, P354, DOI 10.1161/01.CIR.92.9.354; Luhm J, 1998, EUR J BIOCHEM, V256, P325, DOI 10.1046/j.1432-1327.1998.2560325.x; MAHER J, 1993, CEREBROVAS BRAIN MET, V5, P277; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCCREDIE DA, 1992, J PEDIATR, V61, P653; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Schwab M, 1998, ACTA NEUROBIOL EXP, V58, P29; SESSLER DI, 1995, J NEUROSURG ANESTH, V7, P38, DOI 10.1097/00008506-199501000-00008; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; TUREEN JH, 1990, J CLIN INVEST, V85, P577, DOI 10.1172/JCI114475; Weber JR, 1995, J NEUROIMMUNOL, V63, P63	28	34	34	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2000	20	5					834	838		10.1097/00004647-200005000-00010			5	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	312WM	WOS:000086967000010	10826534	Bronze			2021-06-18	
J	Wang, MY; Griffith, P; Sterling, J; McComb, JG; Levy, ML				Wang, MY; Griffith, P; Sterling, J; McComb, JG; Levy, ML			A prospective population-based study of pediatric trauma patients with mild alterations in consciousness (Glasgow Coma Scale Score of 13-14)	NEUROSURGERY			English	Article						closed head trauma; Glasgow Coma Scale; pediatric head trauma	MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; TRIAGE CRITERIA; CT SCANS; EMERGENCY; CHILDREN; RISK	OBJECTIVE: Considerable controversy surrounds the appropriate evaluation of children with mild alterations in consciousness after closed head trauma (Glasgow Coma Scale [GCS] score of 13-14). The objective of the current study was to determine the incidence of intracranial lesions in pediatric patients with a field CCS score of 13 or 14 after closed head injuries. METHODS: The current study is a population-based, multicenter prospective study of all patients to whom emergency medical services responded during a 12-month period. The setting was urban Los Angeles County, encompassing a patient population of 2.3 million children, 13 designated trauma centers, and 94 receiving hospitals. RESULTS: In the pediatric age group (<15 yr old), 8488 patients were transported by emergency medical services for injuries. Of these, 209 had a documented field CCS score of 13 or 14. One hundred fifty-seven patients were taken to trauma centers, and 135 (86%) underwent computed tomography. Forty-three patients (27.4%) had abnormal results on computed tomographic scans, 30 (19.1%) had an intracranial hemorrhage, and 5 required an operative neurosurgical procedure for hematoma evacuation. Positive and negative predictive values of deteriorating mental status (0.500 and 0.844, respectively), loss of consciousness (0.173 and 0.809), cranial fracture (0.483 and 0.875, and extracranial injuries (0.205 and 0.814) were poor predictors of intracranial hemorrhage. CONCLUSION: Pediatric patients who have mild alterations in consciousness in the field have a significant incidence of intracranial injury. The great majority of these patients will not require operative intervention, but the implications of missing these hemorrhages can be severe for this subgroup of head-injured patients. Because clinical criteria and cranial x-rays are poor predictors of intracranial hemorrhage, it is recommended that all children with a GCS score of 13 or 14 routinely undergo screening via non-contrast-enhanced computed tomography.	Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Div Pediat Neurosurg, Los Angeles, CA 90027 USA; Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Trauma Program, Los Angeles, CA 90027 USA	Levy, ML (corresponding author), Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Div Pediat Neurosurg, Suite 906,1300 N Vermont Ave, Los Angeles, CA 90027 USA.						Borczuk Pierre, 1997, Emergency Medicine Clinics of North America, V15, P563, DOI 10.1016/S0733-8627(05)70318-7; BUNTAIN WL, 1987, ADV TRAUMA, V2, P43; COOPER PR, 1983, NEUROSURGERY, V13, P136, DOI 10.1227/00006123-198308000-00005; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; DUUS BR, 1994, ANN EMERG MED, V23, P1279, DOI 10.1016/S0196-0644(94)70352-3; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HECKMAN JD, 1992, EMERGENCY CARE TRANS, P322; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Johnson DL, 1996, PEDIATR NEUROSURG, V25, P309, DOI 10.1159/000121145; Kissoon N, 1996, PEDIATR EMERG CARE, V12, P272, DOI 10.1097/00006565-199608000-00009; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; Moront ML, 1996, J PEDIATR SURG, V31, P1183, DOI 10.1016/S0022-3468(96)90114-1; Phillips S, 1996, PEDIATR EMERG CARE, V12, P394, DOI 10.1097/00006565-199612000-00002; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; RIVARA F, 1987, PEDIATRICS, V80, P579; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SIMMONS E, 1995, ANN EMERG MED, V26, P461, DOI 10.1016/S0196-0644(95)70115-X; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; TEASDALE G, 1974, LANCET, V2, P81	28	34	35	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	MAY	2000	46	5					1093	1099		10.1097/00006123-200005000-00014			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	310JK	WOS:000086822600029	10807241				2021-06-18	
J	Wang, XK; Feuerstein, GZ				Wang, XK; Feuerstein, GZ			Role of immune and inflammatory mediators in CNS injury	DRUG NEWS & PERSPECTIVES			English	Article							FOCAL CEREBRAL-ISCHEMIA; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE SYNTHASE; INTERLEUKIN-1 RECEPTOR ANTAGONIST; MESSENGER-RNA EXPRESSION; CLOSED-HEAD INJURY; GENE-EXPRESSION; RAT-BRAIN; TNF-ALPHA; ARTERY OCCLUSION	Accumulating evidence has shown that the central nervous system can mount a well-defined inflammatory reaction to a variety of insults including trauma, ischemia, transplantation, viral infection, and immune and neurodegenerative disorders. In this review, we summarize the evidence that in brain ischemia and trauma, inflammatory reaction figures prominently in mediation of brain injury. The inflammatory condition consists of inflammatory cells (first neutrophils, followed by monocytes/macrophages) and mediators (cytokines, chemokines and adhesion molecules). De novo up-regulation of various inflammatory mediators has been observed and their roles in brain injury have been extensively studied. In addition, recent evidence emerges on specific signal pathways in brain injury. Taken together, targeting specific inflammatory mediators involved in brain injury may provide novel therapeutic opportunities for CNS injury such as stroke and neurotrauma. (C) 2000 Prous Science. All rights reserved.	Dupont Merck Pharmaceut Co, Expt Stn, Dept Cardiovasc Sci, Wilmington, DE 19880 USA							Baron M, 1997, POINT VET, V28, P1; Barone F. C., 1999, Society for Neuroscience Abstracts, V25, P1060; BARONE FC, 1992, NEUROSCI BIOBEHAV R, V16, P219, DOI 10.1016/S0149-7634(05)80182-4; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; BUTTINI M, 1995, NEUROSCIENCE, V65, P523, DOI 10.1016/0306-4522(94)00525-A; Buttini M, 1996, NEUROSCIENCE, V71, P1, DOI 10.1016/0306-4522(95)00414-9; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CLARK WM, 1991, J NEUROSURG, V75, P623, DOI 10.3171/jns.1991.75.4.0623; Dawson DA, 1996, NEUROSCI LETT, V218, P41, DOI 10.1016/0304-3940(96)13116-5; DeGraba TJ, 1998, NEUROLOGY, V51, pS62, DOI 10.1212/WNL.51.3_Suppl_3.S62; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; DUTKA AJ, 1989, STROKE, V20, P390, DOI 10.1161/01.STR.20.3.390; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1998, CEREBROVASC DIS, P507; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; GARCIA JH, 1994, AM J PATHOL, V144, P188; GARCIA JH, 1974, J NEUROPATH EXP NEUR, V33, P408, DOI 10.1097/00005072-197407000-00007; GOLDBLUM SE, 1990, AM J PHYSIOL, V258, pL57; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Grandati M, 1997, BRIT J PHARMACOL, V122, P625, DOI 10.1038/sj.bjp.0701427; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; Haring HP, 1996, J NEUROPATH EXP NEUR, V55, P236, DOI 10.1097/00005072-199602000-00012; Hayward NJ, 1996, EXP NEUROL, V139, P188, DOI 10.1006/exnr.1996.0093; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P52, DOI 10.1038/jcbfm.1995.6; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Jiang N, 1995, ANN NEUROL, V38, P935, DOI 10.1002/ana.410380615; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; MARTIN D, 1994, EXP NEUROL, V130, P362, DOI 10.1006/exnr.1994.1215; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Miettinen S, 1997, P NATL ACAD SCI USA, V94, P6500, DOI 10.1073/pnas.94.12.6500; MINAMI M, 1991, BIOCHEM BIOPH RES CO, V176, P593, DOI 10.1016/S0006-291X(05)80225-6; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; Nagayama M, 1998, J CEREBR BLOOD F MET, V18, P1107, DOI 10.1097/00004647-199810000-00007; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Nogawa S, 1997, J NEUROSCI, V17, P2746; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; Parmentier S, 1999, BRIT J PHARMACOL, V127, P546, DOI 10.1038/sj.bjp.0702549; Planas AM, 1995, NEUROSCI LETT, V200, P187, DOI 10.1016/0304-3940(95)12108-G; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; Salvemini D, 1996, METHOD ENZYMOL, V269, P12; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIREN AL, 1992, STROKE, V23, P1643, DOI 10.1161/01.STR.23.11.1643; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Vuorte J, 1999, J IMMUNOL, V162, P2353; WANG XK, 1995, STROKE, V26, P1665, DOI 10.1161/01.STR.26.9.1665; WANG XK, 1995, BRAIN RES BULL, V36, P607, DOI 10.1016/0361-9230(94)00243-T; WANG XK, 1994, MOL BRAIN RES, V26, P61, DOI 10.1016/0169-328X(94)90074-4; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; Wang XK, 1998, J NEUROSCI, V18, P2075; WANG XK, 1994, MOL CHEM NEUROPATHOL, V23, P103, DOI 10.1007/BF02815404; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; Zhang RL, 1999, NEUROLOGY, V52, P273, DOI 10.1212/WNL.52.2.273; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; Zhao X., 1999, Society for Neuroscience Abstracts, V25, P793	81	34	36	0	2	PROUS SCIENCE, SAU-THOMSON REUTERS	BARCELONA	398 PROVENCA, 08025 BARCELONA, SPAIN	0214-0934	2013-0139		DRUG NEWS PERSPECT	Drug News Perspect.	APR	2000	13	3					133	140		10.1358/dnp.2000.13.3.657283			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	336RJ	WOS:000088316500001	12937603				2021-06-18	
J	Lee, JY; Park, J; Kim, YH; Kim, DH; Kim, CG; Koh, JY				Lee, JY; Park, J; Kim, YH; Kim, DH; Kim, CG; Koh, JY			Induction by synaptic zinc of heat shock protein-70 in hippocampus after kainate seizures	EXPERIMENTAL NEUROLOGY			English	Article						calcium; NMDA; TFL; cell culture; brain injury; neuronal death	TRAUMATIC BRAIN INJURY; HSP-70 MESSENGER-RNA; KAINIC ACID; RAT-BRAIN; CORTICAL-NEURONS; FOCAL ISCHEMIA; INDUCED DEATH; C-FOS; EXPRESSION; HSP70	Following seizures, heat shock protein (HSP)-70 is induced in various brain regions, Since zinc that can induce HSP-70 in various cell systems is enriched in certain glutamatergic terminals and translocates to postsynaptic neurons with seizures, we examined the possibility that HSP-70 induction in the epileptic brain is mediated by synaptic zinc. Adult rats were injected intraperitoneally with kainate to induce seizures. Seizures were halted 3 h after the kainate administration by the injection of phenytoin. Staining of brain sections with zinc-specific fluorescent dye Tn at 24 h after the kainate injection revealed a one-to one correlation between dense Tn fluorescence and acidophilic neuronal degeneration in the hippocampus. Subsequent staining with anti-HSP-70 antibody, however, revealed that more numerous neurons than degenerating neurons exhibited HSP-70 immunoreactivity, Most of the HSP-70(C) neurons were not stained with acid fuchsin but exhibited mild zinc fluorescence in the cytoplasm, Intraventricular injection of CaEDTA attenuated neuronal death as well. as the HSP-70 induction in a dose-dependent manner. Supporting the specificity of zinc rather than calcium as the inducer of HSP-70 in neurons, exposure to zinc but not to a calcium ionophore or excitotoxins increased expression of HSP-70 mRNA and protein in cultured cortical neurons. The present results suggest that not only selective neuronal death, but also HSP-70 induction in neurons after seizures, is mediated by the translocation of endogenous synaptic zinc. (C) 2000 Academic Press.	Univ Ulsan, Coll Med, Natl Creat Res Initiat, Ctr Study CNS Zinc, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Neurol, Seoul 138736, South Korea; Hanyang Univ, Coll Nat Sci, Dept Biol, Seoul 133791, South Korea	Koh, JY (corresponding author), Univ Ulsan, Coll Med, Natl Creat Res Initiat, Ctr Study CNS Zinc, Seoul 138736, South Korea.		Kim, Yang-Hee/N-7614-2013; Lee, Joo-Yong/F-4545-2014; Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X; Kim, Yang-Hee/0000-0002-0595-8547; Kim, Chul Geun/0000-0002-5848-3338			Armstrong JN, 1996, NEUROSCIENCE, V74, P685, DOI 10.1016/0306-4522(96)00164-9; Budde T, 1997, NEUROSCIENCE, V79, P347, DOI 10.1016/S0306-4522(96)00695-1; CHOI DW, 1988, NEUROSCIENCE, V24, P67, DOI 10.1016/0306-4522(88)90312-0; Detre JA, 1997, J NEUROL SCI, V148, P163, DOI 10.1016/S0022-510X(97)05368-9; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; FERRER I, 1995, BRAIN RES, V692, P41, DOI 10.1016/0006-8993(95)00527-W; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; FREDREICKSON CJ, 1987, BRAIN RES, V446, P383; Gaspary H, 1995, MOL BRAIN RES, V34, P327, DOI 10.1016/0169-328X(95)00195-X; Hasegawa K, 1998, BRAIN RES, V785, P262, DOI 10.1016/S0006-8993(97)01410-8; Hashimoto K, 1998, BRAIN RES, V804, P212, DOI 10.1016/S0006-8993(98)00708-2; HATAYAMA T, 1992, MOL CELL BIOCHEM, V112, P143; Hu RQ, 1998, BRAIN RES, V810, P229, DOI 10.1016/S0006-8993(98)00863-4; Iwata A, 1997, J NEUROTRAUM, V14, P201, DOI 10.1089/neu.1997.14.201; Jaattela M, 1998, EMBO J, V17, P6124, DOI 10.1093/emboj/17.21.6124; KOH JY, 1994, NEUROSCIENCE, V60, P1049, DOI 10.1016/0306-4522(94)90282-8; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Lees GJ, 1998, BRAIN RES, V799, P108, DOI 10.1016/S0006-8993(98)00483-1; Noga M, 1997, NEUROREPORT, V8, P1239, DOI 10.1097/00001756-199703240-00036; Okimura Y, 1996, J NEUROTRAUM, V13, P385, DOI 10.1089/neu.1996.13.385; Parat MO, 1998, BIOL TRACE ELEM RES, V65, P261, DOI 10.1007/BF02789101; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; Plumier JCL, 1997, CELL STRESS CHAPERON, V2, P162, DOI 10.1379/1466-1268(1997)002<0162:TMETHI>2.3.CO;2; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; ROWENSTEIN DH, 1991, NEURON, V7, P1053; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Sensi SL, 1997, J NEUROSCI, V17, P9554; Sharp FR, 1998, ANN NEUROL, V44, P581, DOI 10.1002/ana.410440402; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Suh S. W., 1996, Society for Neuroscience Abstracts, V22, P2101; Tomimoto H, 1999, ACTA NEUROPATHOL, V97, P22, DOI 10.1007/s004010050951; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Yin HZ, 1995, NEUROREPORT, V6, P2553, DOI 10.1097/00001756-199512150-00025; Zhang X, 1996, EUR J NEUROSCI, V8, P1432, DOI 10.1111/j.1460-9568.1996.tb01605.x; Zhang XA, 1997, EUR J NEUROSCI, V9, P760, DOI 10.1111/j.1460-9568.1997.tb01424.x	36	34	36	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	FEB	2000	161	2					433	441		10.1006/exnr.1999.7297			9	Neurosciences	Neurosciences & Neurology	290FW	WOS:000085666500001	10686065				2021-06-18	
J	Baskaya, MK; Dogan, A; Temiz, C; Dempsey, RJ				Baskaya, MK; Dogan, A; Temiz, C; Dempsey, RJ			Application of 2,3,5-triphenyltetrazolium chloride staining to evaluate injury volume after controlled cortical impact brain injury: Role of brain edema in evolution of injury volume	JOURNAL OF NEUROTRAUMA			English	Article						brain edema; brain injury; controlled cortical impact; injury volume; 2,3,5-triphenyltetrazolium chloride (TTC)	CLOSED-HEAD INJURY; CEREBRAL EDEMA; TIME-COURSE; RATS; BARRIER; QUANTIFICATION; ISCHEMIA	A reliable method for measuring injury volume after traumatic brain injury (TBI) is of great importance when studying pharmacological protective agents in the field of head trauma research. Utilization of 2,3,5-triphenyltetrazolium chloride (TTC) has gained extensive acceptance in stroke research and has recently been applied to injury volume measurement in the lateral fluid percussion model. The present study was undertaken to apply this method to the controlled cortical impact (CCI) model and to study the role of brain edema. Male Sprague-Dawley rats were subjected to CCI brain injury at a velocity of 3 m/sec and 1 mm (mild), 2 mm (moderate), and 3 mm (severe injury) deformation, while rats in the control group were subjected to the same surgical procedure but received no injury. Absolute and corrected injury volumes with TTC staining and brain edema measurements with the wet-dry method were evaluated at 1, 2, 3, 4, and 7 days after TBI. The most prominent injury volume in the moderate injury group (2 mm deformation) was seen at postinjury day 1 and 2 (day 1, absolute: 49.1 +/- 5.6, corrected: 40.5 +/- 7.9; day 2, absolute: 46 +/- 6.9, corrected: 40.2 +/- 10.5), whereas the smallest injury volume was found at postinjury day 7 (absolute: 24.9 +/- 7, corrected: 27.4 +/- 7.4). The time course of brain edema studies demonstrates that brain edema formation peaks at postinjury day 1. A statistically significant reduction of injury volume was observed after postinjury day 4. We also observed that due to the presence of brain edema absolute injury volume is more than corrected injury volume in the first 3 days after injury as opposed to injury volume at postinjury day 7. These results suggest that the measurement of injury volume with TTC staining should be corrected for brain edema in the CCI brain injury model.	Louisiana State Univ, Med Ctr, Dept Neurosurg, Shreveport, LA 71130 USA; Univ Wisconsin, Dept Neurol Surg, Madison, WI USA	Baskaya, MK (corresponding author), Louisiana State Univ, Dept Neurosurg, Ctr Hlth Sci, 1501 Kings Highway,POB 33932, Shreveport, LA 71130 USA.		Dogan, Aclan/AAF-8305-2019				Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Baskaya MK, 1997, NEUROSURGERY, V40, P364; BEDERSON JB, 1986, STROKE, V17, P1304, DOI 10.1161/01.STR.17.6.1304; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; LISZCZAK TM, 1984, ACTA NEUROPATHOL, V65, P150, DOI 10.1007/BF00690469; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47	18	34	36	1	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2000	17	1					93	99		10.1089/neu.2000.17.93			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	278WR	WOS:000085012400008	10674761				2021-06-18	
J	Hoffman, N; Donders, J; Thompson, EH				Hoffman, N; Donders, J; Thompson, EH			Novel learning abilities after traumatic head injury in children	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						novel learning; head injury; children	CATEGORY TEST; BRAIN INJURY; WISC-III; SEVERITY	The cognitive abilities of 69 children with traumatic head injury (THI) were evaluated with the California Verbal Learning Test-Children's Version (CVLT-C; Delis, Kramer, Kaplan, & Ober, 1994), the Children's Category Test (CCT; Boll, 1993), and the Wechsler Intelligence Scale for Children-Third Edition (WISC-III; Wechsler, 1991). Compared to children with mild to moderate injuries, children with severe THI demonstrated statistically significant impairments on the CVLT-C Total T-score as well as the WISC-III Processing Speed index, but findings for the CCT were less robust. Longer length of coma and male gender were associated with relatively poorer performance on the CVLT-C. Children with sever-e THI demonstrated difficulties with both capacity and speed of information processing, which could not be accounted for by attentional or general verbal knowledge factors, it is concluded that the combination of the CVLT-C and the WISC-III is useful in the evaluation of cognitive sequelae of THI bnl that findings from the CCT must be considered with some caution in this population. (C) 1999 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.						ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; BOLL T, 1993, CHILDRENS CATEGORY T; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Cohen J, 1977, STAT POWER BEHAV SCI; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DELIS D, 1994, CALIFORNIA VERBAL LE; Donders J, 1996, ARCH CLIN NEUROPSYCH, V11, P131, DOI 10.1016/0887-6177(95)00005-4; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 1998, J INT NEUROPSYCH SOC, V4, P242, DOI 10.1017/S1355617798002422; Donders J, 1996, CHILD NEUROPSYCHOL, V2, P185, DOI 10.1080/09297049608402251; DONDERS J, 1998, HDB PEDIAT PSYCHOL P, V2, P166; DONDERS J, IN PRESS DEV NEUROPS; Fletcher JM, 1995, HDB PEDIAT PSYCHOL, P362; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kramer JH, 1997, NEUROPSYCHOLOGY, V11, P577, DOI 10.1037/0894-4105.11.4.577; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Reitan R.M., 1992, NEUROPSYCHOLOGICAL E; Stevens J., 1992, APPL MULTIVARIATE ST, V2nd ed.; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Wechsler D., 1991, WECHSLER INTELLIGENC; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Ylvisaker M., 1994, ED DIMENSIONS ACQUIR, P69	26	34	34	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2000	15	1					47	58		10.1016/S0887-6177(98)00156-5			12	Psychology, Clinical; Psychology	Psychology	265XN	WOS:000084271600006	14590567	Bronze			2021-06-18	
J	Cooper, JB; Jane, JA; Alves, WM; Cooper, EB				Cooper, JB; Jane, JA; Alves, WM; Cooper, EB			Right median nerve electrical stimulation to hasten awakening from coma	BRAIN INJURY			English	Article								Electrical stimulation of the right median nerve may hasten the awakening of closed head injured, comatose patients. A series of 25 comatose patients have been treated. These patients made better recoveries than similar individuals reported in the literature. In a double-blind pilot project patients in the treated group scored better on interval Glasgow Coma Scale scores, spent fewer days in the intensive care unit, and showed better Glasgow Outcome Scores at 1 month post-injury. Peripheral electrical stimulation of the right median nerve, through activation of the ascending reticular activating system, may be sufficient to arouse the moderate to severely comatose patient.	E Carolina Univ, Sch Med, Greenville, NC USA; Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA; Neuroclin Trials Ctr Inc, Charlottesville, VA USA; E Carolina Univ, Dept Phys Med & Rehabil, Greenville, NC USA	Cooper, JB (corresponding author), 1902 Stanton Rd, Kinston, NC 28504 USA.						CARMICK J, 1993, PHYS THER, V73, P21; COOPER E, 1988, P AM IMP OUTP SYST A; Cooper E B Jr, 1973, Surg Forum, V24, P477; Glanz M, 1996, ARCH PHYS MED REHAB, V77, P549, DOI 10.1016/S0003-9993(96)90293-2; GRADY MS, 1989, J NEUROSURG, V71, P534, DOI 10.3171/jns.1989.71.4.0534; HAMILTON G, 1987, P 10 INT WORLD CONF; KANNO T, 1989, PACE, V12, P733, DOI 10.1111/j.1540-8159.1989.tb02724.x; KANNO T, 1992, SOC TREATMENT COMA, V1, P67; LAWRENCE F, 1991, J NEUROSURG, V75, pS28; MONTGOMERY G, 1989, DISCOVER, V10, P58; SCHERDER EJA, 1992, J CLIN EXP NEUROPSYC, V14, P951, DOI 10.1080/01688639208402546; SNYDERMACKLER L, 1995, J BONE JOINT SURG AM, V77A, P1166, DOI 10.2106/00004623-199508000-00004; Suzuki A, 1994, SOC TREATMENT COMA, V3, P75; Yokoyama T, 1996, SOC TREAT COMA, V5, P117	14	34	39	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	APR	1999	13	4					261	267		10.1080/026990599121638			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	186RH	WOS:000079742400005	10230527				2021-06-18	
J	Bouillon, B; Raum, M; Fach, H; Buchheister, B; Lefering, R; Menzel, J; Klug, N				Bouillon, B; Raum, M; Fach, H; Buchheister, B; Lefering, R; Menzel, J; Klug, N			The incidence and outcome of severe brain trauma - Design and first results of an epidemiological study in an urban area	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						brain trauma; head injury; incidence; epidemiology; outcome	SEVERE HEAD-INJURY; SCORE	Epidemiological data on the incidence, the prehospital and hospital care and the outcome of traumatic brain injury in Germany are scarce. It is therefore difficult to estimate the importance of this injury with respect to magnitude as well as effectiveness and efficiency of therapeutic concepts. We therefore planned a study that was supposed to provide population based epidemiological data in the field of severe brain trauma from the site of the accident until discharge from hospital. All 90,000 prehospital emergencies that were cared for by emergency physicians in Cologne from January 1990 until December 1996 were screened for identification of severe brain trauma. Their clinical course was reviewed using standard records and patients were included if they had their accident within the city of Cologne and fullfilled the final inclusion criteria of GCS less than or equal to 8 or AIS(Head) greater than or equal to 3. 650 eligible patients were identified of whom 530 had complete datasets (follow-up 80 %). Univariate statistical analysis was performed for all relevant variables. The main study endpoints were incidence and outcome of severe brain trauma. The annual incidence of severe brain trauma in Cologne (1 mio. inhabitants) was 93. The average age was 39 years and 71 % of the patients were male. The average prehospital GCS was 6.8, the average prehospital Trauma Score was 8.3 points. 49 % of the study population suffered from multiple injuries. The overall mortality rate was 46,6 %. 60 % of deaths occurred within the prehospital setting. The incidence of severe brain trauma in Cologne in this study was significantly lower compared to what could be expected from the literature. The overall mortality was high, especially the high prehospital death rate is striking.	Univ Cologne, Dept Surg 2, D-51109 Cologne, Germany; Univ Cologne, Inst Med Stat Informat & Epidemiol, D-5000 Cologne 41, Germany; Univ Cologne, Dept Surg 2, Biol & Expt Div, D-51109 Cologne, Germany; Neurosurg Clin, Cologne, Germany; Univ Cologne, Dept Gen Neurosurg, D-5000 Cologne 41, Germany	Bouillon, B (corresponding author), Univ Cologne, Dept Surg 2, Ostmerheimer Str 200, D-51109 Cologne, Germany.						Baethmann A, 1998, Curr Opin Anaesthesiol, V11, P193, DOI 10.1097/00001503-199804000-00013; BAETHMANN A, 1996, ACTA NEUROCHIR S, V66; BOUILLON B, 1990, THEOR SURG, V5, P36; Bouillon B, 1997, J TRAUMA, V42, P652, DOI 10.1097/00005373-199704000-00012; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; *COMM INJ SCAL, 1990, ABBR INJ SCAL 1990 R; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HARTWIG E, 1993, UNFALLCHIRURG, V96, P264; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Lehr D, 1997, J TRAUMA, V42, pS71, DOI 10.1097/00005373-199705001-00015; Moecke H., 1994, Intensivmedizin und Notfallmedizin, V31, P96; Prough DS, 1997, J TRAUMA, V42, pS10, DOI 10.1097/00005373-199705001-00003; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; TEASDALE G, 1974, LANCET, V2, P81; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	17	34	34	0	1	IOS PRESS	AMSTERDAM	VAN DIEMENSTRAAT 94, 1013 CN AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		1999	14	2-3					85	92					8	Neurosciences	Neurosciences & Neurology	183XN	WOS:000079579700002	22387503				2021-06-18	
J	Delmonico, RL; Hanley-Peterson, P; Englander, J				Delmonico, RL; Hanley-Peterson, P; Englander, J			Group psychotherapy for persons with traumatic brain injury: Management of frustration and substance abuse	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anger; frustration; group psychotherapy; substance abuse; traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION; ANGER	Residual emotional and behavioral difficulties in individuals who have sustained a traumatic brain injury (TBI) have been well documented in the literature. The issues are complex, interdependent, and often include substance abuse, depression, anxiety, chronic suicidal or homicidal ideation, poor impulse control, and significant degrees of frustration and anger. Often, preexisting psychological conditions and poor coping strategies are exacerbated by the trauma. Emotional and behavioral difficulties can interfere with the neurorehabilitation process at all levels. In acute rehabilitation, these issues have traditionally been addressed on an individual basis. However, in postacute settings, an interpersonal group format can be effectively implemented. The majority of individuals with TBI have minimal funding for longterm cognitive and behavioral remediation; often the only avenue available is support groups. This article will describe group psychotherapy models used with individuals with acute or postacute TBI within a comprehensive rehabilitation center. Interdisciplinary treatment of frustration and substance abuse and a continuum of care will be emphasized. Education, social support, skills development, interpersonal process, and cognitive-behavioral approaches will also be discussed. The psychotherapy groups focus on treatment of substance abuse and frustration management through education, social support, and development of interpersonal skills. Practical considerations of running such groups are presented.	Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Psychol Serv, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Speech Pathol Serv, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Recreat Serv, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Traumat Brain Injury Project, San Jose, CA 95128 USA	Delmonico, RL (corresponding author), Kaiser Fdn, Rehabil Ctr, 975 Sereno Dr, Vallejo, CA 94589 USA.						Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; BENYISHAY Y, 1979, NYU REHABIL MONOGR, V60, P39; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; CHEMTOB CM, 1997, J CONSULT CLIN PSYCH, V65, P1841; CORRIGAN JD, 1995, BRAIN INJURY, V9, P221, DOI 10.3109/02699059509008195; KLONOFF PS, 1993, B MENNINGER CLIN, V57, P227; KREUTZER J S, 1990, Brain Injury, V4, P1, DOI 10.3109/02699059009026142; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Lakin P, 1989, NEUROPSYCHOLOGICAL T; LIRA FT, 1983, INT J CLIN NEUROPSYC, V5, P159; MacKinley W. W., 1988, J HEAD TRAUMA REHAB, V3, P64; MCGLYNN SM, 1990, PSYCHOL BULL, V108, P420, DOI 10.1037/0033-2909.108.3.420; MONTGOMERY GK, 1995, BRAIN INJURY, V9, P453, DOI 10.3109/02699059509008205; NOVACO RW, 1977, J CONSULT CLIN PSYCH, V45, P600, DOI 10.1037/0022-006X.45.4.600; NOVACO RW, 1997, LEGAL CRIMINOL PSYCH, V2, P77, DOI DOI 10.1111/J.2044-8333.1997.TB00334.X; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; SPARADEO FR, 1992, NEUROREHABILITATION, V2, P65; SPARADEO FR, 1995, ADV MED PSYCHOTHER, V8, P101; SPARADEO FR, 1992, HDB ASSESSING TREATI; Spielberger C., 1991, STATE TRAIT ANGER EX; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; WILLIAMS J, 1991, HEAD INJURY FAMILY M; Yalom ID, 1975, THEORY PRACTICE GROU	25	34	38	0	13	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	1998	13	6					10	22		10.1097/00001199-199812000-00004			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	141KF	WOS:000077142300004	9885315				2021-06-18	
J	Mori, K; Maeda, M; Miyazaki, M; Iwase, H				Mori, K; Maeda, M; Miyazaki, M; Iwase, H			Effects of mild (33 degrees C) and moderate (29 degrees C) hypothermia on cerebral blood flow and metabolism, lactate, and extracellular glutamate in experimental head injury	NEUROLOGICAL RESEARCH			English	Article						head injury; hypothermia; cerebral blood flow; cerebral metabolism; glutamate	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; ISCHEMIA; RAT; MICRODIALYSIS; HIPPOCAMPUS; TEMPERATURE; RELEASE; DAMAGE; ACCUMULATION	The effects of mild (33 degrees C) and moderate (29 degrees C) hypothermia were investigated to determine which temperature was more effective against compression-induced cerebral ischemia. Eighteen cats were anesthetized. The animals were divided into three groups according to deep-brain temperature (control, 37 degrees C; mild hypothermia, 33 degrees C;and moderate hypothermia, 29 degrees C). Intracranial pressure (ICP) and cerebral blood flow (CBF) were monitored, the latter by hydrogen clearance. Arteriovenous oxygen difference (AVDO(2)) and cerebral venous oxygen saturation (ScvO(2)) were measured in blood samples from the superior sagittal sinus. The cerebral metabolic rate of oxygen (CMRO2) and the cerebral metabolic rate of lactate (CMR lactate) were calculated. Extracellular glutamate was measured by microdialysis. ICP was increased by inflation of an epidural balloon until CBF became zero, and this ischemia was maintained for 5 min, after which the balloon was quickly deflated All parameters were recorded over 6 h. Evans blue was injected to examine vascular permeability changes. CBF was decreased by 56% by mild hypothermia and by 77% by moderate hypothermia. Mild hypothermia had a coupled metabolic suppression whereas moderate hypothermia significantly increased AVDO(2) and decreased ScvO(2), producing a low CBF/CMRO2 (relative ischemia). After balloon deflation, all three groups showed reactive hyperemia, which was significantly reduced by mild and moderate hypothermia. CBF then decreased to 50% of pre-inflation values and ScvO(2) decreased (post-ischemic hypoperfusion). CBF/CMRO2, ScvO(2), and AVDO(2) did not differ significantly between the three groups. After balloon deflation, all three groups showed increased CMR lactate, which was significantly reduced by mild and moderate hypothermia. Extracellular glutamate increased:in control animals (3.8+/-1.72 mu M), an effect most effectively suppressed in the mild hypothermia group (1.0+/-0.46 mu M). Damaged tissue volumes as indicated by Evans blue dye extravasation were 729+/-89 mm(3) in control, 247+/-56 mm3 in mild hypothermia, and 267+/-35 mm(3) in moderate hypothermia animals. These data suggest that mild hypothermia (33 degrees C) might be the optimal brain temperature to treat compression-related cerebral ischemia.	Juntendo Univ, Dept Neurosurg, Izunagaoka Hosp, Shizuoka 41022, Japan; Juntendo Univ, Casualty Ctr, Izunagaoka Hosp, Shizuoka 41022, Japan	Mori, K (corresponding author), Juntendo Univ, Dept Neurosurg, Izunagaoka Hosp, 1129 Nagaoka, Shizuoka 41022, Japan.						AUKLAND K, 1964, CIRC RES, V14, P164, DOI 10.1161/01.RES.14.2.164; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BARBOUR B, 1988, NATURE, V335, P433, DOI 10.1038/335433a0; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BOELS PJ, 1985, EXPERIENTIA, V41, P1374, DOI 10.1007/BF01949995; BULLOCK R, 1992, BRIT J CLIN PHARMACO, V34, P396, DOI 10.1111/j.1365-2125.1992.tb05648.x; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P177; CLASEN RA, 1968, ARCH NEUROL-CHICAGO, V19, P472, DOI 10.1001/archneur.1968.00480050042004; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COIMBRA C, 1992, ACTA PHYSIOL SCAND, V146, P543, DOI 10.1111/j.1748-1716.1992.tb09462.x; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HAIKALA H, 1986, BRAIN RES, V375, P313, DOI 10.1016/0006-8993(86)90751-1; HALLENBECK JM, 1977, NEUROLOGY, V27, P3, DOI 10.1212/WNL.27.1.3; Huang FP, 1998, NEUROL RES, V20, P57; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; LEVY DE, 1979, NEUROLOGY, V29, P1245, DOI 10.1212/WNL.29.9_Part_1.1245; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARTINS E, 1988, J CEREBR BLOOD F MET, V8, P531, DOI 10.1038/jcbfm.1988.93; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; MITANI A, 1992, NEUROSCIENCE, V48, P307, DOI 10.1016/0306-4522(92)90492-K; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; NEMOTO EM, 1978, CRIT CARE MED, V6, P203, DOI 10.1097/00003246-197807000-00002; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SAKAMOTO N, 1986, BRAIN RES, V364, P373; Schroder ML, 1996, J NEUROTRAUM, V13, P17, DOI 10.1089/neu.1996.13.17; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; SNYDER JV, 1975, STROKE, V6, P21, DOI 10.1161/01.STR.6.1.21; WELSH FA, 1991, J CEREBR BLOOD F MET, V11, P617, DOI 10.1038/jcbfm.1991.112; YABUKI A, 1991, Neurologia Medico-Chirurgica, V31, P568, DOI 10.2176/nmc.31.568; Yager JY, 1996, STROKE, V27, P919, DOI 10.1161/01.STR.27.5.919	43	34	42	0	0	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897 USA	0161-6412			NEUROL RES	Neurol. Res.	DEC	1998	20	8					719	726					8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	146MG	WOS:000077432400009	9864737				2021-06-18	
J	Sohlberg, MM; Mateer, CA; Penkman, L; Glang, A; Todis, B				Sohlberg, MM; Mateer, CA; Penkman, L; Glang, A; Todis, B			Awareness intervention: Who needs it?	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness deficit; behavior modification; brain injury; intervention	TRAUMATIC BRAIN INJURY; HEAD-INJURY; DEFICITS; DYSFUNCTION; UNAWARENESS; ADULTS	It is widely accepted that awareness deficits present challenges to recovery and should be addressed as part of rehabilitation programming. Response to awareness intervention is commonly inferred from measurements that rely on reports by subjects and significant others. This article describes the findings from a pilot study that examined the relationship among a variety of awareness indicators in three individuals with brain damage over a 9-month period. Results suggest a dissociation between behavioral and perceptual indices of awareness. Changes in behavioral indicators of awareness selected by caregivers were not related to changes in self- or caregiver ratings. nle clinical and research implications of the findings are discussed.	Univ Oregon, Eugene, OR 97403 USA; Univ Victoria, Dept Psychol, Victoria, BC, Canada; Western Oregon Univ, Teaching Res Div, Monmouth, OR USA	Sohlberg, MM (corresponding author), Univ Oregon, 5270, Eugene, OR 97403 USA.						ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Bergquist Thomas F., 1993, Brain Injury, V7, P275, DOI 10.3109/02699059309029680; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CAVELLO MM, 1992, BRAIN INJURY, V6, P327; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; DeLuca J., 1992, NEUROREHABILITATION, V2, P23; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Herbert CM, 1989, CLIN REHABIL, V3, P125; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1986, AWARENESS DEFICIT BR; PRIGATANO GP, 1991, AWARENESS DEFICITS A; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; Rebmann MJ, 1995, REHABIL PSYCHOL, V40, P279, DOI 10.1037/0090-5550.40.4.279; SOHLBERG MM, 1994, TRAINING USE COMPENS; SOHLBERG MM, IN PRESS APHASIOLOGY; Sohlberg MM, 1996, PICTURE THIS STRATEG; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002	28	34	35	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					62	78		10.1097/00001199-199810000-00008			17	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600008	9753536				2021-06-18	
J	Pell, M; Flynn, WJ; Seibel, RW				Pell, M; Flynn, WJ; Seibel, RW			Is colostomy always necessary in the treatment of open pelvic fractures?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	11th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 14-17, 1998	SANIBEL, FLORIDA	E Assoc Surg Trauma		open pelvic fractures; fecal diversion; colostomy	INJURY; MANAGEMENT; CLOSURE	Background: Wound management in open pelvic fractures has used fecal diversion, debridement, and closure by secondary intention to prevent pelvic sepsis. Colostomy care and takedown adds to the morbidity and resource utilization of this approach, We reviewed our experience to determine if a selective approach to fecal diversion based on wound location was possible. Methods: Retrospective analysis of patients admitted to a Level I trauma center during an 8-year period, Fractures were classified as open if the fracture was in continuity with the wound. Wounds were classified as perineal if they involved the rectum, ischiorectal fossa, or genitalia, and as nonperineal if they involved the pubis anteriorly, iliac crest, or anterior thigh, Pelvic sepsis was defined as cellulitis, fasciitis, or infection of a pelvic hematoma. Diversion consisted of loop or end colostomy, Results: Eighteen patients with open fractures were identified. Four died from closed head injury and blood loss, The remaining 14 were treated as follows. Five patients with perineal wounds had diversion of their fecal stream. Their Injury Severity Score was 34 +/- 8.3 and their Revised Trauma Score was 7.69 +/- 0,15, No patient developed pelvic sepsis, Nine patients with nonperineal wounds did not undergo diversion, Their Injury Severity Score was 28.6 +/- 5.3 and their Revised Trauma Score was 7.36 +/- 0,45, No patients developed pelvic sepsis in the nondiverted group. Conclusion: No patients with anterior wounds and an intact fecal stream developed pelvic sepsis. Colostomy may not be necessary in all patients with open pelvic fracture, Protocols using fecal diversion based on wound location appear to be safe and may decrease resource utilization and subsequent morbidity related to colostomy closure.	SUNY Buffalo, Erie Cty Med Ctr & Labs, Dept Surg, Buffalo, NY 14215 USA	Flynn, WJ (corresponding author), SUNY Buffalo, Erie Cty Med Ctr & Labs, Dept Surg, Buffalo, NY 14215 USA.						AGNEW SG, 1994, ORTHOP CLIN N AM, V25, P715; DAVIDSON BS, 1993, J TRAUMA, V35, P36, DOI 10.1097/00005373-199307000-00006; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; FLINT L, 1990, ANN SURG, V211, P730; GRUEN GS, 1994, J TRAUMA, V36, P706, DOI 10.1097/00005373-199405000-00019; Khoury DA, 1996, DIS COLON RECTUM, V39, P605, DOI 10.1007/BF02056935; KUDSK KA, 1990, J TRAUMA, V30, P1155, DOI 10.1097/00005373-199009000-00012; KUSMINSKY RE, 1982, DIS COLON RECTUM, V25, P787, DOI 10.1007/BF02553312; MAULL KI, 1977, J TRAUMA, V17, P685, DOI 10.1097/00005373-197709000-00005; MILESKI W, 1991, SURG GYNECOL OBSTET, V171, P17; PORTER JA, 1989, DIS COLON RECTUM, V32, P299, DOI 10.1007/BF02553484; RICHARDSON JD, 1982, J TRAUMA, V22, P533, DOI 10.1097/00005373-198207000-00002; ROTHENBERGER D, 1978, J TRAUMA, V18, P184, DOI 10.1097/00005373-197803000-00006; SINNOTT R, 1992, AM J SURG, V163, P283, DOI 10.1016/0002-9610(92)90003-A; TRUNKEY DD, 1974, J TRAUMA, V14, P912, DOI 10.1097/00005373-197411000-00002; WONG RW, 1994, J SURG RES, V57, P289, DOI 10.1006/jsre.1994.1147	16	34	37	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	1998	45	2					371	373		10.1097/00005373-199808000-00029			3	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	109VL	WOS:000075344500039	9715198				2021-06-18	
J	Togher, L; Hand, L				Togher, L; Hand, L			Use of politeness markers with different communication partners: an investigation of five subjects with traumatic brain injury	APHASIOLOGY			English	Article; Proceedings Paper	27th Clinical Aphasiology Conference	JUN, 1997	BIGFORK, MONTANA				LANGUAGE; SKILLS	Politeness is a complex interpersonal phenomenon which has received considerable attention by linguists over recent years. This paper presents preliminary work which examines some methodological and theoretical issues related to the concept of politeness using the systemic functional approach. Results are presented for five traumatically brain injured subjects and five matched controls during telephone interactions with four different interlocutors. The results indicate that TBI subjects are able to access a wide variety of politeness strategies; however, their ability to manipulate these across the four different tenor relationships is impaired when compared with control subjects. The richness of this approach in highlighting the unique features of communication disorders following traumatic brain injury and new ways to approach their management is discussed.	Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, Lidcombe, NSW 2141, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Liverpool Are Hlth Serv, Brain Injury Rehabil Unit, Sydney, NSW, Australia	Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, Sch Commun Sci & Disorders, POB 170, Lidcombe, NSW 2141, Australia.		Togher, Leanne/AAC-7083-2019	Togher, Leanne/0000-0002-4518-6748			ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Austin John L, 1962, DO THINGS WORDS, Vsecond; Berry M., 1981, STUDIES DISCOURSE AN, P120; Brown P., 1978, QUESTIONS POLITENESS, P56, DOI DOI 10.1017/CBO9780511813085; Brown Penelope, 1987, POLITENESS SOME UNIV, DOI [10.1017/CBO9780511813085, DOI 10.2307/3587263]; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; FERGUSON A, 1992, J NEUROLINGUIST, V7, P277, DOI 10.1016/0911-6044(92)90019-S; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; Halliday M. A. K., 1978, LANGUAGE SOCIAL SEMI; Halliday M. A. K., 1985, INTRO FUNCTIONAL GRA; Halliday MA., 1970, NEW HORIZONS LINGUIS, V1, P140; Halliday MAK, 1985, LANGUAGE CONTEXT TEX; Hartley L. L., 1995, COGNITIVE COMMUNICAT; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Lakoff R., 1974, BERKLEY STUDIES SYNT, V1, P1; Martin J. R., 1992, ENGLISH TEXT SYSTEM; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MILTON SB, 1984, CLIN APHASIOLOGY C P, P114; Morgan J. L., 1975, SYNTAX SEMANTICS, V3, P59, DOI DOI 10.1017/CBO9780511609213.004; Poynton C., 1985, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Stubbs M., 1983, DISCOURSE ANAL SOCIO; TANNEN D, 1981, DISCOURSE PROCESS, V4, P221, DOI 10.1080/01638538109544517; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; ULICHNY P, 1989, DISCOURSE PROCESS, V12, P309, DOI 10.1080/01638538909544733; Ventola E., 1987, STRUCTURE SOCIAL INT	33	34	35	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	JUL-AUG	1998	12	7-8					755	770		10.1080/02687039808249571			16	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	ZU108	WOS:000074162800020					2021-06-18	
J	Kane, NM; Moss, TH; Curry, SH; Butler, SR				Kane, NM; Moss, TH; Curry, SH; Butler, SR			Quantitative electroencephalographic evaluation of non-fatal and fatal traumatic coma	ELECTROENCEPHALOGRAPHY AND CLINICAL NEUROPHYSIOLOGY			English	Article						quantitative electroencephalogram (EEG); brain-stem auditory evoked potentials (BAEPs); head injury; coma	DIFFUSE AXONAL INJURY; COMPRESSED SPECTRAL ARRAY; NONMISSILE HEAD-INJURY; EEG; PREDICTION; MANAGEMENT; COHERENCE; MILD	Diffuse axonal injury (DAI) is an important cause of morbidity and mortality after traumatic brain injury (TBI), and its severity is therefore a major determinant of outcome. There have been suggestions that the extent of DAI may be reflected in quantitative measures of cerebral function, including the electroencephalogram (EEG) and brain-stem auditory evoked potentials (BAEPs). It has therefore been proposed that these quantitative methods of analysis may provide objective predictors of outcome following TBI. We prospectively investigated the relationship between quantitative EEG and BAEP measures and outcome, in 60 comatose patients (47 male and 13 female; age range 1-80 years, mean 36.4) after severe, closed head injury (post-resuscitation Glasgow Coma Scale (GCS) of 8): The Spearman correlation coefficients (r(s)) have been calculated for quantitative EEG measures (mean regional power and interhemispheric coherence) and BAEPs with patient outcome on the Glasgow Outcome and Disability Rating Scales at 6 months and 1 year. The measures most significantly correlated with outcome (P < 0.001) are over the left hemisphere, beta activity power (amplitude squared) in the fronto-central and centro-temporal regions, and alpha activity power in the centro-temporal region. We found no correlation between interhemispheric coherence (a statistical measure of cross-correlation in the frequency domain) and outcome at either 6 months or 1 year post-injury. In 10 fatalities, we examined the relationship between interhemispheric EEG coherence prior to deaths and the histopathological severity of DAI, in concordant regions. The only significant correlation between DAI and interhemispheric coherence is seen in the alpha band at the temporo-occipital site (r(s) = -0.79, P = 0.007). Our data indicate that there is regional information in EEG power spectra over the left hemisphere, which could be used in prognostic predictions for patients in coma after severe TBI. We were unable to demonstrate a correlation between interhemispheric coherence and outcome, or any clear and consistent evidence of a relationship between interhemispheric coherence and the severity of DAI. (C) 1998 Elsevier Science Ireland Ltd.	Burden Neurol Inst, Bristol BS16 1QT, Avon, England; Frenchay Hosp, Dept Neuropathol, Bristol BS16 1LE, Avon, England	Butler, SR (corresponding author), Burden Neurol Inst, Stoke Lane, Bristol BS16 1QT, Avon, England.						ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALBERT ML, 1976, ARCH NEUROL-CHICAGO, V33, P453, DOI 10.1001/archneur.1976.00500060059013; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BARNES MP, 1991, CURR OPIN NEUROL NEU, V4, P12; BEAUMONT JG, 1978, ELECTROEN CLIN NEURO, V45, P393, DOI 10.1016/0013-4694(78)90190-6; Bricolo A, 1979, Acta Neurochir Suppl (Wien), V28, P35; BRICOLO A, 1976, CLIN ELECTROENCEPHAL, V7, P184, DOI 10.1177/155005947600700402; BRICOLO A, 1978, ELECTROEN CLIN NEURO, V45, P211, DOI 10.1016/0013-4694(78)90005-6; BUSK J, 1975, ELECTROEN CLIN NEURO, V38, P415, DOI 10.1016/0013-4694(75)90265-5; CANT BR, 1984, NEUROLOGY, V34, P35, DOI 10.1212/WNL.34.1.35; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; DASILVA FL, 1991, ELECTROEN CLIN NEURO, V79, P81, DOI 10.1016/0013-4694(91)90044-5; DAWSON RE, 1951, J NEUROSURG, V8, P613, DOI 10.3171/jns.1951.8.6.0613; DEATON A, 1993, BRAIN INJURY, V2, P99; DENNYBROWN D, 1941, BRAIN, V64, P94; DIMITRIJEVIC M R, 1989, Journal of Neurotrauma, V6, P25, DOI 10.1089/neu.1989.6.25; DIRINGER MN, 1992, CURR OPIN NEUROL NEU, V5, P826; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; FRANCZEK S, 1995, J CLIN NEUROPHYSIOL, V12, P521; GARCIALARREA L, 1992, J NEUROL NEUROSUR PS, V55, P792, DOI 10.1136/jnnp.55.9.792; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GESCHWIND N, 1985, ANN NY ACAD SCI, V386, P683; GEVINS A, 1992, J HEAD TRAUMA REHAB, V7, P78; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; KARNAZE DS, 1982, NEUROLOGY, V32, P289, DOI 10.1212/WNL.32.3.289; LEVIN HS, 1989, NEUROTRAUMA TREATMEN, P89; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RUMPL E, 1993, ELECTROENCEPHALOGRAP, P383; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; SERAFETINIDES EA, 1965, BRAIN, V88, P102; SHAW JC, 1981, J MED ENG TECHNOL, V5, P279, DOI 10.3109/03091908109009362; *SOC CRIT CAR MED, 1988, CRIT CARE MED, V16, P807; Steudel W I, 1979, Acta Neurochir Suppl (Wien), V28, P40; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SYMONDS C, 1962, LANCET, V1, P1; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; VESELIS RA, 1992, BRIT J ANAESTH, V69, P246, DOI 10.1093/bja/69.3.246	46	34	40	0	1	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0013-4694			ELECTROEN CLIN NEURO	Electroencephalogr. Clin. Neurophysiol.	MAR	1998	106	3					244	250		10.1016/S0013-4694(97)00141-7			7	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	ZF715	WOS:000072924800010	9743283				2021-06-18	
J	Pike, BR; Hamm, RJ				Pike, BR; Hamm, RJ			Activating the posttraumatic cholinergic system for the treatment of cognitive impairment following traumatic brain injury	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						M-1 agonist; M-2 antagonist; Morris water maze; muscarinic; rats; spatial memory; treatment	CLOSED-HEAD-INJURY; FLUID-PERCUSSION INJURY; MUSCARINIC RECEPTORS; RATS; SCOPOLAMINE; DEFICITS; ADAPTATIONS; ANTAGONIST; BASAL; MOTOR	Cognitive impairment after traumatic brain injury (TBI) is correlated with decreased cholinergic markers of neuronal viability. The purpose of this experiment was to test the hypothesis that pharmacological activation of the muscarinic cholinergic system during the recovery period after TBI will improve cognitive performance. LU 25-109-T is a partial muscarinic M-1 agonist that also acts as an antagonist at presynaptic M-2 autoreceptors (thus, increasing ACh release). Injured rats were injected subcutaneously daily for 15 days with either 0.0, 3.6, or 15 mu mol/kg of LU 25-109-T beginning 24 h after a receiving a moderate (2.1 +/- 0.1 arm) level of central fluid percussion brain injury. Cognitive performance was assessed on days 11-15 postinjury in a Morris water maze (MWM). Injured rats treated with 15 mu mol/kg, but not those treated with 3.6 mu mol/kg, showed a significant improvement (P < 0.01) in MWM performance as compared with injured vehicle-treated rats. This result supports the hypotheses that a decrease in posttraumatic cholinergic neurotransmission contributes to TBI-induced cognitive deficits and that increasing cholinergic tone during the recovery period following TBI will improve cognitive performance. (C) 1997 Elsevier Science Inc.	VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		BECKER RE, 1988, DRUG DEVELOP RES, V12, P163, DOI 10.1002/ddr.430120302; BENBARAK J, 1981, EUR J PHARMACOL, V74, P73, DOI 10.1016/0014-2999(81)90325-3; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BUYUKUYSAL RL, 1989, BRAIN RES, V482, P371; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; Dixon C. E., 1995, Society for Neuroscience Abstracts, V21, P762; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Doods Henri N., 1995, Drugs of the Future, V20, P157; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HAYES RL, 1988, J NEUROTRAUM, V5, P287; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; Liu S. J., 1993, Society for Neuroscience Abstracts, V19, P1881; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARKS MJ, 1981, J PHARMACOL EXP THER, V218, P337; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MEIER E, 1995, LIFE SCI, V56, P1006, DOI 10.1016/0024-3205(95)93724-S; MEIER E, IN PRESS DRUG DEV RE; Moltzen Ejner K., 1995, Drugs of the Future, V20, P37; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PEDIGO NW, 1988, PSYCHOPHARMACOLOGY, V95, P497; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; SARTER M, 1990, PSYCHOPHARMACOLOGY, V101, P1, DOI 10.1007/BF02253710; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SCHMITTEREDGECOMBE ME, 1992, J CLIN EXP NEUROPSYC, V14, P717, DOI 10.1080/01688639208402858; Sinson G., 1995, Society for Neuroscience Abstracts, V21, P2121; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Taylor Palmer, 1994, P231	41	34	34	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	AUG	1997	57	4					785	791		10.1016/S0091-3057(96)00453-4			7	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	XN588	WOS:A1997XN58800021	9259007				2021-06-18	
J	McGregor, K; Pentland, B				McGregor, K; Pentland, B			Head injury rehabilitation in the UK: An economic perspective	SOCIAL SCIENCE & MEDICINE			English	Article						brain injury; rehabilitation; economic evaluation; review; UK	TRAUMATIC BRAIN INJURY; COST-EFFECTIVENESS; HEALTH-STATUS; PROGRAM; DISABILITY; COMMUNITY; BENEFIT; IMPACT; SCALE; COMA	The human and societal costs as a result of traumatic brain injury (TBI) are extensive with approximately 200-300/100000 of the population requiring hospitalisation each year in the U.K. Advances in neurosurgical management have meant that more people sustaining head injuries are surviving. The need for rehabilitation programmes for these individuals is therefore ever increasing. While in the U.S.A. rehabilitation programmes for TBI patients are well established, in the U.K. the provision of such services is patchy and varies widely in different localities. The belated response to the rehabilitation needs of this group of individuals in the U.K., has coincided with an increased awareness of the economic efficiency of health care provision. This paper critically reviews published studies looking at the economics of rehabilitation services for brain injured patients. No studies in the U.K. were identified and all the sources discussed are from the U.S.A. The methodological guidelines underlying economic appraisal of health care are summarised and the studies assessed to determine the extent to which they fulfil these guidelines. The paper concludes that most studies purporting to provide evidence of cost-effectiveness did not include appropriate data, nor followed the methodological guidelines allowing such claims to be made. Some recommendations for future research are presented. (C) 1997 Elsevier Science Ltd.	UNIV EDINBURGH, REHABIL STUDIES UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND	McGregor, K (corresponding author), LOTHIAN CLIN AUDIT, 158-162 CAUSEWAYSIDE, 3RD FLOOR, EDINBURGH EH9 1PZ, MIDLOTHIAN, SCOTLAND.						Abrams D., 1993, J HEAD TRAUMA REHAB, V8, P59; Andrews K, 1991, CLIN REHABIL, V5, P5, DOI DOI 10.1177/026921559100500102; ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; BARRY P, 1993, J HEAD TRAUMA REHAB, V8, P48; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; COLE JR, 1985, ARCH PHYS MED REHAB, V66, P38; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; Drummond ME, 1987, METHODS EC EVALUATIO; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GILES GM, 1994, AM J OCCUP THER, V48, P199, DOI 10.5014/ajot.48.3.199; GLADMAN JRF, 1991, CLIN REHABIL, V5, P9; GRABOW JD, 1984, AM J PUBLIC HEALTH, V74, P710, DOI 10.2105/AJPH.74.7.710; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HARLAN LC, 1990, AM J PUBLIC HEALTH, V80, P453, DOI 10.2105/AJPH.80.4.453; HENDERSON EJ, 1990, CLIN REHABIL, V41, P167; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON M V, 1991, Brain Injury, V5, P155, DOI 10.3109/02699059109008086; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MACKENZIE EJ, 1990, J TRAUMA, V30, P1096, DOI 10.1097/00005373-199009000-00005; MACKENZIE EJ, 1988, JAMA-J AM MED ASSOC, V260, P3290, DOI 10.1001/jama.260.22.3290; MAHONEY F I, 1965, Md State Med J, V14, P61; MAIR A, 1972, MED REHABILITATION P; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; MALKAMUS D, 1979, REHABILITATION HEAD; McKinlay W W, 1987, Brain Inj, V1, P3, DOI 10.3109/02699058709034438; McLaughlin Ann Marie, 1993, Brain Injury, V7, P71, DOI 10.3109/02699059309008158; MCMILLAN T, 1993, NEUROLOGICAL REHABIL, P437; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MILLIMAN JF, 1990, RES PERS H, V2, P21; Pentland B, 1990, Int Disabil Stud, V12, P86; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sakata R, 1991, Brain Inj, V5, P411, DOI 10.3109/02699059109008114; Servadei F, 1988, Brain Inj, V2, P87, DOI 10.3109/02699058809150935; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; TEASDALE G, 1974, LANCET, V2, P81; UDVARHELYI IS, 1992, ANN INTERN MED, V116, P238, DOI 10.7326/0003-4819-116-3-238; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WEST M, 1991, ARCH PHYSICAL REHABI, V72, P1127; 1990, LANCET, V335, P886	50	34	34	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	JUL	1997	45	2					295	303		10.1016/S0277-9536(96)00345-0			9	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	XE610	WOS:A1997XE61000011	9225416				2021-06-18	
J	Heath, DL; Vink, R				Heath, DL; Vink, R			Magnesium sulphate improves neurologic outcome following severe closed head injury in rats	NEUROSCIENCE LETTERS			English	Article						diffuse axonal injury; trauma; magnesium; brain	TRAUMATIC BRAIN INJURY; NEURONS; RECEPTORS; MG-2+	While recent evidence suggests that brain intracellular free magnesium concentration declines following severe diffuse traumatic brain injury. no studies have examined whether magnesium administration following such injury can improve subsequent neurologic outcome. The present study shows that MgSO4 administered as a bolus at 30 min following severe closed head injury in rats significantly improves posttraumatic neurologic outcome as assessed by both rotarod and angleboard tests. Moreover, this improvement in outcome was evident with both intravenous and intramuscular drug administration. We conclude that parenteral administration of magnesium sulphate may be neuroprotective following severe closed head injury of a diffuse nature. (C) 1997 Elsevier Science Ireland Ltd.	JAMES COOK UNIV N QUEENSLAND,DEPT PHYSIOL & PHARMACOL,TOWNSVILLE,QLD 4811,AUSTRALIA			AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667			Bara M, 1984, MAGNESIUM, V3, P212; BRAUGHLER JM, 1992, J NEUROTRAUMA, V9, P1; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1995, J NEUROTRAUM, V12, P1027, DOI 10.1089/neu.1995.12.1027; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	23	34	35	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	JUN 13	1997	228	3					175	178		10.1016/S0304-3940(97)00394-7			4	Neurosciences	Neurosciences & Neurology	XJ901	WOS:A1997XJ90100009	9218636				2021-06-18	
J	Chiu, WT; Yeh, KH; Li, YC; Gan, YH; Chen, HY; Hung, CC				Chiu, WT; Yeh, KH; Li, YC; Gan, YH; Chen, HY; Hung, CC			Traumatic brain injury registry in Taiwan	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; helmet use; Registry	HELMET USE LAWS; HEAD TRAUMA; POPULATION; FATALITIES; REPEAL	This project was designed to examine the epidemiology of traumatic brain injury (TBI) in Taiwan. A total of 58,563 cases of TBI was collected from 114 hospitals in Taiwan during the period July 1, 1988-June 30, 1994. Traffic accident was the major cause of TBI (69.4%), followed by falls and assaults. Motorcyclists accounted for the vast majority of TBI cases among traffic accident victims (64.5%). The Glasgow Coma Scale was used in assessing the severity. 41,646 cases (79.5%) were considered mild, 4,637 cases (8.9%) moderate, and 6,078 cases (11.6%) severe. Skull x-ray showed fracture in 7,663 cases (14.6%). Intracranial hemorrhage was identified in 28.6% of patients receiving CT scanning. Craniotomy was performed in 5,226 cases (9%). The outcome of TBI was determined by the Glasgow Outcome Scale. Death occurred in 2,621 cases (5.4%), vegetative state in 429 cases (0.9%), severe disability in 1,293 cases (2.6%1, moderate disability in 1,890 cases (3.9%), and good recovery in 42,596 cases (87.2%). The severity and outcome were worse than those of Western reports. In order to alleviate this problem, a helmet use persuasion program was conducted by the Police Department in Taipei City from January to lune, 1994. Results of this program showed a significant reduction of TBI-related hospitalization, severity and fatality during this period of intervention. This study points out the seriousness of TBI in Taiwan and suggests some approaches and priorities for prevention.	NATL TAIWAN UNIV,TAIPEI 10764,TAIWAN	Chiu, WT (corresponding author), TAIPEI MED COLL,TAIPEI,TAIWAN.			Chen, Shawn Hsiang-Yin/0000-0001-5535-7152; Li, Yu-Chuan (Jack)/0000-0001-6497-4232			Anderson DW, 1980, J NEUROSURG S, V53, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; ANNEGERS JF, 1979, CENTRAL NERVOUS SYST; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; FRANKOWSKI RF, 1985, ADV PSYCHOSOM MED, V16, P153; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNET B, 1981, BRIT MED J, V282, P153; JENNET B, 1980, CLIN NEUROEPIDEMIOLO, P356; JENNETT B, 1975, LANCET, V1, P480; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; KRAUS JF, 1980, J NEUROSURG, V53, P803; MCHUGH TP, 1985, JSC MED ASS, V6, P588; McSwain N.E., 1984, IMPACT REENACTMENT M; MCSWAIN NE, 1980, SURG GYNECOL OBSTET, V151, P215; MCSWAIN NE, 1990, J TRAUMA, V30, P1189, DOI 10.1097/00005373-199010000-00002; Mounce N., 1992, REINSTATED COMPREHEN; MURDOCK MA, 1991, WESTERN J MED, V155, P370; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; Nygren A, 1986, Acta Neurochir Suppl (Wien), V36, P10; PARKISON D, 1985, CAN J SURG, V28, P78; RUSSO PK, 1978, NEW ENGL J MED, V299, P1074, DOI 10.1056/NEJM197811092991915; Servadei F, 1985, J Neurosurg Sci, V29, P297; TEASDALE G, 1974, LANCET, V2, P81; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; WATSON GS, 1981, AM J PUBLIC HEALTH, V71, P297, DOI 10.2105/AJPH.71.3.297; WATSON GS, 1980, AM J PUBLIC HEALTH, V70, P579, DOI 10.2105/AJPH.70.6.579; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WOODWARD A, 1984, MED J AUSTRALIA, V141, P13, DOI 10.5694/j.1326-5377.1984.tb132660.x	33	34	34	0	3	FOREFRONT PUBL GROUP	WILTON	C/O MARY J RAWLINS, 5 RIVER RD, STE 113, WILTON, CT 06897	0161-6412			NEUROL RES	Neurol. Res.	JUN	1997	19	3					261	264		10.1080/01616412.1997.11740811			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	XC468	WOS:A1997XC46800010	9192378				2021-06-18	
J	Springer, JA; Farmer, JE; Bouman, DE				Springer, JA; Farmer, JE; Bouman, DE			Common misconceptions about traumatic brain injury among family members of rehabilitation patients	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY	Objective: To investigate misconceptions about traumatic brain injury (TBI) held by family members early in the recovery process and to compare family responses to those reported by the general public. Design: Descriptive survey. Setting: Rehabilitation hospital. Participants: 51 family members and close friends (eg, fiances) of patients with acquired brain injury who were admitted for rehabilitation. Convenience sample. Interventions: None. Main Outcome Measure: A 40-item questionnaire assessing knowledge about TBI, adapted from previously published interview surveys of the general public. Results: Family members endorsed common misconceptions about TBI, especially in the areas of unconsciousness, amnesia, and recovery. Compared to previous surveys of the general public, they showed: (1) better understanding of the immediate significance of brain injury and its negative impact on cognition and (2) more misconceptions on items assessing beliefs about the patient's potential long-term outcome and future vulnerability. Conclusions: Some misconceptions held by family members may be detrimental to the rehabilitation process and should be addressed through improved family education. Other misconceptions may be related to optimistic appraisal strategies that help families cope. The self-report TBI questionnaire can be used to clarify family educational needs and may also sensitize professionals to family coping issues. More research is needed to determine the impact of family knowledge and beliefs about TBI on the recovery process.	UNIV MISSOURI, SCH MED, DEPT PHYS MED & REHABIL, COLUMBIA, MO USA; UNIV CINCINNATI, MED CTR, DEPT PHYS MED & REHABIL, CINCINNATI, OH 45267 USA; DRAKE CTR INC, DEPT PSYCHOL, TRAUMAT BRAIN INJURY PROGRAM, CINCINNATI, OH USA	Springer, JA (corresponding author), MED COLL WISCONSIN, DEPT NEUROL, MCW CLIN FROEDTERT, 9200 W WISCONSIN AVE, MILWAUKEE, WI 53226 USA.						Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; MERRITT KL, 1990, PSYCHOL REP, V67, P129, DOI 10.2466/PR0.67.5.129-130; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; SANGER MS, 1993, J DEV BEHAV PEDIATR, V14, P88; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TAYLOR SE, 1989, J SOC CLIN PSYCHOL, V8, P114, DOI 10.1521/jscp.1989.8.2.114; TAYLOR SE, 1990, AM PSYCHOL, V45, P40, DOI 10.1037/0003-066X.45.1.40; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHYTE J, 1994, J HEAD TRAUMA REHAB, V9, pR6, DOI 10.1097/00001199-199409000-00002; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	14	34	34	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1997	12	3					41	50		10.1097/00001199-199706000-00005			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XC699	WOS:A1997XC69900005					2021-06-18	
J	Amirjamshidi, A; Abbassioun, K; Roosbeh, H				Amirjamshidi, A; Abbassioun, K; Roosbeh, H			Air-gun pellet injuries to the head and neck	SURGICAL NEUROLOGY			English	Article						air-gun pellet; brain abscess; brain injury; missile; traumatic aneurysm	CRANIOCEREBRAL GUNSHOT WOUNDS; INTERNAL CAROTID-ARTERY; TRAUMATIC ANEURYSMS; PENETRATING WOUNDS; LEBANESE CONFLICT; CIVILIAN PRACTICE; MISSILE INJURIES; BRAIN; MANAGEMENT; VIETNAM	BACKGROUND Air-gun pellet injuries (AgPI) of the central nervous system (CNS) are rare but catastrophic events. They occur mostly in children and young adults. The entrance is usually either through the orbit or through the neck and the entry wound is so small that it may be disregarded on physical examination in the emergency room. Early recognition and correct management of the possible complications of AgPIs is important and may prevent a poor outcome. METHODS We intend to present our experience with 16 cases of AgPIs of the head and neck referred to the department of neurosurgery during the last 15 years. The characteristic findings on physical examination of the cases and the imaging studies performed are described. Special management undertaken for the rare complications are mentioned and a short literature review is performed on each entity. RESULTS All our cases happened in the first and second decades of life and only in boys playing with toy guns. There were 12 head and face and four neck wounds. Damaged globe that had to be exenterated was the earliest complication, handled by ophthalmologists (four cases). Cerebrospinal fluid (CSF) leakage, meningitis, brain abscess formation, development of traumatic aneurysm (TA), carotid-cavernous sinus fistula (CCF), wandering intracerebral and intraventricular pellet, and splitting of the pellet after striking hard bone were the complications noted. In addition to plain X ray films, computed tomography (CT) scanning and angiography were diagnostic procedures of choice CONCLUSIONS The present series of patients is the largest collection of AgPIs to the head and neck reported in the literature in which nearly all the possible complications of such injuries have been reviewed. Early recognition and awareness of the possible cumbersome complications of such a minor penetrating wound can prevent major catastrophies in this young group of victims. (C) 1997 by Elsevier Science Inc.	UNIV TEHRAN, TEHRAN, IRAN	Amirjamshidi, A (corresponding author), SINA HOSP, DEPT NEUROSURG, IMAM AVE, TEHRAN, IRAN.						AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; APPLEGATE LJ, 1990, NEUROSURGERY, V20, P312; BISHOP EJ, 1967, NEUROSURGERY TRAUMA, P203; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; BYRNES DP, 1974, BRIT J SURG, V61, P169, DOI 10.1002/bjs.1800610302; Campbell E, 1942, ARCH SURG-CHICAGO, V44, P789, DOI 10.1001/archsurg.1942.01210230013002; CAREY ME, 1972, SURG GYNECOL OBSTETR, V135, P386; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; CHAPMAN PH, 1985, CONCEPTS PEDIAT NEUR, V5, P1; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; DEYSINE M, 1969, SURGERY, V66, P1004; EICHLER A, 1969, J NEUROSURG, V31, P72, DOI 10.3171/jns.1969.31.1.0072; FURLOW LT, 1947, J NEUROSURG, V4, P380, DOI 10.3171/jns.1947.4.4.0380; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HAYNES WG, 1945, J NEUROSURG, V2, P365, DOI 10.3171/jns.1945.2.5.0365; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; KOJIMA T, 1987, NEUROSURGERY, V20, P322, DOI 10.1227/00006123-198702000-00022; MALTBY GL, 1946, J NEUROSURG, V3, P239, DOI 10.3171/jns.1946.3.3.0239; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; PENECK TL, 1986, J NEUROSURG, V64, P813; POZZATI E, 1982, J NEUROSURG, V57, P418, DOI 10.3171/jns.1982.57.3.0418; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; RAHMAT H, 1984, J NEUROSURG, V60, P630, DOI 10.3171/jns.1984.60.3.0630; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RICH NM, 1980, AM J SURG, V139, P414, DOI 10.1016/0002-9610(80)90304-9; ROSS DA, 1988, NEUROSURGERY, V22, P414, DOI 10.1227/00006123-198802000-00025; SADAR ES, 1973, SURG GYNECOL OBSTET, V137, P59; SHUMACKER HB, 1955, VASCULAR SURG WORLD, P361; Small JM, 1945, BRIT J SURG, V32, P414, DOI 10.1002/bjs.18003212715; TAHA JM, 1991, NEUROSURGERY, V29, P380, DOI 10.1227/00006123-199109000-00007; TEAL JS, 1973, J NEUROSURG, V38, P568, DOI 10.3171/jns.1973.38.5.0568; THOMAS JN, 1979, J LARYNGOL OTOL, V93, P383, DOI 10.1017/S0022215100087168; VAQUERO J, 1982, NEURORADIOLOGY, V23, P161; YONAS H, 1980, NEUROSURGERY, V7, P499, DOI 10.1227/00006123-198011000-00016	41	34	35	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	APR	1997	47	4					331	338		10.1016/S0090-3019(96)00357-6			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WR392	WOS:A1997WR39200016	9122835				2021-06-18	
J	McKinley, BA; Morris, WP; Parmley, CL; Butler, BD				McKinley, BA; Morris, WP; Parmley, CL; Butler, BD			Brain parenchyma PO2, PCO2, and pH during and after hypoxic, ischemic brain insult in dogs	CRITICAL CARE MEDICINE			English	Article						fiberoptic sensors; tissue Po-2, Pco(2), pH; brain parenchyma; interstitial fluid; intracranial pressure; head injury; oxygenation; tissue perfusion; blood gas analysis; neurologic emergencies; brain; traumatic brain injury; stroke	INTRAARTERIAL BLOOD-GAS; INTRACELLULAR PH; EXTRACELLULAR PH; GLOBAL-ISCHEMIA; RAT-BRAIN; MONITORING-SYSTEM; CEREBRAL-ISCHEMIA; FLUORESCENCE; HYPERCAPNIA; SENSORS	Objectives: 1) The investigation of fiberoptic Po-2, Pco(2), and pH sensor technology as a monitor of brain parenchyma during and after brain injury, and 2) the comparison of brain parenchyma Po-2, Pco(2), acid pH with intracranial pressure during and after hypoxic, ischemic brain insult. Design: Prospective, controlled, animal study in an acute experimental preparation. Setting: Physiology laboratory in a university medical school. Subjects: Fourteen mongrel dogs (20 to 35 kg), anesthetized, room air ventilated, Interventions: Anesthesia was induced with thiopental and maintained after intubation using 1% to 1.5% halothane in room air (Re, 0.21). Mechanical ventilation was established to maintain end-tidal Pco(2) similar to 35 torr (similar to 4.7 kPa). Intravenous, femoral artery, and pulmonary artery catheters were placed. The common carotid arteries were surgically exposed, and ultrasonic blood flow probes were applied. A calibrated intracranial pressure probe was placed through a right side transcranial bolt, and a calibrated intracranial chemistry probe with optical sensors for Po-2, Pco(2), and pH was placed through a left-side bolt into brain parenchyma. Brain insult was induced in the experimental group (n = 6) by hypoxia (Flo(2) 0.1), ischemia (bilateral carotid artery occlusion), and hypotension (mean arterial pressure [MAP] similar to 40 mm Hg produced with isoflurane similar to 4%). After 45 mins, carotid artery occlusion was released, Flo(2) was reset to 0.21, and anesthetic was returned to halothane (similar to 1.25%). The control group (n = 5) had the same surgical preparation and sequence of anesthetic agent exposure but no brain insult. Measurements and Main Results: Monitored variables included brain parenchyma Po-2, Pco(2), and pH, which were monitored at 1-min intervals, and intracranial pressure, MAP, arterial hemoglobin oxygen saturation (by pulse oximetry), end-tidal Pco(2), and carotid artery blood flow rate, for which data were collected at 15-min intervals for 7 hrs. Arterial and mixed venous blood gas analyses were done at similar to 1-hr intervals. Baseline data agreed closely with other published results: brain parenchyma PO2 of 27 +/- 7 (SD) torr (3.6 +/- 0.9 kPa); brain parenchyma PCO2 of 69 +/- 12 torr (9.2 +/- 1.6 kPa); and brain parenchyma pH of 7.13 +/- 0.09. Postcalibration data were accurate, indicating stability and durability over several hours. In six experiments, during the brain insult, brain parenchyma PO2 decreased to 16 +/- 2 torr (2.1 +/- 0.3 kPa), brain parenchyma Pco(2) increased to 105 +/- 44 torr (14 +/- 5.9 kPa) (p <.05), and brain parenchyma pH decreased to 6.75 +/- 0.08 (p <.05). Intracranial pressure (ICP) remained nearly constant (baseline 16 +/- 6 to 14 +/- 5 mm Hg at the end of the brain insult). Cerebral perfusion pressure (CPP = MAP - ICP) decreased (baseline 95 +/- 15 to 28 +/- 8 mm Hg; p <.05). On release of brain insult stresses, ICP increased to 30 +/- 9 mm Hg and CPP increased to 71 +/- 19 mm Hg (p<.05). A biphasic recovery was observed for brain parenchyma pH, which had the slowest recovery of the monitored variables. On average, brain parenchyma pH gradually returned toward baseline, and was no longer significantly different from baseline 3 hrs after release of insult stresses. Brain parenchyma Pco(2) continued to decrease rapidly after brain insult and then remained -52 +/- 10 torr (-6.9 +/- 1.3 kPa) (p <.05). Brain parenchyma Po-2 increased from a minimum at the end of brain insult to a maximum of 43 +/- 17 torr (5.7 +/- 2.3 kPa) within 1.25 hrs (p <.05), and then gradually decreased to -35 +/-10 torr (similar to 4.7 +/- 1.3 kPa). Cerebral perfusion pressure gradually decreased as ICP increased 3 to 5 hrs after insult. Conclusions: Intracranial chemistry probes with optical sensors demonstrated stable, reproducible monitoring of brain parenchyma Po-2, Pco(2), and pH in dogs for periods lasting 28 hrs. Significant changes in brain parenchyma Po-2, Pco(2), and pH occurred without corresponding changes in intracranial pressure. Placement of intracranial chemistry probes can be accomplished with techniques similar to those used for standard intracranial pressure probes.		McKinley, BA (corresponding author), UNIV TEXAS, SCH MED, DEPT ANESTHESIOL, HOUSTON, TX 77030 USA.						ADAMS JE, 1962, J NEUROSURG, V19, P959, DOI 10.3171/jns.1962.19.11.0959; ANDERSON RE, 1983, J CEREBR BLOOD F MET, V3, P493, DOI 10.1038/jcbfm.1983.76; Behar K L, 1993, Acta Neurochir Suppl (Wien), V57, P9; BICKLER PE, 1988, J APPL PHYSIOL, V65, P422; CLARK LC, 1958, J APPL PHYSIOL, V13, P85; CROCKARD HA, 1976, J NEUROL SCI, V27, P17, DOI 10.1016/0022-510X(76)90231-8; CROWELL JW, 1961, AM J PHYSIOL, V200, P743; Gadian D G, 1993, Acta Neurochir Suppl (Wien), V57, P1; GAHAR J, 1995, CRIT CARE MED, V23, P560; GEHRICH JL, 1986, IEEE T BIO-MED ENG, V33, P117, DOI 10.1109/TBME.1986.325886; GLEICHMANN U, 1962, ACTA PHYSIOL SCAND, V55, P127, DOI 10.1111/j.1748-1716.1962.tb02425.x; GRABER ML, 1986, ANAL BIOCHEM, V156, P202, DOI 10.1016/0003-2697(86)90174-0; GRIFFITH JK, 1992, BRAIN RES, V573, P1, DOI 10.1016/0006-8993(92)90108-L; GUYTON AC, 1976, TXB MED PHYSL, P485; HALLER M, 1994, CRIT CARE MED, V22, P580, DOI 10.1097/00003246-199404000-00012; HARRIS RJ, 1987, J CEREBR BLOOD F MET, V7, P599, DOI 10.1038/jcbfm.1987.111; Hossmann K A, 1993, Acta Neurochir Suppl (Wien), V57, P21; INGVAR DH, 1960, ACTA PHYSIOL SCAND, V48, P373, DOI 10.1111/j.1748-1716.1960.tb01870.x; JAVAHERI S, 1982, B EUR PHYSIOPATH RES, V18, P775; KATSURA K, 1993, J CEREBR BLOOD F MET, V13, P820, DOI 10.1038/jcbfm.1993.104; KATSURA K, 1994, BRAIN RES, V651, P47, DOI 10.1016/0006-8993(94)90679-3; KENNEALY JA, 1980, AM REV RESPIR DIS, V122, P407; LARSON CP, 1994, ANESTHESIOLOGY, V81, P543, DOI 10.1097/00000542-199409000-00005; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; LUBBERS DW, 1995, ACTA ANAESTH SCAND, V39, P37; MAAS AIR, 1993, ACTA NEUROCHIR, P50; MAHUTTE CK, 1990, J CLIN MONITOR, V6, P147, DOI 10.1007/BF02828293; MCKINLEY BA, 1995, CRIT CARE MED S, V23, pA247; Middleman S., 1972, TRANSPORT PHENOMENA, P116; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581; OPITZ N, 1987, INT ANESTHESIOL CLIN, V25, P177; PONTEN U, 1966, ACTA PHYSIOL SCAND, V67, P129, DOI 10.1111/j.1748-1716.1966.tb03294.x; PORTMAN MA, 1991, J APPL PHYSIOL, V71, P2168; SCHLAIN L, 1994, P SOC PHOTO-OPT INS, V2131, P452, DOI 10.1117/12.180742; SEITZ WR, 1988, CRC CR REV ANAL CHEM, V19, P135, DOI 10.1080/10408348808085620; SEYLAZ J, 1978, J APPL PHYSIOL, V44, P528; SHAPIRO BA, 1989, CRIT CARE MED, V17, P455, DOI 10.1097/00003246-198905000-00016; SHAPIRO HM, 1986, ANESTHESIA, V2, P1266; SIESJO BK, 1972, J NEUROCHEM, V19, P2483, DOI 10.1111/j.1471-4159.1972.tb01308.x; SNYDER JV, 1975, STROKE, V6, P21, DOI 10.1161/01.STR.6.1.21; SONNENSCHEIN RR, 1953, REV SCI INSTRUM, V24, P702, DOI 10.1063/1.1770819; SUNDT TM, 1980, J NEUROPHYSIOL, V44, P60; SYMON L, 1993, ACTA NEUROCHIR S, V59, P102; TOMLINSON FH, 1993, STROKE, V24, P435, DOI 10.1161/01.STR.24.3.435; VENKATESH B, 1994, CRIT CARE MED, V22, P588, DOI 10.1097/00003246-199404000-00013; ZIMMERMAN J, 1994, CRIT CARE MED, V22, P588	47	34	36	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	1996	24	11					1858	1868		10.1097/00003246-199611000-00016			11	Critical Care Medicine	General & Internal Medicine	VT116	WOS:A1996VT11600016	8917037				2021-06-18	
J	BakerPrice, LA; Persinger, MA				BakerPrice, LA; Persinger, MA			Weak, but complex pulsed magnetic fields may reduce depression following traumatic brain injury	PERCEPTUAL AND MOTOR SKILLS			English	Article							CLINICAL POPULATIONS; NORMATIVE DATA; EPILEPSY; PHENOMENOLOGY; STIMULATION; INDEXES; SENSE	Many patients who display psychological depression following a traumatic brain injury do not respond completely to antidepressant drugs. We hypothesized that this type of depression is strongly correlated with subclinical, complex partial seizure-activity within the hippocampal-amygdaloid region that continues for months to years after apparent neurological and behavioral ''recovery.'' Four depressed patients who had sustained traumatic brain injuries and who exhibited mild to moderate brain impairment according to standardized tests received 30 min. of weak (1 mu T) burst-firing magnetic fields across the temporal lobes once per week for 5 weeks. There was a significant improvement of depression and reduction of phobias while physical symptoms and other complaints were not changed.	LAURENTIAN UNIV,DEPT PSYCHOL,CLIN NEUROPSYCHOL LAB,SUDBURY,ON P3E 2C6,CANADA							BANCAUD J, 1994, BRAIN, V117, P71, DOI 10.1093/brain/117.1.71; Beck A.T., 1987, BECK DEPRESSION INVE; BUREAU YRJ, 1995, ELECTRO MAGNETOBIOL, V14, P1, DOI 10.3109/15368379509028464; DEROGATIS LR, 1994, S CHECK LIST 90 R MI; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; GILLIS C, 1993, PERCEPT MOTOR SKILL, V76, P168, DOI 10.2466/pms.1993.76.1.168; JACOBSON JI, 1994, PANMINERVA MED, V36, P201; JOFFE TR, 1994, ANTICONVULSANTS MOOD; JOHN ER, 1990, MACHINERY OF THE MIND, P27; PERSINGER MA, 1995, PERCEPT MOTOR SKILL, V80, P1011, DOI 10.2466/pms.1995.80.3.1011; Persinger MA, 1995, PERCEPT MOTOR SKILL, V81, P1283, DOI 10.2466/pms.1995.81.3f.1283; PERSINGER MA, 1994, INT J NEUROSCI, V79, P191, DOI 10.3109/00207459408986080; PERSINGER MA, 1993, J CLIN PSYCHOL, V49, P33, DOI 10.1002/1097-4679(199301)49:1<33::AID-JCLP2270490106>3.0.CO;2-H; PERSINGER MA, 1994, PSYCHOL REP, V75, P1059, DOI 10.2466/pr0.1994.75.3.1059; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; PERSINGER MA, 1993, HEALING SUFFERING DE, P227; RICHARDS PM, 1993, INT J NEUROSCI, V71, P71, DOI 10.3109/00207459309000594; Richards PM, 1996, ELECTRO MAGNETOBIOL, V15, P141, DOI 10.3109/15368379609009830; ROBERTS RJ, 1992, EPILEPSY RES, V13, P167, DOI 10.1016/0920-1211(92)90073-3; ROBERTSON MM, 1987, EPILEPSIA, V28, P364, DOI 10.1111/j.1528-1157.1987.tb03659.x; RUTTAN LA, 1990, J BIOELECTRICITY, V9, P33, DOI 10.3109/15368379009027758; SANDYK R, 1994, INT J NEUROSCI, V77, P203, DOI 10.3109/00207459408986032; SANDYK R, 1995, INT J NEUROSCI, V81, P199, DOI 10.3109/00207459509004887; SANDYK R, 1994, INT J NEUROSCI, V75, P213, DOI 10.3109/00207459408986305; TILLER SG, 1994, INT J NEUROSCI, V79, P157, DOI 10.3109/00207459408986076; WAHLER HJ, 1973, WAHLER PHYSICAL SYMP; ZYSS T, 1994, MED HYPOTHESES, V43, P69, DOI 10.1016/0306-9877(94)90052-3	27	34	34	0	0	PERCEPTUAL MOTOR SKILLS	MISSOULA	PO BOX 9229, MISSOULA, MT 59807	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	OCT	1996	83	2					491	498		10.2466/pms.1996.83.2.491			8	Psychology, Experimental	Psychology	VL128	WOS:A1996VL12800023	8902023				2021-06-18	
J	Novack, TA; Caldwell, SG; Duke, LW; Bergquist, TF; Gage, RJ				Novack, TA; Caldwell, SG; Duke, LW; Bergquist, TF; Gage, RJ			Focused versus unstructured intervention for attention deficits after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							HEAD-INJURY; PROGRAM	Objective: To examine the effectiveness of focused versus unstructured cognitive remediation to address attention deficits following traumatic brain injury (TBT). Based on previous reports on postacute TBI subjects, it was hypothesized that focused intervention would yield superior results. Design: Intervention study with pre- and posttreatment data collection. Setting: Acute rehabilitation hospital. Patients: Sixty-one consecutive patients with severe TBI referred for cognitive remediation were randomly assigned to focused or unstructured remediation of attention deficits. From this sample, 22 pairs were selected, matched for age, education, time postonset of injury, and number of remediation sessions. Interventions: Structured, hierarchical interventions were presented to the focused group. The unstructured group participated in nonsequential, nonhierarchical activities. The average number of sessions was 20. Main Outcome Measures: Digit Span, Mental Control, Simple and Choice Reaction Time, Functional Independence Measure, selected neuropsychological tests. Results: No significant group differences were detected in attentional skills, functional skills, or general cognitive abilities. Conclusions: Progress in attentional skills during acute rehabilitation after TBI is similar with focused and unstructured cognitive remediation.	UNIV ALABAMA,DEPT REHABIL MED,BIRMINGHAM,AL; UNIV ALABAMA,DEPT PSYCHOL,BIRMINGHAM,AL 35294; CARLE CLIN ASSOC,URBANA,IL; PALMYRA REG REHAB CTR,DEPT PSYCHOL NEUROPSYCHOL,ALBANY,GA							ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Benton AL, 1978, MULTILINGUAL APHASIA; Carter LT, 1980, THINKING SKILLS WORK; DAVIES A, 1968, J CLIN PSYCHOL, V24, P96; DEACON D, 1991, J CLIN EXP NEUROPSYC, V13, P639, DOI 10.1080/01688639108401079; DUKE LW, 1992, HDB HEAD TRAUMA ACUT; Gansler D A, 1991, Arch Clin Neuropsychol, V6, P335, DOI 10.1016/0887-6177(91)90010-7; Golden C., 1978, STROOP COLOR WORD TE; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hamilton B., 1987, REHABILITATION OUTCO; HARNADEK A, 1979, BASIC THINKING SKILL; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jastak S, 1984, WIDE RANGE ACHIEVEME; KILPATRICK K, 1977, THERAPY GUIDE ADULT; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POSNER MI, 1987, NEUROPSYCHOLOGICAL R; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Wechsler D., 1987, WECHSLER MEMORY SCAL	21	34	34	0	3	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1996	11	3					52	60		10.1097/00001199-199606000-00008			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UP774	WOS:A1996UP77400008					2021-06-18	
J	Rimaniol, AC; Lekieffre, D; Serrano, A; Masson, A; Benavides, J; Zavala, F				Rimaniol, AC; Lekieffre, D; Serrano, A; Masson, A; Benavides, J; Zavala, F			Biphasic transforming growth factor-beta production flanking the pro-inflammatory cytokine response in cerebral trauma	NEUROREPORT			English	Article						transforming growth factor-beta; cytokines; brain; trauma	RAT-BRAIN; INJURY; PROLIFERATION; CHEMOTAXIS; INCREASE	WE determined the time-course of the production of transforming growth factor-beta (TGF-beta) after fluid-percussion injury using a bioassay. Biophasic production of TGF-beta composed mainly of TGF-beta(2) was detected in the ipsilateral cortex, with a first peak 30 min and a second peak 48 h after the lesion, flanking the transient production of tumor necrosis factor-alpha and interleukin-6 occurring between 5 and 18 h after trauma. This temporal pattern suggested that TGF-beta plays alternatively a pro- and anti-inflammatory role in the regulation of the brain cytokine network in response to injury, providing an endogenous mechanism for the control of the inflammatory reaction in traumatic brain injury.	HOP NECKER ENFANTS MALAD, INSERM, U25, F-75743 PARIS 15, FRANCE; SYNTHELABO RECH, F-92225 BAGNEUX, FRANCE			ZAvALA, Flora/E-7973-2017	ZAvALA, Flora/0000-0002-2338-6802			Brownh PD, 1990, GROWTH FACTORS, V3, DOI 10.3109/08977199009037500; CHANTRY D, 1989, J IMMUNOL, V142, P4295; CHAO CC, 1994, MOL CHEM NEUROPATHOL, V23, P159, DOI 10.1007/BF02815409; CHAO CC, 1992, J CLIN INVEST, V90, P1786, DOI 10.1172/JCI116053; FINCH CE, 1993, J CELL BIOCHEM, V53, P314, DOI 10.1002/jcb.240530408; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; HENRICHNOACK P, 1995, J CEREBR BLOOD FLOW, V15, pS403; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LOGAN A, 1993, TRENDS PHARMACOL SCI, V14, P337, DOI 10.1016/0165-6147(93)90007-7; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MCNEILL H, 1994, NEUROREPORT, V5, P901, DOI 10.1097/00001756-199404000-00012; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; NICHOLS NR, 1991, J NEUROSCI RES, V28, P134, DOI 10.1002/jnr.490280114; OWENS T, 1994, IMMUNOL TODAY, V15, P566, DOI 10.1016/0167-5699(94)90218-6; PREHN JHM, 1994, PHARM CEREBRAL ISCHE, P404; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; UNSICKER K, 1991, NEUROSCIENCE, V44, P613, DOI 10.1016/0306-4522(91)90082-Y; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; WAHL SM, 1988, J IMMUNOL, V140, P3026; YAO J, 1990, J NEUROSCI RES, V27, P36, DOI 10.1002/jnr.490270106	25	34	36	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0959-4965	1473-558X		NEUROREPORT	Neuroreport	DEC 29	1995	7	1					133	136		10.1097/00001756-199512290-00032			4	Neurosciences	Neurosciences & Neurology	TX369	WOS:A1995TX36900032	8742435				2021-06-18	
J	FELDMAN, Z; ZACHARI, S; REICHENTHAL, E; ARTRU, AA; SHAPIRA, Y				FELDMAN, Z; ZACHARI, S; REICHENTHAL, E; ARTRU, AA; SHAPIRA, Y			BRAIN EDEMA AND NEUROLOGICAL STATUS WITH RAPID INFUSION OF LACTATED RINGERS OR 5-PERCENT DEXTROSE SOLUTION FOLLOWING HEAD TRAUMA	JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; BRAIN EDEMA; NEUROLOGICAL OUTCOME; RINGERS SOLUTION; DEXTROSE; RAT	HYPERTONIC SALINE 7.5-PERCENT; HEMORRHAGIC-SHOCK; CEREBRAL HEMODYNAMICS; COLLOID SOLUTIONS; RESUSCITATION; INJURY; FLUID; HYPERGLYCEMIA; RAT; METABOLISM	Rapid infusion of 0.25 ml/g of 0.98 saline over 30 minutes has been shown to have no effect on electrolyte balance, neurological severity score (NSS), or brain edema, following closed head trauma (CHT). Rapid infusion of the same volume of 5% dextrose solution decreased blood sodium concentration, increased edema, and decreased NSS following CHT. In the present study the authors examined the effect of rapid infusion (30 minutes) of smaller volumes of 5% dextrose (0.08 ml/g and 0.16 ml/g) and of 0.25 ml/g lactated Ringer's solution on blood electrolyte concentrations, plasma osmolality, brain edema, and NSS. The purposes of this study were to determine whether rapid infusion of a large volume of lactated Ringer's solution could be given after CHT without increasing mortality or brain edema or producing electrolyte disturbances, and whether small volumes of 5% dextrose could be infused with few or none of the deleterious effects expected from large volumes of 5% dextrose. One hundred eighteen mts, which survived halothone anesthesia and CHT, were randomly assigned to one of 15 experimental groups. Fluids were administered beginning 1 hour after scalp incision or CHT. The NSS, extent of edema, blood electrolyte concentrations, and plasma osmolality in the groups treated with lactated Ringer's solution were not significantly different from those values in the nontreated groups. In addition, the mortality rate after CHT was not increased by administration of lactated Ringer's solution. The groups treated with 5% dextrose solution showed a significantly higher mortality rate, but the NSSs of the surviving rats were not different from controls. None of the groups treated with 0.16 ml/g 5% dextrose solution survived 24 hours. Although blood glucose concentration increased to 1126 +/- 102 g% (mean +/- standard deviation) and 1568 +/- 283 g% and blood sodium concentration decreased to 110.4 +/- 4.6 mEq/L and 91.0 +/- 5.2 mEq/L in the groups treated with 0.08 ml/g and 0.16 ml/g of 5% dextrose solution, respectively, plasma osmolality was normal and no significant difference could be found between the brain tissue specific gravity of animals in the nontreated and 5% dextrose treatment groups. It is concluded that in the CHT model used in this study, the large volume of lactated Ringer's solution did not affect blood electrolyte concentration, neurological outcome, or formation of brain edema, whereas smaller volumes of 5% dextrose solution increased blood glucose and decreased blood sodium concentrations, did not affect plasma osmolality, and had a deleterious effect on neurological outcome.	BEN GURION UNIV NEGEV,SOROKA MED CTR,DEPT NEUROSURG,IL-84105 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,SOROKA MED CTR,DEPT ANESTHESIOL,IL-84105 BEER SHEVA,ISRAEL; BEN GURION UNIV NEGEV,FAC HLTH SCI,IL-84105 BEER SHEVA,ISRAEL; WASHINGTON UNIV,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA							BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; COLLINS WF, 1974, PRINCIPLES SURGERY, P1631; DOMINO KB, 1989, ASA ANN REFRESHER CO, V115; DRUMMOND JC, 1992, ASA ANN REFRESHER CO, V116; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GUNNAR W, 1988, SURGERY, V103, P398; KRAMER GC, 1986, SURGERY, V100, P239; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MCCORNISH PB, 1971, ANESTHESIA NEUROLOGI, P304; PETERS RM, 1986, SURG GYNECOL OBSTET, V163, P219; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; POOLE GV, 1986, CRIT CARE MED, V14, P629, DOI 10.1097/00003246-198607000-00009; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; ROBERTSON CS, 1991, J NEUROSURG, V74, P43, DOI 10.3171/jns.1991.74.1.0043; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SHAPIRA Y, 1995, J NEUROSURG ANESTH, V7, P17, DOI 10.1097/00008506-199501000-00004; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHENKIN HA, 1976, J NEUROSURG, V45, P432, DOI 10.3171/jns.1976.45.4.0432; THOMAS LM, 1973, NEUROLOGICAL SURGERY, P956; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; WARNER DS, 1988, ANESTHESIOLOGY, V68, P86, DOI 10.1097/00000542-198801000-00014; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	29	34	35	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	DEC	1995	83	6					1060	1066		10.3171/jns.1995.83.6.1060			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TG914	WOS:A1995TG91400017	7490621				2021-06-18	
J	KEMP, PM; HOUSTON, AS; MACLEOD, MA; PETHYBRIDGE, RJ				KEMP, PM; HOUSTON, AS; MACLEOD, MA; PETHYBRIDGE, RJ			CEREBRAL PERFUSION AND PSYCHOMETRIC TESTING IN MILITARY AMATEUR BOXERS AND CONTROLS	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						BOXING; PSYCHOMETRICS; SPECT	CHRONIC BRAIN-DAMAGE; CLOSED-HEAD-INJURY; ALZHEIMERS-DISEASE; BOXING LEAD; COMPUTED-TOMOGRAPHY; BLOOD-FLOW; TECHNETIUM-99M-HMPAO SPECT; CT; AFTERMATH; DEMENTIA	The objective was to compare two neurophysiological variables in active amateur boxers with non-boxing sportsmen. 41 boxers and 27 controls were given psychometric tests: 34 boxers and 34 controls underwent technetium-99m hexamethylpropyleneamineoxime single photon emission computerised tomography (Tc99m HMPAO SPECT) cerebral perfusion scans. The controls performed better at most aspects of the psychometric tests. Boxers who had fought fewer bouts had a tendency to perform better at psychometric tests than those boxers who had fought more bouts. Tc-99m HMPAO SPECT cerebral perfusion scanning showed that controls had less aberrations in cerebral perfusion than the boxers. In conclusion, significant differences were shown in two neurophysiological variables between young amateur sportsmen who box and those who do not. The long term effects of these findings remain unknown.	INST NAVAL MED,DEPT MED,GOSPORT PO12 2DL,HANTS,ENGLAND	KEMP, PM (corresponding author), ROYAL NAVAL HOSP,DEPT NUCL MED,GOSPORT,HANTS,ENGLAND.						AINSWORTH ME, 1965, THESIS U MANCHESTER; AZARI NP, 1993, J CEREBR BLOOD F MET, V13, P438, DOI 10.1038/jcbfm.1993.58; BARBER DC, 1992, PHYS MED BIOL, V37, P1485, DOI 10.1088/0031-9155/37/7/002; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUEE L, 1994, ACTA NEUROPATHOL, V87, P469; BUTLER RJ, 1993, J NEUROL NEUROSUR PS, V56, P1055, DOI 10.1136/jnnp.56.10.1055; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CLARK C, 1985, J CEREBR BLOOD F MET, V5, P142, DOI 10.1038/jcbfm.1985.18; CLARK CM, 1991, J CEREBR BLOOD F MET, V11, pA96, DOI 10.1038/jcbfm.1991.44; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; FAZEKAS F, 1989, J NUCL MED, V30, P1607; GEMMELL HG, 1990, J NUCL MED, V31, P1595; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GRONWALL D, 1975, LANCET, V2, P995; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P245; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P297; HOUSTON AS, 1994, J NUCL MED, V35, P239; HOUSTON AS, 1992, IEE C PUBL, V354, P369; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1988, ARCH NEUROL-CHICAGO, V45, P1207, DOI 10.1001/archneur.1988.00520350045014; KASTE M, 1982, LANCET, V2, P1186; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MCKEITH IG, 1993, BRIT J PSYCHIAT, V163, P597, DOI 10.1192/bjp.163.5.597; MCLATCHIE G, 1987, J NEUROL NEUROSUR PS, V50, P96, DOI 10.1136/jnnp.50.1.96; MESSA C, 1994, J NUCL MED, V35, P210; MONTALDI D, 1990, J NEUROL NEUROSUR PS, V53, P33, DOI 10.1136/jnnp.53.1.33; MURELIUS O, 1991, ACTA NEUROL SCAND, V83, P9; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROPER SN, 1991, J NUCL MED, V32, P1684; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SMITH M, 1988, USERS MANUAL ESSEX C; STEWART WF, 1994, AM J EPIDEMIOL, V139, P573, DOI 10.1093/oxfordjournals.aje.a117047; TEASDALE G, 1986, CLOSED HEAD INJURY P; THOMASSEN A, 1979, ACTA NEUROL SCAND, V60, P352, DOI 10.1111/j.1600-0404.1979.tb07661.x; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TURNAGE JJ, 1992, ERGONOMICS, V35, P1271, DOI 10.1080/00140139208967393; UNTERHARNSCHEID.FJ, 1975, HDB CLIN NEUROLOGY, V23, P527; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267	43	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	1995	59	4					368	374		10.1136/jnnp.59.4.368			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	RX450	WOS:A1995RX45000006	7561914	Bronze, Green Published			2021-06-18	
J	UNSAL, A; SEGALOWITZ, SJ				UNSAL, A; SEGALOWITZ, SJ			SOURCES OF P300 ATTENUATION AFTER HEAD-INJURY - SINGLE-TRIAL AMPLITUDE, LATENCY JITTER, AND EEG POWER	PSYCHOPHYSIOLOGY			English	Article						P300; LATENCY JITTER; SINGLE-TRIAL ANALYSIS; TRAUMATIC BRAIN INJURY	VARIABILITY; RECOGNITION; PERFORMANCE; POTENTIALS; INTENSITY; TIME	Single trial amplitude, latency jitter, and electroencephalographic (EEG) power were examined as sources of the group difference in averaged P300 amplitude among 15 traumatically brain injured and 20 control individuals in an auditory oddball paradigm. Mean amplitude of the individual trials was highly correlated with the amplitude of the averaged P300, with little additional unique variance attributable to latency jitter or EEC power. The group difference in P300 amplitude was also explained by the mean amplitude of the single trials. These results support the robustness of the event-related potential averaging technique within the paradigm used.	BROCK UNIV,DEPT PSYCHOL,ST CATHARINES,ON L2S 3A1,CANADA	UNSAL, A (corresponding author), MCMASTER UNIV,MED CTR,DEPT PSYCHIAT,HAMILTON,ON L8N 3Z5,CANADA.						Campbell K., 1986, ELECTROENCEPHALOGR S, V38, P486; Curry S H, 1980, Prog Brain Res, V54, P507, DOI 10.1016/S0079-6123(08)61668-4; Deacon-Elliott D., 1987, COGNITIVE REHABILITA, V5, P12; DONCHIN E, 1988, BEHAV BRAIN SCI, V11, P357, DOI 10.1017/S0140525X00058027; DUNCANJOHNSON CC, 1979, PSYCHOPHYSIOLOGY, V16, P53, DOI 10.1111/j.1469-8986.1979.tb01440.x; Fabiani M., 1987, ADV PSYCHOPHYSIOL, V2, P1; FEIN G, 1989, ELECTROEN CLIN NEURO, V72, P384, DOI 10.1016/0013-4694(89)90044-8; FORD JM, 1994, BIOL PSYCHIAT, V35, P96, DOI 10.1016/0006-3223(94)91198-3; Isreal J B, 1980, Prog Brain Res, V54, P416, DOI 10.1016/S0079-6123(08)61653-2; JASIUKAITIS P, 1988, PSYCHOPHYSIOLOGY, V25, P157, DOI 10.1111/j.1469-8986.1988.tb00979.x; MAGLIERO A, 1984, PSYCHOPHYSIOLOGY, V21, P171, DOI 10.1111/j.1469-8986.1984.tb00201.x; MCCARTHY G, 1983, SCIENCE, V211, P77; MICHALEWSKI HJ, 1986, ELECTROEN CLIN NEURO, V65, P59, DOI 10.1016/0168-5597(86)90037-7; OLBRICH HM, 1986, FORTSCHR NEUROL PSYC, V54, P182, DOI 10.1055/s-2007-1001863; PAPANICOLAOU AC, 1985, PSYCHOPHYSIOLOGY, V22, P326, DOI 10.1111/j.1469-8986.1985.tb01608.x; PARASURAMAN R, 1982, PERCEPT PSYCHOPHYS, V31, P1, DOI 10.3758/BF03206196; Pedhazur E.J., 1982, MULTIPLE REGRESSION, V2nd ed.; PICTON TW, 1988, HDB ELECTROENCEPHALO, P361; ROTH WT, 1984, PSYCHOPHYSIOLOGY, V21, P466, DOI 10.1111/j.1469-8986.1984.tb00228.x; RUCHKIN DS, 1978, MULTIDISCIPLINARY PE; RUCHKIN DS, 1988, HUMAN EVENT RELATED, V3, P7; SEGALOWITZ NS, 1993, APPL PSYCHOLINGUIST, V14, P369, DOI 10.1017/S0142716400010845; SEGALOWITZ SJ, 1994, UNPUB SPEED VARIABIL; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742	24	34	35	0	0	SOC PSYCHOPHYSIOL RES	WASHINGTON	1010 VERMONT AVE NW SUITE 1100, WASHINGTON, DC 20005	0048-5772			PSYCHOPHYSIOLOGY	Psychophysiology	MAY	1995	32	3					249	256		10.1111/j.1469-8986.1995.tb02953.x			8	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	QV891	WOS:A1995QV89100006	7784533				2021-06-18	
J	HARTL, R; SCHURER, L; GOETZ, C; BERGER, S; ROHRICH, F; BAETHMANN, A				HARTL, R; SCHURER, L; GOETZ, C; BERGER, S; ROHRICH, F; BAETHMANN, A			THE EFFECT OF HYPERTONIC FLUID RESUSCITATION ON BRAIN EDEMA IN RABBITS SUBJECTED TO BRAIN INJURY AND HEMORRHAGIC-SHOCK	SHOCK			English	Article							SMALL-VOLUME RESUSCITATION; CEREBRAL WATER-CONTENT; SEVERE HEAD-INJURY; BLOOD-FLOW; INTRACRANIAL-PRESSURE; HYPERONCOTIC SOLUTIONS; HYDROCEPHALIC RABBITS; SALINE RESUSCITATION; DOGS; HYPERTENSION	Small-volume resuscitation with 7.2% NaCl/10% dextran 60 (HHS) restores cardiovascular stability faster than all other therapeutic modalities currently known. This study was undertaken to elucidate the effects of HHS on the brain, specifically on the formation of posttraumatic brain edema, HHS was administered to anesthetized albino rabbits with or without a focal cryogenic brain lesion and hemorrhagic shock. Specific gravity of small tissue samples was determined 4 h after injury and values were topographically assembled to form a color-coded map of both hemispheres, allowing for a high resolution mapping of brain edema. Cerebral blood flow on the side of the lesion, as assessed by the H-2 clearance method, increased transiently after injury but remained unchanged from baseline during shock and after infusion of HHS, indicating intact cerebrovascular autoregulation. The cryogenic lesion without subsequent HHS infusion resulted in significant brain edema formation in grey and white matter of the exposed hemisphere, In injured animals resuscitation with HHS led to a global reduction of brain water content in both hemispheres, We conclude that small-volume resuscitation with HHS does not worsen posttraumatic brain edema. To the contrary, our results show that it decreases cerebral water content even in regions close to the injury. This makes it worthwhile to investigate the benefits of HHS for the treatment of intracranial hypertension.	UNIV HEIDELBERG, KLINIKUM MANNHEIM, DEPT NEUROSURG, HEIDELBERG, GERMANY; UNIV MAINZ, DEPT PEDIAT SURG, MAINZ, GERMANY; ZENT KLIN BAD BERKA, DEPT NEUROSURG, BAD BERKA, GERMANY; UNIV MUNICH, INST SURG RES, MUNICH, GERMANY; UNIV MUNICH, DEPT NEUROSURG, MUNICH, GERMANY	HARTL, R (corresponding author), CORNELL UNIV, COLL MED,DEPT SURG,DIV NEUROSURG, AITKEN NEUROSURG LAB,1300 YORK AVE, ROOM LC 807, NEW YORK, NY 10021 USA.						AUKLAND K, 1965, ACTA NEUROL SCAND, VS 41, P42; BATTISTELLA F, 1992, CIRC SHOCK, V37, P16; BATTISTELLA FD, 1991, J TRAUMA, V31, P182, DOI 10.1097/00005373-199131020-00005; BERGER S, 1993, ZBL CHIR, V118, P237; BERGER S, IN PRESS NEUROSURGER; DELBIGIO MR, 1987, PEDIATR NEUROSCI, V13, P72, DOI 10.1159/000120304; GO KG, 1972, J NEUROL SCI, V16, P209, DOI 10.1016/0022-510X(72)90090-1; Groger U, 1990, Adv Neurol, V52, P215; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HERRMANN HD, 1972, EXP NEUROL, V34, P115, DOI 10.1016/0014-4886(72)90192-6; KITA H, 1994, ACTA NEUROCHIR, P452; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KOROSUE K, 1990, J NEUROSURG, V73, P576, DOI 10.3171/jns.1990.73.4.0576; KRAMER GC, 1986, SURGERY, V100, P239; KREIMEIER U, 1988, EUR SURG RES, V20, P277, DOI 10.1159/000128773; KREIMEIER U, 1990, J SURG RES, V49, P493, DOI 10.1016/0022-4804(90)90174-Z; KREIMEIER U, 1993, CURR OPIN ANESTHESIO, V6, P400; KUROIWA T, 1985, ACTA NEUROPATHOL, V66, P3, DOI 10.1007/BF00698288; MARMAROU A, 1989, INTRACRANIAL PRESSUR, V7, P549; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MURR R, 1992, CURR OPIN ANAESTH, V5, P285; NAKAYAMA S, 1984, CIRC SHOCK, V13, P149; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; PERTOFT H, 1978, ANAL BIOCHEM, V88, P271, DOI 10.1016/0003-2697(78)90419-0; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PRIST R, 1992, CIRC SHOCK, V36, P13; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; PROUGH DS, 1991, CRIT CARE MED, V19, P364, DOI 10.1097/00003246-199103000-00015; PROUGH DS, 1991, ANESTH ANALG, V73, P736; SCHURER L, 1992, EUR SURG RES, V24, P1, DOI 10.1159/000129183; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; TAMAKI N, 1990, J NEUROSURG, V73, P274, DOI 10.3171/jns.1990.73.2.0274; TENGVAR C, 1982, ACTA NEUROPATHOL, V57, P143, DOI 10.1007/BF00685382; THEODORSSONNORHEIM E, 1986, COMPUT METH PROG BIO, V23, P57, DOI 10.1016/0169-2607(86)90081-7; VELASCO IT, 1989, CRIT CARE MED, V17, P261, DOI 10.1097/00003246-198903000-00012; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WISNER DH, 1992, J TRAUMA, V32, P351, DOI 10.1097/00005373-199203000-00013; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	42	34	34	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	APR	1995	3	4					274	279					6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	QT198	WOS:A1995QT19800005	7541301				2021-06-18	
J	KOSCIULEK, JF				KOSCIULEK, JF			RELATIONSHIP OF FAMILY COPING WITH HEAD-INJURY TO FAMILY ADAPTATION	REHABILITATION PSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; ASSESSMENT DEVICE; VALIDITY; RELIABILITY; CHILDREN; STRESS	Strategies families use to cope with a member's head injury and their relation to family adaptation were investigated. Participants were primary caregivers of persons with head injuries recruited through the Wisconsin Brain Trauma Association. Using cluster analysis, the following family coping variables were identified: (a) positive appraisal, (b) resource acquisition, (c) family tension management, (d) head injury demand reduction, and (e) acquiring social support. Stepwise multiple regression of these variables on family adaptation indicated that positive appraisal and family tension management were predictive of family adaptation. Thus the hypothesis that family adaptation can be predicted from variables measuring family coping with head injury was supported. Clinical, theoretical, and head injury family research implications are discussed.		KOSCIULEK, JF (corresponding author), UNIV MISSOURI,DEPT EDUC & COUNSELING PSYCHOL,16 HILL HALL,COLUMBIA,MO 65211, USA.						Aldenderfer M.S., 1984, CLUSTER ANAL; Antonovsky A., 1993, COGNITIVE COPING FAM, P111; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; Bond M. R., 1990, REHABILITATION ADULT, P179; BORENSTEIN M, 1988, STATISTICAL POWER AN; Boss P, 1987, HDB MARRIAGE FAMILY, P695; BOX GEP, 1976, J AM STAT ASSOC, V71, P791, DOI 10.2307/2286841; Brooks D. N, 1990, REHABILITATION ADULT, P163; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN BW, 1988, FAM RELAT, V37, P300; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; COHEN J, 1988, STATISTICAL POWER AN; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; DeJong G., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Filsinger E. E., 1990, FAMILY VARIABLES CON, P90; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Graffi S, 1989, J APPLIED SOCIAL SCI, V13, P293; HAIR JF, 1987, MULTIVARIATE DATA AN; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JENNETT B, 1990, REHABILITATION ADULT, P3; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KAY T, 1990, TRAUMATIC BRAIN INJU, P21; KOSCIULEK JF, 1993, J REHABIL, V59, P40; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; Lipsey M. W., 1990, DESIGN SENSITIVITY S; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; Livingston MG., 1990, REHABILITATION ADULT, P225; LOCKE HJ, 1959, J MARRIAGE FAMILY LI, V21, P251; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mathis M, 1984, J Neurosurg Nurs, V16, P36; McCubbin H.I., 1983, SOCIAL STRESS FAMILY, P7, DOI DOI 10.1300/J002V06N01_02; MCCUBBIN HI, 1980, J MARRIAGE FAM, V42, P855, DOI 10.2307/351829; MCCUBBIN HI, 1993, COGNITIVE COPING FAM, P239; MCCUBBIN HI, 1981, FCOPES FAMILY CRISIS; MCCUBBIN MA, 1988, FAM RELAT, V37, P203, DOI 10.2307/584321; McCubin M. A., 1991, FAMILY ASSESSMENT IN, P3; McMordie W R, 1988, Brain Inj, V2, P357, DOI 10.3109/02699058809150908; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; OLSON DH, 1982, FACES II FAMILY ADAP; PARKER RM, 1993, REHABIL COUNS BULL, V36, P130; Patterson J., 1988, FAMILY SYST MED, V6, P202, DOI DOI 10.1037/H0089739; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; SHUTTY M, 1993, REHABIL PSYCHOL, V38, P145; SZYMANSKI EM, 1993, REHABIL COUNS BULL, V36, P178; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TURNBULL AP, 1993, COGNITIVE COPING FAM, P1; VANDERVEEN F, 1981, UNPUB MANUAL HDB FAM; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Willer B., 1990, CANADIAN J REHABILIT, V3, P167; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Williams J.M., 1991, HEAD INJURY FAMILY M, P81; 1992, SPSS WINDOWS BASE SY	59	34	34	0	2	SPRINGER PUBL CO	NEW YORK	536 BROADWAY, NEW YORK, NY 10010-3955	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	WIN	1994	39	4					215	230		10.1037/0090-5550.39.4.215			16	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	QM828	WOS:A1994QM82800001					2021-06-18	
J	PERSINGER, MA				PERSINGER, MA			PERSONALITY CHANGES FOLLOWING BRAIN INJURY AS A GRIEF RESPONSE TO THE LOSS OF SENSE OF SELF - PHENOMENOLOGICAL THEMES AS INDEXES OF LOCAL LABILITY AND NEUROCOGNITIVE STRUCTURING AS PSYCHOTHERAPY	PSYCHOLOGICAL REPORTS			English	Article							SIGNS	Both theoretical and empirical observations suggest that significant alterations in self-concept should occur following most closed head injuries because of diffuse synaptic modification within the temporofrontal regions; this loss of the sense of self should evoke a grief-like response sequence and should encourage paranormal/religious experiences during the subsequent months to years. The marked consistency between phenomenological' experiences and the results of neuropsychological assessments of 56 adults who had sustained brain injuries supported this hypothesis. Subsequent reports by these patients indicated that clinical translation of posttraumatic experiences into rational neurobehavioral terms and interventions tailored for the individual's specific pattern of brain ''dysfunction'' may facilitate adaptation during the grieving period.		PERSINGER, MA (corresponding author), LAURENTIAN UNIV,DEPT PSYCHOL,BEHAV NEUROSCI LAB,SUDBURY P3E 2C6,ONTARIO,CANADA.						BUREAU YRJ, 1992, INT J BIOMETEOROL, V36, P226, DOI 10.1007/BF02726403; ELLIS A, 1989, WHY SOME THERAPIES D; LACHAR D, 1974, MMPI CLIN ASSESSMENT; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; Levin HS, 1989, MILD HEAD INJURY; MISSAGHI B, 1992, PHARMACOL BIOCHEM BE, V43, P1081, DOI 10.1016/0091-3057(92)90485-X; PERSINGER MA, 1993, PERCEPT MOTOR SKILL, V76, P915, DOI 10.2466/pms.1993.76.3.915; PERSINGER MA, 1992, PERCEPT MOTOR SKILL, V75, P568, DOI 10.2466/PMS.75.5.568-570; PERSINGER MA, 1985, PERCEPT MOTOR SKILL, V60, P827, DOI 10.2466/pms.1985.60.3.827; PERSINGER MA, 1987, J GEN PSYCHOL, V114, P179, DOI 10.1080/00221309.1987.9711068; PERSINGER MA, 1993, J CLIN PSYCHOL, V49, P33, DOI 10.1002/1097-4679(199301)49:1<33::AID-JCLP2270490106>3.0.CO;2-H; PERSINGER MA, 1993, IN PRESS PHYSL BEHAV; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Rando T. A., 1984, GRIEF DYING DEATH; Roberts RJ, 1990, NEUROPSYCHOLOGY, V4, P65; ROSS J, 1987, PERCEPT MOTOR SKILL, V64, P828, DOI 10.2466/pms.1987.64.3.828; SKINNER BF, 1957, VERBAL BEHAVIOR; TUCKER IF, 1970, ADJUSTMENT MODELS ME	18	34	35	0	9	PSYCHOLOGICAL REPORTS	MISSOULA	P O BOX 9229, MISSOULA, MT 59807	0033-2941			PSYCHOL REP	Psychol. Rep.	JUN	1993	72	3	2				1059	1068		10.2466/pr0.1993.72.3c.1059			10	Psychology, Multidisciplinary	Psychology	LH985	WOS:A1993LH98500001	8337306				2021-06-18	
J	POPOVICH, PG; STREIT, WJ; STOKES, BT				POPOVICH, PG; STREIT, WJ; STOKES, BT			DIFFERENTIAL EXPRESSION OF MHC CLASS-II ANTIGEN IN THE CONTUSED RAT SPINAL-CORD	JOURNAL OF NEUROTRAUMA			English	Article							CENTRAL NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; HISTOCOMPATIBILITY COMPLEX ANTIGENS; INTERFERON-LIKE IMMUNOREACTIVITY; MICROGLIAL CELLS; IA-ANTIGEN; IMMUNOHISTOCHEMICAL ANALYSIS; UNMYELINATED AXONS; INJURY; BRAIN	Following contusion injury to the dorsal surface of thoracic rat spinal cord, major histocompatibility complex (MHC) class II (Ia) antigen expression by microglia was evaluated throughout the developing lesion. Past investigations of various central nervous system (CNS) lesions have examined short-term or acute sequelae of post-traumatic Ia expression. This report demonstrates that in animals allowed to recover for 18 (sub-chronic) and 45 (chronic) days post-injury, MHC class II antigen is expressed differently at rostral and caudal extents of the lesion as compared with the lesion's epicenter. Following contusion injury to the thoracic spinal cord, sub-chronically injured animals demonstrated Ia-positive microglial staining throughout the white matter rostral and caudal to the epicenter of the lesion, whereas Ia-positive microglia and/or perivascular cells are localized within the gray matter adjacent to it. MHC class II immunoreactivity is down-regulated on microglia at chronic survival times but clusters of Ia-positive macrophages are prominent in regions of maximal degeneration at the epicenter of the lesion. Our findings support the theory that two distinct populations of macrophages participate in resolving traumatic injury. One population is the parenchymal CNS microglia and the other is presumably exudate macrophages derived from the blood. Furthermore, the immunocompetence of these cells as measured by MHC expression may be differentially regulated. This hypothesis is based on differences in Ia-positive staining observed between microglia and macrophages over time concomitant with differences in the spatial distribution of these cell types.	OHIO STATE UNIV,COLL MED,DEPT PHYSIOL,COLUMBUS,OH 43210; OHIO STATE UNIV,COLL MED,DEPT SURG,COLUMBUS,OH 43210; UNIV FLORIDA,COLL MED,DEPT NEUROSCI,GAINESVILLE,FL 32611			Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS010165] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS10165] Funding Source: Medline		AKIYAMA H, 1988, J NEUROSCI RES, V20, P147, DOI 10.1002/jnr.490200202; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; DALLMAN MJ, 1984, EUR J IMMUNOL, V14, P260, DOI 10.1002/eji.1830140311; de Sousa BN, 1979, DEV NEUROSCI, V2, P115; DICKSON DW, 1991, LAB INVEST, V64, P135; FUKOMOTO T, 1982, EUR J IMMUNOL, V12, P237; GEHRMANN J, 1991, RESTOR NEUROL NEUROS, V2, P181, DOI 10.3233/RNN-1991-245605; GEHRMANN J, 1992, J CEREB BLOOD FLOW M, V12, P527; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; GRAEBER MB, 1990, TRENDS NEUROSCI, V13, P366, DOI 10.1016/0166-2236(90)90020-B; KAWAMATA T, 1992, AM J PATHOL, V140, P691; KIEFER R, 1990, NEUROSCIENCE, V37, P725, DOI 10.1016/0306-4522(90)90103-B; KONNO H, 1989, J NEUROIMMUNOL, V25, P151, DOI 10.1016/0165-5728(89)90132-X; LAMPSON LA, 1987, TRENDS NEUROSCI, V10, P211, DOI 10.1016/0166-2236(87)90153-6; LANGFORD LA, 1981, SCIENCE, V211, P176, DOI 10.1126/science.7444459; MATSUMOTO Y, 1986, J IMMUNOL, V136, P3668; MATSUMOTO Y, 1986, J NEUROIMMUNOL, V12, P265; MCMASTER WR, 1979, EUR J IMMUNOL, V9, P426, DOI 10.1002/eji.1830090603; MEANS ED, 1983, J NEUROPATH EXP NEUR, V42, P707, DOI 10.1097/00005072-198311000-00009; MILLIGAN CE, 1991, J COMP NEUROL, V314, P136, DOI 10.1002/cne.903140113; MORIOKA T, 1992, GLIA, V6, P75, DOI 10.1002/glia.440060110; OLSSON T, 1989, J NEUROSCI, V9, P3870; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; SMETANKA AM, 1990, BRAIN RES, V521, P343, DOI 10.1016/0006-8993(90)91564-W; SOBEL RA, 1988, J NEUROPATH EXP NEUR, V47, P19, DOI 10.1097/00005072-198801000-00003; STOKES BT, 1992, EXP NEUROL, V116, P1, DOI 10.1016/0014-4886(92)90171-L; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209; TOOYAMA I, 1990, BRAIN RES, V523, P273, DOI 10.1016/0006-8993(90)91496-4; VASS K, 1986, ACTA NEUROPATHOL, V70, P149, DOI 10.1007/BF00691433; WAKEFIELD CL, 1975, EXP NEUROL, V48, P637, DOI 10.1016/0014-4886(75)90020-5; WEKERLE H, 1986, TRENDS NEUROSCI, V9, P271, DOI 10.1016/0166-2236(86)90077-9; WOODROOFE MN, 1986, J NEUROL SCI, V74, P135, DOI 10.1016/0022-510X(86)90100-0	39	34	36	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SPR	1993	10	1					37	46		10.1089/neu.1993.10.37			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	LC106	WOS:A1993LC10600004	8320731				2021-06-18	
J	HOWARD, MA; BELL, BA; UTTLEY, D				HOWARD, MA; BELL, BA; UTTLEY, D			THE PATHOPHYSIOLOGY OF INFANT SUBDURAL HEMATOMAS	BRITISH JOURNAL OF NEUROSURGERY			English	Article						HEAD INJURY; INFANT; SHAKEN BABY SYNDROME; SUBDURAL HEMATOMA	PERMANENT BRAIN-DAMAGE; MENTAL-RETARDATION; CHILD-ABUSE; HEMATOMA; SHAKEN; INJURIES; SHAKING	The widely accepted theories concerning the pathophysiology of infant subdural haematoma (SDH) were formulated in the pre-computed tomographic (CT) scan era. Violent shaking is considered to be a crucial cause of SDH in non-accidentally injured infants. This theory has been re-examined in a clinical and CT scan review, and our findings have been correlated with results of recent head injury research. A retrospective review was conducted of all head injured infants (up to 18 months old) treated at Atkinson Morley's Hospital over a recent 20-year period (n = 100). Twenty-eight infants with a SDH were identified. CT scans were reviewed and each SDH greater than 0.5 cm thick was morphometrically analysed. Seventeen infants were Caucasian, 10 were non-Caucasian and one was of mixed race. A race-dependent pattern of SDH pathophysiology was noted, with non-Caucasian infants with a head injury more likely to have a SDH than Caucasian infants (67 v 21% p < 0.01). All had a history of, or radiographic and clinical findings most consistent with, an impact injury, and non-Caucasian infants were significantly more likely to have a normal scalp examination despite the impact injury (p < 0.05) and to have developed the SDH after a relatively trivial fall (p < 0.01). They were also more likely to have a large ( > 0.5 cm thick) SDH (p < 0.05), and to suffer post-traumatic seizures (p < 0.05). Our findings do not support shaking as the only cause of infant SDH formation and also suggest that non-accidental injury is a less common cause of SDH than it is believed to be.	ATKINSON MORLEYS HOSP,COPSE HILL,WIMBLEDON,LONDON SW20 0NE,ENGLAND				Howard, Matthew/0000-0003-3935-8889			ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; AOKI N, 1984, J NEUROSURG, V61, P273, DOI 10.3171/jns.1984.61.2.0273; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; GUTIERREZ FA, 1975, CHILD BRAIN, V1, P269; HAHN YS, 1983, CHILD BRAIN, V10, P229; Hendrick E B, 1964, Clin Neurosurg, V11, P46; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; IVAN LP, 1983, CAN MED ASSOC J, V128, P281; MCCLELLAND CQ, 1980, CHILD BRAIN, V7, P225; REKATE HL, 1985, J NEUROSURG, V62, P316; SPORACIO RR, 1971, NY STATE J MED, V71, P212	16	34	35	0	6	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE	0268-8697			BRIT J NEUROSURG	Br. J. Neurosurg.		1993	7	4					355	365		10.3109/02688699309103489			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LT994	WOS:A1993LT99400003	8216905				2021-06-18	
J	WRATHALL, JR; BOUZOUKIS, J; CHOINIERE, D				WRATHALL, JR; BOUZOUKIS, J; CHOINIERE, D			EFFECT OF KYNURENATE ON FUNCTIONAL DEFICITS RESULTING FROM TRAUMATIC SPINAL-CORD INJURY	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						SPINAL CORD CONTUSION; NMDA RECEPTOR ANTAGONISTS; NON-NMDA RECEPTOR ANTAGONISTS; EXCITATORY AMINO ACIDS	EXCITATORY AMINO-ACIDS; NMDA RECEPTOR ANTAGONISTS; BLOOD-FLOW; RAT-BRAIN; GLUTAMATE; CONTUSION; ISCHEMIA; INHIBITION; BLOCKADE; CALCIUM	The potential role of excitatory amino acid (EAA) receptors in spinal cord trauma was examined in a standardized rat model of contusive injury. EAA antagonists were administered in a split-dose protocol with half given 5 min prior to and the remainder 15 min after contusion produced at the T8 vertebral level. Hindlimb function was assessed using a battery of tests of reflex and more complex behaviors at 1 day after injury and weekly thereafter through 4-8 weeks. Functional deficits were compared for groups administered intravenous MK 801 (1 mg/kg), dextromethorphan (10 mg/kg) and kynurenate (300 mg/kg) or the vehicle, saline, alone. In addition, possible effect of the drugs themselves on hindlimb function were assessed in uninjured controls. None of the drugs produced more than transient effect on uninjured rats. In contused rats, only kynurenate produced significant reductions in functional deficits as compared to saline controls. Significant improvement of hindlimb function was also observed when the thoracic cord was locally perfused with kynurenate via intrathecal cannulas and when kynurenate was directly infused into the contusive injury site by stereotaxic microinjection. Using the latter route of administration, a dose-dependent effect of kynurenate (100, 200 and 400 nmol) on the ability of contused rats to use their hindlimbs in locomotion was demonstrated. The highest dose also resulted in a significant reduction in overall functional deficits from 1 week through 1 month and at 2 months after injury. Our results support the hypothesis that EAA receptors at or near the injury site are involved in producing a proportion of the overall functional deficits stemming from traumatic injury. In addition, the efficacy of the broad spectrum antagonist of EAA receptors, kynurenate, and the absence of effect of the NMDA receptor antagonists, MK 801 or dextromethorphan, suggests than non-NMDA receptors may play a hitherto unappreciated role in secondary injury after spinal cord contusion.	GEORGETOWN UNIV, DEPT ANAT & CELL BIOL, 3900 RESERVOIR RD NW, WASHINGTON, DC 20007 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS28130] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS028130] Funding Source: NIH RePORTER		ANDINE P, 1988, NEUROSCI LETT, V90, P208, DOI 10.1016/0304-3940(88)90813-0; BALENTINE JD, 1977, ANN NEUROL, V2, P520, DOI 10.1002/ana.410020612; BIRCH PJ, 1988, EUR J PHARMACOL, V151, P313, DOI 10.1016/0014-2999(88)90814-X; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; COLLINS WF, 1979, NEURAL TRAUMA, P273; DANYSZ W, 1989, NEUROSCI LETT, V96, P340, DOI 10.1016/0304-3940(89)90402-3; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; FERKANY JW, 1988, EUR J PHARMACOL, V151, P151, DOI 10.1016/0014-2999(88)90707-8; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; HEADLEY PM, 1990, TRENDS PHARMACOL SCI, V11, P205, DOI 10.1016/0165-6147(90)90116-P; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HOOVLER D W, 1987, Society for Neuroscience Abstracts, V13, P1500; HOOVLER DW, 1991, ACTA NEUROPATHOL, V81, P303, DOI 10.1007/BF00305872; JAHR CE, 1986, J PHYSIOL-LONDON, V370, P515, DOI 10.1113/jphysiol.1986.sp015948; JENSEN AM, 1991, J NEUROSCI, V11, P1674; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KERASIDIS H, 1987, J NEUROSCI METH, V20, P167, DOI 10.1016/0165-0270(87)90048-3; Kochhar A, 1991, J NEUROTRAUM, V8, P175, DOI 10.1089/neu.1991.8.175; LAPIN IP, 1986, J NEURAL TRANSM, V65, P177, DOI 10.1007/BF01249080; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; MARTINEZARIZALA A, 1990, EXP NEUROL, V108, P232, DOI 10.1016/0014-4886(90)90128-F; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MORONI F, 1988, J NEUROCHEM, V51, P177, DOI 10.1111/j.1471-4159.1988.tb04852.x; MORONI F, 1988, NEUROSCI LETT, V94, P145, DOI 10.1016/0304-3940(88)90285-6; MOSINGER JL, 1991, EXP NEUROL, V113, P10, DOI 10.1016/0014-4886(91)90140-8; NELLGARD B, 1992, J CEREBR BLOOD F MET, V12, P2, DOI 10.1038/jcbfm.1992.2; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Olney J, 1978, KAINIC ACID TOOL NEU, P95; PANJABI MM, 1988, SPINE, V13, P1365, DOI 10.1097/00007632-198812000-00007; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; RAINES A, 1988, Journal of Neurotrauma, V5, P151, DOI 10.1089/neu.1988.5.151; RIVLIN AS, 1978, J NEUROSURG, V49, P844, DOI 10.3171/jns.1978.49.6.0844; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; SIMON RP, 1986, NEUROSCI LETT, V71, P361, DOI 10.1016/0304-3940(86)90648-8; TURSKI WA, 1988, BRAIN RES, V454, P164, DOI 10.1016/0006-8993(88)90815-3; URCA G, 1990, BRAIN RES, V529, P7, DOI 10.1016/0006-8993(90)90805-L; WAXMAN SG, 1991, TRENDS NEUROSCI, V14, P461, DOI 10.1016/0166-2236(91)90046-W; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; WRATHALL JR, IN PRESS BRAIN RES; YAKSH TL, 1976, PHYSIOL BEHAV, V17, P1031, DOI 10.1016/0031-9384(76)90029-9; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667	46	34	34	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	AUG 6	1992	218	2-3					273	281		10.1016/0014-2999(92)90179-8			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	JH152	WOS:A1992JH15200011	1425945				2021-06-18	
J	JINKINS, JR; DADSETAN, MR; SENER, RN; DESAI, S; WILLIAMS, RG				JINKINS, JR; DADSETAN, MR; SENER, RN; DESAI, S; WILLIAMS, RG			VALUE OF ACUTE-PHASE ANGIOGRAPHY IN THE DETECTION OF VASCULAR INJURIES CAUSED BY GUNSHOT WOUNDS TO THE HEAD - ANALYSIS OF 12 CASES	AMERICAN JOURNAL OF ROENTGENOLOGY			English	Article							TRAUMATIC INTRACRANIAL ANEURYSMS; CEREBRAL ANEURYSMS; ORBITOFACIAL WOUNDS; BRAIN	A study of the angiographic findings in consecutive civilian patients with cranial gunshot wounds examined in the acute stage has not been done. Most prior clinical studies have evaluated the findings in survivors in the subacute or chronic stages and have often been of war-time casualties, We determined the clinicoradiologic features of six cases of posttraumatic intracranial aneurysm, vascular occlusion, or arteriovenous fistula caused by penetrating missiles among 12 civilian patients who were examined in the acute posttraumatic stage (within 48 hr of injury) during a 1-year period. Three internal carotid/vertebral artery aneurysms, one external carotid artery aneurysm, one combined aneurysm/arteriovenous fistula of the vertebrobasilar circulation, and one cerebral venous occlusion were identified. The 50% overall prevalence ot major vascular lesions in this series of civilian patients with penetrating missile injuries examined in the acute stage suggests these injuries are more common than previously suspected. It may indicate that selective cerebral angiography should be considered in the evaluation of the cranial vascular system of such persons.	METHODIST HOSP SAN ANTONIO,DEPT RADIOL,SAN ANTONIO,TX 78229	JINKINS, JR (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT RADIOL,NEURORADIOL SECT,SAN ANTONIO,TX 78284, USA.						AARABI B, 1988, NEUROSURGERY, V22, P1056, DOI 10.1227/00006123-198806010-00014; ACHRAM M, 1980, BRIT J RADIOL, V53, P1144, DOI 10.1259/0007-1285-53-636-1144; BANK WO, 1972, AJR, V130, P957; BENOIT BG, 1973, J NEUROL NEUROSUR PS, V36, P127, DOI 10.1136/jnnp.36.1.127; BENZEL EC, 1991, NEUROSURGERY, V29, P67, DOI 10.1227/00006123-199107000-00011; BUCKINGHAM MJ, 1988, NEUROSURGERY, V22, P398, DOI 10.1227/00006123-198802000-00022; BURTON C, 1968, J NEUROSURG, V28, P468, DOI 10.3171/jns.1968.28.5.0468; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; CAROTHERS A, 1978, JAMA-J AM MED ASSOC, V239, P1151, DOI 10.1001/jama.239.12.1151; COCKRILL HH, 1977, J NEUROSURG, V46, P377, DOI 10.3171/jns.1977.46.3.0377; FERRY DJ, 1972, J NEUROSURG, V36, P503, DOI 10.3171/jns.1972.36.4.0503; FLEISCHER A S, 1975, Surgical Neurology, V4, P233; HADDAD FS, 1991, NEUROSURGERY, V28, P1; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HANDEL SF, 1978, AM J ROENTGENOL, V130, P507, DOI 10.2214/ajr.130.3.507; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; JACKSON F, 1976, HDB CLIN NEUROLOGY, P381; JAGGER J, 1986, JAMA-J AM MED ASSOC, V255, P3143, DOI 10.1001/jama.255.22.3143; KIECK CF, 1984, J NEUROSURG, V60, P42, DOI 10.3171/jns.1984.60.1.0042; KIRKPATRICK JB, 1978, J NEUROSURG, V49, P185, DOI 10.3171/jns.1978.49.2.0185; KUHN RA, 1964, J NEUROSURG, V21, P92, DOI 10.3171/jns.1964.21.2.0092; PARKINSON D, 1980, J NEUROSURG, V52, P11, DOI 10.3171/jns.1980.52.1.0011; RAHIMIZADEH A, 1987, ACTA NEUROCHIR, V84, P93, DOI 10.1007/BF01418831; RAIMONDI AJ, 1968, NEUROCHIRURGIA, V11, P219; STEHBENS WE, 1972, PATHOLOGY CEREBRAL B, P452; THOMPSON JR, 1973, AM J ROENTGENOL, V118, P163, DOI 10.2214/ajr.118.1.163	26	34	34	0	1	AMER ROENTGEN RAY SOC	RESTON	1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091	0361-803X			AM J ROENTGENOL	Am. J. Roentgenol.	AUG	1992	159	2					365	368		10.2214/ajr.159.2.1632358			4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	JE567	WOS:A1992JE56700028	1632358	Bronze			2021-06-18	
J	DITUNNO, JF				DITUNNO, JF			FUNCTIONAL ASSESSMENT MEASURES IN CNS TRAUMA	JOURNAL OF NEUROTRAUMA			English	Article							SPINAL-CORD INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; SEVERE HEAD-INJURY; QUADRIPLEGIA; INDEPENDENCE; SENSITIVITY; RELIABILITY; RECOVERY	How effectively the survivor of CNS trauma can function in society is the ultimate clinical outcome. Many victims of spinal cord injury (SCI) and traumatic brain injury (TBI) are frequently left with permanent impairment. Measurements of impairment, and the direct relationship to the functional loss and resultant disability, should be the gold standard for determining the effectiveness of interventions. The primary impairments in SCI are motor and sensory loss while those in TBI are neurobehavioral disorders. Classifications for impairment are reasonably well defined in SCI and several approaches are gaining wide acceptance. We hope that internationally agreed upon standards will be forthcoming within the year. The functional independence measure (FIM), which was developed in the past 6-7 years, will be added to the standards. It shows good reliability for SCI as an overall assessment and some of the specific categories of self-care and mobility. An extension of the FIM is needed for more precise measurement of function in quadriplegic subjects. Classification of impairment in TBI has been more difficult. While the Glasgow Outcome Scale has gained international acceptance for almost 10 years, it has limitations in gradations from the moderate disability to the good recovery groups. The Disability Rating Scale (DRS) has shown good reliability, better precision than the Glasgow Outcome Scale, and greater reliability than other measures. An extension of the FIM, called the functional assessment measure (FAM), and the DRS are currently being tested by regional TBI centers in the United States. Functional assessment measures should be available within the next several years.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT REHABIL MED,PHILADELPHIA,PA 19107							[Anonymous], 1980, INT CLASSIFICATION I; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CHENG LL, 1991, AM J PARAPLEGIA SOC, V14, P94; COLE TM, 1990, REPORT TASK FORCE ME, P30; CROZIER KS, 1991, ARCH PHYS MED REHAB, V72, P119; DAVIDOFF GN, 1990, ARCH PHYS MED REHAB, V71, P326; DEMAGONE D, 1991, J AM PARAPLEGIA SOC, V14, P95; DILLER L, 1989, TRAUMATIC BRAIN INJU, V2; DITUNNO JF, 1991, IN PRESS ARCH PHYS M; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; FUHRER MJ, 1991, J AM PARAPLEGIA SOC, V14, P64; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRESHAM GE, 1986, PARAPLEGIA, V24, P38, DOI 10.1038/sc.1986.7; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HAMILTON BB, 1990, SPINAL CORD INJURY M, P49; HERBISON GJ, 1990, REPORT TASK FORCE ME, P43; HUSSEY RW, 1973, ARCH PHYS MED REHAB, V54, P544; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; NAGAI SZ, 1982, LIMITATIONS FUNCTION; POPE AM, 1991, DISABILITY AM NATION; POTVIN AR, 1985, QUANTITATIVE EXAMINA, V2; POTVIN AR, 1985, QUANTITATIVE EXAMINA, V1; ROGERS JC, 1980, ARCH PHYS MED REHAB, V61, P316; SIOSTEEN A, 1990, PARAPLEGIA, V28, P476, DOI 10.1038/sc.1990.64; WALKER MD, 1991, NEW ENGL J MED, V324, P1885, DOI 10.1056/NEJM199106273242608; WELCH RD, 1986, ARCH PHYS MED REHAB, V67, P235; WHITENECK GG, 1988, 14TH AM SPIN INJ ASS, P48; YARKONY G, 1988, ARCH PHYS MED REHAB, V69, P73; 1989, STANDARDS NEUROLOGIC	32	34	34	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S301	S305					5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600029	1588620				2021-06-18	
J	MCKENNAN, KX; CHOLE, RA				MCKENNAN, KX; CHOLE, RA			FACIAL PARALYSIS IN TEMPORAL BONE TRAUMA	AMERICAN JOURNAL OF OTOLOGY			English	Article							NERVE; PALSY	A retrospective review of 36 patients with delayed-onset (19 patients) and immediate-onset (17 patients) traumatic facial paralysis was performed. We hypothesized that traumatic delayed-onset facial paralysis does not necessitate surgical decompression under any routine circumstances. Of 19 patients in this group, normal recovery (House grade 1) occurred in 94 percent of the patients without surgical intervention. The small percentage (6%) of these patients who failed to recover completely demonstrated mild degrees of weakness and synkinesis (House grade 2). Immediate-onset paralysis occurred in 1 7 patients. It has a much poorer prognosis. Seven patients with penetrating wounds had facial nerve transections, usually of the vertical portion of the facial nerve. Closed head injured patients with immediate-onset facial paralysis sustained injuries usually to the horizontal and perigeniculate portion of the facial nerve. For those cases in which surgical exploration of the traumatized facial nerve is indicated, the operating surgeon should have the capacity to enlarge the exposure with a translabyrinthine or middle-fossa dissection.	UNIV CALIF DAVIS,SACRAMENTO MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,SACRAMENTO,CA 95817	MCKENNAN, KX (corresponding author), SACRAMENTO EAR NOSE & THROAT SURG & MED GRP,3810 J ST,SACRAMENTO,CA 95816, USA.						ADOUR KK, 1977, LARYNGOSCOPE, V87, P389; BOYLE WF, 1967, LARYNGOSCOPE, V77, P1168, DOI 10.1288/00005537-196707000-00009; FISCH U, 1979, CLIN PLAST SURG, V6, P377; GREER JA, 1974, ANN OTO RHINOL LARYN, V83, P582, DOI 10.1177/000348947408300503; HOUSE JW, 1985, OTOLARYNG HEAD NECK, V93, P146, DOI 10.1177/019459988509300202; MAIMAN DJ, 1985, J TRAUMA, V25, P644, DOI 10.1097/00005373-198507000-00012; MAY M, 1979, LARYNGOSCOPE, V89, P906; MCCABE BF, 1972, LARYNGOSCOPE, V82, P1891, DOI 10.1288/00005537-197210000-00011; TURNER JW, 1944, LANCET          0610, P756; YANAGIHARA N, 1982, OTOLARYNG HEAD NECK, V90, P616, DOI 10.1177/019459988209000521	10	34	37	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0192-9763			AM J OTOL	Am. J. Otol.	MAR	1992	13	2					167	172					6	Otorhinolaryngology	Otorhinolaryngology	HJ274	WOS:A1992HJ27400014	1599010				2021-06-18	
J	JANECZKO, K				JANECZKO, K			THE PROLIFERATIVE RESPONSE OF S-100 PROTEIN-POSITIVE GLIAL-CELLS TO INJURY IN THE NEONATAL RAT-BRAIN	BRAIN RESEARCH			English	Article						BRAIN INJURY; REACTIVE ASTROCYTE PROLIFERATION; NEWBORN RAT; S-100 PROTEIN IMMUNOCYTOCHEMISTRY; AUTORADIOGRAPHY	FIBRILLARY ACIDIC PROTEIN; CORPUS-CALLOSUM; MOUSE-BRAIN; ASTROCYTES; LOCALIZATION; CORTEX; IMMUNOFLUORESCENCE; HIPPOCAMPUS; ANTIBODIES; APPEARANCE	Astroglial proliferative response to unilateral injury of the cerebral hemisphere was studied in newborn rats using [H-3]thymidine autoradiography combined with immunocytochemical staining for S-100 protein as an astroglial marker. The animals received [H-3]thymidine at different intervals following injury and the distribution of double-labeled cells was recorded 4 h after each [H-3]thymidine injection. The reactive proliferation of all cells within the investigated areas was detectable as early as about 2 h after injury. However, the quantitative increase in astroglial mitotic rate could be first detected on day 1 following the injury and the reactive changes were observed until day 8. They were regarded as evidence for the ability of astroglia to proliferate in response to injury in the neonatal brain. Since the astroglial divisions occurred mainly at the lesion site, the post-traumatic gliosis could be considered not only a result of astrocyte migration towards the lesion but also an effect of local mitotic activity.		JANECZKO, K (corresponding author), JAGIELLONIAN UNIV,INST ZOOL,DEPT NEUROANAT,KARASIA 6,PL-30060 KRAKOW,POLAND.			Janeczko, Krzysztof/0000-0002-9544-918X			Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BLAKEMORE WF, 1971, J NEUROL SCI, V12, P319, DOI 10.1016/0022-510X(71)90066-9; BOYES BE, 1986, NEUROSCIENCE, V17, P857, DOI 10.1016/0306-4522(86)90050-3; CAVANAGH JB, 1970, J ANAT, V106, P471; COCCHIA D, 1981, CELL TISSUE RES, V214, P529; Duffy PE, 1983, ASTROCYTES NORMAL RE; FERRER I, 1980, ACTA NEUROPATHOL, V50, P69, DOI 10.1007/BF00688538; FOG R, 1983, J HIRNFORSCH, V24, P341; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GOMEZ LA, 1990, INT J DEV NEUROSCI, V8, P55; HAAN EA, 1982, P NATL ACAD SCI-BIOL, V79, P7585, DOI 10.1073/pnas.79.23.7585; HELPAP B, 1976, VIRCHOWS ARCH B, V22, P151; Jacobson M, 1978, DEV NEUROBIOLOGY; JANECZKO K, 1988, BRAIN RES, V456, P280, DOI 10.1016/0006-8993(88)90229-6; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; JANECZKO K, 1985, FOLIA BIOL, V33, P121; KORR H, 1986, ASTROCYTES CELL BIOL, V3, P77; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P501, DOI 10.1098/rstb.1990.0122; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; MOORE IE, 1987, NEUROPATHOL APPL NEU, P219; MORI S, 1972, BRAIN RES, V46, P177, DOI 10.1016/0006-8993(72)90014-5; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; RAPPORT MM, 1974, T AM SOC NEUROCHEM, V5, P58; ROESSMANN U, 1986, ACTA NEUROPATHOL, V70, P302, DOI 10.1007/BF00686088; SCHMIDTKASTNER R, 1990, J CHEM NEUROANAT, V3, P179; SUMI SM, 1968, ACTA NEUROPATHOL, V10, P324, DOI 10.1007/BF00690707; TUCKETT F, 1986, J EMBRYOL EXP MORPH, V94, P95; ZHOU HF, 1990, J COMP NEUROL, V292, P320, DOI 10.1002/cne.902920213; ZUCKERMAN JE, 1970, J NEUROCHEM, V17, P247, DOI 10.1111/j.1471-4159.1970.tb02207.x	31	34	37	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 8	1991	564	1					86	90		10.1016/0006-8993(91)91355-5			5	Neurosciences	Neurosciences & Neurology	GR945	WOS:A1991GR94500012	1777824				2021-06-18	
J	AISEN, ML; HOLZER, M; ROSEN, M; DIETZ, M; MCDOWELL, F				AISEN, ML; HOLZER, M; ROSEN, M; DIETZ, M; MCDOWELL, F			GLUTETHIMIDE TREATMENT OF DISABLING ACTION TREMOR IN PATIENTS WITH MULTIPLE-SCLEROSIS AND TRAUMATIC BRAIN INJURY	ARCHIVES OF NEUROLOGY			English	Article								Glutethimide has been used to control essential tremor. Its efficacy in the treatment of disabling cerebellar and rubral tremor was assessed in an open study of six patients with multiple sclerosis and two patients with traumatic brain injury. Functional and quantitative tremor severity was assessed before treatment and 7 to 14 days after a stable dose was achieved. Six of eight patients exhibited visible functional benefit from treatment with glutethimide; abstract testing results correlated well with functional status in most cases. Four patients chose to continue to receive medication. Controlled trials of glutethimide to compare its efficacy with that of other medications used in the treatment of action tremor are indicated.	ROCKY MT MULTIPLE SCLEROSIS CTR,DENVER,CO; MIT,CAMBRIDGE,MA 02139	AISEN, ML (corresponding author), BURKE REHABIL CTR,785 MAMARONECK AVE,WHITE PLAINS,NY 10605, USA.						ADELSTEIN BD, 1987, NEUROLOGY S, V37, P356; ADELSTEIN BD, 1984, 6TH P ANN IEEE EMB C, P47; BARUZZI A, 1983, NEUROLOGY, V33, P296, DOI 10.1212/WNL.33.3.296; BERINGHAUSE S, 1988, THESIS MIT; COHEN H, 1960, N Y State J Med, V60, P280; FAHN S, 1988, PARKINSON DIS MOVEME, P255; FEELY M, 1981, BRIT MED J, V282, P740, DOI 10.1136/bmj.282.6265.740-b; GROWDON JH, 1975, NEUROLOGY, V25, P259, DOI 10.1212/WNL.25.3.259; MCDOWELL FH, 1989, MOVEMENT DISORD, V4, P75, DOI 10.1002/mds.870040110; SADWIN A, 1958, AM J PSYCHIAT, V115, P469; STEPHEN CR, 1960, ANESTHESIOLOGY, V21, P482, DOI 10.1097/00000542-196009000-00004; TURRIAN H., 1958, HELVETICA PHYSIOL ET PHARMACOL ACTA, V16, P208	12	34	34	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	MAY	1991	48	5					513	515		10.1001/archneur.1991.00530170077023			3	Clinical Neurology	Neurosciences & Neurology	FK271	WOS:A1991FK27100013	2021365				2021-06-18	
J	LEVIN, HS; GOLDSTEIN, FC; HIGH, WM; WILLIAMS, D				LEVIN, HS; GOLDSTEIN, FC; HIGH, WM; WILLIAMS, D			AUTOMATIC AND EFFORTFUL PROCESSING AFTER SEVERE CLOSED HEAD-INJURY	BRAIN AND COGNITION			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		ALBA JW, 1980, J EXP PSYCHOL-HUM L, V6, P370, DOI 10.1037/0278-7393.6.4.370; ATTIG M, 1980, J GERONTOL, V35, P66, DOI 10.1093/geronj/35.1.66; BROOKS JE, 1985, AM J PSYCHOL, V98, P363, DOI 10.2307/1422622; FLEXSER AJ, 1975, B PSYCHONOMIC SOC, V6, P321, DOI 10.3758/BF03336675; GOLDSTEIN D, 1983, AM J PSYCHOL, V96, P229, DOI 10.2307/1422814; GRONWALL D, 1974, LANCET, V2, P605; HASHER L, 1984, AM PSYCHOL, V39, P1372, DOI 10.1037/0003-066X.39.12.1372; HASHER L, 1979, J EXP PSYCHOL GEN, V108, P356, DOI 10.1037/0096-3445.108.3.356; HIRST W, 1982, PSYCHOL BULL, V91, P435, DOI 10.1037/0033-2909.91.3.435; HUPPERT FA, 1978, Q J EXP PSYCHOL, V30, P347, DOI 10.1080/14640747808400681; NEWMAN RP, 1984, NEUROLOGY, V34, P805, DOI 10.1212/WNL.34.6.805; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAIVIO A, 1968, J EXPT PSYCHOL M 2 S, V76; ROYBYRNE PP, 1986, ARCH GEN PSYCHIAT, V43, P265; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SMITH ML, 1983, SOC NEUR ABSTR, V9, P30; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Thorndike EL., 1944, TEACHERS WORD BOOK 3; VAKIL E, 1985, 13TH ANN CONV INT NE; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; WEINGARTNER H, 1983, SCIENCE, V221, P380, DOI 10.1126/science.6867715; WEINGARTNER H, 1984, PSYCHIAT RES, V11, P223, DOI 10.1016/0165-1781(84)90071-4; WEINGARTNER H, 1982, ALZHEIMERS DISEASE R; ZACKS RT, 1982, J EXP PSYCHOL-HUM L, V8, P106, DOI 10.1037/0278-7393.8.2.106	24	34	34	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0278-2626			BRAIN COGNITION	Brain Cogn.	JUN	1988	7	3					283	297		10.1016/0278-2626(88)90003-6			15	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	N7297	WOS:A1988N729700003	3401383				2021-06-18	
J	PARKINSON, D; WEST, M; PATHIRAJA, T				PARKINSON, D; WEST, M; PATHIRAJA, T			CONCUSSION - COMPARISON OF HUMANS AND RATS	NEUROSURGERY			English	Article										PARKINSON, D (corresponding author), UNIV MANITOBA,FAC MED,NEUROL SURG SECT,WINNIPEG R3E OW3,MANITOBA,CANADA.							0	34	35	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery		1978	3	2					176	180		10.1227/00006123-197809000-00008			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FT423	WOS:A1978FT42300008	703936				2021-06-18	
J	Kempuraj, D; Selvakumar, GP; Ahmed, ME; Raikwar, SP; Thangavel, R; Khan, A; Zaheer, SA; Iyer, SS; Burton, C; James, D; Zaheer, A				Kempuraj, Duraisamy; Selvakumar, Govindhasamy Pushpavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P.; Thangavel, Ramasamy; Khan, Asher; Zaheer, Smita A.; Iyer, Shankar S.; Burton, Casey; James, Donald; Zaheer, Asgar			COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation	NEUROSCIENTIST			English	Article						angiotensin-converting enzyme 2; COVID-19; cytokine storm; mast cells; neuroinflammation; severe acute respiratory syndrome coronavirus 2; traumatic brain injury	ALZHEIMERS-DISEASE; BRAIN; SARS-COV-2; PATHOGENESIS; INFLAMMATION; INVOLVEMENT; INFECTIONS; DISRUPTION; MICROGLIA; RELEASE	Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new pandemic infectious disease that originated in China. COVID-19 is a global public health emergency of international concern. COVID-19 causes mild to severe illness with high morbidity and mortality, especially in preexisting risk groups. Therapeutic options are now limited to COVID-19. The hallmark of COVID-19 pathogenesis is the cytokine storm with elevated levels of interleukin-6 (IL-6), IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), chemokine (C-C-motif) ligand 2 (CCL2), and granulocyte-macrophage colony-stimulating factor (GM-CSF). COVID-19 can cause severe pneumonia, and neurological disorders, including stroke, the damage to the neurovascular unit, blood-brain barrier disruption, high intracranial proinflammatory cytokines, and endothelial cell damage in the brain. Mast cells are innate immune cells and also implicated in adaptive immune response, systemic inflammatory diseases, neuroinflammatory diseases, traumatic brain injury and stroke, and stress disorders. SARS-CoV-2 can activate monocytes/macrophages, dendritic cells, T cells, mast cells, neutrophils, and induce cytokine storm in the lung. COVID-19 can activate mast cells, neurons, glial cells, and endothelial cells. SARS-CoV-2 infection can cause psychological stress and neuroinflammation. In conclusion, COVID-19 can induce mast cell activation, psychological stress, cytokine storm, and neuroinflammation.	[Kempuraj, Duraisamy; Selvakumar, Govindhasamy Pushpavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P.; Thangavel, Ramasamy; Khan, Asher; Zaheer, Smita A.; Iyer, Shankar S.; Zaheer, Asgar] Univ Missouri, Sch Med, Dept Neurol, 1 Hosp Dr, Columbia, MO 65211 USA; [Kempuraj, Duraisamy; Selvakumar, Govindhasamy Pushpavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P.; Thangavel, Ramasamy; Khan, Asher; Zaheer, Smita A.; Iyer, Shankar S.; Zaheer, Asgar] Univ Missouri, Sch Med, Ctr Translat Neurosci, 1 Hosp Dr, Columbia, MO 65211 USA; [Kempuraj, Duraisamy; Selvakumar, Govindhasamy Pushpavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P.; Thangavel, Ramasamy; Iyer, Shankar S.; Zaheer, Asgar] US Dept Vet Affairs, Harry S Truman Mem Vet Hosp, Columbia, MO USA; [Burton, Casey; James, Donald] Phelps Hlth, Rolla, MO USA	Kempuraj, D; Zaheer, A (corresponding author), Univ Missouri, Sch Med, Dept Neurol, 1 Hosp Dr, Columbia, MO 65211 USA.; Kempuraj, D; Zaheer, A (corresponding author), Univ Missouri, Sch Med, Ctr Translat Neurosci, 1 Hosp Dr, Columbia, MO 65211 USA.	duraisamyk@health.missouri.edu; Zaheera@health.missouri.edu		Khan, Asher/0000-0001-6314-240X	Leonard Wood Institute; US Army Research LaboratoryUnited States Department of DefenseUS Army Research Laboratory (ARL) [W911NF-14-2-0034]; VA Research Career Scientist Award	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research was sponsored by the Leonard Wood Institute in cooperation with the US Army Research Laboratory and was accomplished under Cooperative Agreement Number W911NF-14-2-0034. The views and conclusions contained in this article are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the Leonard Wood Institute, the Army Research Laboratory, or the US government. The US government is authorized to reproduce and distribute reprints for government purposes, not-withstanding any copyright notation heron. The authors express their gratitude for the Acute Effects of Neurotrauma Consortium in assisting and coordinating the conduct of this project at Fort Leonard Wood. This research was also supported by VA Research Career Scientist Award to Asgar Zaheer.	Acharya A, 2020, J NEUROIMMUNE PHARM, V15, P167, DOI 10.1007/s11481-020-09924-9; [Anonymous], 2020, LANCET, V395, P922, DOI 10.1016/S0140-6736(20)30644-9; Arac A, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00126; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122; Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398; Berger JR, 2020, J NEUROVIROL, V26, P143, DOI 10.1007/s13365-020-00840-5; Bisht K, 2018, NEUROBIOL STRESS, V9, P9, DOI 10.1016/j.ynstr.2018.05.003; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Bostanciklioglu M, 2020, INFLAMM BOWEL DIS, V26, pE89, DOI 10.1093/ibd/izaa131; Cabrera-Pastor A, 2019, ACTA PHYSIOL, V226, DOI 10.1111/apha.13270; Calcia MA, 2016, PSYCHOPHARMACOLOGY, V233, P1637, DOI 10.1007/s00213-016-4218-9; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Chary MA, 2020, J MED TOXICOL, V16, P284, DOI 10.1007/s13181-020-00777-5; Ciotti M, 2020, CRIT REV CL LAB SCI, V57, P365, DOI [10.1159/000507423, 10.1080/10408363.2020.1783198]; Connell NT, 2020, J THROMB HAEMOST, DOI 10.1111/jth.14893; Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000; Conti P, 2020, J Biol Regul Homeost Agents, V34, P339, DOI 10.23812/Editorial-Conti-3; Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E; Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003; Crisci Carlos D, 2020, Curr Treat Options Allergy, P1, DOI 10.1007/s40521-020-00258-8; Cure E, 2020, DIABETES METAB SYND, V14, P349, DOI 10.1016/j.dsx.2020.04.019; De Felice FG, 2020, TRENDS NEUROSCI, V43, P355, DOI 10.1016/j.tins.2020.04.004; Debuc B, 2021, STEM CELL REV REP, V17, P4, DOI 10.1007/s12015-020-09987-4; Dinet V, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01178; Dixon L, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000789; Dong HQ, 2014, MED SCI MONIT BASIC, V20, P200, DOI 10.12659/MSMBR.893093; Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448; Finsterer J, 2020, J MED VIROL, V92, P2316, DOI 10.1002/jmv.26000; Gasparyan AY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e176; Gigante A, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109856; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; Golpanian RS, 2020, CLIN THER, V42, P745, DOI 10.1016/j.clinthera.2020.01.025; Hasegawa T, 2007, MED HYPOTHESES, V69, P1135, DOI 10.1016/j.mehy.2007.02.034; Heneka MT, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00640-3; Hotez PJ, 2020, MICROBES INFECT, V22, P165, DOI 10.1016/j.micinf.2020.04.005; Johnson VE, 2018, ACTA NEUROPATHOL, V135, P711, DOI 10.1007/s00401-018-1824-0; Jones MK, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00171; Karamloo F, 2020, ALLERGY, V75, P1822, DOI 10.1111/all.14360; Kempuraj D., 2016, J NEUROL NEUROSURG S, V1, P1003; Kempuraj D, 2020, NEUROSCIENTIST, V26, P134, DOI 10.1177/1073858419848293; Kempuraj D, 2020, CLIN THER, V42, P974, DOI 10.1016/j.clinthera.2020.02.018; Kempuraj D, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00054; Kempuraj D, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00216; Khalili N, 2020, ACAD RADIOL, V27, P1051, DOI 10.1016/j.acra.2020.04.035; Khalsaa DS, 2015, J ALZHEIMERS DIS, V48, P1, DOI 10.3233/JAD-142766; Kim YK, 2017, BEHAV BRAIN RES, V329, P6, DOI 10.1016/j.bbr.2017.04.020; Komi DEA, 2020, CLIN REV ALLERG IMMU, V58, P342, DOI 10.1007/s12016-019-08769-2; Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Kustrimovic N, 2019, CURR MED CHEM, V26, P3719, DOI 10.2174/0929867325666181009161048; Leonardi M, 2020, J NEUROL, V267, P1573, DOI 10.1007/s00415-020-09896-z; Li H, 2020, NEUROTOX RES, V38, P1, DOI 10.1007/s12640-020-00219-8; Li L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00661-z; Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x; Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001; Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833; Li Y, 2020, BRIT J HAEMATOL, V190, pE24, DOI 10.1111/bjh.16811; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048; Magrone T, 2020, ENDOCR METAB IMMUNE, V20, P1391, DOI 10.2174/1871530320666200406123734; Manjili RH, 2020, J IMMUNOL, V205, P12, DOI 10.4049/jimmunol.2000413; Mankad K, 2020, NEURORADIOLOGY, V62, P647, DOI 10.1007/s00234-020-02437-5; Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472; McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538; McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859; McKittrick CM, 2015, J CEREBR BLOOD F MET, V35, P638, DOI 10.1038/jcbfm.2014.239; Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621; Minihan E, 2020, IRISH J PSYCHOL MED, V37, P259, DOI 10.1017/ipm.2020.41; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Mravec B, 2018, CELL MOL NEUROBIOL, V38, P73, DOI 10.1007/s10571-017-0521-1; Mukai K, 2018, IMMUNOL REV, V282, P121, DOI 10.1111/imr.12634; Natoli S, 2020, EUR J NEUROL, V27, P1764, DOI 10.1111/ene.14277; Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002; Ogier Michael, 2020, Brain Behav Immun Health, V5, P100081, DOI 10.1016/j.bbih.2020.100081; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Park CL, 2020, J GEN INTERN MED, V35, P2296, DOI 10.1007/s11606-020-05898-9; Parrella E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050437; Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647; Piirainen S, 2017, NEUROSCI BIOBEHAV R, V77, P148, DOI 10.1016/j.neubiorev.2017.01.046; de Chambrun MP, 2021, J INTERN MED, V289, P427, DOI 10.1111/joim.13166; Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5; Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7; Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0; Ronconi G, 2020, J BIOL REGUL HOMEOST, V34; Saavedra JM, 2020, CELL MOL NEUROBIOL, V40, P667, DOI 10.1007/s10571-020-00861-y; Saleki K, 2020, REV NEUROSCIENCE, V31, P453, DOI 10.1515/revneuro-2020-0026; Serrano-Castro PJ, 2020, NEUROLOGIA, V35, P245, DOI 10.1016/j.nrl.2020.04.002; Sheraton M, 2020, CUREUS, V12, DOI 10.7759/cureus.8192; Singh AK, 2020, DIABETES METAB SYND, V14, P303, DOI 10.1016/j.dsx.2020.04.004; Skaper SD, 2017, NEUROSCIENTIST, V23, P478, DOI 10.1177/1073858416687249; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Steenblock C, 2020, MOL PSYCHIATR, V25, P1611, DOI 10.1038/s41380-020-0758-9; Stefaniak AA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13477; Stuve O, 2014, CLIN EXP IMMUNOL, V175, P333, DOI 10.1111/cei.12260; Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Theoharides TC, 2020, CLIN THER, V42, P1007, DOI 10.1016/j.clinthera.2020.05.002; Theoharides TC, 2020, BIOFACTORS, V46, P306, DOI 10.1002/biof.1633; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678; Varricchi G, 2019, INT ARCH ALLERGY IMM, V179, P247, DOI 10.1159/000500088; Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037; Vinciguerra M, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104361; Vinkers CH, 2020, EUR NEUROPSYCHOPHARM, V35, P12, DOI 10.1016/j.euroneuro.2020.05.003; Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17051729; Wilson MP, 2020, CLIN NEUROL NEUROSUR, V193, DOI 10.1016/j.clineuro.2020.105866; Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005; Wu WZ, 2020, J MED VIROL, V92, P1962, DOI 10.1002/jmv.25914; Xia HJ, 2008, J NEUROCHEM, V107, P1482, DOI 10.1111/j.1471-4159.2008.05723.x; Xiao H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923549; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037; Yeung D, 2008, ACTA NEUROPATHOL, V115, P635, DOI 10.1007/s00401-008-0364-4; Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046; Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859; Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575; Zheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5	120	33	34	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	OCT	2020	26	5-6					402	414	1073858420941476	10.1177/1073858420941476		JUL 2020	13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	NX6QK	WOS:000549920700001	32684080	Bronze			2021-06-18	
J	Kitchen, P; Salman, MM; Halsey, AM; Clarke-Bland, C; MacDonald, JA; Ishida, H; Vogel, HJ; Almutiri, S; Logan, A; Kreida, S; Al-Jubair, T; Missel, JW; Gourdon, P; Tomroth-Horsefield, S; Conner, MT; Ahmed, Z; Conner, AC; Bill, RM				Kitchen, Philip; Salman, Mootaz M.; Halsey, Andrea M.; Clarke-Bland, Charlotte; MacDonald, Justin A.; Ishida, Hiroaki; Vogel, Hans J.; Almutiri, Sharif; Logan, Ann; Kreida, Stefan; Al-Jubair, Tamim; Missel, Julie Winkel; Gourdon, Pontus; Tomroth-Horsefield, Susanna; Conner, Matthew T.; Ahmed, Zubair; Conner, Alex C.; Bill, Roslyn M.			Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema	CELL			English	Article							TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; X-RAY-STRUCTURE; WATER PERMEABILITY; BARRIER PERMEABILITY; CORTICAL ASTROCYTES; CALMODULIN-BINDING; CEREBRAL EDEMA; CELL-VOLUME; CHANNEL	Swelling of the brain or spinal cord (CNS edema) affects millions of people every year. All potential pharmacological interventions have failed in clinical trials, meaning that symptom management is the only treatment option. The water channel protein aquaporin-4 (AQP4) is expressed in astrocytes and mediates water flux across the blood-brain and blood-spinal cord barriers. Here we show that AQP4 cell-surface abundance increases in response to hypoxia-induced cell swelling in a calmodulin-dependent manner. Calmodulin directly binds the AQP4 carboxyl terminus, causing a specific conformational change and driving AQP4 cell-surface localization. Inhibition of calmodulin in a rat spinal cord injury model with the licensed drug trifluoperazine inhibited AQP4 localization to the blood-spinal cord barrier, ablated CNS edema, and led to accelerated functional recovery compared with untreated animals. We propose that targeting the mechanism of calmodulin-mediated cell-surface localization of AQP4 is a viable strategy for development of CNS edema therapies.	[Kitchen, Philip; Clarke-Bland, Charlotte; Bill, Roslyn M.] Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England; [Salman, Mootaz M.] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA; [Salman, Mootaz M.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA; [Salman, Mootaz M.] Univ Mosul, Coll Pharm, Dept Pharmacol, Mosul 41002, Iraq; [Halsey, Andrea M.; Almutiri, Sharif; Logan, Ann; Ahmed, Zubair] Univ Birmingham, Coll Med & Dent Sci, Inst Inflammat & Ageing, Neurosci & Ophthalmol, Birmingham B15 2TT, W Midlands, England; [MacDonald, Justin A.; Vogel, Hans J.] Univ Calgary, Cumming Sch Med, Dept Biochem & Mol Biol, Calgary, AB T2N 4Z6, Canada; [Ishida, Hiroaki; Vogel, Hans J.] Univ Calgary, Dept Biol Sci, Calgary, AB T2N 4N1, Canada; [Almutiri, Sharif] Shaqra Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Shaqra, Saudi Arabia; [Kreida, Stefan; Al-Jubair, Tamim; Tomroth-Horsefield, Susanna] Lund Univ, Dept Biochem & Struct Biol, POB 124, S-22100 Lund, Sweden; [Missel, Julie Winkel; Gourdon, Pontus] Univ Copenhagen, Dept Biomed Sci, DK-2200 Copenhagen, Denmark; [Gourdon, Pontus] Lund Univ, Dept Expt Med Sci, POB 118, S-22100 Lund, Sweden; [Conner, Matthew T.] Univ Wolverhampton, Sch Sci, Res Inst Healthcare Sci, Wolverhampton WV1 1LY, England; [Conner, Alex C.] Univ Birmingham, Coll Med & Dent Sci, Inst Clin Sci, Birmingham B15 2TT, W Midlands, England	Bill, RM (corresponding author), Aston Univ, Sch Life & Hlth Sci, Birmingham B4 7ET, W Midlands, England.; Ahmed, Z (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Inflammat & Ageing, Neurosci & Ophthalmol, Birmingham B15 2TT, W Midlands, England.; Conner, AC (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Clin Sci, Birmingham B15 2TT, W Midlands, England.	z.ahmed.1@bham.ac.uk; a.c.conner@bham.ac.uk; r.m.bill@aston.ac.uk	Kitchen, Philip/J-6936-2019; Ahmed, Zubair/AAN-1869-2021; Salman, Mootaz M./J-3111-2019; Jubair, Tamim Al/P-8642-2016; Bill, Roslyn M/D-4554-2012	Kitchen, Philip/0000-0002-1558-4673; Salman, Mootaz M./0000-0002-5683-1706; Jubair, Tamim Al/0000-0001-6954-5293; Bill, Roslyn M/0000-0003-1331-0852; Missel, Julie Winkel/0000-0002-9727-1274	Biotechnology & Biosciences Research Council [BB/P025927/1]; Aston University; BiogenBiogen; International Spinal Research Trust [NRB116]; Saudi Education Ministry in London [SHU11]; Swedish Research CouncilSwedish Research CouncilEuropean Commission [2013-05945]; Crafoord Foundation [20140811, 20180916]; Magnus Bergvall Foundation [2015-01534]; Knut and Alice Wallenburg FoundationKnut & Alice Wallenberg Foundation; Lundbeck FoundationLundbeckfonden; Natural Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)CGIAR	We acknowledge grants from the Biotechnology & Biosciences Research Council (to R.M.B., A.C.C., and P.K. through BB/P025927/1); Aston University (to P.K. through a 50th Anniversary Prize Fellowship); Biogen (to M.M.S. through funding to Prof. Tomas Kirchhausen); the International Spinal Research Trust (to A.H., A.L., and Z.A. through NRB116); the Saudi Education Ministry in London (to Z.A. and S.A. through SHU11); the Swedish Research Council (to S.T.-H. through 2013-05945); the Crafoord Foundation (to S.T.-H. through 20140811 and 20180916); the Magnus Bergvall Foundation (to S.T.-H. through 2015-01534); the Knut and Alice Wallenburg Foundation (to P.G.); the Lundbeck Foundation (to P.G.); and the Natural Sciences and Engineering Research Council of Canada (to H.J.V. and J.A.M.). We thank Prof. Sara Linse (Lund University), for recombinantly expressed human CaM and Prof. Tomas Kirchhausen, Dr. Florian Winau, and Prof. John Flanagan (Harvard Medical School) for constructive discussions regarding our study.	Abir-Awan M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071589; Allahyari R.V., 2015, JOVE-J VIS EXP, V100; Almutiri S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29124-z; Benfenati V, 2011, P NATL ACAD SCI USA, V108, P2563, DOI 10.1073/pnas.1012867108; Chen Y, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00022; Chu HL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081249; Cohen DM, 2009, NMR BIOMED, V22, P332, DOI 10.1002/nbm.1343; Creese I, 1996, J NEUROPSYCH CLIN N, V8, P223; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Esmaeili M, 2014, NEURAL REGEN RES, V9, P1653, DOI 10.4103/1673-5374.141797; Fagoe ND, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150141; Farr GW, 2019, NEUROSCIENCE, V404, P484, DOI 10.1016/j.neuroscience.2019.01.034; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Frick A, 2014, P NATL ACAD SCI USA, V111, P6305, DOI 10.1073/pnas.1321406111; Gonen T, 2004, NATURE, V429, P193, DOI 10.1038/nature02503; GOODMAN JH, 1976, J NEUROSURG, V44, P418, DOI 10.3171/jns.1976.44.4.0418; Gopalakrishnan MS, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00977; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; Haj-Yasein NN, 2011, P NATL ACAD SCI USA, V108, P17815, DOI 10.1073/pnas.1110655108; Harries WEC, 2004, P NATL ACAD SCI USA, V101, P14045, DOI 10.1073/pnas.0405274101; Heller Stefan, 2007, P113; Hiroaki Y, 2006, J MOL BIOL, V355, P628, DOI 10.1016/j.jmb.2005.10.081; Ho JD, 2009, P NATL ACAD SCI USA, V106, P7437, DOI 10.1073/pnas.0902725106; HOFMANN F, 1975, J BIOL CHEM, V250, P7795; Horsefield R, 2008, P NATL ACAD SCI USA, V105, P13327, DOI 10.1073/pnas.0801466105; Hoshi Y, 2018, J NEUROSCI, V38, P5700, DOI 10.1523/JNEUROSCI.2888-17.2018; HUERTABAHENA J, 1983, MOL PHARMACOL, V23, P67; Jha RM, 2019, NEUROPHARMACOLOGY, V145, P230, DOI 10.1016/j.neuropharm.2018.08.004; Jo AO, 2015, J NEUROSCI, V35, P13525, DOI 10.1523/JNEUROSCI.1987-15.2015; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Kawamata Tatsuro, 2007, Neurosurg Focus, V22, pE5, DOI 10.3171/foc.2007.22.5.6; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; Kitchen P, 2015, J BIOL CHEM, V290, P16873, DOI 10.1074/jbc.M115.646034; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Kreida S, 2015, CURR OPIN STRUC BIOL, V33, P126, DOI 10.1016/j.sbi.2015.08.004; Kuppers E, 2008, EUR J NEUROSCI, V28, P2173, DOI 10.1111/j.1460-9568.2008.06531.x; Lafrenaye AD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020330; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Lamiable A, 2016, NUCLEIC ACIDS RES, V44, pW449, DOI 10.1093/nar/gkw329; Li S, 1999, SPINAL CORD, V37, P820, DOI 10.1038/sj.sc.3100941; Li W, 2016, MICROVASC RES, V106, P117, DOI 10.1016/j.mvr.2015.12.008; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Luan Q, 2018, MED SCI MONITOR, V24, P5391, DOI 10.12659/MSM.910191; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manley GT, 2004, NEUROSCIENCE, V129, P983, DOI 10.1016/j.neuroscience.2004.06.088; MCKEON TA, 1991, ANAL BIOCHEM, V193, P125, DOI 10.1016/0003-2697(91)90051-T; Nakashima K, 1996, BIOCHEMISTRY-US, V35, P5602, DOI 10.1021/bi952586l; National Institute for Health and Care Excellence (NICE), 2019, BRIT NATL FORMULARY; Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079; O'Connell DJ, 2010, MOL CELL PROTEOMICS, V9, P1118, DOI 10.1074/mcp.M900324-MCP200; Oberg F, 2011, MOL MEMBR BIOL, V28, P398, DOI 10.3109/09687688.2011.602219; Offringa R, 2013, J INTEGR PLANT BIOL, V55, P789, DOI 10.1111/jipb.12096; Oklinski MK, 2014, J HISTOCHEM CYTOCHEM, V62, P598, DOI 10.1369/0022155414537495; Orellana JA, 2010, GLIA, V58, P329, DOI 10.1002/glia.20926; Oshio K, 2004, NEUROSCIENCE, V127, P685, DOI 10.1016/j.neuroscience.2004.03.016; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Bordone MP, 2019, J NEUROCHEM, V151, P139, DOI 10.1111/jnc.14829; Qin J, 2009, PFLUG ARCH EUR J PHY, V458, P643, DOI 10.1007/s00424-009-0658-y; Rabaud NE, 2009, BIOCHEM BIOPH RES CO, V383, P54, DOI 10.1016/j.bbrc.2009.03.128; Raslan Ahmed, 2007, Neurosurg Focus, V22, pE12; Reichow SL, 2008, STRUCTURE, V16, P1389, DOI 10.1016/j.str.2008.06.011; Reichow SL, 2013, NAT STRUCT MOL BIOL, V20, P1085, DOI 10.1038/nsmb.2630; Rosenberg GA, 1999, PROG CARDIOVASC DIS, V42, P209, DOI 10.1016/S0033-0620(99)70003-4; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Salman MM, 2017, EUR J NEUROSCI, V46, P2542, DOI 10.1111/ejn.13723; Salman MM, 2017, EUR J NEUROSCI, V46, P2121, DOI 10.1111/ejn.13652; Sanabra C, 2011, J CHEM NEUROANAT, V41, P43, DOI 10.1016/j.jchemneu.2010.11.001; Sansing LH, 2011, NEUROCRIT CARE, V14, P395, DOI 10.1007/s12028-010-9498-z; Sato T, 2003, J PHARMACOL EXP THER, V304, P1042, DOI 10.1124/jpet.102.045039; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Slovinska L., 2016, IN VITRO MODELS SPIN, DOI [10.5772/63459, DOI 10.5772/63459]; Stefanetti Renae J, 2018, F1000Res, V7, DOI 10.12688/f1000research.15258.1; Stein DG, 2015, BRAIN INJURY, V29, P1259, DOI 10.3109/02699052.2015.1065344; Stokum JA, 2015, NEUROCHEM RES, V40, P317, DOI 10.1007/s11064-014-1374-3; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Surey S, 2014, NEUROSCIENCE, V275, P62, DOI 10.1016/j.neuroscience.2014.06.003; Tang GH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101413; Tani K, 2009, J MOL BIOL, V389, P694, DOI 10.1016/j.jmb.2009.04.049; TANOKURA M, 1986, J BIOL CHEM, V261, P749; Tidow H, 2013, FEBS J, V280, P5551, DOI 10.1111/febs.12296; Tong JH, 2012, BIOPHYS J, V103, P1899, DOI 10.1016/j.bpj.2012.09.025; Torre-Healy A, 2012, NEUROCRIT CARE, V17, P117, DOI 10.1007/s12028-011-9649-x; Tseng WC, 2008, ANAL BIOCHEM, V375, P376, DOI 10.1016/j.ab.2007.12.013; Ullah S, 2016, SCI REP-UK, V6, DOI 10.1038/srep23534; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; Vella J, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00108; Verkman AS, 2017, EXPERT OPIN THER TAR, V21, P1161, DOI 10.1080/14728222.2017.1398236; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Werten PJL, 2001, FEBS LETT, V504, P200, DOI 10.1016/S0014-5793(01)02703-X; Winkler EA, 2016, NEUROSURG CLIN N AM, V27, P473, DOI 10.1016/j.nec.2016.05.008; Yang BX, 1997, BIOCHEMISTRY-US, V36, P7625, DOI 10.1021/bi970231r; Yap Kyoko L., 2000, Journal of Structural and Functional Genomics, V1, P8, DOI 10.1023/A:1011320027914; YU ACH, 1989, J CEREBR BLOOD F MET, V9, P20, DOI 10.1038/jcbfm.1989.3; Zelenina M, 2002, AM J PHYSIOL-RENAL, V283, pF309, DOI 10.1152/ajprenal.00260.2001; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	104	33	34	6	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 14	2020	181	4					784	+		10.1016/j.cell.2020.03.037			35	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	LO4UD	WOS:000533623900007	32413299	Green Published, Other Gold, Green Accepted			2021-06-18	
J	Burek, M; Konig, A; Lang, M; Fiedler, J; Oerter, S; Roewer, N; Bohnert, M; Thal, SC; Blecharz-Lang, KG; Woitzik, J; Thum, T; Forster, CY				Burek, Malgorzata; Koenig, Anna; Lang, Mareike; Fiedler, Jan; Oerter, Sabrina; Roewer, Norbert; Bohnert, Michael; Thal, Serge C.; Blecharz-Lang, Kinga G.; Woitzik, Johannes; Thum, Thomas; Foerster, Carola Y.			Hypoxia-Induced MicroRNA-212/132 Alter Blood-Brain Barrier Integrity Through Inhibition of Tight Junction-Associated Proteins in Human and Mouse Brain Microvascular Endothelial Cells	TRANSLATIONAL STROKE RESEARCH			English	Article						MicroRNA-212; 132; Blood-brain barrier; Tight junctions; Oxygen-glucose deprivation; Traumatic brain injury; Stroke	HIPPOCAMPAL-NEURONS; INJURY; EXPRESSION; MIGRATION; MIR-132; CLAUDIN-1; PROTECTS; MIR-212; TARGETS; MODEL	Blood-brain barrier (BBB) integrity is one of the important elements of central nervous system (CNS) homeostasis. MicroRNAs (miRs) have been demonstrated to play a role in many CNS disorders such as stroke and traumatic brain injury. MiR-212/132 are highly expressed in the CNS but their role at the BBB has not been characterized yet. Thus, we analyzed the expression of miR-212/132 in hypoxic mouse and human brain microvascular endothelial cells (BMEC) as well as in posttraumatic mouse and human brain tissue and serum exosomes. MiR-212/132 expression was detected in brain capillaries by in situ hybridization and was increased up to ten times in hypoxic BMEC. Over-expression of pre-miR-212/132 in BMEC decreased barrier properties and reduced migration of BMEC in the wound healing assay. We identified and validated tight junction proteins claudin-1 (Cldn1), junctional adhesion molecule 3 (Jam3), and tight junction-associated protein 1 (Tjap1) as potential miR-212/132 targets. Over-expression of miRs led to a decrease in mRNA and protein expression of Cldn1, Jam3, and Tjap1, which could be rescued by a respective anti-miR. In conclusion, our study identifies miR-212/132 as critical players at the hypoxic BBB. In addition, we propose three new direct miR-212/132 targets to be involved in miR-212/132-mediated effects on BBB properties.	[Burek, Malgorzata; Koenig, Anna; Lang, Mareike; Roewer, Norbert; Foerster, Carola Y.] Univ Wurzburg, Dept Anesthesia & Crit Care, Wurzburg, Germany; [Fiedler, Jan; Thum, Thomas] Hannover Med Sch, IMTTS, Hannover, Germany; [Oerter, Sabrina; Bohnert, Michael] Univ Wurzburg, Inst Forens Med, Wurzburg, Germany; [Thal, Serge C.] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, Mainz, Germany; [Blecharz-Lang, Kinga G.] Charite Univ Med Berlin, Dept Expt Neurosurg, Berlin, Germany; [Blecharz-Lang, Kinga G.] Free Univ Berlin, Berlin, Germany; [Blecharz-Lang, Kinga G.] Humboldt Univ, Berlin, Germany; [Blecharz-Lang, Kinga G.] Berlin Inst Hlth, Berlin, Germany; [Woitzik, Johannes] Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany; [Woitzik, Johannes] Charite Univ Med Berlin, Ctr Stroke Res Berlin CSB, Berlin, Germany	Burek, M (corresponding author), Univ Wurzburg, Dept Anesthesia & Crit Care, Wurzburg, Germany.	Burek_M@ukw.de	Burek, Malgorzata/AAF-3283-2021; Thal, Serge/D-6593-2011	Burek, Malgorzata/0000-0001-6148-2195; Thal, Serge/0000-0002-1222-8729	European UnionEuropean Commission [HEALTH-F2-2009-241778]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG-WO 1704/1-1]	This work was supported in part by the grant from the European Union (HEALTH-F2-2009-241778) to CF and MB and Deutsche Forschungsgemeinschaft (DFG-WO 1704/1-1) to JW.	Alvarez-Saavedra M, 2011, HUM MOL GENET, V20, P731, DOI 10.1093/hmg/ddq519; Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186; Blecharz KG, 2015, BIOL CELL, V107, P342, DOI 10.1111/boc.201500011; Blecharz-Lang KG, 2018, J CEREBR BLOOD F MET, V38, P1940, DOI 10.1177/0271678X18768443; Burek M., 2013, J STEROIDS HORMONAL, V5, P1, DOI [10.4172/2157-7536.1000128, DOI 10.4172/2157-7536.1000128]; Burek M, 2012, JOVE-J VIS EXP, DOI 10.3791/4022; Burek M, 2010, ARTERIOSCL THROM VAS, V30, P298, DOI 10.1161/ATVBAHA.109.197582; Burek M, 2009, MOL CELL ENDOCRINOL, V298, P19, DOI 10.1016/j.mce.2008.09.041; Cambronne XA, 2012, P NATL ACAD SCI USA, V109, P20473, DOI 10.1073/pnas.1218887109; Charania MA, 2012, GASTROENTEROLOGY, V142, pS725; Cichon C, 2014, TISSUE BARRIERS, V2, DOI 10.4161/21688362.2014.944446; Coisne C, 2011, ANTIOXID REDOX SIGN, V15, P1285, DOI 10.1089/ars.2011.3929; Dilling C, 2017, J CEREBR BLOOD F MET, V37, P3391, DOI 10.1177/0271678X16688706; Fiedler J, 2011, CIRCULATION, V124, P720, DOI 10.1161/CIRCULATIONAHA.111.039008; Fletcher NF, 2012, GASTROENTEROLOGY, V142, P634, DOI 10.1053/j.gastro.2011.11.028; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; Fujibe M, 2004, EXP CELL RES, V295, P36, DOI 10.1016/j.yexcr.2003.12.014; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Helms HC, 2016, J CEREBR BLOOD F MET, V36, P862, DOI 10.1177/0271678X16630991; Hernandez-Rapp J, 2016, SCI REP-UK, V6, DOI 10.1038/srep30953; Hopp S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0815-8; Kawabe H, 2001, J BIOL CHEM, V276, P48350, DOI 10.1074/jbc.M107335200; Keaney J, 2015, FEBS J, V282, P4067, DOI 10.1111/febs.13412; Keasey MP, 2016, J MOL NEUROSCI, V59, P404, DOI 10.1007/s12031-016-0740-9; Kim HR, 2017, EXP CELL RES, V358, P161, DOI 10.1016/j.yexcr.2017.06.009; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Kumarswamy R, 2014, EUR HEART J, V35, P3224, DOI 10.1093/eurheartj/ehu344; Lei ZY, 2015, J CELL MOL MED, V19, P1994, DOI 10.1111/jcmm.12586; Li X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07513-0; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mochida GH, 2010, AM J HUM GENET, V87, P882, DOI 10.1016/j.ajhg.2010.10.026; Orlova VV, 2006, J EXP MED, V203, P2703, DOI 10.1084/jem.20051730; Pfeiffer F, 2011, ACTA NEUROPATHOL, V122, P601, DOI 10.1007/s00401-011-0883-2; Pichler S, 2017, NEUROBIOL AGING, V50, DOI 10.1016/j.neurobiolaging.2016.09.019; Pinczolits A, 2017, J CEREBR BLOOD F MET, V37, P1896, DOI 10.1177/0271678X17699629; Redis RS, 2012, J CELL BIOCHEM, V113, P1451, DOI 10.1002/jcb.24038; Salvador Ellaine, 2016, Curr Pathobiol Rep, V4, P135; Salvador E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00323; Smith PY, 2015, HUM MOL GENET, V24, P6721, DOI 10.1093/hmg/ddv377; Stankowski JN, 2011, ANTIOXID REDOX SIGN, V14, P1841, DOI 10.1089/ars.2010.3292; Sun ZZ, 2017, INT J IMMUNOPATH PH, V30, P253, DOI 10.1177/0394632017715837; Tang YM, 2008, ALCOHOL CLIN EXP RES, V32, P355, DOI 10.1111/j.1530-0277.2007.00584.x; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Timaru-Kast R, 2015, J NEUROTRAUM, V32, P1777, DOI 10.1089/neu.2014.3784; Tognini P, 2012, INT J BIOCHEM CELL B, V44, P6, DOI 10.1016/j.biocel.2011.10.015; Truettner JS, 2011, J CEREBR BLOOD F MET, V31, P1897, DOI 10.1038/jcbfm.2011.33; Ucar A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2090; Ucar A, 2010, NAT GENET, V42, P1101, DOI 10.1038/ng.709; Wanet A, 2012, NUCLEIC ACIDS RES, V40, P4742, DOI 10.1093/nar/gks151; Weksler BB, 2005, FASEB J, V19, P1872; Wilhelm I, 2018, J CEREBR BLOOD F MET, V38, P563, DOI 10.1177/0271678X17732025; Wolburg H, 2001, NEUROSCI LETT, V307, P77, DOI 10.1016/S0304-3940(01)01927-9; Wyss L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045619; Yanev P, 2017, J CEREBR BLOOD F MET, V37, P2768, DOI 10.1177/0271678X16674737; Yao C, 2016, MOL NEUROBIOL, V53, P5129, DOI 10.1007/s12035-015-9449-y	58	33	33	0	10	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2019	10	6					672	683		10.1007/s12975-018-0683-2			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	JL1KU	WOS:000495293000009	30617994	Other Gold, Green Published			2021-06-18	
J	Yuen, KCJ; Biller, BMK; Radovick, S; Carmichael, JD; Jasim, S; Pantalone, KM; Hoffman, AR				Yuen, Kevin C. J.; Biller, Beverly M. K.; Radovick, Sally; Carmichael, John D.; Jasim, Sina; Pantalone, Kevin M.; Hoffman, Andrew R.			AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE 2019 AACE GROWTH HORMONE TASK FORCE	ENDOCRINE PRACTICE			English	Article							GH-REPLACEMENT THERAPY; GLUCAGON STIMULATION TEST; QUALITY-OF-LIFE; BONE-MINERAL DENSITY; TRAUMATIC BRAIN-INJURY; RECOMBINANT HUMAN GH; CARDIOVASCULAR RISK MARKERS; RESEARCH SOCIETY PERSPECTIVE; ANTERIOR-PITUITARY FUNCTION; LEUKEMIA INHIBITORY FACTOR	Objective: The development of these guidelines is sponsored by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPG). Methods: Recommendations are based on diligent reviews of clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols. Results: The Executive Summary of this 2019 updated guideline contains 58 numbered recommendations: 12 are Grade A (21%), 19 are Grade B (33%), 21 are Grade C (36%), and 6 are Grade D (10%). These detailed, evidence-based recommendations allow for nuance-based clinical decision-making that addresses multiple aspects of real-world care of patients. The evidence base presented in the subsequent Appendix provides relevant supporting information for the Executive Summary recommendations. This update contains 357 citations of which 51 (14%) are evidence level (EL) 1 (strong), 168 (47%) are EL 2 (intermediate), 61 (17%) are EL 3 (weak), and 77 (22%) are EL 4 (no clinical evidence). Conclusion: This CPG is a practical tool that practicing endocrinologists and regulatory bodies can refer to regarding the identification, diagnosis, and treatment of adults and patients transitioning from pediatric to adultcare services with growth hormone deficiency (GHD). It provides guidelines on assessment, screening, diagnostic testing, and treatment recommendations for a range of individuals with various causes of adult GHD. The recommendations emphasize the importance of considering testing patients with a reasonable level of clinical suspicion of GHD using appropriate growth hormone (GH) cut-points for various GH-stimulation tests to accurately diagnose adult GHD, and to exercise caution interpreting serum GH and insulin-like growth factor-1 (IGF-1) levels, as various GH and IGF-1 assays are used to support treatment decisions. The intention to treat often requires sound clinical judgment and careful assessment of the benefits and risks specific to each individual patient. Unapproved uses of GH, long-term safety, and the current status of long-acting GH preparations are also discussed in this document.	[Yuen, Kevin C. J.] Univ Arizona, Barrow Pituitary Ctr, Barrow Neurol Inst, Coll Med, Phoenix, AZ 85013 USA; [Yuen, Kevin C. J.] Univ Arizona, St Josephs Hosp & Med Ctr, Coll Med, Phoenix, AZ 85013 USA; [Yuen, Kevin C. J.] Creighton Sch Med, Phoenix, AZ USA; [Biller, Beverly M. K.] Harvard Med Sch, Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02115 USA; [Radovick, Sally] Rutgers Robert Wood Johnson Sch Med, Div Endocrinol, Dept Pediat, New Brunswick, NJ USA; [Carmichael, John D.] Univ Southern Calif, Div Endocrinol, Dept Med, Keck Sch Med, Los Angeles, CA 90007 USA; [Jasim, Sina] Washington Univ, Sch Med, Div Endocrinol Metab & Lipid Res, St Louis, MO USA; [Pantalone, Kevin M.] Cleveland Clin, Dept Endocrinol Diabet & Metab, Cleveland, OH 44106 USA; [Hoffman, Andrew R.] VA Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA USA; [Hoffman, Andrew R.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA	Yuen, KCJ (corresponding author), Barrow Neurol Inst, Barrow Pituitary Ctr, Dept Neuroendocrinol, 124 West Thomas Rd,Suite 300, Phoenix, AZ 85013 USA.; Yuen, KCJ (corresponding author), Barrow Neurol Inst, Barrow Pituitary Ctr, Dept Neurosurg, 124 West Thomas Rd,Suite 300, Phoenix, AZ 85013 USA.	kevin.yuen@dignityhealth.org	Jasim, Sina/ABB-5030-2020	Jasim, Sina/0000-0001-8984-3079			Abbud RA, 2004, ENDOCRINOLOGY, V145, P867, DOI 10.1210/en.2003-0897; Agha A, 2007, CLIN ENDOCRINOL, V66, P72, DOI 10.1111/j.1365-2265.2006.02688.x; Ahmid M, 2016, ENDOCR CONNECT, V5, pR1, DOI 10.1530/EC-16-0024; Aimaretti G, 2015, J ENDOCRINOL INVEST, V38, P377, DOI 10.1007/s40618-014-0201-7; Aimaretti G, 2000, EUR J ENDOCRINOL, V142, P347, DOI 10.1530/eje.0.1420347; ALBINI CH, 1988, PEDIATR RES, V23, P89, DOI 10.1203/00006450-198801000-00020; Allen DB, 2016, EUR J ENDOCRINOL, V174, pP1, DOI 10.1530/EJE-15-0873; Miguel GA, 2016, THER ADV ENDOCRINOL, V7, P93, DOI 10.1177/2042018816643908; Altinova AE, 2016, ENDOCRINE, V52, P374, DOI 10.1007/s12020-015-0789-1; Amato G, 2000, J CLIN ENDOCR METAB, V85, P3720, DOI 10.1210/jc.85.10.3720; Anderson LJ, 2018, MOL CELL ENDOCRINOL, V464, P65, DOI 10.1016/j.mce.2017.06.010; Andiran N, 2007, GROWTH HORM IGF RES, V17, P149, DOI 10.1016/j.ghir.2007.01.002; Anisimov Vladimir N, 2007, Cancer Control, V14, P23; Appelman-Dijkstra NM, 2014, CLIN ENDOCRINOL, V81, P727, DOI 10.1111/cen.12493; Arafat AM, 2010, DIABETOLOGIA, V53, P1304, DOI 10.1007/s00125-010-1738-4; Arwert LI, 2005, CLIN ENDOCRINOL, V63, P310, DOI 10.1111/j.1365-2265.2005.02343.x; Attanasio AF, 2004, J CLIN ENDOCR METAB, V89, P4857, DOI 10.1210/jc.2004-0551; Attanasio AF, 1997, J CLIN ENDOCR METAB, V82, P82, DOI 10.1210/jc.82.1.82; Attanasio AF, 2011, J CLIN ENDOCR METAB, V96, P2255, DOI 10.1210/jc.2011-0448; Attanasio AF, 2010, J CLIN ENDOCR METAB, V95, P74, DOI 10.1210/jc.2009-1326; Auer MK, 2016, CLIN ENDOCRINOL, V84, P862, DOI 10.1111/cen.13030; Bansch D, 1997, METABOLISM, V46, P1039, DOI 10.1016/S0026-0495(97)90275-4; Barake M, 2014, J CLIN ENDOCR METAB, V99, P852, DOI 10.1210/jc.2013-3921; Baroncelli GI, 2004, CLIN ENDOCRINOL, V60, P175, DOI 10.1046/j.1365-2265.2003.01949.x; Bartke A, 2019, WORLD J MENS HEALTH, V37, P19, DOI 10.5534/wjmh.180018; Bartke A, 2017, BEST PRACT RES CL EN, V31, P113, DOI 10.1016/j.beem.2017.02.005; Bassiouny YA, 2016, FERTIL STERIL, V105, P697, DOI 10.1016/j.fertnstert.2015.11.026; Battelino T, 2017, CLIN ENDOCRINOL, V87, P350, DOI 10.1111/cen.13409; Baum HBA, 1996, J CLIN ENDOCR METAB, V81, P84, DOI 10.1210/jc.81.1.84; BAUMANN G, 1991, ENDOCR REV, V12, P424, DOI 10.1210/edrv-12-4-424; Baumann GP, 2012, ENDOCR REV, V33, P155, DOI 10.1210/er.2011-1035; Beauregard C, 2008, J CLIN ENDOCR METAB, V93, P2063, DOI 10.1210/jc.2007-2371; Behan LA, 2011, CLIN ENDOCRINOL, V74, P281, DOI 10.1111/j.1365-2265.2010.03815.x; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; Berberoglu Merih, 2008, J Clin Res Pediatr Endocrinol, V1, P30, DOI 10.4008/jcrpe.v1i1.7; Berg C, 2010, EUR J ENDOCRINOL, V162, P477, DOI 10.1530/EJE-09-0824; Berglund A, 2015, CLIN ENDOCRINOL, V83, P677, DOI 10.1111/cen.12848; Bidlingmaier M, 2007, NAT CLIN PRACT ENDOC, V3, P769, DOI 10.1038/ncpendmet0644; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Bollerslev J, 2006, EUR J ENDOCRINOL, V154, P537, DOI 10.1530/eje.1.02125; Bonfig W, 2008, J PEDIATR ENDOCR MET, V21, P1049; Booij HA, 2018, ENDOCR CONNECT, V7, pR223, DOI 10.1530/EC-18-0147; Boot AM, 2009, HORM RES, V71, P364, DOI 10.1159/000223422; Boschetti M, 2017, ENDOCRINE, V55, P573, DOI 10.1007/s12020-016-0951-4; Brabant G, 2009, EUR J ENDOCRINOL, V161, pS25, DOI 10.1530/EJE-09-0273; Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P3995, DOI 10.1210/jc.2009-0438; Brignardello E, 2015, J ENDOCRINOL INVEST, V38, P171, DOI 10.1007/s40618-014-0179-1; BRIXEN K, 1992, ACTA ENDOCRINOL-COP, V127, P331, DOI 10.1530/acta.0.1270331; Bryden KS, 2003, DIABETES CARE, V26, P1052, DOI 10.2337/diacare.26.4.1052; Bulow B, 1997, CLIN ENDOCRINOL, V46, P75, DOI 10.1046/j.1365-2265.1997.d01-1749.x; BUNT JC, 1986, J APPL PHYSIOL, V61, P1796; Burman P, 1997, J CLIN ENDOCR METAB, V82, P550, DOI 10.1210/jc.82.2.550; Burman P, 2013, J CLIN ENDOCR METAB, V98, P1466, DOI 10.1210/jc.2012-4059; Cakir I, 2012, GROWTH HORM IGF RES, V22, P17, DOI 10.1016/j.ghir.2011.12.001; Capalbo D, 2009, J CLIN ENDOCR METAB, V94, P3347, DOI 10.1210/jc.2008-2639; Carroll PV, 2004, J CLIN ENDOCR METAB, V89, P3890, DOI 10.1210/jc.2003-031588; Castillo AR, 2018, HORM METAB RES, P50; Chandrashekar V, 2004, BIOL REPROD, V71, P17, DOI 10.1095/biolreprod.103.027060; Chikani V, 2016, CLIN ENDOCRINOL, V85, P660, DOI 10.1111/cen.13147; Child CJ, 2019, J CLIN ENDOCR METAB, V104, P379, DOI 10.1210/jc.2018-01189; Child CJ, 2011, EUR J ENDOCRINOL, V165, P217, DOI 10.1530/EJE-11-0286; Choe SA, 2018, ARCH GYNECOL OBSTET, V297, P791, DOI 10.1007/s00404-017-4613-4; Chrisoulidou A, 2000, J CLIN ENDOCR METAB, V85, P3762, DOI 10.1210/jc.85.10.3762; Christ ER, 2016, SCI REP-UK, V6, DOI 10.1038/srep19310; Christiansen JS, 2016, EUR J ENDOCRINOL, V174, pC1, DOI 10.1530/EJE-16-0111; Cittadini A, 2013, JACC-HEART FAIL, V1, P325, DOI 10.1016/j.jchf.2013.04.003; Claessen KMJA, 2014, EUR J ENDOCRINOL, V170, P263, DOI 10.1530/EJE-13-0764; Claessen KMJA, 2013, J CLIN ENDOCR METAB, V98, P352, DOI 10.1210/jc.2012-2940; Clayton P, 2007, GROWTH HORM IGF RES, V17, P369, DOI 10.1016/j.ghir.2007.04.010; Clemmons DR, 2011, CLIN CHEM, V57, P555, DOI 10.1373/clinchem.2010.150631; Colao A, 2002, J CLIN ENDOCR METAB, V87, P3650, DOI 10.1210/jc.87.8.3650; Colao A, 2008, J CLIN ENDOCR METAB, V93, P3416, DOI 10.1210/jc.2007-2810; Colson A, 2006, HORM RES, V66, P257, DOI 10.1159/000095168; Conceicao FL, 2003, J ENDOCRINOL INVEST, V26, P1065, DOI 10.1007/BF03345251; Conway GS, 2009, EUR J ENDOCRINOL, V160, P899, DOI 10.1530/EJE-08-0436; COOK D, 2004, AM J MANAG CARE S, V10, pS41; Cook DM, 2009, ENDOCR PRACT, V15, P580, DOI 10.4158/EP.15.6.580; Cook DM, 1999, J CLIN ENDOCR METAB, V84, P3956, DOI 10.1210/jc.84.11.3956; Correa FA, 2017, J ENDOCR SOC, V1, P1322, DOI 10.1210/js.2017-00005; Courtillot C, 2013, EUR J ENDOCRINOL, V169, P587, DOI 10.1530/EJE-13-0572; Curran AJ, 1998, EUR J ENDOCRINOL, V139, P54, DOI 10.1530/eje.0.1390054; Cutfield WS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016223; Cutfield WS, 2000, LANCET, V355, P610, DOI 10.1016/S0140-6736(99)04055-6; Darzy KH, 2009, CLIN ENDOCRINOL, V70, P287, DOI 10.1111/j.1365-2265.2008.03359.x; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; Deepak D, 2010, GROWTH HORM IGF RES, V20, P220, DOI 10.1016/j.ghir.2010.02.002; di Iorgi N, 2007, J CLIN ENDOCR METAB, V92, P3875, DOI 10.1210/jc.2007-1081; Di Somma C, 2010, J ENDOCRINOL INVEST, V33, P171, DOI [10.3275/6519, 10.1007/BF03346577]; Dichtel LE, 2014, J CLIN ENDOCR METAB, V99, P4712, DOI 10.1210/jc.2014-2830; Diri H, 2015, PITUITARY, V18, P884, DOI 10.1007/s11102-015-0666-1; Drake WM, 2003, J CLIN ENDOCR METAB, V88, P1658, DOI 10.1210/jc.2002-021541; Duchateau PN, 1997, J BIOL CHEM, V272, P25576, DOI 10.1074/jbc.272.41.25576; Elbornsson M, 2017, EUR J ENDOCRINOL, V176, P99, DOI 10.1530/EJE-16-0875; Elbornsson M, 2013, EUR J ENDOCRINOL, V168, P745, DOI 10.1530/EJE-12-1083; Ferro P, 2016, J PHARMACEUT BIOMED, V128, P111, DOI 10.1016/j.jpba.2016.05.022; Feuillan P, 2001, J PEDIATR ENDOCR MET, V14, P141; Fisker S, 1997, METABOLISM, V46, P812, DOI 10.1016/S0026-0495(97)90128-1; Florakis D, 2000, CLIN ENDOCRINOL, V53, P453, DOI 10.1046/j.1365-2265.2000.01108.x; Franks S, 1998, BAILLIERE CLIN ENDOC, V12, P331, DOI 10.1016/S0950-351X(98)80026-8; Freemark M, 2010, J CLIN ENDOCR METAB, V95, P2054, DOI 10.1210/jc.2010-0517; Gaillard RC, 2012, EUR J ENDOCRINOL, V166, P1069, DOI 10.1530/EJE-11-1028; Garcia JM, 2013, J CLIN ENDOCR METAB, V98, P2422, DOI 10.1210/jc.2013-1157; Garcia JM, 2018, J CLIN ENDOCR METAB, V103, P3083, DOI 10.1210/jc.2018-00665; Gardner CJ, 2015, EUR J ENDOCRINOL, V172, P371, DOI 10.1530/EJE-14-0654; GARNERO P, 1994, J CLIN ENDOCR METAB, V79, P780, DOI 10.1210/jc.79.3.780; Gazzaruso C, 2014, J CLIN ENDOCR METAB, V99, P18, DOI 10.1210/jc.2013-2394; GELATO MC, 1986, J CLIN ENDOCR METAB, V63, P174, DOI 10.1210/jcem-63-1-174; GHIGO E, 1994, J ENDOCRINOL INVEST, V17, P849, DOI 10.1007/BF03347790; Giagulli VA, 2017, ENDOCR METAB IMMUNE, V17, P285, DOI 10.2174/1871530317666170919121729; Giampietro A, 2009, FERTIL STERIL, V91, DOI 10.1016/j.fertnstert.2008.09.065; Giannoulis MG, 2006, J CLIN ENDOCR METAB, V91, P477, DOI 10.1210/jc.2005-0957; Giavoli C, 2004, J CLIN ENDOCR METAB, V89, P5397, DOI 10.1210/jc.2004-1114; Gibney J, 1999, J CLIN ENDOCR METAB, V84, P2596, DOI 10.1210/jc.84.8.2596; Gilchrist FJ, 2002, CLIN ENDOCRINOL, V57, P363, DOI 10.1046/j.1365-2265.2002.01608.x; Giritharan S, 2017, PITUITARY, V20, P624, DOI 10.1007/s11102-017-0825-7; Giuliano S, 2017, ENDOCRINE, V58, P115, DOI 10.1007/s12020-016-1183-3; Gleeson HK, 2005, J CLIN ENDOCR METAB, V90, P1061, DOI 10.1210/jc.2004-0501; Gleeson HK, 2004, J CLIN ENDOCR METAB, V89, P662, DOI 10.1210/jc.2003-031224; Glynn N, 2018, ENDOCR PRACT, V24, P342, DOI 10.4158/EP-2017-0223; Glynn N, 2017, CLIN ENDOCRINOL, V86, P747, DOI 10.1111/cen.13272; Gomez JM, 2002, CLIN ENDOCRINOL, V56, P329, DOI 10.1046/j.1365-2265.2002.01472.x; Gonzalez S, 2017, J INT MED RES, V45, P1708, DOI 10.1177/0300060517723798; Gonzalez S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00056; Gonzalez-Duarte D, 2012, PITUITARY, V15, P589, DOI 10.1007/s11102-011-0374-4; Gordon MB, 2016, ENDOCR PRACT, V22, P396, DOI 10.4158/EP14603.OR; Gotherstrom G, 2007, J CLIN ENDOCR METAB, V92, P1442, DOI 10.1210/jc.2006-1487; Gotherstrom G, 2001, J CLIN ENDOCR METAB, V86, P4657, DOI 10.1210/jc.86.10.4657; Gotherstrom G, 2010, EUR J ENDOCRINOL, V163, P207, DOI 10.1530/EJE-10-0009; Hall R, 2006, CLIN ENDOCRINOL, V65, P71, DOI 10.1111/j.1365-2265.2006.02550.x; Hammarstrand C, 2017, EUR J ENDOCRINOL, V177, P251, DOI 10.1530/EJE-17-0340; Hamrahian AH, 2016, PITUITARY, V19, P332, DOI 10.1007/s11102-016-0712-7; Harden PN, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3718; Hartman ML, 2013, J CLIN ENDOCR METAB, V98, P980, DOI 10.1210/jc.2012-2684; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Hazem A, 2012, EUR J ENDOCRINOL, V166, P13, DOI 10.1530/EJE-11-0558; Healy ML, 2003, J CLIN ENDOCR METAB, V88, P5221, DOI 10.1210/jc.2002-021872; Hermansen K, 2017, GROWTH HORM IGF RES, V34, P38, DOI 10.1016/j.ghir.2017.05.005; Hjartaker A, 2008, ADV EXP MED BIOL, V630, P72; Ho KKY, 2007, EUR J ENDOCRINOL, V157, P695, DOI 10.1530/EJE-07-0631; Ho KKY, 2006, FRONT HORM RES, V35, P115, DOI 10.1159/000094314; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; HOECK HC, 1995, EUR J ENDOCRINOL, V133, P305, DOI 10.1530/eje.0.1330305; Hoffman AR, 2004, J CLIN ENDOCR METAB, V89, P3224, DOI 10.1210/jc.2003-032082; Hoffman AR, 2004, J CLIN ENDOCR METAB, V89, P2048, DOI 10.1210/jc.2003-030346; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; Hokken-Koelega A, 2016, ENDOCR CONNECT, V5, pR44, DOI 10.1530/EC-16-0028; Hoybye C, 2006, J ENDOCRINOL INVEST, V29, P950; Hoybye C, 2017, CLIN ENDOCRINOL, V86, P798, DOI 10.1111/cen.13330; Hoybye C, 2015, GROWTH HORM IGF RES, V25, P201, DOI 10.1016/j.ghir.2015.07.004; Hubina Erika, 2004, Horm Res, V61, P211, DOI 10.1159/000076538; Hulthen L, 2001, J CLIN ENDOCR METAB, V86, P4765, DOI 10.1210/jc.86.10.4765; Hwu CM, 1997, J CLIN ENDOCR METAB, V82, P3285, DOI 10.1210/jc.82.10.3285; Ioachimescu AG, 2015, PITUITARY, V18, P535, DOI 10.1007/s11102-014-0606-5; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; Janssen YJ, 2000, J CLIN ENDOCR METAB, P85; Jasim S, 2017, ENDOCRINE, V56, P33, DOI 10.1007/s12020-016-1159-3; Joaquin C, 2008, EUR J ENDOCRINOL, V158, P483, DOI 10.1530/EJE-07-0554; Johannsson G., 1999, Journal of Endocrinological Investigation, V22, P41; Johannsson G, 1999, J CLIN ENDOCR METAB, V84, P4516, DOI 10.1210/jc.84.12.4516; Johannsson G, 2019, J ENDOCR SOC S1, V3; Johannsson G, 2018, EUR J ENDOCRINOL, V178, P491, DOI 10.1530/EJE-17-1073; Johannsson G, 2018, ENDOCR CONNECT, V7, pR126, DOI 10.1530/EC-18-0047; JOHANSSON JO, 1995, METABOLISM, V44, P1126, DOI 10.1016/0026-0495(95)90004-7; Jorgensen AP, 2011, GROWTH HORM IGF RES, V21, P69, DOI 10.1016/j.ghir.2011.01.001; JORGENSEN JOL, 1989, LANCET, V1, P1221; Joustra SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090602; Junnila RK, 2015, ENDOCRIN METAB CLIN, V44, P27, DOI 10.1016/j.ecl.2014.10.003; Kanaley JA, 1997, J APPL PHYSIOL, V83, P1756; Karamouzis I, 2016, ENDOCRINE, V52, P441, DOI 10.1007/s12020-015-0796-2; KELLY JJ, 1993, CLIN ENDOCRINOL, V39, P561, DOI 10.1111/j.1365-2265.1993.tb02410.x; Kipps S, 2002, DIABETIC MED, V19, P649, DOI 10.1046/j.1464-5491.2002.00757.x; Kniess A, 2003, ANAL BIOANAL CHEM, V376, P696, DOI 10.1007/s00216-003-1926-x; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V164, P657, DOI 10.1530/EJE-10-1170; Koltowska-Haggstrom M, 2005, HORM RES, V64, P46, DOI 10.1159/000087444; Kotzmann H, 1998, CALCIFIED TISSUE INT, V62, P40, DOI 10.1007/s002239900392; Krzyzanowska-Mittermayer K, 2018, J CLIN ENDOCR METAB, V103, P523, DOI 10.1210/jc.2017-01899; Kuzma M, 2014, GROWTH HORM IGF RES, V24, P22, DOI 10.1016/j.ghir.2013.12.001; Laursen T, 2001, J CLIN ENDOCR METAB, V86, P1222, DOI 10.1210/jc.86.3.1222; Lee P, 2009, CLIN ENDOCRINOL, V71, P82, DOI 10.1111/j.1365-2265.2008.03466.x; Leger J, 2005, J CLIN ENDOCR METAB, V90, P650, DOI 10.1210/jc.2004-1274; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; Leung KC, 2002, AM J PHYSIOL-ENDOC M, V283, pE836, DOI 10.1152/ajpendo.00122.2002; Leung KC, 2004, ENDOCR REV, V25, P693, DOI 10.1210/er.2003-0035; Li LM, 2012, ENDOCRINE, V42, P375, DOI 10.1007/s12020-012-9697-9; Li ZZ, 2016, ONCOTARGET, V7, P81862, DOI 10.18632/oncotarget.13251; Lillicrap T, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00713; Lindholm J, 2006, CLIN ENDOCRINOL, V65, P51, DOI 10.1111/j.1365-2265.2006.02545.x; LITTLEY MD, 1989, CLIN ENDOCRINOL, V31, P527, DOI 10.1111/j.1365-2265.1989.tb01276.x; Liu H, 2008, ANN INTERN MED, V148, P747, DOI 10.7326/0003-4819-148-10-200805200-00215; Liu H, 2007, ANN INTERN MED, V146, P104, DOI 10.7326/0003-4819-146-2-200701160-00005; Longobardi S, 1996, J CLIN ENDOCR METAB, V81, P1244, DOI 10.1210/jc.81.3.1244; Longobardi S, 1998, CLIN ENDOCRINOL, V48, P137, DOI 10.1046/j.1365-2265.1998.00281.x; Lopez-Siguero JP, 2011, J ENDOCRINOL INVEST, V34, P300, DOI [10.1007/BF03347090, 10.3275/7169]; Loukianou E, 2016, CASE REP OPHTHALMOL, V2016, DOI 10.1155/2016/4756894; Luger A, 2012, DIABETES CARE, V35, P57, DOI 10.2337/dc11-0449; Lyle WG, 2002, PLAST RECONSTR SURG, V110, P1585, DOI 10.1097/00006534-200211000-00032; Macklon NS, 2006, ENDOCR REV, V27, P170, DOI 10.1210/er.2005-0015; Maghnie M, 1999, J CLIN ENDOCR METAB, V84, P1324, DOI 10.1210/jc.84.4.1324; MAGHNIE M, 1991, J CLIN ENDOCR METAB, V73, P79, DOI 10.1210/jcem-73-1-79; Maghnie M, 2001, J CLIN ENDOCR METAB, V86, P1574, DOI 10.1210/jc.86.4.1574; Maison P, 2003, CIRCULATION, V108, P2648, DOI 10.1161/01.CIR.0000100720.01867.1D; Makimura H, 2008, J CLIN ENDOCR METAB, V93, P4254, DOI 10.1210/jc.2008-1333; MALOZOWSKI S, 1995, J PEDIATR-US, V126, P996, DOI 10.1016/S0022-3476(95)70232-6; Gomez JM, 2006, CURR PHARM BIOTECHNO, V7, P125; MASON HD, 1990, J ENDOCRINOL, V126, pR1, DOI 10.1677/joe.0.126R001; Mathus-Vliegen EMH, 2012, OBESITY FACTS, V5, P460, DOI 10.1159/000341193; Mauras N, 2005, J CLIN ENDOCR METAB, V90, P3946, DOI 10.1210/jc.2005-0208; McHugh CM, 2005, CLIN CHEM, V51, P1587, DOI 10.1373/clinchem.2005.047845; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Meazza C, 2017, MINERVA ENDOCRINOL, V42, P325, DOI 10.23736/S0391-1977.16.02510-4; Mechanick JI, 2017, ENDOCR PRACT, V23, P1006, DOI 10.4158/EP171866.GL; Meienberg F, 2016, CLIN ENDOCRINOL, V85, P76, DOI 10.1111/cen.13042; Meinhardt U, 2010, ANN INTERN MED, V152, P568, DOI 10.7326/0003-4819-152-9-201005040-00007; Mitra MT, 2017, CLIN ENDOCRINOL, V86, P526, DOI 10.1111/cen.13291; Mo DJ, 2014, J CLIN ENDOCR METAB, V99, P4581, DOI 10.1210/jc.2014-2892; Mo DJ, 2014, PITUITARY, V17, P477, DOI 10.1007/s11102-013-0529-6; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Monson JP, 2007, CLIN ENDOCRINOL, V67, P623, DOI 10.1111/j.1365-2265.2007.02935.x; Mulder RL, 2009, CANCER TREAT REV, V35, P616, DOI 10.1016/j.ctrv.2009.06.004; MULLER J, 1995, EUR J ENDOCRINOL, V132, P727, DOI 10.1530/eje.0.1320727; Nagra A, 2015, ARCH DIS CHILDHOOD-E, V100, P313, DOI 10.1136/archdischild-2014-307423; Nelson AE, 2008, J CLIN ENDOCR METAB, V93, P2213, DOI 10.1210/jc.2008-0402; Nelson AE, 2008, ASIAN J ANDROL, V10, P416, DOI 10.1111/j.1745-7262.2008.00395.x; Newman CB, 2015, PITUITARY, V18, P297, DOI 10.1007/s11102-014-0571-z; Nicolson A, 1996, CLIN ENDOCRINOL, V44, P311, DOI 10.1046/j.1365-2265.1996.671492.x; Nielsen EH, 2007, CLIN ENDOCRINOL, V67, P693, DOI 10.1111/j.1365-2265.2007.02947.x; Nishizawa H, 2012, EUR J ENDOCRINOL, V167, P67, DOI 10.1530/EJE-12-0252; Norrelund H, 2000, J CLIN ENDOCR METAB, V85, P1912, DOI 10.1210/jc.85.5.1912; O'Sullivan AJ, 2000, J PEDIATR ENDOCR MET, V13, P1457; OGLE GD, 1994, ACTA PAEDIATR, V83, P3, DOI 10.1111/j.1651-2227.1994.tb13274.x; Olsson DS, 2017, EUR J ENDOCRINOL, V176, P67, DOI 10.1530/EJE-16-0450; Olsson DS, 2015, J CLIN ENDOCR METAB, V100, P2651, DOI 10.1210/jc.2015-1475; Orme SM, 1998, CLIN ENDOCRINOL, V49, P773, DOI 10.1046/j.1365-2265.1998.00610.x; Osawa M, 1997, GENE, V196, P121, DOI 10.1016/S0378-1119(97)00216-3; Pappachan JM, 2015, J CLIN ENDOCR METAB, V100, P1405, DOI 10.1210/jc.2014-3787; Patterson BC, 2014, J CLIN ENDOCR METAB, V99, P2030, DOI 10.1210/jc.2013-4159; Pekic S, 2017, EUR J ENDOCRINOL, V176, pR269, DOI 10.1530/EJE-16-1065; Penta L, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16030307; Perls TT, 2004, J GERONTOL A-BIOL, V59, P682; Pfeifer M, 2001, CLIN ENDOCRINOL, V54, P17, DOI 10.1046/j.1365-2265.2001.01179.x; Piccoli F, 2007, J CLIN ENDOCR METAB, V92, P1814, DOI 10.1210/jc.2006-2160; Pijl H, 2001, J CLIN ENDOCR METAB, V86, P5509, DOI 10.1210/jc.86.11.5509; Pokrajac A, 2007, CLIN ENDOCRINOL, V67, P65, DOI 10.1111/j.1365-2265.2007.02836.x; Powrie JK, 2007, GROWTH HORM IGF RES, V17, P220, DOI 10.1016/j.ghir.2007.01.011; Prestidge C, 2012, PEDIATR NEPHROL, V27, P295, DOI 10.1007/s00467-011-1980-0; Profka E, 2015, J ENDOCRINOL INVEST, V38, P413, DOI 10.1007/s40618-014-0196-0; Puche JE, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-224; Rahim A, 1996, CLIN ENDOCRINOL, V45, P557; Regal M, 2001, CLIN ENDOCRINOL, V55, P735, DOI 10.1046/j.1365-2265.2001.01406.x; Riasi HR, 2017, IRAN J MED SCI, V42, P611; Ribeiro de Oliveira Longo Schweizer Junia, 2018, Clin Diabetes Endocrinol, V4, P18, DOI 10.1186/s40842-018-0068-1; Rochira V, 2018, J ENDOCRINOL INVEST, V41, P1259, DOI 10.1007/s40618-018-0860-x; Roelfsema F, 2012, PITUITARY, V15, P71, DOI 10.1007/s11102-011-0347-7; Rogers AH, 1999, OPHTHALMOLOGY, V106, P1186, DOI 10.1016/S0161-6420(99)90266-X; Rosenfeld RG, 2003, HORM RES, V60, P74, DOI 10.1159/000071230; Rosenfeld Ron G, 2008, Endocr Pract, V14, P143; Rufinatscha K, 2018, HEPATOL INT, V12, P474, DOI 10.1007/s12072-018-9893-7; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Sattler FR, 2009, J CLIN ENDOCR METAB, V94, P1991, DOI 10.1210/jc.2008-2338; Savendahl L, 2019, J CLIN ENDOCR METAB, V104, P4730, DOI 10.1210/jc.2019-00775; Savendal L, 2019, J ENDOCR SOC S1, V3; Scacchi M, 2006, J ENDOCRINOL INVEST, V29, P899, DOI 10.1007/BF03349194; Schaefer S, 2008, EUR J ENDOCRINOL, V158, P3, DOI 10.1530/EJE-07-0484; Schiffman JD, 2013, PEDIATR BLOOD CANCER, V60, P1247, DOI 10.1002/pbc.24555; Schneider HJ, 2011, CLIN ENDOCRINOL, V75, P825, DOI 10.1111/j.1365-2265.2011.04137.x; Secco A, 2009, J CLIN ENDOCR METAB, V94, P4195, DOI 10.1210/jc.2009-0602; Serri O, 1999, J CLIN ENDOCR METAB, V84, P58, DOI 10.1210/jc.84.1.58; Sesmilo G, 2000, ANN INTERN MED, V133, P111, DOI 10.7326/0003-4819-133-2-200007180-00010; Setola E, 2008, METABOLISM, V57, P1685, DOI 10.1016/j.metabol.2008.07.024; Sfeir JG, 2018, J CLIN ENDOCR METAB, V103, P2785, DOI 10.1210/jc.2018-01204; Shaw KL, 2007, CHILD CARE HLTH DEV, V33, P368, DOI 10.1111/j.1365-2214.2006.00698.x; Shaw KL, 2014, CHILD CARE HLTH DEV, V40, P663, DOI 10.1111/cch.12110; Siebert DM, 2018, SPORTS HEALTH; Silva PPB, 2017, EUR J ENDOCRINOL, V177, P409, DOI 10.1530/EJE-17-0468; Sklar CA, 2002, J CLIN ENDOCR METAB, V87, P3136, DOI 10.1210/jc.87.7.3136; Sklar CA, 2018, J CLIN ENDOCR METAB, V103, P2761, DOI 10.1210/jc.2018-01175; Sonksen P, 2018, BRIT J SPORT MED, V52, P219, DOI 10.1136/bjsports-2016-096742; Sonksen PH, 2018, CLIN DIABETES ENDOCR, V4, P3; Spielhagen C, 2011, GROWTH HORM IGF RES, V21, P1, DOI 10.1016/j.ghir.2010.10.005; Stochholm K, 2007, EUR J ENDOCRINOL, V157, P9, DOI 10.1530/EJE-07-0013; Stochholm K, 2008, EUR J ENDOCRINOL, V158, P447, DOI 10.1530/EJE-07-0523; Stochholm K, 2006, EUR J ENDOCRINOL, V155, P61, DOI 10.1530/eje.1.02191; Stochholm K, 2018, CLIN ENDOCRINOL, V88, P515, DOI 10.1111/cen.13502; Stochholm K, 2015, GROWTH HORM IGF RES, V25, P149, DOI 10.1016/j.ghir.2015.06.006; Stochholm K, 2014, J CLIN ENDOCR METAB, V99, P4141, DOI 10.1210/jc.2014-1814; Strahm B, 2006, INT J CANCER, V119, P2001, DOI 10.1002/ijc.21962; Sumida Y, 2015, HEPATOL RES, V45, P771, DOI 10.1111/hepr.12408; Svensson J, 2004, J CLIN ENDOCR METAB, V89, P3306, DOI 10.1210/jc.2003-031601; Svensson J, 2002, J CLIN ENDOCR METAB, V87, P2121, DOI 10.1210/jc.87.5.2121; Tamhane S, 2018, J CLIN ENDOCRINOL ME; Tan SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09968-7; Tanriverdi F, 2017, BEST PRACT RES CL EN, V31, P3, DOI 10.1016/j.beem.2017.02.001; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; The World Anti-Doping Agency, 2019, PROH LIST INT STAND; Thevis M, 2016, J PHARMACEUT BIOMED, V130, P220, DOI 10.1016/j.jpba.2016.03.055; Thornton P, 2019, J ENDOCR SOC S1, V3; Tolli A, 2017, J ENDOCRINOL INVEST, V40, P193, DOI 10.1007/s40618-016-0546-1; Tomida M, 2001, CYTOKINE, V14, P202, DOI 10.1006/cyto.2001.0874; Tomlinson JW, 2001, LANCET, V357, P425, DOI 10.1016/S0140-6736(00)04006-X; Toogood AA, 2000, J CLIN ENDOCR METAB, V85, P1727, DOI 10.1210/jc.85.4.1727; Tritos NA, 2012, EUR J ENDOCRINOL, V167, P343, DOI 10.1530/EJE-12-0070; Tsiakalos A, 2010, J CLIN ENDOCR METAB, V95, P3277, DOI 10.1210/jc.2010-0144; Ukropec J, 2008, J CLIN ENDOCR METAB, V93, P2255, DOI 10.1210/jc.2007-2188; Underwood LE, 2003, J CLIN ENDOCR METAB, V88, P5273, DOI 10.1210/jc.2003-030204; Undurti A, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00072; US Food and Drug Administration, DRUG TRIALS SNAPSH M; Utz AL, 2008, J CLIN ENDOCR METAB, V93, P4033, DOI 10.1210/jc.2008-0930; van Bunderen CC, 2018, HEALTH QUAL LIFE OUT, V16, DOI 10.1186/s12955-018-0963-2; van Bunderen CC, 2016, EUR J INTERN MED, V31, P88, DOI 10.1016/j.ejim.2016.03.026; van Bunderen CC, 2014, CLIN ENDOCRINOL, V81, P1, DOI 10.1111/cen.12477; van Bunderen CC, 2011, J CLIN ENDOCR METAB, V96, P3151, DOI 10.1210/jc.2011-1215; van Dam EWCM, 2002, J CLIN ENDOCR METAB, V87, P4225, DOI 10.1210/jc.2002-012006; van der Klaauw AA, 2006, EUR J ENDOCRINOL, V155, P701, DOI 10.1530/eje.1.02283; van der Klaauw AA, 2007, EUR J ENDOCRINOL, V157, P709, DOI 10.1530/EJE-07-0412; Vance ML, 2003, NEW ENGL J MED, V348, P779, DOI 10.1056/NEJMp020186; VELDHUIS JD, 1991, J CLIN ENDOCR METAB, V72, P51, DOI 10.1210/jcem-72-1-51; Verboven C, 2002, NAT STRUCT BIOL, V9, P131, DOI 10.1038/nsb754; Verhelst J, 2018, ENDOCR CONNECT, V7, P653, DOI 10.1530/EC-18-0096; Vila G, 2018, MINERVA ENDOCRINOL, V43, P451, DOI 10.23736/S0391-1977.18.02834-1; Vila G, 2015, FERTIL STERIL, V104, P1210, DOI 10.1016/j.fertnstert.2015.07.1132; Vischi A, 2006, EUR J OPHTHALMOL, V16, P178; VONBULOW FA, 1993, HISTOCHEMISTRY, V99, P13, DOI 10.1007/BF00268015; Wallace JD, 1999, J CLIN ENDOCR METAB, V84, P3591, DOI 10.1210/jc.84.10.3591; Wallace JD, 2000, J CLIN ENDOCR METAB, V85, P124, DOI 10.1210/jc.85.1.124; Wang YT, 2019, ENDOCR PRACT, V25, P446, DOI 10.4158/EP-2018-0541; Watson AR, 2000, PEDIATR NEPHROL, V14, P469, DOI 10.1007/s004670050794; Webb SM, 2010, J CLIN ENDOCR METAB, V95, P630, DOI 10.1210/jc.2009-0806; Weber MM, 2017, CLIN ENDOCRINOL, V86, P192, DOI 10.1111/cen.13256; Wilson JR, 2016, GROWTH HORM IGF RES, V26, P24, DOI 10.1016/j.ghir.2015.12.005; Wilson PWF, 2005, CIRCULATION, V112, P3066, DOI 10.1161/CIRCULATIONAHA.105.539528; Wilson TA, 2003, J PEDIATR-US, V143, P415, DOI 10.1067/S0022-3476(03)00246-4; Tavares ABW, 2017, ENDOCRINE, V56, P317, DOI 10.1007/s12020-017-1275-8; Tavares ABW, 2015, GROWTH HORM IGF RES, V25, P53, DOI 10.1016/j.ghir.2014.11.002; Wiren L, 2002, CLIN ENDOCRINOL, V57, P235, DOI 10.1046/j.1365-2265.2002.01572.x; Woodmansee WW, 2013, EUR J ENDOCRINOL, V168, P565, DOI 10.1530/EJE-12-0967; World Anti-Doping Agency, TD2015GH WADA; World Anti-Doping Agency, 2016, GUID HUM GROWTH HORM; Wu Z, 1999, LANCET, V353, P895, DOI 10.1016/S0140-6736(99)00775-8; Yamauchi I, 2018, ENDOCRINE, V59, P353, DOI 10.1007/s12020-017-1495-y; Yang HB, 2019, EUR J ENDOCRINOL, V180, P147, DOI 10.1530/EJE-18-0711; Yang HB, 2018, J PEDIATR ENDOCR MET, V31, P533, DOI 10.1515/jpem-2018-0019; Yuen KCJ, 2006, HORM RES, V65, P6, DOI 10.1159/000090121; Yuen KCJ, 2005, CLIN ENDOCRINOL, V63, P428, DOI 10.1111/j.1365-2265.2005.02359.x; Yuen KCJ, 2018, CURR OPIN ENDOCRINOL, V25, P267, DOI 10.1097/MED.0000000000000416; Yuen KCJ, 2018, J CLIN ENDOCR METAB, V103, P768, DOI 10.1210/jc.2017-01542; Yuen KCJ, 2016, ENDOCR PRACT, V22, P1235, DOI 10.4158/EP161407.DSCR; Yuen KCJ, 2016, ENDOCRINE, V52, P194, DOI 10.1007/s12020-015-0840-2; Yuen KCJ, 2014, J CLIN ENDOCR METAB, V99, pE1862, DOI 10.1210/jc.2014-1532; Yuen KCJ, 2013, EUR J ENDOCRINOL, V169, P511, DOI 10.1530/EJE-13-0280; Yuen KCJ, 2013, PITUITARY, V16, P220, DOI 10.1007/s11102-012-0407-7; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299; ZADIK Z, 1985, J CLIN ENDOCR METAB, V60, P513, DOI 10.1210/jcem-60-3-513; Zheng XY, 2019, CLIN ENDOCRINOL, V90, P834, DOI 10.1111/cen.13958; Ziagaki A, 2019, EUR J ENDOCRINOL; Zueger T, 2012, J CLIN ENDOCR METAB, V97, pE1938, DOI 10.1210/jc.2012-2432	355	33	35	0	4	AMER ASSOC CLINICAL ENDOCRINOLOGISTS	JACKSONVILLE	245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA	1530-891X	1934-2403		ENDOCR PRACT	Endocr. Pract.	NOV	2019	25	11					1191	1232		10.4158/GL-2019-0405			42	Endocrinology & Metabolism	Endocrinology & Metabolism	JP0HS	WOS:000497953400012	31760824				2021-06-18	
J	Yan, RJ; Sun, S; Yang, J; Long, W; Wang, JY; Mu, XY; Li, QF; Hao, WT; Zhang, SF; Liu, HL; Gao, YL; Ouyang, LF; Chen, JC; Liu, SJ; Zhang, XD; Ming, D				Yan, Ruijuan; Sun, Si; Yang, Jiang; Long, Wei; Wang, Junying; Mu, Xiaoyu; Li, Qifeng; Hao, Wenting; Zhang, Shaofang; Liu, Haile; Gao, Yalong; Ouyang, Lufei; Chen, Junchi; Liu, Shuangjie; Zhang, Xiao-Dong; Ming, Dong			Nanozyme-Based Bandage with Single-Atom Catalysis for Brain Trauma	ACS NANO			English	Article						nanozyme; single-atom catalysis; brain trauma; wound repair; noninvasive therapy	CERIA NANOPARTICLES; LOW-TEMPERATURE; NEUROPROTECTION; ANTIOXIDANTS; DISEASE; PROTECT	Neurotrauma is one of the most serious traumatic injuries, which can induce an excess amount of reactive oxygen and nitrogen species (RONS) around the wound, triggering a series of biochemical responses and neuroinflammation. Traditional antioxidant-based bandages can effectively decrease infection via preventing oxidative stress, but its effectiveness is limited to a short period of time due to the rapid loss of electron-donating ability. Herein, we developed a nanozyme-based bandage using single-atom Pt/CeO2 with a persistent catalytic activity for noninvasive treatment of neurotrauma. Single-atom Pt induced the lattice expansion and preferred distribution on (111) facets of CeO2, enormously increasing the endogenous catalytic activity. Pt/CeO2 showed a 2-10 times higher scavenging activity against RONS as well as 3-10 times higher multienzyme activities compared to CeO2 clusters. The single-atom Pt/CeO2 retained the long-lasting catalytic activity for up to a month without obvious decay due to enhanced electron donation through the Mars-van Krevelen reaction. In vivo studies disclosed that the nanozyme-based bandage at the single-atom level can significantly improve the wound healing of neurotrauma and reduce neuroinflammation.	[Yan, Ruijuan; Sun, Si; Wang, Junying; Mu, Xiaoyu; Zhang, Shaofang; Liu, Haile; Ouyang, Lufei; Chen, Junchi; Zhang, Xiao-Dong] Tianjin Univ, Sch Sci, Dept Phys, Tianjin 300350, Peoples R China; [Yan, Ruijuan; Sun, Si; Wang, Junying; Mu, Xiaoyu; Zhang, Shaofang; Liu, Haile; Ouyang, Lufei; Chen, Junchi; Zhang, Xiao-Dong] Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300350, Peoples R China; [Long, Wei] Chinese Acad Med Sci & Peking Union Med Coll, Inst Radiat Med, 238 Baidi Rd, Tianjin 300192, Peoples R China; [Li, Qifeng; Gao, Yalong] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Li, Qifeng; Gao, Yalong] Tianjin Med Univ, Gen Hosp, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Yang, Jiang] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Hao, Wenting; Liu, Shuangjie; Ming, Dong] Tianjin Univ, Acad Med Engn & Translat Med, Tianjin Int Joint Res Ctr Neural Engn, Tianjin 300072, Peoples R China	Zhang, XD (corresponding author), Tianjin Univ, Sch Sci, Dept Phys, Tianjin 300350, Peoples R China.; Zhang, XD (corresponding author), Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300350, Peoples R China.; Ming, D (corresponding author), Tianjin Univ, Acad Med Engn & Translat Med, Tianjin Int Joint Res Ctr Neural Engn, Tianjin 300072, Peoples R China.	xiaodongzhang@tju.edu.cn; richardming@tju.edu.cn	Nanozymes, Nanozymes/D-8197-2019; Zhang, Xiaodong/F-4665-2015	Zhang, Xiaodong/0000-0002-7212-0138	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [91859101, 81971744, U1932107, 81471786]; National Natural Science Foundation of Tianjin [19JCZDJC34000]; Innovation Foundation of Tianjin University	This work was financially supported by the National Natural Science Foundation of China (Grant Nos. 91859101, 81971744, U1932107, and 81471786) and National Natural Science Foundation of Tianjin (No. 19JCZDJC34000), the Innovation Foundation of Tianjin University.	Bao QQ, 2018, ACS NANO, V12, P6794, DOI 10.1021/acsnano.8b01994; Bhabak KP, 2010, ACCOUNTS CHEM RES, V43, P1408, DOI 10.1021/ar100059g; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bruix A, 2012, J AM CHEM SOC, V134, P8968, DOI 10.1021/ja302070k; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Das R, 2019, ACS NANO, V13, P229, DOI 10.1021/acsnano.8b05370; Ding H, 2019, NANO LETT, V19, P203, DOI 10.1021/acs.nanolett.8b03709; Dvorak F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10801; Fan KL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03903-8; Fan KL, 2012, NAT NANOTECHNOL, V7, P459, DOI [10.1038/nnano.2012.90, 10.1038/NNANO.2012.90]; Feng YX, 2018, J PHYS CHEM C, V122, P22460, DOI 10.1021/acs.jpcc.8b05815; Gao L, 2015, ACS NANO, V9, P10979, DOI 10.1021/acsnano.5b04261; Gao LZ, 2007, NAT NANOTECHNOL, V2, P577, DOI 10.1038/nnano.2007.260; Ghosh S., 2018, Angew Chem Int Ed Eng, V130, P4600, DOI [DOI 10.1002/ANGE.201800681, 10.1002/anie.201800681]; Gupta A, 2018, ACS NANO, V12, P89, DOI 10.1021/acsnano.7b07496; Heckman KL, 2013, ACS NANO, V7, P10582, DOI 10.1021/nn403743b; Holmes D, 2015, NATURE, V527, pS217, DOI 10.1038/527S217a; Huang YY, 2019, CHEM REV, V119, P4357, DOI 10.1021/acs.chemrev.8b00672; Huo MF, 2019, ACS NANO, V13, P2643, DOI 10.1021/acsnano.9b00457; Jiao L., 2019, ANGEW CHEM INT EDIT, DOI [10.1002/ange.201905645, DOI 10.1002/ANGE.201905645]; Jones J, 2016, SCIENCE, V353, P150, DOI 10.1126/science.aaf8800; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kim CK, 2012, ANGEW CHEM INT EDIT, V51, P11039, DOI 10.1002/anie.201203780; Kopelent R, 2015, ANGEW CHEM INT EDIT, V54, P8728, DOI 10.1002/anie.201503022; Kwon HJ, 2016, ACS NANO, V10, P2860, DOI 10.1021/acsnano.5b08045; Li YY, 2015, ANGEW CHEM INT EDIT, V54, P1832, DOI 10.1002/anie.201410398; Lin H, 2018, CHEM SOC REV, V47, P1938, DOI 10.1039/c7cs00471k; Liu BW, 2017, NANO RES, V10, P1125, DOI 10.1007/s12274-017-1426-5; Liu F, 2019, ADV MATER, V31, DOI 10.1002/adma.201902885; Manea F, 2004, ANGEW CHEM INT EDIT, V43, P6165, DOI 10.1002/anie.200460649; Mu XY, 2019, ACS NANO, V13, P1870, DOI 10.1021/acsnano.8b08045; Neri S, 2017, J AM CHEM SOC, V139, P1794, DOI 10.1021/jacs.6b12932; Nie L, 2017, SCIENCE, V358, P1419, DOI 10.1126/science.aao2109; Qiao BT, 2011, NAT CHEM, V3, P634, DOI [10.1038/NCHEM.1095, 10.1038/nchem.1095]; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Singh N, 2017, ANGEW CHEM INT EDIT, V56, P14267, DOI 10.1002/anie.201708573; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Song YC, 2016, 2016 3RD INTERNATIONAL CONFERENCE ON ADVANCED EDUCATION AND TECHNOLOGY AND MANAGEMENT SCIENCE (AETMS 2016), P464; Song YK, 2018, ADV MATH PHYS, V2018, DOI 10.1155/2018/2028657; Sood A, 2014, ADV WOUND CARE, V3, P511, DOI 10.1089/wound.2012.0401; Sun HJ, 2018, ANGEW CHEM INT EDIT, V57, P9224, DOI 10.1002/anie.201712469; Tamura M, 2015, ANGEW CHEM INT EDIT, V54, P864, DOI 10.1002/anie.201409601; Tang Y, 2017, J PHYS CHEM C, V121, P11281, DOI 10.1021/acs.jpcc.7b00313; Vernekar AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6301; Wang AQ, 2018, NAT REV CHEM, V2, P65, DOI 10.1038/s41570-018-0010-1; Wang CL, 2017, ACS CATAL, V7, P887, DOI 10.1021/acscatal.6b02685; Wang Y, 2019, CHEM REV, V119, P1806, DOI 10.1021/acs.chemrev.8b00501; Wang ZZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05798-x; Wei H, 2013, CHEM SOC REV, V42, P6060, DOI 10.1039/c3cs35486e; Wu JJX, 2019, CHEM SOC REV, V48, P1004, DOI 10.1039/c8cs00457a; Xu BL, 2019, ANGEW CHEM INT EDIT, V58, P4911, DOI 10.1002/anie.201813994; Xu YQ, 2019, ANGEW CHEM INT EDIT, V58, P5572, DOI 10.1002/anie.201813771; Yang BW, 2019, CHEM REV, V119, P4881, DOI 10.1021/acs.chemrev.8b00626; Yao J, 2018, CHEM SCI, V9, P2927, DOI 10.1039/c7sc05476a; Yu TY, 2010, ADV MATER, V22, P5188, DOI 10.1002/adma.201002763; Zhang Y, 2018, ACS NANO, V12, P651, DOI 10.1021/acsnano.7b07746; Zhang ZJ, 2017, J AM CHEM SOC, V139, P5412, DOI 10.1021/jacs.7b00601	59	33	33	63	286	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	OCT	2019	13	10					11552	11560		10.1021/acsnano.9b05075			9	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	JH5IF	WOS:000492801600065	31553878				2021-06-18	
J	Gotzl, JK; Brendel, M; Werner, G; Parhizkar, S; Monasor, LS; Kleinberger, G; Colombo, AV; Deussing, M; Wagner, M; Winkelmann, J; Diehl-Schmid, J; Levin, J; Fellerer, K; Reifschneider, A; Bultmann, S; Bartenstein, P; Rominger, A; Tahirovic, S; Smith, ST; Madore, C; Butovsky, O; Capell, A; Haass, C				Goetzl, Julia K.; Brendel, Matthias; Werner, Georg; Parhizkar, Samira; Monasor, Laura Sebastian; Kleinberger, Gernot; Colombo, Alessio-Vittorio; Deussing, Maximilian; Wagner, Matias; Winkelmann, Juliane; Diehl-Schmid, Janine; Levin, Johannes; Fellerer, Katrin; Reifschneider, Anika; Bultmann, Sebastian; Bartenstein, Peter; Rominger, Axel; Tahirovic, Sabina; Smith, Scott T.; Madore, Charlotte; Butovsky, Oleg; Capell, Anja; Haass, Christian			Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism	EMBO MOLECULAR MEDICINE			English	Article						disease-associated and homeostatic microglial signatures; microglia; neurodegeneration; progranulin; TREM2	FRONTOTEMPORAL LOBAR DEGENERATION; TRAUMATIC BRAIN-INJURY; PROGRANULIN DEFICIENCY; ALZHEIMERS-DISEASE; BINDING-AFFINITY; MOUSE MODEL; PROTEIN; MICE; NEUROINFLAMMATION; CELLS	Microglia adopt numerous fates with homeostatic microglia (HM) and a microglial neurodegenerative phenotype (MGnD) representing two opposite ends. A number of variants in genes selectively expressed in microglia are associated with an increased risk for neurodegenerative diseases such as Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD). Among these genes are progranulin (GRN) and the triggering receptor expressed on myeloid cells 2 (TREM2). Both cause neurodegeneration by mechanisms involving loss of function. We have now isolated microglia from Grn(-/-) mice and compared their transcriptomes to those of Trem2(-/-) mice. Surprisingly, while loss of Trem2 enhances the expression of genes associated with a homeostatic state, microglia derived from Grn(-/-) mice showed a reciprocal activation of the MGnD molecular signature and suppression of gene characteristic for HM. The opposite mRNA expression profiles are associated with divergent functional phenotypes. Although loss of TREM2 and progranulin resulted in opposite activation states and functional phenotypes of microglia, FDG (fluoro-2-deoxy-d-glucose)-mu PET of brain revealed reduced glucose metabolism in both conditions, suggesting that opposite microglial phenotypes result in similar wide spread brain dysfunction.	[Goetzl, Julia K.; Reifschneider, Anika; Capell, Anja; Haass, Christian] Ludwig Maximilians Univ Munchen, Fac Med, Chair Metab Biochem, Biomed Ctr BMC, Munich, Germany; [Deussing, Maximilian; Bartenstein, Peter; Rominger, Axel] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Nucl Med, Munich, Germany; [Monasor, Laura Sebastian; Colombo, Alessio-Vittorio; Levin, Johannes; Tahirovic, Sabina; Haass, Christian] German Ctr Neurodegenerat Dis DZNE, Munich, Germany; [Kleinberger, Gernot; Bartenstein, Peter; Rominger, Axel; Haass, Christian] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Kleinberger, Gernot; Bartenstein, Peter; Rominger, Axel; Haass, Christian] Helmholtz Zentrum Munchen, Inst Neurogenom, Munich, Germany; [Wagner, Matias; Winkelmann, Juliane] Tech Univ Munich, Inst Human Genet, Munich, Germany; [Wagner, Matias; Winkelmann, Juliane] Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany; [Diehl-Schmid, Janine] Tech Univ Munich, Dept Psychiat, Munich, Germany; [Levin, Johannes] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Neurol, Munich, Germany; [Bultmann, Sebastian] Ludwig Maximilians Univ Munchen, Dept Biol & Ctr Integrated Prot Sci Munich CIPSM, Munich, Germany; [Smith, Scott T.; Madore, Charlotte; Butovsky, Oleg] Harvard Med Sch, Brigham & Women Hosp, Dept Neurol, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA; [Butovsky, Oleg] Harvard Med Sch, Brigham & Womens Hosp, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA	Capell, A; Haass, C (corresponding author), Ludwig Maximilians Univ Munchen, Fac Med, Chair Metab Biochem, Biomed Ctr BMC, Munich, Germany.; Haass, C (corresponding author), German Ctr Neurodegenerat Dis DZNE, Munich, Germany.; Haass, C (corresponding author), Munich Cluster Syst Neurol SyNergy, Munich, Germany.; Haass, C (corresponding author), Helmholtz Zentrum Munchen, Inst Neurogenom, Munich, Germany.	anja.capell@mail03.med.uni-muenchen.de; christian.haass@mail03.med.uni-muenchen.de	Madore, Charlotte/AAK-8735-2021; Levin, Johannes/W-8686-2019; Bultmann, Sebastian/AAC-7729-2020; Butovsky, Oleg/ABG-9086-2020; Levin, Johannes/E-4052-2010	Madore, Charlotte/0000-0002-0704-6496; Levin, Johannes/0000-0001-5092-4306; Butovsky, Oleg/0000-0003-0186-8867; Levin, Johannes/0000-0001-5092-4306; Parhizkar, Samira/0000-0001-5807-190X; Diehl-Schmid, Janine/0000-0002-7745-1382	Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [EXC 1010 SyNergy]; Koselleck Project [HA1737/16-1]; Cure Alzheimer's fund; NOMIS Foundation; PET imaging grant [BR4580/1-1, RO5194/1-1]; German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF) [FTLDc 01GI1007A]; Hans and Ilse Breuer Foundation; US National Institutes of Health (NIH) NIH-NINDS [R01 NS088137, R21 NS104609, R21 NS101673]; NIH-NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG051812, R01 AG054672]; NIH-NEY [R01 EY027921]; National Multiple Sclerosis SocietyNational Multiple Sclerosis Society [5092A1]; Nancy Davis Foundation Faculty Award; Cure Alzheimer's Fund Award; Amyotrophic Lateral Sclerosis Association; SanofiSanofi-Aventis; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY027921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS088137, R21NS101673, R21NS104609] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG054672, R01AG051812] Funding Source: NIH RePORTER	This work was supported by the Deutsche Forschungsgemeinschaft (DFG) within the framework of the Munich Cluster for Systems Neurology (EXC 1010 SyNergy), the Koselleck Project HA1737/16-1, the Cure Alzheimer's fund and the NOMIS Foundation (to C.H.), by a dedicated PET imaging grant to M.B. & A. Ro. (BR4580/1-1 & RO5194/1-1) and the German Federal Ministry of Education and Research (project: FTLDc 01GI1007A; to J.D.-S.), and a PhD stipend of the Hans and Ilse Breuer Foundation to A. Re. We would like to thank Dr. M. Nishihara (Department of Veterinary Physiology, The University of Tokyo) for providing the founder of the Grn<SUP>-/-</SUP> mouse strain, Dr. David M. Holtzman (Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA) for providing the ApoE antibody, Dr. Feng Zhang (Broad Institute) for providing PX458 and acknowledge the Core Facility Flow Cytometry at the Biomedical Center, Ludwig-Maximilians-Universitat, Munchen, for providing equipment and services and Christian Behrends (Ludwig-Maximilians-Universitat, Munchen) for providing assistance with flow cytometry analysis of cultivated primary microglia. The Trem2<SUP>-/-</SUP> mice were kindly provided by Marco Colonna (Washington University, School of Medicine), and the APPPS1 colony was established from a breeding pair kindly provided by Mathias Jucker (Hertie-Institute for Clinical Brain Research, University of Tubingen and DZNE-Tubingen). GE made GE-180 cassettes available through an early access model. O.B. is supported by the US National Institutes of Health (NIH) NIH-NINDS (R01 NS088137, R21 NS104609, R21 NS101673), NIH-NIA (R01 AG051812, R01 AG054672), NIH-NEY (R01 EY027921), National Multiple Sclerosis Society (5092A1), Nancy Davis Foundation Faculty Award, Cure Alzheimer's Fund Award, and Amyotrophic Lateral Sclerosis Association and Sanofi.	Abduljaleel Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092648; Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Albert NL, 2017, EUR J NUCL MED MOL I, V44, P2230, DOI 10.1007/s00259-017-3799-9; Atagi Y, 2015, J BIOL CHEM, V290, P26043, DOI 10.1074/jbc.M115.679043; Bailey CC, 2015, J BIOL CHEM, V290, P26033, DOI 10.1074/jbc.M115.677286; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; BATEMAN A, 1990, BIOCHEM BIOPH RES CO, V173, P1161, DOI 10.1016/S0006-291X(05)80908-8; Beel S, 2017, HUM MOL GENET, V26, P2850, DOI 10.1093/hmg/ddx162; BELCOURT DR, 1993, J BIOL CHEM, V268, P9230; BOCCHINI V, 1992, J NEUROSCI RES, V31, P616, DOI 10.1002/jnr.490310405; Borroni B, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.09.017; Brendel M, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00008; Brendel M, 2016, J NUCL MED, V57, P954, DOI 10.2967/jnumed.115.167858; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Capell A, 2011, J NEUROSCI, V31, P1885, DOI 10.1523/JNEUROSCI.5757-10.2011; Cenik B, 2012, J BIOL CHEM, V287, P32298, DOI 10.1074/jbc.R112.399170; Chang MC, 2017, J EXP MED, V214, P2611, DOI 10.1084/jem.20160999; Cruts M, 2008, TRENDS GENET, V24, P186, DOI 10.1016/j.tig.2008.01.004; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Cuyvers E, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.09.009; Daria A, 2017, EMBO J, V36, P583, DOI 10.15252/embj.201694591; Deussing M, 2018, NEUROIMAGE, V165, P83, DOI 10.1016/j.neuroimage.2017.10.006; Gotzl JK, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0281-5; Gotzl JK, 2016, AGEING RES REV, V32, P122, DOI 10.1016/j.arr.2016.04.008; Gotzl JK, 2014, ACTA NEUROPATHOL, V127, P845, DOI 10.1007/s00401-014-1262-6; Gosselin D, 2017, SCIENCE, V356, DOI 10.1126/science.aal3222; Guerreiro RJ, 2013, JAMA NEUROL, V70, P78, DOI 10.1001/jamaneurol.2013.579; Holtman IR, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0203-5; Hu FH, 2010, NEURON, V68, P654, DOI 10.1016/j.neuron.2010.09.034; Jonsson T, 2013, NEW ENGL J MED, V369, P1568, DOI 10.1056/NEJMc1306509; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kim J, 2012, J EXP MED, V209, P2149, DOI 10.1084/jem.20121274; Kleinberger G, 2017, EMBO J, V36, P1837, DOI 10.15252/embj.201796516; Kleinberger G, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009093; Krabbe G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060921; Krasemann S, 2017, IMMUNITY, V47, P566, DOI 10.1016/j.immuni.2017.08.008; Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824; Liu B, 2015, J NEUROSCI, V35, P15716, DOI 10.1523/JNEUROSCI.0996-15.2015; Lui HS, 2016, CELL, V165, P921, DOI 10.1016/j.cell.2016.04.001; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; Mazaheri F, 2017, EMBO REP, V18, P1186, DOI 10.15252/embr.201743922; Mizrahi R, 2012, J CEREBR BLOOD F MET, V32, P968, DOI 10.1038/jcbfm.2012.46; Overhoff F, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00045; Owen DR, 2012, J CEREBR BLOOD F MET, V32, P1, DOI 10.1038/jcbfm.2011.147; Parhizkar S, 2019, NAT NEUROSCI, V22, P191, DOI 10.1038/s41593-018-0296-9; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Ransohoff RM, 2016, SCIENCE, V353, P777, DOI 10.1126/science.aag2590; Rayaprolu S, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-19; Rominger A, 2013, J NUCL MED, V54, P1127, DOI 10.2967/jnumed.112.114660; Schlepckow K, 2017, EMBO MOL MED, V9, P1356, DOI 10.15252/emmm.201707672; SHOYAB M, 1990, P NATL ACAD SCI USA, V87, P7912, DOI 10.1073/pnas.87.20.7912; Song WM, 2018, J EXP MED, V215, P745, DOI 10.1084/jem.20171529; Takahashi H, 2017, ACTA NEUROPATHOL, V133, P785, DOI 10.1007/s00401-017-1668-z; Tanaka Y, 2013, NEUROSCIENCE, V250, P8, DOI 10.1016/j.neuroscience.2013.06.049; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023; Ulrich JD, 2017, NEURON, V94, P237, DOI 10.1016/j.neuron.2017.02.042; Ulrich JD, 2016, ACS CHEM NEUROSCI, V7, P420, DOI 10.1021/acschemneuro.5b00313; Van Damme P, 2008, J CELL BIOL, V181, P37, DOI 10.1083/jcb.200712039; Wang YM, 2016, J EXP MED, V213, P667, DOI 10.1084/jem.20151948; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Ward ME, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5642; Wils H, 2012, J PATHOL, V228, P67, DOI 10.1002/path.4043; Xiang XY, 2016, EMBO MOL MED, V8, P992, DOI 10.15252/emmm.201606370; Yeh FL, 2017, TRENDS MOL MED, V23, P512, DOI 10.1016/j.molmed.2017.03.008; Yeh FL, 2016, NEURON, V91, P328, DOI 10.1016/j.neuron.2016.06.015; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zhang N, 2014, EXP THER MED, V8, P1643, DOI 10.3892/etm.2014.1981; Zhou XL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15277; Zhou XL, 2015, J CELL BIOL, V210, P991, DOI 10.1083/jcb.201502029	75	33	34	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1757-4676	1757-4684		EMBO MOL MED	EMBO Mol. Med.	JUN	2019	11	6							e9711	10.15252/emmm.201809711			15	Medicine, Research & Experimental	Research & Experimental Medicine	IC2MH	WOS:000470793600002	31122931	DOAJ Gold, Green Published			2021-06-18	
J	Russo, EB				Russo, Ethan B.			Cannabis Therapeutics and the Future of Neurology	FRONTIERS IN INTEGRATIVE NEUROSCIENCE			English	Article						cannabis; pain; brain tumor; epilepsy; Alzheimer disease; Parkinson disease; traumatic brain injury; microbiome	ACTIVATED-RECEPTOR-GAMMA; IRRITABLE-BOWEL-SYNDROME; DOUBLE-BLIND; PARKINSONS-DISEASE; MEDICAL MARIJUANA; CONTROLLED-TRIAL; GUT MICROBIOTA; PAIN; SYMPTOMS; MIGRAINE	Neurological therapeutics have been hampered by its inability to advance beyond symptomatic treatment of neurodegenerative disorders into the realm of actual palliation, arrest or reversal of the attendant pathological processes. While cannabis-based medicines have demonstrated safety, efficacy and consistency sufficient for regulatory approval in spasticity in multiple sclerosis (MS), and in Dravet and Lennox-Gastaut Syndromes (LGS), many therapeutic challenges remain. This review will examine the intriguing promise that recent discoveries regarding cannabis-based medicines offer to neurological therapeutics by incorporating the neutral phytocannabinoids tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA), and cannabis terpenoids in the putative treatment of five syndromes, currently labeled recalcitrant to therapeutic success, and wherein improved pharmacological intervention is required: intractable epilepsy, brain tumors, Parkinson disease (PD), Alzheimer disease (AD) and traumatic brain injury (TBI)/chronic traumatic encephalopathy (CTE). Current basic science and clinical investigations support the safety and efficacy of such interventions in treatment of these currently intractable conditions, that in some cases share pathological processes, and the plausibility of interventions that harness endocannabinoid mechanisms, whether mediated via direct activity on CB1 and CB2 (tetrahydrocannabinol, THC, caryophyllene), peroxisome proliferator-activated receptor-gamma (PPAR gamma; THCA), 5-HT1A (CBD, CBDA) or even nutritional approaches utilizing prebiotics and probiotics. The inherent polypharmaceutical properties of cannabis botanicals offer distinct advantages over the current single-target pharmaceutical model and portend to revolutionize neurological treatment into a new reality of effective interventional and even preventative treatment.	[Russo, Ethan B.] Int Cannabis & Cannabinoids Inst, Prague, Czech Republic	Russo, EB (corresponding author), Int Cannabis & Cannabinoids Inst, Prague, Czech Republic.	ethan.russo@icci.science	Russo, Ethan B/D-9933-2015	Russo, Ethan B/0000-0003-4715-515X			Ahmed AIA, 2015, CLIN PHARMACOL THER, V97, P597, DOI 10.1002/cpt.117; Aso E, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00037; Babson KA, 2017, CURR PSYCHIAT REP, V19, DOI 10.1007/s11920-017-0775-9; Bagdy G, 2007, J NEUROCHEM, V100, P857, DOI 10.1111/j.1471-4159.2006.04277.x; Baker D, 2003, LANCET NEUROL, V2, P291, DOI 10.1016/S1474-4422(03)00381-8; Bergamaschi MM, 2011, NEUROPSYCHOPHARMACOL, V36, P1219, DOI 10.1038/npp.2011.6; Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327; Bolognini D, 2013, BRIT J PHARMACOL, V168, P1456, DOI 10.1111/bph.12043; Bowe WP, 2011, GUT PATHOG, V3, DOI 10.1186/1757-4749-3-1; Brady CM, 2004, MULT SCLER J, V10, P425, DOI 10.1191/1352458504ms1063oa; Brodie JS, 2015, TRENDS PHARMACOL SCI, V36, P802, DOI 10.1016/j.tips.2015.08.010; Calame W, 2008, BRIT J NUTR, V100, P1269, DOI 10.1017/S0007114508981447; Carroll CB, 2004, NEUROLOGY, V63, P1245, DOI 10.1212/01.WNL.0000140288.48796.8E; Casarejos MJ, 2013, J ALZHEIMERS DIS, V35, P525, DOI 10.3233/JAD-130050; Cascio M.G., 2014, HDB OF CANNABIS, P137; Chagas MHN, 2014, J CLIN PHARM THER, V39, P564, DOI 10.1111/jcpt.12179; Chagas MHN, 2014, J PSYCHOPHARMACOL, V28, P1088, DOI 10.1177/0269881114550355; Chao DHM, 2016, SCI REP-UK, V6, DOI 10.1038/srep29094; Cherry JD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185541; Clarke G, 2012, ALIMENT PHARM THER, V35, P403, DOI 10.1111/j.1365-2036.2011.04965.x; Clendinning J, 1843, Med Chir Trans, V26, P188; Cluny NL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144270; Colle R, 2017, PHARMACOPSYCHIATRY, V50, P49, DOI 10.1055/s-0042-120120; Colle R, 2017, NEUROPSYCH DIS TREAT, V13, P9, DOI 10.2147/NDT.S121149; Cordain L, 2002, ARCH DERMATOL, V138, P1584, DOI 10.1001/archderm.138.12.1584; Devinsky O, 2018, NEUROLOGY, V90, pE1204, DOI 10.1212/WNL.0000000000005254; Devinsky O, 2017, NEW ENGL J MED, V376, P2011, DOI 10.1056/NEJMoa1611618; Devinsky O, 2016, LANCET NEUROL, V15, P270, DOI 10.1016/S1474-4422(15)00379-8; Donovan M., 1845, DUBLIN J MED SCI, V26, P368, DOI DOI 10.1007/BF02971741; Dumitru CA, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00159; Elrod HA, 2008, PPAR RES, V2008, DOI 10.1155/2008/704165; Emery DC, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00195; Esposito G, 2006, NEUROSCI LETT, V399, P91, DOI 10.1016/j.neulet.2006.01.047; Esposito G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028668; Eubanks LM, 2006, MOL PHARMACEUT, V3, P773, DOI 10.1021/mp060066m; Fallon Sally, 1999, NOURISHING TRADITION; Fife Terry D, 2015, Neurol Clin Pract, V5, P344; Finseth TA, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/874849; Foroughi M, 2011, CHILD NERV SYST, V27, P671, DOI 10.1007/s00381-011-1410-4; Gehring S, 2011, J NEURO-ONCOL, V102, P383, DOI 10.1007/s11060-010-0351-1; Gottschling S., 2011, ANGEW SCHMERZTHERAPI, P55, DOI DOI 10.1007/BF03359593; Gowers W., 1888, MANUAL DIS NERVOUS S; Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; He MQ, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0183-1; Hergenrather J., 2017, CANNABIS DEMENTIA; Hill MN, 2013, PSYCHONEUROENDOCRINO, V38, P2952, DOI 10.1016/j.psyneuen.2013.08.004; Iuvone T, 2004, J NEUROCHEM, V89, P134, DOI 10.1111/j.1471-4159.2003.02327.x; Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008; Jones NA, 2010, J PHARMACOL EXP THER, V332, P569, DOI 10.1124/jpet.109.159145; Kales HC, 2007, AM J PSYCHIAT, V164, P1568, DOI 10.1176/appi.ajp.2007.06101710; Karler R, 1979, MARIHUANA BIOL EFFEC, V22-23, P619; Kavia RBC, 2010, MULT SCLER J, V16, P1349, DOI 10.1177/1352458510378020; Keshavarzian A, 2015, MOVEMENT DISORD, V30, P1351, DOI 10.1002/mds.26307; Kim SS, 2008, BIOSCI BIOTECH BIOCH, V72, P2507, DOI 10.1271/bbb.70388; Latorre JGS, 2015, CURR CARDIOL REP, V17, DOI 10.1007/s11886-015-0627-3; Lei P, 2010, INT J BIOCHEM CELL B, V42, P1775, DOI 10.1016/j.biocel.2010.07.016; Leweke FM, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.15; Lewis MA, 2018, PLANTA MED, V84, P225, DOI 10.1055/s-0043-122240; Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247; Lorenz R, 2004, NEUROENDOCRINOL LETT, V25, P40; Lotan I, 2014, CLIN NEUROPHARMACOL, V37, P41, DOI 10.1097/WNF.0000000000000016; Maa E, 2014, EPILEPSIA, V55, P783, DOI 10.1111/epi.12610; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MacCallum CA, 2018, EUR J INTERN MED, V49, P12, DOI 10.1016/j.ejim.2018.01.004; Maccarrone M, 2017, EXPERT REV CLIN PHAR, V10, P443, DOI 10.1080/17512433.2017.1292849; Massi P, 2004, J PHARMACOL EXP THER, V308, P838, DOI 10.1124/jpet.103.061002; Mayeux R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006239; McGuire P, 2018, AM J PSYCHIAT, V175, P225, DOI 10.1176/appi.ajp.2017.17030325; McPartland JM, 2017, CANNABIS CANNABINOID, V2, P87, DOI 10.1089/can.2016.0032; MERRITT JC, 1980, OPHTHALMOLOGY, V87, P222; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Mitchell S. W., 1874, MED SURG REP, V31, P67; Muller-Vahl K. R., 2002, Journal of Cannabis Therapeutics, V2, P145, DOI 10.1300/J175v02n03_10; Muller-Vahl KR, 2003, J CLIN PSYCHIAT, V64, P459, DOI 10.4088/JCP.v64n0417; MUNSON AE, 1975, J NATL CANCER I, V55, P597, DOI 10.1093/jnci/55.3.597; Musso G, 2010, CURR OPIN LIPIDOL, V21, P76, DOI 10.1097/MOL.0b013e3283347ebb; Nadal X, 2017, BRIT J PHARMACOL, V174, P4263, DOI 10.1111/bph.14019; National Academies of Sciences Engineering and Medicine, 2017, HLTH EFF CAN CANN CU; Novotna A, 2011, EUR J NEUROL, V18, P1122, DOI 10.1111/j.1468-1331.2010.03328.x; Nozaki C, 2015, EUR NEUROPSYCHOPHARM, V25, P1388, DOI 10.1016/j.euroneuro.2015.04.001; Nurmikko TJ, 2007, PAIN, V133, P210, DOI 10.1016/j.pain.2007.08.028; O'Shaughnessy WB, 1838, T MED PHYS SOC BENGA, V71-102, P421; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Olah A, 2014, J CLIN INVEST, V124, P3713, DOI 10.1172/JCI64628; Omalu B, 2018, NEUROSURGERY, V82, P237, DOI 10.1093/neuros/nyx536; Osler W, 1915, PRINCIPLES PRACTICE; Pacher P, 2018, NAT REV CARDIOL, V15, P151, DOI 10.1038/nrcardio.2017.130; Pamplona FA, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00759; Perlmutter F., 2015, BRAIN MAKER POWER GU; Pertwee R., 2014, HDB OF CANNABIS, P115; Pisani A, 2005, ANN NEUROL, V57, P777, DOI 10.1002/ana.20462; Porter BE, 2013, EPILEPSY BEHAV, V29, P574, DOI 10.1016/j.yebeh.2013.08.037; Press CA, 2015, EPILEPSY BEHAV, V45, P49, DOI 10.1016/j.yebeh.2015.02.043; Raichlen DA, 2012, J EXP BIOL, V215, P1331, DOI 10.1242/jeb.063677; RAMAN A, 1995, LETT APPL MICROBIOL, V21, P242, DOI 10.1111/j.1472-765X.1995.tb01051.x; Rekand T, 2014, EUR NEUROL, V71, P4, DOI 10.1159/000357742; Reymond E. A. E. E., 1976, CONTENTS LIBRARIES 1; Rhyne DN, 2016, PHARMACOTHERAPY, V36, P505, DOI 10.1002/phar.1673; Rog DJ, 2005, NEUROLOGY, V65, P812, DOI 10.1212/01.wnl.0000176753.45410.8b; Rousseaux C, 2007, NAT MED, V13, P35, DOI 10.1038/nm1521; Rudroff T, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00299; Russo E., 2001, Journal of Cannabis Therapeutics, V1, P21, DOI 10.1300/J175v01n02_04; Russo E. B., 2015, BR J CARDIOL, V22, P7; Russo E.B., 2017, CANNABIS SATIVA L BO, P63; Russo E.B., 2013, COMPREHENSIVE TREATM, P181, DOI [10.1007/978-1-4614- 1560-2_18, DOI 10.1007/978-1-4614-1560-2_18, 10.1007/978-1-4614-1560-2_18]; Russo EB, 2005, NEUROCHEM RES, V30, P1037, DOI 10.1007/s11064-005-6978-1; Russo EB, 2004, NEUROENDOCRINOL LETT, V25, P31; Russo EB, 2015, CLIN RES, P58, DOI DOI 10.14524/CR-15-0004; Russo EB, 2007, CHEM BIODIVERS, V4, P1614, DOI 10.1002/cbdv.200790144; Russo EB, 2007, CHEM BIODIVERS, V4, P1729, DOI 10.1002/cbdv.200790150; Russo EB, 2017, ADV PHARMACOL, V80, P67, DOI 10.1016/bs.apha.2017.03.004; Russo EB, 2017, EPILEPSY BEHAV, V70, P292, DOI 10.1016/j.yebeh.2016.09.040; Russo EB, 2016, CANNABIS CANNABINOID, V1, P154, DOI 10.1089/can.2016.0009; Russo EB, 2016, TRENDS PHARMACOL SCI, V37, P594, DOI 10.1016/j.tips.2016.04.005; Russo EB, 2011, BRIT J PHARMACOL, V163, P1344, DOI 10.1111/j.1476-5381.2011.01238.x; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Sanchez C, 1998, FEBS LETT, V436, P6, DOI 10.1016/S0014-5793(98)01085-0; Sarchielli P, 2007, NEUROPSYCHOPHARMACOL, V32, P1384, DOI 10.1038/sj.npp.1301246; Schenkman M, 2018, JAMA NEUROL, V75, P219, DOI 10.1001/jamaneurol.2017.3517; Seguin E., 1877, MED REC, V12, P774; Serpell M, 2014, EUR J PAIN, V18, P999, DOI 10.1002/j.1532-2149.2013.00445.x; Shen Y, 2016, CURR STEM CELL RES T, V11, P208, DOI 10.2174/1574888X10666150728122034; Slavin J, 2013, NUTRIENTS, V5, P1417, DOI 10.3390/nu5041417; Soni D, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0499-0; Subramenium GA, 2015, J MED MICROBIOL, V64, P879, DOI 10.1099/jmm.0.000105; Sulak D, 2017, EPILEPSY BEHAV, V70, P328, DOI 10.1016/j.yebeh.2016.12.032; Sun H, 2008, INT J DEV NEUROSCI, V26, P505, DOI 10.1016/j.ijdevneu.2008.01.009; Tepper BJ, 2014, NUTRIENTS, V6, P3363, DOI 10.3390/nu6093363; Thiele EA, 2018, LANCET, V391, P1085, DOI 10.1016/S0140-6736(18)30136-3; Torres S, 2011, MOL CANCER THER, V10, P90, DOI 10.1158/1535-7163.MCT-10-0688; van den Elsen GAH, 2015, NEUROLOGY, V84, P2338, DOI 10.1212/WNL.0000000000001675; Venderova K, 2004, MOVEMENT DISORD, V19, P1102, DOI 10.1002/mds.20111; Volicer L, 1997, INT J GERIATR PSYCH, V12, P913, DOI 10.1002/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.3.CO;2-4; Wallace MJ, 2003, J PHARMACOL EXP THER, V307, P129, DOI 10.1124/jpet.103.051920; Walther S, 2006, PSYCHOPHARMACOLOGY, V185, P524, DOI 10.1007/s00213-006-0343-1; Zhang LQ, 2013, BRIT J PHARMACOL, V170, P661, DOI 10.1111/bph.12315; Zuardi AW, 2009, J PSYCHOPHARMACOL, V23, P979, DOI 10.1177/0269881108096519	138	33	33	0	42	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5145			FRONT INTEGR NEUROSC	Front. Integr. Neurosci.	OCT 18	2018	12								51	10.3389/fnint.2018.00051			11	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	GX3GY	WOS:000447611400002	30405366	DOAJ Gold, Green Published			2021-06-18	
J	Maki, T; Morancho, A; Segundo, PMS; Hayakawa, K; Takase, H; Liang, AC; Gabriel-Salazar, M; Medina-Gutierrez, E; Washida, K; Montaner, J; Lok, J; Lo, EH; Arai, K; Rosell, A				Maki, Takakuni; Morancho, Anna; Martinez-San Segundo, Pablo; Hayakawa, Kazuhide; Takase, Hajime; Liang, Anna C.; Gabriel-Salazar, Marina; Medina-Gutierrez, Esperanza; Washida, Kazuo; Montaner, Joan; Lok, Josephine; Lo, Eng H.; Arai, Ken; Rosell, Anna			Endothelial Progenitor Cell Secretome and Oligovascular Repair in a Mouse Model of Prolonged Cerebral Hypoperfusion	STROKE			English	Article						angiogenin; carotid stenosis; endothelial progenitor cell; repair; white matter	TRAUMATIC BRAIN-INJURY; WHITE-MATTER LESIONS; ISCHEMIC-STROKE; ANGIOGENIN; STEM; GROWTH; TRANSPLANTATION; CANCER; MICE; OLIGODENDROCYTE	Background and Purpose-Endothelial progenitor cells (EPCs) have been extensively investigated as a therapeutic approach for repairing the vascular system in cerebrovascular diseases. Beyond vascular regeneration per se, EPCs may also release factors that affect the entire neurovascular unit. Here, we aim to study the effects of the EPC secretome on oligovascular remodeling in a mouse model of white matter injury after prolonged cerebral hypoperfusion. Methods-The secretome of mouse EPCs was analyzed with a proteome array. In vitro, the effects of the EPC secretome and its factor angiogenin were assessed on primary oligodendrocyte precursor cells and mature human cerebral microvascular endothelial cells (hCMED/D3). In vivo, mice were subjected to permanent bilateral common carotid artery stenosis, then treated with EPC secretome at 24 hours and at 1 week, and cognitive outcome was evaluated with the Y maze test together with oligodendrocyte precursor cell proliferation/differentiation and vascular density in white matter at 4 weeks. Results-Multiple growth factors, cytokines, and proteases were identified in the EPC secretome, including angiogenin. In vitro, the EPC secretome significantly enhanced endothelial and oligodendrocyte precursor cell proliferation and potentiated oligodendrocyte precursor cell maturation. Angiogenin was proved to be a key factor since pharmacological blockade of angiogenin signaling negated the positive effects of the EPC secretome. In vivo, treatment with the EPC secretome increased vascular density, myelin, and mature oligodendrocytes in white matter and rescued cognitive function in the mouse hypoperfusion model. Conclusions-Factors secreted by EPCs may ameliorate white matter damage in the brain by boosting oligovascular remodeling.	[Maki, Takakuni; Hayakawa, Kazuhide; Takase, Hajime; Liang, Anna C.; Washida, Kazuo; Lok, Josephine; Lo, Eng H.; Arai, Ken] Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, 149 13th St, Charlestown, MA 02129 USA; [Maki, Takakuni; Hayakawa, Kazuhide; Takase, Hajime; Liang, Anna C.; Washida, Kazuo; Lok, Josephine; Lo, Eng H.; Arai, Ken] Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St, Charlestown, MA 02129 USA; [Maki, Takakuni; Hayakawa, Kazuhide; Takase, Hajime; Liang, Anna C.; Washida, Kazuo; Lok, Josephine; Lo, Eng H.; Arai, Ken] Harvard Med Sch, 149 13th St, Charlestown, MA 02129 USA; [Morancho, Anna; Martinez-San Segundo, Pablo; Gabriel-Salazar, Marina; Medina-Gutierrez, Esperanza; Montaner, Joan; Rosell, Anna] Univ Autonoma Barcelona, Neurovasc Res Lab, Vall dHebron Res Inst, Barcelona, Spain	Arai, K (corresponding author), Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, 149 13th St, Charlestown, MA 02129 USA.; Arai, K (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St, Charlestown, MA 02129 USA.; Arai, K (corresponding author), Harvard Med Sch, 149 13th St, Charlestown, MA 02129 USA.; Rosell, A (corresponding author), Vall dHebron Res Inst, Neurovasc Res Lab, Passeig Vall dHebron 119-129, Barcelona 08035, Spain.	karai@partners.org; anna.rosell@vhir.org	Retana, Anna Morancho/K-8804-2014; 眞木, 崇州/AAO-1160-2020; Montaner, Joan/D-3063-2015	Retana, Anna Morancho/0000-0001-9059-3206; Montaner, Joan/0000-0003-4845-2279; Rosell Novel, Anna/0000-0003-1082-3599	Miguel Servet program [CPII15/00003]; Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission; European Regional Development FundsEuropean Commission [PI13/01094, PI16/00981, RD12/0014/0005]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-NS065089, P201-NS055104]; Uehara Memorial FoundationUehara Memorial Foundation; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS093415, R01NS065089, P01NS055104] Funding Source: NIH RePORTER	This work has been supported by the Miguel Servet program to Dr Rosell (CPII15/00003), by research grants from Instituto de Salud Carlos III with European Regional Development Funds (PI13/01094, PI16/00981, and RD12/0014/0005), by the National Institutes of Health (NIH; R01-NS065089, P201-NS055104), by the Uehara Memorial Foundation, and by the Japan Society for the Promotion of Science.	Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Bai L, 2012, NAT NEUROSCI, V15, P862, DOI 10.1038/nn.3109; Bai YY, 2015, STROKE, V46, P1938, DOI 10.1161/STROKEAHA.114.008495; Bain JM, 2013, TRANSL STROKE RES, V4, P158, DOI 10.1007/s12975-012-0213-6; Barcena C, 2015, SCI REP-UK, V5, DOI 10.1038/srep07916; Carenza E, 2014, ACTA BIOMATER, V10, P3775, DOI 10.1016/j.actbio.2014.04.010; Cho GW, 2010, MOL CELL BIOCHEM, V340, P133, DOI 10.1007/s11010-010-0410-0; Di Santo S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095731; Di Santo S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005643; Fan YF, 2010, ANN NEUROL, V67, P488, DOI 10.1002/ana.21919; Friedrich EB, 2006, CIRC RES, V98, pE20, DOI 10.1161/01.RES.0000205765.28940.93; Gao XW, 2008, ACTA BIOCH BIOPH SIN, V40, P619, DOI 10.1111/j.1745-7270.2008.00442.x; Garbuzova-Davis S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031254; Goncalves KA, 2016, CELL, V166, P894, DOI 10.1016/j.cell.2016.06.042; Gordon D, 2010, J NEUROPATH EXP NEUR, V69, P1087, DOI 10.1097/NEN.0b013e3181f97392; Hayakawa K, 2011, J NEUROSCI, V31, P10666, DOI 10.1523/JNEUROSCI.1944-11.2011; He TR, 2005, AM J PHYSIOL-HEART C, V289, pH968, DOI 10.1152/ajpheart.01166.2004; Horie N, 2011, STEM CELLS, V29, P274, DOI 10.1002/stem.584; Hu GF, 1998, P NATL ACAD SCI USA, V95, P9791, DOI 10.1073/pnas.95.17.9791; Ibaragi S, 2009, CLIN CANCER RES, V15, P1981, DOI 10.1158/1078-0432.CCR-08-2593; Ihara M, 2014, METHODS MOL BIOL, V1135, P95, DOI 10.1007/978-1-4939-0320-7_8; Jadasz JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071814; Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054; Le Bras B, 2006, NAT NEUROSCI, V9, P340, DOI 10.1038/nn1646; Lo EH, 2008, NAT MED, V14, P497, DOI 10.1038/nm1735; Maki T, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00275; Maki T, 2011, STROKE, V42, P1122, DOI 10.1161/STROKEAHA.110.603399; McQueen J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087227; Miyamoto N, 2015, J NEUROSCI, V35, P14002, DOI 10.1523/JNEUROSCI.1592-15.2015; Miyamoto N, 2014, CELL MOL LIFE SCI, V71, P1055, DOI 10.1007/s00018-013-1488-9; Miyamoto N, 2013, STROKE, V44, P3516, DOI 10.1161/STROKEAHA.113.002813; Morancho A, 2015, J CEREBR BLOOD F MET, V35, P1547, DOI 10.1038/jcbfm.2015.180; Morancho A, 2013, J CELL MOL MED, V17, P1543, DOI 10.1111/jcmm.12116; Moubarik C, 2011, STEM CELL REV REP, V7, P208, DOI 10.1007/s12015-010-9157-y; Napoli E, 2016, TRANSL STROKE RES, V7, P452, DOI 10.1007/s12975-016-0490-6; Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495; Park KJ, 2014, J CEREBR BLOOD F MET, V34, P357, DOI 10.1038/jcbfm.2013.216; Reimer MM, 2011, J NEUROSCI, V31, P18185, DOI 10.1523/JNEUROSCI.4936-11.2011; Rosell A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073244; Sebastia J, 2009, CELL DEATH DIFFER, V16, P1238, DOI 10.1038/cdd.2009.52; Shibata M, 2004, STROKE, V35, P2598, DOI 10.1161/01.STR.0000143725.19053.60; Shibata M, 2007, STROKE, V38, P2826, DOI 10.1161/STROKEAHA.107.490151; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tajiri N, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00116; Thiyagarajan N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2126; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Yang ZJ, 2010, ATHEROSCLEROSIS, V211, P103, DOI 10.1016/j.atherosclerosis.2010.02.022; Yoshioka N, 2006, P NATL ACAD SCI USA, V103, P14519, DOI 10.1073/pnas.0606708103; Zhang J, 2013, EXPERT OPIN BIOL TH, V13, P1229, DOI 10.1517/14712598.2013.804507; Zhang RL, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00201; Zhang YQ, 2013, J SURG RES, V185, P441, DOI 10.1016/j.jss.2013.05.073	51	33	33	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	APR	2018	49	4					1003	+		10.1161/STROKEAHA.117.019346			21	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	GB6BW	WOS:000429153900042	29511131	Green Accepted, Bronze			2021-06-18	
J	Lu, Y; Zhang, XS; Zhang, ZH; Zhou, XM; Gao, YY; Liu, GJ; Wang, H; Wu, LY; Li, W; Hang, CH				Lu, Yue; Zhang, Xiang-Sheng; Zhang, Zi-Huan; Zhou, Xiao-Ming; Gao, Yong-Yue; Liu, Guang-Jie; Wang, Han; Wu, Ling-Yun; Li, Wei; Hang, Chun-Hua			Peroxiredoxin 2 activates microglia by interacting with Toll-like receptor 4 after subarachnoid hemorrhage	JOURNAL OF NEUROINFLAMMATION			English	Article						Subarachnoid hemorrhage; Peroxiredoxin 2; Microglial activation; Toll-like receptor 4; Neuronal apoptosis	DUAL ROLE; INTRACEREBRAL HEMORRHAGE; FUNCTIONAL DIFFERENCES; ISCHEMIC-STROKE; CELL-TYPES; BRAIN; INFLAMMATION; PROTEINS	Background: Peroxiredoxin (Prx) protein family have been reported as important damage-associated molecular patterns (DAMPs) in ischemic stroke. Since peroxiredoxin 2 (Prx2) is the third most abundant protein in erythrocytes and the second most protein in the cerebrospinal fluid in traumatic brain injury and subarachnoid hemorrhage (SAH) patients, we assessed the role of extracellular Prx2 in the context of SAH. Methods: We introduced a co-culture system of primary neurons and microglia. Prx2 was added to culture medium with oxyhemoglobin (OxyHb) to mimic SAH in vitro. Neuronal cell viability was assessed by lactate dehydrogenase (LDH) assay, and neuronal apoptosis was determined by TUNEL staining. Inflammatory factors in culture medium were measured by ELISA, and their mRNA levels in microglia were determined by qPCR. Toll-like receptor 4 knockout (TLR4-KO) mice were used to provide TLR4-KO microglia; ST-2825 was used to inhibit MyD88, and pyrrolidine dithiocarbamate (PDTC) was used to inhibit NF-kappa B. Related cellular signals were analyzed by Western blot. Furthermore, we detected the level of Prx2 in aneurysmal SAH patients' cerebrospinal fluids (CSF) and compared its relationship with Hunt-Hess grades. Results: Prx2 interacted with TLR4 on microglia after SAH and then activated microglia through TLR4/MyD88/NF-kappa B signaling pathway. Pro-inflammatory factors were expressed and released, eventually caused neuronal apoptosis. The levels of Prx2 in SAH patients positively correlated with Hunt-Hess grades. Conclusions: Extracellular Prx2 in CSF after SAH is a DAMP which resulted in microglial activation via TLR4/MyD88/NF-kappa B pathway and then neuronal apoptosis. Prx2 in patients' CSF may be a potential indicator of brain injury and prognosis.	[Lu, Yue; Zhang, Xiang-Sheng; Gao, Yong-Yue; Liu, Guang-Jie; Wu, Ling-Yun; Li, Wei; Hang, Chun-Hua] Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Zhang, Zi-Huan] Zhongdu Hosp, Dept Neurosurg, Bengbu, Peoples R China; [Zhou, Xiao-Ming] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Wang, Han] South Med Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Li, W; Hang, CH (corresponding author), Nanjing Univ, Med Sch, Drum Tower Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.	lwxzlw@126.com; hang_neurosurgery@163.com		LU, Yue/0000-0001-9111-5943	National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81371294, 81501022, 81401029, 81771291]	This work was supported by the National Natural Science Foundation of China (NSFC) [grant numbers 81371294, 81501022, 81401029, 81771291].	Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Buttgereit A, 2016, NAT IMMUNOL, V17, P1397, DOI 10.1038/ni.3585; Connor David E Jr, 2017, Pathophysiology, V24, P169, DOI 10.1016/j.pathophys.2017.04.003; Conway JP, 2006, J BIOL CHEM, V281, P27991, DOI 10.1074/jbc.M605026200; Jin MH, 2005, NEUROSCI LETT, V381, P252, DOI 10.1016/j.neulet.2005.02.048; Lan X, 2017, NAT REV NEUROL, V13, P420, DOI 10.1038/nrneurol.2017.69; Lee WS, 2007, J BIOL CHEM, V282, P22011, DOI 10.1074/jbc.M610330200; Li Q, 2017, NAT REV IMMUNOL; Liu DL, 2016, INT IMMUNOPHARMACOL, V41, P82, DOI 10.1016/j.intimp.2016.10.025; Lucke-Wold BP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040497; Matcovitch-Natan O, 2016, SCIENCE, V353, DOI 10.1126/science.aad8670; Matte A, 2007, BLOOD, V110, p529A; Nakagawa Y, 2014, PHARMACEUTICALS, V7, P1028, DOI 10.3390/ph7121028; Park MH, 2016, PHARMACOL THERAPEUT, V163, P1, DOI 10.1016/j.pharmthera.2016.03.018; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Sarafian TA, 1999, J NEUROSCI RES, V56, P206, DOI 10.1002/(SICI)1097-4547(19990415)56:2<206::AID-JNR1>3.0.CO;2-X; Shichita T, 2017, NAT MED, V23, P723, DOI 10.1038/nm.4312; Shichita T, 2012, NAT MED, V18, P911, DOI 10.1038/nm.2749; Smolinska MJ, 2011, J IMMUNOL, V187, P6043, DOI 10.4049/jimmunol.1100967; Sun Q, 2014, J NEUROINFLAMM, V11; Watanabe Y, 2017, BIOCHEM BIOPH RES CO, V483, P930, DOI 10.1016/j.bbrc.2017.01.034; Xu XM, 2017, J NEUROSCI, V37, P10498, DOI 10.1523/JNEUROSCI.1139-17.2017; Yu L, 2010, J CELL MOL MED, V14, P2592, DOI 10.1111/j.1582-4934.2010.01127.x; Zhang DD, 2016, NEUROL SCI, V37, P219, DOI 10.1007/s10072-015-2391-y; Zhang XS, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00611	26	33	35	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 19	2018	15								87	10.1186/s12974-018-1118-4			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FZ9BR	WOS:000427905100001	29554978	DOAJ Gold, Green Published			2021-06-18	
J	Kaupp, C; Pearcey, GEP; Klarner, T; Sun, Y; Cullen, H; Barss, TS; Zehr, EP				Kaupp, Chelsea; Pearcey, Gregory E. P.; Klarner, Taryn; Sun, Yao; Cullen, Hilary; Barss, Trevor S.; Zehr, E. Paul			Rhythmic arm cycling training improves walking and neurophysiological integrity in chronic stroke: the arms can give legs a helping hand in rehabilitation	JOURNAL OF NEUROPHYSIOLOGY			English	Article						arm cycling; cutaneous reflex; locomotor training; stretch reflex; stroke	H-REFLEX AMPLITUDE; SPINAL-CORD-INJURY; NEURAL-CONTROL; CUTANEOUS REFLEXES; HUMAN LOCOMOTION; HOFFMANN REFLEX; ASHWORTH SCALE; ELECTRICAL-STIMULATION; TREADMILL WALKING; PHYSICAL-ACTIVITY	Training locomotor central pattern-generating networks (CPGs) through arm and leg cycling improves walking in chronic stroke. These outcomes are presumed to result from enhanced interlimb connectivity and CPG function. The extent to which rhythmic arm training activates interlimb CPG networks for locomotion remains unclear and was assessed by studying chronic stroke participants before and after 5 wk of arm cycling training. Strength was assessed bilaterally via maximal voluntary isometric contractions in the legs and hands. Muscle activation during arm cycling and transfer to treadmill walking were assessed in the more affected (MA) and less affected (LA) sides via surface electromyography. Changes to interlimb coupling during rhythmic movement were evaluated using modulation of cutaneous reflexes elicited by electrical stimulation of the superficial radial nerve at the wrist. Bilateral soleus stretch reflexes were elicited at rest and during 1-Hz arm cycling. Clinical function tests assessed walking, balance, and motor function. Results show significant changes in function and neurophysiological integrity. Training increased bilateral grip strength, force during MA plantar-flexion, and muscle activation. "Normalization" of cutaneous reflex modulation was found during arm cycling. There was enhanced activity in the dorsiflexor muscles on the MA side during the swing phase of walking. Enhanced interlimb coupling was shown by increased modulation of MA soleus stretch reflex amplitudes during arm cycling after training. Clinical evaluations showed enhanced walking ability and balance. These results are consistent with training-induced changes in CPG function and interlimb connectivity and underscore the need for arm training in the functional rehabilitation of walking after neurotrauma. NEW & NOTEWORTHY It has been suggested but not tested that training the arms may influence rehabilitation of walking due to activation of interneuronal patterning networks after stroke. We show that arm cycling training improves strength, clinical function, coordination of muscle activity during walking, and neurological connectivity between the arms and the legs. The arms can, in fact, give the legs a helping hand in rehabilitation of walking after stroke.	[Kaupp, Chelsea; Pearcey, Gregory E. P.; Klarner, Taryn; Sun, Yao; Cullen, Hilary; Zehr, E. Paul] Univ Victoria, Rehabil Neurosci Lab, POB 3010 STN CSC, Victoria, BC V8W 3P1, Canada; [Kaupp, Chelsea; Pearcey, Gregory E. P.; Klarner, Taryn; Sun, Yao; Cullen, Hilary; Zehr, E. Paul] ICORD, Human Discovery Sci, Vancouver, BC, Canada; [Kaupp, Chelsea; Pearcey, Gregory E. P.; Klarner, Taryn; Sun, Yao; Cullen, Hilary; Zehr, E. Paul] Univ Victoria, Ctr Biomed Res, Victoria, BC, Canada; [Barss, Trevor S.] Univ Alberta, Human Neurophysiol Lab, Edmonton, AB, Canada; [Zehr, E. Paul] Univ Victoria, Div Med Sci, Victoria, BC, Canada	Zehr, EP (corresponding author), Univ Victoria, Rehabil Neurosci Lab, POB 3010 STN CSC, Victoria, BC V8W 3P1, Canada.	pzehr@uvic.ca	Barss, Trevor/L-7045-2019	Barss, Trevor/0000-0003-3466-2750; Pearcey, Gregory/0000-0002-6751-4351			Ada L, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-8; Bakheit AMO, 2003, J NEUROL NEUROSUR PS, V74, P646, DOI 10.1136/jnnp.74.5.646; BALLESTEROS ML, 1965, ACTA PHYSIOL SCAND, V63, P296, DOI 10.1111/j.1748-1716.1965.tb04069.x; Balter JE, 2007, J NEUROPHYSIOL, V97, P1809, DOI 10.1152/jn.01038.2006; Barzi Y, 2008, CLIN NEUROPHYSIOL, V119, P1443, DOI 10.1016/j.clinph.2008.02.016; Burke RE, 1999, EXP BRAIN RES, V128, P263, DOI 10.1007/s002210050847; Burridge JH, 2001, MED ENG PHYS, V23, P427, DOI 10.1016/S1350-4533(01)00061-3; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Cohen J., 1988, SET CORRELATION MULT, V2, P467; Cummings G., 2013, UNDERSTANDING NEW ST; de Kam D, 2013, J APPL PHYSIOL, V115, P34, DOI 10.1152/japplphysiol.00510.2012; Dietz V, 2002, TRENDS NEUROSCI, V25, P462, DOI 10.1016/S0166-2236(02)02229-4; Dietz V, 2001, EUR J NEUROSCI, V14, P1906, DOI 10.1046/j.0953-816x.2001.01813.x; Dragert K, 2013, EXP BRAIN RES, V225, P93, DOI 10.1007/s00221-012-3351-x; Dragert K, 2011, EXP BRAIN RES, V208, P217, DOI 10.1007/s00221-010-2472-3; Dragert K, 2009, NEUROSCI LETT, V450, P235, DOI 10.1016/j.neulet.2008.11.034; Elftman HO, 1939, FUNCTION ARMS WALKIN; Enright Paul L, 2003, Respir Care, V48, P783; Ferris DP, 2006, EXERC SPORT SCI REV, V34, P113, DOI 10.1249/00003677-200607000-00005; Flansbjer UB, 2005, J REHABIL MED, V37, P75, DOI 10.1080/16501970410017215; Frigon A, 2004, J NEUROPHYSIOL, V91, P1516, DOI 10.1152/jn.00695.2003; Frigon A, 2017, J NEUROPHYSIOL, V117, P2224, DOI 10.1152/jn.00978.2016; Gadidi V, 2011, ARCH PHYS MED REHAB, V92, P1802, DOI 10.1016/j.apmr.2011.06.014; Gordon NF, 2004, STROKE, V35, P1230, DOI 10.1161/01.STR.0000127303.19261.19; GOWLAND C, 1993, STROKE, V24, P58, DOI 10.1161/01.STR.24.1.58; HAGE JJ, 1995, J HAND SURG-AM, V20A, P227; Haridas C, 2003, J NEUROPHYSIOL, V90, P2850, DOI 10.1152/jn.00531.2003; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; Hundza SR, 2009, EXP BRAIN RES, V193, P297, DOI 10.1007/s00221-008-1625-0; Hundza SR, 2006, EXP BRAIN RES, V168, P165, DOI 10.1007/s00221-005-0089-8; Kim CM, 2003, PHYS THER, V83, P49, DOI 10.1093/ptj/83.1.49; Klamer T, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00095; Klarner T, 2016, BRAIN SCI, V6, DOI 10.3390/brainsci6040054; Klarner T, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/1517968; Kline TL, 2007, BRAIN, V130, P159, DOI 10.1093/brain/awl278; Lagerquist O, 2006, EXP BRAIN RES, V170, P1, DOI 10.1007/s00221-005-0172-1; Lamont EV, 2007, J NEUROPHYSIOL, V98, P433, DOI 10.1152/jn.00002.2007; Liston RAL, 1996, ARCH PHYS MED REHAB, V77, P425, DOI 10.1016/S0003-9993(96)90028-3; Loadman PM, 2007, EXP BRAIN RES, V179, P199, DOI 10.1007/s00221-006-0782-2; Mayo NE, 2002, ARCH PHYS MED REHAB, V83, P1035, DOI 10.1053/apmr.2002.33984; Mezzarane RA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00136; Mezzarane RA, 2011, EXP BRAIN RES, V208, P157, DOI 10.1007/s00221-010-2467-0; Nakajima T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104910; Nakajima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076313; Nakajima T, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-28; Nielsen JB, 2003, NEUROSCIENTIST, V9, P195, DOI 10.1177/1073858403009003012; Palomino AF, 2011, EXP BRAIN RES, V214, P529, DOI 10.1007/s00221-011-2851-4; Pandyan AD, 2003, CLIN REHABIL, V17, P290, DOI 10.1191/0269215503cr610oa; Pang MYC, 2006, CLIN REHABIL, V20, P97, DOI 10.1191/0269215506cr926oa; Patrick E, 2006, CLIN REHABIL, V20, P173, DOI 10.1191/0269215506cr922oa; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; RICHARDS CL, 1996, GAIT POSTURE, V4, P149; Scherr J, 2013, EUR J APPL PHYSIOL, V113, P147, DOI 10.1007/s00421-012-2421-x; Shiavi R, 1987, J Rehabil Res Dev, V24, P24; STEIN RB, 1993, PROG BRAIN RES, V97, P189; Sun Y, 2015, APPL PHYSIOL NUTR ME, V40, P858, DOI 10.1139/apnm-2014-0523; Tang A, 2006, ARCH PHYS MED REHAB, V87, P1100, DOI 10.1016/j.apmr.2006.04.016; Tester NJ, 2011, SPINAL CORD, V49, P451, DOI 10.1038/sc.2010.128; Vasudevan EVL, 2011, EXP BRAIN RES, V211, P299, DOI 10.1007/s00221-011-2687-y; Wannier T, 2001, EXP BRAIN RES, V141, P375, DOI 10.1007/s002210100875; Zehr EP, 2016, EXP BRAIN RES, V234, P3059, DOI 10.1007/s00221-016-4715-4; Zehr EP, 2007, J NEUROPHYSIOL, V98, P1810, DOI 10.1152/jn.00562.2007; Zehr EP, 2012, J NEUROPHYSIOL, V108, P891, DOI 10.1152/jn.01152.2011; Zehr EP, 2012, CLIN NEUROPHYSIOL, V123, P796, DOI 10.1016/j.clinph.2011.07.049; Zehr EP, 2011, APPL PHYSIOL NUTR ME, V36, pS214, DOI [10.1139/H11-055, 10.1139/h11-055]; Zehr EP, 2005, EXERC SPORT SCI REV, V33, P54; Zehr EP, 2004, CAN J PHYSIOL PHARM, V82, P556, DOI 10.1139/Y04-056; Zehr EP, 1998, J NEUROPHYSIOL, V79, P848; Zehr EP, 2004, EXP BRAIN RES, V159, P382, DOI 10.1007/s00221-004-2092-x; Zehr EP, 2004, NEUROSCIENTIST, V10, P347, DOI 10.1177/1073858404264680; Zehr EP, 2003, EXP BRAIN RES, V149, P260, DOI 10.1007/s00221-003-1377-9; Zehr EP, 2003, J NEUROPHYSIOL, V89, P12, DOI 10.1152/jn.00416.2002; Zehr EP, 2002, EUR J APPL PHYSIOL, V86, P455, DOI 10.1007/s00421-002-0577-5; Zehr EP, 2001, EXP BRAIN RES, V140, P495; Zhou R, 2017, J NEUROPHYSIOL, V118, P2507, DOI 10.1152/jn.00663.2016	77	33	33	1	15	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077	1522-1598		J NEUROPHYSIOL	J. Neurophysiol.	MAR	2018	119	3					1095	1112		10.1152/jn.00570.2017			18	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	FZ1PC	WOS:000427348200030	29212917	Green Published, Bronze			2021-06-18	
J	Chen, VCH; Wu, SI; Huang, KY; Yang, YH; Kuo, TY; Liang, HY; Huang, KL; Gossop, M				Chen, Vincent Chin-Hung; Wu, Shu-I; Huang, Kuo-You; Yang, Yao-Hsu; Kuo, Ting-Yu; Liang, Hsin-Yi; Huang, Kuan-Lun; Gossop, Michael			Herpes Zoster and Dementia: A Nationwide Population-Based Cohort Study	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							INSURANCE RESEARCH DATABASE; COGNITIVE IMPAIRMENT; INFLAMMATORY MARKERS; ALZHEIMERS-DISEASE; VIRUS VASCULOPATHY; RISK; ENCEPHALITIS; METAANALYSIS; INFECTIONS; PREVALENCE	Objective: Some infectious diseases have been found to be associated with cognitive impairment and dementia. However, the relationship between herpes zoster and dementia has received little attention. This study aimed to investigate this association as well as associations of antiviral treatments for herpes zoster and incident dementia using a large national sample. Methods: Cases were identified from the Taiwan National Health Insurance Research Database with a new diagnosis of herpes zoster (ICD-9-CM code: 053) between 1997 and 2013. Each identified individual with a case of herpes zoster was compared with 1 sex-, age-, and residence-matched control subject. Both groups were followed until the first diagnosis of dementia (ICD-9-CM codes: 290.0 to 290.4, 294.1, 331.0 to 331.2, and 331.82), withdrawal from the registry, or the end of 2013. Cox regression analyses and competing risk model were applied, adjusting for sex, age, residence, depression, autoimmune disease, ischemic stroke, traumatic brain injury, alcohol use disorder, and antiviral treatments for herpes zoster to evaluate the risk of interest. Results: A total of 39,205 cases with herpes zoster were identified. Of the 78,410 study and comparison subjects, 4,204 were diagnosed as having dementia during a mean (SD) follow-up period of 6.22 (4.05) years. Herpes zoster was associated with a slightly increased risk of dementia in the fully adjusted model (hazard ratio [HR] = 1.11; 95% CI, 1.04-1.17). Prescriptions of antiviral therapy were associated with a reduced risk of developing dementia following the diagnosis of herpes zoster (HR = 0.55; 95% CI, 0.40-0.77). Conclusions: Herpes zoster was associated with an increased risk of dementia, independent of potential confounding factors. Antiviral treatment might be protective in preventing dementia in patients with herpes zoster.	[Chen, Vincent Chin-Hung] Chiayi Chang Gung Mem Hosp, Chang Gung Med Fdn, Puzi, Chiayi, Taiwan; [Chen, Vincent Chin-Hung; Liang, Hsin-Yi] Chang Gung Univ, Sch Med, Taoyuan, Taiwan; [Wu, Shu-I] Mackay Med Coll, Dept Med, Taipei, Taiwan; [Wu, Shu-I] Mackay Med Coll, Dept Audiol & Speech Language Pathol, Taipei, Taiwan; [Wu, Shu-I] Mackay Mem Hosp, Sect Psychiat, Taipei, Taiwan; [Huang, Kuo-You] Chung Shan Med Univ, Dept Speech Language Pathol & Audiol, Taichung, Taiwan; [Yang, Yao-Hsu] Chang Gung Mem Hosp, Dept Tradit Chinese Med, Chiayi, Taiwan; [Yang, Yao-Hsu; Kuo, Ting-Yu] Chang Gung Mem Hosp, Ctr Excellence Chang Gung Res Datalink, Chiayi, Taiwan; [Yang, Yao-Hsu] Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, Taipei, Taiwan; [Yang, Yao-Hsu] Chang Gung Univ, Coll Med, Sch Tradit Chinese Med, Taoyuan, Taiwan; [Liang, Hsin-Yi] Linkou Chang Gung Mem Hosp, Dept Child Psychiat, Taoyuan, Taiwan; [Huang, Kuan-Lun] Minist Hlth & Welf, Tsaotun Psychiat Ctr, 161 Yu Pin Rd, Nantou, Taiwan; [Gossop, Michael] Kings Coll London, Inst Psychiat, Natl Addict Ctr, London, England	Huang, KL (corresponding author), Minist Hlth & Welf, Tsaotun Psychiat Ctr, 161 Yu Pin Rd, Nantou, Taiwan.	ibulumhuang@gmail.com	楊, 曜旭/A-3450-2019	楊, 曜旭/0000-0002-8080-0504; Wu, Shu-I/0000-0002-8461-5613	Ministry of Science and Technology, R.O.C. [MOST 102-2314-B-040-004-MY3]; Chang Gung Medical Foundation, Chiayi Chang Gung Memorial Hospital [CMRPG6E0261]; Tsaotun Psychiatric Center, Ministry of Health and Welfare, Taiwan [105003]	The present study is supported in part by the Ministry of Science and Technology, R.O.C. (MOST 102-2314-B-040-004-MY3); the Chang Gung Medical Foundation, Chiayi Chang Gung Memorial Hospital (CMRPG6E0261); and the Tsaotun Psychiatric Center, Ministry of Health and Welfare, Taiwan (105003).	APPELBAUM E, 1962, AM J MED, V32, P25, DOI 10.1016/0002-9343(62)90179-1; Bangen KJ, 2010, CLIN NEUROPSYCHOL, V24, P1193, DOI 10.1080/13854041003736778; Bharmal MF, 2007, ALZ DIS ASSOC DIS, V21, P92, DOI 10.1097/WAD.0b013e31805c0835; Chang L., 2004, STUDY VALIDATION COM; Chen MH, 2014, PSYCHOSOM MED, V76, P285, DOI 10.1097/PSY.0000000000000051; Cheng CL, 2014, J EPIDEMIOL, V24, P500, DOI 10.2188/jea.JE20140076; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Cheng-Ching E, 2015, J NEUROL SCI, V351, P168, DOI 10.1016/j.jns.2015.02.017; Dregan A, 2015, J ALZHEIMERS DIS, V46, P1039, DOI 10.3233/JAD-150171; Dworkin RH, 2007, CLIN INFECT DIS, V44, pS1, DOI 10.1086/510206; Engelhart MJ, 2004, ARCH NEUROL-CHICAGO, V61, P668, DOI 10.1001/archneur.61.5.668; GILDEN DH, 1994, NEUROLOGY, V44, P1818, DOI 10.1212/WNL.44.10.1818; Grahn A, 2013, J NEUROL, V260, P2761, DOI 10.1007/s00415-013-7057-1; Gray B., 2014, cmprsk: Subdistribution Analysis of Competing Risks; Haanpaa M, 1998, NEUROLOGY, V51, P1405, DOI 10.1212/WNL.51.5.1405; Heaton RK, 2010, NEUROLOGY, V75, P2087, DOI 10.1212/WNL.0b013e318200d727; Hokkanen L, 1997, J NEUROL, V244, P239, DOI 10.1007/s004150050078; Institutes NHR, 2013, INTR NAT HLTH INS RE; Jackson JL, 1997, ARCH INTERN MED, V157, P909, DOI 10.1001/archinte.157.8.909; Kaplan CP, 1999, BRAIN INJURY, V13, P935; Koyama A, 2013, J GERONTOL A-BIOL, V68, P433, DOI 10.1093/gerona/gls187; Langan SM, 2014, CLIN INFECT DIS, V58, P1497, DOI 10.1093/cid/ciu098; Li QF, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006866.pub2; Liu YC, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-503; Mayeux R, 2003, ANNU REV NEUROSCI, V26, P81, DOI 10.1146/annurev.neuro.26.043002.094919; Nagel MA, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-015-0614-5; O'Brien JT, 2003, LANCET NEUROL, V2, P89, DOI 10.1016/S1474-4422(03)00305-3; Persson A, 2009, J CLIN VIROL, V46, P249, DOI 10.1016/j.jcv.2009.07.014; Piacentini R, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00097; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; PUCHHAMMERSTOCKL E, 1991, J CLIN MICROBIOL, V29, P1513; SCHADLICH HJ, 1991, J NEUROL SCI, V103, P101, DOI 10.1016/0022-510X(91)90291-E; Silver B, 2012, J NEUROL SCI, V323, P245, DOI 10.1016/j.jns.2012.07.059; Staff NP, 2009, ARCH NEUROL-CHICAGO, V66, P1139, DOI 10.1001/archneurol.2009.190; STRAUS SE, 1988, ANN INTERN MED, V108, P221, DOI 10.7326/0003-4819-108-2-221; Tan ZS, 2007, NEUROLOGY, V68, P1902, DOI 10.1212/01.wnl.0000263217.36439.da; Tousseyn T, 2015, J NEUROPATH EXP NEUR, V74, P873, DOI 10.1097/NEN.0000000000000228; Wallin K, 2012, J ALZHEIMERS DIS, V31, P669, DOI 10.3233/JAD-2012-111736; Wang JP, 2005, J VIROL, V79, P12658, DOI 10.1128/JVI.79.20.12658-12666.2005; Wetzel K, 2002, J NEUROL, V249, P1612, DOI 10.1007/s00415-002-0874-2; World Alzheimer Report, 2015, GLOB IMP DEM AN PREV; Wu KY, 2013, BIPOLAR DISORD, V15, P787, DOI 10.1111/bdi.12116; Zhang JX, 2013, J INFECT DIS, V207, P1007, DOI 10.1093/infdis/jis937	43	33	33	0	8	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry	JAN-FEB	2018	79	1							16m11312	10.4088/JCP.16m11312			7	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	GK7MM	WOS:000436389500003	29244265				2021-06-18	
J	Wang, HJ; Song, GB; Chuang, HY; Chiu, CD; Abdelmaksoud, A; Ye, YF; Zhao, L				Wang, Haijun; Song, Guobin; Chuang, Haoyu; Chiu, Chengdi; Abdelmaksoud, Ahmed; Ye, Youfan; Zhao, Lei			Portrait of glial scar in neurological diseases	INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY			English	Article						fibrosis; glial scar; inflammation; neurological diseases	ASTROCYTES; PROTEINS; MATRIX; CELLS	Fibrosis is formed after injury in most of the organs as a common and complex response that profoundly affects regeneration of damaged tissue. In central nervous system (CNS), glial scar grows as a major physical and chemical barrier against regeneration of neurons as it forms dense isolation and creates an inhibitory environment, resulting in limitation of optimal neural function and permanent deficits of human body. In neurological damages, glial scar is mainly attributed to the activation of resident astrocytes which surrounds the lesion core and walls off intact neurons. Glial cells induce the infiltration of immune cells, resulting in transient increase in extracellular matrix deposition and inflammatory factors which inhibit axonal regeneration, impede functional recovery, and may contribute to the occurrence of neurological complications. However, recent studies have underscored the importance of glial scar in neural protection and functional improvement depending on the specific insults which involves various pivotal molecules and signaling. Thus, to uncover the veil of scar formation in CNS may provide rewarding therapeutic targets to CNS diseases such as chronic neuroinflammation, brain stroke, spinal cord injury (SCI), traumatic brain injury (TBI), brain tumor, and epileptogenesis. In this article, we try to describe the new portrait of glial scar and trending of research in neurological diseases to readers.	[Wang, Haijun; Song, Guobin; Abdelmaksoud, Ahmed] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Neurosurg, Wuhan, Hubei, Peoples R China; [Chuang, Haoyu] China Med Univ, Tainan Municipal An Nan Hosp, Dept Neurosurg, Tainan, Taiwan; [Chuang, Haoyu] China Med Univ, Beigang Hosp, Dept Neurosurg, Beigang, Taiwan; [Chuang, Haoyu; Chiu, Chengdi] China Med Univ, Sch Med, Taichung, Taiwan; [Chiu, Chengdi] China Med Univ Hosp, Dept Neurosurg, Taichung, Taiwan; [Ye, Youfan] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Ophthalmol, Wuhan 430022, Hubei, Peoples R China; [Zhao, Lei] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Infect Dis, Wuhan 430022, Hubei, Peoples R China	Ye, YF (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Ophthalmol, Wuhan 430022, Hubei, Peoples R China.; Zhao, L (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Infect Dis, Wuhan 430022, Hubei, Peoples R China.	yeyoufan@sina.com; leizhao@hust.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371840, 81600373, 81201026]; Hubei Province Health and Family Planning Scientific Research Project [WJ2017Q021, WJ2017Z015]; Hubei Provincial Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [2017CFB471, 2016CFB643]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2017KFYXJJ238]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant from the National Natural Science Foundation of China (81371840, 81600373, and 81201026), Hubei Province Health and Family Planning Scientific Research Project (WJ2017Q021 and WJ2017Z015), Hubei Provincial Natural Science Foundation of China (2017CFB471 and 2016CFB643), and the Fundamental Research Funds for the Central Universities (2017KFYXJJ238).	Bardehle S, 2013, NAT NEUROSCI, V16, P580, DOI 10.1038/nn.3371; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Duan CL, 2015, GLIA, V63, P1660, DOI 10.1002/glia.22837; Faiz M, 2015, CELL STEM CELL, V17, P624, DOI 10.1016/j.stem.2015.08.002; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Koulakoff A, 2008, GLIA, V56, P1299, DOI 10.1002/glia.20698; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Schattin A, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00161; Susarla BTS, 2011, J NEUROCHEM, V119, P868, DOI 10.1111/j.1471-4159.2011.07470.x; Yang G, 2009, NATURE, V462, P920, DOI 10.1038/nature08577; Zhang JM, 2017, J CELL SCI, V130, P2447, DOI 10.1242/jcs.196154	15	33	34	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2058-7384			INT J IMMUNOPATH PH	Int. J. Immunopathol. Pharmacol.	JAN-FEB	2018	31									10.1177/2058738418801406			6	Immunology; Pathology; Pharmacology & Pharmacy	Immunology; Pathology; Pharmacology & Pharmacy	HL5GD	WOS:000458753700001	30309271	DOAJ Gold, Green Published			2021-06-18	
J	Vergouwe, Y; Nieboer, D; Oostenbrink, R; Debray, TPA; Murray, GD; Kattan, MW; Koffijberg, H; Moons, KGM; Steyerberg, EW				Vergouwe, Yvonne; Nieboer, Daan; Oostenbrink, Rianne; Debray, Thomas P. A.; Murray, Gordon D.; Kattan, Michael W.; Koffijberg, Hendrik; Moons, Karel G. M.; Steyerberg, Ewout W.			A closed testing procedure to select an appropriate method for updating prediction models	STATISTICS IN MEDICINE			English	Article						model updating; logistic regression; prediction model; closed testing procedure	INDIVIDUAL PARTICIPANT DATA; VALIDATION; FRAMEWORK	Prediction models fitted with logistic regression often show poor performance when applied in populations other than the development population. Model updating may improve predictions. Previously suggested methods vary in their extensiveness of updating the model. We aim to define a strategy in selecting an appropriate update method that considers the balance between the amount of evidence for updating in the new patient sample and the danger of overfitting. We consider recalibration in the large (re-estimation of model intercept); recalibration (re-estimation of intercept and slope) and model revision (re-estimation of all coefficients) as update methods. We propose a closed testing procedure that allows the extensiveness of the updating to increase progressively from a minimum (the original model) to a maximum (a completely revised model). The procedure involves multiple testing with maintaining approximately the chosen type I error rate. We illustrate this approach with three clinical examples: patients with prostate cancer, traumatic brain injury and children presenting with fever. The need for updating the prostate cancer model was completely driven by a different model intercept in the update sample (adjustment: 2.58). Separate testing of model revision against the original model showed statistically significant results, but led to overfitting (calibration slope at internal validation=0.86). The closed testing procedure selected recalibration in the large as update method, without overfitting. The advantage of the closed testing procedure was confirmed by the other two examples. We conclude that the proposed closed testing procedure may be useful in selecting appropriate update methods for previously developed prediction models. Copyright (c) 2016 John Wiley & Sons, Ltd.	[Vergouwe, Yvonne; Nieboer, Daan; Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands; [Oostenbrink, Rianne] Erasmus MC Sophia Childrens Hosp, Dept Gen Paediat, Rotterdam, Netherlands; [Debray, Thomas P. A.; Koffijberg, Hendrik; Moons, Karel G. M.] UMC Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Murray, Gordon D.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Kattan, Michael W.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA	Vergouwe, Y (corresponding author), Erasmus MC, Dept Publ Hlth, NA 2322, NL-3000 CA Rotterdam, Netherlands.	y.vergouwe@erasmusmc.nl	Steyerberg, Ewout W/C-1509-2018; Debray, Thomas/J-7413-2012; Kattan, Michael/AAF-9735-2021	Steyerberg, Ewout W/0000-0002-7787-0122; Debray, Thomas/0000-0002-1790-2719; Kattan, Michael/0000-0002-3840-4161; Koffijberg, Hendrik/0000-0002-1753-0652	Netherlands Organization for Scientific ResearchNetherlands Organization for Scientific Research (NWO) [ZonMw 1709.925.039, 9120.8004]	The Netherlands Organization for Scientific Research (ZonMw 1709.925.039 and 9120.8004)	Abo-Zaid G, 2013, J CLIN EPIDEMIOL, V66, P865, DOI 10.1016/j.jclinepi.2012.12.017; Ambler G, 2001, J STAT COMPUT SIM, V69, P89, DOI 10.1080/00949650108812083; COX DR, 1958, BIOMETRIKA, V45, P562, DOI 10.1093/biomet/45.3-4.562; Debray TPA, 2015, J CLIN EPIDEMIOL, V68, P280, DOI 10.1016/j.jclinepi.2014.06.018; Debray TPA, 2013, STAT MED, V32, P3158, DOI 10.1002/sim.5732; Debray TPA, 2012, STAT MED, V31, P2697, DOI 10.1002/sim.5412; Goeman JJ, 2014, STAT MED, V33, P1946, DOI 10.1002/sim.6082; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543; Harrell Frank E., 2001, REGRESSION MODELING; HOLM S, 1979, SCAND J STAT, V6, P65; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Kattan MW, 2003, J UROLOGY, V170, P1792, DOI 10.1097/01.ju.0000091806.70171.41; MARCUS R, 1976, BIOMETRIKA, V63, P655, DOI 10.1093/biomet/63.3.655; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MILLER ME, 1993, MED DECIS MAKING, V13, P49, DOI 10.1177/0272989X9301300107; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Oostenbrink R, 2001, ACTA PAEDIATR, V90, P611, DOI 10.1080/080352501750258649; Roobol MJ, 2003, BJU INT, V92, P48, DOI 10.1111/j.1464-410X.2003.04390.x; STEIN CM, 1981, ANN STAT, V9, P1135, DOI 10.1214/aos/1176345632; Steyerberg EW, 2004, STAT MED, V23, P2567, DOI 10.1002/sim.1844; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; van Houwelingen HC, 2000, STAT MED, V19, P3401, DOI 10.1002/1097-0258(20001230)19:24<3401::AID-SIM554>3.0.CO;2-2; VANSHOUWELINGEN. H, 1995, STATISTICS IN MEDICI, V14, P1999; Vickers AJ, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-13; Zou H, 2007, ANN STAT, V35, P2173, DOI 10.1214/009053607000000127	28	33	33	3	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0277-6715	1097-0258		STAT MED	Stat. Med.	DEC 10	2017	36	28					4529	4539		10.1002/sim.7179			11	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability	Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics	FN3BA	WOS:000415869400016	27891652				2021-06-18	
J	Madden, LK; Hill, M; May, TL; Human, T; Guanci, MM; Jacobi, J; Moreda, MV; Badjatia, N				Madden, Lori Kennedy; Hill, Michelle; May, Teresa L.; Human, Theresa; Guanci, Mary McKenna; Jacobi, Judith; Moreda, Melissa V.; Badjatia, Neeraj			The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society	NEUROCRITICAL CARE			English	Article						Targeted temperature management; Hypothermia; Normothermia; Controlled normothermia; Fever treatment; Therapeutic hypothermia; Guideline; GRADE methodology; Implementation guideline; Shivering; Metabolism; Patient management; Systematic review; Complications	HOSPITAL CARDIAC-ARREST; MILD THERAPEUTIC HYPOTHERMIA; TRAUMATIC BRAIN-INJURY; WHOLE-BODY HYPOTHERMIA; HYPOXIC-ISCHEMIC ENCEPHALOPATHY; SHIVERING THRESHOLD; INTENSIVE-CARE; COMATOSE SURVIVORS; CARDIOPULMONARY-RESUSCITATION; MODERATE HYPOTHERMIA	Targeted temperature management (TTM) is often used in neurocritical care to minimize secondary neurologic injury and improve outcomes. TTM encompasses therapeutic hypothermia, controlled normothermia, and treatment of fever. TTM is best supported by evidence from neonatal hypoxic-ischemic encephalopathy and out-of-hospital cardiac arrest, although it has also been explored in ischemic stroke, traumatic brain injury, and intracranial hemorrhage patients. Critical care clinicians using TTM must select appropriate cooling techniques, provide a reasonable rate of cooling, manage shivering, and ensure adequate patient monitoring among other challenges. The Neurocritical Care Society recruited experts in neurocritical care, nursing, and pharmacotherapy to form a writing Committee in 2015. The group generated a set of 16 clinical questions relevant to TTM using the PICO format. With the assistance of a research librarian, the Committee undertook a comprehensive literature search with no back date through November 2016 with additional references up to March 2017. The Committee utilized GRADE methodology to adjudicate the quality of evidence as high, moderate, low, or very low based on their confidence that the estimate of effect approximated the true effect. They generated recommendations regarding the implementation of TTM based on this systematic review only after considering the quality of evidence, relative risks and benefits, patient values and preferences, and resource allocation. This guideline is intended for neurocritical care clinicians who have chosen to use TTM in patient care; it is not meant to provide guidance regarding the clinical indications for TTM itself. While there are areas of TTM practice where clear evidence guides strong recommendations, many of the recommendations are conditional, and must be contextualized to individual patient and system needs.	[Madden, Lori Kennedy] Univ Calif Davis, Sacramento, CA 95817 USA; [Hill, Michelle] Riverside Methodist Hosp, Columbus, OH 43214 USA; [May, Teresa L.] Maine Med Ctr, Portland, ME 04102 USA; [Human, Theresa] Washington Univ, Barnes Jewish Hosp, St Louis, MO USA; [Guanci, Mary McKenna] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Jacobi, Judith] Indiana Univ, Hlth Methodist Hosp, Indianapolis, IN 46204 USA; [Moreda, Melissa V.] Duke Raleigh Hosp, Raleigh, NC USA; [Badjatia, Neeraj] Univ Maryland, Baltimore, MD 21201 USA	Madden, LK (corresponding author), Univ Calif Davis, Sacramento, CA 95817 USA.	lkmadden@ucdavis.edu	Madden, Lori K/K-3749-2012; Jacobi, Judith/ABE-2757-2020	Madden, Lori K/0000-0001-9179-4202; Jacobi, Judith/0000-0003-2421-0734			Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Akula VP, 2015, J PEDIATR-US, V166, P856, DOI 10.1016/j.jpeds.2014.12.061; Alfonsi P, 2014, ANESTH ANALG, V119, P58, DOI 10.1213/ANE.0000000000000193; Alfonsi P, 2009, ANESTHESIOLOGY, V111, P102, DOI 10.1097/ALN.0b013e3181a979c1; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; Andrews PJD, 2015, NEW ENGL J MED, V373, P2403, DOI 10.1056/NEJMoa1507581; Argibay-Lago A, 2014, ENFERM CLIN, V24, P323, DOI 10.1016/j.enfcli.2014.07.004; Arulkumaran N, 2012, RESUSCITATION, V83, P151, DOI 10.1016/j.resuscitation.2011.10.002; Avery KR, 2015, CRIT CARE NURSE, V35, P29, DOI 10.4037/ccn2015937; Badjatia N, 2006, NEUROLOGY, V66, P1739, DOI 10.1212/01.wnl.0000218166.54150.0a; Badjatia N, 2007, NEUROCRIT CARE, V6, P186, DOI 10.1007/s12028-007-0011-2; Badjatia N, 2010, NEUROSURGERY, V66, P696, DOI 10.1227/01.NEU.0000367618.42794.AA; Badjatia N, 2009, CRIT CARE MED, V37, P1893, DOI 10.1097/CCM.0b013e31819fffd3; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bagna FC, 2013, OPEN CRIT CARE MED J, V6, P31; Bardutzky J, 2004, INTENS CARE MED, V30, P151, DOI 10.1007/s00134-003-1988-4; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; BEAUFORT AM, 1995, EUR J ANAESTH, V12, P95; Beca J, 2015, CRIT CARE MED, V43, P1458, DOI 10.1097/CCM.0000000000000947; Bednar F, 2016, J THROMB THROMBOLYS, V41, P549, DOI 10.1007/s11239-015-1274-7; Bernard S, 2003, RESUSCITATION, V56, P9, DOI 10.1016/S0300-9572(02)00276-9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bernard SA, 2016, CIRCULATION, V134, P797, DOI 10.1161/CIRCULATIONAHA.116.021989; Bjelland TW, 2014, ACTA ANAESTH SCAND, V58, P709, DOI 10.1111/aas.12300; Bjelland TW, 2013, DRUG METAB DISPOS, V41, P214, DOI 10.1124/dmd.112.045567; Boulant JA, 2006, J APPL PHYSIOL, V100, P1347, DOI 10.1152/japplphysiol.01064.2005; Bourdages M, 2010, PEDIATR CRIT CARE ME, V11, P408, DOI 10.1097/PCC.0b013e3181c51dea; Broessner G, 2009, STROKE, V40, pE657, DOI 10.1161/STROKEAHA.109.557652; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Callaway CW, 2015, CIRCULATION, V132, pS465, DOI 10.1161/CIR.0000000000000262; Callaway CW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129709; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Castren M, 2010, CIRCULATION, V122, P729, DOI 10.1161/CIRCULATIONAHA.109.931691; Chih-Hung W, 2015, MEDICINE, V94, P1; Chmayssani M, 2015, NEUROCRIT CARE, V22, P265, DOI 10.1007/s12028-014-0076-7; Choi HA, 2011, NEUROCRIT CARE, V14, P389, DOI 10.1007/s12028-010-9474-7; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839; Cueni-Villoz N, 2011, CRIT CARE MED, V39, P2225, DOI 10.1097/CCM.0b013e31822572c9; Cumming TB, 2011, STROKE, V42, P153, DOI 10.1161/STROKEAHA.110.594598; Curtis J, 2014, CRIT CARE MED, V42, pA1421; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; de Waard MC, 2015, EMERG MED J, V32, P775, DOI 10.1136/emermed-2014-203811; De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036; DELAUNAY L, 1993, ANESTHESIOLOGY, V79, P470, DOI 10.1097/00000542-199309000-00009; deWitte J, 1997, ACTA ANAESTH SCAND, V41, P506, DOI 10.1111/j.1399-6576.1997.tb04732.x; Deye N, 2015, CIRCULATION, V132, P182, DOI 10.1161/CIRCULATIONAHA.114.012805; Diringer MN, 2011, NEUROCRIT CARE, V15, P211, DOI 10.1007/s12028-011-9605-9; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; Dobak S, 2016, NEUROLOGY, P86; Donnino MW, 2015, CIRCULATION, V132, P2448, DOI 10.1161/CIR.0000000000000313; Doufas AG, 2003, STROKE, V34, P1218, DOI 10.1161/01.STR.0000068787.76670.A4; Earp J K, 1992, Am J Crit Care, V1, P43; Eastwood GM, 2015, J CRIT CARE, V30, P138, DOI 10.1016/j.jcrc.2014.09.022; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Empey PE, 2013, CRIT CARE MED, V41, P2379, DOI 10.1097/CCM.0b013e318292316c; Ettleson MD, 2014, J CLIN ENDOCR METAB, V99, pE2010, DOI 10.1210/jc.2014-1449; Fevold RT, 2015, J CRIT CARE, V30, P574, DOI 10.1016/j.jcrc.2015.01.016; Fink EL, 2012, PEDIATR CRIT CARE ME, V13, P80, DOI 10.1097/PCC.0b013e3181fe27c7; Flint AC, 2007, NEUROCRIT CARE, V7, P109, DOI 10.1007/s12028-007-0068-y; Fox M, 2012, CRIT CARE MED, V40, P235; Frank SM, 1997, AM J PHYSIOL-REG I, V272, pR557; Fries M, 2009, J CRIT CARE, V24, P453, DOI 10.1016/j.jcrc.2008.10.012; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Gajarski RJ, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1199-9; Geocadin RG, 2017, NEUROLOGY, V88, P2141, DOI 10.1212/WNL.0000000000003966; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Greif R, 2001, ANESTH ANALG, V93, P620, DOI 10.1097/00000539-200109000-00018; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Hammer L, 2009, AM J EMERG MED, V27, P570, DOI 10.1016/j.ajem.2008.04.028; Hashiguchi N, 2003, J TRAUMA, V55, P1054, DOI 10.1097/01.TA.0000033252.43742.8B; Hasper D, 2011, EMERG MED J, V28, P483, DOI 10.1136/emj.2009.090464; Hata JS, 2008, NEUROCRIT CARE, V9, P37, DOI 10.1007/s12028-007-9015-1; Haugk M, 2010, CRIT CARE MED, V38, P1569, DOI 10.1097/CCM.0b013e3181e47a20; Heard KJ, 2010, RESUSCITATION, V81, P9, DOI 10.1016/j.resuscitation.2009.09.015; Heier T, 2002, ANESTHESIOLOGY, V97, P90, DOI 10.1097/00000542-200207000-00013; Hemmen TM, 2010, STROKE, V41, P2265, DOI 10.1161/STROKEAHA.110.592295; Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069; Hodgson CL, 2013, CRIT CARE, V17, DOI 10.1186/cc11820; Hoedemaekers CW, 2007, CRIT CARE, V11, DOI 10.1186/cc6104; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzinger U, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0856-2; Hoque N, 2010, PEDIATRICS, V126, pE124, DOI 10.1542/peds.2009-2995; Hostler D, 2009, APPL PHYSIOL NUTR ME, V34, P582, DOI 10.1139/H09-011; Iaizzo PA, 1999, J NEUROSURG ANESTH, V11, P231, DOI 10.1097/00008506-199910000-00002; Iida Y, 2001, THER DRUG MONIT, V23, P192, DOI 10.1097/00007691-200106000-00002; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; Jacob M, 2015, RESUSCITATION, V96, P260, DOI 10.1016/j.resuscitation.2015.08.018; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Jacobshagen C, 2009, RESUSCITATION, V80, P1223, DOI 10.1016/j.resuscitation.2009.06.032; Jalan R, 1999, LANCET, V354, P1164, DOI 10.1016/S0140-6736(98)12440-6; Jarrah S, 2011, NEUROCRIT CARE, V14, P382, DOI 10.1007/s12028-011-9506-y; Jauch EC, 2013, STROKE, V44, P870, DOI 10.1161/STR.0b013e318284056a; Jeppesen AN, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1302-9; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Joffre J, 2014, RESUSCITATION, V85, P769, DOI 10.1016/j.resuscitation.2014.02.013; Jurado LV, 2011, PHARMACOTHERAPY, V31, P1250, DOI 10.1592/phco.31.12.1250; Kaufmann J, 2016, RESUSCITATION, V102, P63, DOI 10.1016/j.resuscitation.2016.02.012; Keegan SP, 2011, NEUROCRIT CARE, V15, pS219; Kimberger O, 2007, CRIT CARE, V11, DOI 10.1186/cc5709; Knapik P, 2012, RESUSCITATION, V83, P208, DOI 10.1016/j.resuscitation.2011.09.001; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOHT A, 1983, INTENS CARE MED, V9, P275, DOI 10.1007/BF01691254; Komatsu R, 2006, BRIT J ANAESTH, V96, P732, DOI 10.1093/bja/ael101; Krawczyk P, 2013, KARDIOL POL, V71, P270, DOI 10.5603/KP.2013.0040; Krizanac D, 2013, RESUSCITATION, V84, P805, DOI 10.1016/j.resuscitation.2012.11.022; Kurz A, 1997, ANESTHESIOLOGY, V86, P1046, DOI 10.1097/00000542-199705000-00007; Laish-Farkash A, 2007, ISR MED ASSOC J, V9, P252; Laptook AR, 2014, THER HYPOTHERMIA TEM, V4, P193, DOI 10.1089/ther.2014.0009; Lascarrou JB, 2014, RESUSCITATION, V85, P1257, DOI 10.1016/j.resuscitation.2014.05.017; Le Roux P, 2014, NEUROCRIT CARE, V21, P1, DOI 10.1007/s12028-014-0041-5; Leary M, 2014, RESUSCITATION, V85, P244, DOI 10.1016/j.resuscitation.2013.10.027; Lenhardt R, 2009, ANESTHESIOLOGY, V111, P110, DOI 10.1097/ALN.0b013e3181a979a3; LESLIE K, 1995, ANESTH ANALG, V80, P1007, DOI 10.1097/00000539-199505000-00027; Logan A, 2011, CRIT CARE NURSE, V31, pE18, DOI 10.4037/ccn2011618; Lord AS, 2014, NEUROCRIT CARE, V21, P200, DOI 10.1007/s12028-013-9948-5; Lyden P, 2016, STROKE, V47, P2888, DOI 10.1161/STROKEAHA.116.014200; MacLellan CL, 2009, J NEUROTRAUM, V26, P313, DOI 10.1089/neu.2008.0580; Maekawa T, 2015, J NEUROTRAUM, V32, P422, DOI 10.1089/neu.2013.3197; Mahmood MA, 2007, J NEUROL SCI, V261, P47, DOI 10.1016/j.jns.2007.04.038; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markota A, 2015, J EMERG MED, V49, P98, DOI 10.1016/j.jemermed.2014.12.059; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P1169, DOI 10.1097/00000542-199505000-00012; May T, 2011, NEUROCRIT CARE, V15, pS212; May T, 2011, RESUSCITATION, V82, P1100, DOI 10.1016/j.resuscitation.2011.03.037; Mayer KA, 2014, ACAD EMERG MED, V21, pS98; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Merchant RM, 2009, CIRC-CARDIOVASC QUAL, V2, P421, DOI 10.1161/CIRCOUTCOMES.108.839605; Milne SE, 2002, J CARDIOTHOR VASC AN, V16, P32, DOI 10.1053/jcan.2002.29657; Mirzoyev SA, 2010, RESUSCITATION, V81, P1632, DOI 10.1016/j.resuscitation.2010.08.007; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Moler FW, 2017, NEW ENGL J MED, V376, P318, DOI 10.1056/NEJMoa1610493; Mort TC, 1996, J CLIN ANESTH, V8, P361, DOI 10.1016/0952-8180(96)00081-5; Mtaweh H, 2014, PEDIATR CRIT CARE ME, V15, P242, DOI 10.1097/PCC.0000000000000041; Nakajima Y, 2002, ANESTH ANALG, V94, P1646, DOI 10.1097/00000539-200206000-00053; Nakamura T, 1998, ACT NEUR S, V71, P85; Nakamura T, 2008, ACTA NEUROCHIR SUPPL, V102, P203, DOI 10.1007/978-3-211-85578-2_40; Nicolaou G, 1997, CAN J ANAESTH, V44, P636, DOI 10.1007/BF03015448; Nielsen N, 2011, CIRCULATION, V124; Nihara Y, 2013, EUR J ANESTH S, V30, P189; O'Grady NP, 2008, CRIT CARE MED, V36, P1330, DOI 10.1097/CCM.0b013e318169eda9; Oddo M, 2010, NEUROCRIT CARE, V12, P10, DOI 10.1007/s12028-009-9280-2; Olson DM, 2013, AM J CRIT CARE, V22, P70, DOI 10.4037/ajcc2013907; Olson DaiWai M, 2008, Nurs Crit Care, V13, P305, DOI 10.1111/j.1478-5153.2008.00298.x; Oshima T, 2015, RESUSCITATION, V88, P81, DOI 10.1016/j.resuscitation.2014.12.025; Osuka A, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2012.05.012; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Park B, 2015, CRIT CARE MED, V43, P1757, DOI 10.1097/CCM.0000000000001014; Park SM, 2012, CRIT CARE MED, V40, P3070, DOI 10.1097/CCM.0b013e31825b931e; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Perrone S, 2010, PEDIATR NEUROL, V43, P236, DOI 10.1016/j.pediatrneurol.2010.05.009; Piironen K, 2014, STROKE, V45, P486, DOI 10.1161/STROKEAHA.113.003180; Pittl U, 2013, CLIN RES CARDIOL, V102, P607, DOI 10.1007/s00392-013-0572-3; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; POLI S, 2014, CRIT CARE, V0018; Presciutti M, 2012, CRIT CARE NURSE, V32, P33, DOI 10.4037/ccn2012189; Puccio AM, 2009, NEUROCRIT CARE, V11, P82, DOI 10.1007/s12028-009-9213-0; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Rana M, 2011, INT J CARDIOL, V152, P321, DOI 10.1016/j.ijcard.2010.07.026; Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6; Riker RR, 2015, BEST PRACT RES-CLIN, V29, P435, DOI 10.1016/j.bpa.2015.09.006; Salciccioli JD, 2013, RESUSCITATION, V84, P1728, DOI 10.1016/j.resuscitation.2013.06.008; Sanuth B, 2015, CRIT CARE MED, V43, P54; Seder DB, 2009, CRIT CARE MED, V37, pS211, DOI 10.1097/CCM.0b013e3181aa5bad; Sessler DI, 2009, CRIT CARE MED, V37, pS203, DOI 10.1097/CCM.0b013e3181aa5568; Seule M, 2012, CRIT CARE, V16, pA16, DOI DOI 10.1186/CC11274; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2014, JAMA-J AM MED ASSOC, V312, P2629, DOI 10.1001/jama.2014.16058; Shinozaki K, 2012, AM J EMERG MED, V30, P1838, DOI 10.1016/j.ajem.2012.03.024; SLADEN RN, 1995, J CARDIOTHOR VASC AN, V9, P147, DOI 10.1016/S1053-0770(05)80185-5; Snider J, 2012, CRIT CARE MED, V40, pU159; Souckova L, 2013, EUR J CLIN PHARMACOL, V69, P309, DOI 10.1007/s00228-012-1360-0; Staykov D, 2013, NEUROCRIT CARE, V18, P178, DOI 10.1007/s12028-012-9762-5; Steblovnik K, 2016, CIRCULATION, V134, P2128, DOI 10.1161/CIRCULATIONAHA.116.024872; Stelfox HT, 2010, BMC ANESTHESIOL, V10, DOI 10.1186/1471-2253-10-13; Stiller K, 2013, CHEST, V144, P825, DOI 10.1378/chest.12-2930; Stockmann H, 2014, RESUSCITATION, V85, P1494, DOI 10.1016/j.resuscitation.2014.07.018; Sund-Levander M, 2000, J CLIN NURS, V9, P55, DOI 10.1046/j.1365-2702.2000.00352.x; Sunjic KM, 2015, CRIT CARE MED, V43, P2228, DOI 10.1097/CCM.0000000000001223; Sweney MT, 2001, ANESTHESIOLOGY, V95, P1089, DOI 10.1097/00000542-200111000-00011; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017; Tanaka H, 2014, CRIT CARE, V18, pS181; Taniguchi Y, 2011, ANESTH ANALG, V113, P540, DOI 10.1213/ANE.0b013e3182273b19; Taniguchi Y, 2010, ANESTH ANALG, V111, P409, DOI 10.1213/ANE.0b013e3181e332bb; Taylor BE, 2016, CRIT CARE MED, V44, P390, DOI 10.1097/CCM.0000000000001525; Tiainen M, 2009, CRIT CARE MED, V37, P403, DOI 10.1097/CCM.0b013e31819572c4; Tilemann LM, 2016, CLIN RES CARDIOL, V105, P332, DOI 10.1007/s00392-015-0925-1; Todd MM, 2005, NEW ENGL J MED, V352, P135, DOI 10.1056/NEJMoa040975; Tokutomi T, 2004, NEUROCRIT CARE, V1, P171, DOI 10.1385/NCC:1:2:171; Toma A, 2010, CRIT CARE MED, V38, P504, DOI 10.1097/CCM.0b013e3181cb0a02; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Trauma Quality Improvement Program (TQIP), 2015, BEST PRACT MAN TRAUM; Vaga A, 2008, RESUSCITATION, V76, P25, DOI 10.1016/j.resuscitation.2007.07.008; Varon J, 2008, RESUSCITATION, V78, P248, DOI 10.1016/j.resuscitation.2008.03.223; Wadhwa A, 2005, BRIT J ANAESTH, V94, P756, DOI 10.1093/bja/aei105; Wahby KA, 2014, RESUSCITATION, V85, P533, DOI 10.1016/j.resuscitation.2013.12.014; Williams ML, 2014, RESUSCITATION, V85, P1469, DOI 10.1016/j.resuscitation.2014.08.018; Wu TC, 2013, LANCET NEUROL, V12, P275, DOI 10.1016/S1474-4422(13)70013-9; Zeiner A, 2004, RESUSCITATION, V60, P253, DOI 10.1016/j.resuscitation.2003.11.006; Zeiner A, 2010, RESUSCITATION, V81, P861, DOI 10.1016/j.resuscitation.2010.03.018; Zhao QJ, 2011, J CRIT CARE, V26, P311, DOI 10.1016/j.jcrc.2010.08.014; Zweifler RM, 2004, STROKE, V35, P2331, DOI 10.1161/01.STR.0000141161.63181.f1	205	33	40	2	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2017	27	3					468	487		10.1007/s12028-017-0469-5			20	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	FN7DT	WOS:000416179300020	29038971				2021-06-18	
J	Nikolian, VC; Georgoff, PE; Pai, MP; Dennahy, IS; Chtraklin, K; Eidy, H; Ghandour, MH; Han, YY; Srinivasan, A; Li, YQ; Alam, HB				Nikolian, Vahagn C.; Georgoff, Patrick E.; Pai, Manjunath P.; Dennahy, Isabel S.; Chtraklin, Kiril; Eidy, Hassan; Ghandour, Mohamed H.; Han, Yanyan; Srinivasan, Ashok; Li, Yongqing; Alam, Hasan B.			Valproic acid decreases brain lesion size and improves neurologic recovery in swine subjected to traumatic brain injury, hemorrhagic shock, and polytrauma	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	47th Annual Meeting of the Western-Trauma-Association (WTA)	MAR 05-10, 2017	Snowbird, UT	Western Trauma Assoc		Valproic acid; traumatic brain injury; polytrauma; neurologic recovery; swine	HISTONE DEACETYLASE INHIBITION; TRANS-RETINOIC ACID; FRESH-FROZEN PLASMA; RODENT MODEL; PHARMACOLOGICAL RESUSCITATION; PROSURVIVAL PHENOTYPE; PORCINE MODEL; DIFFERENTIATION; ACETYLATION; HYPOTHERMIA	BACKGROUND We have previously shown that treatment with valproic acid (VPA) decreases brain lesion size in swine models of traumatic brain injury (TBI) and controlled hemorrhage. To translate this treatment into clinical practice, validation of drug efficacy and evaluation of pharmacologic properties in clinically realistic models of injury are necessary. In this study, we evaluate neurologic outcomes and perform pharmacokinetic analysis of a single dose of VPA in swine subjected to TBI, hemorrhagic shock, and visceral hemorrhage. METHODS Yorkshire swine (n = 5/cohort) were subjected to TBI, hemorrhagic shock, and polytrauma (liver and spleen injury, rib fracture, and rectus abdominis crush). Animals remained in hypovolemic shock for 2 hours before resuscitation with isotonic sodium chloride solution (ISCS; volume = 3x hemorrhage) or ISCS + VPA (150 mg/kg). Neurologic severity scores were assessed daily for 30 days, and brain lesion size was measured via magnetic resonance imaging on postinjury days (PID) 3 and 10. Serum samples were collected for pharmacokinetic analysis. RESULTS Shock severity and response to resuscitation were similar in both groups. Valproic acid-treated animals demonstrated significantly less neurologic impairment between PID 1 to 5 and smaller brain lesions on PID 3 (mean lesion size SEM, mm(3): ISCS = 4,956 1,511 versus ISCS + VPA = 828 +/- 279; p = 0.047). No significant difference in lesion size was identified between groups at PID 10 and all animals recovered to baseline neurologic function during the 30-day observation period. Animals treated with VPA had faster neurocognitive recovery (days to initiation of testing, mean +/- SD: ISCS = 6.2 +/- 1.6 vs ISCS + VPA = 3.6 +/- 1.5; p = 0.002; days to task mastery: ISCS = 7.0 +/- 1.0 vs ISCS + VPA = 4.8 +/- 0.5; p = 0.03). The mean +/- SD maximum VPA concentrations, area under the curve, and half-life were 145 +/- 38.2 mg/L, 616 +/- 150 hour<bold>mg</bold>/L, and 1.70 +/- 0.12 hours. CONCLUSIONS In swine subjected to TBI, hemorrhagic shock, and polytrauma, VPA treatment is safe, decreases brain lesion size, and reduces neurologic injury compared to resuscitation with ISCS alone. These benefits are achieved at clinically translatable serum concentrations of VPA. LEVEL OF EVIDENCE Therapeutic (preclinical study).	[Nikolian, Vahagn C.; Georgoff, Patrick E.; Dennahy, Isabel S.; Chtraklin, Kiril; Eidy, Hassan; Ghandour, Mohamed H.; Han, Yanyan; Alam, Hasan B.] Univ Michigan, Dept Surg, Ann Arbor, MI 48109 USA; [Pai, Manjunath P.] Univ Michigan, Coll Pharm, Dept Clin Pharm, 428 Church St, Ann Arbor, MI 48109 USA; [Han, Yanyan] Univ Michigan, Dept Pharmaceut Sci, Coll Pharm, Ann Arbor, MI 48109 USA; [Srinivasan, Ashok] Univ Michigan, Dept Radiol, Neuroradiol Sect, Ann Arbor, MI 48109 USA	Alam, HB (corresponding author), Univ Michigan Hosp, Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.; Alam, HB (corresponding author), Univ Michigan Hosp, Gen Surg, 2920 Taubman Ctr 5331,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	alamh@med.umich.edu		Dennahy, Isabel/0000-0002-4778-8910	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-09-1-0520]; Frederick A. Coller Surgical Society Research Fellowship Award	This work was supported by a grant from the US Army Medical Research and Materiel Command, Contract W81XWH-09-1-0520 (PI: Hasan B. Alam). In addition, components of this project were funded by grants award from the Frederick A. Coller Surgical Society Research Fellowship Award (Awardee: Vahagn C. Nikolian).	Alam HB, 2011, J TRAUMA, V70, P636, DOI 10.1097/TA.0b013e31820d0dcc; Alam HB, 2009, SURGERY, V146, P325, DOI 10.1016/j.surg.2009.04.007; Alam HB, 2002, SURGERY, V132, P278, DOI 10.1067/msy.2002.125787; Bambakidis T, 2016, J NEUROTRAUM, V33, P1514, DOI 10.1089/neu.2015.4163; Causey MW, 2013, J SURG RES, V184, P533, DOI 10.1016/j.jss.2013.03.087; Cimino G, 2006, CANCER RES, V66, P8903, DOI 10.1158/0008-5472.CAN-05-2726; Das C, 2005, IUBMB LIFE, V57, P137, DOI 10.1080/15216540500090629; de Vries HM, 2014, J TRAUMA ACUTE CARE, V77, P183, DOI 10.1097/TA.0000000000000252; Dekker SE, 2014, J TRAUMA ACUTE CARE, V77, P906, DOI 10.1097/TA.0000000000000345; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Findlay LJ, 2015, THER CLIN RISK MANAG, V11, P75, DOI 10.2147/TCRM.S57695; Fukudome EY, 2010, J SURG RES, V163, P118, DOI 10.1016/j.jss.2010.04.013; Georgoff PE, 2016, J AM COLL SURGEONS, V223, pS160, DOI 10.1016/j.jamcollsurg.2016.06.347; Georgoff PE, 2016, J TRAUMA ACUTE CARE, V81, P1020, DOI 10.1097/TA.0000000000001249; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Halaweish I, 2015, J TRAUMA ACUTE CARE, V79, P911, DOI 10.1097/TA.0000000000000789; Halaweish I, 2015, SHOCK, V44, P6, DOI 10.1097/SHK.0000000000000319; Halaweish I, 2015, J AM COLL SURGEONS, V220, P809, DOI 10.1016/j.jamcollsurg.2015.01.057; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hwabejire JO, 2014, J SURG RES, V186, P363, DOI 10.1016/j.jss.2013.09.016; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Imam AM, 2013, SURGERY, V154, P388, DOI 10.1016/j.surg.2013.05.008; Jepsen CH, 2014, J TRAUMA ACUTE CARE, V77, P292, DOI 10.1097/TA.0000000000000333; Jin G, 2014, SURGERY, V156, P221, DOI 10.1016/j.surg.2014.03.038; Jin G, 2011, SURGERY, V150, P429, DOI 10.1016/j.surg.2011.07.001; Kim K, 2012, RESUSCITATION, V83, P243, DOI 10.1016/j.resuscitation.2011.07.029; Kotwal RS, 2016, JAMA SURG, V151, P15, DOI 10.1001/jamasurg.2015.3104; Kuendgen A, 2006, CANCER-AM CANCER SOC, V106, P112, DOI 10.1002/cncr.21552; Lennartsson A, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0043-3; Li YQ, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/523481; Lin T, 2007, SURGERY, V141, P784, DOI 10.1016/j.surg.2007.01.014; Liu ZC, 2014, SHOCK, V41, P104, DOI 10.1097/SHK.0000000000000074; Loscher W, 1999, PROG NEUROBIOL, V58, P31, DOI 10.1016/S0301-0082(98)00075-6; Munster P, 2007, J CLIN ONCOL, V25, P1979, DOI 10.1200/JCO.2006.08.6165; Nanau RM, 2013, CLIN BIOCHEM, V46, P1323, DOI 10.1016/j.clinbiochem.2013.06.012; Pataskar A, 2016, EMBO J, V35, P24, DOI 10.15252/embj.201591206; Rasmussen Todd E, 2015, J Trauma Acute Care Surg, V79, pS61, DOI 10.1097/TA.0000000000000795; Rhee P, 2000, J TRAUMA, V48, P439, DOI 10.1097/00005373-200003000-00011; Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600; Wanczyk M, 2011, FRONT BIOSCI-LANDMRK, V16, P340, DOI 10.2741/3691	40	33	34	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	DEC	2017	83	6					1066	1073		10.1097/TA.0000000000001612			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	FO4RL	WOS:000416832700010	28697014				2021-06-18	
J	Wade, SL; Cassedy, AE; Shultz, EL; Zang, HY; Zhang, NH; Kirkwood, MW; Stancin, T; Yeates, KO; Taylor, HG				Wade, Shari L.; Cassedy, Amy E.; Shultz, Emily L.; Zang, Huaiyu; Zhang, Nanhua; Kirkwood, Michael W.; Stancin, Terry; Yeates, Keith O.; Taylor, H. Gerry			Randomized Clinical Trial of Online Parent Training for Behavior Problems After Early Brain Injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						traumatic brain injury; behavior problems; parenting	CHILD INTERACTION THERAPY; OUTCOMES; INTERVENTION; ADOLESCENTS; MODERATORS; PROGRAM; HARSH; TERM	Objective: To evaluate the effectiveness of Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT) versus abbreviated parent training (Express) or access to online resources (internet resources comparison [IRC]) in improving parenting skills and decreasing behavior problems after early traumatic brain injury (TBI).& para;& para;Method: In this randomized, controlled, clinical trial, 113 children 3 to 9 years old previously hospitalized for moderate to severe TBI were randomly assigned to receive Express (n = 36), I-InTERACT (n = 39), or IRC (n = 38). Express included 7 online parent skills sessions, and I-InTERACT delivered 10 to 14 sessions addressing parenting skills, TBI education, stress, and anger management. The 2 interventions coupled online modules with therapist coaching through a Health Insurance Portability and Accountability Act-compliant Skype link. The IRC group received access to online TBI and parent skills resources. Co-primary outcomes were blinded ratings of parenting skills and parent report of behavior problems and problem intensity on the Eyberg Child Behavior Inventory (ECBI). Outcomes were assessed before treatment and 3 and 6 months after treatment, with the latter constituting the primary endpoint.& para;& para;Results: The Express and I-InTERACT groups displayed higher levels of positive parenting at follow-up. Only the I-InTERACT group had lower levels of negative parenting at 6 months. The Express group had lower ECBI intensity scores than the IRC group. Baseline symptom levels moderated improvements; children in the Express and I-InTERACT groups with higher baseline symptoms demonstrated greater improvements than those in the IRC group. Changes in parenting skills mediated improvements in behavior in those with higher baseline symptoms.& para;& para;Conclusion: Brief online parent skills training can effectively decrease behavior problems after early TBI in children with existing behavioral symptoms.	[Wade, Shari L.; Shultz, Emily L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Cassedy, Amy E.; Zang, Huaiyu; Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Shultz, Emily L.] Univ Cincinnati, Cincinnati, OH 45221 USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Denver, CO USA; [Stancin, Terry] Metrohlth Med Ctr, Cleveland, OH USA; [Stancin, Terry; Taylor, H. Gerry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Yeates, Keith O.] Univ Calgary, Calgary, ON, Canada; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA	Wade, SL (corresponding author), 3333 Burnet Ave, Cincinnati, OH 45229 USA.	shari.wade@cchmc.org	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892; Zhang, Nanhua/0000-0001-5796-3404	National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [H133B090010]	This study w as funded by the National Institute on Disability, Independent Living, and Rehabilitation Research, formerly known as the National Institute on Disability and Rehabilitation Research (grant H133B090010).	Antonini TN, 2014, BEHAV THER, V45, P455, DOI 10.1016/j.beth.2014.02.003; Bradley RH, 2007, DEV PSYCHOL, V43, P1390, DOI 10.1037/0012-1649.43.6.1390; Brown FL, 2014, J CHILD PSYCHOL PSYC, V55, P1172, DOI 10.1111/jcpp.12227; Brown FL, 2013, BRAIN IMPAIR, V14, P253, DOI 10.1017/BrImp.2013.18; Cohen LL, 2015, J PEDIATR PSYCHOL, V40, P526, DOI 10.1093/jpepsy/jsu162; Eyberg S., 1999, EYBERG CHILD BEHAV I; Eyberg S.M., 2005, MANUAL DYADIC PARENT, V3rd ed; EYBERG SM, 1995, PSYCHOPHARMACOL BULL, V31, P83; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Hayes A.F., 2018, INTRO MEDIATION MODE, V2nd ed.; Hayes AF, 2015, MULTIVAR BEHAV RES, V50, P1, DOI 10.1080/00273171.2014.962683; Kaminski JW, 2008, J ABNORM CHILD PSYCH, V36, P567, DOI 10.1007/s10802-007-9201-9; Kazdin AE, 2003, J CHILD PSYCHOL PSYC, V44, P1116, DOI 10.1111/1469-7610.00195; Kurowski BG, 2013, PM&R, V5, P1026, DOI 10.1016/j.pmrj.2013.08.589; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Lundahl B, 2006, CLIN PSYCHOL REV, V26, P86, DOI 10.1016/j.cpr.2005.07.004; Lundahl BW, 2006, APSAC ADVIS, V18, P7; Micklewright JL, 2012, J INT NEUROPSYCH SOC, V18, P343, DOI 10.1017/S1355617711001792; Narad ME, 2017, DIGIT HEALTH, V3, DOI 10.1177/2055207617719423; Nixon RDV, 2003, J CONSULT CLIN PSYCH, V71, P251, DOI 10.1037/0022-006X.71.2.251; Owens PL, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200206000-00013; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Wade SL, 2008, REHABIL PSYCHOL, V53, P180, DOI 10.1037/0090-5550.53.2.180; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Wade SL, 2015, PEDIATRICS, V135, pE487, DOI 10.1542/peds.2014-1386; Wade SL, 2011, DEV PSYCHOL, V47, P119, DOI 10.1037/a0021028; Wade SL, 2009, J PEDIATR PSYCHOL, V34, P517, DOI 10.1093/jpepsy/jsn081; Waller R, 2012, J CHILD PSYCHOL PSYC, V53, P946, DOI 10.1111/j.1469-7610.2012.02550.x; Webster-Stratton C, 2004, J CLIN CHILD ADOLESC, V33, P105, DOI 10.1207/S15374424JCCP3301_11; Woods D, 2015, SOCIAL CARE NEURODIS, V5, P70, DOI [DOI 10.1108/SCN-01-2014-0001, 10.1108/SCN-01-2014-0001]; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	34	33	33	3	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0890-8567	1527-5418		J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	NOV	2017	56	11					930	939		10.1016/j.jaac.2017.09.413			10	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	FM2MG	WOS:000414818300008	29096775				2021-06-18	
J	Campbell, JC; Anderson, JC; McFadgion, A; Gill, J; Zink, E; Patch, M; Callwood, G; Campbell, D				Campbell, Jacquelyn C.; Anderson, Jocelyn C.; McFadgion, Akosoa; Gill, Jessica; Zink, Elizabeth; Patch, Michelle; Callwood, Gloria; Campbell, Doris			The Effects of Intimate Partner Violence and Probable Traumatic Brain Injury on Central Nervous System Symptoms	JOURNAL OF WOMENS HEALTH			English	Article						intimate partner violence; traumatic brain injury; central nervous system symptoms	AFRICAN-AMERICAN; OUTCOMES; WOMEN; FREQUENCY; SEVERITY; RISK	Introduction: Abused women often report a wide range of physical and psychological symptoms that present challenges to providers. Specifically, injuries to the head or strangulation, may initiate neurological changes that contribute to central nervous system (CNS) symptoms. These symptoms are often attributed to mental health diagnoses in this population. The purpose of this analysis is to examine the prevalence of and associations between reported probable traumatic brain injury (TBI) and CNS symptoms in a sample of women of African descent. Methods: A convenience sample of 901 women of African descent from Baltimore, MD and the US Virgin Islands, aged 18-55, was used to examine relationships among self-reported intimate partner violence (IPV), TBI, and CNS symptoms. Data were collected via Audio Computer-Assisted Self-Interview. Results: Abused women who experienced a probable TBI were more likely to report CNS symptoms than those who did not. When controlling for demographics, IPV, and mental health symptoms, probable TBI was associated with a two point increase in CNS symptom frequency score (95% confidence interval: 1.55-2.93, p<0.001). Conclusions: Women who reported both probable TBI and IPV were more likely than their abused counterparts who reported no TBI to report CNS symptoms. This relationship held true even when controlling for symptoms of depression and post-traumatic stress disorder (PTSD). Clinicians working with women should be aware of TBI as a possible etiology for symptoms in abused women. Appropriate screening and treatment protocols should be designed and implemented across medical settings to improve outcomes for women who have experienced IPV and TBI.	[Campbell, Jacquelyn C.; Anderson, Jocelyn C.; Zink, Elizabeth; Patch, Michelle] Johns Hopkins Univ, Sch Nursing, Community & Publ Hlth Nursing, Baltimore, MD 21205 USA; [Anderson, Jocelyn C.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [McFadgion, Akosoa] Howard Univ, Off Interpersonal Violence Prevent, Washington, DC 20059 USA; [Gill, Jessica] NINR, Bethesda, MD 20892 USA; [Callwood, Gloria; Campbell, Doris] Univ Virgin Isl, Caribbean Exploratory Res Ctr, St Thomas, VI USA	Campbell, JC (corresponding author), Johns Hopkins Univ, Sch Nursing, Dept Community & Publ Hlth Nursing, 525 North Wolfe St, Baltimore, MD 21205 USA.	jcampbe1@jhu.edu	Gill, Gill M/Q-2020-2017		National Institute on Minority Health and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [P20MD002286]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH100995]; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD087162]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD087162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F31MH100995] Funding Source: NIH RePORTER	This work was supported by the National Institute on Minority Health and Health Disparities (P20MD002286). Dr. J.C.A received support from the National Institute of Mental Health (F31MH100995) and the National Institute of Child Health and Development (T32HD087162). The opinions, findings, conclusion, and recommendations expressed are those of the authors and do not necessarily reflect the view of the NIH.	Anderson CA, 2010, NEUROREHABILITATION, V26, P47, DOI 10.3233/NRE-2010-0535; Anderson JC, 2015, J EMERG NURS, V41, P36, DOI 10.1016/j.jen.2014.01.015; Barkhoudarian G, 2016, PHYS MED REH CLIN N, V27, P373, DOI 10.1016/j.pmr.2016.01.003; Black M.C., 2011, NATL INTIMATE PARTNE; Breiding MJ, 2008, AM J PREV MED, V34, P112, DOI 10.1016/j.amepre.2007.10.001; Canady RB, 2009, J NURS MEAS, V17, P91, DOI 10.1891/1061-3749.17.2.91; Dams-O'Connor K, 2014, J HEAD TRAUMA REHAB, V29, P479, DOI 10.1097/HTR.0000000000000099; Faugno D, 2013, ADV EMERG NURS J, V35, P314, DOI 10.1097/TME.0b013e3182aa05d3; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Freedy JR, 2010, FAM PRACT, V27, P615, DOI 10.1093/fampra/cmq049; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; IBM SPSS Statistics for Windows, 2013, IBM SPSS STAT WIND C; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Lui G, 2015, ACTA RADIOL, V56, P1256; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; MARSHALL LL, 1992, J FAM VIOLENCE, V7, P103, DOI 10.1007/BF00978700; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Miller C. D., 1993, RELIABILITY VALIDITY; Minen MT, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0697-7; New York State Office for the Prevention of Domestic Violence, DOM AB TRAUM BRAIN I; Picard M, 1991, HELPS BRAIN INJURY S; Pritchard AJ, 2017, TRAUMA VIOLENCE ABUS, V18, P407, DOI 10.1177/1524838015622439; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sabri B, 2013, J INTERPERS VIOLENCE, V28, P3223, DOI 10.1177/0886260513496902; Sahler CS, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/659652; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Shah MK, 2007, J NEUROL SCI, V260, P95, DOI 10.1016/j.jns.2007.04.012; Smith DJ, 2001, J EMERG MED, V21, P323, DOI 10.1016/S0736-4679(01)00402-4; Smith P H, 1995, Womens Health, V1, P273; St Ivany A, 2016, FAM COMMUNITY HEALTH, V39, P129, DOI 10.1097/FCH.0000000000000094; Stockman JK, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.24772; Strack GB, 2001, J EMERG MED, V21, P303, DOI 10.1016/S0736-4679(01)00399-7; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Valera E, 2016, BRAIN IMAGING BEHAV, DOI 10.1007/s11682-016-9643-1; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; WHO, 2012, UND ADDR VIOL WOM; Wilbur L, 2001, J EMERG MED, V21, P297, DOI 10.1016/S0736-4679(01)00398-5	42	33	33	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	JUN	2018	27	6					761	767		10.1089/jwh.2016.6311		OCT 2017	7	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	GJ4CY	WOS:000414469900001	29083256	Green Published			2021-06-18	
J	Cnossen, MC; Winkler, EA; Yue, JK; Okonkwo, DO; Valadka, AB; Steyerberg, EW; Lingsma, HF; Manley, GT				Cnossen, Maryse C.; Winkler, Ethan A.; Yue, John K.; Okonkwo, David O.; Valadka, Alex B.; Steyerberg, Ewout W.; Lingsma, Hester F.; Manley, Geoffrey T.		TRACK-TBI Investigators	Development of a Prediction Model for Post-Concussive Symptoms following Mild Traumatic Brain Injury: A TRACK-TBI Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						post-concussion symptoms; prediction model; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; COMMON DATA ELEMENTS; OUTCOME PREDICTION; RISK-FACTORS; HEAD-INJURY; POSTCONCUSSIONAL-SYNDROME; CONSTRUCT-VALIDITY; PROGNOSTIC MODELS; RECOVERY; QUESTIONNAIRE	Post-concussive symptoms occur frequently after mild traumatic brain injury (mTBI) and may be categorized as cognitive, somatic, or emotional. We aimed to: 1) assess whether patient demographics and clinical variables predict development of each of these three symptom categories, and 2) develop a prediction model for 6-month post-concussive symptoms. Patients with mTBI (Glasgow Coma Scale score 13-15) from the prospective multi-center Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot study (2010-2012) who completed the Rivermead Post Concussion Symptoms Questionnaire (RPQ) at 6 months post-injury were included. Linear regression was utilized to determine the predictive value of candidate predictors for cognitive, somatic, and emotional subscales individually, as well as the overall RPQ. The final prediction model was developed using least absolute shrinkage and selection operator shrinkage and bootstrap validation. We included 277 mTBI patients (70% male; median age 42 years). No major differences in the predictive value of our set of predictors existed for the cognitive, somatic, and emotional subscales, and therefore one prediction model for the RPQ total scale was developed. Years of education, pre-injury psychiatric disorders, and prior TBI were the strongest predictors of 6-month post-concussive symptoms. The total set of predictors explained 21% of the variance, which decreased to 14% after bootstrap validation. Demographic and clinical variables at baseline are predictive of 6-month post-concussive symptoms following mTBI; however, these variables explain less than one-fifth of the total variance in outcome. Model refinement with larger datasets, more granular variables, and objective biomarkers are needed before implementation in clinical practice.	[Cnossen, Maryse C.; Steyerberg, Ewout W.; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Winkler, Ethan A.; Yue, John K.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA; [Winkler, Ethan A.; Yue, John K.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RC2NS069409-01, 3RC2NS069409-02S1, 5RC2NS069409-02, 1U01NS086090-01, 3U01NS086090-02S1, 3U01NS086090-02S2, 3U01NS086090-03S1, 5U01NS086090-02, 5U01NS086090-03]; U.S. DODUnited States Department of Defense [W81XWH-13-1-0441, W81XWH-14-2-0176]; European UnionEuropean Commission [602150]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086090] Funding Source: NIH RePORTER	This work was supported by the following grants: NINDS 1RC2NS069409-01, 3RC2NS069409-02S1, 5RC2NS069409-02, 1U01NS086090-01, 3U01NS086090-02S1, 3U01NS086090-02S2, 3U01NS086090-03S1, 5U01NS086090-02, 5U01NS086090-03; U.S. DOD W81XWH-13-1-0441, U.S. DOD W81XWH-14-2-0176 (to G.T. Manley). The authors M.C. Cnossen, H.F. Lingsma and E.W. Steyerberg were further supported by the European Union FP 7th Framework program (grant 602150).	Ahman S, 2013, J REHABIL MED, V45, P758, DOI 10.2340/16501977-1182; American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bouwmeester W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001221; Broshek DK, 2015, BRAIN INJURY, V29, P228, DOI 10.3109/02699052.2014.974674; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cary VJ, 2016, FOREIGN; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Clay FJ, 2010, J REHABIL MED, V42, P162, DOI 10.2340/16501977-0495; Collins GS, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.g7594; Crandall M, 2014, BRAIN INJURY, V28, P1359, DOI 10.3109/02699052.2014.919533; Dikmen S, 2017, J NEUROTRAUM, V34, P1524, DOI 10.1089/neu.2016.4618; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goeman JJ, 2010, BIOMETRICAL J, V52, P70, DOI 10.1002/bimj.200900028; Gustavson K, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-918; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Hess DW, 2000, ARCH PHYS MED REHAB, V81, P359, DOI 10.1016/S0003-9993(00)90084-4; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lannsjo M, 2011, J REHABIL MED, V43, P997, DOI 10.2340/16501977-0875; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; McCauley SR, 2014, J NEUROTRAUM, V31, P914, DOI 10.1089/neu.2012.2826; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mueller TI, 1999, AM J PSYCHIAT, V156, P1000; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Steyerberg EW., 2009, CLIN PREDICTION MODE; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; The National Institute of Neurlogical Disorders and Stroke, 2015, NINDS COMM DAT EL TR; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Winkler EA, 2016, NEUROGENETICS, V17, P31, DOI 10.1007/s10048-015-0467-8; Wolke D, 2009, BRIT J PSYCHIAT, V195, P249, DOI 10.1192/bjp.bp.108.053751; World Health Organization, 1993, ICD 10 CLASS MENT BE; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zasler ND, 2006, BRAIN INJURY MED PRI, P374; Zimmerli M, 2014, RESUSCITATION, V85, P801, DOI 10.1016/j.resuscitation.2014.02.022	58	33	33	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2017	34	16					2396	2409		10.1089/neu.2016.4819			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FC6RI	WOS:000406968400003	28343409	Green Published			2021-06-18	
J	Churchill, NW; Caverzasi, E; Graham, SJ; Hutchison, MG; Schweizer, TA				Churchill, Nathan W.; Caverzasi, Eduardo; Graham, Simon J.; Hutchison, Michael G.; Schweizer, Tom A.			White matter microstructure in athletes with a history of concussion: Comparing diffusion tensor imaging (DTI) and neurite orientation dispersion and density imaging (NODDI)	HUMAN BRAIN MAPPING			English	Article						concussion; white matter; diffusion tensor imaging; NODDI	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; SPORTS-RELATED CONCUSSION; RECURRENT CONCUSSION; AXONAL INJURY; RECOVERY; STATE	Sport concussion is associated with disturbances in brain function in the absence of gross anatomical lesions, and may have long-term health consequences. Diffusion-weighted magnetic resonance imaging (MRI) methods provide a powerful tool for investigating alterations in white matter microstructure reflecting the long-term effects of concussion. In a previous study, diffusion tensor imaging (DTI) showed that athletes with a history of concussion had elevated fractional anisotropy (FA) and reduced mean diffusivity (MD) parameters. To better understand these effects, this study compared DTI results to neurite orientation dispersion and density imaging (NODDI), which was used to estimate the intracellular volume fraction (V-IC) and orientation dispersion index (ODI). Sixty-eight (68) varsity athletes were recruited, including 37 without a history of concussion and 31 with concussion >6 months prior to imaging. Univariate analyses showed elevated FA and decreased MD for concussed athletes, along with increased V-IC and reduced ODI, indicating greater neurite density and coherence of neurite orientation within white matter. Multivariate analyses also showed that for athletes with a history of concussion, white matter regions with increased FA had increased V-IC and decreased ODI, with greater effects among athletes who were imaged a longer time since their last concussion. These findings enhance our understanding of the relationship between the biophysics of water diffusion and concussion neurobiology for young, healthy adults. Hum Brain Mapp 38:4201-4211, 2017. (c) 2017 Wiley Periodicals, Inc.	[Churchill, Nathan W.; Hutchison, Michael G.; Schweizer, Tom A.] St Michaels Hosp, Neurosci Res Program, Toronto, ON, Canada; [Churchill, Nathan W.; Schweizer, Tom A.] Univ Toronto, St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON, Canada; [Caverzasi, Eduardo] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA; [Caverzasi, Eduardo] Univ Pavia, Dept Brain & Behav Sci, Pavia, Italy; [Graham, Simon J.] Sunnybrook Res Inst, Phys Sci Platform, Toronto, ON, Canada; [Graham, Simon J.] Univ Toronto, Dept Med Biophys, Fac Med, Toronto, ON, Canada; [Hutchison, Michael G.] Univ Toronto, Fac Kinesiol & Phys Educ, Toronto, ON, Canada; [Schweizer, Tom A.] Univ Toronto, Div Neurosurg, Fac Med, Toronto, ON, Canada	Churchill, NW (corresponding author), 209 Victoria St, Toronto, ON M5B 1M8, Canada.	nchurchill.research@gmail.com	Caverzasi, Eduardo/P-1707-2019	Caverzasi, Eduardo/0000-0002-0350-0460	Siemens Canada, Ltd.; Canadian Institutes of Military and Veterans Health (CIMVHR); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	Contract grant sponsors: Siemens Canada, Ltd., Canadian Institutes of Military and Veterans Health (CIMVHR), and Canadian Institutes of Health Research (CIHR)	Adluru G, 2014, IEEE ENG MED BIO, P742, DOI 10.1109/EMBC.2014.6943697; Arenth PM, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318289ede5; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bro R., 1996, J CHEMOMETRICS, V10; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Caverzasi E, 2016, J NEUROIMAG; Chang YS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123656; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Churchill N, 2016, J NEUROTRAUMA; Colgan N, 2016, NEUROIMAGE, V125, P739, DOI 10.1016/j.neuroimage.2015.10.043; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hasan KM, 2014, J NEUROTRAUM, V31, P466, DOI [10.1089/NEU.2013.3085, 10.1089/neu.2013.3085]; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Huh JW, 2007, J NEUROTRAUM, V24, P15, DOI 10.1089/neu.2006.0072; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Krishnan A, 2011, NEUROIMAGE, V56, P455, DOI 10.1016/j.neuroimage.2010.07.034; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Mayer AR, 2016, BRAIN IMAGING BEHAV, P1; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Murugavel M, 2014, J NEUROTRAUM, V31, P1860, DOI 10.1089/neu.2014.3368; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe V, 2007, BR J NEUROSURG; Owen JP, 2014, J NEUROSCI, V34, P6214, DOI 10.1523/JNEUROSCI.4495-13.2014; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Sasaki Takeshi, 2014, J Neurosurg, V120, P882, DOI 10.3171/2013.12.JNS132092; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Tremblay S, 2014, BRAIN; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021; Zhang H, 2012, NEUROIMAGE, V61, P1000, DOI 10.1016/j.neuroimage.2012.03.072; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhu DC, 2015, J NEUROTRAUM, V32, P327, DOI 10.1089/neu.2014.3413	44	33	36	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1065-9471	1097-0193		HUM BRAIN MAPP	Hum. Brain Mapp.	AUG	2017	38	8					4201	4211		10.1002/hbm.23658			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EZ8GV	WOS:000404963900030	28556431	Bronze, Green Published			2021-06-18	
J	Sompol, P; Furman, JL; Pleiss, MM; Kraner, SD; Artiushin, IA; Batten, SR; Quintero, JE; Simmerman, LA; Beckett, TL; Lovell, MA; Murphy, MP; Gerhardt, GA; Norris, CM				Sompol, Pradoldej; Furman, Jennifer L.; Pleiss, Melanie M.; Kraner, Susan D.; Artiushin, Irina A.; Batten, Seth R.; Quintero, Jorge E.; Simmerman, Linda A.; Beckett, Tina L.; Lovell, Mark A.; Murphy, M. Paul; Gerhardt, Greg A.; Norris, Christopher M.			Calcineurin/NFAT Signaling in Activated Astrocytes Drives Network Hyperexcitability in A beta-Bearing Mice	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; astrocytes; calcineurin; dementia; glutamate; hyperexcitability	POSTSYNAPTICALLY SILENT SYNAPSES; GLIAL GLUTAMATE TRANSPORTER; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; MOUSE MODEL; AMYLOID-BETA; NEURONAL-ACTIVITY; SYNAPTIC FUNCTION; TRANSGENIC MICE	Hyperexcitable neuronal networks are mechanistically linked to the pathologic and clinical features of Alzheimer's disease (AD). Astrocytes are a primary defense against hyperexcitability, but their functional phenotype duringADis poorly understood. Here, we found that activated astrocytes in the5xFADmousemodel were strongly associated with proteolysis of the protein phosphatase calcineurin (CN) and the elevated expression of the CN-dependent transcription factor nuclear factor of activated T cells 4 (NFAT4). Intrahippocampal injections of adeno-associated virus vectors containing the astrocyte-specific promoter Gfa2 and the NFAT inhibitory peptide VIVIT reduced signs of glutamate-mediated hyperexcitability in 5xFAD mice, measured in vivo with microelectrode arrays and ex vivo brain slices, using whole-cell voltage clamp. VIVIT treatment in 5xFAD mice led to increased expression of the astrocytic glutamate transporter GLT-1 and to attenuated changes in dendrite morphology, synaptic strength, and NMDAR-dependent responses. The results reveal astrocytic CN/NFAT4 as a key pathologic mechanism for driving glutamate dysregulation and neuronal hyperactivity during AD.	[Sompol, Pradoldej; Kraner, Susan D.; Artiushin, Irina A.; Beckett, Tina L.; Lovell, Mark A.; Murphy, M. Paul; Norris, Christopher M.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Furman, Jennifer L.; Pleiss, Melanie M.; Norris, Christopher M.] Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 224 Sanders Brown Bldg,800 South Limestone St, Lexington, KY 40536 USA; [Batten, Seth R.; Quintero, Jorge E.; Gerhardt, Greg A.] Univ Kentucky, Coll Med, Dept Neurosci, Lexington, KY 40536 USA; [Batten, Seth R.; Quintero, Jorge E.; Gerhardt, Greg A.] Univ Kentucky, Coll Med, Ctr Microelectrode Technol, Lexington, KY 40536 USA; [Simmerman, Linda A.] Univ Kentucky, Coll Arts & Sci, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Lovell, Mark A.] Univ Kentucky, Coll Arts & Sci, Dept Chem, Lexington, KY 40536 USA; [Murphy, M. Paul] Univ Kentucky, Coll Arts & Sci, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	Norris, CM (corresponding author), Univ Kentucky, Coll Med, Dept Pharmacol & Nutr Sci, 224 Sanders Brown Bldg,800 South Limestone St, Lexington, KY 40536 USA.	cnorr2@uky.edu		Kraner, Susan/0000-0002-1062-4007	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG027297, AG051945, AG000242-20]; The Hazel Embry Research Trust; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027297, T32AG000242, R21AG051945, RF1AG027297] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grants AG027297 and AG051945 to C.M.N. and Grant AG000242-20 to P.S.; and The Hazel Embry Research Trust. We thank Drs. Eric M. Blalock and Richard Kryscio for conceptual and statistical input.	Abdul HM, 2011, AGING CELL, V10, P103, DOI 10.1111/j.1474-9726.2010.00645.x; Abdul HM, 2009, J NEUROSCI, V29, P12957, DOI 10.1523/JNEUROSCI.1064-09.2009; Aida T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036853; Alamed J, 2006, NAT PROTOC, V1, P1671, DOI 10.1038/nprot.2006.275; Andreasson KI, 2016, J NEUROCHEM, V138, P653, DOI 10.1111/jnc.13667; ANDREW RD, 1994, NEUROSCIENCE, V62, P371, DOI 10.1016/0306-4522(94)90372-7; Armbruster M, 2016, J NEUROSCI, V36, P10404, DOI 10.1523/JNEUROSCI.2066-16.2016; Audrain M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0070-y; Bachstetter AD, 2012, J NEUROSCI, V32, P10201, DOI 10.1523/JNEUROSCI.1496-12.2012; Bakker A, 2012, NEURON, V74, P467, DOI 10.1016/j.neuron.2012.03.023; Bomben V, 2014, NEUROBIOL AGING, V35, P2091, DOI 10.1016/j.neurobiolaging.2014.03.029; Bouvier DS, 2015, J ALZHEIMERS DIS, V45, P1001, DOI 10.3233/JAD-143156; Busche MA, 2008, SCIENCE, V321, P1686, DOI 10.1126/science.1162844; Busche MA, 2015, BIOESSAYS, V37, P624, DOI 10.1002/bies.201500004; Carter SF, 2012, J NUCL MED, V53, P37, DOI 10.2967/jnumed.110.087031; Dallas M, 2007, J NEUROSCI, V27, P3946, DOI 10.1523/JNEUROSCI.5030-06.2007; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Fleming TM, 2011, J PHYSIOL-LONDON, V589, P3929, DOI 10.1113/jphysiol.2011.207340; Fontana ACK, 2016, J NEUROTRAUM, V33, P1073, DOI 10.1089/neu.2015.4079; Fontana R, 2017, NEUROBIOL AGING, V50, P64, DOI 10.1016/j.neurobiolaging.2016.10.027; Furman JL, 2016, J NEUROSCI, V36, P1502, DOI 10.1523/JNEUROSCI.1930-15.2016; Furman JL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0158-7; Furman JL, 2012, J NEUROSCI, V32, P16129, DOI 10.1523/JNEUROSCI.2323-12.2012; Gong HY, 2016, INT J MOL MED, V38, P943, DOI 10.3892/ijmm.2016.2663; Gray BC, 2006, BIOCHEM SOC T, V34, P51, DOI 10.1042/BST0340051; Greenwood SM, 2007, J BIOL CHEM, V282, P26235, DOI 10.1074/jbc.M704488200; Grienberger C, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1783; Harvey BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022135; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hascup KN, 2011, NEUROPSYCHOPHARMACOL, V36, P1769, DOI 10.1038/npp.2011.60; Hascup KN, 2007, FRONT NEUROENG, V1, P407; Hefendehl JK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13441; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Huang W, 2005, P NATL ACAD SCI USA, V102, P12242, DOI 10.1073/pnas.0505138102; Huang YHH, 2004, CURR OPIN NEUROBIOL, V14, P346, DOI 10.1016/j.conb.2004.05.007; Hudry E, 2012, J NEUROSCI, V32, P3176, DOI 10.1523/JNEUROSCI.6439-11.2012; Hunsberger HC, 2015, J NEUROCHEM, V132, P169, DOI 10.1111/jnc.12967; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; Kellner V, 2014, NEUROBIOL AGING, V35, P1982, DOI 10.1016/j.neurobiolaging.2014.04.001; Kim JH, 2016, EXP MOL PATHOL, V100, P1, DOI 10.1016/j.yexmp.2015.11.005; Kim SY, 2003, J NEUROCHEM, V86, P1458, DOI 10.1046/j.1471-4159.2003.01958.x; Kuchibhotla KV, 2009, SCIENCE, V323, P1211, DOI 10.1126/science.1169096; Lacey CJ, 2012, J NEUROSCI, V32, P11067, DOI 10.1523/JNEUROSCI.5604-11.2012; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Lim D, 2013, GLIA, V61, P1134, DOI 10.1002/glia.22502; Liu F, 2005, J BIOL CHEM, V280, P37755, DOI 10.1074/jbc.M507475200; Mallolas J, 2006, J EXP MED, V203, P711, DOI 10.1084/jem.20051979; Malm TM, 2015, NEUROTHERAPEUTICS, V12, P81, DOI 10.1007/s13311-014-0316-8; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Masliah E, 2000, EXP NEUROL, V163, P381, DOI 10.1006/exnr.2000.7386; Masliah E, 1996, ANN NEUROL, V40, P759, DOI 10.1002/ana.410400512; Mathis DM, 2011, JOVE-J VIS EXP, DOI 10.3791/2330; Matveeva EA, 2012, EPILEPSIA, V53, P157, DOI 10.1111/j.1528-1167.2011.03345.x; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Meeker KD, 2015, J ALZHEIMERS DIS, V45, P509, DOI 10.3233/JAD-142304; Miller EM, 2015, J NEUROSCI METH, V252, P75, DOI 10.1016/j.jneumeth.2015.01.018; Miller EM, 2014, PSYCHOPHARMACOLOGY, V231, P3019, DOI 10.1007/s00213-014-3479-4; Minkeviciene R, 2009, J NEUROSCI, V29, P3453, DOI 10.1523/JNEUROSCI.5215-08.2009; Moidunny S, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0613-8; Mookherjee P, 2011, J ALZHEIMERS DIS, V26, P447, DOI 10.3233/JAD-2011-110503; Murphy MP, 2007, NEUROBIOL DIS, V27, P301, DOI 10.1016/j.nbd.2007.06.002; Nagamoto-Combs K, 2010, J NEUROSCI, V30, P9641, DOI 10.1523/JNEUROSCI.0828-10.2010; Noebels J, 2011, EPILEPSIA, V52, P39, DOI 10.1111/j.1528-1167.2010.02909.x; Norris CM, 2006, J NEUROPHYSIOL, V96, P2488, DOI 10.1152/jn.00593.2005; Norris CM, 2016, EXP NEUROL, V276, P5, DOI 10.1016/j.expneurol.2015.11.006; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; Norris CM, 2005, J NEUROSCI, V25, P4649, DOI 10.1523/JNEUROSCI.0365-05.2005; Nudmamud-Thanoi S, 2006, NEUROTOXICOLOGY, V27, P623, DOI 10.1016/j.neuro.2006.01.012; Oakley H, 2006, J NEUROSCI, V26, P10129, DOI 10.1523/JNEUROSCI.1202-06.2006; Oberheim NA, 2012, METHODS MOL BIOL, V814, P23, DOI 10.1007/978-1-61779-452-0_3; Padurariu M, 2012, PSYCHIAT DANUB, V24, P152; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Pekny M, 2016, ACTA NEUROPATHOL, V131, P323, DOI 10.1007/s00401-015-1513-1; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; Peskind ER, 2006, AM J GERIAT PSYCHIAT, V14, P704, DOI 10.1097/01.JGP.0000224350.82719.83; Petr GT, 2015, J NEUROSCI, V35, P5187, DOI 10.1523/JNEUROSCI.4255-14.2015; Pleiss MM, 2016, BBA-MOL BASIS DIS, V1862, P1521, DOI 10.1016/j.bbadis.2016.05.007; Prokop Stefan, 2013, Acta Neuropathol, V126, P461; Prow NA, 2008, J NEUROCHEM, V105, P1276, DOI 10.1111/j.1471-4159.2008.05230.x; Putcha D, 2011, J NEUROSCI, V31, P17680, DOI 10.1523/JNEUROSCI.4740-11.2011; Rao VLR, 2001, EUR J NEUROSCI, V13, P119, DOI 10.1046/j.1460-9568.2001.01367.x; Reese LC, 2008, AGING CELL, V7, P824, DOI 10.1111/j.1474-9726.2008.00434.x; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Rojanathammanee L, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0255-2; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sama MA, 2008, J BIOL CHEM, V283, P21953, DOI 10.1074/jbc.M800148200; Sametsky EA, 2010, NEUROBIOL AGING, V31, P813, DOI 10.1016/j.neurobiolaging.2008.05.029; Sattler R, 2006, HANDB EXP PHARM, V175, P277; Schallier A, 2011, J ALZHEIMERS DIS, V24, P287, DOI 10.3233/JAD-2011-101005; Scholl M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16404; Schousboe A, 2004, NEUROCHEM INT, V45, P521, DOI 10.1016/j.neuint.2003.11.001; Scimemi A, 2013, J NEUROSCI, V33, P5312, DOI 10.1523/JNEUROSCI.5274-12.2013; Selkirk JV, 2005, EUR J NEUROSCI, V21, P3217, DOI 10.1111/j.1460-9568.2005.04162.x; Serrano-Perez MC, 2011, GLIA, V59, P94, DOI 10.1002/glia.21079; Shioda N, 2006, J NEUROCHEM, V98, P310, DOI 10.1111/j.1471-4159.2006.03874.x; Simpson JE, 2010, NEUROBIOL AGING, V31, P578, DOI 10.1016/j.neurobiolaging.2008.05.015; Siskova Z, 2014, NEURON, V84, P1023, DOI 10.1016/j.neuron.2014.10.024; Spires TL, 2004, REV NEUROSCIENCE, V15, P267, DOI 10.1515/REVNEURO.2004.15.4.267; Su ZZ, 2003, P NATL ACAD SCI USA, V100, P1955, DOI 10.1073/pnas.0136555100; Tackenberg C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.129; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Tian RJ, 2010, J NEUROPATH EXP NEUR, V69, P335, DOI 10.1097/NEN.0b013e3181d3cb52; Vossel KA, 2016, ANN NEUROL, V80, P858, DOI 10.1002/ana.24794; Wu HY, 2010, J NEUROSCI, V30, P2636, DOI 10.1523/JNEUROSCI.4456-09.2010; Wu HY, 2004, J BIOL CHEM, V279, P4929, DOI 10.1074/jbc.M309767200; Xu MJ, 2016, PHYSIOL BEHAV, V167, P265, DOI 10.1016/j.physbeh.2016.09.018; Yokokura M, 2017, J CEREBR BLOOD F MET, V37, P877, DOI 10.1177/0271678X16646788; Zumkehr J, 2015, NEUROBIOL AGING, V36, P2260, DOI 10.1016/j.neurobiolaging.2015.04.005	110	33	34	0	1	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 21	2017	37	25					6132	6148		10.1523/JNEUROSCI.0877-17.2017			17	Neurosciences	Neurosciences & Neurology	EY2IJ	WOS:000403791500015	28559377	Green Published, Bronze			2021-06-18	
J	Baillieul, S; Chacaroun, S; Doutreleau, S; Detante, O; Pepin, JL; Verges, S				Baillieul, S.; Chacaroun, S.; Doutreleau, S.; Detante, O.; Pepin, J. L.; Verges, S.			Hypoxic conditioning and the central nervous system: A new therapeutic opportunity for brain and spinal cord injuries?	EXPERIMENTAL BIOLOGY AND MEDICINE			English	Article						Central nervous system; conditioning; hypoxia; neurobiology; neuroprotection; physiology	TRANSIENT ISCHEMIC ATTACKS; PERMANENT CEREBRAL-ISCHEMIA; INTERMITTENT HYPOXIA; HIPPOCAMPAL NEUROGENESIS; FUNCTIONAL RECOVERY; HYPOBARIC HYPOXIA; MEMORY IMPAIRMENT; RANDOMIZED-TRIAL; MOTOR FUNCTION; IN-VITRO	Central nervous system diseases are among the most disabling in the world. Neuroprotection and brain recovery from either acute or chronic neurodegeneration still represent a challenge in neurology and neurorehabilitation as pharmacology treatments are often insufficiently effective. Conditioning the central nervous system has been proposed as a potential non-pharmacological neuro-therapeutic. Conditioning refers to a procedure by which a potentially deleterious stimulus is applied near to but below the threshold of damage to the organism to increase resistance to the same or even different noxious stimuli given above the threshold of damage. Hypoxic conditioning has been investigated in several cellular and preclinical models and is now recognized as inducing endogenous mechanisms of neuroprotection. Ischemic, traumatic, or chronic neurodegenerative diseases can benefit from hypoxic conditioning strategies aiming at preventing the deleterious consequences or reducing the severity of the pathological condition (preconditioning) or aiming at inducing neuroplasticity and recovery (postconditioning) following central nervous system injury. Hypoxic conditioning can consist in single (sustained) or cyclical (intermittent, interspersed by short period of normoxia) hypoxia stimuli which duration range from few minutes to several hours and that can be repeated over several days or weeks. This mini-review addresses the existing evidence regarding the use of hypoxic conditioning as a potential innovating neuro-therapeutic modality to induce neuroprotection, neuroplasticity and brain recovery. This mini-review also emphasizes issues which remain to be clarified and future researches to be performed in the field.	[Baillieul, S.; Doutreleau, S.; Pepin, J. L.] CHU Grenoble Alpes, Physiol Sleep & Exercise Dept, F-38042 Grenoble, France; [Baillieul, S.; Chacaroun, S.; Doutreleau, S.; Pepin, J. L.; Verges, S.] INSERM, U1042, F-38042 Grenoble, France; [Baillieul, S.; Chacaroun, S.; Doutreleau, S.; Pepin, J. L.; Verges, S.] Univ Grenoble Alpes, Lab HP2, F-38042 Grenoble, France; [Detante, O.] CHU Grenoble Alpes, Pole Psychiat Neurol, Stroke Unit, F-38042 Grenoble, France; [Detante, O.] Grenoble Inst Neurosci, Inserm U 836, F-38042 Grenoble, France	Baillieul, S (corresponding author), CHU Grenoble Alpes, Physiol Sleep & Exercise Dept, F-38042 Grenoble, France.; Baillieul, S (corresponding author), INSERM, U1042, F-38042 Grenoble, France.; Baillieul, S (corresponding author), Univ Grenoble Alpes, Lab HP2, F-38042 Grenoble, France.	sbaillieul@chu-grenoble.fr	Sebastien, BAILLIEUL/M-7143-2015; Verges, Samuel/M-7040-2014; Detante, Olivier/M-1737-2014	Sebastien, BAILLIEUL/0000-0002-2348-6918; Verges, Samuel/0000-0002-0831-9222; DOUTRELEAU, Stephane/0000-0001-8816-0356; Pepin, Jean Louis/0000-0003-3832-2358	Fond de Dotation Agir pour les maladies chroniques	We thank the "Fond de Dotation Agir pour les maladies chroniques'' for financial support regarding our research in the field of hypoxic conditioning.	Arboix A, 2004, CEREBROVASC DIS, V18, P304, DOI 10.1159/000080356; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Borlongan CV, 2015, FUTUR NEUROL, V10, P313, DOI 10.2217/FNL.15.27; Castillo J, 2003, ANN NEUROL, V54, P811, DOI 10.1002/ana.10765; Chacaroun S, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00675; Coppel J, 2015, EXTREME PHYSIOL MED, V4, DOI 10.1186/s13728-014-0021-6; DAHL NA, 1964, AM J PHYSIOL, V207, P452; Della Morte David, 2008, J Stroke Cerebrovasc Dis, V17, P257, DOI 10.1016/j.jstrokecerebrovasdis.2008.03.004; Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205; Dezfulian C, 2013, TRANSL STROKE RES, V4, P19, DOI 10.1007/s12975-012-0224-3; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Easton JD, 2009, STROKE, V40, P2276, DOI 10.1161/STROKEAHA.108.192218; Gidday JM, 2006, NAT REV NEUROSCI, V7, P437, DOI 10.1038/nrn1927; Gidday JM, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00042; Gonzalez-Rothi EJ, 2015, J APPL PHYSIOL, V119, P1455, DOI 10.1152/japplphysiol.00235.2015; Hayes HB, 2014, NEUROLOGY, V82, P104, DOI 10.1212/01.WNL.0000437416.34298.43; Hoshino T, 2013, J STROKE CEREBROVASC, V22, P260, DOI 10.1016/j.jstrokecerebrovasdis.2011.08.010; Hougaard KD, 2014, STROKE, V45, P159, DOI 10.1161/STROKEAHA.113.001346; Johnston SC, 2004, STROKE, V35, P2680, DOI 10.1161/01.STR.0000143322.20491.0f; Komnenov D, 2016, J APPL PHYSIOL, V121, P545, DOI 10.1152/japplphysiol.00448.2016; Kushwah N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149309; Leconte C, 2009, STROKE, V40, P3349, DOI 10.1161/STROKEAHA.109.557314; Li SJ, 2017, PROG NEUROBIOL, V157, P79, DOI 10.1016/j.pneurobio.2017.01.001; Lin AM, 2003, ANN NY ACAD SCI, V993, P95; Lin AMY, 2003, ANN NY ACAD SCI, V993, P168, DOI 10.1111/j.1749-6632.2003.tb07527.x; Lovett-Barr MR, 2012, J NEUROSCI, V32, P3591, DOI 10.1523/JNEUROSCI.2908-11.2012; Lukyanova LD, 2013, B EXP BIOL MED+, V154, P597, DOI 10.1007/s10517-013-2008-5; Lynch M, 2017, J SPINAL CORD MED, V40, P295, DOI 10.1080/10790268.2016.1142137; Manukhina E B, 2010, Neurosci Behav Physiol, V40, P737, DOI 10.1007/s11055-010-9320-6; Manukhina EB, 2016, EXP BIOL MED, V241, P1351, DOI 10.1177/1535370216649060; Meng R, 2015, NEUROTHERAPEUTICS, V12, P667, DOI 10.1007/s13311-015-0358-6; Meng R, 2012, NEUROLOGY, V79, P1853, DOI 10.1212/WNL.0b013e318271f76a; Miller BA, 2001, NEUROREPORT, V12, P1663, DOI 10.1097/00001756-200106130-00030; Millet GP, 2016, FRONT PHYSIOL, V7, DOI [10.3339/fphys.2016.00224, 10.3389/fphys.2016.00224]; Moisan A, 2016, CELL TRANSPLANT, V25, P2157, DOI 10.3727/096368916X691132; Moncayo J, 2000, NEUROLOGY, V54, P2089, DOI 10.1212/WNL.54.11.2089; Navarrete-Opazo A, 2015, EXP NEUROL, V266, P1, DOI 10.1016/j.expneurol.2015.02.007; Navarrete-Opazo A, 2017, J NEUROTRAUM, V34, P1803, DOI 10.1089/neu.2016.4478; Navarrete-Opazo A, 2016, ARCH CLIN NEUROPSYCH, V31, P332, DOI 10.1093/arclin/acw012; Prosser-Loose EJ, 2015, J NEUROTRAUM, V32, P1403, DOI 10.1089/neu.2014.3789; Qiao YX, 2015, J MOL NEUROSCI, V55, P923, DOI 10.1007/s12031-014-0447-8; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Rybnikova E A, 2008, Neurosci Behav Physiol, V38, P721, DOI 10.1007/s11055-008-9038-x; Rybnikova E, 2008, J NEUROCHEM, V106, P1450, DOI 10.1111/j.1471-4159.2008.05516.x; Rybnikova E, 2007, NEUROSCI LETT, V417, P234, DOI 10.1016/j.neulet.2007.02.048; Rybnikova E, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00388; Rybnikova E, 2009, NEUROSCI RES, V65, P360, DOI 10.1016/j.neures.2009.08.013; Schaller B, 2005, NEUROSCI LETT, V377, P206, DOI 10.1016/j.neulet.2004.12.004; Schega L, 2013, GERONTOLOGY, V59, P316, DOI 10.1159/000350927; SCHURR A, 1986, BRAIN RES, V374, P244, DOI 10.1016/0006-8993(86)90418-X; Semenza GL, 2009, PHYSIOLOGY, V24, P97, DOI 10.1152/physiol.00045.2008; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Stenzel-Poore MP, 2007, STROKE, V38, P680, DOI 10.1161/01.STR.0000251444.56487.4c; Stowe AM, 2011, ANN NEUROL, V69, P975, DOI 10.1002/ana.22367; Studer L, 2000, J NEUROSCI, V20, P7377; Tarumi T, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00006; Tester NJ, 2014, AM J RESP CRIT CARE, V189, P57, DOI 10.1164/rccm.201305-0848OC; Trumbower RD, 2012, NEUROREHAB NEURAL RE, V26, P163, DOI 10.1177/1545968311412055; Tsai YW, 2013, J CEREBR BLOOD F MET, V33, P764, DOI 10.1038/jcbfm.2013.15; Tsai YW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024001; Verges S, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00058; Vetrovoy OV, 2017, BIOCHEMISTRY-MOSCOW+, V82, P392, DOI 10.1134/S000629791703018X; Wegener S, 2004, STROKE, V35, P616, DOI 10.1161/01.STR.0000115767.17923.6A; Weih M, 1999, STROKE, V30, P1851, DOI 10.1161/01.STR.30.9.1851; Yang Y, 2013, NEUROCHEM RES, V38, P123, DOI 10.1007/s11064-012-0899-6; Zhu LL, 2005, BRAIN RES, V1055, P1, DOI 10.1016/j.brainres.2005.04.075; Zhu XH, 2010, J NEUROSCI, V30, P12653, DOI 10.1523/JNEUROSCI.6414-09.2010; Zhu YL, 2007, INVEST OPHTH VIS SCI, V48, P1735, DOI 10.1167/iovs.06-1037	70	33	37	0	11	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1535-3702	1535-3699		EXP BIOL MED	Exp. Biol. Med.	JUN	2017	242	11					1198	1206		10.1177/1535370217712691			9	Medicine, Research & Experimental	Research & Experimental Medicine	EX0PS	WOS:000402923900010	28585890	Green Published			2021-06-18	
J	Erdodi, LA; Tyson, BT; Shahein, AG; Lichtenstein, JD; Abeare, CA; Pelletier, CL; Zuccato, BG; Kucharski, B; Roth, RM				Erdodi, Laszlo A.; Tyson, Bradley T.; Shahein, Ayman G.; Lichtenstein, Jonathan D.; Abeare, Christopher A.; Pelletier, Chantalle L.; Zuccato, Brandon G.; Kucharski, Brittany; Roth, Robert M.			The power of timing: Adding a time-to-completion cutoff to the Word Choice Test and Recognition Memory Test improves classification accuracy	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Embedded validity indicators; Performance validity assessment; Recognition Memory Test; Time-to-completion cutoffs; Word Choice Test	TRAUMATIC BRAIN-INJURY; PERFORMANCE TEST-II; CARD SORTING TEST; LEARNING TEST-II; RESPONSE BIAS; FIGURE TEST; DIGIT SPAN; NEUROPSYCHOLOGICAL TESTS; INVALID PERFORMANCE; INCOMPLETE EFFORT	Introduction: The Recognition Memory Test (RMT) and Word Choice Test (WCT) are structurally similar, but psychometrically different. Previous research demonstrated that adding a time-to-completion cutoff improved the classification accuracy of the RMT. However, the contribution of WCT time-cutoffs to improve the detection of invalid responding has not been investigated. The present study was designed to evaluate the classification accuracy of time-to-completion on the WCT compared to the accuracy score and the RMT. Method: Both tests were administered to 202 adults (M-age=45.3 years, SD=16.8; 54.5% female) clinically referred for neuropsychological assessment in counterbalanced order as part of a larger battery of cognitive tests. Results: Participants obtained lower and more variable scores on the RMT (M=44.1, SD=7.6) than on the WCT (M=46.9, SD=5.7). Similarly, they took longer to complete the recognition trial on the RMT (M=157.2s,SD=71.8) than the WCT (M=137.2s, SD=75.7). The optimal cutoff on the RMT (43) produced .60 sensitivity at .87 specificity. The optimal cutoff on the WCT (47) produced .57 sensitivity at .87 specificity. Time-cutoffs produced comparable classification accuracies for both RMT (192s; .48 sensitivity at .88 specificity) and WCT (171s; .49 sensitivity at .91 specificity). They also identified an additional 6-10% of the invalid profiles missed by accuracy score cutoffs, while maintaining good specificity (.93-.95). Functional equivalence was reached at accuracy scores 43 (RMT) and 47 (WCT) or time-to-completion 192s (RMT) and 171s (WCT). Conclusions: Time-to-completion cutoffs are valuable additions to both tests. They can function as independent validity indicators or enhance the sensitivity of accuracy scores without requiring additional measures or extending standard administration time.	[Erdodi, Laszlo A.; Abeare, Christopher A.; Zuccato, Brandon G.; Kucharski, Brittany] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Erdodi, Laszlo A.; Tyson, Bradley T.; Lichtenstein, Jonathan D.; Pelletier, Chantalle L.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Neuropsychol Serv, Lebanon, NH USA; [Tyson, Bradley T.] Western Washington Med Grp, Everett, WA USA; [Shahein, Ayman G.] Western Univ, Schulich Sch Med, London, ON, Canada	Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434			Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Axelrod BN, 2014, CLIN NEUROPSYCHOL, V28, P876, DOI 10.1080/13854046.2014.907583; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Bigler ED, 2015, BRAIN IMAGING BEHAV, V9, P421, DOI 10.1007/s11682-015-9409-1; Bigler ED, 2012, J INT NEUROPSYCH SOC, V18, P632, DOI 10.1017/S1355617712000252; Blaskewitz N, 2009, APPL NEUROPSYCHOL, V16, P54, DOI 10.1080/09084280802644227; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Conners K. C., 2004, CONNERS CONTINUOUS P; Cottingham ME, 2014, CLIN NEUROPSYCHOL, V28, P1030, DOI 10.1080/13854046.2014.951397; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Davis JJ, 2014, CLIN NEUROPSYCHOL, V28, P1278, DOI 10.1080/13854046.2014.975844; Delis DC, 2000, CALIFORNIA VERBAL LE; Erdodi LA, 2016, PSYCHOL INJ LAW, V9, P112, DOI 10.1007/s12207-016-9254-6; Erdodi LA, 2017, PSYCHOL ASSESSMENT, V29, P148, DOI 10.1037/pas0000319; Erdodi LA, 2014, PSYCHOL INJ LAW, V7, P255, DOI 10.1007/s12207-014-9197-8; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2009, ASSESSMENT, V16, P237, DOI 10.1177/1073191108326227; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2002, CLIN NEUROPSYCHOL, V16, P179, DOI 10.1076/clin.16.2.179.13241; HAYWARD L, 1987, AUST NZ J PSYCHIAT, V21, P87, DOI 10.3109/00048678709160904; Heaton R., 1993, WISCONSIN CARD SORTI; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Inman TH, 2002, ARCH CLIN NEUROPSYCH, V17, P1, DOI 10.1016/S0887-6177(00)00073-1; Kim MS, 2010, ARCH CLIN NEUROPSYCH, V25, P60, DOI 10.1093/arclin/acp088; Kim N, 2010, ARCH CLIN NEUROPSYCH, V25, P420, DOI 10.1093/arclin/acq040; Lange RT, 2013, PSYCHOL ASSESSMENT, V25, P339, DOI 10.1037/a0030915; Larrabee G.J., 2012, FORENSIC NEUROPSYCHO; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lichtenstein JD, 2017, CHILD NEUROPSYCHOL, V23, P284, DOI 10.1080/09297049.2015.1135422; Lu PH, 2003, CLIN NEUROPSYCHOL, V17, P426, DOI 10.1076/clin.17.3.426.18083; Meyers J., 1995, CLIN NEUROPSYCHOL, V9, P63, DOI [DOI 10.1080/13854049508402059, 10.1080/13854049508402059]; Ord JS, 2010, J CLIN EXP NEUROPSYC, V32, P380, DOI 10.1080/13803390903066881; Pearson, 2009, ADV CLIN SOLUTIONS W; Reedy SD, 2013, ARCH CLIN NEUROPSYCH, V28, P30, DOI 10.1093/arclin/acs106; Rey A., 1964, EXAMEN CLINIQUE PSYC; Reznek L, 2005, BRAIN INJURY, V19, P539, DOI 10.1080/02699050400005242; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Spreen O., 1977, NEUROSENSORY CTR COM; Sugarman MA, 2015, APPL NEUROPSYCH-ADUL, V22, P141, DOI 10.1080/23279095.2013.873439; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Trueblood W., 1994, J CLIN EXPT NEUROPSY, V4, P697; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	55	33	33	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2017	39	4					369	383		10.1080/13803395.2016.1230181			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	EQ6HT	WOS:000398183100006	28285575				2021-06-18	
J	Garcia-Gonzalez, D; Jayamohan, J; Sotiropoulos, SN; Yoon, SH; Cook, J; Siviour, CR; Arias, A; Jerusalem, A				Garcia-Gonzalez, D.; Jayamohan, J.; Sotiropoulos, S. N.; Yoon, S. -H.; Cook, J.; Siviour, C. R.; Arias, A.; Jerusalem, A.			On the mechanical behaviour of PEEK and HA cranial implants under impact loading	JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS			English	Article						Finite element head model; Cranial implant; PEEK; Macroporous HA; Impact loading	CONSTITUTIVE MODEL; STRAIN-RATE; IN-VIVO; FAILURE CHARACTERISTICS; DYNAMIC-RESPONSE; HEAD RESPONSE; BRAIN-TISSUE; FRACTURE; INJURIES; STRESS	The human head can be subjected to numerous impact loadings such as those produced by a fall or during sport activities. These accidents can result in skull fracture and in some complex cases, part of the skull may need to be replaced by a biomedical implant. Even when the skull is not damaged, such accidents can result in brain swelling treated by decompressive craniectomy. Usually, after recovery, the part of the skull that has been removed is replaced by a prosthesis. In such situations, a computational tool able to analyse the choice of prosthesis material depending on the patient's specific activity has the potential to be extremely useful for clinicians. The work proposed here focusses on the development and use of a numerical model for the analysis of cranial implants under impact conditions. In particular, two main biomaterials commonly employed for this kind of prosthesis are polyether-ether-ketone (PEEK) and macroporous hydroxyapatite (HA). In order to study the suitability of these implants, a finite element head model comprising scalp, skull, cerebral falx, cerebrospinal fluid and brain tissues, with a cranial implant replacing part of the skull has been developed from magnetic resonance imaging data. The human tissues and these two biocompatible materials have been independently studied and their constitutive models are provided here. A computational model of the human head under impact loading is then implemented and validated, and a numerical comparison of the mechanical impact response of PEEK and HA implants is presented. This comparison was carried out in terms of the effectiveness of both implants in ensuring structural integrity and preventing traumatic brain injury. The results obtained in this work highlight the need to take into account environmental mechanical considerations to select the optimal implant depending on the specific patient: whereas HA implants present attractive biointegration properties, PEEK implant can potentially be a much more appropriate choice in a demanding mechanical life style. Finally, a novel methodology is proposed to assess the need for further clinical evaluation in case of impact with both implants over a large range of impact conditions.	[Garcia-Gonzalez, D.; Arias, A.] Univ Carlos III Madrid, Dept Continuum Mech & Struct Anal, Avda Univ 30, Madrid 28911, Spain; [Jayamohan, J.] Oxford Univ Hosp, Dept Neurosurg, John Radcliffe Hosp, Oxford OX3 9DU, England; [Sotiropoulos, S. N.] John Radcliffe Hosp, Oxford Ctr Funct Magnet Resonance Imaging Brain, Oxford OX3 9DU, England; [Yoon, S. -H.; Cook, J.; Siviour, C. R.; Jerusalem, A.] Univ Oxford, Dept Engn Sci, Parks Rd, Oxford OX1 3PJ, England	Jerusalem, A (corresponding author), Univ Oxford, Dept Engn Sci, Parks Rd, Oxford OX1 3PJ, England.	antoine.jerusalem@eng.ox.ac.uk	Arias, Angel/K-4550-2014; Sotiropoulos, Stamatios/I-1163-2019; Garcia Gonzalez, Daniel/K-7349-2017	Arias, Angel/0000-0003-4696-7754; Sotiropoulos, Stamatios/0000-0003-4735-5776; Garcia Gonzalez, Daniel/0000-0003-4692-3508	University Carlos III are indebted to the Ministerio de Economia y Competitividad de Espana [DPI2014-57989-P]; Vicerrectorado de Politica Cientifica UC3M [2013-00219-002]; European Union's Seventh Framework Programme [306587]; 16 NIH Institutes and CentersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Clinical Center (CC); McDonnell Center for Systems Neuroscience at Washington University; EPSRCUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/M02833X/1]; Engineering and Physical Sciences Research CouncilUK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC) [EP/M02833X/1] Funding Source: researchfish	The researchers of the University Carlos III are indebted to the Ministerio de Economia y Competitividad de Espana (Project DPI2014-57989-P) and Vicerrectorado de Politica Cientifica UC3M (Project 2013-00219-002) for the financial support.; A.J. acknowledges funding from the European Union's Seventh Framework Programme (FP7 2007-2013) ERC Grant Agreement No. 306587.; MRI data were provided by the Human Connectome Project, WUMimi Consortium (Principal Investigators: David Van Essen and Kamil Ugurbil; 1U54MH091657) funded by the 16 NIH Institutes and Centers that support the NIH Blueprint for Neuroscience Research; and by the McDonnell Center for Systems Neuroscience at Washington University. Finally, we would like to thank Dr. S Barhli and Prof. J Marrow for valuable assistance with the X-ray tomography; the machine used was bought from EPSRC Grant EP/M02833X/1 "University of Oxford: experimental equipment upgrade".	Adetchessi AT, 2012, NEUROCHIRURGIE, V58, P382, DOI 10.1016/j.neuchi.2012.06.001; Al-Bsharat A. S., 1999, STAPP CAR CRASH J, V43, P321; Anand L, 1996, COMPUT MECH, V18, P339; Annaidh AN, 2012, J MECH BEHAV BIOMED, V5, P139, DOI 10.1016/j.jmbbm.2011.08.016; Baumgartner D, 2005, EUR J COMPUT MECH, V14, P421; Boyce MC, 2000, POLYMER, V41, P2183, DOI 10.1016/S0032-3861(99)00406-1; Boyde A, 1999, BONE, V24, P579, DOI 10.1016/S8756-3282(99)00083-6; Budday S, 2015, J MECH BEHAV BIOMED, V46, P318, DOI 10.1016/j.jmbbm.2015.02.024; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chen F, 2016, J MECH BEHAV BIOMED, V53, P427, DOI 10.1016/j.jmbbm.2015.08.037; Chistolini P, 1999, J MATER SCI-MATER M, V10, P739, DOI 10.1023/A:1008939524807; Dassault Systemes Abaqus v6.12, 2012, DOC ABAQUS AN US MAN; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; Deng Y, 2016, COMPOS STRUCT, V140, P534, DOI 10.1016/j.compstruct.2016.01.020; Doblare M, 2004, ENG FRACT MECH, V71, P1809, DOI 10.1016/j.engfracmech.2003.08.003; DUNN MG, 1983, CONNECT TISSUE RES, V12, P59, DOI 10.3109/03008208309005612; El Halabi F, 2011, J MECH BEHAV BIOMED, V4, P1819, DOI 10.1016/j.jmbbm.2011.05.039; El-Qoubaa Z, 2016, MECH MATER, V95, P15, DOI 10.1016/j.mechmat.2015.12.008; Eolchiyan S. A., 2014, VOPROSY NEIROKHIRURG, V75, P3; Fahlstedt M, 2012, P INT RES COUNC BIOM, V40, P787; FEI, 2015, FEI AMIRA 6 0 1; Frassanito P, 2013, CLIN NEUROL NEUROSUR, V115, P1496, DOI 10.1016/j.clineuro.2012.11.032; Fredriksson R., 2001, P 17 ESV C AMST NETH; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gambarotta L, 2005, J BIOMECH, V38, P2237, DOI 10.1016/j.jbiomech.2004.09.034; Gao C., 2007, THESIS; Garcia-Gonzalez D, 2017, INT J PLASTICITY, V88, P27, DOI 10.1016/j.ijplas.2016.09.011; Garcia-Gonzalez D, 2015, COMPOS STRUCT, V133, P1116, DOI 10.1016/j.compstruct.2015.08.028; Garcia-Gonzalez D, 2015, COMPOS STRUCT, V124, P88, DOI 10.1016/j.compstruct.2014.12.061; Giovanni B., 2005, P 19 INT TECHN C ENH; Goh JCH, 2002, P I MECH ENG H, V216, P359, DOI 10.1243/095441102321032157; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; HAWARD RN, 1968, PROC R SOC LON SER-A, V302, P453, DOI 10.1098/rspa.1968.0029; Hing KA, 1999, J MATER SCI-MATER M, V10, P135, DOI 10.1023/A:1008929305897; Honeybul S., 2016, INJURY; Horak Z, 2010, ACTA CHIR ORTHOP TR, V77, P463; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Jacquemoud C, 2007, J BIOMECH, V40, P468, DOI 10.1016/j.jbiomech.2005.12.010; Jenkinson M., 2005, P 11 ANN M ORG HUM B; Jerusalem A, 2012, ACTA BIOMATER, V8, P3360, DOI 10.1016/j.actbio.2012.04.039; Jirousek O, 2005, SOLID MECH APPL, V124, P459; JOCKISCH KA, 1992, J BIOMED MATER RES, V26, P133, DOI 10.1002/jbm.820260202; Kang HS, 1997, P STAPP CAR CRASH J, V41, P329; KHALIL TB, 1977, J BIOMECH, V10, P119, DOI 10.1016/0021-9290(77)90075-6; Khatam H, 2014, ACTA MECH SINICA-PRC, V30, P125, DOI 10.1007/s10409-014-0042-9; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Liu ZS, 2007, J BIOMECH, V40, P861, DOI 10.1016/j.jbiomech.2006.03.022; Loyd AM, 2014, ACCIDENT ANAL PREV, V72, P219, DOI 10.1016/j.aap.2014.06.022; Marcacci M, 1999, CALCIFIED TISSUE INT, V64, P83, DOI 10.1007/s002239900583; Melvin JW., 1969, DEV, V5, P811; Milchenko M, 2013, NEUROINFORMATICS, V11, P65, DOI 10.1007/s12021-012-9160-3; Olmi R, 1984, Chir Organi Mov, V69, P383; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; Ottenio M, 2015, J MECH BEHAV BIOMED, V41, P241, DOI 10.1016/j.jmbbm.2014.10.006; Piitulainen JM, 2015, WORLD NEUROSURG, V83, P708, DOI 10.1016/j.wneu.2015.01.014; Posti JP, 2016, J MECH BEHAV BIOMED, V55, P191, DOI 10.1016/j.jmbbm.2015.10.030; Rae PJ, 2007, POLYMER, V48, P598, DOI 10.1016/j.polymer.2006.11.032; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Rivard CH, 2002, J BIOMED MATER RES, V62, P488, DOI 10.1002/jbm.10159; Rosenthal G, 2014, NEUROSURGERY, V75, P523, DOI 10.1227/NEU.0000000000000477; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Sadigh S, 2004, J COMMUN HEALTH, V29, P129, DOI 10.1023/B:JOHE.0000016717.22032.03; Sahoo D, 2016, J MECH BEHAV BIOMED, V57, P24, DOI 10.1016/j.jmbbm.2015.11.014; Sahoo D, 2014, J MECH BEHAV BIOMED, V33, P24, DOI 10.1016/j.jmbbm.2013.08.022; Schulz BW, 2008, J REHABIL RES DEV, V45, P1227, DOI 10.1682/JRRD.2007.06.0092; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stalnaker R, 1969, THESIS; Stefini R., 2013, SURG NEUROL INT, P4; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts EG, 2008, STAPP CAR C, V52, P1; TONG P, 1976, J BIOMECH, V9, P649, DOI 10.1016/0021-9290(76)90107-X; Tse KM, 2015, ACCIDENT ANAL PREV, V79, P13, DOI 10.1016/j.aap.2015.03.012; Ueno K., 1989, CRASHWORTHINESS OCCU, V106; Van Essen DC, 2013, NEUROIMAGE, V80, P62, DOI 10.1016/j.neuroimage.2013.05.041; VOGEL HG, 1972, BIOCHIM BIOPHYS ACTA, V286, P79, DOI 10.1016/0304-4165(72)90090-6; Ward C. C., 1980, P 24 STAPP CAR CRASH, P347; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Willinger R, 2000, P INT RES COUNC BIOK, V28, P209; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; Zahouani H, 2009, SKIN RES TECHNOL, V15, P68, DOI 10.1111/j.1600-0846.2008.00329.x; Vinuela JZ, 2015, COMPOS STRUCT, V134, P613, DOI 10.1016/j.compstruct.2015.08.091; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714; Zhou Z, 2016, COMPUT METH PROG BIO, V131, P13, DOI 10.1016/j.cmpb.2016.04.013	88	33	35	1	35	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1751-6161	1878-0180		J MECH BEHAV BIOMED	J. Mech. Behav. Biomed. Mater.	MAY	2017	69						342	354		10.1016/j.jmbbm.2017.01.012			13	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	ET3SK	WOS:000400199600037	28160738	Other Gold, Green Published			2021-06-18	
J	Barrett, JP; Henry, RJ; Villapol, S; Stoica, BA; Kumar, A; Burns, MP; Faden, AI; Loane, DJ				Barrett, James P.; Henry, Rebecca J.; Villapol, Sonia; Stoica, Bogdan A.; Kumar, Alok; Burns, Mark P.; Faden, Alan I.; Loane, David J.			NOX2 deficiency alters macrophage phenotype through an IL-10/ STAT3 dependent mechanism: implications for traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						NADPH oxidase; NOX2; Traumatic brain injury; Macrophage; Neuroinflammation; Interleukin-10	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; NADPH OXIDASE; ALTERNATIVE ACTIVATION; GENE-EXPRESSION; FUNCTIONAL RECOVERY; OXIDATIVE STRESS; INTERLEUKIN-10; POLARIZATION; INHIBITION; MICROGLIA	Background: NADPH oxidase (NOX2) is an enzyme system that generates reactive oxygen species (ROS) in microglia and macrophages. Excessive ROS production is linked with neuroinflammation and chronic neurodegeneration following traumatic brain injury (TBI). Redox signaling regulates macrophage/ microglial phenotypic responses (pro-inflammatory versus anti-inflammatory), and NOX2 inhibition following moderate-tosevere TBI markedly reduces pro-inflammatory activation of macrophages/ microglia resulting in concomitant increases in anti-inflammatory responses. Here, we report the signaling pathways that regulate NOX2-dependent macrophage/ microglial phenotype switching in the TBI brain. Methods: Bone marrow-derived macrophages (BMDMs) prepared from wildtype (C57Bl/ 6) and NOX2 deficient (NOX2-/-) mice were treated with lipopolysaccharide (LPS; 10 ng/ ml), interleukin-4 (IL-4; 10 ng/ml), or combined LPS/ IL-4 to investigate signal transduction pathways associated with macrophage activation using western immunoblotting and qPCR analyses. Signaling pathways and activation markers were evaluated in ipsilateral cortical tissue obtained from adult male wildtype and NOX2-/-mice that received moderate-level controlled cortical impact (CCI). A neutralizing anti-IL-10 approach was used to determine the effects of IL-10 on NOX2-dependent transitions from pro-to anti-inflammatory activation states. Results: Using an LPS/ IL-4-stimulated BMDM model that mimics the mixed pro-and anti-inflammatory responses observed in the injured cortex, we show that NOX2-/-significantly reduces STAT1 signaling and markers of proinflammatory activation. In addition, NOX2-/-BMDMs significantly increase anti-inflammatory marker expression; IL-10-mediated STAT3 signaling, but not STAT6 signaling, appears to be critical in regulating this anti-inflammatory response. Following moderate-level CCI, IL-10 is significantly increased in microglia/macrophages in the injured cortex of NOX2-/-mice. These changes are associated with increased STAT3 activation, but not STAT6 activation, and a robust anti-inflammatory response. Neutralization of IL-10 in NOX2(-/-)BMDMs or CCI mice blocks STAT3 activation and the anti-inflammatory response, thereby demonstrating a critical role for IL-10 in regulating NOX2-dependent transitions between pro-and anti-inflammatory activation states. Conclusions: These studies indicate that following TBI NOX2 inhibition promotes a robust anti- inflammatory response in macrophages/ microglia that is mediated by the IL-10/ STAT3 signaling pathway. Thus, therapeutic interventions that inhibit macrophage/ microglial NOX2 activity may improve TBI outcomes by not only limiting pro- inflammatory neurotoxic responses, but also enhancing IL-10-mediated anti- inflammatory responses that are neuroprotective.	[Barrett, James P.; Henry, Rebecca J.; Stoica, Bogdan A.; Kumar, Alok; Faden, Alan I.; Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol & Shock, Trauma & Anesthesiol Res STAR Ctr, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Villapol, Sonia; Burns, Mark P.] Georgetown Univ, Dept Neurosci, Lab Brain Injury & Dementia, Washington, DC USA	Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol & Shock, Trauma & Anesthesiol Res STAR Ctr, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@anes.umm.edu	Villapol, Sonia/D-1949-2014; STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Henry, Rebecca/0000-0001-8548-1170; Loane, David/0000-0003-0393-3503; Villapol, Sonia/0000-0002-6174-4113; Faden, Alan I./0000-0003-0128-2348; Burns, Mark P/0000-0003-4750-2000; Barrett, James/0000-0002-0924-9449	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308 (D.J.Loane), R01NS037313 (A.I. Faden), R01 NS067417 (M.P. Burns)]; National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center [P30-AG028747]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082308, R01NS046717, R01NS037313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	This work was supported by NIH grant R01NS082308 (D.J.Loane), R01NS037313 (A.I. Faden), R01 NS067417 (M.P. Burns), and The National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center P30-AG028747 ( D.J. Loane).	Barrett JP, 2015, EXP CELL RES, V335, P258, DOI 10.1016/j.yexcr.2015.05.015; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BERG DJ, 1995, J CLIN INVEST, V96, P2339, DOI 10.1172/JCI118290; Bermudez S, 2016, MOL CELL NEUROSCI, V77, P53, DOI 10.1016/j.mcn.2016.10.001; Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Chen H, 2011, NEUROBIOL DIS, V42, P341, DOI 10.1016/j.nbd.2011.01.027; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Chhor V, 2013, BRAIN BEHAV IMMUN, V32, P70, DOI 10.1016/j.bbi.2013.02.005; Choi SH, 2012, J NEUROCHEM, V120, P292, DOI 10.1111/j.1471-4159.2011.07572.x; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Curtale G, 2013, P NATL ACAD SCI USA, V110, P11499, DOI 10.1073/pnas.1219852110; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012; Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gordon S, 2014, IMMUNOL REV, V262, P36, DOI 10.1111/imr.12223; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Grilli M, 2000, EUR J NEUROSCI, V12, P2265, DOI 10.1046/j.1460-9568.2000.00090.x; Heller NM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164795; Ishii H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.234; Kelly B, 2015, J BIOL CHEM, V290, P20348, DOI 10.1074/jbc.M115.662114; Khayrullina G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0391-8; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2013, J NEUROTRAUM, V30, P403, DOI 10.1089/neu.2012.2589; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Ma SF, 2015, BRAIN BEHAV IMMUN, V45, P157, DOI 10.1016/j.bbi.2014.11.007; Makita N, 2015, INT IMMUNOL, V27, P131, DOI 10.1093/intimm/dxu090; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Murray PJ, 2005, P NATL ACAD SCI USA, V102, P8686, DOI 10.1073/pnas.0500419102; Novak ML, 2013, J LEUKOCYTE BIOL, V93, P875, DOI 10.1189/jlb.1012512; Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Padgett LE, 2015, DIABETES, V64, P4171, DOI 10.2337/db15-0546; Perez-de Puig I, 2013, J CEREBR BLOOD F MET, V33, P1955, DOI 10.1038/jcbfm.2013.155; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Qian L, 2006, J PHARMACOL EXP THER, V319, P44, DOI 10.1124/jpet.106.106351; Qin HW, 2012, J IMMUNOL, V189, P3439, DOI 10.4049/jimmunol.1201168; Qin LY, 2004, J BIOL CHEM, V279, P1415, DOI 10.1074/jbc.M307657200; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; Shimohama S, 2000, BIOCHEM BIOPH RES CO, V273, P5, DOI 10.1006/bbrc.2000.2897; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Thomas KE, 2006, J BIOL CHEM, V281, P31119, DOI 10.1074/jbc.M604958200; Tian DS, 2016, J NEUROCHEM, V139, P96, DOI 10.1111/jnc.13751; Villapol S, 2015, BRAIN, V138, DOI 10.1093/brain/awv172; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001	63	33	34	0	15	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	MAR 24	2017	14								65	10.1186/s12974-017-0843-4			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	EP9BO	WOS:000397668900002	28340575	DOAJ Gold, Green Published			2021-06-18	
J	Li, X; Tan, J; Xiao, ZF; Zhao, YN; Han, SF; Liu, DY; Yin, W; Li, J; Li, J; Wanggou, SY; Chen, B; Ren, CP; Jiang, XJ; Dai, JW				Li, Xing; Tan, Jun; Xiao, Zhifeng; Zhao, Yannan; Han, Sufang; Liu, Dingyang; Yin, Wen; Li, Jing; Li, Juan; Wanggou, Siyi; Chen, Bing; Ren, Caiping; Jiang, Xingjun; Dai, Jianwu			Transplantation of hUC-MSCs seeded collagen scaffolds reduces scar formation and promotes functional recovery in canines with chronic spinal cord injury	SCIENTIFIC REPORTS			English	Article							MESENCHYMAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; AXONAL REGENERATION; REPARATIVE RESPONSE; NERVE REGENERATION; RAT; TRANSECTION; FACILITATE; STRATEGIES; IMPROVE	Spinal cord injury (SCI) can lead to locomotor deficits, and the repair of chronic SCI is considered one of the most challenging clinical problems. Although extensive studies have evaluated treatments for acute SCI in small animals, comparatively fewer studies have been conducted on large-animal SCI in the chronic phase, which is more clinically relevant. Here, we used a collagen-based biomaterial, named the NeuroRegen scaffold, loaded with human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in a canine chronic SCI model. To generate chronic SCI, the T8 spinal cord segment was removed by complete transection of the spinal cord. Two months later, glial scar tissue was removed and a NeuroRegen scaffold was transplanted into the lesion area. Functionalized NeuroRegen scaffold implantation promoted both locomotor recovery and endogenous neurogenesis in the lesion area. Moreover, some newly generated neurons successfully matured into 5-HT-positive neurons at 1 year post-injury. In addition, many regenerated axon fibers in the lesion area exhibited remyelination and synapse formation at 1 year post-injury in the functionalized NeuroRegen scaffold group. In conclusion, the NeuroRegen scaffold functionalized with hUC-MSCs is a promising potential therapeutic approach to chronic SCI that promotes neuronal regeneration, reduces glial scar formation, and ultimately improves locomotor recovery.	[Li, Xing; Xiao, Zhifeng; Zhao, Yannan; Han, Sufang; Li, Jing; Chen, Bing; Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China; [Tan, Jun; Liu, Dingyang; Yin, Wen; Li, Juan; Wanggou, Siyi; Jiang, Xingjun] Cent S Univ, Xiangya Hosp, Dept Neurosurg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China; [Ren, Caiping] Cent S Univ, Sch Basic Med Sci, Collaborat Innovat Ctr Canc Med, Canc Res Inst, Changsha 410008, Hunan, Peoples R China	Dai, JW (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, State Key Lab Mol Dev Biol, Beijing 100101, Peoples R China.; Jiang, XJ (corresponding author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.	jiangxingjun@sina.com; jwdai@genetics.ac.cn			Strategic Priority Research Program of the Chinese Academy of SciencesChinese Academy of Sciences [XDA01030000]; Program of the Chinese Academy of SciencesChinese Academy of Sciences [ZDRW-ZS-2016-2]	This work was supported by the "Strategic Priority Research Program of the Chinese Academy of Sciences" (grant no. XDA01030000), the Key Research Program of the Chinese Academy of Sciences (grant no. ZDRW-ZS-2016-2).	Cao Y, 2008, NEUROREHAB NEURAL RE, V22, P262, DOI 10.1177/1545968307308550; Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469; Ceballos D, 1999, EXP NEUROL, V158, P290, DOI 10.1006/exnr.1999.7111; Cholas R, 2012, TISSUE ENG PT A, V18, P2158, DOI [10.1089/ten.TEA.2011.0577, 10.1089/ten.tea.2011.0577]; Cholas RH, 2012, BIOMATERIALS, V33, P2050, DOI 10.1016/j.biomaterials.2011.11.028; Crespo D, 2007, EXP NEUROL, V206, P159, DOI 10.1016/j.expneurol.2007.05.001; Dasari Venkata Ramesh, 2014, World J Stem Cells, V6, P120, DOI 10.4252/wjsc.v6.i2.120; De Miguel MP, 2012, CURR MOL MED, V12, P574; Ding DC, 2015, CELL TRANSPLANT, V24, P339, DOI 10.3727/096368915X686841; English K, 2010, CELL STEM CELL, V7, P431, DOI 10.1016/j.stem.2010.09.009; Fan JA, 2010, J NEUROTRAUM, V27, P1671, DOI 10.1089/neu.2010.1281; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Garcia-Alias G, 2009, NAT NEUROSCI, V12, P1145, DOI 10.1038/nn.2377; Hamilton LK, 2009, NEUROSCIENCE, V164, P1044, DOI 10.1016/j.neuroscience.2009.09.006; Han QQ, 2009, TISSUE ENG PT A, V15, P2927, DOI [10.1089/ten.tea.2008.0506, 10.1089/ten.TEA.2008.0506]; Han QQ, 2010, BIOMATERIALS, V31, P9212, DOI 10.1016/j.biomaterials.2010.08.040; Han S, 2014, SPINAL CORD, V52, P867, DOI 10.1038/sc.2014.173; Han SF, 2016, J BIOMED MATER RES A, V104, P1759, DOI 10.1002/jbm.a.35708; Han SF, 2015, BIOMATERIALS, V41, P89, DOI 10.1016/j.biomaterials.2014.11.031; Harness ET, 2008, SPINAL CORD, V46, P733, DOI 10.1038/sc.2008.56; He ZG, 2004, ANNU REV NEUROSCI, V27, P341, DOI 10.1146/annurev.neuro.27.070203.144340; Hu SL, 2010, CRIT CARE MED, V38, P2181, DOI 10.1097/CCM.0b013e3181f17c0e; Jeffery ND, 2005, J NEUROTRAUM, V22, P1282, DOI 10.1089/neu.2005.22.1282; Jung DI, 2009, J NEUROL SCI, V285, P67, DOI 10.1016/j.jns.2009.05.027; Kadoya K, 2009, NEURON, V64, P165, DOI 10.1016/j.neuron.2009.09.016; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Labrador RO, 1998, EXP NEUROL, V149, P243, DOI 10.1006/exnr.1997.6650; Lalu MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047559; Lee H, 2010, P NATL ACAD SCI USA, V107, P3340, DOI 10.1073/pnas.0905437106; Lee JH, 2011, J NEUROL SCI, V300, P86, DOI 10.1016/j.jns.2010.09.025; Lin H, 2006, J BIOMED MATER RES A, V79A, P591, DOI 10.1002/jbm.a.30862; Lu P, 2012, CELL, V150, P1264, DOI 10.1016/j.cell.2012.08.020; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Maier IC, 2006, PHILOS T R SOC B, V361, P1611, DOI 10.1098/rstb.2006.1890; Meletis K, 2008, PLOS BIOL, V6, P1494, DOI 10.1371/journal.pbio.0060182; Olby NJ, 2001, AM J VET RES, V62, P1624, DOI 10.2460/ajvr.2001.62.1624; Oliveri RS, 2014, NEUROBIOL DIS, V62, P338, DOI 10.1016/j.nbd.2013.10.014; Pearse DD, 2006, J NEUROTRAUM, V23, P438, DOI 10.1089/neu.2006.23.437; Qin Y, 2015, J NEUROSCI RES, V93, P391, DOI 10.1002/jnr.23480; Quertainmont R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039500; Rocha LB, 2002, BIOMATERIALS, V23, P449, DOI 10.1016/S0142-9612(01)00126-0; Sabelstrom H, 2014, EXP NEUROL, V260, P44, DOI 10.1016/j.expneurol.2013.01.026; Sabelstrom H, 2013, SCIENCE, V342, P637, DOI 10.1126/science.1242576; Torbet J, 2007, BIOMATERIALS, V28, P4268, DOI 10.1016/j.biomaterials.2007.05.024; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; van Velthoven CTJ, 2012, PEDIATR RES, V71, P474, DOI 10.1038/pr.2011.64; Yang ZY, 2015, P NATL ACAD SCI USA, V112, P13354, DOI 10.1073/pnas.1510194112	49	33	37	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	MAR 6	2017	7								43559	10.1038/srep43559			12	Multidisciplinary Sciences	Science & Technology - Other Topics	EM6OE	WOS:000395431200001	28262732	DOAJ Gold, Green Published			2021-06-18	
J	Xu, ZM; Yuan, F; Liu, YL; Ding, J; Tian, HL				Xu, Zhi-ming; Yuan, Fang; Liu, Ying-liang; Ding, Jun; Tian, Heng-li			Glibenclamide Attenuates Blood-Brain Barrier Disruption in Adult Mice after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						animal studies; apoptosis; BBB; TBI	SPINAL-CORD-INJURY; SUBARACHNOID HEMORRHAGE; ISCHEMIC-STROKE; CEREBRAL EDEMA; RAT MODEL; APOPTOSIS; ATP; INHIBITION; CHANNEL; SULFONYLUREAS	Glibenclamide is a hypoglycemic drug that is widely used for the treatment of diabetes mellitus type 2 (DM II), but it also plays a protective role following injury to the central nervous system (CNS). However, the precise mechanisms underlying its neuroprotective actions remain to be elucidated. Therefore, the present study evaluated the effects of glibenclamide on the blood-brain barrier (BBB) in a mouse model of traumatic brain injury (TBI). In the present study, 86 adult male C57BL/6 mice were exposed to a controlled cortical impact (CCI) injury and then received glibenclamide (10 lg) for 3 days. Tight junction (TJ) protein levels, BBB permeability, and tissue hemoglobin levels were evaluated following the CCI injury. Additionally, a biaxial stretch injury was applied to cell cultures of bEnd. 3 cells using the Cell Injury Controller II system to explore the mechanisms by which glibenclamide inhibits apoptosis-signaling pathways. Compared with the control group, glibenclamide-treated mice exhibited decreases in brain water content (p < 0.05), tissue hemoglobin levels (p < 0.05), and Evans Blue extravasation (p < 0.01) after the CCI injury. Glibenclamide primarily attenuated apoptosis via the JNK/c-jun signaling pathway and resulted in an elevation of stretch injury-induced ZO-1 expression in bEnd. 3 cells (p < 0.01). Glibenclamide downregulated the activity of the JNK/c-jun apoptosis-signaling pathway which, in turn, decreased apoptosis in endothelial cells (ECs). This may have prevented the disruption of the BBB in a mouse model of TBI.	[Xu, Zhi-ming; Yuan, Fang; Liu, Ying-liang; Ding, Jun; Tian, Heng-li] Shanghai Jiao Tong Univ, Sch Med, Affiliated Peoples Hosp 6, Dept Neurosurg, Shanghai, Peoples R China	Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Dept Neurosurg, Affiliated Peoples Hosp 6, 600 YiShan Rd, Shanghai 200030, Peoples R China.	tianhlsh@126.com			National Nature and Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271383, 81471245, 81501048]; Shanghai Science and Technique Committee [13411951401]	This work was supported by grants from National Nature and Science Foundation of China (no. 81271383,81471245, 81501048) and the Shanghai Science and Technique Committee (no.13411951401).	Abu-Qare AW, 2001, J TOXICOL ENV HEAL B, V4, P313, DOI 10.1080/109374001301419737; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Anuradha C. V., 2001, Indian Journal of Physiology and Pharmacology, V45, P408; Ashcroft FM, 1996, HORM METAB RES, V28, P456, DOI 10.1055/s-2007-979837; Chen LQ, 2016, ANN HEMATOL, V95, P365, DOI 10.1007/s00277-015-2567-9; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; FELDMAN JM, 1985, AM J MED, V79, P102, DOI 10.1016/S0002-9343(85)80015-2; Jayakumar AR, 2014, TRANSL STROKE RES, V5, P28, DOI 10.1007/s12975-014-0328-z; KRAMER W, 1995, DIABETES RES CLIN PR, V28, pS67, DOI 10.1016/0168-8227(95)01076-P; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Kurland DB, 2013, PHARMACEUTICALS, V6, P1287, DOI 10.3390/ph6101287; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Li Y, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-014-2826-z; MARBLE A, 1971, DRUGS, V1, P109, DOI 10.2165/00003495-197101020-00001; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Panten U, 1996, EXP CLIN ENDOCR DIAB, V104, P1, DOI 10.1055/s-0029-1211414; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Pompermayer K, 2007, EUR J PHARMACOL, V556, P215, DOI 10.1016/j.ejphar.2006.10.065; Riddle MC, 2003, J CLIN ENDOCR METAB, V88, P528, DOI 10.1210/jc.2002-021971; Simard JM, 2007, J CLIN INVEST, V117, P2105, DOI 10.1172/JCI32041; Simard JM, 2012, TRANSL STROKE RES, V3, P286, DOI 10.1007/s12975-012-0149-x; Simard JM, 2012, EXP NEUROL, V233, P829, DOI 10.1016/j.expneurol.2011.11.048; Simard JM, 2012, EXP NEUROL, V233, P566, DOI 10.1016/j.expneurol.2011.11.044; Simard JM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000522; Simard JM, 2010, STROKE, V41, P531, DOI 10.1161/STROKEAHA.109.572644; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Simard JM, 2009, J CEREBR BLOOD F MET, V29, P317, DOI 10.1038/jcbfm.2008.120; Simard JM, 2009, STROKE, V40, P604, DOI 10.1161/STROKEAHA.108.522409; Simard JM, 2006, NAT MED, V12, P433, DOI 10.1038/nm1390; Sinha K, 2013, ARCH TOXICOL, V87, P1157, DOI 10.1007/s00204-013-1034-4; Song JS, 2002, ENVIRON TOXICOL PHAR, V11, P85, DOI 10.1016/S1382-6689(01)00108-9; Stark RJ, 2016, CLIN SCI, V130, P451, DOI 10.1042/CS20150592; Thal SC, 2013, CRIT CARE MED, V41, P1305, DOI 10.1097/CCM.0b013e31827ca494; Thompson EM, 2013, NEOPLASIA, V15, P535, DOI 10.1593/neo.13164; Tien YC, 2011, INT J MOL SCI, V12, P4053, DOI 10.3390/ijms12064053; Tosun C, 2013, STROKE, V44, P3522, DOI 10.1161/STROKEAHA.113.002904; Tosun C, 2013, BRAIN SCI, V3, P215, DOI 10.3390/brainsci3010215; Wali B, 2012, STROKE RES TREAT, V2012, DOI 10.1155/2012/460909; Webster Gregory D, 2008, Biomed Sci Instrum, V44, P483; Woo SK, 2013, J BIOL CHEM, V288, P3655, DOI 10.1074/jbc.M112.428219; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; Zhou YL, 2009, BRAIN RES, V1270, P131, DOI 10.1016/j.brainres.2009.03.010; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	47	33	33	1	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					925	933		10.1089/neu.2016.4491			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200020	27297934				2021-06-18	
J	Maneshi, MM; Maki, B; Gnanasambandam, R; Belin, S; Popescu, GK; Sachs, F; Hua, SZ				Maneshi, Mohammad Mehdi; Maki, Bruce; Gnanasambandam, Radhakrishnan; Belin, Sophie; Popescu, Gabriela K.; Sachs, Frederick; Hua, Susan Z.			Mechanical stress activates NMDA receptors in the absence of agonists	SCIENTIFIC REPORTS			English	Article							D-ASPARTATE RECEPTOR; MECHANOSENSITIVE ION CHANNELS; MOUSE CENTRAL NEURONS; FORCE/TENSION SENSORS; CORTICAL ASTROCYTES; ENDOTHELIAL-CELLS; GLIAL-CELLS; LIVE CELLS; CALCIUM; GLUTAMATE	While studying the physiological response of primary rat astrocytes to fluid shear stress in a model of traumatic brain injury (TBI), we found that shear stress induced Ca2+ entry. The influx was inhibited by MK-801, a specific pore blocker of N-Methyl-D-aspartic acid receptor (NMDAR) channels, and this occurred in the absence of agonists. Other NMDA open channel blockers ketamine and memantine showed a similar effect. The competitive glutamate antagonists AP5 and GluN2B-selective inhibitor ifenprodil reduced NMDA-activated currents, but had no effect on the mechanically induced Ca2+ influx. Extracellular Mg2+ at 2 mM did not significantly affect the shear induced Ca2+ influx, but at 10 mM it produced significant inhibition. Patch clamp experiments showed mechanical activation of NMDAR and inhibition by MK-801. The mechanical sensitivity of NMDARs may play a role in the normal physiology of fluid flow in the glymphatic system and it has obvious relevance to TBI.	[Maneshi, Mohammad Mehdi; Gnanasambandam, Radhakrishnan; Sachs, Frederick; Hua, Susan Z.] Univ Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA; [Maneshi, Mohammad Mehdi; Hua, Susan Z.] Univ Buffalo, Dept Mech & Aerosp Engn, Buffalo, NY 14260 USA; [Maki, Bruce; Belin, Sophie; Popescu, Gabriela K.] Univ Buffalo, Dept Biochem, Buffalo, NY 14260 USA	Hua, SZ (corresponding author), Univ Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA.; Hua, SZ (corresponding author), Univ Buffalo, Dept Mech & Aerosp Engn, Buffalo, NY 14260 USA.	zhua@buffalo.edu	Belin, Sophie/AAJ-7962-2020	Maki, Bruce/0000-0002-6760-375X; Popescu, Gabriela/0000-0003-4658-2002	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS085517, NS098385, NS097016, HL054887]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL054887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS097016, R21NS085517, R21NS098385] Funding Source: NIH RePORTER	This work was supported by National Institute of Health grant NS085517 (S.Z.H.), grants NS098385 and NS097016 (G.K.P.), and grant HL054887 (F.S.).	Akinlaja J, 1998, BIOPHYS J, V75, P247, DOI 10.1016/S0006-3495(98)77511-3; Bae C, 2013, P NATL ACAD SCI USA, V110, pE1162, DOI 10.1073/pnas.1219777110; Bae C, 2011, BIOCHEMISTRY-US, V50, P6295, DOI 10.1021/bi200770q; Besch SR, 2002, PFLUG ARCH EUR J PHY, V445, P161, DOI 10.1007/s00424-002-0903-0; Bowman CL, 2007, TOXICON, V49, P249, DOI 10.1016/j.toxicon.2006.09.030; Bresink I, 1996, BRIT J PHARMACOL, V119, P195, DOI 10.1111/j.1476-5381.1996.tb15971.x; BRODE HL, 1959, PHYS FLUIDS, V2, P217, DOI 10.1063/1.1705911; Combes M, 2015, J NEUROSCI RES, V93, P633, DOI 10.1002/jnr.23524; Conti F, 1996, GLIA, V17, P254, DOI 10.1002/(SICI)1098-1136(199607)17:3<254::AID-GLIA7>3.0.CO;2-0; Coste B, 2012, NATURE, V483, P176, DOI 10.1038/nature10812; Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270; Cox C. D., 2016, NATURE COMMUNICATION, V7; Dai JW, 1996, MOL BIOL CELL, V7, P2614; Drew LJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000515; Dzamba D, 2013, CURR NEUROPHARMACOL, V11, P250, DOI 10.2174/1570159X11311030002; Emnett CM, 2013, MOL PHARMACOL, V84, P935, DOI 10.1124/mol.113.089334; Florian JA, 2003, CIRC RES, V93, pE136, DOI 10.1161/01.RES.0000101744.47866.D5; Gnanasambandam R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125503; Goriely A, 2015, BIOMECH MODEL MECHAN, V14, P931, DOI 10.1007/s10237-015-0662-4; Guo J, 2014, ANTIOXID REDOX SIGN, V20, P986, DOI 10.1089/ars.2013.5708; Haidekker MA, 2000, AM J PHYSIOL-HEART C, V278, pH1401; Hardingham GE, 2010, NAT REV NEUROSCI, V11, P682, DOI 10.1038/nrn2911; Heureaux J, 2014, CELL MOL BIOENG, V7, P307, DOI 10.1007/s12195-014-0337-8; Hua X, 2004, J NEUROSCI RES, V76, P86, DOI 10.1002/jnr.20061; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; Husi H, 2000, NAT NEUROSCI, V3, P661; Innocenti B, 2000, J NEUROSCI, V20, P1800; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Kloda A, 2007, P NATL ACAD SCI USA, V104, P1540, DOI 10.1073/pnas.0609649104; Lalo U, 2006, J NEUROSCI, V26, P2673, DOI 10.1523/JNEUROSCI.4689-05.2006; Lee MC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014123; MACVICAR BA, 1984, SCIENCE, V226, P1345, DOI 10.1126/science.6095454; Malomouzh AI, 2011, MUSCLE NERVE, V44, P987, DOI 10.1002/mus.22250; Maneshi MM, 2015, J NEUROTRAUM, V32, P1020, DOI 10.1089/neu.2014.3677; Markin V S, 2015, Open J Biophys, V5, P80; Martinac B, 2014, ANTIOXID REDOX SIGN, V20, P952, DOI 10.1089/ars.2013.5471; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Palygin O, 2010, CELL CALCIUM, V48, P225, DOI 10.1016/j.ceca.2010.09.004; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; PASTI L, 1995, J BIOL CHEM, V270, P15203, DOI 10.1074/jbc.270.25.15203; Rahimzadeh J, 2011, AM J PHYSIOL-CELL PH, V301, pC646, DOI 10.1152/ajpcell.00099.2011; Sachs Frederick, 2015, World J Neurol, V5, P74, DOI 10.5316/wjn.v5.i3.74; Schipke CG, 2001, FASEB J, V15, P1270; Singh P, 2012, J BIOL CHEM, V287, P4348, DOI 10.1074/jbc.M111.253740; Slavchov RI, 2014, J PHYS CHEM B, V118, P12660, DOI 10.1021/jp506965v; Suchyna TM, 2009, BIOPHYS J, V97, P738, DOI 10.1016/j.bpj.2009.05.018; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Suchyna TM, 2000, BIOPHYS J, V78, p173A; Thrane AS, 2012, P NATL ACAD SCI USA, V109, P18974, DOI 10.1073/pnas.1209448109; Uchino S, 2001, FEBS LETT, V506, P117, DOI 10.1016/S0014-5793(01)02899-X; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Yang C, 2015, BBA-MOL CELL RES, V1853, P1889, DOI 10.1016/j.bbamcr.2015.05.001; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	55	33	33	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 3	2017	7								39610	10.1038/srep39610			10	Multidisciplinary Sciences	Science & Technology - Other Topics	EG6IB	WOS:000391147000001	28045032	DOAJ Gold, Green Published			2021-06-18	
J	Devoto, C; Arcurio, L; Fetta, J; Ley, M; Rodney, T; Kanefsky, R; Gill, J				Devoto, Christina; Arcurio, Lindsay; Fetta, Joseph; Ley, Mary; Rodney, Tamar; Kanefsky, Rebekah; Gill, Jessica			Inflammation Relates to Chronic Behavioral and Neurological Symptoms in Military Personnel with Traumatic Brain Injuries	CELL TRANSPLANTATION			English	Article						mild traumatic brain injury; inflammation; biomarkers; post-traumatic stress disorder	POSTTRAUMATIC-STRESS-DISORDER; PTSD; MORTALITY; VETERANS; HEART; IRAQ; RISK; COMORBIDITY; ACTIVATION; DEPRESSION	Studies have shown that the presence of acute inflammation during recovery is indicative of poor outcomes after a traumatic brain injury (TBI); however, the role of chronic inflammation in predicting post-TBI-related symptoms remains poorly understood. The purpose of this study was to compare inflammatory biomarkers (tumor necrosis factor [TNF]-alpha, interleukin [IL]-6, and IL-10) in active duty personnel who either sustained or did not sustain a TBI. Service members were also assessed for post-traumatic stress disorder (PTSD), depression, and quality of life through self-reported measures. IL-6 and TNF-alpha concentrations were greater in the TBI group than in the control group. Of those with a TBI, IL-6 and TNF-a concentrations were greater in the high-PTSD group than the low-PTSD group. No significant differences were found in IL-10 or the IL-6/IL-10 ratios between those with low and high PTSD. Exploratory factor analysis was conducted to describe the latent structure of variables relating to emotional and physical health (i.e., Short Form 36 subcomponents, etc.) and their relationships within the TBI group with inflammatory cytokines. Four symptom profiles were found, with the third component most relating to PTSD and depression symptoms and high inflammation. This study indicates that the comorbidity of TBI and PTSD is associated with inflammation in a military sample, emphasizing the necessity for intervention in order to mitigate the risks associated with inflammation.	[Devoto, Christina; Arcurio, Lindsay; Fetta, Joseph; Ley, Mary; Kanefsky, Rebekah; Gill, Jessica] NINR, NIH, 1 Cloisters Dr, Bethesda, MD 20892 USA; [Rodney, Tamar] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA	Devoto, C (corresponding author), NINR, NIH, 1 Cloisters Dr, Bethesda, MD 20892 USA.	christina.devoto@nih.gov	Gill, Gill M/Q-2020-2017	Fetta, Joseph/0000-0002-7654-2864	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; National Institutes of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR); Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [ZIANR000027] Funding Source: NIH RePORTER	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The work was performed at the Madigan Army Medical Center, Tacoma, WA. Support for this work included funding from the Intramural department of the National Institutes of Health, National Institutes of Nursing Research, and the Department of Defense in the Center for Neuroscience and Regenerative Medicine.	Armed Forces Health Surveillance Center, 2010, INS ACT COMP, P12; Boscarino JA, 2008, PSYCHOSOM MED, V70, P668, DOI 10.1097/PSY.0b013e31817bccaf; Ferreira LCB, 2014, BRAIN INJURY, V28, P1311, DOI 10.3109/02699052.2014.916818; Brewer-Smyth K, 2014, REHABIL NURS, V39, P183, DOI 10.1002/rnj.150; Brown GC, 2015, BRAIN RES, V1628, P288, DOI 10.1016/j.brainres.2015.08.031; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Centers for Disease Control and Prevention, 2014, INJ PREV CONTR TRAUM; Dallmeier D, 2012, J AM HEART ASSOC, V1, P1; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Edwards R.D., 2010, NBER WORKING PAPER N, DOI [10.3386/w16163, DOI 10.3386/W16163]; Field A., 2013, DISCOVERING STAT USI, V4; Field A. P, 2009, DISCOVERING STAT USI; Fisher H., 2010, US MILITARY CASUALTY; Gill J, 2014, PSYCHIAT RES, V216, P116, DOI 10.1016/j.psychres.2014.01.046; Gill J, 2010, BIOL PSYCHIAT, V68, P999, DOI 10.1016/j.biopsych.2010.07.033; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Grenon SM, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.003010; Groer MW, 2015, BIOL RES NURS, V17, P303, DOI 10.1177/1099800414544949; Kim EJ, 2015, LEARN MEMORY, V22, P411, DOI 10.1101/lm.037291.114; Kou ZF, 2014, GLIA, V62, P1831, DOI 10.1002/glia.22690; Kumar RG, 2016, BRAIN BEHAV IMMUN, V53, P183, DOI 10.1016/j.bbi.2015.12.008; Levkovitz Y, 2015, EUR NEUROPSYCHOPHARM, V25, P124, DOI 10.1016/j.euroneuro.2014.11.012; Lindqvist D, 2014, BRAIN BEHAV IMMUN, V42, P81, DOI 10.1016/j.bbi.2014.06.003; Lustenberger T, 2016, IMMUNOBIOLOGY, V221, P427, DOI 10.1016/j.imbio.2015.11.011; MacKenzie EJ, 2002, QUAL LIFE RES, V11, P797, DOI 10.1023/A:1020820017658; Maes M, 2012, PROG NEURO-PSYCHOPH, V36, P169, DOI 10.1016/j.pnpbp.2011.09.006; Mondello S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06446; O'Donovan A, 2015, PSYCHONEUROENDOCRINO, V51, P557, DOI 10.1016/j.psyneuen.2014.11.010; Oosthuizen Frasia, 2005, Neuropsychiatr Dis Treat, V1, P109, DOI 10.2147/nedt.1.2.109.61049; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Paulus EJ, 2013, J TRAUMA STRESS, V26, P169, DOI 10.1002/jts.21785; Phillips AC, 2009, PSYCHOSOM MED, V71, P395, DOI 10.1097/PSY.0b013e31819e6706; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Pugh MJV, 2014, MED CARE, V52, P172, DOI 10.1097/MLR.0000000000000059; Rathbone ATL, 2015, BRAIN BEHAV IMMUN, V46, P1, DOI 10.1016/j.bbi.2015.02.009; Rusiecki Jennifer A, 2013, Front Psychiatry, V4, P56, DOI 10.3389/fpsyt.2013.00056; Santarsieri M, 2015, BRAIN BEHAV IMMUN, V45, P15, DOI 10.1016/j.bbi.2014.09.003; Scherrer JF, 2010, AM HEART J, V159, P772, DOI 10.1016/j.ahj.2010.02.033; Schlenger WE, 2015, AM J EPIDEMIOL, V182, P980, DOI 10.1093/aje/kwv217; Soares FMS, 2012, NEUROIMMUNOMODULAT, V19, P377, DOI 10.1159/000342141; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Srikanthan K, 2016, INT J MED SCI, V13, P25, DOI 10.7150/ijms.13800; Sun J, 2016, CLIN J AM SOC NEPHRO, V11, P1163, DOI 10.2215/CJN.10441015; Sussman D, 2016, BMC NEUROSCI, V17, DOI 10.1186/s12868-016-0247-x; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trivedi MH, 2004, PSYCHOL MED, V34, P73, DOI 10.1017/S0033291703001107; Tsai JCG, 2010, NEUROREHABILITATION, V26, P85, DOI [10.3233/NRE-2010-0538, 10.3233/NRE-2011-0538]; van Zuiden M, 2012, PSYCHONEUROENDOCRINO, V37, P1822, DOI 10.1016/j.psyneuen.2012.03.018; Varatharaj A, 2017, BRAIN BEHAV IMMUN, V60, P1, DOI 10.1016/j.bbi.2016.03.010; Veer IM, 2015, PSYCHIAT RES-NEUROIM, V233, P436, DOI 10.1016/j.pscychresns.2015.07.016; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Zen AL, 2012, HEALTH PSYCHOL, V31, P194, DOI 10.1037/a0025989	54	33	33	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2017	26	7					1169	1177		10.1177/0963689717714098			9	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	EZ4GO	WOS:000404671800006	28933225	DOAJ Gold, Green Published			2021-06-18	
J	Kawoos, U; Gu, M; Lankasky, J; McCarron, RM; Chavko, M				Kawoos, Usmah; Gu, Ming; Lankasky, Jason; McCarron, Richard M.; Chavko, Mikulas			Effects of Exposure to Blast Overpressure on Intracranial Pressure and Blood-Brain Barrier Permeability in a Rat Model	PLOS ONE			English	Article							CLOSED-HEAD INJURY; SHOCK-WAVES; MOUSE MODEL; TIME-COURSE; IN-VITRO; INFLAMMATION; DYSFUNCTION; DISRUPTION; MILD; PATHOPHYSIOLOGY	Exposure to blast overpressure (BOP) activates a cascade of pathological processes including changes in intracranial pressure (ICP) and blood-brain barrier (BBB) permeability resulting in traumatic brain injury (TBI). In this study the effect of single and multiple exposures at two intensities of BOP on changes in ICP and BBB permeability in Sprague-Dawley rats was evaluated. Animals were exposed to a single or three repetitive (separated by 0.5 h) BOPs at 72 kPa or 110 kPa. ICP was monitored continuously via telemetry for 6 days after exposure to BOP. The alteration in the permeability of BBB was determined by extravasation of Evans Blue (EB) into brain parenchyma. A significant increase in ICP was observed in all groups except the single 72 kPa BOP group. At the same time a marked increase in BBB permeability was also seen in various parts of the brain. The extent of ICP increase as well as BBB permeability change was dependent on intensity and frequency of blast.	[Kawoos, Usmah; Gu, Ming; Lankasky, Jason; McCarron, Richard M.; Chavko, Mikulas] Naval Med Res Ctr, Dept Neurotrauma, Silver Spring, MD 20910 USA; [McCarron, Richard M.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA; [McCarron, Richard M.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA	Kawoos, U (corresponding author), Naval Med Res Ctr, Dept Neurotrauma, Silver Spring, MD 20910 USA.	Usmah.kawoos.ctr@mail.mil			Office of Naval Research (ONR)Office of Naval Research [601152N.0000.000.A1308]	This work was supported by Office of Naval Research (ONR) Work Unit 601152N.0000.000.A1308. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Guild SJ, 2015, J APPL PHYSIOL, V119, P576, DOI 10.1152/japplphysiol.00165.2015; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hue CD, 2016, J NEUROTRAUM, V33, P1202, DOI 10.1089/neu.2015.4067; Hue CD, 2014, J NEUROTRAUM, V31, P951, DOI 10.1089/neu.2013.3149; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Jamali S, 1998, BRAIN INJURY, V12, P525, DOI 10.1080/026990598122485; Kabu S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127971; Kawoos U, 2014, IEEE T BIO-MED ENG, V61, P841, DOI 10.1109/TBME.2013.2291239; Leonardi AD, 2013, ANN BIOMED ENG, V41, P2488, DOI 10.1007/s10439-013-0850-2; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Magnuson J, 2012, CURR NEUROL NEUROSCI, V12, P570, DOI 10.1007/s11910-012-0303-6; Meaney DF, 2014, J BIOMECH ENG-T ASME, V136, DOI 10.1115/1.4026364; Mishra V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26992; Needham CE, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00072; Paxinos G, 1998, ACTA NEUROBIOLOGIAE; Rafaels KA, 2012, J TRAUMA ACUTE CARE, V73, P895, DOI 10.1097/TA.0b013e31825a760e; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Saljo A, 2011, NEUROIMAGE, V54, pS83, DOI 10.1016/j.neuroimage.2010.05.050; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Saunders NR, 2015, FRONT NEUROSCI-SWITZ, V9, DOI [10.3339/fnins.2015.00385, 10.3389/fnins.2015.00385]; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Skotak M, 2013, J NEUROTRAUM, V30, P1147, DOI 10.1089/neu.2012.2652; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Sundaramurthy A, 2012, J NEUROTRAUM, V29, P2352, DOI 10.1089/neu.2012.2413; Tompkins P, 2013, J NEUROTRAUM, V30, P1888, DOI 10.1089/neu.2012.2674; Treggiari MM, 2007, NEUROCRIT CARE, V6, P104, DOI 10.1007/s12028-007-0012-1; Wang Y, 2011, J NEUROTRAUM, V28, P2171, DOI 10.1089/neu.2011.1990; Wojcik BE, 2010, AM J PREV MED, V38, pS108, DOI 10.1016/j.amepre.2009.10.006; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7	46	33	33	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 1	2016	11	12							e0167510	10.1371/journal.pone.0167510			12	Multidisciplinary Sciences	Science & Technology - Other Topics	EE3JC	WOS:000389482700176	27907158	DOAJ Gold, Green Published			2021-06-18	
J	Meizoso, JP; Ray, JJ; Karcutskie, CA; Allen, CJ; Zakrison, TL; Pust, GD; Koru-Sengul, T; Ginzburg, E; Pizano, LR; Schulman, CI; Livingstone, AS; Proctor, KG; Namias, N				Meizoso, Jonathan P.; Ray, Juliet J.; Karcutskie, Charles A.; Allen, Casey J.; Zakrison, Tanya L.; Pust, Gerd D.; Koru-Sengul, Tulay; Ginzburg, Enrique; Pizano, Louis R.; Schulman, Carl I.; Livingstone, Alan S.; Proctor, Kenneth G.; Namias, Nicholas			Effect of time to operation on mortality for hypotensive patients with gunshot wounds to the torso: The golden 10 minutes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						GSW; laparotomy; penetrating trauma; time to operation	ENDOVASCULAR BALLOON OCCLUSION; PATIENTS MULTICENTER COHORT; SYSTOLIC BLOOD-PRESSURE; TRAUMA PATIENTS; ROOM RESUSCITATION; SEVERE SEPSIS; SEPTIC SHOCK; 110 MMHG; DEATHS; CARE	INTRODUCTION Timely hemorrhage control is paramount in trauma; however, a critical time interval from emergency department arrival to operation for hypotensive gunshot wound (GSW) victims is not established. We hypothesize that delaying surgery for more than 10 minutes from arrival increases all-cause mortality in hypotensive patients with GSW. METHODS Data of adults (n = 309) with hypotension and GSW to the torso requiring immediate operation from January 2004 to September 2013 were retrospectively reviewed. Patients with resuscitative thoracotomies, traumatic brain injury, transfer from outside institutions, and operations occurring more than 1 hour after arrival were excluded. Survival analysis using multivariate Cox regression models was used for comparison. Hazard ratios (HRs) and 95% confidence intervals (CIs) are reported. Statistical significance was considered at p 0.05. RESULTS The study population was aged 32 12 years, 92% were male, Injury Severity Score was 24 15, systolic blood pressure was 81 +/- 29 mm Hg, Glasgow Coma Scale score was 13 +/- 4. Overall mortality was 27%. Mean time to operation was 19 +/- 13 minutes. After controlling for organ injury, patients who arrived to the operating room after 10 minutes had a higher likelihood of mortality compared with those who arrived in 10 minutes or less (HR, 1.89; 95% CI, 1.10-3.26; p = 0.02); this was also true in the severely hypotensive patients with systolic blood pressure of 70 mm Hg or less (HR, 2.67; 95% CI, 0.97-7.34; p = 0.05). The time associated with a 50% cumulative mortality was 16 minutes. CONCLUSIONS Delay to the operating room of more than 10 minutes increases the risk of mortality by almost threefold in hypotensive patients with GSW. Protocols should be designed to shorten time in the emergency department. Further prospective observational studies are required to validate these findings. LEVEL OF EVIDENCE Therapeutic study, level IV.	[Meizoso, Jonathan P.; Ray, Juliet J.; Karcutskie, Charles A.; Allen, Casey J.; Zakrison, Tanya L.; Pust, Gerd D.; Ginzburg, Enrique; Pizano, Louis R.; Schulman, Carl I.; Livingstone, Alan S.; Proctor, Kenneth G.; Namias, Nicholas] Univ Miami, Miller Sch Med, Ryder Trauma Ctr, DeWitt Daughtry Family Dept Surg, 1800 NW 10th Ave,Suite T-215 D40, Miami, FL 33136 USA; [Meizoso, Jonathan P.; Ray, Juliet J.; Koru-Sengul, Tulay] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA	Namias, N (corresponding author), Univ Miami, Miller Sch Med, Ryder Trauma Ctr, DeWitt Daughtry Family Dept Surg, 1800 NW 10th Ave,Suite T-215 D40, Miami, FL 33136 USA.	nnamias@miami.edu	Livingstone, Alan/AAA-4026-2019; Schulman, Carl/AAE-7448-2021; Meizoso, Jonathan/AAF-5777-2019	Meizoso, Jonathan/0000-0002-6616-6682; Schulman, Carl/0000-0001-8899-4350; Koru-Sengul, Tulay/0000-0003-0974-8405; Namias, Nicholas/0000-0001-7021-2250	Office of Naval Research, Naval Medical Research Center; US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	Supported in part by grants from the Office of Naval Research, Naval Medical Research Center, and the US Army Medical Research and Materiel Command.	Allen CJ, 2015, J SURG RES, V197, P240, DOI 10.1016/j.jss.2015.03.005; American College of Surgeons Committee on Trauma, 2014, RESOURCES OPTIMAL CA, V6th; Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; Brenner ML, 2013, J TRAUMA ACUTE CARE, V75, P506, DOI 10.1097/TA.0b013e31829e5416; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Clarke JR, 2002, J TRAUMA, V52, P420, DOI 10.1097/00005373-200203000-00002; Dellinger RP, 2013, CRIT CARE MED, V41, P580, DOI 10.1097/CCM.0b013e31827e83af; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Deree J, 2007, J VASC SURG, V45, P493, DOI 10.1016/j.jvs.2006.11.018; FISCHER RP, 1978, JAMA-J AM MED ASSOC, V240, P1731, DOI 10.1001/jama.240.16.1731; Hasler RM, 2012, RESUSCITATION, V83, P476, DOI 10.1016/j.resuscitation.2011.10.018; Hasler RM, 2011, RESUSCITATION, V82, P1202, DOI 10.1016/j.resuscitation.2011.04.021; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; HOYT DB, 1989, ARCH SURG-CHICAGO, V124, P906; Hoyt DB, 1989, ARCH SURG-CHICAGO, V124, P9; Khetarpal S, 1999, J TRAUMA, V47, P576, DOI 10.1097/00005373-199909000-00028; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Martin M, 2012, AM J SURG, V204, P187, DOI 10.1016/j.amjsurg.2012.06.001; Matsushima K, 2015, J TRAUMA ACUTE CARE, V79, P838, DOI 10.1097/TA.0000000000000719; Meizoso JP, 2015, J TRAUMA ACUTE CARE, V79, P227, DOI 10.1097/TA.0000000000000748; Mesar T, 2015, J TRAUMA ACUTE CARE, V79, P39, DOI 10.1097/TA.0000000000000696; Morrison JJ, 2012, J SURG RES, V177, P341, DOI 10.1016/j.jss.2012.04.035; Mowery NT, 2011, J TRAUMA, V70, P1317, DOI 10.1097/TA.0b013e3182175199; Pencina MJ, 2004, STAT MED, V23, P2109, DOI 10.1002/sim.1802; Porter JM, 2001, AM SURGEON, V67, P611; Remick KN, 2014, J TRAUMA ACUTE CARE, V76, P1251, DOI 10.1097/TA.0000000000000218; RHODES M, 1989, J TRAUMA, V29, P907, DOI 10.1097/00005373-198907000-00002; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Saver JL, 2006, STROKE, V37, P263, DOI 10.1161/01.STR.0000196957.55928.ab; Stannard A, 2011, J TRAUMA, V71, P1869, DOI 10.1097/TA.0b013e31823fe90c; Steele JT, 1997, AM J SURG, V174, P683, DOI 10.1016/S0002-9610(97)00194-3; TRUNKEY DD, 1983, SCI AM, V249, P28, DOI 10.1038/scientificamerican0883-28	34	33	33	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2016	81	4					685	691		10.1097/TA.0000000000001198			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DZ2FX	WOS:000385658800009	27488491				2021-06-18	
J	Mychasiuk, R; Hehar, H; Ma, I; Candy, S; Esser, MJ				Mychasiuk, Richelle; Hehar, Harleen; Ma, Irene; Candy, Sydney; Esser, Michael J.			Reducing the time interval between concussion and voluntary exercise restores motor impairment, short-term memory, and alterations to gene expression	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						hippocampus; mild traumatic brain injury; prefrontal cortex; rodent models; telomere length	TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; COGNITIVE DYSFUNCTION; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; SPORTS CONCUSSION; FAT DIET; MODEL; PLASTICITY; RECOVERY	Despite the most common form of brain injury, there has been little progress in the prognosis and treatment of concussion/mild traumatic brain injury (mTBI). Current return-to-play' guidelines are conservative, deterring the initiation of physical and social activity until patients are asymptomatic; but the effects of post-injury exercise have not been adequately investigated. Therefore, this study examined the effects of voluntary exercise on concussion recovery. Using a translational rodent model of concussion, we examined the influence of exercise on injury-associated behaviours that comprise post-concussive syndrome (PCS) and gene expression changes (bdnf, dnmt1, Igf-1, pgc1-a, Tert) in prefrontal cortex and hippocampus. In addition, as we have previously demonstrated telomere length (TL) to be a reliable predictor of mTBI prognosis, TL was also examined. The results suggest that exercise initiated within 1-3days post-concussion significantly improved motor and cognitive functioning, but had limited efficacy treating emotional impairments. What is more, when deprived of social interaction and exercise, a combination similar to clinical recommendations for rest until symptom resolution, animals did not recover and exhibited impairments similar to typical mTBI animals. Exercise aided in restoration of mTBI-induced modifications to gene expression in both brain regions. An inverse relationship between the exercise return interval and TL was identified, indicating greater recovery with acute exercise reinstatement. Although additional strategies may need to be employed for emotional functioning, these findings support re-evaluation of return-to-play' guidelines, suggesting that exercise is valuable for the treatment of concussion.	[Mychasiuk, Richelle; Hehar, Harleen; Ma, Irene] Univ Calgary, Dept Psychol, Alberta Childrens Hosp, Res Inst, Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada; [Candy, Sydney; Esser, Michael J.] Univ Calgary, Fac Med, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Dept Psychol, Alberta Childrens Hosp, Res Inst, Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 1N4, Canada.	rmmychas@ucalgary.ca			Alberta Children's Hospital Research Institute (ACHRI); Alberta Children's Hospital Foundation (ACHF); Canadian Institute for Health Research (CIHR)Canadian Institutes of Health Research (CIHR)	The authors thank Dr C Teskey, K. Yu and R. Tobias for their technical assistance. They also thank the Alberta Children's Hospital Research Institute (ACHRI), the Alberta Children's Hospital Foundation (ACHF) and the Canadian Institute for Health Research (CIHR) for their financial support.	Baek S, 2004, NEUROSCI LETT, V363, P94, DOI 10.1016/j.neulet.2004.03.059; Baker LD, 2010, ARCH NEUROL-CHICAGO, V67, P71, DOI 10.1001/archneurol.2009.307; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bell HC, 2010, BEHAV BRAIN RES, V207, P7, DOI 10.1016/j.bbr.2009.09.029; Bernardo TC, 2016, BRAIN PATHOL, V26, P648, DOI 10.1111/bpa.12403; Blasco MA, 2005, NAT REV GENET, V6, P611, DOI 10.1038/nrg1656; Bonefeld BE, 2008, SYNAPSE, V62, P302, DOI 10.1002/syn.20496; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P186, DOI 10.1093/arclin/act083; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Cotman CW, 2002, EXERC SPORT SCI REV, V30, P75, DOI 10.1097/00003677-200204000-00006; DeMatteo C, 2015, DISABIL REHABIL, V37, P1107, DOI 10.3109/09638288.2014.952452; Dishman RK, 2006, OBESITY, V14, P345, DOI 10.1038/oby.2006.46; Feng J, 2010, NAT NEUROSCI, V13, P423, DOI 10.1038/nn.2514; Golshani Peyman, 2005, Thalamus & Related Systems, V3, P227, DOI 10.1017/S1472928807000222; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2014, J NEUROTRAUM, V31, P674, DOI 10.1089/neu.2013.3151; Griesbach GS, 2013, J NEUROTRAUM, V30, P281, DOI 10.1089/neu.2012.2616; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hamilton M, 2016, BRAIN INJURY, V30, P819, DOI 10.3109/02699052.2016.1146962; Hehar H, 2016, NEUROBIOL DIS, V87, P11, DOI 10.1016/j.nbd.2015.12.007; Heyer GL, 2016, J PEDIATR-US, V174, P33, DOI 10.1016/j.jpeds.2016.03.014; Ji LL, 2010, DOSE-RESPONSE, V8, P73, DOI 10.2203/dose-response.09-048.Ji; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Mangiola A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/736104; Mattson MP, 2000, EXP GERONTOL, V35, P489, DOI 10.1016/S0531-5565(00)00115-7; McCrory P, 2009, J ATHL TRAINING, P36; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; MONDON CE, 1985, J APPL PHYSIOL, V58, P1553; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Mychasiuk R, 2014, JOVE, V8; Mychasiuk R, 2016, J NEUROSCI METH, V257, P168, DOI 10.1016/j.jneumeth.2015.10.002; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Nelson LD, 2016, NEUROLOGY, V86, P1856, DOI 10.1212/WNL.0000000000002679; Ozdemir D, 2012, NEUROSCI LETT, V507, P84, DOI 10.1016/j.neulet.2011.11.059; Panossian LA, 2003, NEUROBIOL AGING, V24, P77, DOI 10.1016/S0197-4580(02)00043-X; PELLIS SM, 1992, BEHAV BRAIN RES, V50, P135, DOI 10.1016/S0166-4328(05)80295-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Piao CS, 2013, NEUROBIOL DIS, V54, P252, DOI 10.1016/j.nbd.2012.12.017; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Seifert TD, 2013, HEADACHE, V53, P726, DOI 10.1111/head.12087; Shi H, 2013, BMC BIOTECHNOL, V13, DOI 10.1186/1472-6750-13-83; Smidt N, 2005, AUST J PHYSIOTHER, V51, P71, DOI 10.1016/S0004-9514(05)70036-2; Solomon GS, 2016, PHYSICIAN SPORTSMED, V44, P14, DOI 10.1080/00913847.2016.1121091; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Zhu HY, 2000, J NEUROCHEM, V75, P117, DOI 10.1046/j.1471-4159.2000.0750117.x	59	33	34	1	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	OCT	2016	44	7					2407	2417		10.1111/ejn.13360			11	Neurosciences	Neurosciences & Neurology	DY8QE	WOS:000385394100002	27521273				2021-06-18	
J	Lorton, F; Poullaouec, C; Legallais, E; Simon-Pimmel, J; Chene, MA; Leroy, H; Roy, M; Launay, E; Gras-Le Guen, C				Lorton, F.; Poullaouec, C.; Legallais, E.; Simon-Pimmel, J.; Chene, M. A.; Leroy, H.; Roy, M.; Launay, E.; Gras-Le Guen, C.			Validation of the PECARN clinical decision rule for children with minor head trauma: a French multicenter prospective study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Minor head trauma; Children; External validation; Clinical decision rule; Cranial computed tomography	PREDICTION RULES; METHODOLOGICAL STANDARDS; COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; INJURY; MANAGEMENT; RISK	Background: To date, the Pediatric Emergency Care Applied Research Network (PECARN) rule for identifying children who are at very low risk of clinically-important traumatic brain injuries after minor head trauma has not been validated prospectively in an independent population. Our goal was to evaluate the diagnostic performance of the PECARN clinical decision rule in a French pediatric population in multiple clinical settings. Methods: We conducted a multicenter, prospective, non-interventional cohort study of patients with minor head trauma who presented to three emergency departments in France. We enrolled patients younger than 16 years of age seeking a consultation within 24 h of head trauma with Glasgow Coma Scale scores of 14-15. Results: During the study period, we included 1499 children of which 421 (28 %) were under 2 years of age, and 955 (64 %) were male. A cranial computed tomography (CT) scan was performed on 76 patients (5.1 %). Of the 1499 included patients, 9 children (0.6 %) had a clinically-important traumatic brain injury, and none were classified as very low risk by the PECARN rule. In our study, the sensitivity of this clinical decision rule was 100 % (95 % CI 66.4 to 100 %), the specificity was 69.9 % (95 % CI 67.5 to 72.2 %) and the negative predictive value was 100 % (95 % CI 99.7 to 100 %). Discussion: Our study confirmed the good predictive performances of the PECARN clinical decision rule for minor head trauma in children. The PECARN rule performed similarly to our study and to its internal validation study. Conclusions: We conducted an external validation study of the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma, according to the methodological standards. The PECARN rule successfully identified all patients with clinically-important traumatic brain injuries, with a limited use of CT scans. Conducting a broad validation study with a large cohort is a prerequisite to provide sufficient statistical power before authorizing its implementation and generalization.	[Lorton, F.; Poullaouec, C.; Legallais, E.; Simon-Pimmel, J.; Roy, M.; Gras-Le Guen, C.] Univ Hosp, Dept Pediat Emergency, F-44093 Nantes 01, France; [Lorton, F.; Gras-Le Guen, C.] Univ Hosp, INSERM CIC 1413, 38 Bd Jean Monnet, F-44093 Nantes 01, France; [Chene, M. A.] Hosp St Nazaire, Dept Pediat, 11 Bd Georges Charpak, F-44606 St Nazaire, France; [Leroy, H.] Dept Hosp Vendee, Dept Emergency, F-85925 Les Oudairies 9, La Roche Sur Yo, France; [Launay, E.] Univ Hosp, Dept Pediat, F-44093 Nantes 01, France	Lorton, F (corresponding author), Univ Hosp, Dept Pediat Emergency, F-44093 Nantes 01, France.; Lorton, F (corresponding author), Univ Hosp, INSERM CIC 1413, 38 Bd Jean Monnet, F-44093 Nantes 01, France.	fleur.lorton@chu-nantes.fr		Launay, Elise/0000-0002-4081-4653; Lorton, Fleur/0000-0003-0921-4622; GRAS-LE GUEN, Christele/0000-0001-9060-2344			Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Easter JS, 2014, ANN EMERG MED, V64, P145, DOI 10.1016/j.annemergmed.2014.01.030; Homer CJ, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.6.e78; Jehle E, 2012, ANN FR MED URGENCE, V2, P199, DOI 10.1007/s13341-012-0202-4; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Larson DB, 2011, RADIOLOGY, V259, P793, DOI 10.1148/radiol.11101939; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Lorton F, 2014, ARCH PEDIATRIE, V21, P790, DOI 10.1016/j.arcped.2014.04.015; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Parkin PC, 2009, LANCET, V374, P1127, DOI 10.1016/S0140-6736(09)61634-2; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306	21	33	33	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	AUG 4	2016	24								98	10.1186/s13049-016-0287-3			8	Emergency Medicine	Emergency Medicine	DT4LV	WOS:000381453500001	27488722	DOAJ Gold, Green Published			2021-06-18	
J	Badner, A; Vawda, R; Laliberte, A; Hong, J; Mikhail, M; Jose, A; Dragas, R; Fehlings, M				Badner, Anna; Vawda, Reaz; Laliberte, Alex; Hong, James; Mikhail, Mirriam; Jose, Alejandro; Dragas, Rachel; Fehlings, Michael			Early Intravenous Delivery of Human Brain Stromal Cells Modulates Systemic Inflammation and Leads to Vasoprotection in Traumatic Spinal Cord Injury	STEM CELLS TRANSLATIONAL MEDICINE			English	Article						Mesenchymal stromal cells; Pericytes; Spinal cord injury; Vasoprotection; Interleukin-10	MESENCHYMAL STEM-CELLS; AUTOLOGOUS BONE-MARROW; MYOCARDIAL-INFARCTION; CEREBRAL-ISCHEMIA; INTRACEREBRAL HEMORRHAGE; BARRIER PERMEABILITY; VASCULAR DISRUPTION; HUMAN PERICYTES; IMMUNE-SYSTEM; IN-VITRO	Spinal cord injury (SCI) is a life-threatening condition withmultifaceted complications and limited treatment options. In SCI, the initial physical trauma is closely followed by a series of secondary events, including inflammation and blood spinal cord barrier (BSCB) disruption, which further exacerbate injury. This secondary pathology is partially mediated by the systemic immune response to trauma, in which cytokine production leads to the recruitment/activation of inflammatory cells. Because early intravenous delivery of mesenchymal stromal cells (MSCs) has been shown to mitigate inflammation in various models of neurologic disease, this study aimed to assess these effects in a rat model of SCI (C7-T1, 35-gram clip compression) using human brain-derived stromal cells. Quantitative polymerase chain reaction for a human-specific DNA sequence was used to assess cell biodistribution/clearance and confirmed that only a small proportion (approximately 0.001%-0.002%) of cells are delivered to the spinal cord, with the majority residing in the lung, liver, and spleen. Intriguingly, although cell populations drastically declined in all aforementioned organs, there remained a persistent population in the spleen at 7 days. Furthermore, the cell infusion significantly increased splenic and circulating levels of interleukin-10-a potent anti-inflammatory cytokine. Through this suppression of the systemic inflammatory response, the cells also reduced acute spinal cord BSCB permeability, hemorrhage, and lesion volume. These early effects further translated into enhanced functional recovery and tissue sparing 10 weeks after SCI. This work demonstrates an exciting therapeutic approach whereby a minimally invasive cell-transplantation procedure can effectively reduce secondary damage after SCI through systemic immunomodulation. SIGNIFICANCE Central nervous system pericytes (perivascular stromal cells) have recently gained significant attention within the scientific community. In addition to being recognized as major players in neurotrauma, pericytes have been discovered to share a common origin and potentially function with traditionally defined mesenchymal stromal cells (MSCs). Although there have been several in vitro comparisons, the in vivo therapeutic application of human brain-derived stromal cells has not been previously evaluated. This study demonstrates that these cells not only display a MSC phenotype in vitro but also have similar in vivo immunomodulatory effects after spinal cord injury that are more potent than those of non-central nervous system tissue-derived cells. Therefore, these cells are of great interest for therapeutic use in spinal cord injury.	[Badner, Anna; Vawda, Reaz; Laliberte, Alex; Hong, James; Mikhail, Mirriam; Jose, Alejandro; Dragas, Rachel; Fehlings, Michael] Univ Hlth Network, Toronto Western Res Inst, Div Genet & Dev, Toronto, ON, Canada; [Badner, Anna; Laliberte, Alex; Hong, James; Dragas, Rachel; Fehlings, Michael] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Fehlings, Michael] Univ Hlth Network, Toronto Western Hosp, Spinal Program, Toronto, ON, Canada	Fehlings, M (corresponding author), Univ Toronto, Inst Med Sci, Toronto Western Hosp, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.on.ca	Badner, Anna/N-8035-2019	Badner, Anna/0000-0002-5244-6165; Fehlings, Michael/0000-0002-5722-6364; Laliberte, Alex/0000-0002-3503-4177	Canadian Institutes of Health Research Training Program in Regenerative MedicineCanadian Institutes of Health Research (CIHR); Ontario Graduate ScholarshipOntario Graduate Scholarship; Halbert Chair in Neural Repair and Regeneration; Dezwirek Family Foundation	We thank Ahad Siddiqui and Madeleine O'Higgins for manuscript review and editing and Jian Wang for technical support. This work was supported by funds from the Canadian Institutes of Health Research Training Program in Regenerative Medicine (A.B.) and the Ontario Graduate Scholarship (A.B.). M.F. was supported by the Halbert Chair in Neural Repair and Regeneration and Dezwirek Family Foundation.	Acosta SA, 2015, STROKE, V46, P2616, DOI 10.1161/STROKEAHA.115.009854; Aertker BM, 2016, EXP NEUROL, V275, P411, DOI 10.1016/j.expneurol.2015.01.008; Alexanian AR, 2010, RESTOR NEUROL NEUROS, V28, P761, DOI 10.3233/RNN-2010-0547; Avolio E, 2015, CIRC RES, V116, pE81, DOI 10.1161/CIRCRESAHA.115.306146; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bedi SS, 2013, STEM CELL TRANSL MED, V2, P953, DOI 10.5966/sctm.2013-0100; Birbrair A, 2015, CLIN SCI, V128, P81, DOI 10.1042/CS20140278; Blocki A, 2013, STEM CELLS DEV, V22, P2347, DOI 10.1089/scd.2012.0415; Bochev I, 2008, CELL BIOL INT, V32, P384, DOI 10.1016/j.cellbi.2007.12.007; Brewer KL, 1999, EXP NEUROL, V159, P484, DOI 10.1006/exnr.1999.7173; Brown A, 2014, J NEUROSURG-SPINE, V20, P164, DOI 10.3171/2013.10.SPINE13113; Burchfield JS, 2008, CIRC RES, V103, P203, DOI 10.1161/CIRCRESAHA.108.178475; Chen CW, 2013, STEM CELLS, V31, P305, DOI 10.1002/stem.1285; Chen M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0284-x; Choi JJ, 2008, CLIN EXP IMMUNOL, V153, P269, DOI 10.1111/j.1365-2249.2008.03683.x; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; DASILVA ML, 2006, J CELL SCI, V119, P2204, DOI DOI 10.1242/JCS.02932; Dayan V, 2011, BASIC RES CARDIOL, V106, P1299, DOI 10.1007/s00395-011-0221-9; De Miguel MP, 2012, CURR MOL MED, V12, P574; Devine SM, 2001, EXP HEMATOL, V29, P244, DOI 10.1016/S0301-472X(00)00635-4; Nguyen DH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-224; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; Figley SA, 2014, J NEUROTRAUM, V31, P541, DOI 10.1089/neu.2013.3034; Fleming JC, 2012, J TRAUMA ACUTE CARE, V72, P1194, DOI 10.1097/TA.0b013e31824d68bd; Forgione N, 2014, J NEUROTRAUM, V31, P1776, DOI 10.1089/neu.2014.3388; Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165; Hegyi B, 2010, INT IMMUNOL, V22, P551, DOI 10.1093/intimm/dxq039; Honma T, 2006, EXP NEUROL, V199, P56, DOI 10.1016/j.expneurol.2005.05.004; Huston JM, 2009, J IMMUNOL, V183, P552, DOI 10.4049/jimmunol.0802684; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; Ivanova-Todorova E, 2009, IMMUNOL LETT, V126, P37, DOI 10.1016/j.imlet.2009.07.010; Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Liao GP, 2015, PEDIATR CRIT CARE ME, V16, P245, DOI 10.1097/PCC.0000000000000324; Lucin KM, 2007, EXP NEUROL, V207, P75, DOI 10.1016/j.expneurol.2007.05.019; Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681; Matsushita T, 2015, EXP NEUROL, V267, P152, DOI 10.1016/j.expneurol.2015.03.001; Meirelles LD, 2008, STEM CELLS, V26, P2287, DOI 10.1634/stemcells.2007-1122; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Mendel TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065691; Menge T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004660; Min CK, 2007, BONE MARROW TRANSPL, V39, P637, DOI 10.1038/sj.bmt.1705644; MOSTAFA ME, 2001, CARDIOVASC RES, V49, P882; Oliveri RS, 2014, NEUROBIOL DIS, V62, P338, DOI 10.1016/j.nbd.2013.10.014; Rice T, 2007, J NEUROPATH EXP NEUR, V66, P184, DOI 10.1097/01.jnen.0000248552.07338.7f; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; Schwartz M, 2006, J NEUROTRAUM, V23, P360, DOI 10.1089/neu.2006.23.360; Soubeyrand M, 2014, J NEUROTRAUM, V31, P1767, DOI 10.1089/neu.2013.3319; Tang GH, 2014, STEM CELLS, V32, P3150, DOI 10.1002/stem.1808; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Thompson CD, 2013, J NEUROTRAUM, V30, P1311, DOI 10.1089/neu.2012.2651; Tsumuraya T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0252-5; Vendrame M, 2006, EXP NEUROL, V199, P191, DOI 10.1016/j.expneurol.2006.03.017; Walker PA, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-228; Walker PA, 2010, EXP NEUROL, V225, P341, DOI 10.1016/j.expneurol.2010.07.005; WARNICK RE, 1995, J NEUROSCI METH, V58, P167, DOI 10.1016/0165-0270(94)00172-D; Watanabe J, 2013, NEUROBIOL DIS, V59, P86, DOI 10.1016/j.nbd.2013.06.017; Williams K, 2001, GLIA, V36, P156, DOI 10.1002/glia.1105; Yu DS, 2015, J MOL NEUROSCI, V56, P388, DOI 10.1007/s12031-015-0564-z; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang Y, 2013, J NEUROSCI, V33, P12970, DOI 10.1523/JNEUROSCI.1974-13.2013	64	33	33	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2157-6564	2157-6580		STEM CELL TRANSL MED	Stem Cells Transl. Med.	AUG	2016	5	8					991	1003		10.5966/sctm.2015-0295			13	Cell & Tissue Engineering	Cell Biology	DY7DE	WOS:000385288800002	27245367	DOAJ Gold, Green Published			2021-06-18	
J	Mannix, R; Meehan, WP; Pascual-Leone, A				Mannix, Rebekah; Meehan, William P., III; Pascual-Leone, Alvaro			OPINION Sports-related concussions - media, science and policy	NATURE REVIEWS NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; WHITE-MATTER INTEGRITY; FOOTBALL-LEAGUE PLAYER; QUALITY-OF-LIFE; BRAIN-INJURY; SOCCER PLAYERS; RECURRENT CONCUSSION; PROFESSIONAL SOCCER; LONG-TERM; PARTICIPATION	Although growing awareness about the potential long-term deleterious effects of sport-related concussion has led to increased attention to the risks of collision sports, calls to ban these sports, such as American football, might be premature. Collision sports have a relatively high incidence of concussions, but participation in these sports also confers a host of benefits. In addition, the associated risks of participation, including concussion, have not been definitively shown to outweigh the benefits they provide, and the risk benefit ratio might vary among individuals. The risks of concussion and repetitive concussions associated with collision sports are unknown in the general population and not well characterized even in elite athlete populations. In this article, we discuss current knowledge on sports-related concussion, its neurological consequences, and implications for regulation of the practice of collision sports.	[Mannix, Rebekah] Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, 300 Longwood Ave, Boston, MA 02115 USA; [Pascual-Leone, Alvaro] Beth Israel Deaconess Med Ctr, Div Cognit Neurol, 330 Brookline Ave, Boston, MA 02115 USA	Mannix, R (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	rebekah.mannix@childrens.harvard.edu	Pascual-Leone, Alvaro/AAC-5101-2019; Mannix, Rebekah/AAD-8702-2020	Pascual-Leone, Alvaro/0000-0001-8975-0382; 	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40128-11A1]; Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH) [UL1 RR025758]; Sidney R. Baer, Jr. Foundation; Football Players Health Study at Harvard University; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER	R.M. is supported by a training grant from the National Institute of Child Health and Human Development (T32 HD40128-11A1). A.P.-L is supported by funding from the Harvard Clinical and Translational Science Center (NCRR and the NCATS NIH, UL1 RR025758), the Sidney R. Baer, Jr. Foundation, the Football Players Health Study at Harvard University, and various grants from the NIH.	bissinger B., 2012, WALL STREET J; Brooks BL, 2013, J NEUROTRAUM, V30, P1469, DOI 10.1089/neu.2012.2720; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dobosz RP, 1999, ADOLESCENCE, V34, P215; Dodge T, 2009, J YOUTH ADOLESCENCE, V38, P813, DOI 10.1007/s10964-008-9371-y; Finch CF, 2013, MED J AUSTRALIA, V198, P427, DOI 10.5694/mja12.11217; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Institute of Medicine & National Research Council, 2011, SCI AD RISK TAK WORK; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; MADDOCKS DL, 1995, MED J AUSTRALIA, V162, P167, DOI 10.5694/j.1326-5377.1995.tb138497.x; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCabe K. O., 2016, J YOUTH ADOLESC; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Nilsson M, 2013, CLIN J SPORT MED, V23, P255, DOI 10.1097/JSM.0b013e31827ee6f8; Noda H, 2005, J AM COLL CARDIOL, V46, P1761, DOI 10.1016/j.jacc.2005.07.038; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; OLSON HW, 1977, J SPORT MED PHYS FIT, V17, P321; Omalu B., 2015, NY TIMES; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904; Puvenna V, 2016, BRAIN RES, V1630, P225, DOI 10.1016/j.brainres.2015.11.007; Sabo Don, 2005, Int Rev Sociol Sport, V40, P5, DOI 10.1177/1012690205052160; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Tremblay S, 2014, BRAIN, V137, P2997, DOI 10.1093/brain/awu236; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Tymula A, 2012, P NATL ACAD SCI USA, V109, P17135, DOI 10.1073/pnas.1207144109; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Vella SA, 2014, J PEDIATR-US, V164, P1469, DOI 10.1016/j.jpeds.2014.01.071; Wafa SWWBSST, 2016, HEALTH QUAL LIFE OUT, V14, DOI 10.1186/s12955-016-0474-y; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	51	33	33	1	15	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1759-4758	1759-4766		NAT REV NEUROL	Nat. Rev. Neurol.	AUG	2016	12	8					486	490		10.1038/nrneurol.2016.99			5	Clinical Neurology	Neurosciences & Neurology	DT8CX	WOS:000381717800008	27364748	Green Accepted			2021-06-18	
J	Wang, KKW; Yang, ZH; Yue, JK; Zhang, ZQ; Winkler, EA; Puccio, AM; Diaz-Arrastia, R; Lingsma, HF; Yuh, EL; Mukherjee, P; Valadka, AB; Gordon, WA; Okonkwo, DO; Manley, GT; Cooper, SR; Dams-O'Connor, K; Hricik, AJ; Inoue, T; Maas, AIR; Menon, DK; Schnyer, DM; Sinha, TK; Vassar, MJ				Wang, Kevin K. W.; Yang, Zhihui; Yue, John K.; Zhang, Zhiqun; Winkler, Ethan A.; Puccio, Ava M.; Diaz-Arrastia, Ramon; Lingsma, Hester F.; Yuh, Esther L.; Mukherjee, Pratik; Valadka, Alex B.; Gordon, Wayne A.; Okonkwo, David O.; Manley, Geoffrey T.; Cooper, Shelly R.; Dams-O'Connor, Kristen; Hricik, Allison J.; Inoue, Tomoo; Maas, Andrew I. R.; Menon, David K.; Schnyer, David M.; Sinha, Tuhin K.; Vassar, Mary J.		TRACK-TBI Investigators	Plasma Anti-Glial Fibrillary Acidic Protein Autoantibody Levels during the Acute and Chronic Phases of Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot Study	JOURNAL OF NEUROTRAUMA			English	Article						autoantibody; autoimmunity; biomarkers; glia; traumatic brain injury	C-TERMINAL HYDROLASE-L1; COMMON DATA ELEMENTS; NEUROSURGICAL INTERVENTION; ANTIPITUITARY ANTIBODIES; INTRACRANIAL LESIONS; MULTIPLE-SCLEROSIS; ALZHEIMERS-DISEASE; HEAD-INJURY; TRACK-TBI; BIOMARKERS	We described recently a subacute serum autoantibody response toward glial fibrillary acidic protein (GFAP) and its breakdown products 5-10 days after severe traumatic brain injury (TBI). Here, we expanded our anti-GFAP autoantibody (AutoAb[GFAP]) investigation to the multicenter observational study Transforming Research and Clinical Knowledge in TBI Pilot (TRACK-TBI Pilot) to cover the full spectrum of TBI (Glasgow Coma Scale 3-15) by using acute (<24 h) plasma samples from 196 patients with acute TBI admitted to three Level I trauma centers, and a second cohort of 21 participants with chronic TBI admitted to inpatient TBI rehabilitation. We find that acute patients self-reporting previous TBI with loss of consciousness (LOC) (n = 43) had higher day 1 AutoAb [GFAP] (mean +/- standard error: 9.11 +/- 1.42; n = 43) than healthy controls (2.90 +/- 0.92; n = 16;p = 0.032) and acute patients reporting no previous TBI (2.97 +/- 0.37; n = 106; p < 0.001), but not acute patients reporting previous TBI without LOC (8.01 +/- 1.80; n = 47; p = 0.906). These data suggest that while exposure to TBI may trigger the AutoAb[GFAP] response, circulating antibodies are elevated specifically in acute TBI patients with a history of TBI. AutoAb[GFAP] levels for participants with chronic TBI (average post-TBI time 176 days or 6.21 months) were also significantly higher (15.08 +/- 2.82; n = 21) than healthy controls (p < 0.001). These data suggest a persistent upregulation of the autoimmune response to specific brain antigen(s) in the subacute to chronic phase after TBI, as well as after repeated TBI insults. Hence, AutoAb [GFAP] may be a sensitive assay to study the dynamic interactions between post injury brain and patient-specific autoimmune responses across acute and chronic settings after TBI.	[Wang, Kevin K. W.; Yang, Zhihui; Zhang, Zhiqun] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; [Wang, Kevin K. W.; Yang, Zhihui; Zhang, Zhiqun] Univ Florida, Dept Neurosci, Gainesville, FL 32611 USA; [Yue, John K.; Winkler, Ethan A.; Yuh, Esther L.; Mukherjee, Pratik; Manley, Geoffrey T.; Cooper, Shelly R.; Inoue, Tomoo; Vassar, Mary J.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Yue, John K.; Winkler, Ethan A.; Manley, Geoffrey T.; Cooper, Shelly R.; Inoue, Tomoo; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Puccio, Ava M.; Okonkwo, David O.; Hricik, Allison J.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Lingsma, Hester F.; Cooper, Shelly R.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Yuh, Esther L.; Mukherjee, Pratik; Sinha, Tuhin K.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Gordon, Wayne A.; Dams-O'Connor, Kristen] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Menon, David K.] Addenbrookes Hosp, Cambridge, England; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA	Wang, KKW (corresponding author), Univ Florida, Dept Psychiat, McKnight Brain Inst, POB 100256, Gainesville, FL 32611 USA.	kwang@ufl.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Cooper, Shelly/0000-0003-0026-6688; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Wang, Kevin/0000-0002-9343-6473	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS085455] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085455] Funding Source: NIH RePORTER; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish		Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Ankeny DP, 2006, J NEUROCHEM, V99, P1073, DOI 10.1111/j.1471-4159.2006.04147.x; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Chang BG, 2009, J VIROL METHODS, V159, P15, DOI 10.1016/j.jviromet.2009.02.019; Colasanti T, 2010, AUTOIMMUN REV, V9, P807, DOI 10.1016/j.autrev.2010.07.008; Cox AL, 2006, J NEUROIMMUNOL, V174, P180, DOI 10.1016/j.jneuroim.2006.01.007; D'Andrea MR, 2005, MED HYPOTHESES, V64, P458, DOI 10.1016/j.mehy.2004.08.024; Dambinova SA, 2003, CLIN CHEM, V49, P1752, DOI 10.1373/49.10.1752; Dams-O'Connor K, 2013, J NEUROTRAUM, V30, P2014, DOI 10.1089/neu.2013.3049; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Derfuss T, 2012, CURR OPIN NEUROL, V25, P231, DOI 10.1097/WCO.0b013e3283533a64; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hedegaard CJ, 2009, IMMUNOLOGY, V128, pe451, DOI 10.1111/j.1365-2567.2008.02999.x; Hergenroeder GW, 2008, MOL DIAGN THER, V12, P345, DOI 10.2165/1250444-200812060-00002; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Iseme RA, 2014, NEUROSCI BIOBEHAV R, V40, P62, DOI 10.1016/j.neubiorev.2014.01.008; Kobeissy FH, 2011, PM&R, V3, pS139, DOI 10.1016/j.pmrj.2011.02.012; Lancaster E, 2012, NAT REV NEUROL, V8, P380, DOI 10.1038/nrneurol.2012.99; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Ponomarenko NA, 2006, IMMUNOL LETT, V103, P45, DOI 10.1016/j.imlet.2005.10.006; Popovich PG, 1996, J NEUROSCI RES, V45, P349, DOI 10.1002/(SICI)1097-4547(19960815)45:4<349::AID-JNR4>3.0.CO;2-9; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI [10.1089/neu.2009.0928, 10.1089/neu.2009-0928]; Rubenstein R, 2010, J GEN VIROL, V91, P1883, DOI 10.1099/vir.0.020164-0; Saltzman J.W., 2013, CURR TRAN GERIATR GE, V1, P149; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sorokina EG, 2010, ZH NEVROL PSIKHIATR, V110, P30; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2010, EUR J ENDOCRINOL, V162, P861, DOI 10.1530/EJE-09-1024; Watanabe M, 2010, CYTOKINE GROWTH F R, V21, P263, DOI 10.1016/j.cytogfr.2010.03.003; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yang ZH, 2015, TRENDS NEUROSCI, V38, P364, DOI 10.1016/j.tins.2015.04.003; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Yue JK, 2015, NEUROGENETICS, V16, P169, DOI 10.1007/s10048-015-0437-1; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698; Zhang ZQ, 2011, TRANSL STROKE RES, V2, P455, DOI 10.1007/s12975-011-0137-6; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	54	33	33	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2016	33	13					1270	1277		10.1089/neu.2015.3881			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DP2QY	WOS:000378336200393	26560343	Green Published			2021-06-18	
J	Vardjan, N; Horvat, A; Anderson, JE; Yu, D; Croom, D; Zeng, X; Luznik, Z; Kreft, M; Teng, YD; Kirov, SA; Zorec, R				Vardjan, Nina; Horvat, Anemari; Anderson, Jamie E.; Yu, Dou; Croom, Deborah; Zeng, Xiang; Luznik, Zala; Kreft, Marko; Teng, Yang D.; Kirov, Sergei A.; Zorec, Robert			Adrenergic Activation Attenuates Astrocyte Swelling Induced by Hypotonicity and Neurotrauma	GLIA			English	Article						astrocytes; contusion trauma; cerebral cortex; spinal cord; cytotoxic edema; epinephrine	BRAIN EDEMA; FUNCTIONAL DEFICITS; WATER-INTOXICATION; VOLUME REGULATION; DENDRITIC INJURY; CELL; RELEASE; CAMP; PHOSPHORYLATION; AQUAPORIN-4	Edema in the central nervous system can rapidly result in life-threatening complications. Vasogenic edema is clinically manageable, but there is no established medical treatment for cytotoxic edema, which affects astrocytes and is a primary trigger of acute post-traumatic neuronal death. To test the hypothesis that adrenergic receptor agonists, including the stress stimulus epinephrine protects neural parenchyma from damage, we characterized its effects on hypotonicity-induced cellular edema in cortical astrocytes by in vivo and in vitro imaging. After epinephrine administration, hypotonicity-induced swelling of astrocytes was markedly reduced and cytosolic 3'-5'-cyclic adenosine monophosphate (cAMP) was increased, as shown by a fluorescence resonance energy transfer nanosensor. Although, the kinetics of epinephrine-induced cAMP signaling was slowed in primary cortical astrocytes exposed to hypotonicity, the swelling reduction by epinephrine was associated with an attenuated hypotonicity-induced cytosolic Ca2+ excitability, which may be the key to prevent astrocyte swelling. Furthermore, in a rat model of spinal cord injury, epinephrine applied locally markedly reduced neural edema around the contusion epicenter. These findings reveal new targets for the treatment of cellular edema in the central nervous system.	[Vardjan, Nina; Kreft, Marko; Zorec, Robert] BIOMEDICAL, Celica, Tehnol Pk 24, Ljubljana 1000, Slovenia; [Vardjan, Nina; Horvat, Anemari; Luznik, Zala; Kreft, Marko; Zorec, Robert] Univ Ljubljana, Fac Med, Inst Pathophysiol, Lab Neuroendocrinol Mol Cell Physiol, Zaloska 4, Ljubljana 1000, Slovenia; [Anderson, Jamie E.; Yu, Dou; Zeng, Xiang; Teng, Yang D.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; [Anderson, Jamie E.; Yu, Dou; Zeng, Xiang; Teng, Yang D.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Croom, Deborah; Kirov, Sergei A.] Med Coll Georgia, Brain & Behav Discovery Inst, Augusta, GA 30912 USA; [Croom, Deborah; Kirov, Sergei A.] Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA; [Kreft, Marko] Univ Ljubljana, Biotech Fac, Dept Biol, Vecna Pot 111, Ljubljana 1000, Slovenia; [Teng, Yang D.] VA Boston Healthcare Syst, Div SCI Res, Boston, MA USA	Zorec, R (corresponding author), BIOMEDICAL, Celica, Tehnol Pk 24, Ljubljana 1000, Slovenia.; Zorec, R (corresponding author), Univ Ljubljana, Fac Med, Inst Pathophysiol, Lab Neuroendocrinol Mol Cell Physiol, Zaloska 4, Ljubljana 1000, Slovenia.; Teng, YD (corresponding author), Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA.; Teng, YD (corresponding author), Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.; Kirov, SA (corresponding author), Med Coll Georgia, Brain & Behav Discovery Inst, Augusta, GA 30912 USA.; Kirov, SA (corresponding author), Med Coll Georgia, Dept Neurosurg, Augusta, GA 30912 USA.; Teng, YD (corresponding author), VA Boston Healthcare Syst, Div SCI Res, Boston, MA USA.	yang_teng@hms.harvard.edu; skirov13@gmail.com; robert.zorec@mf.uni-lj.si	Zeng, Xiang/AAB-6565-2020; Zorec, Robert/AAD-7180-2021; Vardjan, Nina/AAP-1496-2021	Zeng, Xiang/0000-0003-4577-749X; Zorec, Robert/0000-0002-7478-3875; Luznik, Zala/0000-0002-3164-1586	Slovenian Research AgencySlovenian Research Agency - Slovenia [P3 310, J3 4051, J3 3632, J3 6790, J3 4146]; Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins; COST ActionEuropean Cooperation in Science and Technology (COST) [BM1002]; EduGlia ITN EU grant; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS083858]; American Heart AssociationAmerican Heart Association [12GRNT16570006]; US Department of Veterans Affairs Rehabilitation Research and DevelopmentUS Department of Veterans Affairs [B7076R]; US Department of Defense-Center for Integration of Medicine & Innovative Technology grants; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS083858, R01NS083858] Funding Source: NIH RePORTER	We thank Dr. Martin Lohse and Dr. Viacheslav Olegowitsch Nikolaev (University of Wurzburg, Wurzburg, Germany) for providing the Epac1-camps FRET plasmid construct. We also thank Ursa Gubensek for assistance with the experiments. This work was supported by the Slovenian Research Agency (P3 310 to R.Z., J3 4051 to R.Z., J3 3632 to R.Z., J3 6790 to R.Z., J3 4146 to M.K.), the Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins to R.Z., the COST Action BM1002 to R.Z., the EduGlia ITN EU grant to R.Z., the National Institute of Health (NS083858 to S.A.K.), the American Heart Association (12GRNT16570006 to S.A.K.), the US Department of Veterans Affairs Rehabilitation Research and Development (B7076R to Y.D.T.), and the US Department of Defense-Center for Integration of Medicine & Innovative Technology grants to Y.D.T.	Andrew RD, 2007, CEREB CORTEX, V17, P787, DOI 10.1093/cercor/bhk032; Appaix F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035169; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; BENDER AS, 1992, CAN J PHYSIOL PHARM, V70, pS362, DOI 10.1139/y92-284; Betzenhauser MJ, 2009, J BIOL CHEM, V284, P25116, DOI 10.1074/jbc.M109.010132; Borner S, 2011, NAT PROTOC, V6, P427, DOI 10.1038/nprot.2010.198; Conner MT, 2012, J BIOL CHEM, V287, P11516, DOI 10.1074/jbc.M111.329219; Darby M, 2003, J NEUROPHYSIOL, V89, P1870, DOI 10.1152/jn.00510.2002; Dredge BK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021585; Fischer R, 1997, GLIA, V20, P51; Galizia L, 2012, J CELL BIOCHEM, V113, P580, DOI 10.1002/jcb.23382; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gee KR, 2000, CELL CALCIUM, V27, P97, DOI 10.1054/ceca.1999.0095; Green R, 2015, CLIN LAB MED, V35, P1, DOI 10.1016/j.cll.2014.11.003; Harukuni Izumi, 2002, J Anesth, V16, P229, DOI 10.1007/s005400200030; Herculano-Houzel S, 2005, J NEUROSCI, V25, P2518, DOI 10.1523/JNEUROSCI.4526-04.2005; Horvat A, 2016, CELL CALCIUM, V59, P156, DOI 10.1016/j.ceca.2016.01.002; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Khanna A, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.10.FOCUS13404; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; Kirischuk S, 1996, EUR J NEUROSCI, V8, P1198, DOI 10.1111/j.1460-9568.1996.tb01288.x; Kozler P, 2013, PHYSIOL RES, V62, pS75, DOI 10.33549/physiolres.932566; KramerGuth A, 1997, AM J PHYSIOL-CELL PH, V273, pC1409, DOI 10.1152/ajpcell.1997.273.4.C1409; Liu XB, 2006, J BIOL CHEM, V281, P15485, DOI 10.1074/jbc.M600549200; Liu XZ, 1997, J NEUROSCI, V17, P5395; Malarkey EB, 2008, NEUROCHEM INT, V52, P142, DOI 10.1016/j.neuint.2007.06.005; Mamenko M, 2013, J BIOL CHEM, V288, P20306, DOI 10.1074/jbc.M113.466797; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; NAGELHUS EA, 1993, NEUROSCIENCE, V54, P615, DOI 10.1016/0306-4522(93)90233-6; Nikolaev VO, 2004, J BIOL CHEM, V279, P37215, DOI 10.1074/jbc.C400302200; Nimmerjahn A, 2004, NAT METHODS, V1, P31, DOI 10.1038/nmeth706; Nolte C, 2001, GLIA, V33, P72; OCONNOR ER, 1993, J NEUROSCI, V13, P2638; Pangrsic T, 2006, J NEUROCHEM, V99, P514, DOI 10.1111/j.1471-4159.2006.04042.x; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Potokar M, 2013, GLIA, V61, P917, DOI 10.1002/glia.22485; Potokar M, 2009, BIOCHEM BIOPH RES CO, V390, P1192, DOI 10.1016/j.bbrc.2009.10.119; Raslan Ahmed, 2007, Neurosurg Focus, V22, pE12; Reetz G, 1997, NEUROCHEM RES, V22, P621, DOI 10.1023/A:1022430305491; Risher WC, 2012, GLIA, V60, P1709, DOI 10.1002/glia.22390; Risher WC, 2010, J NEUROSCI, V30, P9859, DOI 10.1523/JNEUROSCI.1917-10.2010; Risher WC, 2009, GLIA, V57, P207, DOI 10.1002/glia.20747; SALM AK, 1989, GLIA, V2, P346, DOI 10.1002/glia.440020507; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; SELYE H, 1967, SCIENCE, V156, P1262, DOI 10.1126/science.156.3779.1262; SHAIN W, 1987, J CELL BIOL, V105, P2307, DOI 10.1083/jcb.105.5.2307; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Song YT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034936; Srinivas SP, 2004, EXP EYE RES, V78, P15, DOI 10.1016/j.exer.2003.10.001; Stokum JA, 2015, J CEREB BLOOD FLOW M; Sword J, 2013, BRAIN, V136, P1446, DOI 10.1093/brain/awt026; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; TAUC M, 1990, BIOCHIM BIOPHYS ACTA, V1052, P278, DOI 10.1016/0167-4889(90)90222-Y; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Teng YD, 1997, J NEUROSCI, V17, P4359; Thrane AS, 2014, TRENDS NEUROSCI, V37, P620, DOI 10.1016/j.tins.2014.08.010; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Vardjan N, 2014, GLIA; Verkhratsky A, 1998, PHYSIOL REV, V78, P99; Wang YF, 2013, GLIA, V61, P529, DOI 10.1002/glia.22453; Wurm A, 2010, J NEUROCHEM, V112, P1261, DOI 10.1111/j.1471-4159.2009.06541.x; YAGODIN S, 1995, MOL CELL BIOCHEM, V149, P137, DOI 10.1007/BF01076572; Yamaguchi M, 1997, ACT NEUR S, V70, P152; Yoshioka A, 1998, J NEUROCHEM, V70, P2416; Yu D, 2013, P NATL ACAD SCI USA, V110, pE746, DOI 10.1073/pnas.1300083110; Zorec R, 2012, ASN NEUROL, V4	69	33	34	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUN	2016	64	6					1034	1049		10.1002/glia.22981			16	Neurosciences	Neurosciences & Neurology	DJ6ME	WOS:000374326600012	27018061	Green Accepted			2021-06-18	
J	Imbach, LL; Buchele, F; Valko, PO; Li, TZ; Maric, A; Stover, JF; Bassetti, CL; Mica, L; Werth, E; Baumann, CR				Imbach, Lukas L.; Buchele, Fabian; Valko, Philipp O.; Li, Tongzhou; Maric, Angelina; Stover, John F.; Bassetti, Claudio L.; Mica, Ladislav; Werth, Esther; Baumann, Christian R.			Sleep-wake disorders persist 18 months after traumatic brain injury but remain underrecognized	NEUROLOGY			English	Article							DISTURBANCES; INSOMNIA; NEED	Objective:This study is a prospective, controlled clinical and electrophysiologic trial examining the chronic course of posttraumatic sleep-wake disturbances (SWD).Methods:We screened 140 patients with acute, first-ever traumatic brain injury of any severity and included 60 patients for prospective follow-up examinations. Patients with prior brain trauma, other neurologic or systemic disease, drug abuse, or psychiatric comorbidities were excluded. Eighteen months after trauma, we performed detailed sleep assessment in 31 participants. As a control group, we enrolled healthy individuals without prior brain trauma matched for age, sex, and sleep satiation.Results:In the chronic state after traumatic brain injury, sleep need per 24 hours was persistently increased in trauma patients (8.1 0.5 hours) as compared to healthy controls (7.1 +/- 0.7 hours). The prevalence of chronic objective excessive daytime sleepiness was 67% in patients with brain trauma compared to 19% in controls. Patients significantly underestimated excessive daytime sleepiness and sleep need, emphasizing the unreliability of self-assessments on SWD in trauma patients.Conclusions:This study provides prospective, controlled, and objective evidence for chronic persistence of posttraumatic SWD, which remain underestimated by patients. These results have clinical and medicolegal implications given that SWD can exacerbate other outcomes of traumatic brain injury, impair quality of life, and are associated with public safety hazards.	[Imbach, Lukas L.; Buchele, Fabian; Valko, Philipp O.; Li, Tongzhou; Maric, Angelina; Werth, Esther; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland; [Stover, John F.; Mica, Ladislav] Univ Zurich Hosp, Dept Traumatol, Zurich, Switzerland; [Bassetti, Claudio L.] Inselspital Bern, Dept Neurol, Bern, Switzerland	Imbach, LL (corresponding author), Univ Zurich Hosp, Dept Neurol, Zurich, Switzerland.	lukas.imbach@usz.ch	Werth, E/AAN-7955-2021	Buechele, Fabian/0000-0001-7091-1676; Maric, Angelina/0000-0002-1416-6728; Baumann, Christian/0000-0003-3417-1978; Bassetti, Claudio/0000-0002-4535-0245; Werth, Esther/0000-0002-5099-3122; Imbach, Lukas/0000-0002-6135-8642	Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [SNF 125504]; Clinical Research Priority Program Sleep and Health of the University of Zurich	This study was supported by the Swiss National Science Foundation (SNF 125504) and the Clinical Research Priority Program Sleep and Health of the University of Zurich.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Cippa MAT, 2013, J SLEEP RES, V22, P589, DOI 10.1111/jsr.12053; Drake C, 2010, SLEEP, V33, P745, DOI 10.1093/sleep/33.6.745; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298	17	33	34	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAY 24	2016	86	21					1945	1949		10.1212/WNL.0000000000002697			5	Clinical Neurology	Neurosciences & Neurology	DN3KD	WOS:000376959900008	27164676	Green Published, Green Accepted			2021-06-18	
J	Huber, BR; Alosco, ML; Stein, TD; Mckee, AC				Huber, Bertrand R.; Alosco, Michael L.; Stein, Thor D.; Mckee, Ann C.			Potential Long-Term Consequences of Concussive and Subconcussive Injury	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Neuropathology; Trauma; Traumatic brain injury; Chronic traumatic encephalopathy; Tau; Concussion; Subconcussion	CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; AXONAL INJURY; TAU PATHOLOGY; HEAD IMPACTS; 1ST EXPOSURE; BRAIN TRAUMA; SPECTRUM; DISEASE; ACTIVATION	Repeated concussive and subconcussive trauma is associated with the later development of chronic traumatic encephalopathy (CTE), a neurodegenerative disease associated with clinical symptoms in multiple domains and a unique pattern of pathologic changes. CTE has been linked to boxing and American football; CTE has also been identified in soccer, ice hockey, baseball, rugby, and military service. To date, most large studies of CTE have come from enriched cohorts associated with brain bank donations for traumatic brain injury, although several recent studies re-examining neurodegenerative disease brain banks suggest that CTE is more common than is currently appreciated.	[Huber, Bertrand R.; Stein, Thor D.; Mckee, Ann C.] VA Boston HealthCare Syst, 150 South Huntington Ave, Boston, MA 02130 USA; [Huber, Bertrand R.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Neurol, 72 East Concord St,B-7800, Boston, MA 02118 USA; [Alosco, Michael L.; Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Program, 72 East Concord St,B-7800, Boston, MA 02118 USA; [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol, 72 East Concord St,B-7800, Boston, MA 02118 USA; [Stein, Thor D.] Bedford Vet Affairs Med Ctr, 200 Springs Rd,Bldg 18,Room 118, Bedford, MA 01730 USA	Mckee, AC (corresponding author), Boston Univ, Sch Med, Dept Neurol, 72 East Concord St,B-7800, Boston, MA 02118 USA.	amckee@bu.edu		Stein, Thor/0000-0001-6954-4477	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG036697, P30 AG013846] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32 NS096803, U01 NS086659] Funding Source: Medline; Intramural VA [VA999999] Funding Source: Medline; RRD VA [I01 RX000991] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803, U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG036697, P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000991] Funding Source: NIH RePORTER		Arnaud L, 2006, NEURODEGENER DIS, V3, P313, DOI 10.1159/000095638; Arnaud LT, 2009, J NEUROCHEM, V110, P328, DOI 10.1111/j.1471-4159.2009.06142.x; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Binder LI, 2005, BBA-MOL BASIS DIS, V1739, P216, DOI 10.1016/j.bbadis.2004.08.014; Buerger K, 2006, BRAIN, V129, P3035, DOI 10.1093/brain/awl269; Cajigal S., 2007, NEUROLOGY TODAY, V7, P16; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Critchley M, 1949, HOMMAGE C VINCENT; de Calignon A, 2010, NATURE, V464, P1201, DOI 10.1038/nature08890; Duong TH, 1997, BRAIN RES, V749, P152, DOI 10.1016/S0006-8993(96)01359-5; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hall GF, 2000, J CELL SCI, V113, P1373; Hall GF, 1997, P NATL ACAD SCI USA, V94, P4733, DOI 10.1073/pnas.94.9.4733; Johnson KA, 2015, ANN NEUROL; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Ke YD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007917; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling H, 2015, ACTA NEUROPATHOL; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McKee AC, 2015, ACTA NEUROPATHOL; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McKhann GM, 2011, ALZHEIMERS DEMENT, V7, P263, DOI 10.1016/j.jalz.2011.03.005; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mez J, 2016, TRAUM BRAIN INJ CLIN; Mez J, JAMA NEUROL IN PRESS; Mez J, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0148-8; Mez J, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0407-7; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Millspaugh JA, 1937, US NAV MED B, V35, P7; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Serbest G, 2007, NEUROCHEM RES, V32, P2006, DOI 10.1007/s11064-007-9318-9; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Victoroff J, 2013, NEUROREHABILITATION, V32, P211, DOI 10.3233/NRE-130839; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008	55	33	33	0	53	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2016	27	2					503	+		10.1016/j.pmr.2015.12.007			10	Rehabilitation	Rehabilitation	DN4RU	WOS:000377055700011	27154859	Green Accepted			2021-06-18	
J	Kawata, K; Tierney, R; Phillips, J; Jeka, JJ				Kawata, K.; Tierney, R.; Phillips, J.; Jeka, J. J.			Effect of Repetitive Sub-concussive Head Impacts on Ocular Near Point of Convergence	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						convergence insufficiency; head impact kinematics; sports concussion; eye	ACCOMMODATION; IMPAIRMENT; SYMPTOMS; VERGENCE; INJURY	This study intended to examine effects of repetitive sub-concussive head impacts on ocular near point of convergence (NPC). 20 healthy young adult soccer players were assigned to either a heading or control group. Heading subjects completed 10 headers of soccer balls projected at a speed of 11.2 m/s. Control subjects did not perform heading. Linear head acceleration was measured with a triaxial accelerometer. The NPC assessment was performed at pre-, 0h post-, and 24h post-heading. During the NPC assessment participants were seated and a visual target was moved towards the eyes at 1cm/sec. The participant signaled when he/she experienced diplopia or deviation of the eye was observed, and the distance was recorded. The assessment was repeated twice and average NPC scores were used for further analysis. Soccer heading induced mean group head accelerations of 14.49 +/- 5.4 g. Mild head impacts led to an increased NPC distance, which was supported by a significant Group x Time interaction. In the heading group, 0h post- and 24h post-heading NPC scores were significantly receded compared to baseline. Conversely, NPC scores for the control group showed no difference over time. Our findings indicate that mild frontal head impacts affekt NPC for a minimum of 24h-post heading, suggesting that oculomotor processes are disrupted, at least transiently, by repetitive mild head impact.	[Kawata, K.; Tierney, R.; Phillips, J.; Jeka, J. J.] Temple Univ, Kinesiol, 1800 N Broad st, Philadelphia, PA 19122 USA	Kawata, K (corresponding author), Temple Univ, Kinesiol, 1800 N Broad st, Philadelphia, PA 19122 USA.	tud46150@temple.edu			College of Public Health at Temple University; Pennsylvania Athletic Trainers' Society	This research was supported in part by internal funds from the College of Public Health at Temple University to Dr. Jeka and by the Pennsylvania Athletic Trainers' Society doctoral grant to K. Kawata.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Abraham Neethu G, 2015, Oman J Ophthalmol, V8, P14, DOI 10.4103/0974-620X.149856; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Barnes GR, 2008, BRAIN COGNITION, V68, P309, DOI 10.1016/j.bandc.2008.08.020; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Chen Y, 2002, PROG BRAIN RES, V140, P255; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; DAUM KM, 1984, AM J OPTOM PHYS OPT, V61, P16; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hamed MM, 2013, INDIAN J OPHTHALMOL, V61, P325, DOI 10.4103/0301-4738.97553; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Harriss DJ, 2015, INT J SPORTS MED, V36, P1121, DOI 10.1055/s-0035-1565186; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Higgins MJ, 2009, P I MECH ENG P-J SPO, V223, P117, DOI 10.1243/17543371JSET15; HUNG GK, 1980, IEEE T BIO-MED ENG, V27, P439, DOI 10.1109/TBME.1980.326752; HUNG GK, 1986, DOC OPHTHALMOL, V62, P165, DOI 10.1007/BF00229128; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; King D, 2013, J NEUROL SCI, V326, P59, DOI 10.1016/j.jns.2013.01.012; Linthorne NP, 2006, SPORT BIOMECH, V5, P243, DOI 10.1080/14763140608522877; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Phillips J, 2015, J EYE MOVEMENT RES, V8; Pochon JB, 2001, CEREB CORTEX, V11, P260, DOI 10.1093/cercor/11.3.260; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Red S, 2014, J VIS, V14, P298; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Von Noorden G. K., 2002, BINOCULAR VISION OCU; Xu L, 2014, EXP NEUROL	41	33	33	0	12	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	MAY	2016	37	5					405	410		10.1055/s-0035-1569290			6	Sport Sciences	Sport Sciences	DL4KZ	WOS:000375606000012	26859643				2021-06-18	
J	Antonakakis, M; Dimitriadis, SI; Zervakis, M; Micheloyannis, S; Rezaie, R; Babajani-Feremi, A; Zouridakis, G; Papanicolaou, AC				Antonakakis, Marios; Dimitriadis, Stavros I.; Zervakis, Michalis; Micheloyannis, Sifis; Rezaie, Roozbeh; Babajani-Feremi, Abbas; Zouridakis, George; Papanicolaou, Andrew C.			Altered cross-frequency coupling in resting-state MEG after mild traumatic brain injury	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Magnetoencephalography (MEG); Mild traumatic brain injury; Cross-frequency coupling; Tensors; Biomarkers	FUNCTIONAL CONNECTIVITY; NEURONAL OSCILLATIONS; WORKING-MEMORY; AXONAL INJURY; DYNAMICS; EEG; MAGNETOENCEPHALOGRAPHY; SYNCHRONIZATION; REORGANIZATION; CORTEX	Cross-frequency coupling (CFC) is thought to represent a basic mechanism of functional integration of neural networks across distant brain regions. In this study, we analyzed CFC profiles from resting state Magnetoencephalographic (MEG) recordings obtained from 30 mild traumatic brain injury (mTBI) patients and 50 controls. We used mutual information (MI) to quantify the phase-to-amplitude coupling (PAC) of activity among the recording sensors in six nonoverlapping frequency bands. After forming the CFC-based functional connectivity graphs, we employed a tensor representation and tensor subspace analysis to identify the optimal set of features for subject classification as mTBI or control. Our results showed that controls formed a dense network of stronger local and global connections indicating higher functional integration compared to mTBI patients. Furthermore, mTBI patients could be separated from controls with more than 90% classification accuracy. These findings indicate that analysis of brain networks computed from resting-state MEG with PAC and tensorial representation of connectivity profiles may provide a valuable biomarker for the diagnosis of mTBI. (C) 2016 Elsevier B.V. All rights reserved.	[Antonakakis, Marios; Zervakis, Michalis] Tech Univ Crete, Sch Elect & Comp Engn, Digital Image & Signal Proc Lab, Khania 73100, Greece; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Med, Inst Psychol Med & Clin Neurosci, Cardiff CF10 3AX, S Glam, Wales; [Dimitriadis, Stavros I.] Cardiff Univ, Sch Psychol, CUBRIC, Cardiff CF10 3AX, S Glam, Wales; [Dimitriadis, Stavros I.] Aristotle Univ Thessaloniki, Dept Informat, Artificial Intelligence & Informat Anal Lab, Thessaloniki 54124, Greece; [Dimitriadis, Stavros I.] Aristotle Univ Thessaloniki, Dept Informat, Neuroinformat Grp, Thessaloniki 54124, Greece; [Micheloyannis, Sifis] Univ Crete, Sch Med, L Widen Lab, Iraklion, Greece; [Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Div Clin Neurosci, Memphis, TN 38163 USA; [Rezaie, Roozbeh; Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Le Bonheur Childrens Hosp, Neurosci Inst, Memphis, TN USA; [Zouridakis, George] Basque Ctr Cognit Brain & Language BCBL, Paseo Mikeletegi 69, Donostia San Sebastian 20009, Spain; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Engn Technol, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Comp Sci, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Biomed Engn, Houston, TX 77204 USA; [Zouridakis, George] Univ Houston, Biomed Imaging Lab, Dept Elect & Comp Engn, Houston, TX 77204 USA; [Babajani-Feremi, Abbas; Papanicolaou, Andrew C.] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Zouridakis, George] Univ Houston, Houston, TX 77204 USA	Antonakakis, M (corresponding author), Tech Univ Crete, Sch Elect & Comp Engn, Digital Image & Signal Proc Lab, Khania 73100, Greece.	mantonakakis@isc.tuc.gr	Zouridakis, George/R-8876-2019; DIMITRIADIS, STAVROS I/AAN-8992-2020; Antonakakis, Marios/ABD-8218-2020	Zouridakis, George/0000-0002-7770-9857; DIMITRIADIS, STAVROS I/0000-0002-0000-5392; Rezaie, Roozbeh/0000-0002-7494-339X; Basque Center on Cognition, Brain and Language, BCBL./0000-0002-8345-6892; Antonakakis, Marios/0000-0003-1173-7895	Department of Defense Congressionally Directed Medical Research ProgramUnited States Department of Defense; THALES project (CYBERSENSORS - High Frequency Monitoring System for Integrated Water Resources Management of Rivers) - NSRF of the Greek Ministry of Development; "YPERTHEN" project under the Interreg	The project reported here is part of a larger study, the Integrated Clinical Protocol, conducted by the investigators and staff of the Mission Connect Mild Traumatic Brain Injury Translational Research Consortium and supported by the Department of Defense Congressionally Directed Medical Research Program. The graph representation and analysis is supported by a THALES project (CYBERSENSORS - High Frequency Monitoring System for Integrated Water Resources Management of Rivers) funded by the NSRF2007-13 of the Greek Ministry of Development. The analysis methodology was partly supported by the "YPERTHEN" project under the Interreg framework of Greek-Cyprus Co-operation 2007-2013.	Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900; Antonakakis M., 2013, BIOINF BIOENG BIBE I, V2013, P15, DOI [10.1109/bibe.2013.6701594, DOI 10.1109/BIBE.2013.6701594, 10.1109/BIBE.2013.6701594]; Antonakakis M, 2015, IEEE ENG MED BIO, P7426, DOI 10.1109/EMBC.2015.7320108; Assistant Secretary D. O. D, 2007, TRAUM BRAIN INJ DEF; Axmacher N, 2010, NEURON, V65, P541, DOI 10.1016/j.neuron.2010.02.006; Axmacher N, 2010, P NATL ACAD SCI USA, V107, P3228, DOI 10.1073/pnas.0911531107; Bassett DS, 2009, P NATL ACAD SCI USA, V106, P11747, DOI 10.1073/pnas.0903641106; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bigler ED, 2004, STUD NEUROPSYCHOL DE, P71; Boccaletti S, 2006, PHYS REP, V424, P175, DOI 10.1016/j.physrep.2005.10.009; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Buzsaki G, 2004, SCIENCE, V304, P1926, DOI 10.1126/science.1099745; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Canolty RT, 2010, TRENDS COGN SCI, V14, P506, DOI 10.1016/j.tics.2010.09.001; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Castellanos NP, 2010, BRAIN, V133, P2365, DOI 10.1093/brain/awq174; Cohen MX, 2009, J COGNITIVE NEUROSCI, V21, P875, DOI 10.1162/jocn.2009.21062; Cohen MX, 2009, J COGNITIVE NEUROSCI, V21, P390, DOI 10.1162/jocn.2008.21020; Colgin LL, 2009, NATURE, V462, P353, DOI 10.1038/nature08573; Conover W.J., 1980, PRACTICAL NONPARAMET; Contreras D, 1997, NEUROSCIENCE, V76, P11; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Destexhe A, 1999, J NEUROSCI, V19, P4595, DOI 10.1523/jneurosci.19-11-04595.1999; Dimitriadis SI, 2015, COGN NEURODYNAMICS, V9, P371, DOI 10.1007/s11571-015-9330-8; Dimitriadis SI, 2013, NEUROIMAGE, V83, P307, DOI 10.1016/j.neuroimage.2013.06.036; Dimitriadis SI, 2013, IEEE ENG MED BIO, P2940, DOI 10.1109/EMBC.2013.6610156; Dimitriadis SI, 2012, IEEE T BIO-MED ENG, V59, P1302, DOI 10.1109/TBME.2012.2186568; Dimitriadis S. I., 2013, QUANTIZATION TIME VA, V3, P397; Dimitriadis S. I., 2016, IEEE T NEUR IN PRESS; Dimitriadis SI, 2015, NEUROIMAGE-CLIN, V9, P519, DOI 10.1016/j.nicl.2015.09.011; Dimitriadis SI, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00350; Dimitriadis SI, 2015, ANN BIOMED ENG, V43, P977, DOI 10.1007/s10439-014-1143-0; Dimitriadis SI, 2012, BRAIN COGNITION, V80, P45, DOI 10.1016/j.bandc.2012.04.001; Dimitriadis SI, 2012, NONLIN DYNAM PSYCHOL, V16, P5; Dimitriadis SI, 2010, J NEUROSCI METH, V193, P145, DOI 10.1016/j.jneumeth.2010.08.027; Dimitriadis SI, 2010, NEUROSCI LETT, V483, P11, DOI 10.1016/j.neulet.2010.07.034; Dimitriadis SI, 2009, BRAIN TOPOGR, V22, P119, DOI 10.1007/s10548-008-0071-4; Douw L, 2008, EXP NEUROL, V212, P285, DOI 10.1016/j.expneurol.2008.03.013; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Engel AK, 2013, NEURON, V80, P867, DOI 10.1016/j.neuron.2013.09.038; Engel AK, 2010, CURR OPIN NEUROBIOL, V20, P156, DOI 10.1016/j.conb.2010.02.015; Escudero J, 2011, ANN BIOMED ENG, V39, P2274, DOI 10.1007/s10439-011-0312-7; Florin E, 2015, NEUROIMAGE, V111, P26, DOI 10.1016/j.neuroimage.2015.01.054; FRISTON KJ, 1994, NEUROSCIENCE, V59, P229, DOI 10.1016/0306-4522(94)90592-4; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Gibbons J.D., 2011, NONPARAMETRIC STAT I, V5th; Han K, 2014, NEUROIMAGE, V84, P76, DOI 10.1016/j.neuroimage.2013.08.017; He X., 2005, ADV NEURAL INFORM PR, V18; He Y, 2010, CURR OPIN NEUROL, V23, P341, DOI 10.1097/WCO.0b013e32833aa567; Hipp JF, 2012, NAT NEUROSCI, V15, P884, DOI 10.1038/nn.3101; HORN RA, 1990, SIAM J MATRIX ANAL A, V11, P481, DOI 10.1137/0611034; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Jensen O, 2007, TRENDS COGN SCI, V11, P267, DOI 10.1016/j.tics.2007.05.003; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jirsa V, 2013, FRONT COMPUT NEUROSC, V7, DOI 10.3389/fncom.2013.00078; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Latora V., 2001, CONDMAT0101396; Leahy RM, 1998, ELECTROEN CLIN NEURO, V107, P159, DOI 10.1016/S0013-4694(98)00057-1; Levin H. S., 2009, MISSION CONNECT MILD; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Li L, 2015, C P IEEE ENG MED BIO; Luo Q, 2013, J NEUROTRAUM, V30, P1702, DOI 10.1089/neu.2012.2679; Messe A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065470; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Oostenveld R, 2011, COMPUT INTEL NEUROSC, V2011, DOI 10.1155/2011/156869; Osipova D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003990; Palva JM, 2011, PROG BRAIN RES, V193, P335, DOI 10.1016/B978-0-444-53839-0.00022-3; Palva JM, 2005, J NEUROSCI, V25, P3962, DOI 10.1523/JNEUROSCI.4250-04.2005; Pinal D., 2015, NEUROBIOL AGING; Pollonini L, 2010, IEEE ENG MED BIO, P1730, DOI 10.1109/IEMBS.2010.5626702; Raskin S. A., 2000, NEUROPSYCHOLOGICAL M, P93; Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814; Richiardi J, 2011, NEUROIMAGE, V56, P616, DOI 10.1016/j.neuroimage.2010.05.081; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Ruff R.M., 1989, MILD HEAD INJURY, P176; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shen H, 2010, NEUROIMAGE, V49, P3110, DOI 10.1016/j.neuroimage.2009.11.011; Siegel M, 2012, NAT REV NEUROSCI, V13, P121, DOI 10.1038/nrn3137; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sireci SG, 2003, J EDUC MEAS, V40, P277, DOI 10.1111/j.1745-3984.2003.tb01108.x; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Stam CJ, 2010, INT J PSYCHOPHYSIOL, V77, P186, DOI 10.1016/j.ijpsycho.2010.06.024; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Steriade M, 1996, J NEUROSCI, V16, P2788; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Tarapore PE, 2013, J NEUROSURG, V118, P1306, DOI 10.3171/2013.3.JNS12398; TEASDALE G, 1974, LANCET, V2, P81; Tognoli E, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00122; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; Tort ABL, 2010, J NEUROPHYSIOL, V104, P1195, DOI 10.1152/jn.00106.2010; Tort ABL, 2009, P NATL ACAD SCI USA, V106, P20942, DOI 10.1073/pnas.0911331106; Tort ABL, 2008, P NATL ACAD SCI USA, V105, P20517, DOI 10.1073/pnas.0810524105; Tsiaras V, 2011, COMPUT BIOL MED, V41, P1166, DOI 10.1016/j.compbiomed.2011.04.004; Tsirka V, 2011, INT J PSYCHOPHYSIOL, V79, P89, DOI 10.1016/j.ijpsycho.2010.09.006; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Voytek B, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00191; Zouridakis G, 2012, J MECH MED BIOL, V12, DOI 10.1142/S0219519412400064	108	33	34	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	APR	2016	102						1	11		10.1016/j.ijpsycho.2016.02.002			11	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	DM9QY	WOS:000376702000002	26910049	Bronze, Green Accepted			2021-06-18	
J	Sussman, ES; Ho, AL; Pendharkar, AV; Ghajar, J				Sussman, Eric S.; Ho, Allen L.; Pendharkar, Arjun V.; Ghajar, Jamshid			Clinical evaluation of concussion: the evolving role of oculomotor assessments	NEUROSURGICAL FOCUS			English	Article						concussion screening; concussion diagnosis; vision tracking; eye tracking; oculomotor tracking; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ERROR SCORING SYSTEM; SPORTS-RELATED CONCUSSION; VISUAL SCREENING TOOL; HIGH-SCHOOL; EYE-MOVEMENTS; KING-DEVICK; HEAD-INJURY; DEFICITS; COLLEGIATE	Sports-related concussion is a change in brain function following a direct or an indirect force to the head, identified in awake individuals and accounting for a considerable proportion of mild traumatic brain injury. Although the neurological signs and symptoms of concussion can be subtle and transient, there can be persistent sequelae, such as impaired attention and balance, that make affected patients particularly vulnerable to further injury. Currently, there is no accepted definition or diagnostic criteria for concussion, and there is no single assessment that is accepted as capable of identifying all patients with concussion. In this paper, the authors review the available screening tools for concussion, with particular emphasis on the role of visual function testing. In particular, they discuss the oculomotor assessment tools that are being investigated in the setting of concussion screening.	[Sussman, Eric S.; Ho, Allen L.; Pendharkar, Arjun V.; Ghajar, Jamshid] Stanford Univ, Sch Med, Dept Neurosurg, 300 Pasteur Dr,R200, Stanford, CA 94305 USA	Ghajar, J (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, 300 Pasteur Dr,R200, Stanford, CA 94305 USA.	jghajar@stanford.edu					Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bernstein DM, 2009, BRAIN INJURY, V13, P151; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; Chang JO, 2014, CLIN J SPORT MED, V24, P256, DOI 10.1097/JSM.0000000000000016; Cifu DX, 2015, J HEAD TRAUMA REHAB, V30, P21, DOI 10.1097/HTR.0000000000000036; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; Crevits L, 2000, J NEUROL, V247, P179, DOI 10.1007/s004150050559; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Dziemianowicz MS, 2012, CURR NEUROL NEUROSCI, V12, P547, DOI 10.1007/s11910-012-0299-y; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2015, J NEURO-OPHTHALMOL, V35, P235, DOI 10.1097/WNO.0000000000000226; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Galetta MS, 2013, J NEUROL SCI, V328, P28, DOI 10.1016/j.jns.2013.02.008; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Hunt AW, 2015, J HEAD TRAUMA REHAB, V1, P1; King D, 2014, SPORTS MED, V44, P449, DOI 10.1007/s40279-013-0134-x; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Leong Danielle F, 2015, J Optom, V8, P131, DOI 10.1016/j.optom.2014.12.005; Maruta J, 2014, PROG NEUROL SURG, V28, P226, DOI 10.1159/000358786; Maruta J, 2013, BEHAV RES METHODS, V45, P289, DOI 10.3758/s13428-012-0248-3; Maruta J, 2010, ANN NY ACAD SCI, V1208, P58, DOI 10.1111/j.1749-6632.2010.05695.x; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mullen SJ, 2014, CAN J NEUROL SCI, V41, P58, DOI 10.1017/S0317167100016279; Munce TA, 2014, J CHILD NEUROL, V29, P1601, DOI 10.1177/0883073813509887; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Poltavski DV, 2014, BRAIN INJURY, V28, P475, DOI 10.3109/02699052.2014.888771; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Saigal Rajiv, 2014, Neurosurgery, V75 Suppl 4, pS149, DOI 10.1227/NEU.0000000000000497; Samadani U, 2015, CONCUSSION, V2015, pCNC3; Samadani U, 2015, NEURAL REGEN RES, V10, P1231, DOI 10.4103/1673-5374.162752; Samadani U, 2015, J NEUROTRAUM, V32, P548, DOI 10.1089/neu.2014.3687; Samadani U, 2015, J NEUROSURG, V122, P707, DOI 10.3171/2014.10.JNS14762; Schneiders AG, 2012, SCAND J MED SCI SPOR, V22, P85, DOI 10.1111/j.1600-0838.2010.01141.x; Suh M, 2006, NEUROSCI LETT, V410, P203, DOI 10.1016/j.neulet.2006.10.001; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Ventura R, 2014, NEUROL CLIN PRACT; Ventura RE, 2015, J NEURO-OPHTHALMOL, V35, P73, DOI 10.1097/WNO.0000000000000223; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Williamson Richard W, 2014, Neurosurgery, V75 Suppl 4, pS131, DOI 10.1227/NEU.0000000000000482	56	33	33	0	39	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E7	10.3171/2016.1.FOCUS15610			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500006	27032924	Other Gold			2021-06-18	
J	Zuckerman, SL; Yengo-Kahn, AM; Buckley, TA; Solomon, GS; Sills, AK; Kerr, ZY				Zuckerman, Scott L.; Yengo-Kahn, Aaron M.; Buckley, Thomas A.; Solomon, Gary S.; Sills, Allen K.; Kerr, Zachary Y.			Predictors of postconcussion syndrome in collegiate student-athletes	NEUROSURGICAL FOCUS			English	Article						sport-related concussion; traumatic brain injury; collegiate athletics; NCAA; postconcussion syndrome	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; HIGH-SCHOOL; PROLONGED RECOVERY; RISK-FACTORS; SYNDROME PCS; SYMPTOMS; EPIDEMIOLOGY; MANAGEMENT	OBJECTIVE Sport-related concussion (SRC) has emerged as a public health problem, especially among studentathletes. Whereas most concussions resolve by 2 weeks, a minority of patients experience postconcussion syndrome (PCS), in which symptoms persist for months. The objective of this study was to elucidate factors predictive of PCS among a sample of National Collegiate Athletic Association (NCAA) student-athletes in the academic years 2009-2010 to 2014-2015. METHODS The SRC data originated from the NCAA Injury Surveillance Program (ISP) in the 2009-2010 to 2014-2015 academic seasons. The NCAA ISP is a prospective database made up of a convenience sample of schools across all divisions. All SRCs are reported by certified athletic trainers. The PCS group consisted of concussed student-athletes with concussion-related symptoms that lasted >= 4 weeks. The non-PCS group consisted of concussed student-athletes with symptom resolution in <= 2 weeks. Those with symptoms that resolved in the intermediate area of 2-4 weeks were excluded. Odds ratios (ORs) were estimated using logistic regression. RESULTS During the 2009-2010 to 2014-2015 seasons, 1507 NCAA student-athletes sustained an SRC, 112 (7.4%) of whom developed PCS (i.e., concussion-related symptoms that lasted >= 4 weeks). Men's ice hockey contributed the largest proportion of concussions to the PCS group (28.6%), whereas men's football contributed the largest proportion of concussions in the non-PCS group (38.6%). In multivariate analysis, recurrent concussion was associated with increased odds of PCS (OR 2.08, 95% CI 1.28-3.36). Concussion symptoms that were also associated with increased odds of PCS included retrograde amnesia (OR 2.75, 95% CI 1.34-5.64), difficulty concentrating (OR 2.35, 95% CI 1.23-4.50), sensitivity to light (OR 1.97, 95% CI 1.09-3.57), and insomnia (OR 2.19, 95% CI 1.30-3.68). Contact level, sex, and loss of consciousness were not associated with PCS. CONCLUSIONS Postconcussion syndrome represents one of the most impactful sequelae of SRC. In this study of exclusively collegiate student-athletes, the authors found that recurrent concussions and various concussion-related symptoms were associated with PCS. The identification of initial risk factors for the development of PCS may assist sports medicine clinicians in providing timely interventions and treatments to prevent morbidity and shorten recovery time after SRC.	[Zuckerman, Scott L.; Yengo-Kahn, Aaron M.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Nashville, TN 37232 USA; [Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37232 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA; [Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA	Zuckerman, SL (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Med Ctr North T4224, 1211 Med Ctr Dr, Nashville, TN 37232 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019; Yengo-Kahn, Aaron/AAV-7647-2020; Buckley, Thomas A/B-7525-2016	Yengo-Kahn, Aaron/0000-0002-5989-3064; Buckley, Thomas A/0000-0002-0515-0150; Kerr, Zachary/0000-0003-1423-1259			Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; [Anonymous], 2013, 2013 14 NCAA SPORTS; Baker JG, 2015, CLIN PEDIATR, V54, P961, DOI 10.1177/0009922815588820; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Conder R, 2015, BRAIN INJURY, V29, P249, DOI 10.3109/02699052.2014.965209; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P709, DOI 10.3171/2015.5.PEDS15220; Franke LM, 2015, J HEAD TRAUMA REHAB, V30, pE34, DOI 10.1097/HTR.0000000000000042; Glang AE, 2015, J ADOLESCENT HEALTH, V56, P91, DOI 10.1016/j.jadohealth.2014.08.011; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Luoto TM, 2015, BRAIN INJURY, V29, P565, DOI 10.3109/02699052.2014.1002421; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2014, NEUROLOGY, V83, P2204, DOI 10.1212/WNL.0000000000001073; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Morgan CD, 2015, CHILD NERV SYST, V31, P2305, DOI 10.1007/s00381-015-2916-y; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Olsson KA, 2013, BRAIN INJURY, V27, P145, DOI 10.3109/02699052.2012.729286; Olympia RP, 2015, CLIN J SPORT MED; Ouellet J, 2008, BEHAV NEUROL, V20, P27, DOI [10.3233/BEN-2008-0213, 10.1155/2008/520328]; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Reuben A, 2014, EMERG MED J, V31, P72, DOI 10.1136/emermed-2012-201667; Rice SG, 2008, PEDIATRICS, V121, P841, DOI 10.1542/peds.2008-0080; Rose SC, 2015, BRAIN INJURY, V29, P798, DOI 10.3109/02699052.2015.1004756; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Silverberg ND, 2015, J NEUROTRAUM, V32, P517, DOI 10.1089/neu.2014.3600; Solomon Gary S, 2013, J Surg Orthop Adv, V22, P193; Tator Charles H, 2014, Neurosurgery, V75 Suppl 4, pS106, DOI 10.1227/NEU.0000000000000484; Wasserman EB, 2016, AM J SPORT MED, V44, P226, DOI 10.1177/0363546515610537; Wing R, 2016, CLIN PEDIATR, V55, P228, DOI 10.1177/0009922815592879; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zuckerman SL, 2015, INT J SPORTS MED, V36, P419, DOI 10.1055/s-0034-1395587; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	53	33	33	1	20	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	APR	2016	40	4							E13	10.3171/2016.1.FOCUS15593			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI4NL	WOS:000373476500002	27032916	Bronze			2021-06-18	
J	Shear, DA; Dixon, CE; Bramlett, HM; Mondello, S; Dietrich, WD; Deng-Bryant, Y; Schmid, KE; Wang, KKW; Hayes, RL; Povlishock, JT; Kochanek, PM; Tortella, FC				Shear, Deborah A.; Dixon, C. Edward; Bramlett, Helen M.; Mondello, Stefania; Dietrich, W. Dalton; Deng-Bryant, Ying; Schmid, Kara E.; Wang, Kevin K. W.; Hayes, Ronald L.; Povlishock, John T.; Kochanek, Patrick M.; Tortella, Frank C.			Nicotinamide Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						therapy; fluid percussion; rat; biomarker; vitamin B; neuroprotection; penetrating ballistic-like brain injury; controlled cortical impact	FOCAL CEREBRAL-ISCHEMIA; IMPROVES FUNCTIONAL RECOVERY; CORTICAL CONTUSION INJURY; FLUID PERCUSSION INJURY; INFARCT VOLUME; WISTAR RATS; HYPOTHERMIA THERAPY; DELAYED TREATMENT; MODEL; PRECURSOR	Nicotinamide (vitamin B-3) was the first drug selected for cross-model testing by the Operation Brain Trauma Therapy (OBTT) consortium based on a compelling record of positive results in pre-clinical models of traumatic brain injury (TBI). Adult male Sprague-Dawley rats were exposed to either moderate fluid percussion injury (FPI), controlled cortical impact injury (CCI), or penetrating ballistic-like brain injury (PBBI). Nicotinamide (50 or 500 mg/kg) was delivered intravenously at 15 min and 24 h after injury with subsequent behavioral, biomarker, and histopathological outcome assessments. There was an intermediate effect on balance beam performance with the high (500 mg/kg) dose in the CCI model, but no significant therapeutic benefit was detected on any other motor task across the OBTT TBI models. There was an intermediate benefit on working memory with the high dose in the FPI model. A negative effect of the low (50 mg/kg) dose, however, was observed on cognitive outcome in the CCI model, and no cognitive improvement was observed in the PBBI model. Lesion volume analysis showed no treatment effects after either FPI or PBBI, but the high dose of nicotinamide resulted in significant tissue sparing in the CCI model. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase-1 (UCH-L1) in blood at 4 or 24 h after injury. Negative effects (both doses) were detected on biomarker levels of GFAP after FPI and on biomarker levels of UCH-L1 after PBBI. The high dose of nicotinamide, however, reduced GFAP levels after both PBBI and CCI. Overall, our results showed a surprising lack of benefit from the low dose nicotinamide. In contrast, and partly in keeping with the literature, some benefit was achieved with the high dose. The marginal benefits achieved with nicotinamide, however, which appeared sporadically across the TBI models, has reduced enthusiasm for further investigation by the OBTT Consortium.	[Shear, Deborah A.; Deng-Bryant, Ying; Schmid, Kara E.; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Ayoub IA, 1999, NEUROSCI LETT, V259, P21, DOI 10.1016/S0304-3940(98)00881-7; Ayoub IA, 2002, NEUROREPORT, V13, P213, DOI 10.1097/00001756-200202110-00008; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Browning M, 2016, J NEUROTRAUM, V33, P581, DOI 10.1089/neu.2015.4131; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Goffus AM, 2010, OXID MED CELL LONGEV, V3, P145, DOI 10.4161/oxim.3.2.11315; Haar CV, 2011, BEHAV BRAIN RES, V224, P311, DOI 10.1016/j.bbr.2011.06.009; Hoane MR, 2008, NEUROSCIENCE, V154, P861, DOI 10.1016/j.neuroscience.2008.04.044; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoane MR, 2006, NEUROSCI LETT, V408, P35, DOI 10.1016/j.neulet.2006.07.011; Hoane MR, 2006, J NEUROTRAUM, V23, P1535, DOI 10.1089/neu.2006.23.1535; Hoane MR, 2008, OXID MED CELL LONGEV, V1, P46, DOI 10.4161/oxim.1.1.6694; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Holland MA, 2008, J NEUROTRAUM, V25, P140, DOI 10.1089/neu.2007.0312; Klaidman L, 2003, PHARMACOLOGY, V69, P150, DOI 10.1159/000072668; Klaidman LK, 2001, BBA-GEN SUBJECTS, V1525, P136, DOI 10.1016/S0304-4165(00)00181-1; Klaidman LK, 1996, NEUROSCI LETT, V206, P5, DOI 10.1016/0304-3940(96)12446-0; Kochanek PM, 2016, J NEUROTRAUM, V33, P606, DOI 10.1089/neu.2015.4133; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Li FQ, 2006, CURR MED CHEM, V13, P883, DOI 10.2174/092986706776361058; Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446; Mokudai T, 2000, STROKE, V31, P1679, DOI 10.1161/01.STR.31.7.1679; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2010, CRIT CARE MED, V38, P138, DOI 10.1097/CCM.0b013e3181b788ab; Peterson TC, 2015, J NEUROTRAUM, V32, P765, DOI 10.1089/neu.2014.3530; Peterson TC, 2012, J NEUROTRAUM, V29, P2823, DOI 10.1089/neu.2012.2471; Sakakibara Y, 2000, NEUROSCI LETT, V281, P111, DOI 10.1016/S0304-3940(00)00854-5; Sakakibara Y, 2002, BRAIN RES, V931, P68, DOI 10.1016/S0006-8993(02)02263-1; SCHALLERT T, 1990, CAN J PSYCHOL, V44, P276, DOI 10.1037/h0084244; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; SPECTOR R, 1979, J NEUROCHEM, V33, P895, DOI 10.1111/j.1471-4159.1979.tb09919.x; Swan AA, 2011, J NEUROTRAUM, V28, P431, DOI 10.1089/neu.2010.1519; Vonder Haar C, 2014, J NEUROTRAUM, V31, P1711, DOI 10.1089/neu.2014.3459; Williams AJ, 2006, NEUROSCI LETT, V408, P183, DOI 10.1016/j.neulet.2006.08.086; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Zhang ZQ, 2011, TRANSL STROKE RES, V2, P455, DOI 10.1007/s12975-011-0137-6; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	42	33	34	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					523	537		10.1089/neu.2015.4115			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800003	26670792				2021-06-18	
J	Yang, JJ; Ding, SD; Huang, WL; Hu, JN; Huang, SW; Zhang, Y; Zhuge, QC				Yang, Jianjing; Ding, Saidan; Huang, Weilong; Hu, Jiangnan; Huang, Shengwei; Zhang, Yu; Zhuge, Qichuan			Interleukin-4 Ameliorates the Functional Recovery of Intracerebral Hemorrhage Through the Alternative Activation of Microglia/Macrophage	FRONTIERS IN NEUROSCIENCE			English	Article						stroke; intracerebral hemorrhage; interleukin-4(IL-4); microglia/macrophage; recovery; M1 phenotype; M2 phenotype	TRAUMATIC BRAIN-INJURY; T-CELLS; MICROGLIA; POLARIZATION; BLOOD; INHIBITION; STROKE; RATS	Neuro-inflammation plays an important role in the recovery of brain injury after stroke. Microglia/macrophage is the major executor in the neuro-inflammation, which can be polarized into two distinct phenotypes: injurious/toxic classical activation (M1 phenotype) and protective alternative activation (M2 phenotype). Here, we investigated whether intracerebral administration of interleukin-4 (IL-4) at an early stage could affect the activation of microglia/macrophage and the corresponding outcome after intracerebral hemorrhage (ICH). The neuro-behavior was recorded between different groups in the rat ICH model. The M1 and M2 markers were then determined by qRT-PCR, western blotting, ELISA, and immunofluorescence, respectively. We observed aberrant activation of microglia/macrophage after ICH. After intracerebral injection of IL-4, M1 activation was greatly inhibited while M2 activation was enhanced, along with improving neurobehavioral recovery from deficits after ICH. Our study showed that early intracerebral injection of IL-4 potentially promotes neuro-functional recovery, probably through enhancing the alternative activation of microglia/macrophage.	[Yang, Jianjing; Ding, Saidan; Huang, Weilong; Hu, Jiangnan; Huang, Shengwei; Zhang, Yu; Zhuge, Qichuan] Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China; [Zhuge, Qichuan] Wenzhou Med Univ, Zhejiang Prov Key Lab Aging & Neurol Dis, Wenzhou, Peoples R China	Zhuge, QC (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Neurosurg, Wenzhou, Peoples R China.; Zhuge, QC (corresponding author), Wenzhou Med Univ, Zhejiang Prov Key Lab Aging & Neurol Dis, Wenzhou, Peoples R China.	qichuanzhuge@sina.com	Hu, John/AAL-6376-2021	Hu, Jiangnan/0000-0002-0112-7578	QZ's National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171088, 81371396]; YZ's Natural Science Foundation of Zhejiang Province [Y 2110807]	The research was supported by QZ's National Natural Science Foundation of China (No. 81171088 and 81371396) and YZ's Natural Science Foundation of Zhejiang Province (Y 2110807). We are grateful to Professor Dongming Su and Kunlin Jin (University of North Texas Health Science Center, USA) for critical suggestions on the experiments.	BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; CHAO CC, 1993, J IMMUNOL, V151, P1473; Chen M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0284-x; Chen YJ, 2015, J NEUROSCI RES, V93, P1526, DOI 10.1002/jnr.23612; Colton CA, 2010, CNS NEUROL DISORD-DR, V9, P174, DOI 10.2174/187152710791012053; Deonarine K, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-11; Derecki NC, 2010, J EXP MED, V207, P1067, DOI 10.1084/jem.20091419; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Graeber MB, 2010, SCIENCE, V330, P783, DOI 10.1126/science.1190929; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Kato T, 2000, J IMMUNOL, V164, P3554, DOI 10.4049/jimmunol.164.7.3554; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399; Lu Q, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-44; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Mehndiratta P, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11370; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Mracsko E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00388; Orihuela R, 2016, BRIT J PHARMACOL, V173, P649, DOI 10.1111/bph.13139; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Schallert T, 1997, ADV NEUROL, V73, P229; Tang Y, 2014, CELL DEATH DIFFER, V21, P369, DOI 10.1038/cdd.2013.159; Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5; Wang J, 2005, NEUROCRIT CARE, V3, P77, DOI 10.1385/NCC:3:1:077; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Xie LK, 2014, J IMMUNOL, V192, P6009, DOI 10.4049/jimmunol.1303492; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X; Yang YR, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0245-4; Zhang SC, 2001, GLIA, V34, P101, DOI 10.1002/glia.1045	38	33	35	0	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	MAR 8	2016	10								61	10.3389/fnins.2016.00061			8	Neurosciences	Neurosciences & Neurology	DF7VR	WOS:000371566200001	27013935	DOAJ Gold, Green Published			2021-06-18	
J	Lee, AS; De Jesus-Cortes, H; Kabir, ZD; Knobbe, W; Orr, M; Burgdorf, C; Huntington, P; McDaniel, L; Britt, JK; Hoffmann, F; Brat, DJ; Rajadhyaksha, AM; Pieper, AA				Lee, Anni S.; De Jesus-Cortes, Hector; Kabir, Zeeba D.; Knobbe, Whitney; Orr, Madeline; Burgdorf, Caitlin; Huntington, Paula; McDaniel, Latisha; Britt, Jeremiah K.; Hoffmann, Franz; Brat, Daniel J.; Rajadhyaksha, Anjali M.; Pieper, Andrew A.			The Neuropsychiatric Disease-Associated Gene cacna1c Mediates Survival of Young Hippocampal Neurons	ENEURO			English	Article						anxiety; Cav; neurogenesis; neuroprotection; P7C3; P7C3A20	NEURAL STEM/PROGENITOR CELLS; TRAUMATIC BRAIN-INJURY; BIPOLAR DISORDER; NEUROPROTECTIVE EFFICACY; TRANSCRIPTION FACTOR; ADULT NEUROGENESIS; CA2+ CHANNELS; AMINOPROPYL CARBAZOLES; BDNF TRANSCRIPTION; CALCIUM-CHANNELS	Genetic variations in CACNA1C, which encodes the Ca(v)1.2 subunit of L-type calcium channels (LTCCs), are associated with multiple forms of neuropsychiatric disease that manifest high anxiety in patients. In parallel, mice harboring forebrainspecific conditional knockout of cacna1c (forebrain-Ca(v)1.2 cKO) display unusually high anxiety-like behavior. LTCCs in general, including the Ca(v)1.3 subunit, have been shown to mediate differentiation of neural precursor cells (NPCs). However, it has not previously been determined whether Ca(v)1.2 affects postnatal hippocampal neurogenesis in vivo. Here, we show that forebrain-Ca(v)1.2 cKO mice exhibit enhanced cell death of young hippocampal neurons, with no change in NPC proliferation, hippocampal size, dentate gyrus thickness, or corticosterone levels compared with wild-type littermates. These mice also exhibit deficits in brain levels of brain-derived neurotrophic factor (BDNF), and Cre recombinase-mediated knockdown of adult hippocampal Ca(v)1.2 recapitulates the deficit in young hippocampal neurons survival. Treatment of forebrain-Ca(v)1.2 cKO mice with the neuroprotective agent P7C3-A20 restored the net magnitude of postnatal hippocampal neurogenesis to wild-type levels without ameliorating their deficit in BDNF expression. The role of Ca(v)1.2 in young hippocampal neurons survival may provide new approaches for understanding and treating neuropsychiatric disease associated with aberrations in CACNA1C.	[Lee, Anni S.; Burgdorf, Caitlin; Rajadhyaksha, Anjali M.] Cornell Univ, Feil Family Brain & Mind Res Inst, Weill Cornell Med, New York, NY 10065 USA; [Lee, Anni S.; Kabir, Zeeba D.; Burgdorf, Caitlin; Rajadhyaksha, Anjali M.] Cornell Univ, Div Pediat Neurol, Dept Pediat, Weill Cornell Med, New York, NY 10065 USA; [De Jesus-Cortes, Hector] Univ Texas Southwestern Med Ctr Dallas, Neurosci Grad Program, Dallas, TX 75390 USA; [De Jesus-Cortes, Hector; McDaniel, Latisha; Britt, Jeremiah K.; Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; [Knobbe, Whitney; Orr, Madeline; Huntington, Paula] Univ Texas Southwestern Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Hoffmann, Franz] Tech Univ Munich, Inst Pharmacol, Munich, Germany; [Hoffmann, Franz] Tech Univ Munich, Res Grp 923, Munich, Germany; [Brat, Daniel J.] Emory Univ, Sch Med, Pathol & Lab Med, Atlanta, GA 30322 USA; [Rajadhyaksha, Anjali M.; Pieper, Andrew A.] Weill Cornell Med Coll, Weill Cornell Autism Res Program, New York, NY 10065 USA; [Pieper, Andrew A.] Univ Iowa, Dept Neurol, Carver Coll Med, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Free Radical, 415 Newton Rd, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Radiat Oncol, Holden Comprehens Canc Ctr,Radiat Biol Program, Iowa City, IA 52242 USA; [Pieper, Andrew A.] Univ Iowa, Carver Coll Med, Dept Vet Affairs, Iowa City, IA 52242 USA	Pieper, AA (corresponding author), Univ Iowa, Carver Coll Med, Dept Free Radical, 415 Newton Rd, Iowa City, IA 52242 USA.; Rajadhyaksha, AM (corresponding author), Weill Cornell Med, Div Pediat Neurol, Dept Pediat, 1300 York Ave, New York, NY 10065 USA.; Pieper, AA (corresponding author), Univ Iowa, Carver Coll Med, Holden Comprehens Canc Ctr, Radiat Biol Program,Dept Radiat Oncol, 415 Newton Rd, Iowa City, IA 52242 USA.; Pieper, AA (corresponding author), Univ Iowa, Carver Coll Med, Vet Affairs, 415 Newton Rd, Iowa City, IA 52242 USA.	amr2011@med.cornell.edu; Andrew-Pieper@uiowa.edu	Pieper, Andrew A/R-5552-2016; De Jesus-Cortes, Hector/ABC-9091-2020	De Jesus-Cortes, Hector/0000-0001-6983-6963; Pieper, Andrew/0000-0001-6299-6577	University of Iowa Carver College of Medicine; National Science Foundation fellowshipNational Science Foundation (NSF); Hartwell Foundation; Weill Cornell Autism Research Program; NIH Ruth L. Kirschstein NRSA F31 fellowship	This work was supported by unrestricted funds from the University of Iowa Carver College of Medicine to A.A.P, a National Science Foundation fellowship to H.D.J-C, Funding from The Hartwell Foundation to A.M.R and A.A.P., Weill Cornell Autism Research Program funding to A. M. R, NIH Ruth L. Kirschstein NRSA F31 fellowship to A.S.L.	Ament SA, 2015, P NATL ACAD SCI USA, V112, P3576, DOI 10.1073/pnas.1424958112; Amiri A, 2012, J NEUROSCI, V32, P5880, DOI 10.1523/JNEUROSCI.5462-11.2012; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; CAMERON HA, 1994, NEUROSCIENCE, V61, P203, DOI 10.1016/0306-4522(94)90224-0; Casamassima F, 2010, AM J MED GENET B, V153B, P303, DOI 10.1002/ajmg.b.30962; Chao HT, 2009, P NATL ACAD SCI USA, V106, P4577, DOI 10.1073/pnas.0901518106; Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446; Dabe EC, 2013, NEUROSCIENCE, V231, P125, DOI 10.1016/j.neuroscience.2012.11.028; Dao DT, 2010, BIOL PSYCHIAT, V68, P801, DOI 10.1016/j.biopsych.2010.06.019; De Jesus-Cortes H, 2012, P NATL ACAD SCI USA, V109, P17010, DOI 10.1073/pnas.1213956109; De Jesus-Cortest H, 2015, NPJ PARKINSON DIS, V1, DOI 10.1038/npjparkd.2015.10; Deisseroth K, 2004, NEURON, V42, P535, DOI 10.1016/S0896-6273(04)00266-1; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Dutca LM, 2014, INVEST OPHTH VIS SCI, V55, P8330, DOI 10.1167/iovs.14-15468; Ferreira MAR, 2008, NAT GENET, V40, P1056, DOI 10.1038/ng.209; Fitzsimons CP, 2013, MOL PSYCHIATR, V18, P993, DOI 10.1038/mp.2012.123; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Giordano TP, 2010, J NEUROSCI, V30, P17051, DOI 10.1523/JNEUROSCI.2255-10.2010; Green EK, 2013, MOL PSYCHIATR, V18, P1302, DOI 10.1038/mp.2012.142; Green EK, 2010, MOL PSYCHIATR, V15, P1016, DOI 10.1038/mp.2009.49; Hamshere ML, 2013, MOL PSYCHIATR, V18, P708, DOI 10.1038/mp.2012.67; Heyes S, 2015, PROG NEUROBIOL, V134, P36, DOI 10.1016/j.pneurobio.2015.09.002; Jolly LA, 2013, HUM MOL GENET, V22, P4673, DOI 10.1093/hmg/ddt315; Kemp SWP, 2015, NEUROSCIENCE, V284, P202, DOI 10.1016/j.neuroscience.2014.10.005; Knight HM, 2012, AM J MED GENET B, V159B, P21, DOI 10.1002/ajmg.b.31248; Kobayashi M, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-12; Lancaster TM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.100; Langwieser N, 2010, J NEUROSCI, V30, P8367, DOI 10.1523/JNEUROSCI.4164-08.2010; Le Strat Y, 2009, CURR MOL MED, V9, P506; Lee AS, 2012, MOL PSYCHIATR, V17, P1054, DOI [10.1038/mp.2012.149, 10.1038/mp.2012.71]; Lee MTM, 2011, MOL PSYCHIATR, V16, P548, DOI 10.1038/mp.2010.43; MacMillan KS, 2011, J AM CHEM SOC, V133, P1428, DOI 10.1021/ja108211m; Marschallinger J, 2015, CELL CALCIUM, V58, P606, DOI 10.1016/j.ceca.2015.09.007; Moosmang S, 2005, J NEUROSCI, V25, P9883, DOI 10.1523/JNEUROSCI.1531-05.2005; Naidoo J, 2014, J MED CHEM, V57, P3746, DOI 10.1021/jm401919s; Nurnberger JI, 2014, JAMA PSYCHIAT, V71, P657, DOI 10.1001/jamapsychiatry.2014.176; Nyegaard M, 2010, MOL PSYCHIATR, V15, P119, DOI 10.1038/mp.2009.69; Ohira K, 2013, MOL BRAIN, V6, DOI 10.1186/1756-6606-6-12; Pickard B, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001955; Pickard BS, 2006, ANN MED, V38, P439, DOI 10.1080/07853890600946500; Pieper AA, 2005, P NATL ACAD SCI USA, V102, P14052, DOI 10.1073/pnas.0506713102; Pieper AA, 2014, CHEM SOC REV, V43, P6716, DOI 10.1039/c3cs60448a; Pieper AA, 2010, CELL, V142, P39, DOI 10.1016/j.cell.2010.06.018; Reif A, 2007, EUR ARCH PSY CLIN N, V257, P290, DOI 10.1007/s00406-007-0733-3; Ripke S, 2014, NATURE, V511, P421, DOI 10.1038/nature13595; Ripke S, 2013, NAT GENET, V45, P1150, DOI 10.1038/ng.2742; Schierberl K, 2011, J NEUROSCI, V31, P13562, DOI 10.1523/JNEUROSCI.2315-11.2011; Schreiber R, 2014, NEUROBIOL LEARN MEM, V110, P72, DOI 10.1016/j.nlm.2013.12.015; Serafini G, 2014, CNS NEUROL DISORD-DR, V13, P1708; Singh C, 2013, P NATL ACAD SCI USA, V110, P12816, DOI 10.1073/pnas.1308037110; Sklar P, 2008, MOL PSYCHIATR, V13, P558, DOI 10.1038/sj.mp.4002151; Sklar P, 2011, NAT GENET, V43, P977, DOI 10.1038/ng.943; Smoller JW, 2013, LANCET, V381, P1371, DOI 10.1016/S0140-6736(12)62129-1; Stanco A, 2014, NEURON, V84, P940, DOI 10.1016/j.neuron.2014.10.040; Takamura N, 2014, PROG NEURO-PSYCHOPH, V50, P116, DOI 10.1016/j.pnpbp.2013.12.011; Tao JF, 2009, P NATL ACAD SCI USA, V106, P4882, DOI 10.1073/pnas.0811648106; Tao X, 2002, NEURON, V33, P383, DOI 10.1016/S0896-6273(01)00561-X; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Teh DBL, 2014, DEV GROWTH DIFFER, V56, P583, DOI 10.1111/dgd.12158; Tesla R, 2012, P NATL ACAD SCI USA, V109, P17016, DOI 10.1073/pnas.1213960109; Walker AK, 2015, MOL PSYCHIATR, V20, P500, DOI 10.1038/mp.2014.34; Wang G, 2014, CELL, V158, P1324, DOI 10.1016/j.cell.2014.07.040; Wessa M, 2010, MOL PSYCHIATR, V15, P1126, DOI 10.1038/mp.2009.103; West AE, 2014, NEUROTROPHIC FACTORS, V220; White JA, 2008, LEARN MEMORY, V15, P1, DOI 10.1101/lm.773208; Wu Q, 2013, GENE, V518, P223, DOI 10.1016/j.gene.2013.01.015; Yin TC, 2014, CELL REP, V8, P1731, DOI 10.1016/j.celrep.2014.08.030; Yu S, 2010, ANN NEUROL, V67, P21, DOI 10.1002/ana.21812	69	33	34	1	6	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	2373-2822			ENEURO	eNeuro	MAR-APR	2016	3	2							UNSP e0006-16.2016	10.1523/ENEURO.0006-16.2016			11	Neurosciences	Neurosciences & Neurology	EH7AY	WOS:000391926400004	27066530	DOAJ Gold, Green Published			2021-06-18	
J	Federolf, PA				Federolf, Peter A.			A novel approach to study human posture control: "Principal movements" obtained from a principal component analysis of kinematic marker data	JOURNAL OF BIOMECHANICS			English	Article						Human movement; Motor control; Stability; Balance; Principal component analysis PCA; Principal movements; Center of pressure COP	CEREBRAL CONCUSSION; STANDING PERSONS; MUSCLE SYNERGIES; QUIET STANCE; STABILITY; PRESSURE; BALANCE; SWAY; GAIT; ADJUSTMENTS	Human upright posture is maintained by postural movements, which can be quantified by "principal movements" (PMs) obtained through a principal component analysis (PCA) of kinematic marker data. The current study expands the concept of "principal movements" in analogy to Newton's mechanics by defining "principal position" (PP), "principal velocity" (PV), and "principal acceleration" (PA) and demonstrates that a linear combination of PPs and PAs determines the center of pressure (COP) variance in upright standing. Twenty-one subjects equipped with 27-markers distributed over all body segments stood on a force plate while their postural movements were recorded using a standard motion tracking system. A PCA calculated on normalized and weighted posture vectors yielded the PPs and their time derivatives, the PVs and PAs. COP variance explained by the PPs and PAs was obtained through a regression analysis. The first 15 PMs quantified 99.3% of the postural variance and explained 99.60% 0.22% (mean +/- SD) of the anterior-posterior and 98.82 +/- 0.74% of the lateral COP variance in the 21 subjects. Calculation of the PMs thus provides a data-driven definition of variables that simultaneously quantify the state of the postural system (PPs and PVs) and the activity of the neuro-muscular controller (PM). Since the definition of PPs and PM is consistent with Newton's mechanics, these variables facilitate studying how mechanical variables, such as the COP motion, are governed by the postural control system. (C) 2016 Elsevier Ltd. All rights reserved.	[Federolf, Peter A.] Univ Innsbruck, Dept Sport Sci, Furstenweg 185, A-6020 Innsbruck, Austria; [Federolf, Peter A.] Norwegian Univ Sci & Technol NTNU, Dept Neurosci, Trondheim, Norway; [Federolf, Peter A.] Norwegian Sch Sport Sci, Dept Phys Performance, Oslo, Norway	Federolf, PA (corresponding author), Univ Innsbruck, Dept Sport Sci, Furstenweg 185, A-6020 Innsbruck, Austria.	Peter.Federolf@uibk.ac.at	Federolf, Peter/H-4481-2019	Federolf, Peter/0000-0002-0266-6813			Alexandrov A, 1998, EXP BRAIN RES, V118, P210, DOI 10.1007/s002210050274; Bonnet CT, 2012, HUM MOVEMENT SCI, V31, P1541, DOI 10.1016/j.humov.2012.05.001; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Corriveau H, 2004, ARCH PHYS MED REHAB, V85, P1095, DOI 10.1016/j.apmr.2003.09.023; Daffertshofer A, 2004, CLIN BIOMECH, V19, P415, DOI 10.1016/j.clinbiomech.2004.01.005; Danna-dos-Santos A, 2007, EXP BRAIN RES, V179, P533, DOI 10.1007/s00221-006-0812-0; de Leva P, 1996, J BIOMECH, V29, P1223, DOI 10.1016/0021-9290(95)00178-6; Donker SF, 2008, EXP BRAIN RES, V184, P363, DOI 10.1007/s00221-007-1105-y; Eskofier BM, 2013, COMPUT METHOD BIOMEC, V16, P435, DOI 10.1080/10255842.2011.624515; Federolf P, 2014, SCAND J MED SCI SPOR, V24, P491, DOI 10.1111/j.1600-0838.2012.01455.x; Federolf PA, 2013, J BIOMECH, V46, P2173, DOI 10.1016/j.jbiomech.2013.06.032; Federolf P, 2013, J BIOMECH, V46, P2626, DOI 10.1016/j.jbiomech.2013.08.008; Federolf P, 2012, J BIOMECH, V45, P1127, DOI 10.1016/j.jbiomech.2012.02.008; Federolf PA, 2012, FOOTWEAR SCI, V4, P115, DOI 10.1080/19424280.2012.666270; Federolf PA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078689; Freitas SMSF, 2006, J NEUROPHYSIOL, V95, P636, DOI 10.1152/jn.00482.2005; Hillman CH, 2004, BIOL PSYCHOL, V66, P51, DOI 10.1016/j.biopsycho.2003.07.005; Hodges PW, 2002, EXP BRAIN RES, V144, P293, DOI 10.1007/s00221-002-1040-x; Hsu WL, 2007, J NEUROPHYSIOL, V97, P3024, DOI 10.1152/jn.01142.2006; Klous M, 2011, J NEUROPHYSIOL, V105, P2275, DOI 10.1152/jn.00665.2010; Krishnamoorthy V, 2003, EXP BRAIN RES, V152, P281, DOI 10.1007/s00221-003-1574-6; Krishnamoorthy V, 2003, BIOL CYBERN, V89, P152, DOI 10.1007/s00422-003-0419-5; Lipsitz LA, 2002, J GERONTOL A-BIOL, V57, pB115, DOI 10.1093/gerona/57.3.B115; MAKI BE, 1994, J GERONTOL, V49, pM72, DOI 10.1093/geronj/49.2.M72; Maki BE, 1996, J VESTIBUL RES-EQUIL, V6, P53; Maurer C, 2012, GAIT POSTURE, V36, P40, DOI 10.1016/j.gaitpost.2011.12.023; Nigg BM, 2012, J BIOMECH, V45, P1692, DOI 10.1016/j.jbiomech.2012.03.027; Pinter IJ, 2008, J NEUROPHYSIOL, V100, P3197, DOI 10.1152/jn.01312.2007; Roerdink M, 2006, EXP BRAIN RES, V174, P256, DOI 10.1007/s00221-006-0441-7; Rose J, 2002, DEV MED CHILD NEUROL, V44, P58, DOI 10.1017/S0012162201001669; RUBIN AM, 1995, AM J OTOL, V16, P216; Salavati M, 2009, GAIT POSTURE, V29, P460, DOI 10.1016/j.gaitpost.2008.11.016; Scharli AM, 2013, EXP BRAIN RES, V227, P523, DOI 10.1007/s00221-013-3528-y; Tricon V, 2007, NEUROSCI LETT, V415, P81, DOI 10.1016/j.neulet.2006.12.046; Troje NF, 2002, J VISION, V2, P371, DOI 10.1167/2.5.2; Vernazza S, 1996, NEUROSCI LETT, V206, P77, DOI 10.1016/S0304-3940(96)12464-2; Verrel J, 2009, PSYCHOL AGING, V24, P75, DOI 10.1037/a0014272; WINTER DA, 1993, NEUROSCI RES COMMUN, V12, P141; Winter DA, 1996, J NEUROPHYSIOL, V75, P2334	40	33	34	0	22	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	FEB 8	2016	49	3					364	370		10.1016/j.jbiomech.2015.12.030			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	DF7PA	WOS:000371548700007	26768228	Green Accepted			2021-06-18	
J	Li, XQ; Fang, B; Tan, WF; Wang, ZL; Sun, XJ; Zhang, ZL; Ma, H				Li, Xiao-Qian; Fang, Bo; Tan, Wen-Fei; Wang, Zhi-Lin; Sun, Xi-Jia; Zhang, Zai-Li; Ma, Hong			miR-320a affects spinal cord edema through negatively regulating aquaporin-1 of blood-spinal cord barrier during bimodal stage after ischemia reperfusion injury in rats	BMC NEUROSCIENCE			English	Article						Blood-spinal cord barrier; MicroRNAs; Aquaporin; Ischemia reperfusion injury	TRAUMATIC BRAIN-INJURY; ISCHEMIA/REPERFUSION INJURY; AQP1 EXPRESSION; UP-REGULATION; PERMEABILITY; DAMAGE; DYSFUNCTION; DISRUPTION; PROTEINS; CELLS	Background: Spinal cord edema is a serious complication and pathophysiological change after ischemia reperfusion (IR) injury. It has been demonstrated closely associated with bimodal disruption of blood-spinal cord barrier (BSCB) in our previous work. Aquaporin (AQP) 1 plays important but contradictory roles in water homeostasis. Recently, microRNAs (miRs) effectively regulate numerous target mRNAs during ischemia. However, whether miRs are able to protect against dimodal disruption of BSCB by regulating perivascular AQP1 remains to be elucidated. Results: Spinal water content and EB extravasation were suggested as a bimodal distribution in directly proportion to AQP1, since all maximal changes were detected at 12 and 48 h after reperfusion. Further TEM and double immunofluorescence showed that former disruption of BSCB at 12 h was attributed to cytotoxic edema by up-regulated AQP1 expressions in astrocytes, whereas the latter at 48 h was mixed with vasogenic edema with both endothelial cells and astrocytes involvement. Microarray analysis revealed that at 12 h post-injury, ten miRs were upregulated (>2.0 fold) and seven miRs were downregulated (<0.5 fold) and at 48 h, ten miRs were upregulated and eleven were downregulated compared to Sham-operated controls. Genomic screening and luciferase assays identified that miR-320a was a potential modulator of AQP1 in spinal cord after IR in vitro. In vivo, compared to rats in IR and negative control group, intrathecal infusion of miR-320a mimic attenuated IR-induced lower limb motor function deficits and BSCB dysfunction as decreased EB extravasation and spinal water content through down-regulating AQP1 expressions, whereas pretreated with miR-320a AMO reversed above effects. Conclusion: These findings indicate miR-320a directly and functionally affects spinal cord edema through negatively regulating AQP1 of BSCB after IR.	[Li, Xiao-Qian; Fang, Bo; Tan, Wen-Fei; Wang, Zhi-Lin; Sun, Xi-Jia; Zhang, Zai-Li; Ma, Hong] China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang 110001, Liaoning, Peoples R China	Ma, H (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Shenyang 110001, Liaoning, Peoples R China.	mahong5466@yahoo.com		Li, Xiao-Qian/0000-0001-6676-735X	Fund of Doctoral Fund of the Ministry of Education of ChinaMinistry of Education, China [20092104110009]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271370]; Science and Technology Program of Liaoning [2012408002]	Funding for this project was provided by Fund of Doctoral Fund of the Ministry of Education of China (No. 20092104110009), the Natural Science Foundation of China (No. 81271370) and the Science and Technology Program of Liaoning (No. 2012408002).	Aung LL, 2015, J NEUROIMMUNOL, V278, P185, DOI 10.1016/j.jneuroim.2014.11.004; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; Bhalala OG, 2012, J NEUROSCI, V32, P17935, DOI 10.1523/JNEUROSCI.3860-12.2012; Brandenburger T, 2012, NEUROSCI LETT, V506, P281, DOI 10.1016/j.neulet.2011.11.023; Fang B, 2013, J VASC SURG, V58, P1043, DOI 10.1016/j.jvs.2012.11.087; Gao JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046379; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Geis C, 2015, EXP NEUROL, V265, P8, DOI 10.1016/j.expneurol.2014.12.015; He B, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-22; He F, 2015, J THORAC CARDIOV SUR, V150, P398, DOI 10.1016/j.jtcvs.2015.03.066; Huang XN, 2011, ANAT REC, V294, P46, DOI 10.1002/ar.21286; Jin LJ, 2014, MOL BIOL REP, V41, P3169, DOI 10.1007/s11033-014-3176-8; Kim J, 2011, ANAT CELL BIOL, V44, P295, DOI 10.5115/acb.2011.44.4.295; Li XQ, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0246-3; Li XQ, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-28; Li XQ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-62; Lopez-Ramirez MA, 2014, FASEB J, V28, P2551, DOI 10.1096/fj.13-248880; Lu H, 2013, CHINESE MED J-PEKING, V126, P4316, DOI 10.3760/cma.j.issn.0366-6999.20131139; Moftakhar P, 2010, J NEUROPATH EXP NEUR, V69, P1201, DOI 10.1097/NEN.0b013e3181fd252c; Mohammadi MT, 2015, PATHOL RES PRACT, V211, P43, DOI 10.1016/j.prp.2014.07.014; Nesic O, 2006, NEUROSCIENCE, V143, P779, DOI 10.1016/j.neuroscience.2006.08.079; Nyberg F, 2002, AMINO ACIDS, V23, P231, DOI 10.1007/s00726-001-0134-2; Oklinski MK, 2014, J HISTOCHEM CYTOCHEM, V62, P598, DOI 10.1369/0022155414537495; Oshio K, 2003, ACT NEUR S, V86, P525; Qiu B, 2014, MOL MED REP, V9, P916, DOI 10.3892/mmr.2014.1899; Ren XP, 2009, CIRCULATION, V119, P2357, DOI 10.1161/CIRCULATIONAHA.108.814145; Schrottmaier WC, 2014, ATHEROSCLEROSIS, V235, P1, DOI 10.1016/j.atherosclerosis.2014.03.026; Sepramaniam S, 2012, J BIOL CHEM, V287, P12006, DOI 10.1074/jbc.M111.280701; Sepramaniam S, 2010, J BIOL CHEM, V285, P29223, DOI 10.1074/jbc.M110.144576; Stokum JA, 2015, NEUROCHEM RES, V40, P317, DOI 10.1007/s11064-014-1374-3; Wang DW, 2011, MOL CELL NEUROSCI, V46, P318, DOI 10.1016/j.mcn.2010.10.003; Wang YF, 2011, BRAIN RES, V1370, P220, DOI 10.1016/j.brainres.2010.11.016; Wang YF, 2009, NEUROREPORT, V20, P145, DOI 10.1097/WNR.0b013e32831c6c44; Wu QB, 2014, J MOL NEUROSCI, V54, P714, DOI 10.1007/s12031-014-0430-4; Yang JCS, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/410721; Zhang J, 2013, NEUROSCIENCE, V252, P68, DOI 10.1016/j.neuroscience.2013.08.006; Zhi XF, 2014, FEBS LETT, V588, P757, DOI 10.1016/j.febslet.2014.01.022	37	33	37	0	7	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	FEB 5	2016	17								10	10.1186/s12868-016-0243-1			14	Neurosciences	Neurosciences & Neurology	DC8OH	WOS:000369478400001	26850728	DOAJ Gold, Green Published			2021-06-18	
J	Reynolds, BB; Patrie, J; Henry, EJ; Goodkin, HP; Broshek, DK; Wintermark, M; Druzgal, TJ				Reynolds, Bryson B.; Patrie, James; Henry, Erich J.; Goodkin, Howard P.; Broshek, Donna K.; Wintermark, Max; Druzgal, T. Jason			Practice type effects on head impact in collegiate football	JOURNAL OF NEUROSURGERY			English	Article						biomechanics; football; athlete; subconcussion; traumatic brain injury; accelerometer	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL; EXPOSURE; CONCUSSION; PLAYERS; FREQUENCY	OBJECTIVE This study directly compares the number and severity of subconcussive head impacts sustained during helmet -only practices, shell practices, full -pad practices, and competitive games in a National Collegiate Athletic Association (NCAA) Division I -A football team. The goal of the study was to determine whether subconcussive head impact in collegiate athletes varies with practice type, which is currently unregulated by the NCAA. METHODS Over an entire season, a cohort of 20 collegiate football players wore impact -sensing mastoid patches that measured the linear and rotational acceleration of all head impacts during a total of 890 athletic exposures. Data were analyzed to compare the number of head impacts, head impact burden, and average impact severity during helmet -only, shell, and full -pad practices, and games. RESULTS Helmet -only, shell, and full -pad practices and games all significantly differed from each other (p 5. 0.05) in the mean number of impacts for each event, with the number of impacts being greatest for games, then full -pad practices, then shell practices, and then helmet -only practices. The cumulative distributions for both linear and rotational acceleration differed between all event types (p < 0.01), with the acceleration distribution being similarly greatest for games, then full -pad practices, then shell practices, and then helmet -only practices. For both linear and rotational acceleration, helmet -only practices had a lower average impact severity when compared with other event types (p < 0.001). However, the average impact severity did not differ between any comparisons of shell and full -pad practices, and games. CONCLUSIONS Helmet -only, shell, and full -pad practices, and games result in distinct head impact profiles per event, with each succeeding event type receiving more impacts than the one before. Both the number of head impacts and cumulative impact burden during practice are categorically less than in games. In practice events, the number and cumulative burden of head impacts per event increases with the amount of equipment worn. The average severity of individual impacts is relatively consistent across event types, with the exception of helmet -only -practices. The number of hits experienced during each event type is the main driver of event type differences in impact burden per athletic exposure, rather than the average severity of impacts that occur during the event. These findings suggest that regulation of practice equipment could be a fair and effective way to substantially reduce subconcussive head impact in thousands of collegiate football players.	[Reynolds, Bryson B.; Henry, Erich J.; Druzgal, T. Jason] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA; [Patrie, James] Univ Virginia, Publ Hlth Sci, Charlottesville, VA USA; [Goodkin, Howard P.] Univ Virginia, Dept Neurol, Charlottesville, VA USA; [Broshek, Donna K.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA; [Wintermark, Max] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA	Druzgal, TJ (corresponding author), Univ Virginia Hosp Med Ctr, Div Neuroradiol, Dept Radiol & Med Imaging, Box 800170, Charlottesville, VA 22908 USA.	tjd4m@hscmail.mcc.virginia.edu		Druzgal, Jason/0000-0001-7240-9487	UVa Health System Research Award; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2 T32 GM 8328-21]; UVa Department of Radiology and Medical Imaging; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008328] Funding Source: NIH RePORTER	Financial support was provided by a UVa Health System Research Award (T.J.D.), NIH grant 2 T32 GM 8328-21 (B.B.R.), and the UVa Department of Radiology and Medical Imaging (B.B.R., J.P., and T.J.D.). Access to the xPatch impact sensors was obtained through a research agreement with X2 Biosystems.	Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2012, ANN BIOMED ENG, V40, P37, DOI 10.1007/s10439-011-0396-0; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hardin J.W., 2003, GEN ESTIMATING EQUAT; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Johnson BD, 2014, CONCUSSIONS ATHLETIC, P331, DOI DOI 10.1007/978-1-4939-0295-8_19; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McCulloch C.E., 2001, GEN LINEAR MIXED MOD; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; National Collegiate Athletic Association, FOOTB PRACT GUID; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Therneau TM, 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036	36	33	34	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	FEB	2016	124	2					501	510		10.3171/2015.5.JNS15573			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DB9VR	WOS:000368866300034	26238972	Green Accepted, Bronze			2021-06-18	
J	Kizuka, Y; Nakano, M; Kitazume, S; Saito, T; Saido, TC; Taniguchi, N				Kizuka, Yasuhiko; Nakano, Miyako; Kitazume, Shinobu; Saito, Takashi; Saido, Takaomi C.; Taniguchi, Naoyuki			Bisecting GlcNAc modification stabilizes BACE1 protein under oxidative stress conditions	BIOCHEMICAL JOURNAL			English	Article						Alzheimer's disease; BACE1; bisecting GlcNAc; glycobiology; GnT-III; oxidative stress	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; ASPARAGINE-LINKED OLIGOSACCHARIDES; ALZHEIMERS BETA-SECRETASE; BRANCHED N-GLYCANS; MOUSE MODELS; DISEASE; THERAPEUTICS; CANCER; SENSITIVITY	beta-Site amyloid precursor protein-cleaving enzyme-1 (BACE1) is a protease essential for amyloid-beta (A beta) production in Alzheimer's disease (AD). BACE1 protein is known to be up-regulated by oxidative stress-inducing stimuli but the mechanism for this up-regulation still needs to be clarified. We have recently found that BACE1 is modified with bisecting N-acetylglucosamine (GlcNAc) by N-acetylglucosaminyltransferase-III (GnT-III, encoded by the Mgat3 gene) and that GnT-III deficiency reduces A beta-plaque formation in the brain by accelerating lysosomal degradation of BACE1. Therefore, we hypothesized that bisecting GlcNAc would stabilize BACE1 protein on oxidative stress. In the present study, we first show that A beta deposition in the mouse brain induces oxidative stress, together with an increase in levels of BACE1 and bisecting GlcNAc. Furthermore, prooxidant treatment induces expression of BACE1 protein in wild-type mouse embryonic fibroblasts (MEFs), whereas it reduces BACE1 protein in GnT-III (Mgat3) knock-out MEFs by accelerating lysosomal degradation of BACE1. We purified BACE1 from Neuro2A cells and performed LC/ESI/MS analysis for BACE1-derived glycopeptides and mapped bisecting GlcNAc-modified sites on BACE1. Point mutations at two N-glycosylation sites (Asn(153) and Asn(223)) abolish the bisecting GlcNAc modification on BACE1. These mutations almost cancelled the enhanced BACE1 degradation seen in Mgat3(-/-) MEFs, indicating that bisecting GlcNAc on BACE1 indeed regulates its degradation. Finally, we show that traumatic brain injury-induced BACE1 up-regulation is significantly suppressed in the Mgat3(-/-) brain. These results highlight the role of bisecting GlcNAc in oxidative stress-induced BACE1 expression and offer a novel glycan-targeted strategy for suppressing A beta generation.	[Kizuka, Yasuhiko; Kitazume, Shinobu; Taniguchi, Naoyuki] RIKEN, Max Planck Joint Res Ctr Syst Chem Biol, Syst Glycobiol Res Grp, Dis Glyc Team,Global Res Cluster, 2-1 Hirosawa, Wako, Saitama 3510198, Japan; [Nakano, Miyako] Hiroshima Univ, Grad Sch Adv Sci Matter, 1-3-1 Kagamiyama, Higashihiroshima, Hiroshima 7398530, Japan; [Saito, Takashi; Saido, Takaomi C.] RIKEN, Brain Sci Inst, Lab Proteolyt Neurosci, 2-1 Hirosawa, Wako, Saitama 3510198, Japan	Kitazume, S; Taniguchi, N (corresponding author), RIKEN, Max Planck Joint Res Ctr Syst Chem Biol, Syst Glycobiol Res Grp, Dis Glyc Team,Global Res Cluster, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	shinobuk@riken.jp; dglycotani@riken.jp	Saito, Takashi/G-2563-2015; Saido, Takaomi C/N-5472-2015; Taniguchi, Naoyuki/A-7086-2016; Sado, Takaomi/AAN-2759-2021; Taniguchi, Naoyuki/I-4182-2014	Saito, Takashi/0000-0002-9659-9251; Saido, Takaomi C/0000-0003-1970-6903; Sado, Takaomi/0000-0003-1970-6903; Taniguchi, Naoyuki/0000-0001-5889-5968; Kizuka, Yasuhiko/0000-0002-3181-9743	RIKEN; Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science [26670148, 15K14481, 15H04700, 26110723, 26117522]; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26110723, 15H04700, 26117522, 26290019, 15K14481, 26670148] Funding Source: KAKEN	This work was supported by RIKEN (the Systems Glycobiology Research project to N.T., Special Postdoctoral Researchers Program to Y.K. and Incentive Research Grant to Y.K.) and by the Japan Society for the Promotion of Science (Grant-in-Aid for Challenging Exploratory Research to Y.K. [26670148] and to N.T. [15K14481], Grant-in-Aid for Scientific Research (B) to N.T. [15H04700], and Grant-in-Aid for Scientific Research on Innovative Areas to Y.K. [26110723] and S.K. [26117522]).	Abbott A, 2011, NATURE, V475, pS2, DOI 10.1038/475S2a; Abdul HM, 2006, J NEUROCHEM, V96, P1322, DOI 10.1111/j.1471-4159.2005.03647.x; Akasaka-Manya K, 2010, GLYCOBIOLOGY, V20, P99, DOI 10.1093/glycob/cwp152; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; Fiala M, 2007, P NATL ACAD SCI USA, V104, P12849, DOI 10.1073/pnas.0701267104; Guglielmotto M, 2009, J NEUROCHEM, V108, P1045, DOI 10.1111/j.1471-4159.2008.05858.x; Kandalepas PC, 2013, ACTA NEUROPATHOL, V126, P329, DOI 10.1007/s00401-013-1152-3; Kang EL, 2010, J BIOL CHEM, V285, P24108, DOI 10.1074/jbc.M109.092742; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; Karran E, 2011, NAT REV DRUG DISCOV, V10, P698, DOI 10.1038/nrd3505; Kitazume S, 2001, P NATL ACAD SCI USA, V98, P13554, DOI 10.1073/pnas.241509198; Kizuka Y, 2015, EMBO MOL MED, V7, P175, DOI 10.15252/emmm.201404438; Koh YH, 2005, J BIOL CHEM, V280, P32499, DOI 10.1074/jbc.M506199200; Kurimoto A, 2014, J BIOL CHEM, V289, P11704, DOI 10.1074/jbc.M113.502542; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Miyoshi E, 1997, INT J CANCER, V72, P1117; Mouton-Liger F, 2012, BBA-MOL BASIS DIS, V1822, P885, DOI 10.1016/j.bbadis.2012.01.009; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Nakano M, 2008, INT J CANCER, V122, P2301, DOI 10.1002/ijc.23364; Nakano M, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009001; Nishima W, 2012, J PHYS CHEM B, V116, P8504, DOI 10.1021/jp212550z; O'Brien RJ, 2011, ANNU REV NEUROSCI, V34, P185, DOI 10.1146/annurev-neuro-061010-113613; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Priatel JJ, 1997, GLYCOBIOLOGY, V7, P45, DOI 10.1093/glycob/7.1.45; Re S, 2011, BIOPHYS J, V101, pL44, DOI 10.1016/j.bpj.2011.10.019; Sadleir KR, 2012, J BIOL CHEM, V287, P7224, DOI 10.1074/jbc.M111.333914; Saito T, 2014, NAT NEUROSCI, V17, P661, DOI 10.1038/nn.3697; Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034; Selkoe DJ, 2011, NAT MED, V17, P1060, DOI 10.1038/nm.2460; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Tamagno E, 2008, J NEUROCHEM, V104, P683, DOI 10.1111/j.1471-4159.2007.05072.x; Tan JZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051922; Taniguchi N, 2006, CURR OPIN STRUC BIOL, V16, P561, DOI 10.1016/j.sbi.2006.08.011; Taniguchi N, 2011, BMB REP, V44, P772, DOI 10.5483/BMBRep.2011.44.12.772; Tesco G, 2007, NEURON, V54, P721, DOI 10.1016/j.neuron.2007.05.012; Vassar R, 2014, J NEUROCHEM, V130, P4, DOI 10.1111/jnc.12715; von Bernhardi R, 2012, ANTIOXID REDOX SIGN, V16, P974, DOI 10.1089/ars.2011.4082; Walker KR, 2012, J NEUROSCI, V32, P10423, DOI 10.1523/JNEUROSCI.5491-11.2012; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Zhang XM, 2009, EUR J NEUROSCI, V30, P2271, DOI 10.1111/j.1460-9568.2009.07017.x; Zhao YY, 2008, FEBS J, V275, P1939, DOI 10.1111/j.1742-4658.2008.06346.x	43	33	33	0	15	PORTLAND PRESS LTD	LONDON	CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND	0264-6021	1470-8728		BIOCHEM J	Biochem. J.	JAN 1	2016	473		1				21	30		10.1042/BJ20150607			10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	DK2ZI	WOS:000374783900004	26467158				2021-06-18	
J	Saban, KL; Griffin, JM; Urban, A; Janusek, MA; Pape, TLB; Collins, E				Saban, Karen L.; Griffin, Joan M.; Urban, Amanda; Janusek, Marissa A.; Pape, Theresa Louise-Bender; Collins, Eileen			Perceived health, caregiver burden, and quality of life in women partners providing care to Veterans with traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain injuries; caregiver burden; caregiving; fatigue; informal caregiver; perceived health; quality of life; somatic symptoms; stress; Veterans	CORONARY-HEART-DISEASE; US SERVICE MEMBERS; LOW-BACK-PAIN; SPOUSAL CAREGIVERS; FAMILY CAREGIVERS; CANCER; INDIVIDUALS; ASSOCIATION; IMPAIRMENTS; PREVALENCE	Families of Veterans with traumatic brain injury (TBI) are often faced with providing long-term informal care to their loved one. However, little is known about how their perceived health and caregiving burden contribute to their quality of life (QOL). The purpose of this descriptive study was to describe perceived health, somatic symptoms, caregiver burden, and perceived QOL and to identify the extent to which these variables are associated with QOL in female partners/spouses of Veterans with TBI. Participants completed a written questionnaire including the general health subscale of the 12-Item Short Form Survey version 2, the Patient Health Questionnaire-15, Caregiver Reaction Assessment, and Quality of Life Index. Caregivers reported moderate levels of QOL, and over a quarter of the sample reported high levels of somatic symptoms, particularly fatigue and sleep disturbance. Age, perceived general health, somatic symptoms, the five subscales of caregiver burden (self-esteem, disrupted schedule, effect on finances, lack of family support, and effect on health) predicted QOL and explained 64% of its variance (adjusted r(2) = 0.64, F(8,31) = 9.59). However, only somatic symptoms and the caregiver burden subscales of self-esteem and effect on finances were significant predictors in the model. These findings have implications for development of family-centered interventions to enhance the QOL of informal caregivers of Veterans with TBI.	[Saban, Karen L.; Pape, Theresa Louise-Bender; Collins, Eileen] Edward Hines Jr Dept Vet Affairs VA Hosp, Ctr Innovat Complex Chron Healthcare, Hines, IL USA; [Saban, Karen L.] Loyola Univ, Marcella Niehoff Sch Nursing, Chicago, IL 60611 USA; [Griffin, Joan M.] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA; [Griffin, Joan M.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Urban, Amanda] Edward Hines Jr VA Hosp, 5000 S 5th Ave 151H,Bldg 1,B261, Hines, IL 60141 USA; [Janusek, Marissa A.] Ochsner Med Ctr, Jefferson, LA USA; [Pape, Theresa Louise-Bender] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA; [Collins, Eileen] Univ Illinois, Dept Biobehav Hlth Sci, Chicago, IL USA	Saban, KL (corresponding author), Edward Hines Jr VA Hosp, 5000 S 5th Ave 151H,Bldg 1,B261, Hines, IL 60141 USA.	Karen.Saban@va.gov		Bender Pape, Theresa/0000-0001-7738-5963	VA Nursing Research Initiative [HSRD NRI 12-413]	This material was based on work supported by the VA Nursing Research Initiative (award #HSR&D NRI 12-413).	Ahn S, 2012, MATURITAS, V71, P62, DOI 10.1016/j.maturitas.2011.10.011; Arango-Lasprilla JC, 2011, J REHABIL MED, V43, P983, DOI 10.2340/16501977-0883; Baldassarre M, 2015, PM&R, V7, P845, DOI 10.1016/j.pmrj.2015.03.003; Bardak AN, 2012, J REHABIL MED, V44, P858, DOI 10.2340/16501977-1043; Berg Jenny, 2004, Eur J Health Econ, V5 Suppl 1, pS84, DOI 10.1007/s10198-005-0293-2; Berglund E, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0309-2; Buyck JF, 2013, J GERONTOL A-BIOL, V68, P1316, DOI 10.1093/gerona/glt025; Buyck JF, 2011, AM J PUBLIC HEALTH, V101, P1971, DOI 10.2105/AJPH.2010.300044; Carlsson ME, 2012, PALLIAT SUPPORT CARE, V10, P165, DOI 10.1017/S1478951511000836; Chronister J, 2010, NEUROREHABILITATION, V27, P49, DOI 10.3233/NRE-2010-0580; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Dhruva A, 2012, CANCER NURS, V35, P70, DOI 10.1097/NCC.0b013e3182194a25; DVBIC, 2015, DOD WORLDW NUMB TBI; Ferrans C. E., 2001, QUALITY LIFE INDEX; Fredman L, 2010, J GERONTOL A-BIOL, V65, P565, DOI 10.1093/gerona/glq025; GIVEN CW, 1992, RES NURS HEALTH, V15, P271, DOI 10.1002/nur.4770150406; Griffin J. M., 2014, MILITARY DEPLOYMENT, P259, DOI [10.1007/978-1-4614-8712-8_14, DOI 10.1007/978-1-4614-8712-8_14]; Griffin JM, 2012, J HEAD TRAUMA REHAB, V27, P3, DOI 10.1097/HTR.0b013e3182274260; Griffin JM, 2009, J REHABIL RES DEV, V46, P879, DOI 10.1682/JRRD.2008.08.0104; Hanly P, 2015, SUPPORT CARE CANCER, V23, P1941, DOI 10.1007/s00520-014-2551-2; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; Jenkins LS, 2007, J CARDIOVASC NURS, V22, P472, DOI 10.1097/01.JCN.0000297378.98754.06; Joreskog KG., 1996, LISREL 8 USERS REFER; Kim Y, 2015, CANCER-AM CANCER SOC, V121, P302, DOI 10.1002/cncr.29040; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Kruithof WJ, 2012, J STROKE CEREBROVASC, V21, P801, DOI 10.1016/j.jstrokecerebrovasdis.2011.04.011; Lavela Sherri L, 2013, Womens Health Issues, V23, pe225, DOI 10.1016/j.whi.2013.04.001; Lee S, 2003, AM J PREV MED, V24, P113, DOI 10.1016/S0749-3797(02)00582-2; Lefaiver CA, 2009, PROG TRANSPLANT, V19, P142; Lefebvre H, 2008, BRAIN INJURY, V22, P535, DOI 10.1080/02699050802158243; Lehan T, 2012, NEUROREHABILITATION, V30, P87, DOI 10.3233/NRE-2011-0730; Li QP, 2013, EUR J ONCOL NURS, V17, P578, DOI 10.1016/j.ejon.2013.01.007; Mausbach BT, 2007, PSYCHOSOM MED, V69, P816, DOI 10.1097/PSY.0b013e318157d461; Milbury K, 2013, SUPPORT CARE CANCER, V21, P2371, DOI 10.1007/s00520-013-1795-6; National Alliance of Caregiving, 2009, CAR IN THE US; Norup A, 2015, ARCH PHYS MED REHAB, V96, P56, DOI 10.1016/j.apmr.2014.08.009; Nwankwo Yoon SS, 2013, HYPERTENSION ADULTS; Qutub K, 2014, AMYOTROPH LAT SCL FR, V15, P292, DOI 10.3109/21678421.2014.886699; Rivera P, 2007, NEUROREHABILITATION, V22, P3; Ruiz-Robledillo N, 2013, PSYCHOL HEALTH, V28, P1246, DOI 10.1080/08870446.2013.800517; Rumpold T, 2016, SUPPORT CARE CANCER, V24, P1975, DOI 10.1007/s00520-015-2987-z; Saban KL, 2016, BIOL RES NURS, V18, P50, DOI 10.1177/1099800414568661; Saban KL, 2015, REHABIL NURS, V40, P277, DOI 10.1002/rnj.182; Salonen P, 2014, EUR J CANCER CARE, V23, P274, DOI 10.1111/ecc.12153; Schafer JL., 1997, ANAL INCOMPLETE MULT; Smeets SM, 2012, ARCH PHYS MED REHAB, V93, P834, DOI 10.1016/j.apmr.2011.10.029; STOMMEL M, 1992, RES NURS HEALTH, V15, P399, DOI 10.1002/nur.4770150508; Tavakol M, 2011, INT J MED EDUC, V2, P53, DOI 10.5116/ijme.4dfb.8dfd; Utne I, 2013, SUPPORT CARE CANCER, V21, P2527, DOI 10.1007/s00520-013-1824-5; Van Houtven CH, 2012, INQUIRY-J HEALTH CAR, V49, P339, DOI 10.5034/inquiryjrnl_49.04.01; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; Ware J., 2002, SCORE VERSION 2 SF 1; Yalcinkaya EY, 2010, TOP STROKE REHABIL, V17, P389, DOI 10.1310/tsr1705-389	55	33	34	0	2	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2016	53	6					681	691		10.1682/JRRD.2015.07.0143			11	Rehabilitation	Rehabilitation	EK5SC	WOS:000393985100004	27997670	Bronze			2021-06-18	
J	Singh, AK; Ditkofsky, NG; York, JD; Abujudeh, HH; Avery, LA; Brunner, JF; Sodickson, AD; Lev, MH				Singh, Ajay K.; Ditkofsky, Noah G.; York, John D.; Abujudeh, Hani H.; Avery, Laura A.; Brunner, John F.; Sodickson, Aaron D.; Lev, Michael H.			Blast Injuries: From Improvised Explosive Device Blasts to the Boston Marathon Bombing	RADIOGRAPHICS			English	Article							TRAUMATIC BRAIN-INJURY; TERRORIST BOMBINGS; THORACIC TRAUMA; FOREIGN-BODIES; EXPERIENCE; PATTERN; MECHANISM; SYSTEM; INCIDENTS; HOSPITALS	Although most trauma centers have experience with the imaging and management of gunshot wounds, in most regions blast wounds such as the ones encountered in terrorist attacks with the use of improvised explosive devices (IEDs) are infrequently encountered outside the battlefield. As global terrorism becomes a greater concern, it is important that radiologists, particularly those working in urban trauma centers, be aware of the mechanisms of injury and the spectrum of primary, secondary, tertiary, and quaternary blast injury patterns. Primary blast injuries are caused by barotrauma from the initial increased pressure of the explosive detonation and the rarefaction of the atmosphere immediately afterward. Secondary blast injuries are caused by debris carried by the blast wind and most often result in penetrating trauma from small shrapnel. Tertiary blast injuries are caused by the physical displacement of the victim and the wide variety of blunt or penetrating trauma sustained as a result of the patient impacting immovable objects such as surrounding cars, walls, or fences. Quaternary blast injuries include all other injuries, such as burns, crush injuries, and inhalational injuries. Radiography is considered the initial imaging modality for assessment of shrapnel and fractures. Computed tomography is the optimal test to assess penetrating chest, abdominal, and head trauma. The mechanism of blast injuries and the imaging experience of the victims of the Boston Marathon bombing are detailed, as well as musculoskeletal, neurologic, gastrointestinal, and pulmonary injury patterns from blast injuries. (C) RSNA, 2016.	[Singh, Ajay K.; Abujudeh, Hani H.; Avery, Laura A.; Lev, Michael H.] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND-210, Boston, MA 02114 USA; [Ditkofsky, Noah G.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med Imaging, Toronto, ON, Canada; [York, John D.] Naval Med Ctr, Dept Radiol, Portsmouth, VA USA; [Brunner, John F.] Univ So Calif, Dept Radiol, Los Angeles, CA USA; [Sodickson, Aaron D.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA	Singh, AK (corresponding author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,FND-210, Boston, MA 02114 USA.	mghpartners@yahoo.com	Ditkofsky, Noah/AAE-7817-2021; Singh, Ajay/AAF-4414-2020	Ditkofsky, Noah/0000-0002-5851-8166; Sodickson, Aaron/0000-0003-1275-681X	GE HealthcareGE Healthcare; Millennium PharmaceuticalsTakeda Pharmaceutical Company Ltd	M.H.L. Activities related to the present article: disclosed no relevant relationships. Activities not related to the present article: institutional grant and personal fees from GE Healthcare; personal fees from Millennium Pharmaceuticals. Other activities: disclosed no relevant relationships.	[Anonymous], 2002, AM HER SCI DICT; Aras MH, 2010, DENTOMAXILLOFAC RAD, V39, P72, DOI 10.1259/dmfr/68589458; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bala M, 2010, J TRAUMA, V69, P1022, DOI 10.1097/TA.0b013e3181f35c71; Barnard E, 2013, NEW ENGL J MED, V368, P1045, DOI 10.1056/NEJMicm1203842; Bass CR, 2012, ANN BIOMED ENG, V40, P185, DOI 10.1007/s10439-011-0424-0; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Brunner J, 2015, SEMIN ULTRASOUND CT, V36, P68, DOI 10.1053/j.sult.2014.10.006; Brunner J, 2014, RADIOLOGY, V273, P78, DOI 10.1148/radiol.14140253; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chen Y, 2011, BRAIN INJURY, V25, P641, DOI 10.3109/02699052.2011.580313; Cho SI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067618; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Eskridge SL, 2012, INJURY, V43, P1678, DOI 10.1016/j.injury.2012.05.027; FRYKBERG ER, 1988, ANN SURG, V208, P569, DOI 10.1097/00000658-198811000-00005; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; Golden Tim, 2004, NY TIMES; Goldstein AL, 2014, AM SURGEON, V80, P98; Guermazi A, 2013, ARTHRIT CARE RES, V65, P1893, DOI 10.1002/acr.22113; Heldenberg E, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00047; Hong Seok Min, 2014, Korean J Audiol, V18, P137, DOI 10.7874/kja.2014.18.3.137; Horrocks C L, 2001, J R Army Med Corps, V147, P28; Hull JB, 1996, J TRAUMA, V40, pS198, DOI 10.1097/00005373-199603001-00044; KATZ E, 1989, ANN SURG, V209, P484, DOI 10.1097/00000658-198904000-00016; Kellermann AL, 2013, NEW ENGL J MED, V368, P1956, DOI 10.1056/NEJMp1305304; Landman A, 2015, ANN EMERG MED, V66, P51, DOI 10.1016/j.annemergmed.2014.06.009; Larson P S, 2000, Neurosurg Focus, V8, pe4; Leibovici D, 1996, J TRAUMA, V41, P1030, DOI 10.1097/00005373-199612000-00015; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Luks FI, 2010, ACTA CHIR BELG, V110, P517, DOI 10.1080/00015458.2010.11680667; Mao ZQ, 2012, ACTA NEUROCHIR, V154, P2187, DOI 10.1007/s00701-012-1487-x; Marti M, 2006, EMERG RADIOL, V13, P113, DOI 10.1007/s10140-006-0534-4; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; Meriot P, 1997, RADIOGRAPHICS, V17, P1445, DOI 10.1148/radiographics.17.6.9397457; Millham FH, 2014, J TRAUMA ACUTE CARE, V77, P501, DOI 10.1097/TA.0000000000000397; Oikonomou A, 2012, BMJ CASE REP    0320, P2012; Patel HDL, 2012, J TRAUMA ACUTE CARE, V73, P276, DOI 10.1097/TA.0b013e318256dd80; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Popivanov G, 2014, J ROY ARMY MED CORPS, V160, P52, DOI 10.1136/jramc-2013-000132; Proud WG, 2013, J ROY ARMY MED CORPS, V159, P4, DOI 10.1136/jramc-2013-000030; Putnam AT, 2010, J TRAUMA, V69, P1028; Raja AS, 2010, J TRAUMA, V68, P1421, DOI 10.1097/TA.0b013e3181cf7d32; Ramasamy A, 2008, J TRAUMA, V65, P910, DOI 10.1097/TA.0b013e3181848cf6; Remenschneider AK, 2014, OTOL NEUROTOL, V35, P1825, DOI 10.1097/MAO.0000000000000616; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Rodoplu U, 2005, J TRAUMA, V59, P195; Rosenfeld JV, 2015, WORLD J SURG, V39, P1352, DOI 10.1007/s00268-014-2874-7; Rosenfeld JV, 2013, LANCET NEUROL, V12, P882, DOI 10.1016/S1474-4422(13)70161-3; Sasser SM, 2006, PREHOSP EMERG CARE, V10, P165, DOI 10.1080/10903120500540912; Shaham D, 2002, ISRAEL MED ASSOC J, V4, P564; Shinkman PD., 2013, BOMB EXPERTS OFFER A; Shoichet CE, PROSECUTORS TSARNAEV; Singh AK, 2014, AM J ROENTGENOL, V203, P235, DOI 10.2214/AJR.14.12549; Stuhmiller JH, 2008, BLAST INJURY TRANSLA; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Turegano-Fuentes F, 2014, EUR J TRAUMA EMERG S, V40, P451, DOI 10.1007/s00068-014-0397-4; Turegano-Fuentes F, 2008, WORLD J SURG, V32, P1168, DOI 10.1007/s00268-008-9557-1; U.S. Department of Homeland Security Web site, IED ATT FACT SHEET W; Walls RM, 2013, JAMA-J AM MED ASSOC, V309, P2441, DOI 10.1001/jama.2013.5965; Watchorn J, 2013, CLIN RADIOL, V68, P39, DOI 10.1016/j.crad.2012.05.013; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Yeh DD, 2012, WORLD J SURG, V36, P966, DOI 10.1007/s00268-012-1500-9	65	33	33	0	20	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0271-5333			RADIOGRAPHICS	Radiographics	JAN-FEB	2016	36	1					295	307		10.1148/rg.2016150114			13	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	DE0TD	WOS:000370336700020	26761543	Bronze			2021-06-18	
J	Zhao, MF; Liang, F; Xu, HD; Yan, W; Zhang, JM				Zhao, Mingfei; Liang, Feng; Xu, Hangdi; Yan, Wei; Zhang, Jianmin			Methylene blue exerts a neuroprotective effect against traumatic brain injury by promoting autophagy and inhibiting microglial activation	MOLECULAR MEDICINE REPORTS			English	Article						methylene blue; traumatic brain injury; autophagy; microglia	IMPROVES FUNCTIONAL RECOVERY; EDEMA; MECHANISMS	Traumatic brain injury (TBI) leads to permanent neurological impairment, and methylene blue (MB) exerts central nervous system neuroprotective effects. However, only one previous study has investigated the effectiveness of MB in a controlled cortical impact injury model of TBI. In addition, the specific mechanisms underlying the effect of MB against TBI remain to be elucidated. Therefore, the present study investigated the neuroprotective effect of MB on TBI and the possible mechanisms involved. In a mouse model of TBI, the animals were randomly divided into sham, vehicle (normal saline) or MB groups. The treatment time-points were 24 and 72 h (acute phase of TBI), and 14 days (chronic phase of TBI) post-TBI. The brain water content (BWC), and levels of neuronal death, and autophagy were determined during the acute phase, and neurological deficit, injury volume and microglial activation were assessed at all time-points. The injured hemisphere BWC was significantly increased 24 h post-TBI, and this was attenuated following treatment with MB. There was a significantly higher number of surviving neurons in the MB group, compared with the Vehicle group at 24 and 72 h post-TBI. In the acute phase, the MB-treated animals exhibited significantly upregulated expression of Beclin 1 and increased LC3-II to LC3-I ratios, compared with the vehicle group, indicating an increased rate of autophagy. Neurological functional deficits, measured using the modified neurological severity score, were significantly lower in the acute phase in the MB-treated animals and cerebral lesion volumes in the MB-treated animals were significantly lower, compared with the other groups at all time-points. Microglia were activated 24 h after TBI, peaked at 72 h and persisted until 14 days after TBI. Although the number of Iba-1-positive cells in the vehicle and MB groups 24 h post-TBI were not significantly different, marked microglial inhibition was observed in the MB group 72 h and 14 days after -TBI. These results indicated that MB exerts a neuroprotective effect by increasing autophagy, decreasing brain edema and inhibiting microglial activation.	[Zhao, Mingfei; Liang, Feng; Yan, Wei; Zhang, Jianmin] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg, Hangzhou 310009, Zhejiang, Peoples R China; [Xu, Hangdi] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Resp Med, Hangzhou 310016, Zhejiang, Peoples R China	Yan, W (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurosurg, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.	ywisyw@163.com; zjm135@vip.sina.com		Yan, Wei/0000-0002-1123-0835	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81200956]	This study was supported by a grant from the National Natural Science Foundation of China (grant. no. 81200956). This manuscript was copyedited by an English speaking professional with a science background at Elixigen Corporation (Huntington Beach, CA, USA).	[Anonymous], 2011, GUID CAR US LAB AN; Auchter A, 2014, J ALZHEIMERS DIS, V42, pS525, DOI 10.3233/JAD-141527; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Callaway NL, 2004, PHARMACOL BIOCHEM BE, V77, P175, DOI 10.1016/j.pbb.2003.10.007; Chen JY, 2014, J PINEAL RES, V56, P12, DOI 10.1111/jpi.12086; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Congdon EE, 2012, AUTOPHAGY, V8, P609, DOI 10.4161/auto.19048; Dibaj P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043963; Dibaj P, 2010, GLIA, V58, P1133, DOI 10.1002/glia.20993; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Duan YL, 2003, J NEUROBIOL, V57, P183, DOI 10.1002/neu.10262; Dvela-Levitt M, 2014, J NEUROTRAUM, V31, P1942, DOI 10.1089/neu.2014.3544; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Eroglu B, 2014, J NEUROCHEM, V130, P626, DOI 10.1111/jnc.12781; Esen F, 2003, J NEUROSURG ANESTH, V15, P119, DOI 10.1097/00008506-200304000-00009; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fenn AM, 2014, J NEUROTRAUM, V31, pA100; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Han ZL, 2013, NEUROL MED-CHIR, V53, P630; Hong YA, 2010, ACTA PHARMACOL SIN, V31, P1421, DOI 10.1038/aps.2010.101; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Kwok Edmund S H, 2006, J Intensive Care Med, V21, P359, DOI 10.1177/0885066606290671; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Lim SW, 2013, J SURG RES, V184, P1076, DOI 10.1016/j.jss.2013.04.070; Lu J, 2005, ACT NEUR S, V95, P281; Maslow AD, 2006, ANESTH ANALG, V103, P2, DOI 10.1213/01.ane.0000221261.25310.fe; Paciullo CA, 2010, PHARMACOTHERAPY, V30, P702, DOI 10.1592/phco.30.7.702; Parekkadan B, 2008, NEUROSCI LETT, V438, P190, DOI 10.1016/j.neulet.2008.03.094; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rojas JC, 2012, PROG NEUROBIOL, V96, P32, DOI 10.1016/j.pneurobio.2011.10.007; Shen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079833; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Wang AM, 2010, J BIOL CHEM, V285, P15714, DOI 10.1074/jbc.M109.098806; Wang HQ, 2014, NEUROPHARMACOLOGY, V86, P9, DOI 10.1016/j.neuropharm.2014.06.018; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu FF, 2014, BRAIN INJURY, V28, P1594, DOI 10.3109/02699052.2014.943289; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873	40	33	41	2	12	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	JAN	2016	13	1	A				13	20		10.3892/mmr.2015.4551			8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	DA5UG	WOS:000367867500003	26572258	Other Gold, Green Published			2021-06-18	
J	Melnick, ER; Shafer, K; Rodulfo, N; Shi, J; Hess, EP; Wears, RL; Qureshi, RA; Post, LA				Melnick, Edward R.; Shafer, Katherine; Rodulfo, Nayeli; Shi, Joyce; Hess, Erik P.; Wears, Robert L.; Qureshi, Rija A.; Post, Lori A.			Understanding Overuse of Computed Tomography for Minor Head Injury in the Emergency Department: A Triangulated Qualitative Study	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Academic-Emergency-Medicine (AEM) Consensus Conference	MAY 12, 2015	San Diego, CA	Acad Emergency Med			SHARED DECISION-MAKING; CLUSTER-RANDOMIZED-TRIAL; COGNITIVE TASK-ANALYSIS; PATIENT SATISFACTION; TECHNICAL WORK; BRAIN-INJURY; HEALTH-CARE; MEDICINE; CT; INFORMATION	Background: Overuse of computed tomography (CT) for minor head injury continues despite developed and rigorously validated clinical decision rules like the Canadian CT Head Rule (CCHR). Adherence to this sensitive and specific rule could decrease the number of CT scans performed in minor head injury by 35%. But in practice, the CCHR has failed to reduce testing, despite its accurate performance. Objectives: The objective was to identify nonclinical, human factors that promote or inhibit the appropriate use of CT in patients presenting to the emergency department (ED) with minor head injury. Methods: This was a qualitative study in three phases, each with interview guides developed by a multidisciplinary team. Subjects were recruited from patients treated and released with minor head injuries and providers in an urban academic ED and a satellite community ED. Focus groups of patients (four groups, 22 subjects total) and providers (three groups, 22 subjects total) were conducted until thematic saturation was reached. The findings from the focus groups were triangulated with a cognitive task analysis, including direct observation in the ED (>150 hours), and individual semistructured interviews using the critical decision method with four senior physician subject matter experts. These experts are recognized by their peers for their skill in safely minimizing testing while maintaining patient safety and engagement. Focus groups and interviews were audio recorded and notes were taken by two independent note takers. Notes were entered into ATLAS.ti and analyzed using the constant comparative method of grounded theory, an iterative coding process to determine themes. Data were double-coded and examined for discrepancies to establish consensus. Results: Five core domains emerged from the analysis: establishing trust, anxiety (patient and provider), constraints related to ED practice, the influence of others, and patient expectations. Key themes within these domains included patient engagement, provider confidence and experience, ability to identify and manage patient anxiety, time constraints, concussion knowledge gap, influence of health care providers, and patient expectations to get a CT. Conclusions: Despite high-quality evidence informing use of CT in minor head injury, multiple factors influence the decision to obtain CT in practice. Identifying and disseminating approaches and designing systems that help clinicians establish trust and manage uncertainty within the ED context could optimize CT use in minor head injury. (C) 2015 by the Society for Academic Emergency Medicine	[Melnick, Edward R.; Shafer, Katherine; Rodulfo, Nayeli; Post, Lori A.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT 06520 USA; [Hess, Erik P.] Mayo Clin, Coll Med, Dept Emergency Med, Rochester, MN USA; [Wears, Robert L.] Univ Florida, Dept Emergency Med, Jacksonville, FL USA; [Shi, Joyce] Yale Univ, New Haven, CT USA; [Qureshi, Rija A.] Ziauddin Med Univ, Karachi, Pakistan	Melnick, ER (corresponding author), Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT 06520 USA.	edward.melnick@yale.edu	Post, Lori/AAQ-9653-2021		Agency for Healthcare Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS021271]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS021271] Funding Source: NIH RePORTER	This project was supported by grant number K08HS021271 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.	American College of Emergency Physicians, 10 THINGS PHYS PAT S; [Anonymous], 2014, DAT BOOK HLTH CAR SP; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; Bradley EH, 2007, HEALTH SERV RES, V42, P1758, DOI 10.1111/j.1475-6773.2006.00684.x; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Chisholm CD, 2000, ACAD EMERG MED, V7, P1239, DOI 10.1111/j.1553-2712.2000.tb00469.x; Curry LA, 2009, CIRCULATION, V119, P1442, DOI 10.1161/CIRCULATIONAHA.107.742775; Davis MA, 1999, ACAD EMERG MED, V6, P781, DOI 10.1111/j.1553-2712.1999.tb01206.x; DeMatteo CA, 2010, PEDIATRICS, V125, P327, DOI 10.1542/peds.2008-2720; DEYO RA, 1987, ARCH INTERN MED, V147, P141, DOI 10.1001/archinte.147.1.141; DEYO RA, 1986, SPINE, V11, P28, DOI 10.1097/00007632-198601000-00008; Djulbegovic B, 2011, HBK PHILOS SCI, V16, P299; Elwyn G, 2005, HEALTH EXPECT, V8, P34, DOI 10.1111/j.1369-7625.2004.00311.x; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gravel K, 2006, IMPLEMENT SCI, V1, DOI 10.1186/1748-5908-1-16; Gupta A, 2014, J AM MED INFORM ASSN, V21, pE347, DOI 10.1136/amiajnl-2013-002536; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hess EP, 2012, CIRC-CARDIOVASC QUAL, V5, P251, DOI 10.1161/CIRCOUTCOMES.111.964791; Kanzaria HK, 2015, ACAD EMERG MED, V22, P399, DOI 10.1111/acem.12627; Karsh BT, 2010, J AM MED INFORM ASSN, V17, P617, DOI 10.1136/jamia.2010.005637; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; Katz SJ, 2013, JAMA-J AM MED ASSOC, V310, P1559, DOI 10.1001/jama.2013.278944; KLEIN GA, 1989, IEEE T SYST MAN CYB, V19, P462, DOI 10.1109/21.31053; Korley FK, 2010, JAMA-J AM MED ASSOC, V304, P1465, DOI 10.1001/jama.2010.1408; Melnick ER, 2012, JT COMM J QUAL PATIE, V38, P483, DOI 10.1016/S1553-7250(12)38064-1; Militello LG, 1998, BIOMED INSTRUM TECHN, V32, P535; Montori V, EMPATHIC DECISION MA; Moskop JC, 2009, ANN EMERG MED, V53, P605, DOI 10.1016/j.annemergmed.2008.09.019; Nemeth CP, 2007, ANN EMERG MED, V50, P384, DOI 10.1016/j.annemergmed.2007.08.013; Nemeth CP, 2004, IEEE T SYST MAN CY A, V34, P689, DOI 10.1109/TSMCA.2004.836802; Papa L, 2012, ACAD EMERG MED, V19, P2, DOI 10.1111/j.1553-2712.2011.01247.x; Probst MA, 2014, AM J EMERG MED, V32, P645, DOI 10.1016/j.ajem.2014.01.003; Rosenbaum L, 2015, NEW ENGL J MED, V372, P7, DOI 10.1056/NEJMp1413816; Schuur JD, 2014, JAMA INTERN MED, V174, P509, DOI 10.1001/jamainternmed.2013.12688; Smith-Bindman R, 2011, AM J EMERG MED, V29, P656, DOI 10.1016/j.ajem.2010.01.038; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stiell IG, 2010, CAN MED ASSOC J, V182, P1527, DOI 10.1503/cmaj.091974; Stiell IG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4146; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609; Thompson DA, 1996, ANN EMERG MED, V28, P657, DOI 10.1016/S0196-0644(96)70090-2; Wears RL, 2005, HARWOOD NUSS CLIN PR; Weir CR, 2007, J AM MED INFORM ASSN, V14, P65, DOI 10.1197/jamia.M2231; Wright DW, 2011, TINTINALLIS EMERGENC; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	46	33	33	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	DEC	2015	22	12			SI		1474	1483		10.1111/acem.12824			10	Emergency Medicine	Emergency Medicine	DA5FP	WOS:000367828900014	26568523				2021-06-18	
J	Golub, VM; Brewer, J; Wu, X; Kuruba, R; Short, J; Manchi, M; Swonke, M; Younus, I; Reddy, DS				Golub, Victoria M.; Brewer, Jonathan; Wu, Xin; Kuruba, Ramkumar; Short, Jenessa; Manchi, Maunica; Swonke, Megan; Younus, Iyan; Reddy, Doodipala Samba			Neurostereology protocol for unbiased quantification of neuronal injury and neurodegeneration	FRONTIERS IN AGING NEUROSCIENCE			English	Article						stereology; optical fractionator; optical disector; cavalieri estimator; neuronal injury	DESIGN-BASED STEREOLOGY; RAT HIPPOCAMPUS; TOTAL NUMBER; FRACTIONATOR; DISECTOR; CELLS; CA1; POPULATIONS; EFFICIENCY; SEIZURES	Neuronal injury and neurodegeneration are the hallmark pathologies in a variety of neurological conditions such as epilepsy, stroke, traumatic brain injury, Parkinson's disease and Alzheimer's disease. Quantification of absolute neuron and interneuron counts in various brain regions is essential to understand the impact of neurological insults or neurodegenerative disease progression in animal models. However, conventional qualitative scoring-based protocols are superficial and less reliable for use in studies of neuroprotection evaluations. Here, we describe an optimized stereology protocol for quantification of neuronal injury and neurodegeneration by unbiased counting of neurons and interneurons. Every 20th section in each series of 20 sections was processed for NeuN(+) total neuron and parvalbumin(+) interneuron immunostaining. The sections that contain the hippocampus were then delineated into five reliably predefined subregions. Each region was separately analyzed with a microscope driven by the stereology software. Regional tissue volume was determined by using the Cavalieri estimator, as well as cell density and cell number were determined by using the optical disector and optical fractionator. This protocol yielded an estimate of 1.5 million total neurons and 0.05 million PV(+) interneurons within the rat hippocarnpus. The protocol has greater predictive power for absolute counts as it is based on 3D features rather than 2D images. The total neuron counts were consistent with literature values from sophisticated systems, which are more expensive than our stereology system. This unbiased stereology protocol allows for sensitive, medium-throughput counting of total neurons in any brain region, and thus provides a quantitative tool for studies of neuronal injury and neurodegeneration in a variety of acute brain injury and chronic neurological models.	[Golub, Victoria M.; Brewer, Jonathan; Wu, Xin; Kuruba, Ramkumar; Short, Jenessa; Manchi, Maunica; Swonke, Megan; Younus, Iyan; Reddy, Doodipala Samba] Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Bryan, TX 77807 USA	Reddy, DS (corresponding author), Texas A&M Univ, Hlth Sci Ctr, Coll Med, Dept Neurosci & Expt Therapeut, Bryan, TX 77807 USA.	reddy@medicine.tamhsc.edu		Reddy, Samba/0000-0003-2735-9550; wu, xin/0000-0002-5005-6358; Brewer, Jonathan/0000-0001-9300-3670	CounterACT Program; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Office of the DirectorNational Science Foundation (NSF)NSF - Office of the Director (OD); National Institute of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 N5083460]; Texas A&M University Online Access to Knowledge (OAK) Fund; University Libraries and the Office of the Vice President for Research; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS083460] Funding Source: NIH RePORTER	This work was supported by the CounterACT Program, National Institutes of Health, Office of the Director and the National Institute of Neurologic Disorders and Stroke Grant U01 N5083460 (to DSR). The open access publishing fees for this article have been covered by the Texas A&M University Online Access to Knowledge (OAK) Fund, supported by the University Libraries and the Office of the Vice President for Research.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; AIKA Y, 1994, EXP BRAIN RES, V99, P267; BADDELEY AJ, 1986, J MICROSC-OXFORD, V142, P259, DOI 10.1111/j.1365-2818.1986.tb04282.x; Boyce RW, 2010, TOXICOL PATHOL, V38, P1011, DOI 10.1177/0192623310385140; BRAENDGAARD H, 1986, J NEUROSCI METH, V18, P39, DOI 10.1016/0165-0270(86)90112-3; Bronoosh P, 2015, INT J ORAL MAX SURG, V44, P277, DOI 10.1016/j.ijom.2014.09.020; Charleston J S, 2001, Curr Protoc Toxicol, VChapter 12, DOI 10.1002/0471140856.tx1206s06; Cruz-Orive LM, 2014, J MICROSC-OXFORD, V253, P119, DOI 10.1111/jmi.12103; Cruz-Orive LM, 2004, J MICROSC-OXFORD, V213, P205, DOI 10.1111/j.1365-2818.2004.01291.x; CruzOrive LM, 1997, J MICROSC-OXFORD, V186, P93, DOI 10.1046/j.1365-2818.1997.1380695.x; CRUZORIVE LM, 1981, J MICROSC-OXFORD, V122, P235, DOI 10.1111/j.1365-2818.1981.tb01265.x; Dorph-Petersen KA, 2001, J MICROSC-OXFORD, V204, P232, DOI 10.1046/j.1365-2818.2001.00958.x; Dorph-Petersen KA, 2011, BIOL PSYCHIAT, V69, P113, DOI 10.1016/j.biopsych.2010.04.030; FLODERUS S, 1944, ACTA PATHOL MICROB S, V53, P1; Geuna S, 2015, CELL TISSUE RES, V360, P5, DOI 10.1007/s00441-015-2143-6; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; HARDING AJ, 1994, J NEUROSCI METH, V51, P83, DOI 10.1016/0165-0270(94)90028-0; Hattiangady B, 2011, AGING DIS, V2, P1; Jones NW, 2013, PLACENTA, V34, P1002, DOI 10.1016/j.placenta.2013.08.015; Kaplan S, 2012, NEUROQUANTOLOGY, V10, P44, DOI 10.14704/nq.2012.10.1.425; Keuker JIH, 2001, BRAIN RES PROTOC, V7, P211, DOI 10.1016/S1385-299X(01)00064-2; Kuruba R., 2014, AM EPILEPSY SOC ABST; Kuruba R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024493; Mayhew TM, 2015, CELL TISSUE RES, V360, P43, DOI 10.1007/s00441-014-2038-y; Nomura T, 1997, BRAIN RES, V764, P197, DOI 10.1016/S0006-8993(97)00457-5; PAKKENBERG B, 1988, J MICROSC-OXFORD, V150, P1, DOI 10.1111/j.1365-2818.1988.tb04582.x; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Rao MS, 2006, J NEUROSCI RES, V83, P1088, DOI 10.1002/jnr.20802; ROSE RD, 1987, J COMP NEUROL, V263, P365, DOI 10.1002/cne.902630305; ROYET JP, 1991, PROG NEUROBIOL, V37, P433, DOI 10.1016/0301-0082(91)90009-P; Schettino AE, 2013, HEARING RES, V304, P153, DOI 10.1016/j.heares.2013.07.007; Selemon LD, 2007, PSYCHIAT RES, V151, P1, DOI 10.1016/j.psychres.2006.11.003; Sorensen B, 2003, J COMP NEUROL, V459, P242, DOI 10.1002/cne.10625; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Tang Y, 1997, J NEUROSCI METH, V73, P193, DOI 10.1016/S0165-0270(97)02228-0; Walker MA, 2002, AM J PSYCHIAT, V159, P821, DOI 10.1176/appi.ajp.159.5.821; Weibel E R, 1969, Int Rev Cytol, V26, P235, DOI 10.1016/S0074-7696(08)61637-X; West M. J., 2012, BASIC STEREOLOGY BIO, P1; West M. J., 2012, BASIC STEREOLOGY BIO, P109; West Mark J, 2013, Cold Spring Harb Protoc, V2013, P287, DOI 10.1101/pdb.top071845; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wu X., 2014, AM EPILEPSY SOC ABST	44	33	34	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	OCT 31	2015	7								196	10.5589/fnagi.2015.00196			14	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	CV3JI	WOS:000364155100001	26582988	DOAJ Gold			2021-06-18	
J	Alberts, JL; Thota, A; Hirsch, J; Ozinga, S; Dey, T; Schindler, DD; Koop, MM; Burke, D; Linder, SM				Alberts, Jay L.; Thota, Anil; Hirsch, Joshua; Ozinga, Sarah; Dey, Tanujit; Schindler, David D.; Koop, Mandy M.; Burke, Daniel; Linder, Susan M.			Quantification of the Balance Error Scoring System with Mobile Technology	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						POSTURAL STABILITY; ACCELEROMETER; GYROSCOPE; CONCUSSION; IBESS; BESS	CEREBRAL CONCUSSION; POSTURAL STABILITY; SPORT; STATEMENT; RECOVERY; INJURY	Purpose The aim of this project was to develop a biomechanically based quantification of the Balance Error Scoring System (BESS) using data derived from the accelerometer and gyroscope of a mobile tablet device. Methods Thirty-two healthy young adults completed the BESS while an iPad was positioned at the sacrum. Data from the iPad were compared to position data gathered from a three-dimensional motion capture system. Peak-to-peak (P2P), normalized path length (NPL), and root mean squared (RMS) were calculated for each system and compared. Additionally, a 95% ellipsoid volume, iBESS volume, was calculated using center of mass (CoM) movements in the anteroposterior (AP), mediolateral (ML), and trunk rotation planes of movement to provide a comprehensive, 3D metric of postural stability. Results Across all kinematic outcomes, data from the iPad were significantly correlated with the same outcomes derived from the motion capture system (rho range, 0.37-0.94; P < 0.05). The iBESS volume metric was able to detect a difference in postural stability across stance and surface, showing a significant increase in volume in increasingly difficult conditions, whereas traditional error scoring was not as sensitive to these factors. Conclusions The kinematic data provided by the iPad are of sufficient quality relative to motion capture data to accurately quantify postural stability in healthy young adults. The iBESS volume provides a more sensitive measure of postural stability than error scoring alone, particularly in conditions 1 and 4, which often suffer from floor effects, and condition 5, which can experience ceiling effects. The iBESS metric is ideally suited for clinical and in the field applications in which characterizing postural stability is of interest.	[Alberts, Jay L.; Thota, Anil; Hirsch, Joshua; Ozinga, Sarah; Schindler, David D.; Koop, Mandy M.; Burke, Daniel; Linder, Susan M.] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44106 USA; [Alberts, Jay L.; Thota, Anil; Ozinga, Sarah] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH 44106 USA; [Alberts, Jay L.; Thota, Anil; Hirsch, Joshua; Dey, Tanujit; Burke, Daniel; Linder, Susan M.] Cleveland Clin, Concuss Ctr, Cleveland, OH 44106 USA; [Dey, Tanujit] Cleveland Clin, Qualitat Hlth Serv, Cleveland, OH 44106 USA	Alberts, JL (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	albertj@ccf.org	Thota, Anil/C-5395-2015; Thota, Anil/J-3305-2019	Thota, Anil/0000-0003-0605-2269; Thota, Anil/0000-0003-0605-2269	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS073717-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS073717] Funding Source: NIH RePORTER	This project was supported by NIH 1R01NS073717-01 to JLA.	Alberts JL, J ATHL TRAI IN PRESS; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Broglio SP, 2009, J ATHL TRAINING, V44, P497, DOI 10.4085/1062-6050-44.5.497; Brown HJ, 2014, MED SCI SPORT EXER, V46, P1610, DOI 10.1249/MSS.0000000000000263; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; KADABA MP, 1990, J ORTHOP RES, V8, P383, DOI 10.1002/jor.1100080310; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; Ozinga SJ, 2014, EXP BRAIN RES, V232, P3861, DOI 10.1007/s00221-014-4069-8; Ozinga SJ, 2014, SOC NEUR C 2014 NOV; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Whitney SL, 2011, GAIT POSTURE, V33, P594, DOI 10.1016/j.gaitpost.2011.01.015	19	33	33	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	OCT	2015	47	10					2233	2240		10.1249/MSS.0000000000000656			8	Sport Sciences	Sport Sciences	CR5DP	WOS:000361360500027	26378948	Green Accepted			2021-06-18	
J	Johnson, R; Harkins, K; Cary, M; Sankar, P; Karlawish, J				Johnson, Rebecca; Harkins, Kristin; Cary, Mark; Sankar, Pamela; Karlawish, Jason			The relative contributions of disease label and disease prognosis to Alzheimer's stigma: A vignette-based experiment	SOCIAL SCIENCE & MEDICINE			English	Article						Alzheimer's; Stigma; Ethics; Disease risk; Vignette-based experiments	MENTAL-ILLNESS; ANTICIPATORY DEMENTIA; PUBLIC-ATTITUDES; BELIEFS; PEOPLE; SCALE; SCHIZOPHRENIA; INTERVENTIONS; PSYCHOPATHY; POPULATION	Background: The classification of Alzheimer's disease is undergoing a significant transformation. Researchers have created the category of "preclinical Alzheimer's," characterized by biomarker pathology rather than observable symptoms. Diagnosis and treatment at this stage could allow preventing Alzheimer's cognitive decline. While many commentators have worried that persons given a preclinical Alzheimer's label will be subject to stigma, little research exists to inform whether the stigma attached to the label of clinical Alzheimer's will extend to a preclinical disorder that has the label of "Alzheimer's" but lacks the symptoms or expected prognosis of the clinical form. Research questions: The present study sought to correct this gap by examining the foundations of stigma directed at Alzheimer's. It asked: do people form stigmatizing reactions to the label "Alzheimer's disease" itself or to the condition's observable impairments? How does the condition's prognosis modify these reactions? Methods: Data were collected through a web-based experiment with N = 789 adult members of the U.S. general population (median age = 49, interquartile range, 32-60, range = 18-90). Participants were randomized through a 3 x 3 design to read one of 9 vignettes depicting signs and symptoms of mild stage dementia that varied the disease label ("Alzheimer's" vs. "traumatic brain injury" vs. no label) and prognosis (improve vs. static vs. worsen symptoms). Four stigma outcomes were assessed: discrimination, negative cognitive attributions, negative emotions, and social distance. Results: The study found that the Alzheimer's disease label was generally not associated with more stigmatizing reactions. In contrast, expecting the symptoms to get worse, regardless of which disease label those symptoms received, resulted in higher levels of perceived structural discrimination, higher pity, and greater social distance. Conclusion: These findings suggest that stigma surrounding pre-clinical Alzheimer's categories will depend highly on the expected prognosis attached to the label. They also highlight the need for models of Alzheimer's-directed stigma that incorporate attributions about the condition's mutability. Published by Elsevier Ltd.	[Johnson, Rebecca] Princeton Univ, Dept Sociol, Princeton, NJ 08544 USA; [Harkins, Kristin; Karlawish, Jason] Univ Penn, Perelman Sch Med, Div Geriatr, Philadelphia, PA 19104 USA; [Cary, Mark] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Sankar, Pamela; Karlawish, Jason] Univ Penn, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	Johnson, R (corresponding author), 117 Wallace Hall, Princeton, NJ 08544 USA.	raj2@princeton.edu		Harkins, Kristin/0000-0001-5360-1043	Penn Neurodegenerative Disease Ethics and Policy Program; Marian S. Ware Alzheimers Program	The authors would like to thank the Penn Neurodegenerative Disease Ethics and Policy Program and the Marian S. Ware Alzheimers Program for funding support and the audience at the American Public Health Association Annual Meeting for feedback.	Angermeyer MC, 2003, ACTA PSYCHIAT SCAND, V108, P304, DOI 10.1034/j.1600-0447.2003.00150.x; Angermeyer MC, 1996, SOC PSYCH PSYCH EPID, V31, P316, DOI 10.1007/BF00783419; [Anonymous], 2013, STAT STAT SOFTW REL; AQUILINA C, 2006, DEMENTIA MIND MEANIN, P143; Arkar H., 1996, TURKISH J PSYCHIAT, V7, P191; Beard RL, 2008, SOC SCI MED, V66, P1509, DOI 10.1016/j.socscimed.2007.12.024; Beard RL, 2013, SOCIOL HEALTH ILL, V35, P130, DOI 10.1111/j.1467-9566.2012.01481.x; Behuniak SM, 2011, AGEING SOC, V31, P70, DOI 10.1017/S0144686X10000693; Blay SL, 2008, AGING MENT HEALTH, V12, P577, DOI 10.1080/13607860802343050; Blendon RJ., 2012, INT J ALZHEIMERS DIS; Carpenter BD, 2009, GERONTOLOGIST, V49, P236, DOI 10.1093/geront/gnp023; Chaufan C, 2012, SOC SCI MED, V74, P788, DOI 10.1016/j.socscimed.2011.10.033; Chen ZQ, 2014, TREE GENET GENOMES, V10, P1291, DOI 10.1007/s11295-014-0761-x; Cheng ST, 2011, INT PSYCHOGERIATR, V23, P1433, DOI 10.1017/S1041610211000834; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Corcoran C, 2005, SCHIZOPHR RES, V73, P173, DOI 10.1016/j.schres.2004.05.021; Cormack S, 1998, INT J SOC PSYCHIATR, V44, P235, DOI 10.1177/002076409804400401; Corrigan PW, 2007, SOC WORK, V52, P31, DOI 10.1093/sw/52.1.31; Corrigan PW, 2004, SCHIZOPHRENIA BULL, V30, P477, DOI 10.1093/oxfordjournals.schbul.a007095; Corrigan PW, 2000, CLIN PSYCHOL-SCI PR, V7, P48, DOI 10.1093/clipsy/7.1.48; Crisp AH, 2000, BRIT J PSYCHIAT, V177, P4, DOI 10.1192/bjp.177.1.4; Cutler SJ, 1996, GERONTOLOGIST, V36, P657, DOI 10.1093/geront/36.5.657; DiMillo J, 2015, J HEALTH PSYCHOL, V20, P393, DOI 10.1177/1359105313502566; Dubois B, 2014, LANCET NEUROL, V13, P614, DOI 10.1016/S1474-4422(14)70090-0; Edens JF, 2004, PSYCHOL CRIME LAW, V10, P393, DOI 10.1080/10683160310001629274; FOX P, 1989, MILBANK Q, V67, P58, DOI 10.2307/3350070; French SL, 2012, INT J GERIATR PSYCH, V27, P521, DOI 10.1002/gps.2747; Gauthier S, 2013, PROG NEUROBIOL, V110, P102, DOI 10.1016/j.pneurobio.2013.01.003; Greene J.A., 2007, PRESCRIBING NUMBERS; Haslam N, 2002, J SOC CLIN PSYCHOL, V21, P628, DOI 10.1521/jscp.21.6.628.22793; Haslam N, 2011, PSYCHOL BULL, V137, P819, DOI 10.1037/a0022386; Haslam NO, 1998, SOC RES, V65, P291; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Jones E.E., 1984, SOCIAL STIGMA PSYCHO; Langdon SA, 2007, SOC SCI MED, V64, P989, DOI 10.1016/j.socscimed.2006.10.029; Le Couteur DG, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5125; Lerman C, 2004, NAT REV CANCER, V4, P235, DOI 10.1038/nrc1301; Linden MA, 2005, BRAIN INJURY, V19, P1011, DOI 10.1080/02699050500110314; Link BG, 2001, ANNU REV SOCIOL, V27, P363, DOI 10.1146/annurev.soc.27.1.363; Luck T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050792; Lumley T, 2010, COMPLEX SURVEYS GUID; Murrie DC, 2005, LAW HUMAN BEHAV, V29, P323, DOI 10.1007/s10979-005-2415-x; Phelan JC, 2005, J HEALTH SOC BEHAV, V46, P307, DOI 10.1177/002214650504600401; Rabkin J. G., 1980, ATTITUDES MENTALLY I, P15; Ralph A, 2013, BRAIN INJURY, V27, P1475, DOI 10.3109/02699052.2013.823653; Read J, 2006, ACTA PSYCHIAT SCAND, V114, P303, DOI 10.1111/j.1600-0447.2006.00824.x; Rimmer E, 2005, INT J CLIN PRACT, V59, P17, DOI 10.1111/j.1368-504X.2005.00482.x; Sabat Steven R, 2004, Am J Alzheimers Dis Other Demen, V19, P177, DOI 10.1177/153331750401900311; SARBIN TR, 1970, J CONSULT CLIN PSYCH, V35, P159, DOI 10.1037/h0030056; Sperling RA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007941; Sperling RA, 2011, ALZHEIMERS DEMENT, V7, P280, DOI 10.1016/j.jalz.2011.03.003; Tinghog G, 2013, NATURE, V498, pE1, DOI 10.1038/nature12194; U. S. Department of Agriculture Economic Research Service, 2001, ERS USDA BRIEF ROOM; U. S. Department of Health and Human Services, 2014, NAT PLAN ADDR ALZH D; Van Gorp B, 2012, SOC SCI MED, V74, P1274, DOI 10.1016/j.socscimed.2011.12.045; Vodermaier A, 2010, FAM CANCER, V9, P305, DOI 10.1007/s10689-010-9325-x; von dem Knesebeck O, 2014, INT PSYCHOGERIATR, V26, P435, DOI 10.1017/S1041610213002056; Wadley VG, 2001, J GERONTOL B-PSYCHOL, V56, pP244, DOI 10.1093/geronb/56.4.P244; WEINER B, 1988, J PERS SOC PSYCHOL, V55, P738, DOI 10.1037/0022-3514.55.5.738; Werner P., 2014, STIGMA DIS DISABILIT, P223; Werner P, 2011, ALZ DIS ASSOC DIS, V25, P42, DOI 10.1097/WAD.0b013e3181f32594; Werner P, 2010, QUAL HEALTH RES, V20, P159, DOI 10.1177/1049732309358330; Wright DB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031661	63	33	33	0	32	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	OCT	2015	143						117	127		10.1016/j.socscimed.2015.08.031			11	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	CV4OE	WOS:000364245600014	26356823				2021-06-18	
J	Piatt, JH				Piatt, Joseph H., Jr.			Pediatric spinal injury in the US: epidemiology and disparities	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						disparity; epidemiology; pediatric; SCIWORA; spinal cord injury; spinal dislocation; spinal fracture; spine; trauma	TRAUMATIC BRAIN-INJURY; CERVICAL-SPINE; HEAD TRAUMA; CORD-INJURY; EMERGENCY-DEPARTMENT; CLINICAL ARTICLE; UNITED-STATES; CHILD-ABUSE; MORTALITY; OUTCOMES	OBJECT In the US, race and economic status have pervasive associations with mechanisms of injury, severity of injury, management, and outcomes of trauma. The goal of the current study was to examine these relationships on a large scale in the setting of pediatric spinal injury. METHODS Admissions for spinal fracture without or with spinal cord injury (SCI), spinal dislocation, and SCI without radiographic abnormality were-identified in the Kids' Inpatient Database (KID) and the National Trauma Data Bank (NTDB) registry for 2009. Patients ranged in age from birth up to 21 years. Data from the KID were used to estimate nationwide annual incidences. Data from the NTDB were used to describe patterns of injury in relation to age, race, and payor, with corroboration from the KID. Multiple logistic regression was used to model rates of mortality and spinal fusion. RESULTS In 2009, the estimated incidence of hospital admission for spinal injury in the US was 170 per 1 million in the population under 21 years of age. The incidence of SCI was 24 per 1 million. Incidences varied regionally. Adolescents predominated. Patterns of injury varied by age, race, and payor. Black patients were more severely injured than patients of other races as measured by Injury Severity Scale scores. Among black patients with spinal injury in the NTDB, 23.9% suffered firearm injuries; only 1% of white patients suffered firearm injuries. The overall mortality rate in the NTDB was 3.9%. In a multivariate analysis that included a large panel of clinical and nonclinical factors, black race retained significance as a predictor of mortality (p = 0.006; adjusted OR 1.571 [1.141-2.163]). Rates of spinal fusion were associated with race and payor in the NTDB data and with payor in the KID: patients with better insurance underwent spinal fusion at higher rates. CONCLUSIONS The epidemiology of pediatric spinal injury in the US cannot be understood apart from considerations of race and economic status.	[Piatt, Joseph H., Jr.] Alfred I DuPont Hosp Children, Nemours Neurosci Ctr, Wilmington, DE 19803 USA; [Piatt, Joseph H., Jr.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Neurol Surg, Philadelphia, PA 19107 USA; [Piatt, Joseph H., Jr.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Pediat, Philadelphia, PA 19107 USA	Piatt, JH (corresponding author), Alfred I DuPont Hosp Children, Nemours Neurosci Ctr, 1600 Rockland Rd, Wilmington, DE 19803 USA.	jpiatt@nemours.org		Piatt, Joseph/0000-0002-9332-8376			APPLE JS, 1987, PEDIATR RADIOL, V17, P45, DOI 10.1007/BF02386594; Barber I, 2013, PEDIATR RADIOL, V43, P1507, DOI 10.1007/s00247-013-2726-x; BAYLESS P, 1989, AM J EMERG MED, V7, P139, DOI 10.1016/0735-6757(89)90125-3; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Brown RL, 2010, CURR OPIN PEDIATR, V22, P321, DOI 10.1097/MOP.0b013e3283395f13; Brown RL, 2001, J PEDIATR SURG, V36, P1107, DOI 10.1053/jpsu.2001.25665; Chien LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039264; Choudhary AK, 2012, RADIOLOGY, V262, P216, DOI 10.1148/radiol.11102390; Cirak B, 2004, J PEDIATR SURG, V39, P607, DOI 10.1016/j.jpedsurg.2003.12.011; DICKMAN CA, 1991, J SPINAL DISORD, V4, P296, DOI 10.1097/00002517-199109000-00006; Eleraky MA, 2000, J NEUROSURG, V92, P12, DOI 10.3171/spi.2000.92.1.0012; Falcone RA, 2008, J PEDIATR SURG, V43, P1858, DOI 10.1016/j.jpedsurg.2008.01.058; Falcone RA, 2007, J PEDIATR SURG, V42, P1031, DOI 10.1016/j.jpedsurg.2007.01.038; Finch GD, 1998, J PEDIATR ORTHOPED, V18, P811, DOI 10.1097/00004694-199811000-00022; Firth GB, 2012, SPINE, V37, pE599, DOI 10.1097/BRS.0b013e31824079ea; Fujii Tomoko, 2013, J Emerg Trauma Shock, V6, P252, DOI 10.4103/0974-2700.120365; Gepp RD, 2012, CHILD NERV SYST, V28, P1919, DOI 10.1007/s00381-012-1846-1; Hackl W, 2001, ORAL SURG ORAL MED O, V92, P370, DOI 10.1067/moe.2001.116894; HADLEY MN, 1988, J NEUROSURG, V68, P18, DOI 10.3171/jns.1988.68.1.0018; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hagen EM, 2011, SPINAL CORD, V49, P981, DOI 10.1038/sc.2011.42; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Haider AH, 2013, J TRAUMA ACUTE CARE, V74, P1195, DOI 10.1097/TA.0b013e31828c331d; Hakmeh W, 2010, ACAD EMERG MED, V17, P809, DOI 10.1111/j.1553-2712.2010.00819.x; HILLS MW, 1993, J TRAUMA, V34, P549, DOI 10.1097/00005373-199304000-00011; Hofbauer M, 2012, J TRAUMA ACUTE CARE, V73, P156, DOI 10.1097/TA.0b013e31824e32b5; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Howard I, 2005, ETHNIC DIS, V15, pS51; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; Katz JS, 2010, J NEUROSURG-PEDIATR, V5, P470, DOI 10.3171/2009.11.PEDS09291; Knox JB, 2014, J PEDIATR ORTHOPED, V34, P698, DOI 10.1097/BPO.0000000000000167; LAHAM JL, 1994, PEDIATR NEUROSURG, V21, P221, DOI 10.1159/000120839; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Martin BW, 2004, ARCH DIS CHILD, V89, P860, DOI 10.1136/adc.2003.029223; Martin CA, 2010, AM J SURG, V199, P210, DOI 10.1016/j.amjsurg.2009.05.001; McCarthy ML, 2002, ACAD EMERG MED, V9, P684; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; Mohseni S, 2011, J PEDIATR SURG, V46, P1771, DOI 10.1016/j.jpedsurg.2011.03.007; Mortazavi MM, 2011, CHILD NERV SYST, V27, P1095, DOI 10.1007/s00381-010-1348-y; OMALLEY KF, 1988, J TRAUMA, V28, P1476, DOI 10.1097/00005373-198810000-00013; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; Piatt JH, 2006, J NEUROSURG-SPINE, V5, P210, DOI 10.3171/spi.2006.5.3.210; Piatt JH, 2012, J NEUROSURG-PEDIATR, V10, P257, DOI 10.3171/2012.7.PEDS11532; Platzer P, 2007, J TRAUMA, V62, P389, DOI 10.1097/01.ta.0000221802.83549.46; Ramirez M, 2013, JAMA SURG, V148, P76, DOI 10.1001/2013.jamasurg.3; Rangel EL, 2010, J TRAUMA, V69, P20, DOI 10.1097/TA.0b013e3181bbd7c3; Rangel EL, 2009, J PEDIATR SURG, V44, P1229, DOI 10.1016/j.jpedsurg.2009.02.044; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; Rush JK, 2013, J PEDIATR ORTHOPED, V33, P393, DOI 10.1097/BPO.0b013e318279c7cb; Sabharwal S, 2007, J PEDIATR ORTHOPED, V27, P690, DOI 10.1097/BPO.0b013e3181425653; Schenarts PJ, 2001, J TRAUMA, V51, P663, DOI 10.1097/00005373-200110000-00007; Slover J, 2005, J PEDIATR ORTHOPED, V25, P717, DOI 10.1097/01.bpo.0000184835.79345.0e; SOICHER E, 1991, BRIT J SURG, V78, P1013, DOI 10.1002/bjs.1800780837; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Wood JN, 2010, PEDIATRICS, V126, P408, DOI 10.1542/peds.2010-0031	57	33	33	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	OCT	2015	16	4					463	471		10.3171/2015.2.PEDS1515			9	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CS1XS	WOS:000361862800017	26114993	Bronze			2021-06-18	
J	Stucky, EC; Schloss, RS; Yarmush, ML; Shreiber, DI				Stucky, Elizabeth C.; Schloss, Rene S.; Yarmush, Martin L.; Shreiber, David I.			Alginate micro-encapsulation of mesenchymal stromal cells enhances modulation of the neuro-inflammatory response	CYTOTHERAPY			English	Article						co-culture; inflammation mediators; mesenchymal stromal cells; organ culture; traumatic brain injury	TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; CENTRAL-NERVOUS-SYSTEM; PGE(2) EP2 RECEPTOR; BONE-MARROW; STEM-CELLS; INDUCIBLE CYCLOOXYGENASE; PROSTAGLANDIN E-2; IFN-GAMMA; TNF-ALPHA	Background aims. Modulation of inflammation after brain trauma is a key therapeutic goal aimed at limiting the consequences of the subsequent injury cascade. Mesenchymal stromal cells (MSCs) have been demonstrated to dynamically regulate the inflammatory environment in several tissue systems, including the central nervous system. There has been limited success, however, with the use of direct implantation of cells in the brain caused by low viability and engraftment at the injury site. To circumvent this, we encapsulated MSCs in alginate microspheres and evaluated the ability of these encapsulated MSCs to attenuate inflammation in rat organotypic hippocarnpal slice cultures (OHSC). Methods. OHSC were administered lipopolysaccharide to induce inflammation and immediately co-cultured with encapsulated or monolayer human MSCs. After 24 h, culture media was assayed for the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) produced by OHSC, as well as MSC-produced trophic mediators. Results. Encapsulated MSCs reduced TNF-alpha more effectively than did monolayer MSCs. Additionally, there was a strong correlation between increased prostaglandin E-2 (PGE(2)) and reduction of TNF-alpha. In contrast to monolayer MS Cs, inflammatory signals were not required to stimulate PGE(2) production by encapsulated MSCs. Further encapsulation-stimulated changes were revealed in a multiplex panel analyzing 27 MSC-produced cytokines and growth factors, from which additional mediators with strong correlations to TNF-alpha levels were identified. Conclusions. These results suggest that alginate encapsulation of MSCs may not only provide an improved delivery vehicle for transplantation but may also enhance MSC therapeutic benefit for treating neuro-inflammation.	[Stucky, Elizabeth C.; Yarmush, Martin L.] Rutgers State Univ, Dept Chem & Biochem Engn, Piscataway, NJ 08854 USA; [Schloss, Rene S.; Yarmush, Martin L.; Shreiber, David I.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA; [Yarmush, Martin L.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA	Yarmush, ML (corresponding author), Rutgers State Univ, Dept Biomed Engn, 599 Taylor Rd, Piscataway, NJ 08854 USA.	yarmush@rci.rutgers.edu; shreiber@rci.rutgers.edu		Stucky Hunter, Elizabeth/0000-0003-0797-9453	New Jersey Commission on Brain Injury Research [SNJ-DHSS-CBIR-CBIE12IPG019, 10-3215-BIR-E-0]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P41EB002503]; Rutgers-UMDNJ Biotechnology Training Fellowship [T32GM00008339-21]; NSF Stem Cell IGERT Fellowship [0801620]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB002503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008339] Funding Source: NIH RePORTER	We would like to acknowledge Serom Lee, PhD, and Andrea Gray for their assistance and contribution to the statistical analyses, and Mehdi Ghodbane, PhD, for assistance with multiplex assay and analysis. This research was supported by the New Jersey Commission on Brain Injury Research (SNJ-DHSS-CBIR-CBIE12IPG019 and 10-3215-BIR-E-0), National Institute of Health Grant P41EB002503, Rutgers-UMDNJ Biotechnology Training Fellowship T32GM00008339-21 and NSF Stem Cell IGERT Fellowship 0801620. These funding agencies were not involved in the conduct of the research or preparation of the article.	Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Barminko J, 2011, BIOTECHNOL BIOENG, V108, P2747, DOI 10.1002/bit.23233; Barminko JA, 2014, BIOTECHNOL BIOENG, V111, P2239, DOI 10.1002/bit.25282; Bartosh TJ, 2010, P NATL ACAD SCI USA, V107, P13724, DOI 10.1073/pnas.1008117107; Bernardino L, 2008, J NEUROCHEM, V106, P271, DOI 10.1111/j.1471-4159.2008.05387.x; Buchser E, 1996, ANESTHESIOLOGY, V85, P1005, DOI 10.1097/00000542-199611000-00007; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; CHUNG IY, 1990, J IMMUNOL, V144, P2999; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Detante O, 2009, CELL TRANSPLANT, V18, P1369, DOI 10.3727/096368909X474230; Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995; Dolle JP, 2013, NANO LIFE, V3, DOI 10.1142/S1793984413500049; Engler A, 2004, BIOPHYS J, V86, P617, DOI 10.1016/S0006-3495(04)74140-5; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fenn AM, 2015, J NEUROTRAUM, V32, P127, DOI 10.1089/neu.2014.3514; Foraker JE, 2011, J NEUROCHEM, V119, P1052, DOI 10.1111/j.1471-4159.2011.07511.x; Gilroy DW, 2003, FASEB J, V17, P2269, DOI 10.1096/fj.02-1162fje; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Harting MT, 2009, J NEUROSURG, V110, P1189, DOI 10.3171/2008.9.JNS08158; Haudenschild AK, 2009, ANN BIOMED ENG, V37, P492, DOI 10.1007/s10439-008-9629-2; Heile AMB, 2009, NEUROSCI LETT, V463, P176, DOI 10.1016/j.neulet.2009.07.071; Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Liu D, 2005, ANN NEUROL, V57, P758, DOI 10.1002/ana.20461; Maggini J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009252; Maguire T, 2006, BIOTECHNOL BIOENG, V93, P581, DOI 10.1002/bit.20748; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Markiewicz I, 2006, ACTA NEUROBIOL EXP, V66, P343; Marklein RA, 2012, SOFT MATTER, V8, P8113, DOI 10.1039/c2sm25501d; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; Murua A, 2008, J CONTROL RELEASE, V132, P76, DOI 10.1016/j.jconrel.2008.08.010; Orive G, 2006, BIOMATERIALS, V27, P3691, DOI 10.1016/j.biomaterials.2006.02.048; Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685; Paredes-Juarez GA, 2013, J CONTROL RELEASE, V172, P983, DOI 10.1016/j.jconrel.2013.09.009; Parekkadan B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000941; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Prasanna SJ, 2010, PLOS ONE, V5, DOI [10.1371/journal.pone.0009016, 10.1371/journal.pone.0014189]; Read TA, 1999, INT J DEV NEUROSCI, V17, P653, DOI 10.1016/S0736-5748(99)00052-0; Ross CJD, 1999, HUM GENE THER, V10, P49, DOI 10.1089/10430349950019183; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Sakata D, 2010, J PHARMACOL SCI, V112, P1, DOI 10.1254/jphs.09R03CP; Schafer S, 2012, J NEUROIMMUNOL, V249, P40, DOI 10.1016/j.jneuroim.2012.04.018; Sheibanie AF, 2007, J IMMUNOL, V178, P8138, DOI 10.4049/jimmunol.178.12.8138; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Silva NA, 2013, BIOCHIMIE, V95, P2314, DOI 10.1016/j.biochi.2013.08.016; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Szczepanik AM, 1996, NEUROSCIENCE, V70, P57, DOI 10.1016/0306-4522(95)00296-U; Thanos CG, 2007, J BIOMED MATER RES A, V83A, P216, DOI 10.1002/jbm.a.31472; Thanos CG, 2006, BIOMATERIALS, V27, P3570, DOI 10.1016/j.biomaterials.2006.01.042; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Ylostalo JH, 2012, STEM CELLS, V30, P2283, DOI 10.1002/stem.1191; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhou C, 2009, BRAIN RES, V1269, P23, DOI 10.1016/j.brainres.2009.02.049; Zimmermann U, 2001, ANN NY ACAD SCI, V944, P199, DOI 10.1111/j.1749-6632.2001.tb03833.x	58	33	33	1	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	OCT	2015	17	10					1353	1364		10.1016/j.jcyt.2015.05.002			12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	CR5XX	WOS:000361418800004	26210574	Green Accepted			2021-06-18	
J	Pitman, I; Haddlesey, C; Ramos, SDS; Oddy, M; Fortescue, D				Pitman, Ivan; Haddlesey, Claire; Ramos, Sara D. S.; Oddy, Michael; Fortescue, Deborah			The association between neuropsychological performance and self-reported traumatic brain injury in a sample of adult male prisoners in the UK	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Rehabilitation; Index; Offenders; Questionnaire; Screening	MINOR HEAD-INJURY; CRIMINAL BEHAVIOR; REPEATABLE BATTERY; POPULATION; PREVALENCE; PERSONALITY; DISORDERS; SEQUELAE; HOMELESS; VIOLENT	This study employed a correlational and group comparison design to investigate whether self-report of traumatic brain injury (TBI) in a sample of male prisoners screened using the Brain Injury Screening Index (BISI) was associated with impaired cognitive performance on standardised questionnaires and neuropsychological tests. A total of 139 male prisoners who reported having suffered a TBI in the BISI were interviewed, and completed further questionnaires and neuropsychological assessments. Their results were compared to 50 prisoners who had no reported history of TBI. The results of the screening questionnaire correlated with responses in a follow-up interview, with self-report questionnaires of neurobehavioural disorder (.31 to .50) and neuropsychological measures (-.24 to -.45). The "TBI Index", an indicator summarising the number and severity of self-reported injuries in a single score, also correlated well with scores on formal neuropsychological tests (-.20 to -.42). Self-report of traumatic brain injury among prisoners is consistently associated with measurable neuropsychological and neurobehavioural disability. The implications of these findings for current practice in identifying and referring individuals to specialist services are considered.	[Pitman, Ivan; Haddlesey, Claire; Ramos, Sara D. S.; Oddy, Michael; Fortescue, Deborah] Disabil Trust Fdn, Burgess Hill, W Sussex, England; [Pitman, Ivan; Ramos, Sara D. S.; Oddy, Michael] Brain Injury Rehabil Trust, Slinfold RH13 0TP, W Sussex, England	Ramos, SDS (corresponding author), Brain Injury Rehabil Trust, Kerwin Court, 5 Oaks Rd, Slinfold RH13 0TP, W Sussex, England.	sara.dasilvaramos@thedtgroup.org			Disabilities Trust Foundation, Disabilities Trust	The study was carried out and funded by The Disabilities Trust Foundation, a constituent of The Disabilities Trust.	Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Beck A.T., 1993; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bradley Lord, 2009, REV PEOPLE MENTAL HL; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Coid J. W., 2005, TXB PERSONALITY DISO, P579; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; FOWLES GP, 1988, PSYCHIAT ANN, V18, P692; Goldberg D., 1992, GEN HLTH QUESTIONNAI; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Hansard H. C., 2010, PRISON REFORM TRUST; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Kraus J, 2006, NEUROLOGY AND TRAUMA, P3; Kushel MB, 2005, AM J PUBLIC HEALTH, V95, P1747, DOI 10.2105/AJPH.2005.065094; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Macleod MR, 2002, INTENS CARE MED, V28, P1729, DOI 10.1007/s00134-002-1519-8; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Marwitz J. H., 2000, NEUROBEHAVIOURAL FUN; Merbitz C., 1995, J OFFENDER REHABILIT, V22, P11, DOI DOI 10.1300/J076V22N03_02; Ministry of Justice, 2012, ACC HOM REOFF PRIS; Ministry of Justice, 2012, MIN JUST Q B; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; Mount Sinai Injury Control Research Centre, 1998, BRAIN INJ SCREEN QUE; Novitski J, 2012, ARCH CLIN NEUROPSYCH, V27, P190, DOI 10.1093/arclin/acr119; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; Picard M., 1991, HELPS; Randolph C, 1998, REPEATABLE BATTERY A; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; *US DEP HHS, HEADS FACTS PHYS MIL; Wechsler D., 2011, TEST PREMORBID FUNCT; Wechsler D., 2011, WECHSLER ABBREVIATED; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; Wilson BA, 1996, BEHAV ASSESSMENT DYS	49	33	33	0	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	SEP 3	2015	25	5					763	779		10.1080/09602011.2014.973887			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CP0ZW	WOS:000359606600006	25351687				2021-06-18	
J	Bryan, CJ; Gonzales, J; Rudd, MD; Bryan, AO; Clemans, TA; Ray-Sannerud, B; Wertenberger, E; Leeson, B; Heron, EA; Morrow, CE; Etienne, N				Bryan, Craig J.; Gonzales, Jacqueline; Rudd, M. David; Bryan, AnnaBelle O.; Clemans, Tracy A.; Ray-Sannerud, Bobbie; Wertenberger, Evelyn; Leeson, Bruce; Heron, Elizabeth A.; Morrow, Chad E.; Etienne, Neysa			DEPRESSION MEDIATES THE RELATION OF INSOMNIA SEVERITY WITH SUICIDE RISK IN THREE CLINICAL SAMPLES OF US MILITARY PERSONNEL	DEPRESSION AND ANXIETY			English	Article						suicide; military; veterans; agitation; insomnia; sleep	TRAUMATIC BRAIN-INJURY; SLEEP DISTURBANCES; PSYCHIATRIC OUTPATIENTS; MAJOR DEPRESSION; IDEATION; BEHAVIOR; DISORDERS; HEALTH; PREVALENCE; PREDICTORS	BackgroundA growing body of empirical research suggests insomnia severity is directly related to suicide ideation, attempts, and death in nonmilitary samples, even when controlling for depression and other suicide risk factors. Few studies have explored this relationship in U.S. military personnel. MethodsThe present study entailed secondary data analyses examining the associations of insomnia severity with suicide ideation and attempts in three clinical samples: Air Force psychiatric outpatients (n = 158), recently discharged Army psychiatric inpatients (n = 168), and Army psychiatric outpatients (n = 54). Participants completed the Beck Scale for Suicide Ideation, the Beck Depression Inventory-II or Patient Health Questionnaire-9, the Insomnia Severity Index, and the Posttraumatic Stress Disorder Checklist at baseline; two samples also completed these measures during follow-up. ResultsSleep disturbance was associated with concurrent ('s > 0.21; P's < 0.059) and prospective ('s > 0.39; P's < 0.001) suicide ideation in all three samples. When adjusting for age, gender, depression, and posttraumatic stress, insomnia severity was no longer directly associated with suicide ideation either concurrently ('s < 0.19; P's > 0.200) or prospectively ('s < 0.26; P's > 0.063), but depression was ('s > 0.22; P's < 0.012). Results of a latent difference score mediation model indicated that depression mediated the relation of insomnia severity with suicide ideation. ConclusionsAcross three clinical samples of military personnel, depression explained the relationship between insomnia severity and suicide risk.	[Bryan, Craig J.; Gonzales, Jacqueline; Rudd, M. David; Bryan, AnnaBelle O.; Clemans, Tracy A.; Ray-Sannerud, Bobbie] Univ Utah, Natl Ctr Vet Studies, Salt Lake City, UT 84112 USA; [Bryan, Craig J.; Gonzales, Jacqueline; Bryan, AnnaBelle O.; Clemans, Tracy A.; Ray-Sannerud, Bobbie] Univ Utah, Salt Lake City, UT 84112 USA; [Rudd, M. David] Univ Memphis, Memphis, TN 38152 USA; [Wertenberger, Evelyn; Leeson, Bruce] Fort Carson, Colorado Springs, CO USA; [Heron, Elizabeth A.] Lackland AFB, San Antonio, TX USA; [Morrow, Chad E.] Hurlburt Field, Mary Esther, FL USA; [Etienne, Neysa] Maxwell AFB, Montgomery, AL USA	Bryan, CJ (corresponding author), Univ Utah, Natl Ctr Vet Studies, 260 S Cent Campus Dr,Room 205, Salt Lake City, UT 84112 USA.	craig.bryan@utah.edu	Rudd, M. David/AAF-1359-2019	Bryan, Craig/0000-0002-9714-0733	Military Suicide Research Consortium [W81XWH-10-2-0181]; Department of DefenseUnited States Department of Defense [W81XWH-09-1-0569]; Department of the Air Force [09-198]	Contract grant sponsor: Military Suicide Research Consortium; Contract grant number: W81XWH-10-2-0181; Contract grant sponsor: the Department of Defense; Contract grant number: W81XWH-09-1-0569; Contract grant sponsor: the Department of the Air Force; Contract grant number: 09-198.	Agargun MY, 2007, J AFFECT DISORDERS, V98, P267, DOI 10.1016/j.jad.2006.08.005; Agargun MY, 1997, J CLIN PSYCHIAT, V58, P249; Akiskal HS, 2005, PSYCHOPATHOLOGY, V38, P273, DOI 10.1159/000088445; [Anonymous], 2010, MED SURVEILLANCE MON, V17, P12; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P18; Armed Forces Health Surveillance Center-AFHSC, 2012, MSMR, V19, P4; BARRACLOUGH BM, 1975, PSYCHOL MED, V5, P55, DOI 10.1017/S0033291700007212; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beck AT, 1997, BEHAV RES THER, V35, P1039, DOI 10.1016/S0005-7967(97)00073-9; Beck AT., 1996, BECK DEPRESSION INVE, V2; Benazzi F, 2003, PSYCHIAT RES, V120, P273, DOI 10.1016/S0165-1781(03)00198-7; Benazzi F, 2003, PROG NEURO-PSYCHOPH, V27, P129, DOI 10.1016/S0278-5846(02)00343-3; Bernert RA, 2005, SLEEP, V28, P1135, DOI 10.1093/sleep/28.9.1135; Bernert Rebecca A, 2007, Neuropsychiatr Dis Treat, V3, P735; Brown GK, 2000, J CONSULT CLIN PSYCH, V68, P371, DOI 10.1037/0022-006X.68.3.371; Bryan CJ, 2008, J CLIN PSYCHOL, V64, P519, DOI 10.1002/jclp.20445; Bryan CJ, 2014, GEN HOSP PSYCHIAT, V36, P726, DOI 10.1016/j.genhosppsych.2014.09.013; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Busch KA, 2003, J CLIN PSYCHIAT, V64, P14, DOI 10.4088/JCP.v64n0105; Cole J. C., 2008, BEST PRACTICES QUANT, P214, DOI DOI 10.4135/9781412995627.D19; Department of Defense, 2013, DODSER DEP DEF SUIC; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; Fujino Y, 2005, SUICIDE LIFE-THREAT, V35, P227, DOI 10.1521/suli.35.2.227.62876; Hall RCW, 1999, PSYCHOSOMATICS, V40, P18, DOI 10.1016/S0033-3182(99)71267-3; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kung S, 2013, J AFFECT DISORDERS, V145, P341, DOI 10.1016/j.jad.2012.08.017; Chellappa SL, 2007, PSYCHIAT RES, V153, P131, DOI 10.1016/j.psychres.2006.05.007; LeardMann CA, 2013, JAMA-J AM MED ASSOC, V310, P496, DOI 10.1001/jama.2013.65164; Linehan MM, 2006, PSYCHOL ASSESSMENT, V18, P303, DOI 10.1037/1040-3590.18.3.303; Luxton DD, 2011, SLEEP, V34, P1189, DOI 10.5665/SLEEP.1236; McCall WV, 2010, SLEEP MED, V11, P822, DOI 10.1016/j.sleep.2010.04.004; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Neter J., 1989, APPL LINEAR REGRESSI; Nock MK, 2014, JAMA PSYCHIAT, V71, P514, DOI 10.1001/jamapsychiatry.2014.30; Pigeon WR, 2012, AM J PUBLIC HEALTH, V102, pS93, DOI 10.2105/AJPH.2011.300470; Ribeiro JD, 2012, J AFFECT DISORDERS, V136, P743, DOI 10.1016/j.jad.2011.09.049; Rihmer Z, 2002, BIPOLAR DISORD, V4, P21, DOI 10.1034/j.1399-5618.4.s1.3.x; Rudd MD, 2011, PROF PSYCHOL-RES PR, V42, P354, DOI 10.1037/a0025164; Rudd MD, 2003, SUICIDE LIFE-THREAT, V33, P99, DOI 10.1521/suli.33.1.99.22790; Selig JP, 2009, RES HUM DEV, V6, P144, DOI 10.1080/15427600902911247; Sjostrom N, 2007, SLEEP, V30, P91; Taylor Daniel J, 2003, Behav Sleep Med, V1, P227, DOI 10.1207/S15402010BSM0104_5; Trockel M, 2015, SLEEP, V38, P259, DOI 10.5665/sleep.4410; Turvey CL, 2002, AM J GERIAT PSYCHIAT, V10, P398; Weathers F.W., 1993, PTSD CHECKLIST PCL R	48	33	35	0	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269	1520-6394		DEPRESS ANXIETY	Depress. Anxiety	SEP	2015	32	9					647	655		10.1002/da.22383			9	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	CQ8AD	WOS:000360827400002	26047362				2021-06-18	
J	Flynn, LMC; Rhodes, J; Andrews, PJD				Flynn, Liam M. C.; Rhodes, Jonathan; Andrews, Peter J. D.			Therapeutic Hypothermia Reduces Intracranial Pressure and Partial Brain Oxygen Tension in Patients with Severe Traumatic Brain Injury: Preliminary Data from the Eurotherm3235 Trial	THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT			English	Article							TISSUE OXYGEN; MILD HYPOTHERMIA; MODERATE HYPOTHERMIA; CEREBROVASCULAR AUTOREGULATION; CEREBRAL EDEMA; EPIDEMIOLOGY; HYPERTENSION; MANNITOL; TEMPERATURE; HEMORRHAGE	Traumatic brain injury (TBI) is a significant cause of disability and death and a huge economic burden throughout the world. Much of the morbidity associated with TBI is attributed to secondary brain injuries resulting in hypoxia and ischemia after the initial trauma. Intracranial hypertension and decreased partial brain oxygen tension (PbtO2) are targeted as potentially avoidable causes of morbidity. Therapeutic hypothermia (TH) may be an effective intervention to reduce intracranial pressure (ICP), but could also affect cerebral blood flow (CBF). This is a retrospective analysis of prospectively collected data from 17 patients admitted to the Western General Hospital, Edinburgh. Patients with an ICP >20mmHg refractory to initial therapy were randomized to standard care or standard care and TH (intervention group) titrated between 32 degrees C and 35 degrees C to reduce ICP. ICP and PbtO2 were measured using the Licox system and core temperature was recorded through rectal thermometer. Data were analyzed at the hour before cooling, the first hour at target temperature, 2 consecutive hours at target temperature, and after 6 hours of hypothermia. There was a mean decrease in ICP of 4.3 +/- 1.6mmHg (p<0.04) from 15.7 to 11.4mmHg, from precooling to the first epoch of hypothermia in the intervention group (n=9) that was not seen in the control group (n=8). A decrease in ICP was maintained throughout all time periods. There was a mean decrease in PbtO2 of 7.8 +/- 3.1mmHg (p<0.05) from 30.2 to 22.4mmHg, from precooling to stable hypothermia, which was not seen in the control group. This research supports others in demonstrating a decrease in ICP with temperature, which could facilitate a reduction in the use of hyperosmolar agents or other stage II interventions. The decrease in PbtO2 is not below the suggested treatment threshold of 20mmHg, but might indicate a decrease in CBF.	[Flynn, Liam M. C.; Andrews, Peter J. D.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland; [Rhodes, Jonathan] Univ Edinburgh, Dept Anesthesia & Crit Care, Edinburgh EH16 4SB, Midlothian, Scotland; [Rhodes, Jonathan] Western Gen Hosp, NHS Lothian, Edinburgh EH4 2XU, Midlothian, Scotland	Flynn, LMC (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.	liam.flynn@nhs.net			NIHRH's Technology Assessment Program; National Institute for Health ResearchNational Institute for Health Research (NIHR) [11/01/30] Funding Source: researchfish	The authors would like to thank Cat Graham for her help with designing the methods of statistical analysis. The Eurotherm3235 trial is funded by the NIHRH's Technology Assessment Program and J.R. has a Chief Scientists Office NHS research fellowship. Informed written consent was received from participants/their representatives to take part in the Eurotherm3235 trial and subsequent publication of information thereafter. Copies of the consent form are held in the patients' clinical records and in the Welcome Trust Clinical Research Facility, Edinburgh, and are available for review by the Editor-in-Chief upon request.	Andrews P, 2003, BRIT J ANAESTH, V90, P251, DOI 10.1093/bja/aeg517; Andrews P, 2014, EUROTHERM3235 TRIAL; Andrews PJD, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-8; Arrich J, 2009, COCHRANE DB SYST REV, V4; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; De Georgia MA, 2015, J INTENSIVE CARE MED, V30, P473, DOI 10.1177/0885066614529254; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Geukens P, 2012, ANN UPDATE INTENSIVE, V2012, P735; Gupta AK, 2002, BRIT J ANAESTH, V88, P188, DOI 10.1093/bja/88.2.188; Hoffman WE, 1996, ANESTH ANALG, V82, P582, DOI 10.1097/00000539-199603000-00027; Hutchinson PJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1000; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JAMES HE, 1977, ACTA NEUROCHIR, V36, P189, DOI 10.1007/BF01405391; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Keller E, 2000, Neurosurg Focus, V8, pe4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCGRAW CP, 1978, SURG NEUROL, V10, P127; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; National Institute for Clinical Excellence, THER HYP INTR TEMP M; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Oddo M, 2014, NEUROCRIT CARE, V21, P103, DOI 10.1007/s12028-014-0024-6; Oddo M, 2012, INTENS CARE MED, V38, P1497, DOI 10.1007/s00134-012-2593-1; Oddo M, 2011, NEUROSURGERY, V69, P1037, DOI 10.1227/NEU.0b013e3182287ca7; Pennings FA, 2008, J NEUROTRAUM, V25, P1173, DOI 10.1089/neu.2007.0402; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Romner B, 2013, NAT REV NEUROL, V9, P185, DOI 10.1038/nrneurol.2013.37; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Sahuquillo J, 2009, INTENS CARE MED, V35, P890, DOI 10.1007/s00134-008-1357-4; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smrcka M, 2005, ACT NEUR S, V95, P273; Sorani MD, 2008, J NEUROTRAUM, V25, P291, DOI 10.1089/neu.2007.0411; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub3; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Torre-Healy A, 2012, NEUROCRIT CARE, V17, P117, DOI 10.1007/s12028-011-9649-x; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Zeng JS, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-19; Zhang Sai, 2002, Chin J Traumatol, V5, P43; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	64	33	35	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	2153-7658	2153-7933		THER HYPOTHERMIA TEM	Ther. Hypothermia Temp. Manag.	SEP 1	2015	5	3					143	151		10.1089/ther.2015.0002			9	Critical Care Medicine	General & Internal Medicine	CR1UC	WOS:000361109600007	26060880	Green Published			2021-06-18	
J	Astafiev, SV; Shulman, GL; Metcalf, NV; Rengachary, J; MacDonald, CL; Harrington, DL; Maruta, J; Shimony, JS; Ghajar, J; Diwakar, M; Huang, MX; Lee, RR; Corbetta, M				Astafiev, Serguei V.; Shulman, Gordon L.; Metcalf, Nicholas V.; Rengachary, Jennifer; MacDonald, Christine L.; Harrington, Deborah L.; Maruta, Jun; Shimony, Joshua S.; Ghajar, Jamshid; Diwakar, Mithun; Huang, Ming-Xiong; Lee, Roland R.; Corbetta, Maurizio			Abnormal White Matter Blood-Oxygen-Level-Dependent Signals in Chronic Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; diffusion tensor imaging; MRI; traumatic brain injury	SACCADIC EYE-MOVEMENTS; POST-CONCUSSIVE SYMPTOMS; DIFFUSION-TENSOR; FUNCTIONAL MRI; SMOOTH-PURSUIT; WORKING-MEMORY; HEAD-INJURY; CORPUS-CALLOSUM; REACTION-TIME; MILITARY PERSONNEL	Concussion, or mild traumatic brain injury (mTBI), can cause persistent behavioral symptoms and cognitive impairment, but it is unclear if this condition is associated with detectable structural or functional brain changes. At two sites, chronic mTBI human subjects with persistent post-concussive symptoms (three months to five years after injury) and age- and education-matched healthy human control subjects underwent extensive neuropsychological and visual tracking eye movement tests. At one site, patients and controls also performed the visual tracking tasks while blood-oxygen-level-dependent (BOLD) signals were measured with functional magnetic resonance imaging. Although neither neuropsychological nor visual tracking measures distinguished patients from controls at the level of individual subjects, abnormal BOLD signals were reliably detected in patients. The most consistent changes were localized in white matter regions: anterior internal capsule and superior longitudinal fasciculus. In contrast, BOLD signals were normal in cortical regions, such as the frontal eye field and intraparietal sulcus, that mediate oculomotor and attention functions necessary for visual tracking. The abnormal BOLD signals accurately differentiated chronic mTBI patients from healthy controls at the single-subject level, although they did not correlate with symptoms or neuropsychological performance. We conclude that subjects with persistent post-concussive symptoms can be identified years after their TBI using fMRI and an eye movement task despite showing normal structural MRI and DTI.	[Astafiev, Serguei V.; Shulman, Gordon L.; Metcalf, Nicholas V.; Rengachary, Jennifer; MacDonald, Christine L.; Corbetta, Maurizio] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Harrington, Deborah L.; Diwakar, Mithun; Huang, Ming-Xiong; Lee, Roland R.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA; [Maruta, Jun; Ghajar, Jamshid] Brain Trauma Fdn, New York, NY USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Shimony, Joshua S.] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA	Corbetta, M (corresponding author), Washington Univ, Dept Neurol, 660 S Euclid Ave, St Louis, MO 63110 USA.	mau@npg.wustl.edu	Corbetta, maurizio/AAZ-5219-2020; Maruta, Jun/I-3790-2019	Maruta, Jun/0000-0002-5054-6605; CORBETTA, MAURIZIO/0000-0001-8295-3304; Astafiev, Serguei/0000-0003-3736-7095	James S. McDonnell Foundation; National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD061117-05A2]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061117] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS095741] Funding Source: NIH RePORTER	We gratefully acknowledge Robert Fucetola, PhD, for neuropsychological consultation; A.Z. Snyder, M.D., PhD, for image analysis assistance; K.L. Zinn, P.T., for scheduling patients; David L. Brody, M.D., PhD, for referral of some mTBI subjects; Jerrel Rutlin for TBBS analysis and M.P. McAvoy, PhD, and M.J. Strube, PhD, for statistical advice. Supported by James S. McDonnell Foundation grant for the Attention Dynamics Consortium in Traumatic Brain Injury (ADC-TBI) and National Institute of Child Health and Human Development (NICHD) grant R01 HD061117-05A2.	Astafiev SV, 2004, NAT NEUROSCI, V7, P542, DOI 10.1038/nn1241; BAHILL AT, 1983, VISION RES, V23, P1573; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bouix S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066205; Boynton GM, 1996, J NEUROSCI, V16, P4207, DOI 10.1523/jneurosci.16-13-04207.1996; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Carter AR, 2010, ANN NEUROL, V67, P365, DOI 10.1002/ana.21905; Chang DJ, 2002, EPILEPSIA, V43, P68, DOI 10.1046/j.1528-1157.2002.21601.x; Chen AJW, 2010, NEURON, V66, P11, DOI 10.1016/j.neuron.2010.04.004; Chen Y, 2002, PROG BRAIN RES, V140, P255; COLLEWIJN H, 1984, J PHYSIOL-LONDON, V351, P217, DOI 10.1113/jphysiol.1984.sp015242; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Coronado V. G., 2012, EPIDEMIOLOG IN PRESS; Cortese S, 2012, AM J PSYCHIAT, V169, P1038, DOI 10.1176/appi.ajp.2012.11101521; Crooks Carol Y, 2007, Phys Med Rehabil Clin N Am, V18, P681, DOI 10.1016/j.pmr.2007.06.005; DeFina P, 2009, CLIN NEUROPSYCHOL, V23, P1391, DOI 10.1080/13854040903058978; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Esterman M, 2010, NEUROIMAGE, V50, P572, DOI 10.1016/j.neuroimage.2009.10.092; Fabri M, 2011, BRAIN RES, V1370, P99, DOI 10.1016/j.brainres.2010.11.039; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fraser LM, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-91; Gawryluk JR, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00239; Gawryluk JR, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00589; Gawryluk JR, 2011, NEUROIMAGE, V54, P10, DOI 10.1016/j.neuroimage.2010.07.028; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Ghajar J, 2009, NEUROSCIENTIST, V15, P232, DOI 10.1177/1073858408326429; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grimm S, 2008, BIOL PSYCHIAT, V63, P369, DOI 10.1016/j.biopsych.2007.05.033; Heiss WD, 2010, J CEREBR BLOOD F MET, V30, P1671, DOI 10.1038/jcbfm.2010.131; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Huang MX, 2012, NEUROIMAGE, V61, P1067, DOI 10.1016/j.neuroimage.2012.04.029; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hull AM, 2002, BRIT J PSYCHIAT, V181, P102; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kirov II, 2013, J NEUROTRAUM, V30, P1200, DOI 10.1089/neu.2012.2696; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Krauzlis RJ, 2005, NEUROSCIENTIST, V11, P124, DOI 10.1177/1073858404271196; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Laitinen T. P., 2009, P INT SOC MAG RESON; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee S, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.16; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Liotti M, 2001, J CLIN EXP NEUROPSYC, V23, P121, DOI 10.1076/jcen.23.1.121.1223; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; LISBERGER SG, 1987, ANNU REV NEUROSCI, V10, P97, DOI 10.1146/annurev.ne.10.030187.000525; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Martin LF, 2011, J PSYCHIATR RES, V45, P670, DOI 10.1016/j.jpsychires.2010.09.015; Maruta J, 2013, BEHAV RES METHODS, V45, P289, DOI 10.3758/s13428-012-0248-3; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mathias JL, 2007, BRIT J CLIN PSYCHOL, V46, P457, DOI 10.1348/014466507X190197; Mazerolle EL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058130; Mazerolle EL, 2010, NEUROIMAGE, V50, P616, DOI 10.1016/j.neuroimage.2009.12.102; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McWhinney SR, 2012, J NEUROSCI METH, V209, P351, DOI 10.1016/j.jneumeth.2012.06.014; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Muthukumaraswamy SD, 2012, HUM BRAIN MAPP, V33, P455, DOI 10.1002/hbm.21223; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newman AJ, 2010, P NATL ACAD SCI USA, V107, P7539, DOI 10.1073/pnas.1003174107; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Niskanen JP, 2013, J NEUROTRAUM, V30, P546, DOI 10.1089/neu.2012.2416; Ollinger JM, 2001, NEUROIMAGE, V13, P210, DOI 10.1006/nimg.2000.0710; Palmer HS, 2010, J NEUROTRAUM, V27, P853, DOI 10.1089/neu.2009.1225; Patel MJ, 2012, PSYCHIAT RES-NEUROIM, V204, P117, DOI 10.1016/j.pscychresns.2012.09.006; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; PETIT L, 1993, J NEUROPHYSIOL, V69, P1009; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rowland DJ, 2005, NUCL MED BIOL, V32, P567, DOI 10.1016/j.nucmedbio.2005.05.002; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454; Talairach J., 1988, COPLANAR STEREOTAXIC; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Van Essen DC, 2012, NEUROIMAGE, V62, P2222, DOI 10.1016/j.neuroimage.2012.02.018; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wang P, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00085; Yang Z, 2012, J NEUROTRAUM, V29, P2124, DOI 10.1089/neu.2012.2395; Yarkoni T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004257; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	101	33	33	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1254	1271		10.1089/neu.2014.3547			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400010	25758167	Green Published			2021-06-18	
J	Haghighi, F; Ge, YC; Chen, S; Xin, YR; Umali, MU; De Gasperi, R; Sosa, MAG; Ahlers, ST; Elder, GA				Haghighi, Fatemeh; Ge, Yongchao; Chen, Sean; Xin, Yurong; Umali, Michelle U.; De Gasperi, Rita; Sosa, Miguel A. Gama; Ahlers, Stephen T.; Elder, Gregory A.			Neuronal DNA Methylation Profiling of Blast-Related Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast overpressure; DNA methylation; epigenetic; sleep disturbance; traumatic brain injury	SLEEP DISTURBANCE; INTRACRANIAL-PRESSURE; N-ACETYLTRANSFERASE; MOUSE MODEL; RAT MODEL; EXPOSURE; EXPRESSION; MICE; GENE; INCREASES	Long-term molecular changes in the brain resulting from blast exposure may be mediated by epigenetic changes, such as deoxyribonucleic acid (DNA) methylation, that regulate gene expression. Aberrant regulation of gene expression is associated with behavioral abnormalities, where DNA methylation bridges environmental signals to sustained changes in gene expression. We assessed DNA methylation changes in the brains of rats exposed to three 74.5kPa blast overpressure events, conditions that have been associated with long-term anxiogenic manifestations weeks or months following the initial exposures. Rat frontal cortex eight months post-exposure was used for cell sorting of whole brain tissue into neurons and glia. We interrogated DNA methylation profiles in these cells using Expanded Reduced Representation Bisulfite Sequencing. We obtained data for millions of cytosines, showing distinct methylation profiles for neurons and glia and an increase in global methylation in neuronal versus glial cells (p<10(-7)). We detected DNA methylation perturbations in blast overpressure-exposed animals, compared with sham blast controls, within 458 and 379 genes in neurons and glia, respectively. Differentially methylated neuronal genes showed enrichment in cell death and survival and nervous system development and function, including genes involved in transforming growth factor and nitric oxide signaling. Functional validation via gene expression analysis of 30 differentially methylated neuronal and glial genes showed a 1.2 fold change in gene expression of the serotonin N-acetyltransferase gene (Aanat) in blast animals (p<0.05). These data provide the first genome-based evidence for changes in DNA methylation induced in response to multiple blast overpressure exposures. In particular, increased methylation and decreased gene expression were observed in the Aanat gene, which is involved in converting serotonin to the circadian hormone melatonin and is implicated in sleep disturbance and depression associated with traumatic brain injury.	[Haghighi, Fatemeh] James J Peters Dept Vet Affairs Med Ctr, Dept Psychiat, Bronx, NY USA; [De Gasperi, Rita; Sosa, Miguel A. Gama] James J Peters Dept Vet Affairs Med Ctr, Res & Dev Serv, Bronx, NY USA; [Elder, Gregory A.] James J Peters Dept Vet Affairs Med Ctr, Neurol Serv, Bronx, NY USA; [Haghighi, Fatemeh; Chen, Sean; Xin, Yurong; Umali, Michelle U.] Icahn Sch Med Mt Sinai, Fishberg Dept Neurosci, New York, NY 10029 USA; [Haghighi, Fatemeh; De Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA; [Ge, Yongchao; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [De Gasperi, Rita; Sosa, Miguel A. Gama; Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Ahlers, Stephen T.] Naval Med Res Ctr, Operat & Undersea Med Directorate, Dept Neurotrauma, Silver Spring, MD USA	Haghighi, F (corresponding author), Icahn Sch Med Mt Sinai, 1425 Madison Ave,Floor 10,Room 10-70D, New York, NY 10029 USA.	fatemeh.haghighi@mssm.edu	Ge, Yongchao/AAG-9317-2021	Ge, Yongchao/0000-0001-6448-5703	Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award [1I01RX000996-01];  [MH094774]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH094774] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX001705, I01RX000996] Funding Source: NIH RePORTER	This work was supported by MH094774 and the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service Award 1I01RX000996-01. The views expressed in this article are those of the author and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. The study protocol was reviewed and approved by the Walter Reed Army Institute of Research/Naval Medical Research Center Institutional Animal Care and Use Committee in compliance with all applicable Federal regulations governing the protection of animals in research.	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Akalin A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002781; Archer SN, 2010, SLEEP, V33, P695, DOI 10.1093/sleep/33.5.695; Armed Forces Health Surveillance Center (AFHSC), 2013, MSMR, V20, P9; Baracchi F, 2008, BRAIN BEHAV IMMUN, V22, P982, DOI 10.1016/j.bbi.2008.02.001; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beuckmann CT, 2003, J NEUROSCI, V23, P6793; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Capaldi VF, 2011, MIL MED, V176, P879, DOI 10.7205/MILMED-D-10-00440; Castriotta RJ, 2011, CNS DRUGS, V25, P175, DOI 10.2165/11584870-000000000-00000; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen LC, 2003, BRAIN RES, V973, P214, DOI 10.1016/S0006-8993(03)02484-3; Cheng JM, 2010, J NEUROL SCI, V294, P23, DOI 10.1016/j.jns.2010.04.010; Comuzzie AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051954; Curie T, 2013, SLEEP, V36, P311, DOI 10.5665/sleep.2440; De Gasperi Rita, 2012, Front Neurol, V3, P177, DOI 10.3389/fneur.2012.00177; Dodt Matthias, 2012, Biology (Basel), V1, P895, DOI 10.3390/biology1030895; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Fang JD, 1998, AM J PHYSIOL-REG I, V274, pR655; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Garrett-Bakelman FE, 2015, JOVE-J VIS EXP, DOI 10.3791/52246; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Heinzelmann M, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00198; Horbelt D, 2012, INT J BIOCHEM CELL B, V44, P469, DOI 10.1016/j.biocel.2011.12.013; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Kozlenkov A, 2014, NUCLEIC ACIDS RES, V42, P109, DOI 10.1093/nar/gkt838; Krieglstein K, 2011, TRENDS NEUROSCI, V34, P421, DOI 10.1016/j.tins.2011.06.002; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Lister R, 2013, SCIENCE, V341, P629, DOI 10.1126/science.1237905; Logan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059250; Lundberg J, 2009, NEUROSCI LETT, V457, P8, DOI 10.1016/j.neulet.2009.03.105; Macera CA, 2013, SLEEP, V36, P83, DOI 10.5665/sleep.2306; Maret S, 2007, P NATL ACAD SCI USA, V104, P20090, DOI 10.1073/pnas.0710131104; Matevossian A., 2008, J VIS EXP; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Mitchell AC, 2012, NEUROBIOL DIS, V45, P3, DOI 10.1016/j.nbd.2011.06.001; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112; Morairty SR, 2013, P NATL ACAD SCI USA, V110, P20272, DOI 10.1073/pnas.1314762110; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Pun Pamela B L, 2011, Front Neurol, V2, P19, DOI 10.3389/fneur.2011.00019; Reneer DV, 2011, J NEUROTRAUM, V28, P95, DOI 10.1089/neu.2010.1513; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Rubovitch V, 2011, EXP NEUROL, V232, P280, DOI 10.1016/j.expneurol.2011.09.018; Saljo A, 2010, J NEUROTRAUM, V27, P383, DOI 10.1089/neu.2009.1053; Schober ME, 2012, J NEUROTRAUM, V29, P2075, DOI 10.1089/neu.2011.2276; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Soria V, 2010, J PINEAL RES, V49, P35, DOI 10.1111/j.1600-079X.2010.00763.x; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Tweedie D, 2013, NEUROBIOL DIS, V54, P1, DOI 10.1016/j.nbd.2013.02.006; Viola-Saltzman M, 2012, NEUROL CLIN, V30, P1299, DOI 10.1016/j.ncl.2012.08.008; Wachs FP, 2006, J NEUROPATH EXP NEUR, V65, P358, DOI 10.1097/01.jnen.0000218444.53405.f0; Wang YG, 2011, J NEUROTRAUM, V28, P259, DOI 10.1089/neu.2010.1648; Woods AS, 2013, ACS CHEM NEUROSCI, V4, P594, DOI 10.1021/cn300216h; Xin YR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011357; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061; Zheng WP, 2002, CURR MED CHEM, V9, P1187, DOI 10.2174/0929867023370013	74	33	33	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1200	1209		10.1089/neu.2014.3640			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400003	25594545	Green Published			2021-06-18	
J	Huang, XJ; Glushakova, O; Mondello, S; Van, K; Hayes, RL; Lyeth, BG				Huang, Xian-jian; Glushakova, Olena; Mondello, Stefania; Van, Ken; Hayes, Ronald L.; Lyeth, Bruce G.			Acute Temporal Profiles of Serum Levels of UCH-L1 and GFAP and Relationships to Neuronal and Astroglial Pathology following Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; fluid percussion; GFAP; rat; TBI; UCH-L1	C-TERMINAL HYDROLASE; FIBRILLARY ACIDIC PROTEIN; FLUID-PERCUSSION MODEL; NEUROSURGICAL INTERVENTION; INTRACRANIAL LESIONS; CHOROID-PLEXUS; FLUORO-JADE; BLOOD; BARRIER; MARKERS	A number of potential traumatic brain injury (TBI) biomarkers have been proposed and evaluated in the laboratory and clinic. This study investigated the temporal profile of circulating biomarkers of astrocytic and neuronal injury over the first 24h and relevant histopathological changes after experimental moderate TBI. Twenty male rats were randomly assigned to either moderate parasagittal fluid percussion or sham injury. Blood serum samples were collected 2d prior to TBI (baseline) and at 3, 6, and 24h after TBI. A single cerebrospinal fluid (CSF) sample was collected from the cisterna magna 24h after TBI, followed by euthanasia and brain harvesting for histology. Serum and CSF samples were analyzed for neuronal (ubiquitin carboxy-terminal hydrolase L1 [UCH-L1]) and astroglial (glial fibrillary acidic protein [GFAP]) protein levels using enzyme-linked immunosorbent assay. Brain histology included GFAP immunostaining and Fluoro-Jade histofluorescence. Serum and CSF levels of GFAP were near zero in sham animals. Serum GFAP levels were significantly elevated at 3 and 6h post-TBI, compared with baseline and time-matched sham values, while UCH-L1 was significantly elevated only at 3h post-TBI. Both CSF GFAP and UCH-L1 at 24h post-TBI were significantly elevated, compared with sham. GFAP immunohistochemistry and FJ histofluorescence of degenerating neurons were performed in the same animals after 24h survival. Histology revealed characteristic acute neuronal degeneration in the ipsilateral hippocampus and parietal cortex and reduction in GFAP immunostaining in areas of neuronal cell loss. The data provide evidence of a causal relationship between TBI-induced acute brain pathology and circulating neuronal and glial markers, further demonstrating their role as candidate markers for TBI. Studies of relative changes in biomarker levels in CSF and serum suggest that different mechanisms may underlie the transport and/or clearance of UCH-L1 and GFAP in these two compartments.	[Huang, Xian-jian] Shenzhen Univ, Affiliated Hosp 2, Dept Neurosurg, Shenzhen, Peoples R China; [Huang, Xian-jian; Van, Ken; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Glushakova, Olena; Hayes, Ronald L.] Banyan Biomarkers Inc, Alachua, FL USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,One Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Lyeth, Bruce/0000-0003-4811-1474	Banyan Biomarkers, Inc.; UC Davis Department of Neurological Surgery	This research was supported by funds from Banyan Biomarkers, Inc. and the UC Davis Department of Neurological Surgery.	Arnaoutakis GJ, 2011, J THORAC CARDIOV SUR, V142, P902, DOI 10.1016/j.jtcvs.2011.06.027; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Cikriklar HI, 2013, EUR REV MED PHARMACO, V17, P3391; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Deeken JF, 2007, CLIN CANCER RES, V13, P1663, DOI 10.1158/1078-0432.CCR-06-2854; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ghabriel MN, 2010, ACTA NEUROCHIR SUPPL, V106, P239, DOI 10.1007/978-3-211-98811-4_45; Glushakova OY, 2012, TOXICOL SCI, V130, P158, DOI 10.1093/toxsci/kfs224; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; Graff CL, 2004, CURR DRUG METAB, V5, P95, DOI 10.2174/1389200043489126; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hellewell SC, 2010, J NEUROTRAUM, V27, P1997, DOI 10.1089/neu.2009.1245; Iliff JJ, 2013, STROKE, V44, pS93, DOI 10.1161/STROKEAHA.112.678698; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; RANSOM BR, 1992, J CLIN NEUROPHYSIOL, V9, P224, DOI 10.1097/00004691-199204010-00005; Rao VV, 1999, P NATL ACAD SCI USA, V96, P3900, DOI 10.1073/pnas.96.7.3900; Ren CH, 2013, BRAIN RES, V1540, P84, DOI 10.1016/j.brainres.2013.09.051; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Setsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007; Tongaonkar P, 2000, MOL CELL BIOL, V20, P4691, DOI 10.1128/MCB.20.13.4691-4698.2000; Vernadakis A, 1996, PROG NEUROBIOL, V49, P185, DOI 10.1016/S0301-0082(96)00012-3; Woertgen C, 2002, ACT NEUR S, V81, P205; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zoltewicz JS, 2013, J NEUROTRAUM, V30, P1161, DOI 10.1089/neu.2012.2762	40	33	34	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2015	32	16					1179	1189		10.1089/neu.2015.3873			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CU9RU	WOS:000363883400001	25763798				2021-06-18	
J	Magnoni, S; Mac Donald, CL; Esparza, TJ; Conte, V; Sorrell, J; Macri, M; Bertani, G; Biffi, R; Costa, A; Sammons, B; Snyder, AZ; Shimony, JS; Triulzi, F; Stocchetti, N; Brody, DL				Magnoni, Sandra; Mac Donald, Christine L.; Esparza, Thomas J.; Conte, Valeria; Sorrell, James; Macri, Mario; Bertani, Giulio; Biffi, Riccardo; Costa, Antonella; Sammons, Brian; Snyder, Abraham Z.; Shimony, Joshua S.; Triulzi, Fabio; Stocchetti, Nino; Brody, David L.			Quantitative assessments of traumatic axonal injury in human brain: concordance of microdialysis and advanced MRI	BRAIN			English	Article						traumatic brain injury; traumatic axonal injury; diffusion tensor imaging; microdialysis; tau	POSITRON-EMISSION-TOMOGRAPHY; WHITE-MATTER INTEGRITY; HEAD-INJURY; CEREBRAL MICRODIALYSIS; OUTCOME PREDICTION; METABOLIC CRISIS; MOUSE MODEL; IN-VIVO; MILD; DAMAGE	Axonal injury is a major contributor to adverse outcomes following brain trauma. However, the extent of axonal injury cannot currently be assessed reliably in living humans. Here, we used two experimental methods with distinct noise sources and limitations in the same cohort of 15 patients with severe traumatic brain injury to assess axonal injury. One hundred kilodalton cut-off microdialysis catheters were implanted at a median time of 17 h (13-29 h) after injury in normal appearing (on computed tomography scan) frontal white matter in all patients, and samples were collected for at least 72 h. Multiple analytes, such as the metabolic markers glucose, lactate, pyruvate, glutamate and tau and amyloid-beta proteins, were measured every 1-2 h in the microdialysis samples. Diffusion tensor magnetic resonance imaging scans at 3 T were performed 2-9 weeks after injury in 11 patients. Stability of diffusion tensor imaging findings was verified by repeat scans 1-3 years later in seven patients. An additional four patients were scanned only at 1-3 years after injury. Imaging abnormalities were assessed based on comparisons with five healthy control subjects for each patient, matched by age and sex (32 controls in total). No safety concerns arose during either microdialysis or scanning. We found that acute microdialysis measurements of the axonal cytoskeletal protein tau in the brain extracellular space correlated well with diffusion tensor magnetic resonance imaging-based measurements of reduced brain white matter integrity in the 1-cm radius white matter-masked region near the microdialysis catheter insertion sites. Specifically, we found a significant inverse correlation between microdialysis measured levels of tau 13-36 h after injury and anisotropy reductions in comparison with healthy controls (Spearman's r = -0.64, P = 0.006). Anisotropy reductions near microdialysis catheter insertion sites were highly correlated with reductions in multiple additional white matter regions. We interpret this result to mean that both microdialysis and diffusion tensor magnetic resonance imaging accurately reflect the same pathophysiological process: traumatic axonal injury. This cross-validation increases confidence in both methods for the clinical assessment of axonal injury. However, neither microdialysis nor diffusion tensor magnetic resonance imaging have been validated versus post-mortem histology in humans. Furthermore, future work will be required to determine the prognostic significance of these assessments of traumatic axonal injury when combined with other clinical and radiological measures.	[Magnoni, Sandra; Conte, Valeria; Stocchetti, Nino] IRCCS Ca Granda Osped Maggiore Policlin, Dept Anaesthesiol & Intens Care, Milan, Italy; [Mac Donald, Christine L.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Esparza, Thomas J.; Sorrell, James; Sammons, Brian; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA; [Macri, Mario; Stocchetti, Nino] Univ Milan, Milan, Italy; [Bertani, Giulio] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neurosurg, Milan, Italy; [Biffi, Riccardo; Costa, Antonella; Triulzi, Fabio] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neuroradiol, Milan, Italy; [Snyder, Abraham Z.; Shimony, Joshua S.] Washington Univ, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA; [Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Stocchetti, Nino/O-7444-2017	Stocchetti, Nino/0000-0003-3250-6834; Bertani, Giulio Andrea/0000-0003-1470-3391	Burroughs Wellcome Career Award in the Biomedical SciencesBurroughs Wellcome Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08 NS049237, R01 NS065069]; Fondazione IRCCS Ca Granda-Ospedale Maggiore Policlinico; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065069, K08NS049237] Funding Source: NIH RePORTER	This work was supported by funds from a Burroughs Wellcome Career Award in the Biomedical Sciences to D.L.B.; National Institutes of Health [grant numbers K08 NS049237 to D.L.B. and R01 NS065069 to D.L.B.; and departmental fund of the Fondazione IRCCS Ca Granda-Ospedale Maggiore Policlinico.	Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2008, J MOL NEUROSCI, V34, P51, DOI 10.1007/s12031-007-0029-0; Behrens TEJ, 2014, DIFFUSION MRI QUANTI, P337; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Das C, 2014, J NEUROTRAUM, V31, pA1; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gentry LR, 1988, AIR AM J ROENTGENL, P663; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Marklund N, 2009, J NEUROSURG, V110, P1227, DOI 10.3171/2008.9.JNS08584; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2016, NEUROREHAB NEURAL RE, V30, P49, DOI 10.1177/1545968315584004; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Oishi K, 2008, NEUROIMAGE, V43, P447, DOI 10.1016/j.neuroimage.2008.07.009; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Petzold A, 2011, BRAIN, V134, P464, DOI 10.1093/brain/awq360; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Seunarine K.K., 2014, DIFFUSION MRI, V2nd Ed, P105, DOI [10.1016/B978-0-12-396460-1.00006-8, DOI 10.1016/B978-0-12-396460-1.00006-8]; Shimony JS, 2009, BIOL PSYCHIAT, V66, P245, DOI 10.1016/j.biopsych.2009.02.032; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Yamada K, 2014, J EXP MED, V211, P387, DOI 10.1084/jem.20131685; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783	60	33	34	1	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG 1	2015	138		8				2263	2277		10.1093/brain/awv152			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CQ4MJ	WOS:000360578700023	26084657	Green Published, Bronze			2021-06-18	
J	Ahn, SY; Chang, YS; Sung, DK; Sung, SI; Yoo, HS; Im, GH; Choi, SJ; Park, WS				Ahn, So Yoon; Chang, Yun Sil; Sung, Dong Kyung; Sung, Se In; Yoo, Hye Soo; Im, Geun Ho; Choi, Soo Jin; Park, Won Soon			Optimal Route for Mesenchymal Stem Cells Transplantation after Severe Intraventricular Hemorrhage in Newborn Rats	PLOS ONE			English	Article							UMBILICAL-CORD BLOOD; MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; BONE-MARROW; AGE; HYDROCEPHALUS; RECOVERY; OUTCOMES; THERAPY; INFANTS	Recently, we showed that intracerebroventricular (IC) transplantation of human umbilical cord blood (UCB)-derived mesenchymal stem cells (MSCs) significantly attenuates post-hemorrhagic hydrocephalus (PHH) and brain damage after severe IVH in newborn rats. This study was performed to determine the optimal route for transplanting MSCs for severe IVH by comparing IC transplantation, intravenous (IV) transplantation, and IV transplantation plus mannitol infusion. Severe IVH was induced by injecting 100 uL of blood into each ventricle of Sprague-Dawley rats on postnatal day 4 (P4). After confirming severe IVH with brain magnetic resonance imaging (MRI) at P5, human UCB-derived MSCs were transplanted at P6 by an IC route (1x10(5)), an IV route (5x10(5)), or an IV route with mannitol infused. Follow-up brain MRIs and rotarod tests were performed. At P32, brain tissue samples were obtained for biochemical and histological analyses. Although more MSCs localized to the brain after IC than after IV delivery, both methods were equally effective in preventing PHH; attenuating impaired rotarod test; increasing the number of TUNEL-positive cells, inflammatory cytokines, and astrogliosis; and reducing corpus callosal thickness and myelin basic protein expression after severe IVH regardless of mannitol co-infusion. Despite the superior delivery efficacy with IC than with the IV route, both IC and IV transplantation of MSCs had equal therapeutic efficacy in protecting against severe IVH. These findings suggest that the less invasive IV route might be a good alternative for clinically unstable, very preterm infants that cannot tolerate a more invasive IC delivery of MSCs.	[Ahn, So Yoon; Chang, Yun Sil; Sung, Dong Kyung; Sung, Se In; Yoo, Hye Soo; Park, Won Soon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat, Seoul, South Korea; [Im, Geun Ho] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea; [Choi, Soo Jin] MEDIPOST Co Ltd, Biomed Res Inst, Seoul, South Korea	Park, WS (corresponding author), Sungkyunkwan Univ, Sch Med, Dept Pediat, Seoul, South Korea.	ws123.park@samsung.com			Korean Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea [A110445]; Samsung Biomedical Research Institute grant [SMX1131761, SMX1132321]	This work was supported by a grant from the Korean Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (Number; A110445, Author; Won Soon Park) (https://www.htdream.kr/) and by a Samsung Biomedical Research Institute grant (Number; SMX1131761, Author; Won Soon Park, SMX1132321, Author; So Yoon Ahn) (http://www.skkusm.ac.kr/academics/ri.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript and do not alter our adherence to all the PLOS ONE policies on sharing data and materials.	Ahn SY, 2013, STROKE, V44, P497, DOI 10.1161/STROKEAHA.112.679092; AMTORP O, 1974, J PHYSIOL-LONDON, V243, P387, DOI 10.1113/jphysiol.1974.sp010759; Anthony DC, 1997, BRAIN, V120, P435, DOI 10.1093/brain/120.3.435; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; BRAUN LD, 1980, J NEUROCHEM, V34, P147, DOI 10.1111/j.1471-4159.1980.tb04633.x; Chang YS, 2014, J PEDIATR-US, V164, P966, DOI 10.1016/j.jpeds.2013.12.011; Chang YS, 2009, CELL TRANSPLANT, V18, P869, DOI 10.3727/096368909X471189; Choi YJ, 2010, J NEUROL SCI, V298, P28, DOI 10.1016/j.jns.2010.09.003; Delo DM, 2008, STEM CELLS DEV, V17, P1185, DOI 10.1089/scd.2008.0028; Doorn J, 2012, TISSUE ENG PART B-RE, V18, P101, DOI [10.1089/ten.teb.2011.0488, 10.1089/ten.TEB.2011.0488]; Gang EJ, 2007, BLOOD, V109, P1743, DOI 10.1182/blood-2005-11-010504; Hudgins RJ, 1997, PEDIATR NEUROSURG, V26, P281, DOI 10.1159/000121207; Jang YK, 2006, ANN HEMATOL, V85, P212, DOI 10.1007/s00277-005-0047-3; Kawabori M, 2012, NEUROPATHOLOGY, V32, P217, DOI 10.1111/j.1440-1789.2011.01260.x; Kennedy C, 1998, LANCET, V352, P433; Kim ES, 2012, PEDIATR RES, V72, P277, DOI 10.1038/pr.2012.71; Kingham PJ, 2014, STEM CELLS DEV, V23, P741, DOI 10.1089/scd.2013.0396; Kuchroo P, 2015, STEM CELLS DEV, V24, P437, DOI 10.1089/scd.2014.0184; LARROCHE JC, 1972, BIOL NEONATE, V20, P287; Lee JK, 2007, CELL TRANSPLANT, V16, P849, DOI 10.3727/000000007783465271; LEVENE MI, 1982, ARCH DIS CHILD, V57, P410, DOI 10.1136/adc.57.6.410; Liu R, 2013, STEM CELLS DEV, V22, P1053, DOI 10.1089/scd.2012.0463; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; MUJSCE DJ, 1990, STROKE, V21, P1210, DOI 10.1161/01.STR.21.8.1210; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Payne AH, 2013, JAMA PEDIATR, V167, P451, DOI 10.1001/jamapediatrics.2013.866; Pimentel-Coelho PM, 2010, STEM CELLS DEV, V19, P299, DOI 10.1089/scd.2009.0403; ROMIJN HJ, 1991, EARLY HUM DEV, V26, P61, DOI 10.1016/0378-3782(91)90044-4; Thorp JA, 2001, AM J OBSTET GYNECOL, V185, P859, DOI 10.1067/mob.2001.117355; Tomasoni S, 2013, STEM CELLS DEV, V22, DOI 10.1089/scd.2012.0266; van Velthoven CTJ, 2009, BRAIN RES REV, V61, P1, DOI 10.1016/j.brainresrev.2009.03.003; Vinukonda G, 2010, BRAIN, V133, P2264, DOI 10.1093/brain/awq107; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; Yang SE, 2004, CYTOTHERAPY, V6, P476, DOI 10.1080/14653240410005041; Yasuhara T, 2010, J CELL MOL MED, V14, P914, DOI 10.1111/j.1582-4934.2008.00671.x; Zawadzka M, 2009, ACTA NEUROBIOL EXP, V69, P46; Zhang B, 2014, STEM CELLS DEV, V23, P1233, DOI 10.1089/scd.2013.0479; 1990, ARCH DIS CHILDHOOD, V65, P3	40	33	34	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2015	10	7							e0132919	10.1371/journal.pone.0132919			14	Multidisciplinary Sciences	Science & Technology - Other Topics	CN7NT	WOS:000358622000046	26208299	DOAJ Gold, Green Published			2021-06-18	
J	Gagnon, DJ; Nielsen, N; Fraser, GL; Riker, RR; Dziodzio, J; Sunde, K; Hovdenes, J; Stammet, P; Friberg, H; Rubertsson, S; Wanscher, M; Seder, DB				Gagnon, David J.; Nielsen, Niklas; Fraser, Gilles L.; Riker, Richard R.; Dziodzio, John; Sunde, Kjetil; Hovdenes, Jan; Stammet, Pascal; Friberg, Hans; Rubertsson, Sten; Wanscher, Michael; Seder, David B.			Prophylactic antibiotics are associated with a lower incidence of pneumonia in cardiac arrest survivors treated with targeted temperature management	RESUSCITATION			English	Article						Cardiac arrest; Pneumonia; Hypothermia; Intensive care; Antibiotics; Temperature	VENTILATOR-ASSOCIATED PNEUMONIA; TRAUMATIC BRAIN-INJURY; EARLY-ONSET PNEUMONIA; THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; INFECTIOUS COMPLICATIONS; ADVERSE EVENTS; CARE; METAANALYSIS; GUIDELINES	Introduction: Prophylactic antibiotics (PRO) reduce the incidence of early-onset pneumonia in comatose patients with structural brain injury, but have not been examined in cardiac arrest survivors undergoing targeted temperature management (TTM). We investigated the effect of PRO on the development of pneumonia in that population. Methods: We conducted a retrospective cohort study comparing patients treated with PRO to those not receiving PRO (no-PRO) using Northern Hypothermia Network registry data. Cardiac arrest survivors >= 18 years of age with a GCS < 8 at hospital admission and treated with TTM at 32-34 degrees C were enrolled in the registry. Differences were analyzed in univariate analyses and with logistic regression models to evaluate independent associations of clinical factors with incidence of pneumonia and good functional outcome. Results: 416 of 1240 patients (33.5%) received PRO. Groups were similar in age, gender, arrest location, initial rhythm, and time from collapse to return of spontaneous circulation. PRO patients had less pneumonia (12.6% vs. 54.9%, p < 0.001) and less sepsis (1.2 vs. 5.7%, p < 0.001) compared to no-PRO patients. ICU length of stay (98 vs. 100 h, p = 0.2) and incidence of a good functional outcome (41.1 vs. 36.6%, p = 0.19) were similar between groups. Backwards stepwise logistic regression demonstrated PRO were independently associated with a lower incidence of pneumonia (OR 0.09, 95% 0.06-0.14, p < 0.001) and a similar incidence of good functional outcome. Conclusions: Prophylactic antibiotics were associated with a reduced incidence of pneumonia but a similar rate of good functional outcome. (C) 2015 Elsevier Ireland Ltd. All rights reserved.	[Gagnon, David J.; Fraser, Gilles L.] Maine Med Ctr, Dept Pharm, Portland, ME 04102 USA; [Nielsen, Niklas] Helsingborg Hosp, Dept Anesthesia & Intens Care, Helsingborg, Sweden; [Fraser, Gilles L.; Riker, Richard R.; Dziodzio, John; Seder, David B.] Maine Med Ctr, Dept Crit Care Serv, Portland, ME 04102 USA; [Riker, Richard R.; Seder, David B.] Maine Med Ctr, Neurosci Inst, Portland, ME 04102 USA; [Riker, Richard R.; Seder, David B.] Maine Med Ctr, Div Pulm Med, Portland, ME 04102 USA; [Sunde, Kjetil] Oslo Univ Hosp Ulleval, Dept Anesthesiol, Div Emergencies & Crit Care, Oslo, Norway; [Hovdenes, Jan] Natl Hosp Norway, Oslo Univ Hosp, Dept Anesthesiol, Div Emergencies & Crit Care, Oslo, Norway; [Stammet, Pascal] Ctr Hosp Luxembourg, Dept Anesthesia & Intens Care, Luxembourg, Luxembourg; [Friberg, Hans] Lund Univ, Dept Clin Sci, Lund, Sweden; [Rubertsson, Sten] Uppsala Univ, Dept Anesthesiol & Intens Care, Uppsala, Sweden; [Wanscher, Michael] Rigshosp, Copenhagen Univ Hosp, Dept Cardiothorac Anesthesia, DK-2100 Copenhagen, Denmark	Gagnon, DJ (corresponding author), Maine Med Ctr, Dept Pharm, Portland, ME 04102 USA.	dgagnon@mmc.org	Riker, Richard/AAP-1760-2020; Stammet, Pascal/ABA-7580-2020; Seder, David B./M-4829-2019	Riker, Richard/0000-0002-0682-6204; Seder, David/0000-0002-9717-1038	Scandinavian Critical Care Trials Group; Scandinavian Society of Anesthesiology and Intensive Care; Stig and Ragna Gorthon Foundation; Torsten Birger Segerfalk Foundation; Laerdal Foundation; Gyllenstierna Krapperup Foundation (Nyhamnslage, Sweden); Skane County Council's research and development foundation	Northern Hypothermia Network was supported, in part, by the Scandinavian Critical Care Trials Group and the Scandinavian Society of Anesthesiology and Intensive Care, the Stig and Ragna Gorthon Foundation, the Torsten Birger Segerfalk Foundation, the Laerdal Foundation, the Gyllenstierna Krapperup Foundation (Nyhamnslage, Sweden), and the Skane County Council's research and development foundation.	Acquarolo A, 2005, INTENS CARE MED, V31, P510, DOI 10.1007/s00134-005-2585-5; Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Arrich J, 2012, COCHRANE DB SYST REV, V4, P9; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Crossley S, 2014, CRIT CARE, V18, DOI 10.1186/cc13835; Gajic O, 2004, RESUSCITATION, V60, P65, DOI 10.1016/j.resuscitation.2003.08.005; Geurts M, 2014, CRIT CARE MED, V42, P231, DOI 10.1097/CCM.0b013e3182a276e8; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hong JM, 2014, STROKE, V45, P134, DOI 10.1161/STROKEAHA.113.003143; Jarrah S, 2011, NEUROCRIT CARE, V14, P382, DOI 10.1007/s12028-011-9506-y; JENNETT B, 1975, LANCET, V1, P480; Kalanuria AA, 2014, CRIT CARE, V18, DOI 10.1186/cc13775; Langhelle A, 2005, RESUSCITATION, V66, P271, DOI 10.1016/j.resuscitation.2005.06.005; Levi AD, 2009, J NEUROTRAUM, V26, P407, DOI 10.1089/neu.2008.0745; MacLaren R, 2014, ANN PHARMACOTHER, V48, P17, DOI 10.1177/1060028013511228; Mongardon N, 2011, CRIT CARE MED, V39, P1359, DOI 10.1097/CCM.0b013e3182120b56; Moss M, 2003, CHEST, V123, P923, DOI 10.1378/chest.123.3.923; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Nielsen N, 2011, CRIT CARE MED, V39, P57, DOI 10.1097/CCM.0b013e3181fa4301; Nolan JP, 2003, CIRCULATION, V108, P118, DOI 10.1161/01.CIR.0000079019.02601.90; Noyes AM, 2013, J INTENSIVE CARE MED; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Perbet S, 2011, AM J RESP CRIT CARE, V184, P1048, DOI 10.1164/rccm.201102-0331OC; Rello J, 2002, CHEST, V122, P2115, DOI 10.1378/chest.122.6.2115; Seder DB, 2009, CRIT CARE MED, V37, pS211, DOI 10.1097/CCM.0b013e3181aa5bad; Seule MA, 2009, NEUROSURGERY, V64, P86, DOI 10.1227/01.NEU.0000336312.32773.A0; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Soleimanpour H, 2014, J CARDIOVASC THORAC, V6, P1, DOI 10.5681/jcvtr.2014.001; Stravitz RT, 2008, NEUROCRIT CARE, V9, P90, DOI 10.1007/s12028-008-9090-y; Torres A, 2009, INTENS CARE MED, V35, P9, DOI 10.1007/s00134-008-1336-9; Tsai MS, 2005, INTENS CARE MED, V31, P621, DOI 10.1007/s00134-005-2612-6; Vincent JL, 2006, CLIN CHEST MED, V27, P725, DOI 10.1016/j.ccm.2006.06.010; Woo JH, 2014, AM J EMERG MED, V32, P150, DOI 10.1016/j.ajem.2013.10.035; Xiao GG, 2013, EMERG MED J, V30, P91, DOI 10.1136/emermed-2012-201120; Zygun DA, 2006, NEUROCRIT CARE, V5, P108, DOI 10.1385/NCC:5:2:108	38	33	34	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUL	2015	92						154	159		10.1016/j.resuscitation.2015.01.035			6	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	CQ1JD	WOS:000360352500038	25680823				2021-06-18	
J	Rocque, M				Rocque, Michael			The lost concept: The (re)emerging link between maturation and desistance from crime	CRIMINOLOGY & CRIMINAL JUSTICE			English	Article						Crime theory; desistance; historical perspectives; life-course criminology; maturation	TRAUMATIC BRAIN-INJURY; LIFE-COURSE; ANTISOCIAL-BEHAVIOR; AGE-DIFFERENCES; ADOLESCENCE; CHILDHOOD; PERSONALITY; PERSISTENT; MARRIAGE; MATURITY	Research on desistance or the process of ceasing criminal behavior has increased in recent years. This work has revealed a large number of factors that are related to desistance. To date, these explanations have been generally perceived as mutually exclusive and/or competitive. Interestingly, while research on desistance from crime has been a recent focus, certain work had examined crime over the life-course as far back as the early 20th century. In particular, the Gluecks offered one of the earliest theories of desistance, focusing on maturation. Their maturation theory was somewhat tautological and not well specified. However, the Gluecks were clear that further work was needed in order to specify what maturation means and how it relates to crime. In this article, five domains of maturation are articulated drawing on the literature in the life-course and developmental fields. It is argued that this new framework may help advance the criminological work on desistance.	Bates Coll, Dept Sociol, Lewiston, ME 04240 USA	Rocque, M (corresponding author), Bates Coll, Dept Sociol, 265 Pettengill Hall, Lewiston, ME 04240 USA.	mrocque@bates.edu					Adams K., 2004, DEV THEORIES CRIME D; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; Beaver KM, 2008, SOC SCI RES, V37, P736, DOI 10.1016/j.ssresearch.2007.11.003; Bersani B, 2009, J QUANT CRIMINOL, V25, P3, DOI 10.1007/s10940-008-9056-4; Block J., 1971, LIVES TIME; Blonigen DM, 2008, J PERS, V76, P229, DOI 10.1111/j.1467-6494.2007.00485.x; Blonigen DM, 2010, CLIN PSYCHOL REV, V30, P89, DOI 10.1016/j.cpr.2009.10.001; Blonigen DM, 2006, J ABNORM PSYCHOL, V115, P85, DOI 10.1037/0021-843X.115.1.85; Byrne JM, 2008, VICTIMS OFFENDERS, V3, P319, DOI 10.1080/15564880802338435; Casey BJ, 2008, ANN NY ACAD SCI, V1124, P111, DOI 10.1196/annals.1440.010; Caspi A, 2005, ANNU REV PSYCHOL, V56, P453, DOI 10.1146/annurev.psych.55.090902.141913; Cauffman E, 2000, BEHAV SCI LAW, V18, P741, DOI 10.1002/bsl.416; Collins R., 2004, J OFFENDER REHABILIT, V39, P1; DANNEFER D, 1984, AM SOCIOL REV, V49, P100, DOI 10.2307/2095560; Davies RC, 2012, J HEAD TRAUMA REHAB, V27, pE21, DOI 10.1097/HTR.0b013e31825360da; Diamond A, 1997, MONOGR SOC RES CHILD, V62, P1; Dmitrieva J, 2012, DEV PSYCHOPATHOL, V24, P1073, DOI 10.1017/S0954579412000545; Farrall S., 2006, UNDERSTANDING DESIST; Farrall S, 2011, AUST NZ J CRIMINOL, V44, P218, DOI 10.1177/0004865811405136; Farrington DP, 2009, AGGRESSIVE BEHAV, V35, P150, DOI 10.1002/ab.20296; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Ferguson PL, 2012, J HEAD TRAUMA REHAB, V27, pE11, DOI 10.1097/HTR.0b013e31824e5f47; GIBBONS DC, 1970, SOC SERV REV, V44, P22, DOI 10.1086/642483; Giedd JN, 2008, J ADOLESCENT HEALTH, V42, P335, DOI 10.1016/j.jadohealth.2008.01.007; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Giordano PC, 2002, AM J SOCIOL, V107, P990, DOI 10.1086/343191; Giordano PC, 2007, AM J SOCIOL, V112, P1603, DOI 10.1086/512710; Glueck, 1943, CRIMINAL CAREERS RET; Glueck S., 1937, LATER CRIMINAL CAREE; Glueck S., 1970, TYPOLOGY JUVENILE OF; GLUECK S, 1945, AFTER CONDUCT DISCHA; Glueck S., 1940, JUVENILE DELINQUENTS; Glueck S., 1964, VENTURES CRIMINOLOGY, P306; Glueck S., 1974, DELINQUENCY CRIME PA; Glueck Sheldon, 1968, DELINQUENTS NONDELIN; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gottfredson M.R., 1990, GEN THEORY CRIME, DOI DOI 10.2307/1964276; Gove W. R., 1985, GENDER LIFE COURSE, P115; Graham J., 1995, YOUNG PEOPLE CRIME R; GREEN EJ, 1984, ADV CHEM SER, P1; GREENBERG DF, 1977, CONTEMP CRISES, V1, P189, DOI 10.1007/BF00728871; GREENBERGER E, 1974, J YOUTH ADOLESCENCE, V3, P329, DOI 10.1007/BF02214746; GREENBERGER E, 1975, J YOUTH ADOLESCENCE, V4, P127, DOI 10.1007/BF01537437; Greenberger E, 1986, TEENAGERS WORK PSYCH; Hammersley R, 2008, DRUGS AND CRIME, V2; HIRSCHI T, 1983, AM J SOCIOL, V89, P552, DOI 10.1086/227905; Hirschi T., 1969, CAUSES DELINQUENCY; HOGAN DP, 1986, ANNU REV SOCIOL, V12, P109, DOI 10.1146/annurev.so.12.080186.000545; Iselin AMR, 2009, LAW HUMAN BEHAV, V33, P455, DOI 10.1007/s10979-008-9160-x; Kazemian L, 2009, HANDB SOCIOL SOC RES, P277, DOI 10.1007/978-1-4419-0245-0_15; Kort-Butler LA, 2015, JUSTICE Q, V32, P381, DOI 10.1080/07418825.2013.770547; Laub JH, 2001, CRIME JUSTICE, V28, P1, DOI 10.1086/652208; LAUB JH, 1991, AM J SOCIOL, V96, P1402, DOI 10.1086/229691; Laub JH, 2003, SHARED BEGINNINGS DI; LeBel TP, 2008, EUR J CRIMINOL, V5, P131, DOI 10.1177/1477370807087640; Luna B, 2004, CHILD DEV, V75, P1357, DOI 10.1111/j.1467-8624.2004.00745.x; MARTINSON R, 1974, PUBLIC INTEREST, P22; Maruna S, 2004, PSYCHOL CRIME LAW, V10, P271, DOI 10.1080/10683160410001662762; Maruna S, 2011, PUNISHM SOC, V13, P3, DOI 10.1177/1462474510385641; Massoglia M, 2010, AM J SOCIOL, V116, P543, DOI 10.1086/653835; Matza D., 1964, DELINQUENCY DRIFT; McAdams DP, 1998, GENERATIVITY AND ADULT DEVELOPMENT, P7, DOI 10.1037/10288-001; Modecki KL, 2008, LAW HUMAN BEHAV, V32, P78, DOI 10.1007/s10979-007-9087-7; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Monahan KC, 2009, DEV PSYCHOL, V45, P1654, DOI 10.1037/a0015862; Muir, 2004, HOWARD J CRIMINAL JU, V43, P368, DOI DOI 10.1111/J.1468-2311.2004.00336.X; Nagin D., 2005, GROUP BASED MODELING; Navalta CP, 2006, J NEUROPSYCH CLIN N, V18, P45, DOI 10.1176/appi.neuropsych.18.1.45; Paternoster R, 2009, J CRIM LAW CRIM, V99, P1103; Paternoster R, 2009, J QUANT CRIMINOL, V25, P103, DOI 10.1007/s10940-009-9065-y; Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008; Pulkkinen L, 2009, AGGRESSIVE BEHAV, V35, P117, DOI 10.1002/ab.20297; Restak RM., 2001, SECRET LIFE BRAIN; Rocque M, 2012, J CRIM JUST, V40, P306, DOI 10.1016/j.jcrimjus.2012.05.003; Rumgay, 2004, HOWARD J CRIMINAL JU, V43, P405, DOI DOI 10.1111/J.1468-2311.2004.00338.X; Sampson R. J., 1993, CRIME MAKING PATHWAY; Sampson RJ, 2006, CRIMINOLOGY, V44, P465, DOI 10.1111/j.1745-9125.2006.00055.x; Savolainen J, 2009, BRIT J CRIMINOL, V49, P285, DOI 10.1093/bjc/azn084; Shanahan M.J., 2005, FRONTIER ADULTHOOD T; Shapland J, 2011, PUNISHM SOC, V13, P256, DOI 10.1177/1462474511404334; Shover N., 1985, AGING CRIMINALS; Sohoni T, 2014, J CRIME JUSTICE, V37, P155, DOI 10.1080/0735648X.2012.759884; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Spear L, 2007, ADOLESCENT PSYCHOPAT, P9, DOI DOI 10.1093/ACPR0F:0S0/9780195306255.003.0001; Steinberg L, 2008, DEV REV, V28, P78, DOI 10.1016/j.dr.2007.08.002; Steinberg L, 2009, CHILD DEV, V80, P28, DOI 10.1111/j.1467-8624.2008.01244.x; Sutherland EH, 1937, HARVARD LAW REV, V51, P184, DOI 10.2307/1333300; Sweeten G, 2013, J YOUTH ADOLESCENCE, V42, P921, DOI 10.1007/s10964-013-9926-4; Torney-Purta, 2010, HDB RES CIVIC ENGAGE, P277, DOI DOI 10.1002/9780470767603.CH11; UGGEN C, 2003, HDB LIFE COURSE, P311; Uggen C, 2010, CRIMINOL PUBLIC POL, V9, P725, DOI 10.1111/j.1745-9133.2010.00666.x; Vaske J, 2011, J CRIM JUST, V39, P90, DOI 10.1016/j.jcrimjus.2010.12.006; Vaughn MG, 2014, CRIM BEHAV MENT HEAL, V24, P188, DOI 10.1002/cbm.1900; Walsh A, 2009, CRIMINOL JUST STUD, P154; Warr M, 1998, CRIMINOLOGY, V36, P183, DOI 10.1111/j.1745-9125.1998.tb01246.x; WILKINS LT, 1969, YALE LAW J, V78, P731, DOI 10.2307/795026; Wilson J.Q., 1985, CRIME HUMAN NATURE; Wootton B, 1962, SOCIAL SCI SOCIAL PA; YAMAGUCHI K, 1985, AM J SOCIOL, V90, P1284, DOI 10.1086/228211	99	33	34	0	25	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1748-8958	1748-8966		CRIMINOL CRIM JUSTIC	Crimnol. Crim. Justice	JUL	2015	15	3					340	360		10.1177/1748895814547710			21	Criminology & Penology	Criminology & Penology	CL0AX	WOS:000356601900008					2021-06-18	
J	Yue, JK; Pronger, AM; Ferguson, AR; Temkin, NR; Sharma, S; Rosand, J; Sorani, MD; McAllister, TW; Barber, J; Winkler, EA; Burchard, EG; Hu, DL; Lingsma, HF; Cooper, SR; Puccio, AM; Okonkwo, DO; Diaz-Arrastia, R; Manley, GT				Yue, John K.; Pronger, Angela M.; Ferguson, Adam R.; Temkin, Nancy R.; Sharma, Sourabh; Rosand, Jonathan; Sorani, Marco D.; McAllister, Thomas W.; Barber, Jason; Winkler, Ethan A.; Burchard, Esteban G.; Hu, Donglei; Lingsma, Hester F.; Cooper, Shelly R.; Puccio, Ava M.; Okonkwo, David O.; Diaz-Arrastia, Ramon; Manley, Geoffrey T.		COBRIT Investigators; TRACK-TBI Investigators	Association of a common genetic variant within ANKK1 with six-month cognitive performance after traumatic brain injury	NEUROGENETICS			English	Article						Traumatic brain injury; Genetic factors; Cognition; Outcome measures; Human studies	GENOME-WIDE ASSOCIATION; D2 RECEPTOR GENE; WORKING-MEMORY; DATA ELEMENTS; TAQ1A POLYMORPHISM; OUTCOME PREDICTION; ALZHEIMERS-DISEASE; MOLECULAR-GENETICS; PREFRONTAL CORTEX; CLINICAL-TRIALS	Genetic association analyses suggest that certain common single nucleotide polymorphisms (SNPs) may adversely impact recovery from traumatic brain injury (TBI). Delineating their causal relationship may aid in development of novel interventions and in identifying patients likely to respond to targeted therapies. We examined the influence of the (C/T) SNP rs1800497 of ANKK1 on post-TBI outcome using data from two prospective multicenter studies: the Citicoline Brain Injury Treatment (COBRIT) trial and Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK-TBI Pilot). We included patients with ANKK1 genotyping results and cognitive outcomes at six months post-TBI (n = 492: COBRIT n = 272, TRACK-TBI Pilot n = 220). Using the California Verbal Learning Test Second Edition (CVLT-II) Trial 1-5 Standard Score, we found a dose-dependent effect for the T allele, with T/T homozygotes scoring lowest on the CVLT-II Trial 1-5 Standard Score (T/T 45.1, C/T 51.1, C/C 52.1, ANOVA, p = 0.008). Post hoc testing with multiple comparison-correction indicated that T/T patients performed significantly worse than C/T and C/C patients. Similar effects were observed in a test of non-verbal processing (Wechsler Adult Intelligence Scale, Processing Speed Index). Our findings extend those of previous studies reporting a negative relationship of the ANKK1 T allele with cognitive performance after TBI. In this study, we demonstrate the value of pooling shared clinical, biomarker, and outcome variables from two large datasets applying the NIH TBI Common Data Elements. The results have implications for future multicenter investigations to further elucidate the role of ANKK1 in post-TBI outcome.	[Yue, John K.; Ferguson, Adam R.; Sharma, Sourabh; Sorani, Marco D.; Winkler, Ethan A.; Cooper, Shelly R.; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Yue, John K.; Ferguson, Adam R.; Sharma, Sourabh; Sorani, Marco D.; Winkler, Ethan A.; Cooper, Shelly R.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Pronger, Angela M.; Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Pronger, Angela M.; Diaz-Arrastia, Ramon] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Temkin, Nancy R.; Barber, Jason] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy R.; Barber, Jason] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Rosand, Jonathan] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Rosand, Jonathan] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA USA; [McAllister, Thomas W.] Indiana Univ, Dept Psychiat, Indianapolis, IN 46204 USA; [Burchard, Esteban G.; Hu, Donglei] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Cooper, Shelly R.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Ferguson, Adam/0000-0001-7102-1608; Cooper, Shelly/0000-0003-0026-6688; Diaz-Arrastia, Ramon/0000-0001-6051-3594	 [NIH U01 HD42652];  [NIH R01 HD48179];  [NIH RC2 NS0694909];  [DOD USAMRAAW81XWH-13-1-0441]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042652] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409, U01NS086090] Funding Source: NIH RePORTER	The authors would like to thank the COBRIT and TRACK-TBI Investigators, without whom this work would not have been possible. The authors would like to thank the following contributors to the development of the TRACK-TBI database and repositories by organization and alphabetical order by last name - QuesGen Systems, Inc.: Vibeke Brinck, MS, and Michael Jarrett, MBA; One Mind: General Peter Chiarelli, U.S. Army (Ret.), and Garen Staglin; and Thomson Reuters: Sirimon O'Charoen, PhD. This work was supported by the following Grant Numbers: NIH U01 HD42652, NIH R01 HD48179 (to R.D.-A.), and NIH RC2 NS0694909, DOD USAMRAAW81XWH-13-1-0441 (to G.T.M.).	[Anonymous], 2014, TRAUM BRAIN INJ STAN; Baier B, 2010, J NEUROSCI, V30, P9788, DOI 10.1523/JNEUROSCI.1513-10.2010; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Bettens K, 2013, LANCET NEUROL, V12, P92, DOI 10.1016/S1474-4422(12)70259-4; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Brunetti A, 2014, WORLD J DIABETES, V5, P128, DOI 10.4239/wjd.v5.i2.128; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; Cresci Sharon, 2008, V448, P379, DOI 10.1007/978-1-59745-205-2_12; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; David SP, 2007, NICOTINE TOB RES, V9, P1251, DOI 10.1080/14622200701705027; Delis DC, 2000, CALIFORNIA VERBAL LE; Derogatis L., 2000, BRIEF SYMPTOM INVENT; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Doris PA, 2012, CELL MOL LIFE SCI, V69, P3751, DOI 10.1007/s00018-012-0996-3; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fisher RA, 1936, J R ANTHROPOL INST G, V66, P57, DOI 10.2307/2844116; Gershon ES, 2011, AM J PSYCHIAT, V168, P253, DOI 10.1176/appi.ajp.2010.10091340; Gulcher JR, 2005, TRENDS MOL MED, V11, P217, DOI 10.1016/j.molmed.2005.03.001; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hirvonen M, 2004, MOL PSYCHIATR, V9, P1060, DOI 10.1038/sj.mp.4001561; Hoenicka J, 2010, BIOL PSYCHIAT, V67, P3, DOI 10.1016/j.biopsych.2009.08.012; Jonsson EG, 1999, MOL PSYCHIATR, V4, P290, DOI 10.1038/sj.mp.4000532; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Klein TA, 2007, SCIENCE, V318, P1642, DOI 10.1126/science.1145044; Ku CS, 2010, J HUM GENET, V55, P195, DOI 10.1038/jhg.2010.19; Lum PY, 2013, SCI REP-UK, V3, DOI 10.1038/srep01236; Maas AIR, 2011, J NEUROTRAUM, V28, P177, DOI 10.1089/neu.2010.1617; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Malykhin N, 2008, PSYCHIAT RES-NEUROIM, V164, P132, DOI 10.1016/j.pscychresns.2007.11.007; Manley GT, 2013, JAMA-J AM MED ASSOC, V310, P473, DOI 10.1001/jama.2013.169158; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; Mcnab F, 2008, NAT NEUROSCI, V11, P103, DOI 10.1038/nn2024; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moraes CF, 2012, PSYCHOGERIATRICS, V12, P62, DOI 10.1111/j.1479-8301.2011.00378.x; Munafo MR, 2007, MOL PSYCHIATR, V12, P454, DOI 10.1038/sj.mp.4001938; National Center for Biotechnology Information, 2014, RS1800497 NAT CTR BI; Neville MJ, 2004, HUM MUTAT, V23, P540, DOI 10.1002/humu.20039; Noble EP, 2003, AM J MED GENET B, V116B, P103, DOI 10.1002/ajmg.b.10005; Norris J, 2013, TRAUMATIC BRAIN INJU; Ponce G, 2003, EUR PSYCHIAT, V18, P356, DOI 10.1016/j.eurpsy.2003.06.006; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rose SE, 2006, NEUROIMAGE, V32, P16, DOI 10.1016/j.neuroimage.2006.03.003; Ross OA, 2007, CURR DRUG TARGETS, V8, P850; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Smith L, 2008, AM J EPIDEMIOL, V167, P125, DOI 10.1093/aje/kwm281; Sorani MD, 2010, DRUG DISCOV TODAY, V15, P741, DOI 10.1016/j.drudis.2010.06.005; Takahashi E, 2013, NEUROIMAGE, V65, P488, DOI 10.1016/j.neuroimage.2012.10.002; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toga AW, 2012, NEUROSURGERY, V71, P1, DOI 10.1227/NEU.0b013e318258e9ff; Tosto G, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0381-0; Tsai CT, 2008, J AM COLL CARDIOL, V52, P241, DOI 10.1016/j.jacc.2008.02.072; van de Bunt M, 2010, CURR DIABETES REP, V10, P452, DOI 10.1007/s11892-010-0150-2; van der Sijde M. R., 2014, BIOCH BIOPHYS ACTA; Van Hecke J, 2010, BIOL PSYCHOL, V85, P143, DOI 10.1016/j.biopsycho.2010.06.005; Wang Q, 2005, CURR OPIN CARDIOL, V20, P182, DOI 10.1097/01.hco.0000160373.77190.f1; Wang Qing, 2005, Curr Atheroscler Rep, V7, P235, DOI 10.1007/s11883-005-0012-6; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wheeler E, 2011, BRIEF FUNCT GENOMICS, V10, P52, DOI 10.1093/bfgp/elr008; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yue JK, J NEUROTRAUMA, V30, P1831; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2012, J NEUROTRAUM, V29, P735, DOI 10.1089/neu.2011.2008; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015; Zarei M, 2010, NEUROIMAGE, V49, P1, DOI 10.1016/j.neuroimage.2009.09.001; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	72	33	34	0	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1364-6745	1364-6753		NEUROGENETICS	Neurogenetics	JUL	2015	16	3					169	180		10.1007/s10048-015-0437-1			12	Genetics & Heredity; Clinical Neurology	Genetics & Heredity; Neurosciences & Neurology	CK9AS	WOS:000356532700003	25633559	Green Accepted			2021-06-18	
J	Chen, L; Gao, X; Zhao, S; Hu, WP; Chen, JH				Chen, Liang; Gao, Xiang; Zhao, Shu; Hu, Weipeng; Chen, Jinhui			The Small-Molecule TrkB Agonist 7, 8-Dihydroxyflavone Decreases Hippocampal Newborn Neuron Death After Traumatic Brain Injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						7, 8-dihydroxyflavone; Brain-derived neurotrophic factor; Cell death; Newborn neuron; Neuroprotection; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; NEUROTROPHIC FACTOR; ADULT NEUROGENESIS; DENTATE GYRUS; FLUORO-JADE; SYNAPTIC PLASTICITY; IMMATURE NEURONS; MEMORY DEFICITS; NERVOUS-SYSTEM; MESSENGER-RNAS	Previous studies in rodents have shown that after a moderate traumatic brain injury (TBI) with a controlled cortical impact (CCI) device, the adult-born immature granular neurons in the dentate gyrus are the most vulnerable cell type in the hippocampus. There is no effective approach for preventing immature neuron death after TBI. We found that tyrosine-related kinase B (TrkB), a receptor of brain-derived neurotrophic factor (BDNF), is highly expressed in adult-born immature neurons. We determined that the small molecule imitating BDNF, 7, 8-dihydroxyflavone (DHF), increased phosphorylation of TrkB in immature neurons both in vitro and in vivo. Pretreatment with DHF protected immature neurons from excitotoxicity-mediated death in vitro, and systemic administration of DHF before moderate CCI injury reduced the death of adult-born immature neurons in the hippocampus 24 hours after injury. By contrast, inhibiting BDNF signaling using the TrkB antagonist ANA12 attenuated the neuroprotective effects of DHF. These data indicate that DHF may be a promising chemical compound that promotes immature neuron survival after TBI through activation of the BDNF signaling pathway.	[Gao, Xiang; Chen, Jinhui] Indiana Univ Sch Med, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Chen, Liang; Zhao, Shu] Southern Med Univ, Guangzhou, Guangdong, Peoples R China; [Hu, Weipeng] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou, Peoples R China	Chen, JH (corresponding author), Indiana Univ Sch Med, Dept Neurol Surg, Indiana 320 W 15th St, Indianapolis, IN 46202 USA.	chen204@iupui.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS072631, R21 NS075733, 1R21NS072631-01A] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075733, R21NS072631] Funding Source: NIH RePORTER		Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Andero R, 2012, HIPPOCAMPUS, V22, P399, DOI 10.1002/hipo.20906; Andero R, 2011, AM J PSYCHIAT, V168, P163, DOI 10.1176/appi.ajp.2010.10030326; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; Barnes AP, 2009, ANNU REV NEUROSCI, V32, P347, DOI 10.1146/annurev.neuro.31.060407.125536; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Cazorla M, 2011, J CLIN INVEST, V121, P1846, DOI 10.1172/JCI43992; Chiaretti A, 2003, INTENS CARE MED, V29, P1329, DOI 10.1007/s00134-003-1852-6; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Devi L, 2012, NEUROPSYCHOPHARMACOL, V37, P434, DOI 10.1038/npp.2011.191; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gao X, 2009, J NEUROTRAUM, V26, P1325, DOI 10.1089/neu.2008-0744; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Jang SW, 2010, P NATL ACAD SCI USA, V107, P2687, DOI 10.1073/pnas.0913572107; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kempermann G, 2000, NOVART FDN SYMP, V231, P235; Kempermann G., 2000, NOVART FDN SYMP, V231, P302; KIRSCHENBAUM B, 1995, P NATL ACAD SCI USA, V92, P210, DOI 10.1073/pnas.92.1.210; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lau Anthony C., 2007, V399, P15, DOI 10.1007/978-1-59745-504-6_2; Leal G, 2015, BRAIN RES, V1621, P82, DOI 10.1016/j.brainres.2014.10.019; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Lindholm D, 1996, EUR J NEUROSCI, V8, P1452, DOI 10.1111/j.1460-9568.1996.tb01607.x; Liu LD, 2003, P NATL ACAD SCI USA, V100, P8532, DOI 10.1073/pnas.1332804100; Liu X, 2010, J MED CHEM, V53, P8274, DOI 10.1021/jm101206p; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Magavi SS, 2000, NATURE, V405, P951; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Montalbano A, 2013, HIPPOCAMPUS, V23, P879, DOI 10.1002/hipo.22144; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Romine J, 2014, JOVE-J VIS EXP, DOI 10.3791/51781; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TIMMUSK T, 1994, NEUROSCIENCE, V60, P287, DOI 10.1016/0306-4522(94)90242-9; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yan Q, 1997, J COMP NEUROL, V378, P135; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yavuz BB, 2007, INT PSYCHOGERIATR, V19, P767, DOI 10.1017/S1041610206004303; Zeng Y, 2012, J ALZHEIMERS DIS, V31, P765, DOI 10.3233/JAD-2012-120886; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078	75	33	36	0	7	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUN	2015	74	6					557	567		10.1097/NEN.0000000000000199			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CI5UH	WOS:000354824800008	25933388	Green Accepted			2021-06-18	
J	Dickstein, BD; Weathers, FW; Angkaw, AC; Nievergelt, CM; Yurgil, K; Nash, WP; Baker, DG; Litz, BT				Dickstein, Benjamin D.; Weathers, Frank W.; Angkaw, Abigail C.; Nievergelt, Caroline M.; Yurgil, Kate; Nash, William P.; Baker, Dewleen G.; Litz, Brett T.		Marine Resiliency Study Team	Diagnostic Utility of the Posttraumatic Stress Disorder (PTSD) Checklist for Identifying Full and Partial PTSD in Active-Duty Military	ASSESSMENT			English	Article						PCL; CAPS; PTSD; military; Marines; Sailors; subthreshold	BECK ANXIETY INVENTORY; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; PSYCHOMETRIC PROPERTIES; COMBAT; SUBTHRESHOLD; AFGHANISTAN; IRAQ; IMPAIRMENT; SYMPTOMS	The aim of this study was to determine optimally efficient cutoff scores on the Posttraumatic Stress Disorder Checklist (PCL) for identifying full posttraumatic stress disorder (PTSD) and partial PTSD (P-PTSD) in active-duty Marines and Sailors. Participants were 1,016 Marines and Sailors who were administered the PCL and Clinician-Administered PTSD Scale (CAPS) 3 months after returning from Operations Iraqi and Enduring Freedom. PCL cutoffs were tested against three CAPS-based classifications: full PTSD, stringent P-PTSD, and lenient P-PTSD. A PCL score of 39 was found to be optimally efficient for identifying full PTSD. Scores of 38 and 33 were found to be optimally efficient for identifying stringent and lenient P-PTSD, respectively. Findings suggest that the PCL cutoff that is optimally efficient for detecting PTSD in active-duty Marines and Sailors is substantially lower than the score of 50 commonly used by researchers. In addition, findings provide scores useful for identifying P-PTSD in returning service members.	[Dickstein, Benjamin D.] Cincinnati VA Med Ctr, Cincinnati, OH USA; [Weathers, Frank W.] Auburn Univ, Auburn, AL 36849 USA; [Angkaw, Abigail C.; Nievergelt, Caroline M.; Yurgil, Kate; Baker, Dewleen G.] VA San Diego Healthcare Syst, San Diego, CA USA; [Angkaw, Abigail C.; Nievergelt, Caroline M.; Baker, Dewleen G.] Univ Calif San Diego, San Diego, CA 92103 USA; [Nash, William P.] Def Ctr Excellence Psychol Hlth Traumat Brain Inj, Washington, DC USA; [Litz, Brett T.] VA Boston Healthcare Syst, Boston, MA USA; [Litz, Brett T.] Boston Univ, Boston, MA 02215 USA	Dickstein, BD (corresponding author), Cincinnati VA Med Ctr, Ft Thomas Div, 1000 South Ft Thomas Ave, Ft Thomas, KY 41075 USA.	benjamin.dickstein@va.gov	Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838; Litz, Brett/0000-0002-0479-8887; Nievergelt, Caroline/0000-0001-5766-8923	VA Health Service Research and Development Project [SDR 09-0128]; Marine Corps; Navy Bureau of Medicine and Surgery; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH093500] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by the VA Health Service Research and Development Project No. SDR 09-0128 and by the Marine Corps and the Navy Bureau of Medicine and Surgery.	Adams RE, 2006, AM J DRUG ALCOHOL AB, V32, P203, DOI 10.1080/00952990500479522; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Baker DG, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110134; Beck A.T., 1993; BECK AT, 1991, J ANXIETY DISORD, V5, P213, DOI 10.1016/0887-6185(91)90002-B; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT., 1996, BECK DEPRESSION INVE, V2; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Breslau N, 2004, PSYCHOL MED, V34, P1205, DOI 10.1017/S0033291704002594; Creamer M, 2005, J AFFECT DISORDERS, V86, P175, DOI 10.1016/j.jad.2005.01.015; Dozois DJA, 1998, PSYCHOL ASSESSMENT, V10, P83, DOI 10.1037/1040-3590.10.2.83; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Gorman LA, 2011, PSYCHIAT SERV, V62, P28, DOI 10.1176/ps.62.1.pss6201_0028; Hewitt P. L., 1993, PSYCHOL ASSESS, V5, P408, DOI DOI 10.1037/1040-3590.5.4.408; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jacoby WG, 2000, ELECT STUD, V19, P577, DOI 10.1016/S0261-3794(99)00028-1; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Karam EG, 2010, BIOL PSYCHIAT, V68, P465, DOI 10.1016/j.biopsych.2010.04.032; Keane T. M., 2004, ASSESSING PSYCHOL TR, P262; Kim PY, 2010, PSYCHIAT SERV, V61, P582, DOI 10.1176/ps.2010.61.6.582; Kraemer H.C., 1992, EVALUATING MED TESTS; KRAEMER HC, 1987, PSYCHONEUROENDOCRINO, V12, P411, DOI 10.1016/0306-4530(87)90076-X; Litz B. T., FACILITATIN IN PRESS, P69; Marshall RD, 2001, AM J PSYCHIAT, V158, P1467, DOI 10.1176/appi.ajp.158.9.1467; Mylle J, 2004, J AFFECT DISORDERS, V78, P37, DOI 10.1016/S0165-0327(02)00218-5; Nash WP, 2011, PSYCHOSOC STRES, P33; O'Donnell ML, 2010, PSYCHIAT RES, V176, P257, DOI 10.1016/j.psychres.2009.05.012; Osman A, 1997, J CLIN PSYCHOL, V53, P7, DOI 10.1002/(SICI)1097-4679(199701)53:1<7::AID-JCLP2>3.0.CO;2-S; Pereda N, 2012, J TRAUMA STRESS, V25, P587, DOI 10.1002/jts.21736; Pietrzak RH, 2009, DEPRESS ANXIETY, V26, P739, DOI 10.1002/da.20574; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smith M., 2000, WHODAS 2 TRAINING MA; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Weathers F. W., 1993, INT SOC TRAUM STRESS; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Weiss D. S., 2004, ASSESSING PSYCHOL TR, P103; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zlotnick C, 2002, COMPR PSYCHIAT, V43, P413, DOI 10.1053/comp.2002.35900	44	33	33	0	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	JUN	2015	22	3					289	297		10.1177/1073191114548683			9	Psychology, Clinical	Psychology	CI0FZ	WOS:000354413600003	25178804				2021-06-18	
J	Phelps, TI; Bondi, CO; Ahmed, RH; Olugbade, YT; Kline, AE				Phelps, Thomas I.; Bondi, Corina O.; Ahmed, Rashid H.; Olugbade, Yewande T.; Kline, Anthony E.			Divergent Long-Term Consequences of Chronic Treatment with Haloperidol, Risperidone, and Bromocriptine on Traumatic Brain Injury-Induced Cognitive Deficits	JOURNAL OF NEUROTRAUMA			English	Article						Morris water maze; beam-walking; learning and memory; bromocriptine; behavior; functional recovery; traumatic brain injury; controlled cortical impact; antipsychotics	CONTROLLED CORTICAL IMPACT; MEMBRANE-LIPID PEROXIDATION; ATYPICAL ANTIPSYCHOTICS; FUNCTIONAL RECOVERY; ANTIOXIDANT ENZYMES; TARDIVE-DYSKINESIA; TREATMENT REGIMEN; MOTOR RECOVERY; WORKING-MEMORY; CORTEX INJURY	Antipsychotic drugs (APDs) are provided in the clinic to manage traumatic brain injury (TBI)-induced agitation and aggression. Experimental TBI studies consistently show that daily administration of the APDs, haloperidol (HAL) and risperidone (RISP), hinder recovery. However, it is unknown how long the adverse effects remain after cessation of treatment. To elucidate this clinically relevant issue, anesthetized male rats were randomly assigned to four TBI (controlled cortical impact) and four sham groups administered HAL (0.5 mg/kg), RISP (0.45 mg/kg), bromocriptine (BRO; 5.0 mg/kg, included as a control for D-2 receptor action), or vehicle (VEH; 1 mL/kg) 24 h after surgery and once-daily for 19 days. Motor and cognitive recovery was assessed on days 1-5 and 14-19, respectively, and again at 1 and 3 months after drug withdrawal. No overall group differences were observed for motor function among the TBI groups, although the HAL group showed a greater beam-walk deficit on day 5 versus the VEH and BRO groups. Cognitive recovery was significantly impaired in the HAL and RISP groups during the treatment phase versus VEH and BRO. Further, BRO was superior to VEH (p=0.0042). At 1 month, both groups that received APDs continued to exhibit significant cognitive impairment versus VEH and BRO; at 3 months, only the HAL group was impaired. Moreover, the HAL, RISP, and VEH groups continued to be cognitively deficient versus BRO, which also reduced cortical damage. These data replicate previous reports that HAL and RISP impede cognitive recovery after TBI and expand the literature by revealing that the deleterious effects persist for 3 months after drug discontinuation. BRO conferred cognitive benefits when administered concomitantly with behavioral testing, thus replicating previous findings, and also after cessation demonstrating enduring efficacy.	[Phelps, Thomas I.; Bondi, Corina O.; Ahmed, Rashid H.; Olugbade, Yewande T.; Kline, Anthony E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Phelps, Thomas I.; Bondi, Corina O.; Ahmed, Rashid H.; Olugbade, Yewande T.; Kline, Anthony E.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Bondi, Corina O.; Kline, Anthony E.] Univ Pittsburgh, Ctr Neural Basis Cognit, Pittsburgh, PA USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA; [Kline, Anthony E.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA	Kline, AE (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, Safar Ctr Resuscitat Res, 3471 Fifth Ave,Suite 201, Pittsburgh, PA 15213 USA.	klineae@upmc.edu		Bondi, Corina/0000-0002-5733-4912	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS084967, NS060005, HD069620]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS084967, R01NS060005] Funding Source: NIH RePORTER	This work was supported, in part, by the National Institutes of Health (grant nos.: NS084967, NS060005, and HD069620; to A.E.K.).	BENES FM, 1985, BRAIN RES, V329, P265, DOI 10.1016/0006-8993(85)90532-3; Besret L, 2000, EUR J PHARMACOL, V408, P35, DOI 10.1016/S0014-2999(00)00747-0; Bondi C. O., 2014, NEUROSCI BI IN PRESS; Bondi CO, 2014, J NEUROTRAUM, V31, P926, DOI 10.1089/neu.2013.3295; CADET JL, 1994, NEUROSCI BIOBEHAV R, V18, P457, DOI 10.1016/0149-7634(94)90001-9; CAMPBELL A, 1985, PSYCHOPHARMACOLOGY, V87, P161, DOI 10.1007/BF00431801; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Elovic EP, 2008, J HEAD TRAUMA REHAB, V23, P132, DOI 10.1097/01.HTR.0000314532.07530.e5; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1993, J NEURAL TRANSP PLAS, V4, P199, DOI 10.1155/NP.1993.199; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Galili-Mosberg R, 2000, J NEURAL TRANSM, V107, P479, DOI 10.1007/s007020070089; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Gold PE, 2003, NEUROBIOL LEARN MEM, V80, P194, DOI 10.1016/j.nlm.2003.07.003; Goldstein LB, 2002, NEUROREHAB NEURAL RE, V16, P321, DOI 10.1177/154596830201600402; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hasselmo ME, 2006, CURR OPIN NEUROBIOL, V16, P710, DOI 10.1016/j.conb.2006.09.002; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; Huang GB, 2012, NEUROSCI LETT, V528, P131, DOI 10.1016/j.neulet.2012.09.024; Hutchings EJ, 2013, J PHARMACOL EXP THER, V347, P547, DOI 10.1124/jpet.113.209031; Karl T, 2006, BEHAV BRAIN RES, V171, P286, DOI 10.1016/j.bbr.2006.04.004; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kline AE, 2007, CRIT CARE MED, V35, P919, DOI 10.1097/01.CCM.0000256722.88854.C0; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Kornhuber J, 1999, AM J PSYCHIAT, V156, P885, DOI 10.1176/ajp.156.6.885; LIU XH, 1995, J NEUROL SCI, V129, P9, DOI 10.1016/0022-510X(94)00239-K; Lombard LA, 2005, AM J PHYS MED REHAB, V84, P797, DOI 10.1097/01.phm.0000179438.22235.08; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Naidu PS, 2002, BRIT J PHARMACOL, V136, P193, DOI 10.1038/sj.bjp.0704717; Nyberg S, 1997, ARCH GEN PSYCHIAT, V54, P953; OGAWA N, 1994, BRAIN RES, V657, P207, DOI 10.1016/0006-8993(94)90969-5; Parikh V, 2003, J PSYCHIATR RES, V37, P43, DOI 10.1016/S0022-3956(02)00048-1; Pillai A, 2007, J PSYCHIATR RES, V41, P372, DOI 10.1016/j.jpsychires.2006.01.011; Rosengarten H, 2002, PROG NEURO-PSYCHOPH, V26, P1047, DOI 10.1016/S0278-5846(02)00221-X; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shaw KE, 2013, J NEUROTRAUM, V30, P557, DOI 10.1089/neu.2012.2782; Sozda CN, 2010, J NEUROTRAUM, V27, P1047, DOI 10.1089/neu.2010.1313; Stanislav SW, 1997, BRAIN INJURY, V11, P335, DOI 10.1080/026990597123494; Ukai W, 2004, J NEURAL TRANSM, V111, P667, DOI 10.1007/s00702-004-0109-z; Vogenthaler D R, 1987, Brain Inj, V1, P113; Whyte J, 2008, AM J PHYS MED REHAB, V87, P85, DOI 10.1097/PHM.0b013e3181619609; Wilson MS, 2003, AM J PHYS MED REHAB, V82, P871, DOI 10.1097/01.PHM.0000091982.33232.CB; Yael D., 2013, FRONT SYST NEUROSCI, V7, P1, DOI DOI 10.HTTPS://D0I.0RG/10.3389/FNSYS.2013.00110; YOSHIKAWA T, 1994, J NEUROCHEM, V62, P1034; Zhang L, 2013, TISSUE ENG PT A, V19, P1909, DOI [10.1089/ten.tea.2012.0622, 10.1089/ten.TEA.2012.0622]	52	33	34	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2015	32	8					590	597		10.1089/neu.2014.3711			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CF2BS	WOS:000352352900009	25275833	Green Published			2021-06-18	
J	Camfield, C; Camfield, P				Camfield, Carol; Camfield, Peter			Injuries from seizures are a serious, persistent problem in childhood onset epilepsy: A population-based study	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						Childhood; Epilepsy; Injury; Accidents; Population-based	CHILDREN; CLASSIFICATION; SHOULDER; PEOPLE; RISK	Purpose: Document the frequency, types and risk factors for injuries caused by seizures for people with childhood onset epilepsy. Method: We contacted patients with all types of epilepsy except childhood absence from the Nova Scotia Childhood Epilepsy population-based cohort. Seizure onset was between 1977 and 1985. Patients and parents were asked about serious injuries resulting from a seizure, defined as severe enough for an urgent physician or dentist visit. Results: Of 595 eligible patients, we contacted 472 (79%). During an average follow up of 23.9 +/- 8 years, 52 (11%) experienced >= 1 serious injury for a total of 81 injuries. Of all injuries, 24 (30%) were lacerations requiring sutures, 15 (19%) fractures, 11(14%) broken teeth, 8(10%) concussions, 4(5%) burns, and 20(25%) other. "Other" included 1 fatal drowning, 2 near-drownings, 3 shoulder dislocations and 1 severe eye injury. Four injuries occurred with the first seizure; all others after a long gap from seizure onset (range 1.5-30 years). Injuries occurred in all epilepsy syndromes, most commonly with symptomatic generalized epilepsy (17% vs. 11% p = 0.03) and intractable epilepsy (28% vs. 8% p < 0.0001). Most injuries occurred during normal daily activities and were judged not to be easily preventable. Conclusions: During 24 years of follow up 1 out of 10 patients with childhood onset epilepsy had a serious injury as the result of a seizure. Most injuries occurred years after the initial diagnosis and were more common when seizures were more frequent. The only practical solution to injury prevention is better seizure control. (C) 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[Camfield, Peter] Dalhousie Univ, Dept Pediat, Halifax, NS B3K 6R8, Canada; [Camfield, Peter] IWK Hlth Ctr, Halifax, NS B3K 6R8, Canada	Camfield, P (corresponding author), Dalhousie Univ, Dept Pediat, Halifax, NS B3K 6R8, Canada.	camfield@dal.ca					[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Appleton RE, 2002, EPILEPSIA, V43, P764, DOI 10.1046/j.1528-1157.2002.41101.x; Baca CB, 2013, J PEDIATR-US, V163, P1684, DOI 10.1016/j.jpeds.2013.07.046; Beghi E, 2002, EPILEPSIA, V43, P1076, DOI 10.1046/j.1528-1157.2002.18701.x; Berg AT, 2010, EPILEPSIA, V51, P676, DOI 10.1111/j.1528-1167.2010.02522.x; CAMFIELD C, 1993, J PEDIATR-US, V122, P861, DOI 10.1016/S0022-3476(09)90008-7; Camfield CS, 2009, NEUROLOGY, V73, P1041, DOI 10.1212/WNL.0b013e3181b9c86f; Camfield P, 2007, EPILEPSIA, V48, P1128, DOI 10.1111/j.1528-1167.2007.01072.x; Deekollu D, 2005, SEIZURE-EUR J EPILEP, V14, P347, DOI 10.1016/j.seizure.2005.04.008; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Gosens T, 2000, SEIZURE-EUR J EPILEP, V9, P446, DOI 10.1053/seiz.2000.0418; Goudie EB, 2012, J BONE JOINT SURG BR, V94B, P721, DOI 10.1302/0301-620X.94B6.28259; Kwon CS, 2010, EPILEPSIA, V51, P2247, DOI 10.1111/j.1528-1167.2010.02697.x; Prasad V, 2014, PEDIATRICS, V133, P827, DOI 10.1542/peds.2013-2554; Tellez-Zenteno JF, 2008, EPILEPSIA, V49, P954, DOI 10.1111/j.1528-1167.2007.01499.x; Vestergaard P, 2005, ACTA NEUROL SCAND, V112, P277, DOI 10.1111/j.1600-0404.2005.00474.x; Wirrell EC, 1996, ARCH NEUROL-CHICAGO, V53, P929, DOI 10.1001/archneur.1996.00550090141020; Wirrell EC, 2006, EPILEPSIA, V47, P79, DOI 10.1111/j.1528-1167.2006.00666.x; Wirrell EC, 2011, EPILEPSY RES, V95, P110, DOI 10.1016/j.eplepsyres.2011.03.009	19	33	34	0	6	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	APR	2015	27						80	83		10.1016/j.seizure.2015.02.031			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CH0XH	WOS:000353745200016	25891933	Bronze			2021-06-18	
J	Vaccari, JCD; Brand, FJ; Berti, AF; Alonso, OF; Bullock, MR; Vaccari, JPD				Vaccari, Juan Carlos de Rivero; Brand, Frank J., III; Berti, Aldo F.; Alonso, Ofelia F.; Bullock, M. Ross; Vaccari, Juan Pablo de Rivero			Mincle Signaling in the Innate Immune Response after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						innate immunity; neuroinflammation; traumatic brain injury; mincle; neurons	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; NEURONAL CELL-DEATH; TOLL-LIKE RECEPTORS; SPINAL-CORD-INJURY; FACTOR-ALPHA; RAT-BRAIN; KAPPA-B; TNF; INFLAMMASOME	The innate immune response contributes to the inflammatory activity after traumatic brain injury (TBI). In the present study we identify macrophage-inducible C-type lectin (mincle) as a pattern recognition receptor that contributes to innate immunity in neurons after TBI. Here we report that mincle is activated by SAP130 in cortical neurons in culture, resulting in production of the inflammatory cytokine TNF. In addition, mincle and SAP130 are elevated in the brain and cerebrospinal fluid of humans after TBI and the brain of rodents after fluid percussion brain injury. Thus, these findings suggest the involvement of mincle to the pathology of TBI. Importantly, blocking mincle with a neutralizing antibody against mincle in cortical neurons in culture treated with SAP130 resulted in inhibition of mincle signaling and decreased TNF production. Therefore, our findings identify mincle as a contributor to the inflammatory response after TBI.	[Vaccari, Juan Carlos de Rivero] Louisiana State Univ, Ochsner Med Ctr, Sch Med, Dept Ophthalmol, New Orleans, LA USA; [Brand, Frank J., III; Berti, Aldo F.; Alonso, Ofelia F.; Bullock, M. Ross; Vaccari, Juan Pablo de Rivero] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Dept Neurol Surg, Miami, FL 33136 USA	Vaccari, JPD (corresponding author), Lois Pope LIFE Ctr, Dept Neurol Surg, 1095 NW 14th Terrace,3-25, Miami, FL 33136 USA.	JdeRivero@med.miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; 	Miami Project to Cure Paralysis	This project was supported by The Miami Project to Cure Paralysis.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak SE, 2012, THESIS; Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Brait VH, 2012, J CEREBR BLOOD F MET, V32, P598, DOI 10.1038/jcbfm.2012.6; Breen K, 2012, REPROD SCI, V19, P839, DOI 10.1177/1933719112438439; Cambi A, 2009, CURR BIOL, V19, pR375, DOI 10.1016/j.cub.2009.03.032; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Dubyak GR, 2012, CELL MICROBIOL, V14, P1697, DOI 10.1111/cmi.12001; Engelhardt B, 2005, TRENDS IMMUNOL, V26, P485, DOI 10.1016/j.it.2005.07.004; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Kaltsonoudis E, 2014, AUTOIMMUN REV, V13, P54, DOI 10.1016/j.autrev.2013.09.002; Leung PY, 2012, STROKE, V43, P1383, DOI 10.1161/STROKEAHA.111.641522; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Matsunaga I, 2009, J EXP MED, V206, P2865, DOI 10.1084/jem.20092533; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; Menon Suchithra, 2008, BMC Biochemistry, V9, P1, DOI 10.1186/1471-2091-9-1; Moots RJ, 2012, RHEUMATOLOGY, V51, P2252, DOI 10.1093/rheumatology/kes217; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider P, 1999, EUR J IMMUNOL, V29, P1785, DOI 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sholkina Margarita N, 2002, Russ J Immunol, V7, P365; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Sriram K, 2007, J NEUROIMMUNE PHARM, V2, P140, DOI 10.1007/s11481-007-9070-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stocker BL, 2014, CHEMBIOCHEM, V15, P382, DOI 10.1002/cbic.201300674; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tobinick E, 2012, CNS DRUGS, V26, P1051, DOI 10.1007/s40263-012-0013-2; Tomura S, 2012, J CEREBR BLOOD F MET, V32, P1939, DOI 10.1038/jcbfm.2012.99; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2012, DERMATOL SURG, V38, P1033, DOI 10.1111/j.1524-4725.2012.02378.x; Vaccari JPD, 2012, J NEUROSCI, V32, P3058, DOI 10.1523/JNEUROSCI.4930-11.2012; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Wang YC, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-134; Wells CA, 2008, J IMMUNOL, V180, P7404, DOI 10.4049/jimmunol.180.11.7404; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651; Yu WH, 2012, PHYTOTHER RES, V26, P1838, DOI 10.1002/ptr.4662; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771	47	33	34	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2015	32	4					228	236		10.1089/neu.2014.3436			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CB0KN	WOS:000349314900003	25111533				2021-06-18	
J	Liu, XY; Czosnyka, M; Donnelly, J; Budohoski, KP; Varsos, GV; Nasr, N; Brady, KM; Reinhard, M; Hutchinson, PJ; Smielewski, P				Liu, Xiuyun; Czosnyka, Marek; Donnelly, Joseph; Budohoski, Karol P.; Varsos, Georgios V.; Nasr, Nathalie; Brady, Ken M.; Reinhard, Matthias; Hutchinson, Peter J.; Smielewski, Peter			Comparison of frequency and time domain methods of assessment of cerebral autoregulation in traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral autoregulation index; mean flow index; transcranial doppler; transfer function analysis	TRANSCRANIAL DOPPLER ULTRASOUND; BLOOD-PRESSURE FLUCTUATIONS; HEAD-INJURY; DYNAMIC AUTOREGULATION; FLOW VELOCITY; INTRACRANIAL-PRESSURE; HUMANS; ARTERIAL; OSCILLATIONS; REACTIVITY	The impulse response (IR)-based autoregulation index (ARI) allows for continuous monitoring of cerebral autoregulation using spontaneous fluctuations of arterial blood pressure (ABP) and cerebral flow velocity (FV). We compared three methods of autoregulation assessment in 288 traumatic brain injury (TB!) patients managed in the Neurocritical Care Unit: (1) IR-based ARI; (2) transfer function (TF) phase, gain, and coherence; and (3) mean flow index (Mx). Autoregulation index was calculated using the TF estimation (Welch method) and classified according to the original Tiecks' model. Mx was calculated as a correlation coefficient between 10-second averages of ABP and FV using a moving 300-second data window. Transfer function phase, gain, and coherence were extracted in the very low frequency (VLF, 0 to 0.05 Hz) and low frequency (LF, 0.05 to 0.15 Hz) bandwidths. We studied the relationship between these parameters and also compared them with patients' Glasgow outcome score. The calculations were performed using both cerebral perfusion pressure (CPP; suffix 'c') as input and ABP (suffix 'a'). The result showed a significant relationship between ARI and Mx when using either ABP (r=-0.38, P < 0.001) or CPP (r=-0.404, P < 0.001) as input. Transfer function phase and coherence_a were significantly correlated with ARI_a and ARI_c (P < 0.05). Only ARI_a, ARI_c, Mx_a, Mx_c, and phase_c were significantly correlated with patients' outcome, with Mx_c showing the strongest association.	[Liu, Xiuyun; Czosnyka, Marek; Donnelly, Joseph; Budohoski, Karol P.; Varsos, Georgios V.; Nasr, Nathalie; Hutchinson, Peter J.; Smielewski, Peter] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Nasr, Nathalie] Univ Toulouse 3, Hop Rangueil, INSERM U1048, Serv Neurol Vasc,Team 11,Toulouse I2MC, F-31062 Toulouse, France; [Brady, Ken M.] Texas Childrens Hosp, Baylor Coll Med, Houston, TX 77030 USA; [Reinhard, Matthias] Univ Freiburg, Univ Hosp, Dept Neurol, Freiburg, Germany	Liu, XY (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Hills Rd, Cambridge CB2 0QQ, England.	xl334@cam.ac.uk	Donnelly, Joseph/N-6803-2019; NASR, NATHALIE/K-3521-2019; Donnelly, Joseph/E-9235-2018; Liu, Xiuyun/V-4427-2017	Donnelly, Joseph/0000-0002-6502-8069; Donnelly, Joseph/0000-0002-6502-8069; Liu, Xiuyun/0000-0001-9540-4865; Hutchinson, Peter/0000-0002-2796-1835; Smielewski, Peter/0000-0001-5096-3938; Nasr, Nathalie/0000-0003-1660-8718	National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013] Funding Source: researchfish; Department of HealthEuropean Commission [NIHR-RP-R3-12-013] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0601025] Funding Source: Medline		AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; Bendat J.S., 2010, RANDOM DATA ANAL MEA; Blaber AP, 1997, STROKE, V28, P1686, DOI 10.1161/01.STR.28.9.1686; Budohoski KP, 2013, J CEREBR BLOOD F MET, V33, P449, DOI 10.1038/jcbfm.2012.189; Czosnyka M, 2003, ACT NEUR S, V86, P581; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 2008, ANESTH ANALG, V106, P234, DOI 10.1213/01.ane.0000295802.89962.13; DEBOER RW, 1985, MED BIOL ENG COMPUT, V23, P352, DOI 10.1007/BF02441589; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; Fujii M, 2013, TRANSL STROKE RES, V4, P432, DOI 10.1007/s12975-013-0257-2; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; GILLER CA, 1990, NEUROSURGERY, V27, P362, DOI 10.1227/00006123-199009000-00004; Johnson U, 2011, NEUROSURGERY, V68, P714, DOI 10.1227/NEU.0b013e3182077313; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lemaire JJ, 2002, ACTA NEUROCHIR, V144, P243, DOI 10.1007/s007010200032; Lewis PM, 2007, ACTA NEUROCHIR, V149, P549, DOI 10.1007/s00701-007-1160-y; LINDEGAARD KF, 1987, STROKE, V18, P1025, DOI 10.1161/01.STR.18.6.1025; Mahony PJ, 2000, STROKE, V31, P476, DOI 10.1161/01.STR.31.2.476; Mayer S, 1876, KAIS AKAD WISS SITZ, V74, P281; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Panerai RB, 1998, MED BIOL ENG COMPUT, V36, P315, DOI 10.1007/BF02522477; Panerai RB, 1998, STROKE, V29, P2341, DOI 10.1161/01.STR.29.11.2341; Reinhard M, 2003, STROKE, V34, P2138, DOI 10.1161/01.STR.0000087788.65566.AC; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	37	33	33	0	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2015	35	2					248	256		10.1038/jcbfm.2014.192			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CA2QS	WOS:000348753100012	25407266	Green Published, Bronze, Green Accepted			2021-06-18	
J	Sheriff, FG; Hinson, HE				Sheriff, Faheem G.; Hinson, Holly E.			Pathophysiology and Clinical Management of Moderate and Severe Traumatic Brain Injury in the ICU	SEMINARS IN NEUROLOGY			English	Article						severe traumatic brain injury; pathophysiology; multimodality monitoring; intensive care unit	CEREBRAL PERFUSION-PRESSURE; PAROXYSMAL SYMPATHETIC HYPERACTIVITY; WHITE-MATTER INJURY; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; TISSUE OXYGEN; DECOMPRESSIVE CRANIECTOMY; THERAPEUTIC HYPOTHERMIA; RISK-FACTORS; 4 SCORE	Moderate and severe traumatic brain injury (TBI) is the leading cause of morbidity and mortality among young individuals in high-income countries. Its pathophysiology is divided into two major phases: the initial neuronal injury (or primary injury) followed by secondary insults (secondary injury). Multimodality monitoring now offers neurointensivists the ability to monitor multiple physiologic parameters that act as surrogates of brain ischemia and hypoxia, the major driving forces behind secondary brain injury. The heterogeneity of the pathophysiology of TBI makes it necessary to take into consideration these interacting physiologic factors when recommending for or against any therapies; it may also account for the failure of all the neuroprotective therapies studied so far. In this review, the authors focus on neuroclinicians and neurointensivists, and discuss the developments in therapeutic strategies aimed at optimizing intracranial pressure and cerebral perfusion pressure, and minimizing cerebral hypoxia. The management of moderate to severe TBI in the intensive care unit is moving away from a pure "threshold-based" treatment approach toward consideration of patient-specific characteristics, including the state of cerebral autoregulation. The authors also include a concise discussion on the management of medical and neurologic complications peculiar to TBI as well as an overview of prognostication.	[Sheriff, Faheem G.; Hinson, Holly E.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR USA; [Hinson, Holly E.] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR USA	Hinson, HE (corresponding author), 3181 SW Sam Jackson Pk Rd,CR-127, Portland, OR 97239 USA.	hinson@ohsu.edu	Hinson, Holly/Q-2268-2019; Sheriff, Faheem/ABH-2434-2020	Hinson, Holly/0000-0003-1598-9782; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12HL108974] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K12 HL108974] Funding Source: Medline		Adamides AA, 2009, J AM COLL SURGEONS, V209, P531, DOI 10.1016/j.jamcollsurg.2009.05.028; Alyagari V, 2007, J NEUROL SCI, V261, P39, DOI 10.1016/j.jns.2007.04.030; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Baguley IJ, 2007, BRAIN INJURY, V21, P1175, DOI 10.1080/02699050701687375; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Baguley IJ, 2009, ARCH PHYS MED REHAB, V90, P580, DOI 10.1016/j.apmr.2008.10.020; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; Bohman LE, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0392-x; Bouzat P, 2013, ANN FR ANESTH, V32, P787, DOI 10.1016/j.annfar.2013.09.004; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Etemadrezaie H, 2007, CLIN NEUROL NEUROSUR, V109, P166, DOI 10.1016/j.clineuro.2006.09.001; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; Frattalone AR, 2013, NEUROSURG CLIN N AM, V24, P309, DOI 10.1016/j.nec.2013.03.006; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hawthorne C, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00121; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Izzy S, 2013, NEUROCRIT CARE, V19, P347, DOI 10.1007/s12028-013-9925-z; JENNETT B, 1976, LANCET, V1, P1031; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Johnston AJ, 2004, INTENS CARE MED, V30, P791, DOI 10.1007/s00134-003-2155-7; Kirmani BF, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00170; Krahulik D, 2010, J NEUROSURG, V113, P581, DOI 10.3171/2009.10.JNS09930; Le Roux P, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-012-0331-2; Li J, 2012, J NEUROTRAUM, V29, P96, DOI 10.1089/neu.2011.1753; Ling Geoffrey S F, 2010, Continuum (Minneap Minn), V16, P27, DOI 10.1212/01.CON.0000391451.30299.bc; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; Lv LQ, 2011, J TRAUMA, V71, P538, DOI 10.1097/TA.0b013e31820ebee1; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, NEUROSURGERY, P1173; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Mangat Halinder S, 2012, Continuum (Minneap Minn), V18, P532, DOI 10.1212/01.CON.0000415426.76524.e1; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; Mascia L, 2007, CRIT CARE MED, V35, P1815, DOI 10.1097/01.CCM.0000275269.77467.DF; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nakamura A, 1995, No To Shinkei, V47, P1170; Nangunoori R, 2012, NEUROCRIT CARE, V17, P131, DOI 10.1007/s12028-011-9621-9; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; Oddo Mauro, 2009, Rev Med Suisse, V5, P2506; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Okasha AS, 2014, NEUROCRIT CARE, V21, P496, DOI 10.1007/s12028-014-9995-6; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perkes I, 2010, ANN NEUROL, V68, P126, DOI 10.1002/ana.22066; Purins K, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00064; Ronne-Engstrom E, 2006, ACTA NEUROL SCAND, V114, P47, DOI 10.1111/j.1600-0404.2006.00652.x; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sadaka F, 2012, BRAIN INJURY, V26, P899, DOI 10.3109/02699052.2012.661120; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salim A, 2009, AM SURGEON, V75, P25; Santarsieri M, 2014, BRAIN BEHAV IMMUN; Shahlaie K, 2011, J NEUROSURG, V115, P602, DOI 10.3171/2011.5.JNS101667; Shahlaie K, 2009, NEUROCRIT CARE, V10, P61, DOI 10.1007/s12028-008-9138-z; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2014, ACTA NEUROCHIR, V156, P1615, DOI 10.1007/s00701-014-2127-4; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wijdicks EFM, 2011, NEUROLOGY, V77, P84, DOI 10.1212/WNL.0b013e318220ac06	77	33	36	1	11	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	FEB	2015	35	1					42	49		10.1055/s-0035-1544238			8	Clinical Neurology	Neurosciences & Neurology	CC4AP	WOS:000350293300007	25714866	Green Accepted			2021-06-18	
J	Catroppa, C; Crossley, L; Hearps, SJC; Yeates, KO; Beauchamp, M; Rogers, K; Anderson, V				Catroppa, Cathy; Crossley, Louise; Hearps, Stephen J. C.; Yeates, Keith Owen; Beauchamp, Miriam; Rogers, Kirrily; Anderson, Vicki			Social and Behavioral Outcomes: Pre-Injury to Six Months following Childhood Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						behavioral; social; children; traumatic brain injury	FUNCTIONAL RECOVERY; CHILDREN; ADOLESCENTS; PARTICIPATION; LIFE; PREDICTORS; DISORDERS; MEDIATOR; HEALTH; SKILLS	This study aimed to extend the limited research investigating social and behavioral outcomes following childhood traumatic brain injury (TBI). The study compared pre-and post-injury measures of these skills and investigated the role of pre-injury child status and pre-injury family functioning in the prediction of outcome at six months post-injury. A secondary aim was to compare rates of impairment at six months post-injury between children post-TBI and a typically developing (TD) control group. This study comprised 140 children, 97 survivors of TBI (67 males) and 43 TD children (24 males), matched for age, sex, and socio-economic status. All participants were ascertained between 2007 and 2010, and were between ages 5.5 and 15.0 years. Children with TBI represented consecutive hospital admissions and were recruited at time of injury into a longitudinal study. TD children were recruited from the community, through local schools chosen to provide a range of socio-economic backgrounds. Findings indicated a deterioration of social participation skills post-injury, particularly for those sustaining a more severe injury, and a consistently higher rate of impairment in social and behavioral outcomes in the TBI group. Pre-injury function, injury severity and restrictions to social participation (e.g., reduced sport activities) as recommended by clinicians contributed significantly to outcome. Difficulties are evident in the short-term post-childhood TBI in social and behavioral domains. It is essential to monitor children long-term, particularly as societal expectations and demands increase.	[Catroppa, Cathy; Crossley, Louise; Hearps, Stephen J. C.; Rogers, Kirrily; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Vic, Australia; [Catroppa, Cathy; Rogers, Kirrily; Anderson, Vicki] Univ Melbourne, Melbourne, Vic, Australia; [Beauchamp, Miriam] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam] St Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwides Childrens Hosp, Res Inst, Columbus, OH USA	Catroppa, C (corresponding author), Murdoch Childrens Res Inst, 4 West,Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Hearps, Stephen/L-6853-2016; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892; Rogers, Kirrily/0000-0001-8282-537X	Victorian Neurotrauma Initiative; Victorian Government Operational Infrastructure Scheme	The Victorian Neurotrauma Initiative funded this research, and it was also supported by the Victorian Government Operational Infrastructure Scheme.	Achenbach TM, 2001, MANUAL ASEBA SCH AGE; Anaby D, 2012, DEV MED CHILD NEUROL, V54, P339, DOI 10.1111/j.1469-8749.2011.04204.x; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Bedell G, 2008, J HEAD TRAUMA REHAB, V23, P341, DOI 10.1097/01.HTR.0000336850.29574.7a; Bedell Gary M, 2002, Pediatr Rehabil, V5, P107, DOI 10.1080/1363849021000013540; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2012, J NEUROTRAUM, V29, P2539, DOI 10.1089/neu.2012.2403; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Crowe LM, 2011, CLIN PSYCHOL REV, V31, P767, DOI 10.1016/j.cpr.2011.03.008; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dooley JJ, 2010, BRAIN IMPAIR, V11, P152, DOI 10.1375/brim.11.2.152; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Galvin J, 2010, AUST OCCUP THER J, V57, P118, DOI 10.1111/j.1440-1630.2009.00822.x; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Gauvin-Lepage J, 2010, BRAIN INJURY, V24, P1087, DOI 10.3109/02699052.2010.494593; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hawley CA, 2012, NEUROREHABILITATION, V30, P173, DOI 10.3233/NRE-2012-0742; Jackson C, 2007, OCCUP MED-OXFORD, V57, P79, DOI 10.1093/occmed/kql169; Kaldoja ML, 2012, BRAIN INJURY, V26, P1005, DOI 10.3109/02699052.2012.660516; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Max JE, 2011, J NEUROPSYCH CLIN N, V23, P29, DOI 10.1176/appi.neuropsych.23.1.29; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Prigatano G.P., 2010, PED HLTH, V4, P447; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Prigatano GP, 2008, J HEAD TRAUMA REHAB, V23, P378, DOI 10.1097/01.HTR.0000341433.67251.01; Renstrom B, 2012, BRAIN INJURY, V26, P1405, DOI 10.3109/02699052.2012.694559; Roscigno CI, 2011, BRAIN INJURY, V25, P882, DOI 10.3109/02699052.2011.581638; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Sonnenberg LK, 2010, BRAIN INJURY, V24, P1003, DOI 10.3109/02699052.2010.489033; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; TEASDALE G, 1974, LANCET, V2, P81; Thompson H, 2012, J NEUROTRAUM, V29, pA189; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; UCLA: Academic Technology Services, 2012, STAT DAT AN EX TOB A; Van Tol E., BRAIN INJ, V25, P1279; Vickers AJ, 2001, BMJ-BRIT MED J, V323, P1123, DOI 10.1136/bmj.323.7321.1123; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Warschausky S, 1997, Pediatr Rehabil, V1, P77; WECHSLER D, 1990, WECHSLER ABBREVIATED; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	54	33	33	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					109	115		10.1089/neu.2013.3276			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700005	24773028				2021-06-18	
J	Majdan, M; Steyerberg, EW; Nieboer, D; Mauritz, W; Rusnak, M; Lingsma, HF				Majdan, Marek; Steyerberg, Ewout W.; Nieboer, Daan; Mauritz, Walter; Rusnak, Martin; Lingsma, Hester F.			Glasgow Coma Scale Motor Score and Pupillary Reaction To Predict Six-Month Mortality in Patients with Traumatic Brain Injury: Comparison of Field and Admission Assessment	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Coma Scale; prehospital assessment; pupillary reactivity; assessment at admission; traumatic brain injuries	HEAD-INJURY	The Glasgow Coma Scale (GCS) and pupillary reactivity are well-known prognostic factors in traumatic brain injury (TBI). The aim of this study was to compare the GCS motor score and pupillary reactivity assessed in the field and at hospital admission and assess their prognostic value for 6-month mortality in patients with moderate or severe TBI. We studied 445 patients with moderate or severe TBI from Austria enrolled to hospital in 2009-2012. The area under the curve (AUC) and Nagelkerke's R-2 were used to evaluate the predictive ability of GCS motor score and pupillary reactivity assessed in the field and at admission. Uni- and multi-variable analyses-adjusting for age, other clinical, and computed tomography findings-were performed using combinations of field and admission GCS motor score and pupillary reactivity. Motor scores generally deteriorated from the field to admission, whereas pupillary reactivity was similar. GCS motor score assessed in field (AUC=0.754; R-2=0.273) and pupillary assessment at admission (AUC=0.662; R-2=0.214) performed best as predictors of 6-month mortality in the univariate analysis. This combination also showed best performance in the adjusted analyses (AUC=0.876; R-2=0.508), but the performance of both predictors assessed at admission was not much worse (AUC=0.857; R-2=0.460). Field GCS motor score and pupillary reactivity at hospital admission, compared to other combinations of these parameters, possess the best prognostic value to predict 6-month mortality in patients with moderate-to-severe TBI. Given that differences in prognostic performance are only small, both the field and admission values of GCS motor score and pupillary reaction may be reasonable to use in multi-variable prediction models to predict 6-month outcome.	[Majdan, Marek; Rusnak, Martin] Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Trnava 91701, Slovakia; [Majdan, Marek; Mauritz, Walter; Rusnak, Martin] INRO, Vienna, Austria; [Steyerberg, Ewout W.; Nieboer, Daan; Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands	Majdan, M (corresponding author), Trnava Univ, Fac Hlth Sci & Social Work, Dept Publ Hlth, Univ Namestie 1, Trnava 91701, Slovakia.	mmajdan@igeh.org	Majdan, Marek/K-5017-2012; Rusnak, Martin/K-9349-2016	Majdan, Marek/0000-0001-8037-742X; Rusnak, Martin/0000-0003-3321-1042	Austrian Ministry of Health; Austrian Worker's Compensation Board (AUVA) [FK 11/2008, FK 11/2010]; AUVA [FK 09/13]; European UnionEuropean Commission [602150]	The project was funded jointly by the Austrian Ministry of Health (Contract: October 15, 2008) and by the Austrian Worker's Compensation Board (AUVA; FK 11/2008 and FK 11/2010). Data analysis was supported by a grant from AUVA (FK 09/13). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham and by small donations from various sources. The preparation of this article was partly done within the CENTER-TBI project that has received funding from the European Union Seventh Framework Programme (FP7/2007-2013) under grant agreement 602150.	Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hoffmann M, 2012, BRIT J SURG, V99, P122, DOI 10.1002/bjs.7707; Kerby JD, 2007, J TRAUMA, V63, P1026, DOI 10.1097/TA.0b013e318157d9e8; Kung WM, 2011, INJURY, V42, P940, DOI 10.1016/j.injury.2010.09.019; Majidi S, 2013, AM J EMERG MED, V31, P1215, DOI 10.1016/j.ajem.2013.05.026; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Mauritz W, 2009, EUR J EMERG MED, V16, P153, DOI 10.1097/MEJ.0b013e32832a0864; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81	20	33	34	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2015	32	2					101	108		10.1089/neu.2014.3438			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AY6QM	WOS:000347690700004	25227136	Green Published			2021-06-18	
J	Burke, MJ; Fralick, M; Nejatbakhsh, N; Tartaglia, MC; Tator, CH				Burke, Matthew J.; Fralick, Michael; Nejatbakhsh, Nasrin; Tartaglia, Maria C.; Tator, Charles H.			In search of evidence-based treatment for concussion: characteristics of current clinical trials	BRAIN INJURY			English	Article						Brain concussion; brain injuries; clinical trials; post-concussion syndrome; therapeutics	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; US SOLDIERS; STATEMENT; CLINICALTRIALS.GOV; MANAGEMENT; BIOMARKERS; CONSENSUS; QUALITY; REST	Objective: To assess the characteristics of current clinical trials investigating the treatment of concussion. Background: Recent systematic literature reviews have concluded that there is minimal evidence to support any specific treatment for concussion, including the principles of return-to-activity protocols such as type or duration of rest. Design/methods: Clinical trial data was extracted from Clinicaltrials.gov and seven additional World Health Organization primary registries. The trial databases were accessed up until 3 October 2013. This study used search terms of 'concussion' or 'mild traumatic brain injury' (mTBI) and filtered for interventional trials. Trials that were terminated, already published or not interventional trials of concussion/mTBI were excluded. Results: Of the 142 concussion/mTBI interventional clinical trials identified, 71 met inclusion criteria. Trials had a median estimated enrolment of 60 participants. There was a wide-range of treatments studied, including cognitive/behavioural therapies (28.2%), medications (28.2%), devices (11.3%), dietary supplements (8.5%), return-to-activity/rest (1.4%) and others (22.4%). Heterogeneity among trials for concussion identification/diagnosis and primary outcomes utilized was evident. Symptom-based questionnaires (39.4%) and neuropsychological tests (28.2%) were the most common outcome measures. Conclusions: Diverse, potentially promising therapeutics are currently being studied for the treatment of concussion. However, several deficiencies were identified including a paucity of trials addressing return-to-activity principles. Also, small sample size and trial heterogeneity may threaten scientific evaluation and subsequent clinical application.	[Burke, Matthew J.] Univ Toronto, Div Neurol, Toronto, ON M5T 2S8, Canada; [Fralick, Michael; Nejatbakhsh, Nasrin] Univ Toronto, Toronto, ON M5T 2S8, Canada; [Tartaglia, Maria C.; Tator, Charles H.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; [Tator, Charles H.] Univ Toronto, Div Neurosurg, Toronto, ON M5T 2S8, Canada	Tator, CH (corresponding author), Univ Toronto, 399 Bathurst St,Room 4W-422, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.ca					Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Belanger HG, 2011, CLIN NEUROPSYCHOL, V25, P702, DOI 10.1080/13854046.2011.566892; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Califf RM, 2012, JAMA-J AM MED ASSOC, V307, P1838, DOI 10.1001/jama.2012.3424; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; De Angelis C, 2004, NEW ENGL J MED, V351, P1250, DOI 10.1056/NEJMe048225; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dickersin K, 2012, JAMA-J AM MED ASSOC, V307, P1861, DOI 10.1001/jama.2012.4230; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; National Institute of Health, NAT I NEUR DIS STROK; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; Petraglia Anthony L, 2011, Surg Neurol Int, V2, P146, DOI 10.4103/2152-7806.85987; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Tator CH, 2013, CAN MED ASSOC J, V185, P975, DOI 10.1503/cmaj.120039; Tator CH, 2009, CAN J NEUROL SCI, V36, P405, DOI 10.1017/S031716710000771X; Todd Jamie L, 2013, Ann Am Thorac Soc, V10, P411, DOI 10.1513/AnnalsATS.201305-111OC; World Health Organization, INT STAND CLIN TRIAL; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; Zarin DA, 2005, NEW ENGL J MED, V353, P2779, DOI 10.1056/NEJMsa053234; Zarin DA, 2011, NEW ENGL J MED, V364, P852, DOI 10.1056/NEJMsa1012065; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	34	33	33	0	21	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2015	29	3					300	305		10.3109/02699052.2014.974673			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CB0HQ	WOS:000349307000003	25383510	Green Published			2021-06-18	
J	Lucas, K; Morris, G; Anderson, G; Maes, M				Lucas, Kurt; Morris, Gerwyn; Anderson, George; Maes, Michael			The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Antioxidants; chronic fatigue syndrome; depression; inflammation; myalgic encephalomyelitis; oxidative and nitrosative stress; lipopolysaccharides; toll-like receptor	INFLAMMATORY-BOWEL-DISEASE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TRAUMATIC BRAIN-INJURY; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; FACTOR-KAPPA-B; INCREASED INTESTINAL PERMEABILITY; STRESS-INDUCED NEUROINFLAMMATION; COGNITIVE-BEHAVIORAL THERAPY; POLYUNSATURATED FATTY-ACIDS	In this review we discuss that peripheral and central activation of the Toll-like receptor 2/4 (TLR2/4) Radical Cycle may underpin the pathophysiology of immune-related chronic fatigue secondary to other medical diseases and conditions. The TLR Radical Cycle plays a role in illnesses and conditions that are disproportionately commonly comorbid with secondary chronic fatigue, including a) neuroinflammatory disorders, e.g. Parkinson's disease, stroke, depression, psychological stressors, and b) systemic disorders, e.g. (auto) immune disorders, chronic obstructive pulmonary disease, ankylosing spondylitis, chronic kidney disease, inflammatory bowel disease, cardiovascular disease, incl. myocardial infarction, cancer and its treatments. Increased TLR signaling is driven by activated immune-inflammatory and oxidative and nitrosative stress pathways, pathogen derived molecular patterns, including lipopolysaccharides, and damage associated molecular patterns (DAMPs). Newly formed redox-derived DAMPs, secondary to oxidative processes, may further activate the TLR complex leading to an auto-amplifying TLR Radical feedback loop. Increased gut permeability with translocation of gram negative bacteria and LPS, which activates the TLR Radical Cycle, is another pathway that may play a role in most of the abovementioned diseases and the secondary fatigue accompanying them. It is concluded that secondary fatigue may be associated with activation of the TLR Radical Cycle pathway due to activated immune-inflammatory pathways, classical and redox-derived DAMPs and PAMPs plays a role in its pathophysiology. Such an activation of the TLR Radical Cycle pathway may also explain why the abovementioned conditions are primed for an increased expression of secondary chronic fatigue. Targeting the TLR Radical Cycle pathway may be an effective method to treat TLR-Radical Cycle-related diseases such as secondary chronic fatigue.	[Lucas, Kurt] Max Planck Inst Chem, Multiphase Chem Dept, D-55128 Mainz, Germany; [Morris, Gerwyn] Tir Na Nog, Pembrey, Llanelli, Wales; [Anderson, George] CRC, Glasgow G11, Lanark, Scotland; [Maes, Michael] Deakin Univ, Dept Psychiat, Geelong, Vic 3217, Australia; [Maes, Michael] Chulalongkorn Univ, Dept Psychiat, Bangkok, Thailand; [Maes, Michael] Univ Estadual Londrina, Dept Psychiat, Londrina, Brazil	Maes, M (corresponding author), Deakin Univ, Dept Psychiat, Geelong, Vic 3217, Australia.	dr.michaelmaes@hotmail.com	Maes, Michael/B-8546-2011	Maes, Michael/0000-0002-2012-871X; Anderson, George/0000-0001-7243-0817			Abreu MT, 2010, GASTROENTEROLOGY, V138, P39, DOI 10.1053/j.gastro.2009.11.031; Achitei D, 2013, DIGEST DIS SCI, V58, P1244, DOI 10.1007/s10620-012-2510-z; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; ALEXANDROVSKY YA, 1988, ZH NEVROPATOL PSIKH, V88, P95; Alkan BM, 2013, MOD RHEUMATOL, V23, P1101, DOI [10.3109/s10165-012-0800-0, 10.1007/s10165-012-0800-0]; Alkhawajah MM, 2013, MULT SCLER J, V19, P259, DOI 10.1177/1352458512461393; Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x; Almenier Hazem A, 2012, Front Biosci (Elite Ed), V4, P1335; Alsen P, 2013, J CLIN NURS, V22, P1647, DOI 10.1111/jocn.12114; Anders HJ, 2013, KIDNEY INT, V83, P1010, DOI 10.1038/ki.2012.440; Anderson G, 2014, CURR PHARM DESIGN, V20, P3812, DOI 10.2174/13816128113196660738; Andersson A, 2008, J LEUKOCYTE BIOL, V84, P1248, DOI 10.1189/jlb.1207844; [Anonymous], 2013, OXIDATIVE NITRATIVE; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arrieta MC, 2006, GUT, V55, DOI 10.1136/gut.2005.085373; Aryan Z, 2014, INT ARCH ALLERGY IMM, V164, P46, DOI 10.1159/000362553; Assassi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026061; Assassi S, 2011, J RHEUMATOL, V38, P87, DOI 10.3899/jrheum.100469; Bailey MT, 2007, AM J PHYSIOL-REG I, V293, pR1180, DOI 10.1152/ajpregu.00307.2007; Baltzan MA, 2011, CHRON RESP DIS, V8, P119, DOI 10.1177/1479972310396737; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Barton SH, 2008, GASTROENTEROL CLIN N, V37, P411, DOI 10.1016/j.gtc.2008.02.001; Belforte FS, 2013, MOL BIOL REP, V40, P3015, DOI 10.1007/s11033-012-2374-5; Bellm LA, 2000, SUPPORT CARE CANCER, V8, P33; Bezemer GFG, 2012, PHARMACOL REV, V64, P337, DOI 10.1124/pr.111.004622; Bhattacharyya S, 2007, BLOOD, V109, P4313, DOI 10.1182/blood-2006-10-048215; Blair IA, 2001, EXP GERONTOL, V36, P1473, DOI 10.1016/S0531-5565(01)00133-4; Bombardieri M, 2012, CURR PHARM BIOTECHNO, V13, P1989, DOI 10.2174/138920112802273209; Bonner A, 2013, NURS HEALTH SCI, V15, P360, DOI 10.1111/nhs.12038; Bonomini F, 2008, HISTOL HISTOPATHOL, V23, P381, DOI 10.14670/HH-23.381; Bossola M, 2011, SEMIN DIALYSIS, V24, P550, DOI 10.1111/j.1525-139X.2011.00956.x; Brentano Fabia, 2009, V517, P329, DOI 10.1007/978-1-59745-541-1_20; Brophy S, 2013, SEMIN ARTHRITIS RHEU, V42, P361, DOI 10.1016/j.semarthrit.2012.06.002; BRUENNER BA, 1995, CHEM RES TOXICOL, V8, P552, DOI 10.1021/tx00046a009; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Budulac SE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043124; Cario E, 2010, INFLAMM BOWEL DIS, V16, P1583, DOI 10.1002/ibd.21282; Carta S, 2009, J LEUKOCYTE BIOL, V86, P549, DOI 10.1189/jlb.1008598; Caso JR, 2008, STROKE, V39, P1314, DOI 10.1161/STROKEAHA.107.498212; Caso JR, 2009, AM J PHYSIOL-REG I, V296, pR979, DOI 10.1152/ajpregu.90825.2008; Cervantes JL, 2011, P NATL ACAD SCI USA, V108, P3683, DOI 10.1073/pnas.1013776108; Chandankhede M, 2013, INT J BIOL MED RES, V4, P3088; Chang YL, 2014, J CELL MOL MED, V18, P1344, DOI 10.1111/jcmm.12294; Charalambous BM, 2007, SHOCK, V28, P15, DOI 10.1097/shk.0b013e318033ebc5; Chen YY, 2013, LIFE SCI, V92, P582, DOI 10.1016/j.lfs.2013.01.021; Chen Y, 2007, MOL INTERV, V7, P147, DOI 10.1124/mi.7.3.6; Choi AJS, 2014, MOL CELLS, V37, P441, DOI 10.14348/molcells.2014.0104; Chong ZZ, 2004, ANTIOXID REDOX SIGN, V6, P277, DOI 10.1089/152308604322899341; Christia P, 2013, EUR J CLIN INVEST, V43, P986, DOI 10.1111/eci.12118; Compton T, 2003, J VIROL, V77, P4588, DOI 10.1128/JVI.77.8.4588-4596.2003; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Crane PB, 2005, HEART LUNG, V34, P30, DOI 10.1016/j.hrtlng.2004.08.007; Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200; Davies H, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-163; de Zoete MR, 2010, INFECT IMMUN, V78, P1229, DOI 10.1128/IAI.00897-09; Dhaouadi T, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-20; di Penta A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054722; Dianzani MU, 1999, ACTA BIOCHIM POL, V46, P61, DOI 10.18388/abp.1999_4184; Ding HS, 2013, GENE, V527, P389, DOI 10.1016/j.gene.2013.05.041; Downes CE, 2010, BRIT J PHARMACOL, V160, P1872, DOI 10.1111/j.1476-5381.2010.00864.x; Drexler SK, 2010, INT J BIOCHEM CELL B, V42, P506, DOI 10.1016/j.biocel.2009.10.009; Drouin-Ouellet J, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyu103; Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953; Elsenberg EHAM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060467; Emin O, 2014, ALLERGOL IMMUNOPATHO; Fagundes-Netto FS, 2013, INT IMMUNOPHARMACOL, V17, P924, DOI 10.1016/j.intimp.2013.09.018; Fairweather D, 2003, J IMMUNOL, V170, P4731, DOI 10.4049/jimmunol.170.9.4731; Famakin BM, 2014, J CEREBR BLOOD F MET, V34, P258, DOI 10.1038/jcbfm.2013.182; Farooqui T, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/247467; FAZIO VM, 1993, MOL ASPECTS MED, V14, P217, DOI 10.1016/0098-2997(93)90008-2; Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192; Fellner L, 2013, GLIA, V61, P349, DOI 10.1002/glia.22437; Ferrari CC, 2011, PARKINSONS DIS-US, V2011, DOI 10.4061/2011/436813; Ferrari R, 2005, ANN RHEUM DIS, V64, P1337, DOI 10.1136/ard.2004.034447; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; Forsyth CB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028032; Fortin JD, 2002, WHIPLASH, P249, DOI 10.1016/B978-1-56053-438-9.50020-5; Francescato MP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099062; Francois A, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/123241; Frangogiannis NG, 2014, J CARDIOVASC PHARM, V63, P185, DOI 10.1097/FJC.0000000000000003; Frantz S, 2001, J BIOL CHEM, V276, P5197, DOI 10.1074/jbc.M009160200; Frazer LC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030747; Freitas F, 2014, INT J ENV RES PUB HE, V11, P9024, DOI 10.3390/ijerph110909024; Fresko I, 2001, ANN RHEUM DIS, V60, P65, DOI 10.1136/ard.60.1.65; Friedman JH, 2011, EXPERT OPIN PHARMACO, V12, P1999, DOI 10.1517/14656566.2011.587120; Friis LM, 2009, INFECT IMMUN, V77, P1553, DOI 10.1128/IAI.00707-08; Frisancho-Kiss S, 2007, J IMMUNOL, V178, P6710, DOI 10.4049/jimmunol.178.11.6710; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Furrie E, 2005, IMMUNOLOGY, V115, P565, DOI 10.1111/j.1365-2567.2005.02200.x; Gambuzza ME, 2014, CNS NEUROL DISORD-DR, V13, P1542, DOI 10.2174/1871527313666140806124850; Gamondi Claudia, 2013, Swiss Med Wkly, V143, pw13750, DOI 10.4414/smw.2013.13750; Gao HM, 2011, J NEUROSCI, V31, P1081, DOI 10.1523/JNEUROSCI.3732-10.2011; Garate I, 2013, BIOL PSYCHIAT, V73, P32, DOI 10.1016/j.biopsych.2012.07.005; Garcia-Bonilla L, 2012, NAT MED, V18, P858, DOI 10.1038/nm.2797; Garcia-Bueno B, 2008, ENDOCRINOLOGY, V149, P1969, DOI 10.1210/en.2007-0482; Garip Y, 2011, ACTA REUMATOL PORT, V36, P364; Gazewood JD, 2013, AM FAM PHYSICIAN, V87, P267; Gebhardt C, 2006, BIOCHEM PHARMACOL, V72, P1622, DOI 10.1016/j.bcp.2006.05.017; GEFFARD M, 1993, BRAIN RES BULL, V30, P365, DOI 10.1016/0361-9230(93)90266-E; Gerdle B, 2008, EUR J PAIN, V12, P82, DOI 10.1016/j.ejpain.2007.03.009; Gill R, 2010, FREE RADICAL BIO MED, V48, P1121, DOI 10.1016/j.freeradbiomed.2010.01.006; Gironi M, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/961863; Goehler LE, 2007, BRAIN BEHAV IMMUN, V21, P721, DOI 10.1016/j.bbi.2007.02.005; Goh FG, 2012, RHEUMATOLOGY, V51, P7, DOI 10.1093/rheumatology/ker257; Golovkin AS, 2014, GENE, V550, P101, DOI 10.1016/j.gene.2014.08.022; Gooshe M, 2014, REV NEUROSCIENCE, V25, P713, DOI 10.1515/revneuro-2014-0026; Graff LA, 2011, INFLAMM BOWEL DIS, V17, P1882, DOI 10.1002/ibd.21580; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; Gupta A, 2010, INDIAN J BIOCHEM BIO, V47, P96; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Haldorsen K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3487; Hambali Z, 2011, Indian J Nephrol, V21, P21, DOI 10.4103/0971-4065.75218; Harrington CB, 2010, INT J PSYCHIAT MED, V40, P163, DOI 10.2190/PM.40.2.c; Harris HE, 2004, EUR J IMMUNOL, V34, P1503, DOI 10.1002/eji.200424916; Hartmann A, 1997, NEUROBIOL AGING, V18, P285, DOI 10.1016/S0197-4580(97)80309-0; He WG, 2007, MOL IMMUNOL, V44, P2850, DOI 10.1016/j.molimm.2007.01.022; Helfman DM, 2005, BRIT J CANCER, V92, P1955, DOI 10.1038/sj.bjc.6602613; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hickie IB, 2000, J CLIN PSYCHIAT, V61, P643, DOI 10.4088/JCP.v61n0909; Hilgart AA, 2008, J NEUROCHEM, V104, P123; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Honstettre A, 2004, J IMMUNOL, V172, P3695, DOI 10.4049/jimmunol.172.6.3695; Horigan Ann, 2012, Medsurg Nurs, V21, P158; Horneber M, 2012, DTSCH ARZTEBL INT, V109, P161, DOI 10.3238/arztebl.2012.0161; Hsu GJ, 2011, CHINESE J PHYSIOL, V54, P367, DOI 10.4077/CJP.2011.AMM060; Hua F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-42; Huang Qi-Quan, 2009, Curr Rheumatol Rep, V11, P357; Inoue H, 2014, CELL DEATH DIFFER, V21, P39, DOI 10.1038/cdd.2013.84; INOUE S, 1995, FEBS LETT, V371, P86, DOI 10.1016/0014-5793(95)00873-8; Irie M, 2001, INT ARCH OCC ENV HEA, V74, P153, DOI 10.1007/s004200000209; Ishii T, 2006, CHEM RES TOXICOL, V19, P122, DOI 10.1021/tx050231p; Iwakiri D, 2009, J EXP MED, V206, P2091, DOI 10.1084/jem.20081761; Jelsness-Jorgensen LP, 2011, INFLAMM BOWEL DIS, V17, P1564, DOI 10.1002/ibd.21530; JENKINS RT, 1987, BRIT J RHEUMATOL, V26, P103; Jhamb M, 2011, AM J NEPHROL, V33, P515, DOI 10.1159/000328004; Jimenez-Jimenez FJ, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00369; Jounai N, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2012.00168; Kamat PK, 2014, MOL NEUROBIOL; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; Karatas F, 2003, INDIAN J MED RES, V118, P178; Kasapovic J, 2010, CLIN BIOCHEM, V43, P1287, DOI 10.1016/j.clinbiochem.2010.08.009; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; KEELING DM, 1993, BLOOD REV, V7, P199, DOI 10.1016/0268-960X(93)90006-P; Keri S, 2014, BRAIN BEHAV IMMUN, V40, P235, DOI 10.1016/j.bbi.2014.03.020; Kim C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2534; Kim K, 2013, CLIN NUTR, V32, P855, DOI 10.1016/j.clnu.2012.11.026; Kim WU, 2009, AUTOIMMUN REV, V8, P204, DOI 10.1016/j.autrev.2008.07.046; Kishida KT, 2007, ANTIOXID REDOX SIGN, V9, P233, DOI 10.1089/ars.2007.9.233; Kivioja J, 2001, J CLIN IMMUNOL, V21, P272, DOI 10.1023/A:1010931309088; Kivioja J, 2001, CLIN IMMUNOL, V101, P106, DOI 10.1006/clim.2001.5086; Klein GL, 2013, CURR OPIN SUPPORT PA, V7, P361, DOI 10.1097/SPC.0000000000000017; Klune JR, 2008, MOL MED, V14, P476, DOI 10.2119/2008-00034.Klune; Ko EA, 2012, J IMMUNOL, V188; Koc M, 2011, NEPHROL DIAL TRANSPL, V26, P955, DOI 10.1093/ndt/gfq500; Kong Y, 2011, INT IMMUNOPHARMACOL, V11, P1407, DOI 10.1016/j.intimp.2011.04.025; Konttinen YT, 2012, J AUTOIMMUN, V39, P49, DOI 10.1016/j.jaut.2012.01.004; Kozaci LD, 2010, MOD RHEUMATOL, V20, P34, DOI 10.1007/s10165-009-0230-9; Kraan TCTMV, 2014, J MOL CELL CARDIOL, V67, P94, DOI 10.1016/j.yjmcc.2013.12.021; Krysko O, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.156; Kumagai T, 2000, BIOCHEM BIOPH RES CO, V273, P437, DOI 10.1006/bbrc.2000.2967; Kuroki Y, 2007, INT J MOL MED, V19, P783; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee JY, 2003, J BIOL CHEM, V278, P37041, DOI 10.1074/jbc.M305213200; Lemire P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113940; Lepenies J, 2011, NEPHRON CLIN PRACT, V119, pC97, DOI 10.1159/000324765; Letchmi S, 2011, NURS HEALTH SCI, V13, P60, DOI 10.1111/j.1442-2018.2011.00579.x; Lewthwaite J, 2002, CIRCULATION, V106, P196, DOI 10.1161/01.CIR.0000021121.26290.2C; Lin JL, 2010, COPD, V7, P291, DOI 10.3109/15412555.2010.496818; Lindersson EK, 2004, NEUROREPORT, V15, P2735; Lindqvist D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047387; Lobo JC, 2013, RENAL FAILURE, V35, P361, DOI 10.3109/0886022X.2013.764274; Lorenzen JM, 2011, NEPHROL DIAL TRANSPL, V26, P1421, DOI 10.1093/ndt/gfq758; Low HZ, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3318; Lu C, 2014, BBA-MOL BASIS DIS, V1842, P22, DOI 10.1016/j.bbadis.2013.10.006; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Lucas K, 2013, MOL NEUROBIOL, V48, P190, DOI 10.1007/s12035-013-8425-7; Lyte M, 2006, PHYSIOL BEHAV, V89, P350, DOI 10.1016/j.physbeh.2006.06.019; Maes M, 2005, NEUROENDOCRINOL LETT, V26, P745; Maes M, 1998, PSYCHIAT RES, V77, P63, DOI 10.1016/S0165-1781(97)00131-5; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P313; Maes M, 2007, NEUROENDOCRINOL LETT, V28, P861; Maes M, 2007, J AFFECT DISORDERS, V99, P237, DOI 10.1016/j.jad.2006.08.021; Maes Michael, 2013, Expert Opin Med Diagn, V7, P221, DOI 10.1517/17530059.2013.776039; Maes M, 2012, PSYCHIAT RES, V200, P754, DOI 10.1016/j.psychres.2012.03.031; Maes M, 2012, J AFFECT DISORDERS, V136, P933, DOI 10.1016/j.jad.2011.09.004; Maes M, 2012, J AFFECT DISORDERS, V136, P909, DOI 10.1016/j.jad.2011.09.010; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P784, DOI 10.1016/j.pnpbp.2010.06.023; Maes M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-35; Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P676, DOI 10.1016/j.pnpbp.2010.05.004; Maes M, 2009, NEUROENDOCRINOL LETT, V30, P677; Maghraby A, 2012, RADIAT ENVIRON BIOPH, V51, P255, DOI 10.1007/s00411-012-0415-z; Malathi M, 2011, J CLIN DIAGN RES, V5, P249; MANDEL S, 1989, POSTGRAD MED, V85, P213; Mao H, 1999, P NATL ACAD SCI USA, V96, P6615, DOI 10.1073/pnas.96.12.6615; Martin HJ, 2007, J VIROL, V81, P9748, DOI 10.1128/JVI.01122-07; MARTINEZGONZALEZ O, 1994, BRIT J RHEUMATOL, V33, P644; Masi AT, 2011, ARTHRITIS, DOI 10.1155/2011/205904; Mavragani CP, 2010, J AUTOIMMUN, V35, P225, DOI 10.1016/j.jaut.2010.06.012; McInnes IB, 2001, RHEUM DIS CLIN N AM, V27, P373, DOI 10.1016/S0889-857X(05)70207-6; Meena NK, 2013, J CLIN GASTROENTEROL, V47, P773, DOI 10.1097/MCG.0b013e31828a6e93; Mehmetoglu I, 2012, INT J ARTIF ORGANS, V35, P226, DOI 10.5301/ijao.5000078; Melief J, 2013, ACTA NEUROPATHOL, V126, P237, DOI 10.1007/s00401-013-1140-7; Mengshoel AM, 2010, ARTHRIT CARE RES, V62, P1272, DOI 10.1002/acr.20216; Metcalfe HJ, 2014, CLIN EXP IMMUNOL, V176, P461, DOI 10.1111/cei.12289; MICHELSON D, 1994, J CLIN ENDOCR METAB, V79, P848, DOI 10.1210/jc.79.3.848; Minderhoud IM, 2003, AM J GASTROENTEROL, V98, P1088, DOI 10.1016/S0002-9270(03)00132-1; Miura K, 2014, WORLD J GASTROENTERO, V20, P7381, DOI 10.3748/wjg.v20.i23.7381; Miwa H, 2011, INTERNAL MED, V50, P1553, DOI 10.2169/internalmedicine.50.4954; Moghaddam AE, 2011, J IMMUNOL, V187, P1626, DOI 10.4049/jimmunol.1003906; Monea A, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/917631; Morris G, 2014, CURR NEUROPHARMACOL, V12, P168, DOI 10.2174/1570159X11666131120224653; Morris G, 2013, METAB BRAIN DIS, V28, P523, DOI 10.1007/s11011-012-9324-8; Morris G, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-205; Morris G, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-64; Morris G, 2012, MED HYPOTHESES, V79, P607, DOI 10.1016/j.mehy.2012.07.034; Moss SF, 2005, NAT CLIN PRACT ONCOL, V2, P90, DOI 10.1038/ncponc0081; Mueller C, 2012, DIGEST DIS, V30, P40, DOI 10.1159/000342600; Munoz LE, 2010, AUTOIMMUN REV, V10, P38, DOI 10.1016/j.autrev.2010.08.015; Murakami Y, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-91; Murtagh FEM, 2007, ADV CHRONIC KIDNEY D, V14, P82, DOI 10.1053/j.ackd.2006.10.001; Nabavi SF, 2015, CURR MED CHEM, V22, P343; Naess H, 2012, J NEUROL SCI, V312, P138, DOI 10.1016/j.jns.2011.08.002; Nagyoszi P, 2010, NEUROCHEM INT, V57, P556, DOI 10.1016/j.neuint.2010.07.002; Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1; Nijhof SL, 2014, PSYCHONEUROENDOCRINO, V42, P199, DOI 10.1016/j.psyneuen.2014.01.017; Norris PC, 2012, P NATL ACAD SCI USA, V109, P8517, DOI 10.1073/pnas.1200189109; O'Connell CM, 2011, INFECT IMMUN, V79, P1044, DOI 10.1128/IAI.01118-10; Oliveira SR, 2012, J NEUROL SCI, V321, P49, DOI 10.1016/j.jns.2012.07.045; Ortiz GG, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/708659; Ospelt C, 2010, INT J BIOCHEM CELL B, V42, P495, DOI 10.1016/j.biocel.2009.10.010; Ozgocmen S, 2004, RHEUMATOL INT, V24, P80, DOI 10.1007/s00296-003-0335-y; Paddison JS, 2013, EUR RESPIR J, V41, P565, DOI 10.1183/09031936.00021412; Pagano G, 2013, FREE RADICAL RES, V47, P71, DOI 10.3109/10715762.2012.748904; Pandey R, 2013, J CLIN DIAGN RES, V7, P580, DOI 10.7860/JCDR/2013/4360.2832; Pantcheva P, 2014, NEURAL REGEN RES, V9, P1430, DOI 10.4103/1673-5374.139458; Papadopoulos AS, 2012, NAT REV ENDOCRINOL, V8, P22, DOI 10.1038/nrendo.2011.153; Pardini M, 2014, EUR NEUROPSYCHOPHARM, V24, P939, DOI 10.1016/j.euroneuro.2014.02.010; Pariante CM, 2008, TRENDS NEUROSCI, V31, P464, DOI 10.1016/j.tins.2008.06.006; Park JS, 2004, J BIOL CHEM, V279, P7370, DOI 10.1074/jbc.M306793200; Paul S, 2013, INFLAMM RES, V62, P681, DOI 10.1007/s00011-013-0620-5; Pertsov S S, 1995, Biull Eksp Biol Med, V120, P244; Piccinini AM, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/672395; Pouwels SD, 2014, MUCOSAL IMMUNOL, V7, P215, DOI 10.1038/mi.2013.77; Powell DJH, 2013, PSYCHONEUROENDOCRINO, V38, P2405, DOI 10.1016/j.psyneuen.2013.07.004; Prajapati B, 2014, CURR DIABETES REV, V10, P190, DOI 10.2174/1573399810666140515112609; Puri BK, 2004, INT J CLIN PRACT, V58, P297, DOI 10.1111/j.1368-5031.2004.00073.x; Rahman AH, 2006, SPRINGER SEMIN IMMUN, V28, P131, DOI 10.1007/s00281-006-0034-3; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; Reynaud J.M., 2013, ISRN VIROL, V2013, P1, DOI [10.5402/2013/834890, DOI 10.5402/2013/834890]; Richer MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004127; Rieu P, 2003, NEPHROLOGIE, V24, P329; Roberts ADL, 2010, PSYCHOL MED, V40, P515, DOI 10.1017/S0033291709990390; Roberts BJ, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-25; Rodrigo R, 2013, CLIN SCI, V124, P1, DOI 10.1042/CS20110663; Rogler G, 2014, EUR HEART J, V35, P426, DOI 10.1093/eurheartj/eht271; Rovina N, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/413735; Rutten EPA, 2014, CHEST, V145, P245, DOI 10.1378/chest.13-0584; Sabitha KE, 1999, ORAL ONCOL, V35, P273, DOI 10.1016/S1368-8375(98)00115-8; Saez-Francas N, 2013, BEHAV NEUROSCI, V127, P237, DOI 10.1037/a0031531; Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009; Salat-Foix D, 2012, CAN J NEUROL SCI, V39, P185, DOI 10.1017/S0317167100013202; Salazar JC, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000444; Salman B, 2007, ADV THER, V24, P648, DOI 10.1007/BF02848790; Sandek A, 2008, CURR OPIN CLIN NUTR, V11, P632, DOI 10.1097/MCO.0b013e32830a4c6e; Sander CS, 2003, BRIT J DERMATOL, V148, P913, DOI 10.1046/j.1365-2133.2003.05303.x; Sato Y, 2009, CANCER MICROENVIRON, V2, pS205, DOI 10.1007/s12307-009-0022-y; Sattar N, 2003, CIRCULATION, V108, P2957, DOI 10.1161/01.CIR.0000099844.31524.05; Senes M, 2007, ANN CLIN BIOCHEM, V44, P43, DOI 10.1258/000456307779596057; Shen J, 2013, MOL ASPECTS MED, V34, P39, DOI 10.1016/j.mam.2012.11.001; Shen XD, 2005, AM J TRANSPLANT, V5, P1793, DOI 10.1111/j.1600-6143.2005.00932.x; Sies H, 2014, J BIOL CHEM, V289, P8735, DOI 10.1074/jbc.R113.544635; Silverman MN, 2012, ANN NY ACAD SCI, V1261, P55, DOI 10.1111/j.1749-6632.2012.06633.x; Singh Uma, 2006, Pathophysiology, V13, P129, DOI 10.1016/j.pathophys.2006.05.002; Sivonova M, 2004, STRESS, V7, P183, DOI 10.1080/10253890400012685; Sklar AH, 1996, AM J KIDNEY DIS, V28, P732, DOI 10.1016/S0272-6386(96)90256-5; SLAGA TJ, 1978, J NATL CANCER I, V60, P425; Sloane JA, 2010, P NATL ACAD SCI USA, V107, P11555, DOI 10.1073/pnas.1006496107; SMITH MD, 1985, J RHEUMATOL, V12, P299; Sorini C, 2013, AM J CLIN EXP IMMUNO, V2, P156; Sosnovskii A. S., 1992, Byulleten' Eksperimental'noi Biologii i Meditsiny, V113, P486; Spittle MA, 2001, AM J KIDNEY DIS, V38, P1408, DOI 10.1053/ajkd.2001.29280; Srikrishna G, 2009, NEOPLASIA, V11, P615, DOI 10.1593/neo.09284; Steptoe A, 2001, CLIN SCI, V101, P185, DOI 10.1042/CS20010038; Stockley RA, 2009, CURR MED RES OPIN, V25, P1235, DOI [10.1185/03007990902868971, 10.1185/03007990902868971 ]; Strayer DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031334; Stridsman C, 2014, SCAND J CARING SCI, V28, P130, DOI 10.1111/scs.12033; Sultan SM, 1999, RHEUMATOLOGY, V38, P917, DOI 10.1093/rheumatology/38.10.917; Sun CJ, 2014, HUM IMMUNOL, V75, P1084, DOI 10.1016/j.humimm.2014.09.008; Suzuki Y, 2005, INT J MOL MED, V15, P871; Svensson MY, 1998, ORTHOPADE, V27, P820; Tascilar N, 2010, BRATISL MED J, V111, P194; Theander K, 2004, J ADV NURS, V45, P172, DOI 10.1046/j.1365-2648.2003.02878.x; Tiffin N, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-2; Trudler D, 2010, MEDIAT INFLAMM, V2010; Tsang AHK, 2009, BBA-MOL BASIS DIS, V1792, P643, DOI 10.1016/j.bbadis.2008.12.006; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Urbanska-Krawiec Dagmara, 2010, Pol Merkur Lekarski, V29, P320; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635; van Heukelom RO, 2006, EUR J NEUROL, V13, P55; van Horssen J, 2008, FREE RADICAL BIO MED, V45, P1729, DOI 10.1016/j.freeradbiomed.2008.09.023; van Langenberg DR, 2010, ALIMENT PHARM THER, V32, P131, DOI 10.1111/j.1365-2036.2010.04347.x; van Suijlekom H, 2010, PAIN PRACT, V10, P131, DOI 10.1111/j.1533-2500.2009.00356.x; van Vliet MJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000879; Vivot K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107656; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wakamatsu TH, 2013, INVEST OPHTH VIS SCI, V54, P201, DOI 10.1167/iovs.12-10325; Walsh D, 2013, CYTOKINE GROWTH F R, V24, P91, DOI 10.1016/j.cytogfr.2012.09.003; Wang FQ, 2012, NEPHROLOGY, V17, P733, DOI 10.1111/j.1440-1797.2012.01647.x; Wang GD, 2010, ARTHRITIS RHEUM-US, V62, P2064, DOI 10.1002/art.27442; Wang P, 2014, EUR NEUROL, V72, P249, DOI 10.1159/000363515; Wang Y, 2014, CIRC RES, V114, P421, DOI 10.1161/CIRCRESAHA.114.302153; Wolfe F, 1996, J RHEUMATOL, V23, P1407; Wong SW, 2009, J BIOL CHEM, V284, P27384, DOI 10.1074/jbc.M109.044065; Yacyshyn B, 1996, DIGEST DIS SCI, V41, P2493, DOI 10.1007/BF02100148; Yang ZX, 2007, CLIN EXP IMMUNOL, V149, P48, DOI 10.1111/j.1365-2249.2007.03396.x; Ye DW, 2012, GUT, V61, P1058, DOI 10.1136/gutjnl-2011-300269; Yoon HJ, 2014, WORLD J HEPATOL, V6, P800, DOI 10.4254/wjh.v6.i11.800; Younesi V, 2010, MICROBIOL IMMUNOL, V54, P534, DOI 10.1111/j.1348-0421.2010.00248.x; Yu M, 2006, SHOCK, V26, P174, DOI 10.1097/01.shk.0000225404.51320.82; Zaki MH, 2005, J PHARMACOL SCI, V98, P117, DOI 10.1254/jphs.CRJ05004X; Zamboni DS, 2004, J BIOL CHEM, V279, P54405, DOI 10.1074/jbc.M410340200; Zhang J, 2012, J CANC THER RES, V1, P19, DOI DOI 10.1371/J0URNAL.P0NE.0029902; Zhang X, 2015, JPEN-PARENTER ENTER, V39, P114, DOI 10.1177/0148607113501881; Zhang ZR, 2012, NEUROIMMUNOMODULAT, V19, P10, DOI 10.1159/000326771; Zhou Y, 2009, J NEUROSCI RES, V87, P2916, DOI 10.1002/jnr.22110; Zhu H, 2012, EXP BIOL MED, V237, P474, DOI 10.1258/ebm.2011.011358	331	33	34	0	19	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets		2015	14	7					838	854		10.2174/1871527314666150317224645			17	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	CO0TW	WOS:000358867200003	25801843				2021-06-18	
J	Mendez, MF; Paholpak, P; Lin, A; Zhang, JY; Teng, E				Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Zhang, Jeannie Y.; Teng, Edmond			Prevalence of Traumatic Brain Injury in Early Versus Late-Onset Alzheimer's Disease	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Aging; Alzheimer's disease; concussion; dementia; epidemiology; head injury; memory loss; neurodegeneration; risk factors; traumatic brain injury	HEAD-INJURY; RISK-FACTOR; DEMENTIA; AGE; ENCEPHALOPATHY; POPULATION; INDIVIDUALS; TAUOPATHY; AD	Background: Traumatic brain injury (TBI) is the most established environmental risk factor for Alzheimer's disease (AD), but it is unclear if TBI is specifically associated with early-onset AD (EOAD). Objective: To evaluate the relationship between TBI and EOAD (<65 years). Methods: We identified 1,449 EOAD, 4,337 late-onset AD (LOAD), and corresponding EOAD-matched and LOAD-matched normal controls (NC) in the National Alzheimer's Coordinating Center Uniform (NACC) database and compared the prevalence of any history of TBI as well as measures of cognition, function, behavior, and neuropathology. For validation, we determined TBI prevalence among 115 well-characterized clinic patients with EOAD. Results: Part A: The prevalence of any TBI in the NACC-database EOAD participants (13.3%) was comparable to that observed in the clinic EOAD patients (13.9%) but significantly higher than in the NACC-database LOAD participants (7.7%; p < 0.0001) and trended to higher compared to EOAD-matched NC (11.1%; logistic regression p = 0.053). Part B: When we compared EOAD patients with documented non-acute and non-residually impairing TBI to EOAD without a documented history of prior TBI, those with TBI had significantly more disinhibition. Part C: Autopsies did not reveal differences in AD neuropathology based on a history of TBI. Conclusions: These findings suggest, but do not establish, that TBI is a specific risk factor for EOAD and may lead to disinhibition, a feature that often results from the frontal effects of head injury. This study recommends further research on the effects of TBI in EOAD in larger numbers of participants.	[Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Teng, Edmond] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Zhang, Jeannie Y.; Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Mendez, Mario F.; Paholpak, Pongsatorn; Lin, Andrew; Teng, Edmond] VA Greater Los Angeles Healthcare Syst, Neurobehav Unit, Dept Neurol, Los Angeles, CA USA	Mendez, MF (corresponding author), VA Greater Los Angeles Healthcare Ctr, Neurobehav Unit, 691-116AF,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	mmendez@UCLA.edu			Medical Student Training in Aging Research Program, the National Institute on Aging [T35AG026736]; John A. Hartford Foundation; Lillian R. Gleitsman Foundation; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976, P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017]; NIA/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG016976]; The NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG010161, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50 AG005136, P50 AG033514, P50 AG005681]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR013642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG008702, P30AG010124, P30AG008051, P30AG019610, P50AG005136, P30AG008017, P50AG033514, P50AG005138, P30AG035982, P50AG005146, U01AG016976, P50AG005142, P50AG016573, P30AG010133, P50AG023501, P30AG012300, P30AG010129, P50AG025688, R01AG034499, P30AG028383, P50AG005131, P50AG016574, P50AG016570, P50AG005134, P30AG010161, P50AG005133, P30AG013854, T35AG026736, P30AG013846, P50AG005681] Funding Source: NIH RePORTER	This research was funded by The Medical Student Training in Aging Research Program, the National Institute on Aging (T35AG026736), the John A. Hartford Foundation, the Lillian R. Gleitsman Foundation, and NIA Grant U01 AG016976.; The authors thank Michelle Mather, Kate Heller, and Dr. Stephen Hawes for their contributions. The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD).	Alzheimers Assoc, 2015, ALZHEIMERS DEMENT, V11, P332, DOI 10.1016/j.jalz.2015.02.003; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Beach TG, 2012, J NEUROPATH EXP NEUR, V71, P266, DOI 10.1097/NEN.0b013e31824b211b; Corrada MM, 2008, NEUROLOGY, V71, P337, DOI 10.1212/01.wnl.0000310773.65918.cd; Dams-O'Connor K, 2013, NEUROREHABILITATION, V32, P199, DOI 10.3233/NRE-130838; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kaufer DI, 2000, J NEUROPSYCH CLIN N, V12, P233, DOI 10.1176/jnp.12.2.233; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lezak M., 2012, NEUROPSYCHOLOGICAL A, V5th; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mendez MF, 2012, ARCH MED RES, V43, P677, DOI 10.1016/j.arcmed.2012.11.009; Mendez MF, 2012, AM J ALZHEIMERS DIS, V27, P413, DOI 10.1177/1533317512454711; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Morris JC, 2006, ALZ DIS ASSOC DIS, V20, P210, DOI 10.1097/01.wad.0000213865.09806.92; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PFEFFER RI, 1982, J GERONTOL, V37, P323, DOI 10.1093/geronj/37.3.323; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Prince M, 2013, ALZHEIMERS DEMENT, V9, P63, DOI 10.1016/j.jalz.2012.11.007; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P166, DOI 10.1176/appi.neuropsych.22.2.166; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Yoshiyama Y, 2005, J NEUROTRAUM, V22, P1134, DOI 10.1089/neu.2005.22.1134; Zhu XC, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.01.19; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	51	33	33	0	23	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2015	47	4					985	993		10.3233/JAD-143207			9	Neurosciences	Neurosciences & Neurology	CQ9JS	WOS:000360931300017	26401777	Green Accepted			2021-06-18	
J	Gerrard, P; Zafonte, R; Giacino, JT				Gerrard, Paul; Zafonte, Ross; Giacino, Joseph T.			Coma Recovery Scale-Revised: Evidentiary Support for Hierarchical Grading of Level of Consciousness	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Traumatic brain injury; Disorders of consciousness; Psychometrics; Rehabilitation	RECOMMENDATIONS; DISORDERS; ACCURACY	Objective: To investigate the neurobehavioral pattern of recovery of consciousness as reflected by performance on the subscales of the Coma Recovery Scale-Revised (CRS-R). Design: Retrospective item response theory (IRT) and factor analysis. Setting: Inpatient rehabilitation facilities. Participants: Rehabilitation inpatients (N = 180) with posttraumatic disturbance in consciousness who participated in a double-blinded, randomized, controlled drug trial. Interventions: Not applicable. Main Outcome Measures: Scores on CRS-R subscales. Results: The CRS-R was found to fit factor analytic models adhering to the assumptions of unidimensionality and monotonicity. In addition, subscales were mutually independent based on residual correlations. Nonparametric IRT reaffirmed the finding of monotonicity. A highly constrained confirmatory factor analysis model, which imposed equal factor loadings on all items, was found to fit the data well and was used to estimate a 1-parameter IRT model. Conclusions: This study provides evidence of the unidimensionality of the CRS-R and supports the hierarchical structure of the CRS-R subscales, suggesting that it is an effective tool for establishing diagnosis and monitoring recovery of consciousness after severe traumatic brain injury. (C) 2014 by the American Congress of Rehabilitation Medicine	Spaulding Rehabil Hosp, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Giacino, JT (corresponding author), Spaulding Rehabil Hosp, 300 First Ave, Charlestown, MA 02129 USA.	jgiacino@partners.org	Giacino, Joseph/AAF-1952-2021	Giacino, Joseph/0000-0002-7916-9698	National Institute on Disability and Rehabilitation Research (NIDRR), United States Department of Education [H133A031713]; NIDRR [H133A120085]	The data used in this article were extracted from a database developed with grant support from the National Institute on Disability and Rehabilitation Research (NIDRR), United States Department of Education (grant no. H133A031713: JFK-Johnson Rehabilitation Institute TEE Model System). Contributions were partially supported by NIDRR grant no. H133A120085 (Spaulding-Harvard TBI Model System). The contents do not necessarily represent the policy of the Department of Education, and endorsement by the Federal Government should not be assumed.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Chalmers RP, 2012, J STAT SOFTW, V48, P1; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Crick F., 1990, Seminars in the Neurosciences, V2, P263; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 1993, ARCH PHYS MED REHAB, V74, P662; Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424; Kamata A, 2008, STRUCT EQU MODELING, V15, P136, DOI 10.1080/10705510701758406; La Porta F, 2013, ARCH PHYS MED REHAB, V94, P527, DOI 10.1016/j.apmr.2012.09.035; Lovstad M, 2010, J HEAD TRAUMA REHAB, V25, P349, DOI 10.1097/HTR.0b013e3181cec841; MEIJER RR, 1990, APPL PSYCH MEAS, V14, P283, DOI 10.1177/014662169001400306; MOKKEN RJ, 1982, APPL PSYCH MEAS, V6, P417, DOI 10.1177/014662168200600404; NELKIN N, 1993, PHILOS SCI, V60, P419, DOI 10.1086/289744; Noe E, 2012, ARCH PHYS MED REHAB, V93, P428, DOI 10.1016/j.apmr.2011.08.048; RAMSAY JO, 1991, PSYCHOMETRIKA, V56, P611, DOI 10.1007/BF02294494; Rees G, 2002, NAT REV NEUROSCI, V3, P261, DOI 10.1038/nrn783; Reeve BB, 2007, MED CARE, V45, pS22, DOI 10.1097/01.mlr.0000250483.85507.04; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Seth A, 2009, COGN COMPUT, V1, P50, DOI 10.1007/s12559-009-9007-x; Sijtsma K.C., 1992, APPL MEAN EDUC, V5, P355, DOI DOI 10.1207/S15324818AME0504_; TAKANE Y, 1987, PSYCHOMETRIKA, V52, P393, DOI 10.1007/BF02294363; Tononi G, 1998, SCIENCE, V282, P1846, DOI 10.1126/science.282.5395.1846; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Velozo CA, 2012, ARCH PHYS MED REHAB, V93, pS154, DOI 10.1016/j.apmr.2012.06.001; Zumbo BD, 2007, HANDB STAT, V26, P45, DOI 10.1016/S0169-7161(06)26003-6	29	33	34	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2014	95	12					2335	2341		10.1016/j.apmr.2014.06.018			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AW0AY	WOS:000345954000014	25010536				2021-06-18	
J	Merritt, VC; Arnett, PA				Merritt, Victoria C.; Arnett, Peter A.			Premorbid predictors of postconcussion symptoms in collegiate athletes	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Concussion; Closed head injury; Sports injuries; Postconcussion symptoms; Collegiate athletes	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; COGNITIVE RESERVE; FOOTBALL PLAYERS; HEAD-INJURY; CHILDREN	Introduction: In recent years, the sports community has been faced with the challenge of determining when it is safe to return concussed athletes to play. Given that return-to-play decisions are partially dependent upon athletes' endorsement of symptoms, better understanding what factors contribute to the presence of symptoms following concussion is crucial. The purpose of the present study was to better characterize the symptoms that athletes endorse at baseline and to determine what impact various premorbid (or preinjury) characteristics have on the presence and severity of postconcussion symptoms in the acute injury period following concussion. Method: Two groups of participants with similar ages and levels of education were examined: athletes at baseline (N = 702) and postconcussion (N = 55). Athletes were administered a comprehensive battery of neuropsychological tests, consisting of neurocognitive and neurobehavioral measures, at both time periods. The main outcome measure was the Post-Concussion Symptoms Scale (PCSS). A factor analysis was conducted on the participants' baseline PCSS data to determine the factor structure of the PCSS, and separate logistic regression analyses were conducted that examined the baseline PCSS symptom clusters (derived from the factor analysis), demographic variables, and baseline neurocognitive variables as predictors of dichotomized postconcussion PCSS total scores (i.e., low versus high symptom reporting following concussion). Results: Four distinct clusters emerged from the factor analysis measuring cognitive, physical, affective, and sleep symptoms. Logistic regression results indicated that the physical and affective symptom clusters at baseline reliably predicted athletes' postconcussion symptom group, as did sex and the neurocognitive composite score. Conclusions: These findings show that certain baseline characteristics of athletes confer risk for greater symptomatology postconcussion. Knowledge of these risk factors can assist the management and treatment of sports-related concussion.	[Merritt, Victoria C.; Arnett, Peter A.] Penn State Univ, Dept Psychol, University Pk, PA 16802 USA	Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu	Meijer, Anna/K-5118-2016	Merritt, Victoria/0000-0001-5683-4168	Penn State Sports Medicine	The authors report no conflicts of interest, and no formal grant funding was obtained for this project. However, they would like to thank Wayne Sebastianelli and Penn State Sports Medicine for their generous support of this research.	[Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bailey CM, 2009, J HEAD TRAUMA REHAB, V24, P123, DOI 10.1097/HTR.0b013e31819c1caa; Benedict R., 1997, BRIEF VISUOSPATIAL M; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Brandt J., 2001, HOPKINS VERBAL LEARN; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Cegalis J.A., 1994, VIGIL W CONTINUOUS P; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Cicerone KD, 1997, BRAIN INJURY, V11, P643, DOI 10.1080/026990597123197; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; IBM Corp, 2010, IBM SPSS STAT WIND V; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR., 2000, IMPACT IMMEDIATE POS; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Pardini D., 2004, BR J SPORTS MED, V38, P661; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Psychological Corporation, 2001, WECHSL TEST AD READ; Rabinowitz AR, 2013, NEUROPSYCHOLOGY, V27, P481, DOI 10.1037/a0033023; Reynolds C.R., 2002, COMPREHENSIVE TRAIL; Smith A., 1991, SYMBOL DIGIT MODALIT; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008	59	33	33	0	21	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV 26	2014	36	10					1098	1111		10.1080/13803395.2014.983463			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AX3MB	WOS:000346842300009	25493542				2021-06-18	
J	Feliciano, DP; Sahbaie, P; Shi, XY; Klukinov, M; Clark, JD; Yeomans, DC				Feliciano, David P.; Sahbaie, Peyman; Shi, Xiaoyou; Klukinov, Michael; Clark, J. David; Yeomans, David C.			Nociceptive sensitization and BDNF up-regulation in a rat model of traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Traumatic brain injury; Chronic pain; Brain derived neurotrophic factor	NEUROPATHIC PAIN; SPINAL-CORD; NEUROTROPHIC FACTOR; PERSISTENT PAIN; MICROGLIA; VETERANS; STRESS	Chronic pain after traumatic brain injury (TBI) is very common, but the mechanisms linking TBI to pain experienced in the periphery have not been described. In this set of studies we examined nociceptive sensitization and changes in spinal cord gene expression using the rat lateral fluid percussion model of mild TBI. We did not identify changes in thermal nociceptive thresholds in rats with mild TBI. However, mechanical allodynia in hind paws contralateral to TBI was significant and sustained. We also found that spinal cord levels of brain derived neurotrophic factor (BDNF) but not several other pain-related genes were up-regulated one week after injury. Our findings suggest that TBI-induced up-regulation of spinal BDNF levels might contribute to chronic TBI-related pain, and that the lateral fluid percussion model might be useful for exploring this relationship. Published by Elsevier Ireland Ltd.	[Feliciano, David P.; Shi, Xiaoyou; Klukinov, Michael; Clark, J. David; Yeomans, David C.] Dept Anesthesiol Perioperat & Pain Med, Stanford, CA 94305 USA; [Sahbaie, Peyman; Shi, Xiaoyou; Clark, J. David] VA Palo Alto Healthcare Syst, Anesthesiol Serv, Palo Alto, CA 94304 USA	Clark, JD (corresponding author), VA Palo Alto Healthcare Syst, Anesthesiol Serv, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	djclark@stanford.edu					Beggs S, 2013, NEUROSCI LETT, V557, P37, DOI 10.1016/j.neulet.2013.08.037; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Constandil L, 2011, BRAIN RES BULL, V86, P454, DOI 10.1016/j.brainresbull.2011.08.008; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; DeFelice M, 2013, ANN NEUROL, V74, P257, DOI 10.1002/ana.23922; Golub A, 2013, SUBST USE MISUSE, V48, P811, DOI 10.3109/10826084.2013.796988; Higgins DM, 2014, PAIN MED, V15, P782, DOI 10.1111/pme.12388; Kerr BJ, 1999, J NEUROSCI, V19, P5138; Li CQ, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-27; Lin YT, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-126; Ling G.S.F., 2004, CURR PROTOC NEUROSCI; Macolino CM, 2014, J NEUROSCI METH, V226, P139, DOI 10.1016/j.jneumeth.2014.01.008; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moore DF, 2010, NEUROREHABILITATION, V26, P179, DOI 10.3233/NRE-2010-0553; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Obata K, 2006, NEUROSCI RES, V55, P1, DOI 10.1016/j.neures.2006.01.005; Ofek H, 2007, PAIN, V131, P330, DOI 10.1016/j.pain.2007.06.015; Son BC, 2006, PAIN, V123, P210, DOI 10.1016/j.pain.2006.02.028; Trang T, 2011, NEURON GLIA BIOL, V7, P99, DOI 10.1017/S1740925X12000087; Tzabazis A, 2005, BRAIN RES, V1037, P148, DOI 10.1016/j.brainres.2005.01.019; Wilkinson H A, 1989, Surg Neurol, V31, P412, DOI 10.1016/0090-3019(89)90080-3; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Yang Q, 2014, J NEUROSCI, V34, P10765, DOI 10.1523/JNEUROSCI.5316-13.2014; Zhu XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091303	28	33	33	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	NOV 7	2014	583						55	59		10.1016/j.neulet.2014.09.030			5	Neurosciences	Neurosciences & Neurology	AU4TM	WOS:000345604300011	25246352				2021-06-18	
J	Powell, MR; Powden, CJ; Houston, MN; Hoch, MC				Powell, Meaghan R.; Powden, Cameron J.; Houston, Megan N.; Hoch, Matthew C.			Plantar Cutaneous Sensitivity and Balance in Individuals With and Without Chronic Ankle Instability	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						ankle sprain; somatosensory; balance	TO-BOUNDARY MEASURES; POSTURAL CONTROL; DEFICITS; INJURIES; TIME; OSTEOARTHRITIS; RELIABILITY; AFFERENTS; OUTCOMES; SPRAINS	Objective: To determine if plantar cutaneous sensation and postural control differ between individuals with and without chronic ankle instability (CAI). Design: Case-control. Setting: Laboratory. Participants: Ten subjects with CAI and 10 subjects with no ankle sprain history participated. Interventions: Light touch was evaluated at 3 sites (heel, base of fifth metatarsal, and head of first metatarsal) on the plantar aspect of the foot using Semmes-Weinstein Monofilaments (SWMs). Postural control was assessed using the single leg firm and foam conditions of the Balance Error Scoring System (BESS) and during eyes open and eyes closed static postural control on a force plate. Main Outcome Measures: Semmes-Weinstein Monofilament detection thresholds, BESS errors, and the mean of time-to-boundary (TTB) minima (TTB-mean) and the SD of TTB minima (TTB-SD) in the anterior-posterior (AP) and medial-lateral directions were evaluated for each subject. Results: Subjects with CAI demonstrated increased SWM detection thresholds at the heel (P = 0.009), head of the first (P = 0.01), and base of the fifth metatarsal (P < 0.001) and postural control deficits on the BESS firm (P = 0.04) and foam (P = 0.001) conditions and with eyes open TTB-mean AP (P = 0.007) and TTB-SD AP (P = 0.02). When combining groups, a negative moderate correlation was observed between the base of the fifth metatarsal detection threshold and eyes open TTB-mean AP (r = -0.50; P = 0.03). Conclusions: Light touch and postural control deficits were observed in individuals with CAI. The correlation between light touch over the base of the fifth metatarsal and eyes open TTB-mean AP suggests that there may be a relevant relationship between these measures. Clinical Relevance: Individuals with CAI demonstrated deficits in light touch over the plantar aspect of the foot. The relationship between base of the fifth metatarsal sensation and TTB-mean AP may provide a starting point to link plantar cutaneous sensory deficits to changes in other aspects of sensorimotor function.	[Powell, Meaghan R.; Houston, Megan N.] Old Dominion Univ, Coll Educ, Dept Human Movement Sci, Norfolk, VA 23529 USA; [Powden, Cameron J.; Hoch, Matthew C.] Old Dominion Univ, Sch Phys Therapy & Athlet Training, Coll Hlth Sci, Norfolk, VA 23529 USA	Hoch, MC (corresponding author), Old Dominion Univ, Sch Phys Therapy & Athlet Training, Coll Hlth Sci, 102 Hlth Sci Annex, Norfolk, VA 23529 USA.	mhoch@odu.edu					Anandacoomarasamy A, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.011676; Arnold BL, 2009, MED SCI SPORT EXER, V41, P1048, DOI 10.1249/MSS.0b013e318192d044; Collins S, 2010, DISABIL REHABIL, V32, P2019, DOI 10.3109/09638281003797406; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Docherty CL, 2006, J ATHL TRAINING, V41, P154; DYCK PJ, 1993, NEUROLOGY, V43, P1508, DOI 10.1212/WNL.43.8.1508; Freeman M A, 1965, J Bone Joint Surg Br, V47, P678; Freeman M A, 1965, J Bone Joint Surg Br, V47, P669; Hertel J, 2002, J ATHL TRAINING, V37, P364; Hertel J, 2008, CLIN SPORT MED, V27, P353, DOI 10.1016/j.csm.2008.03.006; Hertel J, 2007, GAIT POSTURE, V25, P33, DOI 10.1016/j.gaitpost.2005.12.009; Hoch MC, 2014, MED SCI SPORT EXER, V46, P546, DOI 10.1249/MSS.0b013e3182a6a93b; Hoch MC, 2012, MED SCI SPORT EXER, V44, P666, DOI 10.1249/MSS.0b013e3182390212; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Jenkins ME, 2009, PARKINSONISM RELAT D, V15, P697, DOI 10.1016/j.parkreldis.2009.04.004; Knikou M, 2010, J NEUROPHYSIOL, V103, P1304, DOI 10.1152/jn.00880.2009; LeClaire J.E., 2012, ATHL TRAIN SPORT HLT, V4, P213, DOI DOI 10.3928/19425864-20120731-02; Liu W, 2002, ARCH PHYS MED REHAB, V83, P171, DOI 10.1053/apmr.2002.28025; McKeon JMM, 2012, J ATHL TRAINING, V47, P444, DOI 10.4085/1062-6050-47.4.15; McKeon PO, 2010, GAIT POSTURE, V32, P374, DOI 10.1016/j.gaitpost.2010.06.016; McKeon PO, 2007, SOMATOSENS MOT RES, V24, P171, DOI 10.1080/08990220701637224; McKeon PO, 2012, J SPORT REHABIL, V21, P1, DOI 10.1123/jsr.21.1.1; McKeon PO, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-76; McKeon PO, 2008, MED SCI SPORT EXER, V40, P1810, DOI 10.1249/MSS.0b013e31817e0f92; McVey ED, 2005, FOOT ANKLE INT, V26, P1055, DOI 10.1177/107110070502601210; Meyer PF, 2004, EXP BRAIN RES, V157, P526, DOI 10.1007/s00221-004-1868-3; Needle AR, 2013, J ATHL TRAINING, V48, P192, DOI 10.4085/1062-6050-48.1.09; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; Palluel E, 2008, AGE, V30, P53, DOI 10.1007/s11357-008-9047-2; Perry SD, 2008, J GERONTOL A-BIOL, V63, P595, DOI 10.1093/gerona/63.6.595; Plante JE, 2013, PHYS THER SPORT, V14, P221, DOI 10.1016/j.ptsp.2012.09.005; Pope M, 2011, GAIT POSTURE, V34, P154, DOI 10.1016/j.gaitpost.2011.04.012; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Roll R, 2002, NEUROREPORT, V13, P1957, DOI 10.1097/00001756-200210280-00025; Rosenbaum D, 2006, RHEUMATOLOGY, V45, P212, DOI 10.1093/rheumatology/kei137; Sedory EJ, 2007, J ATHL TRAINING, V42, P355; Sefton JM, 2009, CLIN BIOMECH, V24, P451, DOI 10.1016/j.clinbiomech.2009.03.003; Shakoor N, 2008, ARTHRIT RHEUM-ARTHR, V59, P1237, DOI 10.1002/art.24004; Shakoor N, 2008, ARTHRIT RHEUM-ARTHR, V59, P117, DOI 10.1002/art.23241; van Rijn RM, 2008, AM J MED, V121, P324, DOI 10.1016/j.amjmed.2007.11.018; VERHAGEN RAW, 1995, ARCH ORTHOP TRAUM SU, V114, P92, DOI 10.1007/BF00422833; Wikstrom EA, 2010, GAIT POSTURE, V32, P82, DOI 10.1016/j.gaitpost.2010.03.015	42	33	33	2	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2014	24	6					490	496					7	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	AT2AM	WOS:000344733000012	24451692				2021-06-18	
J	Bennett, RE; Brody, DL				Bennett, Rachel E.; Brody, David L.			Acute Reduction of Microglia Does Not Alter Axonal Injury in a Mouse Model of Repetitive Concussive Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						axon injury; concussion; microglia	COLLEGIATE FOOTBALL PLAYERS; HEAD-INJURY; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; WHITE-MATTER; BETA; ACTIVATION; ENCEPHALOPATHY; VULNERABILITY; INFLAMMATION	The pathological processes that lead to long-term consequences of multiple concussions are unclear. Primary mechanical damage to axons during concussion is likely to contribute to dysfunction. Secondary damage has been hypothesized to be induced or exacerbated by inflammation. The main inflammatory cells in the brain are microglia, a type of macrophage. This research sought to determine the contribution of microglia to axon degeneration after repetitive closed-skull traumatic brain injury (rcTBI) using CD11b-TK (thymidine kinase) mice, a valganciclovir-inducible model of macrophage depletion. Low-dose (1 mg/mL) valganciclovir was found to reduce the microglial population in the corpus callosum and external capsule by 35% after rcTBI in CD11b-TK mice. At both acute (7 days) and subacute (21 days) time points after rcTBI, reduction of the microglial population did not alter the extent of axon injury as visualized by silver staining. Further reduction of the microglial population by 56%, using an intermediate dose (10mg/mL), also did not alter the extent of silver staining, amyloid precursor protein accumulation, neurofilament labeling, or axon injury evident by electron microscopy at 7 days postinjury. Longer treatment of CD11b-TK mice with intermediate dose and treatment for 14 days with high-dose (50mg/mL) valganciclovir were both found to be toxic in this injury model. Altogether, these data are most consistent with the idea that microglia do not contribute to acute axon degeneration after multiple concussive injuries. The possibility of longer-term effects on axon structure or function cannot be ruled out. Nonetheless, alternative strategies directly targeting injury to axons may be a more beneficial approach to concussion treatment than targeting secondary processes of microglial-driven inflammation.	[Bennett, Rachel E.; Brody, David L.] Washington Univ, Dept Neurol, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Dept Neurol, 660 South Euclid Ave Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS076047, R01NS065069] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31-NS076047, R01-NS065069] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ashki N, 2006, J NEUROTRAUM, V23, P1779, DOI 10.1089/neu.2006.23.1779; Batchelor PE, 2002, MOL CELL NEUROSCI, V21, P436, DOI 10.1006/mcne.2002.1185; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Davies AL, 2006, J NEUROTRAUM, V23, P1261, DOI 10.1089/neu.2006.23.1261; DeVos SL, 2013, JOVE-J VIS EXP, DOI 10.3791/50326; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gowing G, 2006, GLIA, V53, P331, DOI 10.1002/glia.20288; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Hosmane S, 2012, J NEUROSCI, V32, P7745, DOI 10.1523/JNEUROSCI.0203-12.2012; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MORTIMER JA, 1985, MINN MED, V68, P299; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Simard AR, 2006, NEURON, V49, P489, DOI 10.1016/j.neuron.2006.01.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Varvel NH, 2012, P NATL ACAD SCI USA, V109, P18150, DOI 10.1073/pnas.1210150109; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	53	33	34	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 1	2014	31	19					1647	1663		10.1089/neu.2013.3320			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AP5VI	WOS:000342146400007	24797413	Green Published			2021-06-18	
J	Lowrey, KM; Morain, SR				Lowrey, Kerri McGowan; Morain, Stephanie R.			State Experiences Implementing Youth Sports Concussion Laws: Challenges, Successes, and Lessons for Evaluating Impact	JOURNAL OF LAW MEDICINE & ETHICS			English	Article							INJURY; RETURN	While provisions of youth sports concussion laws are very similar, little is known as to how they are being implemented, factors that promote or impede implementation, or the level of compliance in each jurisdiction. We aimed to describe state experiences with implementation in order to inform ongoing efforts to reduce the harm of sports-related traumatic brain injury and to guide future evaluations of the laws' impacts and the development of future public health laws. We conducted key-informant interviews in 35 states with recently enacted concussion legislation. States varied considerably in their readiness and capacity for implementation. Factors facilitating implementation included existing partnerships, procedures, and resources; centralized implementation authority; prior related efforts; and involvement in the policymaking process by those now charged with implementation. Inhibitors included ambiguous statutory language, unclear delegation of authority, and compliance difficulties. Ongoing challenges persist, including primary prevention; determining which providers are qualified to make return-to-play assessments and contents of those assessments; compliance difficulties in rural and under-served areas; and unclear responsibility for enforcement. Despite the similarity of youth sports concussion laws, early evidence suggests there is considerable variation in their implementation. These findings are critical for ongoing empirical investigations to accurately evaluate the laws' provisions and to identify successful legal approaches to protecting young athletes.	[Lowrey, Kerri McGowan] Eastern Reg, Wyndmoor, PA 19038 USA; [Morain, Stephanie R.] Johns Hopkins Bloomberg Sch Publ Hlth, Berman Inst, Baltimore, MD USA	Lowrey, KM (corresponding author), Eastern Reg, Wyndmoor, PA 19038 USA.			Morain, Stephanie/0000-0001-7278-7517	Network for Public Health Law; Robert Wood Johnson FoundationRobert Wood Johnson Foundation (RWJF); Harvard Catalyst \ The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health) [8UL1TR000170-05]; Harvard University; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000170] Funding Source: NIH RePORTER	This work, performed under the auspices of the Network for Public Health Law, was made possible by the generous support of the Robert Wood Johnson Foundation and Harvard Catalyst vertical bar The Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health Award 8UL1TR000170-05, and financial contributions from Harvard University and its affiliated academic health care centers. The authors would like to thank Allison Bogsted for her assistance conducting interviews, Joanne Lucas and Blair Inniss for their research support, and Lainie Rutkow for her review of an earlier draft. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Robert Wood Johnson Foundation, Harvard Catalyst, Harvard University and its affiliated academic health care centers, or the National Institutes of Health.	Bey T, 2009, WEST J EMERG MED, V10, P6; Burris S, 2010, MILBANK Q, V88, P169, DOI 10.1111/j.1468-0009.2010.00595.x; Carroll L J, 2011, CONCUSSION CRISIS AN; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Covassin T., 2012, AM J SPORTS MED, V20, P1; Gilchrist J., 2011, 60 CDC MORB MORT WEE, V60; GOLDING D, 1992, RISK ANAL, V12, P27, DOI 10.1111/j.1539-6924.1992.tb01304.x; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Lowrey K. M., 2011, SUMMARY MATRIX STATE; Matheson GO, 2011, CLIN J SPORT MED, V21, P25, DOI 10.1097/JSM.0b013e3182095f92; Nansel TR, 2002, PATIENT EDUC COUNS, V46, P175, DOI 10.1016/S0738-3991(01)00211-7; Robert Wood Johnson Foundation, STRENGTH ENF PUBL HL; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shrier I, 2014, BRIT J SPORT MED, V48, DOI 10.1136/bjsports-2013-092492; Wood J, 2013, PUBLIC HLTH LAW THEO, P325; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	18	33	33	1	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1105	1748-720X		J LAW MED ETHICS	J. Law Med. Ethics	FAL	2014	42	3			SI		290	296		10.1111/jlme.12146			7	Ethics; Law; Medical Ethics; Medicine, Legal	Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal Medicine	AQ4ED	WOS:000342745000004	25264087				2021-06-18	
J	Pasquier, P; Dubost, C; Boutonnet, M; Chrisment, A; Villevieille, T; Batjom, E; Bordier, E; Ausset, S; Puidupin, M; Martinez, JY; Bay, C; Escarment, J; Pons, F; Lenoir, B; Merat, S				Pasquier, Pierre; Dubost, Clement; Boutonnet, Mathieu; Chrisment, Anne; Villevieille, Thierry; Batjom, Emmanuel; Bordier, Emmanuel; Ausset, Sylvain; Puidupin, Marc; Martinez, Jean-Yves; Bay, Christian; Escarment, Jacques; Pons, Francois; Lenoir, Bernard; Merat, Stephane			Predeployment training for forward medicalisation in a combat zone: The specific policy of the French Military Health Service	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Tactical Combat Casualty Care; French policy; Predeployment training; Forward medicalisation	CASUALTY CARE; CURRENT WAR; TRAUMA; BATTLEFIELD; OPERATIONS; DEPLOYMENT; PERSONNEL; INJURY; MEDICS; DEATH	Introduction: To improve the mortality rate on the battlefield, and especially the potentially survivable pre-Medical Treatment Facility deaths, Tactical Combat Casualty Care (TCCC) is now considered as a reference for management of combat casualty from the point of injury to the first medical treatment facility. TCCC comprises of a set of trauma management guidelines designed for use on the battlefield. The French Military Health Service also standardised a dedicated training programme, entitled "Sauvetage au Combat'' (SC) ("forward combat casualty care''), with the characteristic of forward medicalisation on the battlefield, the medical team being projected as close as possible to the casualty at the point of injury. The aim of our article is to describe the process and the result of the SC training. Materials and methods: Records from the French Military Health Service Academy - Ecole du Val-de-Grace administration, head of the SC teaching programme, defining its guidelines, and supporting its structure and its execution, were examined and analyzed, since the standardisation of the SC training programme in 2008. The total number of trainees was listed following the different courses (SC1, SC2, SC3). Results: At the end of 2013, every deployed combatant underwent SC1 courses (confidential data), 785 health-qualified combatants were graduated for SC2 courses and 672 Role 1 physician-nurse pairs for SC3 courses. Conclusion: The SC concept and programmes were defined in France in 2007 and are now completely integrated into the predeployment training of all combatants but also of French Military Health Service providers. Finally, SC teaching programmes enhance the importance of teamwork in forward combat medicalisation settings. (C) 2014 Elsevier Ltd. All rights reserved.	[Pasquier, Pierre; Dubost, Clement; Chrisment, Anne; Villevieille, Thierry; Batjom, Emmanuel; Bordier, Emmanuel; Merat, Stephane] Mil Teaching Hosp, Hop Instruct Arme Begin, Dept Anesthesiol, St Mande, France; [Pasquier, Pierre; Dubost, Clement; Chrisment, Anne; Villevieille, Thierry; Batjom, Emmanuel; Bordier, Emmanuel; Merat, Stephane] Mil Teaching Hosp, Hop Instruct Arme Begin, Intens Care Unit, St Mande, France; [Boutonnet, Mathieu; Ausset, Sylvain; Lenoir, Bernard] Mil Teaching Hosp, Hop Instruct Arme Percy, Dept Anesthesiol, Clamart, France; [Puidupin, Marc; Martinez, Jean-Yves; Escarment, Jacques] Mil Teaching Hosp, Hop Instruct Arme Percy, Intens Care Unit, Clamart, France; [Bay, Christian] French Mil Hlth Serv Acad, Ecole Val de Grace, Tact Care Training Dept, Paris, France; [Pons, Francois] French Mil Hlth Serv Acad, Ecole Val de Grace, Paris, France	Pasquier, P (corresponding author), Begin Mil Teaching Hosp, Intens Care Unit, 69 Ave Paris, F-94160 St Mande, France.	pasquier9606@me.com; clement.dubost@hotmail.fr; mathieuboutonnet@hotmail.com; anne.chrisment@hotmail.com; t-ville@orange.fr; ebtjm@free.fr; lbordier@club-internet.fr; sylvain.ausset@gmail.com; marc.puidupin@gmail.com; jyvesmartinez@yahoo.com; Christian.bay@sante.defense.gouv.fr; jacques.escarment@yahoo.fr; francois.pons@sante.defense.gouv.fr; Bernard.lenoir@sante.defense.gouv.fr; merat.stephane@wanadoo.fr	Pasquier, Pierre/E-1489-2018; Ausset, Sylvain/M-7394-2019	Pasquier, Pierre/0000-0003-2337-7874; Ausset, Sylvain/0000-0001-8345-1058; Boutonnet, Mathieu/0000-0002-7334-0132; dubost, Clement/0000-0001-7539-6271			Andersson SO, 2013, MIL MED, V178, P861, DOI 10.7205/MILMED-D-13-00048; Apodaca AN, 2013, SHOCK, V40, P5, DOI 10.1097/SHK.0b013e31829793d7; Battlefield Advanced Trauma Life Support (BATLS), 2004, J ROY ARMY MED CORPS, V150, P32; Benson M, 1996, Prehosp Disaster Med, V11, P117; Brooks AJ, 2005, EMERG MED J, V22, P263, DOI 10.1136/emj.2004.014308; Butler F, 2003, J TRAUMA, V54, pS2; Butler FK, 1996, MIL MED, V161, P3; Butler FK, 2010, J TRAUMA, V69, pS10, DOI 10.1097/TA.0b013e3181e4220c; Butler FK, 2012, J TRAUMA ACUTE CARE, V73, pS395, DOI 10.1097/TA.0b013e3182754850; Champion HR, 2010, J TRAUMA, V68, P1139, DOI 10.1097/TA.0b013e3181d86a0d; Chapman PL, 2012, MIL MED, V177, P270, DOI 10.7205/MILMED-D-11-00305; Dubost C, 2013, J TRAUMA ACUTE CARE, V74, P1146, DOI 10.1097/TA.0b013e31828271a8; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Gerhardt RT, 2008, PREHOSP EMERG CARE, V12, P359, DOI 10.1080/10903120802101058; Gerhardt RT, 2013, TRANSFUSION, V53, p9S, DOI 10.1111/trf.12030; Gerhardt RT, 2011, J TRAUMA, V71, pS109, DOI 10.1097/TA.0b013e31822190a7; Gerhardt RT, 2009, ANN EMERG MED, V53, P169, DOI 10.1016/j.annemergmed.2008.04.013; Gerhardt RT, 2005, ANN EMERG MED, V46, pS45; Hoencampemail R, 2014, INJURY; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; Kotwal RS, 2011, ARCH SURG-CHICAGO, V146, P1349, DOI 10.1001/archsurg.2011.213; Lairet JR, 2012, J TRAUMA ACUTE CARE, V73, pS38, DOI 10.1097/TA.0b013e3182606022; Lundberg L, 2008, J R Army Med Corps, V154, P34; Mabry RL, 2012, J TRAUMA ACUTE CARE, V73, pS32, DOI 10.1097/TA.0b013e3182606001; McLeod J, 2007, J R Army Med Corps, V153, P266; Midwinter MJ, 2011, J ROY ARMY MED CORPS, V157, pS299, DOI 10.1136/jramc-157-03s-08; Molde A, 2006, J R Army Med Corps, V152, P217; Nathens AB, 2004, LANCET, V363, P1794, DOI 10.1016/S0140-6736(04)16307-1; NATO, 2011, MED LESS LEARN NEWSL; Parsons IT, 2013, J R ARMY MED CORPS; Purim-Shem-Tov Yanina A, 2013, Mil Med, V178, pe362, DOI 10.7205/MILMED-D-12-00376; Ramasamy A, 2009, J R Army Med Corps, V155, P265; Savage E, 2011, CAN J SURG, V54, pS14, DOI 10.1503/cjs.025011; Singleton JAG, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003130; Sohn VY, 2007, J SURG RES, V138, P25, DOI 10.1016/j.jss.2006.09.006; Sohn Vance Y, 2007, J Surg Educ, V64, P199, DOI 10.1016/j.jsurg.2007.05.007; Tai N R M, 2009, J R Army Med Corps, V155, P253; Tien MHC, 2008, J AM COLL SURGEONS, V207, P174, DOI 10.1016/j.jamcollsurg.2008.01.065; Tyler JA, 2010, J AM COLL SURGEONS, V211, P658, DOI 10.1016/j.jamcollsurg.2010.07.009	39	33	40	0	13	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2014	45	9					1307	1311		10.1016/j.injury.2014.05.037			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AN0NI	WOS:000340280900005	24952973				2021-06-18	
J	Sarmiento, K; Hoffman, R; Dmitrovsky, Z; Lee, R				Sarmiento, Kelly; Hoffman, Rosanne; Dmitrovsky, Zoe; Lee, Robin			A 10-year review of the Centers for Disease Control and Prevention's Heads Up initiatives: Bringing concussion awareness to the forefront	JOURNAL OF SAFETY RESEARCH			English	Article						CDC; Concussion; Heads Up	HIGH-SCHOOL; CDC HEADS; SPORTS; COACHES	TheJournal of Safety Research has partnered with the Office of the Associate Director for Science, Division of 16 Unintentional Injury Prevention in the National Center for Injury Prevention & Control at the Centers for Disease 17 Control and Prevention (CDC) in Atlanta, Georgia, USA, to briefly report on some of the latest findings in the re- 18 search and practice community. This report is the 32nd in a series of CDC articles.	[Sarmiento, Kelly; Lee, Robin] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30041 USA; [Hoffman, Rosanne; Dmitrovsky, Zoe] ICF Int, Strateg Commun & Mkt Div, Fairfax, VA USA	Sarmiento, K (corresponding author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30041 USA.	KSarmiento@cdc.gov			Intramural CDC HHS [CC999999] Funding Source: Medline		Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Brosseau-Lachaine O, 2008, BRAIN INJURY, V22, P657, DOI 10.1080/02699050802203353; *CDCP, 2003, HEADS BRAIN INJ YOUR; Centers for Disease Control and Prevention, 2010, HEADS SCH KNOW YOUR; Centers for Disease Control and Prevention & CDC Foundation, 2013, HEADS PAR; Centers for Disease Control and Prevention National Center for Injury Prevention Control, 2010, HEADS ONL TRAIN COUR; Centers for Disease Control Prevention [CDC], 2007, HEADS CONC YOUTH SPO; Centers for Disease Control Prevention [CDC], 2005, HEADS CONC HIGH SCH; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Harvey HH, 2013, AM J PUBLIC HEALTH, V103, P1249, DOI 10.2105/AJPH.2012.301107; Institute of Medicine (IOM) & National Research Council (NRC), 2013, SPORTS REL CONC YOUT; Library of Congress, 1999, BILL SUMM STAT 106 C; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Federation of State High School Associations, 2010, CONC SPORTS WHAT YOU; National Football League CDC Foundation and Centers for Disease Control and Prevention, 2011, HEADS CLIN ADDR CONC; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e	20	33	33	0	12	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4375	1879-1247		J SAFETY RES	J. Saf. Res.	SEP	2014	50						143	147		10.1016/j.jsr.2014.05.003			5	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	AO6QT	WOS:000341477300017	25142371	Green Accepted			2021-06-18	
J	Albrecht, JS; Liu, XG; Baumgarten, M; Langenberg, P; Rattinger, GB; Smith, GS; Gambert, SR; Gottlieb, SS; Zuckerman, IH				Albrecht, Jennifer S.; Liu, Xinggang; Baumgarten, Mona; Langenberg, Patricia; Rattinger, Gail B.; Smith, Gordon S.; Gambert, Steven R.; Gottlieb, Stephen S.; Zuckerman, Ilene H.			Benefits and Risks of Anticoagulation Resumption Following Traumatic Brain Injury	JAMA INTERNAL MEDICINE			English	Article							VENOUS THROMBOEMBOLISM PROPHYLAXIS; CLINICAL CLASSIFICATION SCHEMES; ATRIAL-FIBRILLATION; NATIONAL REGISTRY; HEMORRHAGE; WARFARIN; STROKE; THROMBOPROPHYLAXIS; VALIDATION; GUIDELINES	IMPORTANCE The increased risk of hemorrhage associated with anticoagulant therapy following traumatic brain injury creates a serious dilemma for medical management of older patients: Should anticoagulant therapy be resumed after traumatic brain injury, and if so, when? OBJECTIVE To estimate the risk of thrombotic and hemorrhagic events associated with warfarin therapy resumption following traumatic brain injury. DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of administrative claims data for Medicare beneficiaries aged at least 65 years hospitalized for traumatic brain injury during 2006 through 2009 who received warfarin in the month prior to injury (n = 10 782). INTERVENTION Warfarin use in each 30-day period following discharge after hospitalization for traumatic brain injury. MAIN OUTCOMES AND MEASURES The primary outcomes were hemorrhagic and thrombotic events following discharge after hospitalization for traumatic brain injury. Hemorrhagic events were defined on inpatient claims using International Classification of Diseases, Ninth Revision, Clinical Modification codes and included hemorrhagic stroke, upper gastrointestinal bleeding, adrenal hemorrhage, and other hemorrhage. Thrombotic events included ischemic stroke, pulmonary embolism, deep venous thrombosis, and myocardial infarction. A composite of hemorrhagic or ischemic stroke was a secondary outcome. RESULTS Medicare beneficiaries with traumatic brain injury were predominantly female (64%) and white (92%), with a mean (SD) age of 81.3 (7.3) years, and 82% had atrial fibrillation. Over the 12 months following hospital discharge, 55% received warfarin during 1 or more 30-day periods. We examined the lagged effect of warfarin use on outcomes in the following period. Warfarin use in the prior period was associated with decreased risk of thrombotic events (relative risk [RR], 0.77 [95% CI, 0.67-0.88]) and increased risk of hemorrhagic events (RR, 1.51 [95% CI, 1.29-1.78]). Warfarin use in the prior period was associated with decreased risk of hemorrhagic or ischemic stroke (RR, 0.83 [95% CI, 0.72-0.96]). CONCLUSIONS AND RELEVANCE Results from this study suggest that despite increased risk of hemorrhage, there is a net benefit for most patients receiving anticoagulation therapy, in terms of a reduction in risk of stroke, from warfarin therapy resumption following discharge after hospitalization for traumatic brain injury.	[Albrecht, Jennifer S.; Liu, Xinggang; Zuckerman, Ilene H.] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA; [Baumgarten, Mona; Langenberg, Patricia; Zuckerman, Ilene H.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Rattinger, Gail B.] Fairleigh Dickinson Univ, Sch Pharm, Div Pharm Practice, Florham Pk, NJ USA; [Smith, Gordon S.] Univ Maryland, Natl Study Ctr Trauma & Emergency Med Serv, Shock Trauma & Anesthesiol Res STAR Organized Res, Baltimore, MD 21201 USA; [Gambert, Steven R.; Gottlieb, Stephen S.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; [Zuckerman, Ilene H.] IMPAQ Int LLC, Columbia, MD 21044 USA	Zuckerman, IH (corresponding author), IMPAQ Int LLC, 10420 Little Patuxent Pkwy,Ste 300, Columbia, MD 21044 USA.	izuckerman@impaqint.com		Smith, Gordon/0000-0002-2911-3071; Albrecht, Jennifer/0000-0003-4838-2274	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AG042768-01, T32AG000262-14]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000262, R21AG042768] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant R21 AG042768-01 (Zuckerman, principal investigator). Dr Albrecht is supported by National Institutes of Health grant T32AG000262-14.	Agarwal S, 2010, AM J CARDIOVASC DRUG, V10, P37, DOI 10.2165/11318870-000000000-00000; Ahmad O, 2009, INTERN MED J, V39, P752, DOI 10.1111/j.1445-5994.2008.01878.x; Allison P.D., 1995, SURVIVAL ANAL USING; Arnason T, 2006, THROMB RES, V118, P253, DOI 10.1016/j.thromres.2005.06.015; Bjorck S, 2013, STROKE, V44, P3103, DOI 10.1161/STROKEAHA.113.002329; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS32, DOI 10.1089/neu.2007.9991; Carlile M, 2010, J TRAUMA, V68, P916, DOI 10.1097/TA.0b013e3181b16d2d; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Centers for Medicare and Medicaid Services Chronic Condition Data Warehouse, CONDITION CATEGORIES; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gage BF, 2006, AM HEART J, V151, P713, DOI 10.1016/j.ahj.2005.04.017; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Gage BF, 2001, JAMA-J AM MED ASSOC, V285, P2864, DOI 10.1001/jama.285.22.2864; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Hernan MA, 2004, EPIDEMIOLOGY, V15, P615, DOI 10.1097/01.ede.0000135174.63482.43; Jasuja GK, 2013, THROMB RES, V131, P31, DOI 10.1016/j.thromres.2012.10.010; Keeling D, 2011, BRIT J HAEMATOL, V154, P311, DOI 10.1111/j.1365-2141.2011.08753.x; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levy AS, 2010, J TRAUMA, V68, P886, DOI 10.1097/TA.0b013e3181d27dd5; Liu X, J HEAD TRAUMA REHABI; Maletis GB, 2012, J BONE JOINT SURG AM, V94A, P714, DOI 10.2106/JBJS.J.01759; Marr AL., 2004, CENTRAL NERVOUS SYST; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Phelan HA, 2012, J NEUROTRAUM, V29, P1821, DOI 10.1089/neu.2012.2459; Pugh D, 2011, AGE AGEING, V40, P675, DOI 10.1093/ageing/afr097; Rogers FB, 2002, J TRAUMA, V53, P142, DOI 10.1097/00005373-200207000-00032; Salottolo K, 2011, J TRAUMA, V70, P19, DOI 10.1097/TA.0b013e318207c54d; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; Singer DE, 2008, CHEST, V133, p546S, DOI 10.1378/chest.08-0678; Sniezek JE, 1995, GUIDELINES FOR SURVE; Wahl PM, 2010, PHARMACOEPIDEM DR S, V19, P596, DOI 10.1002/pds.1924; Witt DM, 2012, ARCH INTERN MED, V172, P1484, DOI 10.1001/archinternmed.2012.4261	38	33	33	2	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	AUG	2014	174	8					1244	1251		10.1001/jamainternmed.2014.2534			8	Medicine, General & Internal	General & Internal Medicine	AN2WP	WOS:000340447000011	24915005	Bronze, Green Accepted			2021-06-18	
J	Zhang, Q; Zhou, C; Hamblin, MR; Wu, MX				Zhang, Qi; Zhou, Chang; Hamblin, Michael R.; Wu, Mei X.			Low-level laser therapy effectively prevents secondary brain injury induced by immediate early responsive gene X-1 deficiency	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						IEX-1; inadequate mitochondrial function; LLLT; mTBI	NECROSIS-FACTOR-ALPHA; F1FO-ATPASE INHIBITOR; IEX-1; NEUROINFLAMMATION; LIGHT; MICE; NEUROTOXICITY; EXPRESSION; PROTEIN; MUSCLE	A mild insult to the brain can sometimes trigger secondary brain injury, causing severe postconcussion syndrome, but the underlying mechanism is ill understood. We show here that secondary brain injury occurs consistently in mice lacking immediate early responsive gene X-1 (IEX-1), after a gentle impact to the head, which closely simulates mild traumatic brain injury in humans. The pathologic lesion was characterized by extensive cell death, widespread leukocyte infiltrates, and severe tissue loss. On the contrary, a similar insult did not induce any secondary injury in wild-type mice. Strikingly, noninvasive exposure of the injured head to a low-level laser at 4 hours after injury almost completely prevented the secondary brain injury in IEX-1 knockout mice. The low-level laser therapy (LLLT) suppressed proinflammatory cytokine expression like interleukin (IL)-1 beta and IL-6 but upregulated TNF-alpha. Moreover, although lack of IEX-1 compromised ATP synthesis, LLLT elevated its production in injured brain. The protective effect of LLLT may be ascribed to enhanced ATP production and selective modulation of proinflammatory mediators. This new closed head injury model provides an excellent tool to investigate the pathogenesis of secondary brain injury as well as the mechanism underlying the beneficial effect of LLLT.	[Zhang, Qi; Zhou, Chang; Hamblin, Michael R.; Wu, Mei X.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Zhang, Qi; Zhou, Chang; Hamblin, Michael R.; Wu, Mei X.] Harvard Med Sch, Dept Dermatol, Boston, MA 02114 USA; [Hamblin, Michael R.; Wu, Mei X.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Wu, MX (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	mwu2@partners.org	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605	Air Force Office of Scientific Research Militory Phtomedicine Program [FA9550-11-1-0331]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA158756, R01AI050875]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA158756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work is supported by Air Force Office of Scientific Research Militory Phtomedicine Program (FA9550-11-1-0331) and the National Institutes of Health Grants CA158756 to MW and National Institutes of Health Grants R01AI050875 to MR.	Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Arlt A, 2011, EUR J CELL BIOL, V90, P545, DOI 10.1016/j.ejcb.2010.10.002; Assis L, 2012, LASER SURG MED, V44, P726, DOI 10.1002/lsm.22077; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Campanella M, 2008, CELL METAB, V8, P13, DOI 10.1016/j.cmet.2008.06.001; Carvey PM, 2003, FRONT BIOSCI-LANDMRK, V8, pS826, DOI 10.2741/1158; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; FAN L, 1995, MOL BRAIN RES, V30, P125; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; KARU T, 1989, Journal of Photochemistry and Photobiology B Biology, V3, P638, DOI 10.1016/1011-1344(89)80088-0; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lehoux S, 2003, CIRC RES, V93, P1139, DOI 10.1161/01.RES.0000108693.79326.A8; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Pastore D, 2000, INT J RADIAT BIOL, V76, P863; Qin LY, 2007, GLIA, V55, P453, DOI 10.1002/glia.20467; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shahid M, 2010, HYPERTENSION, V56, P705, DOI 10.1161/HYPERTENSIONAHA.110.154880; Shen L, 2009, CELL DEATH DIFFER, V16, P603, DOI 10.1038/cdd.2008.184; Shen L, 2006, J BIOL CHEM, V281, P15304, DOI 10.1074/jbc.M600054200; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sutherland JC, 2002, PHOTOCHEM PHOTOBIOL, V76, P164, DOI 10.1562/0031-8655(2002)076<0164:BEOPL>2.0.CO;2; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Wu XJ, 2009, LASER SURG MED, V41, P36, DOI 10.1002/lsm.20729; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147	37	33	33	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	AUG	2014	34	8					1391	1401		10.1038/jcbfm.2014.95			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	AM4ZG	WOS:000339864100016	24849666	Green Published, Bronze			2021-06-18	
J	Lama, S; Auer, RN; Tyson, R; Gallagher, CN; Tomanek, B; Sutherland, GR				Lama, Sanju; Auer, Roland N.; Tyson, Randy; Gallagher, Clare N.; Tomanek, Boguslaw; Sutherland, Garnette R.			Lactate Storm Marks Cerebral Metabolism following Brain Trauma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICARBOXYLIC-ACID CYCLE; OXIDATIVE STRESS; C-13 NMR; COGNITIVE DEFICITS; GLUCOSE-METABOLISM; SUBSTRATE DELIVERY; GLUTAMATE UPTAKE; INJURY; MICRODIALYSIS; ASTROCYTES	Brain metabolism is thought to be maintained by neuronalglial metabolic coupling. Glia take up glutamate from the synaptic cleft for conversion into glutamine, triggering glial glycolysis and lactate production. This lactate is shuttled into neurons and further metabolized. The origin and role of lactate in severe traumatic brain injury (TBI) remains controversial. Using a modified weight drop model of severe TBI and magnetic resonance (MR) spectroscopy with infusion of C-13-labeled glucose, lactate, and acetate, the present study investigated the possibility that neuronal-glial metabolism is uncoupled following severe TBI. Histopathology of the model showed severe brain injury with subarachnoid and hemorrhage together with glial cell activation and positive staining for Tau at 90 min post-trauma. High resolution MR spectroscopy of brain metabolites revealed significant labeling of lactate at C-3 and C-2 irrespective of the infused substrates. Increased C-13-labeled lactate in all study groups in the absence of ischemia implied activated astrocytic glycolysis and production of lactate with failure of neuronal uptake (i.e. a loss of glial sensing for glutamate). The early increase in extracellular lactate in severe TBI with the injured neurons rendered unable to pick it up probably contributes to a rapid progression toward irreversible injury and pan-necrosis. Hence, a method to detect and scavenge the excess extracellular lactate on site or early following severe TBI may be a potential primary therapeutic measure.	[Lama, Sanju; Tyson, Randy; Gallagher, Clare N.; Tomanek, Boguslaw; Sutherland, Garnette R.] Univ Calgary, Dept Clin Neurosci, Fac Med, Calgary, AB T2N 2T9, Canada; [Lama, Sanju; Tyson, Randy; Gallagher, Clare N.; Tomanek, Boguslaw; Sutherland, Garnette R.] Univ Calgary, Hotchkiss Brain Inst, Fac Med, Calgary, AB T2N 2T9, Canada; [Auer, Roland N.] Univ Montreal, Hop Ste Justine, Dept Pathol, Montreal, PQ H3T 1C5, Canada	Sutherland, GR (corresponding author), Univ Calgary, Hlth Res Innovat Ctr 1C60, 3280 Hosp Dr NW, Calgary, AB T2N 4Z6, Canada.	garnette@ucalgary.ca	Tomanek, Boguslaw/J-4720-2014; Tomanek, Boguslaw/AAD-7594-2019; Auer, Roland/G-7164-2011	Tomanek, Boguslaw/0000-0003-2602-0280; Auer, Roland/0000-0001-9044-3419	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) [RT733596]	This work was supported by the Canadian Institutes for Health Research grant entitled Cerebral Metabolism in Traumatic Brain Injury RT733596 (to G. R. S.).	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; ALVES PM, 1995, NEUROREPORT, V6, P2201, DOI 10.1097/00001756-199511000-00024; ANDERSEN BJ, 1992, BRAIN RES, V585, P190, DOI 10.1016/0006-8993(92)91206-T; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Bartnik BL, 2007, J NEUROTRAUM, V24, P1079, DOI 10.1089/neu.2006.0210; Bartnik BL, 2007, J NEUROTRAUM, V24, P181, DOI 10.1089/neu.2006.0038; BECKMANN N, 1991, BIOCHEMISTRY-US, V30, P6362, DOI 10.1021/bi00240a002; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chen T, 2000, ACT NEUR S, V76, P359; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Choi HB, 2012, NEURON, V75, P1094, DOI 10.1016/j.neuron.2012.08.032; Clausen T, 2005, J NEUROSURG, V103, P597, DOI 10.3171/jns.2005.103.4.0597; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Dienel GA, 2012, J CEREBR BLOOD F MET, V32, P1107, DOI 10.1038/jcbfm.2011.175; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gallagher CN, 2009, BRAIN, V132, P2839, DOI 10.1093/brain/awp202; Gruetter R, 2002, NEUROCHEM INT, V41, P143, DOI 10.1016/S0197-0186(02)00034-7; Hassel B, 1997, J CEREBR BLOOD F MET, V17, P1230, DOI 10.1097/00004647-199711000-00012; HASSEL B, 1992, BRAIN RES, V576, P120, DOI 10.1016/0006-8993(92)90616-H; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Ichai C, 2009, INTENS CARE MED, V35, P471, DOI 10.1007/s00134-008-1283-5; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; KISHI K, 1994, BIOCHEMISTRY-US, V33, P8694, DOI 10.1021/bi00195a010; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Magistretti PJ, 2009, AM J CLIN NUTR, V90, p875S, DOI 10.3945/ajcn.2009.27462CC; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McKenna MC, 1995, NEUROCHEM RES, V20, P1491, DOI 10.1007/BF00970599; Melov S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000536; Mondragon-Rodriguez S, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/940603; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; PEELING J, 1992, MAGNET RESON MED, V24, P123, DOI 10.1002/mrm.1910240113; Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Peronnet F, 2006, RESP PHYSIOL NEUROBI, V150, P4, DOI 10.1016/j.resp.2005.04.005; PONTEN U, 1973, J NEUROCHEM, V21, P1127, DOI 10.1111/j.1471-4159.1973.tb07567.x; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Rodriguez-Rodriguez A, 2014, CURR MED CHEM, V21, P1201, DOI 10.2174/0929867321666131217153310; Sala N, 2013, J CEREBR BLOOD F MET, V33, P1815, DOI 10.1038/jcbfm.2013.142; Sanchez Jose J, 2013, Acta Neurochir Suppl, V118, P223, DOI 10.1007/978-3-7091-1434-6_42; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; Tyson RL, 2000, NEUROREPORT, V11, P1845, DOI 10.1097/00001756-200006260-00009; Tyson RL, 2003, BRAIN RES, V992, P43, DOI 10.1016/j.brainres.2003.08.027; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; van de Waterbeemd H, 1998, J DRUG TARGET, V6, P151, DOI 10.3109/10611869808997889; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vogel R, 1998, NEUROSCI LETT, V247, P123, DOI 10.1016/S0304-3940(98)00290-0; Weinstein JS, 2010, J CEREBR BLOOD F MET, V30, P15, DOI 10.1038/jcbfm.2009.192; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	58	33	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2014	289	29					20200	20208		10.1074/jbc.M114.570978			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	AL8NE	WOS:000339395200033	24849602	Green Published, Other Gold			2021-06-18	
J	Jia, F; Yin, YH; Gao, GY; Wang, Y; Cen, L; Jiang, JY				Jia, Feng; Yin, Yu Hua; Gao, Guo Yi; Wang, Yu; Cen, Lian; Jiang, Ji-yao			MMP-9 Inhibitor SB-3CT Attenuates Behavioral Impairments and Hippocampal Loss after Traumatic Brain Injury in Rat	JOURNAL OF NEUROTRAUMA			English	Article						hippocampus; neuroprotection; SB-3CT; traumatic brain injury	MATRIX-METALLOPROTEINASE ACTIVITY; MATRIX-METALLOPROTEINASE-9; EXPRESSION; ISCHEMIA; DEFICITS; BLOOD; FLUID; PROTEOLYSIS; HYPOTHERMIA; APOPTOSIS	The aim of this study was to evaluate the potential efficacy of SB-3CT, a matrix metallopeptidase 9 inhibitor, on behavioral and histological outcomes after traumatic brain injury (TBI) in rats. Adult male Sprague-Dawley rats were randomly divided into three groups (n = 15/group): TBI with SB-3CT treatment, TBI with saline, and sham injury. The TBI model was induced by a fluid percussion TBI device. SB-3CT (50 mg/kg in 10% dimethyl sulfoxide) was administered intraperitoneally at 30 min, 6 h, and 12 h after the TBI. Motor function (beam-balance/beam-walk tests) and spatial learning/memory (Morris water maze) were assessed on post-operative Days 1-5 and 11-15, respectively. Fluoro-Jade staining, immunofluorescence, and cresyl violet-staining were carried out for histopathological evaluation at 24 h, 72 h, and 15 days after TBI, respectively. It was shown that TBI can result in significant behavioral deficit induced by acute neurodegeneration, increased expression of cleaved caspase-3, and long-term neuronal loss. SB-3CT intervention via the current regime provides robust behavioral protection and hippocampal neurons preservation from the deleterious effects of TBI. Hence, the efficacy of SB-3CT on TBI prognosis could be ascertained. It is believed that the current study adds to the growing literature in identifying SB-3CT as a potential therapy for human brain injury.	[Jia, Feng; Yin, Yu Hua; Gao, Guo Yi; Wang, Yu; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Dept Neurosurg, Shanghai 200127, Peoples R China; [Cen, Lian] E China Univ Sci & Technol, Sch Chem Engn, Shanghai 20237, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, RenJi Hosp, Dept Neurosurg, Sch Med, Shanghai 200127, Peoples R China.	cenlian@hotmail.com; jiangjyb@126.com			973 projectNational Basic Research Program of China [2012CB518100, 2010CB944804]; National Key Basic Research ProjectNational Basic Research Program of China [81271381]; National Science and Nature Grant [81000829]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [11QB1402200]	This work was supported by grants from 973 project (No. 2012CB518100, No. 2010CB944804), National Key Basic Research Project (No. 81271381), National Science and Nature Grant (No. 81000829), and the Fundamental Research Funds for the Central Universities (No. 11QB1402200).	Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cui J., 2012, MOL NEURODEGENER, V15, P1186; Demestre M, 2004, NEUROSCIENCE, V124, P767, DOI 10.1016/j.neuroscience.2003.12.037; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eadie BD, 2005, J COMP NEUROL, V486, P39, DOI 10.1002/cne.20493; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Feng JF, 2011, BRAIN RES, V1395, P62, DOI 10.1016/j.brainres.2011.04.022; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gu ZZ, 2005, J NEUROSCI, V25, P6401, DOI 10.1523/JNEUROSCI.1563-05.2005; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Jia F, 2014, J NEUROTRAUM, V31, P387, DOI 10.1089/neu.2008.0814; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; Jia F, 2009, J NEUROTRAUM, V26, P243, DOI 10.1089/neu.2008.0670; Kang SW, 2011, BRAIN RES, V1371, P121, DOI 10.1016/j.brainres.2010.11.057; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kline AE, 2010, J NEUROTRAUM, V27, P2021, DOI 10.1089/neu.2010.1535; Liedtke W, 1998, ANN NEUROL, V44, P35, DOI 10.1002/ana.410440110; Liu J, 2012, J NEUROSCI, V32, P3044, DOI 10.1523/JNEUROSCI.6409-11.2012; Matyszak MK, 1996, J NEUROIMMUNOL, V69, P141; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nagy V, 2006, J NEUROSCI, V26, P1923, DOI 10.1523/JNEUROSCI.4359-05.2006; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135; Noble LJ, 2002, J NEUROSCI, V22, P7526; Ralay R. H., 2011, J NEUROTRAUM, V28, P1757, DOI DOI 10.1089/NEU.2011.1799; Ranasinghe HS, 2012, DEV NEUROSCI-BASEL, V34, P417, DOI 10.1159/000343257; Rau TF, 2012, J TRAUMA ACUTE CARE, V73, pS165, DOI 10.1097/TA.0b013e318260896a; Redford EJ, 1997, BRAIN, V120, P1895, DOI 10.1093/brain/120.10.1895; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sood RR, 2008, J CEREBR BLOOD F MET, V28, P431, DOI 10.1038/sj.jcbfm.9600534; Steinmann-Niggli K, 1998, J AM SOC NEPHROL, V9, P397; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Vyavahare N, 2000, AM J PATHOL, V157, P885, DOI 10.1016/S0002-9440(10)64602-0; Wang J, 2005, NEUROCRIT CARE, V3, P77, DOI 10.1385/NCC:3:1:077; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yu F, 2008, J NEUROTRAUM, V25, P184, DOI 10.1089/neu.2007.0438; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	53	33	33	1	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1225	1234		10.1089/neu.2013.3230			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500011	24661104	Green Published			2021-06-18	
J	Miller, DM; Wang, JA; Buchanan, AK; Hall, ED				Miller, Darren M.; Wang, Juan A.; Buchanan, Ashley K.; Hall, Edward D.			Temporal and Spatial Dynamics of Nrf2-Antioxidant Response Elements Mediated Gene Targets in Cortex and Hippocampus after Controlled Cortical Impact Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						4-hydroxy-2-nonenal; gene expression; lipid peroxidation; Nrf2; oxidative damage; traumatic brain injury	AMYOTROPHIC-LATERAL-SCLEROSIS; TRANSCRIPTION FACTOR NRF2; COMPLEX-II INHIBITION; OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; SYNAPTIC PROTEINS; CARNOSIC ACID; SPINAL-CORD; MOUSE MODEL; HEAD-INJURY	The pathophysiological importance of oxidative damage after traumatic brain injury (TBI) has been extensively demonstrated. The transcription factor nuclear factor erythoid related factor 2 (Nrf2) mediates antioxidant and cytoprotective genes by binding to antioxidant response elements (ARE) present in nuclear DNA. In this study, we characterized the time course of Nrf2-ARE-mediated expression in the cortex and hippocampus using a unilateral controlled cortical impact model of focal TBI. Ipsilateral hippocampal and cortical tissue was collected for Western-blot protein analysis (n = 6/group) or quantitative reverse transcription-polymerase chain reaction for mRNA (n = 3/group) at 3, 6, 12, 24, 48, and 72 h or 1 week post-injury. Multiple genes mediated by Nrf2-ARE were altered post-TBI. Specifically, Nrf2 mRNA increased significantly post-TBI at 48 and 72 h in the cortex and at 48 and 72 h and 1 week in the hippocampus with a coincident increase in glial fibrillary acidic protein mRNA, thereby implying this response is likely occurring in astrocytes. Presumably linked to Nrf2 activation, heme-oxygenase-1, nicotinamide adenine dinucleotide phosphate-quinone-oxidoreductase 1, glutathione reductase, and catalase mRNA overlap throughout the post-injury time course. This study demonstrates the first evidence of such changes during the first week after focal TBI and that increases in expression of some Nrf2-AREmediated cytoprotective genes are not observed until 24-48 h post-injury. Unfortunately, this does not precede, but rather coincides with, the occurrence of lipid peroxidative damage. This is the first known comparison between the time course of peroxidative damage and that of Nrf2-ARE activation during the first week post-TBI. These results underscore the necessity to discover pharmacological agents to accelerate and amplify Nrf2-ARE-mediated expression early post-TBI.	[Miller, Darren M.; Wang, Juan A.; Buchanan, Ashley K.; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Miller, Darren M.; Hall, Edward D.] Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, Spinal Cord & Brain Injury Res Ctr, Coll Med, 741 S Limestone St BBSRB Room B477, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1T32 DA022738]; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1T32 NS077889, 2P30 NS051220-01]; Kentucky Spinal Cord & Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, T32NS077889] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	The authors would like to thank Kimberly M. Carrico for expert technical assistance. This work was supported by grants NIH-NIDA 1T32 DA022738, NIH-NINDS 1T32 NS077889, NIH-NINDS 2P30 NS051220-01, and funds from the Kentucky Spinal Cord & Head Injury Research Trust.	Andrus PK, 1998, J NEUROCHEM, V71, P2041; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Calkins MJ, 2010, TOXICOL SCI, V115, P557, DOI 10.1093/toxsci/kfq072; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; Cheng ZG, 2013, ASIAN PAC J TROP MED, V6, P305, DOI 10.1016/S1995-7645(13)60061-9; Dash PK, 2009, NEUROSCI LETT, V460, P103, DOI 10.1016/j.neulet.2009.04.028; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Dowell JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070163; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680; Innamorato NG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011838; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin W, 2009, EXP BIOL MED, V234, P181, DOI 10.3181/0807-RM-232; Johnson JA, 2008, ANN NY ACAD SCI, V1147, P61, DOI 10.1196/annals.1427.036; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kraft AD, 2007, EXP NEUROL, V207, P107, DOI 10.1016/j.expneurol.2007.05.026; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Miller DM, 2013, FREE RADICAL BIO MED, V57, P1, DOI 10.1016/j.freeradbiomed.2012.12.011; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Satoh T, 2008, J NEUROCHEM, V104, P1116, DOI 10.1111/j.1471-4159.2007.05039.x; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Son TG, 2010, J NEUROCHEM, V112, P1316, DOI 10.1111/j.1471-4159.2009.06552.x; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zhao J, 2005, J NEUROSCI RES, V82, P499, DOI 10.1002/jnr.20649; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506	46	33	35	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2014	31	13					1194	1201		10.1089/neu.2013.3218			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AL2VK	WOS:000338983500008	24628668	Green Published			2021-06-18	
J	Salazar, D; Golz, A; Israel, H; Marra, G				Salazar, Dane; Golz, Andrew; Israel, Heidi; Marra, Guido			Heterotopic Ossification of the Elbow Treated With Surgical Resection: Risk Factors, Bony Ankylosis, and Complications	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							RADIATION-THERAPY; EARLY EXCISION; EXPERIENCE; FIXATION; RELEASE; INJURY; BURNS	Heterotopic ossification is the most common extrinsic cause of elbow contracture and may lead to clinically important stiffness, and rarely, complete bony ankylosis. Surgery sometimes is performed to treat this problem, and published reports differ regarding the factors that are associated with success or failure after this operation and whether the procedure is effective for patients with elbow ankylosis. We wished (1) to identify potential patient characteristics and modifiable risk factors that are associated with improvements in ROM after surgery for heterotopic ossification of the elbow; (2) to compare ROM gains between patients with complete ankylosis and partially restricted ROM; and (3) to characterize the complications of elbows treated by surgical release and excision of heterotopic ossification followed by a standardized rehabilitation program. We reviewed the records of all patients treated operatively for heterotopic ossification of the elbow from September 1999 to February 2012 at one institution by one surgeon. General indications for the surgery were clinically symptomatic or debilitating heterotopic ossification of the elbow. Each patient received prophylaxis postoperatively consisting of indomethacin (or single-shot radiation for patients with sensitivity to antiinflammatory medications). All patients received a physical therapy regimen and used a continuous passive motion machine for 6 weeks. Patient demographics, mechanism of injury, time between injury and surgery, and medical history were reviewed for comparison. Followup was at a mean of 13 months (range, 3-106 months); no patients were lost to followup. Thirty-nine patients (46 elbows) with heterotopic ossification treated with excision were identified: 10 patients (16 elbows) had burns, 28 patients (29 elbows) had trauma, and one patient (one elbow) had a closed head injury. Eight of the 39 patients (12 of 46 elbows [26%]) had complete ankylosis at the time of surgery. Hypertension, obesity, and absence of intraoperative anterior ulnar nerve transposition were associated with an adverse effect on change from preoperative to final arc of motion. The group with ankylosis had greater preoperative to postoperative gain in arc compared with the group with partial restriction (96A degrees, 95% CI, 84A degrees-107A degrees and 59A degrees, 95% CI, 46A degrees-72A degrees, respectively). For the entire cohort there was an overall improvement in mean flexion-extension arc of motion from 35A degrees to 103A degrees at final followup (p < 0.001; 95% CI, 57A degrees-80A degrees), with a 17% rate of complications (three patients [three elbows] with heterotopic ossification, three patients [three elbows] with nerve palsies, one patient [one elbow] with deep wound infection, and one patient [one elbow] with an unstable elbow). Patients with partially and completely restricted ROM showed substantial improvement in postoperative ROM. Hypertension, obesity, and absence of intraoperative anterior ulnar nerve transposition were negative predictors of outcome in our series. Surgery combined with postoperative prophylaxis and a regimented rehabilitation program are feasible modalities to treat patients with heterotopic ossification of the elbow. Level IV, therapeutic study. See the Instructions for Authors for a complete description of levels of evidence.	[Salazar, Dane; Golz, Andrew] Loyola Univ Hlth Syst, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA; [Israel, Heidi] St Louis Univ, Dept Orthopaed Surg, St Louis, MO 63103 USA; [Marra, Guido] Northwestern Univ, Dept Orthopaed Surg, Feinberg Sch Med, Chicago, IL 60611 USA	Salazar, D (corresponding author), Loyola Univ Hlth Syst, Dept Orthopaed Surg & Rehabil, 2160 South First Ave, Maywood, IL 60153 USA.	dsalazar@post.com			Zimmer Inc (Warsaw, IN, USA)	One of the authors certifies that he (GM), or a member of his or her immediate family, has or may receive payments or benefits, during the study period, an amount of less than 10,000 USD from Zimmer Inc (Warsaw, IN, USA).	Abrams GD, 2012, J SHOULDER ELB SURG, V21, P1550, DOI 10.1016/j.jse.2012.05.040; Akman S, 2010, ACTA ORTHOP TRAUMATO, V44, P206, DOI 10.3944/AOTT.2010.2441; Baldwin K, 2011, J HAND SURG-AM, V36A, P798, DOI 10.1016/j.jhsa.2011.01.015; Brouwer KM, 2010, J HAND SURG-AM, V35A, P1115, DOI 10.1016/j.jhsa.2010.03.040; Chao EK, 2002, J TRAUMA, V53, P928, DOI 10.1097/00005373-200211000-00019; Chapleau J, 2011, CLIN ORTHOP RELAT R, V469, P3134, DOI 10.1007/s11999-011-1986-8; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; GARDNER RJM, 1988, J MED GENET, V25, P113, DOI 10.1136/jmg.25.2.113; Garland DE, 1998, J BONE JOINT SURG AM, V80A, P453, DOI 10.2106/00004623-199803000-00023; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; Gaur A, 2003, J BONE JOINT SURG AM, V85A, P1538, DOI 10.2106/00004623-200308000-00016; HASTINGS H, 1994, HAND CLIN, V10, P417; Hunt JL, 2006, J BURN CARE RES, V27, P535, DOI 10.1097/01.BCR.0000226023.58438.14; Keschner MT, 2007, BULL HOSP JT DIS, V65, P24; Koh KH, 2013, J SHOULDER ELB SURG, V22, P1128, DOI 10.1016/j.jse.2013.04.019; Lee EK, 2013, J SHOULDER ELB SURG, V22, P716, DOI 10.1016/j.jse.2012.11.020; Maender C, 2010, J SHOULDER ELB SURG, V19, P1269, DOI 10.1016/j.jse.2010.05.029; McAuliffe JA, 1997, J BONE JOINT SURG AM, V79A, P749, DOI 10.2106/00004623-199705000-00015; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; Park MJ, 2010, J BONE JOINT SURG AM, V92A, P2692, DOI 10.2106/JBJS.I.01367; Ring D, 2003, J BONE JOINT SURG AM, V85A, P849, DOI 10.2106/00004623-200305000-00012; Ring David, 2004, Tech Hand Up Extrem Surg, V8, P25, DOI 10.1097/00130911-200403000-00007; Ruan HJ, 2013, ARCH ORTHOP TRAUM SU, V133, P179, DOI 10.1007/s00402-012-1659-4; Summerfield SL, 1997, J SHOULDER ELB SURG, V6, P321, DOI 10.1016/S1058-2746(97)90025-2; Tsionos I, 2004, J BONE JOINT SURG BR, V86B, P396, DOI 10.1302/0301-620X.86B3.14480	26	33	40	0	37	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	JUL	2014	472	7					2269	2275		10.1007/s11999-014-3591-0			7	Orthopedics; Surgery	Orthopedics; Surgery	AI6XP	WOS:000337021300041	24711127	Bronze, Green Published			2021-06-18	
J	Hess, EP; Wyatt, KD; Kharbanda, AB; Louie, JP; Dayan, PS; Tzimenatos, L; Wootton-Gorges, SL; Homme, JL; Pencille, RNL; LeBlanc, A; Westphal, JJ; Shepel, K; Shah, ND; Branda, M; Herrin, J; Montori, VM; Kuppermann, N				Hess, Erik P.; Wyatt, Kirk D.; Kharbanda, Anupam B.; Louie, Jeffrey P.; Dayan, Peter S.; Tzimenatos, Leah; Wootton-Gorges, Sandra L.; Homme, James L.; Pencille, Laurie R. N.; LeBlanc, Annie; Westphal, Jessica J.; Shepel, Kathy; Shah, Nilay D.; Branda, Megan; Herrin, Jeph; Montori, Victor M.; Kuppermann, Nathan			Effectiveness of the head CT choice decision aid in parents of children with minor head trauma: study protocol for a multicenter randomized trial	TRIALS			English	Article							OPTION SCALE; VALIDATION; RISK; MEDICATIONS; CHILDHOOD; NUMERACY; TRUST; SCANS; CARE	Background: Blunt head trauma is a common cause of death and disability in children worldwide. Cranial computed tomography (CT), the reference standard for the diagnosis of traumatic brain injury (TBI), exposes children to ionizing radiation which has been linked to the development of brain tumors, leukemia, and other cancers. We describe the methods used to develop and test the effectiveness of a decision aid to facilitate shared decision-making with parents regarding whether to obtain a head CT scan or to further observe their child at home. Methods/Design: This is a protocol for a multicenter clinician-level parallel randomized trial to compare an intervention group receiving a decision aid, 'Head CT Choice', to a control group receiving usual care. The trial will be conducted at five diverse emergency departments (EDs) in Minnesota and California. Clinicians will be randomized to decision aid or usual care. Parents visiting the ED with children who are less than 18-years-old, have experienced blunt head trauma within 24 hours, and have one or two risk factors for clinically-important TBI (ciTBI) from the Pediatric Emergency Care Applied Research Network head injury clinical prediction rules will be eligible for enrollment. We will measure the effect of Head CT Choice on: (1) parent knowledge regarding their child's risk of ciTBI, the available diagnostic options, and the risks of radiation exposure associated with a cranial CT scan (primary outcome); (2) parent engagement in the decision-making process; (3) the degree of conflict parents experience related to feeling uninformed; (4) patient and clinician satisfaction with the decision made; (5) the rate of ciTBI at seven days; (6) the proportion of patients in whom a cranial CT scan is obtained; and (7) seven-day healthcare utilization. To capture these outcomes, we will administer parent and clinician surveys immediately after each clinical encounter, obtain video recordings of parent-clinician discussions, administer parent healthcare utilization diaries, analyze hospital billing records, review the electronic medical record, and conduct telephone follow-up. Discussion: This multicenter trial will robustly assess the effectiveness of a decision aid on patient-centered outcomes, safety, and healthcare utilization in parents of children with minor head trauma in five diverse EDs.	[Hess, Erik P.; Pencille, Laurie R. N.; LeBlanc, Annie; Shah, Nilay D.; Branda, Megan; Montori, Victor M.] Mayo Clin, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA; [Hess, Erik P.] Mayo Clin, Div Emergency Med Res, Dept Emergency Med, Rochester, MN 55905 USA; [Hess, Erik P.; LeBlanc, Annie; Shah, Nilay D.; Branda, Megan] Mayo Clin, Dept Hlth Sci Res, Div Hlth Care Policy & Res, Rochester, MN 55905 USA; [Hess, Erik P.; LeBlanc, Annie; Shah, Nilay D.; Branda, Megan] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Healthcare Del, Rochester, MN 55902 USA; [Wyatt, Kirk D.] Mayo Clin, Mayo Med Sch, Coll Med, Rochester, MN 55902 USA; [Kharbanda, Anupam B.] Childrens Hosp & Clin Minnesota, St Paul, MN 55102 USA; [Louie, Jeffrey P.] Univ Minnesota, Amplatz Childrens Hosp, Minneapolis, MN 55455 USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Dept Emergency Med, New York, NY 10032 USA; [Louie, Jeffrey P.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Tzimenatos, Leah; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Emergency Med, Davis, CA 95817 USA; [Tzimenatos, Leah; Kuppermann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95817 USA; [Wootton-Gorges, Sandra L.] Univ Calif Davis, Sch Med, Dept Radiol, Davis, CA 95817 USA; [Homme, James L.] Mayo Clin, Dept Emergency Med, Div Pediat Emergency Med, Rochester, MN 55902 USA; [Homme, James L.] Mayo Clin, Dept Pediat, Div Pediat Emergency Med, Rochester, MN 55902 USA; [Westphal, Jessica J.] Parent Representat, Rochester, MN USA; [Shepel, Kathy] Mayo Clin, Sect Creat Media, Rochester, MN 55902 USA; [Herrin, Jeph] Yale Univ, Sch Med, Dept Cardiol, New Haven, CT 06520 USA; [Herrin, Jeph] Hlth Res & Educ Trust, Chicago, IL 60606 USA; [Montori, Victor M.] Mayo Clin, Dept Internal Med, Div Endocrinol & Metab, Rochester, MN 55902 USA	Hess, EP (corresponding author), Mayo Clin, Knowledge & Evaluat Res Unit, 200 First St SW, Rochester, MN 55905 USA.	hess.erik@mayo.edu	LeBlanc, Annie/AAZ-1381-2020	Montori, Victor/0000-0003-0595-2898	Patient Centered Outcomes Research Institute (PCORI)Patient-Centered Outcomes Research Institute - PCORI [CE-12-11-4435]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000135] Funding Source: NIH RePORTER	The trial was funded by the Patient Centered Outcomes Research Institute (PCORI) under contract number CE-12-11-4435.	Allen Donner, 2000, DESIGN ANAL CLUSTER; ANDERSON LA, 1990, PSYCHOL REP, V67, P1091, DOI 10.2466/pr0.1990.67.3f.1091; Bosker, 2012, MULTILEVEL ANAL INTR; Breslin M, 2008, PATIENT EDUC COUNS, V73, P465, DOI 10.1016/j.pec.2008.07.024; Charles C, 1997, SOC SCI MED, V44, P681, DOI 10.1016/S0277-9536(96)00221-3; Degner L F, 1997, Can J Nurs Res, V29, P21; Elwyn G, 2005, HEALTH EXPECT, V8, P34, DOI 10.1111/j.1369-7625.2004.00311.x; Elwyn G, 2003, QUAL SAF HEALTH CARE, V12, P93, DOI 10.1136/qhc.12.2.93; Fagerlin A, 2007, MED DECIS MAKING, V27, P672, DOI 10.1177/0272989x07304449; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fergusson D, 2002, BMJ-BRIT MED J, V325, P652, DOI 10.1136/bmj.325.7365.652; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Hess EP, 2012, CIRC-CARDIOVASC QUAL, V5, P251, DOI 10.1161/CIRCOUTCOMES.111.964791; Karanicolas PJ, 2009, J CLIN EPIDEMIOL, V62, P479, DOI 10.1016/j.jclinepi.2008.02.009; Koedoot N, 2001, PATIENT EDUC COUNS, V45, P187, DOI 10.1016/S0738-3991(01)00120-3; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LeBlanc A, 2013, TRIALS, V14, DOI 10.1186/1745-6215-14-127; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Moher D, 2012, INT J SURG, V10, P28, DOI 10.1016/j.ijsu.2011.10.001; Montori VM, 2011, AM J MED, V124, P549, DOI 10.1016/j.amjmed.2011.01.013; Montori VM, 2007, PLOS MED, V4, P1303, DOI 10.1371/journal.pmed.0040233; Mullan RJ, 2009, ARCH INTERN MED, V169, P1560, DOI 10.1001/archinternmed.2009.293; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; Schonfeld D, 2014, ARCH DIS CHILD, V99, P427, DOI 10.1136/archdischild-2013-305004; Smith-Bindman R, 2009, ARCH INTERN MED, V169, P2078, DOI 10.1001/archinternmed.2009.427; Stacey D, 2014, COCHRANE DATABASE SY, V1; Thom DH, 1999, MED CARE, V37, P510, DOI 10.1097/00005650-199905000-00010; Zikmund-Fisher BJ, 2007, MED DECIS MAKING, V27, P663, DOI 10.1177/0272989x07303824	32	33	34	0	14	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	JUN 25	2014	15								253	10.1186/1745-6215-15-253			11	Medicine, Research & Experimental	Research & Experimental Medicine	AK5KU	WOS:000338464300001	24965659	DOAJ Gold, Green Published			2021-06-18	
J	Chiaravalloti, ND; Ibarretxe-Bilbao, N; DeLuca, J; Rusu, O; Pena, J; Garcia-Gorostiaga, I; Ojeda, N				Chiaravalloti, Nancy D.; Ibarretxe-Bilbao, Naroa; DeLuca, John; Rusu, Olga; Pena, Javier; Garcia-Gorostiaga, Ines; Ojeda, Natalia			The Source of the Memory Impairment in Parkinson's Disease: Acquisition Versus Retrieval	MOVEMENT DISORDERS			English	Article						learning; memory; Parkinson's disease; cognition; Open Trial Selective Reminding Test	TRAUMATIC BRAIN-INJURY; ADULT AGE-DIFFERENCES; MULTIPLE-SCLEROSIS; COGNITIVE IMPAIRMENT; RECOGNITION MEMORY; PROCESSING-SPEED; WORKING-MEMORY; SUBCORTICAL DEMENTIA; TEST-PERFORMANCE; HIPPOCAMPAL	Memory deficits are common in persons with Parkinson's disease (PD) even without the presence of a frank dementia. These memory deficits have traditionally been attributed to inability of patients to retrieve information from long-term memory, referred to as the retrieval failure hypothesis. However, some studies additionally document problems in recognition memory, noted to be inconsistent with the retrieval failure hypothesis. Given the neuroanatomical abnormalities observed in the hippocampus of PD patients and the role of the hippocampus in learning new information, the current study was designed to specifically examine learning abilities in a nondemented PD sample through the application of a learning paradigm, the Open Trial Selective Reminding Test. We examined 27 patients with PD without dementia and 27 age-, gender-, and education-matched healthy controls (HCs) with a neuropsychological test battery designed to assess new learning and memory. Results indicated a significant difference between the groups in terms of their ability to learn a list of 10 semantically related words. However, once the groups were equated on learning abilities, no significant difference was noted between the PD and HC participants in recall or recognition of the newly learned material. The memory deficit observed in nondemented PD patients is thus largely the result of a deficit in learning new information. This finding should be used to guide treatment for memory deficits in persons with PD, and future research should seek to identify novel means of improving new learning in this population. (c) 2014 International Parkinson and Movement Disorder Society	[Chiaravalloti, Nancy D.; DeLuca, John] Kessler Fdn, W Orange, NJ USA; [Chiaravalloti, Nancy D.; DeLuca, John] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA; [Ibarretxe-Bilbao, Naroa; Rusu, Olga; Pena, Javier; Ojeda, Natalia] Univ Deusto, Fac Psychol & Educ, Dept Methods & Expt Psychol, Neuropsychol Psychiat & Neurol Disorders Res Team, Bilbao, Spain; [DeLuca, John] Rutgers New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ USA; [Garcia-Gorostiaga, Ines] Galdakao Hosp, Dept Neurol, Galdakao, Spain	Ibarretxe-Bilbao, N (corresponding author), Univ Deusto, Fac Psychol & Educ, Univ 24, E-48007 Bilbao, Spain.	naroa.ibarretxe@deusto.es	Ibarretxe-Bilbao, Naroa/C-5575-2011; OJEDA, NATALIA/U-8897-2019	Ibarretxe-Bilbao, Naroa/0000-0002-2434-5252; OJEDA, NATALIA/0000-0002-0952-0649; Pena, Javier/0000-0002-0041-7020; Chiaravalloti, Nancy/0000-0003-2943-7567	Health Department of Basque GovernmentBasque Government [2011111117]; Spanish Ministry of Economy and Competitiveness [PSI2012-32441]	This study was supported by the Health Department of Basque Government (2011111117; to N.I.B) and the Spanish Ministry of Economy and Competitiveness (PSI2012-32441; to N.I.B.).	Aarsland D, 2009, NEUROLOGY, V72, P1121, DOI 10.1212/01.wnl.0000338632.00552.cb; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Beatty WW, 2003, ARCH CLIN NEUROPSYCH, V18, P509, DOI 10.1016/S0887-6177(02)00148-8; BEGG I, 1988, MEM COGNITION, V16, P232, DOI 10.3758/BF03197756; BELLEZZA FS, 1989, J EXP PSYCHOL LEARN, V15, P990, DOI 10.1037/0278-7393.15.5.990; Bouchard TP, 2008, NEUROBIOL AGING, V29, P1027, DOI 10.1016/j.neurobiolaging.2007.02.002; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; Bronnick K, 2011, NEUROPSYCHOLOGY, V25, P114, DOI 10.1037/a0020857; Bruck A, 2004, J NEUROL NEUROSUR PS, V75, P1467, DOI 10.1136/jnnp.2003.031237; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Camicioli R, 2003, MOVEMENT DISORD, V18, P784, DOI 10.1002/mds.10444; Chiaravalloti ND, 2013, NEUROLOGY, V81, P2066, DOI 10.1212/01.wnl.0000437295.97946.a8; Chiaravalloti ND, 2013, J CLIN EXP NEUROPSYC, V35, P180, DOI 10.1080/13803395.2012.760537; Chiaravalloti N, 2009, CLIN NEUROPSYCHOL, V23, P231, DOI 10.1080/13854040802121158; Chiaravalloti ND, 2003, CLIN REHABIL, V17, P58, DOI 10.1191/0269215503cr586oa; Chiaravalloti ND, 2002, ARCH PHYS MED REHAB, V83, P1070, DOI 10.1053/apmr.2002.33729; COOPER JA, 1991, BRAIN, V114, P2095, DOI 10.1093/brain/114.5.2095; CUMMINGS JL, 1984, ARCH NEUROL-CHICAGO, V41, P874, DOI 10.1001/archneur.1984.04050190080019; Daniel S E, 1993, J Neural Transm Suppl, V39, P165; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DeLuca J, 2000, ARCH PHYS MED REHAB, V81, P1327, DOI 10.1053/apmr.2000.9390; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; Dubois B, 1998, COGNITIVE BEHAV ASPE; Dubois B, 2007, MOVEMENT DISORD, V22, P2314, DOI 10.1002/mds.21844; Elgh E, 2009, EUR J NEUROL, V16, P1278, DOI 10.1111/j.1468-1331.2009.02707.x; Emre M, 2007, MOVEMENT DISORD, V22, P1689, DOI 10.1002/mds.21507; FLOWERS KA, 1984, J NEUROL NEUROSUR PS, V47, P1174, DOI 10.1136/jnnp.47.11.1174; Foltynie T, 2004, BRAIN, V127, P550, DOI 10.1093/brain/awh067; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Genova HM, 2013, J CLIN EXP NEUROPSYC, V35, P631, DOI 10.1080/13803395.2013.806649; Gonzalez M, 1991, CREACION VALIDACION; Goverover Y, 2009, AM J OCCUP THER, V63, P543, DOI 10.5014/ajot.63.5.543; Goverover Y, 2009, J CLIN EXP NEUROPSYC, V31, P513, DOI 10.1080/13803390802287042; Hely MA, 2008, MOVEMENT DISORD, V23, P837, DOI 10.1002/mds.21956; Higginson CI, 2005, J CLIN EXP NEUROPSYC, V27, P516, DOI 10.1080/13803390490515469; Ibarretxe-Bilbao N, 2011, J NEUROL SCI, V310, P70, DOI 10.1016/j.jns.2011.07.054; Ibarretxe-Bilbao N, 2009, MOVEMENT DISORD, V24, pS748, DOI 10.1002/mds.22670; Jokinen P, 2009, PARKINSONISM RELAT D, V15, P88, DOI 10.1016/j.parkreldis.2008.03.005; Junque C, 2005, MOVEMENT DISORD, V20, P540, DOI 10.1002/mds.20371; LARRABEE GJ, 1986, J CLIN EXP NEUROPSYC, V8, P275, DOI 10.1080/01688638608401318; Lengenfelder J, 2007, REHABIL PSYCHOL, V52, P290, DOI 10.1037/0090-5550.52.3.290; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Liozidou A, 2012, J GERIATR PSYCH NEUR, V25, P215, DOI 10.1177/0891988712466456; Mahurin RK, 1993, NEUROPSYCHOLOGY ALZH; Muslimovic D, 2005, NEUROLOGY, V65, P1239, DOI 10.1212/01.wnl.0000180516.69442.95; Ojeda N, 2012, SCHIZOPHR RES, V135, P72, DOI 10.1016/j.schres.2011.12.004; Owen AM, 2004, NEUROSCIENTIST, V10, P525, DOI 10.1177/1073858404266776; OWEN AM, 1992, BRAIN, V115, P1727, DOI 10.1093/brain/115.6.1727; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; Sumowski JF, 2010, NEUROPSYCHOLOGY, V24, P267, DOI 10.1037/a0017533; Tam CWC, 2005, NEUROLOGY, V64, P861, DOI 10.1212/01.WNL.0000153070.82309.D4; TAYLOR AE, 1986, BRAIN, V109, P845, DOI 10.1093/brain/109.5.845; TROSTER AI, 1995, BEHAV NEUROL, V8, P59, DOI 10.3233/BEN-1995-8201; van Hooren SAH, 2007, AGING NEUROPSYCHOL C, V14, P40, DOI 10.1080/138255890969483; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Whittington CJ, 2000, NEUROPSYCHOLOGY, V14, P233, DOI 10.1037//0894-4105.14.2.233; WILLIAMS JM, 1991, COGNITIVE BEHAV RATI; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	62	33	33	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0885-3185	1531-8257		MOVEMENT DISORD	Mov. Disord.	MAY	2014	29	6					765	771		10.1002/mds.25842			7	Clinical Neurology	Neurosciences & Neurology	AG4BI	WOS:000335363300011	24615718	Bronze			2021-06-18	
J	Dubrovsky, AS; Friedman, D; Kocilowicz, H				Dubrovsky, Alexander Sasha; Friedman, Debbie; Kocilowicz, Helen			Pediatric Post-Traumatic Headaches and Peripheral Nerve Blocks of the Scalp: A Case Series and Patient Satisfaction Survey	HEADACHE			English	Article						post-concussion syndrome; post-traumatic headache; nerve block	TRAUMATIC BRAIN-INJURY; GREATER OCCIPITAL NERVE; POSTCONCUSSION SYNDROME; SUBOCCIPITAL REGION; DOUBLE-BLIND; CHILDREN; MANAGEMENT; MIGRAINE; ADOLESCENTS; LANDMARKS	Objective This study's objective is to characterize the therapeutic effect of peripheral nerve blocks of the scalp for children and adolescents with post-traumatic headaches. Background Headaches are the most frequently reported persistent symptoms following a pediatric mild traumatic brain injury, may be challenging to treat, and can transform into debilitating chronic headaches. The beneficial use of peripheral nerve blocks of the scalp has been reported for adults with post-traumatic headaches. Methods Retrospective case series on all patients January 2012 and June 2013 in the mild traumatic brain injury clinic with a nerve block. The main outcome measure was the proportion of patients with a good therapeutic effect, defined by the duration of the block being >24 hours and/or repeat blocks requested. A data extractor blinded to main outcome measures performed the chart review. A patient satisfaction survey was also sent to all patients to assess the recalled experience with the interventions received. Results A total of 62 nerve blocks were performed on 28 patients for 30 injuries that led to post-traumatic headaches. The mean (standard deviation) age was 14.6 (1.7) years. The first nerve blocks were performed a mean (standard deviation) of 70 (54.2) days post-injury. The therapeutic effect was good in 93% of patients with 71% reporting immediate complete relief of their headaches; the mean percent headache reduction was 94%. Most (91%) would recommend a nerve block for post-traumatic headaches. Conclusion The ease with which peripheral nerve blocks of the scalp can be performed combined with the immediate relief experienced by patients makes them a potential addition to the armamentarium of headache management strategies for children and adolescent with post-traumatic headaches.	[Dubrovsky, Alexander Sasha] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Div Pediat Emergency Med, Montreal, PQ, Canada; [Friedman, Debbie; Kocilowicz, Helen] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Montreal, PQ, Canada; [Dubrovsky, Alexander Sasha; Friedman, Debbie] McGill Univ, Fac Med, Montreal, PQ, Canada	Dubrovsky, AS (corresponding author), 2300 Tupper St,Room T-132, Montreal, PQ H3H 1P3, Canada.	sasha.dubrovsky@mcgill.ca					Ashkenazi A, 2010, HEADACHE, V50, P943, DOI 10.1111/j.1526-4610.2010.01675.x; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bartsch T, 2003, BRAIN, V126, P1801, DOI 10.1093/brain/awg190; Bes A, 2013, CEPHALALGIA, V33, P629, DOI 10.1177/0333102413485658; Blumenfeld A, 2013, HEADACHE, V53, P437, DOI 10.1111/head.12053; Busch V, 2006, CEPHALALGIA, V26, P50, DOI 10.1111/j.1468-2982.2005.00992.x; COPPOLA M, 1995, ANN EMERG MED, V26, P541, DOI 10.1016/S0196-0644(95)70001-3; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; GAWEL MJ, 1992, CEPHALALGIA, V12, P9, DOI 10.1046/j.1468-2982.1992.1201009.x; Guvencer M, 2011, CLIN NEUROL NEUROSUR, V113, P289, DOI 10.1016/j.clineuro.2010.11.021; Hamalainen ML, 1997, NEUROLOGY, V48, P103, DOI 10.1212/WNL.48.1.103; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hecht JS, 2004, J HEAD TRAUMA REHAB, V19, P58, DOI 10.1097/00001199-200401000-00006; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Lewis DW, 2002, HEADACHE, V42, P780, DOI 10.1046/j.1526-4610.2002.02180.x; Loukas M., 2006, Folia Morphologica, V65, P337; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Marshall S, 2012, CAN FAM PHYSICIAN, V58, P257; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Natsis K, 2006, CLIN ANAT, V19, P332, DOI 10.1002/ca.20190; Petraglia AL, 2012, NEUROSURGERY, V70, P1520, DOI 10.1227/NEU.0b013e31824cebe8; SAADAH HA, 1987, HEADACHE, V27, P201, DOI 10.1111/j.1526-4610.1987.hed2704201.x; Tobin JA, 2009, HEADACHE, V49, P1479, DOI 10.1111/j.1526-4610.2009.01549.x; Ward JB, 2003, SEMIN NEUROL, V23, P59; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; Winner P, 2002, HEADACHE, V42, P49, DOI 10.1046/j.1526-4610.2002.02013.x	28	33	33	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAY	2014	54	5					878	887		10.1111/head.12334			10	Clinical Neurology	Neurosciences & Neurology	AG8IW	WOS:000335663000008	24697265				2021-06-18	
J	Trinka, E; Brigo, F				Trinka, Eugen; Brigo, Francesco			Antiepileptogenesis in humans: disappointing clinical evidence and ways to move forward	CURRENT OPINION IN NEUROLOGY			English	Article						antiseizure drugs; biomarker; drug trial; epileptogenesis; seizure prevention	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POST-TRAUMATIC SEIZURES; TEMPORAL-LOBE EPILEPSY; LONG-TERM TREATMENT; VALPROIC ACID USE; POSTTRAUMATIC EPILEPSY; EPILEPTOGENESIS; ISSUES; PREVENTION; PROPHYLAXIS	Purpose of reviewPreclinical research in epileptology has been very successful in developing antiseizure drugs (ASDs). Several preclinical proof-of-concept studies have also provided evidence for positive treatment effects of some antiepileptogenic drugs to prevent the development of epilepsy. Disappointingly, all human antiepileptogenesis trials to prevent epilepsy after brain insults have failed, because of several reasons.Recent findingsNone of the currently available ASDs have been shown to prevent epilepsy after stroke, traumatic brain injury, or in brain tumours. Retrospective series and post-hoc analyses of randomized controlled trials of patients undergoing combined radiochemotherapy for malignant glioblastoma found an increased survival of patients with valproate, thus suggesting a possible role against the symptoms related to the comorbidity of epilepsy in these patients. Target-oriented treatments such as rapamycin and everolimus are currently under clinical investigation to prevent epilepsy in patients with tuberous sclerosis.SummaryAn orchestrated effort among basic and clinical scientists is needed to develop proper antiepileptogenic drugs, powerful biomarkers, and valid clinical trial designs to bring new treatments on the market that can successfully prevent epilepsy.	[Trinka, Eugen] Paracelsus Med Univ Salzburg, Christian Doppler Med Ctr, Dept Neurol, A-5020 Salzburg, Austria; [Trinka, Eugen] Ctr Cognit Neurosci, Salzburg, Austria; [Brigo, Francesco] Univ Verona, Dept Neurol & Movement Sci, Sect Clin Neurol, I-37100 Verona, Italy; [Brigo, Francesco] Franz Tappeiner Hosp, Dept Neurol, Merano, Italy	Trinka, E (corresponding author), Paracelsus Med Univ Salzburg, Christian Doppler Med Ctr, Dept Neurol, Ignaz Harrerstr 79, A-5020 Salzburg, Austria.	e.trinka@salk.at	; Brigo, Francesco/H-6513-2013	Trinka, Eugen/0000-0002-5950-2692; Brigo, Francesco/0000-0003-0928-1577	Commission on European Affairs; Joint Task Force of the ILAE and the AES	The support of the Commission on European Affairs and the Joint Task Force of the ILAE and the AES is kindly acknowledged by the authors.	Adelow C, 2009, EPILEPSIA, V50, P1094, DOI 10.1111/j.1528-1167.2008.01726.x; Barker CA, 2013, INT J RADIAT ONCOL, V86, P504, DOI 10.1016/j.ijrobp.2013.02.012; Beghi E, 2003, EPILEPSIA, V44, P21, DOI 10.1046/j.1528-1157.44.s10.1.x; Bialer M, 2013, EPILEPSY RES, V103, P2, DOI 10.1016/j.eplepsyres.2012.10.001; Blumenfeld H, 2008, EPILEPSIA, V49, P400, DOI 10.1111/j.1528-1167.2007.01458.x; Brooks-Kayal AR, 2013, EPILEPSIA, V54, P44, DOI 10.1111/epi.12298; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; Cotton BA, 2011, J TRAUMA, V71, P375, DOI 10.1097/TA.0b013e318224d307; DELATTRE JY, 1988, NEUROLOGY, V38, P194, DOI 10.1212/WNL.38.2.194; Dezsi G, 2013, EPILEPSIA, V54, P635, DOI 10.1111/epi.12118; Dichter MA, 2009, ARCH NEUROL-CHICAGO, V66, P443, DOI 10.1001/archneurol.2009.10; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Engel J, 2013, EPILEPSIA, V54, P61, DOI 10.1111/epi.12299; Englot DJ, 2012, NEUROLOGY, V78, P1200, DOI 10.1212/WNL.0b013e318250d7ea; Forsyth PA, 2003, CAN J NEUROL SCI, V30, P106, DOI 10.1017/S0317167100053361; FRANCESCHETTI S, 1990, ACTA NEUROCHIR, V103, P47, DOI 10.1007/BF01420191; French JA, 2013, EPILEPSIA, V54, P3, DOI 10.1111/epi.12294; Galanopoulou AS, 2013, EPILEPSIA, V54, P13, DOI 10.1111/epi.12295; Galanopoulou AS, 2013, EPILEPSIA, V54, P1, DOI 10.1111/epi.12293; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Glantz MJ, 1996, NEUROLOGY, V46, P985, DOI 10.1212/WNL.46.4.985; Glauser TA, 2010, NEW ENGL J MED, V362, P790, DOI 10.1056/NEJMoa0902014; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Helmstaedter C, 2013, EUR J NEUROL; Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84; JENNETT WB, 1969, LANCET, V1, P1023; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Kerkhof M, 2013, NEURO-ONCOLOGY, V15, P961, DOI 10.1093/neuonc/not057; Koyama R, 2012, NAT MED, V18, P1271, DOI 10.1038/nm.2850; Kwan J, 2010, COCHRANE DATABASE SY, V6; LEE ST, 1989, SURG NEUROL, V31, P361, DOI 10.1016/0090-3019(89)90067-0; Loscher W, 2013, NAT REV DRUG DISCOV, V12, P757, DOI 10.1038/nrd4126; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; Mani R, 2011, NEUROSCI LETT, V497, P251, DOI 10.1016/j.neulet.2011.03.010; Marigold R, 2013, COCHRANE DATABASE SY, V6; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; Neligan A, 2013, EPILEPSIA, V54, pe62, DOI 10.1111/epi.12148; NORTH JB, 1983, J NEUROSURG, V58, P672, DOI 10.3171/jns.1983.58.5.0672; O'Brien TJ, 2013, EPILEPSIA, V54, P70, DOI 10.1111/epi.12300; Okuda S, 2012, J STROKE CEREBROVASC, V21, P583, DOI 10.1016/j.jstrokecerebrovasdis.2011.01.006; PECHADRE JC, 1991, PRESSE MED, V20, P841; Pitkanen A, 2013, EPILEPSIA, V54, P35, DOI 10.1111/epi.12297; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Pitkanen A, 2010, EPILEPSIA, V51, P2, DOI 10.1111/j.1528-1167.2010.02602.x; Russo E, 2011, EPILEPSIA, V52, P1341, DOI 10.1111/j.1528-1167.2011.03112.x; Russo E, 2010, EPILEPSIA, V51, P1560, DOI 10.1111/j.1528-1167.2009.02400.x; Ryther RCC, 2012, CURR NEUROL NEUROSCI, V12, P410, DOI 10.1007/s11910-012-0276-5; Schierhout G, 2001, COCHRANE DATABASE SY, V4; Schmidt D, 2012, EPILEPTIC DISORD, V14, P105, DOI 10.1684/epd.2012.0512; Simonato M, 2013, CURR OPIN NEUROL, V26, P195, DOI 10.1097/WCO.0b013e32835efe29; Sloviter RS, 2013, NEUROPHARMACOLOGY, V69, P3, DOI 10.1016/j.neuropharm.2012.01.022; Sloviter RS, 2008, EPILEPSIA, V49, P85, DOI 10.1111/j.1528-1167.2008.01931.x; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Tremont-Lukats IW, 2008, COCHRANE DATABASE SY, V2; Tsai HC, 2012, BRIT J NEUROSURG, V26, P347, DOI 10.3109/02688697.2011.638996; Van Gompel JJ, 2012, ARCH NEUROL-CHICAGO, V69, P1476, DOI 10.1001/archneurol.2012.1200; van Luijtelaar G, 2013, NEUROBIOL DIS, V60, P126, DOI 10.1016/j.nbd.2013.08.013; van Tuijl JH, 2011, SEIZURE-EUR J EPILEP, V20, P285, DOI 10.1016/j.seizure.2010.12.012; Vecht CJ, 2006, NEUROLOGY, V67, pS10, DOI 10.1212/WNL.67.12_suppl_4.S10; Vecht CJ, 2003, SEMIN ONCOL, V30, P49, DOI 10.1053/j.seminoncol.2003.11.030; Vezzani A, 2011, EPILEPSIA, V52, P67, DOI 10.1111/j.1528-1167.2011.03242.x; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; Weller M, 2011, NEUROLOGY, V77, P1156, DOI 10.1212/WNL.0b013e31822f02e1; Wilcox KS, 2013, EPILEPSIA, V54, P24, DOI 10.1111/epi.12296; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1983, CHILD BRAIN, V10, P185	72	33	34	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	APR	2014	27	2					227	235		10.1097/WCO.0000000000000067			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AD5KE	WOS:000333290500013	24556736				2021-06-18	
J	Li, ZZ; Dong, XH; Zhang, JF; Zeng, G; Zhao, HM; Liu, Y; Qiu, RB; Mo, LJ; Ye, Y				Li, Zhengzhao; Dong, Xianhong; Zhang, Jianfeng; Zeng, Guang; Zhao, Huimin; Liu, Yun; Qiu, Rubiao; Mo, Linjian; Ye, Yu			Formononetin protects TBI rats against neurological lesions and the underlying mechanism	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Formononetin; Traumatic brain injury; Rat; Inflammation; Oxidative stress; Neuroprotection	TRAUMATIC BRAIN-INJURY; INDUCED APOPTOSIS; NEUROINFLAMMATION; INFLAMMASOME; ACTIVATION; MANAGEMENT; KINASE; CELLS; NRF2	Traumatic brain injury (TB!) is a major cause of disability or death worldwide, especially in the young. Thus, effective medication with few side effects needs to be developed. This work aimed to explore the potential benefits of formononetin (FN) on TBI rodent model and to discuss the regarding mechanism. These findings showed that FN effectively increased the activities of glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) in brain tissue of TB! rats (P < 0.01), while it reduced intracephalic malonaldehyde (MDA), tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) concentrations (P < 0.01). Meanwhile, the hydrocephalus in the TBI rat was alleviated, and the injured nerve cell of the lesioned brain was reduced as showed in hematoxylin-eosin (HE) staining assay. In addition, the endogenous mRNA level of cyclooxygenase-2 (COX-2) in the brain of the TBI rat was significantly down-regulated (P < 0.01). Furthermore, the protein expression of nuclear factor E2-related factor 2 (Nrf2) was effectively up-regulated (P < 0.01). Taken together, we conclude that formononetin mediates the promising anti-TBI effects against neurocyte damage, whichthe underlying mechanisms are associated with inhibiting intracephalic inflammatory response and oxidative stress for neuroprotection. (C) 2013 Elsevier B.V. All rights reserved.	[Li, Zhengzhao; Zhang, Jianfeng; Zeng, Guang; Zhao, Huimin; Ye, Yu] Guangxi Med Univ, Affiliated Hosp 1, Western Hosp, Emergency Dept, Nanning 530007, Guangxi Zhuang, Peoples R China; [Dong, Xianhong] Xinxiang Med Univ, Dept Physiol & Neurobiol, Xinxiang 453003, Peoples R China; [Qiu, Rubiao] Guangxi Maternal & Child Hlth Hosp, Nanning 530003, Guangxi Zhuang, Peoples R China; [Mo, Linjian] Guangxi Med Univ, Affiliated Hosp 1, Inst Urol & Nephrol, Nanning 530021, Guangxi Zhuang, Peoples R China; [Liu, Yun] Guangxi Med Univ, Affiliated Hosp 1, Spine & Osteopathy Surg Div, Nanning 530021, Guangxi Zhuang, Peoples R China	Ye, Y (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Western Hosp, Emergency Dept, Nanning 530007, Guangxi Zhuang, Peoples R China.	yeyu_doctor@126.com		Zhang, Jianfeng/0000-0003-4213-9310			Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Chen J, 2012, HORM METAB RES, V44, P943, DOI 10.1055/s-0032-1321818; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cosentino-Gomes D, 2012, INT J MOL SCI, V13, P10697, DOI 10.3390/ijms130910697; Davis JJ, 2013, REHABIL PSYCHOL, V58, P36, DOI 10.1037/a0031525; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Dokic I, 2012, GLIA, V60, P1785, DOI 10.1002/glia.22397; Elliott J, 2010, ANESTH ANALG, V110, P1419, DOI 10.1213/ANE.0b013e3181d568c8; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Freigang S, 2011, EUR J IMMUNOL, V41, P2040, DOI 10.1002/eji.201041316; Groeger AL, 2010, NAT CHEM BIOL, V6, P433, DOI 10.1038/nchembio.367; Guerra-Araiza C, 2013, FREE RADICAL RES, V47, P451, DOI 10.3109/10715762.2013.795649; Gupta K, 2013, BRIT J CLIN PHARMACO, V75, P907, DOI 10.1111/bcp.12022; Hurley LL, 2013, NEUROTOX RES, V23, P131, DOI 10.1007/s12640-012-9348-1; Imhoff BR, 2009, BIOCHEM J, V424, P491, DOI 10.1042/BJ20091286; Lannin NA, 2013, AM J OCCUP THER, V67, P543, DOI 10.5014/ajot.2013.008094; Larsson J, 2013, J REHABIL MED, V45, P765, DOI 10.2340/16501977-1184; Levy M, 2005, NEUROREHABILITATION, V20, P279; Liochev SI, 2013, FREE RADICAL BIO MED, V60, P1, DOI 10.1016/j.freeradbiomed.2013.02.011; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Lo YL, 2013, CHEM-BIOL INTERACT, V205, P188, DOI 10.1016/j.cbi.2013.07.003; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Marosova L, 2013, ACTA VIROL, V57, P273, DOI 10.4149/av_2013_03_273; Mu H, 2009, PHYTOMEDICINE, V16, P314, DOI 10.1016/j.phymed.2008.07.005; Muccio CF, 2009, BRAIN INJURY, V23, P466, DOI 10.1080/02699050902841912; Parikh S, 2007, INT ANESTHESIOL CLIN, V45, P119, DOI 10.1097/AIA.0b013e318078cfe7; Roschek B, 2009, J MED FOOD, V12, P615, DOI 10.1089/jmf.2008.0133; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Saito H, 2013, BIOCHEM PHARMACOL, V85, P865, DOI 10.1016/j.bcp.2013.01.006; Torsdottir G, 2010, J NEUROL SCI, V299, P51, DOI 10.1016/j.jns.2010.08.047; Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449; Yamamoto T, 2008, MOL CELL BIOL, V28, P2758, DOI 10.1128/MCB.01704-07; Yang XJ, 2011, INVEST OPHTH VIS SCI, V52, P8442, DOI 10.1167/iovs.11-8152	35	33	35	1	27	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	MAR 15	2014	338	1-2					112	117		10.1016/j.jns.2013.12.027			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AE3NO	WOS:000333883400019	24411660				2021-06-18	
J	Partridge, B				Partridge, Brad			Dazed and Confused: Sports Medicine, Conflicts of Interest, and Concussion Management	JOURNAL OF BIOETHICAL INQUIRY			English	Article						Conflict of interest; Sports medicine; Concussion; Sport; Ethics; Rugby league; Australian Rules football	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL; GUIDELINES; LOYALTIES; ZURICH; NEED	Professional sports with high rates of concussion have become increasingly concerned about the long-term effects of multiple head injuries. In this context, return-to-play decisions about concussion generate considerable ethical tensions for sports physicians. Team doctors clearly have an obligation to the welfare of their patient (the injured athlete) but they also have an obligation to their employer (the team), whose primary interest is typically success through winning. At times, a team's interest in winning may not accord with the welfare of an injured player, particularly when it comes to decisions about returning to play after injury. Australia's two most popular professional football codes-rugby league and Australian Rules football-have adopted guidelines that prohibit concussed players from continuing to play on the same day. I suggest that conflicts of interest between doctors, patients, and teams may present a substantial obstacle to the proper adherence of concussion guidelines. Concussion management guidelines implemented by a sport's governing body do not necessarily remove or resolve conflicts of interest in the doctor-patient-team triad. The instigation of a concussion exclusion rule appears to add a fourth party to this triad (the National Rugby League or the Australian Football League). In some instances, when conflicts of interest among stakeholders are ignored or insufficiently managed, they may facilitate attempts at circumventing concussion management guidelines to the detriment of player welfare.	Univ Queensland, UQCCR, Herston, Qld 4029, Australia	Partridge, B (corresponding author), Univ Queensland, UQCCR, Herston, Qld 4029, Australia.	b.partridge@uq.edu.au			Australia's National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia; Australian Research Council (ARC)Australian Research Council	Brad Partridge receives funding from the Australia's National Health and Medical Research Council (NHMRC) and the Australian Research Council (ARC).	Anderson LC, 2005, J MED ETHICS, V31, P88, DOI 10.1136/jme.2002.000836; Anderson L, 2013, INT REV SOCIOL SPORT, V48, P238, DOI 10.1177/1012690211435031; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Australian Football League (AFL), 2013, MAN CONC AUSTR FOOTB; Australian Football League (AFL), 2011, MAN CONC AUSTR FOOTB; Badel P., 2012, DAILY TELEGRAPH; Choudhry NK, 2002, JAMA-J AM MED ASSOC, V287, P612, DOI 10.1001/jama.287.5.612; Davis M., 2001, CONFLICT INTEREST PR; Davis M., 1982, BUSINESS PROFESSIONA, V1, P17; Devitt BM, 2010, BRIT J SPORT MED, V44, P175, DOI 10.1136/bjsm.2009.068056; Dillon R., 2011, NEWCASTLE HERAL 0329, P56; Dunn WR, 2007, AM J SPORT MED, V35, P840, DOI 10.1177/0363546506295177; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Gardner A, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00141; Gilbert F, 2012, MED J AUSTRALIA, V196, P561, DOI 10.5694/mja11.11218; Kaye AH, 2012, MED J AUSTRALIA, V196, P547, DOI 10.5694/mja12.10539; Lane S., 2011, SYDNEY MORNING HERAL; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McDermott Q., 2012, ABC; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mellifont D, 2012, J BIOETHIC INQ, V9, P369, DOI 10.1007/s11673-012-9386-7; MURRAY TH, 1986, SOC SCI MED, V23, P827, DOI 10.1016/0277-9536(86)90281-9; National Rugby League (NRL), 2012, MAN CONC RUGB LEAG; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Orchard J., 2012, BJSM BLOG       0315; Partridge B, 2011, AJOB NEUROSCI, V2, P62, DOI DOI 10.1080/21507740.2011.620066; Polsky S, 1998, J Contemp Health Law Policy, V14, P503; Price J, 2012, BRIT J SPORT MED, V46, P1000, DOI 10.1136/bjsports-2011-090687; Prichard G., 2012, SYDNEY MORNING HERAL; Thompson M., 2013, AFL MEDIA       0323; Webster A., 2012, COURIER MAIL    0518	34	33	33	1	36	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1176-7529	1872-4353		J BIOETHIC INQ	J. Bioethical Inq.	MAR	2014	11	1					65	74		10.1007/s11673-013-9491-2			10	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	AD4FB	WOS:000333202000011	24249203				2021-06-18	
J	Teng, SX; Molina, PE				Teng, Sophie X.; Molina, Patricia E.			Acute Alcohol Intoxication Prolongs Neuroinflammation without Exacerbating Neurobehavioral Dysfunction following Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						alcohol and drug abuse; animal studies; behavior assessments; inflammation	BINGE ETHANOL EXPOSURE; CLOSED-HEAD INJURY; HOST-DEFENSE; TNF-ALPHA; COGNITIVE DEFICITS; GABA(A) RECEPTORS; DAMAGE; TISSUE; RAT; MECHANISMS	Traumatic brain injury (TBI) represents a leading cause of death and disability among young persons with approximate to 1.7 million reported cases in the United States annually. Although acute alcohol intoxication (AAI) is frequently present at the time of TBI, conflicting animal and clinical reports have failed to establish whether AAI significantly impacts short-term outcomes after TBI. The objective of this study was to determine whether AAI at the time of TBI aggravates neurobehavioral outcomes and neuroinflammatory sequelae post-TBI. Adult male Sprague-Dawley rats were surgically instrumented with gastric and vascular catheters before a left lateral craniotomy. After recovery, rats received either a primed constant intragastric alcohol infusion (2.5g/kg+0.3g/kg/h for 15h) or isocaloric/isovolumic dextrose infusion followed by a lateral fluid percussion TBI (approximate to 1.4J, approximate to 30ms). TBI induced apnea and a delay in righting reflex. AAI at the time of injury increased the TBI induced delay in righting reflex without altering apnea duration. Neurological and behavioral dysfunction was observed at 6h and 24h post-TBI, and this was not exacerbated by AAI. TBI induced a transient upregulation of cortical interleukin (IL)-6 and monocyte chemotactic protein (MCP)-1 mRNA expression at 6h, which was resolved at 24h. AAI did not modulate the inflammatory response at 6h but prevented resolution of inflammation (IL-1, IL-6, tumor necrosis factor-, and MCP-1 expression) at 24h post-TBI. AAI at the time of TBI did not delay the recovery of neurological and neurobehavioral function but prevented the resolution of neuroinflammation post-TBI.	[Teng, Sophie X.; Molina, Patricia E.] Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, New Orleans, LA 70112 USA	Molina, PE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Alcohol & Drug Abuse Ctr Excellence, Dept Physiol, 1901 Perdido St,Room 7212, New Orleans, LA 70112 USA.	pmolin@lsuhsc.edu	Molina, Patricia E./AAK-9814-2021	Molina, Patricia E./0000-0002-3598-384X	 [NIAAA-AA7577];  [LEQSF-EPS(2012)-PFUND-283]	This research was supported by grants NIAAA-AA7577 and LEQSF-EPS(2012)-PFUND-283.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Ahmad A., 2013, PLOS ONE, V8; Arbabi S, 1999, J IMMUNOL, V162, P7441; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Boyko M, 2011, BEHAV BRAIN RES, V223, P17, DOI 10.1016/j.bbr.2011.03.019; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; *CDC N C F I P A C, 2003, REP C MILD TRAUM BRA; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; Chen CM, 2012, J STUD ALCOHOL DRUGS, V73, P531, DOI 10.15288/jsad.2012.73.531; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Crews FT, 2000, ALCOHOL CLIN EXP RES, V24, P1712, DOI 10.1111/j.1530-0277.2000.tb01973.x; Crews FT, 2006, ALCOHOL CLIN EXP RES, V30, P720, DOI 10.1111/j.1530-0277.2006.00084.x; Crews FT, 2003, ALCOHOL CLIN EXP RES, V27, P1075, DOI 10.1097/01.ALC.0000075826.35688.0D; Crews F, 2006, ALCOHOL CLIN EXP RES, V30, P1938, DOI 10.1111/j.1530-0277.2006.00239.x; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DSOUZA NB, 1989, ALCOHOL CLIN EXP RES, V13, P295, DOI 10.1111/j.1530-0277.1989.tb00329.x; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; French LM, 2009, J HEAD TRAUMA REHAB, V24, P1, DOI 10.1097/HTR.0b013e318197a14c; GONZALES RA, 1990, TRENDS PHARMACOL SCI, V11, P137, DOI 10.1016/0165-6147(90)90059-H; Gonzales RA, 1997, ALCOHOL HEALTH RES W, V21, P120; Goodman MD, 2013, J SURG RES, V184, P1053, DOI 10.1016/j.jss.2013.04.058; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Green JA, 2013, NEUROCRIT CARE, V18, P20, DOI 10.1007/s12028-012-9797-7; Greiffenstein P, 2008, J TRAUMA, V64, P230, DOI 10.1097/TA.0b013e318158a4ad; Greiffenstein P, 2007, ALCOHOL CLIN EXP RES, V31, P704, DOI 10.1111/j.1530-0277.2007.00355.x; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hirono M, 2009, NEUROPHARMACOLOGY, V57, P109, DOI 10.1016/j.neuropharm.2009.04.012; HURST PM, 1994, ACCIDENT ANAL PREV, V26, P647, DOI 10.1016/0001-4575(94)90026-4; Igarashi T, 2007, EXP NEUROL, V203, P258, DOI 10.1016/j.expneurol.2006.08.030; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kanny Dafna, 2012, Morbidity and Mortality Weekly Report, V61, P14; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Ling G.S, 2004, CURR PROTOC NEUROSCI, V2; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Mathis KW, 2006, SHOCK, V26, P55, DOI 10.1097/01.shk.0000215320.06866.30; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Mihic SJ, 1997, ALCOHOL HEALTH RES W, V21, P127; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Molina PE, 2013, SHOCK, V39, P240, DOI 10.1097/SHK.0b013e318285b86d; Molina PE, 2010, ALCOHOL RES HEALTH, V33, P97; Molina PE, 2003, ALCOHOL CLIN EXP RES, V27, P563, DOI 10.1097/01.ALC.0000057946.57330.F7; Molina PE, 2004, ALCOHOL, V33, P217, DOI 10.1016/j.alcohol.2004.07.002; Molina PE, 2002, ALCOHOL CLIN EXP RES, V26, P120, DOI 10.1097/00000374-200201000-00017; Molina PE, 1999, LIFE SCI, V66, P399; Naimi TS, 2003, JAMA-J AM MED ASSOC, V289, P70, DOI 10.1001/jama.289.1.70; Nixon K, 2002, J NEUROCHEM, V83, P1087, DOI 10.1046/j.1471-4159.2002.01214.x; Obernier JA, 2002, PHARMACOL BIOCHEM BE, V72, P521, DOI 10.1016/S0091-3057(02)00715-3; Obernier JA, 2002, ALCOHOL CLIN EXP RES, V26, P547, DOI 10.1111/j.1530-0277.2002.tb02573.x; Pandey SC, 2005, ALCOHOL CLIN EXP RES, V29, P176, DOI 10.1097/01.ALC.0000153550.31168.1D; Patel M, 1996, ALCOHOL CLIN EXP RES, V20, P275, DOI 10.1111/j.1530-0277.1996.tb01640.x; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Phelan H, 2002, J TRAUMA, V52, P675, DOI 10.1097/00005373-200204000-00010; Ponsford J, 2013, J CLIN EXP NEUROPSYC, V35, P103, DOI 10.1080/13803395.2012.752437; Ryabinin AE, 1998, PSYCHOPHARMACOLOGY, V139, P34, DOI 10.1007/s002130050687; Santhakumar V, 2007, ALCOHOL, V41, P211, DOI 10.1016/j.alcohol.2007.04.011; Schneider BSP, 2007, SPORTS MED, V37, P837; Shellito JE, 1998, ALCOHOL CLIN EXP RES, V22, p208S, DOI 10.1111/j.1530-0277.1998.tb04003.x; Shellito JE, 1998, ALCOHOL CLIN EXP RES, V22, P658, DOI 10.1111/j.1530-0277.1998.tb04308.x; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Standiford TJ, 1997, ALCOHOL CLIN EXP RES, V21, P1212, DOI 10.1097/00000374-199710000-00009; Sulzer JK, 2013, J TRAUMA ACUTE CARE, V74, P196, DOI 10.1097/TA.0b013e31826fc747; Sulzer JK, 2011, SHOCK, V35, P74, DOI 10.1097/SHK.0b013e3181e9aaaf; Szabo G, 1998, ALCOHOL CLIN EXP RES, V22, p216S, DOI 10.1111/j.1530-0277.1998.tb04005.x; TAKADERA T, 1990, BRAIN RES, V537, P109, DOI 10.1016/0006-8993(90)90346-D; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; U.S. Department of Health and Human Services, 2004, NIAAA NEWSLETTER, V3, P3, DOI DOI 10.1037/E306662005-004; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; Wakita M, 2012, J PHARMACOL EXP THER, V341, P809, DOI 10.1124/jpet.111.189126; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; Wang T, 2013, J NEUROSURG, V118, P390, DOI 10.3171/2012.8.JNS12736; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Whitaker AM, 2011, AM J PHYSIOL-REG I, V301, pR1529, DOI 10.1152/ajpregu.00035.2011; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; Zambell KL, 2004, ALCOHOL CLIN EXP RES, V28, P635, DOI 10.1097/01.ALC.0000122104.85971.55; Zhang P, 2002, ALCOHOL CLIN EXP RES, V26, P65, DOI 10.1097/00000374-200201000-00010; Zhang P, 2002, FRONT BIOSCI-LANDMRK, V7, pD1314; Ziebell JM, 2011, BRAIN RES, V1414, P94, DOI 10.1016/j.brainres.2011.07.056; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7	91	33	34	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2014	31	4					378	386		10.1089/neu.2013.3093			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AA7PY	WOS:000331290600010	24050411	Green Published			2021-06-18	
J	van der Eerden, AW; Khalilzadeh, O; Perlbarg, V; Dinkel, J; Sanchez, P; Vos, PE; Luyt, CE; Stevens, RD; de Champfleur, NM; Delmaire, C; Tollard, E; Gupta, R; Dormont, D; Laureys, S; Benali, H; Vanhaudenhuyse, A; Galanaud, D; Puybasset, L				van der Eerden, Anke W.; Khalilzadeh, Omid; Perlbarg, Vincent; Dinkel, Julien; Sanchez, Paola; Vos, Pieter E.; Luyt, Charles-Edouard; Stevens, Robert D.; de Champfleur, Nicolas Menjot; Delmaire, Christine; Tollard, Eleonore; Gupta, Rajiv; Dormont, Didier; Laureys, Steven; Benali, Habib; Vanhaudenhuyse, Audrey; Galanaud, Damien; Puybasset, Louis		NICER Neuro Imaging Coma Emergence	White Matter Changes in Comatose Survivors of Anoxic Ischemic Encephalopathy and Traumatic Brain Injury: Comparative Diffusion-Tensor Imaging Study	RADIOLOGY			English	Article							AXONAL INJURY; CORPUS-CALLOSUM; CIRCULATORY ARREST; DEMYELINATION; PROTEIN; MYELIN; DAMAGE; NEUROPATHOLOGY; ANISOTROPY; BARRIER	To analyze white matter pathologic abnormalities by using diffusion-tensor (DT) imaging in a multicenter prospective cohort of comatose patients following cardiac arrest or traumatic brain injury (TBI). Institutional review board approval and informed consent from proxies and control subjects were obtained. DT imaging was performed 5-57 days after insult in 49 cardiac arrest and 40 TBI patients. To control for DT imaging-processing variability, patients' values were normalized to those of 111 control subjects. Automated segmentation software calculated normalized axial diffusivity (lambda(perpendicular to)) and radial diffusivity (lambda(perpendicular to)) in 19 predefined white matter regions of interest (ROIs). DT imaging variables were compared by using general linear modeling, and side-to- side Pearson correlation coefficients were calculated. P values were corrected for multiple testing (Bonferroni). In central white matter, lambda(perpendicular to) differed from that in control subjects in six of seven TBI ROIs and five of seven cardiac arrest ROIs (all P < .01). The lambda(perpendicular to) differed from that in control subjects in all ROIs in both patient groups (P < .01). In hemispheres, lambda(perpendicular to) was decreased compared with that in control subjects in three of 12 TBI ROIs (P < .05) and nine of 12 cardiac arrest ROIs (P < .01). The lambda(perpendicular to) was increased in all TBI ROIs (P < .01) and in seven of 12 cardiac arrest ROIs (P < .05). Cerebral hemisphere lambda(perpendicular to) was lower in cardiac arrest than in TBI in six of 12 ROIs (P < .01), while l. was higher in TBI than in cardiac arrest in eight of 12 ROIs (P,.01). Diffusivity values were symmetrically distributed in cardiac arrest (P < .001 for side-to-side correlation) but not in TBI patients. DT imaging findings are consistent with the known predominance of cerebral hemisphere axonal injury in cardiac arrest and chiefly central myelin injury in TBI. This consistency supports the validity of DT imaging for differentiating axon and myelin damage in vivo in humans.	[van der Eerden, Anke W.; Dormont, Didier; Galanaud, Damien] Hop La Pitie Salpetriere, AP HP, Dept Neuroradiol, F-75651 Paris 13, France; [Sanchez, Paola; Puybasset, Louis] Hop La Pitie Salpetriere, AP HP, Neurosurg ICU, F-75651 Paris 13, France; [Luyt, Charles-Edouard] Hop La Pitie Salpetriere, AP HP, Med ICU, F-75651 Paris 13, France; [van der Eerden, Anke W.] Radboud Univ Nijmegen, Med Ctr, Dept Radiol, NL-6525 ED Nijmegen, Netherlands; [Vos, Pieter E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands; [Perlbarg, Vincent; Benali, Habib] Univ Paris 06, INSERM, UMRS 678, Paris, France; [Khalilzadeh, Omid; Dinkel, Julien; Gupta, Rajiv] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Stevens, Robert D.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Div Neurosci Crit Care, Baltimore, MD USA; [de Champfleur, Nicolas Menjot] Guy de Chauliac Hosp, Dept Neuroradiol, Montpellier, France; [Delmaire, Christine] Roger Salengro Hosp, Dept Neuroradiol, Lille, France; [Tollard, Eleonore] Ctr Hosp Univ, Dept Neuroradiol, Rouen, France; [Laureys, Steven; Vanhaudenhuyse, Audrey] Univ Liege, Cyclotron Res Ctr, Liege, Belgium	Galanaud, D (corresponding author), Hop La Pitie Salpetriere, AP HP, Dept Neuroradiol, 47-83 Blvd Hop, F-75651 Paris 13, France.	galanaud@gmail.com	Laureys, Steven/A-3349-2011; Vanhaudenhuyse, Audrey/AAP-2455-2020; Laureys, Steven/AAN-2097-2021; van der Eerden, Anke/H-9413-2017	Laureys, Steven/0000-0002-3096-3807; van der Eerden, Anke/0000-0002-9182-9089			Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Busl KM, 2010, NEUROREHABILITATION, V26, P5, DOI 10.3233/NRE-2010-0531; Elovic E, 2004, PHYS MED REHABILITAT; Galanaud D, 2012, ANESTHESIOLOGY, V117, P1300, DOI 10.1097/ALN.0b013e3182755558; GINSBERG MD, 1972, NEUROLOGY, V22, P998, DOI 10.1212/WNL.22.9.998; GINSBERG MD, 1976, ARCH NEUROL-CHICAGO, V33, P5, DOI 10.1001/archneur.1976.00500010007002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1975, LANCET, V1, P480; Kumar R, 2010, J HEAD TRAUMA REHAB, V25, P31, DOI 10.1097/HTR.0b013e3181bff331; Kumar R, 2011, J NEUROL SCI, V307, P106, DOI 10.1016/j.jns.2011.04.028; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; LENNON VA, 1971, J IMMUNOL, V107, P56; Lovblad KO, 2006, MED RAD DIA IMG, P239, DOI 10.1007/3-540-27738-2_16; Luyt CE, 2012, ANESTHESIOLOGY, V117, P1311, DOI 10.1097/ALN.0b013e318275148c; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MILLER JR, 1972, NEUROLOGY, V22, P888, DOI 10.1212/WNL.22.8.888; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2010, J NEUROL NEUROSUR PS, V81, P552, DOI 10.1136/jnnp.2009.196246; Okamura T, 2010, ANN THORAC SURG, V90, P2001, DOI 10.1016/j.athoracsur.2010.06.118; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Ringelstein EB, 2001, STROKE SYNDROMES, P564; Sharma HS, 2011, J NEURAL TRANSM, V118, P87, DOI 10.1007/s00702-010-0486-4; SHARMA HS, 1993, ACTA NEUROPATHOL, V86, P422; SHARMA HS, 1992, NEUROSCIENCE, V48, P889, DOI 10.1016/0306-4522(92)90277-9; SHARMA HS, 1992, PROG BRAIN RES, V91, P189; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Takahashi M, 2000, RADIOLOGY, V216, P881, DOI 10.1148/radiology.216.3.r00se41881; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90	42	33	33	0	8	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	FEB	2014	270	2					506	516		10.1148/radiol.13122720			11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	AG0WB	WOS:000335135300023	24471392	Bronze			2021-06-18	
J	Raj, R; Skrifvars, MB; Bendel, S; Selander, T; Kivisaari, R; Siironen, J; Reinikainen, M				Raj, Rahul; Skrifvars, Markus Benedikt; Bendel, Stepani; Selander, Tuomas; Kivisaari, Riku; Siironen, Jari; Reinikainen, Matti			Predicting six-month mortality of patients with traumatic brain injury: usefulness of common intensive care severity scores	CRITICAL CARE			English	Article							MULTIPLE ORGAN DYSFUNCTION; FAILURE ASSESSMENT SCORE; GLASGOW COMA SCALE; PROGNOSTIC VALUE; EXTERNAL VALIDATION; HOSPITAL MORTALITY; ACUTE PHYSIOLOGY; ICU PATIENTS; SOFA SCORE; SAPS-II	Introduction: The aim of this study was to evaluate the usefulness of the APACHE II (Acute Physiology and Chronic Health Evaluation II), SAPS II (Simplified Acute Physiology Score II) and SOFA (Sequential Organ Failure Assessment) scores compared to simpler models based on age and Glasgow Coma Scale (GCS) in predicting long-term outcome of patients with moderate-to-severe traumatic brain injury (TBI) treated in the intensive care unit (ICU). Methods: A national ICU database was screened for eligible TBI patients (age over 15 years, GCS 3-13) admitted in 2003-2012. Logistic regression was used for customization of APACHE II, SAPS II and SOFA score-based models for six-month mortality prediction. These models were compared to an adjusted SOFA-based model (including age) and a reference model (age and GCS). Internal validation was performed by a randomized split-sample technique. Prognostic performance was determined by assessing discrimination, calibration and precision. Results: In total, 1,625 patients were included. The overall six-month mortality was 33%. The APACHE II and SAPS II-based models showed good discrimination (area under the curve (AUC) 0.79, 95% confidence interval (CI) 0.75 to 0.82; and 0.80, 95% CI 0.77 to 0.83, respectively), calibration (P > 0.05) and precision (Brier score 0.166 to 0.167). The SOFA-based model showed poor discrimination (AUC 0.68, 95% CI 0.64 to 0.72) and precision (Brier score 0.201) but good calibration (P > 0.05). The AUC of the SOFA-based model was significantly improved after the insertion of age and GCS (Delta AUC + 0.11, P < 0.001). The performance of the reference model was comparable to the APACHE II and SAPS II in terms of discrimination (AUC 0.77; compared to APACHE II, Delta AUC -0.02, P = 0.425; compared to SAPS II, Delta AUC -0.03, P = 0.218), calibration (P > 0.05) and precision (Brier score 0.181). Conclusions: A simple prognostic model, based only on age and GCS, displayed a fairly good prognostic performance in predicting six-month mortality of ICU-treated patients with TBI. The use of the more complex scoring systems APACHE II, SAPS II and SOFA added little to the prognostic performance.	[Raj, Rahul; Kivisaari, Riku; Siironen, Jari] Univ Helsinki, Cent Hosp, Dept Neurosurg, FI-00029 Helsinki, HUS, Finland; [Skrifvars, Markus Benedikt] Univ Helsinki, Cent Hosp, Dept Anesthesiol Intens Care Emergency Care & Pai, FI-00029 Helsinki, HUS, Finland; [Bendel, Stepani] Kuopio Univ Hosp, Dept Intens Care, Kuopio 70211, Finland; [Bendel, Stepani] Univ Kuopio, FIN-70211 Kuopio, Finland; [Selander, Tuomas] Kuopio Univ Hosp, Sci Serv Ctr, Kuopio 70211, Finland; [Reinikainen, Matti] North Karelia Cent Hosp, Dept Intens Care, Joensuu 80210, Finland	Raj, R (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurosurg, Topeliuksenkatu 5,PB 266, FI-00029 Helsinki, HUS, Finland.	rahul.br.raj@icloud.com	Raj, Rahul/K-7693-2012	Raj, Rahul/0000-0003-4243-9591; Reinikainen, Matti/0000-0001-6878-3740	Helsinki University Hospital EVO grant [TYH2012142]; Medicinska Understods foreningen Liv och Halsa; Finska Lakaresallskapet; Maire Taponen Foundation	The authors declare that they have no conflict of interest. The study was funded by a Helsinki University Hospital EVO grant (TYH2012142), Medicinska Understods foreningen Liv och Halsa, Finska Lakaresallskapet and the Maire Taponen Foundation.	Angus DC, 2000, CRIT CARE MED, V28, P2145, DOI 10.1097/00003246-200006000-00088; Bertolini G, 2000, J Epidemiol Biostat, V5, P251; Brinkman S, 2013, INTENS CARE MED, V39, P1925, DOI 10.1007/s00134-013-3042-5; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Ferreira FL, 2001, JAMA-J AM MED ASSOC, V286, P1754, DOI 10.1001/jama.286.14.1754; Finazzi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016110; HILDEN J, 1978, METHOD INFORM MED, V17, P238; Hosmer DW, 1997, STAT MED, V16, P965; Hosmer DW., 2013, APPL LOGISTIC REGRES, V3rd ed.; Huang SS, 2012, RESUSCITATION, V83, P591, DOI 10.1016/j.resuscitation.2011.12.014; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0; Kundu S, 2011, EUR J EPIDEMIOL, V26, P261, DOI 10.1007/s10654-011-9567-4; Le Gall JR, 2005, INTENS CARE MED, V31, P1618, DOI 10.1007/s00134-005-2825-8; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1994, JAMA-J AM MED ASSOC, V272, P1049, DOI 10.1001/jama.272.13.1049; Lingsma H, 2013, J TRAUMA ACUTE CARE, V74, P639, DOI 10.1097/TA.0b013e31827d602e; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Livingston BM, 2000, CRIT CARE MED, V28, P1820, DOI 10.1097/00003246-200006000-00023; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Minne L, 2008, CRIT CARE, V12, DOI 10.1186/cc7160; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Nattino G, 2014, STAT MED, V33, P2390, DOI 10.1002/sim.6100; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Pettila V, 2002, CRIT CARE MED, V30, P1705, DOI 10.1097/00003246-200208000-00005; PICARD RR, 1990, AM STAT, V44, P140, DOI 10.2307/2684155; Poole D, 2012, INTENS CARE MED, V38, P1280, DOI 10.1007/s00134-012-2578-0; Pouw ME, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5913; Raj R, 2013, NEUROSURGERY, V73, P305, DOI 10.1227/01.neu.0000430326.40763.ec; Reinikainen M, 2012, ACTA ANAESTH SCAND, V56, P1114, DOI 10.1111/j.1399-6576.2012.02669.x; Reiter A, 2004, J TRAUMA, V57, P375, DOI 10.1097/01.TA.0000104016.78539.94; Ridley S, 1998, ANAESTHESIA, V53, P1185, DOI 10.1046/j.1365-2044.1998.00615.x; Roberts BW, 2013, CRIT CARE MED, V41, P1492, DOI 10.1097/CCM.0b013e31828a39e9; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; Rothen HU, 2008, CURR OPIN CRIT CARE, V14, P513, DOI 10.1097/MCC.0b013e32830864e9; Schirmer-Mikalsen K, 2013, ACTA ANAESTH SCAND, V57, P46, DOI 10.1111/j.1399-6576.2012.02785.x; Serrano N, 2012, INTENS CARE MED, V38, P1246, DOI 10.1007/s00134-012-2579-z; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vassar MJ, 1999, J TRAUMA, V47, P324, DOI 10.1097/00005373-199908000-00017; Vincent JL, 2010, CRIT CARE, V14, DOI 10.1186/cc8204; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Woodhouse D, 2009, CURR OPIN CRIT CARE, V15, P450, DOI 10.1097/MCC.0b013e32833079fb	51	33	35	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2014	18	2							R60	10.1186/cc13814			9	Critical Care Medicine	General & Internal Medicine	AM1SA	WOS:000339627400078	24708781	DOAJ Gold, Green Published			2021-06-18	
J	Thiagarajan, P; Ciuffreda, KJ				Thiagarajan, Preethi; Ciuffreda, Kenneth J.			Versional eye tracking in mild traumatic brain injury (mTBI): Effects of oculomotor training (OMT)	BRAIN INJURY			English	Article						Neuroplasticity; oculomotor coordination; oculomotor training; traumatic brain injury; versional eye movement disorders; vision therapy	VISUAL FUNCTION; FIXATION; MOVEMENTS; SACCADES; DEFICITS; SEQUENCES; ATTENTION; NETWORK; REHABILITATION; MILITARY	Objective: To evaluate a range of objective measures of versional eye movements before and after oculomotor training (OMT) in individuals with mTBI. The results were compared with placebo (P) training. Methods: Twelve individuals with mTBI (mean age 29 +/- 3 years) having oculomotor-based near-vision symptoms participated in the study. Versional eye movements were recorded objectively before and after OMT (fixation, predictable saccades, simulated reading) and P training (6 weeks each, two sessions/week, 45 minutes/session). Results: Following OMT, there was a significant (p < 0.05) reduction in the horizontal fixational error. Saccadic gain increased both horizontally and vertically (p < 0.05). The saccade ratio for the simulated reading, multiple-line paradigm reduced significantly (p < 0.05). None of the measures changed significantly following the P training. Conclusions: The versional-based OMT had a significant, positive effect on most aspects of versional tracking. These findings are suggestive of improved rhythmicity, accuracy and sequencing of saccades following OMT in mTBI as a result of oculomotor learning.	[Thiagarajan, Preethi; Ciuffreda, Kenneth J.] SUNY State Coll Optometry, Dept Biol & Vis Sci, New York, NY 10036 USA	Thiagarajan, P (corresponding author), SUNY State Coll Optometry, Dept Biol & Vis Sci, 33 West 42nd St, New York, NY 10036 USA.	pthiagarajan@sunyopt.edu					Abernethy B., 2005, BIOPHYSICAL FDN HUMA; ANDERSON TJ, 1994, BRAIN, V117, P1073, DOI 10.1093/brain/117.5.1073; BAHILL AT, 1981, INVEST OPHTH VIS SCI, V21, P116; Bahill AT, 1975, MATH BIOSCI, V24, P19; BON L, 1992, EXP BRAIN RES, V89, P571, DOI 10.1007/BF00229882; Chiu YC, 2009, J NEUROSCI, V29, P3930, DOI 10.1523/JNEUROSCI.5737-08.2009; Ciuffreda K. J., 2007, OPTOMETRY, V78, P55; Ciuffreda K. J., 2005, BRAIN INJURY PROFESS, V2, P16; Ciuffreda KJ, 2006, NEUROREHABILITATION, V21, P9; Ciuffreda Kenneth J, 2002, Optometry, V73, P735; Ciuffreda KJ, 2004, OCULOMOTOR FIXATION; Ciuffreda KJ, 1995, EYE MOVEMENT BASICS; Ciuffreda MA, 2003, J BEHAV OPTOM, V14, P60; Fayos B, 1998, J BEHAV OTPOM, V9, P1; Ferstl EC, 2008, HUM BRAIN MAPP, V29, P581, DOI 10.1002/hbm.20422; GAYMARD B, 1990, ANN NEUROL, V28, P622, DOI 10.1002/ana.410280504; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Han Y, 2004, BRAIN RES PROTOC, V14, P1, DOI 10.1016/j.brainresprot.2004.06.002; Hanes DP, 1998, J NEUROPHYSIOL, V79, P817; Heide W, 2001, EUR J NEUROSCI, V13, P1177, DOI 10.1046/j.0953-816x.2001.01472.x; Heitger MH, 2006, BRAIN INJURY, V20, P807, DOI 10.1080/02699050600676354; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Heitger MH, 2002, PROG BRAIN RES, V140, P433; HIKOSAKA O, 1983, J NEUROPHYSIOL, V49, P1254; Hikosaka O, 1989, J NEUROPHYSIOL, V49, P1254; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Khan AA, 2005, DIGITAL SIGNAL PROCE; Kraus MF, 2007, COGN BEHAV NEUROL, V20, P170, DOI 10.1097/WNN.0b013e318142badb; Kraus MF, 2010, COGN BEHAV NEUROL, V23, P210, DOI 10.1097/WNN.0b013e3181cefe2e; Leigh R. J., 2006, NEUROLOGY EYE MOVEME; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Munoz DP, 2003, J NEUROPHYSIOL, V90, P503, DOI 10.1152/jn.00192.2003; Pearson BC, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.036731; Pierrot-Deseilligny C, 2002, ANN NY ACAD SCI, V956, P16; RON S, 1978, SCAND J REHABIL MED, V10, P39; Ron S, 1981, PROGR OCULOMOTOR RES, P237; SELHORST JB, 1976, BRAIN, V99, P497, DOI 10.1093/brain/99.3.497; Solan HA, 2003, J LEARN DISABIL-US, V36, P556, DOI 10.1177/00222194030360060601; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Taylor EA., 1966, FUNDAMENTAL READING; Thiagarajan P, J REHABILIT IN PRESS; Thiagarajan P, 2012, THESIS SUNY COLL OPT; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Xu J. J., 2009, J BEHAV OPTOMETRY, V20, P67	49	33	33	0	30	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2014	28	7					930	943		10.3109/02699052.2014.888761			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AH9XL	WOS:000336498600007	24826956				2021-06-18	
J	van Delft-Schreurs, CCHM; van Bergen, JJM; de Jongh, MAC; de Sande, PV; Verhofstad, MHJ; de Vries, J				van Delft-Schreurs, C. C. H. M.; van Bergen, J. J. M.; de Jongh, M. A. C.; de Sande, P. van; Verhofstad, M. H. J.; de Vries, J.			Quality of life in severely injured patients depends on psychosocial factors rather than on severity or type of injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Quality of life; Injury; Trauma	TRAUMATIC BRAIN-INJURY; HEALTH-STATUS; MULTIPLE INJURIES; FUNCTIONAL STATUS; WHOQOL-BREF; DETERMINANTS; POPULATION; VALIDITY; IMPACT; WORSE	Background: Former studies have demonstrated that health-related quality of life is decreased in severely injured patients. However, in those studies patients were asked about their functioning and not about their (dis)contentment concerning their functioning. Little is known about how severely injured patients experience their quality of life (QOL). The objective of this cross-sectional study was to measure this subjective QOL of severely injured patients after their rehabilitation phase and to examine which accident- and patient-related factors affect the QOL of these patients. Methods: Patients of 18 years or older with an injury severity score (ISS) above 15 were included 15-53 months after their accident. Comorbidity before the accident, accident and sociodemographic characteristics, and QOL were obtained from the trauma registry and questionnaires. The WHOQOL-BREF was used to measure QOL. A reference group of the Dutch general population was used for comparison. Results: The participation rate was 61% (n = 173). Compared with the reference data, severely injured patients experienced a significantly worse QOL in all domains except social relations. The QOL scores were significantly decreased in all domains for patients with intracranial injury in combination with other injuries. Patients with a severe intracranial injury (AIS > 3) only reported significantly impaired QOL in the general and physical domains. Patients who resumed working or lived with others had significantly higher scores in all domains of QOL than patients who did not work anymore or were living alone. Significantly lower QOL scores were obtained from patients with comorbidity before the accident and from patients with longer durations of intensive care unit (ICU) treatment or hospitalisation. Gender, accident characteristics and time since the accident did not appear to be important for experienced QOL. Conclusions: The experience of impaired QOL appears to depend on living alone, inability to return to work and pre-accidental comorbidity rather than on the injured body area or the severity of the injury. Duration of hospital or ICU stay is important to subsequent QOL, even if ISS or body region is not. (C) 2013 Elsevier Ltd. All rights reserved.	[van Delft-Schreurs, C. C. H. M.; de Jongh, M. A. C.; Verhofstad, M. H. J.] St Elizabeth Hosp, Trauma Ctr Brabant, NL-5000 LC Tilburg, Netherlands; [van Bergen, J. J. M.; de Sande, P. van; de Vries, J.] St Elizabeth Hosp, Dept Med Psychol, NL-5000 LC Tilburg, Netherlands; [Verhofstad, M. H. J.] St Elizabeth Hosp, Dept Surg, NL-5000 LC Tilburg, Netherlands; [Verhofstad, M. H. J.] Erasmus MC, Dept Trauma Surg, Rotterdam, Netherlands; [de Vries, J.] Tilburg Univ, Dept Med Psychol, CoRPS, NL-5000 LE Tilburg, Netherlands	van Delft-Schreurs, CCHM (corresponding author), St Elizabeth Hosp, Trauma Ctr Brabant, POB 90151, NL-5000 LC Tilburg, Netherlands.	k.v.delft@elisabeth.nl					Alves ALA, 2009, REV SAUDE PUBL, V43, P154, DOI 10.1590/s0034-89102009000100020; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Anderson JP, 2007, J CLIN EPIDEMIOL, V60, P300, DOI 10.1016/j.jclinepi.2006.06.003; Association for the Advancement of Automotive Medicine (AAAM), 1998, ABBR INJ SCAL 1990 R; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brasel KJ, 2010, J TRAUMA, V68, P263, DOI 10.1097/TA.0b013e3181caa58f; Breek JC, 2005, J VASC SURG, V41, P443, DOI 10.1016/j.jvs.2004.12.042; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Centraal Bureau Statistiek, 2011, WAT IS KWAL LEV MENS; Christensen MC, 2011, J TRAUMA, V70, P1524, DOI 10.1097/TA.0b013e3181f053c2; de Vries J., 1996, NEDERLANDSE VERSIE W; De Vries J, 2003, NEDERLANDSE HANDLEID; DEVRIES J, 2001, ASSESSMENT BEHAV MED, P353; Hamming JF, 2007, BRIT J SURG, V94, P923, DOI 10.1002/bjs.5948; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Hays R D, 1993, Health Econ, V2, P217, DOI 10.1002/hec.4730020305; Hladki Waldemar, 2009, Przegl Lek, V66, P134; Holbrook TL, 2004, J TRAUMA, V56, P284, DOI 10.1097/01.TA.0000109758.75406.F8; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; KUYKEN W, 1995, SOC SCI MED, V41, P1403, DOI 10.1016/0277-9536(95)00112-k; Livingston DH, 2009, J TRAUMA, V67, P341, DOI 10.1097/TA.0b013e3181a5cc34; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; O'Carroll RE, 2000, QUAL LIFE RES, V9, P121, DOI 10.1023/A:1008901320492; Orwelius L, 2011, J TRAUMA; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Polinder S, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-783; Ringburg AN, 2010, J TRAUMA; Saban KL, 2011, J WOMENS HEALTH, V20, P179, DOI 10.1089/jwh.2010.2334; Sampalis JS, 2006, J TRAUMA, V60, P806, DOI 10.1097/01.ta.0000215103.62783.4d; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Toien K, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-22; Trompenaars F, 2005, QUAL LIFE RES, V14, P151, DOI 10.1007/s11136-004-0787-x; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; van der Steeg AFW, 2004, EJSO-EUR J SURG ONC, V30, P1051, DOI 10.1016/j.ejso.2004.07.003; Van der Zee K.I., 2012, METEN ALGEMENE GEZON; WHOQOL group, 1996, WHOQOL BREF; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	43	33	33	0	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2014	45	1					320	326		10.1016/j.injury.2013.02.025			7	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	264OJ	WOS:000327887800057	23510753				2021-06-18	
J	Begum, G; Harvey, L; Dixon, CE; Sun, DD				Begum, Gulnaz; Harvey, Lloyd; Dixon, C. Edward; Sun, Dandan			ER Stress and Effects of DHA as an ER Stress Inhibitor	TRANSLATIONAL STROKE RESEARCH			English	Article						C/EBP homologous protein; ER-associated protein degradation; ER Ca2+ dysregulation; Eukaryotic translation initiation factor 2 alpha subunit; Unfolded protein response	TRAUMATIC BRAIN-INJURY; ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; POLYUNSATURATED FATTY-ACIDS; SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; INTRACELLULAR CA2+; ANTI-INFLAMMATION; OXIDATIVE STRESS; GENE-EXPRESSION	The endoplasmic reticulum (ER) functions in the synthesis, folding, modification, and transport of newly synthesized transmembrane and secretory proteins. The ER also has important roles in the storage of intracellular Ca2+ and regulation of Ca2+ homeostasis. The integrity of the Ca2+ homeostasis in the ER lumen is vital for proper folding of proteins. Dysregulation of ER Ca2+ could result in an increase in unfolded or misfolded proteins and ER stress. ER stress triggers activation of the unfolded protein response (UPR), which is a fundamentally adaptive cell response and functions as a cytoprotective mechanism by over-expression of relevant chaperones and the global shutdown of protein synthesis. UPR activation occurs when three key ER membrane-sensor proteins detect an accumulation of aberrant proteins. The UPR acts to alleviate ER stress, but if the stress is too severe or prolonged, apoptosis will be triggered. In this review, we focused on ER stress and the effects of docosahexaenoic acid (DHA) on ER stress. DHA and its bioactive compounds, such as protectins and resolvins, provide neuroprotection against oxidative stress and apoptosis and have the ability to resolve inflammation in neurological diseases. New studies reveal that DHA blocks inositol trisphosphate receptor (IP3R)-mediated ER Ca2+ depletion and ER stress. The administration of DHA post-traumatic brain injury (TBI) reduces ER stress, aberrant protein accumulation, and neurological deficits. Therefore, DHA presents therapeutic potentials for TBI via its pleiotropic effects including inhibition of ER stress.	[Begum, Gulnaz; Harvey, Lloyd; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA; [Sun, Dandan] Univ Pittsburgh, Dept Neurol, Sch Med, Pittsburgh, PA 15213 USA	Sun, DD (corresponding author), Univ Pittsburgh, Dept Neurol, Sch Med, S-598 South Biomed Sci Tower BST,500 Terrace St, Pittsburgh, PA 15213 USA.	d.sun64@gmail.com		Harvey, Lloyd/0000-0001-5934-9934	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS048216, R01NS48216]; United States Department of Veterans Affairs VA RRD [B6761R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038118, R01NS048216] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health Research grant R01NS048216 and R01NS48216 (DS) and the United States Department of Veterans Affairs VA RR&D#B6761R grant (CED).	Adibhatla RM, 2007, FUTURE LIPIDOL, V2, P403, DOI 10.2217/17460875.2.4.403; Anderson Ethan J, 2012, F1000 Med Rep, V4, P13, DOI 10.3410/M4-13; Arita M, 2005, J EXP MED, V201, P713, DOI 10.1084/jem.20042031; Banhegyi G, 2007, ANN NY ACAD SCI, V1113, P58, DOI 10.1196/annals.1391.007; Bazan NG, 2006, CELL MOL NEUROBIOL, V26, P901, DOI 10.1007/s10571-006-9064-6; Bazan NG, 2007, CURR OPIN CLIN NUTR, V10, P136, DOI 10.1097/MCO.0b013e32802b7030; Begum G, 2013, DHA REDUCES ER UNPUB; Begum G, 2012, NEUR M PLANN; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; BOURRE JM, 1989, J NUTR, V119, P1880; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Brostrom MA, 2003, CELL CALCIUM, V34, P345, DOI 10.1016/S0143-4160(03)00127-1; Buck TM, 2007, SEMIN CELL DEV BIOL, V18, P751, DOI 10.1016/j.semcdb.2007.09.001; Burdakov D, 2005, CELL CALCIUM, V38, P303, DOI 10.1016/j.ceca.2005.06.010; Calder PC, 2010, NUTRIENTS, V2, P355, DOI 10.3390/nu2030355; Catalan J, 2002, BEHAV NEUROSCI, V116, P1022, DOI 10.1037//0735-7044.116.6.1022; Chalon S, 1998, J NUTR, V128, P2512; Chen XZ, 2008, J NEUROCHEM, V106, P1563, DOI 10.1111/j.1471-4159.2008.05501.x; Chiribau CB, 2010, MOL CELL BIOL, V30, P3722, DOI 10.1128/MCB.01507-09; Deckelbaum RJ, 2006, AM J CLIN NUTR, V83, p1520S, DOI 10.1093/ajcn/83.6.1520S; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Eady Tiffany N, 2012, Exp Transl Stroke Med, V4, P19, DOI 10.1186/2040-7378-4-19; Eady TN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046151; Fedorova I, 2007, PROSTAG LEUKOTR ESS, V77, P269, DOI 10.1016/j.plefa.2007.10.013; Gorlach A, 2006, ANTIOXID REDOX SIGN, V8, P1391, DOI 10.1089/ars.2006.8.1391; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Hong S, 2003, J BIOL CHEM, V278, P14677, DOI 10.1074/jbc.M300218200; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaur P, 2008, NEUROTOXICOLOGY, V29, P978, DOI 10.1016/j.neuro.2008.06.004; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Krajewska M, 2011, BRAIN RES, V1370, P227, DOI 10.1016/j.brainres.2010.11.015; Lai ED, 2007, PHYSIOLOGY, V22, P193, DOI 10.1152/physiol.00050.2006; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Larner SF, 2006, J NEUROTRAUM, V23, P807, DOI 10.1089/neu.2006.23.807; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237; Lukiw WJ, 2005, J CLIN INVEST, V115, P2774, DOI 10.1172/JCI25420; Mahadevan NR, 2011, P NATL ACAD SCI USA, V108, P6561, DOI 10.1073/pnas.1008942108; Marcheselli VL, 2003, J BIOL CHEM, V278, P43807, DOI 10.1074/jbc.M305841200; Michalak M, 2002, CELL CALCIUM, V32, P269, DOI 10.1016/S0143416002001884; Michalik L, 2006, PHARMACOL REV, V58, P726, DOI 10.1124/pr.58.4.5; Mirnikjoo B, 2001, J BIOL CHEM, V276, P10888, DOI 10.1074/jbc.M008150200; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Mogami H, 1998, EMBO J, V17, P435, DOI 10.1093/emboj/17.2.435; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Moriguchi T, 2000, J NEUROCHEM, V75, P2563, DOI 10.1046/j.1471-4159.2000.0752563.x; Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Papp S, 2003, J CELL BIOL, V160, P475, DOI 10.1083/jcb.200207136; Paschen W, 2003, CELL CALCIUM, V34, P365, DOI 10.1016/S0143-4160(03)00139-8; Paschen W, 2003, CELL CALCIUM, V33, P83, DOI 10.1016/S0143-4160(02)00195-1; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134; Seebungkert B, 2002, EUR J NEUROSCI, V16, P2085, DOI 10.1046/j.1460-9568.2002.02288.x; Sergeeva M, 2005, REPROD NUTR DEV, V45, P633, DOI 10.1051/rnd:2005050; Serhan CN, 2008, BRIT J PHARMACOL, V153, pS200, DOI 10.1038/sj.bjp.0707489; Serhan CN, 2002, PROSTAG OTH LIPID M, V68-9, P433, DOI 10.1016/S0090-6980(02)00047-3; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shimazawa M, 2009, BRAIN RES, V1251, P269, DOI 10.1016/j.brainres.2008.11.031; Sidhu VK, 2011, J PROTEOME RES, V10, P5472, DOI 10.1021/pr2007285; Simopoulos AP, 2008, EXP BIOL MED, V233, P674, DOI 10.3181/0711-MR-311; Singh Meharban, 2005, Indian Journal of Pediatrics, V72, P239, DOI 10.1007/BF02859265; Solovyova N, 2002, EMBO J, V21, P622, DOI 10.1093/emboj/21.4.622; Stillwell W, 2003, CHEM PHYS LIPIDS, V126, P1, DOI 10.1016/S0009-3084(03)00101-4; Stillwell W, 2005, REPROD NUTR DEV, V45, P559, DOI 10.1051/rnd:2005046; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Suzuki H, 1998, MECH AGEING DEV, V101, P119, DOI 10.1016/S0047-6374(97)00169-3; Thorell WE, 2002, J NEUROTRAUM, V19, P335, DOI 10.1089/089771502753594909; Truettner JS, 2007, J NEUROTRAUM, V24, P599, DOI 10.1089/neu.2006.0186; Turner N, 2003, NATURWISSENSCHAFTEN, V90, P521, DOI 10.1007/s00114-003-0470-z; Uttara B, 2009, CURR NEUROPHARMACOL, V7, P65, DOI 10.2174/157015909787602823; Valenzuela V, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.8; Vreugdenhil M, 1996, P NATL ACAD SCI USA, V93, P12559, DOI 10.1073/pnas.93.22.12559; Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131; Wang ZF, 2013, EXP THER MED, V5, P107, DOI 10.3892/etm.2012.745; Wuytack F, 2002, CELL CALCIUM, V32, P279, DOI 10.1016/S0143416002001847; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Ying Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052998; Yoshida H, 2007, FEBS J, V274, P630, DOI 10.1111/j.1742-4658.2007.05639.x; Yoshida S, 1997, J NEUROCHEM, V68, P1261; Zhao GX, 2005, BIOCHEM BIOPH RES CO, V336, P909, DOI 10.1016/j.bbrc.2005.08.204	88	33	36	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	DEC	2013	4	6					635	642		10.1007/s12975-013-0282-1			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	258NE	WOS:000327465200006	24323417	Green Accepted			2021-06-18	
J	Metraux, S; Clegg, LX; Daigh, JD; Culhane, DP; Kane, V				Metraux, Stephen; Clegg, Limin X.; Daigh, John D.; Culhane, Dennis P.; Kane, Vincent			Risk Factors for Becoming Homeless Among a Cohort of Veterans Who Served in the Era of the Iraq and Afghanistan Conflicts	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							MENTAL-HEALTH PROBLEMS; PAST HOMELESSNESS; AFFAIRS; ASSOCIATION; DISORDERS; SERVICES; FEMALE; LIFE; CARE	Objectives. In this population-based cohort study, we assessed baseline risk factors for homelessness, including the role of service in the Iraq or Afghanistan conflicts, among a large cohort of recent veterans. Methods. Data for this study came from administrative records for 310 685 veterans who separated from active military duty from July 1, 2005, to September 30, 2006. We used survival analysis methods to determine incidence rates and risk factors for homelessness, based on baseline data for military factors, demographic characteristics, and diagnoses of behavioral health disorders and traumatic brain injury. Results. Service in Iraq or Afghanistan and, more specifically, posttraumatic stress disorder among veterans deployed there, were significant risk factors of modest magnitude for homelessness, and socioeconomic and behavioral health factors provided stronger indicators of risk. Gender was not a significant indicator of differential risk. Conclusions. Although service in Iraq and Afghanistan was significant, socioeconomic and behavioral health indicators show more promise in efforts to use administrative data to inform prevention efforts by identifying veterans who are at elevated risk for becoming homeless upon their return to civilian life.	[Metraux, Stephen; Culhane, Dennis P.; Kane, Vincent] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA 19104 USA; [Metraux, Stephen] Univ Sci, Dept Hlth Policy & Publ Hlth, Philadelphia, PA USA; [Culhane, Dennis P.] Univ Penn, Sch Social Welf Policy & Practice, Philadelphia, PA 19104 USA; [Clegg, Limin X.; Daigh, John D.] US Dept Vet Affairs, Off Inspector Gen, Washington, DC USA	Metraux, S (corresponding author), US Dept Vet Affairs, Ctr Homelessness Vet, 4200 Chester Ave,Suite 201, Philadelphia, PA 19104 USA.	stephen.metraux@va.gov		Metraux, Stephen/0000-0003-4741-1010	US Department of Veterans Affairs, National Center on Homelessness Among Veterans	This project was funded by the US Department of Veterans Affairs, National Center on Homelessness Among Veterans.	Blackstock OJ, 2012, MED CARE, V50, P347, DOI 10.1097/MLR.0b013e318245a738; COX DR, 1972, J R STAT SOC B, V34, P187; Draine J, 2002, PSYCHIAT SERV, V53, P565, DOI 10.1176/appi.ps.53.5.565; Eckholm E., 2007, NY TIMES, pA22; Edens EL, 2011, AM J ADDICTION, V20, P412, DOI 10.1111/j.1521-0391.2011.00166.x; Fairweather A., 2006, RISK PROTECTIVE FACT; Fargo J, 2012, PREV CHRONIC DIS, V9, DOI 10.5888/pcd9.110112; Fothergill KE, 2012, J URBAN HEALTH, V89, P432, DOI 10.1007/s11524-011-9641-y; Greenberg GA, 2010, J HEALTH CARE POOR U, V21, P1234, DOI 10.1353/hpu.2010.0926; Greenberg GA, 2010, ADM POLICY MENT HLTH, V37, P357, DOI 10.1007/s10488-009-0243-x; Greer A, 2011, BIENN M SOC COMM RES; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge CW, 2002, AM J PSYCHIAT, V159, P1576, DOI 10.1176/appi.ajp.159.9.1576; Johnson TP, 2007, AM J PREV MED, V32, pS211, DOI 10.1016/j.amepre.2007.02.015; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kazis LE, 1998, ARCH INTERN MED, V158, P626, DOI 10.1001/archinte.158.6.626; LEDA C, 1992, HOSP COMMUNITY PSYCH, V43, P1026; Montgomery AE., 2012, ANN M NAT ALL END HO; *NAT CTR HLTH STAT, 1980, DHHS PUBL PHS; Office of Public Health Veterans Health Administration, 2012, AN VA HLTH CAR UT OP; ROSENHECK R, 1994, AM J PSYCHIAT, V151, P421; Rosenheck RA., 1996, HOMELESSNESS AM, P97; Rosenheck RA, 1998, PRACT LESS 1998 NAT, P2; SAS Institute Inc, 2008, SAS STAT 9 2 US GUID; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Tsai J, 2012, COMMUNITY MENT HLT J, V48, P705, DOI 10.1007/s10597-012-9482-5; US Department of Veterans Affairs Office of Inspector General, 2010, REV COMB STRESS WOM; US Department of Veterans Affairs Office of Inspector General, 2007, QUANT ASS CAR TRANS; US Department of Veterans Affairs Office of the Inspector General, 2012, INC HOM VET RISK FAC; US Interagency Council on Homelessness, 2012, REP C HOM VET; Washington DL, 2010, J HEALTH CARE POOR U, V21, P81, DOI 10.1353/hpu.0.0237; Williamson V, 2009, COMING HOME HOUSING; Zoroya G., 2012, US TODAY	36	33	33	0	21	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	DEC	2013	103			2			S255	S261		10.2105/AJPH.2013.301432			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	AA4NP	WOS:000331073100023	24148066	Green Published			2021-06-18	
J	Pretz, CR; Dams-O'Connor, K				Pretz, Christopher R.; Dams-O'Connor, Kristen			Longitudinal Description of the Glasgow Outcome Scale-Extended for Individuals in the Traumatic Brain Injury Model Systems National Database: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Longitudinal studies; Outcome assessment (health care); Rehabilitation	MULTICENTER; PREDICTORS	Objective: To comprehensively describe the temporal patterns of global outcome after traumatic brain injury (TBI) in the Traumatic Brain Injury Model Systems National Database (TBIMS NDB). Design: Longitudinal prospective cohort study. Setting: TBI Model Systems centers. Participants: Patients (N=3870) >= 16 years of age with moderate or severe TBI enrolled in the TBIMS NDB. Interventions: None. Main Outcome Measure: Glasgow Outcome Scale-Extended (GOS-E). Results: The trajectory of the GOS-E scores is best described with a model of quadratic change, in which scores initially increase and peak approximately 10 years after the first GOS-E assessment, and then decrease. Change occurs most rapidly in the initial and final years of the timeline. There was significant Variability in each growth parameter (P<.05). A reduced multilevel model was built, including all covariates (age at first GOS-E assessment, FIM, race, sex, rehabilitation length of stay) that related significantly to the growth parameters. An interactive tool was created to generate individual level trajectories based on various combinations of covariate values. Results provide an individual level account of the chronological progression of TBI outcomes, as measured by the GOS-E. Conclusions: Individual growth curve analysis is a statistically rigorous approach to describe temporal change with respect to the GOS-E at the individual level for participants within the TBIMS NDB. Results indicated that, for individuals in the TBIMS NDB as a group, functional status as measured by the GOS-E initially improves, plateaus, and then begins to decline. Factors such as age at first GOS-E assessment, race, FIM score at rehabilitation admission, and rehabilitation length of stay were found to influence baseline GOS-E scores, as well as the rate and extent of both improvement and decline over time. Additional research may be required to determine the generalizability of these findings and the usefulness of this tool for clinical applications. Archives of Physical Medicine and Rehabilitation 2013;94:2486-93 (C) 2013 by the American Congress of Rehabilitation Medicine	[Pretz, Christopher R.] Craig Hosp, Englewood, CO 80132 USA; [Pretz, Christopher R.] Traumat Brain Injury Natl Stat & Data Ctr, Englewood, CO 80132 USA; [Dams-O'Connor, Kristen] Mt Sinai Sch Med, New York, NY USA	Pretz, CR (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80132 USA.	cpretz@craighospital.org			Traumatic Brain Injury Model Systems National Data and Statistical Center; National Institute on Disability and Rehabilitation Research [H133A110006, H133A120084]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER	Supported by the Traumatic Brain Injury Model Systems National Data and Statistical Center, National Institute on Disability and Rehabilitation Research (grant no. H133A110006); and the National Institute on Disability and Rehabilitation Research-funded Traumatic Brain Injury Model System Center at the Mount Sinai Medical Center (grant no. H133A120084).	Arango-Lasprilla JC, 2010, ARCH PHYS MED REHAB, V91, P1495, DOI 10.1016/j.apmr.2010.07.010; Ashman TA, 2006, MT SINAI J MED, V73, P999; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Dijkers MP, 2004, SERVICES MAY NOT BE, pE12; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Graham JE, 2010, ARCH PHYS MED REHAB, V91, P43, DOI 10.1016/j.apmr.2009.09.017; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hox J.J., 2010, MULTILEVEL ANAL TECH, V2nd ed.; JENNETT B, 1975, LANCET, V1, P480; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Norman G, 2010, ADV HEALTH SCI EDUC, V15, P625, DOI 10.1007/s10459-010-9222-y; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Silver JM, 2005, TXB TRAUMATIC BRAIN; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	23	33	33	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2013	94	12					2486	2493		10.1016/j.apmr.2013.06.021			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	264UD	WOS:000327905600023	23838239	Green Accepted			2021-06-18	
J	Schonnop, R; Yang, YJ; Feldman, F; Robinson, E; Loughin, M; Robinovitch, SN				Schonnop, Rebecca; Yang, Yijian; Feldman, Fabio; Robinson, Erin; Loughin, Marie; Robinovitch, Stephen N.			Prevalence of and factors associated with head impact during falls in older adults in long-term care	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Article							TRAUMATIC BRAIN-INJURY; RISK-FACTORS; UPPER EXTREMITY; SERIOUS INJURY; HIP FRACTURE; PEOPLE; EPIDEMIOLOGY; PROGNOSIS; SEVERITY; YOUNG	Background: Falls cause more than 60% of head injuries in older adults. Lack of objective evidence on the circumstances of these events is a barrier to prevention. We analyzed video footage to determine the frequency of and risk factors for head impact during falls in older adults in 2 long-term care facilities. Methods: Over 39 months, we captured on video 227 falls involving 133 residents. We used a validated questionnaire to analyze the mechanisms of each fall. We then examined whether the probability for head impact was associated with upper-limb protective responses (hand impact) and fall direction. Results: Head impact occurred in 37% of falls, usually onto a vinyl or linoleum floor. Hand impact occurred in 74% of falls but had no significant effect on the probability of head impact (p = 0.3). An increased probability of head impact was associated with a forward initial fall direction, compared with backward falls (odds ratio [OR] 2.7, 95% confidence interval [CI] 1.3-5.9) or sideways falls (OR 2.8, 95% CI 1.2-6.3). In 36% of sideways falls, residents rotated to land backwards, which reduced the probability of head impact (OR 0.2, 95% CI 0.04-0.8). Interpretation: Head impact was common in observed falls in older adults living in long-term care facilities, particularly in forward falls. Backward rotation during descent appeared to be protective, but hand impact was not. Attention to upper-limb strength and teaching rotational falling techniques (as in martial arts training) may reduce fall-related head injuries in older adults.	[Schonnop, Rebecca; Yang, Yijian; Feldman, Fabio; Robinson, Erin; Robinovitch, Stephen N.] Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Injury Prevent & Mobil Lab, Burnaby, BC V5A 1S6, Canada; [Robinovitch, Stephen N.] Simon Fraser Univ, Sch Engn Sci, Burnaby, BC V5A 1S6, Canada; [Feldman, Fabio] Fraser Hlth Author, Older Adult Program, Surrey, BC, Canada; [Loughin, Marie] Simon Fraser Univ, Dept Stat & Actuarial Sci, Burnaby, BC V5A 1S6, Canada	Robinovitch, SN (corresponding author), Simon Fraser Univ, Dept Biomed Physiol & Kinesiol, Injury Prevent & Mobil Lab, Burnaby, BC V5A 1S6, Canada.	stever@sfu.ca	Yang, Yijian/G-1580-2016	Yang, Yijian/0000-0002-5831-186X; Schonnop, Rebecca/0000-0003-0236-6711; Robinovitch, Stephen/0000-0003-3881-6227	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [AMG-100487, TIR-103945]; Canada Research Chairs ProgramCanada Research Chairs; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This study was funded by team grants from the Canadian Institutes of Health Research (grant nos. AMG-100487 and TIR-103945). Stephen Robinovitch also received support from the Canada Research Chairs Program, and Rebecca Schonnop received fellowship support from the Canadian Institutes of Health Research. The funding agencies had no direct role in the design and conduct of this study; the collection, management, analysis or interpretation of the data; or the preparation, review or approval of the manuscript.	Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Bowers B, 2008, REHABIL NURS, V33, P253, DOI 10.1002/j.2048-7940.2008.tb00237.x; DeGoede KM, 2003, J BIOMECH, V36, P413, DOI 10.1016/S0021-9290(02)00396-2; DIETZ V, 1978, BRAIN RES, V142, P576, DOI 10.1016/0006-8993(78)90921-6; Drahota A, 2011, INJURY PREV, V17, P1, DOI 10.1136/injuryprev-2011-040154; Feldman F, 2007, J BIOMECH, V40, P2612, DOI 10.1016/j.jbiomech.2007.01.019; Greenspan SL, 1998, AM J MED, V104, P539, DOI 10.1016/S0002-9343(98)00115-6; Harvey LA, 2012, INJURY, V43, P1821, DOI 10.1016/j.injury.2012.07.188; Hayes WC, 1996, BONE, V18, pS77, DOI 10.1016/8756-3282(95)00383-5; Hsiao ET, 1998, J BIOMECH, V31, P1; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Karon SL, 2007, J HEAD TRAUMA REHAB, V22, P350, DOI 10.1097/01.HTR.0000300230.13490.11; Korhonen N, 2013, JAMA-J AM MED ASSOC, V309, P1891, DOI 10.1001/jama.2013.3356; Laing AC, 2009, ACCIDENT ANAL PREV, V41, P642, DOI 10.1016/j.aap.2009.03.001; Mackey DM, 2012, FLOORING INJURY PREV; NEVITT MC, 1993, J AM GERIATR SOC, V41, P1226, DOI 10.1111/j.1532-5415.1993.tb07307.x; NEVITT MC, 1991, J GERONTOL, V46, pM164, DOI 10.1093/geronj/46.5.M164; Raymond DE, 2011, REHABIL NURS, V36, P248, DOI 10.1002/j.2048-7940.2011.tb00090.x; Robinovitch SN, 2005, J GERONTOL A-BIOL, V60, P1553, DOI 10.1093/gerona/60.12.1553; Robinovitch SN, 2003, J BONE MINER RES, V18, P1267, DOI 10.1359/jbmr.2003.18.7.1267; Robinovitch SN, 2013, LANCET, V381, P47, DOI 10.1016/S0140-6736(12)61263-X; RUBENSTEIN LZ, 1994, ANN INTERN MED, V121, P442, DOI 10.7326/0003-4819-121-6-199409150-00009; Saari P, 2007, ARCH GERONTOL GERIAT, V45, P207, DOI 10.1016/j.archger.2006.10.012; Sran MA, 2010, J GERONTOL A-BIOL, V65, P312, DOI 10.1093/gerona/glp153; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; TINETTI ME, 1987, J AM GERIATR SOC, V35, P644, DOI 10.1111/j.1532-5415.1987.tb04341.x; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; TIRET L, 1989, AM J PUBLIC HEALTH, V79, P316, DOI 10.2105/AJPH.79.3.316; Watson WL, 2011, OSTEOPOROSIS INT, V22, P2623, DOI 10.1007/s00198-010-1511-z; Weerdesteyn V, 2008, J ELECTROMYOGR KINES, V18, P235, DOI 10.1016/j.jelekin.2007.06.010; WILD D, 1981, BRIT MED J, V282, P266, DOI 10.1136/bmj.282.6260.266; WILD D, 1981, J EPIDEMIOL COMMUN H, V35, P200, DOI 10.1136/jech.35.3.200; Wright AD, 2012, MED ENG PHYS, V34, P1071, DOI 10.1016/j.medengphy.2011.11.012; Yang YJ, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-40	36	33	33	0	9	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0820-3946	1488-2329		CAN MED ASSOC J	Can. Med. Assoc. J.	NOV 19	2013	185	17					E803	E810		10.1503/cmaj.130498			8	Medicine, General & Internal	General & Internal Medicine	292SY	WOS:000329923900012	24101612	Green Published, Bronze			2021-06-18	
J	Brennan, FH; Cowin, GJ; Kurniawan, ND; Ruitenberg, MJ				Brennan, Faith H.; Cowin, Gary J.; Kurniawan, Nyoman D.; Ruitenberg, Marc J.			Longitudinal assessment of white matter pathology in the injured mouse spinal cord through ultra-high field (16.4 T) in vivo diffusion tensor imaging	NEUROIMAGE			English	Article						Magnetic resonance imaging; Neurotrauma; Spinal cord injury; Tractography; Demyelination; Wallerian degeneration	WALLERIAN DEGENERATION; WATER DIFFUSION; CLINICAL-TRIALS; AXONAL INJURY; EX-VIVO; MODEL; RECOVERY; DAMAGE; DYSMYELINATION; MRI	This study examined the sensitivity of ultra-high field (16.4 T) diffusion tensor imaging (DTI; 70 mu m in-plane resolution, 1 mm slice thickness) to evaluate the spatiotemporal development of severe mid-thoracic contusive spinal cord injury (SCI) in mice. In vivo imaging was performed prior to SCI, then again at 2 h, 1 day, 3 days, 7 days, and 30 days post-SCI using a Bruker 16.4 T small animal nuclear magnetic resonance spectrometer. Cross-sectional spinal cord areas were measured in axial slices and various DTI parameters, i.e. fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (lambda(parallel to)) and radial diffusivity (lambda(perpendicular to)), were calculated for the total spared white matter (WM), ventral funiculi (VF), lateral funiculi (LF) and dorsal columns (DCs) and then correlated with histopathology. Cross-sectional area measurements revealed significant atrophy (32% reduction) of the injured spinal cord at the lesion epicentre in the chronic phase of injury. Analysis of diffusion tensor parameters further showed that tissue integrity was most severely affected in the DCs, i.e. the site of immediate impact, which demonstrated a rapid and permanent decrease in FA and lambda(parallel to). In contrast, DTI parameters for the ventrolateral white matter changed more gradually with time, suggesting that these regions are undergoing more delayed degeneration in a manner that may be amenable to therapeutic intervention. Of all the DTI parameters, lambda(perpendicular to) was most closely correlated to myelin content whereas changes in FA and lambda(parallel to) appeared more indicative of axonal integrity, Wallerian degeneration and associated presence of macrophages. We conclude that longitudinal DTI at 16.4 T provides a clinically relevant, objective measure for assessing white matter pathology following contusive SCI in mice that may aid the translation of putative neuroprotective strategies into the clinic. (C) 2013 Elsevier Inc. All rights reserved.	[Brennan, Faith H.; Ruitenberg, Marc J.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; [Cowin, Gary J.; Kurniawan, Nyoman D.] Univ Queensland, Ctr Adv Imaging, Brisbane, Qld 4072, Australia; [Ruitenberg, Marc J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia	Kurniawan, ND (corresponding author), Univ Queensland, Ctr Adv Imaging, Brisbane, Qld 4072, Australia.	nyoman.kurniawan@cai.uq.edu.au; m.ruitenberg@uq.edu.au	Cowin, Gary J/E-6147-2011; Kurniawan, Nyoman/D-9764-2011; Cowin, Gary/U-8721-2019	Cowin, Gary J/0000-0002-3400-3109; Kurniawan, Nyoman/0000-0001-6340-182X; Cowin, Gary/0000-0002-3400-3109; Ruitenberg, Marc/0000-0002-6917-0708; Brennan, Faith/0000-0002-9201-2476	SpinalCure Australia (Career Development Fellowship); University of QueenslandUniversity of Queensland; Australian Postgraduate Award (The University of Queensland); Queensland Government	This study was funded by SpinalCure Australia (Career Development Fellowship to M.J.R.) and The University of Queensland. F.H.B. was supported by an Australian Postgraduate Award (The University of Queensland). The authors also thank the Queensland Government for funding and operational support of the 16.4 T NMR spectrometer through the QLD NMR Network Initiative.	BEAULIEU C, 1994, MAGNET RESON MED, V31, P394, DOI 10.1002/mrm.1910310408; Blomster LV, 2013, NMR BIOMED, V26, P141, DOI 10.1002/nbm.2829; Boekhoff TM, 2012, J SPINAL DISORD TECH, V25, pE81, DOI 10.1097/BSD.0b013e31823f2f55; Bosma R. L., 2012, Critical Reviews in Biomedical Engineering, V40, P1, DOI 10.1615/CritRevBiomedEng.v40.i1.10; Bozzo A, 2011, J NEUROTRAUM, V28, P1401, DOI 10.1089/neu.2009.1236; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; Budde MD, 2007, MAGN RESON MED, V57, P688, DOI 10.1002/mrm.21200; Budde MD, 2009, J NEUROSCI, V29, P2805, DOI 10.1523/JNEUROSCI.4605-08.2009; BUNGE RP, 1993, ADV NEUROL, V59, P75; Cadotte DW, 2011, CLIN ORTHOP RELAT R, V469, P732, DOI 10.1007/s11999-010-1674-0; Chang Y, 2010, J NEUROTRAUM, V27, P2033, DOI 10.1089/neu.2009.1265; Cheran S, 2011, J NEUROTRAUM, V28, P1881, DOI 10.1089/neu.2010.1741; Cohen-Adad J, 2008, NEUROIMAGE, V40, P685, DOI 10.1016/j.neuroimage.2007.11.031; Cohen-Adad J, 2011, NEUROIMAGE, V57, P1068, DOI 10.1016/j.neuroimage.2011.04.068; Courtine G, 2007, NAT MED, V13, P561, DOI 10.1038/nm1595; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Ellingson BM, 2010, MAGN RESON IMAGING, V28, P1353, DOI 10.1016/j.mri.2010.06.006; Ellingson BM, 2010, J NEUROSURG-SPINE, V13, P181, DOI 10.3171/2010.3.SPINE09523; Ellingson BM, 2008, J MAGN RESON IMAGING, V28, P1068, DOI 10.1002/jmri.21578; Freund P, 2011, BRAIN, V134, P1610, DOI 10.1093/brain/awr093; Gensel JC, 2011, EXPERT OPIN THER TAR, V15, P505, DOI 10.1517/14728222.2011.553605; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Gonzalez-Lara LE, 2009, J NEUROTRAUM, V26, P753, DOI 10.1089/neu.2008.0704; Harrison M, 2013, NEUROIMAGE, V68, P22, DOI 10.1016/j.neuroimage.2012.11.048; Harsan LA, 2006, J NEUROSCI RES, V83, P392, DOI 10.1002/jnr.20742; Harsan LA, 2007, J NEUROSCI RES, V85, P935, DOI 10.1002/jnr.21201; Hawryluk GWJ, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E14; Hesseltine SM, 2006, AM J NEURORADIOL, V27, P1189; Hofling AA, 2009, NMR BIOMED, V22, P1100, DOI 10.1002/nbm.1420; Hui ES, 2010, NEUROIMAGE, V49, P2366, DOI 10.1016/j.neuroimage.2009.10.022; Huisman TAGM, 2001, RADIOLOGE, V41, P1038, DOI 10.1007/s001170170003; Kamble Ravindra B, 2011, Indian J Radiol Imaging, V21, P221, DOI 10.4103/0971-3026.85372; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; Kim JH, 2007, MAGN RESON MED, V58, P253, DOI 10.1002/mrm.21316; Kim JH, 2012, EXP NEUROL, V235, P188, DOI 10.1016/j.expneurol.2011.11.015; Kozlowski P, 2008, J NEUROTRAUM, V25, P653, DOI 10.1089/neu.2007.0462; Krzyzak AT, 2005, ACTA NEUROBIOL EXP, V65, P255; Kwon BK, 2010, SPINE, V35, pS263, DOI 10.1097/BRS.0b013e3181f3286d; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Loy DN, 2007, J NEUROTRAUM, V24, P979, DOI 10.1089/neu.2006.0253; Maas L. C., 2005, APPL RADIOL, V34, P44; Martirosyan NL, 2010, NEUROSURGERY, V66, P131, DOI 10.1227/01.NEU.0000361997.08116.96; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Mulcahey MJ, 2012, SPINE, V37, pE797, DOI 10.1097/BRS.0b013e3182470a08; Ni Mhuircheartaigh N, 2006, SEMIN MUSCULOSKEL R, V10, P293, DOI 10.1055/s-2007-972000; NOBLE LJ, 1989, EXP NEUROL, V103, P34, DOI 10.1016/0014-4886(89)90182-9; Norenberg MD, 2004, J NEUROTRAUM, V21, P429, DOI 10.1089/089771504323004575; OBEIRNE J, 1993, INJURY, V24, P149, DOI 10.1016/0020-1383(93)90278-E; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Petersen JA, 2012, J NEUROTRAUM, V29, P1556, DOI 10.1089/neu.2011.2027; Qin W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041441; Rajasekaran S, 2010, J MAGN RESON IMAGING, V32, P978, DOI 10.1002/jmri.22320; Sandner B, 2009, J MAGN RESON IMAGING, V29, P725, DOI 10.1002/jmri.21477; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Scholtes F, 2011, SPINAL CORD, V49, P345, DOI 10.1038/sc.2010.129; Schwartz ED, 2003, EXP NEUROL, V184, P570, DOI 10.1016/S0014-4886(03)00295-4; Shanmuganathan K, 2008, AM J NEURORADIOL, V29, P655, DOI 10.3174/ajnr.A0916; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Stroman PW, 2012, CLIN NEUROL NEUROSUR, V114, P460, DOI 10.1016/j.clineuro.2012.01.003; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Takahashi T, 1996, SPINE, V21, P166, DOI 10.1097/00007632-199601150-00002; Tatar Ilkan, 2009, BMC Med Imaging, V9, P10, DOI 10.1186/1471-2342-9-10; Tu TW, 2010, J NEUROTRAUM, V27, P253, DOI 10.1089/neu.2009.1026; Underwood CK, 2011, NEUROIMAGE, V55, P455, DOI 10.1016/j.neuroimage.2010.12.044; Yin B, 2010, J CLIN NEUROSCI, V17, P1173, DOI 10.1016/j.jocn.2010.02.020; Zhang JY, 2012, TRENDS NEUROSCI, V35, P412, DOI 10.1016/j.tins.2012.04.010; Zhang JY, 2009, J NEUROSCI, V29, P3160, DOI 10.1523/JNEUROSCI.3941-08.2009	71	33	34	1	37	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	NOV 15	2013	82						574	585		10.1016/j.neuroimage.2013.06.019			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	220FQ	WOS:000324568400054	23770410				2021-06-18	
J	Roberts, DJ; Jenne, CN; Leger, C; Kramer, AH; Gallagher, CN; Todd, S; Parney, IF; Doig, CJ; Yong, VW; Kubes, P; Zygun, DA				Roberts, Derek J.; Jenne, Craig N.; Leger, Caroline; Kramer, Andreas H.; Gallagher, Clare N.; Todd, Stephanie; Parney, Ian F.; Doig, Christopher J.; Yong, V. Wee; Kubes, Paul; Zygun, David A.			Association between the Cerebral Inflammatory and Matrix Metalloproteinase Responses after Severe Traumatic Brain Injury in Humans	JOURNAL OF NEUROTRAUMA			English	Article						brain injuries; cerebrospinal fluid; craniocerebral trauma; cytokines; matrix metalloproteinases; neuroinflammation; microdialysis	ACTIVATED PROTEIN-KINASE; MATRIX-METALLOPROTEINASE-9 EXPRESSION; FUNCTIONAL RECOVERY; CEREBROSPINAL-FLUID; BARRIER DISRUPTION; TISSUE INHIBITORS; EDEMA FORMATION; CARE PATIENTS; HEAD-INJURY; BLOOD	An increasing number of preclinical investigations have suggested that the degree of expression of the matrix metalloproteinase (MMP) family of endopeptidases may explain some of the variability in neurological damage after traumatic brain injury (TBI). As cytokines are a prominent stimulus for MMP expression in animals, we conducted a prospective multimodal monitoring study and determined their association with temporal MMP expression after severe TBI in eight critically ill adults. High cutoff, cerebral microdialysis (n=8); external ventricular drainage (n=3); and arterial and jugular venous bulb catheters were used to measure the concentration of nine cytokines and eight MMPs in microdialysate, cerebrospinal fluid (CSF), and plasma over 6 days. Severe TBI was associated with a robust central inflammatory response, which was largely similar between microdialysate and CSF. At all time points after injury, this response was predominated by the pro-inflammatory cytokines interleukin-6 (IL-6) and IL-8. Use of univariate generalized estimating equations suggested that the concentration of several MMPs varied with cytokine levels in microdialysate. The largest of these changes included increases in microdialysate concentrations of MMP-8 and MMP-9 with increases in the levels of IL-1 and -2 and IL-1 and -2 and TNF-, respectively. In contrast, the microdialysate level of MMP-7 decreased with increases in microdialysate concentrations of IL-1, -2, and -6. These findings support the observations of animal studies that cross-talk exists between the neuroinflammatory and MMP responses after acute brain injury. Further study is needed to determine whether this link between cerebral inflammation and MMP expression may have clinical relevance to the care of patients with TBI.	[Roberts, Derek J.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Roberts, Derek J.; Doig, Christopher J.; Zygun, David A.] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada; [Roberts, Derek J.; Jenne, Craig N.; Leger, Caroline; Kramer, Andreas H.; Todd, Stephanie; Doig, Christopher J.; Kubes, Paul] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [Kramer, Andreas H.; Gallagher, Clare N.; Yong, V. Wee] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada; [Yong, V. Wee] Univ Calgary, Dept Oncol, Calgary, AB, Canada; [Kubes, Paul] Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Kramer, Andreas H.; Gallagher, Clare N.; Yong, V. Wee; Kubes, Paul] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Jenne, Craig N.; Leger, Caroline; Kubes, Paul] Univ Calgary, Calvin Phoebe & Joan Snyder Inst Chron Dis, Calgary, AB, Canada; Foothills Med Ctr, Calgary, AB, Canada; [Parney, Ian F.] Mayo Clin, Coll Med, Dept Neurol Surg, Rochester, MN USA; [Zygun, David A.] Univ Alberta, Div Crit Care Med, Edmonton, AB T6G 2B7, Canada	Zygun, DA (corresponding author), Univ Alberta, Div Crit Care Med, 8440-112 St, Edmonton, AB T6G 2B7, Canada.	zygun@ualberta.ca	Doig, Christopher/AAC-7949-2020; Roberts, Derek J./L-6229-2019	Doig, Christopher/0000-0002-8576-9139; Roberts, Derek J./0000-0001-6111-6291; Yong, V. Wee/0000-0002-2600-3563; Parney, Ian/0000-0002-9702-8047	Alberta Innovates-Health Solutions; Canadian Intensive Care Foundation; Snyder Chair for Translational Research in Critical Care Medicine; Alberta Innovates-Health Solutions Clinician Fellowship Award; Clinician Investigator and Surgeon Scientist Programs at the University of Calgary; Alberta Innovates-Health Solutions Postdoctoral Fellowship Award	This work was supported by grants from Alberta Innovates-Health Solutions (formally the Alberta Heritage Foundation for Medical Research [awarded to Dr. Zygun]), the Canadian Intensive Care Foundation (awarded to Dr. Zygun), and the Snyder Chair for Translational Research in Critical Care Medicine (awarded to Dr. Kubes). Dr. Roberts is supported by an Alberta Innovates-Health Solutions Clinician Fellowship Award and funding from the Clinician Investigator and Surgeon Scientist Programs at the University of Calgary. Dr. Jenne is funded by an Alberta Innovates-Health Solutions Postdoctoral Fellowship Award.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Candelario-Jalil E, 2007, J PHARMACOL EXP THER, V323, P488, DOI 10.1124/jpet.107.127035; Cho A, 2000, ARTERIOSCL THROM VAS, V20, P2527, DOI 10.1161/01.ATV.20.12.2527; Crocker SJ, 2006, J NEUROCHEM, V98, P812, DOI 10.1111/j.1471-4159.2006.03927.x; duPont NC, 2005, J REPROD IMMUNOL, V66, P175, DOI 10.1016/j.jri.2005.03.005; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Genersch E, 2000, J CELL SCI, V113, P4319; GOTTSCHALL PE, 1995, J NEUROCHEM, V64, P1513; Gottschall PE, 1996, NEUROIMMUNOMODULAT, V3, P69, DOI 10.1159/000097229; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; JENNETT B, 1975, LANCET, V1, P480; Kauppinen UM, 2005, J IMMUNOL, V174, P2288, DOI 10.4049/jimmunol.174.4.2288; Kawai N, 2003, J NEUROTRAUM, V20, P649, DOI 10.1089/089771503322144563; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim KS, 2008, BIOCHEM J, V410, P605, DOI 10.1042/BJ20071207; Kramer AH, 2012, CRIT CARE, V16, DOI 10.1186/cc11812; Kushi H, 2003, ACTA NEUROCHIR SUPPL, V86, P347; Lei J, 2013, J NEUROTRAUM, V30, P529, DOI 10.1089/neu.2012.2548; Lescot T, 2010, J NEUROTRAUM, V27, P1069, DOI 10.1089/neu.2009.1188; MACKENZIE EJ, 1988, J TRAUMA, V28, P281, DOI 10.1097/00005373-198803000-00003; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Noble LJ, 2002, J NEUROSCI, V22, P7526; Perez-Barcena J, 2011, CRIT CARE MED, V39, P533, DOI 10.1097/CCM.0b013e318205c7a4; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Roberts DJ, 2009, CRIT CARE MED, V37, P2767, DOI 10.1097/CCM.0b013e3181b755d5; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Schumann G, 1999, J NEUROCHEM, V73, P2009; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; SNOW WG, 1988, CAN J SURG, V31, P191; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; TEASDALE G, 1974, LANCET, V2, P81; Thornton P, 2008, MOL CELL NEUROSCI, V37, P135, DOI 10.1016/j.mcn.2007.09.002; Van Hove I, 2012, J NEUROCHEM, V123, P203, DOI 10.1111/j.1471-4159.2012.07900.x; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vittinghoff E, 2012, REGRESSION METHODS B, P261; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wong Pauline P., 1993, Brain Injury, V7, P283, DOI 10.3109/02699059309034955; Woo MS, 2008, J NEUROCHEM, V106, P770, DOI 10.1111/j.1471-4159.2008.05430.x; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Yong VW, 2005, NAT REV NEUROSCI, V6, P931, DOI 10.1038/nrn1807	55	33	35	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2013	30	20					1727	1736		10.1089/neu.2012.2842			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	232JW	WOS:000325491000005	23799281				2021-06-18	
J	Ganesh, S; Guernon, A; Chalcraft, L; Harton, B; Smith, B; Pape, TLB				Ganesh, Shanti; Guernon, Ann; Chalcraft, Laura; Harton, Brett; Smith, Bridget; Pape, Theresa Louise-Bender			Medical Comorbidities in Disorders of Consciousness Patients and Their Association With Functional Outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Comorbidity; Consciousness disorders; Rehabilitation	TRAUMATIC BRAIN-INJURY; RECOVERY; STATE; HYDROCEPHALUS; COMPLICATIONS; DYSAUTONOMIA; OVERACTIVITY; PREDICTION; EMERGENCE; PROGNOSIS	Objective: To identify, for patients in states of seriously impaired consciousness, comorbid conditions present during inpatient rehabilitation and their association with function at 1 year. Design: Abstracted data from a prospective cross-sectional observational study with data collection occurring January 1996 through December 2007. Setting: Four inpatient rehabilitation facilities in metropolitan areas. Participants: The study sample of 68 participants is abstracted from a database of 157 patients remaining in states of seriously impaired consciousness for at least 28 days. Interventions: Not applicable. Main Outcome Measure: One-year cognitive, motor, and total FIM score. Results: The most common medical complications during inpatient rehabilitation for the study sample are active seizures (46%), spasticity (57%), urinary tract infections (47%), and hydrocephalus with and without shunt (38%). Presence of >= 3 medical complications during inpatient rehabilitation, controlling for injury severity, is significantly (P<.05) associated with poorer total FIM and FIM motor scores 1 year after injury. The presence of hydrocephalus with and without shunt (r=-.20, -.21, -.18; P <=.15), active seizures (r=-.31, -.22, -.42), spasticity (r=-.38, -.28, -.40), and urinary tract infections (r=-.25, -.24, -.26) were significantly (P<.10) associated with total FIM, FIM cognitive, and FIM motor scores, respectively. Conclusions: Reported findings indicate that persons in states of seriously impaired consciousness with higher numbers of medical complications during inpatient rehabilitation are more likely to have lower functional levels 1-year postinjury. The findings indicate that persons with >= 3 medical complications during inpatient rehabilitation are at a higher risk for poorer functional outcomes at 1 year. It is, therefore, prudent to evaluate these patients for indications of these complications during inpatient rehabilitation. (c) 2013 by the American Congress of Rehabilitation Medicine	[Ganesh, Shanti; Harton, Brett; Smith, Bridget; Pape, Theresa Louise-Bender] US Dept Vet Affairs, Dept Vet Affairs, Res Serv, Edward Hines Jr Vet Affairs Hosp, Hines, IL 60141 USA; [Ganesh, Shanti; Harton, Brett; Smith, Bridget; Pape, Theresa Louise-Bender] US Dept Vet Affairs, Ctr Management Complex Chron Care, Ctr Excellence, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA; [Ganesh, Shanti; Chalcraft, Laura] US Dept Vet Affairs, Phys Med & Rehabil Serv, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA; [Guernon, Ann] Marianjoy Rehabil Hosp, Wheaton, IL USA; [Smith, Bridget] Loyola Univ Chicago, Program Hlth Serv Res, Stritch Sch Med, Maywood, IL USA; [Pape, Theresa Louise-Bender] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA	Pape, TLB (corresponding author), Hines VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151H,Bldg 1B260, Hines, IL 60141 USA.	Theresa.Pape@va.gov		Bender Pape, Theresa/0000-0001-7738-5963	United States Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Merit [CCN 07-133]	Supported by the United States Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Merit (grant no. CCN 07-133).	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2008, MED HYPOTHESES, V70, P26, DOI 10.1016/j.mehy.2007.04.037; Bernat JL, 2010, NEUROLOGY, V75, pS33, DOI 10.1212/WNL.0b013e3181fb35dd; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Bernat JL, 2002, NEUROLOGY, V58, P337, DOI 10.1212/WNL.58.3.337; Corral L, 2012, CRIT CARE, V16, DOI 10.1186/cc11243; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Dolce G, 2021, J NEUROTRAUM, V38, P1441, DOI 10.1089/neu.2008.0536; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hendricks HT, 2010, EUR J NEUROL, V17, P1172, DOI 10.1111/j.1468-1331.2010.02989.x; Hirschberg R, 2011, NEUROL CLIN, V29, P773, DOI 10.1016/j.ncl.2011.07.009; Hong KS, 2008, EUR J NEUROL, V15, P1324, DOI 10.1111/j.1468-1331.2008.02310.x; Intiso D, 2012, J TOXICOL-US, V2012, DOI 10.1155/2012/802893; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Katz DI, 2009, PROG BRAIN RES, V177, P73, DOI 10.1016/S0079-6123(09)17707-5; Kozlowski DA, 2013, COMPR PHYSIOL, V3, P121, DOI 10.1002/cphy.c110005; Lammi MH, 2005, ARCH PHYS MED REHAB, V86, P746, DOI 10.1016/j.apmr.2004.11.004; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Mazzini L, 2003, ARCH PHYS MED REHAB, V84, P1637, DOI 10.1053/S0003-9993(03)00314-9; *MULT SOC TASK FOR, 1994, NEW ENGL J MED, V21, P330; Nakase-Richardson R, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.127795; Nakase-Richardson R, 2009, NEUROLOGY, V73, P1120, DOI 10.1212/WNL.0b013e3181bacf34; Pape TLB, 2006, BRAIN INJURY, V20, P743, DOI 10.1080/02699050600676933; Pickard JD, 2005, NEUROPSYCHOL REHABIL, V15, P224, DOI 10.1080/09602010443000614; Pohl M, 2007, BRAIN INJURY, V21, P421, DOI 10.1080/02699050701311109; Stott DJ, 2009, QJM-INT J MED, V102, P243, DOI 10.1093/qjmed/hcp012; Ventura T, 2010, ARCH PHYS MED REHAB, V91, P20, DOI 10.1016/j.apmr.2009.08.151; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	33	33	37	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2013	94	10					1899	1907		10.1016/j.apmr.2012.12.026			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	231TU	WOS:000325442100008	23735521				2021-06-18	
J	Rock, EM; Kopstick, RL; Limebeer, CL; Parker, LA				Rock, E. M.; Kopstick, R. L.; Limebeer, C. L.; Parker, L. A.			Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						THCA; THC; conditioned gaping; vomiting; SR141716; CB1 receptor	CISPLATIN-INDUCED EMESIS; LITHIUM-PAIRED CONTEXT; ARACHIDONOYL-L-SERINE; CHEMOTHERAPY-INDUCED NAUSEA; CANNABINOID CB1 RECEPTORS; TRAUMATIC BRAIN-INJURY; HOUSE MUSK SHREW; ANTICIPATORY NAUSEA; REJECTION REACTIONS; TASTE AVOIDANCE	Background and PurposeWe evaluated the anti-emetic and anti-nausea properties of the acid precursor of (9)-tetrahydrocannabinol (THC), tetrahydrocannabinolic acid (THCA), and determined its mechanism of action in these animal models. Experimental ApproachWe investigated the effect of THCA on lithium chloride- (LiCl) induced conditioned gaping (nausea-induced behaviour) to a flavour, and context (a model of anticipatory nausea) in rats, and on LiCl-induced vomiting in Suncus murinus. Furthermore, we investigated THCA's ability to induce hypothermia and suppress locomotion [rodent tasks to assess cannabinoid(1) (CB1) receptor agonist-like activity], and measured plasma and brain THCA and THC levels. We also determined whether THCA's effect could be blocked by pretreatment with SR141716 (SR, a CB1 receptor antagonist). Key ResultsIn rats, THCA (0.05 and/or 0.5mgkg(-1)) suppressed LiCl-induced conditioned gaping to a flavour and context; the latter effect blocked by the CB1 receptor antagonist, SR, but not by the 5-hydroxytryptamine-1A receptor antagonist, WAY100635. In S.murinus, THCA (0.05 and 0.5mgkg(-1)) reduced LiCl-induced vomiting, an effect that was reversed with SR. A comparatively low dose of THC (0.05mgkg(-1)) did not suppress conditioned gaping to a LiCl-paired flavour or context. THCA did not induce hypothermia or reduce locomotion, indicating non-CB1 agonist-like effects. THCA, but not THC was detected in plasma samples. Conclusions and ImplicationsTHCA potently reduced conditioned gaping in rats and vomiting in S.murinus, effects that were blocked by SR. These data suggest that THCA may be a more potent alternative to THC in the treatment of nausea and vomiting.	[Rock, E. M.; Kopstick, R. L.; Limebeer, C. L.; Parker, L. A.] Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada	Parker, LA (corresponding author), Univ Guelph, Dept Psychol, Guelph, ON N1G 2W1, Canada.	parkerl@uoguelph.ca			GW Pharmaceuticals; Natural Sciences and Engineering Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC) [NSERC-92057]	This research was supported by grants from GW Pharmaceuticals to L. A. P. and from the Natural Sciences and Engineering Council of Canada (NSERC-92057) to L. A. P. The authors would like to thank Quotient Bioresearch (Fordham, Cambridgeshire, UK) for the analysis of plasma samples. The authors would also like to thank Linda Groocock for management of the shrew colony at the University of Guelph, and Martin Sticht for assistance with these studies.	Ahmed SA, 2008, J NAT PROD, V71, P536, DOI 10.1021/np070454a; Bolognini D, 2013, BRIT J PHARMACOL, V168, P1456, DOI 10.1111/bph.12043; CAREY MP, 1983, ANN INTERN MED, V99, P106, DOI 10.7326/0003-4819-99-1-106; Cluny NL, 2008, BASIC CLIN PHARMACOL, V103, P150, DOI 10.1111/j.1742-7843.2008.00253.x; Cohen-Yeshurun A, 2013, J CEREBR BLOOD F MET, V33, P1242, DOI 10.1038/jcbfm.2013.75; Cohen-Yeshurun A, 2011, J CEREBR BLOOD F MET, V31, P1768, DOI 10.1038/jcbfm.2011.53; Cotter J, 2009, ONCOL NURS FORUM, V36, P345, DOI 10.1188/09.ONF.345-352; CRAWFORD SM, 1986, MED ONCOL TUMOR PHAR, V3, P39; CUNNINGHAM D, 1988, EUR J CANCER CLIN ON, V24, P685, DOI 10.1016/0277-5379(88)90300-8; Darmani NA, 2004, EUR J PHARMACOL, V488, P201, DOI 10.1016/j.ejphar.2004.02.018; Darmani NA, 1998, J NEURAL TRANSM, V105, P1143, DOI 10.1007/s007020050118; Darmani NA, 2001, PHARMACOL BIOCHEM BE, V69, P239, DOI 10.1016/S0091-3057(01)00531-7; Darmani NA, 2001, NEUROPSYCHOPHARMACOL, V24, P198, DOI 10.1016/S0893-133X(00)00197-4; Darmani NA, 2007, EUR J PHARMACOL, V563, P187, DOI 10.1016/j.ejphar.2007.01.093; FRYTAK S, 1979, ANN INTERN MED, V91, P825, DOI 10.7326/0003-4819-91-6-825; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; GRUNFELD Y, 1969, PSYCHOPHARMACOLOGIA, V14, P200, DOI 10.1007/BF00404218; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Kwiatkowska M, 2004, PSYCHOPHARMACOLOGY, V174, P254, DOI 10.1007/s00213-003-1739-9; Limebeer CL, 2010, BRIT J PHARMACOL, V161, P336, DOI 10.1111/j.1476-5381.2010.00885.x; Limebeer CL, 2006, PHYSIOL BEHAV, V88, P398, DOI 10.1016/j.physbeh.2006.04.014; Limebeer CL, 1999, NEUROREPORT, V10, P3769, DOI 10.1097/00001756-199912160-00009; Limebeer CL, 2000, J EXP PSYCHOL-ANIM B, V26, P371, DOI 10.1037//0097-7403.26.4.371; MARTIN BR, 1991, PHARMACOL BIOCHEM BE, V40, P471, DOI 10.1016/0091-3057(91)90349-7; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Milman G, 2006, P NATL ACAD SCI USA, V103, P2428, DOI 10.1073/pnas.0510676103; ORR L E, 1980, Archives of Internal Medicine, V140, P1431, DOI 10.1001/archinte.140.11.1431; ORR LE, 1981, J CLIN PHARMACOL, V21, pS76, DOI 10.1002/j.1552-4604.1981.tb02578.x; Parker LA, 2009, PHYSIOL BEHAV, V97, P121, DOI 10.1016/j.physbeh.2009.02.014; Parker LA, 2006, PHYSIOL BEHAV, V87, P66, DOI 10.1016/j.physbeh.2005.08.045; Parker LA, 2004, PSYCHOPHARMACOLOGY, V171, P156, DOI 10.1007/s00213-003-1571-2; Parker LA, 2003, INTEGR PHYS BEH SCI, V38, P133, DOI 10.1007/BF02688831; Parker LA, 2003, LEARN BEHAV, V31, P165; Parker LA, 2003, PSYCHOPHARMACOLOGY, V166, P156, DOI 10.1007/s00213-002-1329-2; Parker LA, 2002, NEUROREPORT, V13, P567, DOI 10.1097/00001756-200204160-00006; Parker LA, 2001, NEUROREPORT, V12, P749, DOI 10.1097/00001756-200103260-00027; Parker LA, 2008, CAN J EXP PSYCHOL, V62, P198, DOI 10.1037/a0012531; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Rock EM, 2013, BRIT J PHARMACOL, V169, P685, DOI 10.1111/bph.12162; Rock EM, 2012, BRIT J PHARMACOL, V165, P2620, DOI 10.1111/j.1476-5381.2011.01621.x; Rock EM, 2008, PSYCHOPHARMACOLOGY, V196, P389, DOI 10.1007/s00213-007-0970-1; Tramer MR, 2001, BMJ-BRIT MED J, V323, P16, DOI 10.1136/bmj.323.7303.16; UNGERLEIDER JT, 1984, RADIOLOGY, V150, P598, DOI 10.1148/radiology.150.2.6318262; Van Sickle MD, 2001, GASTROENTEROLOGY, V121, P767, DOI 10.1053/gast.2001.28466; Verhoeckx KCM, 2006, INT IMMUNOPHARMACOL, V6, P1, DOI 10.1016/j.intimp.2005.05.013; Wiley JL, 2003, EUR J PHARMACOL, V471, P185, DOI 10.1016/S0014-2999(03)01856-9	46	33	33	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	OCT	2013	170	3					641	648		10.1111/bph.12316			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	222SN	WOS:000324751600016	23889598	Green Published			2021-06-18	
J	Harhausen, D; Sudmann, V; Khojasteh, U; Muller, J; Zille, M; Graham, K; Thiele, A; Dyrks, T; Dirnagl, U; Wunder, A				Harhausen, Denise; Sudmann, Violetta; Khojasteh, Uldus; Mueller, Jochen; Zille, Marietta; Graham, Keith; Thiele, Andrea; Dyrks, Thomas; Dirnagl, Ulrich; Wunder, Andreas			Specific Imaging of Inflammation with the 18kDa Translocator Protein Ligand DPA-714 in Animal Models of Epilepsy and Stroke	PLOS ONE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; PERIPHERAL BENZODIAZEPINE-RECEPTORS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VIVO; 18 KDA; MULTIPLE-SCLEROSIS; INITIAL EVALUATION; PET; NEUROINFLAMMATION	Inflammation is a pathophysiological hallmark of many diseases of the brain. Specific imaging of cells and molecules that contribute to cerebral inflammation is therefore highly desirable, both for research and in clinical application. The 18 kDa translocator protein (TSPO) has been established as a suitable target for the detection of activated microglia/macrophages. A number of novel TSPO ligands have been developed recently. Here, we evaluated the high affinity TSPO ligand DPA-714 as a marker of brain inflammation in two independent animal models. For the first time, the specificity of radiolabeled DPA-714 for activated microglia/macrophages was studied in a rat model of epilepsy (induced using Kainic acid) and in a mouse model of stroke (transient middle cerebral artery occlusion, tMCAO) using high-resolution autoradiography and immunohistochemistry. Additionally, cold-compound blocking experiments were performed and changes in blood-brain barrier (BBB) permeability were determined. Target-to-background ratios of 2 and 3 were achieved in lesioned vs. unaffected brain tissue in the epilepsy and tMCAO models, respectively. In both models, ligand uptake into the lesion corresponded well with the extent of Ox42- or Iba1-immunoreactive activated microglia/macrophages. In the epilepsy model, ligand uptake was almost completely blocked by pre-injection of DPA-714 and FEDAA1106, another high-affinity TSPO ligand. Ligand uptake was independent of the degree of BBB opening and lesion size in the stroke model. We provide further strong evidence that DPA-714 is a specific ligand to image activated microglia/macrophages in experimental models of brain inflammation.	[Harhausen, Denise; Khojasteh, Uldus; Mueller, Jochen; Zille, Marietta; Dirnagl, Ulrich; Wunder, Andreas] Charite, Dept Expt Neurol, D-13353 Berlin, Germany; [Harhausen, Denise; Zille, Marietta; Dirnagl, Ulrich; Wunder, Andreas] Ctr Stroke Res Berlin CSB, Berlin, Germany; [Sudmann, Violetta; Graham, Keith; Thiele, Andrea; Dyrks, Thomas] Bayer Healthcare, Global Drug Discovery, Berlin, Germany	Harhausen, D (corresponding author), Charite, Dept Expt Neurol, D-13353 Berlin, Germany.	denise.harhausen@charite.de	Zille, Marietta/P-1700-2018	Zille, Marietta/0000-0002-0609-8956; Dirnagl, Ulrich/0000-0003-0755-6119	European UnionEuropean Commission [201024, 202213]; Deutsche Forschungsgemeinschaft (NeuroCure Cluster of Excellence)German Research Foundation (DFG) [Exc 257]; Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin)Federal Ministry of Education & Research (BMBF) [01 EO 08 01]; TSB grant entitled "Development of diagnostic markers for the diagnosis of stroke and establishment of a center for small animal imaging research at the Charite Berlin"; Bayer Pharma AG	This work was supported by the European Union's Seventh Framework Programme (FP7/2008-2013) under Grant Agreements 201024 and 202213 (European Stroke Network); the Deutsche Forschungsgemeinschaft (NeuroCure Cluster of Excellence, Exc 257); and the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 08 01) and the TSB grant entitled "Development of diagnostic markers for the diagnosis of stroke and establishment of a center for small animal imaging research at the Charite Berlin." Furthermore, this study was supported and conducted together with Bayer Pharma AG and relevant parties are co-authors. Thomas Dyrks, Andrea Thiele, Keith Graham, Violetta Sudmann are employees of Bayer Pharma AG, Berlin, Germany and they hereby declare that they participated in the preclinical preparation for this study as well as the manuscript preparation. They have seen and approved the final version. None of the products in the manuscript are under development or seeking patent approval. All the other funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abourbeh G, 2012, J NEUROSCI, V32, P5728, DOI 10.1523/JNEUROSCI.2900-11.2012; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Arlicot N, 2012, NUCL MED BIOL, V39, P570, DOI 10.1016/j.nucmedbio.2011.10.012; Banati RB, 2000, BRAIN, V123, P2321, DOI 10.1093/brain/123.11.2321; Beckham JD, 2012, NEUROTHERAPEUTICS, V9, P124, DOI 10.1007/s13311-011-0086-5; Boutin H, 2007, GLIA, V55, P1459, DOI 10.1002/glia.20562; Cagnin A, 2007, NEUROTHERAPEUTICS, V4, P443, DOI 10.1016/j.nurt.2007.04.006; Campbell M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1852; Cosenza-Nashat M, 2009, NEUROPATH APPL NEURO, V35, P306, DOI 10.1111/j.1365-2990.2008.01006.x; Doorduin J, 2009, MOL IMAGING BIOL, V11, P386, DOI 10.1007/s11307-009-0211-6; DORMAN G, 1995, J ORG CHEM, V60, P2292, DOI 10.1021/jo00112a066; Engel O, 2011, JOVE-J VIS EXP, DOI 10.3791/2423; Gulyas B, 2005, J NEUROL SCI, V229, P219, DOI 10.1016/j.jns.2004.11.032; Hellier Jennifer L, 2005, Curr Protoc Neurosci, VChapter 9, DOI 10.1002/0471142301.ns0919s31; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Jacobs AH, 2012, J CEREBR BLOOD F MET, V32, P1393, DOI 10.1038/jcbfm.2012.53; James ML, 2008, J NUCL MED, V49, P814, DOI 10.2967/jnumed.107.046151; Klohs J, 2009, J CEREBR BLOOD F MET, V29, P1284, DOI 10.1038/jcbfm.2009.51; Lavisse S, 2012, J NEUROSCI, V32, P10809, DOI 10.1523/JNEUROSCI.1487-12.2012; Martin A, J CEREB BLOOD FLOW M, V30, P230; Martin A, 2011, MOL IMAGING BIOL, V13, P10, DOI 10.1007/s11307-010-0324-y; Mattner F, 2005, EUR J NUCL MED MOL I, V32, P557, DOI 10.1007/s00259-004-1690-y; Scarf AM, 2011, J NUCL MED, V52, P667, DOI 10.2967/jnumed.110.086629; Stoll G, 2009, NEUROSCIENCE, V158, P1151, DOI 10.1016/j.neuroscience.2008.06.045; Thiel A, 2011, STROKE, V42, P507, DOI 10.1161/STROKEAHA.110.598821; Venneti S, 2012, GLIA; Vezzani A, 2012, NEUROPHARMACOLOGY; Wilson AA, 2008, NUCL MED BIOL, V35, P305, DOI 10.1016/j.nucmedbio.2007.12.009; Winkeler A, 2012, EUR J NUCL MED MOL I, V39, P811, DOI 10.1007/s00259-011-2041-4; Wunder A, 2009, NEUROSCIENCE, V158, P1161, DOI 10.1016/j.neuroscience.2008.10.005; Yanamoto K, 2009, SYNAPSE, V63, P961, DOI 10.1002/syn.20678; Zhang MR, 2003, BIOORG MED CHEM LETT, V13, P201, DOI 10.1016/S0960-894X(02)00886-7; Zheng XY, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/457079	34	33	34	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2013	8	8							e69529	10.1371/journal.pone.0069529			9	Multidisciplinary Sciences	Science & Technology - Other Topics	219XU	WOS:000324545800020	23936336	DOAJ Gold, Green Published			2021-06-18	
J	Bonfield, CM; Lam, S; Lin, YM; Greene, S				Bonfield, Christopher M.; Lam, Sandi; Lin, Yimo; Greene, Stephanie			The impact of attention deficit hyperactivity disorder on recovery from mild traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						attention deficit hyperactivity disorder; traumatic brain injury; closed head injury; trauma; disability	CHILDREN; ADOLESCENTS; SCALE	Object. Attention deficit hyperactivity disorder (ADHD) and traumatic brain injury (TBI) are significant independent public health concerns in the pediatric population. This study explores the impact of a premorbid diagnosis of ADHD on outcome following mild TBI. Methods. The charts of all patients with a diagnosis of mild closed head injury (CHI) and ADHD who were admitted to Children's Hospital of Pittsburgh between January 2003 and December 2010 were retrospectively reviewed after institutional review board approval was granted. Patient demographics, initial Glasgow Coma Scale (GCS) score, hospital course, and King's Outcome Scale for Childhood Head Injury (KOSCHI) score were recorded. The results were compared with a sample of age-matched controls admitted with a diagnosis of CHI without ADHD. Results. Forty-eight patients with mild CHI and ADHD, and 45 patients with mild CHI without ADHD were included in the statistical analysis. Mild TBI due to CHI was defined as an initial GCS score of 13-15. The ADHD group had a mean age of 12.2 years (range 6-17 years), and the control group had a mean age of 11.14 years (range 5-16 years). For patients with mild TBI who had ADHD, 25% were moderately disabled (KOSCHI Score 4b), and 56% had completely recovered (KOSCHI Score 5b) at follow-up. For patients with mild TBI without ADHD, 2% were moderately disabled and 84% had completely recovered at follow-up (p < 0.01). Patients with ADHD were statistically significantly more disabled after mild TBI than were control patients without ADHD, even when controlling for age, sex, initial GCS score, hospital length of stay, length of follow-up, mechanism of injury, and presence of other (extracranial) injury. Conclusions. Patients who sustain mild TBIs in the setting of a premorbid diagnosis of ADHD are more likely to be moderately disabled by the injury than are patients without ADHD.	[Bonfield, Christopher M.; Greene, Stephanie] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15224 USA; [Lam, Sandi; Lin, Yimo] Univ Chicago, Neurosurg Sect, Chicago, IL 60637 USA	Bonfield, CM (corresponding author), Univ Pittsburgh, Dept Neurosurg, 4th Floor Fac Pavilion,4401 Penn Ave, Pittsburgh, PA 15224 USA.	bonfieldcm@upmc.edu		Greene, Stephanie/0000-0002-5858-4032; Lam, Sandi/0000-0003-3294-6637			Barkley R.A, 2006, ATTENTION DEFICIT HY; BIEDERMAN J, 1991, AM J PSYCHIAT, V148, P564; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P842; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; FAIGEL HC, 1995, J ADOLESCENT HEALTH, V16, P174, DOI 10.1016/1054-139X(94)00049-K; Hoare P, 2003, EUR J EMERG MED, V10, P98, DOI 10.1097/01.mej.0000072631.17469.71; JENNETT B, 1975, LANCET, V1, P480; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Kupper T, 2012, INT ARCH OCC ENV HEA, V85, P837, DOI 10.1007/s00420-012-0794-0; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; *NAT CTR INJ PREV, 2006, TRAUM BRAIN INJ US A; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Spencer TJ, 2002, J CLIN PSYCHIAT, V63, P3; TEASDALE G, 1974, LANCET, V2, P81; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	18	33	33	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2013	12	2					97	102		10.3171/2013.5.PEDS12424			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	187CM	WOS:000322094500001	23905842	Bronze			2021-06-18	
J	Fraser, CD; Brady, KM; Rhee, CJ; Easley, RB; Kibler, K; Smielewski, P; Czosnyka, M; Kaczka, DW; Andropoulos, DB; Rusin, C				Fraser, Charles D., III; Brady, Ken M.; Rhee, Christopher J.; Easley, R. Blaine; Kibler, Kathleen; Smielewski, Peter; Czosnyka, Marek; Kaczka, David W.; Andropoulos, Dean B.; Rusin, Craig			The frequency response of cerebral autoregulation	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						cerebrovascular autoregulation; neonatal; frequency	TRAUMATIC BRAIN-INJURY; NEAR-INFRARED SPECTROSCOPY; BLOOD-FLOW AUTOREGULATION; CEREBROVASCULAR AUTOREGULATION; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; PHASE RELATIONSHIP; REACTIVITY; ISOFLURANE; VELOCITY	The frequency-response of pressure autoregulation is not well delineated; therefore, the optimal frequency of arterial blood pressure (ABP) modulation for measuring autoregulation is unknown. We hypothesized that cerebrovascular autoregulation is band-limited and delineated by a cutoff frequency for which ABP variations induce cerebrovascular reactivity. Neonatal swine (n = 8) were anesthetized using constant minute ventilation while positive end-expiratory pressure (PEEP) was modulated between 6 and 0.75 cycles/min (min(-1)). The animals were hemorrhaged until ABP was below the lower limit of autoregulation (LLA), and PEEP modulations were repeated. Vascular reactivity was quantified at each frequency according to the phase lag between ABP and intracranial pressure (ICP) above and below the LLA. Phase differences between ABP and ICP were small for frequencies of >2 min(-1), with no ability to differentiate cerebrovascular reactivity between ABPs above or below the LLA. For frequencies of <2 min(-1), ABP and intracranial pressure (ICP) showed phase shift when measured above LLA and no phase shift when measured below LLA [above vs. below LLA at 1 min(-1): 156 degrees (139-174 degrees) vs. 30 degrees (22-50 degrees); P < 0.001 by two-way ANOVA for both frequency and state of autoregulation]. Data taken above LLA fit a Butterworth high-pass filter model with a cutoff frequency at 1.8 min(-1) (95% confidence interval: 1.5-2.2). Cerebrovascular reactivity occurs for sustained ABP changes lasting 30 s or longer. The ability to distinguish intact and impaired autoregulation was maximized by a 60-s wave (1 min(-1)), which was 100% sensitive and 100% specific in this model.	[Fraser, Charles D., III] Univ Texas Houston, Sch Med, Houston, TX USA; [Brady, Ken M.; Easley, R. Blaine; Kibler, Kathleen; Andropoulos, Dean B.] Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Brady, Ken M.; Easley, R. Blaine; Kibler, Kathleen; Andropoulos, Dean B.] Texas Childrens Hosp, Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA; [Rhee, Christopher J.] Texas Childrens Hosp, Baylor Coll Med, Dept Neonatol, Houston, TX 77030 USA; [Smielewski, Peter; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Cambridge CB2 2QQ, England; [Kaczka, David W.] Harvard Univ, Sch Med, Dept Anaesthesia, Boston, MA 02115 USA; [Rusin, Craig] Texas Childrens Hosp, Baylor Coll Med, Dept Cardiol, Houston, TX 77030 USA	Brady, KM (corresponding author), Texas Childrens Hosp, 6621 Fannin,WT 17-417B, Houston, TX 77030 USA.	kmbrady@texaschildrens.org	Kaczka, David W./U-2580-2018	Kaczka, David W./0000-0003-4378-5242; Smielewski, Peter/0000-0001-5096-3938; Rusin, Craig/0000-0003-3812-8133	FAER Medical Student Summer Research Fellowship; American Association of Thoracic Surgery Student Research Fellowship	Charles Fraser was sponsored by both the FAER Medical Student Summer Research Fellowship and the American Association of Thoracic Surgery Student Research Fellowship during the time of these studies. Blaine Easley, Ken Brady, and Craig Rusin are co-inventors of the PEEP-modulation technology used to measure autoregulation in this study, and the method has been submitted for patent protection. ICM+ software used in this study is licensed by the University of Cambridge (Cambridge Enterprise). Marek Czosnyka and Peter Smielewski have a financial interest in a part of its licensing fee.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2007, STROKE, V38, P2818, DOI 10.1161/STROKEAHA.107.485706; Brady KM, 2012, J APPL PHYSIOL, V113, P1362, DOI 10.1152/japplphysiol.00853.2012; Brady KM, 2010, ANESTH ANALG, V111, P191, DOI 10.1213/ANE.0b013e3181e054ba; Brady KM, 2009, ANESTH ANALG, V108, P1278, DOI 10.1213/ane.0b013e3181964848; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Diedler J, 2011, ANESTH ANALG, V113, P849, DOI 10.1213/ANE.0b013e3182285dc0; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; LAPTOOK AR, 1983, PEDIATR RES, V17, P77, DOI 10.1203/00006450-198301000-00015; LASSEN NA, 1959, PHYSIOL REV, V39, P183; Lewis PM, 2008, ACTA NEUROCHIR, V150, P139, DOI 10.1007/s00701-007-1447-z; MCPHERSON RW, 1988, ANESTHESIOLOGY, V69, P493, DOI 10.1097/00000542-198810000-00008; Mertineit C, 2000, CAN J PHYSIOL PHARM, V78, P217, DOI 10.1139/cjpp-78-3-217; Pedersen TF, 2003, AM J PHYSIOL-HEART C, V285, pH1097, DOI 10.1152/ajpheart.00098.2003; Ragauskas A, 2005, ACTA NEUROCHIR SUPPL, V95, P367; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	22	33	33	0	6	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	JUL	2013	115	1					52	56		10.1152/japplphysiol.00068.2013			5	Physiology; Sport Sciences	Physiology; Sport Sciences	174ZW	WOS:000321199200006	23681909				2021-06-18	
J	Nielsen, TH; Olsen, NV; Toft, P; Nordstrom, CH				Nielsen, T. H.; Olsen, N. V.; Toft, P.; Nordstrom, C. H.			Cerebral energy metabolism during mitochondrial dysfunction induced by cyanide in piglets	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							TRAUMATIC BRAIN-INJURY; CYCLOSPORINE-A; SUBARACHNOID HEMORRHAGE; CYTOCHROME-OXIDASE; CELL-DEATH; ISCHEMIA; RATS; MICRODIALYSIS; MECHANISMS; FAILURE	Background Mitochondrial dysfunction is an important factor contributing to tissue damage in both severe traumatic brain injury and ischemic stroke. This experimental study explores the possibility to diagnose the condition bedside by utilising intracerebral microdialysis and analysis of chemical variables related to energy metabolism. Methods Mitochondrial dysfunction was induced in piglets and evaluated by monitoring brain tissue oxygen tension (PbtO2) and cerebral levels of glucose, lactate, pyruvate, glutamate, and glycerol bilaterally. The biochemical variables were obtained by microdialysis and immediate enzymatic analysis. Mitochondrial function was blocked by unilateral infusion of NaCN/KCN (0.5mol/L) through the microdialysis catheter (N=5). As a reference, NaCl (0.5mol/L) was infused by intracerebral microdialysis in one group of animals (N=3). Results PbtO2 increased during cyanide infusion and returned to baseline afterwards. The lactate/pyruvate (LP) ratio increased significantly following cyanide infusion because of a marked increase in lactate level while pyruvate remained within normal limits. Glutamate and glycerol increased after cyanide infusion indicating insufficient energy metabolism and degradation of cellular membranes, respectively. Conclusion Mitochondrial dysfunction is characterised by an increased LP ratio signifying a shift in cytoplasmatic redox state at normal or elevated PbtO2. The condition is biochemically characterised by a marked increase in cerebral lactate with a normal or elevated pyruvate level. The metabolic pattern is different from cerebral ischemia, which is characterised by simultaneous decreases in intracerebral pyruvate and PbtO2. The study supports the hypothesis that cerebral ischemia and mitochondrial dysfunction may be identified and separated at the bedside by utilising intracerebral microdialysis.	Odense Univ Hosp, Dept Anaesthesiol, DK-5000 Odense C, Denmark; [Nielsen, T. H.] Odense Univ Hosp, Dept Neurosurg, DK-5000 Odense C, Denmark; Univ Southern Denmark, Biomed Lab, DK-5000 Odense C, Denmark	Nielsen, TH (corresponding author), Odense Univ Hosp, Dept Neurosurg, Sdr Blvd 29, DK-5000 Odense C, Denmark.	troels.nielsen@ouh.regionsyddanmark.dk	Nielsen, Troels Halfeld/G-3456-2015	Nielsen, Troels Halfeld/0000-0002-3943-8128; Toft, Palle/0000-0002-3188-449X	Odense University Hospital; A.P. Moller foundation	The project was supported by grants from Odense University Hospital and the A.P. Moller foundation.	Akdemir G, 2005, NEUROL RES, V27, P827, DOI 10.1179/016164105X63610; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; CAMERINO PW, 1966, J BIOL CHEM, V241, P970; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Gardenfors A, 2002, ACTA NEUROCHIR, V144, P601, DOI 10.1007/s00701-002-0954-1; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Hillered L, 1998, J NEUROL NEUROSUR PS, V64, P486, DOI 10.1136/jnnp.64.4.486; Hwang JH, 2010, BRAIN RES, V1359, P208, DOI 10.1016/j.brainres.2010.08.047; Kilbaugh TJ, 2011, J NEUROTRAUM, V28, P763, DOI 10.1089/neu.2010.1635; Kopterides P, 2011, INTENS CARE MED, V37, P1756, DOI 10.1007/s00134-011-2336-8; Lawson-Smith P, 2011, UNDERSEA HYPERBAR M, V38, P223; Levy B, 2005, LANCET, V365, P871, DOI 10.1016/S0140-6736(05)71045-X; MACMILLAN VH, 1989, J CEREBR BLOOD F MET, V9, P156, DOI 10.1038/jcbfm.1989.23; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Nielsen TH, 2013, ACTA ANAESTH SCAND, V57, P229, DOI 10.1111/j.1399-6576.2012.02783.x; Nielsen TH, 2011, NEUROCRIT CARE, V15, P585, DOI 10.1007/s12028-011-9563-2; Niizuma K, 2009, J NEUROCHEM, V109, P133, DOI 10.1111/j.1471-4159.2009.05897.x; Nordstrom C H, 1977, Acta Neurol Scand Suppl, V64, P146; NORDSTROM CH, 1978, J NEUROCHEM, V30, P479, DOI 10.1111/j.1471-4159.1978.tb06553.x; PETTERSEN JC, 1993, J APPL TOXICOL, V13, P9, DOI 10.1002/jat.2550130104; REHNCRONA S, 1979, STROKE, V10, P437, DOI 10.1161/01.STR.10.4.437; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Samuelsson C, 2007, J CEREBR BLOOD F MET, V27, P1309, DOI 10.1038/sj.jcbfm.9600433; Siesjo BK, 1999, ACTA NEUROCHIR SUPPL, V73, P7; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Ungerstedt U, 1997, PHYSIOLOGY, STRESS, AND MALNUTRITION, P361; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	33	33	34	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2013	57	6					793	801		10.1111/aas.12092			9	Anesthesiology	Anesthesiology	160JW	WOS:000320116800017	23495747				2021-06-18	
J	Tajiri, N; Dailey, T; Metcalf, C; Mosley, YI; Lau, T; Staples, M; van Loveren, H; Kim, SU; Yamashima, T; Yasuhara, T; Date, I; Kaneko, Y; Borlongan, CV				Tajiri, Naoki; Dailey, Travis; Metcalf, Christopher; Mosley, Yusef I.; Lau, Tsz; Staples, Meaghan; van Loveren, Harry; Kim, Seung U.; Yamashima, Tetsumori; Yasuhara, Takao; Date, Isao; Kaneko, Yuji; Borlongan, Cesario V.			In Vivo Animal Stroke Models A Rationale for Rodent and Non-Human Primate Models	TRANSLATIONAL STROKE RESEARCH			English	Article						Cerebral ischemia; Animals; Basic research; Translational; Clinical application	CEREBRAL-ARTERY OCCLUSION; MARROW STROMAL CELLS; ACUTE ISCHEMIC-STROKE; ENDURING MEMORY IMPAIRMENT; INTRALUMINAL THREAD TECHNIQUE; TISSUE-PLASMINOGEN ACTIVATOR; TRANSIENT FOREBRAIN ISCHEMIA; TRAUMATIC BRAIN-INJURY; DELAYED NEURONAL DEATH; BONE-MARROW	On average, every 4 min an individual dies from a stroke, accounting for one out of every 18 deaths in the United States. Approximately 795,000 Americans have a new or recurrent stroke each year, with just over 600,000 of these being first attack Roger et al. (Circulation, 125(1): 188-197, 2012). There have been multiple animal models of stroke demonstrating that novel therapeutics can help improve the clinical outcome. However, these results have failed to show the same outcomes when tested in human clinical trials. This review will discuss the current in vivo animal models of stroke, advantages and limitations, and the rationale for employing these animal models to satisfy translational gating items for examination of neuroprotective, as well as neurorestorative strategies in stroke patients. An emphasis in the present discussion of therapeutics development is given to stem cell therapy for stroke.	[Tajiri, Naoki; Dailey, Travis; Metcalf, Christopher; Mosley, Yusef I.; Lau, Tsz; Staples, Meaghan; van Loveren, Harry; Kaneko, Yuji; Borlongan, Cesario V.] Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA; [Kim, Seung U.] Univ British Columbia, Dept Neurol, Vancouver, BC V5Z 1M9, Canada; [Yamashima, Tetsumori] Kanazawa Univ, Dept Restorat Neurosurg, Grad Sch Med Sci, Kanazawa, Ishikawa, Japan; [Yasuhara, Takao; Date, Isao] Okayama Univ, Dept Neurol Surg, Grad Sch Med, Okayama, Japan	Borlongan, CV (corresponding author), Univ S Florida, Morsani Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33612 USA.	cborlong@health.usf.edu	Borlongan, Cesar/I-5696-2012; Kaneko, Yuji/J-6447-2012	Borlongan, Cesar/0000-0002-2966-9782; 	NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [UO15U01NS055914-04, R01NS071956-01]; James and Esther King Foundation for Biomedical Research Program; USF Signature Program in Interdisciplinary Neuroscience; SanBio Inc.; Celgene Cellular TherapeuticsCelgene Corporation; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS055914, R01NS071956] Funding Source: NIH RePORTER	The Borlongan Laboratory is supported by NIH NINDS UO15U01NS055914-04, NIH NINDS R01NS071956-01, James and Esther King Foundation for Biomedical Research Program, USF Signature Program in Interdisciplinary Neuroscience, SanBio Inc., Celgene Cellular Therapeutics, KMPHC, and NeuralStem Inc. CVB has patents and pending patents on cell therapy.	Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Borlongan CV, 2008, REGEN MED, V3, P249, DOI 10.2217/17460751.3.3.249; Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Borlongan CV, 2006, FRONT BIOSCI-LANDMRK, V11, P1090, DOI 10.2741/1865; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; BRIERLEY JB, 1969, BRAIN RES, V13, P68, DOI 10.1016/0006-8993(69)90144-9; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Busch E, 1997, BRAIN RES, V778, P16, DOI 10.1016/S0006-8993(97)01008-1; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chopp M, 2009, CELL TRANSPLANT, V18, P691, DOI 10.3727/096368909X470883; CROWELL RM, 1981, NEUROLOGY, V31, P1295, DOI 10.1212/WNL.31.10.1295; Crowell RM, 1970, STROKE, V1, P439, DOI 10.1161/01.STR.1.6.439; Davenport R, 2000, J NEUROL NEUROSUR PS, V68, P277, DOI 10.1136/jnnp.68.3.277; de Crespigny Alex J, 2005, J Stroke Cerebrovasc Dis, V14, P80, DOI 10.1016/j.jstrokecerebrovasdis.2004.12.005; DELZOPPO GJ, 1986, STROKE, V17, P1254, DOI 10.1161/01.STR.17.6.1254; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; EKLOF B, 1972, ACTA PHYSIOL SCAND, V86, P155, DOI 10.1111/j.1748-1716.1972.tb05322.x; EKLOF B, 1972, ACTA PHYSIOL SCAND, V86, P528, DOI 10.1111/j.1748-1716.1972.tb05354.x; Englund U, 2002, P NATL ACAD SCI USA, V99, P17089, DOI 10.1073/pnas.252589099; Fagan SC, 1998, NEUROLOGY, V50, P883, DOI 10.1212/WNL.50.4.883; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Fan X, 2012, STROKE, V43, P567, DOI 10.1161/STROKEAHA.111.635250; Feinklestein SP, 1999, STROKE, V30, P2752, DOI 10.1161/01.STR.30.12.2752; Ferrari A, 2000, FEBS LETT, V486, P121, DOI 10.1016/S0014-5793(00)02251-1; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fisher Marc, 2008, Am J Manag Care, V14, pS204; Frykholm P, 2005, J NEUROSURG, V102, P1076, DOI 10.3171/jns.2005.102.6.1076; Fujioka M, 2000, CEREBROVASC DIS, V10, P2, DOI 10.1159/000016018; Fukuda S, 2003, ILAR J, V44, P96, DOI 10.1093/ilar.44.2.96; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Garcia JH, 1995, STROKE, V26, P635; Gerriets T, 2003, J NEUROSCI METH, V122, P201, DOI 10.1016/S0165-0270(02)00322-9; Ginsberg M. D., 1998, CEREBROVASCULAR DIS; Girouard H, 2006, J APPL PHYSIOL, V100, P328, DOI 10.1152/japplphysiol.00966.2005; GLOBUS MYT, 1988, NEUROSCI LETT, V91, P36, DOI 10.1016/0304-3940(88)90245-5; Glover LE, 2012, TRANSL STROKE RES, V3, P90, DOI 10.1007/s12975-011-0127-8; Hara K, 2007, BRAIN RES BULL, V74, P164, DOI 10.1016/j.brainresbull.2007.06.014; Hattiangady B, 2008, AGING CELL, V7, P207, DOI 10.1111/j.1474-9726.2007.00363.x; Hess DC, 2005, STROKE, V36, P2018, DOI 10.1161/01.STR.0000177534.02969.e4; Hess DC, 2002, STROKE, V33, P1362, DOI 10.1161/01.STR.0000014925.09415.C3; Hurn PD, 2005, STROKE, V36, P193, DOI 10.1161/01.STR.0000153064.41332.f6; Iadecola C, 2008, CELL METAB, V7, P476, DOI 10.1016/j.cmet.2008.03.010; KAWAMURA S, 1991, ACTA NEUROCHIR, V109, P126, DOI 10.1007/BF01403007; KAWAMURA S, 1994, SURG NEUROL, V41, P368, DOI 10.1016/0090-3019(94)90029-9; Kim E, 2012, ANN NEUROL, V71, P753, DOI 10.1002/ana.23569; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Lapchak P. A., 2012, J NEUROL NEUROPHYSIO, V3, pe111, DOI DOI 10.4172/2155-9562.1000E111; Lees JS, 2012, INT J STROKE, V7, P582, DOI 10.1111/j.1747-4949.2012.00797.x; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lindner MD, 2003, J NEUROSCI, V23, P10913; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; MARKGRAF CG, 1993, STROKE, V24, P286, DOI 10.1161/01.STR.24.2.286; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marshall JWB, 2003, ILAR J, V44, P153, DOI 10.1093/ilar.44.2.153; Martini SR, 2007, J CEREBR BLOOD F MET, V27, P435, DOI 10.1038/sj.jcbfm.9600355; Matsukawa N, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-126; Matsumoto Y, 2009, J IMMUNOL, V183, P4773, DOI 10.4049/jimmunol.0900871; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; MOLINARI GF, 1974, STROKE, V5, P334, DOI 10.1161/01.STR.5.3.334; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; NEMOTO EM, 1977, STROKE, V8, P558, DOI 10.1161/01.STR.8.5.558; Nemoto EM, 2005, ADV EXP MED BIOL, V566, P83; NEUBUERGER KT, 1954, J NEUROPATH EXP NEUR, V13, P144; Nudo RJ, 2003, ILAR J, V44, P161, DOI 10.1093/ilar.44.2.161; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; PETITO CK, 1986, LAB INVEST, V55, P696; PULSINELLI WA, 1988, STROKE, V19, P913, DOI 10.1161/01.STR.19.7.913; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood-2004-01-0336; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Rewell SSJ, 2010, J CEREBR BLOOD F MET, V30, P729, DOI 10.1038/jcbfm.2009.273; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Rink C, 2008, P NATL ACAD SCI USA, V105, P14100, DOI 10.1073/pnas.0806678105; Roger VL, 2012, CIRCULATION, V125, P188, DOI 10.1161/CIR.0b013e3182456d46; Roitberg B, 2003, NEUROL RES, V25, P68, DOI 10.1179/016164103101200950; Romero-Perez D, 2008, J AM COLL CARDIOL, V52, P1086, DOI 10.1016/j.jacc.2008.06.028; Sasaki M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026577; Schmahmann JD, 2004, ANN NEUROL, V55, P585, DOI 10.1002/ana.20060; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Shi S, 2008, EUR J CLIN PHARMACOL, V64, P183, DOI 10.1007/s00228-007-0422-1; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x; SPETZLER RF, 1980, SURG NEUROL, V13, P317; Sudlow CLM, 1996, STROKE, V27, P550, DOI 10.1161/01.STR.27.3.550; Symon L, 1975, Adv Neurol, V10, P199; TABUCHI E, 1992, BRAIN RES BULL, V29, P685, DOI 10.1016/0361-9230(92)90139-O; TABUCHI E, 1995, BRAIN RES BULL, V37, P73, DOI 10.1016/0361-9230(94)00262-2; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; Taylor TN, 1996, STROKE, V27, P1459, DOI 10.1161/01.STR.27.9.1459; Toda H, 2001, NEUROSCI LETT, V316, P9, DOI 10.1016/S0304-3940(01)02331-X; Traystman RJ, 2003, ILAR J, V44, P85, DOI 10.1093/ilar.44.2.85; Tsukada T, 2001, J NEUROCHEM, V79, P1196, DOI 10.1046/j.1471-4159.2001.00679.x; Vaitkevicius PV, 2001, P NATL ACAD SCI USA, V98, P1171, DOI 10.1073/pnas.98.3.1171; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245; Veizovic T, 2001, STROKE, V32, P1012, DOI 10.1161/01.STR.32.4.1012; Wang S, 2004, STROKE, V35, P1763, DOI 10.1161/01.STR.0000131858.63829.6e; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Wechsler L, 2009, STROKE, V40, P510, DOI 10.1161/STROKEAHA.108.526863; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; WOLIN LR, 1971, EXP NEUROL, V30, P103, DOI 10.1016/0014-4886(71)90225-1; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Yamashima T, 2003, HIPPOCAMPUS, V13, P791, DOI 10.1002/hipo.10127; Yamashima T, 1996, EUR J NEUROSCI, V8, P1932, DOI 10.1111/j.1460-9568.1996.tb01337.x; Yamashima T, 1998, EUR J NEUROSCI, V10, P1723, DOI 10.1046/j.1460-9568.1998.00184.x; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; YONAS H, 1990, J NEUROSURG, V73, P266, DOI 10.3171/jns.1990.73.2.0266; Yoshida M, 2002, ACTA NEUROPATHOL, V104, P267, DOI 10.1007/s00401-002-0554-4; Yukie M, 2006, REV NEUROSCIENCE, V17, P201; Zhang AG, 1997, J CEREBR BLOOD F MET, V17, P123, DOI 10.1097/00004647-199702000-00001; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; ZOLAMORGAN S, 1992, J NEUROSCI, V12, P2582; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	127	33	34	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	JUN	2013	4	3					308	321		10.1007/s12975-012-0241-2			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	136XU	WOS:000318397800004	23682299	Green Accepted			2021-06-18	
J	Thal, SC; Schaible, EV; Neuhaus, W; Scheffer, D; Brandstetter, M; Engelhard, K; Wunder, C; Forster, CY				Thal, Serge C.; Schaible, Eva-Verena; Neuhaus, Winfried; Scheffer, David; Brandstetter, Moritz; Engelhard, Kristin; Wunder, Christian; Foerster, Carola Y.			Inhibition of Proteasomal Glucocorticoid Receptor Degradation Restores Dexamethasone-Mediated Stabilization of the Blood-Brain Barrier After Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						blood-brain barrier; bortezomib; dexamethasone; GC receptor; glucocorticoid; nuclear receptor; proteasome; steroids; traumatic brain injury	PLACEBO-CONTROLLED TRIAL; FOCAL CEREBRAL-ISCHEMIA; HEAD-INJURY; IN-VITRO; TIGHT JUNCTIONS; RAT-BRAIN; MRC CRASH; TNF-ALPHA; EXPRESSION; EDEMA	Objectives: To establish the molecular background for glucocorticoid insensitivity, that is, failure to reduce edema formation and to protect blood-brain barrier integrity after acute traumatic brain injury. Design: Controlled animal study. Setting: University research laboratory. Subjects: Male C57Bl/6N mice. Interventions: Mechanical brain lesion by controlled cortical impact. Measurements and Main Results: Our study demonstrates that 1) proteasomal glucocorticoid receptor degradation is established in brain endothelial cells after traumatic brain injury as a form of posttranslational glucocorticoid receptor modification; 2) inhibition of the proteasomal degradation pathway with bortezomib (0.2 mg/kg) in combination with the glucocorticoid dexamethasone (10 mg/kg) by subcutaneous injection 30 minutes postinjury restores levels of barrier sealing glucocorticoid receptor target occludin in brain endothelial cells, improves blood-brain barrier integrity, reduces edema formation, and limits neuronal damage after brain trauma. Conclusions: The results indicate that the stabilizing effect of glucocorticoids on the blood-brain barrier is hampered after cerebral lesions by proteasomal glucocorticoid receptor degradation in brain endothelial cells and restored by inhibition of proteasomal degradation pathways. The results provide underlying mechanisms for the clinically observed inefficacy of glucocorticoids. The novel combined treatment strategy might help to attenuate trauma-induced brain edema formation and neuronal damage as secondary effects of brain trauma. (Crit Care Med 2013; 41:1305-1315)	[Thal, Serge C.; Schaible, Eva-Verena; Brandstetter, Moritz; Engelhard, Kristin] Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany; [Neuhaus, Winfried; Scheffer, David; Wunder, Christian; Foerster, Carola Y.] Univ Wurzburg, Ctr Operat Med, Dept Anesthesia & Crit Care, Wurzburg, Germany; [Neuhaus, Winfried] Univ Vienna, Dept Med Chem, A-1010 Vienna, Austria	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Dept Anesthesiol, Med Ctr, D-55122 Mainz, Germany.	thal@uni-mainz.de; Foerster_C@klinik.uni-wuerz-burg.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729; Neuhaus, Winfried/0000-0002-6552-7183	European UnionEuropean Commission [HEALTH-F2-2009-241778]; Bundesministerium fur Bildung und ForschungFederal Ministry of Education & Research (BMBF) [BMBF01 EO1004]; Focus Program Translational Neurosciences (FTN) of the Johannes Gutenberg-University	Supported, in part, by grants from the European Union (HEALTH-F2-2009-241778) to C.F., the Bundesministerium fur Bildung und Forschung (BMBF01 EO1004) to C.F., and the Focus Program Translational Neurosciences (FTN) of the Johannes Gutenberg-University to Dr. Thal.	Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Beato M, 2000, HUM REPROD UPDATE, V6, P225, DOI 10.1093/humupd/6.3.225; Blecharz KG, 2008, J CEREBR BLOOD F MET, V28, P1139, DOI 10.1038/jcbfm.2008.2; Blecharz KG, 2014, BIOL CELL, V106, DOI 10.1111/boc.201300083; Bloch Orin, 2007, Neurosurg Focus, V22, pE3; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS91; BURNHAM JA, 1991, NEUROLOGY, V41, P1349, DOI 10.1212/WNL.41.9.1349; D'Atri F, 2002, MOL MEMBR BIOL, V19, P103, DOI 10.1080/09687680210129236; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Dou Q Ping, 2002, IDrugs, V5, P828; Edwards P, 2005, LANCET, V365, P1957; Fishman RA., 1992, CEREBROSPINAL FLUID; Forster C, 2008, HISTOCHEM CELL BIOL, V130, P55, DOI 10.1007/s00418-008-0424-9; Forster C, 2008, J PHYSIOL-LONDON, V586, P1937, DOI 10.1113/jphysiol.2007.146852; Forster C, 2007, J PHYSIOL-LONDON, V580, P937, DOI 10.1113/jphysiol.2007.129007; Forster C, 2006, J PHYSIOL-LONDON, V573, P413, DOI 10.1113/jphysiol.2006.106385; Forster C, 2005, J PHYSIOL-LONDON, V565, P475, DOI 10.1113/jphysiol.2005.084038; HALL ED, 1992, J NEUROSURG, V76, P13, DOI 10.3171/jns.1992.76.1.0013; Harke N, 2008, MOL CELL ENDOCRINOL, V295, P39, DOI 10.1016/j.mce.2008.08.011; Henninger N, 2006, NEUROSCI LETT, V398, P300, DOI 10.1016/j.neulet.2006.01.015; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Hwang IK, 2006, NEUROSCI RES, V54, P319, DOI 10.1016/j.neures.2005.12.012; KLATZO I, 1994, ACTA NEUROCHIR, P3; Kleinschnitz C, 2011, STROKE, V42, P1081, DOI 10.1161/STROKEAHA.110.592238; Lahiri S, 2009, EUR J PHARMACOL, V609, P118, DOI 10.1016/j.ejphar.2009.03.005; Lee BH, 2007, NEONATOLOGY, V91, P12, DOI 10.1159/000096966; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; McCullers DL, 2002, BRAIN RES, V947, P41, DOI 10.1016/S0006-8993(02)02904-9; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Paramore A, 2003, NAT REV DRUG DISCOV, V2, P611, DOI 10.1038/nrd1159; Poungvarin N, 2004, STROKE, V35, P229, DOI 10.1161/01.STR.0000105931.81723.26; Reichardt Holger M, 2006, Expert Rev Neurother, V6, P1657, DOI 10.1586/14737175.6.11.1657; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; SAPOLSKY RM, 1984, ENDOCRINOLOGY, V114, P287, DOI 10.1210/endo-114-1-287; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHMIDTKASTNER R, 1993, J NEUROSCI METH, V46, P121, DOI 10.1016/0165-0270(93)90147-J; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Taylor AN, 2010, J NEUROTRAUM, V27, P1081, DOI 10.1089/neu.2009.1252; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Weiss H, 2010, PEDIATRICS, V126, P1141, DOI 10.1542/peds.2010-0271; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Zeni P, 2007, AM J PHYSIOL-CELL PH, V293, pC855, DOI 10.1152/ajpcell.00470.2006; Zhou JG, 2005, STEROIDS, V70, P407, DOI 10.1016/j.steroids.2005.02.006	53	33	34	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2013	41	5					1305	1315		10.1097/CCM.0b013e31827ca494			11	Critical Care Medicine	General & Internal Medicine	126ZB	WOS:000317661000034	23474678				2021-06-18	
J	Zhang, LJ; Hu, R; Li, M; Li, F; Meng, H; Zhu, G; Lin, JK; Feng, H				Zhang, Lijun; Hu, Rong; Li, Mei; Li, Fei; Meng, Hui; Zhu, Gang; Lin, Jiangkai; Feng, Hua			Deferoxamine attenuates iron-induced long-term neurotoxicity in rats with traumatic brain injury	NEUROLOGICAL SCIENCES			English	Article						Traumatic brain injury; Deferoxamine; Iron; TRPC6; Spatial learning and memory	HEAD-INJURY; TRANSFERRIN; ERYTHROCYTES; EXPRESSION; THROMBIN; RECEPTOR; 1-YEAR; EDEMA; TRPC6; GENE	This study investigated whether deferoxamine (DFO), an iron chelator attenuates iron-induced toxicity in rats with traumatic brain injury. In this study, three groups of Sprague-Dawley rats (sham, injury and DFO groups) were examined. Rats were killed on day 28 after Morris water maze testing and brains perfused for either non-heme brain binding or hemosiderin staining. Western blotting was used to measure protein levels of ferritin, transferrin and transient receptor potential canonical channel 6 (TRPC6). In TBI rats, there was a significant increase in brain iron on day 28, ferritin L, ferritin H, transferrin and TRPC6 levels were all significantly elevated post-TB1. There were also deficits in spatial learning and memory; however, DFO administration attenuated these effects in TBI rats supporting the notion that DFO may reduce brain injury accentuated by iron overload.	[Zhang, Lijun; Hu, Rong; Li, Mei; Li, Fei; Meng, Hui; Zhu, Gang; Lin, Jiangkai; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China	Feng, H (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Gaotanyan 30, Chongqing 400038, Peoples R China.	fenghua48@yahoo.com			National Nature Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30872674, 30901545]	The authors thank Derong Chen of Third medical military Universty, Chongqing, P. R. China, and Youan Shan of Southwest hospital, Chongqing, P. R. China for technical assistance. This project is supported by grants from National Nature Science Foundation of China (No. 30872674, 30901545).	Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brody DL, 2006, EXP NEUROL, V197, P330, DOI 10.1016/j.expneurol.2005.10.020; Connor JR, 1996, GLIA, V17, P83, DOI 10.1002/(SICI)1098-1136(199606)17:2<83::AID-GLIA1>3.0.CO;2-7; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; [宫国旗 GONG Guoqi], 2008, [第三军医大学学报, Acta Academiae Medicinae Militaris Tertiae], V30, P2172; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hanson LR, 2009, J PHARMACOL EXP THER, V330, P679, DOI 10.1124/jpet.108.149807; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Hua Y, 2006, J NEUROSURG, V104, P305, DOI 10.3171/jns.2006.104.2.305; Hua Y, 2003, J CEREBR BLOOD F MET, V23, P1448, DOI 10.1097/01.WCB.0000090621.86921.D5; IKEDA Y, 1990, ACT NEUR S, V51, P74; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Lee JY, 2011, ACTA NEUROCHIR SUPPL, V112, P101, DOI 10.1007/978-3-7091-0661-7_18; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Moos T, 1998, J COMP NEUROL, V398, P420; MORRIS CM, 1992, J INORG BIOCHEM, V47, P257, DOI 10.1016/0162-0134(92)84071-T; Mwanjewe J, 2004, BIOCHEM J, V378, P975, DOI 10.1042/BJ20031187; Nakamura T, 2005, BRAIN RES, V1039, P30, DOI 10.1016/j.brainres.2005.01.036; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Nilsson UA, 2002, FREE RADICAL RES, V36, P677, DOI 10.1080/10715760290029128; PALMER C, 1994, STROKE, V25, P1039, DOI 10.1161/01.STR.25.5.1039; Park UJ, 2011, ACTA NEUROPATHOL, V121, P459, DOI 10.1007/s00401-010-0785-8; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAYLOR EM, 1991, J NEUROCHEM, V57, P1584, DOI 10.1111/j.1471-4159.1991.tb06355.x; Testa U, 2002, FERRITIN PROTEINS IR, P449; THEIL EC, 1987, ANNU REV BIOCHEM, V56, P289, DOI 10.1146/annurev.biochem.56.1.289; TU GF, 1991, J BIOL CHEM, V266, P6201; WEINFELD A, 1968, J CLIN PATHOL, V21, P35, DOI 10.1136/jcp.21.1.35; Wu H, 2011, J CEREBR BLOOD F MET, V31, P1243, DOI 10.1038/jcbfm.2010.209; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Wu JM, 2002, BRAIN RES, V953, P45, DOI 10.1016/S0006-8993(02)03268-7; Xi G, 2005, STROKE, V36, P365; Xi GH, 2003, J NEUROCHEM, V84, P3, DOI 10.1046/j.1471-4159.2003.01268.x; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zhou J, 2008, NAT NEUROSCI, V11, P741, DOI 10.1038/nn.2127	39	33	34	0	13	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAY	2013	34	5					639	645		10.1007/s10072-012-1090-1			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	163VA	WOS:000320363800004	22538758				2021-06-18	
J	Caron, JG; Bloom, GA; Johnston, KM; Sabiston, CM				Caron, Jeffrey G.; Bloom, Gordon A.; Johnston, Karen M.; Sabiston, Catherine M.			Effects of Multiple Concussions on Retired National Hockey League Players	JOURNAL OF SPORT & EXERCISE PSYCHOLOGY			English	Article						concussions; hockey; depression; social support	SPORTS CONCUSSION; SOCIAL SUPPORT; INJURY; EXPERIENCES; PSYCHOLOGY; GENDER; RISK; PAIN; BODY	The purpose of this study was to understand the meanings and lived experiences of multiple concussions in professional hockey players using hermeneutic, idiographic, and inductive approaches within an interpretative phenomenological analysis. The interviewer was an athlete who had suffered multiple concussions, and the interviewees were five former National Hockey League athletes who had retired due to medically diagnosed concussions suffered during their careers. The men discussed the physical and psychological symptoms they experienced as a result of their concussions and how the symptoms affected their professional careers, personal relationships, and quality of life. The former professional athletes related these symptoms to the turmoil that is ever present in their lives. These findings are of interest to athletes, coaches, sport administrators, family members, sport psychology practitioners, and medical professionals, as they highlight the severity of short-and long-term effects of concussions.	[Caron, Jeffrey G.; Bloom, Gordon A.] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada; [Sabiston, Catherine M.] McGill Univ, Montreal, PQ, Canada; [Johnston, Karen M.; Sabiston, Catherine M.] Univ Toronto, Toronto, ON, Canada	Caron, JG (corresponding author), McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada.		Sabiston, Catherine/AAT-4924-2020	Sabiston, Catherine/0000-0002-8419-6666			Allen-Collinson J, 2009, QUAL RES SPORT EXERC, V1, P279, DOI 10.1080/19398440903192340; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Bianco T, 2001, RES Q EXERCISE SPORT, V72, P376, DOI 10.1080/02701367.2001.10608974; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Brocki JM, 2006, PSYCHOL HEALTH, V21, P87, DOI 10.1080/14768320500230185; Chamberlain K, 2011, HEALTH PSYCHOL REV, V5, P48, DOI 10.1080/17437199.2010.520113; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Clover J, 2010, CLIN SPORT MED, V29, P169, DOI 10.1016/j.csm.2009.09.008; COLBURN K, 1985, CAN J SOCIOL, V10, P153; Defrin R, 2009, PAIN, V145, P230, DOI 10.1016/j.pain.2009.06.028; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echlin PS, 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2F2010.9; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gulli C., 2011, MACLEANS MAG, V124, P56; Horton A. S., 2002, Medicine & Science in Sports & Exercise, V34, pS99, DOI 10.1097/00005768-200205001-00551; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Kontos AP, 2004, J APPL SPORT PSYCHOL, V16, P220, DOI 10.1080/10413200490485568; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Kuehl MD, 2010, CLIN J SPORT MED, V20, P86, DOI 10.1097/JSM.0b013e3181cf4534; Larkin M., 2006, QUAL RES PSYCHOL, V3, P102, DOI [10.1191/1478088706qp062oa, DOI 10.1191/1478088706QP0620A]; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McKnight K.M., 2009, J EXCELLENCE, V13, P63; Melnick M. J., 1992, Journal of Physical Education, Recreation & Dance, V63, P32; Messner M. A., 1990, International Review for the Sociology of Sport, V25, P203, DOI 10.1177/101269029002500303; Mihovilovic M.A., 1968, INT REV SPORT SOCIOL, V3, P73, DOI [10.1177/101269026800300105, DOI 10.1177/101269026800300105]; Nolen-Hoeksema S, 2011, PERS INDIV DIFFER, V51, P704, DOI 10.1016/j.paid.2011.06.012; Ogilvie B.C., 1982, P 5 WORLD C SPORT PS, P176; Osborn M, 1998, BRIT J HEALTH PSYCH, V3, P65, DOI 10.1111/j.2044-8287.1998.tb00556.x; Quinn AM, 1999, J APPL SPORT PSYCHOL, V11, P210, DOI 10.1080/10413209908404201; Rees T., 2007, Social psychology in sport, P223; Rees T, 2000, SPORT PSYCHOL, V14, P327, DOI 10.1123/tsp.14.4.327; Safai P, 2003, SOCIOL SPORT J, V20, P127, DOI 10.1123/ssj.20.2.127; Smith J.A., 2009, INTERPRETATIVE PHENO; Smith J.A., 2004, QUAL RES PSYCHOL, V1, P39, DOI [10.1191/1478088704qp004oa, DOI 10.1191/1478088704QP0040A]; Smith M. D., 1996, CHILDREN YOUTH SPORT, P142; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Tamminen KA, 2013, PSYCHOL SPORT EXERC, V14, P28, DOI 10.1016/j.psychsport.2012.07.002; Taylor J., 1994, J APPL SPORT PSYCHOL, V6, P1, DOI [10.1080/10413209408406462, DOI 10.1080/10413209408406462]; Weinstein MD, 1995, SEX ROLES, V33, P831, DOI 10.1007/BF01544782; WERTHNER P, 1986, INT J SPORT PSYCHOL, V17, P337; Wiese-Bjornstal DM, 1998, J APPL SPORT PSYCHOL, V10, P46, DOI 10.1080/10413209808406377; Willig C., 2001, INTRO QUALITATIVE RE; Yardley L, 2008, QUALITATIVE PSYCHOL, P235; YOUNG K, 1994, SOCIOL SPORT J, V11, P175, DOI 10.1123/ssj.11.2.175	48	33	33	0	68	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	0895-2779	1543-2904		J SPORT EXERCISE PSY	J. Sport Exerc. Psychol.	APR	2013	35	2					168	179		10.1123/jsep.35.2.168			12	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Social Sciences - Other Topics; Psychology; Sport Sciences	127PF	WOS:000317710200005	23535975				2021-06-18	
J	Levin, HS; Li, XQ; McCauley, SR; Hanten, G; Wilde, EA; Swank, P				Levin, Harvey S.; Li, Xiaoqi; McCauley, Stephen R.; Hanten, Gerri; Wilde, Elisabeth A.; Swank, Paul			Neuropsychological Outcome of mTBI: A Principal Component Analysis Approach	JOURNAL OF NEUROTRAUMA			English	Article						mTBI; data reduction; principal components analysis	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; QUESTIONNAIRE; CONCUSSION	The multitude of variables associated with a battery of outcome measures presents a risk for spurious findings in clinical trials and observational studies of mild traumatic brain injury (mTBI). We have used principal components analysis (PCA) to facilitate data reduction by identifying components which represent subsets of neuropsychological measures that are selectively correlated with each other. By merging data from two concurrent mTBI studies using the same outcome measures, we obtained a cohort of 102 mTBI patients and 85 orthopedic injury (OI) comparison patients whom we recruited from 24 hours to 96 hours post-injury and evaluated at one week, 1 month, and 3 months post-injury. Cognitive domains included episodic memory, evaluated by both verbal and visual memory tasks, cognitive processing speed tests, and executive function. Post-concussion and stress-related symptoms were measured by rating scales. PCA identified four components, including cognitive processing speed, verbal memory, visual memory, and a symptom composite representing post-concussion and stress symptoms. mTBI patients older than the mean age of 18 years had slower cognitive processing than the OI patients, but there was no group difference in cognitive processing speed in younger patients. The symptom component score differed significantly as mTBI patients had more severe symptoms than the OI group at each occasion. Our results encourage replication with other cohorts using either the same outcome measures or at least similar domains. PCA is an approach to data reduction that could mitigate spurious findings and increase efficiency in mTBI research.	[Levin, Harvey S.; Li, Xiaoqi; McCauley, Stephen R.; Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Dept Vet Affairs, Neurorehabil Neurons Networks Traumat Brain Injur, Houston, TX USA; [Levin, Harvey S.; Li, Xiaoqi; McCauley, Stephen R.; Hanten, Gerri; Wilde, Elisabeth A.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey S.; McCauley, Stephen R.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Swank, Paul] Univ Texas Houston, Sch Med, Dept Pediat, Houston, TX USA	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	hlevin@bcm.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P01NS056202]; Department of Defense (Post-Traumatic Stress Disorder and Traumatic Brain Injury (PTSD/TBI) Research Program) [W81XWH-08-2-0133 PT074693P2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS056202] Funding Source: NIH RePORTER	This research was supported by Grant 5P01NS056202 from the National Institute of Neurological Disorders and Stroke and by award W81XWH-08-2-0133 PT074693P2 from the Department of Defense (Post-Traumatic Stress Disorder and Traumatic Brain Injury (PTSD/TBI) Research Program). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Institutes of Health, the US Army, or the Department of Defense.	Benedict R., 1997, BRIEF VISUOSPATIAL M; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; Hoteling AJ, 2004, J AM SOC MASS SPECTR, V15, P523, DOI 10.1016/j.jasms.2003.12.004; IOM (Institute of Medicine), 2009, LONG TERM CONS TRAUM, V7; Iverson G.L., 2007, BRAIN INJURY MED PRI; Johnson RA, 2007, APPL MULTIVARIATE ST, Vxviii; JOLLIFFE IT, 1995, J APPL STAT, V22, P29, DOI 10.1080/757584395; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-3590.12.2.186; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Reeves D., 2002, ANAM 2001 USERS MANU; Roebuck-Spencer TM, 2012, CLIN NEUROPSYCHOL, V26, P473, DOI 10.1080/13854046.2011.650214; SAS, 2003, SAS STAT SOFTW US GU; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Smith A., 1982, SYMBOL DIGIT MODALIT; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; TEASDALE G, 1974, LANCET, V2, P81; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	30	33	33	0	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		625	632		10.1089/neu.2012.2627			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500004	22994927	Green Published			2021-06-18	
J	Baker, JF; Devitt, BM; Green, J; McCarthy, C				Baker, J. F.; Devitt, B. M.; Green, J.; McCarthy, C.			Concussion among under 20 rugby union players in Ireland: incidence, attitudes and knowledge	IRISH JOURNAL OF MEDICAL SCIENCE			English	Article						Rugby union; Brain concussion; Head injury; Sports	HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; PROTECTIVE EQUIPMENT; CONSENSUS STATEMENT; SPORTS CONCUSSION; FOOTBALL PLAYERS; HEADGEAR; RETURN; PREVENTION; GUIDELINES	The aim of this study was to determine the incidence of concussion among a cohort of male under 20 rugby players and assess basic knowledge and attitudes. Under 20 age group, players were recruited from local clubs as well as the national academy system. Players were asked to report on their history of concussion as well as a number of factors regarding their recognition of symptoms and behaviours regarding the diagnosis of concussion. 133 players responded (95 % response rate). Players could list a mean of 2.6 concussion related symptoms. 64 reported sustaining at least one concussion (average 2.25) and 36 sought medical attention following a concussion. 61 said that they would report suffering a concussion to their coach while 32 would report it to a 'team physiotherapist' or doctor. 114 believed that concussion is as serious as other rugby injuries and 100 believe that playing on while concussed could lead to long-term medical problems. Further educational efforts are required in this age group of rugby union players to reduce the risk of unnecessary secondary injury. Coaches, managers and players alike need to be targeted in any educational program.	[Baker, J. F.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland; [Devitt, B. M.; McCarthy, C.] Irish Rugby Football Union, Dept Med, Dublin 4, Ireland; [Green, J.] Univ Otago, Sch Pharm, Dunedin, New Zealand	Baker, JF (corresponding author), Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland.	joseph.f.baker@gmail.com; bdevitt@hotmail.com; ajamesgreen@gmail.com; conor.mccarthy@irfu.ie	Green, James A/A-8615-2008; Baker, Joseph F/H-2868-2019	Green, James A/0000-0002-7309-0751; Baker, Joseph F/0000-0002-8518-8780			Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; [Anonymous], 2009, BRIT J SPORT MED, V43, pi85; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Haseler CM, 2010, BRIT J SPORT MED, V44, P1093, DOI 10.1136/bjsm.2010.074021; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; IRFU, 2012, CLUB ENG PROGR MARCH; IRFU, 2007, IR RUGB FOOTB UN ANN; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; Miller G, 2009, SCIENCE, V325, P670, DOI 10.1126/science.325_670; Pettersen JA, 2002, BRIT J SPORT MED, V36, P19, DOI 10.1136/bjsm.36.1.19; Quarrie KL, 2007, J SPORT SCI, V25, P895, DOI 10.1080/02640410600944659; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	26	33	34	1	76	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0021-1265			IRISH J MED SCI	Irish J. Med. Sci.	MAR	2013	182	1					121	125		10.1007/s11845-012-0846-1			5	Medicine, General & Internal	General & Internal Medicine	063YQ	WOS:000313038500019	22898834				2021-06-18	
J	Post, A; Oeur, A; Hoshizaki, B; Gilchrist, MD				Post, Andrew; Oeur, Anna; Hoshizaki, Blaine; Gilchrist, Michael D.			An examination of American football helmets using brain deformation metrics associated with concussion	MATERIALS & DESIGN			English	Article						Concussion; American football; Helmets; Impact biomechanics; Protective devices	INTRACRANIAL-PRESSURE; PROFESSIONAL FOOTBALL; ANGULAR ACCELERATION; HEAD; IMPACT; INJURY; RECONSTRUCTION; MODEL	The sport of American football is associated with a high incidence of concussion, which research has identified may lead to long term neurological damage. As a result, it is important that protective technologies be developed to help mitigate the incidence of this type of brain trauma. This research examines how the design characteristics between different American football helmet models affect the linear and rotational acceleration responses as well as brain deformation metrics using a centric/non-centric impacting protocol. The protocol involved impacting the helmets at nine centric/non-centric sites. Brain deformation metrics were calculated using the University College Dublin Brain Trauma Model. The results revealed that design characteristics do influence the brain deformation metrics associated with incidence of concussion. Further analysis revealed that rotational acceleration was more related to brain deformation metrics than linear acceleration. These results show that when attempting to reduce brain deformation metrics, the development of rotational acceleration diminishing technologies may be beneficial. This research indicates that helmet design may be able to reduce the risk of concussive injury. (C) 2012 Elsevier Ltd. All rights reserved.	[Post, Andrew; Oeur, Anna; Hoshizaki, Blaine; Gilchrist, Michael D.] Univ Ottawa, Ottawa, ON, Canada; [Gilchrist, Michael D.] Univ Coll Dublin, Sch Mech & Mat Engn, Dublin 4, Ireland	Post, A (corresponding author), 200 Lees Ave,Room A106, Ottawa, ON K1N 6N5, Canada.	apost@uottawa.ca; aoeur016@uottawa.ca; thoshiza@uottawa.ca; Michael.gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X; Post, Andrew/0000-0002-5960-5552			Anderson RWG, 1999, P INT IRCOBI C BIOM, P107; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Braddick OJ, 2001, PERCEPTION, V30, P61, DOI 10.1068/p3048; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Cui L, 2009, MATER DESIGN, V30, P3414, DOI 10.1016/j.matdes.2009.03.044; Doorly M. C., 2006, Computer Methods in Biomechanics and Biomedical Engineering, V9, P371, DOI 10.1080/10255840601003551; Doorly M.C., 2007, THESIS U COLL DUBLIN; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Gadd CW, 1966, P 10 STAPP CAR CRASH; Gennarelli T, 1971, P 15 STAPP CAR CRASH; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; Gennarelli TA, 1972, P 16 STAPP CAR CRASH; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P112; Hardy WN, 2001, STAPP CAR CRASH J; Horgan TJ, 2004, INT J CRASHWORTHINES, V9, P401, DOI 10.1533/ijcr.2004.0299; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hoshizaki TB, 2004, NEUROSURGERY, V55, P956, DOI 10.1227/01.NEU.0000137275.50246.0B; King AI, 2003, IRCOBI C LISB PORT; Kleiven S, 2002, P IRCOBI, P161; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Luppino G, 2000, NEWS PHYSIOL SCI, V15, P219; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Miller RT, 1998, P 42 STAPP CAR CRASH; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Nahum A. M., 1977, P 21 STAPP CAR CRASH; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Post A, 2011, COMPUT METHOD BIOMEC; Post A, 2012, J BIOMECH, V45, P679, DOI 10.1016/j.jbiomech.2011.12.005; Price CJ, 2000, J ANAT, V197, P335, DOI 10.1046/j.1469-7580.2000.19730335.x; Purves D., 2001, NEUROSCIENCE; RUAN JS, 1994, THESIS WAYNE STATE U; Rueda MAF, 2011, COMPUT METHOD BIOMEC, V14, P1021, DOI 10.1080/10255842.2010.504922; Rueda MAF, 2009, MATER DESIGN, V30, P3405, DOI 10.1016/j.matdes.2009.03.037; Schreiber DI, 1997, P 41 STAPP CAR CRASH; Singh A, 2006, STAPP CAR CRASH J, V2006, P602; Tinard V, 2012, MATER DESIGN, V37, P79, DOI 10.1016/j.matdes.2011.12.005; Tinard V, 2011, MATER DESIGN, V32, P3112, DOI 10.1016/j.matdes.2010.12.019; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R, 2003, INT J VEHICLE DES, V32, P94, DOI 10.1504/IJVD.2003.003239; Yang YL, 2009, PSYCHIAT RES-NEUROIM, V174, P81, DOI 10.1016/j.pscychresns.2009.03.012; Yoganandan N, 2008, J BIOMECH, V41, P2253, DOI 10.1016/j.jbiomech.2008.04.019; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714	50	33	33	2	69	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-1275	1873-4197		MATER DESIGN	Mater. Des.	MAR	2013	45						653	662		10.1016/j.matdes.2012.09.017			10	Materials Science, Multidisciplinary	Materials Science	061OD	WOS:000312856800082					2021-06-18	
J	Vlahou, CH; Kosmidis, MH; Dardagani, A; Tsotsi, S; Giannakou, M; Giazkoulidou, A; Zervoudakis, E; Pontikakis, N				Vlahou, Christina H.; Kosmidis, Mary H.; Dardagani, Aikaterini; Tsotsi, Stella; Giannakou, Maria; Giazkoulidou, Aikaterini; Zervoudakis, Emmanuel; Pontikakis, Nikolaos			Development of the Greek Verbal Learning Test: Reliability, Construct Validity, and Normative Standards	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Cross-cultural neuropsychology; Verbal learning; Verbal memory; Regression-based norms; Schizophrenia; Traumatic brain injury	TEST-PERFORMANCE; OLDER-ADULTS; IMPACT; LITERACY; NORMS	We developed a multiple-form list learning test appropriate for use with the Greek population and generated norms for clinical and research use. This task, the Greek Verbal Learning Test (GVLT), was based on the California Verbal Learning Test. We administered the standard version (Form A) to a sample of 354 healthy individuals, as well as two alternative forms (B and C) to a subgroup of the initial sample. Performance on the three forms was equivalent, and each test presented excellent internal consistency. We found good sensitivity and specificity in the testas (Form A) utility in differentiating individuals with schizophrenia (n 50) and individuals with traumatic brain injury (n 53) from healthy adults. A multiple regression analysis indicated that age, education and sex predicted performance. Regression-based norms are also provided. Taken together, these data provide preliminary support for the reliability and construct validity of the GVLT.	[Vlahou, Christina H.; Kosmidis, Mary H.; Dardagani, Aikaterini; Tsotsi, Stella; Giannakou, Maria; Giazkoulidou, Aikaterini; Pontikakis, Nikolaos] Aristotle Univ Thessaloniki, Sch Psychol, Thessaloniki 54124, Greece; [Zervoudakis, Emmanuel] Vrije Univ, Fac Psychol & Pedag, Leiden, Netherlands; [Giazkoulidou, Aikaterini] Papageorgiou Gen Hosp, Thessaloniki, Greece	Kosmidis, MH (corresponding author), Aristotle Univ Thessaloniki, Sch Psychol, Thessaloniki 54124, Greece.	kosmidis@psy.auth.gr	Kosmidis, Mary H/AAN-2104-2021	Vlahou, Christina Helen/0000-0002-9222-8269; Kosmidis, Mary/0000-0001-8790-1220	Marie Curie International ReintegrationEuropean Commission [FP7-PEOPLE-2007-4-3-IRG]	This work was supported by a Marie Curie International Reintegration Grant (FP7-PEOPLE-2007-4-3-IRG) awarded by the European Commission to the first author with the scientific coordination of the second.	Barker-Collo S, 2002, CLIN NEUROPSYCHOL, V16, P290, DOI 10.1076/clin.16.3.290.13856; Benedict RHB, 2005, J INT NEUROPSYCH SOC, V11, P727, DOI 10.1017/S1355617705050782; Brandt J., 2001, HOPKINS VERBAL LEARN; Brooks BL, 2006, CLIN NEUROPSYCHOL, V20, P230, DOI 10.1080/13854040590947461; Chelune GJ, 2010, CLIN NEUROPSYCHOL, V24, P454, DOI 10.1080/13854040802360574; Cherner M, 2007, ARCH CLIN NEUROPSYCH, V22, P343, DOI 10.1016/j.acn.2007.01.009; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; Field A. P, 2009, DISCOVERING STAT USI; Folia V, 2003, CLIN NEUROPSYCHOL, V17, P143, DOI 10.1076/clin.17.2.143.16505; Fountoulakis KN, 1998, DEMENT GERIATR COGN, V9, P329, DOI 10.1159/000017085; Giaglis G., 2008, 12 C EUR FED NEUR SO; Giaglis G, 2010, J INT NEUROPSYCH SOC, V15, P159; Hiou K, 2004, PSYCHOL, V11, P388; Kosmidis M. H., 2008, CLIN NEUROPSYCHOLOGI; Kosmidis MH, 2006, CORTEX, V42, P1021, DOI 10.1016/S0010-9452(08)70208-9; Kosmidis MH, 2011, ARCH CLIN NEUROPSYCH, V26, P575, DOI 10.1093/arclin/acr063; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P818, DOI 10.1017/S1355617704106036; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P164, DOI 10.1017/S1355617704102014; Kramer JH, 2003, J INT NEUROPSYCH SOC, V9, P97, DOI 10.1017/S1355617703910113; Lacritz L H, 2001, Appl Neuropsychol, V8, P180, DOI 10.1207/S15324826AN0803_8; Malloy-Diniz LF, 2007, REV BRAS PSIQUIATR, V29, P324, DOI 10.1590/S1516-44462006005000053; McDowell BD, 2004, ARCH CLIN NEUROPSYCH, V19, P319, DOI 10.1016/S0887-6177(03)00023-4; Messinis L, 2007, ARCH CLIN NEUROPSYCH, V22, P739, DOI 10.1016/j.acn.2007.06.002; Muller H, 1997, J CLIN PSYCHOL, V53, P663, DOI 10.1002/(SICI)1097-4679(199711)53:7<663::AID-JCLP4>3.0.CO;2-J; Nell V., 2000, CROSS CULTURAL NEURO; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P68, DOI 10.1097/00001199-200601000-00007; Parmenter BA, 2010, J INT NEUROPSYCH SOC, V16, P6, DOI 10.1017/S1355617709990750; PUENTE AE, 2000, HDB MULTICULTURAL ME, P419; Rey A, 1964, EXAMEN CLIN PSYCHOL; Ribeiro F, 2007, J CLIN EXP NEUROPSYC, V29, P187, DOI 10.1080/13803390600629775; Rieu D, 2006, REV NEUROL-FRANCE, V162, P721, DOI 10.1016/S0035-3787(06)75069-X; Rosselli M, 2001, DEV NEUROPSYCHOL, V20, P355, DOI 10.1207/S15326942DN2001_3; Smerbeck AM, 2011, CLIN NEUROPSYCHOL, V25, P402, DOI 10.1080/13854046.2011.554445; SPSS Inc, 2009, IBM PASW STAT 18 SPS, V18; Testa SM, 2009, J INT NEUROPSYCH SOC, V15, P1012, DOI 10.1017/S1355617709990713; Tremont G, 2000, CLIN NEUROPSYCHOL, V14, P295, DOI 10.1076/1385-4046(200008)14:3;1-P;FT295; UZZELL BP, 2007, INT HDB CROSS CULTUR; Vlahou C. H., 2011, 3 M FED EUR SOC NEUR; Weible JA, 2002, AGING NEUROPSYCHOL C, V9, P38, DOI 10.1076/anec.9.1.38.834; WIENS AN, 1994, CLIN NEUROPSYCHOL, V8, P75, DOI 10.1080/13854049408401545; Woods SP, 2005, NEUROPSYCHOLOGY, V19, P35, DOI 10.1037/0894-4105.19.1.35; Yassuda MS, 2009, ARCH CLIN NEUROPSYCH, V24, P71, DOI 10.1093/arclin/acp009	43	33	34	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2013	28	1					52	64		10.1093/arclin/acs099			13	Psychology, Clinical; Psychology	Psychology	073EP	WOS:000313726600006	23179043	Bronze			2021-06-18	
J	Jourdan, C; Bayen, E; Bosserelle, V; Azerad, S; Genet, F; Fermanian, C; Aegerter, P; Pradat-Diehl, P; Weiss, JJ; Azouvi, P				Jourdan, Claire; Bayen, Eleonore; Bosserelle, Vanessa; Azerad, Sylvie; Genet, Francois; Fermanian, Christophe; Aegerter, Philippe; Pradat-Diehl, Pascale; Weiss, Jean-Jacques; Azouvi, Philippe		Steering Comm Paris TBi Study	Referral to Rehabilitation After Severe Traumatic Brain Injury: Results From the PariS-TBI Study	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury rehabilitation; traumatic brain injury epidemiology; treatment guidelines; outcomes	CLINICAL DECISION-MAKING; MULTIDISCIPLINARY REHABILITATION; STROKE REHABILITATION; DISCHARGE DISPOSITION; PRACTICAL SCALE; HEALTH-CARE; ACCESS; PLACEMENT; MODERATE; OUTCOMES	Background. After a severe traumatic brain injury (TBI), some patients are discharged home without rehabilitation, although rehabilitation is assumed to improve outcome. Objective. To assess factors that predict referral to rehabilitation following acute care. This study is part of a larger inception cohort study assessing the care network in the Parisian area (France). Methods. Between July 2005 and April 2007, 504 adults with severe TBI (Glasgow Coma Scale score acurrency <= 8) were prospectively recruited by mobile emergency services. This study included 254 acute care survivors (80% male, median age 32 years). Data regarding demographics, injury severity, and acute care pathway were collected. The first analysis compared patients referred to a rehabilitation facility with patients discharged to a living place. The second analysis compared patients referred to a specialized neurorehabilitation (NR) facility with patients referred to nonspecialized rehabilitation. Univariate and multivariate statistics were computed. Results. In all, 162 patients (64%) were referred to rehabilitation, 115 (45%) of which were referred to NR and 47 (19%) to nonspecialized rehabilitation. The following factors were significantly predictive of nonreferral to rehabilitation: living alone, a lower income professional category, pretraumatic alcohol abuse, lower TBI severity, and transfer through a nonspecialized medical ward before discharge. Patients referred to specialized NR were significantly younger and from a higher income professional category. Conclusions. These results raise concern regarding care pathways because many patients were discharged to living places, probably without adequate assessment and management of rehabilitation needs. Injury severity and social characteristics influenced discharge destination.	[Jourdan, Claire; Genet, Francois; Azouvi, Philippe] Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, F-92380 Garches, France; [Jourdan, Claire; Aegerter, Philippe; Azouvi, Philippe] Univ Versailles St Quentin, UFR Med, Guyancourt, France; [Jourdan, Claire; Bayen, Eleonore; Pradat-Diehl, Pascale; Azouvi, Philippe] Univ Paris 06, Unite ER 6, Paris, France; [Bayen, Eleonore; Pradat-Diehl, Pascale] Grp Hosp Pitie Salpetriere, AP HP, Serv Med Phys & Readaptat, F-75634 Paris, France; [Bosserelle, Vanessa; Azerad, Sylvie; Weiss, Jean-Jacques] Ctr Ressources Francilien Traumatisme Cranien, Paris, France; [Bosserelle, Vanessa; Azerad, Sylvie; Fermanian, Christophe; Aegerter, Philippe] Hop Ambroise Pare, AP HP, Unite Rech Clin Paris Ouest, Boulogne, France	Azouvi, P (corresponding author), Hop Raymond Poincare, AP HP, Serv Med Phys & Readaptat, 104 Bd Raymond Poincare, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr		AEGERTER, Philippe/0000-0002-9156-5028	French Ministry of Health (Programme Hospitalier de Recherche Clinique) [AOM04084]; AP-HP (Departement de la Recherche Clinique et du Developpement); Unite de Recherche Clinique Paris-Ouest	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by a grant of French Ministry of Health (Programme Hospitalier de Recherche Clinique 2004, AOM04084) and supported by AP-HP (Departement de la Recherche Clinique et du Developpement) and carried out with the support of Unite de Recherche Clinique Paris-Ouest.	Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; BROOKS CA, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199508000-00002; Cavestri R, 1997, ITAL J NEUROL SCI, V18, P9, DOI 10.1007/BF02106224; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; CLARK JA, 1991, SOC SCI MED, V32, P853, DOI 10.1016/0277-9536(91)90241-4; Cuthbert JP, 2011, ARCH PHYS MED REHAB, V92, P721, DOI 10.1016/j.apmr.2010.12.023; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; EISENBERG JM, 1979, ANN INTERN MED, V90, P957, DOI 10.7326/0003-4819-90-6-957; Esselman PC, 2004, ARCH PHYS MED REHAB, V85, P1445, DOI 10.1016/j.apmr.2003.10.018; Foster M, 2004, SOC SCI MED, V59, P1867, DOI 10.1016/j.socscimed.2004.02.017; Foster M, 2003, SOC SCI MED, V56, P2201, DOI 10.1016/S0277-9536(02)00236-8; Gabriel Edward J., 2002, Journal of Neurotrauma, V19, P111; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; Hughes D, 1997, SOC SCI MED, V44, P589, DOI 10.1016/S0277-9536(96)00207-9; Hurst SA, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-137; INSEE, NOM PROF CAT SOC; INSEE, FRENCH POP IL DE FRA; JENNETT B, 1975, LANCET, V1, P480; Jette DU, 2003, PHYS THER, V83, P224, DOI 10.1093/ptj/83.3.224; LITTLE JP, 1995, ANAESTHESIA, V50, P658; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Miyai I, 2000, NEUROREHAB NEURAL RE, V25, P540; Putman K, 2007, J REHABIL MED, V39, P21, DOI 10.2340/16501977-0006; Putman K, 2009, TOP STROKE REHABIL, V16, P20, DOI 10.1310/tsr1601-20; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Sample PL, 2005, J HEAD TRAUMA REHAB, V20, P270, DOI 10.1097/00001199-200505000-00009; Sarajuuri JM, 2005, ARCH PHYS MED REHAB, V86, P2296, DOI 10.1016/j.apmr.2005.06.018; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Worthington AD, 2006, CLIN REHABIL, V20, P79, DOI 10.1191/0269215506cr881oa; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	39	33	33	0	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JAN	2013	27	1					35	44		10.1177/1545968312440744			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	047PQ	WOS:000311853400004	22460612				2021-06-18	
J	Xing, GQ; Barry, ES; Benford, B; Grunberg, NE; Li, H; Watson, WD; Sharma, P				Xing, Guoqiang; Barry, Erin S.; Benford, Brandi; Grunberg, Neil E.; Li, He; Watson, William D.; Sharma, Pushpa			Impact of repeated stress on traumatic brain injury-induced mitochondrial electron transport chain expression and behavioral responses in rats	FRONTIERS IN NEUROLOGY			English	Article						oxidative phosphorylation; mitochondria; electron transport chain; behavior change; TBI; PTSD	ACOUSTIC STARTLE REFLEX; COMPLEX-I DEFICIENCY; HOUSEKEEPING PROTEINS; ALZHEIMERS-DISEASE; MATTER VOLUME; CYTOCHROME-C; WAR VETERANS; ANIMAL-MODEL; NICOTINE; DISORDER	A significant proportion of the military personnel returning from Iraq and Afghanistan conflicts have suffered from both mild traumatic brain injury (mTBI) and post-traumatic stress disorder. The mechanisms are unknown. We used a rat model of repeated stress and mTBI to examine brain activity and behavioral function. Adult male Sprague-Dawley rats were divided into four groups: Naive; 3 days repeated tail-shock stress; lateral fluid percussion mTBI; and repeated stress followed by mTBI (S-mTBI). Open field activity, sensorimotor responses, and acoustic startle responses (ASRs) were measured at various time points after mTBI. The protein expression of mitochondrial electron transport chain (ETC) complex subunits (CI-V) and pyruvate dehydrogenase (PDHE1 alpha 1) were determined in four brain regions at day 7-post mTBI. Compared to Naives, repeated stress decreased horizontal activity; repeated stress and mTBI both decreased vertical activity; and the mTBI and S-mTBI groups were impaired in sensorimotor and ASRs. Repeated stress significantly increased CI, CII, and CIII protein levels in the prefrontal cortex (PFC), but decreased PDH El al protein in the PFC and cerebellum, and decreased CIV protein in the hippocampus. The mTBI treatment decreased CV protein levels in the ipsilateral hippocampus. The S-mTBI treatment resulted in increased CII, CIII, CIV, and CV protein levels in the PFC, increased CI level in the cerebellum, and increased CIII and CV levels in the cerebral cortex, but decreased CI, CII, CIV, and PDHE1a1 protein levels in the hippocampus. Thus, repeated stress or mTBI alone differentially altered ETC expression in heterogeneous brain regions. Repeated stress followed by mTBI had synergistic effects on brain ETC expression, and resulted in more severe behavioral deficits. These results suggest that repeated stress could have contributed to the high incidence of long-term neurologic and neuropsychiatric morbidity in military personnel with or without mTBI.	[Xing, Guoqiang; Benford, Brandi; Sharma, Pushpa] Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Barry, Erin S.; Grunberg, Neil E.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA; [Li, He] Uniformed Serv Univ Hlth Sci, Dept Psychiat, Bethesda, MD 20814 USA; [Watson, William D.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA	Sharma, P (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anesthesiol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gxing99@yahoo.com; pushpa.sharma@usuhs.edu	Sharma, Pushpa/AAY-8756-2020; Xing, Guoqiang/ABA-8450-2020	Barry, Erin/0000-0003-0788-7153	DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [W911NF 111005]; USAMRMCU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-10-1-0507]; Comprehensive National Neuroscience Program (CNNP) [W81XWH-10-2-0198]	This research was supported by DARPA award W911NF 111005 and USAMRMC award W81XWH-10-1-0507 (Pushpa Sharma), and by the Comprehensive National Neuroscience Program (CNNP) award W81XWH-10-2-0198 (William D. Watson). We would like to thank Dr. MM Jia for her contribution with the stress procedure, Mr. Kevin Cravedi for his excellent help in collecting behavioral data and Dr. Prasanth S. Ariyannur for dissecting the brain tissue.	ACRI JB, 1994, PSYCHOPHARMACOLOGY, V114, P369, DOI 10.1007/BF02244861; ACRI JB, 1991, PSYCHOPHARMACOLOGY, V104, P244, DOI 10.1007/BF02244186; Adam-Vizi V, 2005, ANTIOXID REDOX SIGN, V7, P1140, DOI 10.1089/ars.2005.7.1140; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; ASTONJONES G, 1994, J NEUROSCI, V14, P4467; BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Brenner LA, 2009, REHABIL PSYCHOL, V54, P239, DOI 10.1037/a0016908; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Elliott BM, 2004, PHARMACOL BIOCHEM BE, V77, P21, DOI 10.1016/j.pbb.2003.09.016; Faraday MM, 1998, PHARMACOL BIOCHEM BE, V61, P281, DOI 10.1016/S0091-3057(98)00094-X; Faraday MM, 2003, PHARMACOL BIOCHEM BE, V74, P325, DOI 10.1016/S0091-3057(02)00999-1; Felmingham K, 2009, NEUROREPORT, V20, P1402, DOI 10.1097/WNR.0b013e3283300fbc; Ferguson RE, 2005, PROTEOMICS, V5, P566, DOI 10.1002/pmic.200400941; GRUNBERG NE, 1985, PHARMACOL BIOCHEM BE, V23, P851, DOI 10.1016/0091-3057(85)90081-4; Grunberg NE, 2011, REVISED NEUROLOGICAL; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hasegawa T, 2007, MED HYPOTHESES, V69, P1135, DOI 10.1016/j.mehy.2007.02.034; Hattori N, 2004, J NUCL MED, V45, P775; Hattori N, 2003, J NUCL MED, V44, P1709; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jia M, 2012, JOVE-J VIS EXP, DOI 10.3791/3361; Jiang XL, 2011, J PSYCHOPHARMACOL, V25, P287, DOI 10.1177/0269881109106911; Jiang XL, 2009, NEUROPSYCHOPHARMACOL, V34, P410, DOI 10.1038/npp.2008.71; Kim SH, 2000, CELL MOL LIFE SCI, V57, P1810, DOI 10.1007/PL00000661; Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255; Lannuzel A, 2003, NEUROSCIENCE, V121, P287, DOI 10.1016/S0306-4522(03)00441-X; Lazzeri C, 2009, INTERN EMERG MED, V4, P147, DOI 10.1007/s11739-008-0206-3; Li CSR, 2008, NEUROSCI BIOBEHAV R, V32, P581, DOI 10.1016/j.neubiorev.2007.10.003; Li RN, 2013, LIFE SCI, V92, P747, DOI 10.1016/j.lfs.2013.02.014; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Manczak M, 2005, J NEUROCHEM, V92, P494, DOI 10.1111/j.1471-4159.2004.02884.x; Manion ST, 2007, PHARMACOL BIOCHEM BE, V86, P559, DOI 10.1016/j.pbb.2007.01.019; Marti M, 2005, J NEUROSCI, V25, P9591, DOI 10.1523/JNEUROSCI.2546-05.2005; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Matthews S, 2012, PSYCHOSOM MED, V74, P471, DOI 10.1097/PSY.0b013e31824f888f; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morse DE, 1997, PHARMACOL BIOCHEM BE, V56, P221, DOI 10.1016/S0091-3057(96)00214-6; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Nutt DJ, 2004, J CLIN PSYCHIAT, V65, P11; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pynoos RS, 1996, BIOL PSYCHIAT, V39, P129, DOI 10.1016/0006-3223(95)00088-7; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seematter G, 2004, CURR OPIN CLIN NUTR, V7, P169, DOI 10.1097/00075197-200403000-00011; SELIGMAN ME, 1967, J EXP PSYCHOL, V74, P1, DOI 10.1037/h0024514; SERVATIUS RJ, 1995, BIOL PSYCHIAT, V38, P539, DOI 10.1016/0006-3223(94)00369-E; Sharma Pushpa, 2012, Int J Crit Illn Inj Sci, V2, P172, DOI 10.4103/2229-5151.100931; Sharma Pushpa, 2009, J Emerg Trauma Shock, V2, P67, DOI 10.4103/0974-2700.50739; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Srinivasan S, 2012, FREE RADICAL BIO MED, V53, P1252, DOI 10.1016/j.freeradbiomed.2012.07.021; Su YA, 2008, INT J BIOL SCI, V4, P223; SWERDLOW NR, 1992, J PSYCHOPHARMACOL, V6, P176, DOI 10.1177/026988119200600210; Tretter L, 2004, NEUROCHEM RES, V29, P569, DOI 10.1023/B:NERE.0000014827.94562.4b; Tsolaki M, 2009, HELL J NUCL MED, V12, P41; Valenti D, 2011, BIOCHEM J, V435, P679, DOI 10.1042/BJ20101908; Villarreal G, 2002, BIOL PSYCHIAT, V52, P119, DOI 10.1016/S0006-3223(02)01359-8; Vlachos I, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001104; Xing G, 2013, POSTTRAUMATIC STRESS, P83; Xing GQ, 2012, NEUROSCI LETT, V525, P140, DOI 10.1016/j.neulet.2012.07.055; Xing GQ, 2012, EXP NEUROL, V234, P31, DOI 10.1016/j.expneurol.2011.12.007; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zelikowsky M, 2013, P NATL ACAD SCI USA, V110, P9938, DOI 10.1073/pnas.1301691110; Zhang J, 2011, PSYCHIAT RES-NEUROIM, V192, P84, DOI 10.1016/j.pscychresns.2010.09.001	71	33	33	0	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2013	4								196	10.3389/fneur.2013.00196			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	V42QT	WOS:000209629000192	24376434	DOAJ Gold, Green Published			2021-06-18	
J	Lopez, NE; Gaston, L; Lopez, KR; Coimbra, RC; Hageny, A; Putnam, J; Eliceiri, B; Coimbra, R; Bansal, V				Lopez, N. E.; Gaston, L.; Lopez, K. R.; Coimbra, R. C.; Hageny, A.; Putnam, J.; Eliceiri, B.; Coimbra, R.; Bansal, V.			Early ghrelin treatment attenuates disruption of the blood brain barrier and apoptosis after traumatic brain injury through a UCP-2 mechanism	BRAIN RESEARCH			English	Article						Traumatic brain injury; Ghrelin; Apoptosis; UCP-2; Caspase-3	OXYGEN-GLUCOSE DEPRIVATION; PREVENTS NEURONAL DEATH; UNCOUPLING PROTEIN-2; CELL-DEATH; HIPPOCAMPAL-NEURONS; PARKINSONS-DISEASE; CEREBRAL EDEMA; MOUSE MODEL; FOOD-INTAKE; TIME-COURSE	Ghrelin has been shown to be anti-inflammatory and neuroprotective in models of neurologic injury. We hypothesize that treatment with ghrelin will attenuate breakdown of the blood brain barrier (BBB) and apoptosis 24 h following traumatic brain injury (TB!). We believe this protection is at least in part mediated by up-regulation of UCP-2, thereby stabilizing mitochondria and preventing up-regulation of caspase-3. A weight drop model was used to create severe TBI. Balb/c mice were divided into 3 groups. Sham: no TBI or ghrelin treatment; TB!: TB! only; TBI/ghrelin: 20 mu g (IP) ghrelin at the time of TBI. BBB permeability to 70 kDa FITC-Dextran was measured 24 h following injury and quantified in arbitrary integrated fluorescence (afu). Brain tissue was subjected to TUNEL staining and TUNEL positive cells were quantified. Immunohistochemistry was performed on injured tissue to reveal patterns of caspase-3 and UCP-2 expression. TBI increased cerebral vascular permeability by three-fold compared to sham. Ghrelin treatment restored vascular permeability to the level of shams. TUNEL staining showed that ghrelin mitigated the significant increase in apoptosis that follows TBI. TBI increased both caspase-3 compared to sham. Treatment with ghrelin significantly increased UCP-2 compared to TBI alone and this increase in UCP-2 expression was associated with a decrease in expression of caspase-3. Early ghrelin treatment prevents TBI induced BBB disruption and TBI mediated apoptosis 24 h following injury. These results demonstrate the neuroprotective potential of ghrelin as a therapy in TBI. (C) 2012 Elsevier B.V. All rights reserved.	[Lopez, N. E.; Gaston, L.; Lopez, K. R.; Coimbra, R. C.; Hageny, A.; Putnam, J.; Eliceiri, B.; Coimbra, R.; Bansal, V.] Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, San Diego, CA 92103 USA	Bansal, V (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma Surg Crit Care & Burns, 200W Arbor Dr 8896, San Diego, CA 92103 USA.	n1lopez@ucsd.edu; Lindsey.Gaston@kzoo.edu; karinal@email.arizona.edu; ahageny@ucsd.edu; jgputnam@ucsd.edu; beliceiri@ucsd.edu; rcoimbra@ucsd.edu; v3bansal@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Eliceiri, Brian/0000-0003-1811-1916	American Surgical Association Foundation Award	The authors would like to acknowledge the generous support of the American Surgical Association Foundation Award.	Andrews ZB, 2008, NATURE, V454, P846, DOI 10.1038/nature07181; Andrews ZB, 2005, J NEUROSCI, V25, P184, DOI 10.1523/JNEUROSCI.4269-04.2005; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bansal V., 2009, J NEUROTRAUMA; Bansal V, 2010, J NEUROTRAUM, V27, P2255, DOI 10.1089/neu.2010.1372; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chung H, 2008, J ENDOCRINOL, V198, P511, DOI 10.1677/JOE-08-0160; Chung H, 2007, ENDOCRINOLOGY, V148, P148, DOI 10.1210/en.2006-0991; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Coppola A, 2007, CELL METAB, V5, P21, DOI 10.1016/j.cmet.2006.12.002; Degasperi GR, 2008, FEBS LETT, V582, P3103, DOI 10.1016/j.febslet.2008.08.006; Diano S, 2003, ENDOCRINOLOGY, V144, P5014, DOI 10.1210/en.2003-0667; Ersahin M, 2010, J NEUROTRAUM, V27, P1143, DOI 10.1089/neu.2009.1210; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Frago LM, 2011, FRONT MOL NEUROSCI, V4, DOI [10.3389/fnmo1.2011.00023, 10.3389/fnmol.2011.00023]; Friedman A, 2009, EPILEPSY RES, V85, P142, DOI 10.1016/j.eplepsyres.2009.03.005; Hooper C, 2005, J NEUROCHEM, V92, P1363, DOI 10.1111/j.1471-4159.2005.02982.x; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Johnstone B, 1998, BRAIN INJURY, V12, P569, DOI 10.1080/026990598122331; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Larkum ME, 2007, J NEUROSCI, V27, P8999, DOI 10.1523/JNEUROSCI.1717-07.2007; Lee JY, 2010, ENDOCRINOLOGY, V151, P3815, DOI 10.1210/en.2009-1416; Lee J, 2010, J ENDOCRINOL, V205, P262, DOI 10.1677/JOE-10-0040; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu YJ, 2006, CHINESE J PHYSIOL, V49, P244; Liu Yajun, 2009, BMC Physiology, V9, P17, DOI 10.1186/1472-6793-9-17; Lopez NE, 2012, J NEUROTRAUM, V29, P385, DOI 10.1089/neu.2011.2053; Lorberboym M, 2006, BRAIN RES, V1103, P13, DOI 10.1016/j.brainres.2006.05.073; Mailloux RJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013289; Mattiasson G, 2006, ANTIOXID REDOX SIGN, V8, P1, DOI 10.1089/ars.2006.8.1; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; McColl BW, 2008, J NEUROSCI, V28, P9451, DOI 10.1523/JNEUROSCI.2674-08.2008; Moon M, 2009, NEUROTOX RES, V15, P332, DOI 10.1007/s12640-009-9037-x; Moon M, 2009, ENDOCR J, V56, P525, DOI 10.1507/endocrj.K09E-089; Murakami N, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740283; NegreSalvayre A, 1997, FASEB J, V11, P809; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Pan WH, 2006, PEPTIDES, V27, P911, DOI 10.1016/j.peptides.2005.12.014; Paradis E, 2003, TRENDS MOL MED, V9, P522, DOI 10.1016/j.molmed.2003.10.009; Qi L, 2012, MOL MED, V18, P186, DOI 10.2119/molmed.2011.00390; Qiu WC, 2008, WORLD J GASTROENTERO, V14, P2572, DOI 10.3748/wjg.14.2572; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Si QS, 1997, GLIA, V21, P413, DOI 10.1002/(SICI)1098-1136(199712)21:4<413::AID-GLIA9>3.0.CO;2-3; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Wu RQ, 2007, ANN SURG, V245, P480, DOI 10.1097/01.sla.0000251614.42290.ed; Xu JJ, 2009, NEUROSCI LETT, V453, P58, DOI 10.1016/j.neulet.2009.01.067; Zhang CY, 2006, CELL METAB, V3, P417, DOI 10.1016/j.cmet.2006.04.010; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zigman JM, 2006, J COMP NEUROL, V494, P528, DOI 10.1002/cne.20823	65	33	35	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 13	2012	1489						140	148		10.1016/j.brainres.2012.10.031			9	Neurosciences	Neurosciences & Neurology	054PZ	WOS:000312357000016	23099053				2021-06-18	
J	Coelho, C; Le, K; Mozeiko, J; Krueger, F; Grafman, J				Coelho, Carl; Le, Karen; Mozeiko, Jennifer; Krueger, Frank; Grafman, Jordan			Discourse production following injury to the dorsolateral prefrontal cortex	NEUROPSYCHOLOGIA			English	Article						Dorsolateral prefrontal cortex; Discourse production; Language production; Discourse analysis; Working memory	CLOSED-HEAD-INJURY; TRAUMATIC BRAIN-INJURY; WORKING-MEMORY; EXECUTIVE FUNCTIONS; ELICITATION TASK; LANGUAGE; NARRATIVES; ABILITIES; CHILDREN; LESIONS	Individuals with damage. to the prefrontal cortex, and the dorsolateral prefrontal cortex (DLPFC) in particular, often demonstrate difficulties with the formulation of complex language not attributable to aphasia. The present study employed a discourse analysis procedure to characterize the language of individuals with left (L) or right (R) DLPFC lesions. All participants were 30-35 years post-onset of injury and presented with persistent discourse impairments. The discourse performance of the R DLPFC group was not significantly different from either the L DLPFC group or the non-injured comparison group. Individuals from the L DLPFC group demonstrated specific difficulties with narrative coherence and inclusion of critical story components. Both measures were significantly different from the comparison group. The discourse ability of the DLPFC groups was significantly correlated with measures of working memory. Findings support the use of discourse analysis for examining language impairments in individuals with PFC lesions. (C) 2012 Elsevier Ltd. All rights reserved.	[Coelho, Carl; Le, Karen; Mozeiko, Jennifer] Univ Connecticut, Speech Language & Hearing Sci Dept, Storrs, CT 06269 USA; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Grafman, Jordan] Rehabil Inst Chicago, Brain Injury Res Program, Chicago, IL 60611 USA	Coelho, C (corresponding author), Univ Connecticut, Speech Language & Hearing Sci Dept, 850 Bolton Rd, Storrs, CT 06269 USA.	coelho@uconn.edu		Grafman, Jordan H./0000-0001-8645-4457			Alexander MP, 2006, J INT NEUROPSYCH SOC, V12, P236, DOI 10.1017/S1355617706060309; Baddeley A. D., 1986, WORKING MEMORY; BARBIZET J, 1975, REV NEUROL-FRANCE, V131, P525; Barrett J., 1998, OLD MCDONALD HAD APA; Beeman M, 1998, RIGHT HEMISPHERE LANGUAGE COMPREHENSION, P255; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Blumenfeld RS, 2006, J NEUROSCI, V26, P916, DOI 10.1523/JNEUROSCI.2353-05.2006; Brookshire R.H., 1997, DISCOURSE COMPREHENS; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho C, 2003, APHASIOLOGY, V17, P173, DOI 10.1080/729255216; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Ferstl EC, 2008, HUM BRAIN MAPP, V29, P581, DOI 10.1002/hbm.20422; Fletcher P., 1997, HUMAN BRAIN FUNCTION; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; Grafman J, 2002, HDB NEUROPSYCHOLOGY, P157; Henson R., 2001, WORKING MEMORY PERSP; Hughes D., 1997, GUIDE NARRATIVE LANG; KACZMAREK BLJ, 1984, BRAIN LANG, V21, P52, DOI 10.1016/0093-934X(84)90035-X; Kaplan E., 1983, BOSTON NAMING TEST; Kurczek J, 2011, APHASIOLOGY, V25, P700, DOI 10.1080/02687038.2010.537345; Le K, 2011, J SPEECH LANG HEAR R, V54, P118, DOI 10.1044/1092-4388(2010/09-0022); LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Luria Alexander R, 1970, TRAUMATIC APHASIA IT; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Osaka N., 2007, COGNITIVE NEUROSCIEN, P213; Ranganath C, 2003, NEUROPSYCHOLOGIA, V41, P378, DOI 10.1016/S0028-3932(02)00169-0; Robinson G, 1998, BRAIN, V121, P77, DOI 10.1093/brain/121.1.77; Sirigu A, 1998, CORTEX, V34, P771, DOI 10.1016/S0010-9452(08)70780-9; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Stein N., 1979, NEW DIRECTIONS DISCO; Talairach J., 1988, COPLANAR STEREOTAXIC; Tyler E., 2012, CLIN APH C LAK TAH C; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; U. S. Department of Defense, 1984, TEST MAN ARM SERV VO; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; WAPNER W, 1981, BRAIN LANG, V14, P15, DOI 10.1016/0093-934X(81)90061-4; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	48	33	33	0	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	DEC	2012	50	14					3564	3572		10.1016/j.neuropsychologia.2012.09.005			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	065IT	WOS:000313142700041	22982512				2021-06-18	
J	Koyama, Y; Maebara, Y; Hayashi, M; Nagae, R; Tokuyama, S; Michinaga, S				Koyama, Yutaka; Maebara, Yuko; Hayashi, Mio; Nagae, Ryuji; Tokuyama, Shogo; Michinaga, Shotaro			Endothelins reciprocally regulate VEGF-A and angiopoietin-1 production in cultured rat astrocytes: Implications on astrocytic proliferation	GLIA			English	Article						endothelin-1; brain injury; angiogenic factors; gene expression	BLOOD-BRAIN-BARRIER; FOCAL CEREBRAL-ISCHEMIA; GROWTH-FACTOR; RECEPTOR EXPRESSION; CELL-PROLIFERATION; REACTIVE GLIOSIS; ADHESION KINASE; EDEMA FORMATION; D3 EXPRESSION; ANGIOGENESIS	Vascular endothelial growth factors (VEGFs) and angiopoietins (ANGs) are involved in pathophysiological responses in damaged nerve tissues. Astrocytes produce VEGFs and ANGs upon brain ischemia and traumatic injury. To clarify the extracellular signals regulating VEGF and ANG production, effects of endothelins (ETs), a family of endothelium-derived peptides, were examined in cultured rat astrocytes. ET-1 (100 nM) and Ala1,3,11,15-ET-1 (100 nM), an ETB receptor agonist, increased VEGF-A mRNA levels in cultured astrocytes, while ANG-1 mRNA was decreased by ETs. ET-1 did not affect astrocytic VEGF-B, placental growth factor (PLGF), and ANG-2 mRNA levels. The effects of ET-1 on VEGF-A and ANG-1 mRNAs were inhibited by BQ788, an ETB antagonist. Release of VEGF-A proteins from cultured astrocytes was increased by ET-1. In contrast, ET-1 reduced release of astrocytic ANG-1. Exogenous ET-1 (100 nM) and VEGF165 (100 ng/mL), an isopeptide of VEGF-A, stimulated bromodeoxyuridine (BrdU) incorporation into cultured astrocytes. Treatment with ET-1 and VEGF165 increased the numbers of cyclin D1-positive astrocytes. Exogenous ANG-1 (250 ng/mL) did not stimulate the BrdU incorporation. Increases in BrdU incorporation by ET-1 and VEGF165 were not affected by ANG-1. In 6070% confluent cultures, SU4312 (10 mu M), a VEGF receptor tyrosine kinase inhibitor, partially reduced the effects of ET-1 on BrdU incorporation and cyclin D1 expression. ET-induced BrdU incorporation and cyclin D1 expression were reduced by a neutralizing antibody against VEGF-A. Our findings suggest that ET-1 is a factor regulating astrocytic VEGF-A and ANG-1, and that increased VEGF-A production potentiates ET-induced astrocytic proliferation by an autocrine mechanism. (c) 2012 Wiley Periodicals, Inc.	[Koyama, Yutaka; Maebara, Yuko; Hayashi, Mio; Michinaga, Shotaro] Osaka Ohtani Univ, Fac Pharm, Pharmacol Lab, Tondabayashi, Osaka 5848540, Japan; [Nagae, Ryuji; Tokuyama, Shogo] Kobe Gakuin Univ, Dept Clin Pharm, Sch Pharmaceut Sci, Kobe, Hyogo 65121, Japan	Koyama, Y (corresponding author), Osaka Ohtani Univ, Fac Pharm, Pharmacol Lab, 3-11-1 Nishikiori Kita, Tondabayashi, Osaka 5848540, Japan.	koyamay@osaka-ohtani.ac.jp			JPSP [21590108]	Grant sponsor: Grant-in-Aid for Scientific Research (C), JPSP; Grant number: 21590108.	Abdel-Malak NA, 2008, BLOOD, V111, P4145, DOI 10.1182/blood-2007-08-110338; Argaw AT, 2006, J IMMUNOL, V177, P5574, DOI 10.4049/jimmunol.177.8.5574; Beck H, 2002, J NEUROPATH EXP NEUR, V61, P339, DOI 10.1093/jnen/61.4.339; Brindle NPJ, 2006, CIRC RES, V98, P1014, DOI 10.1161/01.RES.0000218275.54089.12; Cobbs CS, 1998, NEUROSCI LETT, V249, P79, DOI 10.1016/S0304-3940(98)00377-2; Fischer S, 2000, AM J PHYSIOL-CELL PH, V279, pC935; Freitas-Andrade M, 2008, J NEUROCHEM, V107, P756, DOI 10.1111/j.1471-4159.2008.05660.x; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; Kanda S, 2005, CANCER RES, V65, P6820, DOI 10.1158/0008-5472.CAN-05-0522; Kim H, 2008, BIOCHEM BIOPH RES CO, V372, P243, DOI 10.1016/j.bbrc.2008.05.025; Kimura R, 2005, STROKE, V36, P1259, DOI 10.1161/01.STR.0000165925.20413.14; Koyama Y, 2004, J NEUROCHEM, V90, P904, DOI 10.1111/j.1471-4159.2004.02546.x; Koyama Y, 2011, NEUROSCIENCE, V192, P689, DOI 10.1016/j.neuroscience.2011.05.058; Koyama Y, 2003, GLIA, V43, P185, DOI 10.1002/glia.10240; Koyama Y, 1999, GLIA, V26, P268, DOI 10.1002/(SICI)1098-1136(199905)26:3<268::AID-GLIA8>3.0.CO;2-G; Koyama Y, 2006, BRAIN RES, V1112, P65, DOI 10.1016/j.brainres.2006.07.013; Koyama Y, 2012, J PHARMACOL SCI, V118, P401, DOI 10.1254/jphs.11R13CP; Krum JM, 2008, EXP NEUROL, V212, P108, DOI 10.1016/j.expneurol.2008.03.019; Krum JM, 2002, NEUROSCIENCE, V110, P589, DOI 10.1016/S0306-4522(01)00615-7; Krum JM, 2003, EXP NEUROL, V181, P241, DOI 10.1016/S0014-4886(03)00039-6; Lee SW, 2003, NAT MED, V9, P900, DOI 10.1038/nm889; Loeffler S, 2005, INT J CANCER, V115, P202, DOI 10.1002/ijc.20871; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nie XJ, 1996, REV NEUROSCIENCE, V7, P177; Ostrow LW, 2005, BRAIN RES REV, V48, P488, DOI 10.1016/j.brainresrev.2004.09.005; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Peters CM, 2003, EXP NEUROL, V180, P1, DOI 10.1016/S0014-4886(02)00023-7; Ramsauer M, 2002, FASEB J, V16, P1274, DOI 10.1096/fj.01-0814fje; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121; Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087; Schmid-Brunclik N, 2008, AM J PHYSIOL-REG I, V295, pR864, DOI 10.1152/ajpregu.00536.2007; Shibuya M, 2009, FEBS J, V276, P4636, DOI 10.1111/j.1742-4658.2009.07175.x; Shim WSN, 2007, MOL CANCER RES, V5, P655, DOI 10.1158/1541-7786.MCR-07-0072; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Teixeira A, 2000, J NEUROCHEM, V74, P1034, DOI 10.1046/j.1471-4159.2000.0741034.x; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Valable S, 2005, J CEREBR BLOOD F MET, V25, P1491, DOI 10.1038/sj.jcbfm.9600148; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Yoshida H, 2002, BRAIN RES, V944, P65, DOI 10.1016/S0006-8993(02)02708-7; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002; Zhang ZG, 2002, NEUROSCIENCE, V113, P683, DOI 10.1016/S0306-4522(02)00175-6	46	33	34	0	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491			GLIA	Glia	DEC	2012	60	12					1954	1963		10.1002/glia.22411			10	Neurosciences	Neurosciences & Neurology	026GM	WOS:000310262600012	22927341				2021-06-18	
J	Mondello, S; Gabrielli, A; Catani, S; D'Ippolito, M; Jeromin, A; Ciaramella, A; Bossu, P; Schmid, K; Tortella, F; Wang, KKW; Hayes, RL; Formisano, R				Mondello, Stefania; Gabrielli, Andrea; Catani, Sheila; D'Ippolito, Mariagrazia; Jeromin, Andreas; Ciaramella, Antonio; Bossu, Paola; Schmid, Kara; Tortella, Frank; Wang, Kevin K. W.; Hayes, Ronald L.; Formisano, Rita			Increased levels of serum MAP-2 at 6-months correlate with improved outcome in survivors of severe traumatic brain injury	BRAIN INJURY			English	Article						MAP2; traumatic brain injury; biomarkers; outcome; cognitive functioning	MICROTUBULE-ASSOCIATED PROTEIN-2; VEGETATIVE STATE; CONSCIOUSNESS; DISORDERS; MARKER; ACTIN	Objective: To evaluate microtubule-associated proteins (MAP-2), a dendritic marker of both acute damage and chronic neuronal regeneration after injury, in serum of survivors after severe TBI and examine the association with long-term outcome. Methods: Serum concentrations of MAP-2 were evaluated in 16 patients with severe TBI (Glasgow Coma Scale score [GCS] <= 8) 6 months post-injury and in 16 controls. Physical and cognitive outcomes were assessed, using the Glasgow Outcome Scale Extended (GOSE) and Levels of Cognitive Functioning Scale (LCFS), respectively. Results: Severe TBI patients had significantly higher serum MAP-2 concentrations than normal controls with no history of TBI (p = 0.008) at 6 months post-injury. MAP-2 levels correlated with the GOSE (r = 0.58, p = 0.02) and LCFS (r = 0.65, p = 0.007) at month 6. Significantly lower serum levels of MAP-2 were observed in patients in a vegetative state (VS) compared to non-VS patients (p < 0.05). A trend tracking the level of consciousness was observed. Conclusions: Severe TBI results in a chronic release of MAP-2 into the peripheral circulation in patients with higher levels of consciousness, suggesting that remodelling of synaptic junctions and neuroplasticity processes occur several months after injury. The data indicate MAP-2 as a potential marker for emergence to higher levels of cognitive function.	[Mondello, Stefania; Jeromin, Andreas; Wang, Kevin K. W.; Hayes, Ronald L.] Univ Florida, Dept Anesthesiol, Gainesville, FL USA; [Mondello, Stefania; Gabrielli, Andrea; Wang, Kevin K. W.; Hayes, Ronald L.] Banyan Biomarkers Inc, Clin Dept, Banyan Labs, Alachua, FL 32615 USA; [Catani, Sheila; D'Ippolito, Mariagrazia; Ciaramella, Antonio; Bossu, Paola; Formisano, Rita] Santa Lucia Fdn, Rome, Italy; [Schmid, Kara; Tortella, Frank] Walter Reed Army Inst Res, Silver Spring, MD USA	Mondello, S (corresponding author), Banyan Biomarkers Inc, Dept Clin Programs, 13400 Progress Blvd, Alachua, FL 32615 USA.	stm_mondello@hotmail.com	Ciaramella, Antonio/AAM-4320-2020; ciaramella, antonio/P-9009-2019; D'Ippolito, Mariagrazia/K-4010-2016; Bosso, Paola/E-4832-2014; Mondello, Stefania/A-1813-2012; NACMIAS, Benedetta/J-5084-2018	Ciaramella, Antonio/0000-0001-9888-8156; D'Ippolito, Mariagrazia/0000-0001-7818-7352; Bosso, Paola/0000-0002-1432-0078; Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473; NACMIAS, Benedetta/0000-0001-9338-9040	Banyan Biomarkers Inc.; Department of DefenseUnited States Department of Defense [DAMD17-03-1-0772, DAMD17-03-1-0066]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS049175-01, R01-NS052831-01, R01 NS051431-01]; Navy [N00014-06-1-1029]; Italian Ministry of HealthMinistry of Health, Italy [RF2008, n.31]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052831, R01NS049175, R01NS051431] Funding Source: NIH RePORTER	Dr Mondello is a consultant of Banyan Biomarkers, Inc.; Dr Jeromin is an employee of Banyan Biomarkers; Dr Wang and Dr Hayes own stock, receive royalties and salaries from, and are officers of Banyan Biomarkers Inc. Drs Gabrielli, Tortella, Schmid, Catani, D'Ippolito, Ciaramella, Bossu and Formisano report no conflicts of interest.; This study was primarily sponsored by Department of Defense Award numbers DAMD17-03-1-0772 and DAMD17-03-1-0066; but we also acknowledge additional fund support from NIH (R01 NS049175-01, R01-NS052831-01 and R01 NS051431-01) and Navy grant number N00014-06-1-1029 (University of Florida). The collection of data in Santa Lucia Foundation was partially supported by the Italian Ministry of Health (grant RF2008, n.31).	ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; AVILA J, 1992, LIFE SCI, V50, P327, DOI 10.1016/0024-3205(92)90433-P; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Blyth BJ, 2011, J NEUROTRAUM, V28, P2453, DOI 10.1089/neu.2010.1653; Blyth BJ, 2009, J NEUROTRAUM, V26, P1497, DOI [10.1089/neu.2008.0738, 10.1089/neu.2008-0738]; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CACERES A, 1983, P NATL ACAD SCI-BIOL, V80, P1738, DOI 10.1073/pnas.80.6.1738; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; DECAMILLI P, 1984, NEUROSCIENCE, V11, P819, DOI 10.1016/0306-4522(84)90194-5; Drewes G, 1998, TRENDS BIOCHEM SCI, V23, P307, DOI 10.1016/S0968-0004(98)01245-6; Formisano R, 2004, ACTA NEUROCHIR, V146, P457, DOI 10.1007/s00701-004-0225-4; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gosseries O, 2011, NEUROREHABILITATION, V28, P3, DOI 10.3233/NRE-2011-0625; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; Hagen C, 1979, REHABILITATION HEAD; HUBER G, 1984, J NEUROSCI, V4, P151; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KITAGAWA K, 1989, NEUROSCIENCE, V31, P401, DOI 10.1016/0306-4522(89)90383-7; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; MACCIONI RB, 1995, PHYSIOL REV, V75, P835; MASLIAH E, 1993, BRAIN PATHOL, V3, P77, DOI 10.1111/j.1750-3639.1993.tb00728.x; MORALES M, 1989, CELL TISSUE RES, V256, P447; Park D, 2012, J NEUROSCI RES, V90, P461, DOI 10.1002/jnr.22769; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Strens LHA, 2004, BRAIN INJURY, V18, P213, DOI 10.1080/0269905031000149533; TEASDALE G, 1974, LANCET, V2, P81; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Wagner AK, 2012, PATHOPHYSIOLOGY; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	34	33	35	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2012	26	13-14					1629	1635		10.3109/02699052.2012.700083			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	041RU	WOS:000311419700009	22794497				2021-06-18	
J	Tomei, KL; Doe, C; Prestigiacomo, CJ; Gandhi, CD				Tomei, Krystal L.; Doe, Christopher; Prestigiacomo, Charles J.; Gandhi, Chirag D.			Comparative analysis of state-level concussion legislation and review of current practices in concussion	NEUROSURGICAL FOCUS			English	Article						concussion legislation; sports injury; concussion; injury prevention	SPORT-RELATED CONCUSSION; HIGH-SCHOOL FOOTBALL; INJURY SURVEILLANCE SYSTEM; TO-PLAY GUIDELINES; BASE-LINE VALUES; DESCRIPTIVE EPIDEMIOLOGY; UNITED-STATES; ICE HOCKEY; LACROSSE INJURIES; HEAD-INJURIES	Object. Forty-two states and the District of Columbia have passed legislation based on the Lystedt law of Washington state, enacted in 2009 to protect young athletes who have sustained a concussion. The aim of this study was to note the several similarities and differences among the various laws. Methods. Concussion legislation was compared for 50 states and the District of Columbia. Evaluation parameters of this study included stipulations of concussion education, criteria for removal from play, requirements for evaluation and return to play after concussion, and individuals required to assess young athletes. Other parameters that were not consistent across states were also noted. Results. Forty-three states and the District of Columbia have passed concussion legislation, and an additional 4 states have pending legislation. All states with existing legislation support concussion education for coaches; however, only 48% require coaches to undergo formal education. Athletes must be educated on concussion in 86% of states and parents in 88.7%. Suspicion of concussion is a criterion for removal from play in 75% of states; signs and symptoms of concussion are criteria for removal from play in 16% of states. The individuals allowed to evaluate and clear an athlete for return to play differ greatly among states. Conclusions. Injury prevention legislation holds historical precedent, and given the increasing attention to long-term sequelae of repeated head trauma and concussion, concussion legislation has been rapidly passed in 43 states and the District of Columbia. Although the exact stipulations of these laws vary among states, the overall theme is to increase recognition of concussion in young athletes and ensure that they are appropriately cleared for return to play after concussion. (http://thejns.org/doi/abs/10.3171/2012.9.FOCUS12280)	[Tomei, Krystal L.; Doe, Christopher; Prestigiacomo, Charles J.; Gandhi, Chirag D.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07101 USA	Tomei, KL (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, 90 Bergen St,Suite 8100,POB 1709, Newark, NJ 07101 USA.	tomeikr@umdnj.edu	Prestigiacomo, Charles J/B-3911-2018; Michiels, Jan/F-1601-2010	Prestigiacomo, Charles J/0000-0002-5979-2378; Michiels, Jan/0000-0001-5829-0897			Ackery A, 2009, CAN J NEUROL SCI, V36, P207, DOI 10.1017/S0317167100120281; Adler RH, 2011, PHYS MED REH CLIN N, V22, P721, DOI 10.1016/j.pmr.2011.08.010; Ahmed OH, 2012, BRIT J SPORT MED, V46, P675, DOI 10.1136/bjsm.2010.081620; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Beck L. F., 2011, Morbidity and Mortality Weekly Report, V59, P1681; Boffano P, 2011, J CRANIOFAC SURG, V22, P2053, DOI 10.1097/SCS.0b013e318231988d; Borglund S T, 1999, J Emerg Nurs, V25, P496, DOI 10.1016/S0099-1767(99)70013-9; Brixey SN, 2011, INJURY PREV, V17, P233, DOI 10.1136/ip.2010.029835; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Cloudburst Group, 2010, POL EV STAT YOUTH SP; Conner KA, 2010, J SAFETY RES, V41, P17, DOI 10.1016/j.jsr.2009.10.005; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P255; Dick R, 2007, J ATHL TRAINING, V42, P211; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10187; Ellenbogen RG, 2010, WORLD NEUROSURG, V74, P560, DOI 10.1016/j.wneu.2010.11.016; Emery CA, 2011, BRIT J SPORT MED, V45, P1289, DOI 10.1136/bjsports-2011-090538; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Foreman Megan, 2010, State Legis, V36, P28; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Giebel S, 2011, J EMERG MED, V41, P649, DOI 10.1016/j.jemermed.2011.03.021; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Goodman D, 2002, CLIN J SPORT MED, V12, P265, DOI 10.1097/00042752-200209000-00001; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Herbert David L, 2007, Curr Sports Med Rep, V6, P20, DOI 10.1007/s11932-007-0007-x; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Ji M, 2006, ACCIDENT ANAL PREV, V38, P128, DOI 10.1016/j.aap.2005.08.002; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Johnson LSM, 2012, J SCHOOL HEALTH, V82, P180, DOI 10.1111/j.1746-1561.2011.00684.x; Laker SR, 2011, PHYS MED REH CLIN N, V22, P619, DOI 10.1016/j.pmr.2011.08.004; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Macias Alexis, 2011, Bull Am Coll Surg, V96, P51; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Masiakos Peter T, 2011, Bull Am Coll Surg, V96, P31; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McLellan TL, 2011, BRIT J SPORT MED, V45, P993, DOI 10.1136/bjsm.2011.083618; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McLeod TCV, 2012, AM J SPORT MED, V40, P927, DOI 10.1177/0363546511431573; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Mrazik M, 2011, CLIN J SPORT MED, V21, P315, DOI 10.1097/JSM.0b013e31821e2b78; Putukian M, 2011, PM&R, V3, pS425, DOI 10.1016/j.pmrj.2011.08.003; Rivara FP, 1999, AM J PREV MED, V16, P30, DOI 10.1016/S0749-3797(98)00113-5; Rogers SC, 2011, J TRAUMA, V71, pS527, DOI 10.1097/TA.0b013e31823a4ba2; Sabini RC, 2011, PHYSICIAN SPORTSMED, V39, P23, DOI 10.3810/psm.2011.09.1917; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Theye Fred, 2004, Clin Med Res, V2, P165; Thomas M, 2011, PEDIATRICS, V128, pE1, DOI 10.1542/peds.2010-2743; Willer B, 2004, INJURY PREV, V10, P144, DOI 10.1136/ip.2003.005017; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171	69	33	33	0	22	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	DEC	2012	33	6							E11	10.3171/2012.9.FOCUS12280			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	048GI	WOS:000311898500012	23199423	Bronze			2021-06-18	
J	Lin, Y; Pan, YH; Wang, ML; Huang, XJ; Yin, YH; Wang, Y; Jia, F; Xiong, WH; Zhang, N; Jiang, JY				Lin, Yong; Pan, Yaohua; Wang, Mingliang; Huang, Xianjian; Yin, Yuhua; Wang, Yu; Jia, Feng; Xiong, Wenhao; Zhang, Nu; Jiang, Ji-yao			Blood-brain barrier permeability is positively correlated with cerebral microvascular perfusion in the early fluid percussion-injured brain of the rat	LABORATORY INVESTIGATION			English	Article						blood brain barrier; MRI; rat; traumatic brain injury; vascular reactivity	CAPILLARY PERFUSION; EDEMA FORMATION; HEAD TRAUMA; CORTICAL CONTUSION; SMALL MOLECULES; TIME-COURSE; MODEL; MATRIX-METALLOPROTEINASE-9; PATHOPHYSIOLOGY; EPIDEMIOLOGY	The blood-brain barrier (BBB) opening following traumatic brain injury (TBI) provides a chance for therapeutic agents to cross the barrier, yet the reduction of the cerebral microvascular perfusion after TBI may limit the intervention. Meanwhile, optimizing the cerebral capillary perfusion by the strategies such as fluid administration may cause brain edema due to the BBB opening post trauma. To guide the TBI therapy, we characterized the relationship between the changes in the cerebral capillary perfusion and BBB permeability after TBI. First, we observed the changes of the cerebral capillary perfusion by the intracardiac perfusion of Evans Blue and the BBB disruption with magnetic resonance imaging (MRI) in the rat subjected to lateral fluid percussion (FP) brain injury. The correlation between two variables was next evaluated with the correlation analysis. Since related to BBB breakdown, matrix metalloproteinase-9 (MMP-9) activity was finally detected by gelatin zymography. We found that the ratios of the perfused microvessel numbers in the lesioned cortices were significantly reduced at 0 and 1 h post trauma compared with that in the normal cortex, which then dramatically recovered at 4 and 24 h after injury, and that the BBB permeability was greatly augmented in the ipsilateral parts at 4, 12, and 24h, and in the contralateral area at 24h after injury compared with that in the uninjured brain. The correlation analysis showed that the BBB permeability increase was related to the restoration of the cerebral capillary perfusion over a 24-h period post trauma. Moreover, the gelatin zymography analysis indicated that the MMP-9 activity in the injured brain increased at 4h and significantly elevated at 12 and 24h as compared to that at 0 or 1 h after TBI. Our findings demonstrate that the 4h post trauma is a critical turning point during the development of TBI, and, importantly, the correlation analysis may guide us how to treat TBI. Laboratory Investigation (2012) 92, 1623-1634; doi:10.1038/labinvest.2012.118; published online 10 September 2012	[Lin, Yong; Pan, Yaohua; Huang, Xianjian; Yin, Yuhua; Wang, Yu; Jia, Feng; Xiong, Wenhao; Jiang, Ji-yao] Shanghai Jiao Tong Univ, Dept Neurol Surg, Renji Hosp, Sch Med, Shanghai 200127, Peoples R China; [Wang, Mingliang] Shanghai Jiao Tong Univ, Dept Radiol, Ruijin Hosp, Sch Med, Shanghai 200127, Peoples R China; [Zhang, Nu] Wenzhou Med Univ, Dept Neurol Surg, Peoples Hosp 2, Wenzhou, Zhejiang, Peoples R China	Jiang, JY (corresponding author), Shanghai Jiao Tong Univ, Dept Neurol Surg, Renji Hosp, Sch Med, 1630 Dongfang Rd, Shanghai 200127, Peoples R China.	jiangjyb@online.sh.cn			National Science and Nature Committee of China [30973086]; National Health Ministry of China [200802093]; Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [10JC1409800]; Program for Shanghai Outstanding Medical Academic Leader	This work was supported by the Grants of National Science and Nature Committee of China (No. 30973086), National Health Ministry of China (No. 200802093), Shanghai Science and Technology Committee (No. 10JC1409800), and Program for Shanghai Outstanding Medical Academic Leader.	Baethmann A, 1998, Curr Opin Anaesthesiol, V11, P193, DOI 10.1097/00001503-199804000-00013; BARTH KNM, 1992, NEUROSURGERY, V30, P138, DOI 10.1227/00006123-199201000-00028; Beaumont A, 2002, ACT NEUR S, V81, P217; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Dawson DA, 1997, BRAIN RES, V749, P200, DOI 10.1016/S0006-8993(96)01166-3; del Valle J, 2008, J NEUROSCI METH, V174, P42, DOI 10.1016/j.jneumeth.2008.06.025; Dewey CW, 2000, VET CLIN N AM-SMALL, V30, P207, DOI 10.1016/S0195-5616(00)50010-2; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; Ford JC, 1997, ACAD RADIOL, V4, P115, DOI 10.1016/S1076-6332(97)80010-4; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GOBEL U, 1990, CIRC RES, V66, P271, DOI 10.1161/01.RES.66.2.271; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hawkins BT, 2006, J NEUROSCI METH, V151, P262, DOI 10.1016/j.jneumeth.2005.08.006; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Hayward NMEA, 2011, J CEREBR BLOOD F MET, V31, P166, DOI 10.1038/jcbfm.2010.67; Higashida T, 2011, J NEUROSURG, V114, P92, DOI 10.3171/2010.6.JNS10207; JANZER RC, 1987, NATURE, V325, P253, DOI 10.1038/325253a0; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Kniesel U, 2000, CELL MOL NEUROBIOL, V20, P57, DOI 10.1023/A:1006995910836; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; Maikos JT, 2007, J NEUROTRAUM, V24, P492, DOI 10.1089/neu.2006.0149; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; McGoron Anthony J, 2008, BMC Med Imaging, V8, P4, DOI 10.1186/1471-2342-8-4; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Sande A, 2010, J VET EMERG CRIT CAR, V20, P177, DOI 10.1111/j.1476-4431.2010.00527.x; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; Shigemori Y, 2006, ACTA NEUROCHIR SUPPL, V96, P130; Smith MJ, 2008, CRIT CARE MED, V36, P2703, DOI 10.1097/CCM.0b013e3181843e9a; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Wang-Fischer Y, 2009, MANUAL STROKE MODELS, P193; WEISS HR, 1988, MICROVASC RES, V36, P172, DOI 10.1016/0026-2862(88)90017-9; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yamaguchi M, 2007, NEUROSURGERY, V61, P1067, DOI 10.1227/01.neu.0000303203.07866.18; Zoccoli G, 1996, J CEREBR BLOOD F MET, V16, P1312, DOI 10.1097/00004647-199611000-00028	47	33	38	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0023-6837	1530-0307		LAB INVEST	Lab. Invest.	NOV	2012	92	11					1623	1634		10.1038/labinvest.2012.118			12	Medicine, Research & Experimental; Pathology	Research & Experimental Medicine; Pathology	032ZL	WOS:000310761800010	22964852	Bronze			2021-06-18	
J	Clifton, GL; Coffey, CS; Fourwinds, S; Zygun, D; Valadka, A; Smith, KR; Frisby, ML; Bucholz, RD; Wilde, EA; Levin, HS; Okonkwo, DO				Clifton, Guy L.; Coffey, Christopher S.; Fourwinds, Sierra; Zygun, David; Valadka, Alex; Smith, Kenneth R., Jr.; Frisby, Melisa L.; Bucholz, Richard D.; Wilde, Elisabeth A.; Levin, Harvey S.; Okonkwo, David O.			Early induction of hypothermia for evacuated intracranial hematomas: a post hoc analysis of two clinical trials Clinical article	JOURNAL OF NEUROSURGERY			English	Article						severe traumatic brain injury; evacuated hematoma; hypothermia	TRAUMATIC BRAIN-INJURY; BLOOD-FLOW	Object. The authors hypothesized that cooling before evacuation of traumatic intracranial hematomas protects the brain from reperfusion injury and, if so, further hypothesized that hypothermia induction before or soon after craniotomy should be associated with improved outcomes. Methods. The National Acute Brain Injury Study: Hypothermia I (NABIS:H I) was a randomized multicenter clinical trial of 392 patients with severe brain injury treated using normothermia or hypothermia for 48 hours with patients reaching 33 degrees C at 8.4 +/- 3 hours after injury. The National Acute Brain Injury Study: Hypothermia II (NABIS:H II) was a randomized, multicenter clinical trial of 97 patients with severe brain injury treated with normothermia or hypothermia for 48 hours with patients reaching 35 degrees C within 2.6 +/- 1.2 hours and 33 degrees C within 4.4 +/- 1.5 hours of injury. Entry and exclusion criteria, management, and outcome measures in the 2 trials were similar. Results. In NABIS:H II among the patients with evacuated intracranial hematomas, outcome was poor (severe disability, vegetative state, or death) in 5 of 15 patients in the hypothermia group and in 9 of 13 patients in the normothermia group (relative risk 0.4-4, 95% CI 0.22-0.88; p = 0.02). All patients randomized to hypothermia reached 35 degrees C within 1.5 hours after surgery start and 33 degrees C within 5.55 hours. Applying these criteria to NABIS:H 1,31 of 54 hypothermia-treated patients reached a temperature of 35 degrees C or lower within 1.5 hours after surgery start time, and the remaining 23 patients reached 35 degrees C at later time points. Outcome was poor in 14(45%) of 31 patients reaching 35 degrees C within 1.5 hours of surgery, in 14 (61%) of 23 patients reaching 35 degrees C more than 1.5 hours of surgery, and in 35 (60%) of 58 patients in the normothermia group (relative risk 0.74,95%, Cl 0.49-1.13; p = 0.16). A meta-analysis of 46 patients with hematomas in both trials who reached 35 degrees C within 1.5 hours of surgery start showed a significantly reduced rate of poor outcomes (41%) compared with 94 patients treated with hypothermia who did not reach 35 degrees C within that time and patients treated at normothermia (62%, p = 0.009). Conclusions. Induction of hypothermia to 35 degrees C before or soon after craniotomy with maintenance at 33 degrees C for 48 hours thereafter may improve outcome of patients with hematomas and severe traumatic brain injury. Clinical trial registration no.: NCT00178711. (http://thejns.org/doi/abs/10.3171/2012.6.JNS111690)	[Clifton, Guy L.; Valadka, Alex] Univ Texas Med Sch, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX 77030 USA; [Frisby, Melisa L.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Rehabil Med, Houston, TX 77030 USA; [Fourwinds, Sierra] Silverwind Enterprises, La Veta, CO USA; [Coffey, Christopher S.] Univ Iowa, Dept Biostat, Iowa City, IA USA; [Zygun, David] Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada; [Smith, Kenneth R., Jr.; Bucholz, Richard D.] St Louis Univ, Dept Surg, Div Neurosurg, St Louis, MO 63103 USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA	Clifton, GL (corresponding author), Univ Texas Med Sch, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, 6431 Fannin,Suite 7-130, Houston, TX 77030 USA.	guy@guyclifton.com			National Institute of Neurological Disorders and Stroke (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS34786, U01 NS043353]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS043353] Funding Source: NIH RePORTER	The NABIS:H I and NABS:H II trials are supported by grants to Guy L. Clifton, M.D., from the National Institute of Neurological Disorders and Stroke (NIH Grant Nos. R01 NS34786 and U01 NS043353).	[Anonymous], 1971, JAMA-J AM MED ASSOC, V215, P277; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS7; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUM, V24, pS7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Burger R, 2004, NEUROSURGERY, V54, P701, DOI 10.1227/01.NEU.0000108784.80585.EE; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Jacobs SE, 2010, J PAEDIATR CHILD H, V46, P568, DOI 10.1111/j.1440-1754.2010.01880.x; Janata A, 2009, PROG CARDIOVASC DIS, V52, P168, DOI 10.1016/j.pcad.2009.07.001; KURODA Y, 1992, NEUROSURGERY, V30, P687; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505	15	33	35	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2012	117	4					714	720		10.3171/2012.6.JNS111690			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	015YZ	WOS:000309485600018	22839656				2021-06-18	
J	Chen, SF; Tsai, HJ; Hung, TH; Chen, CC; Lee, CY; Wu, CH; Wang, PY; Liao, NC				Chen, Szu-Fu; Tsai, Hsin-Ju; Hung, Tai-Ho; Chen, Chien-Cheng; Lee, Chao Yu; Wu, Chun-Hu; Wang, Pei-Yi; Liao, Nien-Chieh			Salidroside Improves Behavioral and Histological Outcomes and Reduces Apoptosis via PI3K/Akt Signaling after Experimental Traumatic Brain Injury	PLOS ONE			English	Article							CONTROLLED CORTICAL IMPACT; PROGRAMMED CELL-DEATH; CEREBRAL-ISCHEMIA; TEMPORAL PROFILE; WHITE-MATTER; KINASE-B; SURVIVAL; BCL-2; ACTIVATION; INCREASES	Background: Traumatic brain injury (TBI) induces a complex sequence of apopototic cascades that contribute to secondary tissue damage. The aim of this study was to investigate the effects of salidroside, a phenolic glycoside with potent anti-poptotic properties, on behavioral and histological outcomes, brain edema, and apoptosis following experimental TBI and the possible involvement of the phosphoinositide 3-kinase/protein kinase B (PI3K)/Akt signaling pathway. Methodology/Principal Findings: Mice subjected to controlled cortical impact injury received intraperitoneal salidroside (20, or 50 mg/kg) or vehicle injection 10 min after injury. Behavioral studies, histology analysis and brain water content assessment were performed. Levels of PI3K/Akt signaling-related molecules, apoptosis-related proteins, cytochrome C (CytoC), and Smac/DIABLO were also analyzed. LY294002, a PI3K inhibitor, was administered to examine the mechanism of protection. The protective effect of salidroside was also investigated in primary cultured neurons subjected to stretch injury. Treatment with 20 mg/kg salidroside_ignificantly improved functional recovery and reduced brain tissue damage up to post-injury day 28. Salidroside_lso significantly reduced neuronal death, apoptosis, and brain edema at day 1. These changes were associated with significant decreases in cleaved caspase-3, CytoC, and Smac/DIABLO at days 1 and 3. Salidroside increased phosphorylation of Akt on Ser473 and the mitochondrial Bcl-2/Bax ratio at day 1, and enhanced phosphorylation of Akt on Thr308 at day 3. This beneficial effect was abolished by pre-injection of LY294002. Moreover, delayed administration of salidroside at 3 or 6 h post-injury reduced neuronal damage at day 1. Salidroside treatment also decreased neuronal vulnerability to stretch-induced injury in vitro. Conclusions/Significance: Post-injury salidroside improved long-term behavioral and histological outcomes and reduced brain edema and apoptosis following TBI, at least partially via the PI3K/Akt signaling pathway.	[Chen, Szu-Fu; Tsai, Hsin-Ju; Wu, Chun-Hu; Wang, Pei-Yi] Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan; [Chen, Szu-Fu; Tsai, Hsin-Ju; Wu, Chun-Hu; Wang, Pei-Yi] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan; [Chen, Szu-Fu; Tsai, Hsin-Ju; Chen, Chien-Cheng; Wu, Chun-Hu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Hung, Tai-Ho] Chang Gung Mem Hosp, Dept Obstet & Gynecol, Taipei 10591, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taipei, Taiwan; [Lee, Chao Yu] Kings Coll London, Dept Neurosci, Inst Psychiat, London WC2R 2LS, England; [Liao, Nien-Chieh] Cheng Hsin Gen Hosp, Dept Clin Pathol, Taipei, Taiwan	Chen, SF (corresponding author), Natl Def Med Ctr, Dept Physiol, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Chen, Szu-Fu/K-5040-2012; Hung, Tai-Ho/C-7584-2011; Hung, Tai-Ho/ABD-1800-2020; WU, CHUN-HU/P-3958-2018	WU, CHUN-HU/0000-0001-6851-7936; Hung, Tai-Ho/0000-0003-2354-7060	National Science Council of Taiwan, R.O.C.Ministry of Science and Technology, Taiwan [98-2314-B-350-001-MY3]; Cheng Hsin General Hospital	This work was supported by the National Science Council of Taiwan, R.O.C. (98-2314-B-350-001-MY3 to S.-F.C.) and the Cheng Hsin General Hospital (S.-F.C.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Benn SC, 2004, NAT REV NEUROSCI, V5, P686, DOI 10.1038/nrn1477; Bigler ED, 2006, AM J PHYS MED REHAB, V85, P793, DOI 10.1097/01.phm.0000237873.26250.e1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chang YW, 2007, J CHROMATOGR B, V857, P164, DOI 10.1016/j.jchromb.2007.06.029; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen X, 2008, BRAIN RES, V1238, P189, DOI 10.1016/j.brainres.2008.07.051; Chen X, 2009, MOL CELL BIOCHEM, V332, P85, DOI 10.1007/s11010-009-0177-3; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Friguls B, 2001, NEUROREPORT, V12, P3381, DOI 10.1097/00001756-200110290-00046; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GOLDSTEIN LB, 1990, J NEUROSCI METH, V31, P101, DOI 10.1016/0165-0270(90)90154-8; Guan S, 2011, INT IMMUNOPHARMACOL, V11, P2194, DOI 10.1016/j.intimp.2011.09.018; Guan S, 2011, IMMUNOPHARM IMMUNOT, V33, P738, DOI 10.3109/08923973.2011.567988; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hiroi Y, 2006, P NATL ACAD SCI USA, V103, P14104, DOI 10.1073/pnas.0601600103; Iadecola C, 2011, NAT NEUROSCI, V14, P1363, DOI 10.1038/nn.2953; Li HX, 2009, J ETHNOPHARMACOL, V123, P257, DOI 10.1016/j.jep.2009.03.009; Li TL, 2007, PHYTOMEDICINE, V14, P601, DOI 10.1016/j.phymed.2006.12.016; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; Madathil SK, 2010, J NEUROTRAUM, V27, P95, DOI 10.1089/neu.2009.1002; Marone R, 2008, BBA-PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; PETKOV V D, 1986, Acta Physiologica et Pharmacologica Bulgarica, V12, P3; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Qu ZQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029641; Qu ZQ, 2009, BIOMED ENVIRON SCI, V22, P318, DOI 10.1016/S0895-3988(09)60062-3; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Shi TY, 2012, NEUROTOX RES, V21, P358, DOI 10.1007/s12640-011-9290-7; Shirakawa H, 2008, BIOCHEM BIOPH RES CO, V377, P1211, DOI 10.1016/j.bbrc.2008.10.152; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Tan CB, 2009, BIOL PHARM BULL, V32, P1359, DOI 10.1248/bpb.32.1359; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Wagner AK, 2011, J CEREBR BLOOD F MET, V31, P1886, DOI 10.1038/jcbfm.2011.31; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yu S, 2008, CELL MOL NEUROBIOL, V28, P1067, DOI 10.1007/s10571-008-9284-z; Zhang L, 2007, EUR J PHARMACOL, V564, P18, DOI 10.1016/j.ejphar.2007.01.089; Zhang SQ, 2011, MOL CELL BIOCHEM, V354, P161, DOI 10.1007/s11010-011-0815-4; Zhang XP, 2006, J CEREBR BLOOD F MET, V26, P915, DOI 10.1038/sj.jcbfm.9600238; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2003, FASEB J, V17, P1367, DOI 10.1096/fj.02-1067fje; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhong H, 2010, J PHARMACOL SCI, V114, P399, DOI 10.1254/jphs.10078FP; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	61	33	40	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2012	7	9							e45763	10.1371/journal.pone.0045763			15	Multidisciplinary Sciences	Science & Technology - Other Topics	016YB	WOS:000309554700067	23029230	DOAJ Gold, Green Published			2021-06-18	
J	Puentedura, EJ; Louw, A				Puentedura, Emilio J.; Louw, Adriaan			A neuroscience approach to managing athletes with low back pain	PHYSICAL THERAPY IN SPORT			English	Article						Athlete; Chronic; Low back pain; Musculoskeletal; Neuroscience education; Pain	FEAR-AVOIDANCE BELIEFS; CHRONIC MUSCULOSKELETAL PAIN; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-PREDICTION RULE; CHRONIC-FATIGUE-SYNDROME; TRAUMATIC BRAIN-INJURY; SPINAL MANIPULATION; CENTRAL SENSITIZATION; PHYSICAL-THERAPISTS; DISC DEGENERATION	Low back pain (LBP) is a common complaint within the athletic population and is commonly managed through a biomedical approach. The injured or damaged structure causing the LBP is identified and treated, and complete recovery from the episode is expected. Clinical experience shows us that often, athletes with LBP will not recover from their episode and may continue their sports participation despite persistent pain, or they may limit participation. Recent neuroscience research into the biology of pain suggests that clinicians involved in the management of athletes with LBP should embrace a biopsychosocial approach by engaging the brain and nervous system. This manuscript provides an overview of such a biopsychosocial approach, and presents information on the neurobiology of the athlete's pain experience. (C) 2011 Elsevier Ltd. All rights reserved.	[Puentedura, Emilio J.] Univ Nevada, Sch Allied Hlth Sci, Dept Phys Therapy, Las Vegas, NV 89154 USA; [Puentedura, Emilio J.; Louw, Adriaan] Int Spine & Pain Inst, Story City, IA USA	Puentedura, EJ (corresponding author), Univ Nevada, Sch Allied Hlth Sci, Dept Phys Therapy, 4505 Maryland Pkwy,Box 453029, Las Vegas, NV 89154 USA.	louie.puentedura@unlv.edu	Puentedura, Emilio J./AAG-7118-2020	Puentedura, Emilio J./0000-0003-4771-4732			Acerra NE, 2005, NEUROLOGY, V65, P751, DOI 10.1212/01.wnl.0000178745.11996.8c; Alyas F, 2007, BRIT J SPORT MED, V41, P836, DOI 10.1136/bjsm.2007.037747; ARNTZ A, 1995, BEHAV RES THER, V33, P49, DOI 10.1016/0005-7967(94)E0017-D; Autio RA, 2006, SPINE, V31, P1247, DOI 10.1097/01.brs.0000217681.83524.4a; Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Baron R, 2004, PROG PAIN RES MANAG, V31, P193; BAYER TL, 1991, PAIN, V44, P45, DOI 10.1016/0304-3959(91)90145-N; Bayer TL, 1998, PAIN, V74, P327, DOI 10.1016/S0304-3959(97)00196-6; Ben Ounis O, 2011, ANN ENDOCRINOL-PARIS, V72, P34, DOI 10.1016/j.ando.2010.04.002; Bischof JE, 2010, GAIT POSTURE, V31, P502, DOI 10.1016/j.gaitpost.2010.02.010; Bono CM, 2004, J BONE JOINT SURG AM, V86A, P382, DOI 10.2106/00004623-200402000-00027; Boyd BS, 2009, J ORTHOP SPORT PHYS, V39, P780, DOI 10.2519/jospt.2009.3002; Butler D, 2003, EXPLAIN PAIN; Butler D, 2000, SENSITIVE NERVOUS SY; Childs JD, 2005, BMC MUSCULOSKEL DIS, V6, DOI 10.1186/1471-2474-6-32; Childs JD, 2004, ANN INTERN MED, V141, P920, DOI 10.7326/0003-4819-141-12-200412210-00008; Childs JD, 2007, MIL MED, V172, P440, DOI 10.7205/MILMED.172.4.440; Cibulka MT, 1999, J ORTHOP SPORT PHYS, V29, P595, DOI 10.2519/jospt.1999.29.10.595; Clarke CL, 2011, MANUAL THER, V16, P544, DOI 10.1016/j.math.2011.05.003; COOK AJ, 1987, NATURE, V325, P151, DOI 10.1038/325151a0; Cook JL, 2002, MANUAL THER, V7, P121, DOI 10.1054/math.2002.0458; Coppieters MW, 2006, ARCH PHYS MED REHAB, V87, P1412, DOI 10.1016/j.apmr.2006.06.012; Coppieters MW, 2006, J ORTHOP RES, V24, P1883, DOI 10.1002/jor.20210; Crewther BT, 2011, J STRENGTH COND RES, V25, P10, DOI 10.1519/JSC.0b013e3181fb47f5; Critchley DJ, 2007, SPINE, V32, P1474, DOI 10.1097/BRS.0b013e318067dc26; d'Hemecourt PA, 2000, CLIN SPORT MED, V19, P663, DOI 10.1016/S0278-5919(05)70231-3; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Fernandez-De-Las-Penas C, 2007, J ORTHOP SPORT PHYS, V37, P325, DOI 10.2519/jospt.2007.2542; Flor H, 1997, NEUROSCI LETT, V224, P5, DOI 10.1016/S0304-3940(97)13441-3; Flor H, 2000, Prog Brain Res, V129, P313; Flor H, 2003, ANN SCI M PAIN SOC B; Flynn T, 2002, SPINE, V27, P2835, DOI 10.1097/00007632-200212150-00021; Foster NE, 2011, PHYS THER, V91, P790, DOI 10.2522/ptj.20100326; Fritz JM, 2002, PHYS THER, V82, P973, DOI 10.1093/ptj/82.10.973; Fritz JM, 2001, PAIN, V94, P7, DOI 10.1016/S0304-3959(01)00333-5; George SZ, 2007, CLIN J PAIN, V23, P76, DOI 10.1097/01.ajp.0000210949.19429.34; George SZ, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-68; George SZ, 2006, J OCCUP REHABIL, V16, P95, DOI 10.1007/s10926-005-9007-y; George SZ, 2006, CLIN J PAIN, V22, P197, DOI 10.1097/01.ajp.0000148627.92498.54; George SZ, 2004, PHYS THER, V84, P538, DOI 10.1093/ptj/84.6.538; George SZ, 2003, SPINE, V28, P2551, DOI 10.1097/01.BRS.0000096677.84605.A2; George SZ, 2002, CLIN SPORT MED, V21, P105, DOI 10.1016/S0278-5919(03)00060-7; George SZ, 2001, SPINE, V26, P2139, DOI 10.1097/00007632-200110010-00019; Geraci Michael C Jr, 2005, Phys Med Rehabil Clin N Am, V16, P711, DOI 10.1016/j.pmr.2005.02.004; Gifford L, 1998, PHYSIOTHERAPY, V84, P27; Gifford L S, 1997, J Hand Ther, V10, P86; Girault JA, 2004, ARCH NEUROL-CHICAGO, V61, P641, DOI 10.1001/archneur.61.5.641; Goldby LJ, 2006, SPINE, V31, P1083, DOI 10.1097/01.brs.0000216464.37504.64; GROSS J, 1996, MUSCULOSKELETAL EXAM; HALDEMAN S, 1990, SPINE, V15, P718, DOI 10.1097/00007632-199007000-00019; Hangai M, 2009, AM J SPORT MED, V37, P149, DOI 10.1177/0363546508323252; Harrison DE, 1997, J MANIP PHYSIOL THER, V20, P607; HIDES JA, 1994, SPINE, V19, P165, DOI 10.1097/00007632-199401001-00009; Hides J, 2008, J ORTHOP SPORT PHYS, V38, P101, DOI 10.2519/jospt.2008.2658; Hind K, 2006, BONE, V39, P880, DOI 10.1016/j.bone.2006.03.012; Hodges PW, 2003, J ELECTROMYOGR KINES, V13, P361, DOI 10.1016/S1050-6411(03)00042-7; Holm LW, 2007, J RHEUMATOL, V34, P193; Iwamoto J, 2004, SCAND J MED SCI SPOR, V14, P346, DOI 10.1111/j.1600-0838.2004.00379.x; Janig W., 2006, P 11 WORLD C PAIN, P331; JOHNSON EO, 1992, NEUROSCI BIOBEHAV R, V16, P115, DOI 10.1016/S0149-7634(05)80175-7; Jull G, 2009, MANUAL THER, V14, P117, DOI 10.1016/j.math.2009.01.004; Kraft DE, 2002, PEDIATR CLIN N AM, V49, P643, DOI 10.1016/S0031-3955(02)00007-X; LARSSON SE, 1995, EUR J APPL PHYSIOL, V70, P451, DOI 10.1007/BF00618497; Linton SJ, 2011, PHYS THER, V91, P700, DOI 10.2522/ptj.20100330; Loeser J. D., 1999, EVALUATION TREATMENT; Loeser JD, 2008, PAIN, V137, P473, DOI 10.1016/j.pain.2008.04.025; Louw A, 2011, ARCH PHYS MED REHAB, V92, P2041, DOI 10.1016/j.apmr.2011.07.198; Louw Adriaan, 2012, Physiotherapy Theory and Practice, V28, P50, DOI 10.3109/09593985.2011.562602; Louw QA, 2008, BRIT J SPORT MED, V42, DOI 10.1136/bjsm.2007.035360; Lundin O, 2001, SCAND J MED SCI SPOR, V11, P103, DOI 10.1034/j.1600-0838.2001.011002103.x; MacDonald DA, 2006, MANUAL THER, V11, P254, DOI 10.1016/j.math.2006.02.004; Malick A, 2000, FUNCT NEUROL, V15, P28; Marras WS, 2007, SPINE, V32, P2387, DOI 10.1097/BRS.0b013e3181557be9; Masui T, 2005, J SPINAL DISORD TECH, V18, P121, DOI 10.1097/01.bsd.0000154452.13579.b2; Melzack R, 2001, J Dent Educ, V65, P1378; Melzack R, 1999, PAIN, pS121, DOI 10.1016/S0304-3959(99)00145-1; Merskey H, 1994, CLASSIFICATION CHRON; Moseley GL, 2007, PHYS THER REV, V12, P169, DOI 10.1179/108331907X223010; Moseley GL, 2007, PAIN, V133, P64, DOI 10.1016/j.pain.2007.03.002; Moseley G Lorimer, 2002, Spine (Phila Pa 1976), V27, pE29, DOI 10.1097/00007632-200201150-00013; Moseley GL, 2005, AUST J PHYSIOTHER, V51, P49; Moseley GL, 2004, CLIN J PAIN, V20, P324, DOI 10.1097/00002508-200409000-00007; Moseley GL, 2004, EUR J PAIN, V8, P39, DOI 10.1016/S1090-3801(03)00063-6; Moseley GL, 2003, AUST J PHYSIOTHER, V49, P263, DOI 10.1016/S0004-9514(14)60142-2; Moseley GL, 2003, MANUAL THER, V8, P130, DOI 10.1016/S1356-689X(03)00051-1; Moseley GL, 2004, BRAIN, V127, P2339, DOI 10.1093/brain/awh248; Moseley GL, 2003, J MAN MANIP THERAP, P88, DOI DOI 10.1179/106698103790826383; Moseley L, 2002, AUST J PHYSIOTHER, V48, P297, DOI 10.1016/S0004-9514(14)60169-0; Nadler SF, 2002, ARCH PHYS MED REHAB, V83, P1753, DOI 10.1053/apmr.2002.35659; Nadler SF, 2002, MED SCI SPORT EXER, V34, P9, DOI 10.1097/00005768-200201000-00003; Nadler SF, 2002, CLIN J SPORT MED, V12, P73, DOI 10.1097/00042752-200203000-00002; Ness R. M., 2000, ENCY STRESS; Nielsen JB, 2008, J PHYSIOL-LONDON, V586, P65, DOI 10.1113/jphysiol.2007.142661; Nijs J, 2011, MANUAL THER, V16, P413, DOI 10.1016/j.math.2011.04.005; Nijs J, 2010, MANUAL THER, V15, P135, DOI 10.1016/j.math.2009.12.001; Oliveira A, 2006, SPINE, V31, P1652, DOI 10.1097/01.brs.0000224172.45828.e3; Ong A, 2003, BRIT J SPORT MED, V37, P263, DOI 10.1136/bjsm.37.3.263; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Puentedura EJ, 2010, J ORTHOP SPORT PHYS, V40, P214, DOI 10.2519/jospt.2010.3115; Raney NH, 2007, J ORTHOP SPORT PHYS, V37, P472, DOI 10.2519/jospt.2007.2523; Richardson C., 2004, THERAPEUTIC EXERCISE, V2nd ed.; Richardson C A, 1995, Man Ther, V1, P2, DOI 10.1054/math.1995.0243; Richardson CA, 2002, SPINE, V27, P399, DOI 10.1097/00007632-200202150-00015; Schoene, 2004, BACK PAIN REVOLUTION; Segal TY, 2005, J PEDIATR ENDOCR MET, V18, P295; Simotas AC, 2005, ARCH PHYS MED REHAB, V86, P693, DOI 10.1016/j.apmr.2004.11.003; Standaert Christopher J, 2004, Curr Sports Med Rep, V3, P35; Sterling M, 2001, J PAIN, V2, P135, DOI 10.1054/jpai.2001.19951; Takemitsu M, 2006, SPINE, V31, P909, DOI 10.1097/01.brs.0000209308.19642.96; Tanskanen MM, 2011, J STRENGTH COND RES, V25, P787, DOI 10.1519/JSC.0b013e3181c1fa5d; Trainor TJ, 2002, CLIN SPORT MED, V21, P93, DOI 10.1016/S0278-5919(03)00059-0; Van Houdenhove B, 2009, MED HYPOTHESES, V72, P701, DOI 10.1016/j.mehy.2008.11.044; Vernon-Roberts B, 2007, SPINE, V32, P2797, DOI 10.1097/BRS.0b013e31815b64d2; Vukelic S, 2011, J BIOL CHEM, V286, P10265, DOI 10.1074/jbc.M110.188268; Wall P.D., 2005, TXB PAIN; Walsh J, 2009, MANUAL THER, V14, P623, DOI 10.1016/j.math.2008.12.007; Walsh J, 2009, J MANIP PHYSIOL THER, V32, P184, DOI 10.1016/j.jmpt.2009.02.006; Waris E, 2007, SPINE, V32, P681, DOI 10.1097/01.brs.0000257523.38337.96; Watkins LR, 2003, PROG PAIN RES MANAG, V24, P369; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; Weiner BK, 2008, SPINE, V33, P219, DOI 10.1097/BRS.0b013e3181604572; Wong RA, 2007, PHYS THER, V87, P986, DOI 10.2522/ptj.20050392; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; WOOLF CJ, 1994, TXB PAIN; WOOLF CJ, 2005, WALL MELZACKS TXB PA, P91; Woolf CJ, 2007, ANESTHESIOLOGY, V106, P864, DOI 10.1097/01.anes.0000264769.87038.55; Woolf Clifford J., 1994, Current Opinion in Neurobiology, V4, P525, DOI 10.1016/0959-4388(94)90053-1; Zhong X, 2005, J APPL PHYSIOL, V98, P2024, DOI 10.1152/japplphysiol.00620.2004	128	33	34	0	39	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1466-853X			PHYS THER SPORT	Phys. Ther. Sport	AUG	2012	13	3					123	133		10.1016/j.ptsp.2011.12.001			11	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	991EB	WOS:000307683200002	22814445				2021-06-18	
J	Seel, RT; Steyerberg, EW; Malec, JF; Sherer, M; Macciocchi, SN				Seel, Ronald T.; Steyerberg, Ewout W.; Malec, James F.; Sherer, Mark; Macciocchi, Stephen N.			Developing and Evaluating Prediction Models in Rehabilitation Populations	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Biostatistics; Evidence-based medicine; Evidence-based practice; Models, statistical; Multivariate analysis; Prognosis; Rehabilitation; Review literature as topic; Statistics as topic	TRAUMATIC BRAIN-INJURY; LOGISTIC-REGRESSION ANALYSIS; IMPACT DATABASE; PROGNOSIS; VALIDATION; HEURISTICS; SIMULATION; SELECTION; DESIGN; CARE	This article presents a 3-part framework for developing and evaluating prediction models in rehabilitation populations. First, a process for developing and refining prognostic research questions and the scientific approach to prediction models is presented. Primary components of the scientific approach include the study design and sampling of patients, outcome measurement, selecting predictor variable(s), minimizing methodologic sources of bias, assuring a sufficient sample size for statistical power, and selecting an appropriate statistical model. Examples focus on prediction modeling using samples of rehabilitation patients. Second, a brief overview for statistically building and validating multivariable prediction models is provided, which includes the following 7 steps: data inspection, coding of predictors, model specification, model estimation, model performance, model validation, and model presentation. Third, we propose a set of primary considerations for evaluating prediction model studies using specific quality indicators as criteria to help stakeholders evaluate the quality of a prediction model study. Lastly, we offer perspectives on the future development and use of rehabilitation prediction models.	[Seel, Ronald T.; Macciocchi, Stephen N.] Shepherd Ctr, Crawford Res Inst, Atlanta, GA 30309 USA; [Seel, Ronald T.; Macciocchi, Stephen N.] Shepherd Ctr, Brain Injury Program, Atlanta, GA 30309 USA; [Steyerberg, Ewout W.] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands; [Malec, James F.] Indiana Univ, Sch Med, Dept Phys Med, Indianapolis, IN USA; [Sherer, Mark] Univ Texas Houston, Sch Med, TIRR Mem Hermann, Baylor Coll Med, Houston, TX USA; [Sherer, Mark] Univ Texas Houston, Sch Med, Dept Phys Med, Baylor Coll Med, Houston, TX USA	Seel, RT (corresponding author), Shepherd Ctr, Crawford Res Inst, 2020 Peachtree Rd, Atlanta, GA 30309 USA.	ron_seel@shepherd.org	Steyerberg, Ewout W/C-1509-2018	Steyerberg, Ewout W/0000-0002-7787-0122	National Institute on Disability and Rehabilitation Research, U.S. Department of EducationUS Department of Education [H133G070171]	Supported in part by the National Institute on Disability and Rehabilitation Research, U.S. Department of Education (grant no. H133G070171).	Agency for Healthcare Research and Quality, 2011, AG HEALTHC RES QUAL; Altman DG, 2000, STAT MED, V19, P453, DOI 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5; Ambler G, 2002, STAT MED, V21, P3803, DOI 10.1002/sim.1422; American Academy of Neurology, 2011, CLIN PRACT GUID PROC; Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Beattie PF, 2007, PHYS THER, V87, P1527, DOI 10.2522/ptj.20060284; Biering-Sorensen F, 2011, SPINAL CORD, V49, P60, DOI 10.1038/sc.2010.90; Bishop MA, 2002, PHILOS SCI, V69, pS197, DOI 10.1086/341846; Bond T.G., 2007, APPL RASCH MODEL FUN; Bouwmeester W, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001221; Cohen J., 2003, APPL MULTIPLE CORREL; Connelly J, 2006, DISABIL REHABIL, V28, P629, DOI 10.1080/09638280500276513; Cook T. D., 2002, EXPT QUASIEXPERIMENT; Crocker L., 1986, INTRO CLASSICAL MODE; DAWES RM, 1989, SCIENCE, V243, P1668, DOI 10.1126/science.2648573; DeVellis R., 2003, SCALE DEV THEORY APP; EVANS RW, 2000, PROGNOSIS NEUROLOGIC; Fischer JE, 2002, ARCH PEDIAT ADOL MED, V156, P1005, DOI 10.1001/archpedi.156.10.1005; Goldman L, 1996, NEW ENGL J MED, V334, P1498, DOI 10.1056/NEJM199606063342303; Grimby G, 2012, J REHABIL MED, V44, P97, DOI 10.2340/16501977-0938; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI 10.1016/j.jclinepi.2011.06.004; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1283, DOI 10.1016/j.jclinepi.2011.01.012; HARRELL FE, 1984, STAT MED, V3, P143, DOI 10.1002/sim.4780030207; Harrell Frank E., 2001, REGRESSION MODELING; Hayden JA, 2006, ANN INTERN MED, V144, P427, DOI 10.7326/0003-4819-144-6-200603210-00010; Hemingway H, 2006, J CLIN EPIDEMIOL, V59, P1229, DOI 10.1016/j.jclinepi.2006.02.005; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Hudak PL, 1996, ARCH PHYS MED REHAB, V77, P586, DOI 10.1016/S0003-9993(96)90300-7; Institute of Medicine of the National Academies, 2011, CLIN PRACT GUID WE C; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Katsikopoulos KV, 2008, THEOR PSYCHOL, V18, P443, DOI 10.1177/0959354308091824; Kattan MW, 2003, J UROLOGY, V170, P1792, DOI 10.1097/01.ju.0000091806.70171.41; Kothari S., 2007, BRAIN INJURY MED PRI, P169; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; Lee KI, 1997, COMMUN STAT-SIMUL C, V26, P559, DOI 10.1080/03610919708813397; Little R, 2002, STAT ANAL MISSING DA, V2nd; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Meehl P.E., 1954, CLIN VERSUS STAT PRE; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; Portney LG, 2000, FDN CLIN RES APPL PR, P113; Roozenbeek B, 2009, J NEUROTRAUM, V26, P1069, DOI 10.1089/neu.2008.0569; Royston P, 2007, COMPUT STAT DATA AN, V51, P4240, DOI 10.1016/j.csda.2006.05.006; Royston P, 2006, STAT MED, V25, P127, DOI 10.1002/sim.2331; Sherer M, 2010, J HEAD TRAUMA REHAB, V25, P92, DOI 10.1097/HTR.0b013e3181c9d887; Steyerberg EW, 2001, MED DECIS MAKING, V21, P45, DOI 10.1177/0272989X0102100106; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.0.CO;2-0; Steyerberg EW, 2003, J CLIN EPIDEMIOL, V56, P441, DOI 10.1016/S0895-4356(03)00047-7; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Streiner DL., 2003, HLTH MEASUREMENT SCA, V3rd; Swets J A, 2000, Psychol Sci Public Interest, V1, P1, DOI 10.1111/1529-1006.001; Tibshirani R, 1996, J ROY STAT SOC B MET, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x; VANHOUWELINGEN JC, 1990, STAT MED, V9, P1303, DOI 10.1002/sim.4780091109; Velozo CA, 2012, ARCH PHYS MED REHAB, V93, pS154, DOI 10.1016/j.apmr.2012.06.001; Vergouwe Y, 2010, J CLIN EPIDEMIOL, V63, P205, DOI 10.1016/j.jclinepi.2009.03.017; Vittinghoff E, 2005, STAT BIOL HEALTH, pVII; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; Wilson M., 2005, CONSTRUCTING MEASURE; World Health Organization ( WHO ), 2002, COMM LANG FUNCT DIS	62	33	32	0	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8		2			S138	S153		10.1016/j.apmr.2012.04.021			16	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	983XL	WOS:000307151900006	22840880				2021-06-18	
J	Masino, SA; Kawamura, M; Ruskin, DN; Geiger, JD; Boison, D				Masino, S. A.; Kawamura, M., Jr.; Ruskin, D. N.; Geiger, J. D.; Boison, D.			Purines and neuronal excitability: Links to the ketogenic diet	EPILEPSY RESEARCH			English	Article						Adenosine; ATP; Epilepsy; Hemichannel; Hippocampus; Long-term potentiation; Metabolism; Seizure; Transgenic mouse	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; POLYUNSATURATED FATTY-ACIDS; ADENOSINE KINASE INHIBITOR; CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; K-ATP CHANNELS; HIPPOCAMPAL SLICES; ANTIINFLAMMATORY PROPERTIES; EXTRACELLULAR ADENOSINE	ATP and adenosine are purines that play dual roles in cell metabolism and neuronal signaling. Acting at the A(1) receptor (A(1)R) subtype, adenosine acts directly on neurons to inhibit excitability and is a powerful endogenous neuroprotective and anticonvulsant molecule. Previous research showed an increase in ATP and other cell energy parameters when an animal is administered a ketogenic diet, an established metabolic therapy to reduce epileptic seizures, but the relationship among purines, neuronal excitability and the ketogenic diet was unclear. Recent work in vivo and in vitro tested the specific hypothesis that adenosine acting at A(1)Rs is a key mechanism underlying the success of ketogenic diet therapy and yielded direct evidence linking A(1)Rs to the antiepileptic effects of a ketogenic diet. Specifically, an in vitro mimic of a ketogenic diet revealed an A(1)R-dependent metabolic autocrine hyperpolarization of hippocampal neurons. In parallel, applying the ketogenic diet in vivo to transgenic mouse models with spontaneous electrographic seizures revealed that intact A(1)Rs are necessary for the seizure-suppressing effects of the diet. This is the first direct in vivo evidence linking A(1)Rs to the antiepileptic effects of a ketogenic diet. Other predictions of the relationship between purines and the ketogenic diet are discussed. Taken together, recent research on the role of purines may offer new opportunities for metabolic therapy and insight into its underlying mechanisms. (c) 2011 Elsevier B.V. All rights reserved.	[Masino, S. A.; Ruskin, D. N.] Trinity Coll, Neurosci Program, Hartford, CT 06106 USA; [Masino, S. A.; Ruskin, D. N.] Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; [Kawamura, M., Jr.] Jikei Univ, Sch Med, Dept Pharmacol, Tokyo, Japan; [Geiger, J. D.] Univ N Dakota, Sch Med & Hlth Sci, Dept Pharmacol Physiol & Therapeut, Grand Forks, ND 58203 USA; [Boison, D.] Legacy Res Inst, Robert Stone Dow Neurobiol Labs, Portland, OR 97232 USA	Masino, SA (corresponding author), Trinity Coll, Neurosci Program, Hartford, CT 06106 USA.	susan.masino@trincoll.edu	Boison, Detlev/ABE-6302-2020	Boison, Detlev/0000-0002-7740-5781	National Institutes of Health NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065957, R15NS066392, R15 065446, 2P20RR017699]; NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR); CHDI; National Science FoundationNational Science Foundation (NSF) [IOS-0843585]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR017699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS065446, R15NS061290, R15NS066392, R01NS065957] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23790303] Funding Source: KAKEN	We acknowledge the support of National Institutes of Health NINDS R01NS065957, R15NS066392, R15 065446 and 2P20RR017699 from the NCRR (a component of the NIH), CHDI, and National Science Foundation IOS-0843585.	AKIMITSU T, 1995, AM J PHYSIOL-HEART C, V269, pH1743; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; ARAI A, 1990, NEUROSCI LETT, V119, P41, DOI 10.1016/0304-3940(90)90750-4; BELFRAGE M, 1995, ANESTH ANALG, V81, P713, DOI 10.1097/00000539-199510000-00010; Boison D, 2011, EXPERT OPIN DRUG DIS, V6, P713, DOI 10.1517/17460441.2011.575777; Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Cheng BH, 2009, BRAIN RES, V1286, P25, DOI 10.1016/j.brainres.2009.06.060; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DEVIVO DC, 1978, ANN NEUROL, V3, P331, DOI 10.1002/ana.410030410; DOLPHIN AC, 1983, NEUROSCI LETT, V39, P83, DOI 10.1016/0304-3940(83)90169-6; Dulla CG, 2005, NEURON, V48, P1011, DOI 10.1016/j.neuron.2005.11.009; Dulla CG, 2009, J NEUROPHYSIOL, V102, P1984, DOI 10.1152/jn.90695.2008; EVANS MC, 1987, NEUROSCI LETT, V83, P287, DOI 10.1016/0304-3940(87)90101-7; Fenoglio-Simeone KA, 2009, EPILEPSIA, V50, P2027, DOI 10.1111/j.1528-1167.2009.02163.x; Freeman JM, 2007, PEDIATRICS, V119, P535, DOI 10.1542/peds.2006-2447; Fuxe K, 2007, PHYSIOL BEHAV, V92, P210, DOI 10.1016/j.physbeh.2007.05.034; Gabriel A, 1998, NEUROSCIENCE, V86, P67, DOI 10.1016/S0306-4522(98)00011-6; Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791; GOLDBERG MP, 1988, NEUROSCI LETT, V89, P323, DOI 10.1016/0304-3940(88)90547-2; Goldman N, 2010, NAT NEUROSCI, V13, P883, DOI 10.1038/nn.2562; Gomes CV, 2011, BBA-BIOMEMBRANES, V1808, P1380, DOI 10.1016/j.bbamem.2010.12.001; Gourine AV, 2005, NATURE, V436, P108, DOI 10.1038/nature03690; Greene AE, 2001, EPILEPSIA, V42, P1371, DOI 10.1046/j.1528-1157.2001.17601.x; HAAS HL, 1984, PFLUG ARCH EUR J PHY, V402, P244, DOI 10.1007/BF00585506; Hallbook T, 2007, EPILEPSIA, V48, P59, DOI 10.1111/j.1528-1167.2006.00834.x; Hemingway C, 2001, PEDIATRICS, V108, P898, DOI 10.1542/peds.108.4.898; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Huang ZL, 2007, CURR OPIN PHARMACOL, V7, P33, DOI 10.1016/j.coph.2006.09.004; HUTTENLOCHER PR, 1976, PEDIATR RES, V10, P536, DOI 10.1203/00006450-197605000-00006; Jarvis MF, 2000, J PHARMACOL EXP THER, V295, P1156; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Juge N, 2010, NEURON, V68, P99, DOI 10.1016/j.neuron.2010.09.002; KARLSTEN R, 1992, Pharmacology and Toxicology, V70, P434; Kawamura M, 2010, J NEUROSCI, V30, P3886, DOI 10.1523/JNEUROSCI.0055-10.2010; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Koranda JL, 2011, J NEUROPHYSIOL, V106, P662, DOI 10.1152/jn.00001.2011; Kossoff EH, 2009, J CHILD NEUROL, V24, P979, DOI 10.1177/0883073809337162; Kukley M, 2005, J NEUROSCI, V25, P2832, DOI 10.1523/JNEUROSCI.4260-04.2005; Lara DR, 2010, J ALZHEIMERS DIS, V20, pS239, DOI 10.3233/JAD-2010-1378; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Li TF, 2007, NEURON GLIA BIOL, V3, P353, DOI 10.1017/S1740925X0800015X; Li TF, 2008, J CLIN INVEST, V118, P571, DOI 10.1172/JCI33737; Li TF, 2008, NEURON GLIA BIOL, V4, P91, DOI 10.1017/S1740925X09990135; Ma WY, 2007, J NEUROSCI, V27, P3618, DOI 10.1523/JNEUROSCI.0132-07.2007; Mantis John G, 2004, Nutr Metab (Lond), V1, P11, DOI 10.1186/1743-7075-1-11; Masino SA, 2009, CURR NEUROPHARMACOL, V7, P257, DOI 10.2174/157015909789152164; Masino SA, 1999, J NEUROSCI, V19, P1932; Masino SA, 2008, TRENDS NEUROSCI, V31, P273, DOI 10.1016/j.tins.2008.02.009; Masino SA, 2011, J CLIN INVEST, V121, P2679, DOI 10.1172/JCI57813; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; MITCHELL JB, 1993, HIPPOCAMPUS, V3, P77, DOI 10.1002/hipo.450030108; Moore KA, 2003, P NATL ACAD SCI USA, V100, P14397, DOI 10.1073/pnas.1835831100; Muzykewicz DA, 2009, EPILEPSIA, V50, P1118, DOI 10.1111/j.1528-1167.2008.01959.x; NAKAZAWA M, 1983, BRAIN DEV-JPN, V5, P375, DOI 10.1016/S0387-7604(83)80042-4; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Newby A C, 1985, Adv Myocardiol, V6, P273; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; Nylen K, 2009, BBA-GEN SUBJECTS, V1790, P208, DOI 10.1016/j.bbagen.2008.12.005; ORO J, 1961, ARCH BIOCHEM BIOPHYS, V94, P217, DOI 10.1016/0003-9861(61)90033-9; Pan JW, 1999, EPILEPSIA, V40, P703, DOI 10.1111/j.1528-1157.1999.tb00766.x; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Panico LR, 2000, REV NEUROLOGIA, V30, P8, DOI 10.33588/rn.3001.99521; Pascual O, 2005, SCIENCE, V310, P113, DOI 10.1126/science.1116916; Pignataro G, 2007, J CEREBR BLOOD F MET, V27, P1, DOI 10.1038/sj.jcbfm.9600334; Poon A, 1999, EUR J PHARMACOL, V384, P123, DOI 10.1016/S0014-2999(99)00626-3; Porkka-Heiskanen T, 1999, ANN MED, V31, P125, DOI 10.3109/07853899908998788; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Puchowicz MA, 2008, J CEREBR BLOOD F MET, V28, P1907, DOI 10.1038/jcbfm.2008.79; Rho JM, 2010, EPILEPSY CURR, V10, P159, DOI 10.1111/j.1535-7511.2010.01387.x; RIBEIRO JA, 1979, BIOCHEM PHARMACOL, V28, P1297, DOI 10.1016/0006-2952(79)90428-3; Ribeiro JA, 2010, J ALZHEIMERS DIS, V20, pS3, DOI 10.3233/JAD-2010-1379; Ruskin D.N., 2010, SOC NEUROSCI, V375, P4; Ruskin DN, 2011, PHYSIOL BEHAV, V103, P501, DOI 10.1016/j.physbeh.2011.04.001; Ruskin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008349; Samoilova M, 2010, J NEUROCHEM, V113, P826, DOI 10.1111/j.1471-4159.2010.06645.x; SATO K, 1995, FASEB J, V9, P651; Schmidt AP, 2009, BRIT J PHARMACOL, V156, P163, DOI 10.1111/j.1476-5381.2008.00025.x; Sitkovsky MV, 2005, TRENDS IMMUNOL, V26, P299, DOI 10.1016/j.it.2005.04.004; Sorkin LS, 2003, EXP NEUROL, V184, P162, DOI 10.1016/S0014-4886(03)00102-X; Studer FE, 2006, NEUROSCIENCE, V142, P125, DOI 10.1016/j.neuroscience.2006.06.016; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Tai KK, 2008, J NEURAL TRANSM, V115, P1011, DOI 10.1007/s00702-008-0050-7; Tekkok S, 1999, J NEUROPHYSIOL, V81, P174; Tendler D, 2007, DIGEST DIS SCI, V52, P589, DOI 10.1007/s10620-006-9433-5; Thio LL, 2010, EPILEPSIA, V51, P1619, DOI 10.1111/j.1528-1167.2009.02515.x; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Van der Auwera Ingrid, 2005, Nutr Metab (Lond), V2, P28, DOI 10.1186/1743-7075-2-28; Vanotti A, 2007, CNS DRUGS, V21, P3, DOI 10.2165/00023210-200721001-00002; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Wilder RM, 1921, MAYO CLINIC B, V2, P307, DOI DOI 10.1111/J.1469-8749.1989.TB03973.X; Xu XP, 2008, EPILEPSY RES, V80, P57, DOI 10.1016/j.eplepsyres.2008.03.013; Yamada KA, 2005, NEUROSCI LETT, V385, P210, DOI 10.1016/j.neulet.2005.05.038; Yang XX, 2010, J MOL NEUROSCI, V42, P145, DOI 10.1007/s12031-010-9336-y; YARBROUGH GG, 1981, EUR J PHARMACOL, V76, P137, DOI 10.1016/0014-2999(81)90495-7; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29	97	33	34	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	JUL	2012	100	3			SI		229	238		10.1016/j.eplepsyres.2011.07.014			10	Clinical Neurology	Neurosciences & Neurology	988ZQ	WOS:000307530400006	21880467	Green Accepted			2021-06-18	
J	Davies, RC; Williams, WH; Hinder, D; Burgess, CNW; Mounce, LTA				Davies, Rebecca C.; Williams, W. H.; Hinder, Darren; Burgess, Cris N. W.; Mounce, Luke T. A.			Self-Reported Traumatic Brain Injury and Postconcussion Symptoms in Incarcerated Youth	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; crime; traumatic brain injury; youth	MILD HEAD-INJURY; CRIMINAL BEHAVIOR; PREVALENCE; POPULATION; QUESTIONNAIRE; PRISONERS; EMPATHY	Objectives: To determine the prevalence rate of traumatic brain injury (TBI) in incarcerated youth and whether frequency and severity of TBI are associated with postconcussion symptoms (PCS), violent offending behaviors, age of first conviction, and substance abuse. Participants: Sixty-one incarcerated male juvenile offenders with an average age of 16 years. Main Measures: Self-rated measures of head injury, TBI, PCS (Rivermead Post-concussion Symptoms Questionnaire), history of alcohol and drug use, and criminal history. Results: More than 70% reported at least 1 head injury at some point in their lives, and 41% reported experiencing a head injury with loss of consciousness. Postconcussion symptoms reliably increased with the frequency and severity of TBI. The relation between frequency and symptoms was mostly accounted for by severity of TBI. Alcohol use reliably increased with the severity of TBI and was associated with PCS. Alcohol use did not account for the dose-response relation between TBI and PCS. Conclusions: Findings indicate a need to account for TBI in offender populations in managing care needs, which may contribute to reduction in offending behaviors.	[Williams, W. H.] Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter EX4 4QG, Devon, England	Williams, WH (corresponding author), Univ Exeter, Washington Singer Labs, Sch Psychol, Exeter EX4 4QG, Devon, England.	w.h.williams@exeter.ac.uk	Mounce, Luke/AAX-1911-2020	Mounce, Luke/0000-0002-6089-0661; williams, huw/0000-0003-0670-2620			Bjerregaard B, 2002, YOUTH SOC, V34, P31, DOI 10.1177/0044118X02034001002; BOHNEN N, 1992, NEUROSURGERY, V30, P692; CORNELL DG, 1987, BEHAVIORAL SCI LAW, V5, P11, DOI DOI 10.1002/BSL.2370050103; Farrer TJ, 2011, PROG NEURO-PSYCHOPH, V35, P390, DOI 10.1016/j.pnpbp.2011.01.007; Fazel S, 2006, ADDICTION, V101, P181, DOI 10.1111/j.1360-0443.2006.01316.x; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Jolliffe D, 2007, LEGAL CRIMINOL PSYCH, V12, P265, DOI 10.1348/135532506X147413; Kenny DT, 2007, COMTEMPORARY ISSUES, V107, P1; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; Marsden J, 1998, ADDICTION, V93, P1857, DOI 10.1046/j.1360-0443.1998.9312185711.x; McGuire LM, 1998, BRAIN INJURY, V12, P207, DOI 10.1080/026990598122683; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Steadman HJ, 1998, ARCH GEN PSYCHIAT, V55, P393, DOI 10.1001/archpsyc.55.5.393; Tonks J, 2009, DEV MED CHILD NEUROL, V51, P8, DOI 10.1111/j.1469-8749.2008.03219.x; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Williams WH, 2010, NEUROPSYCHOL REHABIL, V20, P801, DOI 10.1080/09602011.2010.519613; Williams WH, 2010, BRAIN INJURY, V24, P1184, DOI 10.3109/02699052.2010.495697	26	33	33	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					E21	E27		10.1097/HTR.0b013e31825360da			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500003	22573045				2021-06-18	
J	Indraswari, F; Wang, HC; Lei, BL; James, ML; Kernagis, D; Warner, DS; Dawson, HN; Laskowitz, DT				Indraswari, Fransisca; Wang, Haichen; Lei, Beilei; James, Michael L.; Kernagis, Dawn; Warner, David S.; Dawson, Hana N.; Laskowitz, Daniel T.			Statins Improve Outcome in Murine Models of Intracranial Hemorrhage and Traumatic Brain Injury: A Translational Approach	JOURNAL OF NEUROTRAUMA			English	Article						blood-brain barrier; HMG-CoA reductase inhibitors; intracerebral hemorrhage; neuroinflammation; traumatic brain injury	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; SIMVASTATIN; ATORVASTATIN; RATS; NEUROGENESIS; INCREASE; MOUSE; SYNAPTOGENESIS; DEGENERATION; INFLAMMATION	Traumatic brain injury (TBI) and intracerebral hemorrhage (ICH) are leading causes of neurological mortality and disability in the U.S.. However, therapeutic options are limited and clinical management remains largely supportive. HMG-CoA reductase inhibitors (statins) have pleiotropic mechanisms of action in the setting of acute brain injury, and have been demonstrated to improve outcomes in preclinical models of ICH and TBI. To facilitate translation to clinical practice, we now characterize the optimal statin and dosing paradigm in murine models of ICH and TBI. In a preclinical model of TBI, mice received vehicle, simvastatin, and rosuvastatin at doses of 1mg/kg and 5mg/kg for 5 days after the impact. Immunohistochemistry, differential gene expression, and functional outcomes (rotarod and Morris water maze testing) were assessed to gauge treatment response. Following TBI, administration of rosuvastatin 1 mg/kg was associated with the greatest improvement in functional outcomes. Rosuvastatin treatment was associated with histological evidence of reduced neuronal degeneration at 24 h post-TBI, reduced microgliosis at day 7 post-TBI, and preserved neuronal density in the CA3 region at 35 days post-injury. Administration of rosuvastatin following TBI was also associated with downregulation of inflammatory gene expression in the brain. Following ICH, treatment with simvastatin 1mg/kg was associated with the greatest improvement in functional outcomes, an effect that was independent of hemorrhage volume. Clinically relevant models of acute brain injury may be used to define variables such as optimal statin and dosing paradigms to facilitate the rational design of pilot clinical trials.	[Indraswari, Fransisca; Wang, Haichen; Lei, Beilei; James, Michael L.; Warner, David S.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA; [Indraswari, Fransisca; Wang, Haichen; James, Michael L.; Dawson, Hana N.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Indraswari, Fransisca; Wang, Haichen; James, Michael L.; Dawson, Hana N.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurol, Durham, NC 27710 USA; [Lei, Beilei; James, Michael L.; Warner, David S.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Warner, David S.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Warner, David S.; Laskowitz, Daniel T.] Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; [Kernagis, Dawn] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	Laskowitz, DT (corresponding author), Duke Univ, Med Ctr, Dept Med Neurol, Box 2900, Durham, NC 27710 USA.	danl@neuro.duke.edu	James, Michael L./AAJ-5592-2020	James, Michael L./0000-0002-8715-5210; Indraswari, Fransisca/0000-0002-7308-5768	AstraZenecaAstraZeneca	The authors would like to thank Brenden Dawson for his assistance with some of the histological work. This work was partially supported by an investigator-initiated grant from AstraZeneca, which also supplied rosuvastatin.	Barish GD, 2010, GENE DEV, V24, P2760, DOI 10.1101/gad.1998010; Beray-Berthat V, 2010, J NEUROSCI METH, V191, P180, DOI 10.1016/j.jneumeth.2010.06.025; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Bulsara Ketan R, 2006, Neurosurg Focus, V21, pE11; Chauhan NB, 2011, RESTOR NEUROL NEUROS, V29, P23, DOI 10.3233/RNN-2011-0573; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen SF, 2007, LIFE SCI, V81, P288, DOI 10.1016/j.lfs.2007.05.023; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dawson HN, 2010, NEUROSCIENCE, V169, P516, DOI 10.1016/j.neuroscience.2010.04.037; Dawson HN, 2007, J NEUROSCI, V27, P9155, DOI 10.1523/JNEUROSCI.5492-06.2007; Deng P, 2011, J NEUROTRAUM, V28, P1173, DOI 10.1089/neu.2010.1683; Erdos B, 2006, AM J PHYSIOL-HEART C, V290, pH1264; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; James ML, 2008, NEUROCRIT CARE, V9, P139, DOI 10.1007/s12028-007-9030-2; Jung KH, 2004, STROKE, V35, P1744, DOI 10.1161/01.STR.0000131270.45822.85; Karki K, 2009, STROKE, V40, P3384, DOI 10.1161/STROKEAHA.108.544395; Labovitz DL, 2005, NEUROLOGY, V65, P518, DOI 10.1212/01.wnl.0000172915.71933.00; Lema PP, 2004, J VET PHARMACOL THER, V27, P321, DOI 10.1111/j.1365-2885.2004.00597.x; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Liao JK, 2005, AM J CARDIOL, V96, p24F, DOI 10.1016/j.amjcard.2005.06.009; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lynch JR, 2005, EXP NEUROL, V192, P109, DOI 10.1016/j.expneurol.2004.11.014; McGirt MJ, 2002, STROKE, V33, P2950, DOI 10.1161/01.STR.0000038986.68044.39; McKenney JM, 2003, CLIN CARDIOL, V26, P32, DOI 10.1002/clc.4960261507; McMellen ME, 2010, SURGERY, V148, P364, DOI 10.1016/j.surg.2010.03.020; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8; Qureshi AI, 2001, NEW ENGL J MED, V344, P1450, DOI 10.1056/NEJM200105103441907; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; ROSENBERG GA, 1990, ACT NEUR S, V51, P280; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Seyfried D, 2004, J NEUROSURG, V101, P104, DOI 10.3171/jns.2004.101.1.0104; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sugiyama Y, 2011, STROKE, V42, P770, DOI 10.1161/STROKEAHA.110.597799; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takata K, 2009, J NEUROSURG ANESTH, V21, P326, DOI 10.1097/ANA.0b013e3181acfde7; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wible EF, 2010, NEUROTHERAPEUTICS, V7, P62, DOI 10.1016/j.nurt.2009.11.003; Williams JK, 1998, J AM COLL CARDIOL, V31, P684, DOI 10.1016/S0735-1097(97)00537-8; Wu HT, 2008, J NEUROSURG, V109, P691, DOI 10.3171/JNS/2008/109/10/0691; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Yang DM, 2011, J NEUROSURG, V114, P1135, DOI 10.3171/2010.7.JNS10163; Zacco A, 2003, J NEUROSCI, V23, P11104	49	33	37	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1388	1400		10.1089/neu.2011.2117			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600013	22233347				2021-06-18	
J	Chambers, AR; Hancock, KE; Maison, SF; Liberman, MC; Polley, DB				Chambers, Anna R.; Hancock, Kenneth E.; Maison, Stephane F.; Liberman, M. Charles; Polley, Daniel B.			Sound-Evoked Olivocochlear Activation in Unanesthetized Mice	JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY			English	Article						olivocochlear; corticofugal; arousal; attention; anesthesia; contralateral reflex; outer hair cell	PRODUCT OTOACOUSTIC EMISSIONS; AWAKE GUINEA-PIGS; INFERIOR COLLICULUS; AUDITORY-CORTEX; FINE-STRUCTURE; EFFERENT ACTIVATION; DISTORTION PRODUCTS; COCHLEAR EFFERENT; ACOUSTIC INJURY; BRAIN-STEM	Genetic tools available for the mouse make it a powerful model to study the modulation of cochlear function by descending control systems. Suppression of distortion product otoacoustic emission (DPOAE) amplitude by contralateral acoustic stimulation (CAS) provides a robust tool for noninvasively monitoring the strength of descending modulation, yet investigations in mice have been performed infrequently and only under anesthesia, a condition likely to reduce olivocochlear activation. Here, we characterize the contralateral olivocochlear reflex in the alert, unanesthetized mouse. Head-fixed mice were restrained between two closed acoustic systems, while an artifact rejection protocol minimized contamination from self-generated sounds and movements. In mice anesthetized with pentobarbital, ketamine or urethane, CAS at 80 dB SPL evoked, on average, a <1-dB change in DPOAE amplitude. In contrast, the mean CAS-induced DPOAE suppression in unanesthetized mice was nearly 8 dB. Experiments in mice with targeted deletion of the alpha 9 subunit of the nicotinic acetylcholine receptor confirmed the contribution of the medial olivocochlear efferents to this phenomenon. These findings demonstrate the utility of the CAS assay in the unanesthetized mouse and highlight the adverse effects of anesthesia when probing the functional status of descending control pathways within the auditory system.	[Chambers, Anna R.; Hancock, Kenneth E.; Maison, Stephane F.; Liberman, M. Charles; Polley, Daniel B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA; [Chambers, Anna R.; Polley, Daniel B.] Harvard Univ, Sch Med, Neurosci Program, Boston, MA 02115 USA; [Hancock, Kenneth E.; Maison, Stephane F.; Liberman, M. Charles; Polley, Daniel B.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA	Chambers, AR (corresponding author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.	Anna_Chambers@meei.harvard.edu		Polley, Daniel/0000-0002-5120-2409	NIDCDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30 DC5029, R01 DC0188, R01 DC09836, R03 DC09488]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P30DC005209, R03DC009488, R01DC000188, R01DC009836] Funding Source: NIH RePORTER	We are grateful to Dr. Douglas Vetter for generously sharing his alpha 9-null and wild-type mice with us, to Drs. John Guinan, Jeremiah Cohen and Nao Uchida for helpful advice, and to Sara Anastas and John Thompson for animal care and technical assistance. Financial support was provided by NIDCD grants: P30 DC5029 (MCL), R01 DC0188 (MCL), R01 DC09836 (DBP), and R03 DC09488 (DBP).	Abdala C, 2009, J ACOUST SOC AM, V125, P1584, DOI 10.1121/1.3068442; Avan P, 1996, EXP BRAIN RES, V109, P9, DOI 10.1007/BF00228621; Bauerle P, 2011, J NEUROSCI, V31, P9708, DOI 10.1523/JNEUROSCI.5814-10.2011; Bajo VM, 2010, NAT NEUROSCI, V13, P253, DOI 10.1038/nn.2466; Boyev KP, 2002, JARO, V3, P362, DOI 10.1007/s101620020044; BROWN MC, 1993, J COMP NEUROL, V337, P600, DOI 10.1002/cne.903370406; Coomes DL, 2004, EUR J NEUROSCI, V19, P2188, DOI 10.1111/j.0953-816X.2004.03317.x; de Boer J, 2008, J NEUROSCI, V28, P4929, DOI 10.1523/JNEUROSCI.0902-08.2008; DEWSON JH, 1968, J NEUROPHYSIOL, V31, P122; Doucet JR, 2003, EXP BRAIN RES, V153, P461, DOI 10.1007/s00221-003-1604-4; FELICIANO M, 1995, J NEUROCHEM, V65, P1348; Frisina RD, 2007, J ACOUST SOC AM, V121, pEL29, DOI 10.1121/1.2401226; FUCHS PA, 1992, P ROY SOC B-BIOL SCI, V248, P35, DOI 10.1098/rspb.1992.0039; Groff JA, 2003, J NEUROPHYSIOL, V90, P3178, DOI 10.1152/jn.00537.2003; Guinan JJ, 2006, EAR HEARING, V27, P589, DOI 10.1097/01.aud.0000240507.83072.e7; Guitton MJ, 2004, NEUROREPORT, V15, P1379, DOI 10.1097/01.wnr.0000131672.15566.64; Harkrider AW, 2009, J AM ACAD AUDIOL, V20, P208, DOI 10.3766/jaaa.20.3.7; Harrison RV, 2008, ACTA OTO-LARYNGOL, V128, P404, DOI 10.1080/00016480701784965; Henin S, 2011, J ACOUST SOC AM, V129, P2068, DOI 10.1121/1.3543945; Irving S, 2011, J NEUROSCI, V31, P2493, DOI 10.1523/JNEUROSCI.2679-10.2011; Kalluri R, 2001, J ACOUST SOC AM, V109, P622, DOI 10.1121/1.1334597; Kujawa SG, 2001, JARO, V2, P268, DOI 10.1007/s101620010047; Kumar UA, 2004, EAR HEARING, V25, P142, DOI 10.1097/01.AUD.0000120363.56591.E6; Lauer AM, 2011, JARO-J ASSOC RES OTO, V12, P329, DOI 10.1007/s10162-011-0262-7; LIBERMAN MC, 1988, HEARING RES, V34, P179, DOI 10.1016/0378-5955(88)90105-0; LIBERMAN MC, 1986, HEARING RES, V24, P17, DOI 10.1016/0378-5955(86)90003-1; Maison SF, 2002, J NEUROSCI, V22, P10838; Maison SF, 2000, J NEUROSCI, V20, P4701, DOI 10.1523/JNEUROSCI.20-12-04701.2000; Maison SF, 2003, J COMP NEUROL, V455, P406, DOI 10.1002/cne.10490; MAISON SF, 2011, ANESTHETIZED MICE CO; Maison SF, 2007, J NEUROPHYSIOL, V97, P3269, DOI 10.1152/jn.00067.2007; May BJ, 2004, ARCH OTOLARYNGOL, V130, P660, DOI 10.1001/archotol.130.5.660; Messing DP, 2009, SPEECH COMMUN, V51, P668, DOI 10.1016/j.specom.2009.02.002; Micheyl C, 1996, J ACOUST SOC AM, V99, P1604, DOI 10.1121/1.414734; MOULIN A, 1993, HEARING RES, V65, P193, DOI 10.1016/0378-5955(93)90213-K; Mukerji S, 2010, TRENDS AMPLIF, V14, P170, DOI 10.1177/1084713810381771; Mulders WHA, 2000, HEARING RES, V149, P11, DOI 10.1016/S0378-5955(00)00157-X; Puria S, 1996, J ACOUST SOC AM, V99, P500, DOI 10.1121/1.414508; Rossel M, 2005, DEVELOPMENT, V132, P1175, DOI 10.1242/dev.01683; Scates KW, 1999, HEARING RES, V128, P51, DOI 10.1016/S0378-5955(98)00198-1; Schofield BR, 2005, HEARING RES, V206, P3, DOI 10.1016/j.heares.2005.03.005; SMITH DW, 1994, BRAIN RES, V652, P243, DOI 10.1016/0006-8993(94)90233-X; SRIDHAR TS, 1995, J NEUROSCI, V15, P3667; Suga N, 2002, NEURON, V36, P9, DOI 10.1016/S0896-6273(02)00933-9; Taranda J, 2009, PLOS BIOL, V7, P71, DOI 10.1371/journal.pbio.1000018; THOMPSON AM, 1993, J COMP NEUROL, V335, P402, DOI 10.1002/cne.903350309; VETTER DE, 1993, HEARING RES, V70, P173, DOI 10.1016/0378-5955(93)90156-U; Vetter DE, 1999, NEURON, V23, P93, DOI 10.1016/S0896-6273(00)80756-4; Vetter DE, 2007, P NATL ACAD SCI USA, V104, P20594, DOI 10.1073/pnas.0708545105; Wagner W, 2007, HEARING RES, V223, P83, DOI 10.1016/j.heares.2006.10.001; WHITEHEAD ML, 1991, HEARING RES, V51, P55, DOI 10.1016/0378-5955(91)90007-V; WIEDERHOLD ML, 1970, J ACOUST SOC AM, V48, P950, DOI 10.1121/1.1912234; WIENISCH M, 2011, 2 PHOTON IMAGING NEU; Winer JA, 2006, HEARING RES, V212, P1, DOI 10.1016/j.heares.2005.06.014; Yan J, 2005, J NEUROPHYSIOL, V93, P71, DOI 10.1152/jn.00348.2004; Zhu XX, 2007, J COMP NEUROL, V503, P593, DOI 10.1002/cne.21402	56	33	34	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1525-3961			JARO-J ASSOC RES OTO	JARO	APR	2012	13	2					209	217		10.1007/s10162-011-0306-z			9	Neurosciences; Otorhinolaryngology	Neurosciences & Neurology; Otorhinolaryngology	940MH	WOS:000303893200005	22160753	Bronze, Green Published			2021-06-18	
J	Eakin, K; Miller, JP				Eakin, Katharine; Miller, Jonathan P.			Mild Traumatic Brain Injury Is Associated with Impaired Hippocampal Spatiotemporal Representation in the Absence of Histological Changes	JOURNAL OF NEUROTRAUMA			English	Article						electrophysiology; hippocampus; mild traumatic brain injury; place cells; task-specific cells	FLUID PERCUSSION INJURY; ENTORHINAL CORTEX; MEMORY IMPAIRMENT; RAT; PERFORMANCE; NEURONS	Mild traumatic brain injury (mTBI) accounts for the majority of head trauma cases. Despite some lasting cognitive, emotional, and behavioral deficits, there are frequently no overt morphological defects, suggesting that changes may result from alterations in the physiology of individual neurons. We investigated hippocampal neural activity in rats during a working memory task to determine the effect of mTBI on cellular physiology. Male Sprague-Dawley rats (300-350 g) underwent mTBI via lateral fluid percussion (1.5 atm), and were compared with sham-operated rats. The rats then underwent bilateral implantation of electrodes into the CA1 and CA3 hippocampal subfields and were trained to perform in a delayed nonmatch-to-place swim T-maze. Single-neuron activity was analyzed during task performance 30-90 days after trauma. There were no histological differences between control and mTBI rats. Stereological analysis demonstrated no neuronal loss. Nevertheless, rats subjected to mTBI demonstrated significantly poorer performance on the task with increasing delay. Examination of single-neuron spiking activity revealed no significant difference in firing rates or spike characteristics, but rats exposed to mTBI were found to have significantly fewer cells with activity spatiotemporally correlated with location in the maze ("task-specific cells,'' p < 0.05 by Fisher's exact test). Memory deficits, including disorganized patterns of hippocampal neural activity after mTBI, were seen in rats. Because it is seen in the absence of clear morphological defects, these data suggest that functional impairment after mTBI may result from alterations in the activity of individual neurons.	[Eakin, Katharine; Miller, Jonathan P.] Case Western Reserve Univ, Dept Neurol Surg, Cleveland, OH 44106 USA	Miller, JP (corresponding author), Case Western Reserve Univ, Dept Neurol Surg, 10900 Euclid Ave, Cleveland, OH 44106 USA.	Jonathan.Miller@UHhospitals.org		Miller, Jonathan/0000-0001-5441-1751	Case Western Reserve School of Medicine; Neurosurgery Research and Education Foundation of the American Association of Neurological Surgeons	We thank Osmond Wu, B.A., and Thomas Ostergard, B.S., for assistance with the experiments. Financial support has been provided by Case Western Reserve School of Medicine and the Neurosurgery Research and Education Foundation of the American Association of Neurological Surgeons.	Ahmed OJ, 2009, TRENDS NEUROSCI, V32, P329, DOI 10.1016/j.tins.2009.01.009; Barnes CA, 1997, NATURE, V388, P272, DOI 10.1038/40859; Berger TW, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/4/046017; Clark RE, 2000, J NEUROSCI, V20, P8853; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hampson RE, 1996, P NATL ACAD SCI USA, V93, P13487, DOI 10.1073/pnas.93.24.13487; Hampson RE, 1999, NATURE, V402, P610, DOI 10.1038/45154; HAMPSON RE, 1993, BEHAV NEUROSCI, V107, P715, DOI 10.1037/0735-7044.107.5.715; Hollup SA, 2001, EUR J NEUROSCI, V13, P1197, DOI 10.1046/j.0953-816x.2001.01487.x; Lipton PA, 2007, J NEUROSCI, V27, P5787, DOI 10.1523/JNEUROSCI.1063-07.2007; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MILLER VM, 1980, BRAIN RES, V194, P311, DOI 10.1016/0006-8993(80)91214-7; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Whiting MD, 2006, J NEUROTRAUM, V23, P1529, DOI 10.1089/neu.2006.23.1529; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; Witgen BM, 2005, NEUROSCIENCE, V133, P1, DOI 10.1016/j.neuroscience.2005.01.052	24	33	33	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1180	1187		10.1089/neu.2011.2192			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100018	22229460				2021-06-18	
J	Schwandt, M; Harris, JE; Thomas, S; Keightley, M; Snaiderman, A; Colantonio, A				Schwandt, Marika; Harris, Jocelyn E.; Thomas, Scott; Keightley, Michelle; Snaiderman, Abe; Colantonio, Angela			Feasibility and Effect of Aerobic Exercise for Lowering Depressive Symptoms Among Individuals With Traumatic Brain Injury: A Pilot Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aerobic exercise; community; depression; traumatic brain injury	PHYSICAL-ACTIVITY; CARDIAC REHABILITATION; RATING-SCALE; ENDURANCE; BENEFITS; EFFICACY; PROGRAM; ANXIETY; STROKE	Purpose: To establish the feasibility and effect of an aerobic exercise intervention on symptoms of depression among individuals with traumatic brain injury. Design: A pre-post single group. Participants: Four community dwelling participants (>11 months postinjury) with residual physical impairment recruited from an outpatient clinic. Intervention: 12-week aerobic exercise program. Outcome Measures: The Hamilton Rating Scale for Depression; aerobic capacity (cycle ergometer, heart rate at reference resistance, perceived exertion); Rosenberg Self-Esteem Scale and program perception (survey). Analysis: Descriptive statistics to depict change in outcome measure scores. Answers from the survey were collated and presented as summary statements. Results: All participants had fewer symptoms of depression, improved aerobic capacity and higher self esteem after the intervention. High satisfaction with the program was reported with no adverse effects. Conclusion: The aerobic exercise program was feasible and effective for individuals with traumatic brain injury, leading to improved mood, cardiovascular fitness, and self-esteem. Future research is needed to determine the intensity, frequency, and duration required to reach and maintain improvement.	[Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Schwandt, Marika] Univ Toronto, Grad Program Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Thomas, Scott] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON M5G 1V7, Canada; [Snaiderman, Abe] Toronto Rehabil Inst, Dept Psychiat, Toronto, ON, Canada; [Snaiderman, Abe] Toronto Rehabil Inst, Dept Med PMR, Toronto, ON, Canada	Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Thomas, Scott G/G-4522-2012	Thomas, Scott G/0000-0002-5564-4271; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) [200903MOP]; Toronto Rehabilitation InstituteUniversity of Toronto; Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario; Women's College Research InstituteUniversity of Toronto; Strategic Training Fellowship in Health Care, Technology and Place [FRN: STP 53911]	Funding for this study for AC was obtained from the Canadian Institutes for Health Research (200903MOP), The Toronto Rehabilitation Institute, and a grant from the Ministry of Health and Long Term Care. Support for this study was given to MS from the Toronto Rehabilitation Institute and a Fellowship from the Women's College Research Institute and to JEH in a CIHR Fellowship Award and a Strategic Training Fellowship in Health Care, Technology and Place (FRN: STP 53911). Authors do not have any conflicts to disclose.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Ballesteros J, 2007, J AFFECT DISORDERS, V102, P93, DOI 10.1016/j.jad.2006.12.015; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; Brenes GA, 2007, AGING MENT HEALTH, V11, P61, DOI 10.1080/13607860600736372; Brown C, 2005, MED CARE, V43, P1203, DOI 10.1097/01.mlr.0000185733.30697.f6; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Driver S, 2009, BRAIN INJURY, V23, P203, DOI 10.1080/02699050802695574; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Eng JJ, 2004, ARCH PHYS MED REHAB, V85, P113, DOI 10.1016/S0003-9993(03)00436-2; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hellweg S, 2008, BRAIN INJURY, V22, P365, DOI 10.1080/02699050801998250; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Knapen J, 2005, PSYCHOTHER PSYCHOSOM, V74, P353, DOI 10.1159/000087782; Lai SM, 2006, J AM GERIATR SOC, V54, P240, DOI 10.1111/j.1532-5415.2006.00573.x; Mossberg KA, 2010, J HEAD TRAUMA REHAB, V25, P173, DOI 10.1097/HTR.0b013e3181dc98ff; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Sabapathy NM, 2011, CLIN REHABIL, V25, P14, DOI 10.1177/0269215510375908; Scholz U, 2006, SOC SCI MED, V62, P3109, DOI 10.1016/j.socscimed.2005.11.035; Stroud NM, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-68; Stuart M, 2009, NEUROREHAB NEURAL RE, V23, P726, DOI 10.1177/1545968309332734; THOMAS S, 1992, CAN J SPORT SCI, V17, P338; Topolovec-Vranic J, 2010, BRAIN INJURY, V24, P762, DOI 10.3109/02699051003709599; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Yohannes AM, 2010, J CLIN NURS, V19, P2806, DOI 10.1111/j.1365-2702.2010.03313.x; Zafonte RD, 2002, J HEAD TRAUMA REHAB, V17, P322, DOI 10.1097/00001199-200208000-00006	28	33	36	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2012	27	2					99	103		10.1097/HTR.0b013e31820e6858			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	912LI	WOS:000301799100002	21386712				2021-06-18	
J	Timaru-Kast, R; Wyschkon, S; Luh, C; Schaible, EV; Lehmann, F; Merk, P; Werner, C; Engelhard, K; Thal, SC				Timaru-Kast, Ralph; Wyschkon, Sebastian; Luh, Clara; Schaible, Eva-Verena; Lehmann, Florian; Merk, Philipp; Werner, Christian; Engelhard, Kristin; Thal, Serge C.			Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma	CRITICAL CARE MEDICINE			English	Article						angiotensin; angiotensin II receptor type 1; AT1; AT1 inhibition; brain trauma; controlled cortical impact; mice; renin-angiotensin system; traumatic brain injury	POSSIBLE THERAPEUTIC IMPLICATIONS; SPONTANEOUSLY HYPERTENSIVE-RATS; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; AUTOIMMUNE INFLAMMATION; EDEMA FORMATION; AT(1) RECEPTOR; MESSENGER-RNA; CNS INJURY; AT1	Objective: To investigate the regulation of the cerebral renin angiotensin system and the effect of angiotensin II receptor type 1 inhibition on secondary brain damage, cerebral inflammation, and neurologic outcome after head trauma. Design: The expression of renin angiotensin system components was determined at 15 mins, 3 hrs, 6 hrs, 12 hrs, and 24 hrs after controlled cortical impact in mice. Angiotensin II receptor type 1 was inhibited using candesartan (0.1, 0.5, 1 mg/kg) after trauma to determine its effect on secondary brain damage, brain edema formation, and inflammation. The window of opportunity was tested by delaying angiotensin II receptor type 1 inhibition for 30 mins, 1 hr, 2 hrs, and 4 hrs. The long-term effect was tested by single and daily repeated treatment with candesartan for 5 days after controlled cortical impact. Setting: University research laboratory. Subjects: Male C57BI/6N mice. Interventions: Brain trauma by use of a controlled cortical impact device. Measurements and Main Results: Expression of angiotensin II receptor type 1A decreased by 42% within 24 hrs after controlled cortical impact, whereas angiotensin II receptor type 1B expression increased to 220% between 6 and 12 hrs. Blockage of angiotensin II receptor type 1with 0.1 mg/kg candesartan within 4 hrs of injury significantly reduced secondary brain damage (30 mins: 25 mm(3) vs. vehicle: 41 mm(3)) and improved neurologic function after 24 hrs but failed to reduce brain edema formation. Daily treatment with candesartan afforded sustained reduction of brain damage and improved neurologic function 5 days after traumatic brain injury compared with single and vehicle treatment. Inhibition of angiotensin II receptor type 1 significantly attenuated posttraumatic inflammation (interleukin-6: -56%; interleukin-1 beta: -42%; inducible nitric oxide synthase: -36%; tumor necrosis factor-alpha: -35%) and microglia activation (vehicle: 163 +/- 25/mm(2) vs. candesartan: 118 +/- 13/mm(2)). Higher dosages (0.5 and 1 mg/kg) resulted in prolonged reduction in blood pressure and failed to reduce brain lesion. Conclusions: The results indicate that angiotensin II receptor type 1 plays a key role in the development of secondary brain damage after brain trauma. Inhibition of angiotensin II receptor type 1 with a delay of up to 4 hrs after traumatic brain injury effectively reduces lesion volume. This reduction makes angiotensin II receptor type 1 a promising therapeutic target for reducing cerebral inflammation and limiting secondary brain damage. (Crit Care Med 2012; 40:935-944)	[Timaru-Kast, Ralph; Wyschkon, Sebastian; Luh, Clara; Schaible, Eva-Verena; Lehmann, Florian; Merk, Philipp; Werner, Christian; Engelhard, Kristin; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany	Thal, SC (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729	Johannes Gutenberg-University	This work was financially supported by departmental funding and by the Focus Program Translational Neurosciences (FIN) of the Johannes Gutenberg-University.	AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; Baranov D, 2003, ANESTHESIOLOGY, V99, P1118, DOI 10.1097/00000542-200311000-00018; Benicky J, 2009, CELL MOL NEUROBIOL, V29, P781, DOI 10.1007/s10571-009-9368-4; Brdon J, 2007, J HYPERTENS, V25, P187, DOI 10.1097/01.hjh.0000254376.80864.d3; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; Crowley SD, 2010, HYPERTENSION, V55, P99, DOI 10.1161/HYPERTENSIONAHA.109.144964; Culman J, 2002, J HUM HYPERTENS, V16, pS64, DOI 10.1038/sj.jhh.1001442; Culman J, 2001, J RENIN-ANGIO-ALDO S, V2, P96, DOI 10.3317/jraas.2001.019; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Ferger B, 2004, J NEUROCHEM, V89, P822, DOI 10.1111/j.1471-4159.2004.02399.x; Giulietti A, 2001, METHODS, V25, P386, DOI 10.1006/meth.2001.1261; Groth W, 2003, J HYPERTENS, V21, P2175, DOI 10.1097/00004872-200311000-00028; Inagami T, 1995, Curr Opin Nephrol Hypertens, V4, P47, DOI 10.1097/00041552-199501000-00007; Johren O, 1995, NEUROREPORT, V6, P2549; Johren O, 1996, AM J PHYSIOL-ENDOC M, V271, pE104; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; Kagiyama T, 2003, REGUL PEPTIDES, V110, P241, DOI 10.1016/S0167-0115(02)00223-9; Katayama Y, 1998, ACT NEUR S, V71, P289; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lenkei Z, 1997, FRONT NEUROENDOCRIN, V18, P383, DOI 10.1006/frne.1997.0155; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li J, 2005, FASEB J, V19, P617, DOI 10.1096/fj.04-2960fje; Li JM, 2008, STROKE, V39, P2029, DOI 10.1161/STROKEAHA.107.503458; Luhder F, 2009, J NEUROIMMUNOL, V217, P1, DOI 10.1016/j.jneuroim.2009.08.008; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Makino I, 1996, NEUROPEPTIDES, V30, P596, DOI 10.1016/S0143-4179(96)90043-8; MILLAN MA, 1991, P NATL ACAD SCI USA, V88, P11440, DOI 10.1073/pnas.88.24.11440; Mogi M, 2006, HYPERTENSION, V48, P141, DOI 10.1161/01.HYP.0000229648.67883.f9; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; Oparil S, 2000, AM J HYPERTENS, V13, p18S, DOI 10.1016/S0895-7061(99)00250-2; Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005; Pelisch N, 2011, AM J HYPERTENS, V24, P362, DOI 10.1038/ajh.2010.241; Pelisch N, 2010, HYPERTENS RES, V33, P161, DOI 10.1038/hr.2009.200; Plesnila N, 2007, CELL DEATH DIFFER, V14, P1529, DOI 10.1038/sj.cdd.4402159; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Saad MAA, 2010, ACTA PHYSIOL HUNG, V97, P159, DOI 10.1556/APhysiol.97.2010.2.2; Saavedra JM, 2004, ANN NY ACAD SCI, V1018, P76, DOI 10.1196/annals.1296.009; Saavedra JM, 2005, CELL MOL NEUROBIOL, V25, P485, DOI 10.1007/s10571-005-4011-5; Saavedra JM, 2007, STRESS, V10, P185, DOI 10.1080/10253890701350735; Saavedra JM, 2006, J HYPERTENS, V24, pS131, DOI 10.1097/01.hjh.0000220418.09021.ee; Saavedra JM, 2006, CELL MOL NEUROBIOL, V26, P1099, DOI 10.1007/s10571-006-9009-0; Speth RC, 2008, N-S ARCH PHARMACOL, V377, P283, DOI 10.1007/s00210-007-0238-7; Stegbauer J, 2009, P NATL ACAD SCI USA, V106, P14942, DOI 10.1073/pnas.0903602106; Takemori K, 2000, AM J HYPERTENS, V13, P1233, DOI 10.1016/S0895-7061(00)01202-4; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thal SC, 2009, CRIT CARE MED, V37, P2228, DOI 10.1097/CCM.0b013e3181a068fc; TIMMERMANS PBMWM, 1993, J HUM HYPERTENS, V7, pS19; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; TSUTSUMI K, 1993, BRAIN RES, V631, P212, DOI 10.1016/0006-8993(93)91537-3; Unger T, 2003, CURR MED RES OPIN, V19, P449, DOI 10.1185/030079903125001974; Unger T, 1996, J HYPERTENS, V14, pS95; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; ZIMMERMAN RA, 1978, NEURORADIOLOGY, V16, P320, DOI 10.1007/BF00395288; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	61	33	35	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2012	40	3					935	944		10.1097/CCM.0b013e31822f08b9			10	Critical Care Medicine	General & Internal Medicine	895YO	WOS:000300532800030	21926585				2021-06-18	
J	Xavier, AM; Serafim, KGG; Higashi, DT; Vanat, N; Flaiban, KKMD; Siqueira, CPCM; Venancio, EJ; Ramos, SD				Xavier, A. M.; Serafim, K. G. G.; Higashi, D. T.; Vanat, N.; Flaiban, K. K. M. da C.; Siqueira, C. P. C. M.; Venancio, E. J.; Ramos, S. de P.			Simvastatin improves morphological and functional recovery of sciatic nerve injury in Wistar rats	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Simvastatin; Sciatic nerve; Immunomodulation; Nervous regeneration	TRAUMATIC BRAIN-INJURY; MONOCYTE CHEMOATTRACTANT PROTEIN-1; WALLERIAN DEGENERATION; PERIPHERAL-NERVE; IN-VIVO; MACROPHAGE RECRUITMENT; ISCHEMIC-STROKE; CELL-ACTIVATION; NEURONAL CELLS; SCHWANN-CELLS	Aim: The purpose of this work is to investigate the effects of simvastatin on sciatic nerve regeneration in male Wistar Rats. Materials and methods: Forty animals were allocated into four groups: (1) control (C); (2) control + simvastatin (CS); (3) lesioned animals + sterile PBS (LC) and (4) lesioned animals + simvastatin (LS). Lesioned animals were submitted to crushing lesion of right sciatic nerve. Simvastatin (20 mg/kg/day, i.p.) was administered for five days. Footprints were obtained weekly for evaluation of functional locomotor recovery by means of the Sciatic Function Index (SFI). Blood samples were obtained weekly for quantifying circulating leukocytes. Animals were sacrificed after 21 days for histological analyses of sciatic nerve and spleen. Results: LS Animals presented increased SFI scores, decreased areas of oedema and mononuclear cell infiltration during Wallerian degeneration and nerve regeneration (7,14 and 21 days; P < 0.05). Spleen weight and white pulp areas was increased in LC animals after 21 days. Increased numbers of circulating neutrophils were observed in simvastatin treated animals (CS e LS) at seven, 14 and 21 days, compared to non-treated groups (C and LC). Conclusion: The study suggests that simvastatin accelerates the morphological and functional recovery process of the peripheral nervous system interfering with innate and acquired immunity. (C) 2011 Elsevier Ltd. All rights reserved.	[Ramos, S. de P.] Univ Estadual Londrina, Dept Histol, BR-86051990 Londrina, PR, Brazil; [Vanat, N.; Flaiban, K. K. M. da C.] Univ Estadual Londrina, Vet Hosp, BR-86051990 Londrina, PR, Brazil; [Siqueira, C. P. C. M.] Univ Estadual Londrina, Dept Physiotherapy, BR-86051990 Londrina, PR, Brazil; [Venancio, E. J.] Univ Estadual Londrina, Dept Pathol Sci, BR-86051990 Londrina, PR, Brazil	Ramos, SD (corresponding author), Univ Estadual Londrina, Dept Histol, Rodovia Celso Garcia Cid PR 445,Km 380, BR-86051990 Londrina, PR, Brazil.	ramossolange@yahoo.com	Venancio, Emerson Jose/F-6767-2012; Flaiban, Karina/AAJ-9441-2021	Venancio, Emerson/0000-0002-3735-9207; Flaiban, Karina/0000-0001-6461-6961			Al-Bishri A, 2008, BRIT J ORAL MAX SURG, V46, P455, DOI 10.1016/j.bjoms.2008.01.020; Avellino AM, 2004, EXP NEUROL, V187, P430, DOI 10.1016/j.expneurol.2004.02.004; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; Boivin A, 2007, J NEUROSCI, V27, P12565, DOI 10.1523/JNEUROSCI.3027-07.2007; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Colivicchi F, 2007, STROKE, V38, P2652, DOI 10.1161/STROKEAHA.107.487017; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Dunn SE, 2006, J EXP MED, V203, P401, DOI 10.1084/jem.20051129; Dunzendorfer S, 1997, CIRC RES, V81, P963; Eccles KA, 2008, ATHEROSCLEROSIS, V200, P69, DOI 10.1016/j.atherosclerosis.2007.12.018; Gholami MR, 2008, EUR J PHARMACOL, V590, P111, DOI 10.1016/j.ejphar.2008.05.050; Gholami Mohammad Reza, 2007, Pak J Biol Sci, V10, P4256, DOI 10.3923/pjbs.2007.4256.4260; Golz G, 2006, EUR J NEUROSCI, V24, P2721, DOI 10.1111/j.1460-9568.2006.05155.x; Guasti L, 2006, J HYPERTENS, V24, P2423, DOI 10.1097/01.hjh.0000251903.62804.77; Hakamada-Taguchi R, 2003, CIRC RES, V93, P948, DOI 10.1161/01.RES.0000101298.76864.14; Han KH, 2005, CIRCULATION, V111, P1439, DOI 10.1161/01.CIR.0000158484.18024.1F; Hayashi T, 2005, BRAIN RES, V1037, P52, DOI 10.1016/j.brainres.2004.12.051; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Holmberg E, 2006, J NEUROTRAUM, V23, P1366, DOI 10.1089/neu.2006.23.1366; Jander S, 2001, BRAIN PATHOL, V11, P27; Karanth S, 2006, EXP NEUROL, V202, P161, DOI 10.1016/j.expneurol.2006.05.024; Klopfleisch S, 2008, J NEUROSCI, V28, P13609, DOI 10.1523/JNEUROSCI.2765-08.2008; Lee H, 2006, BIOCHEM BIOPH RES CO, V350, P742, DOI 10.1016/j.bbrc.2006.09.108; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Lilje O, 2002, CELL MOL LIFE SCI, V59, P2191, DOI 10.1007/s000180200018; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Maher BM, 2009, J LEUKOCYTE BIOL, V85, P186, DOI 10.1189/jlb.0608382; Martini R, 2008, GLIA, V56, P1566, DOI 10.1002/glia.20766; Montaner J, 2008, EUR J NEUROL, V15, P82, DOI 10.1111/j.1468-1331.2007.02015.x; Nakamichi K, 2006, NEUROSCI LETT, V407, P205, DOI 10.1016/j.neulet.2006.08.044; Nezic L, 2009, BASIC CLIN PHARMACOL, V104, P185, DOI 10.1111/j.1742-7843.2008.00302.x; Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Park DS, 2009, ACTA OTO-LARYNGOL, V129, P166, DOI 10.1080/00016480802163358; Perrin FE, 2005, BRAIN, V128, P854, DOI 10.1093/brain/awh407; Pienaar IS, 2009, J NEURAL TRANSM, V116, P791, DOI 10.1007/s00702-009-0247-4; Ponce J, 2008, STROKE, V39, P1269, DOI 10.1161/STROKEAHA.107.498923; Rallidis LS, 2008, INT J CARDIOL, V124, P271, DOI 10.1016/j.ijcard.2006.12.059; Ruohonen S, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-26; Schramm R, 2007, IMMUNOLOGY, V120, P315, DOI 10.1111/j.1365-2567.2006.02505.x; Shaw SK, 2008, EXP NEUROL, V210, P286, DOI 10.1016/j.expneurol.2007.11.024; Siebert H, 2000, J NEUROIMMUNOL, V110, P177, DOI 10.1016/S0165-5728(00)00343-X; Ulivieri C, 2008, EUR J IMMUNOL, V38, P2832, DOI 10.1002/eji.200838278; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Wang YP, 2008, J NEUROL SCI, V267, P107, DOI 10.1016/j.jns.2007.10.004; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xin JP, 2008, BRAIN BEHAV IMMUN, V22, P528, DOI 10.1016/j.bbi.2007.10.006; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zhang X, 2008, IMMUNOL RES, V41, P165, DOI 10.1007/s12026-008-8019-z; Zhang X, 2008, J IMMUNOL, V180, P6988, DOI 10.4049/jimmunol.180.10.6988; Zhang ZR, 2008, ACTA NEUROPATHOL, V115, P335, DOI 10.1007/s00401-007-0301-y	51	33	36	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	MAR	2012	43	3					284	289		10.1016/j.injury.2011.05.036			6	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	897HU	WOS:000300640000007	21684542				2021-06-18	
J	Johnson, B; Zhang, K; Gay, M; Neuberger, T; Horovitz, S; Hallett, M; Sebastianelli, W; Slobounov, S				Johnson, Brian; Zhang, Kai; Gay, Michael; Neuberger, Thomas; Horovitz, Silvina; Hallett, Mark; Sebastianelli, Wayne; Slobounov, Semyon			Metabolic alterations in corpus callosum may compromise brain functional connectivity in MTBI patients: An H-1-MRS study	NEUROSCIENCE LETTERS			English	Article						MTBI; Subacute; H-1-MRS; Functional connectivity	MILD; INJURY; SPECTROSCOPY; PERFORMANCE; RECOVERY; MODERATE; NETWORK	After clinical resolution of signs and symptoms of mild traumatic brain injury (MTBI) it is still not clear if there are residual abnormalities of structural or functional brain networks. We have previously documented disrupted interhemispheric functional connectivity in 'asymptomatic' concussed individuals during the sub-acute phase of injury. Testing of 15 normal volunteers (NV) and 15 subacute MTBI subjects was performed within 24 h of clinical symptoms resolution and medical clearance for the first stage of aerobic activity. In this MRS study we report: (a) both in the genu and splenium of the corpus callosum NAA/Cho and NAA/Cr ratios were significantly (p < 0.05) lower in MTBI subjects shortly after the injury compared to NVs, and (b) the metabolic ratio NAA/Cho in the splenium significantly correlated with the magnitude of inter-hippocampal functional connectivity in normal volunteers, but not in MTBI. This novel finding supports our hypothesis that the functional disruption of interhemispheric brain networks in MTBI subjects results from compromised metabolic integrity of the corpus callosum and that this persists despite apparent clinical return to baseline. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Johnson, Brian; Zhang, Kai; Gay, Michael; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Johnson, Brian; Neuberger, Thomas] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; [Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, HMC, Dept Orthoped & Med Rehabil, University Pk, PA 16802 USA; [Horovitz, Silvina; Hallett, Mark; Slobounov, Semyon] NINDS, NIH, Bethesda, MD 20892 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150; Horovitz, Silvina G./0000-0002-5501-5918	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227, ZIANS002667] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 'Identification of Athletes at Risk for Traumatic Brain Injury'.	Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergman K, 2010, J EMERG NURS, V36, P221, DOI 10.1016/j.jen.2009.07.001; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; Gasparovic C., 2009, J NEUROTRAUM; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Henry L. C., 2011, J NEUROTRAUM; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Johnson B., 2011, NEUROIMAGE; Johnston JM, 2008, J NEUROSCI, V28, P6453, DOI 10.1523/JNEUROSCI.0573-08.2008; Kompus K., 2011, BRAIN RES; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; Mathew SJ, 2003, BIOL PSYCHIAT, V54, P727, DOI 10.1016/S0006-3223(03)00004-0; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Nakabayashi M, 2007, J NEUROSURG, V106, P370, DOI 10.3171/jns.2007.106.3.370; Quigley M, 2003, AM J NEURORADIOL, V24, P208; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	33	33	33	0	8	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	FEB 10	2012	509	1					5	8		10.1016/j.neulet.2011.11.013			4	Neurosciences	Neurosciences & Neurology	903DV	WOS:000301097100002	22108503	Green Accepted			2021-06-18	
J	Dizdarevic, K; Hamdan, A; Omerhodzic, I; Kominlija-Smajic, E				Dizdarevic, Kemal; Hamdan, Alhafidz; Omerhodzic, Ibrahim; Kominlija-Smajic, Elvedina			Modified Lund concept versus cerebral perfusion pressure-targeted therapy: A randomised controlled study in patients with secondary brain ischaemia	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Microdialysis; Lund concept; Cerebral perfusion pressure; Secondary brain ischaemia; Traumatic brain injury; Subarachnoid haemorrhage	ANEURYSMAL SUBARACHNOID HEMORRHAGE; RUPTURED INTRACRANIAL ANEURYSMS; INTRACEREBRAL MICRODIALYSIS; ENDOVASCULAR COILING; PROTOCOL; INJURY; TRIAL; ISAT	Purpose: Secondary brain ischaemia (SBI) usually develops after aneurysmal subarachnoid haemorrhage (SAH) and severe traumatic brain injury (TB!). Current approaches to managing these conditions are based either on intracranial pressure-targeted therapy (ICP-targeted) with cerebral microdialysis (CM) monitoring according to the modified Lund concept or cerebral perfusion pressure-targeted therapy (CPP-targeted). We present a prospective, randomised controlled study comparing relative effectiveness of the two management strategies. Methods: Sixty comatose operated patients with SBI following aneurysmal SAH and severe TBI were randomised into ICP-targeted therapy with CM monitoring and CPP-targeted therapy groups. Mortality rates in both groups were calculated and tissue biochemical signs of cerebral ischaemia were analysed using CM. Measured CM data were related to outcome (Glasgow Outcome Scale [GOS] score 1,2 and 3 for poor outcome or GOS score 4 and 5 for good outcome). Results: Patients treated with ICP-targeted therapy with CM monitoring had significantly lower mortality rate as compared with those treated with CPP-targeted therapy (P=0.03). Patients monitored with CM who had poor outcome had lower mean values of glucose and higher mean values of glycerol and lactate/pyruvate ratio as compared with those who had good outcome (glucose: P=0.003; glycerol: P=0.02; lactate/pyruvate ratio: P=0.01). There was no difference in the mortality outcome between aneurysmal SAH and severe TBI in the two groups (P=0.28 for ICP-targeted therapy with CM monitoring, P=0.36 for CPP-targeted therapy). Also, there were no differences in the CM values between patients with aneurysmal SAH and severe TBI who underwent ICP-targeted therapy (glucose: P=0.23; glycerol: P=0.41; lactate/pyruvate ratio: P=0.40). Conclusion: The modified Lund concept, directed at bedside real-time monitoring of brain biochemistry by CM showed better results compared to CPP-targeted therapy in the treatment of comatose patients sustaining SBI after aneurysmal SAH and severe TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Dizdarevic, Kemal; Omerhodzic, Ibrahim] Univ Sarajevo, Ctr Clin, Dept Neurosurg, Sarajevo 71000, Bosnia & Herceg; [Hamdan, Alhafidz] Newcastle Univ, Fac Med Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Kominlija-Smajic, Elvedina] Univ Sarajevo, Ctr Clin, Dept Anaethesiol, Sarajevo 71000, Bosnia & Herceg	Dizdarevic, K (corresponding author), Univ Sarajevo, Ctr Clin, Dept Neurosurg, Bolnika 25, Sarajevo 71000, Bosnia & Herceg.	kemaldiz@bih.net.ba	Omerhodzic, Ibrahim/AAL-7976-2020	Omerhodzic, Ibrahim/0000-0001-5143-8801; Hamdan, Alhafidz/0000-0002-0794-5504			American Association of Neurological Surgeon, 2004, NEUROTRAUMA CRIT SPR, p:3; Belli A, 2008, ACTA NEUROCHIR, V150, P461, DOI 10.1007/s00701-008-1580-3; *BRAIN TRAUM FDN, 2000, GUID MAN TRAUM BRAIN; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; Dizdairevic K, 2007, PROCEEDINGS OF THE 13TH EUROPEAN CONGRESS OF NEUROSURGERY, P505; Dizdarevic K, 2006, 2 BOSN C NEUR, P345; Dizdarevic Kemal, 2004, Med Arh, V58, P301; Dizdarevic Kemal, 2006, Med Arh, V60, P13; Dunham CM, 2004, J TRAUMA, V56, P482, DOI 10.1097/01.TA.0000114537.52540.95; Grande PO, 2006, INTENS CARE MED, V32, P1475, DOI 10.1007/s00134-006-0294-3; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Grande PO, 1997, J TRAUMA, pS42; Guresir E, 2009, J NEUROL NEUROSUR PS, V80, P799, DOI 10.1136/jnnp.2008.155630; Hamada J, 2004, NEUROSURGERY, V54, P31, DOI 10.1227/01.NEU.0000097196.55204.0B; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Huang SJ, 2006, J CLIN NEUROSCI, V13, P818, DOI 10.1016/j.jocn.2005.11.034; K Dizdarevic, 2011, ANEURYSMAL SUBARACHN, P161; Ling GSF, 2005, NEUROCRIT CARE, V2, P75, DOI 10.1385/NCC:2:1:075; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Ng I., 1998, Annals Academy of Medicine Singapore, V27, P332; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Nordstrom CH, 2008, CRIT CARE, V12, DOI 10.1186/cc6826; Oddo Mauro, 2009, Rev Med Suisse, V5, P2506; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Rusnak M, 2006, ACTA INFORM MED, V14, P10; Rusnak M, 2005, EUPHA C; Ryttlefors M, 2010, ACTA NEUROCHIR, V152, P241, DOI 10.1007/s00701-009-0496-x; Sarrafzadeh AS, 2007, ANAESTHESIST, V56, P957, DOI 10.1007/s00101-007-1244-3; Skjoth-Rasmussen J, 2004, J NEUROSURG, V100, P8, DOI 10.3171/jns.2004.100.1.0008; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stocchetti N, 1991, Minerva Anestesiol, V57, P327; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109	36	33	35	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	FEB	2012	114	2					142	148		10.1016/j.clineuro.2011.10.005			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	900WJ	WOS:000300922100008	22036839				2021-06-18	
J	Cekic, M; Johnson, SJ; Bhatt, VH; Stein, DG				Cekic, Milos; Johnson, Sarah J.; Bhatt, Vinay H.; Stein, Donald G.			Progesterone treatment alters neurotrophin/proneurotrophin balance and receptor expression in rats with traumatic brain injury	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Apoptosis; brain-derived growth factor (BDNF); frontal cortex; nerve growth factor (NGF); progesterone; proneurotrophins; recovery of function; traumatic brain injury; TrkA	NERVE GROWTH-FACTOR; NEUROTROPHIC FACTOR; CELL-DEATH; SPINAL-CORD; FUNCTIONAL RECOVERY; UP-REGULATION; BDNF; ALLOPREGNANOLONE; NEUROPROTECTION; SORTILIN	Purpose: The neuroactive steroid progesterone (PROG) has been shown to be an effective treatment for traumatic brain injury (TBI) both in animal models and in humans, but the signaling pathways involved have not yet been fully described. Here we characterize the protein expression of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and their pro-proteins and receptors following PROG treatment for TBI. Methods: To evaluate whether PROG treatment given after TBI alters mature and proneurotrophin protein balance and the expression of receptors involved in apoptotic and cell survival signaling, we used Western blots in tissue obtained 24 h, 72 h, and 7 days after injury from rats with bilateral frontal cortical contusions. Results: Compared to controls, PROG reduced levels of pro-apoptotic NGF precursor (proNGF) at 24 h and 7 days post-injury, reduced levels of pro-apoptotic BDNF precursor (proBDNF) and the BDNF receptor TrkB at all time points, and increased levels of mature NGF at 72 h. Levels of mature BDNF were decreased at 24 and 72 h. These observations were associated with reduced markers of apoptosis and improved behavioral parameters in PROG-treated rats. Conclusions: Some of PROG's protective effects after TBI are mediated, in part, by simultaneous induction of pro-survival neurotrophin signaling and inhibition of apoptotic proneurotrophin signaling.	[Stein, Donald G.] Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Sch Med, Atlanta, GA 30322 USA	Stein, DG (corresponding author), Emory Univ, Emergency Med Brain Res Lab, Dept Emergency Med, Sch Med, Suite 5100,1365B Clifton Rd NE, Atlanta, GA 30322 USA.	donald.stein@emory.edu	Stein, Donald/AAJ-5139-2020; Cekic, Milos/AAR-8250-2020		NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1RO1N540825, 1RO1N538664]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [DP2AI112242] Funding Source: NIH RePORTER	This work was supported by funds from NIH grants 1RO1N540825 and 1RO1N538664.	Althaus HH, 2008, J MOL NEUROSCI, V35, P65, DOI 10.1007/s12031-008-9053-y; Atif F, 2009, MOL MED, V15, P328, DOI 10.2119/molmed.2009.00016; Beattie MS, 2002, NEURON, V36, P375, DOI 10.1016/S0896-6273(02)01005-X; BJERRE B, 1973, BRAIN RES, V60, P161, DOI 10.1016/0006-8993(73)90855-X; Canudas AM, 2005, MOL BRAIN RES, V134, P147, DOI 10.1016/j.molbrainres.2004.11.012; Chandler B, 2012, NEURAL NETWORKS, V25, P21, DOI 10.1016/j.neunet.2011.07.009; Chen ZY, 2005, J NEUROSCI, V25, P6156, DOI 10.1523/JNEUROSCI.1017-05.2005; Cunha C, 2009, NEUROBIOL DIS, V33, P358, DOI 10.1016/j.nbd.2008.11.004; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Cutler SM, 2006, EXP NEUROL, V200, P378, DOI 10.1016/j.expneurol.2006.02.137; Cutler SM, 2005, EXP NEUROL, V195, P423, DOI 10.1016/j.expneurol.2005.06.003; De Nicola AF, 2003, ANN NY ACAD SCI, V1007, P317, DOI 10.1196/annals.1286.030; Dixon KJ, 2006, EXP NEUROL, V202, P44, DOI 10.1016/j.expneurol.2006.05.010; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Esposito D, 2001, J BIOL CHEM, V276, P32687, DOI 10.1074/jbc.M011674200; Fahnestock M, 2001, MOL CELL NEUROSCI, V18, P210, DOI 10.1006/mcne.2001.1016; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Greenberg ME, 2009, J NEUROSCI, V29, P12764, DOI 10.1523/JNEUROSCI.3566-09.2009; Grider MH, 2005, J NEUROSCI RES, V82, P404, DOI 10.1002/jnr.20635; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Harrington AW, 2004, P NATL ACAD SCI USA, V101, P6226, DOI 10.1073/pnas.0305755101; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; Hempstead Barbara L., 2006, Current Alzheimer Research, V3, P19, DOI 10.2174/156720506775697061; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Jansen P, 2007, NAT NEUROSCI, V10, P1449, DOI 10.1038/nn2000; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Kim DH, 2004, J NEUROSURG, V100, P79, DOI 10.3171/jns.2004.100.1.0079; Koyama R, 2004, J NEUROSCI, V24, P7215, DOI 10.1523/JNEUROSCI.2045-04.2004; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Lu B, 2003, LEARN MEMORY, V10, P86, DOI 10.1101/lm.54603; Lu B, 2005, NAT REV NEUROSCI, V6, P603, DOI 10.1038/nrn1726; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Melcangi RC, 2003, J STEROID BIOCHEM, V85, P323, DOI 10.1016/S0960-0760(03)00228-0; Mohammad S, 1998, EPILEPSY RES, V30, P195, DOI 10.1016/S0920-1211(98)00004-7; National Research Council, 2011, GUID CAR US LAB AN; Nygren J, 2006, J NEUROSCI RES, V84, P626, DOI 10.1002/jnr.20956; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pettigrew DB, 2007, EXP NEUROL, V203, P95, DOI 10.1016/j.expneurol.2006.07.026; Pettus EH, 2005, BRAIN RES, V1049, P112, DOI 10.1016/j.brainres.2005.05.004; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; SAUER H, 1994, NEUROREPORT, V5, P609, DOI 10.1097/00001756-199401000-00019; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Scharfman Helen E, 2005, Epilepsy Curr, V5, P83, DOI 10.1111/j.1535-7511.2005.05312.x; Schumacher M, 2007, PHARMACOL THERAPEUT, V116, P77, DOI 10.1016/j.pharmthera.2007.06.001; Seidah NG, 1996, BIOCHEM J, V314, P951, DOI 10.1042/bj3140951; Sobreviela T, 1996, J COMP NEUROL, V375, P417; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; Srinivasan B, 2004, J BIOL CHEM, V279, P41839, DOI 10.1074/jbc.M402872200; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Teng HK, 2005, J NEUROSCI, V25, P5455, DOI 10.1523/JNEUROSCI.5123-04.2005; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; VanLandingham JW, 2007, NEUROSCI LETT, V425, P94, DOI 10.1016/j.neulet.2007.08.045; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	62	33	36	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2012	30	2					115	126		10.3233/RNN-2011-0628			12	Neurosciences	Neurosciences & Neurology	921DV	WOS:000302459100004	22232032				2021-06-18	
J	Franschman, G; Boer, C; Andriessen, TMJC; van der Naalt, J; Horn, J; Haitsma, I; Jacobs, B; Vos, PE				Franschman, Gaby; Boer, Christa; Andriessen, Teuntje M. J. C.; van der Naalt, Joukje; Horn, Janneke; Haitsma, Iain; Jacobs, Bram; Vos, Pieter E.			Multicenter Evaluation of the Course of Coagulopathy in Patients with Isolated Traumatic Brain Injury: Relation to CT Characteristics and Outcome	JOURNAL OF NEUROTRAUMA			English	Article						coagulation disorders; CT characteristics; hemostatic monitoring; neurotrauma; patient outcome	SEVERE HEAD-INJURY; ROTATION THROMBELASTOGRAPHY; COMPUTERIZED-TOMOGRAPHY; PROGNOSTIC VALUE; CLASSIFICATION; DIAGNOSIS; MODERATE; HYPERFIBRINOLYSIS; ABNORMALITIES; PREDICTORS	This prospective multicenter study investigated the association of the course of coagulation abnormalities with initial computed tomography (CT) characteristics and outcome in patients with isolated traumatic brain injury (TBI). Patient demographics, coagulation parameters, CT characteristics, and outcome data of moderate and severe TBI patients without major extracranial injuries were prospectively collected. Coagulopathy was defined as absent, early but temporary, delayed, or early and sustained. Delayed/sustained coagulopathy was associated with a higher incidence of disturbed pupillary responses (40% versus 27%; p < 0.001) and higher Traumatic Coma Data Bank (TCDB) CT classification (5 (2-5) versus 2 (1-5); p = 0.003) than in patients without or with early, but short-lasting coagulopathy. The initial CT of patients with delayed/sustained coagulopathy more frequently showed intracranial hemorrhage and signs of raised intracranial pressure (ICP) compared to patients with early coagulopathy only. This was paralleled by higher in-hospital mortality rates (51% versus 33%; p < 0.05), and poorer 6-month functional outcome in patients with delayed/sustained coagulopathy. The relative risk for in-hospital mortality was particularly related to disturbed pupillary responses (OR 8.19; 95% CI 3.15,21.32; p < 0.001), early, short-lasting coagulopathy (OR 6.70; 95% CI 1.74,25.78; p = 0.006), or delayed/sustained coagulopathy (OR 5.25; 95% CI 2.06,13.40; p = 0.001). Delayed/sustained coagulopathy is more frequently associated with CT abnormalities and unfavorable outcome at 6 months after TBI than early, short-lasting coagulopathy. Our finding that not only the mere presence but also the time course of coagulopathy holds predictive value for patient outcome underlines the importance of systematic hemostatic monitoring over time in TBI.	[Franschman, Gaby; Boer, Christa] Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, Inst Cardiovasc Res, NL-1081 HV Amsterdam, Netherlands; [Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Dept Neurol, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [van der Naalt, Joukje; Jacobs, Bram] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care, NL-1105 AZ Amsterdam, Netherlands; [Haitsma, Iain] Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands	Franschman, G (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, Inst Cardiovasc Res, Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	g.franschman@vumc.nl	Vos, Pieter/A-6043-2012	Boer, Christa/0000-0002-7781-6951	Dutch Brain Foundation [Hersenstichting - HSN-07-01]; Netherlands Brain Foundation [HSN-07-01]	The POCON study is funded by the Dutch Brain Foundation (Hersenstichting - HSN-07-01). The authors express their gratitude to Dick Drost, Annemiek Coers, Annelou van der Veen, Joshua Field, Vivian de Ruijter, and Heleen Biersteker for their help with data collection. We thank Amon Heijne for his help with development and maintenance of the POCON database.; The POCON study has been funded by the Netherlands Brain Foundation (HSN-07-01).	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Barklin A, 2009, ANESTHESIOLOGY, V110, P1287, DOI 10.1097/ALN.0b013e3181a10352; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chesnut R. M., 2000, GUIDELINES MANAGEMEN, P155; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; DRAKE TA, 1989, AM J PATHOL, V134, P1087; Fenger-Eriksen C, 2009, J THROMB HAEMOST, V7, P1099, DOI 10.1111/j.1538-7836.2009.03460.x; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; GOODNIGHT SH, 1974, NEW ENGL J MED, V290, P1043, DOI 10.1056/NEJM197405092901903; Greuters S, 2011, CRIT CARE, V15, DOI 10.1186/cc9399; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Levrat A, 2008, BRIT J ANAESTH, V100, P792, DOI 10.1093/bja/aen083; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1990, ACT NEUR S, V51, P300; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Pahatouridis D, 2010, BRAIN INJURY, V24, P1189, DOI 10.3109/02699052.2010.490510; Perel P., 2010, COCHRANE DB SYST REV, V20; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rugeri L, 2007, J THROMB HAEMOST, V5, P289, DOI 10.1111/j.1538-7836.2007.02319.x; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	38	33	37	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					128	136		10.1089/neu.2011.2044			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300015	21939390				2021-06-18	
J	Kang, JH; Lin, HC				Kang, Jiunn-Horng; Lin, Herng-Ching			Increased Risk of Multiple Sclerosis after Traumatic Brain Injury: A Nationwide Population-Based Study	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; multiple sclerosis; trauma; traumatic brain injury	HEAD-INJURY; PATHOPHYSIOLOGY; COHORT; STROKE; MS	The etiology of multiple sclerosis (MS) is still not well known. Previous data show conflicting results regarding the association between MS and prior brain trauma. This study aims to investigate the risk for MS following a traumatic brain injury (TBI) using a large-scale cohort study design. This study used data from the National Health Insurance Research Database. A total of 72,765 patients with TBI were identified and included as the study cohort, and 218,295 randomly selected subjects were matched with the study cohort by sex and age as controls. We traced each patient individually for a 6-year period from their index health care utilization to identify those who received a subsequent diagnosis of MS. We used the Kaplan-Meier method and the log-rank test to compare the difference in 6-year MS-free survival rates between the two groups. Stratified Cox proportional hazard regressions were computed to compare the risk of developing MS for these two cohorts. Patients with TBI had a higher incidence of MS during the 6-year period than the comparison group (0.055% versus 0.037%). After excluding cases who died from non-MS causes, stratifying for hospitalization of cases as a proxy for severity, and adjusting for monthly income and geographic region of the community in which the patient resided, the hazard ratio (HR) of MS for patients with hospital-treated TBI injuries was 1.97 (95% CI 1.31,2.93, p<0.01) that of patients without TBI during the 6-year follow-up period after index health care use. Our study concludes that patients with TBI are at higher risk for subsequent MS over a 6-year follow-up period.	[Lin, Herng-Ching] Taipei Med Univ, Coll Med, Sch Hlth Care Adm, Taipei 110, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Dept Phys Med & Rehabil, Coll Med, Sch Med, Taipei 110, Taiwan; [Kang, Jiunn-Horng] Taipei Med Univ, Neurosci Res Ctr, Taipei 110, Taiwan	Lin, HC (corresponding author), Taipei Med Univ, Coll Med, Sch Hlth Care Adm, 250 Wu Hsing St, Taipei 110, Taiwan.	henry11111@tmu.edu.tw					ALTER M, 1968, NEUROLOGY, V18, P109, DOI 10.1212/WNL.18.2.109; Chen YH, 2011, LIVER INT, V31, P354, DOI 10.1111/j.1478-3231.2010.02350.x; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chung SD, 2011, J SEX MED, V8, P240, DOI 10.1111/j.1743-6109.2010.01973.x; Compston A, 2002, LANCET, V359, P1221, DOI 10.1016/S0140-6736(02)08220-X; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; EBERS GC, 1993, NEUROEPIDEMIOLOGY, V12, P1, DOI 10.1159/000110293; Goldacre MJ, 2006, J NEUROL NEUROSUR PS, V77, P351, DOI 10.1136/jnnp.2005.077693; Granieri E, 2000, J NEUROVIROL, V6, pS141; Gusev E, 1996, ACTA NEUROL SCAND, V94, P386, DOI 10.1111/j.1600-0404.1996.tb00050.x; Hernan MA, 2001, AM J EPIDEMIOL, V154, P69, DOI 10.1093/aje/154.1.69; JELLINEK EH, 1994, LANCET, V343, P1053, DOI 10.1016/S0140-6736(94)90178-3; KURLAND LT, 1994, ANN NEUROL, V36, pS33, DOI 10.1002/ana.410360711; LAUER K, 1994, NEUROLOGY, V44, P1360, DOI 10.1212/WNL.44.7.1360-a; Marmarou A, 2003, ACT NEUR S, V86, P7; Marrie RA, 2009, NEUROLOGY, V72, P117, DOI 10.1212/01.wnl.0000333252.78173.5f; Martinelli V., 2000, Neurological Sciences, V21, pS849, DOI 10.1007/s100720070024; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Pfleger CCH, 2009, MULT SCLER J, V15, P294, DOI 10.1177/1352458508099475; POSER CM, 1994, CLIN NEUROL NEUROSUR, V96, P103, DOI 10.1016/0303-8467(94)90042-6; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; SIVA A, 1993, NEUROLOGY, V43, P1878, DOI 10.1212/WNL.43.10.1878; Spaethling JM, 2007, PROG BRAIN RES, V161, P27, DOI 10.1016/S0079-6123(06)61003-0; Welsh CJ, 2009, ANN NY ACAD SCI, V1153, P209, DOI 10.1111/j.1749-6632.2008.03984.x	25	33	33	1	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					90	95		10.1089/neu.2011.1936			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300010	22044110				2021-06-18	
J	van de Looij, Y; Mauconduit, F; Beaumont, M; Valable, S; Farion, R; Francony, G; Payen, JF; Lahrech, H				van de Looij, Yohan; Mauconduit, Franck; Beaumont, Marine; Valable, Samuel; Farion, Regine; Francony, Gilles; Payen, Jean-Francois; Lahrech, Hana			Diffusion tensor imaging of diffuse axonal injury in a rat brain trauma model	NMR IN BIOMEDICINE			English	Article						rat brain; traumatic brain injury; diffuse axonal injury; diffusion tensor imaging; fractional anisotropy; fiber tracking; impact-acceleration model	WHITE-MATTER INJURY; FIBER TRACKING; WATER DIFFUSION; SPINAL-CORD; CORPUS-CALLOSUM; SKELETAL-MUSCLE; MOUSE-BRAIN; HEAD-INJURY; MRI; TRACTOGRAPHY	Diffusion tensor imaging (DTI) was used to study traumatic brain injury. The impactacceleration trauma model was used in rats. Here, in addition to diffusivities (mean, axial and radial), fractional anisotropy (FA) was used, in particular, as a parameter to characterize the cerebral tissue early after trauma. DTI was implemented at 7T using fast spiral k-space sampling and the twice-refocused spin echo radiofrequency sequence for eddy current minimization. The method was carefully validated on different phantom measurements. DTI of a trauma group (n=5), as well as a sham group (n=5), was performed at different time points during 6h following traumatic brain injury. Two cerebral regions, the cortex and corpus callosum, were analyzed carefully. A significant decrease in diffusivity in the trauma group versus the sham group was observed, suggesting the predominance of cellular edema in both cerebral regions. No significant FA change was detected in the cortex. In the corpus callosum of the trauma group, the FA indices were significantly lower. A net discontinuity in fiber reconstructions in the corpus callosum was observed by fiber tracking using DTI. Histological analysis using Hoechst, myelin basic protein and Bielschowsky staining showed fiber disorganization in the corpus callosum in the brains of the trauma group. On the basis of our histology results and the characteristics of the impactacceleration model responsible for the presence of diffuse axonal injury, the detection of low FA caused by a drastic reduction in axial diffusivity and the presence of fiber disconnections of the DTI track in the corpus callosum were considered to be related to the presence of diffuse axonal injury. Copyright (c) 2011 John Wiley & Sons, Ltd.	[van de Looij, Yohan; Mauconduit, Franck; Beaumont, Marine; Valable, Samuel; Farion, Regine; Francony, Gilles; Lahrech, Hana] CHU, Inst Neurosci GIN, Res Ctr, INSERM,CEA,UJF,U836, Grenoble, France	Lahrech, H (corresponding author), Univ Grenoble 1, Ctr Rech, INSERM, CHU,CEA,UJF,U836, Chemin Fortune Ferrini,Site Sante Bat Edmond J Sa, F-38706 La Tronche, France.	Hana.Lahrech@ujf-grenoble.fr	Payen, Jean-Francois/L-6667-2014; valable, samuel/B-7578-2008; Lahrech, Hana/M-5229-2018	valable, samuel/0000-0003-0355-0270; Lahrech, Hana/0000-0003-3843-3410; van de Looij, Yohan/0000-0003-2830-5482; Mauconduit, Franck/0000-0002-0128-061X			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; BODENHAUSEN G, 1977, J MAGN RESON, V27, P511, DOI 10.1016/0022-2364(77)90016-6; Catani M, 2006, CURR OPIN NEUROL, V19, P599, DOI 10.1097/01.wco.0000247610.44106.3f; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; Copen WA, 2001, RADIOLOGY, V221, P27, DOI 10.1148/radiol.2211001397; Darquie A, 2001, P NATL ACAD SCI USA, V98, P9391, DOI 10.1073/pnas.151125698; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Ducreux D, 2007, NEUROIMAG CLIN N AM, V17, P137, DOI 10.1016/j.nic.2006.11.005; FIEREMANS E, 2005, P ISMRM, P1301; Fillard P, 2007, IEEE T MED IMAGING, V26, P1472, DOI 10.1109/TMI.2007.899173; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Hasan KM, 2001, J MAGN RESON IMAGING, V13, P769, DOI 10.1002/jmri.1107; Heemskerk AM, 2007, RADIOLOGY, V243, P413, DOI 10.1148/radiol.2432060491; Hsu EW, 1998, AM J PHYSIOL-HEART C, V274, pH1627; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Immonen RJ, 2009, NEUROIMAGE, V45, P1, DOI 10.1016/j.neuroimage.2008.11.022; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 2003, MAGN RESON MED, V49, P7, DOI 10.1002/mrm.10331; Kim DH, 2003, MAGNET RESON MED, V50, P214, DOI 10.1002/mrm.10493; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lansdown DA, 2007, J APPL PHYSIOL, V103, P673, DOI 10.1152/japplphysiol.00290.2007; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lee FKH, 2006, J MAGN RESON IMAGING, V23, P747, DOI 10.1002/jmri.20553; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mauconduit F, 2010, P 18 ANN M ISMRM STO, P4030; Mayer D, 2007, NEUROIMAGE, V35, P1077, DOI 10.1016/j.neuroimage.2007.01.006; Mori S, 2001, MAGN RESON MED, V46, P18, DOI 10.1002/mrm.1155; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Norris DG, 2006, J MAGN RESON IMAGING, V23, P794, DOI 10.1002/jmri.20587; Nucifora PGP, 2007, RADIOLOGY, V245, P367, DOI 10.1148/radiol.2452060445; Numano T, 2006, MAGN RESON IMAGING, V24, P287, DOI 10.1016/j.mri.2005.12.011; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Oppenheim C, 2007, J RADIOL, V88, P510, DOI 10.1016/S0221-0363(07)89850-7; Ozanne A, 2007, AM J NEURORADIOL, V28, P1271, DOI 10.3174/ajnr.A0541; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.0.CO;2-J; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Poupon C, 2001, MED IMAGE ANAL, V5, P1, DOI 10.1016/S1361-8415(00)00030-X; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; SPIELMAN DM, 1995, MAGNET RESON MED, V34, P580, DOI 10.1002/mrm.1910340414; STEJSKAL EO, 1965, J CHEM PHYS, V43, P3597, DOI 10.1063/1.1696526; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Tollard E, 2009, CRIT CARE MED, V37, P1448, DOI 10.1097/CCM.0b013e31819cf050; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu EX, 2007, MAGN RESON IMAGING, V25, P1048, DOI 10.1016/j.mri.2006.12.008; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Xue R, 1999, MAGNET RESON MED, V42, P1123, DOI 10.1002/(SICI)1522-2594(199912)42:6<1123::AID-MRM17>3.0.CO;2-H; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073; Zhang J, 2005, BRAIN RES, V1034, P34, DOI 10.1016/j.brainres.2004.11.036	64	33	33	1	19	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	JAN	2012	25	1					93	103		10.1002/nbm.1721			11	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	875ZF	WOS:000299074600011	21618304				2021-06-18	
J	Hutchison, M; Comper, P; Mainwaring, L; Richards, D				Hutchison, Michael; Comper, Paul; Mainwaring, Lynda; Richards, Doug			The Influence of Musculoskeletal Injury on Cognition Implications for Concussion Research	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; musculoskeletal injury; sport; neuropsychological testing	MILD HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; FOOTBALL PLAYERS; HIGH-SCHOOL; SPORTS; RECOVERY; RELIABILITY; PERFORMANCE; IMPAIRMENT; DEFICITS	Background: Safe return-to-play decisions after concussion can be challenging for sports medicine specialists. Neuropsychological testing is recommended to objectively measure concussion-related cognitive impairments. Purpose: The objective of this study was to measure cognitive functioning among 3 specific athletic groups: (1) athletes with no injuries (n = 36), (2) athletes with musculoskeletal injuries (n = 18), and (3) athletes with concussion (n = 18). Study Design: Case-control study; Level of evidence, 3. Methods: Seventy-two intercollegiate athletes completed preseason baseline cognitive testing and follow-up assessment using the Automated Neuropsychological Assessment Metrics (ANAM) test battery. Injured athletes were tested within 72 hours of injury. A 1-way analysis of covariance adjusted for baseline scores was performed to determine if differences existed in cognitive test scores among the 3 groups. Results: A group of athletes with concussion performed significantly worse than a group of athletes with no injuries on the following subtests of the ANAM at follow-up: Code Substitution Learning, Match to Sample, and Simple Reaction. Athletes with musculoskeletal injuries performed significantly worse than those with no injury on the Match to Sample subtest. No significant differences between athletes with concussion and athletes with musculoskeletal injuries were found on all ANAM subtests. Conclusion: Concussion produces cognitive impairment in the acute recovery period. Interestingly, athletes with musculoskeletal injuries also display a degree of cognitive impairment as measured by computerized tests. Clinical Relevance: Although these findings support previous research that neuropsychological tests can effectively measure concussion-related cognitive impairment, this study provides evidence that athletic injury, in general, also may produce a degree of cognitive disruption. Therefore, a narrow interpretation of scores of neuropsychological tests in a sports concussion context should be avoided.	[Hutchison, Michael] Univ Toronto, Grad Dept Rehabil Sci, Fac Med, Toronto, ON M5G 1V7, Canada	Hutchison, M (corresponding author), Univ Toronto, Grad Dept Rehabil Sci, Fac Med, 500 Univ Ave, Toronto, ON M5G 1V7, Canada.	michael.hutchison@utoronto.ca			Faculty of Physical Education and Health, University of TorontoUniversity of Toronto; Varsity Blues athletic teams; Physicians Incorporated Services (PSI)	The authors thank the Faculty of Physical Education and Health, University of Toronto, and the coaches and athletes of the Varsity Blues athletic teams for their support and contribution. They also thank the research assistants of the University of Toronto Concussion Program, particularly Sam Esfandiari and Sandra Sokoloff, for their assistance in the preparation and review of the article. Finally, the research team is grateful to Physicians Incorporated Services (PSI) for financial support during the study period.	Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Holmes AJ, 2007, EMOTION, V7, P68, DOI 10.1037/1528-3542.7.1.68; Hutchison M, 2009, CLIN J SPORT MED, V19, P13, DOI 10.1097/JSM.0b013e318190ba06; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Jones WP, 2008, CLIN NEUROPSYCHOL, V22, P305, DOI 10.1080/13854040701281483; Kane RL, 2007, ARCH CLIN NEUROPSYCH, V22, pS115, DOI 10.1016/j.acn.2006.10.006; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; Mainwaring LM, 2010, BRAIN INJURY, V24, P589, DOI 10.3109/02699051003610508; MATHEWS A, 1990, BEHAV RES THER, V28, P455, DOI 10.1016/0005-7967(90)90132-3; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; RICHARDS D, 2009, BRIT J SPORT MED, V43, P98, DOI DOI 10.1136/BJSM.2008.046680; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa; Woodard J, 2002, J INT NEUROPSYCH SOC, V8, P175	35	33	33	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2011	39	11					2331	2337		10.1177/0363546511413375			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	838KG	WOS:000296287900007	21768531				2021-06-18	
J	Cuevas, J; Rodriguez, A; Behensky, A; Katnik, C				Cuevas, Javier; Rodriguez, Alex; Behensky, Adam; Katnik, Chris			Afobazole Modulates Microglial Function via Activation of Both sigma-1 and sigma-2 Receptors	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; HEAT-ACCLIMATED MICE; IN-VITRO; CORTICAL-NEURONS; CELLS; RATS; ISCHEMIA; LIGANDS; SENSOR	Microglial cells play a critical role in the neuroinflammatory response that accompanies various diseases of the central nervous system, such as ischemic stroke, and ATP is a major signaling molecule regulating the response of these cells to these pathophysiological conditions. Experiments were carried out to determine the effects of afobazole on microglial function and to identify the molecular mechanisms by which afobazole affects microglial cells. Afobazole was found to inhibit migration of microglial cells in response to ATP and UTP chemoattraction in a concentration-dependent manner. Inhibition of either sigma-1 or sigma-2 receptors decreased the effects of afobazole on microglia. In addition to inhibiting microglial cell migration, activation of sigma receptors by afobazole decreased intracellular calcium elevation produced by focal application of ATP and UTP in isolated microglial cells. Furthermore, afobazole blocked membrane currents elicited by rapid application of ATP in microglial cells. Taken together, our data indicate that afobazole inhibits microglial response to P2Y and P2X purinergic receptor activation by functioning as a pan-selective sigma-receptor agonist. In addition to modulating response to purinergic receptor activation, the effects of afobazole on microglial survival during in vitro ischemia were assessed. Application of afobazole during in vitro ischemia decreased microglial cell death during the ischemic episode and after a 24-h recovery period. Moreover, when afobazole was only applied after the ischemic episode, a significant enhancement in cell survival was still observed. Thus, afobazole acts via sigma receptors to decrease microglial response to ATP and provides cytoprotection during and after ischemia.	[Cuevas, Javier; Rodriguez, Alex; Behensky, Adam; Katnik, Chris] Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, Tampa, FL 33612 USA	Cuevas, J (corresponding author), Univ S Florida, Coll Med, Dept Mol Pharmacol & Physiol, 12901 Bruce B Downs Blvd,MDC-9, Tampa, FL 33612 USA.	jcuevas@health.usf.edu	Cuevas, Javier/I-4941-2012		RF Pharmaceuticals Sarl; MDR Pharmaceutical Limited	This study was supported by grants from RF Pharmaceuticals Sarl and MDR Pharmaceutical Limited (to J.C.).	Ajmo CT, 2006, CURR NEUROVASC RES, V3, P89, DOI 10.2174/156720206776875849; Basso AM, 2009, BEHAV BRAIN RES, V198, P83, DOI 10.1016/j.bbr.2008.10.018; Bucolo C, 2006, NEUROREPORT, V17, P287, DOI 10.1097/01.wnr.0000199469.21734.e1; Connor TJ, 1998, NEUROSCIENCE, V84, P923, DOI 10.1016/S0306-4522(97)00533-2; Cuevas J, 1998, J NEUROSCI, V18, P10335; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Galaeva IP, 2005, B EXP BIOL MED+, V140, P535, DOI 10.1007/s10517-006-0017-3; Ghelardini C, 2000, PHARMACOL BIOCHEM BE, V67, P659, DOI 10.1016/S0091-3057(00)00405-6; Hall AA, 2009, GLIA, V57, P744, DOI 10.1002/glia.20802; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Herrera Y, 2008, J PHARMACOL EXP THER, V327, P491, DOI 10.1124/jpet.108.143974; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Husbands SM, 1999, J MED CHEM, V42, P4446, DOI 10.1021/jm9902943; Katnik C, 2006, J PHARMACOL EXP THER, V319, P1355, DOI 10.1124/jpet.106.107557; Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lyons SA, 2000, J CEREBR BLOOD F MET, V20, P1537, DOI 10.1097/00004647-200011000-00003; Lyons SA, 1998, J CEREBR BLOOD F MET, V18, P521, DOI 10.1097/00004647-199805000-00007; MATSUMOTO RR, 1995, EUR J PHARMACOL, V280, P301, DOI 10.1016/0014-2999(95)00208-3; Narantuya D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011746; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; Rogove AD, 2002, CELL DEATH DIFFER, V9, P801, DOI 10.1038/sj.cdd.4401041; Seredenin SB, 2008, B EXP BIOL MED+, V145, P207, DOI 10.1007/s10517-008-0051-4; Seredenin SB, 2009, B EXP BIOL MED+, V148, P42, DOI 10.1007/s10517-009-0624-x; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Tuglu C, 2003, PSYCHOPHARMACOLOGY, V170, P429, DOI 10.1007/s00213-003-1566-z; Uyanaev AA, 2006, B EXP BIOL MED+, V142, P202, DOI 10.1007/s10517-006-0327-5; Weinstein JR, 2010, FUTUR NEUROL, V5, P227, DOI 10.2217/FNL.10.1; WU Z, 2003, SOC NEUROSCIENCE; Zenina TA, 2005, B EXP BIOL MED+, V140, P194, DOI 10.1007/s10517-005-0443-7; Zhang HL, 2002, J NEUROPHYSIOL, V87, P2867, DOI 10.1152/jn.2002.87.6.2867	35	33	36	0	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	2011	339	1					161	172		10.1124/jpet.111.182816			12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	821UC	WOS:000294998900018	21715561				2021-06-18	
J	Kelava, T; Cavar, I; Culo, F				Kelava, Tomislav; Cavar, Ivan; Culo, Filip			Biological actions of drug solvents	PERIODICUM BIOLOGORUM			English	Article						dimethylsulfoxide; propylene glycol; ethanol	DIMETHYL-SULFOXIDE DMSO; NF-KAPPA-B; CHRONIC ETHANOL-CONSUMPTION; TRAUMATIC BRAIN-INJURY; INDUCED LIVER-INJURY; NATURAL-KILLER-CELL; K-ATP CHANNELS; PROPYLENE-GLYCOL; DIMETHYLSULFOXIDE DMSO; NITRIC-OXIDE	Many biologic agents are weakly soluble in water Therefore, they should be dissolved in organic lipophilic solvents (vehicles). A drug vehicle is a substance of no therapeutic value that is used to convey an active biological agent to the site of its action. Ideally, it should be biocompatible, 100% reliable, with no biological effect per se. However; presently used vehicles have pleiotropic effects, which are often unknown to researchers, and often cause misleading conclusions. In this review we summarize data on biological effects of the three most commonly used lipophilic drug vehicles dimethylsulfoxide (DMSO), propylene glycol (PG) and ethanol. Besides in experimental models, the data, where available, are shown on effects of solvents in therapeutic use in humans. In conclusion, some recommendations are given on the use of drug solvents in experiments.	[Kelava, Tomislav] Univ Zagreb, Dept Physiol, Sch Med, Zagreb 10000, Croatia; [Cavar, Ivan; Culo, Filip] Univ Mostar, Dept Physiol, Sch Med, Mostar 88000, Bosnia & Herceg; [Culo, Filip] Univ Osijek, Dept Physiol, Sch Med, Osijek 31000, Croatia	Kelava, T (corresponding author), Univ Zagreb, Dept Physiol, Sch Med, Salata 3B, Zagreb 10000, Croatia.	tkelava@mef.hr	Culo, Filip/E-7115-2018	Culo, Filip/0000-0001-9493-3407; Kelava, Tomislav/0000-0002-6665-116X			Aita K, 2005, EXP MOL PATHOL, V79, P265, DOI 10.1016/j.yexmp.2005.07.001; ALI BH, 1990, CLIN EXP PHARMACOL P, V17, P463, DOI 10.1111/j.1440-1681.1990.tb01345.x; Ali BH, 2001, HUM EXP TOXICOL, V20, P199, DOI 10.1191/096032701678766859; ALI BH, 1989, PHARMACOLOGY, V39, P98, DOI 10.1159/000138583; ALKHUDHAIRI D, 1986, BRIT J ANAESTH, V58, P897, DOI 10.1093/bja/58.8.897; ALTURA BM, 1981, BRIT J PHARMACOL, V73, P580, DOI 10.1111/j.1476-5381.1981.tb16789.x; Baraona E, 2002, LIFE SCI, V70, P2987, DOI 10.1016/S0024-3205(02)01572-2; Bardutzky J, 2005, J CEREBR BLOOD F MET, V25, P968, DOI 10.1038/sj.jcbfm.9600095; BARTSCH W, 1976, ARZNEIMITTEL-FORSCH, V26, P1581; BAUER MC, 1992, VET HUM TOXICOL, V34, P127; Bautista AP, 1996, ALCOHOL CLIN EXP RES, V20, P1395, DOI 10.1111/j.1530-0277.1996.tb01139.x; BEBAROVA M, ACTA PHYSL OXF, V200, P301; BECKMAN DL, 1981, P SOC EXP BIOL MED, V168, P45; BENTEL JM, 1990, INT J CANCER, V46, P251, DOI 10.1002/ijc.2910460218; Bini R, 2008, J TRAUMA, V64, P1048, DOI 10.1097/TA.0b013e318059362e; BLACK JL, 1198, BR J CLIN PHARM, V18, P349; BROWN FD, 1980, J NEUROSURG, V53, P58, DOI 10.3171/jns.1980.53.1.0058; CATANZARO JM, 1991, J AM ACAD DERMATOL, V24, P90, DOI 10.1016/0190-9622(91)70018-W; CATE JC, 1980, NEW ENGL J MED, V303, P1237; Cavaletti G, 2000, TOXICOL LETT, V118, P103, DOI 10.1016/S0378-4274(00)00269-1; Cavar I, 2010, HISTOL HISTOPATHOL, V25, P819, DOI 10.14670/HH-25.819; Cavar I, 2009, COLLEGIUM ANTROPOL, V33, P25; Chang CK, 1999, J SURG RES, V82, P294, DOI 10.1006/jsre.1998.5527; Chang CK, 2001, J SURG RES, V95, P181, DOI 10.1006/jsre.2000.6033; Chen CH, 1999, P NATL ACAD SCI USA, V96, P12784, DOI 10.1073/pnas.96.22.12784; Choi H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013423; Choi S, 2009, XENOBIOTICA, V39, P205, DOI 10.1080/00498250802613620; Choudhury S. M., 2008, Al Ameen Journal of Medical Sciences, V1, P104; Churchill EN, 2009, J MOL CELL CARDIOL, V46, P278, DOI 10.1016/j.yjmcc.2008.09.713; CORNISH HH, 1977, ENVIRON HEALTH PERSP, V21, P149, DOI 10.2307/3428514; Das D, 1997, FREE RADICAL BIO MED, V23, P8, DOI 10.1016/S0891-5849(96)00547-3; DENNING DW, 1987, J PHARM PHARMACOL, V39, P236, DOI 10.1111/j.2042-7158.1987.tb06258.x; Di Giorgio AM, 2008, RESTOR NEUROL NEUROS, V26, P501; DOEKEL RC, 1978, J APPL PHYSIOL, V44, P76; DRUMMOND WH, 1989, EXP LUNG RES, V15, P447, DOI 10.3109/01902148909087870; EICHBAUM FW, 1976, BASIC RES CARDIOL, V71, P355, DOI 10.1007/BF01910774; Essani NA, 1997, SHOCK, V7, P90, DOI 10.1097/00024382-199702000-00003; EVANS MH, 1973, BRIT J PHARMACOL, V49, P651, DOI 10.1111/j.1476-5381.1973.tb08540.x; Fischer SJ, 2008, NEUROTOXICOLOGY, V29, P444, DOI 10.1016/j.neuro.2008.02.010; FORREST P, 1988, ANAESTH INTENS CARE, V16, P158, DOI 10.1177/0310057X8801600205; Fossum EN, 2008, BRAIN RES, V1204, P53, DOI 10.1016/j.brainres.2008.02.022; Fujimura N, 2000, AM J RESP CRIT CARE, V162, P2159, DOI 10.1164/ajrccm.162.6.9912144; GOODNOUGH J, 1980, SURG NEUROL, V13, P273; GORDON EL, 1995, J CEREBR BLOOD F MET, V15, P532, DOI 10.1038/jcbfm.1995.66; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Greenberg SS, 1999, ALCOHOL CLIN EXP RES, V23, P735, DOI 10.1111/j.1530-0277.1999.tb04177.x; Gross ER, 2001, ANESTH ANALG, V92, P299, DOI 10.1213/00000539-200102000-00003; HAIGLER HJ, 1981, LIFE SCI, V29, P1545, DOI 10.1016/0024-3205(81)90255-1; Hale S L, 2001, Heart Dis, V3, P293; HATTORI T, 1995, RES COMMUN MOL PATH, V88, P237; HATTORI T, 1993, FOOD CHEM TOXICOL, V31, P647, DOI 10.1016/0278-6915(93)90047-3; HAYES SN, 1988, CIRCULATION, V78, P165, DOI 10.1161/01.CIR.78.1.165; Hill DB, 2002, ALCOHOL CLIN EXP RES, V26, P74, DOI 10.1111/j.1530-0277.2002.tb02434.x; HUDSON RD, 1970, ARCH INT PHARMACOD T, V186, P388; Iida C, 2007, J NUTR SCI VITAMINOL, V53, P160, DOI 10.3177/jnsv.53.160; Iida M, 2003, ALCOHOL, V30, P175, DOI 10.1016/j.alcohol.2003.05.001; Jaeschke H, 2006, LIFE SCI, V78, P1670, DOI 10.1016/j.lfs.2005.07.003; Jareo PW, 1996, ALCOHOL CLIN EXP RES, V20, P1646, DOI 10.1111/j.1530-0277.1996.tb01711.x; Jaruga B, 2004, AM J PHYSIOL-GASTR L, V287, pG471, DOI 10.1152/ajpgi.00018.2004; Jiang GS, 2006, INT IMMUNOPHARMACOL, V6, P1204, DOI 10.1016/j.intimp.2006.02.014; Jo SK, 2004, J AM SOC NEPHROL, V15, P2648, DOI 10.1097/01.ASN.0000139933.20109.CB; KANESKI CR, 1991, PROSTATE, V18, P47, DOI 10.1002/pros.2990180105; Karaca M, 2002, NEUROL RES, V24, P73, DOI 10.1179/016164102101199567; Kato H, 2005, ALCOHOL CLIN EXP RES, V29, p285S, DOI 10.1097/01.alc.0000191809.29775.41; Kelava T, 2010, CAN J PHYSIOL PHARM, V88, P960, DOI [10.1139/Y10-065, 10.1139/y10-065]; Kim SJ, 2007, J APPL TOXICOL, V27, P25, DOI 10.1002/jat.1180; Kleindienst A, 2006, ACTA NEUROCHIR SUPPL, V96, P258; Koteish A, 2002, J BIOL CHEM, V277, P13037, DOI 10.1074/jbc.M101632200; KUNZE M, 1975, ANN NY ACAD SCI, V243, P308, DOI 10.1111/j.1749-6632.1975.tb25370.x; LEVETT JM, 1987, CRIT CARE MED, V15, P656, DOI 10.1097/00003246-198707000-00006; Lin HQ, 1998, J PHARM PHARMACOL, V50, P1127, DOI 10.1111/j.2042-7158.1998.tb03323.x; Lind RC, 1997, TOXICOL APPL PHARM, V142, P201, DOI 10.1006/taap.1996.8009; Lind RC, 1999, EXP TOXICOL PATHOL, V51, P537, DOI 10.1016/S0940-2993(99)80134-1; Lind RC, 2000, TOXICOL APPL PHARM, V166, P145, DOI 10.1006/taap.2000.8949; Lu C Y, 1992, J Tongji Med Univ, V12, P253; Lu CB, 2001, EXP NEUROL, V170, P180, DOI 10.1006/exnr.2001.7686; Mandrekar P, 2009, J IMMUNOL, V183, P1320, DOI 10.4049/jimmunol.0803206; Marumo M, 2010, ALCOHOL, V44, P343, DOI 10.1016/j.alcohol.2010.02.002; Mason CM, 2000, ALCOHOL CLIN EXP RES, V24, P553, DOI 10.1111/j.1530-0277.2000.tb02024.x; Masson MJ, 2008, HEPATOLOGY, V48, P889, DOI 10.1002/hep.22400; Matheus MG, 1997, BRAZ J MED BIOL RES, V30, P61, DOI 10.1590/S0100-879X1997000100009; Morshed KM, 1998, TOXICOL SCI, V46, P410, DOI 10.1006/toxs.1998.2521; MOURSI MM, 1983, STROKE, V14, P791, DOI 10.1161/01.STR.14.5.791; Mustafa S, 2007, CLIN PHYSIOL FUNCT I, V27, P185, DOI 10.1111/j.1475-097X.2007.00733.x; MUTHER RS, 1980, JAMA-J AM MED ASSOC, V244, P2081, DOI 10.1001/jama.244.18.2081; Nadruz W, 2004, AM J PHYSIOL-HEART C, V286, pH760, DOI 10.1152/ajpheart.00430.2003; Nishimura Y, 1999, RES COMMUN MOL PATH, V104, P229; Nishiyama D, 2002, HEPATOL RES, V23, P130, DOI 10.1016/S1386-6346(01)00168-1; Obregon ADC, 2005, NEUROCHEM RES, V30, P379, DOI 10.1007/s11064-005-2612-5; OSHIRO TT, 1990, GEN PHARMACOL, V21, P131, DOI 10.1016/0306-3623(90)90608-O; OWASOYO JO, 1981, TOXICOL LETT, V9, P267, DOI 10.1016/0378-4274(81)90159-4; Pagel PS, 2002, ANESTH ANALG, V94, P841, DOI 10.1097/00000539-200204000-00012; Pan HN, 2006, ALCOHOL CLIN EXP RES, V30, P1615, DOI 10.1111/j.1530-0277.2006.00194.x; Parisi A, 2010, J CARDIOVASC PHARM, V55, P106, DOI 10.1097/FJC.0b013e3181c87a65; Parkin J, 1997, UROLOGY, V49, P105, DOI 10.1016/S0090-4295(97)00181-7; PEARL RG, 1989, PHARMACOLOGY, V39, P383, DOI 10.1159/000138627; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PLUMMER JM, 1983, BIOCHEM PHARMACOL, V32, P151, DOI 10.1016/0006-2952(83)90668-8; Qi SH, 2010, NEUROSCIENCE, V167, P1125, DOI 10.1016/j.neuroscience.2010.02.018; Qi SH, 2009, BRAIN RES, V1276, P151, DOI 10.1016/j.brainres.2009.04.040; RANKIN GO, 1995, TOXICOLOGY, V100, P79, DOI 10.1016/0300-483X(95)93709-D; RAY SD, 1990, FUND APPL TOXICOL, V15, P429, DOI 10.1016/0272-0590(90)90029-J; Regoli F, 1999, TOXICOL APPL PHARM, V156, P96, DOI 10.1006/taap.1999.8637; Rosemberg DB, 2010, NEUROSCIENCE, V171, P683, DOI 10.1016/j.neuroscience.2010.09.030; Rubin R, 1999, ALCOHOL CLIN EXP RES, V23, P1114, DOI 10.1111/j.1530-0277.1999.tb04234.x; RUMBEIHA WK, 1992, VET HUM TOXICOL, V34, P21; Sahin M, 2004, TRANSPL P, V36, P2590, DOI 10.1016/j.transproceed.2004.09.057; Saini M, 2001, INDIAN J ANIM SCI, V71, P16; SALIM AS, 1992, J PHARM SCI, V81, P943, DOI 10.1002/jps.2600810921; SALIM AS, 1993, SURG GYNECOL OBSTET, V176, P484; Santos NC, 2003, BIOCHEM PHARMACOL, V65, P1035, DOI 10.1016/S0006-2952(03)00002-9; Sapp DW, 1998, J PHARMACOL EXP THER, V284, P768; SATO C, 1981, GASTROENTEROLOGY, V80, P140; Shimizu S, 1997, NEUROSCI LETT, V239, P125, DOI 10.1016/S0304-3940(97)00915-4; SHIRLEY S W, 1978, Urology, V11, P215, DOI 10.1016/0090-4295(78)90118-8; SINGH PP, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1443; SMITH RS, 1992, MED HYPOTHESES, V39, P248, DOI 10.1016/0306-9877(92)90117-U; Sood R, 2007, J MAGN RESON IMAGING, V25, P39, DOI 10.1002/jmri.20802; SORBYE H, 1993, DIGEST DIS SCI, V38, P1243, DOI 10.1007/BF01296073; Steiner AA, 2007, J NEUROSCI, V27, P7459, DOI 10.1523/JNEUROSCI.1483-07.2007; SWANSON B N, 1985, Reviews in Clinical and Basic Pharmacology, V5, P1; Szabo G, 1996, ALCOHOL CLIN EXP RES, V20, P900, DOI 10.1111/j.1530-0277.1996.tb05269.x; TAMASHIRO H, 1986, J TOXICOL ENV HEALTH, V18, P595, DOI 10.1080/15287398609530897; Thirkill TL, 1997, J CELL BIOCHEM, V65, P460, DOI 10.1002/(SICI)1097-4644(19970615)65:4<460::AID-JCB2>3.0.CO;2-M; THOMSEN MS, 1995, PHARMACOL TOXICOL, V76, P395, DOI 10.1111/j.1600-0773.1995.tb00168.x; Titova E, 2007, CLIN EXP PHARMACOL P, V34, P845, DOI 10.1111/j.1440-1681.2007.04664.x; TOIVANEN J, 1984, THROMB RES, V33, P1, DOI 10.1016/0049-3848(84)90149-X; Trevisani M, 2004, J PHARMACOL EXP THER, V309, P1167, DOI 10.1124/jpet.103.064162; Valenzuela CF, 1997, ALCOHOL HEALTH RES W, V21, P144; Vasdev S, 2006, MOL CELL BIOCHEM, V287, P53, DOI 10.1007/s11010-005-9058-6; Vinson RB, 1998, AM J PHYSIOL-REG I, V275, pR1049; Vrsalovic M, 2007, J CARDIOVASC PHARM, V50, P462, DOI 10.1097/FJC.0b013e31812378fb; Wang Q, 2007, FREE RADICAL BIO MED, V43, P1048, DOI 10.1016/j.freeradbiomed.2007.06.018; Weber TP, 2003, ANESTH ANALG, V96, P665, DOI 10.1213/01.ANE.0000048712.95074.CD; WEETMAN DF, 1982, METHOD FIND EXP CLIN, V4, P99; Wieslander G, 2001, OCCUP ENVIRON MED, V58, P649, DOI 10.1136/oem.58.10.649; WILLMORE LJ, 1984, BRAIN RES, V296, P389, DOI 10.1016/0006-8993(84)90080-5; Wong CK, 2004, TOXICOL MECH METHOD, V14, P167, DOI 10.1080/15376520490429364; WONG LT, 1980, TOXICOLOGY, V17, P297, DOI 10.1016/0300-483X(80)90011-6; Yamagishi Y, 2002, AM J PHYSIOL-GASTR L, V282, pG640, DOI 10.1152/ajpgi.00171.2001; Yamaguchi T, 2003, FREE RADICAL BIO MED, V34, P365, DOI 10.1016/S0891-5849(02)01292-3; Yogi A, 2010, CLIN SCI, V118, P657, DOI 10.1042/CS20090352; Yoon MY, 2006, BIOL PHARM BULL, V29, P1618, DOI 10.1248/bpb.29.1618; Zar T, 2007, SEMIN DIALYSIS, V20, P217, DOI 10.1111/j.1525-139X.2007.00280.x; ZAROSLINSKI JF, 1971, TOXICOL APPL PHARM, V19, P573, DOI 10.1016/0041-008X(71)90289-4; Zhou HZ, 2002, AM J PHYSIOL-HEART C, V283, pH165, DOI 10.1152/ajpheart.00408.2001; Zink BJ, 2006, J NEUROSURG, V105, P884, DOI 10.3171/jns.2006.105.6.884; ZOREFSHANI E, 1994, J CANCER RES CLIN, V120, P717, DOI 10.1007/BF01194269	148	33	33	0	19	PERIODICUM BIOLOGORUM	ZAGREB	HRVATSKO PRIRODOSLOVNO DRUSTVO ILICA 16/111, 41000 ZAGREB, CROATIA	0031-5362			PERIOD BIOL	Period. Biol.	OCT	2011	113	3					311	320					10	Biology	Life Sciences & Biomedicine - Other Topics	864DD	WOS:000298216300005					2021-06-18	
J	Koponen, S; Taiminen, T; Hiekkanen, H; Tenovuo, O				Koponen, Salla; Taiminen, Tero; Hiekkanen, Heli; Tenovuo, Olli			Axis I and II psychiatric disorders in patients with traumatic brain injury: A 12-month follow-up study	BRAIN INJURY			English	Article						Brain injuries; mental disorders; personality disorders	POSTTRAUMATIC-STRESS-DISORDER; COMORBIDITY; ALCOHOL; PREVALENCE; MOOD	Objective: To evaluate the occurrence of axis I and II psychiatric disorders among patients with traumatic brain injury (TBI). Design: Prospective observational study. Forty-five adult patients, who had attended an emergency unit because of TBI, were recruited. At 12 months, 38 patients were interviewed. Measures: Psychiatric disorders were evaluated using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) and the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II). Results: Before TBI, the 12-month rate of axis I psychiatric disorders was relatively high (39.5%) and the rate of alcohol dependence was especially elevated (18.4%). During the 12 months after TBI, axis I disorders were found in 47.4% of subjects. Six patients (15.8%) were found to have a disorder with an onset after TBI. Of these, five patients had depressive disorders (13.2%). Almost one third of the subjects (29.0%) had personality disorders. Antisocial and obsessive-compulsive personality disorders were the most frequent (10.5%). Conclusions: Both axis I and II psychiatric disorders are common among patients with TBI. Alcohol dependence and personality disorders are prevalent in individuals prone to TBI, whereas depressive disorders typically develop after injury. Psychiatric disorders should be addressed in rehabilitation, as otherwise they will hinder the recovery after TBI.	[Koponen, Salla] Univ Helsinki, Dept Psychiat, SF-00180 Helsinki, Finland; [Taiminen, Tero] Turku Univ Hosp, Dept Psychiat, FIN-20520 Turku, Finland; [Hiekkanen, Heli] Jyvaskyla Cent Hosp, Dept Neurol, Jyvaskyla, Finland; [Tenovuo, Olli] Turku Univ Hosp, Dept Neurol, FIN-20520 Turku, Finland	Koponen, S (corresponding author), Univ Helsinki, Dept Psychiat, POB 590, FI-00029 Helsinki, Finland.	salla.koponen@helsinki.fi			Finnish Medical Society Duodecim	This study was supported by the Finnish Medical Society Duodecim. The authors report no conflicts of interest.	Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Deb S, 1999, AM J PSYCHIAT, V156, P374; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; First MB., 1997, STRUCTURED CLIN INTE; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Lenzenweger MF, 2007, BIOL PSYCHIAT, V62, P553, DOI 10.1016/j.biopsych.2006.09.019; Mild Traumatic Brain Injury Committee of the Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHABI, V8, P86; Pirkola SP, 2005, SOC PSYCH PSYCH EPID, V40, P1, DOI 10.1007/s00127-005-0848-7; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Statistical Analysis Software, 2006, SAS ENT GUID 4 1; STEIN SC, 1996, NEUROTRAUMA; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589	25	33	33	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2011	25	11					1029	1034		10.3109/02699052.2011.607783			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	829WC	WOS:000295614900001	21870901				2021-06-18	
J	Rigg, JL; Mooney, SR				Rigg, John L.; Mooney, Scott R.			Concussions and the Military: Issues Specific to Service Members	PM&R			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; BODY SKILLS GROUPS; POSTCONCUSSIVE SYMPTOMS; BASE RATES; RANDOMIZED-TRIAL; DEPRESSION; INTERVENTIONS; ASSOCIATION; AFGHANISTAN	Since October 2001, more than 1.6 million American military service members have deployed to Iraq and Afghanistan in the Global War on Terrorism. It is estimated that between 5% and 35% of them have sustained a concussion, also called mild traumatic brain injury (mTBI), during their deployment. Up to 80% of the concussions experienced in theater are secondary to blast exposures. The unique circumstances and consequences of sustaining a concussion in combat demands a unique understanding and treatment plan. The current literature was reviewed and revealed a paucity of pathophysiological explanations on the nature of the injury and informed treatment plans. However, through observation and experience, a theoretical but scientifically plausible model for why and how blast injuries experienced in combat give rise to the symptoms that affect day-to-day function of service members who have been concussed has been developed. We also are able to offer treatment strategies based on our evaluation of the current literature and experience to help palliate postconcussive symptoms. The purpose of this review is to elucidate common physical, cognitive, emotional, and situational challenges, and possible solutions for this special population of patients who will be transitioning into the civilian sector and interfacing with health professionals. There is a need for further investigation and testing of these strategies. PM R 2011;3:S380-S386	[Rigg, John L.; Mooney, Scott R.] Dwight D Eisenhower Army Med Ctr, Traumat Brain Injury Program, Neurosci & Rehabil Ctr, Ft Gordon, GA USA	Rigg, JL (corresponding author), Dwight D Eisenhower Army Med Ctr, Traumat Brain Injury Program, Neurosci & Rehabil Ctr, Ft Gordon, GA USA.	john.l.rigg@us.army.mil					Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bisson JI, 2007, BRIT J PSYCHIAT, V190, P97, DOI 10.1192/bjp.bp.106.021402; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Bolton P, 2007, JAMA-J AM MED ASSOC, V298, P519, DOI 10.1001/jama.298.5.519; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Farag E, 2011, MINERVA ANESTESIOL, V77, P366; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gordon JS, 2008, J CLIN PSYCHIAT, V69, P1469, DOI 10.4088/JCP.v69n0915; Gordon JS, 2004, J TRAUMA STRESS, V17, P143, DOI 10.1023/B:JOTS.0000022620.13209.a0; Hanna-Pladdy B, 2001, CLIN NEUROPSYCHOL, V15, P289, DOI 10.1076/clin.15.3.289.10272; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hosek JR, 2006, MG432RC RAND CORP; Hovda D, DIRECTOR UCLA BRAIN; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kochanek PA, 2003, JAMA-J AM MED ASSOC, V289, P3007, DOI 10.1001/jama.289.22.3007; Lange RT, 2008, CLIN NEUROPSYCHOL, V22, P209, DOI 10.1080/13854040701290062; Larabee GP, 2005, ASSESSMENT MALINGERE; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McCrea M, 2008, MILD TRAUMATIC BRAIN; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Ness D, 2010, J NEUROL PHYS THER, V31, P30; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Paniak C, 2000, BRAIN INJURY, V14, P219; Sacho RH, 2010, J NEUROTRAUM, V27, P2157, DOI 10.1089/neu.2010.1384; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shapiro AP, 2004, BRIT J PSYCHIAT, V185, P140, DOI 10.1192/bjp.185.2.140; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Silver FW, 1996, AM J PHYS MED REHAB, V75, P134, DOI 10.1097/00002060-199603000-00013; Spencer RJ, 2010, J REHABIL RES DEV, V47, P521, DOI 10.1682/JRRD.2009.11.0181; Staples JK, 2005, ALTERN THER HEALTH M, V11, P36; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	50	33	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S380	S386		10.1016/j.pmrj.2011.08.005			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	966YK	WOS:000305873100005	22035680				2021-06-18	
J	Watson, WL; Mitchell, R				Watson, W. L.; Mitchell, R.			Conflicting trends in fall-related injury hospitalisations among older people: variations by injury type	OSTEOPOROSIS INTERNATIONAL			English	Article						Fall injury; Fractures; Injury epidemiology; Non-fracture injury; Older persons	NEW-SOUTH-WALES; TRAUMATIC BRAIN-INJURY; HIP FRACTURE RATES; NURSING-HOME; AUSTRALIA; IMPACT; EPIDEMIOLOGY; ADMISSION; ADULTS; COSTS	Despite advances in prevention, fall-related hospitalisation rates among older people are still increasing. Rates between 1998/1999 and 2008/2009 for non-facture-related injuries increased by 6.1% while fracture injuries declined by -0.4%. Varying trends in rates of different injury types makes it difficult to provide a definitive explanation for these changes. Introduction Despite advances in fall prevention research and practice, the rate of fall-related hospitalisations continues to increase. However, hip fracture rates appear to be declining. An examination of trends in types of injuries that contribute to the overall fall injury rate is required to establish which injuries are driving the falls admission rate. The aim of this paper is to examine trends in fall-related injury hospital admissions by injury type in New South Wales (NSW), Australia. Methods A retrospective review of fall-related injury hospitalisations in NSW among individuals aged 65+ years, by injury type, was conducted from 1 July 1998 to 30 June 2009. Direct age-standardised admission rates were calculated. Negative binomial regression was used to examine the statistical significance of changes in trend over time of different hospitalised fall-related injuries. Results The fall-related hospitalisation rate increased by 1.7% each year (p < 0.0001; 95% confidence interval (CI), 1.3-2.1%). However, the rate of fracture declined by -0.4% (p < 0.03; 95% CI, -0.8-0.0%); whereas, the non-fracture rate increased by 6.1% (p < 0.0001; 95% CI, 5.5-6.7%) annually. Rates for severe head injuries, rib and pelvic fracture increased while those for hip and forearm fracture declined. Conclusions It appears that while fall prevention efforts in NSW are not yet affecting the overall rate of injury hospitalisation, there has been a significant decline in the rates of some fractures. Opposing trends in the rates of other fracture admissions and a significant increase in the rate of non-fracture injuries associated with falls makes a definitive explanation for these changes difficult.	[Watson, W. L.; Mitchell, R.] Univ New S Wales, NSW Injury Risk Management Res Ctr, Kensington, NSW 2052, Australia; [Mitchell, R.] Univ New S Wales, Sch Aviat, Kensington, NSW 2052, Australia	Watson, WL (corresponding author), Univ New S Wales, NSW Injury Risk Management Res Ctr, Kensington, NSW 2052, Australia.	w.watson@unsw.edu.au	Mitchell, Rebecca J/J-6105-2012; Mitchell, Rebecca/Z-5476-2019	Mitchell, Rebecca J/0000-0003-1939-1761; Mitchell, Rebecca/0000-0003-1939-1761	NSW Health Department; ARCAustralian Research Council [LP0990057]	W. Watson was supported by the NSW Health Department. R. Mitchell was partially supported by the NSW Health Department and by an ARC-linkage post-doctoral fellowship (LP0990057).	Abrahamsen B, 2010, OSTEOPOROSIS INT, V21, P373, DOI 10.1007/s00198-009-0957-3; Armitage P, 2002, STAT METHODS MED RES; Boufous S, 2004, MED J AUSTRALIA, V180, P623, DOI 10.5694/j.1326-5377.2004.tb06124.x; Boufous S, 2005, INJURY, V36, P1323, DOI 10.1016/j.injury.2005.02.008; Boufous S, 2005, INJURY PREV, V11, P334, DOI 10.1136/ip.2005.009837; Boufous S, 2006, BONE, V39, P1144, DOI 10.1016/j.bone.2006.05.011; Bradley C, 2008, HOSPITALISATIONS DUE, P38; Centre for Epidemiology and Research, 2006, HLTH OUTC INF STAT T; Centre for Health Advancement and Centre for Epidemiology and Research, 2010, NEW S WAL FALLS PREV; Chung MC, 2009, INT J GERIATR PSYCH, V24, P955, DOI 10.1002/gps.2201; Cumming RG, 2000, J GERONTOL A-BIOL, V55, pM299, DOI 10.1093/gerona/55.5.M299; Dimai H, 2010, OSTEOPOROSI IN PRESS, P1; DOBSON AJ, 1991, STAT MED, V10, P457, DOI 10.1002/sim.4780100317; DOWNTON JH, 1990, INT J GERIATR PSYCH, V5, P93, DOI 10.1002/gps.930050206; Fisher AA, 2009, BONE, V45, P246, DOI 10.1016/j.bone.2009.04.244; Hartholt KA, 2010, ARCH INTERN MED, V170, P905, DOI 10.1001/archinternmed.2010.106; Hindmarsh DM, 2009, OSTEOPOROSIS INT, V20, P221, DOI 10.1007/s00198-008-0641-z; Jaglal SB, 2005, J BONE MINER RES, V20, P898, DOI 10.1359/JBMR.041231; Jamieson LM, 2007, INJURY PREV, V13, P243, DOI 10.1136/ip.2007.015354; Kannus P, 2002, J BONE MINER RES, V17, P1363, DOI 10.1359/jbmr.2002.17.8.1363; Kannus P, 2008, BONE, V43, P340, DOI 10.1016/j.bone.2008.04.015; Kannus P, 2008, J GERONTOL A-BIOL, V63, P642, DOI 10.1093/gerona/63.6.642; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Kannus P, 2006, J BONE MINER RES, V21, P1836, DOI 10.1359/JBMR.060815; Kannus P, 2009, BONE, V44, P656, DOI 10.1016/j.bone.2008.12.007; Kelsey Jennifer L, 2009, Curr Osteoporos Rep, V7, P127; Koskinen S, 2008, BRAIN INJURY, V22, P205, DOI 10.1080/02699050801938975; Langley J, 2011, OSTEOPOROSIS INT, V22, P105, DOI 10.1007/s00198-010-1205-6; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leslie WD, 2009, JAMA-J AM MED ASSOC, V302, P883, DOI 10.1001/jama.2009.1231; Lord SR, 2007, FALLS IN OLDER PEOPLE: RISK FACTORS AND STRATEGIES FOR PREVENTION, 2ND EDITION, P1, DOI 10.1017/CBO9780511722233; Melton L, 2009, OSTEOPOROSIS INT, V20, P687, DOI 10.1007/s00198-008-0742-8; National Centre for Classification in Health, 2006, INT STAT CLASS DIS R; NSW Department of Health Public Health Division, 2000, NEW S WAL OLD PEOPL; NSW Health Quality and Safety Branch, 2008, POL DIR CLOS HEAD IN; Nymark T, 2006, ACTA ORTHOP, V77, P109, DOI 10.1080/17453670610045777; Orces CH, 2009, AGEING RES, V1, pe1, DOI DOI 10.4081/AR.2010.E1; Population Health Division, 2008, HLTH PEOPL NEW S WAL; Rogmark C, 1999, ACTA ORTHOP SCAND, V70, P19, DOI 10.3109/17453679909000950; SAS Institute, 2003, SAS STAT SOFTW VERS; Scuffham P, 2003, J EPIDEMIOL COMMUN H, V57, P740, DOI 10.1136/jech.57.9.740; Stevens JA, 2006, INJURY PREV, V12, P290, DOI 10.1136/ip.2005.011015; Stevens JA, 2010, AGE AGEING, V39, P500, DOI 10.1093/ageing/afq044; TINETTI ME, 1993, J GERONTOL, V48, P35, DOI 10.1093/geronj/48.Special_Issue.35; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; Watson W, 2010, AUSTR NZ J IN PRESS	46	33	34	0	4	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0937-941X	1433-2965		OSTEOPOROSIS INT	Osteoporosis Int.	OCT	2011	22	10					2623	2631		10.1007/s00198-010-1511-z			9	Endocrinology & Metabolism	Endocrinology & Metabolism	819BT	WOS:000294801100007	21161644				2021-06-18	
J	Ziebell, JM; Bye, N; Semple, BD; Kossmann, T; Morganti-Kossmann, MC				Ziebell, Jenna M.; Bye, Nicole; Semple, Bridgette D.; Kossmann, Thomas; Morganti-Kossmann, Maria Cristina			Attenuated neurological deficit, cell death and lesion volume in Fas-mutant mice is associated with altered neuroinflammation following traumatic brain injury	BRAIN RESEARCH			English	Article						Cell death; Caspase; Cytokine; Fas; Neuroinflammation; Traumatic brain injury	TUMOR-NECROSIS-FACTOR; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; TNF-ALPHA; NEUTROPHIL INFILTRATION; MONOCLONAL-ANTIBODY; EXPRESSION; APOPTOSIS; LIGAND; RAT	Progressive neurodegeneration following traumatic brain injury (TBI) involves the Fas and TNF-receptor1 protein systems which have been implicated in mediating delayed cell death. In this study, we used two approaches to assess whether inhibition of these pathways reduced secondary brain damage and neurological deficits after TBI. Firstly, we investigated whether the expression of non-functional Fas in lpr mice subjected to TBI altered tissue damage and neurological outcome. Compared to wild-type, lpr mice showed improved neurological deficit (p=0.0009), decreased lesion volume (p=0.017), number of TUNEL+cells (p=0.011) and caspase-3+ cells (p=0.007). Changes in cellular inflammation and cytokine production were also compared between mouse strains. Accumulation of macrophages/microglia occurred earlier in lpr mice, likely due to enhanced production of the chemotactic mediators IL-12(p40) and MCP-1 (p<0.05). Cortical production of IL-1 alpha and IL-6 increased after injury to a similar extent regardless of strain (p<0.05), while TNT and G-CSF were significantly higher in lpr animals (p<0.05). Secondly, we assessed whether therapeutic inhibition of FasL and TNF via intravenous injection of neutralizing antibodies in wild-type mice post-TBI could reproduce the beneficial effects observed in lpr animals. No differences were found with this approach in animals treated with anti-FasL and anti-TNF antibodies alone or the combination of both. Altogether, reduced neurological deficits and lesion volume in lpr mice was associated with altered cellular and humoral inflammation, possibly contributing to neuroprotection, whereas neutralization of FasL and TNF had no effect. In future studies, the lpr mouse strain may be utilized as a model to further characterize molecular and cellular mechanisms protecting against secondary brain damage after TBI. (C) 2011 Elsevier B.V. All rights reserved.	[Ziebell, Jenna M.; Bye, Nicole; Semple, Bridgette D.; Morganti-Kossmann, Maria Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Ziebell, Jenna M.; Bye, Nicole; Semple, Bridgette D.; Morganti-Kossmann, Maria Cristina] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Kossmann, Thomas] EpworthHealth, Melbourne, Vic, Australia	Morganti-Kossmann, MC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, 89 Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@monash.edu	Ziebell, Jenna/Y-4496-2019	Morganti-Kossmann, Cristina/0000-0002-0807-2063; Ziebell, Jenna/0000-0003-2497-4347	Victorian Neurotrauma Initiative (VNI); Transport Accident Commission (TAC); Bethlehem Griffiths Research Foundation; L.E.W. Carty Charitable Fund	The authors would like to thank Dr Ian Musgrave for his advice on nonparametric data analysis. This study was supported by the Victorian Neurotrauma Initiative (VNI) program grant and Senior research Fellowship to CM-K, Transport Accident Commission (TAC), Bethlehem Griffiths Research Foundation and L.E.W. Carty Charitable Fund.	Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conti AC, 1998, J NEUROSCI, V18, P5663; Cooper AM, 2007, TRENDS IMMUNOL, V28, P33, DOI 10.1016/j.it.2006.11.002; Davoli MA, 2002, NEUROSCIENCE, V115, P125, DOI 10.1016/S0306-4522(02)00376-7; Demjen D, 2004, NAT MED, V10, P389, DOI 10.1038/nm1007; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; Faherty CJ, 1999, MOL BRAIN RES, V70, P159, DOI 10.1016/S0169-328X(99)00143-6; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fujikawa DG, 2002, J NEUROCHEM, V83, P229, DOI 10.1046/j.1471-4159.2002.01152.x; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hutchison JS, 2001, J NEUROTRAUM, V18, P1333, DOI 10.1089/08977150152725632; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Letellier E, 2010, IMMUNITY, V32, P240, DOI 10.1016/j.immuni.2010.01.011; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Mehmet H, 2001, CELL DEATH DIFFER, V8, P659, DOI 10.1038/sj.cdd.4400899; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Qiu JH, 2002, J NEUROSCI, V22, P3504; Sabelko KA, 1997, J IMMUNOL, V159, P3096; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Schroeter M, 2003, MOL BRAIN RES, V117, P1, DOI 10.1016/S0169-328X(03)00255-9; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Yang JS, 2010, J NEUROTRAUM, V27, P1037, DOI 10.1089/neu.2009.1229; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; Yoshimoto T, 1998, J IMMUNOL, V160, P588; Yoshino O, 2004, SPINE, V29, P1394, DOI 10.1097/01.BRS.0000129894.34550.48; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	47	33	35	1	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	SEP 26	2011	1414						94	105		10.1016/j.brainres.2011.07.056			12	Neurosciences	Neurosciences & Neurology	830MI	WOS:000295660700011	21871613				2021-06-18	
J	Li, Y; Zhang, LY; Kallakuri, S; Zhou, RZ; Cavanaugh, JM				Li, Yan; Zhang, Liying; Kallakuri, Srinivasu; Zhou, Runzhou; Cavanaugh, John M.			Quantitative Relationship between Axonal Injury and Mechanical Response in a Rodent Head Impact Acceleration Model	JOURNAL OF NEUROTRAUMA			English	Article						corpus callosum; head impact acceleration model; linear and angular head motion; rat; traumatic axonal injury	TRAUMATIC BRAIN-INJURY; INTRAAXONAL NEUROFILAMENT COMPACTION; CONTROLLED CORTICAL IMPACT; OPTIC-NERVE; RAT MODEL; AXOLEMMAL PERMEABILITY; DIFFUSE; DAMAGE; BIOMECHANICS; EXPRESSION	A modified Marmarou impact acceleration model was developed to study the mechanical responses induced by this model and their correlation to traumatic axonal injury (TAI). Traumatic brain injury (TBI) was induced in 31 anesthetized male Sprague-Dawley rats (392 +/- 13 g) by a custom-made 450-g impactor from heights of 1.25 m or 2.25 m. An accelerometer and angular rate sensor measured the linear and angular responses of the head, while the impact event was captured by a high-speed video camera. TAI distribution along the rostro-caudal direction, as well as across the left and right hemispheres, was determined using beta-amyloid precursor protein (beta-APP) immunocytochemistry, and detailed TAI injury maps were constructed for the entire corpus callosum. Peak linear acceleration 1.25 m and 2.25 m impacts were 666 +/- 165 g and 907 +/- 501 g, respectively. Peak angular velocities were 95 +/- 24 rad/sec and 124 +/- 48 rad/sec, respectively. Compared to the 2.25-m group, the observed TAI counts in the 1.25-m impact group were significantly lower. Average linear acceleration, peak angular velocity, average angular acceleration, and surface righting time were also significantly different between the two groups. A positive correlation was observed between normalized total TAI counts and average linear acceleration (R-2=0.612, p < 0.05), and time to surface right (R-2=0.545, p < 0.05). Our study suggested that a 2.25-m drop in the Marmarou model may not always result in a severe injury, and TAI level is related to the linear and angular acceleration response of the rat head during impact, not necessarily the drop height.	[Li, Yan; Zhang, Liying; Kallakuri, Srinivasu; Zhou, Runzhou; Cavanaugh, John M.] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA	Zhang, LY (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock St, Detroit, MI 48201 USA.	lzhang@wayne.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 EB006508]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB006508] Funding Source: NIH RePORTER	The work was supported by National Institutes of Health grant R01 EB006508.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; Carre E, 2004, J NEUROSCI METH, V140, P23, DOI 10.1016/j.jneumeth.2004.04.037; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Czeiter E, 2008, J NEUROTRAUM, V25, P205, DOI 10.1089/neu.2007.0331; Dieterich DC, 2002, NEUROSCI LETT, V317, P29, DOI 10.1016/S0304-3940(01)02418-1; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fei Z, 2007, BMC NEUROSCI, V8, DOI 10.1186/1471-2202-8-96; Fei Z, 2006, J CLIN NEUROSCI, V13, P1023, DOI 10.1016/j.jocn.2005.11.042; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gilchrist MD, 2004, STRAIN, V40, P180, DOI 10.1111/j.1475-1305.2004.00168.x; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Kallakuri S, 2007, NEUROL RES, V29, P362, DOI 10.1179/016164107X204675; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; King A.I., 2003, IRCOBI C LISB PORT, P1; KING AI, 1995, J NEUROTRAUM, V12, P651, DOI 10.1089/neu.1995.12.651; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Marmarou A, 2006, ACTA NEUROCHIR SUPPL, V96, P24; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MEANEY DF, 1993, CRASHWORTHINESS OCCU, V169, P169; Park CO, 2001, YONSEI MED J, V42, P518, DOI 10.3349/ymj.2001.42.5.518; Pascual JM, 2007, J NEUROTRAUM, V24, P944, DOI 10.1089/neu.2006.0190; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Piper IR, 1996, J NEUROSCI METH, V69, P171, DOI 10.1016/S0165-0270(96)00046-5; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; PRASAD P, 1985, 851246 SAE; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Rhodes JKJ, 2002, NEUROSCI LETT, V335, P1, DOI 10.1016/S0304-3940(02)00811-X; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Sawauchi S, 2004, J NEUROTRAUM, V21, P563, DOI 10.1089/089771504774129892; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Sengul G, 2008, J CLIN NEUROSCI, V15, P1125, DOI 10.1016/j.jocn.2007.11.005; Shafieian M, 2009, J BIOMECH, V42, P2136, DOI 10.1016/j.jbiomech.2009.05.041; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Ueda T, 2001, MOL BRAIN RES, V86, P63, DOI 10.1016/S0169-328X(00)00261-8; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Wang HC, 2010, J NEUROTRAUM, V27, P707, DOI 10.1089/neu.2009.1071; Wang HC, 2010, J CLIN NEUROSCI, V17, P157, DOI 10.1016/j.jocn.2009.07.099; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Zhang L, 2001, Stapp Car Crash J, V45, P369; ZHANG L, 2010, P IBIA 8 WORLD C BRA; ZHANG L, 2010, J NEUROTRAUM, V26, pA18; ZHANG L, 2005, P ASME BIOENG C 5480; ZHANG L, 2011, J NEUROTRAUMA, V28, pA26; Zhang LY, 2011, J NEUROSCI METH, V198, P93, DOI 10.1016/j.jneumeth.2011.03.024; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	87	33	34	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1767	1782		10.1089/neu.2010.1687			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000010	21895482	Green Published			2021-06-18	
J	Ma, HY; Yu, B; Kong, L; Zhang, YY; Shi, YX				Ma, Haiying; Yu, Bo; Kong, Li; Zhang, Yuanyuan; Shi, Yuxiu			Transplantation of neural stem cells enhances expression of synaptic protein and promotes functional recovery in a rat model of traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						neural stem cell; transplantation; traumatic brain injury; synaptogenesis	FLUID PERCUSSION INJURY; SPINAL-CORD; BEHAVIORAL RECOVERY; ADULT-RAT; GAP-43; MICE; HIPPOCAMPUS; NEURONS; CORTEX; MOUSE	Transplantion of neural stem cells (NSCs) has shown promise for the treatment of traumatic brain injury (TBI). Although the functional mechanisms underlying transplant-mediated recovery following TBI have yet to be determined, previous studies demonstrated that transplanted NSCs may respond to the release of specific neurotransmitters, and/or the production of factors that promote neuronal growth. Therefore, we hypothesize that the direct transplantation of NSCs into the injured brain enhanced the expression of synaptic protein and regeneration-associated protein, which may be responsible for promoting functional recovery in a rat model of TBI. Our results showed that NSC transplant significantly improved neurological motor function in selected behavioral tests compared to saline control rats. Our data showed that the number of surviving cells engrafted into the rats was 4.1 +/- 0.9% of engrafted cells at 8 weeks post-transplantation, with 11.4 +/- 1.6% beta III-tubulin-immunopositive cells of these cells. RT-PCR and Western blot analysis demonstrated that the expression of synaptophysin (SYP) and regeneration-associated protein (GAP43) in the injured brain of NSC-transplanted rats was significantly increased compared to the saline control rats during the experimental period. These data suggest that NSCs transplanted directly into the injured brain are capable of surviving, differentiating into neurons and promoting functional recovery in a rat model of TBI. Engrafted NSCs increase the expression of SYP and GAP43 in the injured brain of NSC-transplanted rats, which is suggested as one of the mechanisms underlying the improved functional recovery on motor behavior due to the transplantation of NSCs following TBI.	[Ma, Haiying; Kong, Li; Shi, Yuxiu] China Med Univ, Dept Histol & Embryol, Inst Pathol & Pathophysiol, Shenyang 110001, Peoples R China; [Yu, Bo] China Med Univ, Shengjing Hosp, Dept Neurosurg, Shenyang 110004, Peoples R China; [Ma, Haiying; Kong, Li; Zhang, Yuanyuan] Dalian Med Univ, Dept Histol & Embryol, Liaoning 116044, Peoples R China; [Zhang, Yuanyuan] Wake Forest Inst Regenerat Med, Winston Salem, NC 27157 USA	Shi, YX (corresponding author), China Med Univ, Dept Histol & Embryol, Inst Pathol & Pathophysiol, 92 Beima Rd, Shenyang 110001, Peoples R China.	yuxiushi@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30850001]; Education Bureau, Liaoning Province, China [2008779, 2008851]	This study was supported by grants from the National Natural Science Foundation of China (No. 30850001) and the S&T Research Project of the Education Bureau, Liaoning Province, China (No. 2008779 and 2008851). We thank Professor Xuehu Ma and Associate Professor Shui Guan from the Stem Cell and Tissue Engineering Laboratory of Dalian University of Technology for their support in culturing NSCs.	AEBISCHER P, 1994, EXP NEUROL, V126, P151, DOI 10.1006/exnr.1994.1053; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Benninger Y, 2000, BRAIN PATHOL, V10, P330; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; Buffo A, 2003, EUR J NEUROSCI, V18, P2146, DOI 10.1046/j.1460-9568.2003.02940.x; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Fauza DO, 2008, SURGERY, V144, P367, DOI 10.1016/j.surg.2008.05.009; Fournier AE, 1997, J NEUROSCI RES, V47, P561, DOI 10.1002/(SICI)1097-4547(19970315)47:6<561::AID-JNR1>3.3.CO;2-Q; Fricker-Gates RA, 2001, RESTOR NEUROL NEUROS, V19, P119; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hughes-Davis EJ, 2005, NEUROSCIENCE, V135, P1231, DOI 10.1016/j.neuroscience.2005.07.017; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; JACOBS KM, 1993, J COMP NEUROL, V336, P151, DOI 10.1002/cne.903360112; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Kong L, 2010, NEUROBIOL DIS, V38, P446, DOI 10.1016/j.nbd.2010.03.005; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liebau S, 2007, STEM CELLS, V25, P1720, DOI 10.1634/stemcells.2006-0823; Lubjuhn J, 2009, J NEUROSCI METH, V184, P95, DOI 10.1016/j.jneumeth.2009.07.029; Ma XH, 2010, CRYOBIOLOGY, V60, P184, DOI 10.1016/j.cryobiol.2009.10.013; MASLIAH E, 1994, ACTA NEUROPATHOL, V87, P135; Modo M, 2002, STROKE, V33, P2270, DOI 10.1161/01.STR.0000027693.50675.C5; Mothe AJ, 2008, EXP NEUROL, V213, P176, DOI 10.1016/j.expneurol.2008.05.024; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Shojo H, 2010, NEUROSCIENCE, V171, P1273, DOI 10.1016/j.neuroscience.2010.10.018; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4	32	33	37	0	8	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997			MOL MED REP	Mol. Med. Rep.	SEP-OCT	2011	4	5					849	856		10.3892/mmr.2011.510			8	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	801JQ	WOS:000293435300013	21687946	Bronze			2021-06-18	
J	Picard, C; Pasquier, F; Martinaud, O; Hannequin, D; Godefroy, O				Picard, Candice; Pasquier, Florence; Martinaud, Olivier; Hannequin, Didier; Godefroy, Olivier			Early Onset Dementia Characteristics in a Large Cohort From Academic Memory Clinics	ALZHEIMER DISEASE & ASSOCIATED DISORDERS			English	Article						dementia; Alzheimer's disease; frontotemporal lobar degeneration; lewy body dementia; alcoholic dementia	DIAGNOSTIC-CRITERIA; INTERNATIONAL WORKSHOP; PREVALENCE; FREQUENCY; CONSENSUS; DISEASE	Aim: To describe the characteristics of early-onset dementia (EOD) in a cohort from 3 memory clinics. Methods: We assessed all patients with dementia referred to the Academic Memory Clinics at Amiens, Lille, and Rouen University Medical Centers between 2005 and 2007. Patients aged less than 65 years at the time of onset of symptom were included in the EOD group, whereas older patients were included in the late-onset dementia (LOD) group. Results: Three thousand four hundred and seventy-three patients (including 1932 women) were included and 811 (23.4%) were classified as EOD. The sex ratio was 1.12, whereas women were overrepresented in LOD (P = 0.001). Patients with EOD were more frequently (P = 0.001) living at home (87.3%), they had a lower educational level than the general population (P = 0.0001) but were more educated (P = 0.001). The current Mini Mental State Examination did not differ (P = 0.3) between EOD (18.6 +/- 7.6) and LOD (18.9 +/- 6). The most common causes of EOD were Alzheimer's (22.3%) and vascular (15.9%) diseases and 4 pathologies that were significantly more frequent (P = 0.001) than in the LOD group: frontotemporal dementia (9.7%), alcohol-related dementia (9.4%), traumatic brain injury (3.8%), and Huntington's disease (3%). Conclusions: EOD is characterized by specific features and different causes although Alzheimer's and vascular dementias remain the main causes of dementia in EOD.	[Picard, Candice; Godefroy, Olivier] Univ Hosp Amiens, Dept Neurol, Amiens, France; [Martinaud, Olivier; Hannequin, Didier] Lille Nord France, UDSL EA 1046, Lille, France; [Martinaud, Olivier; Hannequin, Didier] INSERM, F-75654 Paris 13, France; [Martinaud, Olivier; Hannequin, Didier] Rouen CNR MAJ, Rouen, France	Picard, C (corresponding author), Hop Nord Amiens, Picard Serv Neurol, F-80054 Amiens, France.	picard.candice@chu-amiens.fr	Godefroy, Olivier/D-6117-2012; Martinaud, Olivier/AAS-9307-2020; Pasquier, Florence/F-1527-2017	Pasquier, Florence/0000-0001-9880-9788; Godefroy, Olivier/0000-0001-6789-6620			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Emre M, 2007, MOVEMENT DISORD, V22, P1689, DOI 10.1002/mds.21507; Harvey RJ, 2003, J NEUROL NEUROSUR PS, V74, P1206, DOI 10.1136/jnnp.74.9.1206; *HAS, 2008, DIAGN TREATM; HOFMAN A, 1991, INT J EPIDEMIOL, V20, P736, DOI 10.1093/ije/20.3.736; Ikejima C, 2009, STROKE, V40, P2709, DOI 10.1161/STROKEAHA.108.542308; Kelley BJ, 2008, ARCH NEUROL-CHICAGO, V65, P1502, DOI 10.1001/archneur.65.11.1502; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; McMurtray A, 2006, DEMENT GERIATR COGN, V21, P59, DOI 10.1159/000089546; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Oslin D, 1998, INT J GERIATR PSYCH, V13, P203, DOI 10.1002/(SICI)1099-1166(199804)13:4<203::AID-GPS734>3.0.CO;2-B; Panegyres Peter K, 2007, Am J Alzheimers Dis Other Demen, V22, P48, DOI 10.1177/1533317506295887; Papageorgiou SG, 2009, ALZ DIS ASSOC DIS, V23, P347, DOI 10.1097/WAD.0b013e31819e6b28; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Shinagawa S, 2007, DEMENT GERIATR COGN, V24, P42, DOI 10.1159/000102596; Yokota O, 2005, EUR J NEUROL, V12, P782, DOI 10.1111/j.1468-1331.2005.01072.x	18	33	35	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0893-0341			ALZ DIS ASSOC DIS	Alzheimer Dis. Assoc. Dis.	JUL-SEP	2011	25	3					203	205		10.1097/WAD.0b013e3182056be7			3	Clinical Neurology; Pathology	Neurosciences & Neurology; Pathology	811JW	WOS:000294206600003	21192236				2021-06-18	
J	McAllister, TW; Flashman, LA; McDonald, BC; Ferrell, RB; Tosteson, TD; Yanofsky, NN; Grove, MR; Saykin, AJ				McAllister, Thomas W.; Flashman, Laura A.; McDonald, Brenna C.; Ferrell, Richard B.; Tosteson, Tor D.; Yanofsky, Norman N.; Grove, Margaret R.; Saykin, Andrew J.			Dopaminergic Challenge With Bromocriptine One Month After Mild Traumatic Brain Injury: Altered Working Memory and BOLD Response	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							COGNITIVE FUNCTION; MECHANISMS; MODULATION; EXPRESSION; DEFICITS; TASK; LOAD	Catecholamines, particularly dopamine, modulate working memory (WM). Altered sensitivity to dopamine might play a role in WM changes observed after traumatic brain injury (TBI). Thirty-one healthy controls (HC) and 26 individuals with mild TBI (MTBI) 1 month after injury were challenged with bromocriptine versus placebo before administration of a verbal WM functional MRI task. Bromocriptine was associated with improved WM performance in the HC but not the MTBI group. On bromocriptine, the MTBI group showed increased activation outside of a task-specific region of interest. Findings are consistent with the hypothesis that individuals with MTBI have altered responsivity to dopamine. (The Journal of Neuropsychiatry and Clinical Neurosciences 2011; 23:277-286)	Dartmouth Med Sch, Dept Psychiat, Sect Neuropsychiat, Lebanon, NH USA; Indiana Univ Sch Med, Ctr Neuroimaging, Dept Radiol & Imaging Sci, Indianapolis, IN USA; Dartmouth Med Sch, Dept Community & Family Med, Lebanon, NH USA; Dartmouth Med Sch, Sect Emergency Med, Lebanon, NH USA	McAllister, TW (corresponding author), Dartmouth Hitchcock Med Ctr, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	; Saykin, Andrew/A-1318-2007	Ferrell, Richard/0000-0002-7492-210X; Saykin, Andrew/0000-0002-1376-8532	NIDRR [H133G70031, H133000136]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS40472-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD047242, R01HD048176] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW000018] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG019771, P30AG010133] Funding Source: NIH RePORTER	This research was supported in part by NIDRR Grants H133G70031 and H133000136, and NIH Grant R01 NS40472-01.	Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Arnsten A F, 1998, Adv Pharmacol, V42, P764; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; ARNSTEN AFT, 1994, PSYCHOPHARMACOLOGY, V116, P143, DOI 10.1007/BF02245056; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Cai JX, 1997, J PHARMACOL EXP THER, V283, P183; Chen KW, 2004, NEUROIMAGE, V22, P134, DOI 10.1016/j.neuroimage.2004.01.002; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; DELLIS DC, 2001, DELISKAPLAN EXECUTIV; First MB., 1997, STRUCTURED CLIN INTE; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gordon M., 1986, GORDON DIAGNOSTIC SY; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI DOI 10.1016/S1053-8119(18)31587-8; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; PIZZOLATO G, 1985, BRAIN RES, V341, P303, DOI 10.1016/0006-8993(85)91069-8; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; *PSYCH CORP, 1997, WAIS 3 WAIS WMS 3 WE; Seamans JK, 1998, J NEUROSCI, V18, P1613; Spreen O., 1998, COMPENDIUM NEUROPSYC, P447; Verbois SL, 2002, J NEUROTRAUM, V19, P1569, DOI 10.1089/089771502762300238; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Whyte J, 2008, AM J PHYS MED REHAB, V87, P85, DOI 10.1097/PHM.0b013e3181619609; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Wolfson D., 1993, HALSTEAD REITAN NEUR	45	33	35	0	3	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2011	23	3					277	286					10	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	822BI	WOS:000295018300004	21948888	Green Accepted			2021-06-18	
J	Yuan, TF; Arias-Carrion, O				Yuan, Ti-Fei; Arias-Carrion, Oscar			Adult Neurogenesis in the Hypothalamus: Evidence, Functions and Implications	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Neurogenesis; hypothalamus; third ventricle; proliferation; bromodeoxyuridine; proliferating cell nuclear antigen; Ki67; neural stem cell; cell transplantation	CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; TRAUMATIC BRAIN-INJURY; OLFACTORY-BULB; HIPPOCAMPAL NEUROGENESIS; POSTNATAL NEUROGENESIS; SUBVENTRICULAR ZONE; NEUROTROPHIC FACTOR; MAMMALIAN BRAIN; SUPRACHIASMATIC NUCLEUS	Neurogenesis occurs in the adult brain in a constitutive manner under physiological circumstances within two regions: the dentate gyrus of the hippocampus and the subventricular zone of the lateral ventricles. In contrast to these two so-called neurogenic areas, other regions of the brain were considered to be primarily non-neurogenic in nature, implying that no new neurons were formed there under normal conditions. Recently, low proliferative activity was reported in the hypothalamus and the cell layers surrounding the third ventricle. This review summarizes recent evidence for adult neurogenesis in the hypothalamus, and points out the potential contributions of these new neurons to neural processing. We also discussed some technical considerations in investigating neurogenesis in the adult hypothalamus. It is believed that the hypothalamus could serve as a new source and target for stem cell transplantation.	[Arias-Carrion, Oscar] Univ Marburg, Dept Neurol, D-35033 Marburg, Germany; [Yuan, Ti-Fei] NCI, Shanghai 200001, Peoples R China	Arias-Carrion, O (corresponding author), Univ Marburg, Dept Neurol, Baldingerstr, D-35033 Marburg, Germany.	arias@exp-neuro.de	Arias-Carrion, Oscar/A-4248-2018	Arias-Carrion, Oscar/0000-0002-9982-7571	Forderverein Neurologie Marburg	The authors would like to thank Melissa Sinding M.Sc., for editing the manuscript. OA-C was supported in part by the Forderverein Neurologie Marburg.	Alonso M, 2006, J NEUROSCI, V26, P10508, DOI 10.1523/JNEUROSCI.2633-06.2006; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Arias-Carrion O, 2007, REV NEUROLOGIA, V45, P739, DOI 10.33588/rn.4512.2007245; Arias-Carrion Oscar, 2007, CNS & Neurological Disorders-Drug Targets, V6, P326, DOI 10.2174/187152707783220875; Arias-Carrion O, 2009, J NEURAL TRANSM-SUPP, P279, DOI 10.1007/978-3-211-92660-4_23; Arias-Carrion O, 2009, MED HYPOTHESES, V73, P757, DOI 10.1016/j.mehy.2009.04.029; Bath KG, 2010, DEV NEUROBIOL, V70, P339, DOI 10.1002/dneu.20781; Becker S, 2007, TRENDS COGN SCI, V11, P70, DOI 10.1016/j.tics.2006.10.013; Belsham DD, 2009, FASEB J, V23, P4256, DOI 10.1096/fj.09-133454; Bernier PJ, 2002, P NATL ACAD SCI USA, V99, P11464, DOI 10.1073/pnas.172403999; Bhardwaj RD, 2006, P NATL ACAD SCI USA, V103, P12564, DOI 10.1073/pnas.0605177103; Breton-Provencher V, 2009, J NEUROSCI, V29, P15245, DOI 10.1523/JNEUROSCI.3606-09.2009; Breunig JJ, 2007, CELL STEM CELL, V1, P612, DOI 10.1016/j.stem.2007.11.008; Cameron HA, 2008, BIOL PSYCHIAT, V63, P650, DOI 10.1016/j.biopsych.2007.09.023; Chen G, 2006, J NEUROBIOL, V66, P537, DOI 10.1002/neu.20247; Chen K, 2007, MOL CELL NEUROSCI, V36, P108, DOI 10.1016/j.mcn.2007.06.004; Cho KO, 2010, ARCH PHARM RES, V33, P1475, DOI 10.1007/s12272-010-1002-y; Chojnacki AK, 2009, NAT REV NEUROSCI, V10, P153, DOI 10.1038/nrn2571; Chow Tiffany W, 2007, Neuropsychiatr Dis Treat, V3, P627; DAVIS FC, 1990, BRAIN RES, V519, P192, DOI 10.1016/0006-8993(90)90077-O; DEVITRY F, 1980, P NATL ACAD SCI-BIOL, V77, P4165, DOI 10.1073/pnas.77.7.4165; Dhanushkodi A, 2008, NEUROSCI BIOBEHAV R, V32, P657, DOI 10.1016/j.neubiorev.2007.10.004; Doetsch F, 2005, CURR OPIN NEUROBIOL, V15, P121, DOI 10.1016/j.conb.2005.01.018; Doetsch F, 1997, J NEUROSCI, V17, P5046; Eisch AJ, 2007, CURR PHARM BIOTECHNO, V8, P147; Fan Y, 2007, EUR J NEUROSCI, V25, P38, DOI 10.1111/j.1460-9568.2006.05269.x; Fowler CD, 2005, J COMP NEUROL, V489, P166, DOI 10.1002/cne.20638; Fowler CD, 2002, J NEUROBIOL, V51, P115, DOI 10.1002/neu.10042; Fowler CD, 2008, BRAIN RES REV, V57, P342, DOI 10.1016/j.brainresrev.2007.06.011; Geoghegan D, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-2; Gould E, 1999, SCIENCE, V286, P548, DOI 10.1126/science.286.5439.548; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; Hawken PAR, 2009, BIOL REPROD, V80, P1146, DOI 10.1095/biolreprod.108.075341; Hess DC, 2008, CELL PROLIFERAT, V41, P94, DOI 10.1111/j.1365-2184.2008.00486.x; Huang LY, 1998, J NEUROBIOL, V36, P410, DOI 10.1002/(SICI)1097-4695(19980905)36:3<410::AID-NEU8>3.0.CO;2-Z; Ihrie RA, 2008, CELL TISSUE RES, V331, P179, DOI 10.1007/s00441-007-0461-z; IQBAL J, 1995, DEV BRAIN RES, V85, P151, DOI 10.1016/0165-3806(94)00189-7; Jansen HT, 1998, BRAIN RES BULL, V45, P27, DOI 10.1016/S0361-9230(97)00279-7; Jiao J, 2008, STEM CELLS, V26, P1221, DOI 10.1634/stemcells.2007-0513; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kokoeva MV, 2007, J COMP NEUROL, V505, P209, DOI 10.1002/cne.21492; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Lazarini F, 2011, TRENDS NEUROSCI, V34, P20, DOI 10.1016/j.tins.2010.09.006; Lazarini F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007017; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lledo PM, 2005, TRENDS NEUROSCI, V28, P248, DOI 10.1016/j.tins.2005.03.005; Lopez-Toledano MA, 2010, J ALZHEIMERS DIS, V20, P395, DOI 10.3233/JAD-2010-1388; Loseva E, 2009, BRAIN RES REV, V59, P374, DOI 10.1016/j.brainresrev.2008.10.004; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Moraes JC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005045; Mu YL, 2010, CURR OPIN NEUROBIOL, V20, P416, DOI 10.1016/j.conb.2010.04.010; Padilla SL, 2010, NAT MED, V16, P403, DOI 10.1038/nm.2126; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Pencea V, 2001, J NEUROSCI, V21, P6706; Pierce AA, 2010, J NEUROSCI, V30, P723, DOI 10.1523/JNEUROSCI.2479-09.2010; PRICE JL, 1991, J COMP NEUROL, V306, P447, DOI 10.1002/cne.903060309; Rankin SL, 2003, BRAIN RES, V971, P189, DOI 10.1016/S0006-8993(03)02350-3; Raymond AD, 2006, BRAIN RES, V1102, P44, DOI 10.1016/j.brainres.2006.04.113; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; SERESS L, 1985, DEV BRAIN RES, V22, P156, DOI 10.1016/0165-3806(85)90080-X; Seri B, 2004, J COMP NEUROL, V478, P359, DOI 10.1002/cne.20288; Shepherd GM, 2007, BRAIN RES REV, V55, P373, DOI 10.1016/j.brainresrev.2007.03.005; Snapyan M, 2009, J NEUROSCI, V29, P4172, DOI 10.1523/JNEUROSCI.4956-08.2009; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Taupin P, 2006, CURR OPIN MOL THER, V8, P225; Thompson CK, 2009, J NEUROSCI, V29, P4586, DOI 10.1523/JNEUROSCI.5423-08.2009; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Young KM, 2007, J NEUROSCI, V27, P5146, DOI 10.1523/JNEUROSCI.0654-07.2007; Yuan TF, 2010, CELL TISSUE RES, V340, P211, DOI 10.1007/s00441-010-0964-x; Zhang L, 2011, EUR J NEUROSCI, V33, P1, DOI 10.1111/j.1460-9568.2010.7483.x; Zhang RL, 2005, NEUROSCIENTIST, V11, P408, DOI 10.1177/1073858405278865; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033	80	33	33	1	18	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	JUN	2011	10	4					433	439		10.2174/187152711795563985			7	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	777PG	WOS:000291634700004	21495965				2021-06-18	
J	Luh, C; Gierth, K; Timaru-Kast, R; Engelhard, K; Werner, C; Thal, SC				Luh, Clara; Gierth, Katharina; Timaru-Kast, Ralph; Engelhard, Kristin; Werner, Christian; Thal, Serge C.			Influence of a Brief Episode of Anesthesia during the Induction of Experimental Brain Trauma on Secondary Brain Damage and Inflammation	PLOS ONE			English	Article							INCOMPLETE CEREBRAL-ISCHEMIA; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD TRAUMA; INTRACRANIAL-PRESSURE; ARTERIAL-HYPERTENSION; RATS; INJURY; ISOFLURANE; MICE; SEVOFLURANE	It is unclear whether a single, brief, 15-minute episode of background anesthesia already modulates delayed secondary processes after experimental brain injury. Therefore, this study was designed to characterize three anesthesia protocols for their effect on molecular and histological study endpoints. Mice were randomly separated into groups that received sevoflurane (sevo), isoflurane (iso) or an intraperitoneal anesthetic combination (midazolam, fentanyl and medetomidine; comb) prior to traumatic brain injury (controlled cortical impact, CCI; 8 m/s, 1 mm impact depth, 3 mm diameter). Twenty-four hours after insult, histological brain damage, neurological function (via neurological severity score), cerebral inflammation (via real-time RT-PCR for IL6, COX-2, iNOS) and microglia (via immunohistochemical staining for Iba1) were determined. Fifteen minutes after CCI, the brain contusion volume did not differ between the anesthetic regimens (sevo = 17.9 +/- 5.5 mm 3; iso = 20.5 +/- 3.7 mm(3); comb = 19.5 +/- 4.6 mm(3)). Within 24 hours after injury, lesion size increased in all groups (sevo = 45.3 +/- 9.0 mm(3); iso = 31.5 +/- 4.0 mm(3); comb = 44.2 +/- 6.2 mm(3)). Sevo and comb anesthesia resulted in a significantly larger contusion compared to iso, which was in line with the significantly better neurological function with iso (sevo = 4.6 +/- 1.3 pts.; iso = 3.9 +/- 0.8 pts.; comb = 5.1 +/- 1.6 pts.). The expression of inflammatory marker genes was not significantly different at 15 minutes and 24 hours after CCI. In contrast, significantly more Iba1-positive cells were present in the pericontusional region after sevo compared to comb anesthesia (sevo = 181 +/- 48/mm(3); iso = 150 +/- 36/mm(3); comb = 113 +/- 40/mm(3)). A brief episode of anesthesia, which is sufficient for surgical preparations of mice for procedures such as delivering traumatic brain injury, already has a significant impact on the extent of secondary brain damage.	[Luh, Clara; Gierth, Katharina; Timaru-Kast, Ralph; Engelhard, Kristin; Werner, Christian; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany; [Luh, Clara] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Med Ctr, D-6500 Mainz, Germany	Luh, C (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729			Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Brecht M, 2004, NATURE, V427, P704, DOI 10.1038/nature02266; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Engelhard K, 1999, BRIT J ANAESTH, V83, P415; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HATASHITA S, 1986, J NEUROSURG, V64, P643, DOI 10.3171/jns.1986.64.4.0643; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; JANSSEN BJ, 2004, AM J PHYSL HEART CIR; Khosrovani S, 2007, P NATL ACAD SCI USA, V104, P15911, DOI 10.1073/pnas.0702727104; Kongstad L, 2001, J TRAUMA, V51, P490, DOI 10.1097/00005373-200109000-00011; Li L, 2009, NEUROSCIENCE, V164, P497, DOI 10.1016/j.neuroscience.2009.08.011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matchett GA, 2009, NEUROL RES, V31, P128, DOI 10.1179/174313209X393546; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ozsuer H, 2005, NEUROSURG REV, V28, P143, DOI 10.1007/s10143-004-0374-1; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; Solt K, 2006, ANESTH ANALG, V102, P1407, DOI 10.1213/01.ane.0000204252.07406.9f; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wen YS, 2007, ENDOCRINOLOGY, V148, P1313, DOI 10.1210/en.2006-0665; WERNER C, 1995, BRIT J ANAESTH, V75, P756, DOI 10.1093/bja/75.6.756; Yurdakoc A, 2008, ACTA ANAESTH SCAND, V52, P658, DOI 10.1111/j.1399-6576.2008.01635.x; ZORNOW MH, 1992, ANESTH ANALG, V75, P232; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	31	33	34	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2011	6	5							e19948	10.1371/journal.pone.0019948			8	Multidisciplinary Sciences	Science & Technology - Other Topics	766HI	WOS:000290771200032	21625505	DOAJ Gold, Green Published			2021-06-18	
J	Tepas, JJ; Pracht, EE; Orban, BL; Flint, LM				Tepas, Joseph J., III; Pracht, Etienne E.; Orban, Barbara L.; Flint, Lewis M.			Insurance Status, Not Race, Is a Determinant of Outcomes from Vehicular Injury	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article; Proceedings Paper	122nd Annual Meeting of the Southern-Surgical-Association	DEC, 2010	Palm Beach, FL	So Surg Assoc			ETHNIC DISPARITIES; RACIAL-DIFFERENCES; TRAUMA CENTERS; MORTALITY; CARE; SURVIVAL; SYSTEM	BACKGROUND: Hypothesizing that outcomes from specific injury mechanisms should not vary by race or socioeconomic status, we analyzed the relationship of race and ethnicity to fatality in motor vehicle crash victims treated during 2008 and 2009. STUDY DESIGN: Logistic regression analysis of pooled administrative data assessed the contribution of patient demographics and injury severity to outcome, defined as mortality during acute hospitalization. Demographic factors included age, sex, race, ethnicity, and insurance. Severe injury was defined using ICD-9 Injury Severity Score (survival probability) p < 0.85, presence of up to 3 comorbidities, and/or diagnosis of spinal cord injury and/or traumatic brain injury. Mortality was stratified by survival time after trauma center arrival to death within 24 hours or thereafter. Factors contributing to outcomes were tested using chi square analysis of the calculated model estimate. RESULTS: For 8,758 motor vehicle crash victims treated in state-designated trauma centers, age, sex, injury severity, and 2 or more comorbidities consistently predicted survival. Neither race nor ethnicity was associated with increased mortality risk. Being uninsured was related to death within 24 hours (p < 0.001). The majority of the uninsured who died within 24 hours had an ICD-9 Injury Severity Score p <= 0.5. Mortality risk after 24 hours was driven by traumatic brain injury and comorbidities. CONCLUSIONS: The results of this study indicated that higher immediate mortality of the uninsured is a behavioral and socioeconomic rather than physiologic marker. This higher mortality is driven by increased injury severity that increases cost of care in uninsured survivors. This disparity suggests that risk-taking behavior, especially relating to safety practices and licensing regulations, is an important etiologic factor. Improved outcomes require better public education and enforcement in conjunction with improvements in processes of care. (J Am Coll Surg 2011; 212:722-729. (C) 2011 by the American College of Surgeons)	[Tepas, Joseph J., III] Univ Florida, Hlth Sci Ctr, Dept Surg, Jacksonville, FL 32209 USA; [Orban, Barbara L.] Univ S Florida, Coll Publ Hlth, Jacksonville, FL USA; [Flint, Lewis M.] Univ S Florida, Dept Hlth Policy & Management, Jacksonville, FL USA; [Pracht, Etienne E.] Amer Coll Surg, Chicago, IL USA	Tepas, JJ (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Surg, 655 W 8th St, Jacksonville, FL 32209 USA.						Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Crompton JG, 2010, AM J SURG, V200, P191, DOI 10.1016/j.amjsurg.2009.07.047; Dillingham TR, 2002, ARCH PHYS MED REHAB, V83, P1252, DOI 10.1053/apmr.2002.34805; Durham R, 2006, ANN SURG, V243, P775, DOI 10.1097/01.sla.0000219644.52926.f1; Greene WR, 2010, AM J SURG, V199, P554, DOI 10.1016/j.amjsurg.2009.11.005; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Hart T, 2007, J HEAD TRAUMA REHAB, V22, P122, DOI 10.1097/01.HTR.0000265100.37059.44; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 1999, J TRAUMA, V47, pS34, DOI 10.1097/00005373-199909001-00008; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Maybury RS, 2010, SURGERY, V148, P202, DOI 10.1016/j.surg.2010.05.010; Mullins RJ, 1998, J TRAUMA, V44, P609, DOI 10.1097/00005373-199804000-00009; Osler T, 1996, J TRAUMA, V41, P380, DOI 10.1097/00005373-199609000-00002; Osler TM, 1998, J TRAUMA, V45, P234, DOI 10.1097/00005373-199808000-00006; Pracht EE, 2007, MED CARE RES REV, V64, P83, DOI 10.1177/1077558706296241; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; Smith WR, 2007, ANN INTERN MED, V147, P654, DOI 10.7326/0003-4819-147-9-200711060-00010; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Tyburski JG, 1998, J TRAUMA, V45, P237	21	33	33	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	APR	2011	212	4					722	727		10.1016/j.jamcollsurg.2010.12.016			6	Surgery	Surgery	748YU	WOS:000289430000058	21463821				2021-06-18	
J	Hsieh, CT; Chen, GJ; Ma, HI; Chang, CF; Cheng, CM; Su, YH; Ju, DT; Hsia, CC; Chen, YH; Wu, HY; Liu, MY				Hsieh, Cheng-Ta; Chen, Guann-Juh; Ma, Hsin-I; Chang, Cheng-Fu; Cheng, Cheng-Ma; Su, Yih-Huei; Ju, Da-Tong; Hsia, Chung-Ching; Chen, Yuan-Hao; Wu, Hao-Yiang; Liu, Ming-Ying			The misplacement of external ventricular drain by freehand method in emergent neurosurgery	ACTA NEUROLOGICA BELGICA			English	Article						Hydrocephalus; traumatic brain injury; ventriculostomy; subarachnoid hemorrhages; stroke	PLACEMENT; GUIDE	External ventricular drain (EVD) placement is one of the most basic and common neurosurgical procedure which most was performed by young neurosurgical trainees. This study is conducted to determinate the safe and accuracy of Er VD placement by freehand method. About 129 EVD placements were evaluated in this study. Eighty-three catheters (64.3%) were located in the ipsilateral frontal horn or third ventricle. The functional accuracy was 86%. Of eighteen misplaced catheters, only 4 (3.1%) catheters were nonfunctional, requiring a replacement or reposition. The higher misplaced rate was significantly observed in patients whose head CT scans revealed the lower hydrocephalus ratio (28.85%) and the smaller ventricular size (5.6mm). Twenty-one (16.2%) new hemorrhages associated with EVD placements were observed. Using the freehand method, EVD placement is a safe and effective procedure in management of these emergent neurosurgical diseases.	[Hsieh, Cheng-Ta; Chen, Guann-Juh; Ma, Hsin-I; Chang, Cheng-Fu; Cheng, Cheng-Ma; Su, Yih-Huei; Ju, Da-Tong; Hsia, Chung-Ching; Chen, Yuan-Hao; Wu, Hao-Yiang; Liu, Ming-Ying] Tri Serv Gen Hosp, Dept Neurol Surg, Natl Def Med Ctr, Taipei, Taiwan; [Hsieh, Cheng-Ta] Taipei Med Univ, Taipei Med Univ Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan	Liu, MY (corresponding author), Tri Serv Gen Hosp, Dept Neurol Surg, Natl Def Med Ctr, 325,Sec 2,Cheng Kung Rd, Taipei, Taiwan.	nogor@mail2000.com.tw					Anderson RCE, 2004, J NEUROSURG, V101, P53, DOI 10.3171/ped.2004.101.2.0053; BOGDAHN U, 1992, NEUROSURGERY, V31, P898, DOI 10.1227/00006123-199211000-00011; Gardner PA, 2009, J NEUROSURG, V110, P1021, DOI 10.3171/2008.9.JNS17661; GHAJAR JBG, 1985, J NEUROSURG, V63, P985, DOI 10.3171/jns.1985.63.6.0985; Huyette DR, 2008, J NEUROSURG, V108, P88, DOI 10.3171/JNS/2008/108/01/0088; Kakarla UK, 2008, NEUROSURGERY, V63, P162, DOI 10.1227/01.NEU.0000312390.83127.7F; Khan SH, 1998, ACT NEUR S, V71, P50; KHANNA RK, 1995, J NEUROSURG, V83, P791, DOI 10.3171/jns.1995.83.5.0791; Krotz M, 2004, EUR RADIOL, V14, P227, DOI 10.1007/s00330-003-2134-y; Lind CRP, 2008, J CLIN NEUROSCI, V15, P886, DOI 10.1016/j.jocn.2007.05.013; Lind CRP, 2009, J CLIN NEUROSCI, V16, P918, DOI 10.1016/j.jocn.2008.09.015; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; O'Leary ST, 2000, J NEUROSURG, V92, P801, DOI 10.3171/jns.2000.92.5.0801; Prat R, 2009, CLIN NEUROL NEUROSUR, V111, P579, DOI 10.1016/j.clineuro.2009.04.008; Roitberg BZ, 2001, BRIT J NEUROSURG, V15, P324; Saladino A, 2009, NEUROCRIT CARE, V10, P248, DOI 10.1007/s12028-008-9154-z; Stangl AP, 1998, SURG NEUROL, V50, P77, DOI 10.1016/S0090-3019(97)00301-7	17	33	33	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0300-9009	2240-2993		ACTA NEUROL BELG	Acta Neurol. Belg.	MAR	2011	111	1					22	28					7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	743HR	WOS:000289009500005	21510229				2021-06-18	
J	Thomas, DG; Collins, MW; Saladino, RA; Frank, V; Raab, J; Zuckerbraun, NS				Thomas, Danny G.; Collins, Michael W.; Saladino, Richard A.; Frank, Virginia; Raab, Jenny; Zuckerbraun, Noel S.			Identifying Neurocognitive Deficits in Adolescents Following Concussion	ACADEMIC EMERGENCY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; COLLEGE FOOTBALL PLAYERS; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; HEAD-INJURIES; IMPACT; RECOVERY; PERFORMANCE; SYMPTOMS	P>Objectives: This study of concussed adolescents sought to determine if a computer-based neurocognitive assessment (Immediate Postconcussion Assessment and Cognitive Test [ImPACT]) performed on patients who present to the emergency department (ED) immediately following head injury would correlate with assessments performed 3 to 10 days postinjury and if ED neurocognitive testing would detect differences in concussion severity that clinical grading scales could not. Methods: A prospective cohort sample of patients 11 to 17 years of age presenting to the ED within 12 hours of a head injury were evaluated using two traditional concussion grading scales and neurocognitive testing. ED neurocognitive scores were compared to follow-up scores obtained at least 3 days postinjury. Postconcussive symptoms, outcomes, and complications were assessed via telephone follow-up for all subjects. Results: Sixty patients completed phone follow-up. Thirty-six patients (60%) completed follow-up testing a median of 6 days postinjury. Traditional concussion grading did not correlate with neurocognitive deficits detected in the ED or at follow-up. For the neurocognitive domains of verbal memory, processing speed, and reaction time, there was a significant correlation between ED and follow-up scores trending toward clinical improvement. By 2 weeks postinjury, 23 patients (41%) had not returned to normal activity. At 6 weeks, six patients (10%) still had not returned to normal activity. Conclusions: Immediate assessment in the ED can predict neurocognitive deficits seen in follow-up and may be potentially useful to individualize management or test therapeutic interventions. Neurocognitive assessment in the ED detected deficits that clinical grading could not and correlated with deficits at follow-up.	[Thomas, Danny G.; Saladino, Richard A.; Frank, Virginia; Raab, Jenny; Zuckerbraun, Noel S.] Univ Pittsburgh, Med Ctr, Dept Pediat, Emergency Med Div, Pittsburgh, PA 15260 USA; [Collins, Michael W.] Univ Pittsburgh, Med Ctr, Ctr Sports Med, Dept Orthoped Surg,Sports Concuss Program, Pittsburgh, PA USA	Thomas, DG (corresponding author), Univ Pittsburgh, Med Ctr, Dept Pediat, Emergency Med Div, Pittsburgh, PA 15260 USA.	dthomas@mcw.edu	Thomas, Danny G/C-8314-2014	Thomas, Danny/0000-0002-7470-9835	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5-T32-NS07495]; Pittsburgh Emergency Medicine Foundation; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS007495] Funding Source: NIH RePORTER	Disclosures: NIH 5-T32-NS07495. Source of funding: NIH National Research Service Award Training Grant in Pediatrics.; Role: Trainee (P. I.: Ira Bergman MD, PhD); Pittsburgh Emergency Medicine Foundation Research Grant.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Collins Michael W, 2002, Curr Sports Med Rep, V1, P12; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GIOIA G, 2007, GALV TX GALV BRAIN I; GIOIA G, 2007, ANN M INT NEUR SOC P; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2003, ARCH CLIN NEUROPSYCH, V18, P744; IVERSON GL, 2003, DALL TX NAT AC NEUR; JACOBS ES, 2010, VANC BC PED AC SOC A; Langlois J., HEADS BRAIN INJURY Y; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOVELL M, NORMATIVE DATA IMPAC; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P287; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Paniak C, 2000, BRAIN INJURY, V14, P219; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Webbe FM, 2003, CLIN SPORT MED, V22, P577, DOI 10.1016/S0278-5919(02)00103-5	45	33	33	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	MAR	2011	18	3					246	254		10.1111/j.1553-2712.2011.01015.x			9	Emergency Medicine	Emergency Medicine	734YM	WOS:000288379600007	21401786	Green Accepted			2021-06-18	
J	Wong, AC; Kowalenko, T; Roahen-Harrison, S; Smith, B; Maio, RF; Stanley, RM				Wong, Andrew C.; Kowalenko, Terry; Roahen-Harrison, Stephanie; Smith, Barbara; Maio, Ronald F.; Stanley, Rachel M.			A Survey of Emergency Physicians' Fear of Malpractice and Its Association With the Decision to Order Computed Tomography Scans for Children With Minor Head Trauma	PEDIATRIC EMERGENCY CARE			English	Article						malpractice; computed tomography; mild traumatic brain injury	RISK	Objective: The objective of the study was to determine whether fear of malpractice is associated with emergency physicians' decision to order head computed tomography (CT) in 3 age-specific scenarios of pediatric minor head trauma. We hypothesized that physicians with higher fear of malpractice scores will be more likely to order head CT scans. Methods: Board-eligible/board-certified members of the Michigan College of Emergency Physicians were sent a 2-part survey consisting of case scenarios and demographic questions. Effect of fear of malpractice on the decision to order a CT scan was evaluated using a cumulative logit model. Results: Two hundred forty-six members (36.5%) completed the surveys. In scenario 1 (infant), being a male and working in a university setting were associated with reduced odds of ordering a CT scan (odds ratio [OR], 0.40; 95% confidence interval [CI], 0.18-0.88; and OR, 0.35; 95% CI, 0.13-0.96, respectively). In scenario 2 (toddler), working for 15 years or more, at multiple hospitals, and for a private group were associated with reduced odds of ordering a CT scan (OR, 0.46; 95% CI, 0.26-0.79; OR, 0.36; 95% CI, 0.16-0.80; and OR, 0.51; 95% CI, 0.27-0.94, respectively). No demographic variables were significantly associated with ordering a CT scan in scenario 3 (teen). Overall, the fear of malpractice was not significantly associated with ordering a CT scan (OR, 1.28; 95% CI, 0.73-2.26; and OR, 1.70; 95% CI, 0.97-3.0). Only in scenario 2 was high fear significantly associated with increased odds of ordering a CT scan (OR, 2.09; 95% CI, 1.08-4.05). Conclusions: Members of Michigan College of Emergency Physicians with a higher fear of malpractice score tended to order more head CT scans in pediatric minor head trauma. However, this trend was shown to be statistically significant only in 1 case and not overall.	[Wong, Andrew C.; Kowalenko, Terry; Roahen-Harrison, Stephanie; Smith, Barbara; Maio, Ronald F.; Stanley, Rachel M.] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA	Wong, AC (corresponding author), Univ Michigan Hosp, Dept Emergency Med, Taubman Ctr B1 380,1500 E Med Ctr, Ann Arbor, MI 48109 USA.	andrewcw@med.umich.edu		Wong, Andrew/0000-0002-5350-1947			GAMEROFF M, SUGI 30 STAT DATA AN; Katz DA, 2005, ANN EMERG MED, V46, P525, DOI 10.1016/j.annemergmed.2005.04.016; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Schriger DL, 2005, ANN EMERG MED, V46, P534, DOI 10.1016/j.annemergmed.2005.06.445; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609	7	33	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	MAR	2011	27	3					182	185		10.1097/PEC.0b013e31820d64f7			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	730CD	WOS:000288007000005	21346679				2021-06-18	
J	Filippetti, VA; Allegri, RF				Aran Filippetti, Vanessa; Allegri, Ricardo F.			Verbal Fluency in Spanish-Speaking Children: Analysis Model According to Task Type, Clustering, and Switching Strategies and Performance Over Time	CLINICAL NEUROPSYCHOLOGIST			English	Article						Verbal fluency; Cognitive strategies; Cognitive processing; Executive functions; Child neuropsychology	DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; SCHOOL-AGED CHILDREN; WORD FLUENCY; EXECUTIVE FUNCTIONS; CATEGORY FLUENCY; NORMATIVE DATA; FRONTAL-LOBE; DEVELOPMENTAL ASPECTS; 12-YEAR-OLD CHILDREN	Verbal fluency (VF) tasks are extensively used to measure strategic retrieval and executive functioning. Results for total production of words, clustering and switching strategies, and performance over time for Spanish-speaking children are provided. A total of 120 children, ranging in age from 8 to 11, were divided by age into two groups and evaluated. A higher total score for words produced in the semantic compared with the phonological task, a correlation between clustering and switching strategies and total score, and decreased task performance over time were evidenced. These scores were higher in the older group. Moreover, an association was found between verbal fluency tasks, strategies employed, and cognitive executive functions. This indicates that clustering and switching strategies provide indicators of strategic retrieval and executive processes. Together the results suggest that these fluency scores are valuable to measure underlying cognitive processes and retrieval strategies and therefore could be useful to assess executive function deficits in children.	[Aran Filippetti, Vanessa] CIIPME CONICET, Interdisciplinary Ctr Math & Expt Psychol Res, RA-1040 Buenos Aires, DF, Argentina; [Allegri, Ricardo F.] FLENI, Serv Cognit Neurol, Buenos Aires, DF, Argentina	Filippetti, VA (corresponding author), CIIPME CONICET, Interdisciplinary Ctr Math & Expt Psychol Res, Tte Gral Peron 2158, RA-1040 Buenos Aires, DF, Argentina.	vanessaaranf@gmail.com		Allegri, Ricardo Francisco/0000-0001-7166-1234	National Council of Scientific and Technological Research (CONICET), ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	This research was supported by the National Council of Scientific and Technological Research (CONICET), Argentina.	Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; ARAM DM, 1987, BRAIN LANG, V31, P61, DOI 10.1016/0093-934X(87)90061-7; ARDILA A, 1994, DEV NEUROPSYCHOL, V10, P97, DOI 10.1080/87565649409540571; Baldo JV, 2006, J INT NEUROPSYCH SOC, V12, P896, DOI 10.1017/S1355617706061078; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Brickenkamp R., 1962, AUFMERKSAMKEITS BELA; Brucki SMD, 2004, BRAZ J MED BIOL RES, V37, P1771, DOI 10.1590/S0100-879X2004001200002; Chugani HT, 1999, NEUROSCIENTIST, V5, P29, DOI 10.1177/107385849900500105; Cohen MJ, 1999, ARCH CLIN NEUROPSYCH, V14, P433, DOI 10.1016/S0887-6177(98)00038-9; Crowe SF, 1998, J CLIN EXP NEUROPSYC, V20, P391, DOI 10.1076/jcen.20.3.391.810; Fernaeus SE, 1998, J CLIN EXP NEUROPSYC, V20, P137, DOI 10.1076/jcen.20.2.137.1170; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Golden C., 1978, STROOP COLOR WORD TE; HALPERIN JM, 1989, J CLIN EXP NEUROPSYC, V11, P518, DOI 10.1080/01688638908400910; Heaton R., 1993, WISCONSIN CARD SORTI; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Hernandez MT, 2002, NEUROPSYCHOLOGIA, V40, P384, DOI 10.1016/S0028-3932(01)00130-0; Hurks PPM, 2006, J CLIN EXP NEUROPSYC, V28, P684, DOI 10.1080/13803390590954191; Hurks PPM, 2004, BRAIN COGNITION, V55, P535, DOI 10.1016/j.bandc.2004.03.003; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jurado MA, 2000, BRAIN INJURY, V14, P789; Kaufman A. S., 1990, K BIT KAUFMAN BRIEF; Kave G, 2006, DEV NEUROPSYCHOL, V29, P493, DOI 10.1207/s15326942dn2903_7; Kave G, 2008, J CLIN EXP NEUROPSYC, V30, P349, DOI 10.1080/13803390701416197; Klenberg L, 2001, DEV NEUROPSYCHOL, V20, P407, DOI 10.1207/S15326942DN2001_6; Kodituwakku PW, 2006, J STUD ALCOHOL, V67, P502, DOI 10.15288/jsa.2006.67.502; Koren R, 2005, ARCH CLIN NEUROPSYCH, V20, P1087, DOI 10.1016/j.acn.2005.06.012; Korkman M, 2001, DEV NEUROPSYCHOL, V20, P325, DOI 10.1207/S15326942DN2001_1; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P164, DOI 10.1017/S1355617704102014; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lindgren A, 2004, EPILEPSY BEHAV, V5, P903, DOI 10.1016/j.yebeh.2004.08.004; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; MARTIN A, 1994, NEUROPSYCHOLOGIA, V32, P1487, DOI 10.1016/0028-3932(94)90120-1; MARTIN RC, 1990, NEUROPSYCHOLOGIA, V28, P823, DOI 10.1016/0028-3932(90)90006-A; Martins IP, 2007, CHILD NEUROPSYCHOL, V13, P319, DOI 10.1080/09297040600837370; Matute E, 2004, DEV NEUROPSYCHOL, V26, P647, DOI 10.1207/s15326942dn2602_7; Milner B, 1964, FRONTAL GRANULAR COR, P313; Mummery CJ, 1996, P ROY SOC B-BIOL SCI, V263, P989, DOI 10.1098/rspb.1996.0146; Nash HM, 2008, COGN NEUROPSYCHOL, V25, P690, DOI 10.1080/02643290802274064; Nieto A, 2008, REV NEUROLOGIA, V46, P2, DOI 10.33588/rn.4601.2007390; Paus T, 1999, SCIENCE, V283, P1908, DOI 10.1126/science.283.5409.1908; PENDLETON MG, 1982, J CLIN NEUROPSYCHOL, V4, P307, DOI 10.1080/01688638208401139; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; Phillips LH, 1997, Methodology of frontal " and executive function, P191; Pineda D, 1998, INT J NEUROSCI, V96, P177, DOI 10.3109/00207459808986466; Pineda D, 1999, J LEARN DISABIL, V32, P159, DOI 10.1177/002221949903200206; Raboutet C, 2010, J CLIN EXP NEUROPSYC, V32, P268, DOI 10.1080/13803390902984464; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Reiter A, 2005, DYSLEXIA, V11, P116, DOI 10.1002/dys.289; Rey A, 1964, EXAMEN CLIN PSYCHOL; Riva D, 2000, BRAIN LANG, V71, P267, DOI 10.1006/brln.1999.2166; Rosselli M, 2009, AGING NEUROPSYCHOL C, V16, P721, DOI 10.1080/13825580902912739; Ruff RM, 1997, BRAIN LANG, V57, P394, DOI 10.1006/brln.1997.1755; Sauzeon H, 2004, BRAIN LANG, V89, P192, DOI 10.1016/S0093-934X(03)00367-5; SCHNEIDER W, 1977, PSYCHOL REV, V84, P1, DOI 10.1037/0033-295X.84.1.1; Schonfeld AM, 2001, J STUD ALCOHOL, V62, P239, DOI 10.15288/jsa.2001.62.239; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Sowell ER, 2004, J NEUROSCI, V24, P8223, DOI 10.1523/JNEUROSCI.1798-04.2004; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; Szatkowska I, 2000, ACTA NEUROBIOL EXP, V60, P503; Thompson PM, 2000, NATURE, V404, P190, DOI 10.1038/35004593; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Villodre R, 2006, NEUROLOGIA, V21, P124; Wechsler D., 2003, WECHSLER INTELLIGENC; Zelazo P. D., 1997, LANGUAGE STRUCTURE D, V12, P113; Zelazo PD, 1998, CURR DIR PSYCHOL SCI, V7, P121, DOI 10.1111/1467-8721.ep10774761	71	33	33	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	3					413	436	PII 936246304	10.1080/13854046.2011.559481			24	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	751RU	WOS:000289636100006	21491348				2021-06-18	
J	Bao, YH; Bramlett, HM; Atkins, CM; Truettner, JS; Lotocki, G; Alonso, OF; Dietrich, WD				Bao, Ying-hui; Bramlett, Helen M.; Atkins, Coleen M.; Truettner, Jessie S.; Lotocki, George; Alonso, Ofelia F.; Dietrich, W. Dalton			Post-Traumatic Seizures Exacerbate Histopathological Damage after Fluid-Percussion Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						epilepsy; immunohistochemistry; neuronal cell death; traumatic brain injury	HEAD-INJURY; DENTATE GYRUS; INTRACEREBRAL HEMORRHAGE; BARRIER PERMEABILITY; HIPPOCAMPAL CA1; SMALL MOLECULES; EPILEPSY; HYPEREXCITABILITY; DISRUPTION; TRAUMA	The purpose of this study was to investigate the effects of an induced period of post-traumatic epilepsy (PTE) on the histopathological damage caused by traumatic brain injury (TBI). Male Sprague Dawley rats were given a moderate parasagittal fluid-percussion brain injury (1.9-2.1 atm) or sham surgery. At 2 weeks after surgery, seizures were induced by administration of a GABA(A) receptor antagonist, pentylenetetrazole (PTZ, 30 mg/kg). Seizures were then assessed over a 1-h period using the Racine clinical rating scale. To evaluate whether TBI-induced pathology was exacerbated by the seizures, contusion volume and cortical and hippocampal CA3 neuronal cell loss were measured 3 days after seizures. Nearly all TBI rats showed clinical signs of PTE following the decrease in inhibitory activity. In contrast, clinically evident seizures were not observed in TBI rats given saline or sham-operated rats given PTZ. Contusions in TBI-PTZ-treated rats were significantly increased compared to the TBI-saline-treated group (p < 0.001). In addition, the TBI-PTZ rats showed less NeuN-immunoreactive cells within the ipsilateral parietal cerebral cortex (p < 0.05) and there was a trend for decreased hippocampal CA3 neurons in TBI-PTZ rats compared with TBI-saline or sham-operated rats. These results demonstrate that an induced period of post-traumatic seizures significantly exacerbates the structural damage caused by TBI. These findings emphasize the need to control seizures after TBI to limit even further damage to the injured brain.	[Bao, Ying-hui; Bramlett, Helen M.; Atkins, Coleen M.; Truettner, Jessie S.; Lotocki, George; Alonso, Ofelia F.; Dietrich, W. Dalton] Univ Miami, Sch Med, Neurotrauma Res Ctr, Dept Neurol Surg, Miami, FL 33136 USA; [Bao, Ying-hui; Bramlett, Helen M.; Atkins, Coleen M.; Truettner, Jessie S.; Lotocki, George; Alonso, Ofelia F.; Dietrich, W. Dalton] Univ Miami, Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Bruce W Carter Dept Vet Affairs Med Ctr, Miami, FL USA; [Bao, Ying-hui] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai, Peoples R China	Dietrich, WD (corresponding author), Univ Miami, Sch Med, Neurotrauma Res Ctr, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu		Atkins, Coleen/0000-0003-4718-7493	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS030291, NS042133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, R01NS042133, P50NS030291] Funding Source: NIH RePORTER	We thank Dr. Beata Frydel for assistance with the histopathological analysis and Jeremy Lytle for editorial assistance. This work was supported by NIH NS030291 and NS042133.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; ATKINS CM, 2010, EUR J NEURO IN PRESS; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Bautista RED, 2009, EPILEPSY BEHAV, V16, P325, DOI 10.1016/j.yebeh.2009.07.037; Bigford GE, 2009, J NEUROTRAUM, V26, P703, DOI 10.1089/neu.2008.0783; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Garga Nina, 2006, Epilepsy Curr, V6, P1, DOI 10.1111/j.1535-7511.2005.00083.x; Golarai G, 2001, J NEUROSCI, V21, P8523; Graber KD, 2004, ANN NEUROL, V55, P860, DOI 10.1002/ana.20124; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hitiris N, 2007, EPILEPSY RES, V75, P192, DOI 10.1016/j.eplepsyres.2007.06.003; Hunt RF, 2010, J NEUROPHYSIOL, V103, P1490, DOI 10.1152/jn.00957.2009; Hunt RF, 2009, EXP NEUROL, V215, P243, DOI 10.1016/j.expneurol.2008.10.005; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Lenzlinger PM, 2001, J NEUROTRAUM, V18, P479, DOI 10.1089/089771501300227288; Loscher W, 2002, EPILEPSY RES, V50, P3, DOI 10.1016/S0920-1211(02)00063-3; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Somera-Molina KC, 2007, EPILEPSIA, V48, P1785, DOI 10.1111/j.1528-1167.2007.01135.x; Statler KD, 2008, EPILEPSY RES, V80, P163, DOI 10.1016/j.eplepsyres.2008.04.001; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Swartz BE, 2006, EPILEPSIA, V47, P1373, DOI 10.1111/j.1528-1167.2006.00602.x; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Thapa A, 2010, SEIZURE-EUR J EPILEP, V19, P211, DOI 10.1016/j.seizure.2010.02.004; Tomkins O, 2008, J NEUROL NEUROSUR PS, V79, P774, DOI 10.1136/jnnp.2007.126425; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; van Vliet EA, 2007, BRAIN, V130, P521, DOI 10.1093/brain/awl318; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Wang HY, 2008, ACTA CRYSTALLOGR E, V64, pM26, DOI 10.1107/S1600536807061715; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	63	33	35	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					35	42		10.1089/neu.2010.1383			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800004	20836615	Green Published			2021-06-18	
J	Creamer, M; Wade, D; Fletcher, S; Forbes, D				Creamer, Mark; Wade, Darryl; Fletcher, Susan; Forbes, David			PTSD among military personnel	INTERNATIONAL REVIEW OF PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; TRAUMATIC BRAIN-INJURY; GULF-WAR VETERANS; VIETNAM VETERANS; EXPOSED ADULTS; IRAQ; SOLDIERS; COMBAT; METAANALYSIS	Although symptoms characteristic of post-traumatic stress disorder (PTSD) have been noted in military personnel for many centuries, it was not until 1980 that the disorder was formally recognized and became the focus of legitimate study. This paper reviews our current state of knowledge regarding the prevalence and course of this complex condition in past and present members of the defence forces. Although rates vary across conflicts and countries, there is no doubt that PTSD affects substantial numbers of personnel and results in considerable impairment in functioning and quality of life. The paper goes on to discuss recent attempts to build resilience and to promote adjustment following deployment, noting that there is little evidence at this stage upon which to draw firm conclusions. Finally, effective treatment for PTSD is reviewed, with particular reference to the challenges posed by this population in a treatment setting.	[Creamer, Mark] Australian Ctr Posttraumat Mental Hlth, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia	Creamer, M (corresponding author), Australian Ctr Posttraumat Mental Hlth, Level 1,340 Albert St, Melbourne, Vic 3002, Australia.	markcc@unimelb.edu.au		Forbes, David/0000-0001-9145-1605; Wade, Darryl/0000-0002-8079-321X; Fletcher, Susan/0000-0001-6359-8650			*ACPMH, 2007, AUSTR GUID TREATM AD; Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.ajp.2007.06091491; BISSON J, 2009, PSYCHOL TREATMENTS P; Bowles SV, 2010, MIL MED, V175, P382, DOI 10.7205/MILMED-D-10-00099; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Breslau N, 2005, ARCH GEN PSYCHIAT, V62, P1343, DOI 10.1001/archpsyc.62.12.1343; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Browne T, 2007, BRIT J PSYCHIAT, V190, P484, DOI 10.1192/bjp.bp.106.030544; Cohn A, 2008, MIL MED, V173, P1151, DOI 10.7205/MILMED.173.12.1151; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2701; Dohrenwend BP, 2006, SCIENCE, V313, P979, DOI 10.1126/science.1128944; Fear NT, 2010, LANCET, V375, P1783, DOI 10.1016/S0140-6736(10)60672-1; Fletcher S, 2010, AUST NZ J PSYCHIAT, V44, P1064, DOI 10.3109/00048674.2010.509858; Foa EB., 1998, TREATING TRAUMA RAPE; Forbes D, 2007, AUST NZ J PSYCHIAT, V41, P637, DOI 10.1080/00048670701449161; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KUBANY ES, 1995, COGN BEHAV PRACT, V2, P27, DOI 10.1016/S1077-7229(05)80004-5; Kulka RA, 1988, CONTRACTUAL REPORT F; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; McFarlane AC, 2009, J AFFECT DISORDERS, V118, P166, DOI 10.1016/j.jad.2009.01.017; McNally RJ, 2007, J TRAUMA STRESS, V20, P481, DOI 10.1002/jts.20257; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; National Institute for Clinical Excellence (NICE), 2005, POSTTR STRESS DIS; O'Donnell ML, 2010, PSYCHIAT RES, V176, P257, DOI 10.1016/j.psychres.2009.05.012; O'Toole BI, 2009, AM J EPIDEMIOL, V170, P318, DOI 10.1093/aje/kwp146; Orcutt HK, 2004, J TRAUMA STRESS, V17, P195, DOI 10.1023/B:JOTS.0000029262.42865.c2; Orth U, 2006, J CONSULT CLIN PSYCH, V74, P698, DOI 10.1037/0022-006X.74.4.698; Reger MA, 2009, J CLIN PSYCHIAT, V70, P1266, DOI 10.4088/JCP.08m04361; Resick P. A., 1993, COGNITIVE PROCESSING; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; Rona RJ, 2007, BRIT MED J, V335, P603, DOI 10.1136/bmj.39274.585752.BE; Sareen J, 2007, PSYCHOSOM MED, V69, P242, DOI 10.1097/PSY.0b013e31803146d8; Schnurr PP, 2009, CLIN PSYCHOL REV, V29, P727, DOI 10.1016/j.cpr.2009.08.006; Schnurr PP, 2004, TRAUMA HLTH PHYS HLT; Shay J, 1994, ACHILLES VIETNAM COM; Shay Jonathan, 2002, ODYSSEUS AM COMBAT T; Solomon Z, 2006, AM J PSYCHIAT, V163, P659, DOI 10.1176/appi.ajp.163.4.659; Spitzer RL, 2007, J ANXIETY DISORD, V21, P233, DOI 10.1016/j.janxdis.2006.09.006; Stein DJ, 2009, CNS SPECTRUMS, V14, P25; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; US Department of Veterans Affairs, 2010, FED REGISTER, P39843; *VA DOD CLIN PRACT, 2003, MAN POSTTR STRESS	50	33	34	1	16	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0954-0261			INT REV PSYCHIATR	Int. Rev. Psych.		2011	23	2					160	165		10.3109/09540261.2011.559456			6	Psychiatry	Psychiatry	755PO	WOS:000289946800006	21521085				2021-06-18	
J	Schatz, P; Moser, RS				Schatz, Philip; Moser, Rosemarie Scolaro			Current Issues in Pediatric Sports Concussion	CLINICAL NEUROPSYCHOLOGIST			English	Article						Concussion; Mild traumatic brain injury; Long-term effects	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; STATES EMERGENCY-DEPARTMENTS; UNITED-STATES; ICE HOCKEY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; LACROSSE INJURIES; WOMENS LACROSSE; HEAD-INJURY	This article reviews current issues in the following areas of pediatric sports-related concussion: incidence of concussion, potential long-term effects, return to play, and the emergence of legislation regarding concussion education and management programs. Incidence of concussion is presented in context of emergency room visits, as well as under-reporting of concussions. The literature on history of concussion is reviewed, for high school, collegiate, and professional athletes, with respect to potential long-term effects of cerebral concussion. Specific discussions of effects include: decreased cognition and increased symptom reporting following multiple concussions, and recent diagnoses of chronic traumatic encephalopathy in non-professional and youth athletes. Recent legislative and advocacy efforts are reviewed, including mandated programs in specific states.	[Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; [Moser, Rosemarie Scolaro] RSM Psychol Ctr LLC, Sports Concuss Ctr New Jersey SM, Lawrenceville, NJ USA	Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 222 Post Hall, Philadelphia, PA 19131 USA.	pschatz@sju.edu		Schatz, Philip/0000-0002-6222-6545			2007-09 Official Rules of Ice Hockey, 2007, 2007 09 OFFICIAL RUL; ALVES WM, 1987, CLIN SPORT MED, V6, P211; Aubry M, 2002, PHYSICIAN SPORTSMED, V30, P1; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; BRESLAU N, 1985, J AM ACAD CHILD PSY, V24, P87, DOI 10.1016/S0002-7138(09)60415-5; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Coghlin Craig J, 2009, J Can Chiropr Assoc, V53, P233; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Dick R, 2007, J ATHL TRAINING, V42, P262; Dick R, 2007, J ATHL TRAINING, V42, P255; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Evans T., 2009, NY TIMES        1230; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fisher J, 2004, TOP EMERG MED, V26, P260; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; Hohler B., 2009, BOSTON GLOBE    0127; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kraus JF, 1993, HEAD INJURY, P1; LOGAN K, 2009, ATHLETIC TRAINING SP, V1, P251; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2004, BRIT J SPORT MED, V29, P196; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; NATA, 2010, NAT ATHL TRAIN ASS I; Pardini D., 2004, BR J SPORTS MED, V38, P661; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schwarz A., 2010, NY TIMES        0913; Schwarz A., 2010, NY TIMES        0916; Schwarz A., 2010, NY TIMES        0726; Shields BJ, 2009, J ATHL TRAINING, V44, P586, DOI 10.4085/1062-6050-44.6.586; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; [U.S.Census Bureau http://factfinder.census. gov/servlet/ Metadata BrowserServlet?type=program&id=PEP], 2009, 2009 POP EST PROJ; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Wagner J., 2010, WASHINGTON POST 0924; Waicus KM, 2002, CLIN J SPORT MED, V12, P24, DOI 10.1097/00042752-200201000-00008; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yard EE, 2006, J ATHL TRAINING, V41, P441; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	81	33	34	0	28	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	6					1042	1057		10.1080/13854046.2011.556669			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	882JH	WOS:000299559400009	21391151				2021-06-18	
J	Wu, WQ; Sun, JF; Jin, Z; Guo, XL; Qiu, YH; Zhu, YS; Tong, SB				Wu, Wenqing; Sun, Junfeng; Jin, Zheng; Guo, Xiaoli; Qiu, Yihong; Zhu, Yisheng; Tong, Shanbao			Impaired neuronal synchrony after focal ischemic stroke in elderly patients	CLINICAL NEUROPHYSIOLOGY			English	Article						Cortical synchrony; Phase synchronization; Ischemic stroke; Electroencephalography	TRAUMATIC BRAIN-INJURY; FUNCTIONAL CONNECTIVITY; PHASE SYNCHRONIZATION; SURFACE LAPLACIANS; SYMMETRY INDEX; EEG; MAGNETOENCEPHALOGRAPHY; ELECTRODE; NETWORKS; SIGNALS	Objective: This study investigated whether cortical synchrony derived from electroencephalography (EEG) in elderly patients is impaired and if the impairment might reflect long-term functional recovery after stroke. Methods: The scalp EEG signals of stroke patients (N = 42) were collected within seven days after the onset of stroke and analyzed with phase synchronization (PS). Neurodeficit outcome was scored twice according to the National Institute of Health Stroke Scale (NIHSS): (1) at the same day of EEG recording and (2) two months after stroke. The correlation between cortical synchrony and NIHSS was analyzed. Results: The level of synchronization between lesion and intact areas in the ipsilateral hemisphere was reduced significantly after stroke, while the synchronization among intact areas increased to 114% among the control subjects. Furthermore, the patients with lower inter-hemispheric synchrony after stroke were observed to have a higher NIHSS two months after stroke. Conclusions: Results indicated that the infarct broke down the cortical synchrony networks and affected large-scale neural communication. Inter-hemispheric synchrony was relevant to long-term functional recovery after stroke. Significance: The prognostic value of PS for functional recovery after stroke might be helpful in understanding the alteration of cortical networks after ischemic injury. (C) 2010 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Sun, Junfeng; Tong, Shanbao] Shanghai Jiao Tong Univ, Med Res Inst X, Shanghai 200030, Peoples R China; [Wu, Wenqing; Guo, Xiaoli; Qiu, Yihong; Zhu, Yisheng] Shanghai Jiao Tong Univ, Dept Biomed Engn, Shanghai 200030, Peoples R China; [Jin, Zheng] Fifth Peoples Hosp Shanghai, Dept Neurol, Shanghai, PR, Peoples R China	Tong, SB (corresponding author), Shanghai Jiao Tong Univ, Med Res Inst X, 1954 Huashan Rd, Shanghai 200030, Peoples R China.	stong@sjtu.edu.cn	Sun, Junfeng/D-1590-2010	Sun, Junfeng/0000-0002-7614-7127; Jin, Zheng/0000-0002-9499-934X	Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [07ZR14054]; Med-X research fund	This work was supported in part by the Science and Technology Commission of Shanghai Municipality (07ZR14054). S. Tong was also supported by the Med-X research fund. The authors are grateful to Dr. Jimin Zhang for her assistance in recording EEG.	Andrew C, 1996, ELECTROEN CLIN NEURO, V98, P144; Angelini L, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.038103; Assenza G, 2009, NEUROIMAGE, V44, P1267, DOI 10.1016/j.neuroimage.2008.09.049; Babiloni Fabio, 1995, Brain Topography, V8, P35, DOI 10.1007/BF01187668; Barry RJ, 2007, CLIN NEUROPHYSIOL, V118, P2765, DOI 10.1016/j.clinph.2007.07.028; Bob P, 2008, NEUROSCI LETT, V447, P73, DOI 10.1016/j.neulet.2008.09.055; Cuspineda E, 2007, CLIN EEG NEUROSCI, V38, P155, DOI 10.1177/155005940703800312; Cuspineda E, 2003, CLIN ELECTROENCEPHAL, V34, P1; David O, 2004, NEUROIMAGE, V21, P659, DOI 10.1016/j.neuroimage.2003.10.006; Fallani FD, 2009, ANAT REC, V292, P2023, DOI 10.1002/ar.20965; Fingelkurts AA, 2005, NEUROSCI BIOBEHAV R, V28, P827, DOI 10.1016/j.neubiorev.2004.10.009; Finnigan SP, 2007, CLIN NEUROPHYSIOL, V118, P2525, DOI 10.1016/j.clinph.2007.07.021; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Galvan A, 2008, CLIN NEUROPHYSIOL, V119, P1459, DOI 10.1016/j.clinph.2008.03.017; Hammond C, 2007, TRENDS NEUROSCI, V30, P357, DOI 10.1016/j.tins.2007.05.004; He BJ, 2007, NEURON, V53, P905, DOI 10.1016/j.neuron.2007.02.013; Herrmann CS, 2005, CLIN NEUROPHYSIOL, V116, P2719, DOI 10.1016/j.clinph.2005.07.007; Ito J, 2005, BIOL CYBERN, V92, P54, DOI 10.1007/s00422-004-0533-z; KRASKOV A, 2008, NIC SERIES, V24; LAW SK, 1993, IEEE T BIO-MED ENG, V40, P145, DOI 10.1109/10.212068; Lehnertz K, 1998, PHYS REV LETT, V80, P5019, DOI 10.1103/PhysRevLett.80.5019; Lukashevich I P, 1999, Neurosci Behav Physiol, V29, P283, DOI 10.1007/BF02465339; Nenadovic V, 2008, J NEUROTRAUM, V25, P615, DOI 10.1089/neu.2007.0474; NUNEZ PL, 1994, ELECTROEN CLIN NEURO, V90, P40, DOI 10.1016/0013-4694(94)90112-0; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; Pereda E, 2005, PROG NEUROBIOL, V77, P1, DOI 10.1016/j.pneurobio.2005.10.003; Pikovsky A., 2002, AM J PHYS, V70, P655, DOI [10.1119/1.1475332, DOI 10.1119/1.1475332]; Quiroga RQ, 2000, PHYS REV E, V61, P5142, DOI 10.1103/PhysRevE.61.5142; Quiroga RQ, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.041903; SAUSENG P, 2008, NEUROSCI BIOBEHAV R; Shields DC, 2007, SURG NEUROL, V67, P354, DOI 10.1016/j.surneu.2006.09.036; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; Sun JF, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.046219; Tecchio F, 2006, J NEUROSCI RES, V83, P1077, DOI 10.1002/jnr.20796; Tecchio F, 2007, J NEUROL, V254, P296, DOI 10.1007/s00415-006-0355-0; Thakor NV, 2004, ANNU REV BIOMED ENG, V6, P453, DOI 10.1146/annurev.bioeng.5.040202.121601; Thatcher RW., 1998, J NEUROTHERAPY, V2, P8, DOI [DOI 10.1300/J184V02N04_, 10.1300/J184v02n04_02, DOI 10.1300/J184V02N04_02]; van Putten MJAM, 2007, CLIN NEUROPHYSIOL, V118, P2362, DOI 10.1016/j.clinph.2007.07.019; van Putten MJAM, 2004, CLIN NEUROPHYSIOL, V115, P1189, DOI 10.1016/j.clinph.2003.12.002; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550	40	33	34	2	21	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	JAN	2011	122	1					21	26		10.1016/j.clinph.2010.06.003			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	695XS	WOS:000285406600007	20591730				2021-06-18	
J	Perrin, FE; Boniface, G; Serguera, C; Lonjon, N; Serre, A; Prieto, M; Mallet, J; Privat, A				Perrin, Florence E.; Boniface, Guillaume; Serguera, Che; Lonjon, Nicolas; Serre, Angeline; Prieto, Monica; Mallet, Jacques; Privat, Alain			Grafted Human Embryonic Progenitors Expressing Neurogenin-2 Stimulate Axonal Sprouting and Improve Motor Recovery after Severe Spinal Cord Injury	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; TRAUMATIC INJURY; MOUSE MODEL; AUTOFLUORESCENCE; REPAIR; RATS; PROMOTES; BRAIN; DIFFERENTIATION	Background: Spinal cord injury (SCI) is a widely spread pathology with currently no effective treatment for any symptom. Regenerative medicine through cell transplantation is a very attractive strategy and may be used in different non-exclusive ways to promote functional recovery. We investigated functional and structural outcomes after grafting human embryonic neural progenitors (hENPs) in spinal cord-lesioned rats. Methods and Principal Findings: With the objective of translation to clinics we have chosen a paradigm of delayed grafting, i.e., one week after lesion, in a severe model of spinal cord compression in adult rats. hENPs were either naive or engineered to express Neurogenin 2 (Ngn2). Moreover, we have compared integrating and non-integrating lentiviral vectors, since the latter present reduced risks of insertional mutagenesis. We show that transplantation of hENPs transduced to express Ngn2 fully restore weight support and improve functional motor recovery after severe spinal cord compression at thoracic level. This was correlated with partial restoration of serotonin innervations at lumbar level, and translocation of 5HT1A receptors to the plasma membrane of motoneurons. Since hENPs were not detectable 4 weeks after grafting, transitory expression of Ngn2 appears sufficient to achieve motor recovery and to permit axonal regeneration. Importantly, we also demonstrate that transplantation of naive hENPs is detrimental to functional recovery. Conclusions and Significance: Transplantation and short-term survival of Ngn2-expressing hENPs restore weight support after SCI and partially restore serotonin fibers density and 5HT1A receptor pattern caudal to the lesion. Moreover, grafting of naive-hENPs was found to worsen the outcome versus injured only animals, thus pointing to the possible detrimental effect of stem cell-based therapy per se in SCI. This is of major importance given the increasing number of clinical trials involving cell grafting developed for SCI patients.	[Perrin, Florence E.; Privat, Alain] Univ Basque Country UPV EHU, Dept Neurosci, IKERBASQUE Basque Fdn Sci, Bilbao, Spain; [Perrin, Florence E.; Boniface, Guillaume; Lonjon, Nicolas; Privat, Alain] St Eloi Hosp, INSERM, U583, Inst Neurosci Montpellier Pathophysiol & Therapy, Montpellier, France; [Boniface, Guillaume; Lonjon, Nicolas] Gui de Chauliac Hosp, Dept Neurosurg, Montpellier, France; [Serguera, Che; Serre, Angeline; Mallet, Jacques] Univ Paris 06, INSERM UMRS 975, Inst Cerveau & Moelle Epiniere, Hop La Pitie Salpetriere,Ctr Rech,CNRS UMR 7225, Paris, France; [Serguera, Che] CEA INSERM, MIRCen, Fontenay Aux Roses, France; [Prieto, Monica; Privat, Alain] St Eloi Hosp, Neureva Inc INM, Montpellier, France	Perrin, FE (corresponding author), Univ Basque Country UPV EHU, Dept Neurosci, IKERBASQUE Basque Fdn Sci, Bilbao, Spain.	f.perrin@ikerbasque.org	Serguera, Che/J-8918-2012	Serguera, Che/0000-0002-9210-0636; PERRIN, Florence/0000-0002-7630-0515	European UnionEuropean Commission; Institut pour la Recherche sur la Moelle Epiniere; Academie de Medecine; Societe Francaise de Neurochirurgie; Verticale; Association Demain Debout Aquitaine	This study was supported by the European Union FP6 "RESCUE" STREP; the "Institut pour la Recherche sur la Moelle Epiniere"; the "Academie de Medecine"; the "Societe Francaise de Neurochirurgie"; "Verticale" and the "Association Demain Debout Aquitaine". The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abematsu M, 2010, J CLIN INVEST, V120, P3255, DOI 10.1172/JCI42957; AUBIN JE, 1979, J HISTOCHEM CYTOCHEM, V27, P36, DOI 10.1177/27.1.220325; Baptiste DC, 2007, PROG BRAIN RES, V161, P217, DOI 10.1016/S0079-6123(06)61015-7; Barnabe-Heider F, 2008, CELL STEM CELL, V3, P16, DOI 10.1016/j.stem.2008.06.011; Bauchet L., 2009, Annals of Physical and Rehabilitation Medicine, V52, P330, DOI 10.1016/j.annrmp.2008.10.004; BENSON RC, 1979, J HISTOCHEM CYTOCHEM, V27, P44, DOI 10.1177/27.1.438504; BUCCARON MH, 1995, NEUROBIOL DIS, V2, P37, DOI 10.1006/nbdi.1995.0004; Buchet D, 2002, MOL CELL NEUROSCI, V19, P389, DOI 10.1006/mcne.2001.1086; CAVALIERI B, 1635, CERTAIN METHOD DEV N, P1; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Gaviria M, 2002, J NEUROTRAUM, V19, P205, DOI 10.1089/08977150252806965; HAVENITH CEG, 1993, J LEUKOCYTE BIOL, V53, P504; Heinrich C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000373; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Kim SU, 2009, J NEUROSCI RES, V87, P2183, DOI 10.1002/jnr.22054; LONJON N, 2010, SPINAL CORD IN PRESS; Lonjon N, 2010, J NEUROSURG-SPINE, V12, P106, DOI 10.3171/2009.7.SPINE0989; Lonjon N, 2009, J NEUROSCI RES, V87, P403, DOI 10.1002/jnr.21871; MALLEY A, 1988, J LEUKOCYTE BIOL, V43, P557; MARTIN D, 1992, J NEUROSCI RES, V32, P539, DOI 10.1002/jnr.490320409; NICOD LP, 1989, J LEUKOCYTE BIOL, V45, P458; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Ramos-Cabrer P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012779; Ribotta MG, 2002, PROG BRAIN RES, V137, P191; RIBOTTA MGY, 1995, J NEUROSCI RES, V41, P79, DOI 10.1002/jnr.490410110; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; Rossi SL, 2009, CURR OPIN BIOTECH, V20, P552, DOI 10.1016/j.copbio.2009.09.008; Sahni V, 2010, NAT REV NEUROL, V6, P363, DOI 10.1038/nrneurol.2010.73; Salazar DL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012272; Sarkis C, 2008, CURR GENE THER, V8, P430, DOI 10.2174/156652308786848012; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Sedy J, 2007, J NEUROTRAUM, V24, P1487, DOI 10.1089/neu.2006.0252; SHAPIRO S, 1995, J SURG RES, V59, P393, DOI 10.1006/jsre.1995.1181; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Vanicky I, 2001, J NEUROTRAUM, V18, P1399, DOI 10.1089/08977150152725687; Zennou V, 2001, NAT BIOTECHNOL, V19, P446, DOI 10.1038/88115	37	33	34	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2010	5	12							e15914	10.1371/journal.pone.0015914			7	Multidisciplinary Sciences	Science & Technology - Other Topics	701DD	WOS:000285793600050	21209909	DOAJ Gold, Green Published			2021-06-18	
J	Jeong, SL; Cho, SY; Oh, SJ				Jeong, Seong Lin; Cho, Sung Yong; Oh, Seung-June			Spinal Cord/Brain Injury and the Neurogenic Bladder	UROLOGIC CLINICS OF NORTH AMERICA			English	Article						Neurogenic bladder; Spinal cord injury; Cerebrovascular accident; Traumatic brain injury; Urodynamics; Disease management	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; CLEAN INTERMITTENT CATHETERIZATION; POSTSTROKE URINARY-INCONTINENCE; AUTONOMIC REFLEX PATHWAY; CORD-INJURY; FOLLOW-UP; CEREBROVASCULAR ACCIDENT; SPHINCTER DYSSYNERGIA; UROLOGICAL MANAGEMENT	This article reviews neurogenic bladder related to traumatic injury as well as vascular lesion of brain/spinal cord Because urological manifestations of traumatic or vascular brain/spinal cord injury are highly diversified and complex, the approaches to achieve accurate diagnosis and administer proper treatment can be complicated The goal of primary treatment is preservation of renal function and attainment of social continence Maintaining low intravesical pressure and adequate bladder emptying are central to the treatment strategy Diagnosis and appropriate urological management of these disease entities should depend on urodynamic studies because of poor correlation between clinical symptoms or somatic neurologic signs and urodynamic findings	[Cho, Sung Yong; Oh, Seung-June] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Urol, Seoul 110744, South Korea; [Jeong, Seong Lin] Seoul Natl Univ, Bundang Hosp, Dept Urol, Songnam 463707, Seongnam, South Korea; [Jeong, Seong Lin] Seoul Natl Univ, Bundang Hosp, Dept Urol, Gyeonggi Do, South Korea	Oh, SJ (corresponding author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Urol, 28 Yeongeon Dong, Seoul 110744, South Korea.		Oh, Seung-June/D-6015-2012	Oh, Seung-June/0000-0002-0322-3539			A. the National Spinal Cord Injury Statistical Center Birmingham, 2009, FACTS FIG GLANC; Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052; Abrams P, 2008, BJU INT, V101, P989, DOI 10.1111/j.1464-410X.2008.07457.x; [Anonymous], 2006, J SPINAL CORD MED, V29, P527; BEJANY DE, 1987, J UROLOGY, V138, P1390, DOI 10.1016/S0022-5347(17)43651-2; BENNETT CJ, 1995, J UROLOGY, V153, P1458, DOI 10.1016/S0022-5347(01)67432-9; BRINDLEY GS, 1986, J NEUROL NEUROSUR PS, V49, P1104, DOI 10.1136/jnnp.49.10.1104; Brittain KR, 1998, STROKE, V29, P524, DOI 10.1161/01.STR.29.2.524; Burney TL, 1996, UROL CLIN N AM, V23, P483, DOI 10.1016/S0094-0143(05)70327-X; Burney TL, 1996, J UROLOGY, V156, P1748, DOI 10.1016/S0022-5347(01)65498-3; CARDENAS DD, 1995, PARAPLEGIA, V33, P326, DOI 10.1038/sc.1995.73; CARLSSON CA, 1978, ACTA PHARMACOL TOX, V43, P8; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; de la Barrera SS, 2001, SPINAL CORD, V39, P520, DOI 10.1038/sj.sc.3101201; Ersoz M, 2005, CEREBROVASC DIS, V20, P395, DOI 10.1159/000088670; Feifer A, 2008, NEUROUROL URODYNAM, V27, P475, DOI 10.1002/nau.20569; GELBER DA, 1993, STROKE, V24, P378, DOI 10.1161/01.STR.24.3.378; Giannantoni A, 1998, SPINAL CORD, V36, P29, DOI 10.1038/sj.sc.3100509; Giannantoni A, 2009, EUR UROL, V55, P705, DOI 10.1016/j.eururo.2008.08.048; Gomelsky A, 2003, J UROLOGY, V170, P122, DOI 10.1097/01.ju.0000065245.88262.a9; Groah SL, 2002, ARCH PHYS MED REHAB, V83, P346, DOI 10.1053/apmr.2002.29653; Gupta A, 2009, ANN INDIAN ACAD NEUR, V12, P104, DOI 10.4103/0972-2327.53078; Hamid R, 2003, BJU INT, V91, P51, DOI 10.1046/j.1464-410X.2003.04009.x; Han KS, 2010, NEUROUROL URODYNAM, V29, P387, DOI 10.1002/nau.20708; Hansen RB, 2004, SPINAL CORD, V42, P631, DOI 10.1038/sj.sc.3101637; Heard Laura, 2005, Rehabil Nurs, V30, P44; KAPLAN SA, 1991, J UROLOGY, V146, P113, DOI 10.1016/S0022-5347(17)37727-3; KHAN Z, 1990, UROLOGY, V35, P265, DOI 10.1016/0090-4295(90)80048-R; Krimchansky BZ, 1999, BRAIN INJURY, V13, P899; Kutzenberger J, 2005, ARTIF ORGANS, V29, P239, DOI 10.1111/j.1525-1594.2005.29043.x; Larsen LD, 1997, UROLOGY, V50, P418, DOI 10.1016/S0090-4295(97)00224-0; Leary SM, 2006, CLIN REHABIL, V20, P1094, DOI 10.1177/0269215506071258; Lin HD, 2009, J NEUROSURG-SPINE, V10, P452, DOI 10.3171/2009.1.SPINE08540; Lujan MS, 2008, ACTAS UROL ESP, V32, P926; MACDIARMID SA, 1995, J UROLOGY, V154, P492, DOI 10.1016/S0022-5347(01)67083-6; Masson C, 2004, J NEUROL NEUROSUR PS, V75, P1431, DOI 10.1136/jnnp.2003.031724; Mayer S. A, 2005, MERRITTS NEUROLOGY, P483; Mehta SS, 2006, SPINAL CORD, V44, P1, DOI 10.1038/sj.sc.3101800; Mitsui T, 2000, EUR UROL, V38, P434, DOI 10.1159/000020320; Moiyadi AV, 2007, NEUROREHABILITATION, V22, P93; Nakayama H, 1997, STROKE, V28, P58, DOI 10.1161/01.STR.28.1.58; Nedeltchev K, 2004, STROKE, V35, P560, DOI 10.1161/01.STR.0000111598.78198.EC; Nitti VW, 1996, J UROLOGY, V155, P263, DOI 10.1016/S0022-5347(01)66614-X; Nosseir M, 2007, NEUROUROL URODYNAM, V26, P228, DOI 10.1002/nau.20319; Nygaard IE, 1996, SPINE, V21, P128, DOI 10.1097/00007632-199601010-00028; Oh SJ, 2005, UROLOGY, V65, P306, DOI 10.1016/j.urology.2004.09.032; Oostra K, 1996, BRAIN INJURY, V10, P459, DOI 10.1080/026990596124313; Pan D, 2009, J UROLOGY, V181, P705, DOI 10.1016/j.juro.2008.10.004; Patel M, 2001, J AM GERIATR SOC, V49, P1229, DOI 10.1046/j.1532-5415.2001.49242.x; Patki P, 2006, J UROLOGY, V175, P1784, DOI 10.1016/S0022-5347(05)00979-1; RABAS PLK, 2003, NEUROUROL URODYNAM, V22, P322; Rapidi CA, 2008, SPINAL CORD, V46, P673, DOI 10.1038/sc.2008.16; Rigby Deborah, 2005, Nurs Stand, V19, P57; ROSSIER AB, 1979, J UROLOGY, V122, P783, DOI 10.1016/S0022-5347(17)56603-3; Sacomani CAR, 2003, SPINAL CORD, V41, P12, DOI 10.1038/sj.sc.3101354; Samson Gregory, 2007, Phys Med Rehabil Clin N Am, V18, P255; Schurch B, 2000, J UROLOGY, V164, P692, DOI 10.1016/S0022-5347(05)67283-7; Shekelle P G, 1999, J Spinal Cord Med, V22, P258; SIROKY MB, 1992, J UROLOGY, V148, P1211, DOI 10.1016/S0022-5347(17)36863-5; Sugimura T, 2008, BJU INT, V101, P1396, DOI 10.1111/j.1464-410X.2007.07404.x; TAUB NA, 1994, STROKE, V25, P352, DOI 10.1161/01.STR.25.2.352; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Turhan N, 2006, J AM GERIATR SOC, V54, P1022, DOI 10.1111/j.1532-5415.2006.00764.x; Vaidyananthan S, 1998, SPINAL CORD, V36, P409, DOI 10.1038/sj.sc.3100573; Vastenholt JM, 2003, SPINAL CORD, V41, P397, DOI 10.1038/sj.sc.3101465; Wein AJ, 2007, CAMPBELL WALSH UROLO, P2011; Weld KJ, 2000, J UROLOGY, V163, P768, DOI 10.1016/S0022-5347(05)67800-7; Weld KJ, 2000, UROLOGY, V55, P490, DOI 10.1016/S0090-4295(99)00553-1; Weld KJ, 2000, J UROLOGY, V163, P1228, DOI 10.1016/S0022-5347(05)67730-0; Wyndaele JJ, 1997, SPINAL CORD, V35, P213, DOI 10.1038/sj.sc.3100391; XIAO C-G, 1990, Journal of Urology, V143, p356A; Xiao CG, 2006, EUR UROL, V49, P22, DOI 10.1016/j.eururo.2005.10.004; Xiao CG, 2003, J UROLOGY, V170, P1237, DOI 10.1097/01.ju.0000080710.32964.d0; Yokoyama O, 1998, J UROLOGY, V159, P577, DOI 10.1016/S0022-5347(01)63987-9	74	33	40	1	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0094-0143	1558-318X		UROL CLIN N AM	Urol. Clin. N. Am.	NOV	2010	37	4					537	+		10.1016/j.ucl.2010.06.005			11	Urology & Nephrology	Urology & Nephrology	687RW	WOS:000284796600007	20955905				2021-06-18	
J	Reed, N; Taha, T; Keightley, M; Duggan, C; McAuliffe, J; Cubos, J; Baker, J; Faught, B; McPherson, M; Montelpare, W				Reed, N.; Taha, T.; Keightley, M.; Duggan, C.; McAuliffe, J.; Cubos, J.; Baker, J.; Faught, B.; McPherson, M.; Montelpare, W.			Measurement of Head Impacts in Youth Ice Hockey Players	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						concussion; head acceleration; youth athletes; ice hockey	COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CHILDREN; RATES; ACCELERATION; MAGNITUDE; STATEMENT	Despite growing interest in the biomechanical mechanisms of sports-related concussion, ice hockey and the youth sport population has not been studied extensively. The purpose of this pilot study was: 1) to describe the biomechanical measures of head impacts in youth minor ice hockey players; and, 2) to investigate the influence of player and game characteristics on the number and magnitude of head impacts. Data was collected from 13 players from a single competitive Bantam boy's (ages 13-14 years) AAA ice hockey team using telemetric accelerometers implanted within the players' helmets at 27 ice hockey games. The average linear acceleration, rotational acceleration, Gadd Severity Index and Head Injury Criterion of head impacts were recorded. A significantly higher number of head impacts per player per game were found for wingers when compared to centre and defense player positions (df = 355, t = 3.087, p = 0.00218) and for tournament games when compared to regular season and playoff games (df = 355, t = 2.641, p = 0.086). A significant difference in rotational acceleration according to player position (F-2,F-1812 = 4.9551, p = 0.0071) was found. This study is an initial step towards a greater understanding of head impacts in youth ice hockey.	[Reed, N.; Taha, T.] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON M5G 1V7, Canada; [McAuliffe, J.] Nipissing Univ, Dept Phys & Hlth Educ, N Bay, ON, Canada; [Cubos, J.; Baker, J.] York Univ, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada; [Faught, B.] Brock Univ, Fac Appl Hlth Sci, St Catharines, ON L2S 3A1, Canada; [McPherson, M.; Montelpare, W.] Lakehead Univ, Sch Kinesiol, Thunder Bay, ON P7B 5E1, Canada	Reed, N (corresponding author), Univ Toronto, Fac Phys Educ & Hlth, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	nick.reed@utoronto.ca	Baker, Joseph/J-6164-2014	Baker, Joseph/0000-0002-5686-1737	Ontario Neurotrauma Foundation	The authors would like to thank the Ontario Neurotrauma Foundation who provided funding for this project. Additionally, special thanks must be given to our participant hockey team, the Greater Toronto Hockey League, the Ontario Hockey Federation and the Ontario Hockey Research Group for all their cooperation and support.	BARNSLEY R, 1988, RESTOR NEUROL NEUROS, V20, P167; Benz B, 1999, RESTOR NEUROL NEUROS, V14, P135; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; CHU JJ, 2006, J BIOMECH, V39, pS153; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Crisco JJ, 1997, MED SCI SPORT EXER, V29, P26, DOI 10.1097/00005768-199701000-00005; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gwin J., 2006, J BIOMECH, V39, pS153; Harriss DJ, 2009, INT J SPORTS MED, V30, P701, DOI 10.1055/s-0029-1237378; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; LEHR E, 1990, COMMUNITY INTEGRATIO; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; MIHALIK J, 2008, J SPORTS ENG TECHNOL, V222, P45; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Sons J.W., 2007, R BOOK, P449; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Wattie N, 2007, PEDIATRICS, V120, P142, DOI 10.1542/peds.2006-2672; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	53	33	33	0	13	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	NOV	2010	31	11					826	833		10.1055/s-0030-1263103			8	Sport Sciences	Sport Sciences	675PN	WOS:000283842800011	20830655				2021-06-18	
J	Roberts, DJ; MacCulloch, KAM; Versnick, EJ; Hall, RI				Roberts, Derek J.; MacCulloch, Kate A. M.; Versnick, Eric J.; Hall, Richard I.			Should ancillary brain blood flow analyses play a larger role in the neurological determination of death?	CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							TRANSTENTORIAL HERNIATION; INJURY; VARIABILITY; MANAGEMENT; GUIDELINES; DIAGNOSIS; CRITERIA; REVERSAL; ORGANS	Purpose We present two patients who regained spontaneous respiration following clinical neurological determination of death (NDD) while ancillary radiological imaging demonstrated brain blood flow. Clinical features A 26-yr-old male with chronic otitis media presented with a Glasgow Coma Scale (GCS) score of 3 and fixed 7-mm pupils. Computed tomography demonstrated right-sided mastoiditis and a temporal lobe abscess associated with uncal herniation. The patient was diagnosed brain dead seven-hr later when motor responses and brainstem reflexes were absent and his apnea test was positive. Approximately 28-hr after NDD, during post-declaration organ resuscitation, the patient regained spontaneous respiration and magnetic resonance imaging revealed brain blood flow. Spontaneous respirations persisted for five-days before cardiovascular collapse occurred. In the second case, a 50-yr-old female presented with a GCS score of 3 and fixed 6-mm pupils following a traumatic brain injury and a five-minute cardiac arrest. The patient was deemed clinically brain dead six-hr later when physical examination revealed absent motor responses and brainstem reflexes and her apnea test was positive. As confirmation of brain death, a cerebral radionuclide angiogram was performed, which surprisingly revealed intracranial arterial flow. During organ resuscitation, 11-hr after NDD, the patient regained spontaneous respiration. She expired hours after family decision to withdraw treatment. Conclusion For both patients, several unrecognized confounding factors for NDD were present. These cases illustrate the difficulties encountered by experienced clinicians in determining brain death using clinical criteria alone, and they suggest that more routine use of ancillary brain blood flow analyses should be recommended.	[Hall, Richard I.] Dalhousie Univ, Dept Anesthesia, Halifax, NS B3H 3A7, Canada; [Hall, Richard I.] Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 3A7, Canada; [Hall, Richard I.] Dalhousie Univ, Dept Surg, Halifax, NS B3H 3A7, Canada; [Roberts, Derek J.] Univ Calgary, Dept Surg, Calgary, AB, Canada; [Roberts, Derek J.] Foothills Med Ctr, Calgary, AB, Canada; [Roberts, Derek J.; MacCulloch, Kate A. M.; Hall, Richard I.] Dalhousie Univ, Div Crit Care Med, Dept Med, Halifax, NS B3H 3A7, Canada; [Roberts, Derek J.; MacCulloch, Kate A. M.; Versnick, Eric J.; Hall, Richard I.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada; [Versnick, Eric J.] Dalhousie Univ, Div Neuroradiol, Dept Radiol, Halifax, NS B3H 3A7, Canada	Hall, RI (corresponding author), Dalhousie Univ, Dept Anesthesia, Halifax, NS B3H 3A7, Canada.	rihall@dal.ca	Roberts, Derek J./L-6229-2019	Roberts, Derek J./0000-0001-6111-6291			Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Chamoun RB, 2009, J NEUROSURG, V111, P683, DOI 10.3171/2009.2.JNS08817; Greer DM, 2008, NEUROLOGY, V70, P284, DOI 10.1212/01.wnl.0000296278.59487.c2; Heran MKS, 2008, CAN J NEUROL SCI, V35, P409, DOI 10.1017/S0317167100009069; Hornby K, 2006, CAN J ANAESTH, V53, P613, DOI 10.1007/BF03021854; Koenig MA, 2008, NEUROLOGY, V70, P1023, DOI 10.1212/01.wnl.0000304042.05557.60; KOHRMAN MH, 1990, PEDIATR NEUROL, V6, P47, DOI 10.1016/0887-8994(90)90078-F; Kutsogiannis DJ, 2006, CAN J ANAESTH, V53, P820, DOI 10.1007/BF03022800; Lang CJG, 2005, ACTA NEUROL SCAND, V112, P358, DOI 10.1111/j.1600-0404.2005.00527.x; Mauritz W, 2009, EUR J EMERG MED, V16, P153, DOI 10.1097/MEJ.0b013e32832a0864; Powner DJ, 2004, CRIT CARE MED, V32, P1284, DOI 10.1097/01.ccm.0000127265.62431.0d; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; Rosendale JD, 2003, TRANSPLANTATION, V75, P482, DOI 10.1097/01.TP.0000045683.85282.93; Salim A, 2005, J TRAUMA, V58, P991, DOI 10.1097/01.TA.0000168708.78049.32; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shemie SD, 2008, CAN J NEUROL SCI, V35, P140, DOI 10.1017/S0317167100008544; Shemie Sam D, 2007, Philos Ethics Humanit Med, V2, P18, DOI 10.1186/1747-5341-2-18; Shemie SD, 2006, CAN MED ASSOC J, V174, pS1, DOI 10.1503/cmaj.045142; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Stiver SI, 2009, J NEUROSURG, V110, P1242, DOI 10.3171/2008.8.JNS08314; Wijdicks EFM, 2008, NEUROLOGY, V71, P1240, DOI 10.1212/01.wnl.0000327612.69106.4c; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20; Xiao FR, 2005, SURG NEUROL, V63, P442, DOI 10.1016/j.surneu.2004.08.093; 2000, J NEUROTRAUMA, V17, P471	25	33	34	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X	1496-8975		CAN J ANESTH	Can. J. Anesth.	OCT	2010	57	10					927	935		10.1007/s12630-010-9359-4			9	Anesthesiology	Anesthesiology	654RF	WOS:000282185000008	20706879	Bronze			2021-06-18	
J	Toklu, HZ; Hakan, T; Celik, H; Biber, N; Erzik, C; Ogunc, AV; Akakin, D; Cikler, E; Cetinel, S; Ersahin, M; Sener, G				Toklu, Hale Z.; Hakan, Tayfun; Celik, Hasan; Biber, Necat; Erzik, Can; Ogunc, Ayliz V.; Akakin, Dilek; Cikler, Esra; Cetinel, Sule; Ersahin, Mehmet; Sener, Goksel			Neuroprotective Effects of Alpha-Lipoic Acid in Experimental Spinal Cord Injury in Rats	JOURNAL OF SPINAL CORD MEDICINE			English	Article						Alpha-lipoic acid; Antioxidants; Spinal cord injuries; Trauma; Neuroprotection; Lipid Peroxidation; Glutathione, Myeloperoxidase; DNA damage	ISCHEMIA-REPERFUSION INJURY; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; DIHYDROLIPOIC ACID; ANTIOXIDANT; METHYLPREDNISOLONE; GLUTATHIONE; PROTECTS	Background: Oxidative stress is a mediator of secondary injury to the spinal cord following trauma. Objective: To investigate the putative neuroprotective effect of a-lipoic acid (LA), a powerful antioxidant, in a rat model of spinal cord injury (SCI). Methods: Wistar albino rats were divided as control, vehicle-treated SCI, and LA-treated SCI groups. To induce SCI, a standard weight-drop method that induced a moderately severe injury (100 g/cm force) at T10 was used. Injured animals were given either 50 mg/kg LA or saline at 30 minutes postinjury by intraperitoneal injection. At 7 days postinjury, neurologic examination was performed, and rats were decapitated. Spinal cord samples were taken for histologic examination or determination of malondialdehyde (MDA) and glutathione (GSH) levels, myeloperoxidase (MPO) activity, and DNA fragmentation. Formation of reactive oxygen species in spinal cord tissue samples was monitored by using a chemiluminescence (CL) technique. Results: SCI caused a significant decrease in spinal cord GSH content, which was accompanied with significant increases in luminol CL and MDA levels, MPO activity, and DNA damage. Furthermore, LA treatment reversed all these biochemical parameters as well as SO-induced histopathologic alterations. Conversely, impairment of the neurologic function caused by SCI remained unchanged. Conclusion: The present study suggests that LA reduces SCI-induced oxidative stress and exerts neuroprotection by inhibiting lipid peroxidation, glutathione depletion, and DNA fragmentation.	[Toklu, Hale Z.; Hakan, Tayfun; Celik, Hasan; Biber, Necat; Erzik, Can; Ogunc, Ayliz V.; Akakin, Dilek; Cikler, Esra; Cetinel, Sule; Ersahin, Mehmet; Sener, Goksel] Marmara Univ Sch Pharm, Dept Pharmacol, TR-34668 Istanbul, Turkey	Toklu, HZ (corresponding author), Marmara Univ Sch Pharm, Dept Pharmacol, Tibbiye Cad 49, TR-34668 Istanbul, Turkey.	haletoklu@yahoo.com	Hakan, Tayfun/P-8626-2015; Hakan, Tayfun/O-9979-2019; Toklu, Hale/AAR-2330-2020; Sener, Goksel/AAN-4461-2021	Hakan, Tayfun/0000-0003-1444-7076; Hakan, Tayfun/0000-0003-1444-7076; Toklu, Hale/0000-0002-9797-3591; Sener, Goksel/0000-0001-7444-6193; Erzik, Can/0000-0002-7914-1169			Adibhatla RM, 2008, BMB REP, V41, P560, DOI 10.5483/BMBRep.2008.41.8.560; ALLEN AR, 1911, SURGERY */* JAMA, V57, P878; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bernards CM, 2006, SPINAL CORD, V44, P594, DOI 10.1038/sj.sc.3101891; BEUTLER E, 1963, J LAB CLIN MED, V61, P882; Biewenga GP, 1997, DRUG METAB REV, V29, P1025, DOI 10.3109/03602539709002242; Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0; Bilska A, 2005, PHARMACOL REP, V57, P570; Buege J A, 1978, Methods Enzymol, V52, P302; Burton K., 1968, METHODS ENZYMOL, V12, P163; DAVIES GR, 1992, GUT, V33, P1467, DOI 10.1136/gut.33.11.1467; Dulundu E, 2007, PHARMACOLOGY, V79, P163, DOI 10.1159/000098953; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; Ersahin M, 2010, NEUROCHEM RES, V35, P418, DOI 10.1007/s11064-009-0072-z; Foster TS, 2007, DIABETES EDUCATOR, V33, P111, DOI 10.1177/0145721706297450; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Glantzounis GK, 2006, CURR PHARM DESIGN, V12, P2891, DOI 10.2174/138161206777947641; GNS D, 2008, Exp Neural, V211, P259; Haklar G, 1998, MARMARA MED J, V11, P55; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Han D, 1997, BIOFACTORS, V6, P321, DOI 10.1002/biof.5520060303; HILLEGASS LM, 1990, J PHARMACOL METHOD, V24, P285, DOI 10.1016/0160-5402(90)90013-B; Jia ZQ, 2009, MOL CELL BIOCHEM, V323, P131, DOI 10.1007/s11010-008-9971-6; KAGAN VE, 1992, BIOCHEM PHARMACOL, V44, P1637, DOI 10.1016/0006-2952(92)90482-X; Kolgazi M, 2007, J GASTROEN HEPATOL, V22, P1859, DOI 10.1111/j.1440-1746.2006.04504.x; Maczurek A, 2008, ADV DRUG DELIVER REV, V60, P1463, DOI 10.1016/j.addr.2008.04.015; Manda K, 2007, BEHAV BRAIN RES, V177, P7, DOI 10.1016/j.bbr.2006.11.013; Moini H, 2002, TOXICOL APPL PHARM, V182, P84, DOI 10.1006/taap.2002.9437; NOSEWORTHY IH, 2000, MULTIPLE SCLEROSIS *, V343, P938; Packer L, 1997, FREE RADICAL BIO MED, V22, P359, DOI 10.1016/S0891-5849(96)00269-9; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Roy S, 1998, BIOFACTORS, V8, P17, DOI 10.1002/biof.5520080104; Salinthone Sonemany, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P132, DOI 10.2174/187153008784534303; Sehirli O, 2008, CLIN EXP PHARMACOL P, V35, P249, DOI 10.1111/j.1440-1681.2007.04810.x; Sehirli O, 2008, PHARMACOLOGY, V81, P173, DOI 10.1159/000111145; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; SUZUKI YJ, 1993, FREE RADICAL RES COM, V18, P115, DOI 10.3109/10715769309147348; Taoka Y, 2001, J NEUROTRAUM, V18, P533, DOI 10.1089/089771501300227332; Tilleux S, 2007, J NEUROSCI RES, V85, P2059, DOI 10.1002/jnr.21325; Toklu HZ, 2009, FREE RADICAL RES, V43, P658, DOI 10.1080/10715760902988843; Wu GY, 2004, J NUTR, V134, P489; Zhang WJ, 2007, P NATL ACAD SCI USA, V104, P4077, DOI 10.1073/pnas.0700305104	42	33	35	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1079-0268	2045-7723		J SPINAL CORD MED	J. Spinal Cord. Med.	OCT	2010	33	4					401	409		10.1080/10790268.2010.11689719			9	Clinical Neurology	Neurosciences & Neurology	674AJ	WOS:000283705200010	21061900	Green Published			2021-06-18	
J	Deits, J; Yard, EE; Collins, CL; Fields, SK; Comstock, RD				Deits, Jeff; Yard, Ellen E.; Collins, Christy L.; Fields, Sarah K.; Comstock, R. Dawn			Patients With Ice Hockey Injuries Presenting to US Emergency Departments, 1990-2006	JOURNAL OF ATHLETIC TRAINING			English	Article						epidemiology; injury surveillance; face shields; mouth guards; body checking	NECK INJURIES; UNITED-STATES; DESCRIPTIVE EPIDEMIOLOGY; SURVEILLANCE SYSTEM; PLAYERS; HEAD; CONCUSSIONS; PROTECTION; SOCCER; RATES	Context: Although the number of US ice hockey participants doubled from 1990 to 2006, no nationally representative studies have examined US ice hockey injuries among participants of all ages during this period. Objective: To describe patients with ice hockey injuries presenting to a representative sample of US emergency departments (EDs) from 1990 through 2006. Design: Prospective injury surveillance study. Setting: The US Consumer Product Safety Commission collects data from 100 nationally representative EDs via the National Electronic Injury Surveillance System (NEISS). Patients or Other Participants: Individuals injured while playing ice hockey and presenting to a NEISS-affiliated ED from 1990 through 2006. Main Outcome Measure(s): Incidence and patterns of ice hockey-related injuries. Results: From 1990 through 2006, 8228 patients with ice hockey-related injuries presented to NEISS-affiliated EDs, representing an estimated 302 368 ice hockey-related injuries sustained nationally during this time. Injuries occurred predominantly among males (93.5%). More than half of the injured were aged 9 to 14 years (28.9%) or 1510 18 years (30.1%), and injury incidence in these age groups increased over the study period (P =.009 and P < .001, respectively). The most commonly injured body sites were the face (19.1%), wrist/hand/finger (14.1%), shoulder/upper arm (13.8%), and lower leg/ankle/foot (11.1%). Lacerations (27.0%), contusions/abrasions (23.6%), fractures (17.3%), and sprains/strains (16.9%) were the most common injuries. Falls (16.5%), contact with boards (13.6%), and contact with stick (13.0%) were the most common injury mechanisms. Compared with those aged 9 to 18 years, those aged 2 to 8 years and those older than 18 years sustained larger proportions of face (injury proportion ratio [IPR] = 2.66; 95% confidence interval [Cl] = 2.29, 3.08) and mouth (IPR = 4.34; 95% Cl = 2.87, 6.56) injuries. Concussions were more common among those aged 2 to 18 years (9.0%) than in those who were older than 18 years (3.7%) (IPR = 2.47; 95% Cl = 1.75, 3.49). Conclusions: Ice hockey injury patterns vary by age and sex. Our findings indicate that many trips to the ED might be prevented by using protective equipment appropriately.	[Yard, Ellen E.; Collins, Christy L.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Deits, Jeff; Fields, Sarah K.] Ohio State Univ, Sch Phys Act & Educ Serv, Columbus, OH 43210 USA; [Yard, Ellen E.; Comstock, R. Dawn] Ohio State Univ, Coll Publ Hlth, Columbus, OH 43210 USA; [Yard, Ellen E.; Comstock, R. Dawn] Ohio State Univ, Coll Med, Columbus, OH 43210 USA	Collins, CL (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	christy.collins@nationwidechildrens.org					Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Anderson AJ, 2000, PEDIATRICS, V105, P657; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Berry DC, 2005, J PUBLIC HEALTH DENT, V65, P71, DOI 10.1111/j.1752-7325.2005.tb02789.x; Biasca N, 2002, BRIT J SPORT MED, V36, P410, DOI 10.1136/bjsm.36.6.410; *CONS PROD SAF COM, NEISS COD MAN; *CONS PROD SAF COM, NEISS SAMPL DES IMPL; Delaney JS, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.015735; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Dryden D M, 2000, J Sci Med Sport, V3, P140, DOI 10.1016/S1440-2440(00)80076-6; Dryden DM, 2000, MED SCI SPORT EXER, V32, P1378, DOI 10.1097/00005768-200008000-00004; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Hagel BE, 2006, CAN MED ASSOC J, V175, P155, DOI 10.1503/cmaj.051531; Hostetler SG, 2004, PEDIATRICS, V114, pE661, DOI 10.1542/peds.2004-1565; Knox CL, 2006, BRIT J SPORT MED, V40, P268, DOI 10.1136/bjsm.2005.022855; Le Menestrel Suzanne, 2007, New Dir Youth Dev, P13; McKnight Cynthia M., 1992, Journal of Athletic Training, V27, P342; Molsa J, 2000, AM J SPORT MED, V28, P322; Molsa J, 2003, AM J SPORT MED, V31, P751; *NAT FED STAT HIGH, NFHS PART FIG SEARCH; Neussl Amy, 2008, J Dent Hyg, V82, P44; Stuart MJ, 2002, AM J SPORT MED, V30, P39, DOI 10.1177/03635465020300012001; *US HOCK, 2009, MEMB STAT; *US HOCK, 2007 2009 OFF RUL IC; Wattie N, 2007, PEDIATRICS, V120, P142, DOI 10.1542/peds.2006-2672; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Woods SE, 2008, SOUTH MED J, V101, P991, DOI 10.1097/SMJ.0b013e3181830d42; Woods SE, 2007, FAM MED, V39, P473; Yard EE, 2006, J ATHL TRAINING, V41, P441	32	33	34	0	10	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2010	45	5					467	474		10.4085/1062-6050-45.5.467			8	Sport Sciences	Sport Sciences	654GZ	WOS:000282157800005	20831391	Green Published			2021-06-18	
J	Holli, KK; Waljas, M; Harrison, L; Liimatainen, S; Luukkaala, T; Ryymin, P; Eskola, H; Soimakallio, S; Ohman, J; Dastidar, P				Holli, Kirsi K.; Waljas, Minna; Harrison, Lara; Liimatainen, Suvi; Luukkaala, Tiina; Ryymin, Pertti; Eskola, Hannu; Soimakallio, Seppo; Ohman, Juha; Dastidar, Prasun			Mild Traumatic Brain Injury: Tissue Texture Analysis Correlated to Neuropsychological and DTI Findings	ACADEMIC RADIOLOGY			English	Article						Mild traumatic brain injury; texture analysis; magnetic resonance imaging; diffusion tensor imaging	DIFFUSE AXONAL INJURY; NON-HODGKIN-LYMPHOMA; INTRACRANIAL TUMORS; CORPUS-CALLOSUM; SCLEROSIS; MODERATE; IMAGES	Rationale and Objectives: The aim of this study was to evaluate whether texture analysis (TA) can detect subtle changes in cerebral tissue caused by mild traumatic brain injury (MTBI) and to determine whether these changes correlate with neuropsychological and diffusion tensor imaging (DTI) findings. Materials and Methods: Forty-two patients with MTBIs were imaged using 1.5T magnetic resonance imaging within 3 weeks after head injury. TA was performed for the regions corresponding to the mesencephalon, centrum semiovale, and corpus callosum. Using DTI, the fractional anisotropic and apparent diffusion coefficient values for the same regions were evaluated. The same analyses were performed on a group of 10 healthy volunteers. Patients also underwent a battery of neurocognitive tests within 6 weeks after injury. Results: TA revealed textural differences between the right and left hemispheres in patients with MTBIs, whereas differences were minimal in healthy controls. A significant correlation was found between scores on memory tests and texture parameters (sum of squares, sum entropy, inverse difference moment, and sum average) in patients in the area of the mesencephalon and the genu of the corpus callosum. Significant correlations were also found between texture parameters for the left mesencephalon and both fractional anisotropic and apparent diffusion coefficient values. Conclusions: The data suggest that heterogeneous texture and abnormal DTI patterns in the area of the mesencephalon may be linked with verbal memory deficits among patients with MTBIs. Therefore, TA combined with DTI in patients with MTBIs may increase the ability to detect early and subtle neuropathologic changes.	[Holli, Kirsi K.; Harrison, Lara; Ryymin, Pertti; Eskola, Hannu; Soimakallio, Seppo; Dastidar, Prasun] Tampere Univ Hosp, Med Imaging Ctr, Tampere 33521, Finland; [Liimatainen, Suvi] Tampere Univ Hosp, Dept Neurol & Rehabil, Tampere 33521, Finland; [Waljas, Minna; Ohman, Juha] Tampere Univ Hosp, Dept Neurosurg, Tampere 33521, Finland; [Liimatainen, Suvi] Tampere Univ Hosp, Dept Emergency Med Acuta, Tampere 33521, Finland; [Holli, Kirsi K.; Harrison, Lara; Eskola, Hannu] Tampere Univ Technol, Dept Biomed Engn, FIN-33101 Tampere, Finland; [Harrison, Lara; Soimakallio, Seppo; Dastidar, Prasun] Tampere Med Sch, Tampere, Finland; [Luukkaala, Tiina] Pirkanmaa Hosp Dist, Ctr Sci, Tampere, Finland; [Luukkaala, Tiina] Univ Tampere, Tampere Sch Publ Hlth, FIN-33101 Tampere, Finland	Holli, KK (corresponding author), Tampere Univ Hosp, Med Imaging Ctr, Post Box 2000, Tampere 33521, Finland.	kirsi.holli@tut.fi	Eskola, Hannu/G-4279-2014	Eskola, Hannu/0000-0003-1673-2305; Ohman, Juha/0000-0002-6592-1367; Luukkaala, Tiina/0000-0003-4636-9586	Pirkanmaa Hospital District, Tampere University Hospital (Tampere, Finland); Jenny and Antti Wihuri Foundation (Helsinki, Finland); Instrumentarium Science Foundation (Helsinki, Finland)	This study was supported by grants for research funding from the Pirkanmaa Hospital District, Tampere University Hospital (Tampere, Finland); the Jenny and Antti Wihuri Foundation (Helsinki, Finland); and the Instrumentarium Science Foundation (Helsinki, Finland).	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bonilha L, 2003, EPILEPSIA, V44, P1546, DOI 10.1111/j.0013-9580.2003.27103.x; *CAMBR COGN, 2004, CANTAB CAMBR NEUR AU; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Freeborough PA, 1998, IEEE T MED IMAGING, V17, P475, DOI 10.1109/42.712137; Gibbs P, 2003, MAGN RESON MED, V50, P92, DOI 10.1002/mrm.10496; Harrison L, 2008, COMPUT BIOL MED, V38, P519, DOI 10.1016/j.compbiomed.2008.01.016; Harrison LCV, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-87; Herlidou-Meme S, 2003, MAGN RESON IMAGING, V21, P989, DOI 10.1016/S0730-725X(03)00212-1; Holli K, 2010, ACAD RADIOL, V17, P135, DOI 10.1016/j.acra.2009.08.012; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jirak D, 2002, J MAGN RESON IMAGING, V15, P68, DOI 10.1002/jmri.10042; KJAER L, 1995, ACTA RADIOL, V36, P127; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lerski, 2006, TEXTURE ANAL MAGNETI; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; MAHMOUDGHONEIM D, 2008, BMC MED IMAGING, V23, P8; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mitrushina M., 2005, NORMATIVE DATA NEURO; Morrow LA, 2002, CLIN NEUROPSYCHOL, V16, P373, DOI 10.1076/clin.16.3.373.13850; POSSE S, 1995, MAGN RESON MED, V33, P34, DOI 10.1002/mrm.1910330106; Rauscher A, 2006, Z MED PHYS, V16, P240, DOI 10.1078/0939-3889-00322; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; SCHAD LR, 1993, MAGN RESON IMAGING, V11, P889, DOI 10.1016/0730-725X(93)90206-S; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; TEASDALE G, 1974, LANCET, V2, P81; Tuceryan M., 1998, HDB PATTERN RECOGNIT, P207; Zhang J, 2008, MAGN RESON IMAGING, V26, P1160, DOI 10.1016/j.mri.2008.01.016	33	33	34	1	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1076-6332	1878-4046		ACAD RADIOL	Acad. Radiol.	SEP	2010	17	9					1096	1102		10.1016/j.acra.2010.04.009			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	643PL	WOS:000281310500006	20605490				2021-06-18	
J	Krawczyk, DC; Hanten, G; Wilde, EA; Li, XQ; Schnelle, KP; Merkley, TL; Vasquez, AC; Cook, LG; McClelland, M; Chapman, SB; Levin, HS				Krawczyk, Daniel C.; Hanten, Gerri; Wilde, Elisabeth A.; Li, Xiaoqi; Schnelle, Kathleen P.; Merkley, Tricia L.; Vasquez, Ana C.; Cook, Lori G.; McClelland, Michelle; Chapman, Sandra B.; Levin, Harvey S.			Deficits in analogical reasoning in adolescents with traumatic brain injury	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						analogy; reasoning; traumatic brain injury; gray matter; adolescent; distraction	CLOSED-HEAD INJURY; HUMAN CEREBRAL-CORTEX; ATTENTION DEFICIT/HYPERACTIVITY DISORDER; ROSTROLATERAL PREFRONTAL CORTEX; TYPICALLY DEVELOPING-CHILDREN; MAGNETIC-RESONANCE IMAGES; LONG-TERM OUTCOMES; INHIBITORY CONTROL; WORKING-MEMORY; EXECUTIVE FUNCTIONS	Individuals with traumatic brain injury (TBI) exhibit deficits in executive control, which may impact their reasoning abilities. Analogical reasoning requires working memory and inhibitory abilities. In this study, we tested adolescents with moderate to severe TBI and typically developing (TD) controls on a set of picture analogy problems. Three factors were varied: complexity (number of relations in the problems), distraction (distractor item present or absent), and animacy (living or non-living items in the problems). We found that TD adolescents performed significantly better overall than TBI adolescents. There was also an age effect present in the TBI group where older participants performed better than younger ones. This age effect was not observed in the TD group. Performance was affected by complexity and distraction. Further, TBI participants exhibited lower performance with distractors present than TD participants. The reasoning deficits exhibited by the TBI participants were correlated with measures of executive function that required working memory updating, attention, and attentional screening. Using MRI-derived measures of cortical thickness, correlations were carried out between task accuracy and cortical thickness. The TD adolescents showed negative correlations between thickness and task accuracy in frontal and temporal regions consistent with cortical maturation in these regions. This study demonstrates that adolescent TBI results in impairments in analogical reasoning ability. Further, TBI youth have difficulty effectively screening out distraction, which may lead to failures in comprehension of the relations among items in visual scenes. Lastly, TBI youth fail to show robust cortical-behavior correlations as observed in TD individuals.	[Krawczyk, Daniel C.; Cook, Lori G.; McClelland, Michelle; Chapman, Sandra B.] Univ Texas Dallas, Ctr Brain Hlth, Sch Behav & Brain Sci, Dallas, TX 75235 USA; [Krawczyk, Daniel C.] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX USA; [Hanten, Gerri; Wilde, Elisabeth A.; Li, Xiaoqi; Schnelle, Kathleen P.; Vasquez, Ana C.; Levin, Harvey S.] Univ Texas Houston Med Sch, Houston, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Wilde, Elisabeth A.; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Krawczyk, DC (corresponding author), Univ Texas Dallas, Ctr Brain Hlth, Sch Behav & Brain Sci, 2200 Mockingbird Lane, Dallas, TX 75235 USA.	daniel.krawczyk@utdallas.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-21889]	We thank Lindsey Richland for assistance with the task materials and procedure. We thank Carrie McAdams, Kevin Murch, Ehsan Shokri, and Gloria Yang for helpful comments and suggestions. We also acknowledge the assistance of Drs. Jill V. Hunter and Zili Chu in image acquisition and pre-processing. This work was supported by NIH grant NS-21889 (Harvey S. Levin). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would also like to acknowledge the generous support by Mission Connect of the TIRR Foundation.	Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; BROWN AL, 1989, SIMILARITY AND ANALOGICAL REASONING, P369, DOI 10.1017/CBO9780511529863.019; Bunge SA, 2005, CEREB CORTEX, V15, P239, DOI 10.1093/cercor/bhh126; Bunge SA, 2009, NEUROIMAGE, V46, P338, DOI 10.1016/j.neuroimage.2009.01.064; Christoff K, 2009, BRAIN RES, V1286, P94, DOI 10.1016/j.brainres.2009.05.096; Colom R, 2006, NEUROIMAGE, V31, P1359, DOI 10.1016/j.neuroimage.2006.01.006; Crone EA, 2009, DEVELOPMENTAL SCI, V12, P55, DOI 10.1111/j.1467-7687.2008.00743.x; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; DALE AM, 1993, J COGNITIVE NEUROSCI, V5, P162, DOI 10.1162/jocn.1993.5.2.162; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Geake JG, 2010, NEUROIMAGE, V49, P3489, DOI 10.1016/j.neuroimage.2009.09.008; GENTNER D, 1983, COGNITIVE SCI, V7, P155, DOI 10.1207/s15516709cog0702_3; GENTNER D, 1986, COGNITIVE SCI, V10, P277, DOI 10.1207/s15516709cog1003_2; Gentner D., 1991, PERSPECTIVES LANGUAG, P225, DOI DOI 10.1017/CBO9780511983689.008; Ghosh A, 2009, BRAIN INJURY, V23, P228, DOI 10.1080/02699050802672789; Giedd JN, 2009, J AM ACAD CHILD PSY, V48, P465, DOI 10.1097/CHI.0b013e31819f2715; GOSWAMI U, 1990, COGNITION, V35, P69, DOI 10.1016/0010-0277(90)90037-K; Goswami U, 2001, BRIT J PSYCHOL, V92, P257, DOI 10.1348/000712601162068; Goswami U, 1998, BRIT J DEV PSYCHOL, V16, P553, DOI 10.1111/j.2044-835X.1998.tb00771.x; Green AE, 2006, BRAIN RES, V1096, P125, DOI 10.1016/j.brainres.2006.04.024; Green AE, 2010, CEREB CORTEX, V20, P70, DOI 10.1093/cercor/bhp081; Haier RJ, 2004, NEUROIMAGE, V23, P425, DOI 10.1016/j.neuroimage.2004.04.025; HALFORD GS, 1994, CHILD DEV, V65, P1338, DOI 10.1111/j.1467-8624.1994.tb00820.x; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hiscock Merrill, 2002, Appl Neuropsychol, V9, P129, DOI 10.1207/S15324826AN0903_1; Holyoak K.J., 1996, MENTAL LEAPS ANALOGY; Hummel JE, 1997, PSYCHOL REV, V104, P427, DOI 10.1037/0033-295X.104.3.427; Hummel JE, 2003, PSYCHOL REV, V110, P220, DOI 10.1037/0033-295X.110.2.220; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kotovsky L, 1996, CHILD DEV, V67, P2797, DOI 10.2307/1131753; Krawczyk DC, 2008, NEUROPSYCHOLOGIA, V46, P2020, DOI 10.1016/j.neuropsychologia.2008.02.001; Kuperberg GR, 2003, ARCH GEN PSYCHIAT, V60, P878, DOI 10.1001/archpsyc.60.9.878; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Leblanc N, 2006, BRAIN COGNITION, V60, P208; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Luo Q, 2003, COGNITIVE BRAIN RES, V17, P527, DOI 10.1016/S0926-6410(03)00167-8; MARKMAN AB, 1993, COGNITIVE PSYCHOL, V25, P431, DOI 10.1006/cogp.1993.1011; McCauley SR, 2010, DEV NEUROPSYCHOL, V35, P318, DOI 10.1080/87565641003696866; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Morrison RG, 2004, J COGNITIVE NEUROSCI, V16, P260, DOI 10.1162/089892904322984553; Morrison RG, 2008, BEHAV BRAIN SCI, V31, P391, DOI 10.1017/S0140525X08004615; Morsanyi K, 2010, DEVELOPMENTAL SCI, V13, P578, DOI 10.1111/j.1467-7687.2009.00915.x; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Newsome MR, 2008, NEUROPSYCHOLOGY, V22, P419, DOI 10.1037/0894-4105.22.4.419; O'Keeffe FM, 2007, EXP BRAIN RES, V180, P59, DOI 10.1007/s00221-006-0832-9; OHARE E, 2009, J COGNITIVE NEUROS S, V36, P46; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Penn DC, 2008, BEHAV BRAIN SCI, V31, P130; Penn DC, 2008, BEHAV BRAIN SCI, V31, P109, DOI 10.1017/S0140525X08003543; Rattermann MJ, 1998, COGNITIVE DEV, V13, P453, DOI 10.1016/S0885-2014(98)90003-X; Raven JC, 1938, PROGRESSIVE MATRICES; Richland LE, 2006, J EXP CHILD PSYCHOL, V94, P249, DOI 10.1016/j.jecp.2006.02.002; Rosas HD, 2002, NEUROLOGY, V58, P695, DOI 10.1212/WNL.58.5.695; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Salvucci DD, 2001, COGNITIVE SCI, V25, P67; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shaw P, 2008, J NEUROSCI, V28, P3586, DOI 10.1523/JNEUROSCI.5309-07.2008; Smith R, 2007, NEUROIMAGE, V36, P1387, DOI 10.1016/j.neuroimage.2007.04.032; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; STERNBERG RJ, 1979, J EXP CHILD PSYCHOL, V27, P195, DOI 10.1016/0022-0965(79)90044-4; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; Tohill J.M., 2000, THINK REASONING, V6, P27, DOI [10.1080/135467800393911., DOI 10.1080/135467800393911]; Viskontas IV, 2004, PSYCHOL AGING, V19, P581, DOI 10.1037/0882-7974.19.4.581; Waltz JA, 1999, PSYCHOL SCI, V10, P119, DOI 10.1111/1467-9280.00118; Waltz JA, 2004, NEUROPSYCHOLOGY, V18, P296, DOI 10.1037/0894-4105.18.2.296; Waltz JA, 2000, MEM COGNITION, V28, P1205, DOI 10.3758/BF03211821; Wendelken C, 2008, J COGNITIVE NEUROSCI, V20, P682, DOI 10.1162/jocn.2008.20055; Wharton CM, 2000, COGNITIVE PSYCHOL, V40, P173, DOI 10.1006/cogp.1999.0726; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wright SB, 2008, FRONT HUM NEUROSCI, V1, DOI 10.3389/neuro.09.008.2007; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; YNTEMA DB, 1967, ACTA PSYCHOL, V27, P325, DOI 10.1016/0001-6918(67)90075-3	99	33	34	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	AUG 19	2010	4								62	10.3389/fnhum.2010.00062			13	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	747FH	WOS:000289305200001	20844604	DOAJ Gold, Green Published			2021-06-18	
J	Stojsih, S; Boitano, M; Wilhelm, M; Bir, C				Stojsih, S.; Boitano, M.; Wilhelm, M.; Bir, C.			A prospective study of punch biomechanics and cognitive function for amateur boxers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							HEAD-INJURIES; FOOTBALL; ACCELERATION; CONCUSSION; IMPACTS	Objective To evaluate several biomechanical factors of the head during a sparring session and their link to cognitive function. Design Instrumented Boxing Headgear (IBH) was used for data collection during four 2 min sparring sessions. Neurocognitive assessment was measured using the ImPACT (c) Concussion management software. A baseline neurocognitive test was obtained from each athlete prior to sparring; two additional tests were obtained and compared with the baseline. Setting Male and female amateur boxers. Participants Data were collected from 30 male and 30 female amateur boxers. Main outcome measurements Head accelerations (translational and rotational), injury severity indexes (Head Injury Criteria (HIC) and Gadd Severity Index (051)) and cognitive function scores. Results Peak translational and rotational acceleration values were 191 g and 17 156 rad/s(2), respectively, for males and 184 g and 13 113 rad/s(2), respectively, for females. The peak HIC and GSI values for males were 1652 and 2292, respectively, and for females 1079 and 1487, respectively. There was no significant difference in the neurocognitive scores between genders. A decrease was exhibited in the delayed memory postbout scores. All other scores either increased or did not significantly decrease when compared with the baseline. Conclusions The majority of impacts experienced by both genders were under the threshold for mild head injury. There was a statistically significant difference between peak translational and rotational acceleration, HIC and GSI when comparing genders. When analysing cognitive functions, there was no statistical difference between genders.	[Stojsih, S.; Wilhelm, M.; Bir, C.] Wayne State Univ, Detroit, MI 48201 USA; [Boitano, M.] McMaster Univ, Hamilton, ON, Canada	Bir, C (corresponding author), Wayne State Univ, 818 W Hancock, Detroit, MI 48201 USA.	cbir@wayne.edu		Bir, Cynthia/0000-0002-0777-0951	National Operating Committee on Standards for Athletic Equipment	The National Operating Committee on Standards for Athletic Equipment provided funding for this research project. Impact Boxing Headgear was developed for this study by Simbex, and the IBH data were postprocessed by J Beckwith of Simbex. K Paden assisted in the postprocessing of the neurocognitive data. Boxers from USA boxing, U of M, the Armed Forces, Ramos Boxing Gym, Zarzamora Street Gym, Windsor Boxing Club and Border City Boxing Gym volunteered their time to participate in the study. E Hanlon, C Schreiner, R Bolander and 0 Pinto Neto assisted in data collection for the study. Statistical analysis was completed by B Ozkan, from Wayne State University.; Funding The National Operating Committee on Standards for Athletic Equipment provided funding for this research project.	ATHA J, 1985, BRIT MED J, V291, P1756, DOI 10.1136/bmj.291.6511.1756; Backaitis S.H., 1981, HEAD NECK INJURY CRI, P175; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; BROOKS N, 1987, J NEUROL NEUROSUR PS, V50, P997, DOI 10.1136/jnnp.50.8.997; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Cross KM, 2003, CLIN SPORT MED, V22, P639, DOI 10.1016/S0278-5919(02)00099-6; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; EPPINGER RH, 1981, HEAD NECK INJURY CRI, P204; HEILBRONNER RL, 1991, AM J SPORT MED, V19, P376, DOI 10.1177/036354659101900409; Holbourn AHS, 1943, LANCET, V2, P438; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; MCELHANEY JH, 1976, HDB HUMAN TOLERANCE, P288; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Porter MD, 2003, CLIN J SPORT MED, V13, P339, DOI 10.1097/00042752-200311000-00002; Smith MS, 2000, J SPORT SCI, V18, P445, DOI 10.1080/02640410050074377; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Zazryn T, 2006, BRIT J SPORT MED, V40, P670, DOI 10.1136/bjsm.2006.025924; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	25	33	33	0	28	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2010	44	10					725	730		10.1136/bjsm.2008.052845			6	Sport Sciences	Sport Sciences	635MC	WOS:000280658800010	19019907				2021-06-18	
J	Brown, KV; Dharm-Datta, S; Potter, BK; Etherington, J; Mistlin, A; Hsu, JR; Clasper, JC				Brown, Kate V.; Dharm-Datta, Shresth; Potter, B. Kyle; Etherington, John; Mistlin, Alan; Hsu, Joseph R.; Clasper, Jon C.			Comparison of Development of Heterotopic Ossification in Injured US and UK Armed Services Personnel With Combat-Related Amputations: Preliminary Findings and Hypotheses Regarding Causality	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Heterotopic ossification; Risk factors; Amputation level; Blast; Patient exposure	TRAUMATIC BRAIN-INJURY; STAPHYLOCOCCUS-AUREUS; HUMAN OSTEOBLASTS; BONE-FORMATION; RISK-FACTORS; EXPRESSION; EXPERIENCE; MANAGEMENT; SEVERITY; MOUSE	Background: Recent reports have documented the rate of heterotopic ossification (HO) formation in the residual limbs of combat-related amputees from the US Armed Forces injured in Operations Iraqi and Enduring Freedom. Final amputation level within the zone of injury and blast as the mechanism of injury were identified as possible risk factors for the occurrence and grade of HO. There has been no previous description of HO in combat-related amputees from the UK service personnel. The purpose of this study was to examine potential differences in the prevalence of HO between UK and US Allied Forces, with particular attention to these risk factors, patient exposures, and any treatment differences between these two groups. Methods: We reviewed the medical records and radiographs of 35 combat-related amputations from the UK and contrasted them with 213 previously reported amputations in US military personnel. We evaluated prevalence and severity of residual limb HO, Injury Severity Score (ISS), the mechanism and zone of injury, type and level of amputation, number of debridements, method of wound irrigation, presence of severe head injury and/or burns injury, use of topical negative pressure therapy and pulse lavage, number of days until wound closure, type of closure, and subsequent infections. All patients had a minimum of 2-month posthospital discharge radiographic follow-up. Comparisons were made using Fisher's exact, one-way analysis of variance, and chi(2) analyses. Results: There was no significant difference in either the overall prevalence of HO or the prevalence of moderate to severe HO in the two populations. Twenty of 35 (57.1%) limbs in the UK amputations developed HO compared with 134 of 213 (63%) in the US amputations (p > 0.05). The UK amputations had 12 cases (34.3%) of moderate to severe HO compared with 72 cases (33.8%) in the US amputations (p > 0.05). However, there was a significant difference in the number of UK amputations 0 of 20 (0%) versus the number of US amputations 25 of 134 (12%; p = 0.04), which required excision of symptomatic lesions. There was a significant association in the development of HO in UK personnel with the use of topical negative pressure treatment (p = 0.05) and increasing ISS scores (p = 0.04) and in the development of moderate to severe HO with increasing ISS (p = 0.006) and severe HI (p = 0.04). Unlike in the previous report, no significant association was found in UK personnel between any of the remaining hypothesized risk factors and either the presence or grade of HO. Conclusions: Although no difference was identified in the overall prevalence of HO, there are inconsistencies in the possible underlying causes of HO between the two cohorts. Further research is required in an ongoing effort to determine a causal relationship between treatment and subsequent HO formation.	[Brown, Kate V.] USA, Inst Surg Res, Ft Sam Houston, TX 78234 USA; [Dharm-Datta, Shresth; Etherington, John; Mistlin, Alan] Def Med Rehabil Ctr, Epsom, Surrey, England; [Potter, B. Kyle] Walter Reed Army Med Ctr, Amputee Patient Care Program, Integrated Dept Orthopaed & Rehabil, Washington, DC 20307 USA; [Potter, B. Kyle] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA; [Hsu, Joseph R.] Brooke Army Med Ctr, Dept Trauma & Orthopaed, Ft Sam Houston, TX 78234 USA; [Clasper, Jon C.] Acad Dept Mil Surg & Trauma, Birmingham, W Midlands, England	Brown, KV (corresponding author), USA, Inst Surg Res, 3400 Rawley E Chambers, Ft Sam Houston, TX 78234 USA.	kate.brown2@amedd.army.mil	Potter, Benjamin/U-1769-2019	Potter, MD, Benjamin K./0000-0002-8771-0317			Alexander EH, 2001, INFECT IMMUN, V69, P1581, DOI 10.1128/IAI.69.3.1581-1586.2001; Barrack RL, 2002, CLIN ORTHOP RELAT R, P208, DOI 10.1097/01.blo.0000030497.43495.3f; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Bost KL, 2000, INFECT IMMUN, V68, P5075, DOI 10.1128/IAI.68.9.5075-5083.2000; BRACKETT EG, 1927, MED DEP US ARMY WO 1, V2, P713; Brown KV, 2009, J TRAUMA, V66, pS93, DOI 10.1097/TA.0b013e31819cdcb0; Chen XQ, 2007, J ORTHOP TRAUMA, V21, P693, DOI 10.1097/BOT.0b013e31815a7e91; Ebinger T, 2000, J TRAUMA, V48, P1058, DOI 10.1097/00005373-200006000-00010; EVANS EB, 1991, CLIN ORTHOP RELAT R, P94; GUSTILO RB, 1990, J BONE JOINT SURG AM, V72A, P299, DOI 10.2106/00004623-199072020-00023; HANSEN MO, 1994, MIL MED, V159, P376; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; Hunt JL, 2006, J BURN CARE RES, V27, P535, DOI 10.1097/01.BCR.0000226023.58438.14; Islinger RB, 2000, MIL MED, V165, P463; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; Marriott I, 2004, AM J PATHOL, V164, P1399, DOI 10.1016/S0002-9440(10)63226-9; McCarthy EF, 2005, SKELETAL RADIOL, V34, P609, DOI 10.1007/s00256-005-0958-z; Otis G, 1883, MED SURG HIST CIVI 3, V2, P880; Owens BD, 2007, J ORTHOP TRAUMA, V21, P254, DOI 10.1097/BOT.0b013e31802f78fb; Pape HC, 2004, J BONE JOINT SURG BR, V86B, P783, DOI 10.1302/0301-620X.86B6.15356; PETERSON SL, 1989, J TRAUMA, V29, P365, DOI 10.1097/00005373-198903000-00015; Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS191; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; REDDI AH, 1995, CLIN ORTHOP RELAT R, P115; Richards AM, 1997, BURNS, V23, P64, DOI 10.1016/S0305-4179(96)00074-5; Rush RM, 2007, MIL MED, V172, P777; SAWYER JR, 1991, CALCIFIED TISSUE INT, V49, P208, DOI 10.1007/BF02556120; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; VENIER L H, 1971, Archives of Physical Medicine and Rehabilitation, V52, P475	29	33	33	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2010	69			1			S116	S122		10.1097/TA.0b013e3181e44cc7			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	627AC	WOS:000280009000018	20622605				2021-06-18	
J	Goldshmit, Y; Munro, K; Leong, SY; Pebay, A; Turnley, AM				Goldshmit, Yona; Munro, Kathryn; Leong, Soo Yuen; Pebay, Alice; Turnley, Ann M.			LPA receptor expression in the central nervous system in health and following injury	CELL AND TISSUE RESEARCH			English	Article						Lysophosphatidic acid; LPA receptor; Spinal cord injury; Cortical injury neurotrauma; Mouse (C57BL/6)	LYSOPHOSPHATIDIC ACID RECEPTOR; RAT ASTROCYTES; GLUCOSE-UPTAKE; CELL-LINES; MICE; PROLIFERATION; NEURONS; GENE; RHO; VZG-1/LP(A1)/EDG-2	Lysophosphatidic acid (LPA) is released from platelets following injury and also plays a role in neural development but little is known about its effects in the adult central nervous system (CNS). We have examined the expression of LPA receptors 1-3 (LPA(1-3)) in intact mouse spinal cord and cortical tissues and following injury. In intact and injured tissues, LPA(1) was expressed by ependymal cells in the central canal of the spinal cord and was upregulated in reactive astrocytes following spinal cord injury. LPA(2) showed low expression in intact CNS tissue, on grey matter astrocytes in spinal cord and in ependymal cells lining the lateral ventricle. Following injury, its expression was upregulated on astrocytes in both cortex and spinal cord. LPA(3) showed low expression in intact CNS tissue, viz. on cortical neurons and motor neurons in the spinal cord, and was upregulated on neurons in both regions after injury. Therefore, LPA(1-3) are differentially expressed in the CNS and their expression is upregulated in response to injury. LPA release following CNS injury may have different consequences for each cell type because of this differential expression in the adult nervous system.	[Goldshmit, Yona; Munro, Kathryn; Leong, Soo Yuen; Pebay, Alice; Turnley, Ann M.] Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia; [Pebay, Alice] Univ Melbourne, Dept Pharmacol, Melbourne, Vic 3010, Australia; [Goldshmit, Yona] Monash Univ, Australian Regenerat Med Inst, Clayton, Vic 3800, Australia	Turnley, AM (corresponding author), Univ Melbourne, Ctr Neurosci, Melbourne, Vic 3010, Australia.	apebay@unimelb.edu.au; turnley@unimelb.edu.au	Turnley, Ann/A-8125-2010	Turnley, Ann/0000-0002-8442-127X; Pebay, Alice/0000-0002-7408-9453	NHMRCNational Health and Medical Research Council of Australia [454723, 454384]; SpinalCure Australia Research Fellowship	This work was supported by NHMRC Project Grants 454723 and 454384, an NHMRC-Senior Research Fellowship (A.M.T.) and a SpinalCure Australia Research Fellowship (Y.G.).	Bouquet C, 2007, MOL CELL NEUROSCI, V36, P235, DOI 10.1016/j.mcn.2007.07.002; Choi JW, 2008, BBA-MOL CELL BIOL L, V1781, P531, DOI 10.1016/j.bbalip.2008.03.004; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Contos JJA, 2002, MOL CELL BIOL, V22, P6921, DOI 10.1128/MCB.22.19.6921-6929.2002; Contos JJA, 2001, GENE, V267, P243, DOI 10.1016/S0378-1119(01)00410-3; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Elmes SJR, 2004, BRAIN RES, V1022, P205, DOI 10.1016/j.brainres.2004.07.005; Frohnert PW, 2003, J NEUROPATH EXP NEUR, V62, P520, DOI 10.1093/jnen/62.5.520; Fujita R, 2007, NEUROCHEM INT, V50, P351, DOI 10.1016/j.neuint.2006.09.003; Fukushima N, 2002, MOL CELL NEUROSCI, V20, P271, DOI 10.1006/mcne.2002.1123; Fukushima N, 2002, MOL BIOL CELL, V13, P2692, DOI 10.1091/mbc.01-09-0465; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Hama K, 2007, BIOL REPROD, V77, P954, DOI 10.1095/biolreprod.107.060293; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Holtsberg FW, 1998, J NEUROCHEM, V70, P66; Inoue M, 2004, NAT MED, V10, P712, DOI 10.1038/nm1060; Ishii I, 2000, MOL PHARMACOL, V58, P895; Keller JN, 1997, J NEUROCHEM, V69, P1073; Keller JN, 1996, J NEUROCHEM, V67, P2300; Koh JS, 1998, J CLIN INVEST, V102, P716, DOI 10.1172/JCI1002; Kotarsky K, 2006, J PHARMACOL EXP THER, V318, P619, DOI 10.1124/jpet.105.098848; Lee CW, 2007, J BIOL CHEM, V282, P4310, DOI 10.1074/jbc.M610826200; Liszewska E, 2009, ENDOCRINOLOGY, V150, P422, DOI 10.1210/en.2008-0749; Manning TJ, 1997, GLIA, V20, P163, DOI 10.1002/(SICI)1098-1136(199706)20:2<163::AID-GLIA8>3.0.CO;2-A; Moller T, 1999, NEUROREPORT, V10, P2929; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Noguchi K, 2009, CURR OPIN PHARMACOL, V9, P15, DOI 10.1016/j.coph.2008.11.010; Ohuchi H, 2008, DEV DYNAM, V237, P3280, DOI 10.1002/dvdy.21736; Pebay A, 1999, GLIA, V28, P25, DOI 10.1002/(SICI)1098-1136(199910)28:1<25::AID-GLIA3>3.0.CO;2-D; Pebay A, 2007, PROSTAG OTH LIPID M, V84, P83, DOI 10.1016/j.prostaglandins.2007.08.004; Ramakers GJA, 1998, EXP CELL RES, V245, P252, DOI 10.1006/excr.1998.4224; Renback K, 1999, NEUROSCI LETT, V270, P59, DOI 10.1016/S0304-3940(99)00464-4; Renback K, 2000, MOL BRAIN RES, V75, P350, DOI 10.1016/S0169-328X(99)00333-2; Rouach N, 2006, EUR J NEUROSCI, V23, P1453, DOI 10.1111/j.1460-9568.2006.04671.x; Savaskan NE, 2007, CELL MOL LIFE SCI, V64, P230, DOI 10.1007/s00018-006-6412-0; Shano S, 2008, NEUROCHEM INT, V52, P216, DOI 10.1016/j.neuint.2007.07.004; Sorensen SD, 2003, MOL PHARMACOL, V64, P1199, DOI 10.1124/mol.64.5.1199; Spohr TCDSE, 2008, J BIOL CHEM, V283, P7470, DOI 10.1074/jbc.M707758200; Stankoff B, 2002, MOL CELL NEUROSCI, V20, P415, DOI 10.1006/mcne.2002.1129; Steiner MR, 2000, ANN NY ACAD SCI, V905, P132; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; TIGYI G, 1995, AM J PHYSIOL-HEART C, V268, pH2048; Tomas M, 2003, J NEUROCHEM, V87, P220, DOI 10.1046/j.1471-4159.2003.01993.x; Ueda H, 2006, PHARMACOL THERAPEUT, V109, P57, DOI 10.1016/j.pharmthera.2005.06.003; Weiner JA, 1998, J COMP NEUROL, V398, P587; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Zheng Zhao-Qing, 2004, Shengli Xuebao, V56, P163; zu Heringdorf DM, 2007, BBA-BIOMEMBRANES, V1768, P923, DOI 10.1016/j.bbamem.2006.09.026	50	33	35	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	JUL	2010	341	1					23	32		10.1007/s00441-010-0977-5			10	Cell Biology	Cell Biology	620LE	WOS:000279500600003	20495828				2021-06-18	
J	Goldshmit, Y; Bourne, JA				Goldshmit, Yona; Bourne, James A.			Upregulation of EphA4 on Astrocytes Potentially Mediates Astrocytic Gliosis after Cortical Lesion in the Marmoset Monkey	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; brain injury; EphA4; glial fibrillary acidic protein	CENTRAL-NERVOUS-SYSTEM; RECEPTOR TYROSINE KINASES; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; GENE-EXPRESSION; VISUAL-CORTEX; NITRIC-OXIDE; HUMAN BRAIN; GROWTH; REGENERATION	Glial scar formation occurs in response to brain injury in mammalian models and inhibits axonal growth. Identification of molecules that may mediate reactivity of astrocytes has become a leading therapeutic goal in the field of neurotrauma. In adult rodent brain and spinal cord, many of the Eph receptors and their ephrin ligands have been demonstrated to be upregulated on reactive astrocytes at the injury site; however, little is known about the expression of these molecules in nonhuman primate injury models. This study examines the role of the tyrosine kinase EphA4 receptor, which predominantly binds most ephrin ligands, after injury in marmoset monkey brain. Following lesioning of the primary visual cortex (V1) in the adult marmoset, EphA4 is strongly upregulated on reactive astrocytes around the lesion site, which secrete extracellular matrix molecules such as chondroitin sulfate proteoglycans, which are known for their inhibitory effect on axonal growth and regeneration. This astrocyte reactivity was also associated with neuronal death in the area adjacent to the lesion site. EphA4 activation induced by clustered ephrin A5-Fc-mediated astrocyte proliferation and glial fibrillary acidic protein expression in vitro, as demonstrated by closure of scratched wound and MTT assays, occurs via two potential signaling pathways, the mitogen-activated protein kinase and Rho pathways. These results in a nonhuman primate model highlight the importance of developing pharmacotherapeutic approaches to block these molecules following brain injury.	[Goldshmit, Yona; Bourne, James A.] Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3800, Australia	Goldshmit, Y (corresponding author), Monash Univ, Australian Regenerat Med Inst, Melbourne, Vic 3800, Australia.	yona.goldshmit@med.monash.edu.au	Bourne, James/B-5265-2018	Bourne, James/0000-0002-0902-3108	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [491022, 433620]; Australian Regenerative Medicine Institute	The authors thank Prof. Marcello Rosa (Monash University) for providing brain tissue, which was collected as part of experiments funded by National Health and Medical Research Council (NHMRC) Project Grant 491022. Also, the authors would like to thank Dr. Samuel McLenachan for revision of earlier versions of this manuscript. This work was supported by the Australian Regenerative Medicine Institute; an NHMRC Project Grant 433620 (J.A.B.); a VNI Fellowship to Y.G.; and an R.D. Wright Fellowship (NHMRC) to J.A.B.	Bourne JA, 2006, CEREB CORTEX, V16, P405, DOI 10.1093/cercor/bhi119; Bowden TA, 2009, STRUCTURE, V17, P1386, DOI 10.1016/j.str.2009.07.018; Brown GC, 2003, MOL NEUROBIOL, V27, P325, DOI 10.1385/MN:27:3:325; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Bundesen LQ, 2003, J NEUROSCI, V23, P7789; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Donoghue MJ, 1999, J NEUROSCI, V19, P5967, DOI 10.1523/JNEUROSCI.19-14-05967.1999; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Fukai J, 2008, MOL CANCER THER, V7, P2768, DOI 10.1158/1535-7163.MCT-07-2263; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Goldshmit Y, 2004, J NEUROSCI, V24, P10064, DOI 10.1523/JNEUROSCI.2981-04.2004; Goldshmit Y, 2006, J COMP NEUROL, V497, P864, DOI 10.1002/cne.21029; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Herrmann JE, 2010, EXP NEUROL, V223, P582, DOI 10.1016/j.expneurol.2010.02.005; Himanen JP, 2004, NAT NEUROSCI, V7, P501, DOI 10.1038/nn1237; Holland SJ, 1998, CURR OPIN NEUROBIOL, V8, P117, DOI 10.1016/S0959-4388(98)80015-9; Kullander K, 2001, GENE DEV, V15, P877, DOI 10.1101/gad.868901; Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404; Liebl DJ, 2003, J NEUROSCI RES, V71, P7, DOI 10.1002/jnr.10457; Lim JH, 2007, BRAIN RES, V1164, P1, DOI 10.1016/j.brainres.2007.06.020; Lin R, 2008, J NEUROCHEM, V104, P400, DOI 10.1111/j.1471-4159.2007.05066.x; Lyckman AW, 2001, J NEUROSCI, V21, P7684; Martone ME, 1997, BRAIN RES, V771, P238, DOI 10.1016/S0006-8993(97)00792-0; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Minghetti L, 2005, CURR OPIN NEUROL, V18, P315, DOI 10.1097/01.wco.0000169752.54191.97; Miranda JD, 1999, EXP NEUROL, V156, P218, DOI 10.1006/exnr.1998.7012; Moreno-Flores MT, 1999, NEUROSCIENCE, V91, P193, DOI 10.1016/S0306-4522(98)00568-5; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Puschmann TB, 2010, J NEUROCHEM, V113, P881, DOI 10.1111/j.1471-4159.2010.06655.x; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Salgado D, 2008, BIOINFORMATICS, V24, P447, DOI 10.1093/bioinformatics/btm599; Sestan N, 2001, CURR BIOL, V11, P39, DOI 10.1016/S0960-9822(00)00043-9; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; Sobel RA, 2005, BRAIN PATHOL, V15, P35; Symonds ACE, 2007, EUR J NEUROSCI, V25, P744, DOI 10.1111/j.1460-9568.2007.05321.x; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Wang Y, 2003, MOL BRAIN RES, V120, P79, DOI 10.1016/j.molbrainres.2003.10.005; Willson CA, 2002, CELL TRANSPLANT, V11, P229; Xiao DQ, 2006, BRAIN RES, V1067, P67, DOI 10.1016/j.brainres.2005.10.073; Zhao ML, 1998, BRAIN RES, V813, P402, DOI 10.1016/S0006-8993(98)01023-3	47	33	35	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1321	1332		10.1089/neu.2010.1294			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100016	20486805				2021-06-18	
J	Anderson, V; Brown, S; Newitt, H				Anderson, Vicki; Brown, Sandra; Newitt, Heidi			What Contributes to Quality of Life in Adult Survivors of Childhood Traumatic Brain Injury?	JOURNAL OF NEUROTRAUMA			English	Article						child; long-term outcome; quality of life; traumatic brain injury	OUTCOME 30 MONTHS; FUNCTIONAL RECOVERY; HEAD-INJURY; SHORT-TERM; FOLLOW-UP; PREDICTORS; SEVERITY; CHILDREN; TBI	Adult outcome from childhood brain injury is largely unknown, and health professionals have minimal evidence available to inform families about their child's long-term prognosis. This study aimed to investigate long-term outcomes in this group, focusing on quality of life (QOL) and the injury, developmental, and environmental factors that influence this domain, using a retrospective and cross-sectional design. The sample was ascertained via medical record audit at the Royal Children's Hospital, Melbourne, Australia, and included 130 adult survivors of child traumatic brain injury (TBI) (84 men). Participants were 18-42 years at evaluation (mean=23.2, SD=3.3) and completed questionnaires regarding QOL and educational, employment, and psychological status. Analysis of variance, chi-square, and regression were employed to assess group differences and predictors of outcome. While most adult survivors of childhood TBI rated their QOL as intact, 17% of the sample reported poor QOL. Poor QOL was more likely with low levels of perceived independence, severe TBI, younger age at injury, failure to complete high school, and psychological problems. In conclusion, QOL in adult survivors of childhood TBI is better than expected and closely associated with both injury and noninjury factors, most consistently with the individual's perception of their level of independence.	[Anderson, Vicki] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Anderson, Vicki; Brown, Sandra] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, Vicki; Newitt, Heidi] Univ Melbourne, Melbourne, Vic, Australia	Anderson, V (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au					Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; *AUSTR BUR STAT, 2006, DIS LONG TERM HLTH C; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Daniel A. E., 1983, POWER PRIVILEGE PRES; Donders J, 2007, J HEAD TRAUMA REHAB, V22, P296, DOI 10.1097/01.HTR.0000290974.01872.82; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Kieslich M, 2001, DISABIL REHABIL, V23, P665; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Nybo T, 1999, BRAIN INJURY, V13, P759; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; VIGNOLO G, 1980, ITAL J NEUROL, V2, P65; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	28	33	33	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					863	870		10.1089/neu.2009.1169			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400008	20144003				2021-06-18	
J	Figaji, AA; Zwane, E; Kogels, M; Fieggen, AG; Argent, AC; Le Roux, PD; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Kogels, M.; Fieggen, A. Graham; Argent, Andrew C.; Le Roux, Peter D.; Peter, Jonathan C.			The effect of blood transfusion on brain oxygenation in children with severe traumatic brain injury	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						blood transfusion; brain tissue oxygen tension; children; traumatic brain injury; head injury	CEREBRAL OXYGENATION; CRITICALLY-ILL; TISSUE OXYGENATION; CELL TRANSFUSION; ANEMIA; METABOLISM; MECHANISMS; DIFFUSION; DELIVERY; TENSION	Objective: The indications for blood transfusion in traumatic brain injury are controversial. In particular, little is known about the effect of blood transfusion in childhood traumatic brain injury. This study aimed to examine the influence of blood transfusion on brain tissue oxygen tension in children with severe traumatic brain injury. Design: A retrospective analysis of a prospective observational database of children with severe traumatic brain injury who received brain tissue oxygen tension monitoring and a blood transfusion. Setting: University-affiliated pediatric hospital. Patients: Children with severe traumatic brain injury and blood transfusion. Interventions: None. Measurments and Main Results: Brain tissue oxygen tension was measured in normal-appearing white matter with a commercially available polarographic Clarke-type electrode. Brain tissue oxygen tension values after blood transfusion were compared with pre-transfusion values in hemodynamically stable patients. Limited interventions were allowed during the studied period. Brain tissue oxygen tension values were examined for early (1-4 hrs) and late (24 hrs) changes after blood transfusion, controlling for multiple clinical and physiologic variables with regression techniques. Further comparison was made with matched non-transfused controls to examine the influence of time after injury. Nineteen blood transfusions in 17 patients were evaluated. Brain tissue oxygen tension increased significantly in the early period after blood transfusion (p = .0018; 79% increased, 21% decreased) in comparison with baseline values and matched controls, but the overall changes were small and, in part, influenced by accompanying cerebral perfusion pressure changes. Also, this effect was limited to the early period after blood transfusion and was not significant after 24 hrs. In general, the brain tissue oxygen tension increase was larger in patients with higher baseline brain tissue oxygen tension and lower initial hemoglobin; however, no factors associated with the magnitude of the brain tissue oxygen tension change were significant in multivariate analysis. Increased age of blood did not appear to impair brain tissue oxygen tension changes, but most blood transfusion were < 14 days old. Conclusions: Brain tissue oxygen tension increased transiently in 79% of blood transfusion in pediatric traumatic brain injury patients, and decreased transiently in 21%. Brain tissue oxygen tension returned to baseline within 24 hrs. Reliable predictors of this brain tissue oxygen tension response to blood transfusion, however, remain elusive. (Pediatr Crit Care Med 2010; 11: 325-331)	[Figaji, Anthony A.; Kogels, M.; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa; [Argent, Andrew C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Pediat Crit Care, ZA-7925 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit Biostat, ZA-7925 Cape Town, South Africa; [Le Roux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Figaji, AA (corresponding author), Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za	Argent, Andrew/J-1605-2019	Argent, Andrew/0000-0001-9333-2036; Fieggen, Graham/0000-0001-6541-8377; Figaji, Anthony/0000-0002-3357-6490	Integra Foundation	Dr. Figaji and Dr. Le Roux have received a grant from the Integra Foundation for the study of cerebral perfusion pressure thresholds in children but no funds were used for the purposes of this study. The remaining authors have not disclosed any potential conflicts of interest.	Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS45; Armano R, 2005, CRIT CARE MED, V33, P2637, DOI 10.1097/01.CCM.0000185645.84802.73; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; Desmet L, 2004, CRIT CARE CLIN, V20, P299, DOI 10.1016/S0749-0704(03)00113-1; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Fitzgerald RD, 1997, CRIT CARE MED, V25, P726, DOI 10.1097/00003246-199705000-00004; Hare GMT, 2008, ANESTH ANALG, V107, P1356, DOI 10.1213/ane.0b013e318184cfe9; Hare GMT, 2007, J APPL PHYSIOL, V103, P1021, DOI 10.1152/japplphysiol.01315.2006; Hebert PC, 2001, CRIT CARE MED, V29, P227, DOI 10.1097/00003246-200102000-00001; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Netzer G, 2008, CRIT CARE MED, V36, P1383, DOI 10.1097/CCM.0b013e31816a10a3; Raat NJH, 2007, VOX SANG, V93, P12, DOI 10.1111/j.1423-0410.2007.00909.x; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vincent JL, 2006, CRIT CARE MED, V34, pS96, DOI 10.1097/01.CCM.0000214314.57109.CD; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	30	33	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2010	11	3					325	331		10.1097/PCC.0b013e3181b80a8e			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	593WO	WOS:000277493200001	19794323				2021-06-18	
J	Gilmer, LK; Ansari, MA; Roberts, KN; Scheff, SW				Gilmer, Lesley K.; Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.			Age-Related Mitochondrial Changes after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						aging; cortical contusion injury; oxidative damage; respiration; synaptic and extrasynaptic mitochondria; traumatic brain injury	OXYGEN SPECIES PRODUCTION; INDUCED AXONAL INJURY; OXIDATIVE-STRESS; RAT-BRAIN; SYNAPTIC MITOCHONDRIA; LIPID-PEROXIDATION; SKELETAL-MUSCLE; OLDER-ADULTS; DYSFUNCTION; DAMAGE	Mitochondrial dysfunction is known to occur following traumatic brain injury (TBI) and has been well characterized. This study assessed possible age-related changes in the cortical mitochondrial bioenergetics following TBI. Three hours following a moderate TBI, tissue from the ipsilateral hemisphere (site of impact and penumbra) and the corresponding contralateral region were harvested from young (3- to 5-month-old) and aged (22- to 24-month-old) Fischer 344 rats. Synaptic and extrasynaptic mitochondria were isolated using a Ficoll gradient, and several bioenergetic parameters were examined using a Clark-type electrode. Injury-related respiration deficits were observed in both young and aged rats. Synaptic mitochondria showed an age-related decline in the rate of ATP production, and a decline in respiratory control ratios (RCR), which were not apparent in the extrasynaptic fraction. Following respiration analysis, mitochondrial samples were probed for oxidative damage (3-nitrotyrosine [3-NT], 4-hydroxynonenal [4-HNE], and protein carbonyls [PC]). All markers of oxidative damage were elevated with injury and age in the synaptic fraction, but only with injury in the extrasynaptic fraction. Synaptic mitochondria displayed the highest levels of oxidative damage and may contribute to the synaptic bioenergetic deficits seen following injury. Data indicate that cortical synaptic mitochondria appear to have an increased susceptibility to perturbation with age, suggesting that the increased mitochondrial dysfunction observed following injury may impede recovery in aged animals.	[Gilmer, Lesley K.; Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Gilmer, Lesley K.; Scheff, Stephen W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, 101 Sanders Brown Bldg, Lexington, KY 40536 USA.	sscheff@email.uky.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG21981]; NIH-NIDAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [1T32 DA 022738-01]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA022738] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health grant AG21981 and training grant NIH-NIDA 1T32 DA 022738-01.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ansari MA, 2008, FREE RADICAL BIO MED, V45, P443, DOI 10.1016/j.freeradbiomed.2008.04.038; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Atamna H, 2007, MITOCHONDRION, V7, P297, DOI 10.1016/j.mito.2007.06.001; Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624; Brown MR, 2004, J BIOENERG BIOMEMBR, V36, P401, DOI 10.1023/B:JOBB.0000041775.10388.23; Brown MR, 2006, J BIOL CHEM, V281, P11658, DOI 10.1074/jbc.M510303200; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bustamante J, 2008, NEUROCHEM RES, V33, P1216, DOI 10.1007/s11064-007-9570-z; Butterfield DA, 2001, CURR MED CHEM, V8, P815, DOI 10.2174/0929867013373048; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; CHIU YJD, 1980, EXP GERONTOL, V15, P511, DOI 10.1016/0531-5565(80)90003-0; Cocco T, 2005, FREE RADICAL BIO MED, V38, P796, DOI 10.1016/j.freeradbiomed.2004.11.034; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; COTMAN CW, 1979, MECH AGEING DEV, V9, P103, DOI 10.1016/0047-6374(79)90124-6; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Davey GP, 1997, J NEUROCHEM, V69, P2564; Davey GP, 1996, J NEUROCHEM, V66, P1617; Dellinger AM, 2006, J SAFETY RES, V37, P519, DOI 10.1016/j.jsr.2006.10.001; Dencher NA, 2007, ANN NY ACAD SCI, V1100, P291, DOI 10.1196/annals.1395.030; DESHMUKH DR, 1980, J NEUROCHEM, V34, P1219, DOI 10.1111/j.1471-4159.1980.tb09962.x; Driver AS, 2000, NEUROTOXICOL TERATOL, V22, P175, DOI 10.1016/S0892-0362(99)00069-0; Erecinska M, 1996, BBA-BIOENERGETICS, V1277, P13, DOI 10.1016/S0005-2728(96)00103-X; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Feng J, 2008, J GERONTOL A-BIOL, V63, P1137, DOI 10.1093/gerona/63.11.1137; Finsterer J, 2008, J NEUROL SCI, V272, P20, DOI 10.1016/j.jns.2008.05.011; Flaada JT, 2007, J NEUROTRAUM, V24, P435, DOI 10.1089/neu.2006.0119; Fukui H, 2008, TRENDS NEUROSCI, V31, P251, DOI 10.1016/j.tins.2008.02.008; Gilmer LK, 2010, MECH AGEING DEV, V131, P133, DOI 10.1016/j.mad.2009.12.011; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Gong Y, 2005, ACT NEUR S, V95, P425; Gouspillou G, 2010, BBA-BIOENERGETICS, V1797, P143, DOI 10.1016/j.bbabio.2009.09.004; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; Hoane MR, 2004, BEHAV BRAIN RES, V153, P189, DOI 10.1016/j.bbr.2003.11.012; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacoby SF, 2006, J NURS SCHOLARSHIP, V38, P133, DOI 10.1111/j.1547-5069.2006.00090.x; Joseph JA, 1996, FREE RADICAL BIO MED, V20, P821, DOI 10.1016/0891-5849(95)02225-2; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kovacs EJ, 2005, EXP GERONTOL, V40, P549, DOI 10.1016/j.exger.2005.04.009; LaFrance R, 2005, AGING CELL, V4, P139, DOI 10.1111/j.1474-9726.2005.00156.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LESLIE SW, 1985, BRAIN RES, V329, P177, DOI 10.1016/0006-8993(85)90523-2; Lesnefsky EJ, 2006, AGEING RES REV, V5, P402, DOI 10.1016/j.arr.2006.04.001; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Long JG, 2006, LIFE SCI, V79, P1466, DOI 10.1016/j.lfs.2006.04.024; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Maughan PH, 2000, J NEUROTRAUM, V17, P1141, DOI 10.1089/neu.2000.17.1141; Meng QY, 2007, MECH AGEING DEV, V128, P286, DOI 10.1016/j.mad.2006.12.008; Merry BJ, 2004, AGING CELL, V3, P7, DOI 10.1046/j.1474-9728.2003.00074.x; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Navarro A, 2005, AM J PHYSIOL-REG I, V289, pR1392, DOI 10.1152/ajpregu.00834.2004; Navarro A, 2008, AM J PHYSIOL-REG I, V294, pR501, DOI 10.1152/ajpregu.00492.2007; Navarro A, 2007, AM J PHYSIOL-CELL PH, V292, pC670, DOI 10.1152/ajpcell.00213.2006; Nicholls DG, 2004, AGING CELL, V3, P35, DOI 10.1111/j.1474-9728.2003.00079.x; Petrosillo G, 2008, NEUROCHEM INT, V53, P126, DOI 10.1016/j.neuint.2008.07.001; Petrosillo G, 2008, REJUV RES, V11, P935, DOI 10.1089/rej.2008.0772; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 1999, ACT NEUR S, V73, P15; Renes J, 2000, BIOCHEM J, V350, P555, DOI 10.1042/0264-6021:3500555; Richmond TS, 2002, J AM GERIATR SOC, V50, P215, DOI 10.1046/j.1532-5415.2002.50051.x; RICHTER C, 1995, INT J BIOCHEM CELL B, V27, P647, DOI 10.1016/1357-2725(95)00025-K; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9; Scafidi S, 2009, J NEUROCHEM, V109, P189, DOI 10.1111/j.1471-4159.2009.05896.x; Shah SA, 2006, EXP GERONTOL, V41, P1201, DOI 10.1016/j.exger.2006.07.006; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI [10.1089/ars.2008.2331, 10.1089/ARS.2008.2331]; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Swerdlow RH, 2007, ANTIOXID REDOX SIGN, V9, P1591, DOI 10.1089/ars.2007.1676; Thompson Hilaire J, 2006, Crit Care Nurs Clin North Am, V18, P419, DOI 10.1016/j.ccell.2006.05.008; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toescu EC, 2003, CELL CALCIUM, V34, P311, DOI 10.1016/S0143-4160(03)00142-8; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; Trifunovic A, 2008, J INTERN MED, V263, P167, DOI 10.1111/j.1365-2796.2007.01905.x; UCHIDA K, 1993, P NATL ACAD SCI USA, V90, P8742, DOI 10.1073/pnas.90.18.8742; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Van Remmen H, 2001, EXP GERONTOL, V36, P957; Victorino GP, 2003, ARCH SURG-CHICAGO, V138, P1093, DOI 10.1001/archsurg.138.10.1093; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Walker LM, 2001, TOXICOL SCI, V63, P143, DOI 10.1093/toxsci/63.1.143; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yager JY, 2006, BEHAV BRAIN RES, V173, P171, DOI 10.1016/j.bbr.2006.06.019; Zhu W, 2003, J GERONTOL A-BIOL, V58, P117	97	33	34	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2010	27	5					939	950		10.1089/neu.2009.1181			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	599LX	WOS:000277915400015	20175672	Green Published			2021-06-18	
J	Purins, K; Enblad, P; Sandhagen, B; Lewen, A				Purins, Karlis; Enblad, Per; Sandhagen, Bo; Lewen, Anders			Brain tissue oxygen monitoring: a study of in vitro accuracy and stability of Neurovent-PTO and Licox sensors	ACTA NEUROCHIRURGICA			English	Article						Licox; Neurovent-PTO; Brain tissue oxygenation; Accuracy; Neurointensive care; Traumatic brain injury	SEVERE HEAD-INJURY; CEREBRAL OXYGENATION; PARTIAL-PRESSURE; INSPIRED OXYGEN; SATURATION; PO2; EXPERIENCE; TENSION; LACTATE	Periods of brain tissue ischemia are common after severe head injury, and their occurrence and duration are negatively correlated with outcome. Accurate and reliable measurement of brain tissue oxygenation (B-ti pO(2)) may be a key to improve patient outcome after severe head injury. Knowledge of stability and accuracy of the B-ti pO(2) systems is crucial. We have therefore conducted a bench test study of new Neurovent-PTOA (R) (NV) and LicoxA (R) (LX) oxygen tension catheters to evaluate the sensor accuracy, response time to different oxygen tensions, response to temperature changes and long-term stability. For all experiments five new fluorescent NV sensors and five new electrochemical LX sensors were used. The catheter probes were placed into a container filled with a buffer solution. The solution was equilibrated with five high precision calibration gases. The accuracy of the probes was recorded after an equilibration period of 20 min in O-2 concentrations of 5, 10, 20, 30 and 40 mmHg at 37.0 +/- 0.2A degrees C. The probe response to an increase in temperature from 37.0A degrees C to 38.5A degrees C to 40.0A degrees C in two different gases with O-2 concentrations of 10 and 20 mmHg were analysed. We also recorded the time for reaching 90% of a new oxygen concentration level when switching from one concentration to another. Finally, to test if there was a time-dependant drift in pO(2) recordings, all sensors were left in 10 mmHg O-2 solution for 10 days, and recordings were taken every 24 h. In all gas concentrations, NV and LX sensors measured pO(2) with high accuracy and stability in vitro (mean differences from calculated values were for NV 0.76-1.6 mmHg and for LX -0.46-0.26 mmHg). Both sensors showed a shorter response time to pO(2) increase (for NV 56 +/- 22 s and for LX 78 +/- 21 s) compared to pO(2) decrease (for NV 131 +/- 42 s and for LX 215 +/- 63 s). NV pO(2) values were more stable for changes in temperature, while LX sensors showed larger standard deviations with increasing temperature (the difference from the calculated values in 19.7 mmHg O-2 at 40A degrees C were for NV probes between 0.5 and 1.7 mmHg and LX between -2.3 and 1.9 mmHg). Both sensors gave stable results with low standard deviations during long-term (10 days) use, but with a slight elevation of measured pO(2) levels by time. Both NV and LX were accurate in detecting different oxygen tensions, and they did not deviate over longer recording times. However, LX needed a significantly longer time to detect changes in pO(2) levels compared to NV. Furthermore, LX probes showed an increased standard deviation with higher temperatures.	[Purins, Karlis; Enblad, Per; Lewen, Anders] Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden; [Sandhagen, Bo] Univ Uppsala Hosp, Dept Med Sci, Sect Clin Physiol, S-75185 Uppsala, Sweden	Enblad, P (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Neurosurg Sect, S-75185 Uppsala, Sweden.	per.enblad@neuro.uu.se	Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	Swedish Research CouncilSwedish Research CouncilEuropean Commission	The study was supported by The Swedish Research Council. We would like to acknowledge Lars Berglund, Ph. D., Uppsala Clinical Research Center, Uppsala University for statistical advice.	Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Fandino J, 1999, ACTA NEUROCHIR, V141, P825, DOI 10.1007/s007010050383; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Haitsma IK, 2007, PROG BRAIN RES, V161, P207, DOI 10.1016/S0079-6123(06)61014-5; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 2003, BRIT J NEUROSURG, V17, P311, DOI 10.1080/02688690310001601199; Lang EW, 2007, NEUROSURG REV, V30, P99, DOI 10.1007/s10143-006-0062-4; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1993, ACTA NEUROCHIR, P50; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Sarrafzadeh A S, 2000, Neurosurg Focus, V9, pe2; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stocchetti N, 2005, J NEUROL NEUROSUR PS, V76, P1135, DOI 10.1136/jnnp.2004.041269; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	23	33	33	0	8	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	APR	2010	152	4					681	688		10.1007/s00701-009-0532-x			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	573WI	WOS:000275945600017	19826757				2021-06-18	
J	Ott, MM; Eriksson, E; Vanderkolk, W; Christianson, D; Davis, A; Scholten, D				Ott, Mickey Meilinger; Eriksson, Evert; Vanderkolk, Wayne; Christianson, David; Davis, Alan; Scholten, Donald			Antiplatelet and Anticoagulation Therapies Do Not Increase Mortality in the Absence of Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Anticoagulation; Antiplatelet; Blunt trauma; Outcomes; Clopidogrel; Warfarin	PREINJURY WARFARIN USE; INTRACRANIAL HEMORRHAGE; HEAD-INJURY; IMPACT; COMPLICATIONS; REVERSAL; OLDER	Background: As the population continues to age, the number of patients undergoing traumatic injury while on antiplatelet or anticoagulation therapies is increasing. Mortality has been shown to increase in traumatic brain injury patients on warfarin therapy. Whether this increased mortality is seen in trauma patients without traumatic brain injury remains controversial. We investigated whether patients on antiplatelet and/or anticoagulation therapy were at increased risk of death from blunt traumatic injury in the absence of head injury. Methods: A retrospective review of our Level I trauma center database was performed from 2002 to 2007. Inclusion criteria included all patients older than 60 years admitted to the trauma service. Only patients with a computed tomography scan negative for intracranial injury were analyzed. Results: Two hundred twelve patients were found, of which 67 were found to be taking aspirin, warfarin, clopidogrel, or a combination of the three. Injury Severity Score (21 vs. 21), length of stay (11 days vs. 9 days), intensive care unit days (5 days vs. 4 days), and deaths (13% vs. 10%) were similar between those patients on antiplatelet/anticoagulation therapy and those who were not. Conclusion: In the absence of traumatic brain injury, the use of preinjury antiplatelet and/or anticoagulation therapy does not significantly increase the risk of mortality in the trauma patient. As the number of active seniors rises, this patient population will continue to present to the trauma service. To the best of our knowledge, this study is one of the largest addressing this question, and the only study examining the addition of antiplatelet therapy.	[Ott, Mickey Meilinger; Eriksson, Evert; Vanderkolk, Wayne; Christianson, David; Davis, Alan; Scholten, Donald] Grand Rapids Michigan State Univ, Gen Surg Residency Program, Grand Rapids, MI USA	Ott, MM (corresponding author), Vanderbilt Univ, Med Ctr, Div Trauma & Surg Crit Care, 1211 21st Ave S,404 Med Arts Bldg, Nashville, TN 37212 USA.	meilingerott@hotmail.com		Eriksson, Evert/0000-0002-4099-325X			Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2006, J TRAUMA, V61, P318, DOI 10.1097/01.ta.0000223944.25922.91; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; STEIN J, 1995, ARCH PHYS MED REHAB, V76, P840, DOI 10.1016/S0003-9993(95)80549-4; Tharmarajah P, 2007, J ORTHOP TRAUMA, V21, P26, DOI 10.1097/BOT.0b013e31802c4f3c; U.S. Bureau of the Census, 2008, STAT ABSTR US; Wahl WL, 2001, J TRAUMA, V51, P1151; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	13	33	36	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2010	68	3					560	563		10.1097/TA.0b013e3181ad6600			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	567ZY	WOS:000275491200013	20065871				2021-06-18	
J	Brasel, KJ; deRoon-Cassini, T; Bradley, CT				Brasel, Karen J.; deRoon-Cassini, Terri; Bradley, Ciaran T.			Injury Severity and Quality of Life: Whose Perspective Is Important?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	68th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 01-03, 2009	Pittsburgh, PA	Amer Assoc Surg Trauma		Organ donation; Organ donor; Brain death; Consent; Medical ethics	MAJOR TRAUMA; FUNCTIONAL CONSEQUENCES; POSTTRAUMATIC-STRESS; MULTIPLE INJURIES; HEALTH; DETERMINANTS; CARE	Background: Ambiguity exists regarding factors that predict postinjury quality of life (QOL). We hypothesized that patient-perceived injury severity, not injury Severity Score (ISS), would be correlated with QOL in a model that included severity of post-traumatic stress disorder (PTSD) symptoms. Methods: Four hundred twenty-six trauma patients admitted to a Level I trauma center completed a questionnaire during inpatient stay and 6 months after injury. ne questionnaire assessed physical component Score and mental component score QOL with the SF-36, PTSD severity using the PTSD checklist, and used a four-point rating of perceived injury severity. ISS and demographic information were obtained from the trauma registry. Statistical analysis was done with Pear-son's correlation and multiple regressions. Results: ISS was not significantly correlated with perceived injury severity, PTSD symptom severity, physical component score, or mental component score. The majority of patients overestimated injury severity when compared with ISS. An increase in PTSD symptom severity and perceived injury severity significantly predicted both decreased physical and mental QOL at 6 months. Conclusions: ISS does not give the full picture of the severity of injury. Surgeons should consider early screening of patients for perception of injury severity and PTSD symptoms to determine which patients may need psychologic intervention to improve long-term QOL.	[Brasel, Karen J.] Med Coll Wisconsin, Dept Surg, Div Trauma Crit Care, Milwaukee, WI 53226 USA	Brasel, KJ (corresponding author), Med Coll Wisconsin, Dept Surg, Div Trauma Crit Care, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	kbrasel@mcw.edu					Aitken LM, 2007, INJURY, V38, P19, DOI 10.1016/j.injury.2006.05.020; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Breslau N, 2002, CAN J PSYCHIAT, V47, P923; DEROONCASSINI TA, 2008, 24 ISTSS ANN M CHIC; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; Harris I, 2007, INJURY, V38, P1102, DOI 10.1016/j.injury.2007.05.004; Harris IA, 2008, J TRAUMA, V64, P969, DOI 10.1097/01.ta.0000245972.83948.1a; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Kiely JM, 2006, J TRAUMA, V61, P791, DOI 10.1097/01.ta.0000239360.29852.1d; MacKenzie EJ, 1998, AM J PUBLIC HEALTH, V88, P1630, DOI 10.2105/AJPH.88.11.1630; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Ringdal M, 2009, J TRAUMA, V66, P1226, DOI 10.1097/TA.0b013e318181b8e3; Sluys K, 2005, J TRAUMA, V59, P223, DOI 10.1097/01.TA.0000173832.01547.CB; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; Ulvik A, 2008, ACTA ANAESTH SCAND, V52, P195, DOI 10.1111/j.1399-6576.2007.01533.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	21	33	34	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2010	68	2					263	267		10.1097/TA.0b013e3181caa58f			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	555FC	WOS:000274492600003	20154536				2021-06-18	
J	Batti, L; O'Connor, JJ				Batti, Laura; O'Connor, John J.			Tumor necrosis factor-alpha impairs the recovery of synaptic transmission from hypoxia in rat hippocampal slices	JOURNAL OF NEUROIMMUNOLOGY			English	Article						Hypoxia; Adenosine A(1) receptor; TNF-alpha; LTP; Hippocampus; p38 MAP kinase	LONG-TERM POTENTIATION; ADENOSINE RECEPTOR ANTAGONISTS; PROTEIN-KINASE INHIBITOR; TNF-ALPHA; BRAIN-INJURY; IN-VITRO; AREA CA1; PROINFLAMMATORY CYTOKINES; INDUCED EXCITOTOXICITY; PRESYNAPTIC CALCIUM	Cerebral ischaemia is a common occurrence in a range of pathological conditions, including stroke and traumatic brain injury. Two of the components in ischaemia are tissue hypoxia and the release of pro-inflammatory agents such as TNF-alpha. The role of TNF-alpha in an ischaemic/hypoxic episode is still controversial, although deleterious effects of pro-inflammatory cytokines in the area of injury are well documented. One of the prime adaptive mechanisms in response to hypoxia is the cellular activation of adenosine 1 receptors (A1Rs), which inhibits excitatory synaptic transmission. In the present study we have examined the effect of TNF-alpha application on synaptic transmission during hypoxic exposure and re-oxygenation using extrarcellular recordings in the CA1 region of the rat hippocampal slice. Hypoxia caused a reversible depression of the field EPSP (29.6 +/- 9.7% of control, n = 5), which was adenosine A(1) receptor-dependent (85.7 +/- 4.3%, in the presence of DPCPX (200 nM), the adenosine A(1) receptor antagonist). DPCPX inhibited the maintenance of long-term potentiation obtained 30 min post hypoxia (143.8 +/- 8.2% versus 96.4 +/- 10.6% respectively, 1 h post tetanus; n = 5; p<0.005). In TNF-alpha (150 pM) treated slices hypoxic depression was similar to controls but a reduction in fEPSP slope was observed during re-oxygenation (66.8 +/- 1.4%, n = 5). This effect was reversed by pre-treatment with SB 203580 (1 mu M). a p38 MAP kinase inhibitor (91.8 +/- 6.9%, n = 5). These results demonstrate a novel p38 MAPK dependent role for TNF-alpha in attenuating synaptic transmission after a hypoxic episode. (C) 2009 Elsevier B.V. All rights reserved.	[Batti, Laura; O'Connor, John J.] UCD Conway Inst Biomol & Biomed Res, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland	O'Connor, JJ (corresponding author), UCD Conway Inst Biomol & Biomed Res, UCD Sch Biomol & Biomed Sci, Dublin 4, Ireland.	john.oconnor@ucd.ie		Batti, Laura/0000-0003-3717-8470; O'Connor, John/0000-0001-8229-8602	Marie Curie ActionsEuropean Commission	We would like to thank Marie Curie Actions for financial support and Professor Cormac Taylor for comments on the manuscript.	Arrigoni E, 2005, NEUROSCIENCE, V132, P575, DOI 10.1016/j.neuroscience.2004.12.009; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bernardino L, 2005, J NEUROSCI, V25, P6734, DOI 10.1523/JNEUROSCI.1510-05.2005; BLOMQVIST P, 1985, J CEREBR BLOOD F MET, V5, P420, DOI 10.1038/jcbfm.1985.57; Bon CLM, 2002, J NEUROPHYSIOL, V87, P1781, DOI 10.1152/jn.00630.2001; Brust TB, 2006, J NEUROSCI, V26, P12427, DOI 10.1523/JNEUROSCI.4052-06.2006; Butler MP, 2004, NEUROSCIENCE, V124, P319, DOI 10.1016/j.neuroscience.2003.11.040; Centonze D, 2001, BRAIN, V124, P1855, DOI 10.1093/brain/124.9.1855; Chaparro-Huerta V, 2005, J NEUROIMMUNOL, V165, P53, DOI 10.1016/j.jneuroim.2005.04.025; Chavez-Valdez R, 2009, PEDIATR RES, V65, P203, DOI 10.1203/PDR.0b013e31818d66b1; Chen ZF, 1996, BRAIN RES, V708, P82, DOI 10.1016/0006-8993(95)01269-9; Coppi E, 2007, PURINERG SIGNAL, V3, P203, DOI 10.1007/s11302-006-9049-4; Cumiskey D, 2007, BRAIN RES, V1136, P13, DOI 10.1016/j.brainres.2006.12.019; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; de Mendonca A, 2000, NEUROSCI LETT, V291, P81, DOI 10.1016/S0304-3940(00)01391-4; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; DOOLETTE DJ, 1995, BRAIN RES, V677, P127, DOI 10.1016/0006-8993(95)00139-H; Feng YZ, 2003, ANN NY ACAD SCI, V1009, P152, DOI 10.1196/annals.1304.017; FUJIWARA N, 1987, J PHYSIOL-LONDON, V384, P131, DOI 10.1113/jphysiol.1987.sp016447; Gervitz LM, 2001, AM J PHYSIOL-REG I, V280, pR639; Hsu KS, 2000, J NEUROPHYSIOL, V84, P1279; Izumi Y, 1998, J CEREBR BLOOD F MET, V18, P97, DOI 10.1097/00004647-199801000-00010; Kim JH, 2006, NEUROSCI LETT, V400, P1, DOI 10.1016/j.neulet.2006.01.035; Lee HT, 2004, AM J PHYSIOL-RENAL, V286, pF298, DOI 10.1152/ajprenal.00185.2003; Liang YC, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-13; LIPTON P, 1982, J PHYSIOL-LONDON, V325, P51, DOI 10.1113/jphysiol.1982.sp014135; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MacEwan DJ, 2002, CELL SIGNAL, V14, P477, DOI 10.1016/S0898-6568(01)00262-5; Markus T, 2009, J CEREBR BLOOD F MET, V29, P73, DOI 10.1038/jcbfm.2008.90; Mayne M, 1999, ANN NEUROL, V45, P633, DOI 10.1002/1531-8249(199905)45:5<633::AID-ANA12>3.0.CO;2-X; Murakami Y, 2005, J NEUROCHEM, V93, P1616, DOI 10.1111/j.1471-4159.2005.03163.x; Ozawa H, 1999, NEUROSCI LETT, V262, P57, DOI 10.1016/S0304-3940(99)00034-8; Pickering M, 2005, EXP PHYSIOL, V90, P663, DOI 10.1113/expphysiol.2005.030734; Pincheira R, 2008, J IMMUNOL, V181, P1288, DOI 10.4049/jimmunol.181.2.1288; Pugliese AM, 2006, BRIT J PHARMACOL, V147, P524, DOI 10.1038/sj.bjp.0706646; Renauld AE, 2002, J NEUROSCI RES, V67, P264, DOI 10.1002/jnr.10101; Rex CS, 2005, J NEUROSCI, V25, P5956, DOI 10.1523/JNEUROSCI.0880-05.2005; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; Saleshando G, 2000, NEUROSCI LETT, V288, P119, DOI 10.1016/S0304-3940(00)01210-6; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; Scholz KP, 1996, J NEUROPHYSIOL, V76, P39; Sebastiao AM, 2001, J NEUROSCI, V21, P8564; Seta K, 2002, ANN NY ACAD SCI, V971, P379, DOI 10.1111/j.1749-6632.2002.tb04500.x; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; Souza LF, 2005, LIFE SCI, V77, P3117, DOI 10.1016/j.lfs.2005.05.049; Sperlagh B, 2007, NEUROSCIENCE, V149, P99, DOI 10.1016/j.neuroscience.2007.07.035; Stellwagen D, 2006, NATURE, V440, P1054, DOI 10.1038/nature04671; Stellwagen D, 2005, J NEUROSCI, V25, P3219, DOI 10.1523/JNEUROSCI.4486-04.2005; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Sun XC, 2006, BRAIN RES, V1084, P165, DOI 10.1016/j.brainres.2006.02.041; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Taylor CP, 1999, J NEUROSCI, V19, P619; Tha KK, 2000, BRAIN RES, V885, P25, DOI 10.1016/S0006-8993(00)02883-3; Walton KM, 1998, J NEUROCHEM, V70, P1764; Wang QW, 2005, EUR J NEUROSCI, V22, P2827, DOI 10.1111/j.1460-9568.2005.04457.x; WU LG, 1994, J NEUROSCI, V14, P645; WU LG, 1994, NEURON, V12, P1139, DOI 10.1016/0896-6273(94)90321-2; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; ZHU PJ, 1993, NEUROSCI LETT, V155, P128, DOI 10.1016/0304-3940(93)90689-I; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	63	33	37	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	JAN 25	2010	218	1-2					21	27		10.1016/j.jneuroim.2009.11.002			7	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	557MH	WOS:000274672700004	19942300				2021-06-18	
J	Houlden, DA; Taylor, AB; Feinstein, A; Midha, R; Bethune, AJ; Stewart, CP; Schwartz, ML				Houlden, David A.; Taylor, Amanda B.; Feinstein, Anthony; Midha, Rajiv; Bethune, Allison J.; Stewart, Craig P.; Schwartz, Michael L.			Early somatosensory evoked potential grades in comatose traumatic brain injury patients predict cognitive and functional outcome	CRITICAL CARE MEDICINE			English	Article						somatosensory evoked potentials; traumatic brain injury; coma; grading system; outcome prediction; cognitive function	EVENT-RELATED POTENTIALS; SEVERE HEAD-INJURY; PROGNOSTIC VALUE; SCALE; RESPONSES; QUESTIONNAIRE; RECOVERY	Objectives: To relate early somatosensory evoked potential grades from comatose traumatic brain injury patients to neuropsychological and functional outcome 1 yr later; to determine the day (within the first week after traumatic brain injury) that somatosensory evoked potential grade best correlates with outcome; to determine whether somatosensory evoked potential grade improvement in the first week after traumatic brain injury is associated with improved outcome. Design: Prospective cohort study. Setting: Critical care unit at a university hospital. Patients: Median nerve somatosensory evoked potentials were obtained from 81 comatose patients with traumatic brain injury. Somatosensory evoked potential grades were calculated from results obtained on days 1, 3, and 7 after traumatic brain injury. Glasgow Outcome Scale, Barthel Index, Rivermead Head Injury Follow-up Questionnaire, General Health Questionnaire, Stroop Color-Word Test, Paced Auditory Serial Addition Task, and Symbol-Digit Modalities Test scores were obtained 1 yr after injury. Interventions. None. Measurements and Main Results: Somatosensory evoked potential grade on days 1, 3, and 7 related significantly with Glasgow Outcome Scale and Barthel scores (day 3 better than day 1) but did not relate with Rivermead Head Injury Follow-up Questionnaire or General Health Questionnaire scores. Day 3 and day 7 somatosensory evoked potential grades related significantly with Stroop scores. Day 3 somatosensory evoked potential grades related significantly with Symbol-Digit Modalities Test scores. Patients with bilaterally present but abnormal somatosensory evoked potentials, whose somatosensory evoked potential grade improved between days 1 and 3, had marginally better functional outcome than those without somatosensory evoked potential grade improvement. Conclusions: Day 3 somatosensory evoked potential grade related to information-processing speed, working memory, and the ability to attend to tasks 1 yr after traumatic brain injury. Day 3 somatosensory evoked potential grade had the strongest relationship with functional outcome. Somatosensory evoked potential grades were not related to emotional well-being. (Crit Care Med 2010; 38:167-174)	[Houlden, David A.; Taylor, Amanda B.; Bethune, Allison J.; Stewart, Craig P.] Sunnybrook Hlth Sci Ctr, Dept Surg Neuromonitoring, Toronto, ON M4N 3M5, Canada; [Feinstein, Anthony] Sunnybrook Hlth Sci Ctr, Dept Psychiat, Toronto, ON M4N 3M5, Canada; [Schwartz, Michael L.] Sunnybrook Hlth Sci Ctr, Div Neurosurg, Toronto, ON M4N 3M5, Canada; [Midha, Rajiv] Univ Calgary, Div Neurosurg, Calgary, AB, Canada	Houlden, DA (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Surg Neuromonitoring, Toronto, ON M4N 3M5, Canada.	david.houlden@sunnybrook.ca			Ontario Neurotrauma [00173]	This study was supported, in part, by Grant ONAO-#00173 received from the Ontario Neurotrauma Fund (DAH, AF, RM, MLS).	Amantini A, 2005, CLIN NEUROPHYSIOL, V116, P229, DOI 10.1016/j.clinph.2004.07.008; Carter BG, 2005, INTENS CARE MED, V31, P765, DOI 10.1007/s00134-005-2633-1; Chiappa KH, 1998, ELECTROEN CLIN NEURO, V106, P149, DOI 10.1016/S0013-4694(97)00118-1; Claassen J, 2001, CRIT CARE MED, V29, P494, DOI 10.1097/00003246-200103000-00005; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Daltrozzo J, 2007, CLIN NEUROPHYSIOL, V118, P606, DOI 10.1016/j.clinph.2006.11.019; DUNN OJ, 1969, J AM STAT ASSOC, V64, P366, DOI 10.2307/2283746; FACCO E, 1990, ELECTROEN CLIN NEURO, P330; Fischer C, 2004, NEUROLOGY, V63, P669, DOI 10.1212/01.WNL.0000134670.10384.E2; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GOLDIE WD, 1981, NEUROLOGY, V31, P248, DOI 10.1212/WNL.31.3.248; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HOULDEN DA, 1992, J TRAUMA, V33, P244, DOI 10.1097/00005373-199208000-00014; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JENNETT B, 1975, LANCET, V1, P480; Kotchoubey B, 2007, CLIN NEUROPHYSIOL, V118, P477, DOI 10.1016/j.clinph.2006.11.018; Lew HL, 2006, J HEAD TRAUMA REHAB, V21, P350, DOI 10.1097/00001199-200607000-00006; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; LOEWEN SC, 1988, PHYS THER, V68, P1077, DOI 10.1093/ptj/68.7.1077; Logi F, 2003, CLIN NEUROPHYSIOL, V114, P1615, DOI 10.1016/S1388-2457(03)00086-5; Luaute J, 2005, ARCH PHYS MED REHAB, V86, P917, DOI 10.1016/j.apmr.2004.08.011; MAHONEY F I, 1965, Md State Med J, V14, P61; Moulton RJ, 1998, CAN J NEUROL SCI, V25, pS7, DOI 10.1017/S031716710003465X; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Newton PG, 1982, J NEUROSURG, V57, P168; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Smith A., 1968, LEARNING DISORDERS, P83; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; WALSER H, 1986, J NEUROL, V233, P34, DOI 10.1007/BF00313989; Wang JT, 2004, CAN J NEUROL SCI, V31, P438, DOI 10.1017/S0317167100003619	31	33	36	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2010	38	1					167	174		10.1097/CCM.0b013e3181c031b3			8	Critical Care Medicine	General & Internal Medicine	539AE	WOS:000273224800025	19829103				2021-06-18	
J	Kreutzer, JS; Stejskal, TM; Godwin, EE; Powell, VD; Arango-Lasprilla, JC				Kreutzer, Jeffrey S.; Stejskal, Taryn M.; Godwin, Emilie E.; Powell, Victoria D.; Arango-Lasprilla, Juan Carlos			A mixed methods evaluation of the Brain Injury Family Intervention	NEUROREHABILITATION			English	Article						Traumatic brain injury; caregivers; family intervention; family therapy	SEVERE HEAD-INJURY; CAREGIVER BURDEN; PSYCHOLOGICAL DISTRESS; MARITAL STABILITY; CARERS; NEEDS; PROGRAM; REHABILITATION; IMPACT; INDIVIDUALS	Objective: To describe and compare caregivers' and patients' helpfulness and goal attainment ratings of the Brain Injury Family Intervention (BIFI), and qualitatively evaluate their perceptions of most important things learned. Methods: 76 caregivers and 76 patients with acquired brain injury participated in the BIFI, a structured family intervention program which includes educational, skill building, and psychological support components. Outcome measures were obtained following each of the five intervention sessions and following completion of the entire program. Results: Session helpfulness ratings for caregivers and patients were uniformly high as were ratings of the extent to which session goals were met. Between group comparisons did not indicate differences for individual session helpfulness or goal attainment ratings. Qualitative analysis of most important things learned provided corroboratory evidence that BIFI topics were relevant and consistent with program goals. Conclusions: The present investigation provides evidence that the BIFI is perceived as helpful and that treatment methods facilitate achievement of goals. The investigation also suggests that investigators may benefit from using mixed methods to evaluate outcomes, complementing traditional quantitative methods with qualitative approaches.	[Kreutzer, Jeffrey S.; Stejskal, Taryn M.; Godwin, Emilie E.; Powell, Victoria D.; Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA 23298 USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Box 980542, Richmond, VA 23298 USA.	jskreutz@vcu.edu					ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Anderson-Parente JK, 1990, COGNITIVE REHABILITA, P22; Arango-Lasprilla JC, 2008, BRAIN INJURY, V22, P565, DOI 10.1080/02699050802172004; Bouwens SFM, 2009, CLIN REHABIL, V23, P310, DOI 10.1177/0269215508101744; Broderick C. B., 1993, UNDERSTANDING FAMILY; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Brown R, 1999, J HEAD TRAUMA REHAB, V14, P257, DOI 10.1097/00001199-199906000-00006; Carnes S.L., 2005, FAM SYST HEALTH, V23, P186, DOI DOI 10.1037/1091-7527.23.2.186; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Creswell J., 2003, RES DESIGN QUALITATI, V2nd edn; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Ellis A., 1975, NEW GUIDE RATIONAL L; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Jackson D, 2009, BRAIN INJURY, V23, P433, DOI 10.1080/02699050902788451; Kim JW, 2007, SOC WORK HEALTH CARE, V45, P81, DOI 10.1300/J010v45n01_06; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Kreutzer JS, 2002, J HEAD TRAUMA REHAB, V17, P349, DOI 10.1097/00001199-200208000-00008; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Maxwell J., 2005, QUALITATIVE RES DESI, V2nd; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; Murray HM, 2006, BRAIN INJURY, V20, P575, DOI 10.1080/02699050600664590; Nichols M.P., 2004, FAMILY THERAPY CONCE; Panting A., 1972, REHABILITATION, V38, P33; Patton M.Q., 2002, QUALITATIVE RES EVAL; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Pinquart M, 2006, J GERONTOL B-PSYCHOL, V61, pP33, DOI 10.1093/geronb/61.1.P33; Riley GA, 2007, CLIN REHABIL, V21, P82, DOI 10.1177/0269215506071279; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rossman G.B., 2003, LEARNING FIELD INTRO, V2nd ed; Rotondi AJ, 2007, J HEAD TRAUMA REHAB, V22, P14, DOI 10.1097/00001199-200701000-00002; Schlosser RW, 2004, J COMMUN DISORD, V37, P217, DOI 10.1016/j.jcomdis.2003.09.003; Sinnakaruppan I, 2005, BRAIN INJURY, V19, P283, DOI 10.1080/02699050400003924; Sinnakaruppan I, 2001, BRAIN INJURY, V15, P653; State University of New York at Buffalo, 1997, GUID UN DAT SET MED; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Turner-Stokes L, 2009, J REHABIL MED, V41, P528, DOI 10.2340/16501977-0383; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	54	33	34	0	16	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2010	27	1					19	29		10.3233/NRE-2010-0578			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	629GA	WOS:000280182000003	20634598				2021-06-18	
J	Kumar, R; Saksena, S; Husain, M; Srivastava, A; Rathore, RKS; Agarwal, S; Gupta, RK				Kumar, Raj; Saksena, Sona; Husain, Mazhar; Srivastava, Arti; Rathore, Ram K. S.; Agarwal, Shruti; Gupta, Rakesh K.			Serial Changes in Diffusion Tensor Imaging Metrics of Corpus Callosum in Moderate Traumatic Brain Injury Patients and Their Correlation With Neuropsychometric Tests: A 2-Year Follow-up Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						corpus callosum; diffuse axonal injury; diffusion tensor imaging; fractional anisotropy; neuropsychological test; radial diffusivity; traumatic brain injury	AXONAL INJURY; WHITE-MATTER; HEAD-INJURY; MILD; MR; DEGENERATION; PERFORMANCE; RECOVERY; ATROPHY; STATE	Objective: To assess longitudinally the severity of diffuse axonal injury in the corpus callosum, in patients with moderate traumatic brain injury (TBI) through quantitative diffusion tensor imaging and to correlate these changes with neuropsychometric tests (NPT) at 6 and 24 months after injury. Design: Prospective longitudinal study. Participants: Sixteen patients with TBI and 17 age/sex-matched healthy controls. Methods: Patients underwent magnetic resonance imaging at 3 time points: within 2 weeks (range = 5-14 days), 6 months, and 24 months after injury. NPT could be performed only at 6 and 24 months. Results: In patients with TBI, a significant increase in fractional anisotropy (FA) values in genu as well as an insignificant decrease in radial diffusivity (RD) and mean diffusivity values in genu and splenium were observed over time, respectively. FA, RD, and mean diffusivity values continued to be abnormal in patients compared with controls at the end of 2 years. Although some NPT scores improved over time in these patients, these were still significantly impaired compared with controls. Conclusions: FA and RD indices appear to be surrogate markers of microstructural alterations in patients over time and correlate significantly with some of the NPT scores. The recovery in these indices associated with recovery in neurocognitive deficits suggests that these indices may be used as an objective marker for residual injury in these patients.	[Saksena, Sona; Srivastava, Arti; Gupta, Rakesh K.] Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Lucknow 226014, Uttar Pradesh, India; [Kumar, Raj; Husain, Mazhar] Chhatrapati Shahuji Maharaj Med Univ, Dept Neurosurg, Lucknow, Uttar Pradesh, India; [Rathore, Ram K. S.; Agarwal, Shruti] Indian Inst Technol, Dept Math & Stat, Kanpur 208016, Uttar Pradesh, India	Gupta, RK (corresponding author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Radiodiag, Lucknow 226014, Uttar Pradesh, India.	rgupta@sgpgi.ac.in		Agarwal, Shruti/0000-0003-0902-5354	Indian Council of Medical Research, New Delhi, IndiaIndian Council of Medical Research (ICMR) [5/4-5/13/Neuro/2004-NCD-1]	Part of the study was supported by Indian Council of Medical Research (grant 5/4-5/13/Neuro/2004-NCD-1). Raj Kumar and Sona Saksena thank the Indian Council of Medical Research, New Delhi, India, for the financial assistance.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Batchelor PG, 2003, MAGN RESON MED, V49, P1143, DOI 10.1002/mrm.10491; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; DHIMAN RK, 1995, J GASTROEN HEPATOL, V10, P14, DOI 10.1111/j.1440-1746.1995.tb01041.x; Dougherty RF, 2005, P NATL ACAD SCI USA, V102, P7350, DOI 10.1073/pnas.0500003102; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; FRENCHMAN KA, 2005, J CLIN EXP NEUROPSYC, V27, P324; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Graham D.I., 2002, GREENFIELDS NEUROPAT; Huang H, 2005, NEUROIMAGE, V26, P195, DOI 10.1016/j.neuroimage.2005.01.019; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jover R, 2003, AM J GASTROENTEROL, V98, P1599, DOI 10.1016/S0002-9270(03)00310-1; KATZ D, 1997, NEUROLOGICAL REHABIL; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar M, 2008, NMR BIOMED, V21, P581, DOI 10.1002/nbm.1228; LAMPERT PW, 1966, AM J PATHOL, V49, P1139; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MARR A, 2001, CENTRAL NERVOUS SYST; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ramalingaswamy P, 1974, MANUAL INDIAN ADAPTA; Ramnani N, 2004, BIOL PSYCHIAT, V56, P613, DOI 10.1016/j.biopsych.2004.02.004; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; RAPPORT M, 2008, J NEUROPSYCHIATRY CL, V20, P68; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schiff ND, 2006, J HEAD TRAUMA REHAB, V21, P388, DOI 10.1097/00001199-200609000-00003; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Stewart CA, 2007, NAT CLIN PRACT GASTR, V4, P677, DOI 10.1038/ncpgasthep0999; Thomalla G, 2005, J NEUROL NEUROSUR PS, V76, P266, DOI 10.1136/jnnp.2004.046375; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799; Wolfson D., 1993, HALSTEAD REITAN NEUR	51	33	36	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					31	42		10.1097/HTR.0b013e3181bff331			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800005	20051898				2021-06-18	
J	Talving, P; Lustenberger, T; Kobayashi, L; Inaba, K; Barmparas, G; Schnuriger, B; Lam, L; Chan, LS; Demetriades, D				Talving, Peep; Lustenberger, Thomas; Kobayashi, Leslie; Inaba, Kenji; Barmparas, Galinos; Schnueriger, Beat; Lam, Lydia; Chan, Linda S.; Demetriades, Demetrios			Erythropoiesis Stimulating Agent Administration Improves Survival After Severe Traumatic Brain Injury A Matched Case Control Study	ANNALS OF SURGERY			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; HUMAN ERYTHROPOLETIN; ANEMIA; NEUROPROTECTION; INFANTS; SAFETY	Objective: Erythropoiesis stimulating agent (ESA) administration may reduce mortality in severe traumatic brain injury (sTBI). Summary Background Data: It has been established that the administration of ESA in critically ill trauma victims has been associated with improved outcomes. Recent experimental and clinical data showed neuroprotective effects of ESA, however, the literature regarding impact on outcome in sTBI is lacking. Methods: A retrospective matched case control study in patients with sTBI [head Abbreviated Injury Scale (AIS), >= 3] receiving ESA while in the surgical intensive care unit from January 1, 1996 to December 31, 2007 (n = 89). were matched I to 2 (n = 178) by age, gender, mechanism of injury, Glasgow Coma Scale, presence of hypotension on admission, Injury Severity Score, AIS for all body regions, and presence of anemia with patients who did not receive the agent. Each case's controls were chosen to have surgical intensive care unit length of stay more than or equal to the time from admission to first dose of ESA. The primary outcome measure in this study was mortality. Results: Cases and controls had similar age, gender, mechanisms of injury, incidence of hypotension, Glasgow Coma Scale on admission, Injury Severity Score, and AIS for all body regions. Although the ESA+ patients experienced protracted hospital length of stay and comparable surgical intensive care unit free days, they demonstrated a significantly lower in-hospital mortality in comparison to controls at 7.9% versus 24.2%, respectively (OR: 0.27; 95% CI = 0.12-0.62; P = 0.001). Conclusions: Erythropoiesis stimulating agent administration in sTBI is associated with a significant in-hospital survival advantage without increase in morbidity. Prospective validation of our findings is warranted.	[Talving, Peep; Lustenberger, Thomas; Kobayashi, Leslie; Inaba, Kenji; Barmparas, Galinos; Schnueriger, Beat; Lam, Lydia; Chan, Linda S.; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, Div Acute Care Surg Emergency Surg Trauma & Surg, Los Angeles, CA 90033 USA	Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Div Acute Care Surg Emergency Surg Trauma & Surg, Los Angeles Cty Gen Hosp,Dept Surg, 1200 N State St,C4E100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Barmparas, Galinos/L-6530-2019; Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			*AM ASS NEUR SURG, 2007, J NEUROTRAUMA S1, V24, pS7; Arcasoy MO, 2008, BRIT J HAEMATOL, V141, P14, DOI 10.1111/j.1365-2141.2008.07014.x; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Caucio L, 2008, J TRAUMA, V65, P297; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2007, BRAIN, V130, P2577, DOI 10.1093/brain/awm203; Fauchere JC, 2008, PEDIATRICS, V122, P375, DOI 10.1542/peds.2007-2591; Fliser D, 2007, SEMIN HEMATOL, V44, P212, DOI 10.1053/j.seminhematol.2007.04.008; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Juul SE, 2008, PEDIATRICS, V122, P383, DOI 10.1542/peds.2007-2711; Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Napolitano LM, 2008, J TRAUMA, V65, P285, DOI 10.1097/TA.0b013e31817f2c6e; Noguchi CT, 2007, CRIT REV ONCOL HEMAT, V64, P159, DOI 10.1016/j.critrevonc.2007.03.001; Pacary E, 2006, NEURODEGENER DIS, V3, P87, DOI 10.1159/000092098; Robinson Y, 2008, ACTA ANAESTH SCAND, V52, P587, DOI 10.1111/j.1399-6576.2008.01617.x; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Wang Y, 2007, BRIT J PHARMACOL, V151, P1377, DOI 10.1038/sj.bjp.0707285; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510	24	33	35	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-4932			ANN SURG	Ann. Surg.	JAN	2010	251	1					1	4		10.1097/SLA.0b013e3181b844fa			4	Surgery	Surgery	538SF	WOS:000273203600001	19779323				2021-06-18	
J	Han, RZ; Hu, JJ; Weng, YC; Li, DF; Huang, Y				Han, Rui-Zhang; Hu, Jin-Jia; Weng, Yuan-Chi; Li, Ding-Feng; Huang, Yi			NMDA receptor antagonist MK-801 reduces neuronal damage and preserves learning and memory in a rat model of traumatic brain injury	NEUROSCIENCE BULLETIN			English	Article						traumatic brain injury; MK-801; learning and memory; caspase-3; microglia; neuronal nitric oxide synthase		Objective NMDA receptor channel plays an important role in the pathophysiological process of traumatic brain injury (TBI). The present study aims to study the pathological mechanism of TBI and the impairment of learning and memory after TBI, and to investigate the mechanism of the protective effect of NMDA receptor antagonist MK-801 on learning and memory disorder after TBI. Methods Forty Sprague-Dawley rats (weighing approximately 200 g) were randomized into 5 groups (n = 8 in each group): control group, model group, low-dose group (MK-801 0.5 mg/kg), middle-dose group (MK-801 2 mg/kg), and high-dose group (MK-801 10 mg/kg). TBI model was established using a weight-drop head injury mode. After 2-month drug treatment, learning and memory ability was evaluated by using Morris water maze test. Then the animals were sacrificed, and brain tissues were taken out for morphological and immunohistochemical assays. Results The ability of learning and memory was significantly impaired in the TBI model animals. Besides, the neuronal caspase-3 expression, neuronal nitric oxide synthase (nNOS)-positive neurons and OX-42-positive microglia were all increased in TBI animals. Meanwhile, the number of neuron synapses was decreased, and vacuoles degeneration could be observed in mitochondria. After MK-801 treatment at 3 different dosages, the ability of learning and memory was markedly improved, as compared to that of the TBI model animals. Moreover, neuronal caspase-3 expression, OX-42-positive microglia and nNOS-positive neurons were all significantly decreased. Meanwhile, the mitochondria degeneration was greatly inhibited. Conclusion MK-801 could significantly inhibit the degeneration and apoptosis of neurons in damaged brain areas. It could also inhibit TBI-induced increase in nNOS-positive neurons and OX-42-positive microglia. Impairment in learning and memory in TBI animals could be repaired by treatment with MK-801.	[Hu, Jin-Jia; Weng, Yuan-Chi; Li, Ding-Feng; Huang, Yi] Shanghai Jiao Tong Univ, Coll Med, Shanghai 200025, Peoples R China; [Han, Rui-Zhang] 98th Hosp PLA, Dept Neurosurg, Huzhou 313000, Peoples R China	Hu, JJ (corresponding author), Shanghai Jiao Tong Univ, Coll Med, Shanghai 200025, Peoples R China.	jjhu2609@126.com			Nanjing Military Medical Science and Technology [08MA007]	This work was supported by the grants from Nanjing Military Medical Science and Technology Innovation Project (No. 08MA007).	Acarin L, 1996, J COMP NEUROL, V367, P361; Beray-Berthat V, 2003, EXP NEUROL, V182, P446, DOI 10.1016/S0014-4886(03)00106-7; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Celik SE, 2006, J NEUROTRAUM, V23, P1355, DOI 10.1089/neu.2006.23.1355; Chen Jian-Ye, 2006, Ai Zheng, V25, P170; Gilland E, 1998, J CEREBR BLOOD F MET, V18, P297, DOI 10.1097/00004647-199803000-00008; Golarai G, 2001, J NEUROSCI, V21, P8523; Haga KK, 2003, BRAIN RES, V993, P42, DOI 10.1016/j.brainres.2003.08.063; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Heath D L, 1999, J Neurosci Nurs, V31, P97; Huang PL, 1999, BRAZ J MED BIOL RES, V32, P1353, DOI 10.1590/S0100-879X1999001100005; Ishida A, 2001, BRAIN DEV-JPN, V23, P349, DOI 10.1016/S0387-7604(01)00237-6; Kim JH, 2004, EXP NEUROL, V189, P122, DOI 10.1016/j.expneurol.2004.05.029; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Love S, 1999, BRAIN PATHOL, V9, P119; MERRILL JE, 1993, J IMMUNOL, V151, P2132; Oehmichen M, 2000, J NEUROTRAUM, V17, P155, DOI 10.1089/neu.2000.17.155; Phillips LL, 1997, J NEUROSCI RES, V49, P197; Ravishankar S, 2001, BRAIN RES, V901, P23, DOI 10.1016/S0006-8993(01)02109-6; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Sairanen TR, 1997, J CEREBR BLOOD F MET, V17, P1107, DOI 10.1097/00004647-199710000-00013; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Stover JF, 2001, J NEUROSURG, V94, P782, DOI 10.3171/jns.2001.94.5.0782; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Zhao XR, 2003, BRAIN RES, V966, P308, DOI 10.1016/S0006-8993(02)04223-3	28	33	39	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1673-7067	1995-8218		NEUROSCI BULL	Neurosci. Bull.	DEC	2009	25	6					367	375		10.1007/s12264-009-0608-x			9	Neurosciences	Neurosciences & Neurology	V19RL	WOS:000208089400006	19927173	Green Published			2021-06-18	
J	Palmio, J; Suhonen, J; Keranen, T; Hulkkonen, J; Peltola, J; Pirttila, T				Palmio, Johanna; Suhonen, Jaana; Keranen, Tapani; Hulkkonen, Janne; Peltola, Jukka; Pirttila, Tuula			Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure	SEIZURE-EUROPEAN JOURNAL OF EPILEPSY			English	Article						Axonal damage; Cerebrospinal fluid; Epileptic seizure; Phosphorylated tau protein; Tau protein	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; TONIC-CLONIC SEIZURES; ALZHEIMERS-DISEASE; S-100 PROTEIN; TRANSIENT INCREASE; BIOCHEMICAL MARKER; CSF; ENOLASE; DISCRIMINATION	Purpose: Whether repeated brief seizures can cause neuronal damage is controversial. Cerebrospinal fluid (CSF) total tau (T-tau) and phosphorylated tau (P-tau) measurements have been suggested for the diagnosis of Alzheimer's disease, and T-tau may also be a marker of axonal damage and neuronal degeneration. We studied T-tau and P-tau levels and P-tau/T-tau ratio in CSF after epileptic seizures in order to determine whether they are increased after seizures. Methods: A total of 54 patients with tonic-clonic or partial secondarily generalized seizures due to various etiologies were studied and CSF obtained within 48 h after the seizure. Results: There were no statistical differences in the levels of T-tau (p = 0.09, ANOVA) or P-tau (p = 0.60) between different etiologic groups or controls. No patients with epilepsy of unknown origin had abnormal CSF T-tau whereas 11 patients with acute or remote symptomatic seizures had abnormal T-tau levels and the P-tau/T-tau ratio showed significant differences between the groups and controls (p = 0.003). Conclusions: Epileptic seizures with unknown etiology did not increase CSF tau levels. Abnormal tau levels were associated with either acute or remote symptomatic seizures with known etiology. The presence of elevated CSF tau increases the probability of symptomatic cause in a patient with a seizure. (C) 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.	[Palmio, Johanna] Univ Tampere, Dept Neurol, FIN-33014 Tampere, Finland; [Palmio, Johanna; Keranen, Tapani; Peltola, Jukka] Tampere Univ Hosp, Dept Neurol, FIN-33521 Tampere, Finland; [Suhonen, Jaana] Jokilaakso Hosp, Dept Neurol, FIN-42120 Jamsa, Finland; [Pirttila, Tuula] Univ Kuopio, Dept Neurol, FIN-70211 Kuopio, Finland	Palmio, J (corresponding author), Univ Tampere, Dept Neurol, FIN-33014 Tampere, Finland.	johanna.palmio@uta.fi			Medical Research Fund of Tampere University Hospital	This work was supported by the Medical Research Fund of Tampere University Hospital.	Blasko I, 2006, DEMENT GERIATR COGN, V21, P9, DOI 10.1159/000089137; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Blennow K, 2006, LANCET, V368, P387, DOI 10.1016/S0140-6736(06)69113-7; Buch KBN, 1999, NEUROSCI LETT, V277, P21; Buttner T, 1999, J NEUROL, V246, P459, DOI 10.1007/s004150050383; Correale J, 1998, NEUROLOGY, V50, P1388, DOI 10.1212/WNL.50.5.1388; CULLEN KM, 1995, NEUROPATH APPL NEURO, V21, P312, DOI 10.1111/j.1365-2990.1995.tb01065.x; DELACOURTE A, 1994, BIOMED PHARMACOTHER, V48, P287, DOI 10.1016/0753-3322(94)90174-0; Engel J, 2002, PROG BRAIN RES, V135, P509; Green AJE, 2000, SEX TRANSM INFECT, V76, P443, DOI 10.1136/sti.76.6.443; Herukka SK, 2005, NEUROLOGY, V64, P1294, DOI 10.1212/01.WNL.0000156914.16988.56; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Kapaki E, 2005, INT J GERIATR PSYCH, V20, P722, DOI 10.1002/gps.1351; Kapaki EN, 2007, EUR J NEUROL, V14, P168, DOI 10.1111/j.1468-1331.2006.01593.x; Leutmezer F, 2002, EPILEPSIA, V43, P1172, DOI 10.1046/j.1528-1157.2002.50101.x; MANDELKOW EM, 1995, NEUROBIOL AGING, V16, P355, DOI 10.1016/0197-4580(95)00025-A; Matsui T, 2007, J AM GERIATR SOC, V55, P2096, DOI 10.1111/j.1532-5415.2007.01440.x; Morikawa Y, 1999, ALCOHOL CLIN EXP RES, V23, P575, DOI 10.1097/00000374-199904001-00001; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Palmio J, 2001, J NEUROL SCI, V183, P27, DOI 10.1016/S0022-510X(00)00478-0; Pitkanen A, 2002, PROG BRAIN RES, V135, P67; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Riemenschneider M, 2003, MOL PSYCHIATR, V8, P343, DOI 10.1038/sj.mp.4001220; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Shiiya N, 2004, ANN THORAC SURG, V77, P2034, DOI 10.1016/j.athoracsur.2003.12.057; Sjogren M, 2001, CLIN CHEM, V47, P1776; Steinhoff BJ, 1999, EPILEPSY RES, V36, P75, DOI 10.1016/S0920-1211(99)00026-1; Sussmuth SD, 2001, NEUROSCI LETT, V300, P95, DOI 10.1016/S0304-3940(01)01556-7; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x	30	33	33	0	1	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	1059-1311	1532-2688		SEIZURE-EUR J EPILEP	Seizure	SEP	2009	18	7					474	477		10.1016/j.seizure.2009.04.006			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	507ID	WOS:000270844800003	19428269				2021-06-18	
J	Wartella, JE; Auerbach, SM; Ward, KR				Wartella, Jennifer E.; Auerbach, Stephen M.; Ward, Kevin R.			Emotional distress, coping and adjustment in family members of neuroscience intensive care unit patients	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						Emotional distress; Coping; Family members; Neuroscience intensive care unit; Caregiver adjustment	TRAUMATIC BRAIN-INJURY; CAREGIVING APPRAISAL; STRESS; PREDICTORS; DEPRESSION; SYMPTOMS; ANXIETY; HEALTH; ADOLESCENTS; RESPONSES	Objective: We evaluated emotional distress, coping strategy use, caregiver adjustment, and the relationship among these variables in family members (FMs) of patients hospitalized in a neuroscience intensive care unit (NSICU). Methods: Fifty-one primary relatives of NSICU patients were administered the Brief Symptom Inventory (BSI) and an abbreviated version of the COPE within 2 days of admission to the NSICU, just prior to patient discharge from the unit, and approximately 30 days after patient discharge (follow-Lip). FMs' adjustment to the role of caregiver was also evaluated at follow-up with the Caregiver Appraisal Scale (CAS). Results: BSI emotional distress levels were higher than those of the nonpatient normative sample at patient admission, but, except for anxiety, were within a standard deviation of the mean of the said group;, with the exception of anxiety they declined to below nonpatient non-native levels at follow-up. Females' distress levels were higher than those of males'. FMs' use of both problem-focused and emotion-focused coping strategies increased from admission through follow-up. Emotional distress was unrelated to problem-focused coping but was associated with emotion-focused coping at admission and discharge, with use of denial as a coping strategy primarily accounting for this relationship. Extent of use of both problem-focused and emotion-focused coping at admission was associated with better caregiver adjustment at follow-up, but over time only increases in problem-focused coping were associated with better subsequent caregiver adjustment. Conclusions: Findings suggest that interventions fostering increased use of problem-focused coping and sense of control will be effective in lowering FM distress level and enhancing subsequent adjustment in the role of caregiver. (C) 2009 Elsevier Inc. All rights reserved.	[Wartella, Jennifer E.; Auerbach, Stephen M.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA; [Auerbach, Stephen M.; Ward, Kevin R.] Virginia Commonwealth Univ, Reanimat Engn Shock Ctr, Richmond, VA 23284 USA; [Ward, Kevin R.] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA 23284 USA	Auerbach, SM (corresponding author), Virginia Commonwealth Univ, Dept Psychol, 806 W Franklin St,Box 842018, Richmond, VA 23284 USA.	sauerbac@vcu.edu					Auerbach SM, 2005, AM J CRIT CARE, V14, P202, DOI 10.4037/ajcc2005.14.3.202; AUERBACH SM, 1989, J CONSULT CLIN PSYCH, V57, P388, DOI 10.1037/0022-006X.57.3.388; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bond A Elaine, 2003, Crit Care Nurse, V23, P63; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS DN, 1985, J NEURO NEUROPSYCHIA, V49, P764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; DEROGATIS L, 1979, BRIEF SYMPTOM INVENT; FLORIAN V, 1991, NEUROPSYCHOLOGIA, V5, P478; Frye B A, 1982, Rehabil Nurs, V7, P27; Gillen R, 1998, J HEAD TRAUMA REHAB, V13, P31, DOI 10.1097/00001199-199806000-00004; HALM MA, 1990, HEART LUNG, V19, P62; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Johansson I, 2006, J ADV NURS, V56, P463, DOI 10.1111/j.1365-2648.2006.04040.x; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P221; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lazarus R.S., 1984, STRESS APPRAISAL COP; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; McAdam JL, 2008, INTENS CARE MED, V34, P1097, DOI 10.1007/s00134-008-1066-z; McKinley Sharon, 2002, Intensive Crit Care Nurs, V18, P27, DOI 10.1054/iccn.2002.1611; Minnes P, 2000, BRAIN INJURY, V14, P737; Moskowitz JT, 1996, ANN BEHAV MED, V18, P49, DOI 10.1007/BF02903939; NARSAVAGE GL, 1994, NURS RES, V43, P90; Paparrigopoulos T, 2006, J PSYCHOSOM RES, V61, P719, DOI 10.1016/j.jpsychores.2006.05.013; Perez-San Gregorio M A, 1992, Intensive Care Med, V18, P278, DOI 10.1007/BF01706473; Pochard F, 2005, J CRIT CARE, V20, P90, DOI 10.1016/j.jcrc.2004.11.004; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Rivera P, 2007, NEUROREHABILITATION, V22, P3; ROBERTS JG, 1987, NURS RES, V36, P94; Rodriguez AM, 2005, J PSYCHOSOM RES, V58, P447, DOI 10.1016/j.jpsychores.2004.11.011; RUCKHOLM E, 1992, CAN J CARDIO NURS, V2, P15; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2007, NEUROREHABILITATION, V22, P1; STRENTZ T, 1988, J PERS SOC PSYCHOL, V55, P652, DOI 10.1037/0022-3514.55.4.652; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Wade SL, 2001, J CONSULT CLIN PSYCH, V69, P406, DOI 10.1037//0022-006X.69.3.406	43	33	35	1	10	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999	1879-1360		J PSYCHOSOM RES	J. Psychosomat. Res.	JUN	2009	66	6					503	509		10.1016/j.jpsychores.2008.12.005			7	Psychiatry	Psychiatry	452BR	WOS:000266515100004	19446709				2021-06-18	
J	Kim, J; Kim, TY; Hwang, JJ; Lee, JY; Shin, JH; Gwag, BJ; Koh, JY				Kim, Jean; Kim, Tae-Youn; Hwang, Jung Jin; Lee, Joo-Yong; Shin, Jin-Hee; Gwag, Byung Joo; Koh, Jae-Young			Accumulation of labile zinc in neurons and astrocytes in the spinal cords of G93A SOD-1 transgenic mice	NEUROBIOLOGY OF DISEASE			English	Article						Excitotoxicity; Motoneurons; HNE; Zinc chelator; ALS	AMYOTROPHIC-LATERAL-SCLEROSIS; GLIAL GLUTAMATE TRANSPORTER; TRAUMATIC BRAIN-INJURY; ALS-LINKED SOD1; HIPPOCAMPAL-NEURONS; MOUSE MODEL; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; OXIDATIVE STRESS; MOTOR-NEURONS	Zinc dyshomeostasis may trigger oxidative stress, which is likely the key mechanism of neuronal death in amyotrophic lateral sclerosis (AILS), including familial forms such as G93A SOD-1 ALS. Since zinc binding by G93A SOD-1 is weaker than by normal SOD-1, we assessed whether labile zinc levels are altered in the spinal cords of G93A SOD-1 transgenic (Tg) mice. Whereas no zinc-containing cells were found in wild-type (WT) mice, neurons and astrocytes with high levels of labile zinc appeared in G93A SOD-1 Tg mice, in correlation with motoneuron degeneration. The level of HNE, an endogenous neurotoxic molecule, was increased around zinc-accumulating cells and mSOD-1 positive cells, suggesting a link between HNE, SOD-1 mutation and zinc accumulation. Moreover. exposure of cultured spinal neurons and astrocytes from G93A SOD-1 Tg mice to HNE increased labile zinc levels, and exposure to zinc increased 4-hydroxynonenal (HNE) levels, to a greater degree than in WT neurons and astrocytes. Administration of the zinc chelator TPEN extended survival in G93A SOD-1 Tg mice. These results indicate that zinc dyshomeostasis occurs in the spinal cords of Tg mice, and that this dyshomeostasis may contribute to motoneuron degeneration. (C) 2009 Elsevier Inc. All rights reserved.	[Kim, Jean; Kim, Tae-Youn; Koh, Jae-Young] Univ Ulsan, Coll Med, Neural Injury Res Lab, Seoul, South Korea; [Hwang, Jung Jin; Lee, Joo-Yong; Koh, Jae-Young] Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul, South Korea; [Shin, Jin-Hee; Gwag, Byung Joo] Ajou Univ, Coll Med, Suwon 441749, South Korea	Koh, JY (corresponding author), Univ Ulsan, Coll Med, Neural Injury Res Lab, Seoul, South Korea.	jkko@amc.seoul.kr	Lee, Joo-Yong/F-4545-2014; Hwang, Jung Jin/F-3424-2014; Koh, Jae-Young/C-9014-2011	Koh, Jae-Young/0000-0002-4318-495X	Korea Science and Engineering FoundationKorea Science and Engineering Foundation [M10600000181-06J0000-18110]; Korean Ministry of Science and TechnologyMinistry of Science and Technology (MOST) Korea [M103KV010020-06K2201-02010]; Korean Ministry of Education and Human Resources DevelopmentMinistry of Education & Human Resources Development (MOEHRD), Republic of Korea [KRF-2005-084-C00026]	This work was supported by the Korea Science and Engineering Foundation through the National Research Laboratory Program (M10600000181-06J0000-18110), by the Brain Research Center of 21st Century Frontier Research Program (M103KV010020-06K2201-02010) funded by Korean Ministry of Science and Technology, and by the Korea Research Foundation (Grant MOEHRD, KRF-2005-084-C00026) funded by the Korean Ministry of Education and Human Resources Development.	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Baldwin SA, 1998, J NEUROSURG, V88, P874, DOI 10.3171/jns.1998.88.5.0874; Bishop GM, 2007, FREE RADICAL BIO MED, V42, P1222, DOI 10.1016/j.freeradbiomed.2007.01.022; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Chang I, 2003, DIABETOLOGIA, V46, P1220, DOI 10.1007/s00125-003-1171-z; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Crow JP, 1997, J NEUROCHEM, V69, P1936; Frederickson CJ, 2005, NAT REV NEUROSCI, V6, P449, DOI 10.1038/nrn1671; FREDERICKSON CJ, 1989, BRAIN RES, V480, P317, DOI 10.1016/0006-8993(89)90199-6; Gong YH, 2000, EXP NEUROL, V162, P27, DOI 10.1006/exnr.2000.7323; Groeneveld GJ, 2003, NEUROSCI LETT, V352, P175, DOI 10.1016/j.neulet.2003.08.062; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; Hwang JJ, 2008, J NEUROSCI, V28, P3114, DOI 10.1523/JNEUROSCI.0199-08.2008; Jia YS, 2002, J PHYSIOL-LONDON, V543, P35, DOI 10.1113/jphysiol.2002.020172; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kelland EE, 2004, EUR J NEUROSCI, V19, P287, DOI 10.1111/j.0953-816X.2003.03134.x; Kim TY, 2007, EXP NEUROL, V208, P159, DOI 10.1016/j.expneurol.2007.08.013; Kim YH, 2002, EXP NEUROL, V177, P407, DOI 10.1006/exnr.2002.7990; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lee JY, 2003, EXP NEUROL, V184, P337, DOI 10.1016/S0014-4886(03)00382-0; Lee JY, 2002, P NATL ACAD SCI USA, V99, P7705, DOI 10.1073/pnas.092034699; Lee JY, 2001, J NEUROSCI, V21; Lee JY, 2000, J NEUROSCI, V20; Lino MM, 2002, J NEUROSCI, V22, P4825, DOI 10.1523/JNEUROSCI.22-12-04825.2002; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Malecki A, 2000, J NEUROCHEM, V74, P2278, DOI 10.1046/j.1471-4159.2000.0742278.x; Matyja E, 2006, FOLIA NEUROPATHOL, V44, P183; Menzies FM, 2002, NEUROCHEM INT, V40, P543, DOI 10.1016/S0197-0186(01)00125-5; Mocchegiani E, 2007, J ALZHEIMERS DIS, V12, P101; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Noh KM, 2000, J NEUROSCI, V20; Park JA, 2000, J NEUROSCI, V20, P9096; Park JH, 2007, NEUROSCI LETT, V413, P265, DOI 10.1016/j.neulet.2006.11.058; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Petri S, 2007, J NEUROCHEM, V102, P991, DOI 10.1111/j.1471-4159.2007.04604.x; Post JI, 2008, AMYOTROPH LATERAL SC, V9, P149, DOI 10.1080/17482960801934015; Pramatarova A, 2001, J NEUROSCI, V21, P3369, DOI 10.1523/JNEUROSCI.21-10-03369.2001; Puttaparthi K, 2002, J NEUROSCI, V22, P8790; Rao SD, 2004, TRENDS NEUROSCI, V27, P17, DOI 10.1016/j.tins.2003.11.001; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Robberecht W, 2000, J NEUROL, V247, P1; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; Sillevis Smitt Peter A. E., 1994, Biological Signals, V3, P193; Simpson EP, 2004, NEUROLOGY, V62, P1758, DOI 10.1212/WNL.62.10.1758; Smith AP, 2007, AMYOTROPH LATERAL SC, V8, P131, DOI 10.1080/17482960701249241; Suh SW, 2007, MOL MED, V13, P344, DOI 10.2119/2007-00043.Suh; Suh SW, 2007, J CLIN INVEST, V117, P910, DOI 10.1172/JCI30077; Suh SW, 2006, J CEREBR BLOOD F MET, V26, P161, DOI 10.1038/sj.jcbfm.9600176; Suh SW, 2004, NEUROBIOL DIS, V16, P538, DOI 10.1016/j.nbd.2004.04.017; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Tokuda E, 2007, TOXICOLOGY, V229, P33, DOI 10.1016/j.tox.2006.09.011; Tortarolo M, 2006, J NEUROSCI RES, V83, P134, DOI 10.1002/jnr.20715; Vanoni C, 2004, J CELL SCI, V117, P5417, DOI 10.1242/jcs.01411; Vigh L, 2005, ACTA NEUROPATHOL, V109, P567, DOI 10.1007/s00401-004-0977-1; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Yoo MH, 2004, INVEST OPHTH VIS SCI, V45, P1523, DOI 10.1167/iovs.03-1315; Zarkovic Kamelija, 2003, Molecular Aspects of Medicine, V24, P293, DOI 10.1016/S0098-2997(03)00024-4	60	33	34	1	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAY	2009	34	2					221	229		10.1016/j.nbd.2009.01.004			9	Neurosciences	Neurosciences & Neurology	442VT	WOS:000265869400004	19344646				2021-06-18	
J	Eken, C; Kartal, M; Bacanli, A; Eray, O				Eken, Cenker; Kartal, Mutlu; Bacanli, Ayse; Eray, Oktay			Comparison of the Full Outline of Unresponsiveness Score Coma Scale and the Glasgow Coma Scale in an emergency setting population	EUROPEAN JOURNAL OF EMERGENCY MEDICINE			English	Article						altered level consciousness; emergency population; Full Outline of Unresponsiveness Score; Glasgow Coma Scale	TRAUMATIC BRAIN-INJURY; APACHE-II; INTERRATER RELIABILITY; PREDICTION; CONSCIOUSNESS; VALIDATION; MORTALITY; SYSTEM	Background The Glasgow Coma Scale (GCS) is the most widely used tool for the evaluation of the level of consciousness. The Full Outline of Unresponsiveness (FOUR) Score is a new coma Scale that was developed considering the limitations of the GCS, and has been found to be useful in an intensive care setting. We aimed to compare FOUR Score and GCS in the emergency setting. Methods All patients older than 17 years who presented with an altered level of consciousness, after any trauma to the head or with neurological complaints were included in this study. Three-month mortality, in-hospital mortality, and poor outcome using a Modified Rankin Scale (MRS) of 3-6 points were used as the primary outcome measures. Results A total of 185 patients were included in the study, Area under the curve (AUC) values in predicting 3-month mortality for GCS was 0.726 [P=0.0001 and 95% confidence interval (Cl): 0.656-0.789] and 0.776 (P=0.0001 and 95% Cl: 0.709-834) for FOUR Score. AUC in predicting hospital mortality for GCS was 0.735 (P=0.0001 and 95% Cl: 0.655-0.797) and 0.788 (P=0.0001 and 95% Cl: 0.722-0.844) for FOUR Score. AUC in predicting poor outcome (Modified Rankin Scale: 3-6) was 0.720 (P = 0.001 and 95% Cl: 0.650-784) for GCS and 0.751 (P = 0.0001 and 95% Cl: 0.682-0.812) for FOUR Score. Conclusion The new coma Scale, FOUR Score, is not superior to the GCS. However, the combination of the eye and motor components of FOUR Score is a valuable tool that can be used instead of either the FOUR Score or GCS. European Journal of Emergency Medicine 16:29-36 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.	[Eken, Cenker; Kartal, Mutlu; Bacanli, Ayse; Eray, Oktay] Akdeniz Univ, Fac Med, Dept Emergency Med, TR-07058 Antalya, Turkey	Eken, C (corresponding author), Akdeniz Univ, Akdeniz Univ Hastanesi, Acil Tip Anabilim Dali, TR-07059 Antalya, Turkey.	cenkereken@akdeniz.edu.tr	Eray, Oktay/AAU-2598-2020; Eken, Cenker/C-1821-2016	Eray, Oktay/0000-0002-1643-6007; Eken, Cenker/0000-0002-2743-5608	Akdeniz University FoundationAkdeniz University	This study was supported by Akdeniz University Foundation and great thanks to Dr Feras Khan for his contributions to the syntax of the article.	*AM COLL SURG COMM, 1993, ADV SUPP COURS PHYS; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Cho D Y, 1995, Clin Intensive Care, V6, P9, DOI 10.1080/714028868; Cho DY, 1997, INTENS CARE MED, V23, P77, DOI 10.1007/s001340050294; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2007, ANN EMERG MED, V49, P403, DOI 10.1016/j.annemergmed.2006.03.031; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Grmec S, 2001, CRIT CARE, V5, P19; HARTLEY C, 1995, BRIT J NEUROSURG, V9, P179, DOI 10.1080/02688699550041520; Hennes HJ, 1992, NOTFALLMEDIZIN, V18, P130; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; LIDDY CM, 1999, CRIT CARE MED, V27, P1999; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TEASDALE G, 1974, LANCET, V2, P81; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611; Wolf CA, 2007, MAYO CLIN PROC, V82, P435, DOI 10.4065/82.4.435	22	33	37	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0969-9546			EUR J EMERG MED	Eur. J. Emerg. Med.	FEB	2009	16	1					29	36		10.1097/MEJ.0b013e32830346ab			8	Emergency Medicine	Emergency Medicine	400CC	WOS:000262844600006	19106717				2021-06-18	
J	Bergwerf, I; De Vocht, N; Tambuyzer, B; Verschueren, J; Reekmans, K; Daans, J; Ibrahimi, A; Van Tendeloo, V; Chatterjee, S; Goossens, H; Jorens, PG; Baekelandt, V; Ysebaert, D; Van Marck, E; Berneman, ZN; Van Der Linden, A; Ponsaerts, P				Bergwerf, Irene; De Vocht, Nathalie; Tambuyzer, Bart; Verschueren, Jacob; Reekmans, Kristien; Daans, Jasmijn; Ibrahimi, Abdelilah; Van Tendeloo, Viggo; Chatterjee, Shyama; Goossens, Herman; Jorens, Philippe G.; Baekelandt, Veerle; Ysebaert, Dirk; Van Marck, Eric; Berneman, Zwi N.; Van Der Linden, Annemie; Ponsaerts, Peter			Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice	BMC BIOTECHNOLOGY			English	Article							MESSENGER-RNA ELECTROPORATION; LENTIVIRAL VECTOR PRODUCTION; GREEN FLUORESCENT PROTEIN; ADULT STEM-CELLS; HIGHLY EFFICIENT; FUNCTIONAL RECOVERY; IN-VIVO; DIFFERENTIATION; TRANSPLANTATION; BRAIN	Background: Cell transplantation is likely to become an important therapeutic tool for the treatment of various traumatic and ischemic injuries to the central nervous system (CNS). However, in many pre-clinical cell therapy studies, reporter gene-assisted imaging of cellular implants in the CNS and potential reporter gene and/or cell-based immunogenicity, still remain challenging research topics. Results: In this study, we performed cell implantation experiments in the CNS of immunocompetent mice using autologous (syngeneic) luciferase-expressing bone marrow-derived stromal cells (BMSC-Luc) cultured from ROSA26-L-S-L-Luciferase transgenic mice, and BMSC-Luc genetically modified using a lentivirus encoding the enhanced green fluorescence protein (eGFP) and the puromycin resistance gene (Pac) (BMSC-Luc/eGFP/Pac). Both reporter gene-modified BMSC populations displayed high engraftment capacity in the CNS of immunocompetent mice, despite potential immunogenicity of introduced reporter proteins, as demonstrated by real-time bioluminescence imaging (BLI) and histological analysis at different time-points post-implantation. In contrast, both BMSC-Luc and BMSC-Luc/eGFP/Pac did not survive upon intramuscular cell implantation, as demonstrated by real-time BLI at different time-points post-implantation. In addition, ELISPOT analysis demonstrated the induction of IFN-gamma-producing CD8+ T-cells upon intramuscular cell implantation, but not upon intracerebral cell implantation, indicating that BMSCLuc and BMSC-Luc/eGFP/Pac are immune-tolerated in the CNS. However, in our experimental transplantation model, results also indicated that reporter gene-specific immune-reactive T-cell responses were not the main contributors to the immunological rejection of BMSC-Luc or BMSCLuc/eGFP/Pac upon intramuscular cell implantation. Conclusion: We here demonstrate that reporter gene-modified BMSC derived from ROSA26-LSL- Luciferase transgenic mice are immune-tolerated upon implantation in the CNS of syngeneic immunocompetent mice, providing a research model for studying survival and localisation of autologous BMSC implants in the CNS by real-time BLI and/or histological analysis in the absence of immunosuppressive therapy.	[Bergwerf, Irene; De Vocht, Nathalie; Tambuyzer, Bart; Reekmans, Kristien; Daans, Jasmijn; Van Tendeloo, Viggo; Berneman, Zwi N.; Ponsaerts, Peter] Univ Antwerp, Lab Expt Hematol, B-2020 Antwerp, Belgium; [Bergwerf, Irene; De Vocht, Nathalie; Tambuyzer, Bart; Reekmans, Kristien; Daans, Jasmijn; Van Tendeloo, Viggo; Goossens, Herman; Berneman, Zwi N.; Ponsaerts, Peter] Univ Antwerp, Vaccine & Infect Dis Inst, B-2020 Antwerp, Belgium; [De Vocht, Nathalie; Verschueren, Jacob; Van Der Linden, Annemie] Univ Antwerp, Bioimaging Lab, B-2020 Antwerp, Belgium; [Ibrahimi, Abdelilah] Katholieke Univ Leuven, Lab Mol Virol & Gene Therapy, Louvain, Belgium; [Chatterjee, Shyama; Van Marck, Eric] Univ Antwerp, Pathol Lab, B-2020 Antwerp, Belgium; [Baekelandt, Veerle] Katholieke Univ Leuven, Lab Neurobiol & Gene Therapy, Louvain, Belgium; [Ysebaert, Dirk] Univ Antwerp, Expt Surg Lab, B-2020 Antwerp, Belgium; [Van Tendeloo, Viggo; Jorens, Philippe G.; Ysebaert, Dirk; Berneman, Zwi N.; Ponsaerts, Peter] Univ Antwerp Hosp, Ctr Cellular Therapy & Regenerat Med CCRG, Antwerp, Belgium; [Ibrahimi, Abdelilah; Baekelandt, Veerle] Katholieke Univ Leuven, Mol Small Anim Imaging Ctr Mosaic, Louvain, Belgium	Ponsaerts, P (corresponding author), Univ Antwerp, Lab Expt Hematol, B-2020 Antwerp, Belgium.	irene.bergwerf@ua.ac.be; nathalie.devocht@ua.ac.be; bart.tambuyzer@ua.ac.be; jacob.verschueren@ua.ac.be; kristien.reekmans@ua.ac.be; jasmijn.daans@ua.ac.be; abdelilah.ibrahimi@med.kuleuven.be; viggo.van.tendeloo@uza.be; shyama.chatterjee@ua.ac.be; herman.goossens@ua.ac.be; philippe.jorens@uza.be; veerle.baekelandt@med.kuleuven.be; dirk.ysebaert@uza.be; eric.van.marck@uza.be; zwi.berneman@uza.be; annemie.vanderlinden@ua.ac.be; peter.ponsaerts@ua.ac.be	Ponsaerts, Peter/B-6213-2017; Van Tendeloo, Viggo FI/A-1233-2010; Ghosh, Shyama/AAK-1173-2020; Van der Linden, Annemie/L-7855-2017; Baekelandt, Veerle/ABB-9736-2020; Ysebaert, Dirk/J-6800-2013	Ponsaerts, Peter/0000-0002-1892-6499; Van Tendeloo, Viggo FI/0000-0003-3217-9917; Ghosh, Shyama/0000-0003-4550-7780; Van der Linden, Annemie/0000-0003-2941-6520; Baekelandt, Veerle/0000-0001-8966-2921; Ysebaert, Dirk/0000-0002-3350-6994			Arbab Ali Syed, 2004, Mol Imaging, V3, P24, DOI 10.1162/153535004773861697; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Baekelandt V, 2003, GENE THER, V10, P1933, DOI 10.1038/sj.gt.3302094; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Bradbury MS, 2007, J NEUROCHEM, V102, P2029, DOI 10.1111/j.1471-4159.2007.04681.x; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Di Ianni M, 1999, GENE THER, V6, P703; Gambotto A, 2000, GENE THER, V7, P2036, DOI 10.1038/sj.gt.3301335; Geraerts M, 2005, J GENE MED, V7, P1299, DOI 10.1002/jgm.778; Hakamata Y, 2006, TRANSPLANTATION, V81, P1179, DOI 10.1097/01.tp.0000203137.06587.4a; Keyaerts M, 2008, EUR J NUCL MED MOL I, V35, P999, DOI 10.1007/s00259-007-0664-2; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kurozumi K, 2005, MOL THER, V11, P96, DOI 10.1016/j.ymthe.2004.09.020; Li J, 2007, BIOMED ENVIRON SCI, V20, P242; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Magnitsky S, 2005, NEUROIMAGE, V26, P744, DOI 10.1016/j.neuroimage.2005.02.029; Ormerod BK, 2008, PHILOS T R SOC B, V363, P153, DOI 10.1098/rstb.2006.2018; Peister A, 2004, BLOOD, V103, P1662, DOI 10.1182/blood-2003-09-3070; Ponsaerts P, 2006, LEUKEMIA, V20, P767, DOI 10.1038/sj.leu.2404219; Ponsaerts P, 2004, GENE THER, V11, P1606, DOI 10.1038/sj.gt.3302342; Ponsaerts P, 2002, J IMMUNOL, V169, P1669, DOI 10.4049/jimmunol.169.4.1669; Ronsyn MW, 2008, SPINAL CORD, V46, P532, DOI 10.1038/sc.2008.13; Ronsyn MW, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-90; Rosser AE, 2007, CURR OPIN NEUROL, V20, P688, DOI 10.1097/WCO.0b013e3282f132fc; Ryan Jennifer M, 2005, J Inflamm (Lond), V2, P8, DOI 10.1186/1476-9255-2-8; Safran Michal, 2003, Mol Imaging, V2, P297, DOI 10.1162/153535003322750637; Smits E, 2004, LEUKEMIA, V18, P1898, DOI 10.1038/sj.leu.2403463; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; Van den Plas D, 2003, BIOCHEM BIOPH RES CO, V305, P10, DOI 10.1016/S0006-291X(03)00669-7; Van Tendeloo VFI, 2001, BLOOD, V98, P49, DOI 10.1182/blood.V98.1.49; Van Tendeloo VF, 2007, CURR OPIN MOL THER, V9, P423; Vandermeulen G, 2007, J CONTROL RELEASE, V124, P81, DOI 10.1016/j.jconrel.2007.08.010; Webber DJ, 2007, REGEN MED, V2, P929, DOI 10.2217/17460751.2.6.929; Wiehe JM, 2007, J CELL MOL MED, V11, P521, DOI 10.1111/j.1582-4934.2007.00038.x	34	33	34	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1472-6750		BMC BIOTECHNOL	BMC Biotechnol.	JAN 7	2009	9								1	10.1186/1472-6750-9-1			14	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	397YO	WOS:000262698500001	19128466	DOAJ Gold, Green Published			2021-06-18	
J	Arango-Lasprilla, JC; Ketchum, JM; Gary, KW; Kreutzer, JS; O'Neil-Pirozzi, TM; Wehman, P; de la Plata, CM; Jha, A				Arango-Lasprilla, Juan Carlos; Ketchum, Jessica M.; Gary, Kelli W.; Kreutzer, Jeffrey S.; O'Neil-Pirozzi, Therese M.; Wehman, Paul; de la Plata, Carlos Marquez; Jha, Amitabh			The Influence of Minority Status on Job Stability After Traumatic Brain Injury	PM&R			English	Article								Objective: To determine the influence of minority status on job stability after traumatic brain injury (TBI). Setting: TBI Model Systems Centers. Participants: 633 individuals (414 Caucasians vs. 219 Minorities) with primarily moderate to severe TBI hospitalized at one of the TBI Model Systems Centers between 1988 and 2001 with 3 years of continuous follow up employment data after discharge. Main Outcome Measures: Job stability was defined as "stable" (competitively employed at all three follow-up visits), "unemployed" (not competitively employed at all three visits), and "unstable" (any other mixture of competitively employed and not competitively employed over the three follow-up visits). Methods: A multinomial logistic regression model was used to model the effect of ethnicity on job stability post TBI after adjusting for injury and demographic characteristics. Results: Compared to Caucasians, the adjusted odds for minorities were 3.587 times greater for being unemployed versus being stably employed (95% CI = 1.930, 6.668), 1.911 times greater for being unstably employed versus being stably employed (95% Cl = 1.006, 3.628), and 1.878 times more greater for being unemployed versus being unstably employed (95% Cl = 1.157, 3.046) after adjusting for preinjury employment status, age, marital status, education, cause of injury, total length of stay in acute and rehabilitation hospitals, and DRS at discharge. Conclusions: Minority status is an independent predictor of short-term job stability after TBI. Minority TBI survivors were more likely than Caucasians to be unemployed or unstably employed. Rehabilitation professionals should develop employment interventions that will address the specific needs of these racial/ethnic groups and facilitate optimal employment outcomes for minority TBI survivors.	[Arango-Lasprilla, Juan Carlos] Virginia Commonwealth Univ Rehabil Psychol & Neur, VCU W Hosp, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Gary, Kelli W.; Kreutzer, Jeffrey S.; Wehman, Paul] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA; [de la Plata, Carlos Marquez] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Jha, Amitabh] Univ Colorado, Sch Med, Craig Hosp, Dept Phys Med & Rehabil, Englewood, CO USA	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ Rehabil Psychol & Neur, VCU W Hosp, Dept Phys Med & Rehabil, 3rd Floor,Room 3-102,1200 E Broad St, Richmond, VA 23298 USA.	jcarangolasp@vcu.edu	Ketchum, Jessica/AAE-8200-2020	Ketchum, Jessica/0000-0002-5566-3691	National Institute on Disability and Rehabilitation Research, United States Department of EducationUS Department of Education [H133A070036, H133P040006]	This research was supported by grants H133A070036 and H133P040006 from the National Institute on Disability and Rehabilitation Research, United States Department of Education.	Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Botuck S, 1998, J REHABIL, V64, P42; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Drake RE, 1996, J CONSULT CLIN PSYCH, V64, P391, DOI 10.1037/0022-006X.64.2.391; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hosmer D. W., 2000, APPL LOGISTIC REGRES; James P., 2002, HUMAN RESOURCE MANAG, V12, P82; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P238, DOI 10.1053/apmr.2003.50097; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kregel J, 1994, NeuroRehabilitation, V4, P1, DOI 10.3233/NRE-1994-4103; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leff HS, 2005, PSYCHIAT SERV, V56, P1237, DOI 10.1176/appi.ps.56.10.1237; Lehman AF, 2002, ARCH GEN PSYCHIAT, V59, P165, DOI 10.1001/archpsyc.59.2.165; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; McLeod A, 2004, OCCUP ENVIRON MED, V61, P414, DOI 10.1136/oem.2003.007336; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pierce K, 2003, RES DEV DISABIL, V24, P369, DOI 10.1016/S0891-4222(03)00057-X; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Possl O, 2001, BRAIN INJURY, V15, P15; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Schopp LH, 2006, J HEAD TRAUMA REHAB, V21, P213, DOI 10.1097/00001199-200605000-00002; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802	39	33	33	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	JAN	2009	1	1					41	49		10.1016/j.pmrj.2008.07.001			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	V24LD	WOS:000208411000007	19627871				2021-06-18	
J	Beijer, U; Andreasson, S				Beijer, Ulla; Andreasson, Sven			Physical diseases among homeless people: Gender differences and comparisons with the general population	SCANDINAVIAN JOURNAL OF PUBLIC HEALTH			English	Article						Homeless people; gender; physical health; hospital care	NEW-YORK-CITY; PATTERNS; ADULTS	Aim: To study morbidity amongst homeless men and women by comparing prevalence of hospital care for somatic diseases and injuries with a control group of men and women from the general population. Methods: A cohort of 1,364 men and 340 women were documented as homeless in 1996. Comparisons are made concerning hospital care for somatic diseases and injuries (1996-2002) among 3,750 men and 1,250 women from the general population. Results: The relative risk (RR) for homeless men and women of being hospitalised was double that of the men and women in the controls (1.93 and 1.96 respectively). Homeless women had a slightly, not significant, increased risk compared to homeless men (RR 1.10). Younger homeless women had a significant higher risk. Among diagnostic categories, the highest prevalence was found among homeless men in the diagnosis group injury/poisoning (22%). The highest risk was found for skin diseases (RR 36.96) and concerned homeless women. There were a number of gender specific diagnoses, where risks were considerably elevated, such as diseases of the genital organs, viral hepatitis, and poisoning for homeless women, and cerebrovascular diseases, diseases of the liver, and concussion for homeless men. Conclusions: Homeless people had twice the risk of being hospitalised for physical diseases compared to the general population. Younger women were particularly at risk compared to homeless men and to women in the controls. There were a number of gender specific diagnoses that are important to take into account when planning services for homeless people.	[Beijer, Ulla; Andreasson, Sven] Karolinska Inst, Dept Publ Hlth Sci, Div Social Med, Stockholm, Sweden; [Andreasson, Sven] Swedish Natl Inst Publ Hlth, Stockholm, Sweden	Beijer, U (corresponding author), Beroendecentrum, M4-02 Karolinska Solna, S-17176 Stockholm, Sweden.	u.beijer@telia.com		Beijer, Ulla/0000-0002-4274-6607	Swedish National Institute of Public Health, Stockholm	This study was supported by a grant from the Swedish National Institute of Public Health, Stockholm. The authors would also like to thank Stefan Borg, Karolinska Institutet, Stockholm, Sweden, for his support, and Anders Leifman for his statistical contribution.	AGREN G, 1994, HEMLOSA STOCKHOLM, P18; AGREN G, 1997, HEMLOSA STOCKHOLM 19, P9; Beijer U, 2007, NORD J PSYCHIAT, V61, P363, DOI 10.1080/08039480701644637; BEIJER U, 1997, PSYKISKT STORDA HEML, P10; Beijer U, 1998, HEMLOSA KVINNOR STOC, V1998, P7; Burstrom B., 2007, HALSA LIVSVILLKOR BL; Culhane DP, 2001, J EPIDEMIOL COMMUN H, V55, P515, DOI 10.1136/jech.55.7.515; Epele ME, 2002, CULT MED PSYCHIAT, V26, P33, DOI 10.1023/A:1015237130328; FINNE E, 2003, STAT SUBSTANCE ABUSE, P6; Finney A, 2002, BR J NURS S6, V11, P17; GELBERG L, 1993, MED CARE, V31, P757, DOI 10.1097/00005650-199309000-00001; HALLDIN J, 2001, KLINISK PILOTSTUDIE; Lim YW, 2002, MED CARE, V40, P510; Nyamathi AM, 2002, J GEN INTERN MED, V17, P134, DOI 10.1046/j.1525-1497.2002.10415.x; PADGETT DK, 1995, SOC SCI MED, V41, P547, DOI 10.1016/0277-9536(94)00364-Y; PEDERSEN PV, 2008, SUSY UDSAT HLTH PROF; Pitz S, 2005, OPHTHALMOLOGICA, V219, P345, DOI 10.1159/000088376; Rehm J, 2003, ADDICTION, V98, P1209, DOI 10.1046/j.1360-0443.2003.00467.x; Salit SA, 1998, NEW ENGL J MED, V338, P1734, DOI 10.1056/NEJM199806113382406; STADIG I, 1987, VART HAR KVINNORNA F, P58; STATIGOS AJ, 2003, MED CUTANEOUS DISORD, V2, P168; Takano T, 1999, J URBAN HEALTH, V76, P73, DOI 10.1007/BF02344463; Wamala SP, 2002, GENDER SOCIAL INEQUI; WIECHA JL, 1991, PUBLIC HEALTH REP, V106, P364	24	33	33	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1403-4948			SCAND J PUBLIC HEALT	Scand. J. Public Health	JAN	2009	37	1					93	100		10.1177/1403494808099972			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	403BU	WOS:000263057600013	19141558				2021-06-18	
J	Greve, KW; Etherton, JL; Ord, J; Bianchini, KJ; Curtis, KL				Greve, Kevin W.; Etherton, Joseph L.; Ord, Jonathan; Bianchini, Kevin J.; Curtis, Kelly L.			Detecting Malingered Pain-Related Disability: Classification Accuracy of the Test of Memory Malingering	CLINICAL NEUROPSYCHOLOGIST			English	Article						Chronic pain; Cognition; Malingering; Criterion groups validation; Symptom validity test; Response bias; Test of Memory Malingering	LABORATORY-INDUCED PAIN; TRAUMATIC BRAIN-INJURY; MMPI-2 VALIDITY SCALES; NEUROCOGNITIVE DYSFUNCTION; COGNITIVELY INTACT; NORMATIVE DATA; DIGIT SPAN; DEPRESSION; INDICATORS; TOMM	This study used criterion groups validation to determine the accuracy of the Test of Memory Malingering (TOMM) in detecting malingered pain-related disability (MPRD) across a range of cutoffs in chronic pain patients undergoing psychological evaluation (n = 604). Data from patients with traumatic brain injury (n = 45) and dementia (n = 59) are presented for comparison. TOMM scores decreased and failure rates increased as a function of greater external evidence of intentional under-performance. The TOMM detected from 37.5% to 60.2% of MPRD patients, depending on the cutoff. False positive (FP) error rates ranged from 0% to 5.1%. Accuracy data for Trial 1 are also reported. In chronic pain the original cutoffs produced no FP errors but were associated with high false negative error rates. Higher cutoffs increased sensitivity without adversely affecting specificity. The relevance of these findings to research and clinical practice is discussed.	[Greve, Kevin W.; Ord, Jonathan; Bianchini, Kevin J.; Curtis, Kelly L.] Univ New Orleans, Dept Psychol, New Orleans, LA 70148 USA; [Greve, Kevin W.; Etherton, Joseph L.; Bianchini, Kevin J.; Curtis, Kelly L.] Jefferson Neurobehav Grp, Metairie, LA USA; [Etherton, Joseph L.] Texas State Univ, San Marcos, TX USA	Greve, KW (corresponding author), Univ New Orleans Lakefront, Dept Psychol, New Orleans, LA 70148 USA.	kgreve@uno.edu					American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini K. J., 2004, J FORENSIC NEUROPSYC, V4, P65; Bianchini KJ, 2008, ASSESSMENT, V15, P435, DOI 10.1177/1073191108317341; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1993, PORTLAND DIGIT RECOG; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Butcher J. N., 1989, MMPI 2 MANUAL ADM SC; Curtis KL, 2006, ASSESSMENT, V13, P46, DOI 10.1177/1073191105285210; Delis DC, 2000, CALIFORNIA VERBAL LE; Delis DC, 1987, CALIFORNIA VERBAL LE; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Etherton JL, 2005, ASSESSMENT, V12, P101, DOI 10.1177/1073191104270789; Etherton Joseph L, 2006, Spine J, V6, P61, DOI 10.1016/j.spinee.2005.05.382; Etherton JL, 2006, J CLIN EXP NEUROPSYC, V28, P1218, DOI 10.1080/13803390500346595; Frederick RI, 2007, ASSESSMENT, V14, P3, DOI 10.1177/1073191106292009; Gervais R.O., 2001, J FORENSIC NEUROPSYC, V2, DOI [DOI 10.1300/J151V02N02_01, https://doi.org/10.1300/J151v02n02_01]; Green P., 2005, GREENS WORD MEMORY T; Green P., 1996, WORD MEMORY TEST USE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Greve KW, 2003, ARCH PHYS MED REHAB, V84, P1233, DOI 10.1016/S0003-9993(03)00145-X; GREVE KW, ASSESSMENT IN PRESS; Grote C.L., 2007, ASSESSMENT MALINGERE, P44; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Iverson G.L., 2001, J FORENSIC NEUROPSYC, V2, P19, DOI [https://doi.org/10.1300/J151v02n01_02, DOI 10.1300/J151v02n01_02]; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Meyers J E, 2000, Appl Neuropsychol, V7, P133, DOI 10.1207/S15324826AN0703_3; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Reynolds CR, 1998, CRIT ISS NE, P261; Rogers R., 1997, CLIN ASSESSMENT MALI, V2nd; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002	51	33	33	2	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	7					1250	1271	PII 914408817	10.1080/13854040902828272			22	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	497WI	WOS:000270094200008	19728222				2021-06-18	
J	Jaffee, CMS; Meyer, KS				Jaffee, Col Michael S.; Meyer, Kimberly S.			A BRIEF OVERVIEW OF TRAUMATIC BRAIN INJURY (TBI) AND POST-TRAUMATIC STRESS DISORDER (PTSD) WITHIN THE DEPARTMENT OF DEFENSE	CLINICAL NEUROPSYCHOLOGIST			English	Article						Traumatic brain injury (TBI); Post-traumatic stress disorder (PTSD); Department of Defense	ENDURING-FREEDOM; IRAQI FREEDOM; US ARMY; EXPERIENCE; BLAST; TEAM	The current conflicts in the Middle East have yielded increasing awareness of the acute and chronic effect of traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD). The increasing frequency of exposure to blast and multiple deployments potentially impact the probability that a service member may sustain one of these injuries. The 2008 International Conference on Behavioral Health and Traumatic Brain Injury united experts in the fields of behavioral health and traumatic brain injury to address these significant health concerns. This article summarizes current Department of Defense (DoD) initiatives related to TBI and PTSD.	[Jaffee, Col Michael S.; Meyer, Kimberly S.] Def & Vet Brain Injury Ctr, Washington, DC 20012 USA	Jaffee, CMS (corresponding author), Def & Vet Brain Injury Ctr, Washington, DC 20012 USA.	Michael.jaffee@amedd.army.mil	Meyer, Kimberly/L-5430-2019				Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; DEMITTENBERG W, 1996, ARCH CLIN NEUROPSYCH, V11, P139; *DEP DEF, 2006, 602521E DOD; *DEP DEF, 2008, EV MAN MTBI CONC DEP; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Grissom Thomas E, 2005, Crit Care Med, V33, pS13, DOI 10.1097/01.CCM.0000151063.85112.5A; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; *IOM, 2008, LONG TERM CONS TRAUM; *MAN CONC MILD TBI, 2009, VA DOD CLIN PRACT GU; McCrea M., 2000, STANDARDIZED ASSESSM; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Patel TH, 2004, J TRAUMA, V57, P201, DOI 10.1097/01.TA.0000133638.30269.38; Peoples GE, 2005, MIL MED, V170, P451, DOI 10.7205/MILMED.170.6.451; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; REEVES D, 2004, ANN REPORT C FEDERAL; RESNICK HS, 1995, AM J PSYCHIAT, V152, P1675; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Tanelian T., 2008, INVISIBLE WOUNDS WAR; TARIVERDI F, 2006, J CLIN ENDOCRINOLOGY, V91, P2105; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; WALILKO T, J HEAD TRAU IN PRESS	24	33	34	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	8					1291	1298		10.1080/13854040903307250			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	524KF	WOS:000272141500004	19882472				2021-06-18	
J	Li, CY; Wu, PM; Jung, W; Ahn, CH; Shutter, LA; Narayan, RK				Li, Chunyan; Wu, Pei-Ming; Jung, WooSeok; Ahn, Chong H.; Shutter, Lori A.; Narayan, Raj K.			A novel lab-on-a-tube for multimodality neuromonitoring of patients with traumatic brain injury (TBI)	LAB ON A CHIP			English	Article							IRIDIUM OXIDE; MICRODIALYSIS; ELECTRODE	A novel lab-on-a-tube integrated with spirally-rolled pressure, temperature, oxygen and glucose microsensors is described for multimodal neuromonitoring of patients with traumatic brain injury. In addition to measuring various crucial parameters in real-time continuous formats, the newly developed device also works as an intraventricular catheter to lower the elevated intracranial pressure by draining cerebrospinal fluid.	[Li, Chunyan; Shutter, Lori A.; Narayan, Raj K.] Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Cincinnati, OH 45267 USA; [Li, Chunyan; Wu, Pei-Ming; Jung, WooSeok; Ahn, Chong H.] Univ Cincinnati, Microsyst & BioMEMS Lab, Dept Elect & Comp Engn, Cincinnati, OH 45221 USA	Li, CY (corresponding author), Univ Cincinnati, Dept Neurosurg, Inst Neurosci, Cincinnati, OH 45267 USA.	lic2@email.uc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628	Integra Lifesciences Foundation	The work was supported from the Integra Lifesciences Foundation. The authors thank Mr Ron Flenniken and Mr Jeff Simkins in the Nano/Micro Fabrication Engineering Research Center at the University of Cincinnati for their technical support, and also thank Mr Michael Rust and Mr Andrew Browne for valuable discussion.	Chu X, 2007, TALANTA, V71, P2040, DOI 10.1016/j.talanta.2006.09.013; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Hutchinson P, 2009, ACTA NEUROCHIR, V151, P51, DOI 10.1007/s00701-008-0169-1; Lee IS, 2005, THIN SOLID FILMS, V475, P332, DOI 10.1016/j.tsf.2004.08.076; LI C, 2008, P 12 INT C MICR TOT, P1916; Li CY, 2008, J MICROELECTROMECH S, V17, P334, DOI 10.1109/JMEMS.2007.911375; Li CY, 2008, BIOMED MICRODEVICES, V10, P671, DOI 10.1007/s10544-008-9178-3; Li CY, 2007, BIOSENS BIOELECTRON, V22, P1988, DOI 10.1016/j.bios.2006.08.043; Li J, 2007, BIOSENS BIOELECTRON, V22, P2898, DOI 10.1016/j.bios.2006.12.004; Lu Y, 2008, ELECTROCHEM COMMUN, V10, P778, DOI 10.1016/j.elecom.2008.02.013; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Tisdall MM, 2006, BRIT J ANAESTH, V97, P18, DOI 10.1093/bja/ael109; Yang YX, 2004, PROG COMPUT FLUID DY, V4, P46, DOI 10.1504/PCFD.2004.003785	13	33	34	2	12	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1473-0197			LAB CHIP	Lab Chip		2009	9	14					1988	1990		10.1039/b900651f			3	Biochemical Research Methods; Chemistry, Multidisciplinary; Chemistry, Analytical; Nanoscience & Nanotechnology; Instruments & Instrumentation	Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics; Instruments & Instrumentation	465GY	WOS:000267572000002	19568663				2021-06-18	
J	Xiong, YQ; Singh, IN; Hall, ED				Xiong, Yiqin; Singh, Indrapal N.; Hall, Edward D.			Tempol protection of spinal cord mitochondria from peroxynitrite-induced oxidative damage	FREE RADICAL RESEARCH			English	Article						Tempol; spinal cord; mitochondria; nitrotyrosine; lipid peroxidation; oxidative damage	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE; CYTOCHROME-C; LIPID-PEROXIDATION; MOUSE MODEL; PERMEABILITY TRANSITION; NITROXIDE ANTIOXIDANT; ELECTRON-TRANSPORT; TYROSINE NITRATION; HEAD-INJURY	Peroxynitrite (PN)-mediated mitochondrial dysfunction has been implicated in the secondary injury process after traumatic spinal cord injury (SCI). This study investigated the detrimental effects of the PN donor SIN-1(3-morpholinosydnonimine) on isolated healthy spinal cord mitochondria and the protective effects of tempol, a catalytic scavenger of PN-derived radicals. A 5 min exposure of the mitochondria to SIN-1 caused a dose-dependent decrease in the respiratory control ratio (RCR) that was accompanied by significant increases in complex I-driven states II and IV respiration rates and decreases in states III and V. These impairments occurred together with an increase in mitochondrial protein 3-nitrotyrosine (3-NT), but not in lipid peroxidation (LP)-related 4-hydroxynonenal (4-HNE). Tempol significantly antagonized the respiratory effects of SIN-1 in parallel with an attenuation of 3-NT levels. These results show that the exogenous PN donor, SIN-1, rapidly causes mitochondrial oxidative damage and complex I dysfunction identical to traumatic spinal cord mitochondrial impairment and that this is mainly due to tyrosine nitration. Consistent with that, the protection of mitochondrial respiratory function by tempol is associated with a decrease in 3-NT levels in mitochondrial proteins also similar to the previously reported antioxidant actions of tempol in traumatically-injured spinal cord mitochondria.	[Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Dept Anat & Neurobiol, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Xiong, Yiqin/H-1710-2012; Hall, Edward D/F-8930-2013		Kentucky Spinal Cord & Head Injury Research Trust6-5; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566, P30NS051220] Funding Source: NIH RePORTER	Support for this study was provided by a grant from the Kentucky Spinal Cord & Head Injury Research Trust ( KSCHIRT # 6-5).	Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Batthyany C, 2005, BIOCHEMISTRY-US, V44, P8038, DOI 10.1021/bi0474620; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Brookes PS, 1998, J NEUROCHEM, V70, P2195; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Cassina AM, 2000, J BIOL CHEM, V275, P21409, DOI 10.1074/jbc.M909978199; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Denicola A, 1996, ARCH BIOCHEM BIOPHYS, V333, P49, DOI 10.1006/abbi.1996.0363; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Genovese T, 2007, FREE RADICAL BIO MED, V43, P763, DOI 10.1016/j.freeradbiomed.2007.05.012; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Hillard VH, 2004, J NEUROTRAUM, V21, P1405, DOI 10.1089/neu.2004.21.1405; HOGG N, 1992, BIOCHEM J, V281, P419, DOI 10.1042/bj2810419; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Murray J, 2003, J BIOL CHEM, V278, P37223, DOI 10.1074/jbc.M305694200; Patel SP, 2009, J NEUROSCI RES, V87, P130, DOI 10.1002/jnr.21814; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; Radi R, 2001, FREE RADICAL BIO MED, V30, P463, DOI 10.1016/S0891-5849(00)00373-7; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; SALGO MG, 1995, BIOCHEM BIOPH RES CO, V210, P1025, DOI 10.1006/bbrc.1995.1759; SALGO MG, 1995, ARCH BIOCHEM BIOPHYS, V322, P500, DOI 10.1006/abbi.1995.1493; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2007, J NEUROTRAUM, V24, P991, DOI 10.1089/neu.2006.0242; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P662, DOI 10.1038/nrd2222; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xiong YQ, 2009, EXP NEUROL, V216, P105, DOI 10.1016/j.expneurol.2008.11.025	50	33	36	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.		2009	43	6					604	612		10.1080/10715760902977432			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	457ZR	WOS:000266979100010	19513907	Green Accepted			2021-06-18	
J	Mahmood, A; Goussev, A; Lu, DY; Qu, CS; Xiong, Y; Kazmi, H; Chopp, M				Mahmood, Asim; Goussev, Anton; Lu, Dunyue; Qu, Changsheng; Xiong, Ye; Kazmi, Humaira; Chopp, Michael			Long-Lasting Benefits after Treatment of Traumatic Brain Injury (TBI) in Rats with Combination Therapy of Marrow Stromal Cells (MSCs) and Simvastatin	JOURNAL OF NEUROTRAUMA			English	Article						combination therapy; marrow stromal cells (MSCs); simvastatin; traumatic brain injury (TBI)	ADULT RATS; TRANSPLANTATION; ATORVASTATIN; NEUROGENESIS; RECOVERY; MODEL	This study was designed to investigate the beneficial effects of combination therapy of simvastatin and marrow stromal cells (MSCs) in improving functional outcome after traumatic brain injury (TBI) in rats. Adult female Wistar rats (n = 72 and 8, per group) were injured with controlled cortical impact and treated either with monotherapy of MSCs or simvastatin or a combination therapy of these two agents. Different combination doses were tested, and nine groups of animals were studied. Neurological function was evaluated using Modified Neurological Severity Score (MNSS), and animals were sacrificed 3 months after injury. Coronal brain sections were stained with standard hematoxylin and eosin immunohistochemistry. Our results showed that, though functional improvement was seen with monotherapies of MSCs and simvastatin, the combination therapy when used in optimal doses was significantly better in improving functional outcome. This improvement was long lasting and persisted until the end of the trial (3 months). The optimum combination dose was 0.5mg of simvastatin combined with 2 x 10(6) MSCS. post mortem analysis showed the presence of donor MSCs within the injured cortex. Endogenous cellular proliferation induced by the neurorestorative treatments was also observed in the lesion boundary zone. Our data show that MSCs and simvastatin have a synergistic effect in improving functional outcome after TBI.	[Mahmood, Asim; Goussev, Anton; Qu, Changsheng; Xiong, Ye; Kazmi, Humaira] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Lu, Dunyue] SUNY Brooklyn, Dept Psychiat, Brooklyn, NY USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Mahmood, A (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052280-02, R01 NS052280-04] Funding Source: Medline		Ballantyne CM, 2004, AM J CARDIOL, V93, P1487, DOI 10.1016/j.amjcard.2004.02.060; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Leventhal C, 1999, MOL CELL NEUROSCI, V13, P450, DOI 10.1006/mcne.1999.0762; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; POSTMANTUR R, 1997, NEUROSCIENCE, V77, P875; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Yurek DM, 1996, EXP NEUROL, V137, P105, DOI 10.1006/exnr.1996.0011; Zacco A, 2003, J NEUROSCI, V23, P11104	23	33	36	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2008	25	12					1441	1447		10.1089/neu.2007.0495			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	400IY	WOS:000262862500005	19072586	Green Accepted, Green Published			2021-06-18	
J	Choi, JH; Jakob, M; Stapf, C; Marshall, RS; Hartmann, A; Mast, H				Choi, Jae H.; Jakob, Michael; Stapf, Christian; Marshall, Randolph S.; Hartmann, Andreas; Mast, Henning			Multimodal Early Rehabilitation and Predictors of Outcome in Survivors of Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	130th Annual Meeting of the American-Neurological-Association	SEP 25-28, 2005	San Diego, CA	Amer Neurol Assoc, AstraZeneca		Severe traumatic brain injury; Outcome; Early rehabilitation; Multimodal rehabilitation	SEVERE HEAD-INJURY	Background: To determine the effect of brain lesion pattern on early recovery after severe traumatic brain injury (TBI). Methods: In a setting of a multimodal early rehabilitation unit at a level I trauma center, 135 consecutive survivors of severe TBI (mean age, 40 years, 25% women) were studied prospectively. Assessment of disability was performed weekly using an extended Barthel Index (eBI) ranging from -325 to +100 points. Clinical and brain morphologic variables were tested in multivariate logistic regression models to determine predictors of outcome. Results: Imaging revealed cerebral contusion in 115 patients (85%) affecting the frontal (n = 80), temporal (n = 62), parieto-occipital (n = 17), brain stern (n = 13), and cerebellar (n = 5) regions. In addition, 80 patients (59%) showed diffuse brain edema, 75 (55%) subarachnoid, 37 (28%) subdural, and 18 (13%) epidural hemorrhage. After a mean stay of 72 +/- 51 days in the early rehabilitation unit, one patient died, 40 (30%) revealed good outcome (median eBI, +55), and a further 43 patients (32%) showed excellent outcomes (eBI, 90-100). Temporal (odds ratio 2.6; 95% confidence interval 1.1-6.5) and brain stem contusions (odds ratio 13.8; 95% confidence interval 3.0-64.1) were independent predictors of poor outcome. Conclusions: Temporal and brain stern contusions constitute independent risk factors for poor outcome in survivors of severe TBI. The results further suggest a high potential for multimodal early rehabilitation after severe TBI.	[Choi, Jae H.; Jakob, Michael; Mast, Henning] BG Kliniken Bergmannstrost, Dept Neurol, D-06112 Halle, Germany; [Choi, Jae H.; Stapf, Christian; Marshall, Randolph S.; Hartmann, Andreas; Mast, Henning] Columbia Univ, Med Ctr, Neurol Inst, New York, NY USA; [Choi, Jae H.] Columbia Univ, Med Ctr, Dept Radiol, New York, NY USA; [Stapf, Christian] Hop Lariboisiere, AP HP, Dept Neurol, F-75475 Paris, France; [Hartmann, Andreas; Mast, Henning] Charite Campus Benjamin Franklin, Dept Neurol, Berlin, Germany	Choi, JH (corresponding author), BG Kliniken Bergmannstrost, Dept Neurol, Merseburger Str 165, D-06112 Halle, Germany.	jchoi@neuro.columbia.edu		Stapf, Christian/0000-0002-3193-1006			Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Collin C, 1988, Int Disabil Stud, V10, P61; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; *DEP HLTH SOC SEC, FED HLTH REP; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FIRSCHING R, 2003, DTSCH ARZEBL, V100, P1868; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; *NAT CTR INJ PREV, 2006, TRAUM INJ US EM DEP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; REGEL G, 1993, UNFALLCHIRURG, V96, P350; Schonle P. W., 1996, NEUROL REHABIL, V1, P21; Semlyen JK, 1998, ARCH PHYS MED REHAB, V79, P678, DOI 10.1016/S0003-9993(98)90044-2; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; 1994, N ENG J MED, V330, P1572	28	33	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2008	65	5					1028	1035		10.1097/TA.0b013e31815eba9b			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	372DD	WOS:000260881000011	19001970				2021-06-18	
J	Jin, GZ; Cho, SJ; Choi, EG; Lee, YS; Yu, XF; Choi, KS; Yee, ST; Jeon, JT; Kim, MO; Kong, IK				Jin, Guang-Zhen; Cho, Su-Jin; Choi, Eu-Gene; Lee, Young-S.; Yu, Xian-Feng; Choi, Kap-Seong; Yee, Sung-Tae; Jeon, Jin-Tae; Kim, Myeong-Ok; Kong, Il-Keun			Rat mesenchymal stem cells increase tyrosine hydroxylase expression and dopamine content in ventral mesencephalic cells in vitro	CELL BIOLOGY INTERNATIONAL			English	Article						Co-culture; Dopamine; Mesenchymal stem cells; Tyrosine hydroxylase; Ventral mesencephalic cells	MARROW STROMAL CELLS; NERVE GROWTH-FACTOR; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; FUNCTIONAL RECOVERY; PC12 CELLS; BONE; DIFFERENTIATION; TRANSPLANTATION; NEURONS	Mesenchymal stem cells (MSCs) are pluripotent adult stem cells. It has been shown that MSCs secrete neurotrophic factors involving nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF). Also, these neurotrophic factors can upregulate tyrosine hydroxylase (TH) gene expression in PC12 cells and neural stem cells. Here, we investigated the effect of co-culturing rat E13.5 ventral mesencephalic cells (VMCs) with MSCs from rat bone marrow on TH expression and dopamine (DA) content. The study consisted of 3 groups: MSC, VMC and a combined MSC + VMC group. All groups were cultured in serum-free neuro-basal medium for 3 days. Thereafter, each group was analyzed by RT-PCR, western blotting, and HPLC. The co-culture group showed a higher expression at TH and DA than the VMC group. However, TH and DA were not present in the MSC group. These observations suggest that MSCs could be an alternative source for treating neurodegenerative diseases such as Parkinson's disease (PD). Crown Copyright (C) 2008 Published by Elsevier Ltd on behalf of International Federation for Cell Biology. All rights reserved.	[Jin, Guang-Zhen; Cho, Su-Jin; Choi, Eu-Gene; Lee, Young-S.; Jeon, Jin-Tae; Kim, Myeong-Ok; Kong, Il-Keun] Gyeongsang Natl Univ, Grad Sch, Inst Agr & Life Sci, Div Appl Life Sci BK21, Jinju 660701, Gyeongnam Prov, South Korea; [Yu, Xian-Feng] Sunchon Natl Univ, Dept Anim Sci & Technol, Sunchon 540742, South Korea; [Choi, Kap-Seong] Sunchon Natl Univ, Dept Food Sci & Technol, Sunchon 540742, South Korea; [Yee, Sung-Tae] Sunchon Natl Univ, Dept Biol, Sunchon 540742, South Korea	Kong, IK (corresponding author), Gyeongsang Natl Univ, Grad Sch, Inst Agr & Life Sci, Div Appl Life Sci BK21, Jinju 660701, Gyeongnam Prov, South Korea.	ikong@gnu.kr		Choi, Eugene/0000-0002-0964-7615	Korea Science and Engineering Foundation (KOSEF)Korea Science and Engineering Foundation [M10525010001-05N2501-00110]; Korean government (MOEST)Ministry of Education, Science and Technology, Republic of KoreaKorean Government; Post BK21 ProgramMinistry of Education & Human Resources Development (MOEHRD), Republic of Korea	This work was supported by a grant from the Korea Science and Engineering Foundation (KOSEF; #M10525010001-05N2501-00110) and funding from the Korean government (MOEST). Guang-Zhen Jin, Eugene Choi, Young-S Lee, and Su-Jin Cho were supported by scholarships from the Post BK21 Program.	Chaturvedi RK, 2006, NEUROBIOL DIS, V22, P421, DOI 10.1016/j.nbd.2005.12.008; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Garcia R, 2004, BIOCHEM BIOPH RES CO, V316, P753, DOI 10.1016/j.bbrc.2004.02.111; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Jin GZ, 2007, J VET SCI, V8, P377, DOI 10.4142/jvs.2007.8.4.377; Kan I, 2007, NEUROSCI LETT, V419, P28, DOI 10.1016/j.neulet.2007.03.070; Kim TE, 2003, BIOCHEM BIOPH RES CO, V305, P1040, DOI 10.1016/S0006-291X(03)00879-9; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Li XM, 1997, J NEUROSCI RES, V47, P449; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lu LL, 2005, BRAIN RES PROTOC, V15, P46, DOI 10.1016/j.brainresprot.2005.03.002; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; MARSDEN CD, 1990, LANCET, V335, P948, DOI 10.1016/0140-6736(90)91006-V; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; O'Byrne MB, 2000, ADV EXP MED BIOL, V483, P369; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Sawamoto K, 2001, J NEUROSCI, V21, P3895, DOI 10.1523/JNEUROSCI.21-11-03895.2001; Tao H, 2005, DEV GROWTH DIFFER, V47, P423; ZHOU JW, 1994, DEV BRAIN RES, V81, P318, DOI 10.1016/0165-3806(94)90318-2; Zhou JW, 1998, NEUROSCI LETT, V252, P215, DOI 10.1016/S0304-3940(98)00577-1	24	33	43	0	2	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	1065-6995			CELL BIOL INT	Cell Biol. Int.	NOV	2008	32	11					1433	1438		10.1016/j.cellbi.2008.08.014			6	Cell Biology	Cell Biology	369CU	WOS:000260671900012	18778785				2021-06-18	
J	Wong, DY; Krebsbach, PH; Hollister, SJ				Wong, Darice Y.; Krebsbach, Paul H.; Hollister, Scott J.			Brain cortex regeneration affected by scaffold architectures	JOURNAL OF NEUROSURGERY			English	Article						poly-(epsilon-caprolactone); polymer scaffold; regeneration; solid free-form fabrication; traumatic brain injury	INJURED RAT-BRAIN; CO-GLYCOLIC ACID; TRAUMATIC BRAIN; TOPOGRAPHICAL CONTROL; NESTIN EXPRESSION; TITANIUM IMPLANTS; CELL-DEATH; ADULT-RAT; TISSUE; TRANSPLANTATION	Object. The aim of this study was to compare designed scaffolds with a random-pored sponge scaffold to determine what role scaffold architecture plays in a cortical injury model. Methods. Cylindrical scaffolds (3 x 3 mm) were made of a poly-(epsilon-caprolactone) polymer with 2 different molds from a 3D printer and had either: 1) unidirectional channels and microgrooves oriented longitudinally within the cylinder or 2) orthogonally intersecting channels and axial microgrooves within the cylinder. Additional randomized porosity was imparted using a salt-leaching method. A control scaffold without channels or microgrooves but containing random pores was also made. Scaffolds were implanted for 1, 4, and 8 weeks in a cylindrical defect created 3 mm posterior to the bregma in rat cortex. Control animals had tissue removed but received no implant. Brains were coronally cryosectioned and sections were stained. Antibodies for nestin, glial fibrillary acidic protein (GFAP), and TUJ1 were used to identify neural progenitors, activated astrocytes, and neuronal axons. Tissue ingrowth (H & E) astrocytic infiltration (GFAP), parenchymal inflammation (GFAP), and defect width (H & E) were quantified from images. Results. Defect widths grew and parenchymal inflammation decreased over time with no statistical difference between groups. Total tissue ingrowth and astrocytic infiltration increased over time and was greatest in the orthogonal design group. Specific cell ingrowth, which was aligned with microgrooves interiorly in the orthogonal group and exteriorly in the longitudinal channel group, was qualitatively assessed from nestin and TUJ1 labeling. Conclusions. Scaffold architecture can benefit brain tissue regeneration by integrating the following design principles: 1) large ( 100s of micrometers) pores or channels oriented toward the parenchyma for increased astrocytic infiltration; 2) microgrooves oriented in the desired direction of cellular migration and neuronal alignment; and 3) fully interconnecting channels for cellular migration and tissue integration.	[Wong, Darice Y.; Krebsbach, Paul H.; Hollister, Scott J.] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA; [Hollister, Scott J.] Univ Michigan, Dept Mech Engn, Coll Engn, Ann Arbor, MI 48109 USA; [Krebsbach, Paul H.] Univ Michigan, Dept Biol & Mat Sci, Sch Dent, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Sch Med, Ann Arbor, MI 48109 USA; [Hollister, Scott J.] Univ Michigan, Dept Neurosurg, Sch Med, Ann Arbor, MI 48109 USA	Wong, DY (corresponding author), 1011 N Univ Ave,Room 4214 Dent Bldg, Ann Arbor, MI USA.	dywong@umich.edu	Krebsbach, Paul H./AAC-4765-2021	Hollister, Scott/0000-0001-7625-892X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DE-007057-31]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR) [T32DE007057] Funding Source: NIH RePORTER	Funding was provided by the National Institutes of Health Training Grant No. T32 DE-007057-31 (D.Y.W.).	Bullock MR, 2006, NEUROSURGERY S, V58, pSi; CLARK P, 1990, DEVELOPMENT, V108, P635; Curtis A, 1997, BIOMATERIALS, V18, P1573, DOI 10.1016/S0142-9612(97)00144-0; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Goldner JS, 2006, BIOMATERIALS, V27, P460, DOI 10.1016/j.biomaterials.2005.06.035; Hollister SJ, 2005, NAT MATER, V4, P518, DOI 10.1038/nmat1421; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; KRISTT DA, 1987, J NEUROPATH EXP NEUR, V46, P668, DOI 10.1097/00005072-198711000-00006; Li JP, 2007, BIOMATERIALS, V28, P2810, DOI 10.1016/j.biomaterials.2007.02.020; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Malda J, 2005, BIOMATERIALS, V26, P63, DOI 10.1016/j.biomaterials.2004.02.046; Manwaring ME, 2004, BIOMATERIALS, V25, P3631, DOI 10.1016/j.biomaterials.2003.10.043; Marion DW, 2006, NEUROSURGERY, V58, P655; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Mountcastle VB, 1997, BRAIN, V120, P701, DOI 10.1093/brain/120.4.701; Otsuki B, 2006, BIOMATERIALS, V27, P5892, DOI 10.1016/j.biomaterials.2006.08.013; Park KI, 2002, NAT BIOTECHNOL, V20, P1111, DOI 10.1038/nbt751; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Schouten JW, 2004, J NEUROTRAUM, V21, P1501, DOI 10.1089/neu.2004.21.1501; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Tate MC, 2001, BIOMATERIALS, V22, P1113, DOI 10.1016/S0142-9612(00)00348-3; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Tian WM, 2005, J CONTROL RELEASE, V102, P13, DOI 10.1016/j.jconrel.2004.09.025; Tsuruma A, 2006, COLLOID SURFACE A, V284, P470, DOI 10.1016/j.colsurfa.2005.11.100; Vance RJ, 2004, BIOMATERIALS, V25, P2095, DOI 10.1016/j.biomaterials.2003.08.064; Williams AJ, 2006, J NEUROTRAUM, V23, P1828, DOI 10.1089/neu.2006.23.1828; Wong DY, 2007, TISSUE ENG, V13, P2515, DOI 10.1089/ten.2006.0440	29	33	34	1	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					715	722		10.3171/JNS/2008/109/10/0715			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100018	18826360				2021-06-18	
J	Li, N; Yang, H; Lu, LL; Duan, CL; Zhao, CL; Zhao, HY				Li, Na; Yang, Hui; Lu, Lingling; Duan, Chunli; Zhao, Chunli; Zhao, Huanying			Comparison of the labeling efficiency of BrdU, DiI and FISH labeling techniques in bone marrow stromal cells	BRAIN RESEARCH			English	Article						BrdU; FISH; DiI; labeling; marrow stromal cell	TRAUMATIC BRAIN INJURY; ACUTE MYOCARDIAL-INFARCTION; STEM-CELLS; TRANSPLANTATION; RATS; MICROSCOPY; NEOVASCULARIZATION; HYBRIDIZATION; PROLIFERATION; MACROPHAGES	Cells are generally labeled during in vivo implantation studies enabling the cells to be traced. The relationship between the labeling efficiency and cellular proliferation after transplantation is critical for the interpretation of data obtained by detection of the signals on tissue sections. Here, we compare cellular labeling methods of rat marrow stromal cells that were labeled with 5-bromo-2-deoxyuridine (BrdU), 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI) and fluorescence in situ hybridization (FISH). Our data show that (i) BrdU uniformly labeled the nuclei, (ii) DiI-labeled cells had many dots or stained clear and uniform when a longer exposure time was used during detection and (iii) FISH labeled the cells with dots along the edges of the nuclei. The labeling efficiency was 94.1 +/- 8.6%, 97.6 +/- 3.4% and 90.5 +/- 3.0%, in BrdU, DiI- and FISH-labeled cells, respectively. After sub-culturing of labeled cells, the percentage of BrdU-positive cells was found to be 71.9 +/- 18.0% and 18.4 +/- 6.9%, after the first and second passages, respectively. The percentage of DiI-labeled cells detected depended on the exposure time: a long exposure time (> 10 s) resulted in identification of 95.1 +/- 4.0% and 94.5 +/- 3.9% DiI-positive cells after the first and second sub-cultures, respectively. The percentage of FISH-positive cells was found to be 87.0 +/- 3.0% and 89.1 +/- 9.7%. The BrdU labeling signal quickly decreased over time. Thus, BrdU should only be used to temporarily label dividing cells. In contrast, our data indicate that DiI and FISH labeling maybe used to steadily trace cells during in vivo experiments. To our knowledge, this is the first time that the effects of different labeling methods over time have been examined during a cell transplantation study. (c) 2007 Elsevier B.V. All rights reserved.	[Li, Na; Yang, Hui; Lu, Lingling; Duan, Chunli; Zhao, Chunli; Zhao, Huanying] Capital Med Univ, Minist Educ, Beijing Ctr Neural Regenerat & Repairing, Key Lab Neurodegenerat Dis,Beijing Inst Neurosci, Beijing 100069, Peoples R China	Yang, H (corresponding author), Capital Med Univ, Minist Educ, Beijing Ctr Neural Regenerat & Repairing, Key Lab Neurodegenerat Dis,Beijing Inst Neurosci, 10 YouanMen Wai Xitoutiao, Beijing 100069, Peoples R China.	huiyang@ccmu.edu.cn					An J, 1997, J ANDROL, V18, P289; Andrassy M, 2005, CIRC RES, V96, P476, DOI 10.1161/01.RES.0000156903.37007.d1; ARCHARD LC, 1987, EUR HEART J, V8, P437, DOI 10.1093/eurheartj/8.suppl_J.437; ASIM M, 2001, NEUROSURGERY, V49, P1196; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BERG E, 2005, NEUROREPORT, V16, P1419; Cheng Q.N., 2007, CARDIOVASC PATHOL, V16, P127; Coenen M, 2005, J NEUROPATH EXP NEUR, V64, P681, DOI 10.1097/01.jnen.0000173892.24800.03; Dai WD, 2005, CIRCULATION, V112, P214, DOI 10.1161/CIRCULATIONAHA.104.527937; Dalgaard LZ, 1999, NATURE, V400, P181, DOI 10.1038/22139; Deng J, 2001, ANAT EMBRYOL, V204, P437, DOI 10.1007/s429-001-8001-3; Ehmcke J, 2005, HUM REPROD, V20, P1185, DOI 10.1093/humrep/deh766; Fang BJ, 2004, TRANSPLANTATION, V78, P83, DOI 10.1097/01.TP.0000128326.95294.14; GOZ B, 1977, PHARMACOL REV, V29, P249; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Higuchi Yutaka, 2005, Eur Arch Otorhinolaryngol, V262, P64, DOI 10.1007/s00405-003-0667-y; Hildebrandt K, 1999, J NEURAL TRANSM, V106, P549, DOI 10.1007/s007020050178; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Kamolz LP, 2006, BURNS, V32, P16, DOI 10.1016/j.burns.2005.08.020; Kellermayer R, 2005, DIAGN MOL PATHOL, V14, P159, DOI 10.1097/01.pas.0000176770.56541.dd; Konnai Y, 2000, SPINE, V25, P776, DOI 10.1097/00007632-200004010-00004; LINDEBERG H, 1990, CLIN OTOLARYNGOL, V15, P367, DOI 10.1111/j.1365-2273.1990.tb00485.x; Liu C, 2005, ANN VASC SURG, V19, P241, DOI 10.1007/s10016-004-0173-8; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; McLennan R, 2007, DEV BIOL, V301, P227, DOI 10.1016/j.ydbio.2006.08.019; Michel K, 2000, PFLUG ARCH EUR J PHY, V440, P393, DOI 10.1007/s004240000299; Pasula R, 2002, J IMMUNOL, V169, P4504, DOI 10.4049/jimmunol.169.8.4504; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; Radtke C, 2005, NEUROSCI LETT, V387, P85, DOI 10.1016/j.neulet.2005.06.073; RUTTER WJ, 1973, ANNU REV BIOCHEM, V42, P601, DOI 10.1146/annurev.bi.42.070173.003125; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; Van Lommel A, 1998, ANAT EMBRYOL, V197, P325, DOI 10.1007/s004290050142; Vogetseder A, 2005, HISTOCHEM CELL BIOL, V124, P97, DOI 10.1007/s00418-005-0023-y; Yang H, 1999, J HISTOCHEM CYTOCHEM, V47, P431, DOI 10.1177/002215549904700402; Yang ZJ, 2007, CLIN CHIM ACTA, V381, P114, DOI 10.1016/j.cca.2007.02.035; Yoon YS, 2004, CIRCULATION, V109, P3154, DOI 10.1161/01.CIR.0000134696.08436.65; Yoshiba K, 2002, HISTOCHEM CELL BIOL, V118, P205, DOI 10.1007/s00418-002-0442-y; Zhou R, 2006, J AM COLL CARDIOL, V48, P2094, DOI 10.1016/j.jacc.2006.08.026	40	33	41	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUN 18	2008	1215						11	19		10.1016/j.brainres.2007.09.095			9	Neurosciences	Neurosciences & Neurology	323CK	WOS:000257421400002	18468584				2021-06-18	
J	Colantonio, A; Kontos, PC; Gilbert, JE; Rossiter, K; Gray, J; Keightley, ML				Colantonio, Angela; Kontos, Pia C.; Gilbert, Julie E.; Rossiter, Kate; Gray, Julia; Keightley, Michelle L.			After the crash: Research-based theater for knowledge transfer	JOURNAL OF CONTINUING EDUCATION IN THE HEALTH PROFESSIONS			English	Article						education; continuing; brain injury theater; knowledge transfer; professional education; evaluation	TRAUMATIC BRAIN-INJURY; BREAST-CANCER; REFLECTIONS; FAMILY; STAGE	Introduction: The aim of this project was to develop and evaluate a research-based dramatic production for the purpose of transferring knowledge about traumatic brain injury (TBI) to health care professionals, managers, and decision makers. Methods: Using results drawn from six focus group discussions with key stakeholders (consumers, informal care-givers, and health care practitioners experienced in the field of TBI) and relevant scientific literature, a 50-minute play was produced for the purpose of conveying the experiences of TBI survivors, informal care providers, and health practitioners and best practice for TBI care. A self-administered postperformance survey was distributed to audience members at the end of four performances in Ontario, Canada, to evaluate the play's efficacy. Two hundred ninety-one questionnaires were completed. The questionnaire had five questions scored on a 5-item Likert scale with space for open-ended comments. Results: Consistently high mean scores from the questionnaires indicate that theater is a highly efficacious and engaging method of knowledge transfer, particularly for complex material that deals with human emotion and interpersonal relationships. Discussion: Responses supported the effectiveness of drama as a knowledge translation strategy and identified its potential to impact practice positively.	[Colantonio, Angela; Kontos, Pia C.] Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Kontos, Pia C.] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; [Gilbert, Julie E.] Univ Toronto, Canc Care Ontario, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada	Colantonio, A (corresponding author), Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765; Kontos, Pia/0000-0002-8893-2544	Health Care, Technology, and Place (HCTP); Canadian Institutes for Health Research [CIHR]Canadian Institutes of Health Research (CIHR); Strategic Alliance Fund; Ontario Rehabilitation Research Network; Toronto Rehabilitation InstituteUniversity of Toronto; Ontario Work Study Program; Ministry of Health and Long-Term Care in OntarioMinistry of Health and Long-Term Care, Ontario	We Would like to acknowledge and thank these institutions for financial support for this project: Health Care, Technology, and Place (HCTP): An Interdisciplinary Capacity Enhancement Team (Institute of Health Services and Policy Research-Canadian Institutes for Health Research [CIHR]), Strategic Alliance Fund (The Change Foundation and HCTP), the Ontario Rehabilitation Research Network, the Toronto Rehabilitation Institute, and the Ontario Work Study Program. Toronto Rehabilitation Institute receives funding under the Provincial Rehabilitation Research Program from the Ministry of Health and Long-Term Care in Ontario. We wish to thank all the many participants. organizations, and artistic team who contributed to this project.	BATES B, 1988, WAY ACTOR PATH KNOWL; COLANTONIO A, 2006, WORLD FED OCC THER C; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; Crisp R., 1993, DISABILITY HANDICAP, V8, P393, DOI [DOI 10.1080/02674649366780371, 10.1080/02674649366780371]; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; GRAY J, 2006, CRASH PLAY BRA UNPUB; GRAY R, 2002, STANDING OVATION; Gray RE, 2003, J CANCER EDUC, V18, P223, DOI 10.1207/s15430154jce1804_10; Gray RE, 2002, ETHNOGR ALT BOOK SER, V9, P57; Gray RE, 2003, QUAL INQ, V9, P254, DOI 10.1177/1077800402250957; Gray RE, 2001, HEALTH, V5, P233, DOI 10.1177/136345930100500205; Gray Ross, 2000, Health Expect, V3, P137, DOI 10.1046/j.1369-6513.2000.00071.x; Gray Ross, 2003, QUALITATIVE RES, V3, P284; Hagen U., 1973, RESPECT ACTING; Hobson S. J. G., 1999, CLIENT CTR PRACTICE, P51; Jackson A, 2005, J AESTHET EDUC, V39, P104; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; KONTOS R, 2006, QUAL RES, V6, P301; Levy J, 2005, J AESTHET EDUC, V39, P20, DOI 10.1353/jae.2005.0042; Lorenz KA, 2004, ACAD MED, V79, P481, DOI 10.1097/00001888-200405000-00020; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Mienczakowski J, 1999, STUD EDUC ETHNOG, V2, P145; Mienczakowski J., 1995, QUALITATIVE INQUIRY, V1, P360, DOI DOI 10.1177/107780049500100306; Mienczakowski J., 2001, HDB ETHNOGRAPHY, P468; Mitchell GJ, 2006, NURS SCI QUART, V19, P198, DOI 10.1177/0894318406289878; Morgan D.L., 1998, FOCUS GROUP KIT; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Rosenbaum ME, 2005, MED EDUC, V39, P622, DOI 10.1111/j.1365-2929.2005.02181.x; Rossiter K, 2008, SOC SCI MED, V66, P130, DOI 10.1016/j.socscimed.2007.07.021; Rossiter K, 2008, J HEALTH PSYCHOL, V13, P277, DOI 10.1177/1359105307086707; Salda?a Johhny., 1998, RES DRAMA ED, V3, P181, DOI DOI 10.1080/1356978980030205; Saldana J, 2003, QUAL INQ, V9, P218, DOI 10.1177/1077800402250932; Salverson J, 2001, THEATER, V31, P118; Sinding C, 2002, QUAL HEALTH RES, V12, P61, DOI 10.1177/1049732302012001005; Strauss A.L., 1994, HDB QUAL RES, P273, DOI DOI 10.1007/BF00988593; Sumsion T, 1999, CLIENT CTR PRACTICE, P1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TURK M, 2006, BRAIN INJURY MED PRI, P227; Wilkins S, 2001, Can J Occup Ther, V68, P70	40	33	34	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-1912	1554-558X		J CONTIN EDUC HEALTH	J. Contin. Educ. Health Prof.	SUM	2008	28	3					180	185		10.1002/chp.177			6	Education, Scientific Disciplines; Health Care Sciences & Services	Education & Educational Research; Health Care Sciences & Services	348VP	WOS:000259238500009	18712795				2021-06-18	
J	Kobeissy, FH; Warren, MW; Ottens, AK; Sadasivan, S; Zhang, ZQ; Gold, MS; Wang, KKW				Kobeissy, Firas H.; Warren, Matthew W.; Ottens, Andrew K.; Sadasivan, Shankar; Zhang, Zhiqun; Gold, Mark S.; Wang, Kevin K. W.			Psychoproteomic analysis of rat cortex following acute methamphetamine exposure	JOURNAL OF PROTEOME RESEARCH			English	Article						autophagy; neurotoxicity; methamphetamine; proteomics; drug of abuse; proteolysis	TRAUMATIC BRAIN-INJURY; TANDEM MASS-SPECTROMETRY; DOPAMINERGIC NEUROTOXICITY; PRELIMINARY VALIDATION; TERMINAL HYDROLASE-L1; NEURONAL APOPTOSIS; ALPHA-SYNUCLEIN; UP-REGULATION; CELL-DEATH; IDENTIFICATION	Methamphetamine (METH) is recognized as one of the most abused psychostimulants in the United States. METH is an illicit drug that is known to exert neurotoxic effects on both dopaminergic and serotonergic neural systems both in vivo and in vitro. Our laboratory and others have been Studying the biochemical mechanisms underlying METH-induced neurotoxicity. Here, we applied a novel psychoproteomic approach to evaluate METH-induced neurotoxicity following acute METH administration (4 x 10 mg/kg, ip injections every 1 h). Samples of cortical tissue collected 24h post METH treatment were pooled, processed and analyzed via a selective psychoproteomic platform. Protein separation was performed using our previously established offline tandem cation-anion exchange chromatography-SDS-1 D-PAGE platform (CAX-PAGE). Gel bands exhibiting 2 or more fold changes were extracted, trypsinized and subjected to reversed-phase liquid chromatography-tandem mass spectrometry (RPLCMS/MS) analyses for protein identification. Differential changes of the selected proteins were further confirmed by quantitative immunoblotting. We identified 82 differentially expressed proteins, 40 of which were downregulated and 42 of which were upregulated following acute METH treatment. Proteins that decreased in abundance included collapsin response mediator protein-2 (CRMP-2), superoxide dismutase 1 (SOD 1), phosphatidylethanolamine-binding protein-1 (PEBP-1) and mitogen activated kinase kinase-1 (MKK-1). Proteins that increased in abundance included authophagy-linked microtubule-associated protein light chain 3 (LC3), synapsin-1, and Parkinsonism linked ubiquitin carboxy-terminal hydroxylase-L1 (UCH-L1). Lastly, we used these differentially expressed protein subsets to construct a "psychoproteomic" spectrum map in an effort to uncover potential protein interactions relevant to acute METH neurotoxicity.	[Kobeissy, Firas H.; Warren, Matthew W.; Ottens, Andrew K.; Sadasivan, Shankar; Zhang, Zhiqun; Gold, Mark S.; Wang, Kevin K. W.] Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32610 USA; [Kobeissy, Firas H.; Gold, Mark S.; Wang, Kevin K. W.] Univ Florida, Ctr Traumat Brain Injury Studies, Dept Neurosci, McKnight Brain Inst, Gainesville, FL 32610 USA; [Gold, Mark S.] Univ Florida, Coll Med, Dept Community Hlth & Family Med, McKnight Brain Inst, Gainesville, FL 32610 USA	Kobeissy, FH (corresponding author), Univ Florida, Dept Psychiat, L4-100F,POB 100256, Gainesville, FL 32611 USA.	firasko@ufl.edu; kwang@psychiatry.ufl.edu	Kobeissy, Firas/E-7042-2017; Ottens, Andrew/K-3352-2012; Sadasivan, Shankar/C-9620-2009	Kobeissy, Firas/0000-0002-5008-6944; Ottens, Andrew/0000-0002-2118-3796; Wang, Kevin/0000-0002-9343-6473			Bae SC, 2006, DRUG ALCOHOL DEPEN, V81, P83, DOI 10.1016/j.drugalcdep.2005.05.016; Bodovitz S, 2004, TRENDS BIOTECHNOL, V22, P4, DOI 10.1016/j.tibtech.2003.10.013; Bowyer JF, 2007, NEUROSCIENCE, V144, P66, DOI 10.1016/j.neuroscience.2006.08.076; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Carolan BJ, 2006, CANCER RES, V66, P10729, DOI 10.1158/0008-5472.CAN-06-2224; Castegna A, 2002, J NEUROCHEM, V82, P1524, DOI 10.1046/j.1471-4159.2002.01103.x; Chen Q, 2006, J NEUROCHEM, V99, P1133, DOI 10.1111/j.1471-4159.2006.04160.x; Choi J, 2004, J BIOL CHEM, V279, P13256, DOI 10.1074/jbc.M314124200; Culotta VC, 2006, BBA-MOL CELL RES, V1763, P747, DOI 10.1016/j.bbamcr.2006.05.003; Davidson C, 2001, BRAIN RES REV, V36, P1, DOI 10.1016/S0165-0173(01)00054-6; Fornai F, 2004, ANN NY ACAD SCI, V1025, P162, DOI 10.1196/annals.1316.021; Fornai F, 2004, J NEUROCHEM, V88, P114, DOI 10.1046/j.1471-4159.2003.02137.x; Fornai F, 2006, ANN NY ACAD SCI, V1074, P84, DOI 10.1196/annals.1369.007; Funada M, 2004, ANN NY ACAD SCI, V1025, P76, DOI 10.1196/annals.1316.010; Harada T, 2004, AM J PATHOL, V164, P59, DOI 10.1016/S0002-9440(10)63096-9; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; Iwazaki T, 2006, BRAIN RES, V1097, P19, DOI 10.1016/j.brainres.2006.04.052; Jayanthi S, 2004, FASEB J, V18, P238, DOI 10.1096/fj.03-0295com; Jimenez A, 2004, TOXICOL APPL PHARM, V196, P223, DOI 10.1016/j.taap.2003.12.017; Kanthasamy A, 2006, ANN NY ACAD SCI, V1074, P234, DOI 10.1196/annals.1369.022; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Lan KC, 1998, J FORMOS MED ASSOC, V97, P528; Larsen KE, 2002, J NEUROSCI, V22, P8951; Liao PC, 2005, J NEUROCHEM, V95, P160, DOI 10.1111/j.1471-4159.2005.03346.x; Lonart G, 2006, BRAIN RES, V1107, P42, DOI 10.1016/j.brainres.2006.05.092; Lopez-Ferrer D, 2004, ANAL CHEM, V76, P6853, DOI 10.1021/ac049305c; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Maxwell JC, 2005, CURR OPIN PSYCHIATR, V18, P235, DOI 10.1097/01.yco.0000165592.52811.84; Morel J, 2006, MOL CELL PROTEOMICS, V5, P1396, DOI 10.1074/mcp.M600044-MCP200; Nishikawa K, 2003, BIOCHEM BIOPH RES CO, V304, P176, DOI 10.1016/S0006-291X(03)00555-2; Noailles PAH, 2003, DEV BRAIN RES, V147, P153, DOI 10.1016/j.devbrainres.2003.11.003; *NSDUH, 2006, REP METH US AB DEP 2; Ottens AK, 2005, ANAL CHEM, V77, P4836, DOI 10.1021/ac050478r; PENG J, 1979, J BIOL CHEM, V279; Perez JA, 1999, J EMERG MED, V17, P469, DOI 10.1016/S0736-4679(99)00009-8; Pu CF, 1996, SYNAPSE, V23, P328, DOI 10.1002/(SICI)1098-2396(199608)23:4<328::AID-SYN11>3.0.CO;2-T; Quinton MS, 2007, PSYCHOPHARMACOLOGY, V193, P341, DOI 10.1007/s00213-007-0796-x; Rakhit R, 2006, BBA-MOL BASIS DIS, V1762, P1025, DOI 10.1016/j.bbadis.2006.05.004; Sadasivan S, 2006, APOPTOSIS, V11, P1573, DOI 10.1007/s10495-006-7690-6; *SAMHSA, 2007, SUBS AB MENT HLTH SE; Semple SJ, 2005, J SUBST ABUSE TREAT, V29, P85, DOI 10.1016/j.jsat.2005.05.001; SHACKA JJ, 2006, NEUROSCI LETT; Soares HD, 2004, INT REV NEUROBIOL, V61, P97; Sokolov BP, 2006, NEUROPSYCHOPHARMACOL, V31, P956, DOI 10.1038/sj.npp.1300891; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Staszewski RD, 2006, J NEUROCHEM, V96, P1267, DOI 10.1111/j.1471-4159.2005.03618.x; Stumm G, 1999, FASEB J, V13, P1065; Svetlov SI, 2006, BIOMARKERS, V11, P355, DOI 10.1080/13547500600775110; United Nations Office on Drugs and Crime, 2004, WORLD DRUG REP; Venton BJ, 2006, J NEUROSCI, V26, P3206, DOI 10.1523/JNEUROSCI.4901-04.2006; Wallace TL, 2003, NEUROSCIENCE, V116, P1063, DOI 10.1016/S0306-4522(02)00795-9; Warren MW, 2007, ACTA NEUROPATHOL, V114, P277, DOI 10.1007/s00401-007-0259-9; Warren MW, 2006, J ADDICT DIS, V25, P115, DOI 10.1300/J069v25n04_11; Warren MW, 2005, LIFE SCI, V78, P301, DOI 10.1016/j.lfs.2005.04.058; WARREN MW, 2006, INT J NEUROPSYCHOPH, P1; Yuan J, 2001, J NEUROCHEM, V77, P1338, DOI 10.1046/j.1471-4159.2001.00339.x; Zhang ZQ, 2007, J NEUROTRAUM, V24, P460, DOI 10.1089/neu.2006.0078	59	33	34	0	3	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1535-3893	1535-3907		J PROTEOME RES	J. Proteome Res.	MAY	2008	7	5					1971	1983		10.1021/pr800029h			13	Biochemical Research Methods	Biochemistry & Molecular Biology	296CD	WOS:000255520200018	18452277				2021-06-18	
J	Thornton, AE; Cox, DN; Whitfield, K; Fouladi, RT				Thornton, Allen E.; Cox, David N.; Whitfield, Kevin; Fouladi, Rachel T.			Cumulative concussion exposure in rugby players: Neurocognitive and symptomatic outcomes	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; COLLEGIATE FOOTBALL PLAYERS; RECURRENT CONCUSSION; WORKING MEMORY; RECOVERY; EXPECTATION; IMPAIRMENT	A total of 111 rugby players underwent comprehensive testing to determine the impact of self-reported concussion exposure. Reliable estimates of concussion exposure were associated with an increase in postconcussion symptoms (PCS), but not diminished neurocognitive functioning. Importantly, the effects of concussion exposure on PCS varied as a function of player status. More specifically, extent of concussion exposure was associated with increased memory complaints and overall PCS endorsements in a dose-dependent manner for retired and older recreational players, but not for those who were younger and playing at more competitive levels. Future work should systematically evaluate the constituent participant factors that may influence differential concussion outcomes.	[Thornton, Allen E.; Cox, David N.; Whitfield, Kevin; Fouladi, Rachel T.] Simon Fraser Univ, Dept Psychol, Human Neuropsychol Lab, Burnaby, BC V5A 1S6, Canada	Thornton, AE (corresponding author), Simon Fraser Univ, Dept Psychol, Human Neuropsychol Lab, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	aethornt@sfu.ca		Thornton, Allen/0000-0002-9942-0122			Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; CATTELL RB, 1973, HDB INDIVIDUAL GROUP; Chan RCK, 2005, BRAIN INJURY, V19, P1117, DOI 10.1080/026990500150088; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Ekstrom R.B., 1976, MANUAL KIT FACTOR RE; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GRONWALL D, 1975, LANCET, V2, P995; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heaton R. K, 1981, WISCONSIN CARD SORTI; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; SALTHOUSE TA, 1989, J EXP PSYCHOL LEARN, V15, P507, DOI 10.1037/0278-7393.15.3.507; Schmidt M., 1996, REY AUDITORY VERBAL; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI70, DOI 10.1136/bjsm.2005.019646; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Tabachnick BG, 2007, USING MULTIVARIATE S; THORNTON A, 2002, J INT NEUROPSYCH SOC, V8, P172; *WAR DEP ADJ GEN O, 1994, ARM IND TEST BATT MA; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M	44	33	35	0	23	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAY	2008	30	4					398	409		10.1080/13803390701443662			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	303FM	WOS:000256026400002	18938678				2021-06-18	
J	Utagawa, A; Bramlett, HM; Daniels, L; Lotocki, G; Dekaban, GA; Weaver, LC; Dietrich, WD				Utagawa, Akira; Bramlett, Helen M.; Daniels, Linda; Lotocki, George; Dekaban, Gregory A.; Weaver, Lynne C.; Dietrich, W. Dalton			Transient blockage of the CD11d/CD18 integrin reduces contusion volume and macrophage infiltration after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						traumatic brain injury; microglia/macrophages; CD11d/CD18 integrin; adhesion molecules; inflammation; histopathology	INTERCELLULAR-ADHESION MOLECULE-1; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; FLUID-PERCUSSION INJURY; TNF-ALPHA; INFLAMMATORY RESPONSE; BARRIER DYSFUNCTION; IMPROVED RECOVERY; MICE DEFICIENT; CELL-DEATH	The early inflammatory response to traumatic brain injury (TBI) may result in secondary damage. The purpose of this study was to evaluate the effects of a transient treatment employing a blocking monoclonal antibody (mAb) to the CD11d/CD18 integrin on histopathological outcome and macrophage infiltration following TBI. A parasagittal fluid percussion (FP) brain injury (1.8-2.1 atm) was induced in male Sprague-Dawley rats. Rats were randomized into two trauma groups, treated (N = 7) and nontreated (N = 8) animals. In the treated group, a mAb to the CD11d subunit of the CD11d/CD18 integrin was administered 30 min, 24 and 48 h after brain injury. Control animals received an isotype-matched irrelevant mAb using the same dose and treatment regimen. At 3 days after TBI, animals were perfusion-fixed for histopathological and immunocytochemical analysis. The anti-CD11d mAb treatment reduced contusion areas as well as overall contusion volume compared to vehicle treated animals. For example, overall contusion volume was reduced from 2.7 +/- 0.5 mm(3) (mean +/- SEM) to 1.4 +/- 0.4 with treatment (p < 0.05). Immunocytochemical studies identifying CD68 immunoreactive macrophages showed that treatment caused significant attenuation of leukocyte infiltration into the contused cortical areas. These data emphasize the beneficial effects of blocking inflammatory cell recruitment into the injured brain on histopathological outcome following traumatic brain injury. (C) 2008 Elsevier B.V. All rights reserved.	[Utagawa, Akira; Bramlett, Helen M.; Daniels, Linda; Lotocki, George; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Utagawa, Akira; Bramlett, Helen M.; Daniels, Linda; Lotocki, George; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Neurotrauma Res Ctr, Miami, FL 33136 USA; [Utagawa, Akira; Bramlett, Helen M.; Daniels, Linda; Lotocki, George; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Dekaban, Gregory A.; Weaver, Lynne C.] Univ Western Ontario, Robarts Res Inst, Spinal Cord Injury Team, Biotherapeut Res Grp, London, ON, Canada	Dietrich, WD (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, 1095 NW 14th Terrace,LPLC 2-30, Miami, FL 33136 USA.	ddietrich@miami.edu	Weaver, Lynne C/K-8491-2013; Dekaban, Gregory A./L-1987-2013	Dekaban, Gregory A./0000-0002-3087-4660	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056072, P50NS030291, R01NS042133] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS030291-15, R01 NS056072, P50 NS030291, NS042133, R01 NS042133-05, NS030291, NS056072, R01 NS042133] Funding Source: Medline		Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Becker Kyra J, 2002, Curr Med Res Opin, V18 Suppl 2, ps18, DOI 10.1185/030079902125000688; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; CARLOS TM, 1994, BLOOD, V84, P2068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Farooque M, 1999, NEUROREPORT, V10, P131, DOI 10.1097/00001756-199901180-00024; Faxon DP, 2002, J AM COLL CARDIOL, V40, P1199, DOI 10.1016/S0735-1097(02)02136-8; Furuya K, 2001, STROKE, V32, P2665, DOI 10.1161/hs3211.098535; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Grady MS, 1999, J NEUROTRAUM, V16, P13, DOI 10.1089/neu.1999.16.13; Grayson MH, 1999, INT ARCH ALLERGY IMM, V118, P263, DOI 10.1159/000024094; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hamada Y, 1996, J NEUROCHEM, V66, P1525; LODDICK SA, 2002, IMMUN INFLAMM DIS, P90; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Noti JD, 2000, J BIOL CHEM, V275, P8959, DOI 10.1074/jbc.275.12.8959; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rancan M, 2004, J CEREBR BLOOD F MET, V24, P1110, DOI 10.1097/01.WCB.0000133470.91843.72; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Saville LR, 2004, J NEUROIMMUNOL, V156, P42, DOI 10.1016/j.jneuroim.2004.07.002; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Scholz M, 2007, MED RES REV, V27, P401, DOI 10.1002/med.20064; Shanley TP, 1998, J IMMUNOL, V160, P1014; Sherman DG, 2001, NEUROLOGY, V57, P1428, DOI 10.1212/wnl.57.8.1428; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH CW, 1993, SEMIN HEMATOL, V30, P45; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Suzuki T, 2004, J NEUROTRAUM, V21, P842, DOI 10.1089/0897715041526186; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Van der Vieren M, 1999, J IMMUNOL, V163, P1984; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Whalen MJ, 1998, J NEUROTRAUM, V15, P777, DOI 10.1089/neu.1998.15.777; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Zausinger S, 2002, BRAIN RES PROTOC, V9, P112, DOI 10.1016/S1385-299X(02)00138-1; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZILLES L, 1985, CORTEX RAT STEREOTAX	54	33	33	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 1	2008	1207						155	163		10.1016/j.brainres.2008.02.057			9	Neurosciences	Neurosciences & Neurology	299AW	WOS:000255729200016	18374312	Green Accepted			2021-06-18	
J	Rosenthal, G; Morabito, D; Cohen, M; Roeytenberg, A; Derugin, N; Panter, SS; Knudson, MM; Manley, G				Rosenthal, Guy; Morabito, Diane; Cohen, Mitchell; Roeytenberg, Anntna; Derugin, Nikita; Panter, S. Scott; Knudson, M. Margaret; Manley, Geoffrey			Use of hemoglobin-based oxygen-carrying solution-201 to improve resuscitation parameters and prevent secondary brain injury in a swine model of traumatic brain injury and hemorrhage	JOURNAL OF NEUROSURGERY			English	Article						hemoglobin-based oxygen-carrying solution; hemorrhage; resuscitation; secondary brain injury; swine model; traumatic brain injury	CROSS-LINKED HEMOGLOBIN; CEREBRAL PERFUSION-PRESSURE; TENSION; NEUROTOXICITY; CIRCULATION; HYPOTENSION; HBOC-201; VOLUME; DAMAGE; DEATH	Object. Traumatic brain injury (TBI) often occurs as part of a multisystem trauma that may lead to hemorrhagic shock. Effective resuscitation and restoration of oxygen delivery to the brain is important in patients with TBI because hypotension and hypoxia are associated with poor outcome in head injury. We studied the effects of hemoglobin-based oxygen-carrying (HBOC)-201 solution compared with lactated Ringer (LR) solution in a large animal model of brain injury and hemorrhage, in a blinded prospective randomized study. Methods. Swine underwent brain impact injury and hemorrhage to a mean arterial pressure (MAP) of 40 mm Hg. Twenty swine were randomized to undergo resuscitation with HBOC-201 (6 ml/kg) or LR solution (12 ml/kg) and were observed for an average of 6.5 +/- 0.5 hours following resuscitation. At the end of the observation period, magnetic resonance (MR) imaging was performed. Histological studies of swine brains were performed using Fluoro-Jade B, a marker of early neuronal degeneration. Results. Swine resuscitated with HBOC-201 had higher MAP, higher cerebral perfusion pressure (CPP), improved base deficit, and higher brain tissue oxygen tension (PbtO(2)) than animals resuscitated with LR solution. No significant difference in total injury volume on T2-weighted MR imaging was observed between animals resuscitated with HBOC-201 solution (1155 +/- 374 mm(3)) or LR solution (1246 +/- 279 mm(3); p = 0.55). On the side of impact injury, no significant difference in the mean number of Fluoro-Jade B-positive cells/hpf was seen between HBOC-201 solution (61.5 +/- 14.7) and LR solution (48.9 +/- 17.7; p = 0.13). Surprisingly, on the side opposite impact injury, a significant increase in Fluoro-Jade B-positive cells/hpf was seen in animals resuscitated with LR solution (42.8 +/- 28.3) compared with those resuscitated with HBOC-201 solution (5.6 +/- 8.1; p < 0.05), implying greater neuronal injury in LR-treated swine. Conclusions. The improved MAP, CPP, and PbtO(2) observed with HBOC-201 solution in comparison with LR solution indicates that HBOC-201 solution may be a preferable agent for small-volume resuscitation in brain-injured patients with hemorrhage. The use of HBOC-201 solution appears to decrease cellular degeneration in the brain area not directly impacted by the primary injury. Hemoglobin-based oxygen-carrying-201 solution may act by improving cerebral blood flow or increasing the oxygen-carrying capacity of blood, mitigating a second insult to the injured brain.	[Rosenthal, Guy; Roeytenberg, Anntna; Derugin, Nikita; Panter, S. Scott; Manley, Geoffrey] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; [Morabito, Diane; Cohen, Mitchell; Knudson, M. Margaret] Univ Calif San Francisco, Dept Gen Surg, San Francisco, CA 94143 USA	Manley, G (corresponding author), San Francisco Gen Hosp, Dept Neurosurg, Bldg 1,Room 101,1001 Potrero Ave, San Francisco, CA 94117 USA.	manley@itsa.ucsf.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR903697] Funding Source: Medline		Adams J H, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P176; ADAMS JH, 1966, BRAIN, V89, P235, DOI 10.1093/brain/89.2.235; Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Barve A, 1997, ARTIF CELL BLOOD SUB, V25, P75, DOI 10.3109/10731199709118899; Bishop GM, 2001, BRAIN RES, V907, P175, DOI 10.1016/S0006-8993(01)02303-4; Boulton M, 1998, AM J PHYSIOL-REG I, V274, pR88; Boulton M, 1998, AM J PHYSIOL-REG I, V275, pR889; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FREAS W, 1995, J LAB CLIN MED, V125, P762; Gould SA, 1996, WORLD J SURG, V20, P1200; GRAHAM DI, 1979, STROKE, V10, P724, DOI 10.1161/01.STR.10.6.724; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hattori N, 2003, ACTA NEUROCHIR SUPPL, V86, P49; Heller A, 1998, SHOCK, V10, P401, DOI 10.1097/00024382-199812000-00004; Hess JR, 1996, TRANSFUS MED REV, V10, P276, DOI 10.1016/S0887-7963(96)80003-4; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Ketcham EM, 1999, ANN EMERG MED, V33, P326, DOI 10.1016/S0196-0644(99)70370-7; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; Knudson MM, 2003, J TRAUMA, V54, P242, DOI 10.1097/01.TA.0000037776.28201.75; Lee SK, 2002, ACAD EMERG MED, V9, P969; Longhi L, 2002, ACT NEUR S, V81, P315; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Mollanji R, 2002, AM J PHYSIOL-REG I, V282, pR1593, DOI 10.1152/ajpregu.00695.2001; Mollanji R, 2001, AM J PHYSIOL-REG I, V280, pR1573; Muldoon SM, 1996, J LAB CLIN MED, V128, P579, DOI 10.1016/S0022-2143(96)90130-4; Ortegon DP, 2002, J TRAUMA, V53, P1068, DOI 10.1097/00005373-200212000-00007; PANTER SS, 1994, ARTIF CELL BLOOD SUB, V22, P399, DOI 10.3109/10731199409117870; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; Rieger A, 1999, BRIT J NEUROSURG, V13, P454; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Scott MG, 1997, CLIN CHEM, V43, P1724; SHARMA AC, 1995, AM J PHYSIOL-HEART C, V269, pH1379; Stollings JL, 2006, PHARMACOTHERAPY, V26, P1453, DOI 10.1592/phco.26.10.1453; Stowell CP, 2001, TRANSFUSION, V41, P287, DOI 10.1046/j.1537-2995.2001.41020287.x; Tan H, 2001, Chin J Traumatol, V4, P156; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018	45	33	34	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2008	108	3					575	587		10.3171/JNS/2008/108/3/0575			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	270PM	WOS:000253732700021	18312106				2021-06-18	
J	Dooley, JJ; Anderson, V; Hemphill, SA; Ohan, J				Dooley, Julian J.; Anderson, Vicki; Hemphill, Sheryl A.; Ohan, Jeneva			Aggression after paediatric traumatic brain injury: A theoretical approach	BRAIN INJURY			English	Article						Traumatic brain injury; aggression; measurement	PROACTIVE AGGRESSION; REACTIVE AGGRESSION; PHYSICAL AGGRESSION; YOUNG-ADULTS; PRESCHOOL-CHILDREN; SOCIAL COMPETENCE; LATE ADOLESCENCE; HEAD-INJURY; PEER STATUS; BEHAVIOR	Primary objective: To examine aggression in adolescent males with and without traumatic brain injury (TBI). Design: Quasi-experimental, matched-participants design. Methods: Thirty-nine adolescents were examined, including a TBI group (n = 11) and a matched, uninjured comparison group (n = 28). Participants with TBI were injured an average of 8.3 years (SD = 4.2 years) prior. Participants and parents completed the Youth Self Report (YSR) and the Child Behavior Checklist (CBCL), both measures of global psychopathology. In addition, the theoretically-driven Reactive and Proactive Aggression Questionnaire (RPQ) and the Form of Aggression Scale (FAS) were completed. Main outcomes and results: When compared using the YSR and CBCL, no group differences were detected. In contrast, using the self-report RPQ, participants with TBI reported more reactive and proactive aggression than non-injured peers. Using the FAS, participants with TBI reported engaging in aggression out of frustration and not to dominate or acquire objects. Conclusion: Aggressive behaviours are a long-term outcome after paediatric TBI. Measures of global psychopathology do not permit detailed examination of specific behaviour problems such as aggression, which may provide inaccurate data from which to derive incidence rates. In contrast, theoretically-driven measures can provide greater insight into post-TBI aggression with important treatment implications.	[Dooley, Julian J.; Anderson, Vicki; Hemphill, Sheryl A.] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; [Dooley, Julian J.; Anderson, Vicki; Hemphill, Sheryl A.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Anderson, Vicki; Hemphill, Sheryl A.] Royal Childrens Hosp, Parkville, Vic 3052, Australia; [Ohan, Jeneva] Univ British Columbia Okanagan, Irving K Barber Sch Arts & Sci, Psychol & Comp Sci Unit, Kelowna, BC, Canada	Dooley, JJ (corresponding author), Edith Cowan Univ, Dept Psychol & Social Sci, 100 Joondalup Dr, Joondalup, WA 6027, Australia.	j.dooley@ecu.edu.au		Ohan, Jeneva/0000-0002-4801-4239			Achenbach T. M., 1991, MANUAL CHILD BEHAV C, P288; ACHENBACH TM, 1991, MANUAL YOUTH SELF RE, P210; American Psychiatric Association, 1994, DIAGN STAT MAN MENT, P886; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; BANDURA A, 1978, J COMMUN, V28, P12, DOI 10.1111/j.1460-2466.1978.tb01621.x; BANDURA A, 1973, AGGRESSION SOCIAL LE, P390; BANDURA A, 1983, AGGRESSION THEORETIC, V1, P40; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Brame B, 2001, J CHILD PSYCHOL PSYC, V42, P503, DOI 10.1017/S0021963001007120; Brendgen M, 2001, J ABNORM CHILD PSYCH, V29, P293, DOI 10.1023/A:1010305828208; Brown K, 1996, J ABNORM CHILD PSYCH, V24, P473, DOI 10.1007/BF01441569; Camodeca M, 2002, SOC DEV, V11, P332, DOI 10.1111/1467-9507.00203; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; CATROPPA C, J PEDIAT PS IN PRESS; Connor DF, 2003, CHILD PSYCHIAT HUM D, V33, P279, DOI 10.1023/A:1023084112561; CRICK NR, 1995, CHILD DEV, V66, P710, DOI 10.1111/j.1467-8624.1995.tb00900.x; DANIEL A, 1983, POWER PRIVILEGE PRES, P235; DAY DM, 1992, J CLIN CHILD PSYCHOL, V21, P210, DOI 10.1207/s15374424jccp2103_2; DODGE KA, 1991, DEVELOPMENT AND TREATMENT OF CHILDHOOD AGGRESSION, P201; DODGE KA, 1987, J PERS SOC PSYCHOL, V53, P1146, DOI 10.1037/0022-3514.53.6.1146; Dodge KA, 1997, J ABNORM PSYCHOL, V106, P37, DOI 10.1037/0021-843X.106.1.37; DOLLARD J, 1939, FRUSTRATION AGGRESS, P150; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; FESHBACH S, 1964, PSYCHOL REV, V71, P257, DOI 10.1037/h0043041; Fontaine RG, 2007, PSYCHOL PUBLIC POL L, V13, P143, DOI 10.1037/1076-8971.13.2.143; GAMES PA, 1983, PSYCHOL BULL, V93, P382; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hawley CA, 2004, ARCH DIS CHILD, V89, P136, DOI 10.1136/adc.2002.025577; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; Hubbard JA, 2002, CHILD DEV, V73, P1101, DOI 10.1111/1467-8624.00460; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Laird RD, 2005, DEV PSYCHOPATHOL, V17, P127, DOI 10.1017/S0954579405050078; Little TD, 2003, MERRILL PALMER QUART, V49, P343, DOI 10.1353/mpq.2003.0014; Marcus RF, 2001, J GENET PSYCHOL, V162, P260, DOI 10.1080/00221320109597483; Martin JL, 2004, J DEV BEHAV PEDIATR, V25, P150, DOI 10.1097/00004703-200406000-00002; McEvoy MA, 2003, TOP EARLY CHILD SPEC, V23, P53; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; MILLER L, 1994, J OFFENDER REHABILIT, V21, P91, DOI DOI 10.1300/J076; Nagin D, 1999, CHILD DEV, V70, P1181, DOI 10.1111/1467-8624.00086; Polman H, 2007, J ABNORM CHILD PSYCH, V35, P522, DOI 10.1007/s10802-007-9109-4; Poulin F, 2000, DEV PSYCHOL, V36, P233, DOI 10.1037//0012-1649.36.2.233; Poulin F, 2000, PSYCHOL ASSESSMENT, V12, P115, DOI 10.1037/1040-3590.12.2.115; PRICE JM, 1989, J ABNORM CHILD PSYCH, V17, P455, DOI 10.1007/BF00915038; Prigatano GP, 2006, J HEAD TRAUMA REHAB, V21, P505, DOI 10.1097/00001199-200611000-00005; Prinstein MJ, 2003, MERRILL PALMER QUART, V49, P310, DOI 10.1353/mpq.2003.0015; Pulkkinen L, 1996, AGGRESSIVE BEHAV, V22, P241, DOI 10.1002/(SICI)1098-2337(1996)22:4<241::AID-AB1>3.0.CO;2-O; Raine A, 2006, AGGRESSIVE BEHAV, V32, P159, DOI 10.1002/ab.20115; Saxe R, 2004, ANNU REV PSYCHOL, V55, P87, DOI 10.1146/annurev.psych.55.090902.142044; Sharp NL, 2006, DISABIL REHABIL, V28, P767, DOI 10.1080/09638280500386668; Vaughn BE, 2003, MERRILL PALMER QUART, V49, P245, DOI 10.1353/mpq.2003.0017; Vitiello B, 1997, J AM ACAD CHILD PSY, V36, P307, DOI 10.1097/00004583-199703000-00008; Waschbusch DA, 2002, J ABNORM CHILD PSYCH, V30, P641, DOI 10.1023/A:1020867831811; Watson C, 2001, BRAIN INJURY, V15, P1003, DOI 10.1080/02699050010022662; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	62	33	33	3	132	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	11					836	846		10.1080/02699050802425444			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700003	18850342				2021-06-18	
J	Griesemer, D; Mautes, AM				Griesemer, Desiree; Mautes, Angelika M.			Closed head injury causes hyperexcitability in rat hippocampal CA1 but not in CA3 pyramidal cells	JOURNAL OF NEUROTRAUMA			English	Article						CA1/CA3 pyramidal cell; closed head injury; epilepsy; hyperexcitability	TRAUMATIC BRAIN-INJURY; SELECTIVE VULNERABILITY; REGIONAL DIFFERENCES; MECHANISMS; PATHOPHYSIOLOGY; INTERNEURONS; HOMEOSTASIS; POTASSIUM; EPILEPSY; NEURONS	Traumatic brain injury frequently elicits epileptic seizures hours or days after the impact. The mechanisms on cellular level are poorly understood. Because posttraumatic epilepsy appears in many cases as a temporal-lobe epilepsy which originated the hippocampus, we studied trauma-induced hyperexcitability on the cellular level in this brain area. We used the model of closed head injury to analyse the electrophysiological changes in CA1 and CA3 pyramidal cells and in interneurones of the CA1 field, which is extremely sensitive to ischemia. We found that morphologically closed head injury (CHI) led to a gradual progressive, cell type specific time course in neuronal degeneration. To analyse electrophysiological impairment we measured resting membrane potential, recorded spontaneous action potentials and induced action potentials by current pulses at different times after CHI. We found a dramatic increase in the frequency of spontaneous action potentials of CA1 but not of CA3 pyramidal cells after CHI. This hyperexcitability was maximal at 2 h (4.5-fold higher than sham), was also observed at 24 h after CHI and disappeared after 3 days. We found that CA1 interneurones responded by a much weaker increase of AP frequency after CHI. We conclude that the strong hyperexcitability after CHI is cell-type specific and transient. The understanding of the complex neuronal interactions probably offers a promising possibility for pharmacological intervention to prevent posttraumatic epilepsy.	[Griesemer, Desiree] Univ Saarland, Dept Physiol, D-66421 Homburg, Germany; [Mautes, Angelika M.] Univ Saarland, Neurosurg Res Lab, D-6650 Homburg, Germany	Griesemer, D (corresponding author), Univ Saarland, Dept Physiol, Bldg 58, D-66421 Homburg, Germany.	desiree.griesemer@uniklinik-saarland.de	Griesemer, Desiree/A-9152-2018	Griesemer, Desiree/0000-0002-0551-038X			AMARAL DG, 1978, J COMP NEUROL, V182, P851, DOI 10.1002/cne.901820508; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BUCKMASTER PS, 1994, HIPPOCAMPUS, V4, P393, DOI 10.1002/hipo.450040402; BUZSAKI G, 1983, BRAIN RES, V266, P334, DOI 10.1016/0006-8993(83)90665-0; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CREPEL V, 1992, NEUROSCIENCE, V47, P579, DOI 10.1016/0306-4522(92)90167-Z; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; Engel J, 2003, EPILEPSIA, V44, P60, DOI 10.1111/j.0013-9580.2003.12002.x; FEENEY DM, 1979, BRAIN RES, V178, P329, DOI 10.1016/0006-8993(79)90697-8; Golarai G, 2001, J NEUROSCI, V21, P8523; Griesemer W, 2002, EUR BIOPHYS J BIOPHY, V31, P467, DOI 10.1007/s00249-002-0241-3; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Huh JW, 2006, DEV NEUROSCI-BASEL, V28, P466, DOI 10.1159/000094172; Jennett B, 1998, ARCH DIS CHILD, V78, P403, DOI 10.1136/adc.78.5.403; JOHANSEN FF, 1983, ACTA NEUROPATHOL, V61, P135, DOI 10.1007/BF00697393; JOHNSTON D, 1992, ANNU REV PHYSIOL, V54, P489; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; Kreisman NR, 2000, J NEUROPHYSIOL, V83, P1031; KROBERT KA, 1992, J NEUROTRAUM, V9, P64; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; NEWMAN GC, 1995, J NEUROSCI METH, V61, P33, DOI 10.1016/0165-0270(95)00020-U; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PEREZPINON MA, 1995, J NEUROPHYSIOL, V74, P565; Raza M, 2007, NEUROSCI LETT, V418, P77, DOI 10.1016/j.neulet.2007.03.005; SANTHAKUMAR V, 2000, HYPOTHESIS J PHYSL, P117; SCHMIDTKASTNER R, 1991, NEUROSCIENCE, V40, P599, DOI 10.1016/0306-4522(91)90001-5; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 2000, J MOL MED-JMM, V78, P228, DOI 10.1007/s001090000104; SIESJO BK, 1988, CRIT CARE MED, V16, P954, DOI 10.1097/00003246-198810000-00006; SLOVITER RS, 1994, HIPPOCAMPUS, V4, P250, DOI 10.1002/hipo.450040304; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Temkin N R, 1995, New Horiz, V3, P518; TSUBOKAWA H, 1992, NEUROSCIENCE, V49, P807, DOI 10.1016/0306-4522(92)90358-9; Villanueva V, 2005, EPILEPTIC DISORD, V7, P83	43	33	34	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2007	24	12					1823	1832		10.1089/neu.2006.0237			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	245BR	WOS:000251910000005	18159994				2021-06-18	
J	Pappas, E				Pappas, Evangelos			Boxing, wrestling, and martial arts related injuries treated in emergency departments in the United States, 2002-2005	JOURNAL OF SPORTS SCIENCE AND MEDICINE			English	Article						combat sports injuries; sports injuries; emergency department visits; complex sample design	OSTEOARTHRITIS; PREVALENCE; AMATEUR; SPORTS; KARATE	The incidence of injury in combat sports has not been adequately reported although it is important to identify the nature and frequency of injuries prior to the implementation of prevention programs. This study compared injury rates treated in Hospital Emergency Departments between different combat sports of boxing, wrestling, and martial arts. A secondary objective described anatomic region and diagnosis of these injuries. Data were obtained on all boxing, wrestling, and martial arts-related injuries that were in the National Electronic Injury Surveillance System database and resulted in Emergency Department visits between 2002 and 2005. Pearson's chi-square statistics were calculated to compare injury rates for each activity accounting for complex sample design. Martial arts had lower injury rates compared to boxing and wrestling for all diagnoses (p < 0.001). Boxing had lower injury rates compared to wrestling for strains/sprains and dislocations. Boxing and wrestling had similar injury rates for concussions. Injury prevention efforts should consider the distribution of injuries and concentrate on preventing strains/sprains in wrestling, concussions in boxing and wrestling, and fractures for all three activities. The findings of the present study do not provide evidence that combat sports have alarmingly high rates of injuries resulting in emergency department visits.	Long Isl Univ, Div Phys Therapy, Brooklyn, NY 11201 USA	Pappas, E (corresponding author), Long Isl Univ, Div Phys Therapy, 1 Univ Pl,Brooklyn Campus, Brooklyn, NY 11201 USA.	evangelos.pappas@liu.edu	Pappas, Evangelos/A-4467-2008	Pappas, Evangelos/0000-0002-8340-0303			Arriaza R, 2005, KNEE SURG SPORT TR A, V13, P603, DOI 10.1007/s00167-004-0593-6; BIRRER RB, 1988, AM J SPORT MED, V16, P408, DOI 10.1177/036354658801600418; Bledsoe GH, 2006, J SPORT SCI MED, V5, P136; IOANNOU S, 1984, CAN MED ASSOC J, V131, P10; Jarrett GJ, 1998, AM J SPORT MED, V26, P674, DOI 10.1177/03635465980260051301; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LUNDBERG GD, 1983, JAMA-J AM MED ASSOC, V249, P250, DOI 10.1001/jama.1983.03330260068037; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pasque CB, 2000, AM J SPORT MED, V28, P509, DOI 10.1177/03635465000280041101; Porter M, 1996, CLIN J SPORT MED, V6, P97, DOI 10.1097/00042752-199604000-00006; Roos H, 1998, ARTHRITIS RHEUM, V41, P687, DOI 10.1002/1529-0131(199804)41:4<687::AID-ART16>3.0.CO;2-2; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; TENVERGERT EM, 1992, J SPORT MED PHYS FIT, V32, P214; von Porat A, 2004, ANN RHEUM DIS, V63, P269, DOI 10.1136/ard.2003.008136; Zazryn T, 2006, BRIT J SPORT MED, V40, P670, DOI 10.1136/bjsm.2006.025924; Zazryn TR, 2003, BRIT J SPORT MED, V37, P321, DOI 10.1136/bjsm.37.4.321; Zetaruk MN, 2005, BRIT J SPORT MED, V39, P29, DOI 10.1136/bjsm.2003.010322	17	33	33	0	9	JOURNAL SPORTS SCIENCE & MEDICINE	BURSA	MEDICAL FACULTY ULUDAG UNIV, DEPT SPORTS MEDICINE, BURSA, 16059, TURKEY	1303-2968			J SPORT SCI MED	J. Sport. Sci. Med.	OCT	2007	6				2		58	61					4	Sport Sciences	Sport Sciences	215DS	WOS:000249789100011	24198705	DOAJ Gold			2021-06-18	
J	Lim, JH; Gibbons, HM; O'Carroll, SJ; Narayan, PJ; Faull, RLM; Dragunow, M				Lim, Joanne H.; Gibbons, Hannah M.; O'Carroll, Simon J.; Narayan, Pritika J.; Faull, Richard L. M.; Dragunow, Michael			Extracellular signal-regulated kinase involvement in human astrocyte migration	BRAIN RESEARCH			English	Article						glial scar; astrocyte	FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN-INJURY; ASTROGLIAL ACTIVATION; REACTIVE GLIOSIS; CELL-MIGRATION; ERK/MAP KINASE; GLIAL SCAR; RAT-BRAIN; IN-VITRO; GLUTAMINE-SYNTHETASE	Glial scar formation occurs after virtually any injury to the brain. The migration of astrocytes into regions of brain injury underlies the formation of the glial scar. The exact role of the glial scar has yet to be elucidated, although it is likely to impair brain recovery. Understanding astrocyte migration is fundamental to understanding the formation of the glial scar. We have used human astrocytes (NT2A cells), derived from human NT2/D1 precursor cells to study astrocyte migration using an in vitro scratch wound model. Time-lapse microscopy and bromodeoxyuridine labeling revealed that the astrocytes migrated rather than proliferated across the scratch. Time course immunocytochemical studies showed that scratching human astrocytes induced the activation (phosphorylation) of ERK 1/2 at 10 min after scratch. The MEK 1/2 inhibitor U0126 inhibited both the ERK 1/2 phosphorylation and the migration of the astrocytes across the wound after scratch. Thus, the migration of human astrocytes after injury is partly initiated by activation of the MEK-ERK signalling pathway. (c) 2007 Elsevier B.V. All rights reserved.	Univ Auckland, Fac Med & Hlth Sci, Dept Pharmacol & Clin Pharmacol, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Dept Anat & Radiol, Auckland 1, New Zealand	Dragunow, M (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Dept Pharmacol & Clin Pharmacol, Private Bag 92019, Auckland 1, New Zealand.	m.dragunow@auckland.ac.nz		Faull, Richard/0000-0003-3385-9498; Narayan, Pritika/0000-0002-8713-1470			Alonso G, 2005, GLIA, V49, P318, DOI 10.1002/glia.20121; ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; ANDREWS PW, 1984, LAB INVEST, V50, P147; Bani-Yaghoub M, 1999, NEUROREPORT, V10, P3843, DOI 10.1097/00001756-199912160-00022; BEACH TG, 1989, GLIA, V2, P420, DOI 10.1002/glia.440020605; Carbonell WS, 2003, J NEUROTRAUM, V20, P327, DOI 10.1089/089771503765172282; Colodner KJ, 2005, J NEUROPATH EXP NEUR, V64, P163, DOI 10.1093/jnen/64.2.163; DELACOURTE A, 1990, NEUROLOGY, V40, P33, DOI 10.1212/WNL.40.1.33; DELAMONTE SM, 1987, NEUROLOGY, V37, P562, DOI 10.1212/WNL.37.4.562; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Entschladen F, 2005, EXP CELL RES, V307, P418, DOI 10.1016/j.yexcr.2005.03.029; FaberElman A, 1996, J CLIN INVEST, V97, P162, DOI 10.1172/JCI118385; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GOLDMAN JE, 1978, J CELL BIOL, V78, P426, DOI 10.1083/jcb.78.2.426; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Holley JE, 2003, NEUROPATH APPL NEURO, V29, P434, DOI 10.1046/j.1365-2990.2003.00491.x; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kornyei Z, 2000, J NEUROSCI RES, V61, P421, DOI 10.1002/1097-4547(20000815)61:4<421::AID-JNR8>3.0.CO;2-4; Lind CRP, 2006, NEUROSCIENCE, V141, P1925, DOI 10.1016/j.neuroscience.2006.05.038; Mandell JW, 1999, NEUROREPORT, V10, P3567, DOI 10.1097/00001756-199911260-00019; Mandell JW, 2001, GLIA, V34, P283, DOI 10.1002/glia.1062; MILLER RH, 1984, J NEUROSCI, V4, P585; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; NORTON WT, 1992, NEUROCHEM RES, V17, P877, DOI 10.1007/BF00993263; Oberheim NA, 2006, TRENDS NEUROSCI, V29, P547, DOI 10.1016/j.tins.2006.08.004; ONG WY, 1993, J NEUROCYTOL, V22, P893, DOI 10.1007/BF01186359; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Rutka JT, 1997, J NEUROSURG, V87, P420, DOI 10.3171/jns.1997.87.3.0420; Sandhu JK, 2002, J NEUROSCI RES, V68, P604, DOI 10.1002/jnr.10236; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Vis JC, 1998, CELL BIOL INT, V22, P837, DOI 10.1006/cbir.1998.0388; Walz W, 1998, NEUROSCI LETT, V257, P127, DOI 10.1016/S0304-3940(98)00813-1; Wang John Q., 2003, Current Neuropharmacology, V1, P1, DOI 10.2174/1570159033360548; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Webster B, 2006, J NEUROPATH EXP NEUR, V65, P142, DOI 10.1097/01.jnen.0000199599.63204.6f; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.0.CO;2-8; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Zhao ML, 1998, BRAIN RES, V813, P402, DOI 10.1016/S0006-8993(98)01023-3; ZLOTNIK I, 1968, BRIT J EXP PATHOL, V49, P555	52	33	38	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 20	2007	1164						1	13		10.1016/j.brainres.2007.06.020			13	Neurosciences	Neurosciences & Neurology	208LX	WOS:000249321900001	17644078				2021-06-18	
J	Maegele, M; Sauerland, S; Bouillon, B; Schafer, U; Trubel, H; Riess, P; Neugebauer, EAM				Maegele, M.; Sauerland, S.; Bouillon, B.; Schaefer, U.; Truebel, H.; Riess, P.; Neugebauer, E. A. M.			Differential immunoresponses following experimental traumatic brain injury, bone fracture and "two-hit"-combined neurotrauma	INFLAMMATION RESEARCH			English	Article						cytokines; traumatic brain injury; tibia fracture; combined neurotrauma; inflammatory response	TUMOR-NECROSIS-FACTOR; MULTIPLE ORGAN FAILURE; INTERLEUKIN 6 IL-6; CIRCULATING LEVELS; HEMORRHAGIC-SHOCK; BURNED PATIENTS; SOLUBLE RECEPTORS; MAJOR SURGERY; FACTOR-ALPHA; HEAD-INJURY	Cytokine-mediated immunoresponses are consequences of isolated traumatic brain injury (TBI) and muskuloskeletal trauma but little is known when both impacts occur simulanteously in combined neurotrauma (CNT), i. e. TBI + muskuloskeletal trauma (bone fracture). A "two-hit"-experimental model of CNT (TBI + tibia fracture) was used to investigate circulating cytokine interleukin-1-beta, -6, -10 and sTNF-R1 concentrations following peripheral bone fracture only, TBI only and CNT. Blood samples were drawn at 30 min, 6 h, 24 h, 48 h, and 7 days following trauma and circulating cytokine concentrations were determined via immunoassay. Circulating cytokines were increased after trauma (p < 0.001 vs. controls), but peaked at different time points. sTNF R1 peaked first at 30 min, followed by IL-6 at 6 h after trauma. IL-10 levels were highest at 24 h, and those for IL-1beta at 48 h after trauma. Circulating IL-6 and IL-10 levels were highest in CNT at 8/10 time points studied (p < 0.001). Circulating cytokine IL-1-beta, -6, -10 and sTNF-R1 concentrations are increased after trauma (TBI, fracture and CNT) but peak at different time points. Pronounced IL-6 and IL-10 responses after CNT may contribute to the increased susceptibility for complications in CNT versus monotrauma.	Univ Witten Herdecke, Inst Res Operat Med, D-51109 Cologne, Germany; Univ Witten Herdecke, Cologne Merheim Med Ctr, Dept Traumat & Orthoped Surg, D-51109 Cologne, Germany	Maegele, M (corresponding author), Univ Witten Herdecke, Inst Res Operat Med, Ostmerheimerstr 200, D-51109 Cologne, Germany.	Marc.Maegele@t-online.de		Sauerland, Stefan/0000-0003-1048-796X			BAIGRIE RJ, 1991, LYMPHOKINE CYTOK RES, V10, P253; BAIGRIE RJ, 1992, BRIT J SURG, V79, P757, DOI 10.1002/bjs.1800790813; Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301-620x.86b6.14176; Biffl WL, 1996, ANN SURG, V224, P647, DOI 10.1097/00000658-199611000-00009; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; BOURQUE WT, 1992, LAB ANIM SCI, V42, P369; CANNON JG, 1992, CRIT CARE MED, V20, P1414, DOI 10.1097/00003246-199210000-00009; Chuang D, 2005, ANZ J SURG, V75, P813, DOI 10.1111/j.1445-2197.2005.03530.x; CROZIER TA, 1993, ANAESTHESIST, V42, P343; ERTEL W, 1995, J TRAUMA, V39, P879, DOI 10.1097/00005373-199511000-00011; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Fulton R L, 1993, J Invest Surg, V6, P117, DOI 10.3109/08941939309141603; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GUO Y, 1990, CLIN IMMUNOL IMMUNOP, V54, P361, DOI 10.1016/0090-1229(90)90050-Z; Hauser CJ, 1997, J TRAUMA, V42, P895, DOI 10.1097/00005373-199705000-00021; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Meixensberger J, 1998, LANGENBECK ARCH SURG, V383, P214, DOI 10.1007/s004230050121; Menger MD, 2004, LANGENBECK ARCH SURG, V389, P475, DOI 10.1007/s00423-004-0472-0; Neely AN, 1996, BURNS, V22, P524, DOI 10.1016/0305-4179(96)00029-0; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; Partrick DA, 1996, AM J SURG, V172, P425, DOI 10.1016/S0002-9610(96)00252-8; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; PULLICINO EA, 1990, LYMPHOKINE RES, V9, P231; REICHLIN S, 1993, NEW ENGL J MED, V329, P1246; Ribeiro CA, 2002, INTENS CARE MED, V28, P472, DOI 10.1007/s00134-001-1190-5; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Segal JL, 1997, ARCH PHYS MED REHAB, V78, P44, DOI 10.1016/S0003-9993(97)90008-3; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; TAN LR, 1993, J TRAUMA, V34, P634, DOI 10.1097/00005373-199305000-00004; Townsend RN, 1998, J TRAUMA, V44, P977, DOI 10.1097/00005373-199806000-00008; Vindenes HA, 1998, EUR J SURG, V164, P647; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yeh FL, 1999, BURNS, V25, P131, DOI 10.1016/S0305-4179(98)00150-8; Yeh FL, 2000, BURNS, V26, P454, DOI 10.1016/S0305-4179(99)00174-6; Yokoyama Y, 2004, AM J PHYSIOL-GASTR L, V286, pG942, DOI 10.1152/ajpgi.00502.2003; Zhang B, 1998, BURNS, V24, P599, DOI 10.1016/S0305-4179(98)00091-6	49	33	36	0	0	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1023-3830	1420-908X		INFLAMM RES	Inflamm. Res.	AUG	2007	56	8					318	323		10.1007/s00011-007-6141-3			6	Cell Biology; Immunology	Cell Biology; Immunology	201DC	WOS:000248810700002	17687516				2021-06-18	
J	Gopcevic, A; Mazul-Sunko, B; Marout, J; Sekulic, A; Antoljak, N; Siranovic, M; Ivanec, Z; Margaritoni, M; Bekavac-Beslin, M; Zarkovic, N				Gopcevic, Aleksandar; Mazul-Sunko, Branka; Marout, Jasminka; Sekulic, Ante; Antoljak, Natasa; Siranovic, Mladen; Ivanec, Zeljko; Margaritoni, Marko; Bekavac-Beslin, Miroslav; Zarkovic, Neven			Plasma interleukin-8 as a potential predictor of mortality in adult patients with severe traumatic brain injury	TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						traumatic brain injury (TBI); coma; mortality; inflammation; Interleukin-8 (IL-8)	CEREBROSPINAL-FLUID; HEAD-INJURY; BARRIER DYSFUNCTION; MICE DEFICIENT; CARDIAC-ARREST; TNF-ALPHA; ASTROCYTES; EXPRESSION; CHEMOKINES; MEDIATORS	Because of complex pathophysiology and severe consequences, traumatic brain injuries (TBI) are an important medical problem. Pathophysiology of TBI includes local and systemic stress response, in which interleukin-8 (IL-8) is considered as a key mediator of neuroinflammation. However, prognostic relevance of IL-8 measurement in adult patients with severe TBI is not certain. Therefore, IL-8 was determined in blood samples from central venous and jugular bulb catheter and in cerebrospinal fluid of twenty patients with isolated TBI at admission to Intensive Care Unit. None of the patients had history of stroke, dementia, autoimmune diseases, acute infection or medication with anti-inflammatory drugs. Ten patients died due to traumatic brain injury, while the other ten recovered well. While there was no significant difference of IL-8 levels in cerebrospinal fluid between survivors and nonsurvivors, central venous plasma level of IL-8 was significantly lower in survivors (71.00 +/- 14.17 pg/ml), than in nonsurvivors (111.26 +/- 16.9 pg/ml). Receiver Operating Characteristic (ROC) analysis revealed significant prognostic value for IL-8 in the blood as well as for the age of patients, Glasgow Coma Scale (GCS) and Acute Physiologic and Chronic Health Evaluation (APACHE II). These findings suggest that the central venous plasma values of IL-8 at admission might be an early predictive marker in patients with severe TBI, comparative to standard clinical prognostic markers such as APACHE II and GCS.	Rudjer Boskovic Inst, Dept Mol Med, HR-1000 Zagreb, Croatia; Univ Zagreb, Sestre Milosrdnice Univ Hosp, Dept Anesthesiol & Intens Care, Zagreb 41000, Croatia; Univ Zagreb, Sestre Milosrdnice Univ Hosp, Lab Endocrinol, Zagreb 41000, Croatia; Univ Zagreb, Dept Anesthesiol, Zagreb 41000, Croatia; Univ Zagreb, Univ Hosp, Div Neuroanesthesia & Neurointens Care, Zagreb, Croatia; Univ Zagreb, Inst Publ Hlth, Zagreb, Croatia; Univ Dubrovnik, Gen Hosp, Dubrovnik, Croatia; Univ Zagreb, Sestre Milosrdnice Univ Hosp, Dept Surg, Zagreb 41000, Croatia	Zarkovic, N (corresponding author), Rudjer Boskovic Inst, Dept Mol Med, Bijenicka 54, HR-1000 Zagreb, Croatia.	zarkovic@irb.hr	Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Boto GR, 2006, J NEUROL NEUROSUR PS, V77, P1054, DOI 10.1136/jnnp.2005.087056; Choi C, 2002, MOL CELL BIOL, V22, P724, DOI 10.1128/MCB.22.3.724-736.2002; Chuang D, 2005, ANZ J SURG, V75, P813, DOI 10.1111/j.1445-2197.2005.03530.x; Croitoru-Lamoury J, 2003, GLIA, V41, P354, DOI 10.1002/glia.10181; Ehrlich LC, 1998, J IMMUNOL, V160, P1944; Emir M, 2005, TOHOKU J EXP MED, V207, P119, DOI 10.1620/tjem.207.119; FELDMAN Z, 1993, J TRAUMA, V34, P806, DOI 10.1097/00005373-199306000-00010; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hoch RC, 1996, J LAB CLIN MED, V128, P134, DOI 10.1016/S0022-2143(96)90005-0; IMAI Y, 2003, JAMA-J AM MED ASSOC, V9, P2104; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; KUSHI H, 2003, CRIT CARE MED S, V31, P363; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; MASTROIANNI CM, 1994, PEDIATR INFECT DIS J, V13, P1008; MASTROIANNI CM, 1998, CLIN EXP IMMUNOL, V22, P724; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Mimasaka S, 2002, TOHOKU J EXP MED, V197, P145, DOI 10.1620/tjem.197.145; Minami K, 2004, TOHOKU J EXP MED, V203, P129, DOI 10.1620/tjem.203.129; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nikolic-Heitzler V, 2006, TOHOKU J EXP MED, V210, P247, DOI 10.1620/tjem.210.247; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Papathanassoglou EDE, 2000, CRIT CARE MED, V28, P537, DOI 10.1097/00003246-200002000-00042; Pratschke J, 2000, ANN SURG, V232, P263, DOI 10.1097/00000658-200008000-00017; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schlag G, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P3; SMITH WB, 1991, IMMUNOLOGY, V72, P65; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stoeck K, 2006, J NEUROIMMUNOL, V172, P175, DOI 10.1016/j.jneuroim.2005.10.008; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119; Wildburger R, 1998, J ENDOCRINOL INVEST, V21, P78, DOI 10.1007/BF03350319; Wildburger R, 2000, WIEN KLIN WOCHENSCHR, V112, P798; Yamasaki Y, 1997, BRAIN RES, V759, P103, DOI 10.1016/S0006-8993(97)00251-5; Zhang WD, 1999, J NEUROIMMUNOL, V101, P148, DOI 10.1016/S0165-5728(99)00137-X	38	33	36	0	4	TOHOKU UNIV MEDICAL PRESS	SENDAI	2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN	0040-8727	1349-3329		TOHOKU J EXP MED	Tohoku J. Exp. Med.	APR	2007	211	4					387	393		10.1620/tjem.211.387			7	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	156JO	WOS:000245644200010	17409679	Bronze			2021-06-18	
J	Maroon, JC; El-Kadi, H; Abla, AA; Wecht, DA; Bost, J; Norwig, J; Bream, T				Maroon, Joseph C.; El-Kadi, Hikmat; Abla, Adnan A.; Wecht, Daniel A.; Bost, Jeffrey; Norwig, John; Bream, Tim			Cervical neurapraxia in elite athletes: evaluation and surgical treatment - Report of five cases	JOURNAL OF NEUROSURGERY-SPINE			English	Article						neurapraxia; spinal concussion; spinal stenosis; transient spinal cord injury; quadriplegia	SPINE INTERBODY FUSION; FINITE-ELEMENT MODEL; CREST BONE-GRAFT; FOOTBALL PLAYERS; MANAGEMENT GUIDELINES; DISC DEGENERATION; STENOSIS; STABILITY; ADJACENT; CORD	Object. Neurapraxia, transient posttraumtic paralysis of the motor and/or sensory tracts in the spinal cord, may be a career-ending event in an athlete. Management, rehabilitation, and return-to-play decisions remain controversial. Methods. Five elite football players were evaluated after experiencing episodes of neurapraxia. All patients experienced bilateral paresthesias-three in all four extremities and two in the upper extremities-lasting a few minutes to more than 24 hours. Transient motor deficits occurred in two individuals but caused no permanent sequelae. Neuroimaging confirmed the presence of herniated discs, focal cord compression, and no parenchymal changes in all cases. All patients underwent anterior cervical microdiscectomy and fusion, and cervical plates were placed in four. After aggressive rehabilitation and confirmation of fusion ranging from 9 weeks to 8 months postoperatively, the players were allowed to return to active play. Two of the players developed recurrent career-ending disc herniations, one above and the other below the fusion level. One player required repeated spinal cord decompression. Conclusions. Neurologically intact athletes with focal cord compression due to a single-level herniated disc may safely return to football after undergoing decompressive surgery and confirmation of fusion. It appears, however, that there may be an increased chance of repeated herniation above or below a fused level.	Univ Pittsburgh, Presbyterian Hosp, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; Pittsburgh Steelers Football Org, Pittsburgh, PA USA; Chicago Bears Football Org, Chicago, IL USA	Maroon, JC (corresponding author), Univ Pittsburgh, Presbyterian Hosp, Sch Med, Dept Neurosurg, Suite C-500,200 Lothrop St, Pittsburgh, PA 15213 USA.	maroonjc@upme.edu					Arrington ED, 1996, CLIN ORTHOP RELAT R, P300, DOI 10.1097/00003086-199608000-00037; Bailes JE, 2005, J NEUROSURG-SPINE, V2, P11, DOI 10.3171/spi.2005.2.1.0011; BUCKWALTER JA, 1995, SPINE, V20, P1307, DOI 10.1097/00007632-199506000-00022; Cantu RC, 1998, CLIN SPORT MED, V17, P137, DOI 10.1016/S0278-5919(05)70068-5; CANTU RC, 1993, MED SCI SPORT EXER, V25, P316; Dai LY, 1998, SPINE, V23, P1734, DOI 10.1097/00007632-199808150-00005; DiAngelo DJ, 2000, SPINE, V25, P783, DOI 10.1097/00007632-200004010-00005; Eck JC, 2002, SPINE, V27, P2431, DOI 10.1097/00007632-200211150-00003; Goulet JA, 1997, CLIN ORTHOP RELAT R, P76; HASHIMOTO I, 1977, J NEUROSURG, V47, P912, DOI 10.3171/jns.1977.47.6.0912; HERZOG RJ, 1991, SPINE, V16, pS178, DOI 10.1097/00007632-199106001-00001; Hilibrand AS, 1999, J BONE JOINT SURG AM, V81A, P519, DOI 10.2106/00004623-199904000-00009; Kandziora F, 2001, SPINE, V26, P1850, DOI 10.1097/00007632-200109010-00007; Kettler A, 2001, J NEUROSURG, V94, P97, DOI 10.3171/spi.2001.94.1.0097; Kumaresan S, 1997, BIO-MED MATER ENG, V7, P221; Lopez-Espina CG, 2006, SPINE, V31, P972, DOI 10.1097/01.brs.0000215205.66437.c3; Maiman DJ, 1999, BIO-MED MATER ENG, V9, P27; MAROON JC, 1991, CLIN NEUR, V37, P612; MAROON JC, 1977, JAMA-J AM MED ASSOC, V238, P2049; MEYER SA, 1994, AM J SPORT MED, V22, P158, DOI 10.1177/036354659402200202; MUELLER FO, 2005, ANN SURVEY FOOTBALL; Natarajan RN, 2000, SPINE, V25, P955, DOI 10.1097/00007632-200004150-00010; Phillips W C Jr, 1986, Del Med J, V58, P559; Pitzen TR, 2002, J NEUROSURG, V97, P128, DOI 10.3171/spi.2002.97.1.0128; ROBERTSON WC, 1979, JAMA-J AM MED ASSOC, V241, P1480, DOI 10.1001/jama.241.14.1480; SALLIS RE, 1992, PHYSICIAN SPORTSMED, V20, P47, DOI 10.1080/00913847.1992.11947521; Smith M G, 1993, J Ky Med Assoc, V91, P273; TORG JS, 1986, J BONE JOINT SURG AM, V68A, P1354, DOI 10.2106/00004623-198668090-00008; Torg JS, 1997, J NEUROSURG, V87, P843, DOI 10.3171/jns.1997.87.6.0843; Torg JS, 1997, MED SCI SPORT EXER, V29, pS256, DOI 10.1097/00005768-199707001-00008; Vaccaro Alexander R, 2002, Spine J, V2, P351; WATKINS RG, 1996, SPINE SPORTS, P157	32	33	34	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	APR	2007	6	4					356	363		10.3171/spi.2007.6.4.13			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	152DV	WOS:000245341900014	17436927				2021-06-18	
J	Lienhart, HG; Wenzel, V; Braun, J; Dorges, V; Dunser, M; Gries, A; Hasibeder, WR; Helm, M; Lefering, R; Schlechtriemen, T; Trimmel, H; Ulmer, H; Ummenhofer, W; Voelckel, WG; Waydhas, C; Lindner, K				Lienhart, H. G.; Wenzel, V.; Braun, J.; Doerges, V.; Duenser, M.; Gries, A.; Hasibeder, W. R.; Helm, M.; Lefering, R.; Schlechtriemen, T.; Trimmel, H.; Ulmer, H.; Ummenhofer, W.; Voelckel, W. G.; Waydhas, C.; Lindner, K.			Vasopressin for therapy of persistent traumatic hemorrhagic shock. The VITRIS at study	ANAESTHESIST			German	Article						VITRIS study; traumatic hemorrhagic shock; shock therapy; helicopter; emergency medical service; air rescue service; vasopressin	CARDIAC-ARREST; BRAIN-INJURY; FLUID RESUSCITATION; BLOOD-PRESSURE; LIFE-SUPPORT; HYPOTENSION; SURVIVAL; MODEL	While fluid management is established in controlled hemorrhagic shock, its use in uncontrolled hemorrhagic shock is being controversially discussed, because it may worsen bleeding. In the irreversible phase of hemorrhagic shock that was unresponsive to volume replacement, airway management and catecholamines, vasopressin was beneficial due to an increase in arterial blood pressure, shift of blood away from a subdiaphragmatic bleeding site towards the heart and brain and decrease of fluid resuscitation requirements. The purpose of this multicenter, randomized, controlled, international trial is to assess the effects of vasopressin (10 IU IV) vs. saline placebo IV (up to 3 injections at least 5 min apart) in patients with prehospital traumatic hemorrhagic shock that persists despite standard shock treatment. The study will be carried out by helicopter emergency medical service teams in Austria, Germany, Czech Republic, Portugal, the Netherlands and Switzerland. Inclusion criteria are adult trauma patients with presumed traumatic hemorrhagic shock (systolic arterial blood pressure < 90 mmHg) that does not respond to the first 10 min of standard shock treatment (endotracheal intubation, fluid resuscitation and use of vasopressors) after arrival of the first emergency physician at the scene. The time window for randomization will close after 30 min of shock treatment. Exclusion criteria are terminal illness, no intravenous access, age < 18 years, injury > 60 min before randomization, cardiac arrest before randomization, presence of a do-not-resuscitate order, untreated tension pneumothorax, untreated cardiac tamponade, or known pregnancy. Primary study end-point is the hospital admission rate, secondary end-points are hemodynamic variables, fluid resuscitation requirements and hospital discharge rate.	Med Univ Innsbruck, Klin Anasthesie & Allg Intens Med, A-6020 Innsbruck, Austria; Univ Kiel, Klin Anasthesie & Operat Intens Med, Kiel, Germany; Deutsch Rettungsflugwacht, Stuttgart, Germany; Univ Kliniken Bern, Inselspital, Klin Intens Med, Bern, Switzerland; Heidelberg Univ, Klin Anasthesie & Intens Med, Heidelberg, Germany; Allg Krankenhaus, Klin Anasthesie & Intens Med, Ried Im Innkreis, Germany; Bundeswehrkrankenhaus, Abt Anasthesie & Intens Med, Ulm, Germany; Bundeswehr, Luftrettungsdienst, Ulm, Germany; Krankenhaus Merheim, Abt Unfallchirurg, Cologne, Germany; Deutsch Gesellschaft Unfallchirurg, Cologne, Germany; Stadt Klinikum, Abt Anasthesie & Intens Med, Saarbrucken, Germany; ADAC, Luftrettung, Munich, Germany; Allg Krankenhaus, Abt Anasthesie Intens & Notfallmed, Wiener Neustadt, Germany; OAMTC, Flugrettung, Vienna, Austria; Med Univ, Dept Med Stat Informat & Gesundheitsokonomie, Innsbruck, Austria; Univ Klinikum Basel, Klin Anasthesie & Intens Med, Basel, Switzerland; REGA, Zurich, Switzerland; Univ Klinikum Essen, Unfallchirurg Klin, Essen, Germany	Wenzel, V (corresponding author), Med Univ Innsbruck, Klin Anasthesie & Allg Intens Med, Anichstr 35, A-6020 Innsbruck, Austria.	volker.wenzel@UKI.AT	Ulmer, Hanno/S-6615-2019	Ulmer, Hanno/0000-0001-5911-1002			BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Chan L, 1997, ACAD EMERG MED, V4, P785, DOI 10.1111/j.1553-2712.1997.tb03785.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coats TJ, 2001, LANCET, V357, P2070, DOI 10.1016/S0140-6736(00)05225-9; DEAKIN CD, 1994, J ACCID EMERG MED, V11, P154; Dick W F, 2000, Acta Anaesthesiol Belg, V51, P18; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Ericsson B F, 1971, Acta Chir Scand Suppl, V414, P1; ERICSSON BF, 1971, ACTA CHIR SCAND, V137, P729; Feinstein AJ, 2005, J TRAUMA, V59, P876, DOI 10.1097/01.ta.0000187654.24146.22; Fialka C, 2004, J TRAUMA, V57, P809, DOI 10.1097/01.TA.0000124266.39529.6E; Haas T, 2004, J TRAUMA, V57, P177, DOI 10.1097/01.TA.0000044357.25191.1B; Hackbarth RM, 2002, CRIT CARE MED, V30, P1630, DOI 10.1097/00003246-200207000-00038; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Krausz MM, 2003, J TRAUMA, V54, pS39, DOI 10.1097/01.TA.0000064506.47688.51; Kreimeier U, 2002, ANAESTHESIST, V51, P787, DOI 10.1007/s00101-002-0398-2; Krismer AC, 2005, ANAESTHESIST, V54, P220, DOI 10.1007/s00101-004-0793-y; KWAN I, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002245; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Roberts I, 2001, LANCET, V357, P385, DOI 10.1016/S0140-6736(00)03653-9; Ruchholtz S, 2000, UNFALLCHIRURG, V103, P30, DOI 10.1007/s001130050005; Sanui M, 2006, CRIT CARE MED, V34, P433, DOI 10.1097/01.CCM.0000196206.83534.39; Schummer W, 2005, ANAESTHESIST, V54, P707, DOI 10.1007/s00101-005-0854-x; Sharma RM, 2005, ANESTH ANALG, V101, P833, DOI 10.1213/01.ANE.0000175209.61051.7F; SHELLY MP, 1988, INTENS CARE MED, V14, P526, DOI 10.1007/BF00263525; Shoemaker WC, 1996, CRIT CARE MED, V24, pS12; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Stadlbauer KH, 2005, ANESTH ANALG, V101, P830, DOI 10.1213/01.ANE.0000175217.55775.1C; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; Thomas A, 2000, ANASTH INTENSIV NOTF, V35, P91, DOI 10.1055/s-2000-13006; Tsuneyoshi Isao, 2005, J Anesth, V19, P170, DOI 10.1007/s00540-004-0299-4; Voelckel WG, 2000, ANESTH ANALG, V91, P627, DOI 10.1213/00000539-200009000-00024; Yeh CC, 2003, ANESTH ANALG, V97, P577, DOI 10.1213/01.ANE.0000070231.16378.A6; Zenati MS, 2002, J TRAUMA, V53, P232, DOI 10.1097/00005373-200208000-00007	38	33	34	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	FEB	2007	56	2					145	+		10.1007/s00101-006-1114-4			5	Anesthesiology	Anesthesiology	139SN	WOS:000244453000006	17265038				2021-06-18	
J	Rosso, A; Brazinova, A; Janciak, I; Wilbacher, I; Rusnak, M; Mauritz, W				Rosso, Annalisa; Brazinova, Alexandra; Janciak, Ivan; Wilbacher, Ingrid; Rusnak, Martin; Mauritz, Walter		Austrian Severe TBI Study Investig	Severe traumatic brain injury in Austria II: Epidemiology of hospital admissions	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						brain injury; traumatic; epidemiology; Austria	HEAD-INJURY; POPULATION; CARE	OBJECTIVES: The goal of this paper is to describe the hospital-based epidemiology of severe TBI in Austria. PATIENTS AND METHODS: Data sets from 492 patients included in the study by 5 Austrian hospitals were available. Age and gender distribution, education, occupation, location of trauma, mechanism of injury, alcohol use, type and severity of injury, associated injuries, length of intensive care unit stay, and intensive care unit outcome were evaluated for each of the 5 centers. RESULTS: The sample represents roughly 13% of all cases with severe TBI which were treated in Austrian hospitals during the study period. Mean age was 48 +/- 21 years, and most patients were male (72%). The most important trauma locations were roads (50%), home (24%), outdoors (10%), and workplace (7%). Transportrelated trauma was the most important mechanism (44%) followed by falls < 3 m (30%), falls > 3 m (11%), and sports injuries (5%). Detailed analysis of transport-related trauma showed that car accidents (45%) were most common, followed by pedestrian (20%), motorbike (19%), and bicycle (16%) accidents. Significant differences between the centers were found for most of the variables analyzed. The severe traumatic brain injury was associated with spinal cord injury in 10%, and with severe multiple trauma in 38% of cases. Intensive care mortality was 31.7%. There were no significant correlations between mechanisms of injury and severity of trauma, nor between mechanisms and ICU outcome. CONCLUSIONS: Epidemiology of severe traumatic brain injuries in Austria is not much different from other industrialized countries. Traffic accidents are responsible for the majority of traumas, stressing the importance of road injury prevention. Attention should also be paid to the specific risks of older people and to prevent injuries at home.	INRO, Med Advisory Board, A-1080 Vienna, Austria; Trauma Hosp Lorenz Boehler, Dept Anesthesia & Crit Care Med, Vienna, Austria	Mauritz, W (corresponding author), INRO, Med Advisory Board, Molkergasse 4-3, A-1080 Vienna, Austria.	walter.mauritz@igeh.org	Rusnak, Martin/K-9349-2016; Brazinova, Alexandra/C-4265-2016	Rusnak, Martin/0000-0003-3321-1042; Brazinova, Alexandra/0000-0003-0625-256X; Mauritz, Walter/0000-0001-9043-3712			ADEKOYA N, 2002, MMWR SURVEILL SUMM, V6, P1; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Boswell JE, 2002, AM J EMERG MED, V20, P177, DOI 10.1053/ajem.2002.32641; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Drobetz H, 2000, ANASTH INTENSIV NOTF, V35, P630, DOI 10.1055/s-2000-7365; Elesha S O, 2002, Niger Postgrad Med J, V9, P38; Firsching R, 2001, WORLD J SURG, V25, P1221; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Koizumi MS, 2000, ARQ NEURO-PSIQUIAT, V58, P81, DOI 10.1590/S0004-282X2000000100013; LANGLOIS JA, 2003, MMWR SURVEILL SUMM, V27, P1; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; MEERHOFF SR, 2000, NED TIJDSCHR GENEES, V30, P1915; Nakamura N, 2002, NEUROL RES, V24, P45, DOI 10.1179/016164102101199530; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Raja IA, 2001, WORLD J SURG, V25, P1230; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Servadei F, 2002, NEUROEPIDEMIOLOGY, V21, P297, DOI 10.1159/000065523; *STAT AUSTR, 2004, JB GES I002; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; World Health Organization, 2002, INJ CHARTB GRAPH OV	27	33	34	0	14	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	FEB	2007	119	1-2					29	34		10.1007/s00508-006-0761-4			6	Medicine, General & Internal	General & Internal Medicine	142GQ	WOS:000244637800008	17318748				2021-06-18	
J	Demakis, GJ; Hammond, F; Knotts, A; Cooper, DB; Clement, P; Kennedy, J; Sawyer, T				Demakis, George J.; Hammond, Flora; Knotts, Allison; Cooper, Douglas B.; Clement, Pamelia; Kennedy, Jan; Sawyer, Tom			The Personality Assessment Inventory in individuals with traumatic brain injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Personality Assessment Inventory; Traumatic Brain Injury; psychometric research	HEAD-INJURY; MMPI-2; SCALE; VALIDITY	This study examined the Personality Assessment Inventory (PAI) in 95 individuals who had suffered a traumatic brain injury (TBI). Participants were recruited from a rehabilitation hospital (n=60) and a military hospital (n=35); despite differences in demographics and injury characteristics groups did not differ on any of the clinical scales and were thus combined. In the combined group, the highest mean clinical scale elevations were on Somatic Complaints, Depression, and Borderline Features and the most common configural profiles, based on cluster analysis, were Cluster I (no prominent elevations), Cluster 6 (social isolation and confused thinking), and Cluster 2 (depression and withdrawal). Factor analysis indicated a robust three-factor solution that accounted for 74.86 percent of the variance and was similar to findings from the psychiatric and non-psychiatric populations in the standardization sample. The above findings are compared with the previous literature on psychopathology in TBI, particularly in regards to the Minnesota Multiphasic Personality Inventory-2 (MMPI-2), as well as previous psychometric research on the PAI. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ N Carolina, Charlotte, NC 28223 USA; Charlotte Inst Rehabil, Charlotte, NC USA; Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA; Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA	Demakis, GJ (corresponding author), Univ N Carolina, 9201 Univ City Blvd, Charlotte, NC 28223 USA.	gdemakis@email.uncc.edu					Alfano Dennis P, 1992, Clin Neuropsychol, V6, P134, DOI 10.1080/13854049208401850; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Caperton JD, 2004, PSYCHOL ASSESSMENT, V16, P187, DOI 10.1037/1040-3590.16.2.187; Chervinsky AB, 1998, ARCH CLIN NEUROPSYCH, V13, P433, DOI 10.1016/S0887-6177(97)00016-4; Cureton E, 1983, FACTOR ANAL APPL APP; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Deisinger J. A., 1995, ASSESSMENT, V2, P173; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Kellogg SH, 2002, J PERS ASSESS, V79, P73, DOI 10.1207/S15327752JPA7901_05; KOSCHAT MA, 1991, PSYCHOMETRIKA, V56, P229, DOI 10.1007/BF02294460; Lally SJ, 2003, PROF PSYCHOL-RES PR, V34, P491, DOI 10.1037/0735-7028.34.5.491; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Morey L. C., 1991, PERSONALITY ASSESSME; Morey LC, 1998, ASSESSMENT, V5, P203, DOI 10.1177/107319119800500301; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; Parker JD, 1999, PSYCHOL ASSESSMENT, V11, P507, DOI 10.1037/1040-3590.11.4.507; Piotrowski C, 2000, PSYCHOL REP, V86, P65, DOI 10.2466/PR0.86.1.65-66; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Ruiz MA, 2002, ASSESSMENT, V9, P261, DOI 10.1177/1073191102009003005; Tasca GA, 2002, J PERS ASSESS, V79, P337, DOI 10.1207/S15327752JPA7902_14; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	22	33	33	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2007	22	1					123	130		10.1016/j.acn.2006.09.004			8	Psychology, Clinical; Psychology	Psychology	144RV	WOS:000244814700014	17182214				2021-06-18	
J	Fletcher, AE; Khalid, S; Mallonee, S				Fletcher, Amy E.; Khalid, Sumera; Mallonee, Sue			The epidemiology of severe traumatic brain injury among persons 65 years of age and older in Oklahoma, 1992-2003	BRAIN INJURY			English	Article						traumatic brain injury; injury epidemiology; elderly injury; injury surveillance	FALLS; MORTALITY	Primary objective: To describe the epidemiology of traumatic brain injury ( TBI) among persons 65 years of age and older in Oklahoma from 1992 - 2003. Research design: Descriptive epidemiology of data collected through active statewide surveillance on TBI inpatient hospitalizations and fatalities. Methods and procedures: Data collected from hospital medical records and the Office of the Chief Medical Examiner. TBI was defined by ICD- 9- CM codes for skull fracture 800.0 - 801.9, 803.0 - 804.9, concussion or other intracranial injury 850.0 - 854.1 and head injury, unspecified 959.01; all cases included a description of TBI. Main outcome and results: TBI rates increased 79% for the study population; however, case- fatality rates decreased from 32% in 1992 to 18% in 2003. The TBI rate increase was observed among all elderly age groups, both genders and all races. Unintentional injuries nearly doubled while both assault and self- inflicted injuries decreased. Fall- related TBI increased by 126%, while MVC- related TBI increased by 17%. Survivors were hospitalized for an average of 6.8 days and over half required post- acute care. Conclusions: The increased TBI rate and decreased case- fatality rate among elderly persons means potentially more persons living with TBI disability. TBI prevention efforts among the elderly must be expanded, especially for fall- related TBI.	Oklahoma Dept Hlth, Oklahoma City, OK 73117 USA	Fletcher, AE (corresponding author), Oklahoma Dept Hlth, 1000 NE 10th St, Oklahoma City, OK 73117 USA.	amyt@health.ok.gov					Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P276; *CDCP NAT CTR HLTH, 2004, US CENS POP BRIDG RA; *CDCP NAT CTR INJ, 2006, WEB BAS INJ STAT QUE; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cox E, 2001, WMJ, V100, P39; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fuller GF, 2000, AM FAM PHYSICIAN, V61, P2159; GOLEBURN CR, 2001, J CLIN GEROPSYCHOLOG, V7, P161; Guideline for the prevention of falls in older persons, 2001, J AM GERIATR SOC, V49, P664, DOI DOI 10.1046/J.1532-5415.2001.49115.X; Gunnell D, 2003, SOC SCI MED, V57, P595, DOI 10.1016/S0277-9536(02)00408-2; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 2000, ARCH INTERN MED, V160, P2145, DOI 10.1001/archinte.160.14.2145; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Lin Julie T, 2005, Phys Med Rehabil Clin N Am, V16, P109, DOI 10.1016/j.pmr.2004.06.005; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Schootman M, 2000, J TRAUMA, V48, P70, DOI 10.1097/00005373-200001000-00012; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Stevens JA, 2001, JAMA-J AM MED ASSOC, V286, P2665, DOI 10.1001/jama.286.21.2665; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thurman DJ, 2001, HEAD TRAUMA, P327; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tinetti ME, 2003, NEW ENGL J MED, V348, P42, DOI 10.1056/NEJMcp020719; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055; WENDLING T, 2004, SUMMARY REPORTABLE I	33	33	36	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	7					691	699		10.1080/02699050701426873			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	192LX	WOS:000248204400005	17653943				2021-06-18	
J	Gautschi, OP; Toffoli, AM; Joesbury, KA; Skirving, AP; Filgueira, L; Zellweger, R				Gautschi, Oliver P.; Toffoli, Andrew M.; Joesbury, Karen A.; Skirving, Allan P.; Filgueira, Luis; Zellweger, Rene			Osteoinductive effect of cerebrospinal fluid from brain-injured patients	JOURNAL OF NEUROTRAUMA			English	Article						BMP; cerebrospinal fluid; osteoinductive factor; S100B; traumatic brain injury	SEVERE HEAD-INJURY; HETEROTOPIC OSSIFICATION; BONE-FORMATION; S100B; PROTEIN; OSTEOGENESIS; TRAUMA; MARKER; DAMAGE; CELLS	Patients with traumatic brain injury (TBI) are predisposed to heterotopic ossification, which is believed to be due to osteoinductive factors released at the site of the brain injury. To date, little is known about the presence of such factors in human cerebrospinal fluid (CSF). This study investigated whether CSF of TBI patients is osteoinductive. In addition, known osteoinductive factors-such as bone morphogenetic protein (BMP)-2, BMP-4, and BMP-7, and S100B-were measured in CSF. Eighty-four consecutive patients were classified according to brain pathology: TBI (n = 11), non-traumatic brain pathology (NTBP) (n = 26), and no brain pathology (control group) (n = 47). The osteoinductive effect of CSF was measured repeatedly in proliferation assays using a fetal human osteoblast cell line. The mean proliferation rate (normalized to the internal negative control) of the TBI, NTBP, and control groups was 138.2% (SD 13.1), 110.0% (SD 22.1), and 118.8% (SD 16.9), respectively. The potentially confounding effect of age was investigated further by restricting the selection of patients for analysis to that of the oldest patient in the TBI group and use of multiple regression analysis. After implementation of both, it was shown that age is highly unlikely to account for the higher rates of proliferation observed among the TBI patients in this study. Of note, the TBI group had a significantly higher mean proliferation rate than the NTBP (P < 0.001) and the control group (p = 0.006). S100B and BMP-2, -4, or -7 concentrations were measured using enzyme-linked immunosorbent assay (ELISA). There was no correlation between proliferation rates and S100B (r = 0.023). Only three of 36 CSF samples had measurable levels of BMP-2 and -7, and none had detectable concentrations of BMP-4. Consequently, it is unlikely that S100B or BMP-2, -4, or -7 are the putative osteoinductive factors. The results indicate that CSF from TBI patients has an osteoinductive effect in vitro. However, the osteoinductive factor has still to be characterized.	Royal Perth Hosp, Dept Orthopaed & Trauma Surg, Perth, WA 6000, Australia; Univ Western Australia, Sch Anat & Human Biol, Perth, WA 6009, Australia	Gautschi, OP (corresponding author), Royal Perth Hosp, Dept Orthopaed & Trauma Surg, North Block,Level 5,Wellington St, Perth, WA 6000, Australia.	ogautschi@datacomm.ch	Filgueira, Luis/B-6492-2008	Filgueira, Luis/0000-0002-2266-6650			Baltzer AWA, 1999, ZBL CHIR, V124, P1011; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Bottiger BW, 2001, CIRCULATION, V103, P2694; Cheng HW, 2003, J BONE JOINT SURG AM, V85A, P1544, DOI 10.2106/00004623-200308000-00017; CRAVEN PL, 1971, CLIN ORTHOP RELAT R, P231; Dattatreyamurty B, 2001, EXP NEUROL, V172, P273, DOI 10.1006/exnr.2001.7728; HARRIS SA, 1995, J BONE MINER RES, V10, P178; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Kang Q, 2004, GENE THER, V11, P1312, DOI 10.1038/sj.gt.3302298; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635-200403000-00007; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; KNUDSEN L, 1982, SCAND J RHEUMATOL, V11, P27, DOI 10.3109/03009748209098110; KURER MHJ, 1992, PARAPLEGIA, V30, P165, DOI 10.1038/sc.1992.48; MATHURIYA SN, 1989, CLIN NEUROL NEUROSUR, V91, P269, DOI 10.1016/0303-8467(89)90124-8; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Pittenger D E, 1991, Orthop Rev, V20, P33; PUZAS JE, 1989, CLIN ORTHOP RELAT R, P269; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rothermundt M, 2003, MICROSC RES TECHNIQ, V60, P614, DOI 10.1002/jemt.10303; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Scher A T, 1976, Paraplegia, V14, P202; Shehab D, 2002, J NUCL MED, V43, P346; STOVER SL, 1975, ARCH PHYS MED REHAB, V56, P199; Subramaniam M, 2002, J CELL BIOCHEM, V87, P9, DOI 10.1002/jcb.10259; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; van Kuijk AA, 2002, SPINAL CORD, V40, P313, DOI 10.1038/sj.sc.3101309; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Willoughby KA, 2004, J NEUROCHEM, V91, P1284, DOI 10.1111/j.1471-4159.2004.02812.x	32	33	37	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					154	162		10.1089/neu.2006.0166			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100015	17263679				2021-06-18	
J	Pickett, TC; Radfar-Baublitz, LS; McDonald, SD; Walker, WC; Cifu, DX				Pickett, Treven C.; Radfar-Baublitz, Laleh S.; McDonald, Scott D.; Walker, William C.; Cifu, David X.			Objectively assessing balance deficits after TBI: Role of computerized posturography	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						assessment; balance; computerized posturography; mobility; posttraumatic amnesia; postural instability; rehabilitation; traumatic brain injury; vestibular dysfunction; visual cues	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; MULTICENTER ANALYSIS; POSTURAL STABILITY; REHABILITATION; CONCUSSION; STRENGTH; GAIT; SWAY	Balance impairment, or postural instability, is a common source of residual physical disability after severe traumatic brain injury (TBI). Standardized functional measures such as the Functional Independence Measure (FIM) do not specifically assess balance. Furthermore, no agreement exists as to the optimal way to objectively measure balance problems in the TBI population. Technological advances have led to force-plate balance measurement known as computerized posturography testing (CPT). Published CPT data for severe TBI are lacking, and the feasibility of using CPT during rehabilitation has not been described. This study described CPT findings in 21 ambulatory patients with severe TBI who were undergoing inpatient rehabilitation at a Defense and Veterans Brain Injury Center. Results demonstrated the utility of CPT in detecting and quantifying postural instability. Comparisons with the normative database indicate that the sample had a high degree of balance impairment despite some participants having reached the ceiling of the FIM ambulation scale at discharge from the acute rehabilitation setting. The quantitative CPT measures are a promising way to characterize postural instability in severe TBI populations.	[Pickett, Treven C.; McDonald, Scott D.; Cifu, David X.] Vet Adm Med Ctr, Hunter Holmes McGuire Dept, Polytrauma Rehabil Ctr, Mental Hlth Serv Line, Richmond, VA 23249 USA; [Pickett, Treven C.; Walker, William C.; Cifu, David X.] Def & Vet Brain Injury Ctr, Richmond, VA USA; [Pickett, Treven C.; Radfar-Baublitz, Laleh S.; Walker, William C.; Cifu, David X.] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA	Pickett, TC (corresponding author), Vet Adm Med Ctr, Hunter Holmes McGuire Dept, Polytrauma Rehabil Ctr, Mental Hlth Serv Line, 1201 Broad Rock Blvd,116B, Richmond, VA 23249 USA.	Treven.Pickett@va.gov	Walker, William C/N-3162-2014	Cifu, David/0000-0003-1600-9387			Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; BERG K, 1992, CAN J PUBLIC HLTH, V83, P7; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Black FO, 2001, CURR OPIN OTOLARYNGO, V9, P314, DOI DOI 10.1097/00020840-200110000-00011; CHOI SC, 1996, NEUROTRAUMA, P779; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Duong TT, 2004, ARCH PHYS MED REHAB, V85, P1291, DOI 10.1016/j.apmr.2003.11.032; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Hillier SL, 1997, BRAIN INJURY, V11, P661; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Nallegowda M, 2004, AM J PHYS MED REHAB, V83, P898, DOI 10.1097/01.PHM.0000146505.18244.43; *NEUROCOM INT INC, 1993, OBJ QUANT BAL MOB; NeuroCom International Inc, 1993, BAL MAST OP MAN; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SALAZAR AM, 1999, BRAIN INJ SOURCE, V3, P8; *SPSS INC, 2003, SPSS 12 0 WIND REL 1; TEASDALE G, 1974, LANCET, V2, P81; Whyte J., 1998, REHABILITATION MED P; Williams G, 2004, AM J PHYS MED REHAB, V83, P910, DOI 10.1097/01.PHM.0000146503.25221.1D; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	28	33	34	0	8	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2007	44	7					983	989		10.1682/JRRD.2007.01.0001			7	Rehabilitation	Rehabilitation	253NL	WOS:000252524800011	18075955	Bronze			2021-06-18	
J	Riley, GA				Riley, Gerard A.			Stress and depression in family carers following traumatic brain injury: the influence of beliefs about difficult behaviours	CLINICAL REHABILITATION			English	Article							ATTRIBUTIONS; CHILDREN; MOTHERS	Objective: Difficult behaviours are significant contributors to the distress experienced by carers of people with a traumatic brain injury. This study investigated whether the beliefs carers hold about such behaviours also contribute to the distress. Design: Questionnaire survey. Participants: Forty family carers recruited from Headway, a traumatic brain injury support organization. Main measures: Zung's Self-Rating Depression Scale, Perceived Stress Scale, Social Support Questionnaire, a measure of the severity of difficult behaviours shown by the person cared for and two measures of carer beliefs about the behaviour (including the Controlling Beliefs Scale). Results: Higher depression and stress scores were associated with more severe behaviours and less social support. Carer belief in their own ability to control the behaviours was associated with less stress. Belief that the behaviour was under the control of the person with traumatic brain injury and/or was motivated by hostile intentions was associated with more depression but less stress. Taken together, severity of behaviour and social support accounted for about 19% of the variance in both depression and stress scores. Carer beliefs accounted for another 5% of the depression scores, and another 11% of the stress scores. Conclusions: The results were consistent with the idea that carer beliefs about difficult behaviour contribute to carer distress, but longitudinal and treatment studies are needed to establish causality.	Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England	Riley, GA (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.	rileyga@bham.ac.uk	Riley, Gerard/A-4328-2008; riley, gerard/AAP-1439-2020; Riley, Gerard Anthony/J-1646-2012	Riley, Gerard Anthony/0000-0002-1167-8023			Bolton C, 2003, J CHILD PSYCHOL PSYC, V44, P242, DOI 10.1111/1469-7610.00117; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S., 1988, SOCIAL PSYCHOL HLTH; Dagnan D, 2004, BEHAV COGN PSYCHOTH, V32, P501, DOI 10.1017/S1352465804001675; Dopke CA, 2000, CHILD ABUSE NEGLECT, V24, P493, DOI 10.1016/S0145-2134(00)00110-1; Hastings RP, 2002, AM J MENT RETARD, V107, P222, DOI 10.1352/0895-8017(2002)107<0222:BPOCWA>2.0.CO;2; Jones C, 2003, BRIT J CLIN PSYCHOL, V42, P189, DOI 10.1348/014466503321903599; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MITCHLEY N, 1996, CLIN REHABIL, V10, P3; Nix RL, 1999, CHILD DEV, V70, P896, DOI 10.1111/1467-8624.00065; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	12	33	33	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2155	1477-0873		CLIN REHABIL	Clin. Rehabil.	JAN	2007	21	1					82	88		10.1177/0269215506071279			7	Rehabilitation	Rehabilitation	130PM	WOS:000243811500011	17213245				2021-06-18	
J	Sander, AM; Davis, LC; Struchen, MA; Atchison, T; Sherer, M; Malec, JF; Nakase-Richardson, R				Sander, Angelle M.; Davis, Lynne Cole; Struchen, Margaret A.; Atchison, Timothy; Sherer, Mark; Malec, James F.; Nakase-Richardson, Risa			Relationship of race/ethnicity to caregivers' coping, appraisals, and distress after traumatic brain injury	NEUROREHABILITATION			English	Article						traumatic brain injury; caregiving; race/ethnicity	SEVERE HEAD-INJURY; FAMILY CAREGIVERS; SOCIAL SUPPORT; BURDEN; DEMENTIA; PREDICTORS; IMPACT; RACE; HEALTH	The objective of the current study was to determine the relationship between race/ethnicity and caregivers' coping, appraisals of the caregiving role, and distress after traumatic brain injury (TBI). Participants were 195 caregivers (75% white; 25% black/Hispanic) of persons with TBI who were admitted to comprehensive inpatient rehabilitation at one of three participating centers and were followed up at 1 year after injury. Caregivers completed interview and self-report questionnaires, including the Ways of Coping Questionnaire, Caregiver Appraisal Scale, and Brief Symptom Inventory. Compared to whites, blacks/Hispanics reported lower levels of education, lower annual household income, and were more likely to be caring for an extended family member. After adjusting for relationship to the person with injury, age, education and income, race/ethnicity significantly predicted caregivers' use of the coping strategies distancing and accepting responsibility. Blacks/Hispanics made greater use of these strategies compared to whites. Blacks/Hispanics also showed more traditional beliefs regarding the caregiving role. Race/ethnicity was not predictive of distress. However, an interaction was noted between race/ethnicity and caregiver ideology. For Blacks/Hispanics, more traditional ideology was associated with increased distress. Future research using a larger sample of non-whites and including measures of acculturation is warranted.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Inst Rehabil & Res, Houston, TX USA; W Texas A&M Univ, Dept Behav Sci, Canyon, TX USA; Methodist Rehabil Ctr, Jackson, MS USA; Univ Mississippi, Med Ctr, Dept Neurol, Jackson, MS USA; Univ Mississippi, Med Ctr, Dept Psychiat, Jackson, MS USA; Mayo Clin & Mayo Fdn, Med Ctr, Rochester, MN USA; Mayo Clin & Mayo Fdn, Sch Med, Rochester, MN USA	Sander, AM (corresponding author), Brain Injury Res Ctr, 2455 S Braeswood, Houston, TX 77030 USA.	asander@bcm.tmc.edu					Braun KL, 1998, HEALTH SOC WORK, V23, P262, DOI 10.1093/hsw/23.4.262; Calderon V, 1998, J GERONTOL SOC WORK, V30, P159, DOI 10.1300/J083v30n01_10; Connell CM, 1997, GERONTOLOGIST, V37, P355, DOI 10.1093/geront/37.3.355; COX C, 1995, SOC WORK, V40, P343; COX C, 1990, J APPLIED GERONTOLOG, V9, P340, DOI DOI 10.1177/073346489000900308; Cox C, 1993, AM J ALZHEIMERS CARE, V8, P33; Derogatis L., 1982, BRIEF SYMPTOM INVENT; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Farran CJ, 1997, J AGING HEALTH, V9, P316, DOI 10.1177/089826439700900303; Folkman S., 1988, MANUAL WAYS COPING Q; Haley WE, 1996, J CONSULT CLIN PSYCH, V64, P121, DOI 10.1037/0022-006X.64.1.121; Haley WE, 1995, PSYCHOL AGING, V10, P540, DOI 10.1037/0882-7974.10.4.540; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HINRICHSEN GA, 1992, GERONTOLOGIST, V32, P375, DOI 10.1093/geront/32.3.375; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Knight BG, 2000, J GERONTOL B-PSYCHOL, V55, pP142, DOI 10.1093/geronb/55.3.P142; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; LAWTON MP, 1992, J GERONTOL, V47, pS156, DOI 10.1093/geronj/47.4.S156; Lazarus R.S., 1984, STRESS APPRAISAL COP; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MACERA CA, 1992, AM J ALZHEIMERS  SEP, P4; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MILLER B, 1995, J GERONTOL B-PSYCHOL, V50, pS374, DOI 10.1093/geronb/50B.6.S374; Minnes P, 2000, BRAIN INJURY, V14, P737; MORYCZ RK, 1987, J GERONTOL SOC WORK, V10, P133, DOI 10.1300/J083V10N01_10; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Panting A., 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; Sander A. M., 2005, REHABILITATION TRAUM, P156; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood J.B., 1990, J APPL GERONTOL, V9, P325, DOI [10.1177/073346489000900307, DOI 10.1177/073346489000900307]; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Wykle M, 1991, J Natl Black Nurses Assoc, V5, P29	47	33	33	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	1					9	17					9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	150TE	WOS:000245240600003	17379945				2021-06-18	
S	Sharma, HS; Johanson, CE		Slikker, W; Andrew, RJ; Trembly, B		Sharma, Hari Shanker; Johanson, Conrad E.			Intracerebroventricularly administered neurotrophins attenuate - Blood-cerebrospinal fluid barrier breakdown and brain pathology following whole-body hyperthermia - An experimental study in the rat using biochemical and morphological approaches	NEUROPROTECTIVE AGENTS: EIGHTH INTERNATIONAL NEUROPROTECTION SOCIETY MEETING	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	8th International Conference on Neuroprotective Agents	SEP 18-20, 2006	Mackinac Isl, MI	Int Neuroprotect Soc		whole-body hyperthermia; heat stress; body temperature; blood-brain barrier; CSF barrier; brain edema; neurotrophins; BDNF; GDNF; IGF-1; cell injury; ependyma; choroid plexus	GROWTH-FACTOR-I; INJURY FOLLOWING TRAUMA; CHOROID-PLEXUS; SPINAL-CORD; UP-REGULATION; PERMEABILITY; EXPRESSION; TRANSPORT; RECEPTORS; SYSTEM	Previous studies from our laboratory show that apart from blood-brain barrier (BBB) disruption, the blood-cerebrospinal fluid (CSF) barrier (BCSFB) for proteins is also broken down following wholebody hyperthermia (WBH) in a rat model. Breakdown of the BCSFB alters brain homeostasis and adversely affects the structure and function of the central nervous system (CNS). Since neurotrophins and growth factors (e.g., brain-derived growth factor [BDNF], glial cell line-derived neurotrophic factor [GDNF], and insulin-like growth factor 1 [IGF-1]) are known neuroprotective agents in traumatic and ischemic brain injuries, a possibility exists that these neurotrophins will also attenuate neuronal and choroidal injury in WBH. Subjection of adult rats to 4 h of WBH at 38 degrees C in a biological oxygen demand (BOD) incubator exhibited a profound increase in BCSFB permeability to Evans blue and radioiodine. Degeneration of choroidal epithelial cells and underlying ependyma, dilatation of the lateral ventricular space, and degenerative changes in the adjacent neuropil were frequent. The hippocampus, caudate nucleus, thalamus, and hypothalamus showed profound BBB disruption and brain edema formation. Intracerebroventricular (i.c.v.) administration of BDNF, GDNF, and IGF-1 into the right lateral cerebral ventricle (1, 2, or 5 mu g in 30 mu L, 24 h before WBH) significantly reduced the BCSFB and BBB breakdown, brain edema formation, and cellular/tissue injuries. These beneficial effects were most pronounced in GDNF- or IGF-1-pretreated animals. These novel observations suggest that neurotrophins administered into ventricular CSF can attenuate BCSFB and BBB damage following WBH and thereby confer neuroprotection. Stabilization of BCSFB function is thus one of the crucial factors in achieving neuroprotection in WBH.	[Sharma, Hari Shanker] Uppsala Univ, Inst Surg Sci, Dept Anaesthesiol & Intens Care, Lab Cerebrovasc Res, Uppsala, Sweden; [Johanson, Conrad E.] Rhode Isl Hosp, Brown Med Sch, Dept Neurosurg, Providence, RI USA	Sharma, HS (corresponding author), Frodingsgatan 12 28, SE-75421 Uppsala, Sweden.	sharma@surgsci.uu.se		Johanson, Conrad/0000-0002-1297-5484	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG027910] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG27910] Funding Source: Medline		Al-Sarraf H, 2007, J VASC RES, V44, P99, DOI 10.1159/000098260; Armstrong CS, 2000, J NEUROSCI RES, V59, P649, DOI 10.1002/(SICI)1097-4547(20000301)59:5<649::AID-JNR8>3.0.CO;2-W; Borlongan CV, 2004, STROKE, V35, P2206, DOI 10.1161/01.STR.0000138954.25825.0b; Carro E, 2006, NEUROBIOL AGING, V27, P1250, DOI 10.1016/j.neurobiolaging.2005.06.015; Chiaretti A, 2004, ACTA PAEDIATR, V93, P1178, DOI 10.1080/08035250410031314; Chodobski A, 2001, MICROSC RES TECHNIQ, V52, P65; DEKEYSER J, 1994, SYNAPSE, V17, P196, DOI 10.1002/syn.890170309; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; Ghersi-Egea JF, 2006, J CEREBR BLOOD F MET, V26, P1165, DOI 10.1038/sj.jcbfm.9600267; Ikeda T, 1999, INT J DEV NEUROSCI, V17, P681, DOI 10.1016/S0736-5748(99)00057-X; JOHANSON C, 2005, INT J NEUROPROTECTIO, V1, P77; Johanson CE, 2005, BLOOD-CEREBROSPINAL FLUID BARRIER, P311; Johanson CE, 2005, PHARM RES-DORDR, V22, P1011, DOI 10.1007/s11095-005-6039-0; Johanson CE, 2000, CELL MOL NEUROBIOL, V20, P197, DOI 10.1023/A:1007097622590; JOHANSON CE, 2003, NEUROSCIENCE MED, P165; JOHANSON CE, 2004, BLOOD SPINAL CORD BR, P361; Johanson Conrad, 2004, Cerebrospinal Fluid Res, V1, P3, DOI 10.1186/1743-8454-1-3; Koo H, 2001, INT J DEV NEUROSCI, V19, P549, DOI 10.1016/S0736-5748(01)00042-9; Korhonen L, 1998, NEUROSCI LETT, V240, P151, DOI 10.1016/S0304-3940(97)00937-3; MURPHY VA, 1985, J CEREBR BLOOD F MET, V5, P401, DOI 10.1038/jcbfm.1985.55; RAPOPORT SI, 1976, BLOOD BRAIN BARRIER, P1; Redzic ZB, 2005, CURR TOP DEV BIOL, V71, P1, DOI 10.1016/S0070-2153(05)71001-2; REINHARDT RR, 1994, ENDOCRINOLOGY, V135, P1753, DOI 10.1210/en.135.5.1753; Saura J, 1999, NEUROREPORT, V10, P161, DOI 10.1097/00001756-199901180-00031; Segal MB, 2001, MICROSC RES TECHNIQ, V52, P38, DOI 10.1002/1097-0029(20010101)52:1<38::AID-JEMT6>3.3.CO;2-A; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P426; SHARMA H S, 1984, Indian Journal of Physiology and Pharmacology, V28, P259; Sharma H. S., 2004, BLOOD SPINAL CORD BR, P231; Sharma H. S., 1982, THESIS BANARAS HINDU, P1; Sharma HS, 2007, PROG BRAIN RES, V162, P173, DOI 10.1016/S0079-6123(06)62010-4; Sharma HS, 2007, PROG BRAIN RES, V162, P295, DOI 10.1016/S0079-6123(06)62015-3; Sharma HS, 2007, PROG BRAIN RES, V162, P459, DOI 10.1016/S0079-6123(06)62023-2; Sharma HS, 2007, CURR PHARM DESIGN, V13, P1841; Sharma HS, 2005, ANN NY ACAD SCI, V1053, P407, DOI 10.1196/annals.1344.036; Sharma HS, 2006, J NEURAL TRANSM, V113, P497, DOI 10.1007/s00702-005-0406-1; Sharma HS, 1998, PROG BRAIN RES, V115, P351; Sharma HS, 2005, INDIAN J MED RES, V121, P621; Sharma HS, 2003, ACT NEUR S, V86, P383; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; SHARMA HS, 1987, NEUROPHARMACOLOGY, V26, P85, DOI 10.1016/0028-3908(87)90049-9; Sharma HS, 1998, AMINO ACIDS, V14, P121, DOI 10.1007/BF01345252; Sharma HS, 2000, AMINO ACIDS, V19, P351, DOI 10.1007/s007260070066; SHARMA HS, 1990, ACT NEUR S, V51, P383; SHARMA HS, 2006, ACTA NEUROCHIR SUPP, P329; Sharma HS, 1999, ACTA U UPSAL, V830, P1; Smith DE, 2004, ADV DRUG DELIVER REV, V56, P1765, DOI 10.1016/j.addr.2004.07.008; Spector R, 2007, J NEUROCHEM, V103, P425, DOI 10.1111/j.1471-4159.2007.04773.x; Spector R, 2006, PHARM RES-DORDR, V23, P2515, DOI 10.1007/s11095-006-9091-5; TIMMUSK T, 1995, NEUROREPORT, V6, P1997, DOI 10.1097/00001756-199510010-00011; WEAVER CE, 2004, ADV MOL CEL, V31, P269	50	33	37	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA	0077-8923		978-1-57331-685-9	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2007	1122						112	129		10.1196/annals.1403.008			18	Multidisciplinary Sciences; Neurosciences; Pharmacology & Pharmacy	Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BHD20	WOS:000252267100008	18077568				2021-06-18	
J	Hewett, SJ; Silakova, JM; Hewett, JA				Hewett, Sandra J.; Silakova, Janna M.; Hewett, James A.			Oral treatment with rofecoxib reduces hippocampal excitotoxic neurodegeneration	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							SELECTIVE CYCLOOXYGENASE-2 INHIBITOR; TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; CULTURED CORTICAL-NEURONS; INDUCED OXIDATIVE DAMAGE; TRANSGENIC MOUSE MODEL; CEREBRAL-ISCHEMIA; ALZHEIMERS-DISEASE; H SYNTHASE-1; CELL-DEATH	The purpose of this study was to determine whether the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib [ 4-[ 4-(methylsulfonyl) phenyl]-3-phenyl-2(5H)-furanone] could effectively prevent hippocampal neuronal injury in an animal model of excitotoxic neurodegeneration. COX-2 protein levels increased between 3 and 6 h, peaked at 12 h, and declined to near baseline levels 24 h after injection of N-methyl-D-aspartate (NMDA; 18 nmol) into the CA1 region of the left hippocampus. Mice that were fed ad libitum a control rodent diet for 4 days before and 3 days after injection of NMDA demonstrated marked neuronal loss in the primary cell layers of the ipsilateral CA1, CA3, and dentate gyrus (50, 30, and 20% cell loss, respectively). This injury was potently and dose-dependently reduced by feeding animals a diet standardized to deliver 15 or 30 mg/ kg rofecoxib per day. Neurodegeneration in the CA1 region was reduced by 30.1 +/- 5.6 and 51.5 +/- 9.0%, respectively; in the CA3 by 64.6 +/- 12.4 and 69.0 +/- 14.1%, respectively; and in the dentate gyrus by 47.8 +/- 15.2 and 58.0 +/- 18.2%, respectively. Moreover, rofecoxib chow slightly but significantly reduced injury-induced brain edema. These findings demonstrate that rofecoxib can ameliorate excitotoxic neuronal injury in vivo and, as such, may be a particularly promising pharmaceutical for the treatment of neurological diseases associated with overactivation of NMDA receptors.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Program Cellular & Mol Pharmacol, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Neurosci, Program Neurosci, Farmington, CT 06030 USA	Hewett, SJ (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, Program Cellular & Mol Pharmacol, MC-3401,263 Farmington Ave, Farmington, CT 06030 USA.	shewett@neuron.uchc.edu		Hewett, Sandra/0000-0002-2987-3791	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036812, R29NS036812] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36812, R01 NS036812] Funding Source: Medline		Adams J, 1996, J NEUROCHEM, V66, P6; AKAIKE A, 1994, BRAIN RES, V663, P237, DOI 10.1016/0006-8993(94)91268-8; Azari MF, 2005, EUR J NEUROL, V12, P357, DOI 10.1111/j.1468-1331.2004.00987.x; BREDER CD, 1995, J COMP NEUROL, V355, P296, DOI 10.1002/cne.903550208; Candelario-Jalil E, 2000, EUR J PHARMACOL, V390, P295, DOI 10.1016/S0014-2999(99)00908-5; Candelario-Jalil E, 2003, NEUROSCI RES, V47, P245, DOI 10.1016/S0168-0102(03)00184-6; Candelario-Jalil E, 2003, J NEUROCHEM, V86, P545, DOI 10.1046/j.1471-4159.2003.01812.x; Carlson NG, 2003, J NEUROSCI RES, V71, P79, DOI 10.1002/jnr.10465; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CAZEVIEILLE C, 1994, NEUROCHEM INT, V24, P395, DOI 10.1016/0197-0186(94)90118-X; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chan CC, 1999, J PHARMACOL EXP THER, V290, P551; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dembo G, 2005, ANESTHESIOLOGY, V102, P409, DOI 10.1097/00000542-200502000-00026; Dempsey RJ, 2000, NEUROSURGERY, V47, P399, DOI 10.1097/00006123-200008000-00024; Depre M, 2000, EUR J CLIN PHARMACOL, V56, P167, DOI 10.1007/s002280050736; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Drachman DB, 2002, ANN NEUROL, V52, P771, DOI 10.1002/ana.10374; FitzGerald G, 2003, NAT REV DRUG DISCOV, V2, P879, DOI 10.1038/nrd1225; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Halpin RA, 2000, DRUG METAB DISPOS, V28, P1244; Hewett SJ, 2000, J PHARMACOL EXP THER, V293, P417; Hoozemans JJM, 2001, ACTA NEUROPATHOL, V101, P2, DOI 10.1007/s004010000251; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Jiang JF, 2004, J NEUROCHEM, V90, P1036, DOI 10.1111/j.1471-4159.2004.02577.x; Kawano T, 2006, NAT MED, V12, P225, DOI 10.1038/nm1362; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Klivenyi P, 2004, J NEUROCHEM, V88, P576, DOI 10.1046/j.1471-4159.2003.02160.x; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KRAEMER SA, 1992, ARCH BIOCHEM BIOPHYS, V293, P391, DOI 10.1016/0003-9861(92)90411-O; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Ladecola C, 2001, P NATL ACAD SCI USA, V98, P1294, DOI 10.1073/pnas.98.3.1294; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Manabe Y, 2004, ANN NEUROL, V55, P668, DOI 10.1002/ana.20078; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; McCullough L, 2004, J NEUROSCI, V24, P257, DOI 10.1523/JNEUROSCI.4485-03.2004; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; Mirjany M, 2002, J PHARMACOL EXP THER, V301, P494, DOI 10.1124/jpet.301.2.494; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nogawa S, 1997, J NEUROSCI, V17, P2746; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Pasinetti GM, 1998, NEUROSCIENCE, V87, P319, DOI 10.1016/S0306-4522(98)00218-8; POWERS MM, 1955, STAIN TECHNOL, V30, P83, DOI 10.3109/10520295509113749; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; Sandhya TL, 1998, BRAIN RES, V788, P223, DOI 10.1016/S0006-8993(97)01552-7; Sanz O, 1997, NEUROSCIENCE, V80, P221, DOI 10.1016/S0306-4522(97)00089-4; Scali C, 2003, NEUROSCIENCE, V117, P909, DOI 10.1016/S0306-4522(02)00839-4; Silakova JM, 2004, J PHARMACOL EXP THER, V309, P1060, DOI 10.1124/jpet.103.063867; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; Steel R G D, 1980, PRINCIPLES PROCEDURE, V2nd; Strauss KI, 2002, J NEUROTRAUM, V19, P627, DOI 10.1089/089771502753754091; Teismann P, 2003, P NATL ACAD SCI USA, V100, P5473, DOI 10.1073/pnas.0837397100; Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109; WANG LH, 1993, BIOCHEM BIOPH RES CO, V190, P406, DOI 10.1006/bbrc.1993.1062; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Ye XB, 2002, J BIOL CHEM, V277, P31863, DOI 10.1074/jbc.M205544200; Yokota O, 2004, ACTA NEUROPATHOL, V107, P399, DOI 10.1007/s00401-004-0826-2	67	33	34	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	DEC	2006	319	3					1219	1224		10.1124/jpet.106.109876			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	105QX	WOS:000242048500025	16963621				2021-06-18	
J	Nitch, S; Boone, KB; Wen, J; Arnold, G; Alfano, K				Nitch, Stephen; Boone, Kyle Brauer; Wen, Johnny; Arnold, Ginger; Alfano, Kimberly			The utility of the Rey Word Recognition Test in the detection of suspect effort	CLINICAL NEUROPSYCHOLOGIST			English	Article							FORCED-CHOICE METHOD; PERFORMANCE; VALIDATION; SENSITIVITY; VALIDITY	The Rey Word Recognition Test potentially represents an underutilized tool for clinicians to use in the detection of suspect effort. The present study examined the predictive accuracy of the test by examining the performance of three groups of participants: (a) 92 noncredible patients (as determined by failed psychometric and behavioral criteria and external motive to feign), (b) 51 general clinical patients with no motive to feign, and (c) 31 learning disabled college students. Results demonstrated gender differences in performance that necessitated separate cutoff scores for men and women. Use of a cutoff score of <= 7 words correctly recognized identified 80.5% of noncredible female patients while maintaining specificity of > 90%. However, to achieve this level of specificity in male noncredible patients, the cutoff score had to be lowered to <= 5, with resultant sensitivity of only 62.7%. A combination variable (recognition correct minus false positive errors + number of words recognized from the first 8 words) showed enhanced sensitivity in identifying suspect effort in a subset of the noncredible sample who were claiming cognitive symptoms secondary to traumatic brain injury (i.e., cutoff score of <= 9= 81.6% sensitivity with 90% specificity). Results indicate that the Rey Word Recognition Test is an accurate and cost-effective method for the detection of noncredible cognitive performance.	Harbor UCLA Med Ctr, Dept Psychiat, Torrance, CA 90509 USA; Patton State Hosp, Patton, CA USA; Kaiser Permanente, Los Angeles, CA USA; Inst Rehabil, Santa Barbara, CA USA	Boone, KB (corresponding author), Harbor UCLA Med Ctr, Dept Psychiat, Box 495,1000 W Carson St,Bldg F-9, Torrance, CA 90509 USA.	kboone@labiomed.org					ARNOLD G, 2004, CLIN NEUROPSYCHOL, V18, P1; Babikian T, 2006, CLIN NEUROPSYCHOL, V20, P145, DOI 10.1080/13854040590947362; Baker R, 2000, Appl Neuropsychol, V7, P111, DOI 10.1207/S15324826AN0702_8; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Boone K., 2002, B TEST MANUAL; Boone K. B., 2002, DOT COUNTING TEST MA; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2000, ARCH CLIN NEUROPSYCH, V15, P227, DOI 10.1016/S0887-6177(99)00014-1; Frederick R.I., 1997, VALIDITY INDICATOR P; Frederick R.I., 2003, J FORENSIC NEUROPSYC, V2, P1, DOI [DOI 10.1300/J151v02n03_01, 10.1300/J151v02n03_01, DOI 10.1300/J151V02N03_01]; Frederick RI, 2000, J CLIN EXP NEUROPSYC, V22, P720, DOI 10.1076/jcen.22.6.720.951; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greiffenstein MF, 1996, ARCH CLIN NEUROPSYCH, V11, P283, DOI 10.1016/0887-6177(95)00038-0; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; GUILMETTE TJ, 1993, CLIN NEUROPSYCHOL, V7, P59, DOI 10.1080/13854049308401888; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; Iverson G.L., 1994, ASSESSMENT, V1, P323, DOI [DOI 10.1177/1073191, https://doi.org/10.1177/107319119400100401, DOI 10.1177/107319119400100401]; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; WARNERCHACON KR, 1994, THESIS CALIFORNIA SC	26	33	33	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	DEC	2006	20	4					873	887		10.1080/13854040590967603			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	085IE	WOS:000240597000020	16980268				2021-06-18	
J	Bhambhani, Y; Maikala, R; Farag, M; Rowland, G				Bhambhani, Yagesh; Maikala, Ram; Farag, Mamdouh; Rowland, Gary			Reliability of near-infrared spectroscopy measures of cerebral oxygenation and blood volume during handgrip exercise in nondisabled and traumatic brain-injured subjects	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						Bland-Altman analysis; blood volume; cerebral oxygenation; handgrip contractions; intraclass correlations; motor function; near infrared spectroscopy; rehabilitation; testretest reliability; traumatic brain injury	SEVERE HEAD-INJURY; FUNCTIONAL MRI; ACTIVATION; FLOW; NIRS; REPRODUCIBILITY; MONITOR; HUMANS; SIGNAL; AREAS	We compared the test-retest reliability of nedrinfrared spectroscopy (NIRS) measures of cerebral oxygenation and blood volume during a rhythmic handgrip exercise in 13 nondisabled subjects and 25 subjects with moderate to severe traumatic brain injury (TBI). Subjects with TBI (average Glasgow Coma Scale score = 4.2, average time since injury = 21 mo) had completed an acute brain injury rehabilitation program. After 2 min of rest, each subject performed 60 s of maximal rhythmic handgrip contractions with the right hand in two trials 24 to 48 h apart. We used NIRS to measure cerebral oxygenation and blood volume responses from the left prefrontal lobe. Both groups' cerebral oxygenation and blood volume increased during handgrip contractions. The change in cerebral oxygenation was significantly lower in subjects with TBI compared with nondisabled subjects. Intraclass correlations between the two trials for cerebral oxygenation and blood volume were 0.83 and 0.80, respectively, in nondisabled subjects and 0.70 and 0.64, respectively, in subjects with TBI. The findings indicate that NIRS is a reliable noninvasive technique for evaluating cerebral oxygenation and ' blood volume changes during motor function. NIRS can be useful in monitoring recovery of cerebral oxygenation during rehabilitation of patients with TBI.	Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2G4, Canada; Alberta Hosp Ponoka, Brain Injury Rehabil Program, Ponoka, AB, Canada	Bhambhani, Y (corresponding author), Univ Alberta, Fac Rehabil Med, Corbett Hall,Room 373, Edmonton, AB T6G 2G4, Canada.	yagesh.bhambhani@ualberta.ca					ADELSON PD, 1988, ACTA NEUROCHIR S, V71, P250; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; Buchner K, 2000, ZBL NEUROCHIR, V61, P69, DOI 10.1055/s-2000-8262; Cheng OSK, 2002, ACTA NEUROCHIR SUPPL, V81, P135; Colier WNJM, 1999, EXP BRAIN RES, V129, P457, DOI 10.1007/s002210050913; Fallgatter AJ, 1998, EUR ARCH PSY CLIN N, V248, P245, DOI 10.1007/s004060050045; Fujiwara N, 2004, NEUROIMAGE, V21, P1464, DOI 10.1016/j.neuroimage.2003.10.042; Giller CA, 2000, J APPL PHYSIOL, V88, P2205; Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; Hirth C, 1997, ADV EXP MED BIOL, V411, P461; Houtman S, 1999, CLIN PHYSIOL, V19, P169; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1997, ACT NEUR S, V70, P112; Kastrup A, 1999, J CEREBR BLOOD F MET, V19, P1066, DOI 10.1097/00004647-199910000-00002; KAWASHIMA R, 1993, BRAIN RES, V623, P33, DOI 10.1016/0006-8993(93)90006-9; Keppel G., 1973, DESIGN ANAL RES HDB, V3rd; Kleinschmidt A, 1996, J CEREBR BLOOD F MET, V16, P817, DOI 10.1097/00004647-199609000-00006; Koike A, 2004, CHEST, V125, P182, DOI 10.1378/chest.125.1.182; Kurihara K, 2003, CLIN PHYSIOL FUNCT I, V23, P177, DOI 10.1046/j.1475-097X.2003.00488.x; Mehagnoul-Schipper DJ, 2002, HUM BRAIN MAPP, V16, P14, DOI 10.1002/hbm.10026; Mehagnoul-Schipper DJ, 2001, CLIN PHYSIOL, V21, P77, DOI 10.1046/j.1365-2281.2001.00290.x; Obrig H, 1997, ADV EXP MED BIOL, V413, P113; Obrig H, 1996, J APPL PHYSIOL, V81, P1174; Pollard V, 1996, ANESTH ANALG, V82, P269, DOI 10.1097/00000539-199602000-00010; RODRIGUEZ G, 1988, J CEREBR BLOOD F MET, V8, P783, DOI 10.1038/jcbfm.1988.133; Roth R, 1996, NEUROREPORT, V7, P1280, DOI 10.1097/00001756-199605170-00012; Saitou H, 2000, ARCH PHYS MED REHAB, V81, P1348, DOI 10.1053/apmr.2000.9400; Sakatani K, 2003, ACT NEUR S, V87, P59; Schroeter ML, 2006, NEUROIMAGE, V30, P349, DOI 10.1016/j.neuroimage.2005.09.048; Simonson SG, 1996, CRIT CARE CLIN, V12, P1019, DOI 10.1016/S0749-0704(05)70290-6; Totaro R, 1998, CLIN SCI, V95, P497, DOI 10.1042/CS19980122; UZUNER N, 2000, EUR J ULTRASOUND, V11, P1147; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; VILLRINGER A, 1993, NEUROSCI LETT, V154, P101, DOI 10.1016/0304-3940(93)90181-J; Watanabe A, 2003, J NEUROPSYCH CLIN N, V15, P442, DOI 10.1176/appi.neuropsych.15.4.442	36	33	33	0	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.	NOV-DEC	2006	43	7					845	856		10.1682/JRRD.2005.09.0151			12	Rehabilitation	Rehabilitation	156FO	WOS:000245633700007	17436171	Bronze			2021-06-18	
J	Egan, J; Chenoweth, L; McAuliffe, D				Egan, Jennifer; Chenoweth, Lesley; McAuliffe, Donna			Email-facilitated qualitative interviews with traumatic brain injury survivors: A new and accessible method	BRAIN INJURY			English	Article						email interviewing; traumatic brain injury; disability; qualitative research; Internet	COMPUTER-MEDIATED COMMUNICATION; HEAD-INJURY; PEOPLE; INTERNET; ISSUES; EMOTION	Primary objective: To trial the method of email-facilitated qualitative interviewing with people with traumatic brain injury (TBI). Research design: Qualitative semi-structured email-facilitated interviews. Procedures: Nineteen people (17 severe diagnosis) with a TBI participated in email interviews. Main outcomes and results: Findings indicate that this method facilitates the participation of people with TBI in qualitative interviews. Advantages include increased time for reflection, composing answers and greater control of the interview setting. In addition, the data indicates that people with a TBI are capable of greater insight, reflection and humour than indicated by previous research. Conclusion: Findings indicate that new technologies may advance data collection methods for people with cognitive-linguistic impairments who face participation barriers in face-to-face interviews.	Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia; Griffith Univ, Sch Human Serv, Nathan, Qld 4111, Australia	Egan, J (corresponding author), Univ Queensland, Sch Social Work & Appl Human Sci, Brisbane, Qld 4072, Australia.	j.egan@social.uq.edu.au	McAuliffe, Donna A/F-1853-2011	McAuliffe, Donna/0000-0002-6584-0540			*ASS INT RES, 2002, ETH DEC MAK INT RES; BAMPTON R, 2002, E INTERVIEW FORUM QU, V19, P3; BENNETT C, 1998, MEN ONLINE DISCUSSIN; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Bowker N, 2002, DISABIL SOC, V17, P327, DOI 10.1080/09687590220139883; COELHO C, 1996, J SPEECH HEAR RES, V39, P5; Crisp R, 1992, Aust Occup Ther J, V39, P15, DOI 10.1111/j.1440-1630.1992.tb01730.x; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; Dunne G. A., 1999, DIFFERENT DIMENSIONS; Egan J, 2005, BRAIN INJURY, V19, P555, DOI 10.1080/02699050400013659; Egan J, 2004, APHASIOLOGY, V18, P265, DOI 10.1080/02687030344000562; Fontana A., 1994, HDB QUALITATIVE RES; Galinsky MJ, 1997, HEALTH SOC WORK, V22, P181, DOI 10.1093/hsw/22.3.181; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; HUTCHINSON S, 1992, NURS RES, V41, P117; KARPMAN T, 1985, J APPL REHABILITATIO, V17, P28; KENDALL L, 1999, DOING INTERNET RES C, P57, DOI DOI 10.4135/9781452231471.N3; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Mann C., 2000, INTERNET COMMUNICATI; Mantovani G, 2001, CYBERPSYCHOL BEHAV, V4, P47, DOI 10.1089/10949310151088370; MARKHAM AN, 1998, ETHNOGRAPHICS ALTERN, V6, P246; MCAULIFFE D, 2000, HYPOTHETICAL PRACTIT, P371; MCAULIFFE D, 2003, QUALITATIVE REPORT, V8, P8; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; MCDONALD S, 2005, BRAIN IMPAIRMENT, V6, P55; *NAT HLTH MRC, 1999, NAT STAT ETH COND RE; *NHMRC, 2004, HUM RES ETH HDB; *NHMRC, JOINT NHMRC AVCC STA; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Parks MR, 1996, J COMMUN, V46, P80, DOI 10.1111/j.1460-2466.1996.tb01462.x; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Patton M., 2002, QUALITATIVE RES EVAL; *QSR INT PTY LTD, 2002, NVIVO QUAL DAT AN PR; RICE RE, 1987, J COMMUN, V37, P65, DOI 10.1111/j.1460-2466.1987.tb01009.x; RICE RE, 1987, COMMUN RES, V14, P85, DOI 10.1177/009365087014001005; SPROULL L, 1991, CONNECTIONS NEW WAYS; STEWART F, 2004, ADV SPEECH LANGUAGE, V6, P209; TEASDALE G, 1974, LANCET, V2, P81; THORNE SE, 1998, ANN REV NURSING RES, V18, P3; Togher L., 2000, BRAIN DAM B, P1; TREMBLAY MA, 1957, AM ANTHROPOL, V59, P688, DOI 10.1525/aa.1957.59.4.02a00100; Williams CC, 1999, PSYCHIATRY, V62, P61, DOI 10.1080/00332747.1999.11024853	44	33	34	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2006	20	12					1283	1294		10.1080/02699050601049692			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DF	WOS:000242357800007	17132551				2021-06-18	
J	Nolin, P; Villemure, R; Heroux, L				Nolin, P.; Villemure, R.; Heroux, L.			Determining long-term symptoms following mild traumatic brain injury: Method of interview affects self-report	BRAIN INJURY			English	Article						mild traumatic brain injury; subjective symptoms; assessment	POST-CONCUSSIONAL SYNDROME; MINOR HEAD-INJURY; POSTCONCUSSIONAL DISORDER; CHRONIC PAIN; MEMORY PERFORMANCE; MAJOR DEPRESSION; UNITED-STATES; RISK-FACTORS; STRESS; COMPENSATION	Primary objective: To examine the role played by two interviewing methods used ( spontaneous response and suggested response) in the evaluation of long- term subjective post- mild traumatic brain injury ( mTBI) symptoms. Research design: Cohort study. Method and procedures: One hundred and eight adult participants were contacted for a follow- up telephone interview 12 - 36 months after their mTBI. The participants had to firstly spontaneously indicate symptoms that were still present following their mTBI ( spontaneous response). Secondly, a list of symptoms was read to the participants and they had to say whether or not they were afflicted by each symptom ( suggested response). Paired t- tests were performed to compare the means obtained using the two methods. The percentage of symptoms reported with the two interviewing methods were used to analyse symptom types. Experimental intervention: None. Main outcomes and results: Results show that participants reported significantly more symptoms and a given symptom when a list was read to the participants. Furthermore, neither the number of symptoms nor the type of symptoms reported is identical for the two interviewing methods. Conclusion: The interviewing method used influences the number and type of long- term post- mTBI symptoms reported by participants.	Univ Quebec Trois Rivieres, Child & Family Dev Res Unit, Dept Psychol, Trois Rivieres, PQ G9A 5H7, Canada	Nolin, P (corresponding author), Univ Quebec Trois Rivieres, Child & Family Dev Res Unit, Dept Psychol, POB 500, Trois Rivieres, PQ G9A 5H7, Canada.	pierre.nolin@uqtr.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Brand N, 1997, INT J PSYCHOPHYSIOL, V25, P17, DOI 10.1016/S0167-8760(97)85373-1; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CAVANAUGH JC, 1986, EDUC GERONTOL, V12, P385, DOI 10.1080/0380127860120413; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DUBORD S, 2000, B PSYCHOL, V53, P185; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; EYSENCK MW, 1991, PERSPECTIVES COGNITI, P314; Fabiano RJ, 1998, J REHABIL, V64, P9; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Horan WP, 1997, ARCH CLIN NEUROPSYCH, V12, P575, DOI 10.1016/S0887-6177(97)00012-7; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kraus JF, 1993, HEAD INJURY, P1; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LOWDON IMR, 1989, INJURY, V20, P193, DOI 10.1016/0020-1383(89)90109-5; MARCOTTE AC, 2005, CADRE REFERENCE CLIN, P1; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; NOLIN P, 1996, UNPUB QUESTIONNAIRE; NOLIN P, 1997, REPERE ESSAIS ED, V18, P93; Paniak C, 2000, J MUSCULOSKELET PAIN, V8, P193, DOI 10.1300/J094v08n01_16; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Reynolds S, 2003, J HEAD TRAUMA REHAB, V18, P139, DOI 10.1097/00001199-200303000-00005; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Teasdale TW, 1997, BRIT MED J, V315, P569; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trepanier S, 1997, CAN J AGING, V16, P84, DOI 10.1017/S0714980800014173; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; WEST RL, 1984, EXP AGING RES, V10, P197, DOI 10.1080/03610738408258464; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	64	33	33	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2006	20	11					1147	1154		10.1080/02699050601049247			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	110DD	WOS:000242357600005	17123931				2021-06-18	
J	Fujiki, M; Hikawa, T; Ishii, TAK; Kobayashi, H				Fujiki, Minoru; Hikawa, Takarnitsu; Ishii, Tatsuya Abe Keisuke; Kobayashi, Hidenori			Reduced short latency afferent inhibition in diffuse axonal injury patients with memory impairment	NEUROSCIENCE LETTERS			English	Article						diffuse axonal injury; traumatic brain injury; transcranial magnetic stimulation; short latency afferent inhibition; cholinergic inhibition	TRANSCRANIAL MAGNETIC STIMULATION; HUMAN MOTOR CORTEX; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; EXCITABILITY; DONEPEZIL; FACILITATION; CIRCUITS	The present study used short interval intracortical inhibition (SICI), intracortical facilitation (ICF), and short latency afferent inhibition (SAI) to evaluate motor cortex excitability in 16 diffuse axonal injury (DAI) patients with memory impairment and compared the data with those of 16 healthy controls. SAI was reduced in patients compared with controls (92 +/- 12 versus 39 +/- 11% of the test size; p < 0.0001, unpaired t-test). DAI patients tended to have a high resting motor threshold (RMT) and less pronounced SICI and ICF than controls, but these differences were not significant. A single oral dose (3 mg) of donepezil, an acetylcholinesterase inhibitor that is commonly used to treat Alzheimer's disease (AD), improved SAI in DAI patients with wide individual variations that ranged from an increase of 77-18% of test size. These findings suggest that measuring SAI may provide a means of probing the integrity of cholinergic networks in an injured human brain. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Oita Univ, Sch Med, Dept Neurosurg, Oita 8795593, Japan	Fujiki, M (corresponding author), Oita Univ, Sch Med, Dept Neurosurg, 1-1 Idaigaoka, Oita 8795593, Japan.	fujilci@med.oita-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17591521] Funding Source: KAKEN		Alagona G, 2001, NEUROSCI LETT, V314, P57, DOI 10.1016/S0304-3940(01)02288-1; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Di Lazzaro V, 2005, J NEUROL NEUROSUR PS, V76, P1064, DOI 10.1136/jnnp.2004.051334; Di Lazzaro V, 2004, J NEUROL NEUROSUR PS, V75, P555, DOI 10.1136/jnnp.2003.018127; Di Lazzaro V, 2002, NEUROLOGY, V59, P392, DOI 10.1212/WNL.59.3.392; Di Lazzaro V, 2000, EXP BRAIN RES, V135, P455, DOI 10.1007/s002210000543; Kessler KR, 2005, MOVEMENT DISORD, V20, P238, DOI 10.1002/mds.20295; Kosasa T, 2000, EUR J PHARMACOL, V389, P173, DOI 10.1016/S0014-2999(99)00876-6; KUJIRAI T, 1993, J PHYSIOL-LONDON, V471, P501, DOI 10.1113/jphysiol.1993.sp019912; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; Pennisi G, 2002, NEUROSCI LETT, V329, P293, DOI 10.1016/S0304-3940(02)00701-2; Taverni JP, 1998, BRAIN INJURY, V12, P77; Tokimura H, 2000, J PHYSIOL-LONDON, V523, P503, DOI 10.1111/j.1469-7793.2000.t01-1-00503.x; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Ziemann U, 1996, J PHYSIOL-LONDON, V496, P873, DOI 10.1113/jphysiol.1996.sp021734; Ziemann U, 2004, CLIN NEUROPHYSIOL, V115, P1717, DOI 10.1016/j.clinph.2004.03.006	17	33	33	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	SEP 25	2006	405	3					226	230		10.1016/j.neulet.2006.07.005			5	Neurosciences	Neurosciences & Neurology	083PL	WOS:000240470600015	16901641				2021-06-18	
J	Holavanahalli, RK; Lezotte, DC; Hayes, MP; Minhajuddin, A; Fauerbach, JA; Engrav, LH; Helm, PA; Kowalske, KJ				Holavanahalli, Radha K.; Lezotte, Dennis C.; Hayes, Michael P.; Minhajuddin, Abu; Fauerbach, James A.; Engrav, Loren H.; Helm, Phala A.; Kowalske, Karen J.			Profile of patients lost to follow-up in the burn injury rehabilitation model systems' longitudinal database	JOURNAL OF BURN CARE & RESEARCH			English	Article							TRAUMATIC BRAIN-INJURY; SUBSTANCE-ABUSERS; ATTRITION; COHORT; INTERVENTION; PREVENTION; RATES; OLDER; BIAS	We sought to identify whether patterns exist in the Burn Injury Rehabilitation Model Systems' database among participants lost to follow-up at 6, 12, or 24 months after injury and to define characteristics that reliably discriminate between persons who are lost to follow-up and those who are not. All participants met the American Burn Association criteria for major burn injury, were 18 years of age or older, received care from one of four burn model systems, and consented to participate in a 2-year prospective data-collection process. Step-wise logistic regression was used to develop three prediction models for the probability of loss to follow-up. The percent of individuals successfully contacted for follow-up were 64% at 6 months, 54% at 12 months, and 42% at 24 months after injury. Individuals who were younger, not employed at time of burn, with less than a high school level education, a history of drug abuse, circumstances of injury involving suspected assault, and having no insurance for care were lost to follow-up. Longer stay in the hospital, on the other hand, increased the likelihood of follow-up. The same risk factors remained significant with or with out adjusting for site indicating that these factors are independent and significant in spite of any potential site differences. Successful follow-up at 6- and 12-month intervals increased the likelihood of achieving a follow-up at 24 months after injury. The sociodemographic risk factors for attrition identified in this study represent significant enduring vulnerabilities. The findings necessitate a close examination of several factors and the use of strategies to reduce the risk of attrition.	Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA	Holavanahalli, RK (corresponding author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Hayes, Michael/0000-0002-3392-6163			Agosti V, 1996, AM J DRUG ALCOHOL AB, V22, P29, DOI 10.3109/00952999609001643; Altman DG, 2000, STAT MED, V19, P3275, DOI 10.1002/1097-0258(20001215)19:23<3275::AID-SIM626>3.0.CO;2-M; Boys A, 2003, J ADOLESCENCE, V26, P363, DOI 10.1016/S0140-1971(03)00011-3; Canupp KC, 1997, SPINAL CORD, V35, P314, DOI 10.1038/sj.sc.3100367; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cottler LB, 1996, DRUG ALCOHOL DEPEN, V41, P209, DOI 10.1016/0376-8716(96)01254-9; Deeg DJH, 2002, J CLIN EPIDEMIOL, V55, P213, DOI 10.1016/S0895-4356(01)00472-3; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Edwards AGK, 1997, ADDICTION, V92, P1699, DOI 10.1046/j.1360-0443.1997.9212169911.x; Fairclough D., 2002, DESIGN ANAL QUALITY; Fauerbach JA, 1998, J BURN CARE REHABIL, V19, P247; Frack SA, 1997, AM J PREV MED, V13, P131; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Hansten ML, 2000, ADDICTION, V95, P1403, DOI 10.1046/j.1360-0443.2000.959140310.x; JEBSEN R H, 1969, Archives of Physical Medicine and Rehabilitation, V50, P311; Kristman V, 2004, EUR J EPIDEMIOL, V19, P751, DOI 10.1023/B:EJEP.0000036568.02655.f8; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Laursen P, 1997, Acta Neurol Scand Suppl, V172, P7; Littell R.C., 1996, SAS SYSTEM MIXED MOD, P633; Mihelic AH, 1997, J GERONTOL B-PSYCHOL, V52, pS37, DOI 10.1093/geronb/52B.1.S37; Minder CE, 2002, AM J PUBLIC HEALTH, V92, P445, DOI 10.2105/AJPH.92.3.445; Nishimoto RH, 1998, SUBST USE MISUSE, V33, P1291, DOI 10.3109/10826089809062218; PSATY BM, 1994, AM J EPIDEMIOL, V140, P161, DOI 10.1093/oxfordjournals.aje.a117226; Richards J. Scott, 1995, P10; Rubin DB., 1987, MULTIPLE IMPUTATION; *SAS I INC, 1999, SAS STAT US GUID VER, P3884; Scott CK, 2004, DRUG ALCOHOL DEPEN, V74, P21, DOI 10.1016/j.drugalcdep.2003.11.007; Siddiqui O, 1996, PREV MED, V25, P554, DOI 10.1006/pmed.1996.0089; Spotts D, 1996, SUBST USE MISUSE, V31, P1891, DOI 10.3109/10826089609064004; VACH W, 1991, AM J EPIDEMIOL, V134, P895, DOI 10.1093/oxfordjournals.aje.a116164; Van Beijsterveldt CEM, 2002, J CLIN EPIDEMIOL, V55, P216, DOI 10.1016/S0895-4356(01)00473-5; Walton MA, 1998, AM J COMMUN PSYCHOL, V26, P233, DOI 10.1023/A:1022128519196; Ware JE., 1993, SF 36 HLTH SURVEY MA; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Zunzunegui MV, 2001, J CLIN EPIDEMIOL, V54, P501, DOI 10.1016/S0895-4356(00)00325-5	37	33	33	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1559-047X			J BURN CARE RES	J. Burn Care Res.	SEP-OCT	2006	27	5					703	712		10.1097/01.BCR.0000238085.87863.81			10	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	089MQ	WOS:000240885100021	16998404				2021-06-18	
J	Bouillon, L; Mazer, B; Gelinas, I				Bouillon, Louise; Mazer, Barbara; Gelinas, Isabelle			Validity of the Cognitive Behavioral Driver's Inventory in predicting driving outcome	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article; Proceedings Paper	6th National Workshop on Driver Rehabilitation Specialists	MAY 28, 2004	Edmonton, CANADA	Jewish Rehabilitat Hosp Fdn			BRAIN-DAMAGE; STROKE; FITNESS; INJURY; SKILLS	OBJECTIVE. This study seeks to (a) compare Cognitive Behavioral Driver's Inventory (CBDI) scores for clients who passed and failed a driving evaluation and for diagnostic groups (left cerebrovascular accident [CVA], right CVA, traumatic brain injury [TBI], and cognitive decline); (b) determine sensitivity, specificity, and positive and negative predictive values of the CBDI; (c) compare validity of the CBDI with other tools; and (d) identity factors associated with outcome. PARTICIPANTS. This historical cohort study included clients with neurological conditions who completed a driving evaluation. MEASURES. CBDI, Motor-Free Visual Perception Test (MVPT), Bells test, and driving results were extracted from the charts. RESULTS. Mean CBDI (p < 0.0001) and MVPT (p < 0.0001) scores were significantly worse for those failing compared to passing the driving evaluation, Sensitivity of the CBDI was 62%, specificity was 81%, positive predictive values were 73%, and negative predictive values were 71%. Results varied according to diagnostic group. CONCLUSIONS. The CBDI is not sufficiently predictive of outcome to replace a driving evaluation, and is predictive only for clients with R-CVA and TBI. Evaluation of driving should vary according to diagnosis.	Jewish Rehabil Hosp, CRIR, Laval, PQ H7V 1R2, Canada; McGill Univ, Sch Phys & Occupat Therapy, CRIR, Jewish Rehabil Hosp, Montreal, PQ H7V 1R2, Canada	Bouillon, L (corresponding author), Jewish Rehabil Hosp, CRIR, 3205 Pl Alton, Laval, PQ H7V 1R2, Canada.	barbara.mazer@mcgill.ca					Antrim J. M., 1989, COGNITIVE REHABILITA, V7, P16; BALL K, 1993, INVEST OPHTH VIS SCI, V34, P3110; BOUSKA MJ, 1982, MANUAL APPL MOTOR FR; BRACY OL, 1985, COGNITIVE REHABILITA, V4, P10; Engum E. S., 1988, COGNITIVE REHABILITA, V6, P34; Engum ES, 1990, MANUAL COGNITIVE BEH; ENGUM ES, 1988, COGNITIVE REHABILITA, V6, P12; Engum ES, 1990, COGNITIVE REHABILITA, V8, P20; Fisk GD, 1997, ARCH PHYS MED REHAB, V78, P1338, DOI 10.1016/S0003-9993(97)90307-5; Galski T, 2000, J HEAD TRAUMA REHAB, V15, P895, DOI 10.1097/00001199-200006000-00004; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; GREEN RC, 1994, ARCH NEUROL-CHICAGO, V51, P779, DOI 10.1001/archneur.1994.00540200055017; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Klavora P, 2000, ARCH PHYS MED REHAB, V81, P701, DOI 10.1053/apmr.2000.6285; Korner-Bitensky N, 2000, AM J PHYS MED REHAB, V79, P253, DOI 10.1097/00002060-200005000-00007; Korner-Bitensky N, 1994, Can J Occup Ther, V61, P141; Korner-Bitensky NA, 1998, AM J OCCUP THER, V52, P916, DOI 10.5014/ajot.52.10.916; Korteling JE, 1996, ARCH PHYS MED REHAB, V77, P138, DOI 10.1016/S0003-9993(96)90158-6; LAMBERT EW, 1990, COGNITIVE REHABILITA, V8, P34; Liddle J., 2003, BRIT J OCCUP THER, V66, DOI [https://doi.org/10.1177/030802260306600307, DOI 10.1177/030802260306600307]; Lister R., 1999, BRIT J OCCUPATIONAL, V62, P514; Marottoli RA, 1997, J AM GERIATR SOC, V45, P202, DOI 10.1111/j.1532-5415.1997.tb04508.x; Mazer BL, 1998, ARCH PHYS MED REHAB, V79, P743, DOI 10.1016/S0003-9993(98)90350-1; Michon J.A., 1985, HUMAN BEHAV TRAFFIC, P485; Nouri F.M., 1992, CLIN REHABIL, V6, DOI [https://doi.org/10.1177/026921559200600402, DOI 10.1177/026921559200600402]; Owsley C, 1993, Clin Geriatr Med, V9, P389; QUIGLEY FL, 1983, AM J OCCUP THER, V37, P474, DOI 10.5014/ajot.37.7.474; Reitan R, 1986, TRAIL MAKING TEST MA; Simms B., 1985, BR J OCCUP THER, V48, P363; SIVAK M, 1981, ARCH PHYS MED REHAB, V62, P476; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697	31	33	33	0	1	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	JUL-AUG	2006	60	4					420	427		10.5014/ajot.60.4.420			8	Rehabilitation	Rehabilitation	065RN	WOS:000239177100008	16915872				2021-06-18	
J	Patel, MB; Feinstein, AJ; Saenz, AD; Majetschak, M; Proctor, KG				Patel, Mayur B.; Feinstein, Ara J.; Saenz, Alvaro D.; Majetschak, Matthias; Proctor, Kenneth G.			Prehospital HBOC-201 after traumatic brain injury and hemorrhagic shock in swine	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	19th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 10-14, 2006	Orlando, FL	Eastern Assco Surg Trauma		brain injury; swine; blood substitute; HBOC; hemoglobin based oxygen carrier	CEREBRAL PERFUSION-PRESSURE; TUMOR-NECROSIS-FACTOR; BOVINE POLYMERIZED HEMOGLOBIN; SMALL-VOLUME RESUSCITATION; CROSS-LINKED HEMOGLOBIN; TISSUE OXYGEN-TENSION; SEVERE HEAD-INJURY; BLOOD SUBSTITUTES; SUBARACHNOID HEMORRHAGE; ARGININE-VASOPRESSIN	Background. Data are limited on the actions of hemoglobin based oxygen carriers (HBOCs) after traumatic brain injury (TBI). This study evaluates neurotoxicity, vasoactivity, cardiac toxicity, and inflammatory activity of HBOC-201 (Biopure, Cambridge, Mass.) resuscitation in a TBI model. Methods: Swine received TBI and hemorrhage. After 30 minutes, resuscitation was initiated with 10 mL/kg normal saline (NS), followed by either HBOC-201 (6 mL/kg, n = 10) or NS control (n = 10). Supplemental NS was administered to both groups to maintain mean arterial pressure (MAP) > 60 mm Hg until 60 minutes, and to maintain cerebral perfusion pressure (CPP) > 70 mm Hg from 60 to 300 minutes. The control group received mannitol (1 g/kg) and blood (10 mL/kg) at 90 minutes and half (n = 5) received CPP directed phenylephrine (PE) therapy after 120 minutes. Serum cytokines; were measured with ELISA and coagulation was evaluated with thromboelastography. Brains were harvested for neuropathology. Results. With HBOC administration, MAP, CPP, and brain tissue PO2 were restored within 30 minutes and maintained until 300 minutes. Clot strength and fibrin formation were maintained and 9/10 successfully extubated. In contrast, with control, MAP and brain tissue PO2 did not correct until 120 minutes, after mannitol, transfusion and 40% more crystalloid. Furthermore, without PE, CPP did not reach target and 0/5 could be extubated. Lactate, heart rate, cardiac output, mixed venous oxygenation, muscle oxygenation, serum cytokines, and histology did not differ between groups. Conclusions. After TBI, a single HBOC-201 bolus with minimal supplements provided rapid resuscitation, while maintaining CPP and improving brain oxygenation, without causing cardiac dysfunction, coagulopathy, cytokine release, or brain structural changes.	Univ Miami, Sch Med, Ryder Trauma Ctr, Div Trauma, Miami, FL 33136 USA; Univ Miami, Miller Sch Med, Div Surg Crit Care, Miami, FL USA; Univ Miami, Miller Sch Med, DeWitt Daughtry Familt Dept Surg, Miami, FL USA; Univ Miami, Miller Sch Med, Dept Pathol, Miami, FL USA	Proctor, KG (corresponding author), Univ Miami, Sch Med, Ryder Trauma Ctr, Div Trauma, 1800 NW 10th Ave, Miami, FL 33136 USA.	kproctor@miami.edu	Patel, Mayur/K-2363-2013	Feinstein, Ara/0000-0001-6214-5334	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008749] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32 GM08749-01] Funding Source: Medline		Arnaud F, 2005, SHOCK, V24, P145, DOI 10.1097/01.shk.0000170354.18437.2f; *BRAIN TRAUM FDN A, 2000, MAN PROGN SEV TRAUM; Carrillo EH, 2002, J TRAUMA, V52, P449, DOI 10.1097/00005373-200203000-00006; Cole DJ, 1998, J NEUROSURG ANESTH, V10, P153, DOI 10.1097/00008506-199807000-00005; Cole DJ, 1999, CRIT CARE MED, V27, P972, DOI 10.1097/00003246-199905000-00038; Crookes BA, 2004, SURGERY, V135, P662, DOI 10.1016/j.surg.2003.11.017; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Dong F, 2006, SHOCK, V25, P50, DOI 10.1097/01.shk.0000187982.56030.94; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Fitzpatrick CM, 2004, J AM COLL SURGEONS, V199, P693, DOI 10.1016/j.jamcollsurg.2004.07.025; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Greenburg AG, 2004, CRIT CARE, V8, pS61, DOI 10.1186/cc2455; Hamilton RG, 2001, TRANSFUSION, V41, P219, DOI 10.1046/j.1537-2995.2001.41020219.x; Hare GMT, 2004, ANESTH ANALG, V99, P528, DOI 10.1213/01.ANE.0000136769.65960.D1; Jahr Jonathan S, 2002, Am J Ther, V9, P431, DOI 10.1097/00045391-200209000-00011; James MF, 2004, ANESTH ANALG, V99, P1593, DOI 10.1213/01.ANE.0000136477.46472.EB; Johnson JL, 2001, J TRAUMA, V50, P449, DOI 10.1097/00005373-200103000-00008; Johnson JL, 2003, J TRAUMA, V54, P133, DOI 10.1097/00005373-200301000-00016; Katz LM, 2002, RESUSCITATION, V54, P77, DOI 10.1016/S0300-9572(02)00053-9; King DR, 2005, J TRAUMA, V59, P553, DOI 10.1097/01.ta.0000177711.52191.62; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Lee SK, 2002, ACAD EMERG MED, V9, P969; Levy JH, 2003, EXPERT OPIN BIOL TH, V3, P509, DOI 10.1517/14712598.3.3.509; Loke KE, 2000, J CARDIOVASC PHARM, V35, P84, DOI 10.1097/00005344-200001000-00011; Malhotra AK, 2004, J TRAUMA, V56, P1049, DOI 10.1097/01.TA.0000127765.75643.66; Malhotra AK, 2003, J NEUROTRAUM, V20, P827, DOI 10.1089/089771503322385764; Manley GT, 2003, ADV EXP MED BIOL, V530, P311; Marret E, 2004, ANESTH ANALG, V98, P604, DOI 10.1213/01.ANE.0000099366.73625.DD; Maxwell RA, 2000, J TRAUMA, V49, P200, DOI 10.1097/00005373-200008000-00005; MCFAUL SJ, 1994, BLOOD, V84, P3175, DOI 10.1182/blood.V84.9.3175.bloodjournal8493175; Moore EE, 2003, J AM COLL SURGEONS, V196, P1, DOI 10.1016/S1072-7515(02)01704-0; Moore EE, 2005, SHOCK, V24, P197, DOI 10.1097/01.shk.0000180075.76766.fe; Moreira PL, 1997, CLIN CHEM, V43, P1792; Ortegon DP, 2003, J TRAUMA, V55, P755, DOI 10.1097/01.TA.0000085722.52921.6D; Piper IR, 1998, BRIT J ANAESTH, V80, P639; Raedler C, 2004, ANESTH ANALG, V98, P1759, DOI 10.1213/01.ANE.0000117150.29361.5A; Reid TJ, 2003, TRANSFUSION, V43, P280, DOI 10.1046/j.1537-2995.2003.00314.x; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Sahuquillo J, 1996, ACTA NEUROCHIR, V138, P435, DOI 10.1007/BF01420306; Sampson JB, 2003, J TRAUMA, V55, P747, DOI 10.1097/01.TA.0000084519.47163.77; Sanui M, 2006, CRIT CARE MED, V34, P433, DOI 10.1097/01.CCM.0000196206.83534.39; Saxena R, 1999, STROKE, V30, P993, DOI 10.1161/01.STR.30.5.993; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Sheppard FR, 2004, J TRAUMA, V57, P720, DOI 10.1097/01.TA.0000140479.65350.28; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Torres IP, 2005, ANESTH ANALG, V100, P912, DOI 10.1213/01.ANE.0000146960.79532.DB; *US DEP HHS FDA CT, 2005, CRIT SAF EFF EV OX T; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Wahr Joyce A, 2003, Anesthesiol Clin North Am, V21, P553, DOI 10.1016/S0889-8537(03)00044-0	49	33	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2006	61	1					46	56		10.1097/01.ta.0000219730.71206.3a			11	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	065TV	WOS:000239183600012	16832248				2021-06-18	
J	Olga, NK; Murashov, AK; Hoane, MR				Olga, N. Kokiko; Murashov, Alexander K.; Hoane, Michael R.			Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						recovery of function; traumatic brain injury; SERM; neuroprotection; rat	ESTROGEN-RECEPTOR MODULATORS; OVARIECTOMIZED FEMALE; POSTMENOPAUSAL WOMEN; GENDER-DIFFERENCES; NMDA ANTAGONISTS; SEX-DIFFERENCES; UNITED-STATES; ESTRADIOL; RECOVERY; PROGESTERONE	Hormonal differences between males and females have surfaced as a crucial component in the search for effective treatments after experimental models of traumatic brain injury (TBI). Recent findings have shown that selective estrogen receptor modulators (SERMs) may have therapeutic benefit. The present study examined the effects of raloxifene, a SERM, on functional recovery after bilateral cortical contusion injury (bCCI) or sham procedure. Male rats received injections of raloxifene (3.0 mg/kg, i.p.) or vehicle (1.0 ml/kg, i.p.) 15 min, 24, 48, 72, and 96 h after bCCl or sham procedure. Rats were tested on both sensorimotor (bilateral tactile removal and locomotor placing tests) and cognitive tests (reference and working memory in the Morris water maze). Raloxifene-treated animals showed a significant reduction in the initial magnitude of the deficit and facilitated the rate of recovery for the bilateral tactile removal test, compared to vehicle-treated animals. The raloxifene-treated animals also showed a significant improvement in the acquisition of working memory compared to vehicle-treated animals. However, raloxifene did not significantly improve the acquisition of reference memory or locomotor placing ability. Raloxifene treatment also did not result in a significant reduction in the size of the lesion cavity. Thus, the task-dependent improvements seen following raloxifene treatment do not appear to be the result of cortical neuroprotection. However, these results suggest that raloxifene improves functional outcome following bCCI and may present an interesting avenue for future research. (c) 2006 Elsevier B.V. All rights reserved.	So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Carbondale, IL 62901 USA; E Carolina Univ, Sch Med, Dept Physiol, Greenville, NC 27858 USA	Olga, NK (corresponding author), So Illinois Univ, Restorat Neurosci Lab, Dept Psychol, Carbondale, IL 62901 USA.	kokikoon@vcu.edu; murashoval@mail.ecu.edu; mhoane@siu.edu	Murashov, Alexander/ABB-2151-2020; Murashov, Alexander K/F-2241-2011	Murashov, Alexander/0000-0002-8912-5891; Murashov, Alexander K/0000-0002-8912-5891; Hoane, Michael/0000-0001-7779-2657	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS045647] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045647] Funding Source: Medline		Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; Arteaga E, 2003, MENOPAUSE, V10, P142, DOI 10.1097/00042192-200310020-00005; Behl C, 2002, J STEROID BIOCHEM, V83, P195, DOI 10.1016/S0960-0760(02)00271-6; BIRGE SJ, 1994, CLIN GERIATR MED, V10, P589, DOI 10.1016/S0749-0690(18)30318-5; BROWN TJ, 1988, ENDOCRINOLOGY, V123, P1761, DOI 10.1210/endo-123-4-1761; Callier S, 2001, SYNAPSE, V41, P131, DOI 10.1002/syn.1067; Cyr M, 2001, BRAIN RES REV, V37, P153, DOI 10.1016/S0165-0173(01)00115-1; Cyr M, 2001, NEUROPSYCHOPHARMACOL, V25, P242, DOI 10.1016/S0893-133X(01)00233-0; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FERRIS DC, 1995, NEUROREPORT, V6, P1485, DOI 10.1097/00001756-199507310-00005; Galanopoulou AS, 2003, NEUROSCI LETT, V342, P201, DOI 10.1016/S0304-3940(03)00282-9; Gibbs RB, 2004, PSYCHONEUROENDOCRINO, V29, P741, DOI 10.1016/S0306-4530(03)00118-5; Goekoop R, 2005, NEUROIMAGE, V25, P63, DOI 10.1016/j.neuroimage.2004.11.012; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; HALL ED, 1991, J CEREBR BLOOD F MET, V11, P292, DOI 10.1038/jcbfm.1991.61; HAMPSON E, 1990, PSYCHONEUROENDOCRINO, V15, P97, DOI 10.1016/0306-4530(90)90018-5; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 2003, J NEUROTRAUM, V20, P1189, DOI 10.1089/089771503770802871; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Lacreuse A, 2002, NEUROBIOL AGING, V23, P589, DOI 10.1016/S0197-4580(02)00002-7; Littleton-Kearney MT, 2002, CNS DRUG REV, V8, P309; McMurray R, 2003, BRAIN RES, V980, P140, DOI 10.1016/S0006-8993(03)02984-6; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Murray HE, 2003, NEUROSCIENCE, V116, P213, DOI 10.1016/S0306-4522(02)00578-X; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P412, DOI 10.1016/S0002-9378(97)70207-2; Nilsen J, 2003, P NATL ACAD SCI USA, V100, P10506, DOI 10.1073/pnas.1334098100; O'Neill K, 2004, EXP NEUROL, V185, P63, DOI 10.1016/j.expneurol.2003.09.005; Ozgonul M, 2003, ENDOCR RES, V29, P183, DOI 10.1081/ERC-120022299; Purdie DW, 1999, BRIT J CLIN PHARMACO, V48, P785; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Schmidt R, 1996, J AM GERIATR SOC, V44, P1307, DOI 10.1111/j.1532-5415.1996.tb01400.x; Scott JA, 1999, AM FAM PHYSICIAN, V60, P1131; Sherwin BB, 1996, OBSTET GYNECOL, V87, pS20, DOI 10.1016/0029-7844(95)00431-9; SMITH SS, 1989, BRAIN RES, V503, P354, DOI 10.1016/0006-8993(89)91691-0; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Tsang KL, 2000, NEUROLOGY, V54, P2292, DOI 10.1212/WNL.54.12.2292; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Wise PM, 2001, FRONT NEUROENDOCRIN, V22, P33, DOI 10.1006/frne.2000.0207	49	33	33	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	JUN 30	2006	170	2					233	240		10.1016/j.bbr.2006.02.026			8	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	051RX	WOS:000238179500008	16580743				2021-06-18	
J	Plurad, D; Demetriades, D; Gruzinski, G; Preston, C; Chan, L; Gaspard, D; Margulies, D; Cryer, HG				Plurad, D; Demetriades, D; Gruzinski, G; Preston, C; Chan, L; Gaspard, D; Margulies, D; Cryer, HG			Pedestrian injuries: The association of alcohol consumption with the type and severity of injuries and outcomes	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRAUMATIC BRAIN-INJURY; HEMORRHAGIC-SHOCK; EXPERIMENTAL-MODEL; ETHANOL; INTOXICATION; PREVALENCE; RESUSCITATION	BACKGROUND: Literature on the effect of alcohol ingestion on short-term outcomes for trauma patients shows conflicting results. We performed this study to investigate the prevalence of positive alcohol screens and the effect of alcohol level on injury patterns, injury severity, and outcomes in pedestrians and bicyclists involved in a collision with an automobile. STUDY DESIGN: The study population included all pedestrians and bicyclists older than 10 years, treated in any of the 13 trauma centers in the Los Angeles County Emergency Services System during the calendar year 2003, who were involved in a collision with an automobile and had a blood alcohol level measured. The alcohol negative group was defined as those patients with a blood alcohol level <= 0.05 g/dL. Low and high alcohol groups were defined as those having blood alcohol levels > 0.05 g/dL to < 0.08 g/dL and >= 0.08 g/dL, respectively. We compared the three study groups with respect to demographics, injury patterns, injury severity, complications, and outcomes. Logistic regression was used to determine if alcohol had an independent association with any outcomes. RESULTS: There were 1,042 patients who met study criteria. Overall, 606 patients (58%) had a negative alcohol screen, 84 (8%) had low alcohol levels, and 352 (34%) had high alcohol levels. Alcohol level was not notably associated with severity of injury, admission hypotension, ICU length of stay, major complications, and injury pattern (head, chest, abdomen, or extremity Area Injury Score). Mortality was similar in the three alcohol level groups, but the overall complication rate and hospital length of stay were markedly higher in the high alcohol level group than they were in the negative alcohol level group. CONCLUSIONS: In pedestrians and bicyclists involved in a collision with an automobile, a high alcohol level is not associated with body area severity of injury, overall severity of injury, and hospital mortality. But high alcohol level is notably associated with higher overall complication rate and longer hospital length of stay.	Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Los Angeles, CA 90033 USA; Los Angeles Cty Dept Hlth Serv, Los Angeles, CA USA; Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; Huntington Mem Hosp, Dept Surg, Los Angeles, CA USA; Univ Calif Los Angeles, Dept Surg, Los Angeles, CA USA	Demetriades, D (corresponding author), Univ So Calif, Los Angeles Cty Med Ctr, Dept Surg, Rm 1105,1200 N State St, Los Angeles, CA 90033 USA.						BOTTOMS GD, 1990, ALCOHOL CLIN EXP RES, V14, P776, DOI 10.1111/j.1530-0277.1990.tb01245.x; BRICKLEY MR, 1995, INJURY, V26, P311, DOI 10.1016/0020-1383(95)00034-7; Chen SC, 1999, J TRAUMA, V47, P881, DOI 10.1097/00005373-199911000-00011; Cornwell EE, 1998, AM SURGEON, V64, P461; DAUGHTERS K, 1995, AM SURGEON, V61, P896; Delgado-Rodriguez M, 2003, BRIT J SURG, V90, P1287, DOI 10.1002/bjs.4186; Demetriades D, 2004, J AM COLL SURGEONS, V199, P687, DOI 10.1016/j.jamcollsurg.2004.07.017; Fabian MJ, 2002, J TRAUMA, V53, P864, DOI 10.1097/00005373-200211000-00010; Field CA, 2001, J TRAUMA, V50, P13, DOI 10.1097/00005373-200101000-00002; Girasek DC, 2002, ANN EMERG MED, V39, P622, DOI 10.1067/mem.2002.122864; Hewitt PM, 1999, J TRAUMA, V47, P346, DOI 10.1097/00005373-199908000-00022; Li GH, 1997, J TRAUMA, V42, P562, DOI 10.1097/00005373-199703000-00032; Madan AK, 1999, J TRAUMA, V47, P568, DOI 10.1097/00005373-199909000-00026; McDonough KH, 2002, J TRAUMA, V53, P541, DOI 10.1097/00005373-200209000-00024; Molina PE, 2003, ALCOHOL CLIN EXP RES, V27, P563, DOI 10.1097/01.ALC.0000057946.57330.F7; Phelan H, 2002, J TRAUMA, V52, P675, DOI 10.1097/00005373-200204000-00010; Shih HC, 2003, AM J EMERG MED, V21, P91, DOI 10.1053/ajem.2003.50025; SLOAN EP, 1989, J TRAUMA, V29, P1647, DOI 10.1097/00005373-198912000-00011; TULLOH BR, 1994, INJURY, V25, P539, DOI 10.1016/0020-1383(94)90097-3; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	21	33	34	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	JUN	2006	202	6					919	927		10.1016/j.jamcollsurg.2006.02.024			9	Surgery	Surgery	050EW	WOS:000238071300009	16735206				2021-06-18	
J	Ponsford, J; Harrington, H; Olver, J; Roper, M				Ponsford, J; Harrington, H; Olver, J; Roper, M			Evaluation of a community-based model of rehabilitation following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article								In recent years there has been a growing trend towards community-based post-acute rehabilitation for individuals with traumatic brain injury (TBI), as opposed to the traditional centre-based model, based on the premise that these individuals will learn more effectively in settings where they usually have to perform. In the present study, outcomes at two years post-injury in 77 individuals with TBI, treated within the community were compared on measures of activities of daily living (ADL), vocational status, and emotional adjustment with those of 77 TBI patients individually matched for gender, age, education, occupation, post-traumatic amnesia ( PTA) duration, Glasgow Coma Scale (GCS) score and time in inpatient rehabilitation, who had attended the hospital for outpatient therapy. There were no significant differences between groups in terms of employment outcomes or independence in personal or domestic ADL. However those treated in the community were less likely to be independent in shopping and financial management and reported more changes in communication and social behaviour. Due to constraints of time and resources, these patients had received fewer one-on-one therapy sessions and thus treatment costs were somewhat lower. Attendant care costs were also lower in the community treatment group. Strengths and weaknesses of community-based post-acute rehabilitation are discussed.	Epworth Med Fdn, Epworth Rehabil Ctr, Dept Psychol, Richmond, Vic 3121, Australia; Monash Univ, Clayton, Vic 3168, Australia; Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic 3121, Australia; Epworth Hosp Melbourne, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Epworth Rehabil Ctr, Dept Psychol, 89 Bridge Rd, Richmond, Vic 3121, Australia.	jennie.ponsford@med.monash.edu.au		Olver, John/0000-0001-7069-1191			Bowen A, 1999, NEUROREHABILITATION, V13, P147; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519	8	33	33	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUN	2006	16	3					315	328		10.1080/09602010500176534			14	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	054XR	WOS:000238412400005	16835154				2021-06-18	
J	Busnello, JV; Leke, R; Oses, JP; Feier, G; Bruch, RS; Quevedo, J; Kapczinski, F; Souza, DO; Portela, LVC				Busnello, Joao Vicente; Leke, Renata; Oses, Jean Pierre; Feier, Gustavo; Bruch, Ricardo S.; Quevedo, Joao; Kapczinski, Flavio; Souza, Diogo O.; Portela, Luis Valmor Cruz			Acute and chronic electroconvulsive shock in rats: Effects on peripheral markers of neuronal injury and glial activity	LIFE SCIENCES			English	Article						NSE; S100B; lactate; electroconvulsive shock; electroconvulsive therapy	TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; CEREBROSPINAL-FLUID; INDUCED SEIZURES; S100B PROTEIN; ENOLASE; THERAPY; SERUM; ASTROCYTES; DAMAGE	Electroconvulsive therapy is considered one of the most effective treatments of major depression, but controversy still exists on whether it may be brain damaging. The aim of this work was to evaluate the cerebrospinal fluid (CSF) levels of neuron specific enolase (NSE), protein S100B and lactate of rats submitted to acute and chronic models of ECS. Rats were submitted to either one shock (acute) or a series of eight shocks, applied one at even, 48 h (chronic). CSF samples were collected at 0, 3, 6, 12, 24, 48 and 72 h after the shock in the acute model and at these same time intervals after the last shock in the chronic model. Both models did not produce significant alterations in the levels of NSE. S100B levels were significantly increased at 6 h in the chronic model (p < 0.0001). There was a significant increase in the levels of lactate at 0 h in both models (p < 0.001). These results support the proposition that ECS does not produce neural damage, and suggest that the alterations in the levels of S100B and lactate may reflect an astrocytic activity of a protective nature. (c) 2005 Elsevier Inc. All rights reserved.	Univ Fed Rio Grande Sul, Dept Bioquim, Inst Ciencias Basicas Saude, BR-90035003 Porto Alegre, RS, Brazil; Hosp Clin Porto Alegre, Ctr Pesquisa, Lab Psiquiatria Expt, BR-90035000 Porto Alegre, RS, Brazil; Univ Fed Rio Grande Sul, BR-90035000 Porto Alegre, RS, Brazil; Univ Extremo Sul Catarinense, Programa Pos Grad Ciencias Saude, Lab Neurociencias, BR-88806000 Criciuma, SC, Brazil; FUC, Inst Cardiol Rio Grande Sul, BR-90620001 Porto Alegre, RS, Brazil	Busnello, JV (corresponding author), Univ Fed Rio Grande Sul, Dept Bioquim, Inst Ciencias Basicas Saude, Ramiro Barcelos,2600 Anexo, BR-90035003 Porto Alegre, RS, Brazil.	joaovi@terra.com.br	de Quevedo, Joao Luciano/E-5491-2013; Oses, Jean Pierre/E-2534-2013; Souza, Diogo O/J-8894-2014; Kapczinski, Flavio/D-3175-2013; Kapczinski, Flavio/J-5803-2014; de Quevedo, Joao Luciano/N-1407-2019	de Quevedo, Joao Luciano/0000-0003-3114-6611; Souza, Diogo O/0000-0002-4322-0404; Kapczinski, Flavio/0000-0001-8738-856X; de Quevedo, Joao Luciano/0000-0003-3114-6611; Oses, Jean Pierre/0000-0002-2012-273X			Agelink MW, 2001, J NEUROL NEUROSUR PS, V71, P394, DOI 10.1136/jnnp.71.3.394; Berrouschot J, 1997, J NEUROL SCI, V150, P173, DOI 10.1016/S0022-510X(97)00086-5; Bouzier-Sore AK, 2003, BIOCHIMIE, V85, P841, DOI 10.1016/j.biochi.2003.08.003; Brewton LS, 2001, BRAIN RES, V912, P9, DOI 10.1016/S0006-8993(01)02519-7; Carney S, 2003, LANCET, V361, P799; Deitmer JW, 2001, RESP PHYSIOL, V129, P71, DOI 10.1016/S0034-5687(01)00283-3; DEVANAND DP, 1994, AM J PSYCHIAT, V151, P957; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; FILLENZ M, 2005, EPUB ROLE LACATE BRA; FINK M, 2005, PSYCHOBIOLOGY ELECTR; Haglid KG, 1997, BRAIN RES, V753, P196, DOI 10.1016/S0006-8993(96)01463-1; Heizmann CW, 2004, CLIN CHEM, V50, P249, DOI 10.1373/clinchem.2003.027367; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Hu JG, 1996, J BIOL CHEM, V271, P2543, DOI 10.1074/jbc.271.5.2543; INGVAR M, 1983, ACTA NEUROL SCAND, V68, P129, DOI 10.1111/j.1600-0404.1983.tb05339.x; KAISER E, 1989, CLIN CHIM ACTA, V183, P13, DOI 10.1016/0009-8981(89)90268-4; Kogel D, 2004, NEUROSCIENCE, V127, P913, DOI 10.1016/j.neuroscience.2004.06.013; Koppal T, 2001, NEUROCHEM INT, V39, P401, DOI 10.1016/S0197-0186(01)00047-X; KRAGH J, 1993, BIOL PSYCHIAT, V33, P794, DOI 10.1016/0006-3223(93)90020-E; Kulpa J, 2002, CLIN CHEM, V48, P1931; Leviton A, 2002, ACTA PAEDIATR, V91, P9, DOI 10.1080/080352502753457851; LINDEFORS N, 1995, NEUROSCIENCE, V65, P661, DOI 10.1016/0306-4522(94)00550-O; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Manev H, 2003, J AFFECT DISORDERS, V75, P59, DOI 10.1016/S0165-0327(02)00044-7; Manev R, 2001, EUR J PHARMACOL, V420, pR1, DOI 10.1016/S0014-2999(01)00989-X; Ongur D, 2004, HARVARD REV PSYCHIAT, V12, P253, DOI 10.1080/10673220490886185; Pellerin L, 2005, MOL NEUROBIOL, V32, P59, DOI 10.1385/MN:32:1:059; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Portela LVC, 2002, CLIN CHEM, V48, P950; Portela LVC, 2002, BRAIN RES, V950, P74, DOI 10.1016/S0006-8993(02)02987-6; Rabinowicz AL, 1996, EPILEPSIA, V37, P122, DOI 10.1111/j.1528-1157.1996.tb00002.x; RASMUSSEN CV, 1994, NEUROCHEM RES, V19, P1527, DOI 10.1007/BF00969001; Sterling P, 2000, NATURE, V403, P242, DOI 10.1038/35002188; TORRE ER, 1993, BRAIN RES, V631, P256, DOI 10.1016/0006-8993(93)91543-2; Van Eldik LJ, 2003, RESTOR NEUROL NEUROS, V21, P97; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wong ML, 2001, NAT REV NEUROSCI, V2, P343, DOI 10.1038/35072566; Zachrisson OCG, 2000, PSYCHIAT RES, V96, P157, DOI 10.1016/S0165-1781(00)00202-X; Zetterstrom TSC, 1998, MOL BRAIN RES, V57, P106, DOI 10.1016/S0169-328X(98)00077-1	40	33	34	1	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	MAY 22	2006	78	26					3013	3017		10.1016/j.lfs.2005.11.028			5	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	045NR	WOS:000237749300005	16413036				2021-06-18	
J	Cox, AL; Coles, AJ; Nortje, J; Bradley, PG; Chatfield, DA; Thompson, SJ; Menon, DK				Cox, A. L.; Coles, A. J.; Nortje, J.; Bradley, P. G.; Chatfield, D. A.; Thompson, S. J.; Menon, D. K.			An investigation of auto-reactivity after head injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						autoimmunity; T lymphocytes; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; REGULATORY T-CELLS; SPINAL-CORD-INJURY; PRACTICAL SCALE; AUTOIMMUNITY; DAMAGE	Murine models of CNS injury show auto-reactive T cell responses directed at myelin antigens, associated with improved neuronal survival and functional recovery. This pilot study shows, for the first time, that similar immune responses against myelin occur in human traumatic brain injury (TBI), with an expansion of lymphocytes recognising myelin basic protein observed in 40% of patients studied. "Reactive" patients did not have greater contusion volume on imaging, but were younger than the "unreactive" subgroup and tended towards a more favorable outcome. These findings are consistent with the concept of "beneficial autoimmunity". (c) 2006 Elsevier B.V. All rights reserved.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England	Coles, AJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Hills Rd, Cambridge CB2 2QQ, England.	ajc1020@medschl.cam.ac.uk		Coles, Alasdair/0000-0003-4738-0760	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: Medline		Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Givan AL, 1999, J IMMUNOL METHODS, V230, P99, DOI 10.1016/S0022-1759(99)00136-2; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Ibarra A, 2004, EUR J NEUROSCI, V19, P2984, DOI 10.1111/j.0953-816X.2004.03402.x; JENNETT B, 1975, LANCET, V1, P480; Kipnis J, 2002, P NATL ACAD SCI USA, V99, P15620, DOI 10.1073/pnas.232565399; Kipnis J, 2002, J NEUROIMMUNOL, V130, P78, DOI 10.1016/S0165-5728(02)00219-9; Kipnis J, 2001, J NEUROSCI, V21, P4564, DOI 10.1523/JNEUROSCI.21-13-04564.2001; Lyons AB, 2001, METHOD CELL BIOL, V63, P375; MCKENZIE JF, 1992, SOFTWARE LJ, V5, P1; Meinl E, 1997, AM J PATHOL, V150, P445; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; PETTE M, 1990, NEUROLOGY, V40, P1770, DOI 10.1212/WNL.40.11.1770; TEASDALE G, 1974, LANCET, V2, P81	15	33	33	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	MAY	2006	174	1-2					180	186		10.1016/j.jneuroim.2006.01.007			7	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	045QA	WOS:000237755600021	16519951				2021-06-18	
J	Rickards, H				Rickards, H			Depression in neurological disorders: an update	CURRENT OPINION IN PSYCHIATRY			English	Article						brain injury; depression; epilepsy; multiple sclerosis; Parkinson's disease	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; MULTIPLE-SCLEROSIS; PARKINSONS-DISEASE; MAJOR DEPRESSION; EPILEPSY; INVENTORY; SYMPTOMS; VALIDITY; SCALE	Purpose of review Depressions are a heterogeneous group of conditions that contribute significantly to impairments in quality of life, independent of the severity of neurological illness. Depression may predate neurological signs and symptoms in the evolution of neurodegenerative disorders, and there is some evidence that depressive illness itself may be a risk factor in the aetiology of some dementias. This review aims to summarize the relevant current literature on diagnosis, aetiology and treatment of depression in neurology. Recent findings Diagnosing depression in neurological conditions can be particularly difficult because of communication difficulties and changes in emotional expression as a result of the underlying neurological disease. Rating scales loaded towards somatic symptoms can show poor validity for screening or rating of severity in this setting. The evidence for the treatment of depression in neurological disease is scant, and often the treatment advice is based on consensus views of clinicians. Nevertheless, there have been some clinical trials, which are reported. Summary Depression is common in neurology. It is underrecognized and undertreated. Recent research has allowed us to define depression more clearly in this setting. Trials of treatment are urgently needed, especially as depression is a significant factor in quality of life and may affect prognosis.	Queen Elizabeth Psychiat Hosp, Dept Neuropsychiat, Birmingham B15 2QZ, W Midlands, England	Rickards, H (corresponding author), Queen Elizabeth Psychiat Hosp, Dept Neuropsychiat, Mindelsohn Way, Birmingham B15 2QZ, W Midlands, England.	hugh.rickards@bsmht.nhs.uk					Al-Adawi S, 2004, J NEUROPSYCH CLIN N, V16, P435, DOI 10.1176/appi.neuropsych.16.4.435; Arnett P, 2005, MULT SCLER J, V11, P328, DOI 10.1191/1352458505ms1162oa; Chou KL, 2005, PARKINSONISM RELAT D, V11, P403, DOI 10.1016/j.parkreldis.2005.04.005; Chwastiak L, 2002, AM J PSYCHIAT, V159, P1862, DOI 10.1176/appi.ajp.159.11.1862; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Ertan FS, 2005, J NEUROL NEUROSUR PS, V76, P1445, DOI 10.1136/jnnp.2004.057984; Ettinger A, 2004, NEUROLOGY, V63, P1008, DOI 10.1212/01.WNL.0000138430.11829.61; Feinstein A, 2004, NEUROLOGY, V62, P586, DOI 10.1212/01.WNL.0000110316.12086.0C; Gilliam FG, 2005, CURR OPIN NEUROL, V18, P129, DOI 10.1097/01.wco.0000162853.29650.ec; Gold R, 2005, EUR J NEUROL, V12, P649, DOI 10.1111/j.1468-1331.2005.01083.x; Hart S, 2005, QUAL LIFE RES, V14, P695, DOI 10.1007/s11136-004-1364-z; Jones JE, 2005, J NEUROPSYCH CLIN N, V17, P172, DOI 10.1176/appi.neuropsych.17.2.172; Jones JE, 2005, EPILEPSIA, V46, P731, DOI 10.1111/j.1528-1167.2005.49704.x; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kuhn KU, 2003, EPILEPSY BEHAV, V4, P674, DOI 10.1016/S1525-5050(03)00211-7; Leentjens AFG, 2000, MOVEMENT DISORD, V15, P1221, DOI 10.1002/1531-8257(200011)15:6<1221::AID-MDS1024>3.0.CO;2-H; Leentjens AFG, 2003, J NEUROPSYCH CLIN N, V15, P74, DOI 10.1176/appi.neuropsych.15.1.74; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Lincoln NB, 2003, STROKE, V34, P111, DOI 10.1161/01.STR.0000044167.44670.55; Loring DW, 2004, EPILEPSY BEHAV, V5, P976, DOI 10.1016/j.yebeh.2004.08.019; Menza M, 2004, J NEUROPSYCH CLIN N, V16, P315, DOI 10.1176/appi.neuropsych.16.3.315; Mergl R, 2005, J NEUROL NEUROSUR PS, V76, P138, DOI 10.1136/jnnp.2004.037127; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; Moran PJ, 2005, J BEHAV MED, V28, P35, DOI 10.1007/s10865-005-2561-0; Patten SB, 2003, NEUROLOGY, V61, P1524, DOI 10.1212/01.WNL.0000095964.34294.B4; Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; RUPANG P, 2005, PSYCHOSOMATICS, V46, P131; Shabnam GN., 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003465; Specchio LM, 2004, CLIN NEUROPHARMACOL, V27, P133, DOI 10.1097/00002826-200405000-00009; Thapar A, 2005, J PSYCHOSOM RES, V59, P269, DOI 10.1016/j.jpsychores.2005.04.001; Turner-Stokes L, 2005, J NEUROL NEUROSUR PS, V76, P1273, DOI 10.1136/jnnp.2004.050096; Veazey C, 2005, J NEUROPSYCH CLIN N, V17, P310, DOI 10.1176/appi.neuropsych.17.3.310; Weintraub D, 2005, J NUCL MED, V46, P227	35	33	37	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0951-7367	1473-6578		CURR OPIN PSYCHIATR	Curr. Opin. Psychiatr.	MAY	2006	19	3					294	298		10.1097/01.yco.0000218601.17722.5b			5	Psychiatry	Psychiatry	035YX	WOS:000237038800010	16612216				2021-06-18	
J	Shojo, H; Kibayashi, K				Shojo, H; Kibayashi, K			Changes in localization of synaptophysin following fluid percussion injury in the rat brain	BRAIN RESEARCH			English	Article						synaptophysin; traumatic brain injury; fluid percussion injury; axonal transport	SPINAL-CORD; TRANSMITTER SECRETION; AXONAL-TRANSPORT; TRANSECTION; MECHANISM; NEURONS; KINESIN; PROTEIN; MARKER	Traumatic brain injuries damage neurons and cause progressing dysfunctions of the brain. Synaptophysin (SYP), a major integral transmembrane protein of synaptic vesicles, provides a molecular marker for the synapse and serves as a functional marker of the brain. This study examined magnitude -dependent changes of SYP in the rat brain 2 days following low, moderate or high fluid percussion injuries and investigated time-dependent changes of SYP in the rat brain with moderate fluid percussion injury 2, 15 and 30days after trauma using immunohistochemistry and Western blotting. SYP immunoreactivity increased in the lateral cortex and in the subcortical white matter, with increasing magnitude of injury and time after trauma. Increased SYP immunoreactivity was accompanied with degeneration of neuronal cell bodies, their processes and terminals as well as glial cell proliferations. Amounts of SYP measured by Western blotting remained unchanged in brains with moderate fluid percussion within 30days after trauma. These findings indicate that trauma accumulates SYP at injured sites of neurons without changing SYP contents and that increased SYP immunoreactivity in the cerebral cortex following traumatic injury reflects an inhibition of synaptic vesicle transportation and dysfunction of synapses, thus providing a histological substrate for brain dysfunctions. (c) 2006 Elsevier B.V. All rights reserved.	Saga Univ, Fac Med, Dept Forens Med, Saga 8498501, Japan	Shojo, H (corresponding author), Saga Univ, Fac Med, Dept Forens Med, 5-1-1 Nabeshima, Saga 8498501, Japan.	shojo@med.saga-u.ac.jp	Kazuhiko, Kibayashi/F-5173-2013	Kazuhiko, Kibayashi/0000-0001-6510-5215			ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; BRUCE A, 2002, INTRACELLULAR VES 4, P711; Callahan LM, 2002, J NEUROPATH EXP NEUR, V61, P384, DOI 10.1093/jnen/61.5.384; Chou AK, 2002, NEUROSCI LETT, V333, P155, DOI 10.1016/S0304-3940(02)00575-X; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Duchen L. W., 1992, GREENFIELDS NEUROPAT, P1; Eastwood SL, 2001, BRAIN RES BULL, V55, P569, DOI 10.1016/S0361-9230(01)00530-5; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; LI JY, 1992, J NEUROBIOL, V23, P1094, DOI 10.1002/neu.480230813; Li JY, 2000, J NEUROSCI RES, V61, P151, DOI 10.1002/1097-4547(20000715)61:2<151::AID-JNR6>3.3.CO;2-E; MASLIAH E, 1989, NEUROSCI LETT, V103, P234, DOI 10.1016/0304-3940(89)90582-X; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Moran LB, 2004, BRAIN RES REV, V44, P154, DOI 10.1016/j.brainresrev.2003.11.004; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Nakayama Y, 2001, J NEUROTRAUM, V18, P545, DOI 10.1089/089771501300227341; RINK A, 1995, AM J PATHOL, V147, P1575; SANES JR, 2000, DEV NERVOUS SYSTEM P, P1087; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; STROEMER RP, 1992, NEUROSCI LETT, V147, P21, DOI 10.1016/0304-3940(92)90765-Y; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; Sugita S, 1999, J BIOL CHEM, V274, P18893, DOI 10.1074/jbc.274.27.18893; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Tiraihi T, 2004, DEV BRAIN RES, V148, P97, DOI 10.1016/j.devbrainres.2003.11.002; Valtorta F, 2004, BIOESSAYS, V26, P445, DOI 10.1002/bies.20012; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082	37	33	35	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 17	2006	1078						198	211		10.1016/j.brainres.2006.01.063			14	Neurosciences	Neurosciences & Neurology	035CO	WOS:000236977800020	16497279				2021-06-18	
J	Fujimura, K; Segami, N; Kobayashi, S				Fujimura, K; Segami, N; Kobayashi, S			Anatomical study of the complications of intraoral vertico-sagittal ramus osteotomy	JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article								Purpose: The present study was performed to determine the variations in anatomical features of the ramus and the course of the maxillary artery to reduce the risk of injury during intraoral vertico-sagittal ramus osteotomy (IVSRO). Materials and Methods: The locations and sizes of anatomical features of the medial aspect of mandibular rami were measured in 94 bilateral sides of 47 dry mandibles as a control group, and the results were compared with 3-dimensional computed tomography images of 44 sides of 22 patients with prognathism. We also dissected 12 sides of 6 mandibles from cadavers in a simulated IVSRO procedure to determine the course of the maxillary artery near the medial aspect of the ramus. Results: In the dry mandibles and patients with prognathism, the mandibular foramen was located slightly posterior to the center of the width of the mandibular ramus, and the lingula tip was located about one third the distance from the sigmoid notch to the inferior border of the ramus. The distance from the lateral margin of the mandibular foramen to the lateral surface of the mandibular ramus ranged from 3.1 to 4.4 mm. However, these distances showed various ranges. In the mandibles from Asian cadavers, the maxillary artery approached close to the ramus and passed lateral to the lower head of the lateral pterygoid muscle. Conclusions: The position of the mandibular foramen in rami varies among individuals and, therefore, should be confirmed preoperatively on axial CT images. In addition, the maxillary artery approaches close to the medial aspect of the sigmoid notch in many cases. Therefore, the medial aspect from the sigmoid notch should be exposed carefully in the IVSRO procedure to avoid damaging the maxillary artery. (c) 2006 American Association of Oral and Maxillofacial Surgeons.	Kanazawa Med Univ, Dept Oral & Maxillofacial Surg, Kahoku, Ishikawa 9200293, Japan	Fujimura, K (corresponding author), Kanazawa Med Univ, Dept Oral & Maxillofacial Surg, 1-1 Uchinada, Kahoku, Ishikawa 9200293, Japan.	1-kkk@kanazawa-med.ac.jp					CHOUNG PH, 1992, J CRANIO MAXILL SURG, V20, P153, DOI 10.1016/S1010-5182(05)80390-7; da Fontoura RA, 2002, J ORAL MAXIL SURG, V60, P660, DOI 10.1053/joms.2002.33115; Fujimura K, 2004, J ORAL MAXIL SURG, V62, P1246, DOI 10.1016/j.joms.2004.01.026; Hall HD, 1992, MODERN PRACTICE ORTH, P2111; KAMIJOU Y, 1967, ORAL ANATOMY, V3, P494; Kim Hee-Jin, 1997, Yonsei Medical Journal, V38, P19; LOVESTEDT SA, 1961, ANATOMY SURGEONS, V1, P340; SMITH BR, 1991, J ORAL MAXIL SURG, V49, P112, DOI 10.1016/0278-2391(91)90095-4; Westermark A, 1998, BRIT J ORAL MAX SURG, V36, P425, DOI 10.1016/S0266-4356(98)90457-0	9	33	36	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-2391	1531-5053		J ORAL MAXIL SURG	J. Oral Maxillofac. Surg.	MAR	2006	64	3					384	389		10.1016/j.joms.2005.11.009			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	018TD	WOS:000235786800006	16487798				2021-06-18	
J	Pleacher, MD; Dexter, WW				Pleacher, MD; Dexter, WW			Concussion management by primary care providers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS; GUIDELINES; PERFORMANCE	Objective: To assess current concussion management practices of primary care providers. Methods: An 11 item questionnaire was mailed to primary care providers in the state of Maine, with serial mailings to non-respondents. Results: Over 50% of the questionnaires were completed, with nearly 70% of primary care providers indicating that they routinely use published guidelines as a tool in managing patients with concussion. Nearly two thirds of providers were aware that neuropsychological tests could be used, but only 16% had access to such tests within a week of injury. Conclusions: Primary care providers are using published concussion management guidelines with high frequency, but many are unable to access neuropsychological testing when it is required.	Maine Med Ctr, Portland, ME 04102 USA	Pleacher, MD (corresponding author), Maine Med Ctr, Portland, ME 04102 USA.	pleacherm@hotmail.com					Barth JT., 1989, MILD HEAD INJURY, P257; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; *CONC SPORT GROUP, 2002, PHYSICIAN SPORTSMED, V30, P57; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	16	33	33	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2006	40	1							e2	10.1136/bjsm.2005.019067			2	Sport Sciences	Sport Sciences	995YG	WOS:000234140600022	16371479	Green Published, Bronze			2021-06-18	
J	Yi, JH; Hoover, R; McIntosh, TK; Hazell, AS				Yi, JH; Hoover, R; McIntosh, TK; Hazell, AS			Early, transient increase in complexin I and complexin II in the cerebral cortex following traumatic brain injury is attenuated by N-acetylcysteine	JOURNAL OF NEUROTRAUMA			English	Article						antioxidant; complexin; excitoxicity; fluid-percussion, neurotransmitter; traumatic brain injury	NEUROTRANSMITTER RELEASE; SNARE COMPLEX; VESICLE EXOCYTOSIS; AMINO-ACIDS; 2 ISOFORMS; RAT; MODEL; EXPRESSION; PROTEINS; DEPLETION	Alteration of excitatory neurotransmission is a key feature of traumatic brain injury (TBI) in which extracellular glutamate levels rise. Although increased synaptic release of glutamate occurs at the injury site, the precise mechanism is unclear. Complexin I and complexin II constitute a family of cytosolic proteins involved in the regulation of neurotransmitter release, competing with the chaperone protein alpha-SNAP (soluble N-ethylmaleimide-sensitive factor-attachment protein) for binding to the synaptic vesicle protein synaptobrevin as well as the synaptic membrane proteins SNAP-25 and syntaxin, which together form the SNAP receptor (SNARE) complex. Complexin I is predominantly a marker of axosomatic (inhibitory) synapses, whereas complexin II mainly labels axodendritic and axospinous synapses, the majority of which are excitatory. In order to examine the role of these proteins in TBI, we have studied levels of both complexins in the injured hemisphere by immunoblotting over a time period ranging from 6 h to 7 days following lateral fluid-percussion brain injury in the rat. Transient increases in the levels of complexin I and complexin II proteins were detected in the injured cerebral cortex 6 h following TBI. This increase was followed by a decrease of complexin I in the injured cortex and hippocampus, and a decrease in both complexins in the injured thalamus region at day 3 and day 7 post-injury. The early, transient increase in the injured cortex was completely blocked by N-acetylcysteine (NAC) administered 5 min following trauma, suggesting an involvement of oxidative stress. Neuronal loss was also reduced in the injured hemisphere with post-TBI NAC treatment. Our findings suggest a dysregulation of both inhibitory and excitatory neurotransmission following traumatic injury that is responsive to antioxidant treatment. These alterations in complexin levels may also play an important role in neuronal cell loss following TBI, and thus contribute to the pathophysiology of cerebral damage following brain injury.	Univ Montreal, Hop St Luc, Dept Med, Montreal, PQ, Canada; Univ Penn, Dept Neurosurg, Philadelphia, PA USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Hazell, AS (corresponding author), Univ Montreal, Hop St Luc, Dept Med, Montreal, PQ, Canada.	alan.stewart.hazell@umontreal.ca	Sanjuan, Miguel AF/B-7709-2011	Sanjuan, Miguel AF/0000-0003-3515-0837	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-P50-08803, NS-R01-40978] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803] Funding Source: NIH RePORTER		Abderrahmani A, 2004, J CELL SCI, V117, P2239, DOI 10.1242/jcs.01041; Archer DA, 2002, J BIOL CHEM, V277, P18249, DOI 10.1074/jbc.C200166200; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Eastwood SL, 2001, BRAIN RES BULL, V55, P569, DOI 10.1016/S0361-9230(01)00530-5; Eastwood SL, 2001, NEUROSCIENCE, V105, P219, DOI 10.1016/S0306-4522(01)00141-5; Edwardson JM, 2003, J BIOL CHEM, V278, P30849, DOI 10.1074/jbc.M304615200; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Freeman W, 2004, BRAIN RES BULL, V63, P33, DOI 10.1016/j.brainresbull.2003.12.003; Hazell AS, 2001, J NEUROCHEM, V78, P560, DOI 10.1046/j.1471-4159.2001.00436.x; Ishizuka T, 1999, NEUROSCIENCE, V88, P295, DOI 10.1016/S0306-4522(98)00223-1; Itakura M, 1999, BIOCHEM BIOPH RES CO, V265, P691, DOI 10.1006/bbrc.1999.1756; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Morton AJ, 2001, J NEUROCHEM, V76, P166, DOI 10.1046/j.1471-4159.2001.00059.x; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Peters A, 1996, J NEUROCYTOL, V25, P687, DOI 10.1007/BF02284835; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Sawada K, 2002, MOL PSYCHIATR, V7, P484, DOI 10.1038/sj.mp.4000978; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; TAKAHASHI S, 1995, FEBS LETT, V368, P455, DOI 10.1016/0014-5793(95)00713-J; Tokumaru H, 2001, CELL, V104, P421, DOI 10.1016/S0092-8674(01)00229-X; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Yamada M, 1999, NEUROSCIENCE, V93, P7, DOI 10.1016/S0306-4522(99)00104-9; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099	32	33	35	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2006	23	1					86	96		10.1089/neu.2006.23.86			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	009GP	WOS:000235100100007	16430375				2021-06-18	
J	De Guise, E; Leblanc, J; Feyz, M; Lamoureux, J				De Guise, E; Leblanc, J; Feyz, M; Lamoureux, J			Prediction of the level of cognitive functional independence in acute care following traumatic brain injury	BRAIN INJURY			English	Article						functional independence measure; traumatic brain injury; acute care	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; INTERRATER RELIABILITY; POSTTRAUMATIC AMNESIA; OUTCOME PREDICTION; REHABILITATION; MORTALITY; AGE; PERFORMANCE; RECOVERY	Primary objective: To determine a predictive model for cognitive functional outcome of patients with traumatic brain injury (TBI) at discharge from acute care. Methods and procedure: Three hundred and thirty-five patients were included in this analysis. Variables considered were age, education, initial score on the Glasgow Coma Scale (GCS), duration of post-traumatic amnesia ( PTA), cerebral imaging results and the need for neurosurgical intervention. Experimental interventions: Functional Independence Measure (FIM). Main outcomes and results: Results of this analysis indicated better cognitive FIM at discharge from acute care settings for patients with TBI when PTA was less than 24 hours, when level of education was higher, when no parietal lesion was identified, when no neurosurgical intervention was required, for patients with TBI who were younger and who presented with a higher GCS score upon admission. Conclusions: This model will help to plan resource allocation for treatment and discharge planning within the first weeks following TBI.	McGill Univ, Montreal Gen Hosp, Ctr Hlth, Traumat Brain Injury Program, Montreal, PQ H3G 1A4, Canada	De Guise, E (corresponding author), McGill Univ, Montreal Gen Hosp, Ctr Hlth, Traumat Brain Injury Program, Local D13-124,1650 Av Cedar, Montreal, PQ H3G 1A4, Canada.	elaine.deguise@muhc.mcgill.ca					Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Caille S, 2000, BRAIN COGNITION, V44, P30; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Chesnut R M, 1995, New Horiz, V3, P366; CHOI SC, 1994, J NEUROSURG, V81, P169, DOI 10.3171/jns.1994.81.2.0169; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Courville CB, 1942, ARCH SURG-CHICAGO, V45, P19, DOI 10.1001/archsurg.1942.01220010022002; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Donaghy S, 1998, ARCH PHYS MED REHAB, V79, P1231, DOI 10.1016/S0003-9993(98)90267-2; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gan BK, 2004, ANN ACAD MED SINGAP, V33, P63; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; Hawley CA, 1999, J NEUROL NEUROSUR PS, V67, P749, DOI 10.1136/jnnp.67.6.749; HETHERINGTON H, 1995, INJURY, V26, P97, DOI 10.1016/0020-1383(95)92185-D; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hymel KP, 1997, PEDIATRICS, V99, P371, DOI 10.1542/peds.99.3.371; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Lane PL, 2000, CAN J SURG, V43, P442; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Ritchie PD, 2000, J CLIN NEUROSCI, V7, P301, DOI 10.1054/jocn.1999.0198; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SOLOMON DA, 1992, NEUROPSYCHOL REV, V3, P249, DOI 10.1007/BF01109050; Stineman MG, 1997, ARCH PHYS MED REHAB, V78, P636, DOI 10.1016/S0003-9993(97)90430-5; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Toschlog EA, 2003, AM SURGEON, V69, P491; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vath A, 2001, NEUROL RES, V23, P315, DOI 10.1179/016164101101198677; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	66	33	34	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2005	19	13					1087	1093		10.1080/02699050500149882			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	983ZD	WOS:000233270000003	16286322				2021-06-18	
J	Hernandez, AV; Steyerberg, EW; Taylor, GS; Marmarou, A; Habbema, JDF; Maas, AIR				Hernandez, AV; Steyerberg, EW; Taylor, GS; Marmarou, A; Habbema, JDF; Maas, AIR			Subgroup analysis and covariate adjustment in randomized clinical trials of traumatic brain injury: A systematic review	NEUROSURGERY			English	Article						acute traumatic brain injury; CONSORT; covanate adjustment; randomized clinical trials; reporting; subgroup analysis; systematic review	SEVERE HEAD-INJURY; NEUROPROTECTIVE AGENTS; MULTICENTER TRIAL; SAMPLE-SIZE; OUTCOMES; EPIDEMIOLOGY; HYPOTHERMIA; INCREASES; MORTALITY; MANNITOL	OBJECTIVE: Few randomized clinical trials (RCTs) in the field of traumatic brain injury (TBI) have shown a significant treatment benefit. We critically reviewed the use of two types of secondary analyses, covariate adjustment and subgroup analysis, which are common in TBI trials. METHODS: We performed a systematic, review of therapeutic phase III RCTs, including adult patients with acute, moderate-to-severe TBI. Glasgow Outcome Scale (GOS) at >= 3 months as outcome, and >= 50 patients per arm were required. We compared the actual reporting of covariate adjustment and subgroup analyses with the Consolidated Standards of Reporting Trials (CONSORT) recommendations. Likewise, we reviewed six protocols of large multicenter RCTs and compared planned and reported subgroups. RESULTS: We identified 18 RCTs (n = 6439). Sixteen trials used GOS at 6 months as outcome. Five RCTs reported covariate adjustment. The number of covariates was limited (<= 5), most frequently including age. Many covariates were outcome predicus tors. Four RCTs reported only adjusted treatment effects as the main efficacy parameter. Eleven RCTs reported subgroup analyses. Several subgroup factors (<= 7, mainly outcome predictors) and outcomes (<= 4) were included. The highest total number of subgroups was 15, and only three RCTs completely pre-specified subgroups. Notably, 10 of 11 RCTs performed inappropriate separate subgroup analyses. Of 11 RCTs, 5 gave subgroups the same emphasis as the overall effect. Reported subgroup analyses were insufficiently described, and clearly differed from those planned in the protocol. CONCLUSION: The reported covariate adjustment and subgroup analyses from TBI trials had several methodological shortcomings. Appropriate performance and reporting of covariate adjustment and subgroup analysis should be considerably improved in future TBI trials because interpretation of treatment benefits may be misleading otherwise.	Univ Rotterdam, Med Ctr, Erasmus MC, Dept Publ Hlth,Ctr Clin Decis Sci, Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Div Commun Hlth Sci, Edinburgh, Midlothian, Scotland; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biostat, Richmond, VA USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA USA; Univ Rotterdam, Erasmus MC, Dept Neurol Surg, Rotterdam, Netherlands	Hernandez, AV (corresponding author), Univ Rotterdam, Med Ctr, Erasmus MC, Dept Publ Hlth,Ctr Clin Decis Sci, Rotterdam, Netherlands.	a.hernandez@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Hernandez, Adrian V./0000-0002-9999-4003; Steyerberg, Ewout/0000-0002-7787-0122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS-042691-001A] Funding Source: Medline		Altman DG, 2001, ANN INTERN MED, V134, P663, DOI 10.7326/0003-4819-134-8-200104170-00012; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; Brookes ST, 2004, J CLIN EPIDEMIOL, V57, P229, DOI 10.1016/j.jclinepi.2003.08.009; BULLOCK MR, 2002, NEUROSURG FOCUS; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Choi S C, 1998, J Biopharm Stat, V8, P367, DOI 10.1080/10543409808835246; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cook DI, 2004, MED J AUSTRALIA, V180, P289, DOI 10.5694/j.1326-5377.2004.tb05928.x; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; *CPMP, 2003, CPMPEWP286399 EMEA; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Dutton Richard P, 2003, Curr Opin Crit Care, V9, P503, DOI 10.1097/00075198-200312000-00007; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Harris C, 2003, J AM COLL SURGEONS, V197, P711, DOI 10.1016/S1072-7515(03)00729-4; Hauck WW, 1998, CONTROL CLIN TRIALS, V19, P249, DOI 10.1016/S0197-2456(97)00147-5; Hernandez AV, 2004, J CLIN EPIDEMIOL, V57, P454, DOI 10.1016/j.jclinepi.2003.09.014; HERNANDEZ AV, 2004, 9 BIANN C EUR SOC ME; HUKKELHOVEN CW, 2000, BRIT MED J, P321; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Lu Li-quan, 2003, Chin J Traumatol, V6, P302; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Masson F, 2000, ANN FR ANESTH, V19, P261; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Moye LA, 2001, CONTROL CLIN TRIALS, V22, P605, DOI 10.1016/S0197-2456(01)00180-5; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; ROCKSWOLD GL, 1992, J NEUROSURG, V76, P929, DOI 10.3171/jns.1992.76.6.0929; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; Simes RJ, 2004, MED J AUSTRALIA, V180, P467, DOI 10.5694/j.1326-5377.2004.tb06027.x; Vranos G, 2004, NEUROSURGERY, V55, P18, DOI 10.1227/01.NEU.0000126873.00845.A7; Wilson JTL, 2001, CURR PHARM DESIGN, V7, P1537, DOI 10.2174/1381612013397276; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	51	33	35	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2005	57	6					1244	1253		10.1227/01.NEU.0000186039.57548.96			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	991PQ	WOS:000233826300050	16331173				2021-06-18	
J	Inoue, Y; Shiozaki, T; Tasaki, O; Hayakata, T; Ikegawa, H; Yoshiya, K; Fujinaka, T; Tanaka, H; Shimazu, T; Sugimoto, H				Inoue, Y; Shiozaki, T; Tasaki, O; Hayakata, T; Ikegawa, H; Yoshiya, K; Fujinaka, T; Tanaka, H; Shimazu, T; Sugimoto, H			Changes in cerebral blood flow from the acute to the chronic phase of severe head injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; neurological outcome; severe head injury; xenon-CT	MILD HYPOTHERMIA THERAPY; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; METABOLISM; PRESSURE; ISCHEMIA; COMA; VASOSPASM; TRAUMA; SCALE	We studied cerebral blood flow (CBF) in the transition from the acute to the chronic phase of severe head injury in order to determine patterns of change in relation to neurological outcome. We measured CBF with stable xenon-enhanced computed tomography (Xe-CT) in 20 consecutive patieints at 1, 2, 3, 4, and 6 weeks after severe head injury, and analyzed the relation between the pattern of change in CBF and neurological outcome at 6 months after injury. CBF values were significantly lower in the brain-injured patients than in 14 healthy volunteers, except at 3 weeks after injury, when CBF increased in the patients to a value that did not differ significantly from that in the normal volunteers. We therefore focused on the change in CBF at 3 weeks after injury. We separated the 20 brain-injured patients into two subgroups, of which the first (subgroup A) consisted of nine patients whose CBF had returned to normal by week 3 post-injury, while the second (subgroup B) consisted of 11 patients whose CBF was subnormal at week 3 post-injury. CBF was significantly higher in subgroup A than in subgroup B at 2 weeks post-injury (P < 0.05). CBF in subgroup B remained significantly lower than that in subgroup A throughout the study period. At 6 months post-injury, subgroup A had a significantly better neurological outcome than did subgroup B (p < 0.05). We conclude that patients whose CBF returns to normal at 2-3 weeks following severe traumatic brain injury after being abnormally low in the acute phase of injury can be expected to achieve a good neurological outcome.	Osaka Univ, Grad Sch Med, Dept Traumatol & Acute Crit Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Neurosurg, Suita, Osaka 5650871, Japan	Inoue, Y (corresponding author), Osaka Univ, Grad Sch Med, Dept Acute Crit Med, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan.	yinoue@hp-emerg.med.osaka-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15390545] Funding Source: KAKEN		BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CORTE FD, 1997, ACTA NEUROCHIR, V139, P639; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; GUR D, 1982, STROKE, V13, P750, DOI 10.1161/01.STR.13.6.750; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; PLOUGMANN J, 1994, J NEUROSURG, V81, P822, DOI 10.3171/jns.1994.81.6.0822; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SAWADA Y, 1982, ANESTHESIOLOGY, V56, P53, DOI 10.1097/00000542-198201000-00013; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SEGAWA H, 1983, STROKE, V14, P356, DOI 10.1161/01.STR.14.3.356; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; TEASDALE G, 1974, LANCET, V2, P81	23	33	33	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1411	1418		10.1089/neu.2005.22.1411			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500004	16379579				2021-06-18	
J	Parton, A; Coulthard, E; Husain, M				Parton, A; Coulthard, E; Husain, M			Neuropharmacological modulation of cognitive deficits after brain damage	CURRENT OPINION IN NEUROLOGY			English	Article						cognitive function; neuropharmacology; stroke; traumatic brain injury	ACUTE ISCHEMIC-STROKE; HEAD-INJURY; DOSE-ESCALATION; CAFFEINOL; NEUROPROTECTION; ANTAGONIST; DONEPEZIL; MEMORY; METHYLPHENIDATE; REHABILITATION	Purpose of review This review discusses recent studies that have implications for potential neuropharmacological interventions which target cognitive deficits resulting from traumatic brain injury or stroke. Recent findings An important new study concerning the activity of N-methyl-D-aspartate (NMDA) receptors after brain injury reveals that previous influential hypotheses about an increase in glutamate triggering neuronal death may need to be revised. Furthermore, the study suggests that cognitive function may be best preserved by stimulation of NMDA receptors with agonists rather than by the use of antagonists, as previously believed. Investigations of animal models of stroke and traumatic brain injury have further demonstrated the possibility of intervening in the acute and sub-acute stages to protect specific brain systems, such as preservation of the cholinergic system (via cholinesterase inhibitors) and hippocampal neurons (via a D2 agonist). Clinical trials in humans indicate it is also possible to target these neurotransmitter systems to enhance cognitive performance in patients with chronic deficits. In particular, recent studies demonstrated that it is possible to ameliorate the effects of two common cognitive syndromes, visual neglect and aphasia. Summary Cognitive deficits are an extremely common consequence of either traumatic brain injury or stroke. Recent studies demonstrate the potential for using neuropharmacological intervention after acquired brain injury to prevent or ameliorate the effects of cognitive impairments. These treatments, however, are still in their preliminary stages and further research is required to identify the most effective compounds.	Univ London Imperial Coll Sci & Technol, Div Neurosci & Mental Hlth, Charing Cross Hosp, London W6 8RF, England; UCL, Inst Cognit Neurosci, London WC1E 7HU, England	Parton, A (corresponding author), Univ London Imperial Coll Sci & Technol, Div Neurosci & Mental Hlth, Charing Cross Hosp, London W6 8RF, England.	a.parton@imperial.ac.uk	Parton, Andrew/J-8174-2012; Husain, Masud/C-2074-2008	Husain, Masud/0000-0002-6850-9255; Parton, Andrew/0000-0003-0633-7846; coulthard, elizabeth/0000-0002-0017-9595			Albers GV, 2001, JAMA-J AM MED ASSOC, V286, P2673, DOI 10.1001/jama.286.21.2673; Albers GW, 1999, STROKE, V30, P508, DOI 10.1161/01.STR.30.3.508; APHASIA BT, 2005, ADV CLIN NEUROSCIENC, V5, P30; Aronowski J, 2003, STROKE, V34, P1246, DOI 10.1161/01.STR.0000068170.80517.B3; Belayev L, 2004, BRAIN RES, V1008, P278, DOI 10.1016/j.brainres.2004.02.039; Berthier ML, 2003, NEUROLOGY, V60, P1218, DOI 10.1212/01.WNL.0000055871.82308.41; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Borlongan CV, 2005, LIFE SCI, V76, P1503, DOI 10.1016/j.lfs.2004.09.022; Borlongan CV, 2005, BRAIN RES, V1038, P50, DOI 10.1016/j.brainres.2005.01.028; Breitenstein C, 2004, NEUROPSYCHOPHARMACOL, V29, P1704, DOI 10.1038/sj.npp.1300464; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Cohen L, 2004, NEW ENGL J MED, V350, P949, DOI 10.1056/NEJM200402263500922; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; Davis SM, 2000, STROKE, V31, P347, DOI 10.1161/01.STR.31.2.347; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; EGELKO S, 1989, ARCH PHYS MED REHAB, V70, P297; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman RS, 1997, PRINCIPLES NEUROPSYC; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Husain M, 2003, NAT REV NEUROSCI, V4, P26, DOI 10.1038/nrn1005; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Knecht S, 2004, ANN NEUROL, V56, P20, DOI 10.1002/ana.20125; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lipton P, 1999, PHYSIOL REV, V79, P1431; MALHOTRA PA, IN PRESS ANN NEUROL; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Nys GMS, 2005, NEUROLOGY, V64, P821, DOI 10.1212/01.WNL.0000152984.28420.5A; Parton A, 2004, J NEUROL NEUROSUR PS, V75, P13; Piriyawat P, 2003, STROKE, V34, P1242, DOI 10.1161/01.STR.0000067706.23777.04; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Sacco RL, 2001, JAMA-J AM MED ASSOC, V285, P1719, DOI 10.1001/jama.285.13.1719; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Walker W, 2004, BRAIN INJURY, V18, P739, DOI 10.1080/02699050310001646224; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; Zhao CS, 2005, BEHAV BRAIN RES, V156, P85, DOI 10.1016/j.bbr.2004.05.011; Zhao XR, 2005, STROKE, V36, P129, DOI 10.1161/01.STR.0000149624.87661.18	39	33	36	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2005	18	6					675	680		10.1097/01.wco.0000189872.54245.13			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	989MT	WOS:000233678800009	16280679				2021-06-18	
J	Henninger, N; Dutzmann, S; Sicard, KM; Kollmar, R; Bardutzky, J; Schwab, S				Henninger, N; Dutzmann, S; Sicard, KM; Kollmar, R; Bardutzky, J; Schwab, S			Impaired spatial learning in a novel rat model of mild cerebral concussion injury	EXPERIMENTAL NEUROLOGY			English	Article						ADC; animal model; beta APP; diffuse axonal injury; DWI; histology; MAP-2; Morris water maze; MRI; traumatic brain injury	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURY; CONTROLLED CORTICAL IMPACT; MORRIS WATER MAZE; COGNITIVE DEFICITS; NEUROPSYCHOLOGICAL DEFICITS; NEURONAL APOPTOSIS; MEMORY IMPAIRMENT; FUNCTIONAL MRI; ANIMAL-MODELS	The aim of the present study was to develop a model of mild traumatic brain injury in the rat that mimics human concussive brain injury suitable to study pathophysiology and potential treatments. 34 male Wistar rats received a closed head trauma (TBI) and 30 animals served as controls (CON). Immediately following trauma, animals lost their muscle tone and righting reflex response, recovering from the latter within 11.4 +/- 8.2 min. Corneal reflex and whisker responses returned within 4.5 +/- 3.0 min and 6.1 +/- 2.9 min, respectively. The impact resulted in a short transient decrease of pO(2) (P < 0.001), increase in mean arterial blood pressure (P = 0.026), and a reduction of heart rate (P < 0.01). Serial MRI did not show any abnormalities across the entire cerebrum on diffusion, T1, T2, and T2*-weighted images at all investigated time points. TBI animals needed significantly longer to locate the hidden platform in a Morris water maze and spent less time in the training quadrant than controls. TBI led to a significant neuronal loss in frontal cortex (P < 0.001), as well as hippocampal CA3 (P = 0.017) and CA1 (P = 0.002) at 9 days after the trauma; however, cytoskeletal architecture was preserved as indicated by normal beta APP- and MAP-2 staining. We present a unique, noninvasive rat model of mild closed head trauma with characteristics of human concussion injury, including brief loss of consciousness, cognitive impairment, and minor brain injury. (c) 2005 Elsevier Inc. All rights reserved.	Univ Massachusetts, Sch Med, Ctr Comparat Neuroimaging, Dept Psychiat, Worcester, MA 01655 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA; Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany	Henninger, N (corresponding author), Univ Massachusetts, Sch Med, Ctr Comparat Neuroimaging, Dept Psychiat, 303 Belmont St, Worcester, MA 01655 USA.	nils.henninger@umassmed.edu		Henninger, Nils/0000-0002-3883-5623			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BOHNEN N, 1993, ACTA NEUROL BELG, V93, P23; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Caner H, 2004, ACTA NEUROCHIR, V146, P611, DOI 10.1007/s00701-003-0209-9; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Davis KL, 1998, J NEUROTRAUM, V15, P615, DOI 10.1089/neu.1998.15.615; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gluck MA, 1997, ANNU REV PSYCHOL, V48, P481, DOI 10.1146/annurev.psych.48.1.481; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heiland S, 1999, ROFO-FORTSCHR RONTG, V171, P3, DOI 10.1055/s-1999-9889; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hoiland S, 1997, JMRI-J MAGN RESON IM, V7, P1109, DOI 10.1002/jmri.1880070625; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Janus C, 2004, LEARN MEMORY, V11, P337, DOI 10.1101/lm.70104; Jarrard LE, 1995, BEHAV BRAIN RES, V71, P1, DOI 10.1016/0166-4328(95)00034-8; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; KRAUS JF, 1989, MILD HEAD INJURY, P8; Lado WE, 2003, PERCEPT MOTOR SKILL, V97, P1115, DOI 10.2466/PMS.97.7.1115-1127; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lukoyanov NV, 2000, ALCOHOL, V20, P139, DOI 10.1016/S0741-8329(99)00069-5; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Lythgoe MF, 2003, BRIT MED BULL, V65, P235, DOI 10.1093/bmb/65.1.235; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sanders MJ, 1999, J NEUROTRAUM, V16, P915, DOI 10.1089/neu.1999.16.915; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sicard K, 2003, J CEREBR BLOOD F MET, V23, P472, DOI 10.1097/01.WCB.0000054755.93668.20; Sicard KM, 2005, NEUROIMAGE, V25, P850, DOI 10.1016/j.neuroimage.2004.12.010; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tang SL, 1997, J CHART INST WATER E, V11, P14; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; TREIT D, 1988, PHARMACOL BIOCHEM BE, V31, P959, DOI 10.1016/0091-3057(88)90413-3; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	70	33	33	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2005	195	2					447	457		10.1016/j.expneurol.2005.06.013			11	Neurosciences	Neurosciences & Neurology	968VI	WOS:000232190600019	16084512				2021-06-18	
J	Holsti, M; Kadish, HA; Sill, BL; Firth, SD; Nelson, DS				Holsti, M; Kadish, HA; Sill, BL; Firth, SD; Nelson, DS			Pediatric closed head injuries treated in an observation unit	PEDIATRIC EMERGENCY CARE			English	Article; Proceedings Paper	Research Forum of the American-College-of-Emergency-Physicians	OCT 12-13, 2003	Boston, MA	Amer Coll Emergency Physicians		observation unit; closed head injuries		Background: Closed head injury (CHI) is common in childhood and frequently results in hospital admission for observation and treatment. Observation units (OUs) have shown significant benefits for patients and physicians. At our institution, a level 1 pediatric trauma center, patients with CHI are often admitted to an OU for up to 24 hours of observation and treatment. Study Objectives: To describe characteristics of patients with a CHI admitted to a pediatric OU and to identify demographic, historical, clinical, and radiographic factors associated with the need for unplanned inpatient admission (UIA) after OU management. Methods: Retrospective cohort review of all OU admissions for CHI at Primary Children's Medical Center (PCMC) from August 1999 through July 2001. Data collected included age, gender, mechanism of injury, presenting symptoms, physical examination findings, head computed tomography (CT) results, diagnosis, length of stay, outcome of the injury, and need for UIA. Results: During the study period, 827 patients were seen in the ED for CHI. Two hundred eighty-five patients (34%) were admitted to the OU, 273 (33%) were admitted to an inpatient service, and 269 (33%) were discharged home. OU patients had a median age of 5.2 years, ranging from 2 weeks to 17 years. Sixty-one percent were male. The median admission length of stay was 13 hours. Common mechanisms of injury included: falls (60%), motor vehicle accidents (12%), bicycle accidents (10%), impacts from objects (9%), autopedestrian accidents (4.6%), and snow-related accidents (4.6%). Presenting symptoms in the ED included vomiting (39%), loss of consciousness (26%), amnesia to event (19%), persistent amnesia (5%), and seizures (4%). Physical examination findings noted in the ED included altered mental status (45%), facial abnormalities (43%), scalp abnormalities (38%), and neurologic deficits (9%). Two hundred eighty patients (98%) admitted to the OU had a head CT performed. Skull fractures were present in 109 patients (39%) and intracranial pathology (ie, epidural hematoma, subdural hematoma, or intraparenchymal contusion) was present in 38 patients (13%). Only 13 patients (5%) required admission to an inpatient service from the OU for the following reasons: continued need for intravenous (IV) fluids (n = 5), venous thrombosis (n = 2), persistent CSF leakage (n = 3), decreased level of consciousness (n = 1), pain management (n = 1), and clearing of the patient's cervical spine (n = 1). No patient deteriorated or required neurosurgery. Patients with basilar skull fractures, a head laceration (scalp or facial), and patients that needed IV fluids in the ED were more likely to need inpatient admission after a 24-hour observation stay. Logistic regression analysis identified basilar skull fractures (OR 11.61), face/scalp lacerations (OR 7.52), and the need for ED IV fluid administration (OR 4.26) to be associated with UIA. Most children with these findings were successfully discharged within 24 hours, however. Age, sex, loss of consciousness, seizure, vomiting, arnnesia, altered mental status, neurologic deficits, intracranial pathology, and skull fractures (aside from basilar skull fractures) were not related to UIA. Conclusion: The vast majority (96%) of pediatric OU patients with CHI such as small intracranial hematomas, skull fractures, and concussions were discharged safely within 24 hours without serious comp 1 i cations. The presence of a basilar skull fracture, head laceration, and the need for ED IV fluids were associated with increased risk ofUIA. OU admission is an efficient and effective management setting for children with stable intracranial pathology, skull fractures, and concussions.	Univ Utah, Sch Med, Div Pediat Emergency Med, Dept Pediat,Primary Childrens Med Ctr, Salt Lake City, UT 84158 USA; Univ Utah, Primary Childrens Med Ctr, Dept Pediat, Salt Lake City, UT 84158 USA	Holsti, M (corresponding author), Univ Utah, Sch Med, Div Pediat Emergency Med, Dept Pediat,Primary Childrens Med Ctr, POB 581289, Salt Lake City, UT 84158 USA.	maija.holsti@hsc.utah.edu					DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; OCHOAGOMEZ J, 2000, EUR J EMERG MED, V7, P257; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Scribano PV, 2001, PEDIATR EMERG CARE, V17, P321, DOI 10.1097/00006565-200110000-00001	5	33	36	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	OCT	2005	21	10					639	644		10.1097/01.pec.0000181426.25342.a9			6	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	975MY	WOS:000232667800001	16215464				2021-06-18	
J	Koob, AO; Duerstock, BS; Babbs, CF; Sun, YL; Borgens, RB				Koob, AO; Duerstock, BS; Babbs, CF; Sun, YL; Borgens, RB			Intravenous polyethylene glycol inhibits the loss of cerebral cells after brain injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; degeneration; ethidium bromide; neuroprotection; polyethylene glycol (PEG)	SPINAL-CORD-INJURY; AXONAL INJURY; NEURONAL APOPTOSIS; MOLECULAR REPAIR; NERVE MEMBRANES; MODEL; RAT; RECOVERY; FUSION; RECONNECTION	We have tested the effectiveness of polyethylene glycol (PEG) to restore the integrity of neuronal membranes after mechanical damage secondary to severe traumatic brain injury (TBI) produced by a standardized head injury model in rats. We provide additional detail on the standardization of this model, particularly the use and storage of foam bedding that serves to both support the animal during the impact procedure-and as a dampener to the acceleration of the brass weight. Further, we employed a dye exclusion technique using ethidium bromide (EB; quantitative evaluation) and horseradish peroxidase (HRP; qualitative evaluation). Both have been successfully used previously to evaluate neural injury in the spinal cord since they enter cells when their plasma membranes are damaged. We quantified EB labeling (90 mu M in 110 mu L of sterile saline) after injection into the left lateral ventricle of the rat brain 2 h after injury. At six h after injection and 8 h after injury, the animals were sacrificed and the brains were analyzed. In the injured rat brain, EB entered cells lining and medial to the ventricles, particularly the axons of the corpus callosum. There was minimal EB labeling in uninjured control brains, limited to cells lining the luminal surfaces of the ventricles. Intravenous injections of PEG (1 cc of saline, 30% by volume, 2000 MW) immediately after severe TBI resulted in significantly decreased EB uptake compared with injured control animals. A similar result was achieved using the larger marker, HRP. PEG-treated brains closely resembled those of uninjured animals.	Purdue Univ, Ctr Paralysis Res, Dept Biol Sci, Neurosci Program, W Lafayette, IN 47907 USA; Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Comp Sci, W Lafayette, IN 47907 USA; Purdue Univ, Coll Engn, Dept Biomed Engn, W Lafayette, IN 47907 USA	Borgens, RB (corresponding author), Purdue Univ, Ctr Paralysis Res, Dept Biol Sci, Neurosci Program, 408 S Univ St, W Lafayette, IN 47907 USA.	cpr@purdue.edu					AESCHBACHER M, 1986, CELL BIOL TOXICOL, V2, P247, DOI 10.1007/BF00122693; AHKONG QF, 1987, J CELL SCI, V88, P389; Bajaj CL, 1997, VISUALIZATION '97 - PROCEEDINGS, P167, DOI 10.1109/VISUAL.1997.663875; BITTNER GD, 1986, BRAIN RES, V367, P351, DOI 10.1016/0006-8993(86)91617-3; Borgens R B, 1988, Adv Neurol, V47, P51; Borgens RB, 2000, FASEB J, V14, P27; BORGENS RB, 1986, J COMP NEUROL, V250, P157, DOI 10.1002/cne.902500203; Borgens RB, 2002, J EXP BIOL, V205, P1; Borgens RB, 2001, NEUROSURGERY, V49, P370, DOI 10.1097/00006123-200108000-00021; Borgens RB, 2001, J NEUROSCI RES, V66, P1179; BORGENS RB, 2003, ADV ANAT EMBRYOLOGY, P1; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DEY CS, 1988, BIOCHEM INT, V17, P367; Donaldson J, 2002, NEUROSURGERY, V50, P147, DOI 10.1097/00006123-200201000-00023; Duerstock BS, 2000, COMPUT MED IMAG GRAP, V24, P389, DOI 10.1016/S0895-6111(00)00034-3; Duerstock BS, 2003, J MICROSC-OXFORD, V210, P138, DOI 10.1046/j.1365-2818.2003.01130.x; Feng YZ, 2003, EUR J PHARMACOL, V481, P169, DOI 10.1016/j.ejphar.2003.09.016; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Koenig E, 1999, NEUROSCIENCE, V89, P5, DOI 10.1016/S0306-4522(98)00282-6; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KRAUSE TL, 1991, BRAIN RES, V561, P350, DOI 10.1016/0006-8993(91)91615-8; KRAUSE TL, 1990, P NATL ACAD SCI USA, V87, P1471, DOI 10.1073/pnas.87.4.1471; Laverty PH, 2004, J NEUROTRAUM, V21, P1767, DOI 10.1089/neu.2004.21.1767; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Luo J, 2004, J NEUROTRAUM, V21, P994, DOI 10.1089/0897715041651097; Luo J, 2002, J NEUROCHEM, V83, P471, DOI 10.1046/j.1471-4159.2002.01160.x; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Movsesyan VA, 2001, EXP NEUROL, V167, P366, DOI 10.1006/exnr.2000.7567; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; Piper M, 2004, ANNU REV CELL DEV BI, V20, P505, DOI 10.1146/annurev.cellbio.20.010403.111746; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Roy M, 1999, TRENDS NEUROSCI, V22, P419, DOI 10.1016/S0166-2236(99)01435-6; SHAPIRA Y, 1989, Neurological Research, V11, P169; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; SUNKYUNG L, 1995, J CELL SCI, V116, P4467; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Versace J, 1971, REV SEVERITY INDEX; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Working PK, 1997, ACS SYM SER, V680, P45; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	55	33	33	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1092	1111		10.1089/neu.2005.22.1092			20	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600006	16238486				2021-06-18	
J	Motin, M; Keren, O; Groswasser, Z; Gordon, CR				Motin, M; Keren, O; Groswasser, Z; Gordon, CR			Benign paroxysmal positional vertigo as the cause of dizziness in patients after severe traumatic brain injury: diagnosis and treatment	BRAIN INJURY			English	Article; Proceedings Paper	2nd World Congress of the International-Society-of-Physical-and-Rehabilitation-Medicine (ISPRM)	MAY 18-23, 2003	Prague, CZECH REPUBLIC	Int Soc Phys & Rehabilitat Med		traumatic brain injury; rehabilitation; benign paroxysmal positional vertigo; particle repositioning maneouvre	FEATURES	Objectives: To identify patients with benign paroxysmal positional vertigo (BPPV) among patients with severe traumatic brain injury (TBI) and to evaluate the effectiveness of the Particle Repositioning Maneouvre (PRM). Design and methods: Eighteen months prospective study of 150 consecutive patients with severe TBI referred to an in-patients rehabilitation department. Interventions: A structured interview emphasizing the possible presence of vertigo followed by a detailed neuro-otological examination. Patients diagnosed with BPPV were immediately treated with the PRM. Main outcomes and results: BPPV diagnosis was based on a positive Dix-Hallpike positional test. PRM efficacy was determined by repeating the positional test 1 or 2 weeks after treatment. Twenty out of 150 (13.3%) patients complained about positional vertigo. The diagnosis of BPPV was confirmed in 10 patients. Signs and symptoms were completely relieved in six patients after a single PRM, while the other four patients needed repeated treatment for complete resolution of BPPV. Conclusions: About half of the patients with severe TBI who complain about positional vertigo suffer from BPPV. These patients can be efficiently treated by physical maneouvres improving the rehabilitation outcome.	Meir Hosp, Dept Neurol, IL-44281 Kefar Sava, Israel; Loewenstein Rahabil Hosp, Raanana, Israel; Tel Aviv Univ, Tel Aviv, Israel	Gordon, CR (corresponding author), Meir Hosp, Dept Neurol, IL-44281 Kefar Sava, Israel.	cgordon@post.tau.ac.il		Gordon, Carlos/0000-0003-1576-214X			BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Baloh RW, 1998, LANCET, V352, P1841, DOI 10.1016/S0140-6736(98)05430-0; BRANDT T, 1994, NEUROLOGY, V44, P796, DOI 10.1212/WNL.44.5.796; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Furman JM, 1999, NEW ENGL J MED, V341, P1590, DOI 10.1056/NEJM199911183412107; Gordon Carlos R, 2002, Harefuah, V141, P944; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; GYO K, 1988, LARYNGOSCOPE, V98, P332; HERDMAN SJ, 1993, ARCH OTOLARYNGOL, V119, P450; Honrubia V, 1999, AM J OTOL, V20, P465; Hughes CA, 1997, LARYNGOSCOPE, V107, P607, DOI 10.1097/00005537-199705000-00010; KATSARKAS A, 1978, J OTOLARYNGOL, V7, P320; Katsarkas A, 1999, ACTA OTO-LARYNGOL, V119, P745, DOI 10.1080/00016489950180360; LEMPERT T, 1995, BRIT MED J, V311, P489, DOI 10.1136/bmj.311.7003.489; Longridge N., 1978, CANADIAN J OTOLOGY, V7; Nuti D, 1996, J VESTIBUL RES-EQUIL, V6, P173; PARNES LS, 1993, ANN OTO RHINOL LARYN, V102, P325, DOI 10.1177/000348949310200501; Semont A, 1988, Adv Otorhinolaryngol, V42, P290; ZEE DS, 1996, DISORDERS VESTIBULAR, P178	22	33	37	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2005	19	9					693	697		10.1080/02699050400013600			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	945EH	WOS:000230484600007	16195183				2021-06-18	
J	Kotchoubey, B				Kotchoubey, B			Apallic syndrome is not apallic: Is vegetative state vegetative?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Joint Conference of the International-Neuropsychological-Society/German-Society-for-Neuropsychology	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc, German Soc Neuropsychol			EVENT-RELATED POTENTIALS; CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN-INJURY; LOCKED-IN SYNDROME; MISMATCH NEGATIVITY; EVOKED-POTENTIALS; TEMPORAL-LOBE; GLUCOSE-METABOLISM; NOVELTY DETECTION; DEVIANT STIMULI	Initial conceptualisation about the nature of vegetative state (VS) assumed at least temporary loss of the entire cortical functioning. Since a broad range of stimulus-related cortical activations was demonstrated in VS patients, this simplified idea is not tenable any longer, but no alternative concept emerges instead. Two recent hypotheses, empirically testable and well grounded, could fill this vacuum: (1) In VS, isolated cortical areas may work, but their integration into a distributed network is lacking. (2) In VS, complex stimulus processing is limited to primary sensory and motor areas; the co-ordination between them and the secondary and tertiary areas is lacking. To test these hypotheses, we estimated the frequency of occurrence of late event-related potential components P3 and N400, presumably indicating activity of complex distributed networks including high-level sensory and associative areas. Both components occurred in VS with above-chance frequencies, but less frequently than in two control groups. Besides these frequent normal brain activations, some VS patients exhibit highly significant but abnormal activations, whose functional meaning remains unclear. A methodological analysis leads to the conclusion that any neurophysiological assessment of VS patients is biased toward under-, rather than over-estimation, of their remaining information processing abilities.	Univ Tubingen, Inst Med Psychol & Behav Neurobiol, D-72074 Tubingen, Germany	Kotchoubey, B (corresponding author), Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Gartenstr 29, D-72074 Tubingen, Germany.	boris.kotchoubey@uni-tuebingen.de					Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; AGARDH CD, 1983, ANN NEUROL, V14, P482, DOI 10.1002/ana.410140414; Agresti A., 1992, STAT SCI, V7, P131, DOI [10.1214/ss/1177011454, DOI 10.1214/SS/1177011454]; Alkire MT, 2004, ANESTHESIOLOGY, V100, P939, DOI 10.1097/00000542-200404000-00026; Anderer P, 1998, NEUROPSYCHOBIOLOGY, V37, P20, DOI 10.1159/000026472; ARCENI S, 1981, ACTA NEUROCHIRURGIAE, V59, P45; Atienza M, 2001, CLIN NEUROPHYSIOL, V112, P2031, DOI 10.1016/S1388-2457(01)00650-2; BENTIN S, 1993, PSYCHOPHYSIOLOGY, V30, P161, DOI 10.1111/j.1469-8986.1993.tb01729.x; Bingel U, 2003, NEUROIMAGE, V18, P740, DOI 10.1016/S1053-8119(02)00033-2; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Bostanov V, 2004, IEEE T BIO-MED ENG, V51, P1057, DOI 10.1109/TBME.2004.826702; Bostanov V, 2004, PSYCHOPHYSIOLOGY, V41, P259, DOI 10.1111/j.1469-8986.2003.00142.x; Casey K L, 2000, Prog Brain Res, V129, P277; Coghill RC, 2003, P NATL ACAD SCI USA, V100, P8538, DOI 10.1073/pnas.1430684100; COLES MGH, 1990, TUTORIALS PSYCHOPHYS, P413; deJong BM, 1997, CLIN NEUROL NEUROSUR, V99, P213, DOI 10.1016/S0303-8467(97)00024-3; DEVOLDER AG, 1990, ARCH NEUROL-CHICAGO, V47, P197, DOI 10.1001/archneur.1990.00530020103022; DOUGHERTY JH, 1981, NEUROLOGY, V31, P991, DOI 10.1212/WNL.31.8.991; FALK RH, 1990, POSTGRAD MED J, V66, P384, DOI 10.1136/pgmj.66.775.384; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; Garcia-Larrea L, 2003, NEUROPHYSIOL CLIN, V33, P279, DOI 10.1016/j.neucli.2003.10.008; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; Guerit JM, 1999, CLIN NEUROPHYSIOL, V110, P1260, DOI 10.1016/S1388-2457(99)00061-9; Halgren E, 2002, NEUROIMAGE, V17, P1101, DOI 10.1006/nimg.2002.1268; HALGREN E, 1995, ELECTROEN CLIN NEURO, V94, P229, DOI 10.1016/0013-4694(95)98475-N; Heindl UT, 1996, NEUROPEDIATRICS, V27, P94, DOI 10.1055/s-2007-973756; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; JENNETT B, 2002, VEGETATIVE STATE; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; KANEKO S, 2000, KINO ZAIRYO, V3, P5; Kiehl KA, 2002, NEUROIMAGE, V17, P842, DOI 10.1006/nimg.2002.1244; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Klein M, 1997, Eur J Pain, V1, P165, DOI 10.1016/S1090-3801(97)90075-6; Knight RT, 1998, J CLIN NEUROPHYSIOL, V15, P3, DOI 10.1097/00004691-199801000-00003; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; Kotchoubey B, 2003, J NEUROL, V250, P1121, DOI 10.1007/s00415-003-0132-2; Kotchoubey B, 2002, NEWS PHYSIOL SCI, V17, P38; Kotchoubey B, 2003, NEUROPHYSIOL CLIN, V33, P23, DOI 10.1016/S0987-7053(03)00003-0; Kotchoubey B, 2001, NEUROSCI LETT, V301, P37, DOI 10.1016/S0304-3940(01)01600-7; Kretschmer E, 1940, Z GESAMTE NEUROL PSY, V169, P576, DOI 10.1007/BF02871384; Kuperberg GR, 2003, J COGNITIVE NEUROSCI, V15, P272, DOI 10.1162/089892903321208204; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; Kutas M, 1997, PSYCHOPHYSIOLOGY, V34, P383, DOI 10.1111/j.1469-8986.1997.tb02382.x; Lakatos I., 1976, PROOFS REFUTATIONS; Laureys S, 2002, ACTA NEUROL BELG, V102, P176; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; LEVY DE, 1987, ANN NEUROL, V22, P673, DOI 10.1002/ana.410220602; Llinas R, 1998, PHILOS T ROY SOC B, V353, P1841, DOI 10.1098/rstb.1998.0336; Loewy DH, 2000, CLIN NEUROPHYSIOL, V111, P863, DOI 10.1016/S1388-2457(00)00256-X; Lotze M, 2001, BRAIN, V124, P2268, DOI 10.1093/brain/124.11.2268; Makela AM, 2001, NEUROREPORT, V12, P249; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MCCARTHY G, 1995, J NEUROSCI, V15, P1080; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; MOLNAR M, 1994, INT J PSYCHOPHYSIOL, V17, P129, DOI 10.1016/0167-8760(94)90028-0; Mutschler V, 1996, NEUROPHYSIOL CLIN, V26, P158, DOI 10.1016/0987-7053(96)89626-2; Naatanen R, 2000, INT J PSYCHOPHYSIOL, V37, P3, DOI 10.1016/S0167-8760(00)00091-X; Neumann N, 2004, BRAIN RES PROTOC, V14, P25, DOI 10.1016/j.brainresprot.2004.09.001; Niddam DM, 2002, NEUROIMAGE, V17, P1437, DOI 10.1006/nimg.2002.1270; Onofrj M, 1997, J NEUROL NEUROSUR PS, V63, P759, DOI 10.1136/jnnp.63.6.759; Onofrj M, 1996, COGNITIVE BRAIN RES, V4, P95; ORE GD, 1987, APALLIC SYNDROME; Owen AM, 2002, NEUROCASE, V8, P394, DOI 10.1076/neur.8.4.394.16184; Perrin F, 2002, NEUROREPORT, V13, P1345, DOI 10.1097/00001756-200207190-00026; Perrin F, 2000, NEUROREPORT, V11, P1637, DOI 10.1097/00001756-200006050-00008; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Peyron R, 2002, NEUROIMAGE, V17, P1336, DOI 10.1006/nimg.2002.1315; Picton T.W., 1988, HUMAN EVENT RELATED, VVolume 1, P361; PLATT JR, 1964, SCIENCE, V146, P347, DOI 10.1126/science.146.3642.347; Plum F, 1998, PHILOS T ROY SOC B, V353, P1929, DOI 10.1098/rstb.1998.0345; POLICH J, 1993, ELECTROEN CLIN NEURO, V86, P408, DOI 10.1016/0013-4694(93)90136-J; POLICH J, 1991, American Journal of EEG Technology, V31, P201; Polich J, 2003, BRAIN TOPOGR, V15, P141, DOI 10.1023/A:1022637732495; Popper K., 1963, CONJECTURES REFUTATI; Portas CM, 2000, NEURON, V28, P991, DOI 10.1016/S0896-6273(00)00169-0; PRITCHARD WS, 1981, PSYCHOL BULL, V89, P506, DOI 10.1037/0033-2909.89.3.506; PUCE A, 1991, EPILEPSIA, V32, P629, DOI 10.1111/j.1528-1157.1991.tb04701.x; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; Rossell SL, 2003, NEUROPSYCHOLOGIA, V41, P550, DOI 10.1016/S0028-3932(02)00181-1; Rudolf J, 1999, J NEUROSURG ANESTH, V11, P17, DOI 10.1097/00008506-199901000-00004; Rudolf J, 2000, FORTSCHR NEUROL PSYC, V68, P344, DOI 10.1055/s-2000-11800; SALISBURY D, 1993, J SLEEP RES, V2, P232, DOI 10.1111/j.1365-2869.1993.tb00094.x; Sallinen M, 1997, ELECTROEN CLIN NEURO, V102, P363, DOI 10.1016/S0013-4694(96)96614-6; SAZBON L, 1990, J NEUROL NEUROSUR PS, V56, P407; SCHEFFERS MK, 1991, PSYCHOPHYSIOLOGY, V28, P274, DOI 10.1111/j.1469-8986.1991.tb02194.x; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Shah MK, 2004, BRAIN INJURY, V18, P111, DOI 10.1080/0269905031000149551; Signorino M, 1997, J PSYCHOPHYSIOL, V11, P59; Spencer KM, 2001, PSYCHOPHYSIOLOGY, V38, P343, DOI 10.1111/1469-8986.3820343; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P409, DOI 10.1017/S0048577299981180; Steriade M, 2000, NEUROSCIENCE, V101, P243, DOI 10.1016/S0306-4522(00)00353-5; Tarkka IM, 1998, BRAIN TOPOGR, V11, P141, DOI 10.1023/A:1022258606418; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Tononi G, 2000, BRAIN RES REV, V31, P391, DOI 10.1016/S0165-0173(99)00056-9; VANPETTEN C, 1995, PSYCHOPHYSIOLOGY, V32, P511; VERLEGER R, 1994, PSYCHOPHYSIOLOGY, V31, P359, DOI 10.1111/j.1469-8986.1994.tb02444.x; Walter GF, 1999, CRIT REV NEUROSURG, V9, P367, DOI 10.1007/s003290050157; WINTER O, 1995, EVOKED POTENTIAL, V96, P398, DOI 10.1016/0168-5597(95)00030-V; WITZKE W, 1996, NEUROL REHAB, V2, P68; YAMAGUCHI S, 1991, J NEUROSCI, V11, P2039; Ypparila H, 2002, CLIN NEUROPHYSIOL, V113, P1357, DOI 10.1016/S1388-2457(02)00158-X; Zhang WT, 2003, BRAIN RES, V982, P168, DOI 10.1016/S0006-8993(03)02983-4	111	33	34	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					333	356		10.1080/09602010443000416			24	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900020	16350976				2021-06-18	
J	Larner, SF; McKinsey, DM; Hayes, RL; Wang, KKW				Larner, SF; McKinsey, DM; Hayes, RL; Wang, KKW			Caspase 7: increased expression and activation after traumatic brain injury in rats	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; caspase; caspase 7; cell death; traumatic brain injury	ENDOPLASMIC-RETICULUM STRESS; CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; NERVOUS-SYSTEM; NEURONAL DEATH; SPECTRIN BREAKDOWN; PROTEASE FAMILIES; CONVERTING-ENZYME; ALPHA-SPECTRIN; PC12 CELLS	Caspases, a cysteine proteinase family, are required for the initiation and execution phases of apoptosis. It has been suggested that caspase 7, an apoptosis executioner implicated in cell death proteolysis, is redundant to the main executioner caspase 3 and it is generally believed that it is not present in the brain or present in only minute amounts with highly restricted activity. Here we report evidence that caspase 7 is up-regulated and activated after traumatic brain injury (TBI) in rats. TBI disrupts homeostasis resulting in pathological apoptotic activation. After controlled cortical impact TBI of adult male rats we observed, by semiquantitative real-time PCR, increased mRNA levels within the traumatized cortex and hippocampus peaking in the former about 5 days post-injury and in the latter within 6-24 h of trauma. The activation of caspase 7 protein after TBI, demonstrated by immunoblot by the increase of the active form of caspase 7 peaking 5 days post-injury in the cortex and hippocampus, was found to be up-regulated in both neurons and astrocytes by immunohistochemistry. These findings, the first to document the up-regulation of caspase 7 in the brain after acute brain injury in rats, suggest that caspase 7 activation could contribute to neuronal cell death on a scale not previously recognized.	Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, McKnight Brain Inst, Gainesville, FL 32610 USA; Univ Florida, Dept Psychiat, Ctr Neuroproteom & Biomarkers Res, McKnight Brain Inst, Gainesville, FL 32610 USA	Larner, SF (corresponding author), Univ Florida, Dept Neurosci, Ctr Traumat Brain Injury Studies, McKnight Brain Inst, 100 S Newell Dr,Box 100244, Gainesville, FL 32610 USA.	sflarner@ufl.edu		Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039091, R01NS040182] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS39091, R01-NS40182] Funding Source: Medline		Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Ethell DW, 2001, BBA-MOL CELL RES, V1541, P231, DOI 10.1016/S0167-4889(01)00159-8; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379; Harrison DC, 2001, MOL BRAIN RES, V89, P133, DOI 10.1016/S0169-328X(01)00058-4; Haviv R, 1998, J NEUROSCI RES, V52, P491, DOI 10.1002/(SICI)1097-4547(19980601)52:5<491::AID-JNR1>3.0.CO;2-7; Henshall DC, 2002, NEUROBIOL DIS, V10, P71, DOI 10.1006/nbdi.2002.0505; HOLLENBECK PJ, 1989, J CELL BIOL, V108, P2335, DOI 10.1083/jcb.108.6.2335; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Juan TSC, 1997, GENOMICS, V40, P86, DOI 10.1006/geno.1996.4548; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Korfali N, 2004, J BIOL CHEM, V279, P1030, DOI 10.1074/jbc.M306277200; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; Machleidt T, 1998, FEBS LETT, V436, P51, DOI 10.1016/S0014-5793(98)01095-3; Meller R, 2002, NEUROSCI LETT, V324, P33, DOI 10.1016/S0304-3940(02)00166-0; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Nicolini G, 2001, NEUROSCI LETT, V302, P41, DOI 10.1016/S0304-3940(01)01654-8; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.neuro.14.1.453; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pompl PN, 2003, ARCH NEUROL-CHICAGO, V60, P369, DOI 10.1001/archneur.60.3.369; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; RAY N, 2002, APOPTOSIS MOL BIOL P, P117; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Repici M, 2003, NEUROSCIENCE, V117, P859, DOI 10.1016/S0306-4522(02)00968-5; Riedl SJ, 2001, P NATL ACAD SCI USA, V98, P14790, DOI 10.1073/pnas.221580098; RINK A, 1995, AM J PATHOL, V147, P1575; Rozen S, 1998, PRIMER3; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Slee EA, 2001, J BIOL CHEM, V276, P7320, DOI 10.1074/jbc.M008363200; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Soung YH, 2003, ONCOGENE, V22, P8048, DOI 10.1038/sj.onc.1206727; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wei YY, 2000, CHEM BIOL, V7, P423, DOI 10.1016/S1074-5521(00)00123-X; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang Y, 2000, J NEUROSCI, V20, P8384, DOI 10.1523/JNEUROSCI.20-22-08384.2000	56	33	33	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUL	2005	94	1					97	108		10.1111/j.1471-4159.2005.03172.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	934JO	WOS:000229705300010	15953353	Bronze			2021-06-18	
J	Kane, RL; Short, P; Sipes, W; Flynn, CF				Kane, RL; Short, P; Sipes, W; Flynn, CF			Development and validation of the spaceflight cognitive assessment tool for windows (WinSCAT)	AVIATION SPACE AND ENVIRONMENTAL MEDICINE			English	Article; Proceedings Paper	Workshop on New Directions in Spaceflight Behavioral Health	DEC 02-03, 2003	Davis, CA			spaceflight; behavioral health; cognitive assessment; psychometrics	INDUCED ALLERGIC RHINITIS; BRAIN INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; MENTAL PERFORMANCE; DIPHENHYDRAMINE; CONCUSSION; VIGILANCE; TESTS	The Spaceflight Cognitive Assessment Tool for Windows (WinSCAT) was developed by an integrated product team as a tool to support medical operations at NASA Johnson Space Center and as way to monitor the neurocognitive status of space crews. It is based on 20 yr of experience in performance and cognitive testing within the U.S. Department of Defense. As a result, WinSCAT development has benefited from diverse efforts supporting its technical reliability and validation. The rationale, background, and development of WinSCAT are described, research supporting its use is summarized, and recommendations are made for its continued development.	Univ Maryland, Sch Med, VA Med Ctr, Baltimore, MD 21201 USA; Baltimore Educ & Res Fdn, Baltimore, MD USA; Wyle Labs, Houston, TX USA; NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA	Kane, RL (corresponding author), Univ Maryland, Sch Med, VA Med Ctr, 10 N Greene St, Baltimore, MD 21201 USA.	robert.kane@med.va.gov					Anger WK, 1996, NEUROTOXICOL TERATOL, V18, P347, DOI 10.1016/0892-0362(96)00079-7; BANDERET LE, 2002, MID S AM PSYCH ASS A; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg J, 2003, ARCH CLIN NEUROPSYCH, V18, P740; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; Eddy DR, 1998, ACTA ASTRONAUT, V43, P193, DOI 10.1016/S0094-5765(98)00154-4; Farmer K, 2000, HEADACHE, V40, P657, DOI 10.1046/j.1526-4610.2000.040008657.x; FRENCH J, 1999, SENSITIVITY SCAT SLE; GAMACHE G, 1998, NCRFTR9801; Holliday SL, 2003, LUPUS, V12, P697, DOI 10.1191/0961203303lu442oa; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; Kane R., 1997, NEUROPSYCHOLOGY HDB; KANE RL, 1992, NEUROPSYCHOL REV, V3, P1, DOI 10.1007/BF01108787; KANE RL, 1997, CONT APPROACHES NEUR; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; LAW WA, 2003, J INT NEUROPSYCH SOC, V9, P248; Levinson DM, 1997, ARCH CLIN NEUROPSYCH, V12, P155, DOI 10.1016/S0887-6177(96)00026-1; LOWE M, 1920, IN PRESS ACCELERATED; LOWE M, 1998, 1301 NEDU TR; LOWE M, 2000, UNDERSEA HYPERBAR M, V27, P15; LOWE M, 1999, UNDERSEA HYPERB ME S, V26, P17; Manzey D, 1998, ERGONOMICS, V41, P537, DOI 10.1080/001401398186991; Manzey D, 2000, AVIAT SPACE ENVIR MD, V71, pA69; RETZLAFF P, 1999, MS80665 NASA LB JOHN; RIKKEN G, 2000, ANN M EUR AC ALL CLI; ROEBUCKSPENCER T, 2004, ANN M AM PSYCH ASS 2; SARABIA S, 2004, ANN M AM COLL CLIN P; STARBUCK VN, 1995, NEUROPSY NEUROPSY BE, V8, P189; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; WARDEN DL, 2003, M AM AC NEUR 2003 AP, V60, pA302; Wilken JA, 2003, ANN ALLERG ASTHMA IM, V91, P375, DOI 10.1016/S1081-1206(10)61685-7; Wilken JA, 2003, MULT SCLER, V9, P119, DOI 10.1191/1352458503ms893oa; Wilken JA, 2002, ANN ALLERG ASTHMA IM, V89, P372, DOI 10.1016/S1081-1206(10)62038-8	34	33	35	0	10	AEROSPACE MEDICAL ASSOC	ALEXANDRIA	320 S HENRY ST, ALEXANDRIA, VA 22314-3579 USA	0095-6562			AVIAT SPACE ENVIR MD	Aviat. Space Environ. Med.	JUN	2005	76	6		S			B183	B191					9	Public, Environmental & Occupational Health; Medicine, General & Internal; Sport Sciences	Public, Environmental & Occupational Health; General & Internal Medicine; Sport Sciences	933GJ	WOS:000229616600024	15943211				2021-06-18	
J	Rocchi, G; Caroli, E; Belli, E; Salvati, M; Cimatti, M; Delfini, R				Rocchi, G; Caroli, E; Belli, E; Salvati, M; Cimatti, M; Delfini, R			Severe craniofacial fractures with frontobasal involvement and cerebrospinal fluid fistula: indications for surgical repair	SURGICAL NEUROLOGY			English	Article						cerebrospinal fluid fistula; fracture; head injury; management; meningitis; rhinorrhea; surgical repair	CT CISTERNOGRAPHY; RHINORRHEA; LOCALIZATION; DIAGNOSIS; MANAGEMENT; COMPLICATIONS; TOMOGRAPHY; SELECTION; LEAKAGE	Background: The management of posttraumatic cerebrospinal fluid (CSF) fistulae is a controversial topic. Although recent literature shows that endoscopic repair of CSF fistula is efficacious and minimally invasive, in specific conditions open operative approach remains imperative. Methods: A series of 36 patients underwent surgery for posttraumatic CSF fistula according to specific selection criteria. These criteria included: bone displacement more than I cm (5 cases), location of fracture in proximity to the midline (6 cases), involvement of cribriform plate (12 cases), presence of encephalocele (3 cases), and failure of the conservative treatment (10 cases). The dural defect was closed using vascularized pericranium and fibrin glue. Closure of the basal bone defect was necessary in very large fractures or in special localization of the fistula, such as near the optic nerve. Mean clinical follow-up was 5.7 years. Results: Two patients presented meningitis without sequelae, and 12 with hyposmia. One patient died of the severity of the primary brain injury and associated extracranial lesions. None of the patients had recurrence. Conclusions: Our results indicate that surgical dural repair in selected cases is related to low morbidity and mortality preserving from delayed risks such as recurrence and infections. (c) 2005 Elsevier Inc. All rights reserved.	Univ Roma La Sapienza, Dept Neurol Sci, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Neurosurg, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Maxillofacial Surg, I-00185 Rome, Italy; IRCCS, Dept Neurosurg, INM Neuromed, Pozzilli, Italy	Caroli, E (corresponding author), Via Meropia 85, I-00147 Rome, Italy.	manucarol2000@yahoo.it					AARABI B, 1992, Ear Nose and Throat Journal, V71, P300; AHMADI J, 1985, NEUROSURGERY, V16, P54, DOI 10.1227/00006123-198501000-00011; ALLEN MB, 1972, J NEUROL NEUROSUR PS, V35, P664, DOI 10.1136/jnnp.35.5.664; ALMEFTY O, 1993, SURG CRANIAL BASE TU; BRUTON E, 1990, AM J NEURORADIOL, V11, P205; Cairns H., 1937, J LARYNG, V52, P589, DOI 10.1017/S0022215100043991; CHRISTIE M, 1987, NEUROSURGERY, V20, P31, DOI 10.1227/00006123-198701000-00008; COMOY J, 1986, J NEURORADIOLOGY, V13, P248; Dandy WE, 1926, ARCH SURG-CHICAGO, V12, P949, DOI 10.1001/archsurg.1926.01130050003001; DRAYER BP, 1978, J NEUROSURG, V48, P946, DOI 10.3171/jns.1978.48.6.0946; DUCKERT LG, 1977, LARYNGOSCOPE, V87, P18; El Gammal T, 1998, AM J NEURORADIOL, V19, P627; ELJAMEL M S M, 1990, British Journal of Neurosurgery, V4, P479, DOI 10.3109/02688699008993796; ELJAMEL MS, 1995, J NEUROSURG, V83, P795, DOI 10.3171/jns.1995.83.5.0795; ELJAMEL MS, 1993, THESIS U LIVERPOOL L, P207; GHOSHHAJRA K, 1980, J COMPUT ASSIST TOMO, V4, P306, DOI 10.1097/00004728-198006000-00003; GRAF CJ, 1981, J NEUROSURG, V54, P392, DOI 10.3171/jns.1981.54.3.0392; Griffith H B, 1990, Br J Neurosurg, V4, P369, DOI 10.3109/02688699008992757; JEFFERSON A, 1972, BRIT J SURG, V59, P585, DOI 10.1002/bjs.1800590802; JENNETT B, 1981, MANAGEMENT HEAD INJU, P193; LANTZ EJ, 1980, AM J NEURORADIOL, V1, P391; LEECH PJ, 1973, LANCET, V1, P1013; LEVIN S, 1972, AM J MED SCI, V264, P319, DOI 10.1097/00000441-197210000-00010; LEWIN W, 1954, BRIT J SURG, V42, P1, DOI 10.1002/bjs.18004217102; Loew F, 1984, Adv Tech Stand Neurosurg, V11, P169; MANELFE C, 1982, AM J ROENTGENOL, V138, P471, DOI 10.2214/ajr.138.3.471; Minutoli F, 1999, EUR RADIOL, V9, P571; NAIDICH TP, 1980, J NEUROSURG, V53, P222, DOI 10.3171/jns.1980.53.2.0222; OKADA J, 1991, SURG NEUROL, V35, P213, DOI 10.1016/0090-3019(91)90073-I; OMMAYA AK, 1985, NEUROSURGERY, P1637; PARK JI, 1983, LARYNGOSCOPE, V93, P1294; Passagia JG, 1999, ADV TECH STAND NEUR, V25, P195; RAY BS, 1968, J NEUROSURG, V28, P180, DOI 10.3171/jns.1968.28.2.0180; Sakas DE, 1998, J NEUROSURG, V88, P471, DOI 10.3171/jns.1998.88.3.0471; SALAR G, 1978, NEURORADIOLOGY, V15, P185, DOI 10.1007/BF00329067; SAMII J, 1989, SURG SKULL BASE INTE, P12; Servadei F, 1998, ACTA NEUROCHIR, V140, P1183, DOI 10.1007/s007010050235; Shetty PG, 1998, AM J NEURORADIOL, V19, P633; TAKAHASHI T, 1988, J NEUROSURG, V68, P721, DOI 10.3171/jns.1988.68.5.0721; Talamonti G, 1995, ACTA NEUROCHIR, V137, P164, DOI 10.1007/BF02187189; Talamonti G, 1995, J Neurosurg Sci, V39, P191; WAKHLOO AK, 1991, ACTA NEUROCHIR, V111, P119, DOI 10.1007/BF01400499; YEATES AE, 1994, AM J NEURORADIOL, V5, P820	43	33	38	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	JUN	2005	63	6					559	564		10.1016/j.surneu.2004.07.047			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	938JU	WOS:000229996700013	15936387				2021-06-18	
J	Takeda, T; Ishigami, K; Hoshina, S; Ogawa, T; Handa, J; Nakajima, K; Shimada, A; Nakajima, T; Regner, CW				Takeda, T; Ishigami, K; Hoshina, S; Ogawa, T; Handa, J; Nakajima, K; Shimada, A; Nakajima, T; Regner, CW			Can mouthguards prevent mandibular bone fractures and concussions? A laboratory study with an artificial skull model	DENTAL TRAUMATOLOGY			English	Article						mouthguard; distortion; acceleration; concussions; mandibular bone fractures	AMERICAN FOOTBALL; MOUTH PROTECTORS; DENTAL INJURIES; ABSORPTION; BASKETBALL; PLAYERS; SPORTS; SHOCK	Some sports' accidents are responsible for inflicting traumatic brain injuries and mandibular bone fractures when impacts occur to the chin. It is often thought that mouthguards can prevent many of these injuries. However, such assertions may be insufficient without adequate research. It is therefore necessary to establish a systematic method of investigation to solve this problem. In the present laboratory study, tests were performed using pendulum impact equipment and an artificial skull model connected to strain gages and accelerometers to simulate and measure the surface distortions related to bone deformation or fractures and the acceleration of the head related to concussions. As impacts, direct blows to the mandibular undersurface were applied. As a result, wearing a mouthguard decreased (P < 0.01) the distortion to the mandibular bone and the acceleration of the head significantly compared with not wearing a mouthguard (54.7%: to the mandible - measured at a total of three different points, 18.5%: to the head measured at a total of three different points). Within the limits of this study, the following conclusions were drawn: The present measuring system in this study was able to evaluate the distortion to the mandibular and the acceleration of the head from the direct blow to the mandibular undersurface. Mouthguards can reduce distortion to the mandibular and the acceleration of the head from the same blow. So mouthguards might have the possibility to prevent mandibular bone fractures and concussions. However, further well-designed and exhaustive studies are vital to show that mouthguards reduce the incidence of concussions and mandibular bone fractures.	Tokyo Dent Coll, Dept Sports Dent, Mihama Ku, Chiba 2618502, Japan; Tokyo Natl Coll Technol, Tokyo, Japan	Takeda, T (corresponding author), Tokyo Dent Coll, Dept Sports Dent, Mihama Ku, 1-2-2 Masago, Chiba 2618502, Japan.	takedat@attglobal.net					*C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CHAPMAN PJ, 1985, AUST DENT J, V30, P364, DOI 10.1111/j.1834-7819.1985.tb02533.x; de Wet F A, 1981, J Dent Assoc S Afr, V36, P249; de Wet FA, 1999, J PROSTHET DENT, V82, P301, DOI 10.1016/S0022-3913(99)70084-3; DORNEY B, 1994, PHILLIP J, V9, P311; GARON MW, 1986, J AM DENT ASSOC, V112, P663, DOI 10.14219/jada.archive.1986.0063; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HICKEY JC, 1967, J AM DENT ASSOC, V74, P735, DOI 10.14219/jada.archive.1967.0145; ISHIKAWA G, 1982, DENT PATHOLOGY, P344; KAWAMATA T, 2002, J JAPN SOC CLIN SPOR, V19, P637; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; KUMAZAWA Y, 1992, KANAGAWA SHIGAKU, V26, P412; KURITA H, 1994, J JPN STOMATOL SOC, V43, P270; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; MARROW RM, 1986, DENT SCH Q U TEXAS, V2, P11; MASESTRELLODEMO.MG, 1989, J DENT CHILD, V1, P36; MCNUTT T, 1989, Pediatric Dentistry, V11, P209; MORROW RM, 1991, ATHLETIC TRAINING, V26, P344; Morton J G, 1979, N Z Dent J, V75, P151; PICCININNI P, 2001, BRIT J SPORT MED, V35, P375; POWERS J M, 1984, Journal of the American Dental Association, V109, P84; SANE J, 1988, AM J SPORT MED, V16, P647, DOI 10.1177/036354658801600616; Satoh T, 1990, J JPN SOC BIOMECHANI, V14, P68; STENGER JM, 1964, J AM DENT ASSOC, V69, P273, DOI 10.14219/jada.archive.1964.0290; SUEI Y, 1993, J JPN STOMATOL SOC, V42, P739; SUMIYOSHI S, 1996, NIHON KOUKUU GEKA GA, V42, P1192; Taguchi Y, 2002, J JAPN SOC CLIN SPOR, V19, P609; Takeda T, 2004, DENT TRAUMATOL, V20, P150, DOI 10.1111/j.1600-4469.2004.00247.x; Takeda T, 2004, DENT TRAUMATOL, V20, P29, DOI 10.1111/j.1600-4469.2004.00220.x; Takeda T, 2004, DENT TRAUMATOL, V20, P12, DOI 10.1111/j.1600-4469.2004.00210.x; TAKEDA T, 1995, J JPN SOC CLIN SPORT, V12, P569; TAKEDA T, 1996, J JPN SOC CLIN SPORT, V13, P1152; TANAKA N, 1992, J STOMATOL SOC JPN, V59, P571; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; Winters JE, 2001, J ATHL TRAINING, V36, P339; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Woodmansey K F, 1999, Gen Dent, V47, P64	38	33	35	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	JUN	2005	21	3					134	140		10.1111/j.1600-9657.2005.00320.x			7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	924FF	WOS:000228963600004	15876323				2021-06-18	
J	Ji, YC; Kim, YB; Park, SW; Hwang, SN; Min, BK; Hong, HJ; Kwon, JT; Suk, JS				Ji, YC; Kim, YB; Park, SW; Hwang, SN; Min, BK; Hong, HJ; Kwon, JT; Suk, JS			Neuroprotective effect of ginseng total saponins in experimental traumatic brain injury	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						brain injuries; panax; saponins; neuroprotective agents; hippocampus	CONTROLLED CORTICAL IMPACT; INDUCED APOPTOSIS; PANAX-GINSENG; RG1; GINSENOSIDES; NEURONS	In the present study, we investigated whether ginseng total saponins (GTSs) protect hippocampal neurons after experimental traumatic brain injury (TBI) in rats. A moderate-grade TBI was made with the aid of a controlled cortical impact (CCI) device set at a velocity of 3.0 m/sec, a deformation of 3.0 mm, and a compression time of 0.2 sec at the right parietal area for adult male Sprague-Dawley rats. Shamoperated rats that underwent craniectomy without impact served as controls. GTSs (100 and 200 mg/kg) or saline was injected intraperitoneally into the rats immediately post-injury. Twenty-four hours after the injury, the rats underwent neurological evaluation. Contusion volume and the number of hippocampal neurons were calculated with apoptosis evaluated by TUNEL staining. 24 hr post-injury, saline-injected rats showed a significant loss of neuronal cells in the CA2 region of the right hippocampus (53.4%, p < 0.05) and CA3 (34.6%, p < 0.05) compared with contralateral hippocampal region, a significant increase in contusion volume (34 +/- 8 mu L), and significant increase in neurologic deficits compared with the GTSs groups. Treating rats with GTSs seemed to protect the CCI-induced neuronal loss in the hippocampus, decrease cortical contusion volume, and improve neurological deficits.	Chung Ang Univ Hosp, Coll Med, Dept Neurosurg, Seoul 156755, South Korea	Kim, YB (corresponding author), Chung Ang Univ Hosp, Coll Med, Dept Neurosurg, 224-4 Heukseok Dong, Seoul 156755, South Korea.	ybkim1218@cau.ac.kr					Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; Baskaya MK, 2000, J NEUROTRAUM, V17, P93, DOI 10.1089/neu.2000.17.93; Chen XC, 2003, EUR J PHARMACOL, V473, P1, DOI 10.1016/S0014-2999(03)01945-9; Chen XC, 2002, ACTA PHARMACOL SIN, V23, P829; CHOI SM, 2002, J KOREAN NEUROSURG S, V32, P29; CHOI SM, 2002, J KOREAN NEUROSURG S, V32, P458; Faden AI, 2002, CURR OPIN NEUROL, V15, P707, DOI 10.1097/00019052-200212000-00008; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Kim HE, 1999, LIFE SCI, V65, pPL33, DOI 10.1016/S0024-3205(99)00252-0; Kim S, 2002, BIOCHEM BIOPH RES CO, V296, P247, DOI 10.1016/S0006-291X(02)00870-7; Lee JH, 2002, NEUROSCI LETT, V325, P129, DOI 10.1016/S0304-3940(02)00256-2; Lee YJ, 1997, MOL CELL ENDOCRINOL, V133, P135, DOI 10.1016/S0303-7207(97)00160-3; Liao BS, 2002, EXP NEUROL, V173, P224, DOI 10.1006/exnr.2001.7841; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lim JH, 1997, NEUROSCI RES, V28, P191, DOI 10.1016/S0168-0102(97)00041-2; Shen LH, 2003, NEUROSCI LETT, V344, P1, DOI 10.1016/S0304-3940(03)00318-5; Shibata S, 2001, J KOREAN MED SCI, V16, pS28, DOI 10.3346/jkms.2001.16.S.S28; Stelmasiak Z, 2000, Med Sci Monit, V6, P426; Wang LJ, 2002, J NEUROSCI, V22, P6920; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y	23	33	36	0	2	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934	1598-6357		J KOREAN MED SCI	J. Korean Med. Sci.	APR	2005	20	2					291	296		10.3346/jkms.2005.20.2.291			6	Medicine, General & Internal	General & Internal Medicine	920QE	WOS:000228704400022	15832003	Green Published			2021-06-18	
J	Scheibel, M; Martinek, V; Imhoff, AB				Scheibel, M; Martinek, V; Imhoff, AB			Arthroscopic reconstruction of an isolated avulsion fracture of the lesser tuberosity	ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY			English	Article						lesser tuberosity fracture; subscapularis avulsion lesion; arthroscopic reconstruction; suture anchor repair	ISOLATED RUPTURE; HUMERUS; TENDON	Isolated avulsion fracture of the lesser tuberosity represents an extremely rare injury that occurs mainly in younger patients. This report outlines the case of a 35-year-old healthy man who sustained a bony avulsion of the subscapularis tendon during an abduction external rotation trauma to his left shoulder. The injury was diagnosed by physical examination, standard radiographs, and magnetic resonance imaging. An arthroscopic reconstruction including closed reduction and internal fixation using suture anchors was performed. After a follow-up of 6 months, the patient's Constant Score increased from 62.4 points preoperatively to 91.3 points. At the latest follow-up, the patient was completely pain free, had regained a full work activity level, and returned to overhead sports. On postoperative standard radiographs and magnetic resonance images, the bony fragment was shown to be consolidated in an anatomic position. In cases of displaced isolated fractures of the lesser tuberosity without significant subluxation or dislocation of the long head of the biceps arthroscopic reconstruction using suture anchors can lead to a good clinical and radiological result.	Tech Univ, Dept Orthopaed & Sports Med, D-80809 Munich, Germany	Scheibel, M (corresponding author), Tech Univ, Dept Orthopaed & Sports Med, Connollystr 32, D-80809 Munich, Germany.	scheibel91@hotmail.com	Imhoff, Andreas B./E-8829-2013	Imhoff, Andreas B./0000-0001-5085-6446			Caniggia M, 1996, PANMINERVA MED, V38, P56; EARWAKER J, 1990, SKELETAL RADIOL, V19, P121; Gerber C, 1996, J BONE JOINT SURG AM, V78A, P1015, DOI 10.2106/00004623-199607000-00005; GERBER C, 1991, J BONE JOINT SURG BR, V73, P389; HAAS SL, 1944, AM J SURG, V63, P253; Kuroda T, 1993, J Shoulder Elbow Surg, V2, P221, DOI 10.1016/1058-2746(93)90066-P; LABRIOLA JH, 1975, J BONE JOINT SURG AM, V57, P1011, DOI 10.2106/00004623-197557070-00032; Le Huec J C, 1994, Acta Orthop Belg, V60, P427; Ogawa K, 1997, J TRAUMA, V42, P955, DOI 10.1097/00005373-199705000-00029; PASCHAL SO, 1995, J BONE JOINT SURG AM, V77, P1427, DOI 10.2106/00004623-199509000-00020; ROSS GJ, 1989, RADIOLOGY, V172, P833, DOI 10.1148/radiology.172.3.2772197; Schwamborn T, 1999, SCHULTERINSTABILITAT, P193; SHIBUYA S, 1986, CLIN ORTHOP RELAT R, P215; VANLAARHOVEN HAJ, 1995, J TRAUMA, V39, P997, DOI 10.1097/00005373-199511000-00031; WHITE GM, 1987, J BONE JOINTJ SURG A, V69, P1454	15	33	34	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-8063			ARTHROSCOPY	Arthroscopy	APR	2005	21	4					487	494		10.1016/j.arthro.2004.11.012			8	Orthopedics; Sport Sciences; Surgery	Orthopedics; Sport Sciences; Surgery	917RT	WOS:000228487600015	15800530				2021-06-18	
J	Solaroglu, I; Okutan, O; Kaptanoglu, E; Beskonakli, E; Kilinc, K				Solaroglu, I; Okutan, O; Kaptanoglu, E; Beskonakli, E; Kilinc, K			Increased xanthine oxidase activity after traumatic brain injury in rats	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						brain injury; oxygen free radical; lipid peroxidation; xanthine oxidase	CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; RADICAL PRODUCTION; OXYGEN RADICALS; NITRIC-OXIDE; SUPEROXIDE; ISCHEMIA; PEROXYNITRITE; ALLOPURINOL; REPERFUSION	Oxidative stress may contribute to many of the pathophysiologic changes that occur after traumatic brain injury (TBI). There are a number of potential sources and mechanisms for oxygen free radical (OFR) production and lipid peroxiclation after TBI. In this study, we investigate the time-dependent changes in xanthine oxidase (XO) activity and lipid peroxiclation using a focal TBI animal model. We demonstrate that there is an immediate increase in lipid peroxiclation by-products and in XO enzyme activity after TBI. (c) 2005 Elsevier Ltd. All rights reserved.	Hacettepe Univ, Sch Med, Ankara Numune Res & Educ Hosp, Dept Neurol Surg, Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biochem, Ankara, Turkey	Solaroglu, I (corresponding author), Yeni Ziraat Mehallesi,13 Sokak Fulya Apt 8-15, TR-06550 Ankara, Turkey.	isolaroglu@hotmail.com	Solaroglu, Ihsan/ABE-8816-2020; Solaroglu, Ihsan/ABF-7606-2020	Solaroglu, Ihsan/0000-0002-9472-1735; 			Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HILLERED L, 1991, RES EXP MED, V191, P219, DOI 10.1007/BF02576677; ITOH T, 1986, STROKE, V17, P1284, DOI 10.1161/01.STR.17.6.1284; KANEMITSU H, 1989, BRAIN RES, V499, P367, DOI 10.1016/0006-8993(89)90786-5; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEFFLER CW, 1990, AM J PHYSIOL, V259, pH1230, DOI 10.1152/ajpheart.1990.259.4.H1230; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Nishio S, 1997, ACT NEUR S, V70, P84; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Stover JF, 1997, NEUROSCI LETT, V238, P25, DOI 10.1016/S0304-3940(97)00840-9; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEI EP, 1986, AM J PHYSIOL, V251, P693	27	33	40	0	11	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0967-5868			J CLIN NEUROSCI	J. Clin. Neurosci.	APR	2005	12	3					273	275		10.1016/j.jocn.2004.12.002			3	Clinical Neurology; Neurosciences	Neurosciences & Neurology	929YU	WOS:000229383400014	15851081				2021-06-18	
J	Colak, A; Karaoglan, A; Barut, S; Kokturk, S; Akyildiz, AI; Tasyurekli, M				Colak, A; Karaoglan, A; Barut, S; Kokturk, S; Akyildiz, AI; Tasyurekli, M			Neuroprotection and functional recovery after application of the caspase-9 inhibitor z-LEHD-fmk in a rat model of traumatic spinal cord injury	JOURNAL OF NEUROSURGERY-SPINE			English	Article						z-LEHD-fmk; apoptosis; caspase-9; programmed cell death; spinal cord injury; rat	APOPTOTIC CELL-DEATH; NEURONAL APOPTOSIS; CEREBRAL-ISCHEMIA; CYTOCHROME-C; BRAIN-INJURY; MITOCHONDRIA; EXPRESSION; NECROSIS; ICE; INTERLEUKIN-1-BETA	Object. Apoptosis is considered one of the most significant mechanisms in the pathogenesis of neuronal damage after spinal cord injury (SCI). This form of cell death occurs via mediators known as caspases. The aim of this study was to evaluate the neuroprotective effect of the caspase-9 inhibitor, z-LEHD-fmk, in a rat model of spinal cord trauma. Methods. Fifty-four Wistar albino rats were studied in the following three groups of 18 animals each: sham-operated controls (Group 1); trauma-only controls (Group 2); and trauma combined with z-LEND-fmk-treated animals (0.8 mu M/kg; Group 3). Spinal cord injury was produced at the thoracic level by using the weight-drop technique. Responses to SCI and the efficacy of z-LEHD-fmk treatment were determined on the basis of terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling staining and light and electron microscopy findings in cord tissue at 24 hours and 7 days posttrauma. Six rats from each group were also assessed for functional recovery at 3 and 7 days after SCI. This was conducted using the inclined-plane technique and a modified version of the Tarlov motor grading scale. At 24 hours postinjury, light microscopic examination of Group 2 tissue samples showed hemorrhage, edema, necrosis, polymorphonuclear leukocyte infiltration, and vascular thrombi. Those obtained in Group 3 rats at this stage showed similar features. At 24 hours postinjury, the mean apoptotic cell count in Group 2 was significantly higher than that in Group 3 (90.25 +/- 2.6 and 50.5 +/- 1.9, respectively; p < 0.05). At 7 days postinjury, the corresponding mean apoptotic cell counts were 49 +/- 2.1 and 17.7 +/- 2.6, also a significant difference (p < 0.05). Electron microscopy findings confirmed the occurrence of programmed cell death in different cell types in the spinal cord and showed that z-LEHD-fmk treatment protected neurons, glia, myelin, axons, and intracellular organelles. Conclusions. Examination of the findings in this rat model of SCI revealed that apoptosis occurs not only in neurons and astrocytes but also in oligodendrocytes and microglia. Furthermore, immediate treatment with the caspase-9 inhibitor z-LEHD-fmk blocked apoptosis effectively and was associated with better functional outcome. More in-depth research of the role of programmed cell death in spinal cord trauma and further study of the ways in which caspases are involved in this process may lead to new strategies for treating SCI.	Taksim Educ & Res Hosp, Neurosurg Clin, Istanbul, Turkey; Taksim Educ & Res Hosp, Pathol Clin, Istanbul, Turkey; Istanbul Univ, Dept Histol & Embryol, Cerrahpasa Med Sch, Istanbul, Turkey	Colak, A (corresponding author), Terakki Caddesi,47-7, Istanbul, Turkey.	drahmetcolak@yahoo.com	Kokturk, Sibel/H-5559-2019; Kokturk, Sibel/I-4296-2014	Kokturk, Sibel/0000-0001-5636-3300; Kokturk, Sibel/0000-0001-5636-3300			Allen AR, 1914, J NERV MENT DIS, V41, P141, DOI 10.1097/00005053-191403000-00002; Bresnahan J. C., 1996, Society for Neuroscience Abstracts, V22, P1185; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; Ekert PG, 1999, CELL DEATH DIFFER, V6, P1081, DOI 10.1038/sj.cdd.4400594; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1996, J EXP MED, V184, P717, DOI 10.1084/jem.184.2.717; Friedlander RM, 1998, CELL DEATH DIFFER, V5, P823, DOI 10.1038/sj.cdd.4400433; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Kato H, 1997, EXP NEUROL, V148, P464, DOI 10.1006/exnr.1997.6707; Katoh K, 1996, NEUROSCI LETT, V216, P9; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Li H, 2000, STROKE, V31, P176, DOI 10.1161/01.STR.31.1.176; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; Lu JK, 2000, SPINE, V25, P1859, DOI 10.1097/00007632-200007150-00022; Mouw G, 2002, METAB BRAIN DIS, V17, P143, DOI 10.1023/A:1019921904378; Nakatsuka H, 1999, BRAIN RES, V849, P216, DOI 10.1016/S0006-8993(99)01971-X; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; Prehn JHM, 1997, J NEUROCHEM, V68, P1679; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; RINK A, 1995, AM J PATHOL, V147, P1575; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rudel T, 1999, HERZ, V24, P236, DOI 10.1007/BF03044967; Samali A, 1999, CELL DEATH DIFFER, V6, P495, DOI 10.1038/sj.cdd.4400520; Schulz JB, 1999, ANN NEUROL, V45, P421, DOI 10.1002/1531-8249(199904)45:4<421::AID-ANA2>3.0.CO;2-Q; Sugawara T, 2002, FASEB J, V16, P1997, DOI 10.1096/fj.02-0251fje; TARLOV IM, 1957, SPINAL CORD COMPRESS; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; Van de Craen M, 1998, CELL DEATH DIFFER, V5, P838, DOI 10.1038/sj.cdd.4400444; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zurita M, 2001, J NEUROSURG, V94, P257, DOI 10.3171/spi.2001.94.2.0257	46	33	35	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	MAR	2005	2	3					327	334		10.3171/spi.2005.2.3.0327			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	917IW	WOS:000228455300013	15796358				2021-06-18	
J	Church, AJ; Andrew, RD				Church, AJ; Andrew, RD			Spreading depression expands traumatic injury in neocortical brain slices	JOURNAL OF NEUROTRAUMA			English	Article						anoxic depolarization; cortical spreading depression; ischemia; migraine aura; neocortex; peri-infarct depolarization; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; SEVERE HEAD-INJURY; CENTRAL NERVOUS-SYSTEM; ANOXIC DEPOLARIZATION; EXTRACELLULAR POTASSIUM; MODERATE HYPOTHERMIA; HIPPOCAMPAL SLICE; IN-VITRO; MILD HYPOTHERMIA; ARTERY OCCLUSION	Traumatic brain injury (TBI) is particularly common in young people, generating healthcare costs that can span decades. The cellular processes activated in the first minutes following injury are poorly understood, and the 3-4 h following trauma are crucial for reducing. subsequent injury. Spreading depression (SD) is a profound inactivation of neurons and glia lasting 1-2 min that arises focally and migrates outward across gray matter. In the hours following focal stroke, the metabolic stress of energy reduction and recurring SD-like events (peri-infarct depolarizations, PIDs) interact to promote neuronal injury. Similar recurring depolarizations might evolve immediately following TBI and exacerbate neuronal damage peripheral to the impact site. To test this possibility and examine if certain drugs might limit damage by inhibiting what we term traumatic spreading depression (tSD), we developed a technique whereby a small weight was dropped onto a live slice of rat neocortex while imaging changes in light transmittance (LT). Imaging revealed a propagating front of increased LT arising at the border of the impact site. Traumatic SD significantly expanded the region of ensuing damage. Both tSD and subsequent damage were blocked by the NMDA receptor antagonist MK-801 (100 muM) or the sigma-1 receptor (sigma(1)R) ligands dextromethorphan (30 muM) or BD-1063 (100 muM). Co-application of the sigma(1)R antagonist (+)3-PPP with DM reversed the block as did lowering temperature from 35degreesC to 32degreesC. This study provides evidence that an event similar to peri-infarct depolarization can arise from an injury site in neocortex within seconds following impact and act to expand the region of acute neuronal damage.	Queens Univ, Dept Anat & Cell Biol, Kingston, ON K7L 3N6, Canada; Queens Univ, Ctr Neurosci Studies, Kingston, ON K7L 3N6, Canada	Andrew, RD (corresponding author), Queens Univ, Dept Anat & Cell Biol, Botterell Hall, Kingston, ON K7L 3N6, Canada.	andrewd@post.queensu.ca					Anderson TR, 2002, J NEUROPHYSIOL, V88, P2713, DOI 10.1152/jn.00321.2002; ANDERSON TR, 2005, J NEUROPHYSIOL; Arundine M, 2003, J NEUROTRAUM, V20, P1377, DOI 10.1089/089771503322686166; Ba AM, 2002, J NEUROPHYSIOL, V88, P2726, DOI 10.1152/jn.00729.2001; BACK T, 1994, J CEREBR BLOOD F MET, V14, P12, DOI 10.1038/jcbfm.1994.3; BALESTRINO M, 1995, J NEUROSCI METH, V59, P99, DOI 10.1016/0165-0270(94)00199-Q; Basarsky TA, 1998, J NEUROSCI, V18, P7189; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BURES J, 1975, EPILEPSIA, V16, P111, DOI 10.1111/j.1528-1157.1975.tb04727.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1995, J NEUROSURG ANESTH, V7, P152, DOI 10.1097/00008506-199504000-00023; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Footitt DR, 1998, BRAIN RES, V781, P339, DOI 10.1016/S0006-8993(97)01359-0; Frantseva MV, 2002, J NEUROSCI, V22, P644, DOI 10.1523/JNEUROSCI.22-03-00644.2002; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; GOETZ CG, 1999, TXB CLIN NEUROLOGY, P810; GORDON N, 1989, DEV MED CHILD NEUROL, V31, P682; HAAS DC, 1988, J NEUROSURG, V68, P181, DOI 10.3171/jns.1988.68.2.0181; HAAS DC, 1975, ARCH NEUROL-CHICAGO, V32, P727, DOI 10.1001/archneur.1975.00490530049003; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hartings JA, 2003, J NEUROSCI, V23, P11602; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; HORI N, 1994, EXP NEUROL, V129, P279, DOI 10.1006/exnr.1994.1170; Jarvis CR, 1999, NEUROIMAGE, V10, P357, DOI 10.1006/nimg.1999.0473; Jarvis CR, 2001, CEREB CORTEX, V11, P249, DOI 10.1093/cercor/11.3.249; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Joshi I, 2001, J NEUROPHYSIOL, V85, P414; KATAYAMA Y, 1995, BRAIN PATHOL, V5, P427, DOI 10.1111/j.1750-3639.1995.tb00621.x; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kirov SA, 2004, NEUROSCIENCE, V127, P69, DOI 10.1016/j.neuroscience.2004.04.053; Koistinaho J, 1999, STROKE, V30, P114, DOI 10.1161/01.STR.30.1.114; Koroleva VI, 1998, BRAIN RES, V786, P104, DOI 10.1016/S0006-8993(97)01448-0; Largo C, 1997, J NEUROPHYSIOL, V78, P295; LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Martins-Ferreira H, 2000, BRAIN RES REV, V32, P215, DOI 10.1016/S0165-0173(99)00083-1; Mayevsky A, 1996, BRAIN RES, V740, P268, DOI 10.1016/S0006-8993(96)00874-8; MCINTYRE LA, 2003, JAMA-J AM MED ASSOC, V289, P3007; MCLACHLAN RS, 1994, BRAIN RES, V666, P133, DOI 10.1016/0006-8993(94)90295-X; MEDEN P, 1994, BRAIN RES, V647, P131, DOI 10.1016/0006-8993(94)91407-9; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Mitsikostas DD, 2001, BRAIN RES REV, V35, P20, DOI 10.1016/S0165-0173(00)00048-5; Nallet H, 1999, BRAIN RES, V842, P148, DOI 10.1016/S0006-8993(99)01859-4; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; NELLGARD B, 1992, ACTA PHYSIOL SCAND, V146, P497, DOI 10.1111/j.1748-1716.1992.tb09451.x; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Obeidat AS, 1998, EUR J NEUROSCI, V10, P3451, DOI 10.1046/j.1460-9568.1998.00358.x; Obeidat AS, 2000, J CEREBR BLOOD F MET, V20, P412, DOI 10.1097/00004647-200002000-00024; Obrenovitch TP, 1996, J CEREBR BLOOD F MET, V16, P923, DOI 10.1097/00004647-199609000-00016; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OKA H, 1977, BRAIN, V100, P287, DOI 10.1093/brain/100.2.287; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; Pietrobon D, 2003, NAT REV NEUROSCI, V4, P386, DOI 10.1038/nrn1102; REID KH, 1988, J PHARMACOL METHOD, V19, P1, DOI 10.1016/0160-5402(88)90040-X; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Sakas DE, 1997, NEUROSURGERY, V41, P661, DOI 10.1097/00006123-199709000-00031; Sakas DE, 1997, MED HYPOTHESES, V48, P431, DOI 10.1016/S0306-9877(97)90042-6; Somjen GG, 2001, PHYSIOL REV, V81, P1065; SOMJEN GG, 1990, STROKE, V21, P179; SOMJEN GG, 1992, CAN J PHYSIOL PHARM, V70, pS248, DOI 10.1139/y92-268; SOMJEN GG, 1979, ANNU REV PHYSIOL, V41, P159, DOI 10.1146/annurev.ph.41.030179.001111; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tanaka E, 1999, J NEUROPHYSIOL, V81, P1872; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; Walz W, 1997, NEUROSCI BIOBEHAV R, V21, P135, DOI 10.1016/S0149-7634(96)00003-6; Whittemore ER, 1997, J PHARMACOL EXP THER, V282, P326; Yenari MA, 2000, BRAIN RES, V885, P208, DOI 10.1016/S0006-8993(00)02942-5; Zink Brian J., 1996, Emergency Medicine Clinics of North America, V14, P115	78	33	36	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					277	290		10.1089/neu.2005.22.277			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400007	15716633				2021-06-18	
J	Leblanc, N; Chen, S; Swank, PR; Ewing-Cobbs, L; Barnes, M; Dennis, M; Max, J; Levin, H; Schachar, R				Leblanc, N; Chen, S; Swank, PR; Ewing-Cobbs, L; Barnes, M; Dennis, M; Max, J; Levin, H; Schachar, R			Response inhibition after traumatic brain injury (TBI) in children: Impairment and recovery	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; WORKING-MEMORY; PRESCHOOL-CHILDREN; LIFE-SPAN; MILD; SEVERITY; AGE; CHILDHOOD	Children who experience traumatic brain injury (TBI) often show cognitive impairments postinjury, some of which recover over time. We examined the recovery of motor response inhibition immediately following TBI and over 2 years. We assessed the role of injury severity, age at injury, and lesion characteristics on initial impairment and recovery while considering the role of pre-injury psychiatric disorder. Participants were 136 children with TBI aged 5-16 years. Latency of motor response inhibition was measured with the stop-signal task within 1 month of the injury and again at 3, 6, 12, and 24 months. The performance of the TBI participants at each measurement occasion was standardized with 117 children of similar age, but without injury. Residualized latency scores were calculated. Growth curve analyses showed an initial impairment in response inhibition and improvement over the 2 years following injury. Younger TBI patients were initially more impaired although they exhibited greater recovery of response inhibition than did older TBI patients. Longer duration of coma, but not reactivity of pupils or Glasgow Coma Scale score, predicted initial deficit. Lesion characteristics or pre-injury attention deficit hyperactivity disorder did not predict initial impairment or recovery. Replication with longitudinal testing of a comparison group of children sustaining extracranial injury is necessary to confirm our findings.	Univ Toronto, Hosp Sick Children, Dept Psychiat, Brain & Behav Programme, Toronto, ON M5G 1X8, Canada; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Univ Toronto, Hosp Sick Children, Dept Psychol, Brain & Behav Program, Toronto, ON M5G 1X8, Canada; Univ Texas, Sch Med, Dept Pediat, Houston, TX USA	Schachar, R (corresponding author), Univ Toronto, Hosp Sick Children, Dept Psychiat, Brain & Behav Programme, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	russell.schachar@sickkids.ca		Schachar, Russell/0000-0002-2015-4395	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-01800] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2000, BRAIN INJURY, V14, P679; Aron AR, 2003, NAT NEUROSCI, V6, P115, DOI 10.1038/nn1003; Bakker K, 1999, Pediatr Rehabil, V3, P149; Band GPH, 2000, J EXP CHILD PSYCHOL, V75, P263, DOI 10.1006/jecp.1999.2538; Band GPH, 1999, ACTA PSYCHOL, V101, P179, DOI 10.1016/S0001-6918(99)00005-0; Bedard AC, 2002, DEV NEUROPSYCHOL, V21, P93, DOI 10.1207/S15326942DN2101_5; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Casey BJ, 1997, J AM ACAD CHILD PSY, V36, P374, DOI 10.1097/00004583-199703000-00016; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Dennis M, 1998, BRAIN LANG, V61, P450, DOI 10.1006/brln.1997.1886; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Duval J, 2002, BRAIN COGNITION, V48, P337, DOI 10.1006/brcg.2001.1373; ERIKSEN CW, 1979, PERCEPT PSYCHOPHYS, V25, P249, DOI 10.3758/BF03198804; Ewing-Cobbs L, 2003, DEV NEUROPSYCHOL, V24, P669, DOI 10.1207/S15326942DN242&3_08; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; Graham D I, 2002, GREENFIELDS NEUROPAT, P823; Harnishfeger KK, 1996, J EXP CHILD PSYCHOL, V62, P292, DOI 10.1006/jecp.1996.0032; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; Houghton George, 1994, P53; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Jennings JR, 1997, DEV PSYCHOL, V33, P308, DOI 10.1037/0012-1649.33.2.308; JENNINGS JR, 1992, J EXP PSYCHOL HUMAN, V18, P422, DOI 10.1037/0096-1523.18.2.422; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; KINDLON D, 1995, J CHILD PSYCHOL PSYC, V36, P645, DOI 10.1111/j.1469-7610.1995.tb02319.x; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; Kolb Bryan, 2003, Phys Med Rehabil Clin N Am, V14, pS7, DOI 10.1016/S1047-9651(02)00056-6; Konrad K, 2000, CHILD NEUROPSYCHOL, V6, P286, DOI 10.1076/chin.6.4.286.3145; Konrad KN, 2000, BRAIN INJURY, V14, P859; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Logan Gordon D., 1994, P189; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Moses P, 2002, DEV PSYCHOBIOL, V40, P266, DOI 10.1002/dev.10031; Norman D.A., 1986, CONSCIOUSNESS SELF R, V4, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; OSMAN A, 1986, J EXP PSYCHOL HUMAN, V12, P243, DOI 10.1037/0096-1523.12.3.243; Pascual-Leone J, 2000, J EXP CHILD PSYCHOL, V77, P138, DOI 10.1006/jecp.2000.2593; Perner J, 2002, CHILD DEV, V73, P752, DOI 10.1111/1467-8624.00436; Raudenbush S. W., 2000, HLM 5 HIERARCHICAL L; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rubia K, 2001, BRIT J PSYCHIAT, V179, P138, DOI 10.1192/bjp.179.2.138; Russell J., 1998, AUTISM EXECUTIVE DIS, P256; Schachar R, 2000, J ABNORM CHILD PSYCH, V28, P227, DOI 10.1023/A:1005140103162; Schachar R, 2004, DEV NEUROPSYCHOL, V25, P179, DOI 10.1207/s15326942dn2501&2_10; Sosin DM, 1996, BRAIN INJURY, V10, P47; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; TEASDALE G, 1974, LANCET, V2, P81; Temple CM, 1997, J CHILD PSYCHOL PSYC, V38, P27, DOI 10.1111/j.1469-7610.1997.tb01504.x; Thompson Matthew D, 2003, Semin Pediatr Neurol, V10, P130, DOI 10.1016/S1071-9091(03)00021-4; Tranel D, 2000, DEV NEUROPSYCHOL, V18, P273, DOI 10.1207/S1532694201Tranel; Vicari S, 2000, CORTEX, V36, P31, DOI 10.1016/S0010-9452(08)70834-7; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763	79	33	33	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2005	28	3					829	848		10.1207/s15326942dn2803_5			20	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	987UC	WOS:000233541800005	16266251				2021-06-18	
J	Oermann, E; Bidmon, HJ; Witte, OW; Zilles, K				Oermann, E; Bidmon, HJ; Witte, OW; Zilles, K			Effects of 1 alpha,25 dihydroxyvitamin D-3 on the expression of HO-1 and GFAP in glial cells of the photothrombotically lesioned cerebral cortex	JOURNAL OF CHEMICAL NEUROANATOMY			English	Article						1.25 dihydroxycholecalciferol; brain; ischemia; heme oxygenase; glial fibrillary acidic proteins; oxidative stress; rat	NITRIC-OXIDE SYNTHASE; FOCAL CORTICAL ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; HEME OXYGENASE-1 HO-1; NECROSIS-FACTOR-ALPHA; D ENDOCRINE SYSTEM; GROWTH-FACTOR-BETA; NF-KAPPA-B; 1,25-DIHYDROXYVITAMIN D-3	In ischemic cerebral injuries a cascade of degenerative mechanisms, all participating in the development of oxidative stress, influence the condition of the tissue. The survival of viable tissue affected by secondary injury largely depends on the balance between endogenous protective mechanisms and the ongoing degenerative processes. The inducible enzyme, heme oxygenase-1 metabolizes and thus detoxifies free heme to the powerful endogenous antioxidants biliverdin and bilirubin therefore enhancing neuroprotection. The secosteroid 1alpha,25-dihydroxyvitamin D-3 (1,25-D-3) is a modulator of the immune system and also exhibits a strong potential for neuroprotection as recently shown in the MCAO model of cerebral ischemia. We studied the effects of 1,25-D-3 treatment on heme oxygenase-1 expression following focal cortical ischemia elicited by photo-thrombosis. Postlesional treatment with 1,25-D-3 (4 mug/kg body weight) resulted in a transient, but significant upregulation of glial heme oxygenase-1 immunoreactivity concomitant with a reduction in glial fibrillary acidic protein immunoreactivity in remote cortical regions affected by a secondary spread of injury, whereas the size of the lesion's core remained unaffected. 1,25-D-3 did not produce a temporal shift or extension of injury-related heme oxygenase-1 responses, indicating that 1,25-D-3 did not prolong ischemia-related heme oxygenase-1 expression. In contrast to glial heme oxygenase-1 upregulation, glial fibrillary acidic protein, a sensitive marker for reactive gliosis, was significantly reduced. These findings support an additional protective action of 1,25-D-3 at the cellular level in regions affected by secondary injury-related responses. (C) 2004 Elsevier B.V. All rights reserved.	Univ Dusseldorf, C&O Vogt Inst Brain Res, D-40225 Dusseldorf, Germany; Univ Jena, Neurol Clin, D-07743 Jena, Germany; Inst Med, Res Ctr, D-52425 Julich, Germany	Oermann, E (corresponding author), Univ Dusseldorf, C&O Vogt Inst Brain Res, Moorenstr 5, D-40225 Dusseldorf, Germany.	oermann@uni-duesseldorf.de	Witte, Otto/P-4127-2018; Zilles, Karl/J-9704-2013; Zilles, Karl/Y-3784-2019	Witte, Otto/0000-0003-2101-4105; Zilles, Karl/0000-0001-9296-9959; Zilles, Karl/0000-0002-4705-4175			Baas D, 2000, GLIA, V31, P59, DOI 10.1002/(SICI)1098-1136(200007)31:1<59::AID-GLIA60>3.0.CO;2-Y; BAN EM, 1993, NEUROSCIENCE, V52, P725, DOI 10.1016/0306-4522(93)90421-B; BARONE FC, 1993, J CEREBR BLOOD F MET, V13, P683, DOI 10.1038/jcbfm.1993.87; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Bidmon HJ, 1998, NEUROSCIENCE, V82, P397; Bidmon HJ, 2001, EXP NEUROL, V168, P1, DOI 10.1006/exnr.2000.7456; Bidmon HJ, 2000, J CHEM NEUROANAT, V20, P163, DOI 10.1016/S0891-0618(00)00081-8; Brewer LD, 2001, J NEUROSCI, V21, P98, DOI 10.1523/JNEUROSCI.21-01-00098.2001; Buisson A, 2003, CELL MOL NEUROBIOL, V23, P539, DOI 10.1023/A:1025072013107; Calabrese V, 2003, AMINO ACIDS, V25, P437, DOI 10.1007/s00726-003-0048-2; Chen KB, 2003, ANN NY ACAD SCI, V993, P313, DOI 10.1111/j.1749-6632.2003.tb07539.x; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Colville-Nash PR, 1998, J IMMUNOL, V161, P978; d'Hellencourt CL, 2003, J NEUROSCI RES, V71, P575, DOI 10.1002/jnr.10491; DERYCK M, 1990, EUR NEUROL, V30, P21; DIETRICH WD, 1987, ACTA NEUROPATHOL, V72, P326, DOI 10.1007/BF00687263; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; DUVERGER D, 1988, J CEREBR BLOOD F MET, V8, P449, DOI 10.1038/jcbfm.1988.86; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438; Elias J, 2003, RECENT RESULTS CANC, V164, P319; FORSTING M, 1994, NEURORADIOLOGY, V36, P264, DOI 10.1007/BF00593255; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Garcion E, 1999, J NEUROCHEM, V73, P859, DOI 10.1046/j.1471-4159.1999.0730859.x; Garcion E, 2002, TRENDS ENDOCRIN MET, V13, P100, DOI 10.1016/S1043-2760(01)00547-1; Garcion E, 2003, ACTA NEUROPATHOL, V105, P438, DOI 10.1007/s00401-002-0663-0; Garcion E, 1997, MOL BRAIN RES, V45, P255, DOI 10.1016/S0169-328X(96)00260-4; Garcion E, 1998, GLIA, V22, P282, DOI 10.1002/(SICI)1098-1136(199803)22:3<282::AID-GLIA7>3.0.CO;2-7; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Gladilin S, 2000, ARCH BIOCHEM BIOPHYS, V380, P237, DOI 10.1006/abbi.2000.1943; GUNDERSEN HJG, 1977, J MICROSC-OXFORD, V111, P219, DOI 10.1111/j.1365-2818.1977.tb00062.x; Hahn M, 1997, J NEUROCHEM, V69, P102; Hamann GF, 1997, RADIOLOGE, V37, P843, DOI 10.1007/s001170050292; Harant H, 1997, EUR J BIOCHEM, V250, P63, DOI 10.1111/j.1432-1033.1997.00063.x; Hayes CE, 2003, CELL MOL BIOL, V49, P277; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Horvath B, 2003, J CEREBR BLOOD F MET, V23, P653, DOI 10.1097/01.WCB.0000071890.63724.C9; Isenmann S, 1998, BRAIN PATHOL, V8, P49; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Kitamura Y, 1998, GLIA, V22, P138; LAVROVSKY Y, 1994, P NATL ACAD SCI USA, V91, P5987, DOI 10.1073/pnas.91.13.5987; Lemire J, 2000, Z RHEUMATOL, V59, P24; Lin AMY, 2003, FREE RADICAL BIO MED, V34, P1416, DOI 10.1016/S0891-5849(03)00105-9; Lipton P, 1999, PHYSIOL REV, V79, P1431; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI 10.1037/mai.2003.1703; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; MCAULEY MA, 1995, CEREBROVAS BRAIN MET, V7, P153; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Mennel HD, 2000, EXP TOXICOL PATHOL, V52, P395, DOI 10.1016/S0940-2993(00)80070-6; NEVEU I, 1994, J NEUROSCI RES, V38, P214, DOI 10.1002/jnr.490380212; NEVEU I, 1994, MOL BRAIN RES, V24, P70, DOI 10.1016/0169-328X(94)90119-8; Pettigrew LC, 2003, NEUROL RES, V25, P201; Riachy R, 2002, ENDOCRINOLOGY, V143, P4809, DOI 10.1210/en.2002-220449; RICCHETTI GA, 2004, J LEUKOC BIOL, V7; Rostworowski M, 1997, J NEUROSCI, V17, P3664; SAGGESE G, 1993, ACTA PAEDIATR, V82, P54, DOI 10.1111/j.1651-2227.1993.tb12930.x; Sanchez B, 2002, MOL BRAIN RES, V108, P143, DOI 10.1016/S0169-328X(02)00545-4; Satoh T, 2003, EUR J NEUROSCI, V17, P2249, DOI 10.1046/j.1460-9568.2003.02688.x; Schroeter M, 2002, J NEUROSCI METH, V117, P43, DOI 10.1016/S0165-0270(02)00072-9; SCHROETER M, 1995, EXP BRAIN RES, V106, P1; STUMPF WE, 1995, HISTOCHEM CELL BIOL, V104, P417, DOI 10.1007/BF01464331; STUMPF WE, 2003, DRUG TARGETING DELIV; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Sweeney MI, 1995, CAN J PHYSIOL PHARM, V73, P1525, DOI 10.1139/y95-211; TAOKA T, 1993, MOL CELL ENDOCRINOL, V95, P51, DOI 10.1016/0303-7207(93)90028-I; Timms PM, 2002, QJM-INT J MED, V95, P787, DOI 10.1093/qjmed/95.12.787; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wang JY, 2001, BRAIN RES, V904, P67, DOI 10.1016/S0006-8993(01)02450-7; Wang Y, 2000, NEUROPHARMACOLOGY, V39, P873, DOI 10.1016/S0028-3908(99)00255-5; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; Witte OW, 2000, J CEREBR BLOOD F MET, V20, P1149, DOI 10.1097/00004647-200008000-00001; Yacobi R, 1996, J ENDOCRINOL, V149, P327, DOI 10.1677/joe.0.1490327; Yu ACH, 2000, NEUROCHEM INT, V36, P369, DOI 10.1016/S0197-0186(99)00145-X; YU XP, 1995, P NATL ACAD SCI USA, V92, P10990, DOI 10.1073/pnas.92.24.10990; Zhai QH, 1997, J NEUROL SCI, V152, P119, DOI 10.1016/S0022-510X(97)00154-8; Zhang WD, 1999, J NEUROIMMUNOL, V101, P148, DOI 10.1016/S0165-5728(99)00137-X; Zhuang H, 2003, ANN NY ACAD SCI, V993, P276, DOI 10.1111/j.1749-6632.2003.tb07534.x; Zhuang H, 2003, ANN NY ACAD SCI, V993, P208, DOI 10.1111/j.1749-6632.2003.tb07531.x; ZILLES K, 1985, STEREOTAXIC ATLAS; Zittermann A, 2003, BRIT J NUTR, V89, P552, DOI 10.1079/BJN2003837; Zittermann A, 2004, PEDIAT ALLERG IMM-UK, V15, P242, DOI 10.1111/j.1399-3038.2004.00140.x	82	33	35	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0891-0618	1873-6300		J CHEM NEUROANAT	J. Chem. Neuroanat.	DEC	2004	28	4					225	238		10.1016/j.jchemneu.2004.07.003			14	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	874EW	WOS:000225334700003	15531134				2021-06-18	
J	McMillan, TM; Herbert, CM				McMillan, TM; Herbert, CM			Further recovery in a potential treatment withdrawal case 10 years after brain injury	BRAIN INJURY			English	Article							LIFE	A young woman was rendered tetraplegic and anarthric as a result of a traumatic brain injury in 1993. Two years later, she was considered to be in a minimally conscious state and became the subject of legal debate in the UK with regard to withdrawal of artificial feeding and hydration. Before injury, she made a verbal advanced directive that she would not wish to continue living if ever becoming severely disabled. Neuropsychological assessment found statistically significant evidence for sentience and expression of a wish to live and the application to Court was withdrawn. Further meaningful recovery occurred between 7-10 years after injury. She now lives in the community with 24 hour care. She speaks, initiates conversation and actions, expresses clear and consistent preferences and has a spontaneous sense of humour. She uses an electric wheelchair, eats solid food and drinks through a straw. Her mood is variable and sometimes low. This case demonstrates the need for careful consideration of advanced directives and for specialist neuropsychological assessment in people with severe cognitive and communication difficulties. It supports the view that routine assessment and follow-up of people thought to be in minimally conscious states is important. In addition, it shows that recovery with reduction in disability and significant implications for quality of life can continue for at least 10 years after extremely severe traumatic brain injury.	Brain Injury Rehabil Trust, Dept Clin Psychol, Burgess Hill, W Sussex, England	McMillan, TM (corresponding author), Univ Glasgow, Fac Med, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					ANDERSON C, 1993, LANCET, V342, P867, DOI 10.1016/0140-6736(93)92728-C; Andrew K, 1993, NEUROPSYCHOL REHABIL, V3, P109; DYER C, 1993, BRIT MED J, V306, P413; JENNETT B, 2002, VEGETATIVE STATE; KATZ RT, 1992, ARCH PHYS MED REHAB, V73, P403; McMillan T, 2003, STUD NEUROPSYCHOL DE, P271; McMillan TM, 1997, BRAIN INJURY, V11, P483, DOI 10.1080/713802184; McMillan TM, 2000, BRAIN INJURY, V14, P197, DOI 10.1080/026990500120853; Phipps E, 1999, AM J PHYS MED REHAB, V78, P77, DOI 10.1097/00002060-199901000-00020; Pickl GB, 2002, FOLIA PHONIATR LOGO, V54, P26, DOI 10.1159/000048594; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; *SCOTT EX, 2000, AD INC SCOTL ACT; Shiel A, 1998, BRAIN INJURY, V12, P809, DOI 10.1080/026990598122043; The Royal College of Physicians, 2003, VEG STAT GUID DIAGN	14	33	35	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2004	18	9					935	940		10.1080/02699050410001675915			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700008	15223745				2021-06-18	
J	Rath, JF; Langenbahn, DM; Simon, D; Sherr, RL; Fletcher, J; Diller, L				Rath, JF; Langenbahn, DM; Simon, D; Sherr, RL; Fletcher, J; Diller, L			The construct of problem solving in higher level neuropsychological assessment and rehabilitation	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	109th Annual Convention of the American-Psychological-Association	AUG 24-28, 2001	SAN FRANCISCO, CA	Amer Psychol Assoc		neuropsychological assessment; rehabilitation; traumatic brain injury	TRAUMATIC BRAIN-INJURY; COMMUNITY INTEGRATION; DEPRESSION; ATTENTION; VALIDITY; DEFICITS; PERFORMANCE; OUTPATIENTS; DISABILITY; COMPLAINTS	Three inter-related studies examine the construct of problem solving as it relates to the assessment of deficits in higher level outpatients with traumatic brain injury (TBI). Sixty-one persons with TBI and 58 uninjured participants completed measures of problem solving and conceptually related constructs, which included neuropsychological tests, self-report inventories, and roleplayed scenarios. In Study I, TBI and control groups performed with no significant differences on measures of memory, reasoning, and executive function, but medium to large between-group differences were found on timed attention tasks. The largest between-group differences were found on psychosocial and problem-solving self-report inventories. In Study II, significant-other (SO) ratings of patient functioning were consistent with patient self-report, and for both self-report and SO ratings of patient problem solving, there was a theoretically meaningful pattern of correlations with timed attention tasks. In Study III, a combination of self-report inventories that accurately distinguished between participants with and without TBI, even when cognitive tests scores were in the normal range, was determined. The findings reflect intrinsic differences in measurement approaches to the construct of problem solving and suggest the importance of using a multidimensional approach to assessment. (C) 2003 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	NYU, Sch Med, Rusk Inst Rehabil Med, Dept Rehabil Med, New York, NY 10016 USA	Rath, JF (corresponding author), NYU, Sch Med, Rusk Inst Rehabil Med, Dept Rehabil Med, 400 E 34th St, New York, NY 10016 USA.	joseph.rath@med.nyu.edu	Rath, Joseph F./C-4823-2008	Rath, Joseph F./0000-0003-2933-6299; Diller, Leonard/0000-0001-7295-7846	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01-HD32943] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD032943] Funding Source: NIH RePORTER		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Babin PR, 2002, J REHABIL, V68, P4; BENTON AL, 1994, ANNU REV PSYCHOL, V45, P1, DOI 10.1146/annurev.ps.45.020194.000245; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; Bruner J. S., 1956, STUDY THINKING; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BUTLER M, 1991, PROF PSYCHOL-RES PR, V22, P510, DOI 10.1037/0735-7028.22.6.510; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; D'Zurilla TJ, 2001, HANDBOOK OF COGNITIVE-BEHAVIORAL THERAPIES, SECOND EDITION, P211; DANIEL M, 1986, BEHAV THERAPIST, V4, P71; DEROGATIS LR, 1990, BRIEF SYMPTOM INVENT; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DILLER L, 1993, ADV STROKE REHABILIT; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; DOWNEY J, 1923, WILL TEMPERAMENT ITS; DZurilla T. J., 1982, ADV COGNITIVE BEHAV, V1, P201, DOI DOI 10.1016/B978-0-12-010601-1.50010-3; DZURILLA TJ, 1971, J ABNORM PSYCHOL, V78, P107, DOI 10.1037/h0031360; DZURILLA TJ, 1995, BEHAV THER, V26, P409, DOI 10.1016/S0005-7894(05)80091-7; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Geffen L., 1998, OXFORD HDB SPORTS ME, P152; GOLDSTEIN FC, 1987, NEUROPSYCHOL REHABIL, P327; HANIG BS, 1993, ADJUNCT SKILLS QUEST; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; HART T, 1986, CLIN NEUROPSYCHOLOGY; Heaton R., 1993, WISCONSIN CARD SORTI; Heaton R. K, 1981, WISCONSIN CARD SORTI; Heppner PP., 1988, PROBLEM SOLVING INVE; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; KING MC, 1981, J CLIN PSYCHOL, V37, P400, DOI 10.1002/1097-4679(198104)37:2<400::AID-JCLP2270370233>3.0.CO;2-B; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Langenbahn DM, 1999, PSYCHOTHERAPEUTIC INTERVENTIONS FOR ADULTS WITH BRAIN INJURY OR STROKE: A CLINICIAN'S TREATMENT RESOURCE, P167; Levin HS, 1989, MILD HEAD INJURY; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Lovejoy DW, 2001, ARCH CLIN NEUROPSYCH, V16, P743; Luria A. R., 1966, HIGHER CORTICAL FUNC; Luria A. R., 1963, RESTORATION FUNCTION; Meyer GJ, 2001, AM PSYCHOL, V56, P128, DOI 10.1037//0003-066X.56.2.128; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Montgomery GK, 1999, ARCH CLIN NEUROPSYCH, V14, P794, DOI 10.1016/S0887-6177(99)80337-0; NEZU AM, 1989, J CONSULT CLIN PSYCH, V57, P408, DOI 10.1037/0022-006X.57.3.408; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paniak C, 2000, BRAIN INJURY, V14, P219; Paul RH, 1998, APPL NEUROPSYCHOL, V5, P143, DOI 10.1207/s15324826an0503_5; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; RABIN LA, 2001, DISS ABSTR INT, V68, pB3934; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Rath JF, 2000, J HEAD TRAUMA REHAB, V15, P724, DOI 10.1097/00001199-200002000-00010; RONAN GF, 1993, J PERS ASSESS, V61, P28, DOI 10.1207/s15327752jpa6101_3; Rosenblatt J. S., 1979, Advances in the Study of Behavior, V10, P225, DOI 10.1016/S0065-3454(08)60096-0; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Sherr RL, 1998, REHABIL PSYCHOL, V43, P184; SHERR RL, 1996, PROBLEM SOLVING ROLE; SHERR RL, 1992, NEUROPSYCHOLOGY, V6, P417, DOI DOI 10.1037/0894-4105.6.4.417; SHERR RL, 1996, PROBLEM SOLVING QUES; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spikman JM, 2000, J CLIN EXP NEUROPSYC, V22, P325, DOI 10.1076/1380-3395(200006)22:3;1-V;FT325; Spreen O., 1977, NEUROSENSORY CTR COM; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANCRAMON DY, 1992, NEUROPSYCHOL REHABIL, V2, P207; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Watson G., 1980, WATSON GLASER CRITIC; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wiegner S, 1999, ASSESSMENT, V6, P179, DOI 10.1177/107319119900600205; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; Zasler ND, 2003, NEUROPSYCHOL REHABIL, V13, P31, DOI 10.1080/09602010	85	33	33	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2004	19	5					613	635		10.1016/j.acn.2003.08.006			23	Psychology, Clinical; Psychology	Psychology	845PT	WOS:000223257500002	15271407	Bronze			2021-06-18	
J	Wassenberg, R; Max, JE; Lindgren, SD; Schatz, A				Wassenberg, R; Max, JE; Lindgren, SD; Schatz, A			Sustained attention in children and adolescents after traumatic brain injury: relation to severity of injury, adaptive functioning, ADHD and social background	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; DEFICIT-HYPERACTIVITY DISORDER; FAMILY ASSESSMENT DEVICE; SCHOOL-AGE-CHILDREN; INHIBITORY CONTROL; PERFORMANCE; RELIABILITY; PREDICTORS; CHILDHOOD; BEHAVIOR	Primary objective: To examine the relationship of child and family psychosocial variables and traumatic brain injury (TBI) severity as it relates to sustained attention ( the Paediatric Assessment of Cognitive Efficiency, PACE). Research design: Forty-two children and adolescents were recruited and participated in a 2 year longitudinal study to evaluate sustained attention using the computerized testing metric, PACE. More specifically, errors of omission ( inattention) and commission ( impulsiveness) were measured. Main outcomes and results: Significant improvement on inattention and impulsiveness were observed over time. High pre-injury psychosocial adversity and low pre-injury adaptive functioning significantly predicted a greater number of inattention errors. Severity of injury predicted the reduction of impulsiveness. Moreover, omission errors immediately after TBI predicted later secondary attention-deficit/hyperactivity disorder (SADHD, ADHD that emerges after TBI). Conclusions: Based on these findings, it is important to consider pre-injury child and family psychosocial characteristics in addition to severity of injury when predicting outcome of TBI in children.	Childrens Hosp & Hlth Ctr, San Diego, CA 92123 USA; Univ Maastricht, Maastricht, Netherlands; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Univ Iowa Hosp & Clin, Dept Pediat, Ctr Disabil & Dev, Iowa City, IA 52242 USA	Max, JE (corresponding author), Childrens Hosp & Hlth Ctr, 3020 Childrens Way,MC 5033, San Diego, CA 92123 USA.	jmax@ucsd.edu			NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH01800] Funding Source: Medline		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V.A, 2001, DEV NEUROPSYCHOLOGY; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; ARMSTRONG K, 2001, J INT NEUROPSYCH SOC, V7, P238; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Berger A, 2000, NEUROSCI BIOBEHAV R, V24, P3, DOI 10.1016/S0149-7634(99)00046-9; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; CHAMBERS WJ, 1985, ARCH GEN PSYCHIAT, V42, P696; Chhabildas N, 2001, J ABNORM CHILD PSYCH, V29, P529, DOI 10.1023/A:1012281226028; CORKUM PV, 1993, J CHILD PSYCHOL PSYC, V34, P1217, DOI 10.1111/j.1469-7610.1993.tb01784.x; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; FISHER M, 1995, J CLIN CHILD PSYCHOL, V24, P427; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Konrad KN, 2000, BRAIN INJURY, V14, P859; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LINDGREN S, 1983, PEDIAT ASSESSMENT CO; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; PLISZKA SR, 1992, J AM ACAD CHILD PSY, V31, P197, DOI 10.1097/00004583-199203000-00003; Posner M., 1996, IMAGES MIND; POSNER MI, 1994, P NATL ACAD SCI USA, V91, P7398, DOI 10.1073/pnas.91.16.7398; Reich T., 1994, PSYCHIAT EPIDEMIOLOG, P349; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Robin DA, 1999, APHASIOLOGY, V13, P701, DOI 10.1080/026870399401812; RUTTER M, 1981, AM J PSYCHIAT, V48, P564; *SAS I INC, 1999, SAS PROPR SOFTW VERS; Sparrow S., 1984, VINELAND ADAPTIVE BE; Swanson J, 1998, ATTENTIVE BRAIN, P445; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TROMMER BL, 1988, J DEV BEHAV PEDIATR, V9, P339; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Vriezen ER, 2000, BRAIN COGNITION, V44, P67; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WOLRAICH ML, 1994, NEW ENGL J MED, V330, P301, DOI 10.1056/NEJM199402033300501; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	61	33	33	0	12	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2004	18	8					751	764		10.1080/02699050410001671775			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826AN	WOS:000221801300002	15204316				2021-06-18	
J	Dash, PK; Kobori, N; Moore, AN				Dash, PK; Kobori, N; Moore, AN			A molecular description of brain trauma pathophysiology using microarray technology: An overview	NEUROCHEMICAL RESEARCH			English	Article						brain derived neurotrophic factor (BDNF); hypoxia inducible factor (HIF); transtheritin urokinase plasminogen activator receptor-1 (uPAR-1); urokinase plasminogen activator (uPA)	ENDOTHELIAL GROWTH-FACTOR; SPATIAL MEMORY DEFICITS; CORTICAL IMPACT INJURY; GENE-EXPRESSION; NEUROTROPHIC FACTOR; RAT-BRAIN; ALTERED EXPRESSION; DNA MICROARRAY; MESSENGER-RNA; UP-REGULATION	It has been estimated that 50% of human transcriptome, the collection of mRNA in a cell, is expressed in the brain, making it one of the most complex organs to understand in terms of genomic responses to injury ( 1). The availability of genome sequences for several organisms coupled with the increasing affordability of microarray technologies makes it feasible to monitor the mRNA levels of thousands of genes simultaneously. In this paper, we provide an overview of findings using both cDNA-and oligonucleotide-based microarray analyses after experimental traumatic brain injury (TBI). Specifically, the utility of this methodology as a means of cataloging the biochemical sequelae of brain trauma and elucidating novel genes or pathways for further study is discussed. Furthermore, we offer future directions for the continued evaluation of microarray results and discuss the usefulness of microarray techniques as a testing format for determining the efficacy of mechanism-based therapies.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35457] Funding Source: Medline		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Beschorner R, 2000, NEUROPATH APPL NEURO, V26, P522, DOI 10.1046/j.0305-1846.2000.287.x; Birnbaum SG, 2000, PHARMACOL BIOCHEM BE, V67, P397, DOI 10.1016/S0091-3057(00)00306-3; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; BOLL TJ, 1982, HEAD INJURY, P363; Cao YX, 2001, CURR OPIN NEUROBIOL, V11, P615, DOI 10.1016/S0959-4388(00)00258-0; Chaki S, 2003, EUR J PHARMACOL, V464, P49, DOI 10.1016/S0014-2999(03)01368-2; Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Dabrowski M, 2003, J NEUROCHEM, V85, P1279, DOI 10.1046/j.1471-4159.2003.01753.x; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; DASH PK, 1995, J NEUROSCI, V15, P2030; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; de Veer MJ, 2001, J LEUKOCYTE BIOL, V69, P912; DENT MAR, 1993, EUR J NEUROSCI, V5, P633, DOI 10.1111/j.1460-9568.1993.tb00529.x; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dobrogowska DH, 1998, J NEUROCYTOL, V27, P163, DOI 10.1023/A:1006907608230; DomanskaJanik K, 1996, ACTA NEUROBIOL EXP, V56, P579; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; Gorski JA, 2003, J NEUROSCI, V23, P6856; GRAHAM DL, 1996, TRAUMA, P1386; Halgren RG, 2001, NUCLEIC ACIDS RES, V29, P582, DOI 10.1093/nar/29.2.582; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hertel P, 1999, SCIENCE, V286, P105, DOI 10.1126/science.286.5437.105; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; Ishii M, 2000, GENOMICS, V68, P136, DOI 10.1006/geno.2000.6284; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; Kato K, 1999, J NEUROCHEM, V73, P229, DOI 10.1046/j.1471-4159.1999.0730229.x; Kjoller L, 2002, BIOL CHEM, V383, P5, DOI 10.1515/BC.2002.002; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lock C, 2002, NAT MED, V8, P500, DOI 10.1038/nm0502-500; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Luo Z, 2001, NEUROBIOL DIS, V8, P183, DOI 10.1006/nbdi.2001.0387; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; MCINTOSH TK, 1992, J CEREBR BLOOD F MET, V12, P697, DOI 10.1038/jcbfm.1992.95; Merched A, 1998, FEBS LETT, V425, P225, DOI 10.1016/S0014-5793(98)00234-8; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Mirnics K, 2001, NAT REV NEUROSCI, V2, P444, DOI 10.1038/35077587; Murphy D, 2002, ADV PHYSIOL EDUC, V26, P256, DOI 10.1152/advan.00043.2002; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Nisenbaum LK, 2002, GENES BRAIN BEHAV, V1, P27, DOI 10.1046/j.1601-1848.2001.00013.x; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Palha JA, 1996, NEUROSCI LETT, V204, P212, DOI 10.1016/0304-3940(96)12334-X; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Polazzi E, 2002, REV NEUROSCIENCE, V13, P221; POLSKYCYNKIN R, 1985, CLIN CHEM, V31, P1438; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Romano J, 2002, J MOL NEUROSCI, V18, P37, DOI 10.1385/JMN:18:1-2:37; Rothman RB, 2003, PEPTIDES, V24, P413, DOI 10.1016/S0196-9781(03)00056-1; Saito M, 2002, NEUROCHEM RES, V27, P1221, DOI 10.1023/A:1020937728506; Sendera TJ, 2002, NEUROCHEM RES, V27, P1005, DOI 10.1023/A:1020948603490; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Tachibana T, 2002, NEUROSCI LETT, V327, P133, DOI 10.1016/S0304-3940(02)00375-0; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Waxham MN, 1996, J CEREBR BLOOD F MET, V16, P1, DOI 10.1097/00004647-199601000-00001; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C; Yuferov V, 2003, SYNAPSE, V48, P157, DOI 10.1002/syn.10198	65	33	36	1	2	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	JUN	2004	29	6					1275	1286		10.1023/B:NERE.0000023614.30084.eb			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	812CB	WOS:000220816500025	15176484				2021-06-18	
J	Willer, B; Dumas, J; Hutson, A; Leddy, J				Willer, B; Dumas, J; Hutson, A; Leddy, J			A population based investigation of head injuries and symptoms of concussion of children and adolescents in schools	INJURY PREVENTION			English	Article							SPORTS-RELATED CONCUSSION; EPIDEMIOLOGY; EXPERIENCE	Objective: To examine the incidence of head injury and symptoms of concussion among children at school and to determine the relationship of age, gender, and cause to incidence rates. Design: Incident reports involving head injury for schools in the Province of Ontario, Canada during the year 2000 were evaluated. Participants: The population base for the schools represented was 1 372 979 children aged 6 to 16. Setting: 95% of schools in the province of Ontario, Canada participated in the injury reporting system. Main outcome measures: A head injury was defined as any injury to the head that came to the attention of a school official. Head injuries accompanied by symptoms of concussion became a secondary outcome measure. Results: There were 11 068 unduplicated head injury reports for the year 2000 of which 1861 qualified as producing signs or symptoms of concussion. Young children were more likely to have a head injury than older children, but slightly less likely to experience concussive symptoms. The primary cause of injury to young children was falls. Older children were more likely to receive head injuries and symptoms of concussion from sports activities. Conclusions: Overall rate of injury (3.98 per 100 children) was consistent with previous studies using prospective injury reporting systems. Probability of a head injury with symptoms of concussion among schoolchildren was only 1.9% for boys and <1% for girls during the course of their school years. There is ample justification for prevention efforts in schools.	SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA; Brock Univ, St Catharines, ON L2S 3A1, Canada; Ontario Brain Injury Assoc, St Catharines, ON, Canada; SUNY Buffalo, Inst Sports Med, Buffalo, NY USA	Willer, B (corresponding author), SUNY Buffalo, Dept Psychiat, G96 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	willer@vaxxine.com					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; BOYCE WT, 1984, PEDIATRICS, V74, P342; BOYCE WT, 1989, AM J DIS CHILD, V143, P338, DOI 10.1001/archpedi.1989.02150150096024; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GLOR ED, 1989, CAN J PUBLIC HEALTH, V80, P435; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; HAMMARSTROM A, 1994, SCAND J SOC MED, V22, P120, DOI 10.1177/140349489402200207; Iverson GL, 2004, BRAIN INJURY, V18, P1; Junkins EP, 1999, J SCHOOL HEALTH, V69, P409, DOI 10.1111/j.1746-1561.1999.tb06360.x; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; LENAWAY DD, 1992, AM J PREV MED, V8, P193; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McKeag DB, 2003, JAMA-J AM MED ASSOC, V290, P2604, DOI 10.1001/jama.290.19.2604; Schuller A A, 2000, Tidsskr Nor Laegeforen, V120, P301; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; SHEPS SB, 1987, PEDIATRICS, V79, P69; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003	21	33	33	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	JUN	2004	10	3					144	148		10.1136/ip.2003.005017			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	844YY	WOS:000223203300004	15178669	Bronze, Green Published			2021-06-18	
J	Daugherty, WP; Levasseur, JE; Sun, D; Spiess, BD; Bullock, MR				Daugherty, WP; Levasseur, JE; Sun, D; Spiess, BD; Bullock, MR			Perfluorocarbon emulsion improves cerebral oxygenation and mitochondrial function after fluid percussion brain injury in rats	NEUROSURGERY			English	Article						cerebral oxygenation; mitochondrial function; perfluorocarbon; traumatic brain injury	ARTIFICIAL BLOOD SUBSTITUTES; HUMAN HEAD-INJURY; FLUOSOL-DA; TISSUE OXYGENATION; TRANSPORT; ISCHEMIA; METABOLISM; MODEL; DOGS; PERFLUOROCHEMICALS	OBJECTIVE: Cerebral ischemia is a common secondary sequela of traumatic brain injury (TBI). Experimental models of stroke have demonstrated reductions in ischemia after perfluorocarbon (PFC) administration; however, there are no published reports of PFC efficacy after TBI. The current study analyzed the effect of the PFC emulsion Oxygent (AF0144; Alliance Pharmaceutical Corp., San Diego, CA) on cerebral oxygenation, mitochondrial redox potential, and free radical formation after lateral fluid percussion injury. METHODS: After fluid percussion injury, five 2.25 ml/kg doses of PFC or saline were administered to rats breathing 100% O-2, and oxygen tension was recorded. In a second experiment, a single bolus (11.25 ml/kg) of PFC or saline was given after injury, and redox potential and free radical formation were measured at I or 4 hours with Alamar blue dye and dihydrorhodamine 123, respectively. RESULTS: Cerebral oxygen tension was significantly increased in both injured and sham animals treated with 11.25 ml/kg of PFC as compared with saline (P < 0.05). Likewise, PFC significantly increased mitochondrial redox potential as compared with saline at 4 hours after injury (P < 0.01). Mitochondrial peroxynitrite and peroxide production also increased with the administration of PFC (P < 0.05). CONCLUSION: The current study demonstrates that a PFC emulsion can significantly increase cerebral oxygenation after TBI and enhance mitochondrial function at 4 hours after injury as compared with saline. This study demonstrates a new therapeutic potential for PFC to enhance cerebral oxygenation and aerobic metabolism after TBI. However, the increased free radical formation with high-dose PFCs suggests the need for further studies combining PFCs with free radical scavengers.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anesthesiol, Richmond, VA 23298 USA	Bullock, MR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, POB 980631,1200 E Marshall St, Richmond, VA 23298 USA.	robulloc@hsc.vcu.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587] Funding Source: NIH RePORTER		Alessandri B, 1999, ACT NEUR S, V75, P21; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; CLARK LC, 1966, SCIENCE, V152, P1755, DOI 10.1126/science.152.3730.1755; COKELET GR, 1987, HDB BIOENGINEERING, P1; DAUGHERTY WP, 2002, J NEUROTRAUM, V19, P1357; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EYER CL, 1991, BIOMAT ARTIF CELL IM, V19, P719, DOI 10.3109/10731199109117850; FAITHFULL NS, 1988, J CRIT CARE, V3, P14; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; GEYER RP, 1988, BIOMATER ARTIF CELL, V16, P31; GEYER RP, 1982, NEW ENGL J MED, V307, P304, DOI 10.1056/NEJM198207293070509; GEYER RP, 1975, FED PROC, V34, P1499; GEYER RP, 1973, NEW ENGL J MED, V289, P1077; GLOGAR DH, 1981, SCIENCE, V211, P1439, DOI 10.1126/science.7466402; GUO J, 1995, NEUROSURGERY, V36, P350, DOI 10.1227/00006123-199502000-00015; HENDERSON LM, 1993, EUR J BIOCHEM, V217, P973, DOI 10.1111/j.1432-1033.1993.tb18328.x; JOHNSON EC, 1995, J APPL PHYSIOL, V79, P1777; KAUFMAN RJ, 1995, BLOOD SUBSTITUTES, P53; KAUFMAN RJ, 1996, BLOOD SUBSTITUTES NE, P60; KLINE RA, 1991, AM J SURG, V162, P103, DOI 10.1016/0002-9610(91)90168-D; KOLODGIE FD, 1985, VIRCHOWS ARCH B, V50, P119; LEHNINGER AL, 1982, PRINCIPLES BIOCH, P435; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Matthews OA, 1998, PROG POLYM SCI, V23, P1, DOI 10.1016/S0079-6700(97)00025-7; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MITSUNO T, 1982, ANN SURG, V195, P60, DOI 10.1097/00000658-198201001-00010; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, P1; O'Brien J, 2000, EUR J BIOCHEM, V267, P5421, DOI 10.1046/j.1432-1327.2000.01606.x; OSTERHOLM JL, 1983, NEUROSURGERY, V13, P381, DOI 10.1227/00006123-198310000-00006; Padnick LB, 1999, J APPL PHYSIOL, V86, P1497; Patel S, 1998, ASAIO J, V44, P157, DOI 10.1097/00002480-199805000-00007; Patel S, 1998, ASAIO J, V44, P144, DOI 10.1097/00002480-199805000-00006; PEERLESS SJ, 1985, STROKE, V16, P38, DOI 10.1161/01.STR.16.1.38; PEERLESS SJ, 1981, STROKE, V12, P558, DOI 10.1161/01.STR.12.5.558; RIESS JG, 1991, VOX SANG, V61, P225, DOI 10.1111/j.1423-0410.1991.tb00952.x; SATTERFIELD R, 1993, INVEST RADIOL, V28, P325, DOI 10.1097/00004424-199304000-00013; Springer JE, 1998, BRAIN RES PROTOC, V2, P259, DOI 10.1016/S1385-299X(97)00045-7; Stowell CP, 2001, TRANSFUSION, V41, P287, DOI 10.1046/j.1537-2995.2001.41020287.x; SUZUKI J, 1984, STROKE, V15, P672, DOI 10.1161/01.STR.15.4.672; Taguchi Y, 1986, No To Shinkei, V38, P177; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yoles E, 2000, NEUROL RES, V22, P404, DOI 10.1080/01616412.2000.11740691; ZUCK TF, 1994, CRIT REV CL LAB SCI, V31, P295, DOI 10.3109/10408369409084678	51	33	34	2	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2004	54	5					1223	1230		10.1227/01.NEU.0000119238.68938.5D			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	819JA	WOS:000221310000054	15113478				2021-06-18	
J	Kao, CQ; Goforth, PB; Ellis, EF; Satin, LS				Kao, CQ; Goforth, PB; Ellis, EF; Satin, LS			Potentiation of GABA(A) currents after mechanical injury of cortical neurons	JOURNAL OF NEUROTRAUMA			English	Article						cortex; GABA; GABA(A) receptor; NMDA antagonist; traumatic brain injury	TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; INTRACELLULAR FREE CALCIUM; FLUID-PERCUSSION INJURY; STRETCH-INDUCED INJURY; AMINO-ACIDS; AMPA RECEPTORS; NEGATIVE MODULATION; SILENT SYNAPSES; HEAD TRAUMA	Numerous studies have implicated glutamate receptors, glutamate neurotoxicity, and hyperexcitation in the pathobiology of traumatic brain injury, yet much less is known about the effects of neurotrauma on inhibitory GABA channels of the brain. Using an in vitro cell injury model, we tested whether mild stretch injury altered the GABA(A) Currents of cultured rat cortical neurons. The application of 1-100 muM GABA to single pyramidal neurons voltage clamped to -60 mV activated an inward current that reversed near 0 mV in solutions containing symmetrical [Cl-]. This current was inhibited by bicuculline, consistent with mediation by GABAA receptor channels. In injured neurons, 50 muM GABA elicited a peak current density of 41.2 +/- 2.6 pA/pF (n = 82), which was significantly larger than in uninjured control neurons, 20.2 +/- 1.7 pA/pF (n = 69,p < 0.01). The GABAA currents of injured neurons did not differ from those of control neurons in their sensitivity to GABA or their reversal potentials, suggesting that GABA current potentiation did not result from changes in the agonist affinity or ionic selectivity of the channels. GABA current potentiation was prevented by injuring neurons in the presence of the NMDA antagonist APV, or the CaMKII inhibitor KN93. These results thus suggest that NMDA receptor activation following neuronal injury may potentiate GABAA channels through the activation of CaMKII. The increase in GABAA receptor function observed following injury could potentially contribute to dysfunctional synaptic function and information processing as well as unconsciousness and coma following human brain trauma.	Virginia Commonwealth Univ, Ctr Med, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Med, Dept Physiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Ctr Med, Dept Med Endocrinol, Richmond, VA 23298 USA; Vanderbilt Univ, Ctr Med, Dept Neurol Surg, Nashville, TN 37232 USA	Satin, LS (corresponding author), Virginia Commonwealth Univ, Ctr Med, Dept Pharmacol & Toxicol, Box 980524, Richmond, VA 23298 USA.	lsatin@hsc.vcu.edu			PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [5T32N50 7288-13, 521084] Funding Source: Medline		Aguayo LG, 1998, PFLUG ARCH EUR J PHY, V435, P382, DOI 10.1007/s004240050527; Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Allison DW, 2000, J NEUROSCI, V20, P4545, DOI 10.1523/JNEUROSCI.20-12-04545.2000; ANDINE P, 1991, DEV BRAIN RES, V64, P115, DOI 10.1016/0165-3806(91)90214-4; BEDFORD FK, 2000, SOC NEUR M ABST, P1657; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; BULLOCK R, 1997, HEAD INJURY PATHOPHY, P120; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; CELENTANO JJ, 1991, MOL PHARMACOL, V40, P766; CHOI DW, 1987, J NEUROSCI, V7, P369; Churn SB, 2000, P NATL ACAD SCI USA, V97, P5604, DOI 10.1073/pnas.080071697; CHURN SB, 2000, SOC NEUR M ABST, P1657; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GOFORTH PB, 2000, SOC NEUR ABST, V26; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HERRINGTON J, 1994, PULSE CONTROL V4 3 I; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KANTHAN R, 1995, J NEUROL NEUROSUR PS, V59, P326, DOI 10.1136/jnnp.59.3.326; KAO CQ, 1999, SOC NEUR M ABST, V29, P314; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; LEGENDRE P, 1991, MOL PHARMACOL, V39, P267; LIAO D, 2000, NATURE, V405, P955; Liao DH, 1999, NAT NEUROSCI, V2, P37; Lissin DV, 1999, J NEUROSCI, V19, P1263; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu WY, 2001, NEURON, V29, P243, DOI 10.1016/S0896-6273(01)00194-5; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.ne.17.030194.003033; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Dell DM, 2000, BRAIN RES, V861, P325, DOI 10.1016/S0006-8993(00)02055-2; ODELL DM, 1995, J NEUROSURG, V83, P878, DOI 10.3171/jns.1995.83.5.0878; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Pickard L, 2001, NEUROPHARMACOLOGY, V41, P700, DOI 10.1016/S0028-3908(01)00127-7; Reeves TM, 1997, NEUROSCIENCE, V77, P431, DOI 10.1016/S0306-4522(96)00486-1; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Sieghart W, 1999, NEUROCHEM INT, V34, P379, DOI 10.1016/S0197-0186(99)00045-5; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; SMART TG, 1990, BRIT J PHARMACOL, V99, P643, DOI 10.1111/j.1476-5381.1990.tb12984.x; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; Toth Z, 1997, J NEUROSCI, V17, P8106; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; Weber JT, 2002, J NEUROTRAUM, V19, P1433, DOI 10.1089/089771502320914660; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Whiting PJ, 1999, NEUROCHEM INT, V34, P387, DOI 10.1016/S0197-0186(99)00048-0; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	63	33	34	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					259	270		10.1089/089771504322972059			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600004	15115601				2021-06-18	
J	Eriksson, PO; Zafar, H; Haggman-Henrikson, B				Eriksson, PO; Zafar, H; Haggman-Henrikson, B			Deranged jaw-neck motor control in whiplash-associated disorders	EUROPEAN JOURNAL OF ORAL SCIENCES			English	Article						human; jaw; neck; movement; whiplash	OPENING-CLOSING TASKS; HUMAN MASSETER MUSCLE; TEMPOROMANDIBULAR DISORDERS; INTRAMUSCULAR CONCENTRATION; CRANIOFACIAL PAIN; FUSIMOTOR DRIVE; HEAD; MOVEMENTS; BRADYKININ; SPINDLES	Recent findings of simultaneous and well coordinated head-neck movements during single as well as rhythmic jaw opening-closing tasks has led to the conclusion that 'functional jaw movements' are the result of activation of jaw as well as neck muscles, leading to simultaneous movements in the temporomandibular, atlanto-occipital and cervical spine joints. It can therefore be assumed that disease or injury to any of these joint systems would disturb natural jaw function. To test this hypothesis, amplitudes, temporal coordination, and spatiotemporal consistency of concomitant mandibular and head-neck movements during single maximal jaw opening-closing tasks were analysed in 25 individuals suffering from whiplash-associated disorders (WAD) using optoelectronic movement recording technique. In addition, the relative durations for which the head position was equal to, leading ahead of, or lagging behind the mandibular position during the entire jaw opening-closing cycle were determined. Compared with healthy individuals, the WAD group showed smaller amplitudes, and changed temporal coordination between mandibular and head-neck movements. No divergence from healthy individuals was found for the spatiotemporal consistency or for the analysis during the entire jaw opening-closing cycle. These findings in the WAD group of a 'faulty', but yet consistent, jaw-neck behavior may reflect a basic importance of linked control of the jaw and neck sensory-motor systems. In conclusion, the present results suggest that neck injury is associated with deranged control of mandibular and head-neck movements during jaw opening-closing tasks, and therefore might compromise natural jaw function.	Umea Univ, Dept Odontol Clin Oral Physiol, S-90187 Umea, Sweden; Gavle Univ, Ctr Musculoskeletal Res, Gavle, Sweden	Eriksson, PO (corresponding author), Umea Univ, Dept Clin Oral Physiol, S-90187 Umea, Sweden.	per-olof.eriksson@odont.umu.se	Haggman-Henrikson, Birgitta/C-6998-2008	Haggman-Henrikson, Birgitta/0000-0001-6088-3739; Zafar, Hamayun/0000-0001-9318-3691			Browne PA, 1998, ORAL SURG ORAL MED O, V86, P633, DOI 10.1016/S1079-2104(98)90195-0; Capra NF, 2000, PAIN, V86, P151, DOI 10.1016/S0304-3959(00)00231-1; De Laat A, 1998, Clin Oral Investig, V2, P54, DOI 10.1007/s007840050045; Dessem D, 1999, EXP BRAIN RES, V128, P451, DOI 10.1007/s002210050868; DJUPSJOBACKA M, 1995, NEUROSCI RES, V22, P325, DOI 10.1016/0168-0102(95)00906-A; Eriksson PO, 2000, J DENT RES, V79, P1378, DOI 10.1177/00220345000790060501; Eriksson PO, 1998, J ORAL REHABIL, V25, P859, DOI 10.1046/j.1365-2842.1998.00333.x; ERIKSSON PO, 1987, ARCH ORAL BIOL, V32, P483, DOI 10.1016/S0003-9969(87)80009-2; ERIKSSON PO, 1994, MUSCLE NERVE, V17, P31, DOI 10.1002/mus.880170105; Ferrari R, 1998, J AM DENT ASSOC, V129, P1739, DOI 10.14219/jada.archive.1998.0144; Freeman MD, 1999, SPINE, V24, P86, DOI 10.1097/00007632-199901010-00022; Goldberg MB, 1999, J OROFAC PAIN, V13, P291; Haggman-Henrikson B, 2002, J DENT RES, V81, P747, DOI 10.1177/154405910208101105; Helkimo M, 1974, Sven Tandlak Tidskr, V67, P165; Hellstrom F, 2000, J DENT RES, V79, P1815, DOI 10.1177/00220345000790101401; HELLSTROM F, 2002, THESIS UMEA U UMEA; HU JW, 1993, PAIN, V55, P243, DOI 10.1016/0304-3959(93)90153-G; Johansson H, 1999, AM J IND MED, P104; Josefsson T, 1996, COMPUT METH PROG BIO, V49, P119, DOI 10.1016/0169-2607(96)01715-4; Karppinen K, 1999, J ORAL REHABIL, V26, P715, DOI 10.1046/j.1365-2842.1999.00448.x; Kasch H, 2002, J OROFAC PAIN, V16, P118; KIRVESKARI P, 1984, COMMUNITY DENT ORAL, V12, P78, DOI 10.1111/j.1600-0528.1984.tb01417.x; Kirveskari P, 1984, Proc Finn Dent Soc, V80, P227; KIRVESKARI P, 1988, ACTA ODONTOL SCAND, V46, P281, DOI 10.3109/00016358809004778; Kohno S, 2001, J ORAL REHABIL, V28, P740, DOI 10.1046/j.1365-2842.2001.00707.x; Kolbinson Dean A., 1996, Journal of Orofacial Pain, V10, P101; LUND JP, 1991, CAN J PHYSIOL PHARM, V69, P683, DOI 10.1139/y91-102; McKay DC, 1998, J ORAL REHABIL, V25, P731, DOI 10.1046/j.1365-2842.1998.00321.x; OKESON JP, 1996, OROFACIAL PAIN GUIDE, P19; Pedersen J, 1997, PAIN, V70, P83, DOI 10.1016/S0304-3959(96)03305-2; Ro JY, 2001, PAIN, V92, P117, DOI 10.1016/S0304-3959(00)00477-2; SPITZER WO, 1995, SPINE, V20, pS1; Stohler CS, 1999, CRIT REV ORAL BIOL M, V10, P504, DOI 10.1177/10454411990100040601; Svensson P, 2001, J OROFAC PAIN, V15, P117; VISSCHER CM, 2000, THESIS ACAD CTR DENT; Wenngren BI, 1998, NEUROSCI RES, V32, P119, DOI 10.1016/S0168-0102(98)00074-1; Zafar H, 2000, ARCH ORAL BIOL, V45, P675, DOI 10.1016/S0003-9969(00)00032-7; Zafar H, 2000, J ORAL REHABIL, V27, P227, DOI 10.1046/j.1365-2842.2000.00505.x; Zafar H, 2002, EXP BRAIN RES, V146, P70, DOI 10.1007/s00221-002-1157-y; ZAFAR H, 2000, SWED DENT J S, V143, P1	40	33	34	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0909-8836	1600-0722		EUR J ORAL SCI	Eur. J. Oral Sci.	FEB	2004	112	1					25	32		10.1111/j.0909-8836.2004.00098.x			8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	772WF	WOS:000188864400006	14871190				2021-06-18	
J	Paschen, W; Yatsiv, I; Shoham, S; Shohami, E				Paschen, W; Yatsiv, I; Shoham, S; Shohami, E			Brain trauma induces X-box protein 1 processing indicative of activation of the endoplasmic reticulum unfolded protein response	JOURNAL OF NEUROCHEMISTRY			English	Article						brain trauma; endoplasmic reticulum; heat-shock protein 70; growth arrest and DNA damage-inducible gene; 153; glucose-regulated proteins; unfolded protein response; X-box protein 1 processing	CLOSED-HEAD INJURY; NITRIC-OXIDE SYNTHASE; XBP1 MESSENGER-RNA; CEREBRAL-ISCHEMIA; TRANSCRIPTION FACTOR; STRESS-RESPONSE; TRANSLATIONAL CONTROL; CELL INJURY; ER STRESS; RAT-BRAIN	Brain trauma was induced in mice using a closed head injury (CHI) model. At 1, 6 or,24 h after trauma, brains were dissected into the cortex, striatum and hippocampus. Changes in levels of processed X-box protein 1 (xbp1), glucose-regulated protein 78 (grp78), growth arrest and DNA damage-inducible gene 153 (gadd153) and heat-shock protein 70 (hsp70) mRNA, indicating impaired endoplasmic reticulum (ER) and cytoplasmic functioning, were evaluated by quantitative PCR. In the cortex, processed xbp1 mRNA levels rose to 2000% of control 1 h after CHI, and stayed high throughout the experiments. In the hippocampus and striatum, processed xbp1 mRNA levels rose in a delayed fashion, peaking at 6 h (1000% of control) and 24 h after, CHI (1500% of control) respectively. Levels of grp78 mRNA were only slightly increased in the cortex 24 h after CHI (150% of control), and were unchanged or transiently decreased in the hippocampus and striatum. Levels of gadd153 mRNA did not change significantly after trauma. A transient rise in hsp70 mRNA levels was observed-only in the cortex, peaking at 1 h after CHI (600% of control). Processing of xbp1 mRNA is a sign of activation of the unfolded protein response indicative of ER dysfunction. The results suggest that brain trauma induces ER dysfunction, which spreads from the ipsilateral cortex to the hippocampus and striatum., These observations may have clinical implications and should therefore be considered for future investigations on therapeutic intervention of brain injury caused by contusion-induced neurotrauma.	Max Planck Inst Neurol Res, Dept Expt Neurol, Lab Mol Neurol, D-50931 Cologne, Germany; Hebrew Univ Jerusalem, Hadassah Med Ctr, Pediat Intens Care Unit, Jerusalem, Israel; Res Dept Herzog Hosp, Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Paschen, W (corresponding author), Max Planck Inst Neurol Res, Dept Expt Neurol, Lab Mol Neurol, Gleueler Str 50, D-50931 Cologne, Germany.	paschen@mpin-koeln.mpg.de					Alagarsamy S, 1998, J NEUROTRAUM, V15, P627, DOI 10.1089/neu.1998.15.627; Anwaar I, 1999, ANGIOLOGY, V50, P1, DOI 10.1177/000331979905000101; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Ashwal S, 1998, STROKE, V29, P1037, DOI 10.1161/01.STR.29.5.1037; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berridge MJ, 1998, NEURON, V21, P13, DOI 10.1016/S0896-6273(00)80510-3; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Gahm C, 2000, NEUROSURGERY, V46, P169; GALLYAS F, 1990, ACTA NEUROPATHOL, V79, P620, DOI 10.1007/BF00294239; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gissel C, 1997, J NEUROCHEM, V69, P2538; GOSH TK, 1991, J BIOL CHEM, V266, P24690; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Harding HP, 1999, NATURE, V397, P271; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kumar R, 2001, J NEUROCHEM, V77, P1418, DOI 10.1046/j.1471-4159.2001.00387.x; KUZNETSOV G, 1992, J BIOL CHEM, V265, P3932; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LODISH HF, 1992, J BIOL CHEM, V267, P12753; LONGO FM, 1993, J NEUROSCI RES, V36, P325, DOI 10.1002/jnr.490360310; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; Miyoshi K, 2000, MOL BRAIN RES, V85, P68, DOI 10.1016/S0169-328X(00)00243-6; PARFETT CLJ, 1989, GENE, V82, P291, DOI 10.1016/0378-1119(89)90054-1; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Paschen W, 2003, J CEREBR BLOOD F MET, V23, P449, DOI 10.1097/01.WCB.0000054216.21675.AC; Paschen W, 1996, MED HYPOTHESES, V47, P283, DOI 10.1016/S0306-9877(96)90068-7; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Petrov T, 2001, J NEUROTRAUM, V18, P799, DOI 10.1089/089771501316919166; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; WILETTE RN, 1993, LIFE SCI, V52, P35; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	58	33	35	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	2004	88	4					983	992		10.1046/j.1471-4159.2003.02218.x			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	774UK	WOS:000189003500023	14756820	Bronze			2021-06-18	
J	Ueda, Y; Suehiro, E; Wei, EP; Kontos, HA; Povlishock, JT				Ueda, Y; Suehiro, E; Wei, EP; Kontos, HA; Povlishock, JT			Uncomplicated rapid posthypothermic rewarming alters cerebrovascular responsiveness	STROKE			English	Article						cerebrovascular circulation; hypothermia; rewarming; rats	PIAL ARTERIOLES; POSTTRAUMATIC HYPOTHERMIA; POTASSIUM CHANNELS; VASODILATION; TEMPERATURE; OPENERS; VESSELS; INJURY	Background and Purpose - Recently, we focused on the cerebrovascular protective effects of moderate hypothermia after traumatic brain injury, noting that the efficacy of posttraumatic hypothermia is related to the rate of posthypothermic rewarming. In the current communication, we revisit the use of hypothermia with varying degrees of rewarming to ascertain whether, in the normal cerebral vasculature, varying rates of rewarming can differentially affect cerebrovascular responsiveness. Methods - Pentobarbital-anesthetized rats equipped with a cranial window were randomized to 3 groups. In 1 group, a 1-hour period of hypothermia ( 32 degreesC) followed by slow rewarming ( over 90 minutes) was used. In the remaining 2 groups, either a 1- or 2-hour period of hypothermia was followed by rapid rewarming ( within 30 minutes). Vasoreactivity to hypercapnia and acetylcholine was assessed before, during, and after hypothermia. Additionally, the vascular responses to sodium nitroprusside ( SNP) and pinacidil, a K-ATP channel opener, were also examined. Results - Hypothermia itself generated modest vasodilation and reduced vasoreactivity to all utilized agents. The slow rewarming group showed restoration of normal vascular responsivity. In contrast, hypothermia followed by rapid rewarming was associated with continued impaired responsiveness to acetylcholine and arterial hypercapnia. These abnormalities persisted even with the use of more prolonged (2-hour) hypothermia. Furthermore, posthypothermic rapid rewarming impaired the dilator responses of SNP and pinacidil. Conclusions - Posthypothermic rapid rewarming caused cerebral vascular abnormalities, including a diminished response to acetylcholine, hypercapnia, pinacidil, and SNP. Our data with acetylcholine and SNP suggest that rapid rewarming most likely causes abnormality at both the vascular smooth muscle and endothelial levels.	Virginia Commonwealth Univ, VCU Hlth Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA; Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, VCU Hlth Ctr, Dept Anat & Neurobiol, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu	Suehiro, Eiichi/I-5852-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; Erecinska M, 2003, J CEREBR BLOOD F MET, V23, P513, DOI 10.1097/01.WCB.0000066287.21705.21; Horiuchi T, 2001, STROKE, V32, P218, DOI 10.1161/01.STR.32.1.218; Inoue S, 2001, CRIT CARE MED, V29, P2162, DOI 10.1097/00003246-200111000-00019; Irikura K, 1998, J CEREBR BLOOD F MET, V18, P1294, DOI 10.1097/00004647-199812000-00003; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; Mustafa S, 2002, STROKE, V33, P256, DOI 10.1161/hs0102.101545; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; OGURA K, 1991, J NEUROSURG, V75, P433, DOI 10.3171/jns.1991.75.3.0433; Polderman KH, 2001, J NEUROSURG, V94, P853; Rosenblum WI, 2001, EUR J PHARMACOL, V430, P101, DOI 10.1016/S0014-2999(01)01361-9; Sagher O, 1997, J NEUROSURG, V87, P431, DOI 10.3171/jns.1997.87.3.0431; Saito W, 1998, J CARDIOVASC PHARM, V31, P327, DOI 10.1097/00005344-199802000-00021; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862	20	33	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	FEB	2004	35	2					601	606		10.1161/01.STR.0000113693.56783.73			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	769VB	WOS:000188669500062	14739414	Bronze			2021-06-18	
J	Hashiguchi, N; Shiozaki, T; Ogura, H; Tanaka, H; Koh, T; Noborio, M; Fugita, K; Akimau, P; Kuwagata, Y; Shimazu, T; Sugimoto, H				Hashiguchi, N; Shiozaki, T; Ogura, H; Tanaka, H; Koh, T; Noborio, M; Fugita, K; Akimau, P; Kuwagata, Y; Shimazu, T; Sugimoto, H			Mild hypothermia reduces expression of heat shock protein 60 in leukocytes from severely head-injured patients	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						heat shock protein 60; head injury; mild hypothermia; infectious complication; polymorphonuclear leukocyte; flow cytometry	LOW INTRACRANIAL-PRESSURE; TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; ENHANCED EXPRESSION; SHOCK PROTEINS; THERAPY; CELLS; MYCOBACTERIAL; INFECTIONS; INVITRO	Background. Infectious complications are among the most serious problems that occur in severely head-injured patients treated with mild hypothermia. The mechanism underlying the susceptibility to infection has not been clarified. Heat shock protein (HSP) 60 has been reported to play an essential role in innate immunity. Thus, we conducted a study to clarify the impact of mild hypothermia on the expression of HSPs in polymorphonuclear leukocytes (PMNLs) in severely head-injured patients. Methods. Between September 1997 and November 1999, 17 severely head-injured patients with a Glasgow Coma Scale score of 8 or less at admission in whom intracranial pressure could be maintained below 20 mm Hg by conventional therapy were randomly assigned to two treatment groups: a mild hypothermia group (HT group, nine patients) and a normothermia group (NT group, eight patients). The HT group was subjected to mild hypothermia (intracranial temperature, 34degreesC) for 48 hours followed by rewarming at a rate of VC per day for 3 days, whereas the NT group was subjected to normothermia (intracranial temperature, 37degreesC) for 5 days. Blood samples were serially obtained at three time points; days 0 to 1, days 2 to 5, and days 6 to 14 after head injury. We measured the expression of HSP27, HSP60, HSP70, and HSP90 by flow cytometry. Results. The two groups were similar with respect to prognostic factors, and there was no difference in clinical outcome. The expression of PMNL HSP60 in the HT group was significantly lower in all three time periods compared with that in the NT group (p < 0.05), whereas expression of the other HSPs did not differ significantly between the groups. The incidence of infectious complications was significantly increased in the HT group over that in the NT group (p < 0.05). In in vitro studies, PMNLs from 10 healthy volunteers were incubated at 37degreesC, 34degreesC, or 26degreesC for 1 hour with sodium arsenite (100,mumol/L), an HSP inducer. The expression of HSP60 at 26degreesC and 34degreesC was significantly lower than that at 37degreesC (p < 0.05), whereas expression of the other HSPs did not differ significantly at 26degreesC, 34degreesC, or 37degreesC. Conclusion: Mild hypothermia reduces the expression of HSP60 in PMNLs from severely head-injured patients. Thus, mild hypothermia may suppress innate immunity.	Osaka Univ, Dept Traumatol D 8, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Clin Invest, Grad Sch Med, Suita, Osaka 5650871, Japan; Tottori Prefectual Cent Hosp, Dept Traumatol & Crit Care Med, Tottori, Japan	Hashiguchi, N (corresponding author), Osaka Univ, Dept Traumatol D 8, Grad Sch Med, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan.	hashiguchi@mx51.tiki.ne.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15390545] Funding Source: KAKEN		AKRIOTIS V, 1985, J LEUKOCYTE BIOL, V37, P51; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; CHANT ID, 1995, BRIT J HAEMATOL, V90, P163, DOI 10.1111/j.1365-2141.1995.tb03395.x; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; FERRICK DA, 1992, CHEM IMMUNOL, V53, P17; Hashiguchi N, 2001, J TRAUMA, V51, P1104, DOI 10.1097/00005373-200112000-00015; Hashiguchi N, 2001, J TRAUMA, V50, P102, DOI 10.1097/00005373-200101000-00018; Jason J, 2000, J INFECT DIS, V182, P474, DOI 10.1086/315740; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KAUFMANN SHE, 1991, IMMUNOL REV, V121, P67, DOI 10.1111/j.1600-065X.1991.tb00823.x; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; LEE KJ, 1998, J CELL PHYSL, V136, P411; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; OBRIEN RL, 1991, IMMUNOL REV, V121, P155, DOI 10.1111/j.1600-065X.1991.tb00827.x; PEETERMANS WE, 1994, SCAND J IMMUNOL, V39, P613, DOI 10.1111/j.1365-3083.1994.tb03421.x; SHINNICK TM, 1991, CURR TOP MICROBIOL, V167, P145; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; THOMAS G, 1986, J PHARM PHARMACOL, V38, P936, DOI 10.1111/j.2042-7158.1986.tb03390.x; Wiegant FAC, 1996, J CELL PHYSIOL, V169, P364, DOI 10.1002/(SICI)1097-4652(199611)169:2<364::AID-JCP16>3.0.CO;2-9	24	33	36	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	2003	55	6					1054	1060		10.1097/01.TA.0000033252.43742.8B			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	758TL	WOS:000187666200009	14676650				2021-06-18	
J	Taylor, HG; Yeates, KO; Wade, SL; Drotar, D; Stancin, T; Montpetite, M				Taylor, HG; Yeates, KO; Wade, SL; Drotar, D; Stancin, T; Montpetite, M			Long-term educational interventions after traumatic brain injury in children	REHABILITATION PSYCHOLOGY			English	Article							ACADEMIC-PERFORMANCE; SCHOOL REENTRY; HEAD-INJURIES; BIRTH-WEIGHT; ADOLESCENTS; OUTCOMES; RECOVERY; DISABILITIES; ACHIEVEMENT; PLACEMENT	Objectives: To track educational interventions received by children with traumatic brain injury (TBI), examine factors associated with placement in special education, and explore the concordance of placement with children's needs. Methods: Interventions were monitored in 42 children with severe TBI, 42 with moderate TBI, and 50 with orthopedic injuries only (ORTHO group). A baseline assessment was completed soon after injury. Follow-up assessments were conducted 6 and 12 months after the baseline and at an extended follow-up about 4 years postinjury. Results: Rates of special education were higher in the severe TBI group than in the ORTHO. Predictors of special education included TBI severity, socioeconomic status, and measures of pre- and postinjury child status. Several children with TBI with residual deficits who were in regular education prior to injury did not receive special education at the extended follow-up. Conclusion: Although special education is frequently provided for several years after severe TBI, existing programs are of limited scope.	Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Ohio State Univ, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA; Univ Cincinnati, Dept Phys Med & Rehabil, Cincinnati, OH USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Metrohlth Med Ctr, Cleveland, OH 44109 USA	Taylor, HG (corresponding author), Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.		Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892			Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach T.M., 1991, MANUAL TEACHERS REPO; BEERY KE, 1989, REVISED ADM SCORING; Bernstein JH, 1986, DEV SCORING SYSTEM R; Blosser JL, 1991, J HEAD TRAUMA REHAB, V6, P73; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Brown L., 1990, TEST NONVERBAL INTEL; CARNEY J, 1994, PEDIATR ANN, V23, P47, DOI 10.3928/0090-4481-19940101-10; CARNEY J, 1990, Pediatrician, V17, P222; Catroppa C, 1999, Pediatr Rehabil, V3, P167; DELIS DC, 1986, CALIFORNIA VERBAL LE; DiSimoni F., 1978, TOKEN TEST CHILDREN; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Ewing-Cobbs L, 1999, COGNITIVE ASPECTS OF CHRONIC ILLNESS IN CHILDREN, P262; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; FARMER JE, 1995, NEUROREHABILITATION, V5, P49, DOI 10.3233/NRE-1995-5105; FARMER JE, 1995, SCHOOL PSYCHOL REV, V24, P230; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; HANSON SL, 1992, PHYSICAL MED REHABIL, V6, P483; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KNIGHTS RM, 1980, REVISED SMOOTHED NOR; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; MAYER T, 1980, J PEDIATR SURG, V15, P19; MOOS R, 1988, LIFE STRESSORS SOCIA; Paniak C, 1997, CLIN NEUROPSYCHOL, V11, P198, DOI 10.1080/13854049708407051; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Resnick MB, 1998, PEDIATRICS, V102, P308, DOI 10.1542/peds.102.2.308; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; Semel E., 1987, CELF R CLIN EVALUATI; SHAYWITZ SE, 1990, JAMA-J AM MED ASSOC, V264, P998, DOI 10.1001/jama.264.8.998; SHURTLEFF HA, 1995, J HEAD TRAUMA REHAB, V10, P64, DOI 10.1097/00001199-199510000-00008; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O., 1991, COMPENDIUM NEUROPSYC; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; SZEKERES SF, 1994, TOP LANG DISORD, V15, P21, DOI 10.1097/00011363-199411000-00004; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 1998, CHILD NEUROPSYCHOL, V4, P21, DOI 10.1076/chin.4.1.21.3188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; TELZROW CF, 1991, J HEAD TRAUMA REHAB, V6, P23; Wechsler D., 1991, WISC 3 WECHSLER INTE; Wiig E.H., 1985, TEST LANGUAGE COMPET; WOODCOCK RW, 1989, WOODCOCKJOHNSON TEST; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; Ylvisaker M, 1998, TRAUMATIC BRAIN INJU, P369; Ylvisaker M, 1991, J HEAD TRAUMA REHAB, V6, P10, DOI DOI 10.1097/00001199-199103000-00006; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	67	33	33	0	10	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2003	48	4					227	236		10.1037/0090-5550.48.4.227			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	741ER	WOS:000186446200001					2021-06-18	
J	Patrick, PD; Buck, ML; Conaway, MR; Blackman, JA				Patrick, PD; Buck, ML; Conaway, MR; Blackman, JA			The use of dopamine enhancing medications with children in low response states following brain injury	BRAIN INJURY			English	Article							FRONTAL-LOBE DYSFUNCTION; VEGETATIVE STATE; AMANTADINE	Primary objective: The study examines the possible relationship between dopamine-enhancing medications and improvement of arousal and awareness in children during persistent low response states (Rancho Los Amigos Levels I, II and III). Research design: A retrospective review was conducted of 10 children enrolled in an existing clinical protocol. The Kluge Children's Rehabilitation Center (KCRC) low response protocol provides a double baseline serial measure (A, A, B, B, B) design. Scores on the Western NeuroSensory Stimulation Profile (WNSSP) are the dependent variable. Methods and procedures: Ten children, mean age of 13.7 years low response state (30 days or more) who were treated with dopamine agonists. Co-morbid or iatrogenic influences were addressed or ruled out. Seven children had traumatic brain injury, one cerebral vascular accident, one anoxia and one encephalitis. Experimental intervention: On average, dopamine medications were started 52.9 days post-event. Main outcomes and results: Paired t-test of WNSSP scores before medications and on medications were significant at p=0.03 (paired t-test). Also, the distributions of the slopes (rates of change of WNSSP scores over time) were significantly different in the pre-medication and medication phases (Paired T-test, p=0.02). Random coefficient model comparison of individuals during pre- and medication phase response variability on WNSSP yielded F-test at p=0.02. Conclusions: These results suggest a promising relationship between acceleration of recovery for some children in a low response state and administration of dopamine-enhancing medications.	Univ Virginia, Childrens Med Ctr, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, Charlottesville, VA 22903 USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA	Patrick, PD (corresponding author), Univ Virginia, Childrens Med Ctr, Kluge Childrens Rehabil Ctr & Res Inst, Dept Pediat, 2270 Ivy Rd, Charlottesville, VA 22903 USA.	pdp2n@virginia.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD39631] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039631] Funding Source: NIH RePORTER		Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Ansell BJ, 1989, W NEUROSENSORY STIMU; BACHMAN DL, 1992, J HEAD TRAUMA REHAB, V7, P50; BALL WS, 1990, CURR OPIN RADIOL, V2, P877; Cantais E, 2001, INTENS CARE MED, V27, P1511, DOI 10.1007/s001340101039; Crowder M.J., 1990, ANAL REPEATED MEASUR; Di Rocco C, 1974, J Neurosurg Sci, V18, P169; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; GAULTIERI CT, 1989, CLIN NEUROPHARMACOL, V4, P258; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P79, DOI 10.1097/00001199-199708000-00008; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Hagen C., 1979, LEVELS COGNITIVE FUN; HAYES RI, 1992, J HEAD TRAUMA REHAB, V77, P16; HAYES RI, 1989, MILD HEAD INJURY; HORVATH TB, 1974, J NEUROL NEUROSUR PS, V37, P416, DOI 10.1136/jnnp.37.4.416; JENNETT B, 1972, LANCET, V1, P734; Jennett B, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199708000-00003; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Maj J, 1997, EUR J PHARMACOL, V324, P31, DOI 10.1016/S0014-2999(97)00066-6; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; PLUM F, 1991, CEREBRAL CORTEX; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; Schneider WN, 1999, BRAIN INJURY, V13, P863; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; WOLF AP, 1995, BRAIN INJURY, V9, P487, DOI 10.3109/02699059509008208; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	40	33	36	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2003	17	6					497	506		10.1080/0269905031000070279			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	672GG	WOS:000182512400004	12745705				2021-06-18	
J	Penkowa, M; Camats, J; Giralt, M; Molinero, A; Hernandez, J; Carrasco, J; Campbell, IL; Hidalgo, J				Penkowa, M; Camats, J; Giralt, M; Molinero, A; Hernandez, J; Carrasco, J; Campbell, IL; Hidalgo, J			Metallothionein-I overexpression alters brain inflammation and stimulates brain repair in transgenic mice with astrocyte-targeted interleukin-6 expression	GLIA			English	Article						metallothionein-I; overexpression; transgenic mice; interleukin-6	CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INCREASED OXIDATIVE STRESS; FOCAL CEREBRAL-ISCHEMIA; ACID-INDUCED SEIZURES; DEFICIENT MICE; GENE-EXPRESSION; NEURODEGENERATIVE DISEASES; CYTOKINE ACTIONS; IMMUNE FUNCTION	Transgenic expression of IL-6 in the CNS under the control of the GFAP gene promoter, glial fibrillary acidic protein-interleukin-6 (GFAP-IL-6) mice, raises an inflammatory response and causes significant brain damage. However, the results obtained in the GFAP-IL-6 mice after a traumatic brain injury, such as a cryolesion, demonstrate a neuroprotective role of IL-6. Thus, the GFAP-IL-6 mice showed faster tissue repair and decreased oxidative stress and apoptosis compared with control litter-mate mice. The neuroprotective factors metallothionein-I + II (MT-I+II) were upregulated by the cryolesion to a higher extent in the GFAP-IL-6 mice, suggesting that they could be related to the neuroprotection afforded by the transgenic expression of IL-6. To examine this possibility, we have crossed GFAP-IL-6 mice with transgenic mice overexpressing MT-I (TgMT), producing double transgenic GFAP-IL-6 TgMT mice. The results obtained after cryolesion in GFAP-IL-6 TgMT mice, as well as in TgMT mice, consistently supported the idea that the increased MT-I+II levels observed in GFAP-IL-6 mice are a fundamental and important mechanism for coping with brain damage. Accordingly, MT-I overexpression regulated the inflammatory response, decreased oxidative stress and apoptosis significantly, and increased brain tissue repair in comparison with either GFAP-IL-6 or control litter-mate mice. Overall, the results demonstrate that brain MT-I+II proteins are fundamental neuroprotective factors.	Univ Autonoma Barcelona, Fac Ciencias, Dept Biol Celular Fisiol & Inmunol, Unidad Fisiol Anim, E-08193 Barcelona, Spain; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2200 Copenhagen, Denmark; Univ Autonoma Barcelona, Fac Ciencias, Inst Neurosci, E-08193 Barcelona, Spain; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA USA	Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Dept Biol Celular Fisiol & Inmunol, Unidad Fisiol Anim, E-08193 Barcelona, Spain.		Giralt, Mercedes/K-1626-2014; Hernandez, Joaquim/E-1298-2011; Hidalgo, Juan/C-9082-2011; molinero, amalia/K-2147-2014; Carrasco, Javier/C-9732-2011	Giralt, Mercedes/0000-0002-1806-1528; Hernandez, Joaquim/0000-0003-1409-5568; Hidalgo, Juan/0000-0003-0921-1122; molinero, amalia/0000-0001-8661-8570; Carrasco, Javier/0000-0001-6436-0863	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA12444] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH50426] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH050426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA012444] Funding Source: NIH RePORTER		Abdel-Mageed AB, 1998, CANCER RES, V58, P2335; AbdelMageed AB, 1997, CANCER GENE THER, V4, P199; Aravindakumar CT, 1999, BIOCHEM J, V344, P253, DOI 10.1042/0264-6021:3440253; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Benveniste EN, 1998, CYTOKINE GROWTH F R, V9, P259, DOI 10.1016/S1359-6101(98)00015-X; Borghesi LA, 1996, TOXICOLOGY, V108, P129, DOI 10.1016/S0300-483X(95)03243-9; Campagne MV, 2000, J NEUROSCI, V20, P5200, DOI 10.1523/JNEUROSCI.20-14-05200.2000; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carrasco J, 1998, EXP NEUROL, V153, P184, DOI 10.1006/exnr.1998.6861; Carrasco J, 2000, EUR J NEUROSCI, V12, P2311, DOI 10.1046/j.1460-9568.2000.00128.x; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; Chen Y, 2002, BIOCHEMISTRY-US, V41, P8360, DOI 10.1021/bi020030+; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; CHUBATSU LS, 1993, BIOCHEM J, V291, P193, DOI 10.1042/bj2910193; Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Coyle P, 2002, CELL MOL LIFE SCI, V59, P627, DOI 10.1007/s00018-002-8454-2; Crowthers KC, 2000, TOXICOL APPL PHARM, V166, P161, DOI 10.1006/taap.2000.8961; Dalton T, 1996, ENVIRON HEALTH PERSP, V104, P68, DOI 10.2307/3432762; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Floyd RA, 1999, FREE RADICAL BIO MED, V26, P1346, DOI 10.1016/S0891-5849(98)00293-7; Galiano M, 2001, EUR J NEUROSCI, V14, P327, DOI 10.1046/j.0953-816x.2001.01647.x; GASULL T, 1993, J IMMUNOASSAY, V14, P209, DOI 10.1080/15321819308019851; GASULL T, 1994, AM J PHYSIOL, V266, pE760; Ghoshal K, 2001, MOL CELL BIOL, V21, P8301, DOI 10.1128/MCB.21.24.8301-8317.2001; Giralt M, 2002, NEUROBIOL DIS, V9, P319, DOI 10.1006/nbdi.2002.0480; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Hernandez J, 1997, MOL BRAIN RES, V48, P125, DOI 10.1016/S0169-328X(97)00087-9; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; Hidalgo J, 2002, METHOD ENZYMOL, V348, P238, DOI 10.1016/S0076-6879(02)48642-9; Hidalgo J, 2001, BRAIN RES BULL, V55, P133, DOI 10.1016/S0361-9230(01)00452-X; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kondo Y, 1997, MOL PHARMACOL, V52, P195; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Lee YS, 1999, J AM ASSOC GYN LAP, V6, P59, DOI 10.1016/S1074-3804(99)80042-5; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MASTERS BA, 1994, P NATL ACAD SCI USA, V91, P584, DOI 10.1073/pnas.91.2.584; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Mendel I, 1998, EUR J IMMUNOL, V28, P1727, DOI 10.1002/(SICI)1521-4141(199805)28:05<1727::AID-IMMU1727>3.0.CO;2-#; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Miles AT, 2000, CRIT REV BIOCHEM MOL, V35, P35, DOI 10.1080/10409230091169168; Nagano S, 2001, EUR J NEUROSCI, V13, P1363, DOI 10.1046/j.0953-816x.2001.01512.x; Okuda Y, 1999, J NEUROIMMUNOL, V101, P188, DOI 10.1016/S0165-5728(99)00139-3; PALMITER RD, 1993, MOL CELL BIOL, V13, P5266, DOI 10.1128/MCB.13.9.5266; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Penkowa M, 2000, EXP NEUROL, V163, P72, DOI 10.1006/exnr.2000.7383; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 2001, NEUROSCIENCE, V102, P805, DOI 10.1016/S0306-4522(00)00515-7; Penkowa M, 2001, J NEUROTRAUM, V18, P447, DOI 10.1089/089771501750171056; Penkowa M, 1999, J NEUROSCI, V19, P2535; Penkowa M, 2000, J CEREBR BLOOD F MET, V20, P1174, DOI 10.1097/00004647-200008000-00003; Penkowa M, 2000, GLIA, V32, P247, DOI 10.1002/1098-1136(200012)32:3<247::AID-GLIA50>3.0.CO;2-T; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; Sugiura S, 2000, EUR J NEUROSCI, V12, P457, DOI 10.1046/j.1460-9568.2000.00922.x; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; Van Wagoner NJ, 1999, J NEUROIMMUNOL, V100, P124, DOI 10.1016/S0165-5728(99)00187-3; Wang GW, 2001, J PHARMACOL EXP THER, V298, P461; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; YOUN J, 1995, J TOXICOL ENV HEALTH, V45, P397, DOI 10.1080/15287399509532004; Youn J, 1999, TOXICOL SCI, V52, P199, DOI 10.1093/toxsci/52.2.199	73	33	36	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0894-1491			GLIA	Glia	MAY	2003	42	3					287	306		10.1002/glia.10208			20	Neurosciences	Neurosciences & Neurology	671TT	WOS:000182480700007	12673834				2021-06-18	
J	Furuya, Y; Hlatky, R; Valadka, AR; Diaz, P; Robertson, CS				Furuya, Y; Hlatky, R; Valadka, AR; Diaz, P; Robertson, CS			Comparison of cerebral blood flow in computed tomographic hypodense areas of the brain in head-injured patients	NEUROSURGERY			English	Article						brain contusion; brain ischemia; cerebral blood flow; computed tomography; head injury; xenon-enhanced computed tomography	ISCHEMIC STROKE; FOCAL ISCHEMIA; TISSUE; CT; OXYGENATION; CONTUSIONS; PTIO(2)	OBJECTIVE: Hypodense lesions identified on computed tomographic (CT) scans are often assumed to indicate ischemia. The purpose of this study was to investigate regional cerebral blood flow, (rCBF) in hypodense areas of the brain after severe traumatic brain injury. METHODS: CBF was measured by stable xenon-enhanced CT scans. Hypodense areas were identified, and rCBF values as well as CT density were averaged for the region. RESULTS: Thirty (60%) of the 50 patients had a total of 45 hypodense regions; which were associated with either contusion (n = 30) or areas of infarction (n = 15). rCBF in the hypodense regions was variable, ranging from a low of 3.3 to a high of 72.5 ml/100 g/min. The cause of the lesion was the major factor associated with the. level of rCBF. Although the average decrease-in CT density was similar for the two types of lesions, the average rCBF was significantly lower and the difference in rCBF between the lesion and the contralateral side was greater when the,hypodense lesion was associated with a contusion. A critical reduction in rCBF (<20 ml/100 g/min) was found in 19 (63%) of the hypodense regions associated with contusions but in only 4 (27%) of those from areas of infarction. CONCLUSION: Hypodensity on plain CT scans does not always indicate reduction in CBF. This association was found more commonly when the low-density area was associated with a contusion. In hypodense areas associated with infarction, rCBF was variable and not commonly in the ischemic range at the time the CBF measurement was obtained.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; Univ Hosp, Dept Neurosurg, Hradec Kralove, Czech Republic; St Marianna Univ, Sch Med, Dept Neurosurg, Kawasaki, Kanagawa 213, Japan	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin,Suite 944, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline		BARON JC, 1983, AM J NEURORADIOL, V4, P536; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BULLOCK R, 1985, J NEUROSURG, V63, P64, DOI 10.3171/jns.1985.63.1.0064; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Krieger DW, 1999, STROKE, V30, P287, DOI 10.1161/01.STR.30.2.287; Marks MP, 1999, STROKE, V30, P389, DOI 10.1161/01.STR.30.2.389; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Scott JN, 1999, CAN J NEUROL SCI, V26, P182, DOI 10.1017/S0317167100000226; Stocchetti N, 1998, ACT NEUR S, V71, P162; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; YONAS H, 1988, STROKE, V19, P228, DOI 10.1161/01.STR.19.2.228	13	33	34	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	FEB	2003	52	2					340	345		10.1227/01.NEU.0000043931.83041.AA			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	644DA	WOS:000180901600017	12535362				2021-06-18	
S	Ford, J; Farid, H; Makedon, F; Flashman, LA; McAllister, TW; Megalooikonomou, V; Saykin, AJ		Ellis, RE; Peters, TM		Ford, J; Farid, H; Makedon, F; Flashman, LA; McAllister, TW; Megalooikonomou, V; Saykin, AJ			Patient classification of fMRI activation maps	MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION - MICCAI 2003, PT 2	Lecture Notes in Computer Science		English	Article; Proceedings Paper	6th International Conference on Medical Image Computing and Computer-Assisted Intervention	NOV 15-18, 2003	MONTREAL, CANADA	Robarts Res Inst, No Digital Inc			FUNCTIONAL MRI ACTIVATION; PATTERNS; REPRODUCIBILITY; SCHIZOPHRENIA; TASK	The analysis of brain activations using functional magnetic resonance imaging (fMRI) is an active area of neuropsychological research. Standard techniques for analysis have traditionally focused on finding the most significant areas of brain activation, and have only recently begun to explore the importance of their spatial characteristics. We compare fMRI contrast images and significance maps to training sets of similar maps using the spatial distribution of activation values. We demonstrate that a Fisher linear discriminant (FLD) classifier for either type of map can differentiate patients from controls accurately for Alzheimer's disease, schizophrenia, and mild traumatic brain injury (MTBI).	Dartmouth Coll, Dept Comp Sci, Hanover, NH 03755 USA; Dartmouth Coll, Ctr Cognit Neurosci, Hanover, NH 03755 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat,Brain Imaging Lab, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Radiol, Hanover, NH 03756 USA; Temple Univ, Dept Comp & Informat Sci, Philadelphia, PA 19122 USA	Ford, J (corresponding author), Dartmouth Coll, Dept Comp Sci, Hanover, NH 03755 USA.	jford@cs.dartmouth.edu; farid@cs.dartmouth.edu; makedon@cs.dartmouth.edu	Ford, James/AAF-7039-2020; Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532			Aguirre GK, 1998, NEUROIMAGE, V8, P302, DOI 10.1006/nimg.1998.0367; Casey BJ, 1998, NEUROIMAGE, V8, P249, DOI 10.1006/nimg.1998.0360; Cohen MS, 1999, JMRI-J MAGN RESON IM, V10, P33, DOI 10.1002/(SICI)1522-2586(199907)10:1<33::AID-JMRI5>3.0.CO;2-N; Coulon O, 1999, LECT NOTES COMPUT SC, V1613, P448; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hastie T., 2009, ELEMENTS STAT LEARNI; HUGHES GF, 1968, IEEE T INFORM THEORY, V14, P55, DOI 10.1109/TIT.1968.1054102; Hutchinson M, 1999, MAGN RESON IMAGING, V17, P1427, DOI 10.1016/S0730-725X(99)00093-4; Liow JS, 2000, J NUCL MED, V41, P612; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MOELLER JR, 1987, J CEREBR BLOOD F MET, V7, P649, DOI 10.1038/jcbfm.1987.118; RAUDYS SJ, 1991, IEEE T PATTERN ANAL, V13, P252, DOI 10.1109/34.75512; Rubia K, 2001, SCHIZOPHR RES, V52, P47, DOI 10.1016/S0920-9964(00)00173-0; Saykin AJ, 1999, SCHIZOPHR RES, V36, P233; Saykin AJ, 1999, J INT NEUROPSYCH SOC, V5, P377, DOI 10.1017/S135561779955501X; Skurichina M., 1996, P 13 INT C PATT REC, V2, P891; Tegeler C, 1999, HUM BRAIN MAPP, V7, P267, DOI 10.1002/(SICI)1097-0193(1999)7:4<267::AID-HBM5>3.0.CO;2-3	18	33	34	1	7	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0302-9743		3-540-20464-4	LECT NOTES COMPUT SC			2003	2879						58	65					8	Computer Science, Interdisciplinary Applications; Computer Science, Theory & Methods; Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Computer Science; Engineering; Radiology, Nuclear Medicine & Medical Imaging	BY19R	WOS:000188180400008		Bronze			2021-06-18	
J	Hough, MS; Barrow, I				Hough, MS; Barrow, I			Descriptive discourse abilities of traumatic brain-injured adults	APHASIOLOGY			English	Article							CLOSED HEAD-INJURY; NARRATIVE DISCOURSE; ADOLESCENTS; CHILDREN; COHESION	Background: Studies examining the discourse abilities of adults who have suffered traumatic brain injuries (TBI) have revealed that although these individuals display relatively normal language skills on traditional aphasia tests, they demonstrate varying levels of impairment in the coherence, cohesion, and informational content of their extended verbal output. Discourse studies with the TBI population have varied relative to the type of discourse task as well as the level or approach of analysis. One approach to discourse analysis has involved examination of the cognitive functions distinguishing macrostructural and microstructural discourse processing. Macrostructural analyses are global analyses focused at the level of the entire text, dealing with large supra-sentential discourse units. Microstructural analyses are concerned with smaller structural elements in a text and the relations between these elements; the focus is at the local level of the word or sentence. Aims: In the current investigation, three analyses were undertaken to examine descriptive discourse production of five high-functioning TBI adults (three males, two females) who had suffered brain injury as the result of motor vehicle accidents. The first analysis, thematic coherence, is a macrostructural analysis, whereas the other two analyses, cohesion and lexical errors, are microstructural analyses. Methods & Procedures: Two topics, family description and work experience, were used to elicit discourse; performance was compared between the language samples. Each participant's performance was reviewed individually and findings were compared to the mean performance of a group of 15 normal functioning young adults. For thematic coherence, global and local coherence were evaluated and scored separately on different 5-point rating scales. Cohesion analysis involved identification of three types of cohesive ties (closed-class appropriate, open-class appropriate, incomplete cohesion) with scores computed as proportions of total spoken words. Lexical error production included identification of verbal paraphasias and indefinite terms, also computed as proportions of total words spoken. Outcomes & Results: The results revealed that mean coherence ratings for each TBI participant were consistently lower than those observed for the control group, regardless of coherence type (local, global) or discourse topic (family, work). Furthermore, the TBI participants demonstrated greater difficulty with global than local coherence and showed more performance variability among participants in global as compared to local coherence. However, all five TBI adults displayed minimal deficits in lexical production and cohesion. Conclusions: Overall, the findings revealed dissociation of microlinguistic and macrolinguistic cognitive functions in the TBI participants, thus providing support for the distinction between and independent organisation of microstructural and macrostructural discourse components.	E Carolina Univ, Greenville, NC 27858 USA; Hampton Univ, Hampton, VA 23668 USA	Hough, MS (corresponding author), E Carolina Univ, Greenville, NC 27858 USA.						American Speech-Language-Hearing Association (ASHA), 1997, GUID AUD SCREEN; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Cherney L.R., 1998, ANAL DISCOURSE COMMU; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1994, DISCOURSE ANAL APPL; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Fayol M., 1993, NARRATIVE DISCOURSE; GLOSSER G, 1988, J SPEECH HEAR DISORD, V53, P115, DOI 10.1044/jshd.5302.115; GLOSSER G, 1993, NARRATIVE DISCOURSE; Glosser G., 1992, J GERONTOL B-PSYCHOL, V47, P266; Glosser G., 1990, BRAIN LANG, V40, P67; Glosser G., 1992, J CLIN EXPT NEUROPSY, V14, P40; Goodglass H., 1983, ASSESSMENT APHASIA R; HAGEN C, 1984, LANGUAGE DISORDERS A; HAGEN C, 1979, INTERVENTION STRATEG; Halliday MAK, 1989, LANGUAGE CONTEXT TEX; Halliday Michael A. K., 1976, COHESION ENGLISH; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HODGES T, 1998, THESIS CAROLINA U; Loban W, 1963, LANGUAGE ELEMENTARY; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Myers P.S., 1999, RIGHT HEMISPHERE DAM; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; PIERCE RS, 1990, COGNITIVE LANGUAGE A; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; Van Dijk T.A., 1983, STRATEGIES DISCOURSE; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; YLVISAKER M, 1994, LANGUAGE INTERVENTIO	32	33	34	0	5	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology		2003	17	2					183	191		10.1080/02687030244000608			9	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	641UK	WOS:000180765100007					2021-06-18	
J	Potter, DD; Jory, SH; Bassett, MRA; Barrett, K; Mychalkiw, W				Potter, DD; Jory, SH; Bassett, MRA; Barrett, K; Mychalkiw, W			Effect of mild head injury on event-related potential correlates of Stroop task performance	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						ERP; traumatic brain injury; memory; P3; CHI; closed head injury	AUDITORY ODDBALL TASK; BRAIN POTENTIALS; INTERFERENCE; ATTENTION; SYMPTOMS; SEQUELAE; DISTRACTIBILITY; PERSISTENCE; ANATOMY; P300	The effect of mild head injury on event-related potential (ERP) correlates of Stroop task performance was explored with the aim of further elucidating the basis of processing impairments after mild head injury. Computer- and card-bused Stroop tasks were employed to assess attention function. A sequence of incongruent color words were presented followed by a sequence of congruent color words (printed in congruent colors). Control performance was equivalent on computer- and card-based versions of the incongruent task and faster on the congruent card task than the preceding congruent computer task. The mild head injury group were as fast as controls on the computer-based task but made more errors. However, they were relatively slower on both the congruent and incongruent parts of the card-based task and made more errors in the incongruent task. ERP correlates of computer-based Stroop task performance suggested a greater allocation of attention resources in the incongruent condition in both groups in the form of relatively greater negativity in the latency range 350 to 450 ins with a distribution consistent with the activation of the anterior cingulate gyrus. In addition the mild head injured group showed relatively greater enhancement than the control group in this latency range in both congruent and incongruent conditions. There was, however no evidence of reduced amplitude P1, N1, N2, or P3b deflections. Trails, digit symbol, digit span and auditory verbal learning tests (AVLT) were also administered. Mild head injured participants were impaired only on the AVLT. The finding of greater ERP negativity in the mild head injured group is consistent with greater allocation of attention resources to achieve equivalent performance in the computer-based Stroop task.	Keele Univ, Dept Psychol, Keele, Staffs, England; Haywood Hosp, Neurobehav Unit, Stoke On Trent ST6 7AG, Staffs, England; City Gen Hosp, Dept Psychol, Stoke On Trent, Staffs, England	Potter, DD (corresponding author), Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland.	d.d.potter@dundee.ac.uk					Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, V6, P193; BOHNEN N, 1992, NEUROSURGERY, V30, P692; COHEN JD, 1990, PSYCHOL REV, V97, P332, DOI 10.1037/0033-295X.97.3.332; Corbetta M, 1998, NEURON, V21, P761, DOI 10.1016/S0896-6273(00)80593-0; CZIGLER I, 1991, INT J PSYCHOPHYSIOL, V11, P281, DOI 10.1016/0167-8760(91)90023-Q; Dehaene S, 1998, P NATL ACAD SCI USA, V95, P14529, DOI 10.1073/pnas.95.24.14529; DUNCANJOHNSON CC, 1981, SCIENCE, V214, P938, DOI 10.1126/science.7302571; EVANS RW, 1992, NEUROL CLIN, V10, P815; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; George M S, 1994, Hum Brain Mapp, V1, P194, DOI 10.1002/hbm.460010305; Grapperon J, 1998, NEUROPHYSIOL CLIN, V28, P207, DOI 10.1016/S0987-7053(98)80112-3; Jory SH, 2000, J PSYCHOPHYSIOL, V14, P187; Kaipio ML, 1999, NEUROREPORT, V10, P2125, DOI 10.1097/00001756-199907130-00024; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Kaiser J, 1997, INT J PSYCHOPHYSIOL, V27, P215, DOI 10.1016/S0167-8760(97)00055-X; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; LARRUE V, 1994, J CEREBR BLOOD F MET, V14, P958, DOI 10.1038/jcbfm.1994.128; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; MACLEOD CM, 1988, J EXP PSYCHOL LEARN, V14, P126, DOI 10.1037/0278-7393.14.1.126; MacLeod CM, 2000, TRENDS COGN SCI, V4, P383, DOI 10.1016/S1364-6613(00)01530-8; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; McKeown MJ, 1998, P NATL ACAD SCI USA, V95, P803, DOI 10.1073/pnas.95.3.803; Nelson HE, 1982, NATL ADULT READING T; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Nobre AC, 2000, NEUROIMAGE, V11, P210, DOI 10.1006/nimg.2000.0539; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; Peterson BS, 1999, BIOL PSYCHIAT, V45, P1237, DOI 10.1016/S0006-3223(99)00056-6; Petrides M, 1998, PREFRONTAL CORTEX EX, P103; Posner M.I., 1975, INFORM PROCESSING CO, P55; POSNER MI, 1994, TRENDS NEUROSCI, V17, P75, DOI 10.1016/0166-2236(94)90078-7; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; Potter DD, 1999, J PSYCHOPHYSIOL, V13, P173, DOI 10.1027//0269-8803.13.3.173; POTTER DD, 2001, BRIT PSYCH SOC ANN C; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; Rey A, 1964, EXAMEN CLIN PSYCHOL; Robbins T. W., 1998, PREFRONTAL CORTEX EX, P117; ROLLS ET, 1998, PREFRONTAL CORTEX EX, P67; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Smith EE, 1999, SCIENCE, V283, P1657, DOI 10.1126/science.283.5408.1657; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spreen O., 1991, COMPENDIUM NEUROPSYC; Taylor SF, 1997, NEUROIMAGE, V6, P81, DOI 10.1006/nimg.1997.0285; VAKIL E, 1995, J CLIN EXP NEUROPSYC, V17, P335, DOI 10.1080/01688639508405127; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; West R, 1999, COGNITIVE BRAIN RES, V8, P157, DOI 10.1016/S0926-6410(99)00017-8; Wylie G, 2000, PSYCHOL RES-PSYCH FO, V63, P212, DOI 10.1007/s004269900003; Zhang HZ, 1998, J EXP PSYCHOL HUMAN, V24, P3, DOI 10.1037/0096-1523.24.1.3	57	33	36	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2002	8	6					828	837		10.1017/S1355617702860118			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	592CZ	WOS:000177920300011	12240747				2021-06-18	
J	Taubenfeld, SM; Stevens, KA; Pollonini, G; Ruggiero, J; Alberini, CM				Taubenfeld, SM; Stevens, KA; Pollonini, G; Ruggiero, J; Alberini, CM			Profound molecular changes following hippocampal slice preparation: loss of AMPA receptor subunits and uncoupled mRNA/protein expression	JOURNAL OF NEUROCHEMISTRY			English	Article						hippocampus; glutamate receptor; neurotrophin; slice; transcription factor	IMMEDIATE-EARLY GENES; LONG-TERM POTENTIATION; CONDITIONED TASTE-AVERSION; TRAUMATIC BRAIN INJURY; HEAT-SHOCK-PROTEIN; C-FOS; MESSENGER-RNA; SYNAPTIC TRANSMISSION; ANTISENSE OLIGONUCLEOTIDE; PROTOONCOGENE EXPRESSION	The acute hippocampal slice preparation is a convenient, in vitro model widely used to study the biological basis of synaptic plasticity. Although slices may preserve their electrophysiological properties for several hours, profound molecular changes in response to the injury caused by the slicing procedure are likely to occur. To determine the magnitude and duration of these changes we examined the post-slicing expression kinetics of three classes of genes known to be implicated in long-term synaptic plasticity: glutamate AMPA receptors (GluR), transcription factors and neurotrophins. Slicing resulted in a striking loss of GluR1 and GluR3, but not of GluR2 proteins suggesting that rapid changes in the composition of major neurotransmitter receptors may occur. Slicing caused a significant induction of the transcription factors c-fos , zif268 , CCAAT enhancer binding protein (C/EBP ) beta and delta mRNAs and of the neurotrophin brain-derived neurothophic factor (BDNF ) mRNA. In contrast, there was no augmentation, and sometimes a decline, in the levels of the corresponding proteins. These data reveal that significant discrepancies exist between the slice preparation and the intact hippocampus in terms of the metabolism of molecular components known to be involved in synaptic plasticity.	Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Alberini, CM (corresponding author), Mt Sinai Sch Med, Dept Physiol & Biophys, Box 1218,1 Gustave L Levy Pl, New York, NY 10029 USA.						AITKEN PG, 1995, J NEUROSCI METH, V59, P139, DOI 10.1016/0165-0270(94)00204-T; Akaneya Y, 1997, J NEUROSCI, V17, P6707; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Berardi N, 1999, J NEUROBIOL, V41, P119, DOI 10.1002/(SICI)1097-4695(199910)41:1<119::AID-NEU15>3.0.CO;2-N; Cammarota M, 1998, EUR J NEUROSCI, V10, P2669, DOI 10.1046/j.1460-9568.1998.t01-1-00254.x; Castren E, 1998, PROG BRAIN RES, V117, P57; Chaudhuri A, 1997, NEUROREPORT, V8, pR5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK GD, 1987, NEUROSCIENCE, V21, P665, DOI 10.1016/0306-4522(87)90027-3; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DJURICIC B, 1994, METAB BRAIN DIS, V9, P377, DOI 10.1007/BF02098884; Dragunow M, 1996, BEHAV GENET, V26, P293, DOI 10.1007/BF02359385; Dutcher SA, 1999, NEUROL RES, V21, P234, DOI 10.1080/01616412.1999.11740924; FEIG S, 1993, J NEUROSCI, V13, P1010; Gall CM, 1998, NEUROBIOL LEARN MEM, V70, P14, DOI 10.1006/nlme.1998.3835; Hasegawa K, 1998, BRAIN RES, V785, P262, DOI 10.1016/S0006-8993(97)01410-8; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; HOSSMANN KA, 1993, RESUSCITATION, V26, P225, DOI 10.1016/0300-9572(93)90143-E; Hossmann KA, 1999, ADV EXP MED BIOL, V474, P155; Houpt TA, 1996, LEARN MEMORY, V3, P25, DOI 10.1101/lm.3.1.25; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; KACZMAREK L, 1993, J NEUROSCI RES, V34, P377, DOI 10.1002/jnr.490340402; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kennis JHH, 1997, EXP NEUROL, V147, P18, DOI 10.1006/exnr.1997.6576; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kjoller C, 2000, NEUROCHEM INT, V37, P7, DOI 10.1016/S0197-0186(00)00008-5; Lamprecht R, 1996, LEARN MEMORY, V3, P31, DOI 10.1101/lm.3.1.31; Lessmann V, 1998, GEN PHARMACOL-VASC S, V31, P667; Linnarsson S, 1997, EUR J NEUROSCI, V9, P2581, DOI 10.1111/j.1460-9568.1997.tb01687.x; LIPTON P, 1979, J PHYSIOL-LONDON, V287, P427, DOI 10.1113/jphysiol.1979.sp012668; Lipton P, 1999, METHODS, V18, P127, DOI 10.1006/meth.1999.0766; Lynch G, 1998, NEUROBIOL LEARN MEM, V70, P82, DOI 10.1006/nlme.1998.3840; Ma YL, 1998, NEUROSCIENCE, V82, P957; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; Monje ML, 2000, BRAIN RES, V857, P172, DOI 10.1016/S0006-8993(99)02404-X; Montag-Sallaz M, 1999, J NEUROBIOL, V38, P234, DOI 10.1002/(SICI)1097-4695(19990205)38:2<234::AID-NEU6>3.0.CO;2-G; Montkowski A, 1997, NEUROREPORT, V8, P779, DOI 10.1097/00001756-199702100-00040; MORLEY P, 1994, BRAIN PATHOL, V4, P37; Nayak A, 1998, NATURE, V394, P680, DOI 10.1038/29305; NIKOLAEV E, 1991, BRAIN RES, V560, P346, DOI 10.1016/0006-8993(91)91257-2; NOWAK TS, 1993, PROG BRAIN RES, V96, P195; Oorschot DE, 2000, EXP NEUROL, V161, P227, DOI 10.1006/exnr.1999.7248; Paschen W, 1999, ACT NEUR S, V73, P1; Radulovic J, 1998, J NEUROSCI, V18, P7452; RAGHUPATHI R, 1995, BRAIN PATHOL, V5, P437, DOI 10.1111/j.1750-3639.1995.tb00622.x; Raley-Susman KM, 1998, BRAIN RES, V782, P281, DOI 10.1016/S0006-8993(97)01329-2; RALEYSUSMAN KM, 1995, BRAIN RES, V694, P94, DOI 10.1016/0006-8993(95)00770-Q; Riedel G, 1996, PROG NEURO-PSYCHOPH, V20, P761, DOI 10.1016/0278-5846(96)00058-9; SCHLINGENSIEPEN R, 1994, NEUROREPORT, V30, P101; Schuman EM, 1999, CURR OPIN NEUROBIOL, V9, P105, DOI 10.1016/S0959-4388(99)80013-0; SHARP FR, 1993, STROKE S, V24, P172; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Siklos L, 1997, NEUROSCIENCE, V79, P1013, DOI 10.1016/S0306-4522(97)00031-6; Sterneck E, 1998, P NATL ACAD SCI USA, V95, P10908, DOI 10.1073/pnas.95.18.10908; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TAKEMOTO O, 1995, STROKE, V26, P1639, DOI 10.1161/01.STR.26.9.1639; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; Tischmeyer W, 1999, CELL MOL LIFE SCI, V55, P564, DOI 10.1007/s000180050315; Tomimoto H, 1999, ACTA NEUROPATHOL, V97, P22, DOI 10.1007/s004010050951; VORNOV JJ, 1991, J NEUROCHEM, V56, P996, DOI 10.1111/j.1471-4159.1991.tb02020.x; Walton M, 1999, BRAIN RES REV, V29, P137, DOI 10.1016/S0165-0173(98)00053-8; Wan HM, 1999, J NEUROSCI, V19, P1142; Watson PL, 1997, BRAIN RES, V775, P134, DOI 10.1016/S0006-8993(97)00893-7; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; Zhang Y, 1999, BRAIN RES, V832, P112, DOI 10.1016/S0006-8993(99)01459-6; ZHOU QH, 1995, J NEUROSCI METH, V59, P85, DOI 10.1016/0165-0270(94)00197-O; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	74	33	33	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	JUN	2002	81	6					1348	1360		10.1046/j.1471-4159.2002.00936.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	559ZN	WOS:000176056700020	12068082				2021-06-18	
J	Gellrich, NC; Schimming, R; Zerfowski, M; Eysel, UT				Gellrich, NC; Schimming, R; Zerfowski, M; Eysel, UT			Quantification of histological changes after calibrated crush of the intraorbital optic nerve in rats	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							RETINAL GANGLION-CELLS; FETAL BRAIN GRAFTS; ADULT-RATS; INJURY; FIBERS; CAT; LESIONS; TECTUM; BLOCK	Background: Traumatic optic nerve lesions (TONL) are probable but unpredictable consequence after severe midface or skull base trauma. Based on a previously described rat model, the authors developed a new model in order to simulate optic nerve crush during trauma on the optic canal. Methods: To achieve a calibrated TONL, a microinjuring device was designed that made it possible, to assess the correlation between a defined trauma and the neuronal degeneration in the rat retinal ganglion cell (RGC) layer. This device is based on a small dynamometer mounted onto a conventional micromanipulator. The supraorbital approach was chosen to expose the extracranial optic nerve. Results: In this rat model (n=100, Wistar strain) the parameters of "force' and "time" could be precisely monitored during the experiment. The decrease in he mean number of retinal neurons (N) according to the pressure exerted (2-30 cN.mm(-2)) on the optic nerve was linear for 1, 6, and 15 minutes of injuring time; the decrease in N for varying injuring forces also appears to be nearly linear. Conclusion: The results show that this model provides a reliable method for studying quantitatively the anatomical effects of TONL on the RGC layer and the optic nerve itself, and may allow the design of treatment strategies following TONL.	Univ Hosp Freiburg, Dept Oral & Maxillofacial Surg, D-79106 Freiburg, Germany; Univ Tubingen Hosp, Dept Oral & Maxillofacial Surg, Tubingen, Germany; Ruhr Univ Bochum, Dept Neurophysiol, Bochum, Germany	Gellrich, NC (corresponding author), Univ Hosp Freiburg, Dept Oral & Maxillofacial Surg, Hugstetterstr 55, D-79106 Freiburg, Germany.			Eysel, Ulf/0000-0001-6087-957X			BAHR M, 1992, J COMP NEUROL, V320, P370, DOI 10.1002/cne.903200308; BERRY M, 1986, BRAIN RES S, V13, P18; BLAUGRUND E, 1992, EXP NEUROL, V118, P105, DOI 10.1016/0014-4886(92)90027-N; BURKE W, 1986, J PHYSIOL-LONDON, V376, P461, DOI 10.1113/jphysiol.1986.sp016164; BURKE W, 1985, J PHYSIOL-LONDON, V364, P81, DOI 10.1113/jphysiol.1985.sp015731; COTTEE LJ, 1991, EUR J NEUROSCI, V3, P1245, DOI 10.1111/j.1460-9568.1991.tb00058.x; CRESPO D, 1985, DEV BRAIN RES, V19, P129, DOI 10.1016/0165-3806(85)90238-X; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; EYSEL UT, 1978, PFLUG ARCH EUR J PHY, V375, P251, DOI 10.1007/BF00582438; FORRESTER J, 1967, NATURE, V214, P245, DOI 10.1038/214245a0; FUKUDA Y, 1982, EXP NEUROL, V75, P525, DOI 10.1016/0014-4886(82)90181-9; Gellrich N C, 1999, Mund Kiefer Gesichtschir, V3, P176, DOI 10.1007/s100060050128; Gellrich N C, 1996, Fortschr Kiefer Gesichtschir, V41, P1; GELLRICH NC, 1994, INT J ORAL MAX SURG, V23, P403, DOI 10.1016/S0901-5027(05)80030-X; GREHN F, 1987, CHIBRET INT J OPHTHA, V5, P17; HOLLANDER H, 1968, Brain Research, V10, P120, DOI 10.1016/0006-8993(68)90117-0; LINDEN R, 1987, J COMP NEUROL, V258, P138, DOI 10.1002/cne.902580111; MATSUZAKI H, 1982, JPN J OPHTHALMOL, V26, P447; MCKERRACHER L, 1992, J NEUROBIOL, V23, P568, DOI 10.1002/neu.480230510; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; OWUSUYAW V, 1992, BRAIN RES, V576, P220, DOI 10.1016/0006-8993(92)90684-2; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; PERRY VH, 1983, J COMP NEUROL, V219, P356, DOI 10.1002/cne.902190309; POTTS RA, 1982, DEV BRAIN RES, V3, P481, DOI 10.1016/0165-3806(82)90013-X; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SIEVERS J, 1989, J COMP NEUROL, V281, P467, DOI 10.1002/cne.902810310	26	33	38	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161			BRIT J OPHTHALMOL	Br. J. Ophthalmol.	FEB	2002	86	2					233	237		10.1136/bjo.86.2.233			5	Ophthalmology	Ophthalmology	519QN	WOS:000173737100024	11815353	Green Published, Bronze			2021-06-18	
J	Romano, J; Beni-Adani, L; Nissenbaum, OL; Brenneman, DE; Shohami, E; Gozes, I				Romano, J; Beni-Adani, L; Nissenbaum, OL; Brenneman, DE; Shohami, E; Gozes, I			A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury - Gene atlas array analysis	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						NAP; Mac-1; atlas array; head trauma; ADNP; VIP	TRAUMATIC BRAIN INJURY; VASOACTIVE-INTESTINAL-PEPTIDE; CEREBRAL-ARTERY OCCLUSION; NECROSIS-FACTOR-ALPHA; RAT-BRAIN; INFLAMMATORY RESPONSE; MONOCLONAL-ANTIBODIES; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; TNF-ALPHA	The femtomolar-acting eight-amino-acid peptide (NAP), derived from activity-dependent neuroprotective protein (ADNP), provides long-term protection against the deleterious effects of closed head injury (CHI) in mice. Fifteen minutes after injury, mice were divided into two groups, control and NAP-treated and a single subcutaneous injection of NAP or vehicle was administered. A third group served as sham-treated (not subjected to head trauma). Each mouse was assessed for its clinical function, using neurological severity score, at various time intervals following CHI, up to 30-45 d. Total cerebral cortex RNA was prepared from the site of injury of CHI mice, and from parallel regions in peptide-treated and sham brains. RNA was then reversed transcribed to yield radioactive cDNA preparations that were hybridized to Atlas array membranes containing 1200 cDNAs spots. Comparison of sham-treated individual mice showed differential expression levels of at least 15 mRNA species. Furthermore, results indicated that one of the genes that did not change among individuals but specifically increased after CHI and decreased after NAP treatment was the cell surface glycoprotein Mac-1 (CD11B antigen). Thus, Mac-1 is suggested as a marker for the long-term outcome of head injury and as a potential target for NAP protective actions.	Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sourasky Med Ctr, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, IL-69978 Tel Aviv, Israel; NICHHD, Sect Dev & Mol Pharmacol, LDN, NIH, Bethesda, MD 20892 USA; Hebrew Univ Jerusalem, Sch Pharm, IL-91120 Jerusalem, Israel	Gozes, I (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [Z01HD000047] Funding Source: NIH RePORTER		ARNAOUT MA, 1983, J CLIN INVEST, V72, P171, DOI 10.1172/JCI110955; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CORIA F, 1994, REV NEUROSCIENCE, V5, P275; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Engel S, 1996, Acta Neurochir Suppl, V66, P89; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; Gozes I, 1999, CURR MED CHEM, V6, P1019; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; MATSUO Y, 1995, J CEREBR BLOOD F MET, V15, P941, DOI 10.1038/jcbfm.1995.119; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Steingart RA, 2000, J MOL NEUROSCI, V15, P137, DOI 10.1385/JMN:15:3:137; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Walzog B, 1999, FASEB J, V13, P1855; Whalen MJ, 1999, CRIT CARE MED, V27, P1014, DOI 10.1097/00003246-199905000-00049; WHALEN MJ, 1998, CRIT CARE MED, V25, pA85; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Zamostiano R, 2001, J BIOL CHEM, V276, P708, DOI 10.1074/jbc.M007416200; Zemlyak I, 2000, REGUL PEPTIDES, V96, P39, DOI 10.1016/S0167-0115(00)00198-1	41	33	34	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696			J MOL NEUROSCI	J. Mol. Neurosci.	FEB-APR	2002	18	1-2					37	45		10.1385/JMN:18:1-2:37			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	533FR	WOS:000174519200005	11931348				2021-06-18	
S	Logan, A; Berry, M		Alzheimer, C		Logan, A; Berry, M			Cellular and molecular determinants of glial scar formation	MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS	Advances in Experimental Medicine and Biology		English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD-INJURY; GROWTH-FACTOR-BETA; TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; CHONDROITIN-SULFATE PROTEOGLYCAN; CEREBRAL-ARTERY OCCLUSION; MESSENGER-RNA EXPRESSION; RAT OPTIC-NERVE; FIBRILLARY ACIDIC PROTEIN		Queen Elizabeth Hosp, Wolfson Res Labs, Dept Med, Birmingham B15 2TH, W Midlands, England; Ctr Neurosci, GKT Sch Biomed Res, London SE1 1UL, England	Logan, A (corresponding author), Queen Elizabeth Hosp, Wolfson Res Labs, Dept Med, Birmingham B15 2TH, W Midlands, England.			Logan, Ann/0000-0003-3215-5042			Abe Y, 1999, J NEUROTRAUM, V16, P945, DOI 10.1089/neu.1999.16.945; Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Acarin L, 1999, J NEUROPATH EXP NEUR, V58, P389, DOI 10.1097/00005072-199904000-00009; ADZICK NS, 1994, ANN SURG, V220, P10, DOI 10.1097/00000658-199407000-00003; AJEMIAN A, 1994, J COMP NEUROL, V340, P233, DOI 10.1002/cne.903400208; Ajtai BM, 2000, ANAT EMBRYOL, V202, P313, DOI 10.1007/s004290000117; Albrecht C, 2000, J BIOL CHEM, V275, P28929, DOI 10.1074/jbc.M003053200; Aldskogius H, 1999, J NEUROSCI RES, V58, P33, DOI 10.1002/(SICI)1097-4547(19991001)58:1<33::AID-JNR5>3.3.CO;2-D; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Andjelkovic AV, 2000, J LEUKOCYTE BIOL, V68, P545; ANTONIADES HN, 1991, P NATL ACAD SCI USA, V88, P565, DOI 10.1073/pnas.88.2.565; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; Bagley C, 1928, ARCH SURG-CHICAGO, V17, P18, DOI 10.1001/archsurg.1928.01140070021002; BAIRD A, 1985, BIOCHEM BIOPH RES CO, V126, P358, DOI 10.1016/0006-291X(85)90614-X; Balasingam V, 1996, J NEUROSCI, V16, P2945; BALENTINE JD, 1978, LAB INVEST, V39, P236; BANATI RB, 1994, DEV NEUROSCI-BASEL, V16, P114, DOI 10.1159/000112098; BARDAKDJIAN J, 1979, NEUROCHEM RES, V4, P517, DOI 10.1007/BF00964645; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BARTSCH U, 1992, EUR J NEUROSCI, V4, P338, DOI 10.1111/j.1460-9568.1992.tb00881.x; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bell MD, 1996, EUR J NEUROSCI, V8, P1803, DOI 10.1111/j.1460-9568.1996.tb01324.x; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Benjelloun N, 1999, STROKE, V30, P1916, DOI 10.1161/01.STR.30.9.1916; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; Berry M, 1996, J NEUROCYTOL, V25, P147, DOI 10.1007/BF02284793; BERRY M, 1979, J ANAT, V128, P859; Berry M, 2001, MOL CELL NEUROSCI, V17, P706, DOI 10.1006/mcne.2001.0975; Berry M, 1982, Bibl Anat, P1; BERRY M, 1989, J NEUROCYTOL, V18, P141, DOI 10.1007/BF01206658; Berry M, 1999, J NEUROCYTOL, V28, P721, DOI 10.1023/A:1007086004022; Berry M, 1998, J NEUROCYTOL, V27, P915, DOI 10.1023/A:1006953107636; BERRY M, 1992, J NEUROCYTOL, V21, P426, DOI 10.1007/BF01191507; BERRY M, 2000, NEUROSURGERY, V1, P479; BERRY M, 2001, UNPUB J NEUROSCI; BERRY M, 2001, UNPUB J COMP NEUROL; BERRY M, 1999, CNS INJURIES CELLULA, P1; BERRY M, 1992, BRAIN RES B, V20, P223; BERRY M, 2001, GREENFIELDS NEUROPAT; BERRY M, 2000, NEUROSURG; Bethea JR, 1999, J NEUROTRAUM, V16, P851, DOI 10.1089/neu.1999.16.851; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; Bolton SJ, 1998, EXP NEUROL, V154, P231, DOI 10.1006/exnr.1998.6927; Bona E, 1999, PEDIATR RES, V45, P500, DOI 10.1203/00006450-199904010-00008; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Bresjanac M, 2000, EXP NEUROL, V164, P53, DOI 10.1006/exnr.2000.7416; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brook GA, 2000, EUR J NEUROSCI, V12, P3224, DOI 10.1046/j.1460-9568.2000.00228.x; BROWN KS, 1998, CNS INJURIES CELLULA, P63; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Bruni JE, 1998, MICROSC RES TECHNIQ, V41, P2, DOI 10.1002/(SICI)1097-0029(19980401)41:1<2::AID-JEMT2>3.0.CO;2-Z; Bu J, 2001, GLIA, V34, P296, DOI 10.1002/glia.1063; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Butt AM, 2000, J NEUROSCI RES, V59, P477, DOI 10.1002/(SICI)1097-4547(20000215)59:4<477::AID-JNR2>3.0.CO;2-J; Butt AM, 1999, GLIA, V26, P84, DOI 10.1002/(SICI)1098-1136(199903)26:1<84::AID-GLIA9>3.3.CO;2-C; Buytaert KA, 2001, BRAIN RES, V894, P121, DOI 10.1016/S0006-8993(01)01987-4; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Cajal R., 1928, DEGENERATION REGENER; CARBONELL AL, 1991, HISTOL HISTOPATHOL, V6, P443; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Cartmell T, 2001, J PHYSIOL-LONDON, V531, P171, DOI 10.1111/j.1469-7793.2001.0171j.x; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; CASO A, 1953, B I ESTUD MED BIOL, V11, P61; Cerutti SM, 2000, CELL BIOL INT, V24, P35, DOI 10.1006/cbir.1999.0451; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clarke WE, 2001, MOL CELL NEUROSCI, V17, P17, DOI 10.1006/mcne.2000.0920; CLEMENTE CD, 1958, J COMP NEUROL, V109, P123, DOI 10.1002/cne.901090107; CLEMENTE CD, 1954, J COMP NEUROL, V101, P691, DOI 10.1002/cne.901010304; CLEMENTE CD, 1964, INT REV NEUROBIOL, V6, P257, DOI 10.1016/S0074-7742(08)60771-0; CLEMENTE CD, 1995, REGENERATION CENTRAL, P147; Cohen IR, 1999, J NEUROIMMUNOL, V100, P111, DOI 10.1016/S0165-5728(99)00190-3; COLLINS P, 1990, NEUROPATH APPL NEURO, V16, P45, DOI 10.1111/j.1365-2990.1990.tb00931.x; Condorelli DF, 1999, NEUROCHEM RES, V24, P709, DOI 10.1023/A:1021016828704; CORNELLBELL AH, 1991, CELL CALCIUM, V12, P185, DOI 10.1016/0143-4160(91)90020-F; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Cui W., 1996, GROW FACT CYTOK  A&B, P319; D'Angelo M, 2001, J BIOL CHEM, V276, P11347, DOI 10.1074/jbc.M009725200; DANIEL M, 1997, J ENDOCRINOL, V152, P126; Davies SJA, 1997, NATURE, V390, P680; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; DAVIES SJA, 1993, EUR J NEUROSCI, V5, P95, DOI 10.1111/j.1460-9568.1993.tb00474.x; DAVIES SJA, 1994, J NEUROSCI, V14, P1596; Dawson MRL, 2000, J NEUROSCI RES, V61, P471, DOI 10.1002/1097-4547(20000901)61:5<471::AID-JNR1>3.3.CO;2-E; de Castro R, 2000, NEUROREPORT, V11, P3551, DOI 10.1097/00001756-200011090-00029; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; DEROUICHE A, 1994, J COMP NEUROL, V341, P340, DOI 10.1002/cne.903410305; Di Bello IC, 1999, J NEUROCYTOL, V28, P365, DOI 10.1023/A:1007069815302; Dietzmann K, 2000, PATHOL RES PRACT, V196, P15, DOI 10.1016/S0344-0338(00)80017-5; Dijkstra S, 2000, J COMP NEUROL, V428, P266, DOI 10.1002/1096-9861(20001211)428:2<266::AID-CNE6>3.0.CO;2-0; Dore-Duffy P, 2000, MICROVASC RES, V60, P55, DOI 10.1006/mvre.2000.2244; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Dreyfus CF, 1999, J NEUROSCI RES, V56, P1, DOI 10.1002/(SICI)1097-4547(19990401)56:1<1::AID-JNR1>3.0.CO;2-3; Du S, 1999, EXP NEUROL, V157, P96, DOI 10.1006/exnr.1999.7041; DUBOIS A, 1988, BRAIN RES, V445, P77, DOI 10.1016/0006-8993(88)91076-1; DUCKER TB, 1971, J NEUROSURG, V35, P700, DOI 10.3171/jns.1971.35.6.0700; Duncan MR, 1999, FASEB J, V13, P1774; Dusart I, 1999, J COMP NEUROL, V408, P399; ECLANCHER F, 1990, GLIA, V3, P502, DOI 10.1002/glia.440030609; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1988, BIOCH PATHOLOGY ASTR, P79; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Erlich S, 2000, MOL CELL NEUROSCI, V16, P597, DOI 10.1006/mcne.2000.0894; FAGAN AM, 1990, EXP NEUROL, V110, P105, DOI 10.1016/0014-4886(90)90055-W; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FAWCETT JW, 1990, DEVELOPMENT, V108, P59; FERTIG A, 1971, EXP NEUROL, V33, P372, DOI 10.1016/0014-4886(71)90029-X; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Fidler PS, 1999, J NEUROSCI, V19, P8778, DOI 10.1523/JNEUROSCI.19-20-08778.1999; Fields RD, 2000, TRENDS NEUROSCI, V23, P625, DOI 10.1016/S0166-2236(00)01674-X; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; Fischer D, 2000, INVEST OPHTH VIS SCI, V41, P3943; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; FLINT G, 1973, EXPERIENTIA, V29, P566, DOI 10.1007/BF01926668; Flood C, 2001, J CEREBR BLOOD F MET, V21, P157, DOI 10.1097/00004647-200102000-00007; Flugel A, 2001, J CEREBR BLOOD F MET, V21, P69; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Friedman WJ, 2001, EXP NEUROL, V168, P23, DOI 10.1006/exnr.2000.7595; Fukui N, 2001, J ORTHOPAED RES, V19, P456, DOI 10.1016/S0736-0266(00)90016-0; FULTON BP, 1992, J NEUROSCI, V12, P4816; Gabellec MM, 1999, NEUROSCI RES, V33, P251, DOI 10.1016/S0168-0102(99)00014-0; Galasso JM, 2000, NEUROSCIENCE, V101, P737, DOI 10.1016/S0306-4522(00)00399-7; GARDNER WJ, 1950, J NEUROSURG, V7, P199, DOI 10.3171/jns.1950.7.3.0199; Gates MA, 1996, NEUROSCIENCE, V74, P579, DOI 10.1016/0306-4522(96)00146-7; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Ghirnikar RS, 2000, J NEUROSCI RES, V59, P63, DOI 10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.0.CO;2-W; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Ghirnikar RS, 1996, J NEUROSCI RES, V46, P727; GIAUME C, 1991, NEURON, V6, P133, DOI 10.1016/0896-6273(91)90128-M; Giovannoni G, 1998, J NEUROL SCI, V156, P53, DOI 10.1016/S0022-510X(98)00021-5; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; Gomide VC, 1999, BRAIN RES, V835, P162, DOI 10.1016/S0006-8993(99)01557-7; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; GONZALEZ AM, 1990, J CELL BIOL, V110, P753, DOI 10.1083/jcb.110.3.753; GONZALEZ AM, 2000, P SOC NEUROSCI, V26, P1888; GOODMAN ML, 1999, CELL, V99, P71; GRABHAM P, 1995, J NEUROCHEM, V64, P583; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; GRAFFRADFORD NR, 1989, ARCH NEUROL-CHICAGO, V46, P744, DOI 10.1001/archneur.1989.00520430038014; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Guh JY, 1996, J AM SOC NEPHROL, V7, P1207; GUILIAN D, 1990, DIFFERENTIATION FUNC, P379; Haas CA, 1999, J NEUROSCI, V19, P9953; HALL S, 1989, J NEUROCYTOL, V18, P171, DOI 10.1007/BF01206660; HALL SM, 1992, J NEUROCYTOL, V21, P402, DOI 10.1007/BF01191505; Hallscheidt P, 2001, TRANSPLANT P, V33, P2157, DOI 10.1016/S0041-1345(01)01926-1; Hammes EM, 1944, ARCH NEURO PSYCHIATR, V52, P505, DOI 10.1001/archneurpsyc.1944.02290360077006; Hashizume H, 2000, SPINE, V25, P1206, DOI 10.1097/00007632-200005150-00003; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; Hauss-Wegrzyniak B, 1999, BRAIN RES, V815, P36, DOI 10.1016/S0006-8993(98)01081-6; Hayashi M, 2000, J NEUROTRAUM, V17, P203, DOI 10.1089/neu.2000.17.203; HEINO J, 1989, J BIOL CHEM, V264, P21806; HEINO J, 1989, J BIOL CHEM, V264, P380; Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hill C, 2001, DIABETOLOGIA, V44, P495, DOI 10.1007/s001250051648; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Huang J, 1999, SCIENCE, V285, P595, DOI 10.1126/science.285.5427.595; Hughes PE, 1999, PROG NEUROBIOL, V57, P421, DOI 10.1016/S0301-0082(98)00057-4; Igarashi Atsuyuki, 1992, Journal of Dermatology (Tokyo), V19, P642; IGNOTZ RA, 1989, J BIOL CHEM, V264, P389; Isaksson J, 1999, J NEUROTRAUM, V16, P165, DOI 10.1089/neu.1999.16.165; JACKOWSKI A, 1990, J CEREBR BLOOD F MET, V10, P835, DOI 10.1038/jcbfm.1990.140; James G, 1999, NEUROSCI LETT, V268, P53, DOI 10.1016/S0304-3940(99)00370-5; JAMES G, 2001, IN PRESS CELL CALCIU; JAMES G, 2001, IN PRESS NEUROSCI LE; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Jensen MB, 1999, NEUROSCIENCE, V93, P507, DOI 10.1016/S0306-4522(99)00139-6; Jiang Y, 2000, NEUROSCIENCE, V97, P735, DOI 10.1016/S0306-4522(00)00084-1; Jones LL, 2000, J COMP NEUROL, V426, P468, DOI 10.1002/1096-9861(20001023)426:3<468::AID-CNE9>3.0.CO;2-I; KAGAMI S, 1994, J CLIN INVEST, V93, P2431, DOI 10.1172/JCI117251; Kalman M, 2000, BRAIN RES, V857, P291, DOI 10.1016/S0006-8993(99)02399-9; Kalman Mihaly, 2000, Neural Plasticity, V7, P147, DOI 10.1155/NP.2000.147; Kamei H, 2000, J SURG RES, V89, P20, DOI 10.1006/jsre.1999.5802; KANEKO R, 1994, P NATL ACAD SCI USA, V91, P4529, DOI 10.1073/pnas.91.10.4529; KAO CC, 1977, EXP NEUROL, V54, P591, DOI 10.1016/0014-4886(77)90259-X; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; King VR, 2000, EXP NEUROL, V165, P327, DOI 10.1006/exnr.2000.7480; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KITAZAWA K, 1994, STROKE, V25, P1400, DOI 10.1161/01.STR.25.7.1400; KLAHR S, 1997, KIDNEY INT S, V63, pS111; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLEMPT ND, 1992, MOL BRAIN RES, V13, P93, DOI 10.1016/0169-328X(92)90048-G; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; KNOWLES JF, 1978, EXP NEUROL, V62, P1, DOI 10.1016/0014-4886(78)90037-7; Kolb M, 2001, AM J RESP CRIT CARE, V163, P770, DOI 10.1164/ajrccm.163.3.2006084; Kondo Y, 1999, BRAIN RES, V834, P146, DOI 10.1016/S0006-8993(99)01517-6; KORSCHING S, 1993, J NEUROSCI, V13, P2739; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kothapalli D, 1998, FASEB J, V12, P1151; Kothapalli D, 2000, J CELL PHYSIOL, V182, P119, DOI 10.1002/(SICI)1097-4652(200001)182:1<119::AID-JCP13>3.0.CO;2-4; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Kozlova EN, 1999, GLIA, V27, P249, DOI 10.1002/(SICI)1098-1136(199909)27:3<249::AID-GLIA6>3.3.CO;2-5; Krenz NR, 2000, J NEUROCHEM, V74, P730, DOI 10.1046/j.1471-4159.2000.740730.x; KREUTZBERG CW, 1994, J COMP NEUROL, V340, P233; KREUTZBERG CW, 1997, GREENFIELDS NEUROPAT, V1, pCH3; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KREUTZBERG GW, 1978, J NEUROCYTOL, V7, P601, DOI 10.1007/BF01260892; KRUGER S, 1986, J COMP NEUROL, V249, P103, DOI 10.1002/cne.902490108; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Krupinski J, 1998, NITRIC OXIDE-BIOL CH, V2, P442, DOI 10.1006/niox.1998.0204; Kudo A, 2000, CEREBROVASC DIS, V10, P424, DOI 10.1159/000016102; Kyrkanides S, 1999, J NEUROIMMUNOL, V95, P95, DOI 10.1016/S0165-5728(98)00270-7; LAGORD C, 2001, IN PRESS EUR J NEURO; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAYWELL ED, 1992, P NATL ACAD SCI USA, V89, P2634, DOI 10.1073/pnas.89.7.2634; Lee YL, 2000, NEUROCHEM INT, V36, P417, DOI 10.1016/S0197-0186(99)00133-3; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Lemons ML, 1999, EXP NEUROL, V160, P51, DOI 10.1006/exnr.1999.7184; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; LEPRINCE G, 1990, DEV BRAIN RES, V51, P295, DOI 10.1016/0165-3806(90)90290-F; LEPRINCE G, 1991, GLIA, V4, P322, DOI 10.1002/glia.440040310; Leskovar A, 2000, J EXP BIOL, V203, P1783; LEVINE JM, 1987, J NEUROSCI, V7, P2711; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LEVINE JM, 1993, GLIA, V7, P307, DOI 10.1002/glia.440070406; LEVINE JM, 1987, J NEUROSCI, V7, P2721; Lew SM, 1999, BRAIN RES BULL, V48, P325, DOI 10.1016/S0361-9230(99)00004-0; Li GL, 1999, ACTA NEUROPATHOL, V98, P473, DOI 10.1007/s004010051112; Li Y, 1999, J NEUROCYTOL, V28, P417, DOI 10.1023/A:1007026001189; Liebl DJ, 2001, EXP NEUROL, V167, P15, DOI 10.1006/exnr.2000.7548; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; LINDA H, 1992, J COMP NEUROL, V318, P188, DOI 10.1002/cne.903180205; LINDHOLM D, 1992, J CELL BIOL, V117, P395, DOI 10.1083/jcb.117.2.395; LINDSAY RM, 1986, ASTROCYTES CELL BIOL, V3, P231; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; LIPPOLDT A, 1994, BRAIN RES, V668, P144, DOI 10.1016/0006-8993(94)90520-7; LIPS K, 1995, J NEUROCYTOL, V24, P449, DOI 10.1007/BF01181606; Liu DX, 2001, J NEUROCHEM, V77, P1036, DOI 10.1046/j.1471-4159.2001.00306.x; Liu L, 1999, EXP NEUROL, V157, P69, DOI 10.1006/exnr.1999.7046; LIUZZI JL, 1987, SCIENCE, V237, P449; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Logan A, 1999, EXP NEUROL, V159, P504, DOI 10.1006/exnr.1999.7180; Logan A, 1999, EUR J NEUROSCI, V11, P2367, DOI 10.1046/j.1460-9568.1999.00654.x; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; LOGAN A, 1999, CNS INJURIES CELLULA, P1; LOGAN A, 1994, P 76 ANN M END SOC A, P1663; LOTAN M, 1994, FASEB J, V8, P1026; Lucius R, 1998, J EXP MED, V188, P661, DOI 10.1084/jem.188.4.661; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; Maclennan KM, 1996, PROG NEUROBIOL, V50, P585, DOI 10.1016/S0301-0082(96)00047-0; MANSOUR H, 1990, J NEUROSCI RES, V25, P300, DOI 10.1002/jnr.490250306; MARTIN P, 1994, EYE, V8, P155, DOI 10.1038/eye.1994.39; MARTIN P, 1993, DEV GENET, V14, P225, DOI 10.1002/dvg.1020140309; Martinez G, 2001, BRAIN RES, V894, P1, DOI 10.1016/S0006-8993(00)03140-1; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; MATSUMOTO Y, 1987, J NEUROIMMUNOL, V17, P71, DOI 10.1016/0165-5728(87)90032-4; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P501, DOI 10.1098/rstb.1990.0122; MAXWELL WL, 1984, HISTOCHEM J, V16, P1219, DOI 10.1007/BF01003445; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; Mayhan WG, 1999, AM J PHYSIOL-CELL PH, V276, pC1148; MCCONNELL P, 1984, BRAIN RES, V323, P257, DOI 10.1016/0006-8993(84)90296-8; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McKeon RJ, 1999, J NEUROSCI, V19, P10778; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; MCMASTER RE, 1962, J COMP NEUROL, V119, P113, DOI 10.1002/cne.901190110; McPherron A.C., 1996, GROWTH FACTORS CYTOK, P357; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Michael GJ, 1999, EUR J NEUROSCI, V11, P3539, DOI 10.1046/j.1460-9568.1999.00767.x; MILHORAT TH, 1995, J NEUROSURG, V82, P802, DOI 10.3171/jns.1995.82.5.0802; Mita T, 1998, GRAEF ARCH CLIN EXP, V236, P834, DOI 10.1007/s004170050168; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moller T, 2000, J NEUROCHEM, V75, P1539, DOI 10.1046/j.1471-4159.2000.0751539.x; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; Monzon-Mayor M, 2000, BRAIN RES, V865, P245, DOI 10.1016/S0006-8993(00)02231-9; Moon LDF, 2001, NAT NEUROSCI, V4, P465; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; MORSHEAD CM, 1990, BRAIN RES, V535, P237, DOI 10.1016/0006-8993(90)91606-H; Moss DW, 2001, EUR J NEUROSCI, V13, P529, DOI 10.1046/j.1460-9568.2001.01418.x; MOTOHASHI O, 1995, NEUROSCI LETT, V190, P105, DOI 10.1016/0304-3940(95)11513-V; Moussad EEDA, 2000, MOL GENET METAB, V71, P276, DOI 10.1006/mgme.2000.3059; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; Nadal A, 1997, GLIA, V19, P343, DOI 10.1002/(SICI)1098-1136(199704)19:4<343::AID-GLIA7>3.0.CO;2-Y; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; NELSON RB, 1990, DEV BRAIN RES, V54, P93, DOI 10.1016/0165-3806(90)90069-B; Newman EA, 2001, J NEUROSCI, V21, P2215; Ng YK, 2001, HISTOL HISTOPATHOL, V16, P167, DOI 10.14670/HH-16.167; Nieto-Sampedro M, 1999, ADV EXP MED BIOL, V468, P207; NIETOSAMPEDRO M, 1985, BRAIN RES, V343, P320, DOI 10.1016/0006-8993(85)90750-4; Nishiyama A, 1996, J NEUROSCI RES, V43, P315, DOI 10.1002/(SICI)1097-4547(19960201)43:3<315::AID-JNR6>3.0.CO;2-M; Nishiyama A, 1999, J NEUROPATH EXP NEUR, V58, P1113, DOI 10.1097/00005072-199911000-00001; Nishiyama A, 1997, J NEUROSCI RES, V48, P299, DOI 10.1002/(SICI)1097-4547(19970515)48:4<299::AID-JNR2>3.0.CO;2-6; Nishiyama A, 1996, J NEUROSCI RES, V43, P299, DOI 10.1002/(SICI)1097-4547(19960201)43:3<299::AID-JNR5>3.0.CO;2-E; Nomoto Y, 2001, NEUROSURGERY, V48, P158, DOI 10.1097/00006123-200101000-00027; Norton WT, 1999, NEUROCHEM RES, V24, P213, DOI 10.1023/A:1022505903312; Nouel D, 1999, NEUROSCIENCE, V94, P1189, DOI 10.1016/S0306-4522(99)00354-1; Oehmichen M, 1999, ACTA NEUROPATHOL, V97, P491, DOI 10.1007/s004010051018; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; Otten U, 2000, ANN NY ACAD SCI, V917, P322; Oudega M, 1999, EUR J NEUROSCI, V11, P2453, DOI 10.1046/j.1460-9568.1999.00666.x; Pan WH, 1999, J NEUROSCI, V19, P3649; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Park KI, 2000, YONSEI MED J, V41, P825, DOI 10.3349/ymj.2000.41.6.825; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 2001, BRAIN RES REV, V35, P36, DOI 10.1016/S0165-0173(00)00050-3; Pasterkamp RJ, 2001, EUR J NEUROSCI, V13, P457, DOI 10.1046/j.0953-816X.2000.01398.x; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; Penkowa M, 1999, GLIA, V25, P343; PERRY VH, 1988, TRENDS NEUROSCI, V11, P273, DOI 10.1016/0166-2236(88)90110-5; PERRY VH, 1991, INT REV CYTOL, V125, P203, DOI 10.1016/S0074-7696(08)61220-6; PERRY VH, 1995, CURR OPIN NEUROBIOL, V5, P636, DOI 10.1016/0959-4388(95)80069-7; Phillips AO, 1997, LAB INVEST, V76, P591; Pindon A, 2000, J NEUROSCI, V20, P2543; POBER JS, 1990, HUM IMMUNOL, V28, P258, DOI 10.1016/0198-8859(90)90027-M; Pratt Bruce M., 1997, Cytokine and Growth Factor Reviews, V8, P267, DOI 10.1016/S1359-6101(97)00018-X; Preston E, 2001, J NEUROTRAUM, V18, P83, DOI 10.1089/089771501750055794; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Probstmeier R, 2000, J NEUROSCI RES, V60, P21, DOI 10.1002/(SICI)1097-4547(20000401)60:1<21::AID-JNR3>3.0.CO;2-H; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RAMSAY SC, 1992, LANCET, V339, P1054, DOI 10.1016/0140-6736(92)90576-O; Rathke-Hartlieb S, 2000, FEBS LETT, V481, P227, DOI 10.1016/S0014-5793(00)02011-1; RAYMOND AA, 1994, J NEUROL NEUROSUR PS, V57, P1195, DOI 10.1136/jnnp.57.10.1195; Redwine JM, 1998, J NEUROBIOL, V37, P413, DOI 10.1002/(SICI)1097-4695(19981115)37:3<413::AID-NEU7>3.0.CO;2-8; Reier P J, 1988, Adv Neurol, V47, P87; Reier PJ, 1986, ASTROCYTES, V3, P263; Reynolds R, 1997, J NEUROSCI RES, V47, P455, DOI 10.1002/(SICI)1097-4547(19970301)47:5<455::AID-JNR1>3.0.CO;2-G; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; RISLING M, 1983, BRAIN RES, V280, P15, DOI 10.1016/0006-8993(83)91169-1; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, V1, P418; Rohm B, 2000, MECH DEVELOP, V93, P95, DOI 10.1016/S0925-4773(00)00269-0; Roitbak T, 1999, GLIA, V28, P40, DOI 10.1002/(SICI)1098-1136(199910)28:1<40::AID-GLIA5>3.0.CO;2-6; ROMANIC AM, 1994, BRAIN PATHOL, V4, P145, DOI 10.1111/j.1750-3639.1994.tb00825.x; Rosenberg GA, 2001, BRAIN RES, V893, P104, DOI 10.1016/S0006-8993(00)03294-7; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; ROTHWELL NJ, 1993, CEREBROVAS BRAIN MET, V5, P178; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Saito N, 2000, J NEUROTRAUM, V17, P173, DOI 10.1089/neu.2000.17.173; Saliba E, 2001, BIOL NEONATE, V79, P224; Sanderson MJ, 1996, NEWS PHYSIOL SCI, V11, P262, DOI 10.1152/physiologyonline.1996.11.6.262; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; SARNAT HB, 1995, J NEUROPATH EXP NEUR, V54, P1, DOI 10.1097/00005072-199501000-00001; Sasamura H, 2001, HYPERTENS RES, V24, P165, DOI 10.1291/hypres.24.165; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; Schiefer J, 1998, J NEUROIMMUNOL, V89, P168, DOI 10.1016/S0165-5728(98)00133-7; Schlomann U, 2000, J NEUROSCI, V20, P7964; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab JM, 2000, NEUROPATH APPL NEURO, V26, P434, DOI 10.1046/j.1365-2990.2000.00271.x; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Schwartz M, 2001, J NEUROIMMUNOL, V113, P185, DOI 10.1016/S0165-5728(00)00447-1; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHEWAN D, 1995, J NEUROSCI, V15, P2057; SHEWAN D, 1993, EUR J NEUROSCI, V5, P809, DOI 10.1111/j.1460-9568.1993.tb00932.x; Shimakura A, 2000, BRAIN RES, V858, P55, DOI 10.1016/S0006-8993(99)02431-2; SIEVERS J, 1985, NEURAL GRAFTING MAMM, P159; Silverstein FS, 1997, NEUROCHEM INT, V30, P375, DOI 10.1016/S0197-0186(96)00072-1; Skold M, 2000, EUR J NEUROSCI, V12, P3675, DOI 10.1046/j.1460-9568.2000.00263.x; Slevin M, 2000, STROKE, V31, P1863, DOI 10.1161/01.STR.31.8.1863; Smith C, 2001, EUR J NEUROSCI, V13, P443, DOI 10.1046/j.1460-9568.2001.01400.x; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; STEIT WJ, 1997, GREENFIELDS NEUROPAT, P85; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; STICHEL CC, 1995, EUR J NEUROSCI, V7, P401, DOI 10.1111/j.1460-9568.1995.tb00336.x; Stichel CC, 1999, NEUROSCIENCE, V93, P321, DOI 10.1016/S0306-4522(99)00112-8; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STRUCKHOFF G, 1995, NEUROSCI LETT, V189, P117, DOI 10.1016/0304-3940(95)11468-C; Sugiura S, 2000, EUR J NEUROSCI, V12, P457, DOI 10.1046/j.1460-9568.2000.00922.x; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; SUNG JH, 1981, J NEUROPATH EXP NEUR, V40, P645, DOI 10.1097/00005072-198111000-00006; Suzuki H, 1999, NEUROL RES, V21, P269, DOI 10.1080/01616412.1999.11740930; SUZUKI S, 1977, ACTA NEUROCHIR, V39, P1, DOI 10.1007/BF01405236; Szczepanik AM, 1996, NEUROSCIENCE, V70, P57, DOI 10.1016/0306-4522(95)00296-U; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takahashi T, 1998, NAT NEUROSCI, V1, P487, DOI 10.1038/2203; TAKAYAMA S, 1994, BRAIN RES, V653, P131, DOI 10.1016/0006-8993(94)90381-6; Tallant EA, 1997, GLIA, V19, P333; Tang HB, 2000, NEUROSCI LETT, V285, P143, DOI 10.1016/S0304-3940(00)00998-8; Taoka Y, 2001, J NEUROTRAUM, V18, P533, DOI 10.1089/089771501300227332; TAPANINAHO A, 1993, ACTA NEUROCHIR, V123, P118, DOI 10.1007/BF01401866; TARDY M, 1991, ANN NY ACAD SCI, V633, P630; TAYLOR J, 1993, J NEUROSCI RES, V35, P347, DOI 10.1002/jnr.490350402; Thiel VE, 2001, ANTIOXID REDOX SIGN, V3, P273, DOI 10.1089/152308601300185223; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; Tokita Y, 2001, J NEUROSCI, V21, P1257; Tonai T, 1999, J NEUROCHEM, V72, P302, DOI 10.1046/j.1471-4159.1999.0720302.x; Tretter YP, 2000, NAT MED, V6, P812, DOI 10.1038/77548; Tretter YP, 1996, NEUROREPORT, V7, P1819, DOI 10.1097/00001756-199607290-00026; Tsao MN, 1999, J NEUROPATH EXP NEUR, V58, P1051, DOI 10.1097/00005072-199910000-00003; Tzeng SF, 2001, LIFE SCI, V68, P1005, DOI 10.1016/S0024-3205(00)01003-1; Uhl E, 1999, STROKE, V30, P880, DOI 10.1161/01.STR.30.4.880; Vale FL, 1997, J NEUROSURG, V86, P462, DOI 10.3171/jns.1997.86.3.0462; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Vaquero J, 1999, J NEUROSURG, V90, P220, DOI 10.3171/spi.1999.90.2.0220; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5; Wahl M, 1993, Acta Neurochir Suppl (Wien), V57, P64; WAHL SM, 1989, J CELL BIOCHEM, V40, P193, DOI 10.1002/jcb.240400208; WALLACE MC, 1987, SURG NEUROL, V27, P209, DOI 10.1016/0090-3019(87)90031-0; Walter HJ, 1999, ENDOCRINOLOGY, V140, P520, DOI 10.1210/en.140.1.520; Walter HJ, 1997, ENDOCRINOLOGY, V138, P3024, DOI 10.1210/en.138.7.3024; WANG L, 1994, CELL IMMUNOL, V159, P152, DOI 10.1006/cimm.1994.1304; WELLS MR, 1985, TRAUMA CENTRAL NERVO, P245; Whalen MJ, 1999, J NEUROTRAUM, V16, P583, DOI 10.1089/neu.1999.16.583; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1998, ACT NEUR S, V71, P212; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1; WICTORIN K, 1992, J COMP NEUROL, V323, P475, DOI 10.1002/cne.903230403; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; WILLIAMS B, 1981, PARAPLEGIA, V19, P67, DOI 10.1038/sc.1981.18; WILLIAMS B, 1980, J ROY SOC MED, V73, P798; WINDLE WF, 1952, T AM NEUROL ASSOC, P164; WINDLE WF, 1956, PHYSIOL REV, V36, P427; WINDLE WF, 1952, J COMP NEUROL, V96, P359, DOI 10.1002/cne.900960207; WINTER CG, 1995, P NATL ACAD SCI USA, V92, P5865, DOI 10.1073/pnas.92.13.5865; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Yang GY, 1999, BRAIN RES, V817, P123, DOI 10.1016/S0006-8993(98)01236-0; Yick LW, 1998, NEUROSCI LETT, V241, P155; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; YONG VW, 1992, GLIA, V6, P269, DOI 10.1002/glia.440060405; YONG VW, 1996, CYTOKINES CNS DEV DE, P309; Yoon DH, 1999, YONSEI MED J, V40, P313, DOI 10.3349/ymj.1999.40.4.313; Yoshimoto T, 1997, ACTA NEUROPATHOL, V93, P154, DOI 10.1007/s004010050596; Young KA, 1999, GLIA, V26, P333, DOI 10.1002/(SICI)1098-1136(199906)26:4<333::AID-GLIA7>3.0.CO;2-S; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang LZ, 2001, AM J PHYSIOL-GASTR L, V280, pG1247; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; Zhang Y, 2001, MOL CELL NEUROSCI, V17, P444, DOI 10.1006/mcne.2000.0952; Zhang Y, 1997, J NEUROSCI RES, V49, P433	456	33	35	0	1	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598	2214-8019	0-306-47414-X	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2002	513						115	158					44	Medicine, Research & Experimental	Research & Experimental Medicine	BW92A	WOS:000183600500004	12575819				2021-06-18	
J	Vitaz, TW; McIlvoy, L; Raque, GH; Spain, D; Shields, CB				Vitaz, TW; McIlvoy, L; Raque, GH; Spain, D; Shields, CB			Development and implementation of a clinical pathway for severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						clinical pathway; severe traumatic brain injury	TRACHEOSTOMY; GASTROSTOMY; CARE	Background. Clinical pathways (CPs) have been shown to be beneficial in optimizing patient care and resource use. Methods. A multidisciplinary CP for the treatment of severe traumatic brain injury (Glasgow Coma Scale score of 3-7) was developed. Data from these patients (group I) were collected prospectively and compared with a retrospective database (group II). Results. There were a total of 119 patients managed in conjunction with the CP and 43 patients in the control group. No statistical differences were found between the groups in age, Glasgow Coma Scale score at 24 hours, or Injury Severity Scores. There was a significant decrease in the length of hospital stay, intensive care unit stay, and length of ventilator support in the study group (group I: 22.5, 16.8, and 11.5 days, respectively; group II: 31.0, 21.2, and 14.4 days, respectively; p < 0.03). Conclusion: The use of this CP helped to standardize and improve patient care with fewer complications and a potential cost savings of approximately $14,000 per patient.	Univ Louisville, Sch Med, Dept Neurol Surg, Louisville, KY 40292 USA; Univ Louisville, Sch Med, Dept Gen Surg, Louisville, KY 40292 USA; Univ Hlth Care, Louisville, KY USA	Vitaz, TW (corresponding author), 210 E Gray St,Suite 1102, Louisville, KY 40202 USA.						*AM COLL SURG COMM, 1998, ADV TRAUM LIF SUPP C; Armstrong PA, 1998, SURGERY, V124, P763, DOI 10.1067/msy.1998.91224; Aronson B, 1996, J Contin Educ Nurs, V27, P215; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BORZOTTA AP, 1994, J TRAUMA, V37, P459, DOI 10.1097/00005373-199409000-00022; DAMELIO LF, 1994, AM SURGEON, V60, P180; FLORIN R, 1995, GUIDELINES MANAGEMEN; Ibarra VL, 1997, SPINE, V22, P352, DOI 10.1097/00007632-199702010-00022; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; Kitchiner D, 1996, ARCH DIS CHILD, V75, P166, DOI 10.1136/adc.75.2.166; MOORE FA, 1992, J TRAUMA, V33, P435, DOI 10.1097/00005373-199209000-00017; Ross BJ, 1996, AM SURGEON, V62, P19; Spain DA, 1995, J TRAUMA, V39, P1100, DOI 10.1097/00005373-199512000-00015; Zevola D R, 1997, Crit Care Nurse, V17, P20	14	33	33	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2001	51	2					369	375		10.1097/00005373-200108000-00025			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	463DW	WOS:000170462400024	11493802				2021-06-18	
J	Nakahara, M; Ericson, K; Bellander, BM				Nakahara, M; Ericson, K; Bellander, BM			Diffusion-weighted MR and apparent diffusion coefficient in the evaluation of severe brain injury	ACTA RADIOLOGICA			English	Article						brain death; severe brain injury; MR imaging; diffusion, apparent diffusion coefficient	CEREBRAL-ISCHEMIA; WHITE-MATTER; T2-WEIGHTED MRI; WATER DIFFUSION; STROKE; DEATH; TEMPERATURE; EDEMA; RATS; CATS	Purpose: To study apparent diffusion coefficient (ADC) maps in severely brain-injured patients. Material and Methods. Four deeply comatose patients with severe brain injury were investigated with single-shot, diffusion-weighted, spin-echo echoplanar imaging. The tetrahedral diffusion gradient configuration and four iterations of a set of b-values tone time of 0 mm(2)/s, and four times of 1000 mm(2)/s) were used to create isotropic ADC maps with high signal-to-noise ratio. ADC values of gray and white matter were compared among patients and 4 reference subjects. Results. One patient was diagnosed as clinically brain dead after the MR examination. The patient's ADC values of gray and white matter were significantly lower than these of 3 other brain-injured patients. In addition the ADC value of white matter was significantly lower than that of gray matter. Conclusion: The patient with fatal outcome shortly after MR examination differed significantly from other patients with severe brain injury but non-fatal outcome, with regard to ADC values in gray and white matter. This might indicate a prognostic value of ADC maps in the evaluation of traumatic brain injury.	Nippon Med Sch, Dept Radiol, Bunkyo Ku, Tokyo 1138603, Japan; Karolinska Hosp, Dept Neuroradiol, S-10401 Stockholm, Sweden; Karolinska Hosp, Dept Neurosurg, S-10401 Stockholm, Sweden	Nakahara, M (corresponding author), Nippon Med Sch, Dept Radiol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan.						BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; Conturo TE, 1996, MAGNET RESON MED, V35, P399, DOI 10.1002/mrm.1910350319; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; Falini A, 1998, AM J NEURORADIOL, V19, P648; Grohn OHJ, 1998, J CEREBR BLOOD F MET, V18, P911; HASEGAWA Y, 1994, J CEREBR BLOOD F MET, V14, P383, DOI 10.1038/jcbfm.1994.49; HOSSMANN KA, 1994, J CEREBR BLOOD F MET, V14, P723, DOI 10.1038/jcbfm.1994.93; Ishii K, 1996, AM J NEURORADIOL, V17, P731; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kumada K, 2000, No To Shinkei, V52, P719; Kuroiwa T, 1998, STROKE, V29, P859, DOI 10.1161/01.STR.29.4.859; LEBIHAN D, 1989, RADIOLOGY, V171, P853, DOI 10.1148/radiology.171.3.2717764; LEE DH, 1995, CAN ASSOC RADIOL J, V46, P174; LINK J, 1994, FORENSIC SCI INT, V69, P195, DOI 10.1016/0379-0738(94)90384-0; Lovblad KO, 2000, STROKE, V31, P539, DOI 10.1161/01.STR.31.2.539; MELLERGARD P, 1995, SURG NEUROL, V43, P91, DOI 10.1016/0090-3019(95)80049-M; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; Miyabe M, 1996, J CEREBR BLOOD F MET, V16, P881, DOI 10.1097/00004647-199609000-00012; Miyasaka N, 2000, RADIOLOGY, V215, P199, DOI 10.1148/radiology.215.1.r00ap24199; MORI S, 1995, MAGNET RESON MED, V33, P41, DOI 10.1002/mrm.1910330107; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; Mukherjee P, 2000, RADIOLOGY, V215, P211, DOI 10.1148/radiology.215.1.r00ap29211; Nagesh V, 1998, STROKE, V29, P1778, DOI 10.1161/01.STR.29.9.1778; Pantoni L, 1996, STROKE, V27, P1641, DOI 10.1161/01.STR.27.9.1641; ROUSSEL SA, 1995, J CEREBR BLOOD F MET, V15, P578, DOI 10.1038/jcbfm.1995.71; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; Ulug AM, 1997, STROKE, V28, P483, DOI 10.1161/01.STR.28.3.483	28	33	35	0	1	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0284-1851			ACTA RADIOL	Acta Radiol.	JUL	2001	42	4					365	369		10.1034/j.1600-0455.2001.420404.x			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	454ZN	WOS:000170001800004	11442459				2021-06-18	
J	Oliaro, S; Anderson, S; Hooker, D				Oliaro, S; Anderson, S; Hooker, D			Management of cerebral concussion in sports: The athletic trainer's perspective	JOURNAL OF ATHLETIC TRAINING			English	Article						mild head injury; neuropsychological testing; postural stability testing; grading scales	MILD HEAD-INJURY; POSTURAL STABILITY; FOOTBALL PLAYERS; EPIDEMIOLOGY; GUIDELINES; COLLEGIATE; SEQUELAE	Objective: To present a new approach in the evaluation and management of concussion from the athletic trainer's perspective. Background: The evaluation and management of concussion continues to be a controversial topic among sports medicine professionals. Inconsistent management, lack of objective data, and confusion concerning assessment techniques may lead to inappropriate decisions regarding when to return an athlete to competition after concussion. In this article, we provide recommendations and considerations for the certified athletic trainer in the management of concussion. We also present a quantifiable assessment technique that provides more information on which return-to-play decisions can be made; this technique can be used during the initial sideline examination as well as during subsequent follow-up examinations. Recommendations: Certified athletic trainers and team physicians should consistently use appropriate grading scales. Assessment of concussion should include a symptom checklist, the Balance Error Scoring System, and the Standardized Assessment of Concussion, and the results should be compared with the athlete's normal baseline scores. Follow-up neuropsychological and postural stability testing is recommended. Return-to-play decisions should be based on the grade of concussion, scores on objective tests, and presence of concussive symptoms during exertional activities.	Univ N Carolina, Chapel Hill, NC 27515 USA; Univ Oklahoma, Norman, OK 73019 USA	Oliaro, S (corresponding author), Univ N Carolina, POB 2126, Chapel Hill, NC 27515 USA.						ARNHEIM DD, 1997, PRINCIPLES ATHLETIC; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; *C NEUR SURG INC, 1966, CLIN NEUROSURG, V14, P424; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; EVANS RW, 1992, NEUROL CLIN, V10, P815; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; GUSKIEWICZ KM, 1999, ATHLETIC TRAINING SP, P143; Jordan B, 1989, SPORTS NEUROLOGY; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Onate JA, 2000, J ATHL TRAINING, V35, P155; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Torg JS., 1991, ATHLETIC INJURIES HE	21	33	33	0	3	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					257	262					6	Sport Sciences	Sport Sciences	557NC	WOS:000175913800008	12937494				2021-06-18	
J	van Reekum, R; Streiner, DL; Conn, DK				van Reekum, R; Streiner, DL; Conn, DK			Applying Bradford Hill's criteria for causation to neuropsychiatry: Challenges and opportunities	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							TRAUMATIC BRAIN INJURY; PSYCHIATRIC-DISORDERS; ALZHEIMERS-DISEASE; DEPRESSION; STROKE; RISK	Establishing an argument of causation is an important research activity with major clinical and scientific implications. Sir Austin Bradford Hill proposed criteria to establish such an argument. These criteria include the strength of the association, consistency, specificity, temporal sequence, biological gradient, biologic rationale, coherence, experimental evidence, and analogous evidence. These criteria are reviewed with the goal of facilitating an increase in rigor for establishing arguments of causation in neuropsychiatry. The challenges and opportunities related to these criteria in neuropsychiatry are reviewed, as are two important arguments for causation: one for poststroke depression and one for brain injury as a cause of psychiatric disorders.	Baycrest Ctr Geriatr Care, Dept Psychiat, Toronto, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON, Canada; Univ Toronto, Div Geriatr Psychiat, Toronto, ON, Canada; Univ Toronto, Dept Psychiat, Toronto, ON, Canada	van Reekum, R (corresponding author), Baycrest Ctr Geriatr Care, Dept Psychiat, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Streiner, David/E-6563-2011	Streiner, David/0000-0003-0610-6271			Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dep. Clin. Epidemiol. Biostat. McMaster Univ., 1981, CAN MED ASSOC J, V124, P985; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; HILL AB, 1965, P ROY SOC MED, V58, P293; House A, 1996, J NEUROPSYCH CLIN N, V8, P453; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Lyketsos CG, 1998, J NEUROPSYCH CLIN N, V10, P103, DOI 10.1176/jnp.10.1.103; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MORRIS PLP, 1992, AUST NZ J PSYCHIAT, V26, P208, DOI 10.3109/00048679209072029; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; STARKSTEIN SE, 1988, BRAIN, V111, P375, DOI 10.1093/brain/111.2.375; Streiner DS, 1989, PDQ EPIDEMIOLOGY; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; van Reekum R, 1999, J PSYCHIATR NEUROSCI, V24, P413; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340	19	33	33	0	1	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2001	13	3					318	325		10.1176/appi.neuropsych.13.3.318			8	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	462RP	WOS:000170433800002	11514637				2021-06-18	
J	Johnston, KM; Lassonde, M; Ptito, A				Johnston, KM; Lassonde, M; Ptito, A			A contemporary neurosurgical approach to sport-related head injury: The McGill concussion protocol	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							DIFFUSION-WEIGHTED MR; TRAUMATIC BRAIN-INJURY; STANDARDIZED ASSESSMENT; FOLLOW-UP; GUIDELINES; SPECT; RETURN; DYSFUNCTION; MANAGEMENT; SYMPTOMS		McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ H3G 1A4, Canada; Univ Montreal, Dept Psychol & Neuropsychol, McGill Sport Med, Montreal, PQ, Canada	Johnston, KM (corresponding author), McGill Univ, Ctr Hlth, Dept Neurosurg, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.						Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; ANDERSON SD, 1995, CAN J DIAGN, V12, P77; BANICH MT, 1997, NEURAL BASES MENTAL; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1997, CLIN J SPORT MED, V7, P83, DOI 10.1097/00042752-199704000-00001; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; FICK DS, 1995, POSTGRAD MED, V97, P53; Fox W.L, 1984, DANDY J HOPKINS; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; Hofman PAM, 1999, MAGN RESON MED, V42, P803, DOI 10.1002/(SICI)1522-2594(199910)42:4<803::AID-MRM24>3.3.CO;2-6; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Jacobs A, 1996, J NUCL MED, V37, P1605; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; JOHNSTON KM, IN PRESS CLIN J SPOR; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; LEBIHAN D, 1997, BASICS PHYSICS MR IM, P131; LEBLANC KE, 1994, AM FAM PHYSICIAN, V50, P801; LECLERC S, 2000, MED SCI SPORTS EXERC; LECLERC S, IN PRESS SPORTS MED; Li TQ, 1998, ACTA RADIOL, V39, P460; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lovblad KO, 1998, AM J NEURORADIOL, V19, P1061; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makris N, 1997, ANN NEUROL, V42, P951, DOI 10.1002/ana.410420617; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCCRORY P, IN PRESS PHYS SPORTS; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; Milner B, 1964, FRONTAL GRANULAR COR, P313; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; PETRIDES M, 1995, J NEUROSCI, V15, P359; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; Shallice T., 1990, NEUROPSYCHOLOGY MENT; *SPORT MED COUNC A, 1999, HEADS UP; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TATOR CH, 1987, CLIN SPORT MED, V6, P101; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Umile EM, 1998, BRAIN INJURY, V12, P577; von Bierbrauer A, 1998, ACTA NEUROL BELG, V98, P21; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	61	33	33	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1072-7515	1879-1190		J AM COLL SURGEONS	J. Am. Coll. Surg.	APR	2001	192	4					515	524		10.1016/S1072-7515(01)00797-9			10	Surgery	Surgery	416QX	WOS:000167792600015	11294409				2021-06-18	
J	Hauser, KF; Knapp, PE; Turbek, CS				Hauser, KF; Knapp, PE; Turbek, CS			Structure-activity analysis of dynorphin A toxicity in spinal cord neurons: Intrinsic neurotoxicity of dynorphin A and its carboxyl-terminal, nonopioid metabolites	EXPERIMENTAL NEUROLOGY			English	Article						kappa-opioid receptors; N-methyl-D-aspartate (NMDA) receptor complex; MK-801 (dizocilpine); nor-binaltorphimine; intracellular calcium; neurotoxicology; spinal cord injury; neurotrauma	EXCITATORY AMINO-ACIDS; NMDA-RECEPTOR CHANNELS; LONG-LASTING ALLODYNIA; KAPPA-OPIOID RECEPTOR; BRAIN-INJURY; IN-VITRO; EXPRESSION; PEPTIDES; ANTINOCICEPTION; INFLAMMATION	Dynorphin A [dynorphin A (1-17)] is an endogenous opioid peptide that is antinociceptive at physiological concentrations. Levels of dynorphin A increase markedly following spinal cord trauma and may contribute to secondary neurodegeneration. Both kappa opioid and N-methyl-D-aspartate (NMDA) receptor antagonists can modulate the effects of dynorphin, suggesting that dynorphin is acting through kappa opioid and/or NMDA receptor types. Despite these findings, few studies have critically examined the mechanisms of dynorphin A neurotoxicity at the cellular level. To better understand how dynorphin affects cell viability, structure-activity studies were performed examining the effects of dynorphin A and dynorphin A-derived peptide fragments on the survival of mouse spinal cord neurons coexpressing kappa opioid and NMDA receptors in vitro. Time-lapse photography was used to repeatedly follow the same neurons before and during experimental treatments. Dynorphin A caused significant neuronal losses that were dependent on concentration (greater than or equal to1 muM) and duration of exposure. Moreover, exposure to an equimolar concentration of dynorphin A fragments (100 muM) also caused a significant loss of neurons. The rank order of toxicity was dynorphin A (1-17) > dynorphin A (1-13) congruent to dynorphin A (2-13) congruent to dynorphin A (13-17) (least toxic) > dynorphin A (1-5) ([Leu(5)]-enkephalin) or dynorphin A (1-11). Dynorphin A (1-5) or dynorphin A (1-11) did not cause neuronal losses even following 96 h of continuous exposure, while dynorphin A (3-13), dynorphin A (6-17), and dynorphin A (13-17) were neurotoxic. The NMDA receptor antagonist MK-801 (dizocilpine) (10 muM) significantly attenuated the neurotoxic effects of dynorphin A and/or dynorphin-derived fragments except dynorphin A (13-17), suggesting that the neurotoxic effects of dynorphin were largely mediated by NMDA receptors. Thus, toxicity resides in the carboxyl-terminal portion of dynorphin A and this minimally includes dynorphin A (3-13) and (13-17). Our findings suggest that dynorphin A and/or its metabolites may contribute significantly to neurodegeneration during spinal cord injury and that alterations in dynorphin A biosynthesis, metabolism, and/or degradation may be important in determining injury outcome. (C) 2001 Academic Press.	Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA; Univ Kentucky, Markey Canc Ctr, Coll Med, Lexington, KY 40536 USA	Hauser, KF (corresponding author), Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA.		Hauser, Kurt/AAX-8361-2020	Hauser, Kurt/0000-0001-7886-0332	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 06204] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA006204] Funding Source: NIH RePORTER		ARVIDSSON U, 1995, P NATL ACAD SCI USA, V92, P5062, DOI 10.1073/pnas.92.11.5062; BAKSHI R, 1992, BRAIN RES, V580, P255, DOI 10.1016/0006-8993(92)90952-6; BAKSHI R, 1990, J NEUROSCI, V10, P3793; Boyce S, 1999, NEUROPHARMACOLOGY, V38, P611, DOI 10.1016/S0028-3908(98)00218-4; Brauneis U, 1996, J PHARMACOL EXP THER, V279, P1063; Caudle RM, 1998, NEUROPEPTIDES, V32, P87, DOI 10.1016/S0143-4179(98)90022-1; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1995, J PHYSIOL-LONDON, V482, P575, DOI 10.1113/jphysiol.1995.sp020541; Chen L, 1998, J PHARMACOL EXP THER, V284, P826; CHEN L, 1995, J NEUROSCI, V15, P4602; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; DUBNER R, 1992, TRENDS NEUROSCI, V15, P96, DOI 10.1016/0166-2236(92)90019-5; Duggan AW, 1996, PROG BRAIN RES, V110, P137; EVANS CJ, 1988, OPIATE RECEPTORS, P23; Faden A I, 1996, NIDA Res Monogr, V163, P318; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1992, J NEUROSCI, V12, P425; FADEN AI, 1985, ANN NEUROL, V17, P386, DOI 10.1002/ana.410170414; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; GOLDSTEIN A, 1979, P NATL ACAD SCI USA, V76, P6666, DOI 10.1073/pnas.76.12.6666; Gurwell JA, 1996, BRAIN RES, V737, P175, DOI 10.1016/0006-8993(96)00728-7; HAUSER KF, 1989, BRAIN RES, V485, P157, DOI 10.1016/0006-8993(89)90677-X; Hauser KF, 1999, EXP NEUROL, V160, P361, DOI 10.1006/exnr.1999.7235; HERMAN BH, 1985, J PHARMACOL EXP THER, V232, P27; Hu WH, 1998, EUR J PHARMACOL, V342, P325, DOI 10.1016/S0014-2999(97)01492-1; IADAROLA MJ, 1988, PAIN, V35, P313, DOI 10.1016/0304-3959(88)90141-8; ISAAC L, 1990, BRAIN RES, V531, P83, DOI 10.1016/0006-8993(90)90760-9; Jarvis CR, 1997, J NEUROPHYSIOL, V78, P2363; KAKIDANI H, 1982, NATURE, V298, P245, DOI 10.1038/298245a0; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; KOLAJ M, 1995, BRAIN RES, V671, P227, DOI 10.1016/0006-8993(94)01333-D; Laughlin TM, 1997, PAIN, V72, P253, DOI 10.1016/S0304-3959(97)00046-8; Laughlin TM, 1999, PAIN, V80, P37, DOI 10.1016/S0304-3959(98)00191-2; Lipton SA, 1996, BRAIN PATHOL, V6, P507, DOI 10.1111/j.1750-3639.1996.tb00879.x; Long J B, 1986, Cent Nerv Syst Trauma, V3, P295; Long J B, 1986, NIDA Res Monogr, V75, P524; LONG JB, 1994, J PHARMACOL EXP THER, V269, P358; LONG JB, 1988, EUR J PHARMACOL, V153, P45, DOI 10.1016/0014-2999(88)90586-9; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1994, AM J PHYSIOL, V267, pR665; Messersmith DJ, 1998, MOL BRAIN RES, V53, P259, DOI 10.1016/S0169-328X(97)00308-2; MILLAN MJ, 1988, PAIN, V35, P299, DOI 10.1016/0304-3959(88)90140-6; MORRIS BJ, 1995, TRENDS NEUROSCI, V18, P350, DOI 10.1016/0166-2236(95)93927-P; NOGUCHI K, 1991, MOL BRAIN RES, V10, P227, DOI 10.1016/0169-328X(91)90065-6; OLESHANSKY M A, 1991, Society for Neuroscience Abstracts, V17, P1268; PETRALIA RS, 1994, J NEUROSCI, V14, P667; PORRECA F, 1998, INT NARC RES C, V29, P31; Prokai L, 1998, J CHROMATOGR A, V800, P59, DOI 10.1016/S0021-9673(97)01295-8; Shukla VK, 1997, J PHARMACOL EXP THER, V283, P604; SHUKLA VK, 1994, TRENDS PHARMACOL SCI, V15, P420, DOI 10.1016/0165-6147(94)90091-4; SHUKLA VK, 1992, J PSYCHIATR NEUROSCI, V17, P106; SKILLING SR, 1992, BRAIN RES, V575, P272, DOI 10.1016/0006-8993(92)90090-V; Sykova E, 1997, ADV NEUROL, V73, P121; Sykova E, 1999, GLIA, V25, P56, DOI 10.1002/(SICI)1098-1136(19990101)25:1<56::AID-GLIA6>3.0.CO;2-4; Tachibana T, 1998, J NEUROTRAUM, V15, P485, DOI 10.1089/neu.1998.15.485; Tang QB, 2000, J NEUROPHYSIOL, V83, P2610; Tang QB, 1999, J PHARMACOL EXP THER, V291, P760; TUCKER RP, 1988, J NEUROSCI, V8, P4503; Vanderah TW, 1996, PAIN, V68, P275, DOI 10.1016/S0304-3959(96)03225-3; WALKER JM, 1982, SCIENCE, V218, P1136, DOI 10.1126/science.6128791; WALKER JM, 1982, LIFE SCI, V31, P1821, DOI 10.1016/0024-3205(82)90219-3; WALKER JM, 1982, EUR J PHARMACOL, V85, P121, DOI 10.1016/0014-2999(82)90433-2; WEIHE E, 1989, NEUROSCIENCE, V31, P77, DOI 10.1016/0306-4522(89)90031-6; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; Yaksh TL, 1999, P NATL ACAD SCI USA, V96, P7680, DOI 10.1073/pnas.96.14.7680; Ye ZC, 1998, GLIA, V22, P237, DOI 10.1002/(SICI)1098-1136(199803)22:3<237::AID-GLIA3>3.0.CO;2-2; YOUNG EA, 1987, PEPTIDES, V8, P701, DOI 10.1016/0196-9781(87)90046-5; Zhang L, 1997, J NEUROPHYSIOL, V78, P582; Ziak D, 1998, PHYSIOL RES, V47, P365; Zoli M, 1999, TRENDS PHARMACOL SCI, V20, P142, DOI 10.1016/S0165-6147(99)01343-7	74	33	34	0	6	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAR	2001	168	1					78	87		10.1006/exnr.2000.7580			10	Neurosciences	Neurosciences & Neurology	406ER	WOS:000167202400006	11170722				2021-06-18	
J	Mautes, AEM; Thome, D; Steudel, WI; Nacimiento, AC; Yang, Y; Shohami, E				Mautes, AEM; Thome, D; Steudel, WI; Nacimiento, AC; Yang, Y; Shohami, E			Changes in regional energy metabolism after closed head injury in the rat	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						regional; ATP; glucose; lactate; closed head injury (CHI); rat	EXPERIMENTAL BRAIN-INJURY; NECROSIS-FACTOR-ALPHA; AMYLOID PRECURSOR PROTEIN; TNF-ALPHA; IMPAIRED MITOCHONDRIAL; GLUCOSE-UTILIZATION; EXPRESSION; INTERLEUKIN-6; DYSFUNCTION	We examined in the present investigation regional ATP, glucose, and lactate content in the cortical and subcortical structures, in a rat model of closed head injury (CHI). In serial tissue sections bioluminescence imaging of ATP, glucose, and lactate was performed at 4 h, 12 h and 24 h (n 4/5 per time point with) after the induction of CHI or sham surgery. Bioluminescence images were analyzed by computer-assisted densitometry, at the lesion site, in remote cortical areas, and in the subcortical structures (thalamus and caudate nucleus). ATP content was significantly decreased at the lesion site after 4 h and in the remote cortex at 12 h post-injury. At 12 h, the ATP content reached baseline levels on the ipsilateral side and at 24 h also at remote lateral parietal sites. In the contralateral cortex, ATP increased transiently above the baseline at 12 h. No significant changes in ATP were found in the thalamus and caudate nucleus. Cortical glucose and lactate contents could not be discerned over time. Following CHI there is an acute and progressive, yet transient, ischemic cortical profile, which is not reflected in subcortical areas.	Univ Saarland, Sch Med, Neurosurg Res Lab, Homburg, Germany; Univ Saarland, Sch Med, Dept Neurosurg, Homburg, Germany; Hebrew Univ Jerusalem, Dept Pharmacol, Sch Pharm, Jerusalem, Israel	Mautes, AEM (corresponding author), Univ Saarland, Sch Med, Neurosurg Res Lab, Homburg, Germany.						Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Krishnappa IK, 1999, J NEUROTRAUM, V16, P213, DOI 10.1089/neu.1999.16.213; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; Mautes A. E., 2000, EUR J TRAUMA, V26, P122; MeierRuge WA, 1997, ANN NY ACAD SCI, V826, P229, DOI 10.1111/j.1749-6632.1997.tb48474.x; Murakami N, 1998, J NEUROTRAUM, V15, P993, DOI 10.1089/neu.1998.15.993; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Pierce JES, 1996, J NEUROSCI, V16, P1083; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU NC, 1995, MOL PHARMACOL, V48, P550	28	33	33	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	FEB	2001	16	1					33	39		10.1385/JMN:16:1:33			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	429NW	WOS:000168524700004	11345518				2021-06-18	
J	Schellinger, PD; Schwab, S; Krieger, D; Fiebach, JB; Steiner, T; Hund, EF; Hacke, W; Meinck, HM				Schellinger, PD; Schwab, S; Krieger, D; Fiebach, JB; Steiner, T; Hund, EF; Hacke, W; Meinck, HM			Masking of vertebral artery dissection by severe trauma to the cervical spine	SPINE			English	Article						acute spinal injury; cervical spine; dissection; trauma; vertebral artery	CLINICAL-FEATURES; NECK PAIN; THERAPY; INJURY; SUBLUXATION; OCCLUSION; DIAGNOSIS; INFARCTS; HEADACHE	Study Design. A prospective case study was performed. Objectives. To illustrate the association of cervical trauma with vertebral artery dissection, and to propose a diagnostic and therapeutic algorithm for suspected traumatic vertebral artery dissection. Summary of Background Data. Vertebral artery dissection is a recognized but underdiagnosed complication of trauma to the cervical spine. Symptoms of spinal cord injury, however, may obscure those of vertebral artery dissection, presumably causing gross underdiagnosis of this complication. Methods. All patients with vertebral artery dissection admitted to the authors' facility between 1992 and 1997 were screened for cervical trauma. Results. This article presents four patients with severe trauma to the cervical spine, defined as luxation, subluxation, or fracture, in whom symptoms of vertebral artery dissection developed after a delay ranging from several hours to weeks. The traumatic vertebral artery dissection typically was located at the site of vertebral injury or cranial to it. One patient with fracture of the odontoid process survived symptom free without ischemic brain infarctions. Another patient survived with traumatic quadriplegia in addition to large cerebellar and posterior cerebral artery infarctions. Two patients died as a result of fulminant vertebrobasilar infarctions, both with only moderate impairment from the primary spinal cord injury. Conclusions. Early signs of vertebral artery dissection include head and neck pain, often localized to the site of intimal disruption, which may be disguised by the signs of the spinal injury. Early Doppler ultrasound and duplex sonography as a noninvasive screening method should be performed for patients with severe trauma to the cervical spine. In cases of vertebral artery dissection, immediate anticoagulation should be initiated. Traumatologists should be aware of this complication in evaluating patients with severe trauma of the cervical spine, and also for a variety of forensic reasons.	Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Neuroradiol, D-69120 Heidelberg, Germany; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA	Schellinger, PD (corresponding author), Univ Heidelberg, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.		Steiner, Thorsten/L-2868-2018; Steiner, Thorsten/A-7391-2014	Steiner, Thorsten/0000-0002-5080-8222; Fiebach, Jochen B./0000-0002-7936-6958			Adamek RJ, 1998, HELICOBACTER, V3, P206, DOI 10.1046/j.1523-5378.1998.08044.x; aternus KS., 1985, ARTERIA VERTEBRALIS, P61; Bartels E, 1996, STROKE, V27, P290, DOI 10.1161/01.STR.27.2.290; Brandt T, 1996, STROKE, V27, P875, DOI 10.1161/01.STR.27.5.875; BRANDT T, 1995, NERVENARZT, V66, P267; CARPENTER S, 1961, J NEUROSURG, V18, P849, DOI 10.3171/jns.1961.18.6.0849; Chiles BW, 1996, NEW ENGL J MED, V334, P514, DOI 10.1056/NEJM199602223340807; Hart R G, 1983, Neurol Clin, V1, P155; HINSE P, 1991, J NEUROL NEUROSUR PS, V54, P863, DOI 10.1136/jnnp.54.10.863; HINZ P, 1963, ARCH ORTHOP UNFALLCH, V64, P268; HOFFMANN M, 1993, STROKE, V24, P815, DOI 10.1161/01.STR.24.6.815; JABRE A, 1991, NEUROSURGERY, V29, P912, DOI 10.1227/00006123-199112000-00020; KAY R, 1995, NEW ENGL J MED, V333, P1588, DOI 10.1056/NEJM199512143332402; Khurana DS, 1996, PEDIATR NEUROL, V14, P255, DOI 10.1016/0887-8994(96)00015-X; Krayenbuhl H, 1957, VASKULAREN ERKRANKUN, P13; KRIEGER D, 1990, DEUT MED WOCHENSCHR, V115, P580, DOI 10.1055/s-2008-1065050; LOUW JA, 1990, J BONE JOINT SURG BR, V72, P679; MAS JL, 1987, STROKE, V18, P1037, DOI 10.1161/01.STR.18.6.1037; PARENT AD, 1992, NEUROSURGERY, V31, P501, DOI 10.1227/00006123-199209000-00012; PRATTTHOMAS HR, 1947, JAMA-J AM MED ASSOC, V133, P600, DOI 10.1001/jama.1947.02880090022005; Provenzale JM, 1996, J COMPUT ASSIST TOMO, V20, P185, DOI 10.1097/00004728-199603000-00004; PULLICINO P, 1994, STROKE, V25, P1870, DOI 10.1161/01.STR.25.9.1870; Schellinger PD, 1997, FORTSCHR NEUROL PSYC, V65, P425, DOI 10.1055/s-2007-996348; SILBERT PL, 1995, NEUROLOGY, V45, P1517, DOI 10.1212/WNL.45.8.1517; STURZENEGGER M, 1993, STROKE, V24, P1910, DOI 10.1161/01.STR.24.12.1910; Sturzenegger M, 1996, Ther Umsch, V53, P544; STURZENEGGER M, 1993, SCHWEIZ MED WSCHR, V123, P1389; STURZENEGGER M, 1994, HEADACHE, V34, P187, DOI 10.1111/j.1526-4610.1994.hed3404187.x; STURZENEGGER M, 1994, NERVENARZT, V65, P402; SUECHTING RL, 1955, J NEUROSURG, V12, P187, DOI 10.3171/jns.1955.12.2.0187; TULYAPRONCHOTE R, 1994, NEUROLOGY, V44, P1397, DOI 10.1212/WNL.44.8.1397; WILLIS BK, 1994, NEUROSURGERY, V34, P435, DOI 10.1227/00006123-199403000-00008	32	33	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	FEB 1	2001	26	3					314	319		10.1097/00007632-200102010-00019			6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	400TE	WOS:000166887100013	11224870				2021-06-18	
J	Mancini, J; Lethel, V; Hugonenq, C; Chabrol, B				Mancini, J; Lethel, V; Hugonenq, C; Chabrol, B			Brain injuries in early foetal life: consequences for brain development	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							NEURONAL MIGRATION; MATERNAL TRAUMA; EXPOSURE; LESIONS; INFANTS; DAMAGE	Learning disability and cerebral palsy are often related to factors present before birth. We report three patients (two with schizencephaly, one with unilateral cerebellar agenesis) in whom the timing of an insult to the foetus was known. In the first case, the mother had a trauma at 16 weeks of pregnancy and schizencephaly was discovered in the male infant associated with a left hemiplegia. In the second child, amniocentesis performed at 16 weeks into pregnancy may have been responsible for the same cortical anomaly. In the third case, sequential foetal echographies clearly demonstrated that an apparent unilateral cerebellar agenesis was related to an haemorrhagic event secondary to cerebellar trauma that occurred at 19 weeks of pregnancy, It is suggested that these brain malformations are related to an ischemic mechanism or a traumatic event in foetal life.	Paediat Univ Hosp, Dept Paediat Neurol, Marseille, France	Mancini, J (corresponding author), Paediat Univ Hosp, Dept Paediat Neurol, Marseille, France.						Baethmann M, 1996, ACTA PAEDIATR, V85, P1331, DOI 10.1111/j.1651-2227.1996.tb13920.x; BURNELLI S, 1996, NAT GENET, V12, P94; COHEN M, 1994, DEV MED CHILD NEUROL, V36, P263; des Portes V, 1998, CELL, V92, P51; EATON DGM, 1991, BRIT J OBSTET GYNAEC, V98, P1292, DOI 10.1111/j.1471-0528.1991.tb15406.x; ELLER KM, 1995, OBSTET GYNECOL, V85, P865, DOI 10.1016/0029-7844(94)00315-5; FERRIE CD, 1995, NEUROLOGY, V45, P150, DOI 10.1212/WNL.45.1.150; KOMARNISKI CA, 1990, J ULTRAS MED, V9, P305; LANDRIEU P, 1994, CLIN NEUROPATHOL, V13, P192; MARRET S, 1995, J NEUROPATH EXP NEUR, V54, P358, DOI 10.1097/00005072-199505000-00009; Mercuri E, 1997, PEDIATR RADIOL, V27, P139, DOI 10.1007/s002470050085; PATI S, 1994, REPROD TOXICOL, V8, P115, DOI 10.1016/0890-6238(94)90018-3; YAKOVLEV PI, 1946, J NEUROPATH EXP NEUR, V5, P169, DOI 10.1097/00005072-194607000-00001; YAKOVLEV PI, 1946, J NEUROPATH EXP NEUR, V5, P116, DOI 10.1097/00005072-194604000-00003	14	33	33	0	1	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JAN	2001	43	1					52	55		10.1017/S0012162201000081			4	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	394EA	WOS:000166510100008	11201424				2021-06-18	
J	Arroyos-Jurado, E; Paulsen, JS; Merrell, KW; Lindgren, SD; Max, JE				Arroyos-Jurado, E; Paulsen, JS; Merrell, KW; Lindgren, SD; Max, JE			Traumatic brain injury in school-age children academic and social outcome	JOURNAL OF SCHOOL PSYCHOLOGY			English	Article						traumatic brain injury; neuropsychology; academic achievement; social behavior; children and adolescents	COGNITIVE SEQUELAE; PERFORMANCE; RESERVE; SCALE; COMA	School-aged children with a traumatic blain injury (TBI) require extraordinary effort and energy from individuals in their school, home, and community. The purpose of this study was to examine the academic, behavioral, and social outcomes of a cohort of children and adolescents following TBI. A comprehensive assessment of cognitive functioning, achievement, and adaptive behavior was administered to 43 school-aged children 2 pars after their TBI. Premorbid functioning for each participant was obtained from state-mandated test scores assessed prior to the TBI. The predictive utility of premorbid functioning, TBI severity, and age at injury were examined. Findings revealed that premorbid functions were significant predictors of reading and spelling achievement and adaptive functioning. Severity of injury was predictive of adaptive functioning. Implications of findings include program development, reintegration into school, and educating parents and teachers. (C) 2000 Society for the Study of School Psychology. Published by Elsevier Science Ltd.	Univ Iowa, Iowa City, IA 52242 USA	Paulsen, JS (corresponding author), Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.		Paulsen, Jane/AAQ-2932-2020	Paulsen, Jane/0000-0002-0983-228X			ALBERTS MS, 1991, COGNITIVE REHABILITA, P95; Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BEGALI V, 1992, HEAD INJURY CHILDREN; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Clark E., 1997, CHILDHOOD TRAUMATIC, P191; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; DEATON AV, 1987, J LEARN DISABIL, V20, P581, DOI 10.1177/002221948702001003; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Geerlings MI, 1999, PSYCHOL MED, V29, P1219, DOI 10.1017/S0033291799008867; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; HARRISON PL, 1989, 10 MENTAL MEASUREMEN, P903; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; HOOVER H, 1993, IOWA TEST BASIC SKIL; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Jastak S, 1984, WIDE RANGE ACHIEVEME; Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Kehle T. J., 1997, CHILDHOOD TRAUMATIC, P135; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Lehr E, 1990, PSYCHOL MANAGEMENT T; Max JE, 1998, BRAIN INJURY, V12, P31; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; SAVAGE RC, 1994, ED DIMENSIONS ACQUIR; SEGATORE M, 1992, HEART LUNG, V21, P548; Slater E. J., 1989, J ADOLESCENT RES, V4, P371; Sparrow S., 1984, VINELAND ADAPTIVE BE; *SPSS INC, 1993, SPSS WIND PROF STAT; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1987, SCIENCE, V236, P1110, DOI 10.1126/science.3576224	39	33	33	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4405			J SCHOOL PSYCHOL	J. Sch. Psychol.	NOV-DEC	2000	38	6					571	587		10.1016/S0022-4405(00)00053-4			17	Psychology, Educational	Psychology	387HC	WOS:000166116300004					2021-06-18	
J	Chua, KSG; Kong, KH				Chua, KSG; Kong, KH			Alcohol neurolysis of the sciatic nerve in the treatment of hemiplegic knee flexor spasticity: Clinical outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						ethyl alcohol; hemiplegia; muscle spasticity; rehabilitation; sciatic nerve	BOTULINUM TOXIN	Objective: To study clinical outcomes after 50% to 100% alcohol neurolysis of the sciatic nerve in the treatment of chronic hemiplegic knee flexor spasticity. Design: Case series using a convenience sample. Setting: Rehabilitation teaching hospital. Patients: Eight patients (mean age, 55.1 +/- 12.1 yr; mean duration to block, 4.4 +/- 3.7 mo) with chronic hemiplegia and severe spasticity (modified Ashworth scale [MAS] score < 2) secondary to cerebrovascular accidents (n = 5) and traumatic brain injuries (n = 3). Two patients were ambulant, 6 were wheelchair-bound. Interventions: Fifty percent to 100% alcohol neurolysis of the sciatic nerve using repetitive electric stimulation to localize the sciatic nerve. Main Outcome Measures: MAS score, gain in knee range of motion (ROM), and visual inspection of gait at 0, 1, and 6 months postneurolysis. Nonparametric tests were used in statistical analysis. Results: The mean preinjection MAS score was 2.8 +/- 0.7, which improved to 1.4 +/- 0.7 at 1 month (p = .005), and 1.8 +/- 0.9 (p = .01) and 1.9 +/- 1.1 (p = .02) at 3 and 6 months postinjection, respectively. The mean gain in knee ROM was 34.4 degrees +/- 15.7 degrees at 1 month postinjection and was maintained at 6 months postinjection. Improvements in gait were noted in both ambulant patients, and improved positioning in 3 of 6 wheel-chair-bound patients. The incidence of dysesthetic pain was 0%. Conclusion: Fifty percent to 100% alcohol neurolysis of the sciatic nerve is a safe and effective method for treatment of hemiplegic knee flexor spasticity, with therapeutic effects lasting 6 months.	Tan Tock Seng Hosp, Rehabil Ctr, Dept Rehabil Med, Singapore 569766, Singapore	Chua, KSG (corresponding author), Tan Tock Seng Hosp, Rehabil Ctr, Dept Rehabil Med, 17 Ang Mo Kio Ave 9, Singapore 569766, Singapore.						AWAD EA, 1972, ARCH PHYS MED REHAB, V53, P554; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; CARPENTER EB, 1980, DEV MED CHILD NEUROL, V22, P497; DENGLER R, 1992, J NEUROL, V239, P375; GLENN MB, 1990, PRACTICAL MANAGEMENT, P27; HALPERN DANIEL, 1966, ARCH PHYS MED REHABIL, V47, P659; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; KHALILI AA, 1967, JAMA-J AM MED ASSOC, V200, P1166; Kong KH, 1999, ARCH PHYS MED REHAB, V80, P1234, DOI 10.1016/S0003-9993(99)90021-7; Kong KH, 1999, INT J REHABIL RES, V22, P327, DOI 10.1097/00004356-199912000-00011; Lance J. W., 1980, SPASTICITY DISORDERE, P485; MAY O, 1912, BRIT MED J, V31, P465; O'Hanlan J T, 1969, Va Med Mon (1918), V96, P429; Pelissier J, 1993, Cah Anesthesiol, V41, P139; Petrillo C R, 1988, Int Disabil Stud, V10, P97; SHIN DY, 1996, PHYSIATRIC PROCEDURE, P150; TARDIEU G, 1968, DEV MED CHILD NEUROL, V10, P555	17	33	38	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2000	81	10					1432	1435		10.1053/apmr.2000.9395			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	360WA	WOS:000089689300017	11030512				2021-06-18	
J	Ringel, F; Chang, RCC; Staub, F; Baethmann, A; Plesnila, N				Ringel, F; Chang, RCC; Staub, F; Baethmann, A; Plesnila, N			Contribution of anion transporters to the acidosis-induced swelling and intracellular acidification of glial cells	JOURNAL OF NEUROCHEMISTRY			English	Article						brain edema; lactacidosis; Cl-/HCO3- exchanger; Na+-K+-Cl- cotransporter; C6 glioma cells	C6 GLIOMA-CELLS; RABBIT ESOPHAGEAL EPITHELIUM; BRAIN EDEMA; PH REGULATION; RAT ASTROCYTES; EXTRACELLULAR ACIDOSIS; CEREBRAL-ISCHEMIA; VOLUME REGULATION; NA+/H+ EXCHANGE; INVITRO MODEL	This study examines the contribution of anion transporters to the swelling and intracellular acidification of glial cells from an extracellular lactacidosis, a condition well-known to accompany cerebral ischemia and traumatic brain injury. Suspended C6 glioma cells were exposed to lactacidosis in physiological or anion-depleted media, and different anion transport inhibitors were applied, Changes in cell volume and intracellular pH (pH(i)) were simultaneously quantified by flow cytometry. Extracellular lactacidosis (pH 6.2) led to an increase in cell volume to 125.1 +/- 2.5% of baseline within 60 min, whereas the pH, dropped from the physiological value of 7.13 +/- 0.05 to 6.32 +/- 0.03, Suspension in Cl--free or HCO3-/CO2-free media or application of anion transport inhibitors 0.1 mM bumetanide or 0.5 mM 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS)I did not affect cell volume during baseline conditions but significantly reduced cell swelling from lactacidosis. In addition, the Cl--free or HCO3-/CO2-free media and DIDS attenuated intracellutar acidosis on extracellular acidification. From these findings it is concluded that besides the known activation of the Na+/H+ exchanger, activation of the Na+-independent Cl-/HCO3- exchanger and the Na+-K+-Cl- cotransporter contributes to acidosis-induced glial swelling and the intracellular acidification. Inhibition of these processes may be of interest for future strategies in the treatment of cytotoxic brain edema from cerebral ischemia or traumatic brain injury.	Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81366 Munich, Germany; Univ Cologne, Dept Neurosurg, Cologne, Germany	Plesnila, N (corresponding author), Univ Munich, Klinikum Grosshadern, Inst Surg Res, Marchioninistr 15, D-81366 Munich, Germany.		Chang, Raymond Chuen-Chung/C-1107-2009; Ringel, Florian/E-4933-2014; Plesnila, Nikolaus/T-7522-2019	Chang, Raymond Chuen-Chung/0000-0001-8538-7993; 			BAETHMAN A, 1978, NEUROSURG REV, V1, P85; BENDA P, 1968, SCIENCE, V161, P370, DOI 10.1126/science.161.3839.370; Bourke R S, 1980, Adv Neurol, V28, P99; BOYARSKY G, 1993, GLIA, V8, P241, DOI 10.1002/glia.440080404; CABANTCHIK ZI, 1992, AM J PHYSIOL, V262, pC803; CHASSANDE O, 1988, EUR J BIOCHEM, V171, P425, DOI 10.1111/j.1432-1033.1988.tb13807.x; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GOLDMAN SA, 1989, J CEREBR BLOOD F MET, V9, P471, DOI 10.1038/jcbfm.1989.70; HOSSMANN KA, 1989, NEUROSURG REV, V12, P263, DOI 10.1007/BF01780838; JAKUBOVICZ DE, 1987, BRAIN RES, V435, P138, DOI 10.1016/0006-8993(87)91594-0; JAKUBOVICZ DE, 1989, BRAIN RES, V485, P215, DOI 10.1016/0006-8993(89)90564-7; JEAN T, 1986, EUR J BIOCHEM, V160, P211, DOI 10.1111/j.1432-1033.1986.tb09959.x; Jenkins L.W., 1984, RECENT PROGR STUDY T, P523; KACHEL V, 1976, J HISTOCHEM CYTOCHEM, V24, P2111; KEMPSKI O, 1988, STROKE, V19, P385, DOI 10.1161/01.STR.19.3.385; KEMPSKI O, 1983, BRAIN RES, V279, P217, DOI 10.1016/0006-8993(83)90180-4; KEMPSKI O, 1988, NEUROCHEM PATHOL, V9, P109; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KRAIG RP, 1987, J CEREBR BLOOD F MET, V7, P379, DOI 10.1038/jcbfm.1987.80; LeBars E, 1996, NEUROSCI LETT, V213, P123; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; MELLERGARD P, 1994, AM J PHYSIOL, V267, pC581; MELLERGARD P, 1993, EXP BRAIN RES, V95, P371; MELLERGARD PE, 1991, NEUROREPORT, V2, P695, DOI 10.1097/00001756-199111000-00016; Mongin AA, 1996, BBA-BIOMEMBRANES, V1285, P229, DOI 10.1016/S0005-2736(96)00165-4; NAKAI H, 1988, STROKE, V19, P764, DOI 10.1161/01.STR.19.6.764; Plesnila N, 1998, ACT NEUR S, V71, P203; Plesnila N, 1999, J NEUROTRAUM, V16, P831, DOI 10.1089/neu.1999.16.831; RINGEL F, 1996, CEREBROVASC DIS S2, V6, P120; ROOS A, 1981, PHYSIOL REV, V61, P296; SHRODE LD, 1994, GLIA, V12, P196, DOI 10.1002/glia.440120305; SIESJO BK, 1993, PROG BRAIN RES, V96, P23; STAUB F, 1994, J NEUROTRAUM, V11, P679, DOI 10.1089/neu.1994.11.679; STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135; STAUB F, 1990, J CEREBR BLOOD F MET, V10, P866, DOI 10.1038/jcbfm.1990.143; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; TOBEY NA, 1995, GASTROENTEROLOGY, V109, P414, DOI 10.1016/0016-5085(95)90328-3; Tobey NA, 1997, GASTROENTEROLOGY, V112, P847, DOI 10.1053/gast.1997.v112.pm9041246; Volk C, 1998, BBA-BIOMEMBRANES, V1372, P28, DOI 10.1016/S0005-2736(98)00044-3	39	33	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	2000	75	1					125	132		10.1046/j.1471-4159.2000.0750125.x			8	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	325CP	WOS:000087659000016	10854255	Bronze			2021-06-18	
J	Ylvisaker, M; Feeney, T				Ylvisaker, M; Feeney, T			Reflections on Dobermanns, poodles, and social rehabilitation for difficult-to-serve individuals with traumatic brain injury	APHASIOLOGY			English	Article							CLOSED-HEAD-INJURY; FOLLOW-UP; BEHAVIORAL MOMENTUM; FRONTAL-LOBE; CHILDREN; COMPREHENSION; DISABILITIES; METAPHOR; DAMAGE; INTERVENTIONS		Coll St Rose, Dept Commun Disorders, Albany, NY USA; Wildwood Inst, Wildwood TBI Behav Resource Project, Schenectady, NY USA	Ylvisaker, M (corresponding author), 1171 Van Antwerp Rd, Schenectady, NY 12309 USA.						ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Anderson, 1989, TRANSFER COGNITIVE S; BAER DM, 1987, J APPL BEHAV ANAL, V20, P313, DOI 10.1901/jaba.1987.20-313; BANNERMAN DJ, 1990, J APPL BEHAV ANAL, V23, P79, DOI 10.1901/jaba.1990.23-79; Barkley RA., 1987, DEFIANT CHILDREN CLI; BILLOW RM, 1975, DEV PSYCHOL, V11, P415, DOI 10.1037/h0076668; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BOND MR, 1990, REHABILITATION ADULT; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROWN F, 1993, EDUC TRAIN MENT RET, V28, P318; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Carr E.G., 1994, COMMUNICATION BASED; Carr EG, 1998, ANTECEDENT CONTROL, P3; CARR EG, 1997, POSITIVE BEHAV SUPPO, P403; CHILDS KE, 1994, J APPL BEHAV ANAL, V27, P7, DOI 10.1901/jaba.1994.27-7; CONGER JJ, 1984, ADOLESCENCE YOUTH; CZIKSZENTMILHAL.M, 1984, BEING ADOLESCENT; Damasio A. R., 1994, DESCARTESERROR; DAMASIO AR, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P217; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; FEENEY TJ, 1997, CHILDREN ACQUIRED BR, P229; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Fletcher JM, 1995, HDB PEDIAT PSYCHOL, P362; FOWLER R, 1996, OREGON C MONOGRAPH, V8, P137; Frankl VE., 1984, MANS SEARCH MEANING; GARDNER H, 1974, CHILD DEV, V45, P84, DOI 10.2307/1127753; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HALLOWELL E, 1994, DRIVEN DISTRACTION; Harchik A E, 1993, Ann Clin Psychiatry, V5, P151, DOI 10.3109/10401239309148979; HARLAN D, 1994, MAPPING MOTIVATIONAL; JACOBS HE, 1993, BEHAV ANAL GUIDELINE; KAVALE K, 1983, J LEARN DISABIL, V16, P165, DOI 10.1177/002221948301600307; KENNEDY CH, 1995, J APPL BEHAV ANAL, V28, P97, DOI 10.1901/jaba.1995.28-97; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Lakoff G., 1980, METAPHORS WE LIVE; LAKOFF G, 1998, PHILOS FLESH EMBODIE; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEWIN J, 1998, COLLABORATIVE BRAIN; LEWIS L, 1990, J NERV MENT DIS, V178, P69, DOI 10.1097/00005053-199002000-00001; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; MACE FC, 1990, J EXP ANAL BEHAV, V54, P163, DOI 10.1901/jeab.1990.54-163; MACE FC, 1988, J APPL BEHAV ANAL, V21, P123, DOI 10.1901/jaba.1988.21-123; Mace FC, 1997, J APPL BEHAV ANAL, V30, P1, DOI 10.1901/jaba.1997.30-1; MANN L, 1979, TRAIL PROCESS HIST P; MCINTOSH R, 1991, J LEARN DISABIL, V24, P451, DOI 10.1177/002221949102400802; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Nippold M., 1998, LATER LANGUAGE DEV S; PEARSON BZ, 1990, J CHILD LANG, V17, P185, DOI 10.1017/S0305000900013179; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; POLLACK I, 1994, ED DIMENSIONS ACQUIR, P303; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Robinson TR, 1999, J EDUC PSYCHOL, V91, P195, DOI 10.1037/0022-0663.91.2.195; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; Shammi P, 1999, BRAIN, V122, P657, DOI 10.1093/brain/122.4.657; Skinner BF., 1938, BEHAV ORGANISMS EXPT; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, IN PRESS MEMORY CONS; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WAGGONER JE, 1985, CHILD DEV, V56, P1156, DOI 10.1111/j.1467-8624.1985.tb00184.x; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; *WHO, 1998, COMM LANG FUNCT DIS; WIENER J, 1998, LEARNING DISABILITIE, V12, P40; World Health Organization, 1980, INT CLASS IMP DIS HA; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YVLISAKER M, 1999, CLIN PRACTICE MANAGE, P117; YVLISAKER M, 1995, SEMINARS SPEECH LANG, V16, P32; YVLISAKER M, 1996, SEMINARS SPEECH LANG, V17, P217; YVLISAKER M, 1998, TRAUMATIC BRAIN INJU, P271; YVLISAKER M, 1987, COMMUNITY REENTRY HE; YVLISAKER M, 1998, TRAUMATIC BRAIN INJU, P221; YVLISAKER M, 1985, CLIN MANAGEMENT NEUR, P243; YVLISAKER M, 1994, TOP LANG DISORD, V15, P37; ZARAGOZA P, 1991, 42ND ANN M EUR ASS A, V1, P260	82	33	35	0	2	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	APR	2000	14	4					407	431		10.1080/026870300401432			25	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	315AV	WOS:000087091200005					2021-06-18	
J	Mattiasson, GJ; Philips, MF; Tomasevic, G; Johansson, BB; Wieloch, T; McIntosh, TK				Mattiasson, GJ; Philips, MF; Tomasevic, G; Johansson, BB; Wieloch, T; McIntosh, TK			The rotating pole test: evaluation of its effectiveness in assessing functional motor deficits following experimental head injury in the rat	JOURNAL OF NEUROSCIENCE METHODS			English	Article						traumatic brain injury; lateral fluid percussion; neurological motor deficit; outcome measure; behavior; rat	EXPERIMENTAL BRAIN INJURY; FLUID-PERCUSSION MODEL; GLASGOW OUTCOME SCALE; ENRICHED ENVIRONMENT; CEREBRAL INFARCTION; DAMAGE; GROWTH; DYSFUNCTION; ANTAGONIST; APOPTOSIS	Neurological motor dysfunction is often an integral component of the neurological sequelae of traumatic brain injury (TBI). In experimental TBI, neurological motor testing is an outcome measure used to monitor severity of injury, and the response to treatment. This study evaluates the effectiveness and sensitivity of the rotating pole test (RP) to characterize and evaluate the temporal course of motor deficits after lateral fluid percussion (FP) injury to the rat brain. The results are compared with the previously characterized and widely used composite neuroscore of motor function (NS). The animals were required to walk across an elevated wooden pole that was either stationary or rotating to left or right directions at different speeds. Male Wistar rats underwent lateral FP injury of moderate severity (mean 2.4 atm, n = 9) or sham surgery (n = 9), and were tested at 48 h and 7 days post-injury using the NS and RP. The results of the NS directly correlated to the results of the RP, showing a significant injury effect at both 48 h and 7 days. This is the first study to show that the RP-test detects neurological motor deficits after lateral FP injury, and suggests that this technique is a reliable behavioral tool for evaluating neurological motor function in the acute period after experimental TBI. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Lund Hosp, Wallenberg Neurosci Ctr, Div Expt Brain Res, S-22185 Lund, Sweden; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Lund Hosp, Wallenberg Neurosci Ctr, Div Expt Neurol, S-22185 Lund, Sweden	Mattiasson, GJ (corresponding author), Univ Lund Hosp, Wallenberg Neurosci Ctr, Div Expt Brain Res, S-22185 Lund, Sweden.			Wieloch, Tadeusz/0000-0002-7669-2520			ALTMAN DG, 1993, PRACTICAL STAT MED R, P210; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Conti AC, 1998, J NEUROSCI, V18, P5663; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRABOWSKI M, 1995, EXP NEUROL, V133, P96, DOI 10.1006/exnr.1995.1011; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS SP, 1975, AM J ANAT, V143, P1, DOI 10.1002/aja.1001430102; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Johansson BB, 1996, STROKE, V27, P324, DOI 10.1161/01.STR.27.2.324; JONES TA, 1994, J NEUROSCI, V14, P2140; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KOLB B, 1983, CAN J PSYCHOL, V37, P211, DOI 10.1037/h0080724; Kraus JF, 1993, HEAD INJURY, P1; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Mautes AEM, 1996, NEUROSCI LETT, V214, P95, DOI 10.1016/0304-3940(96)12916-5; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PAXINOS G, 1995, RAT NERVOUS SYSTEM, P632; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; RINK A, 1995, AM J PATHOL, V147, P1575; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, J NEUROSCI, V13, P5383; SULLIVAN SJ, 1994, BRAIN INJURY, V8, P613, DOI 10.3109/02699059409151014; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	41	33	34	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	JAN 31	2000	95	1					75	82		10.1016/S0165-0270(99)00162-4			8	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	284NN	WOS:000085338600008	10776817				2021-06-18	
J	Posmantur, RM; Newcomb, JK; Kampfl, A; Hayes, RL				Posmantur, RM; Newcomb, JK; Kampfl, A; Hayes, RL			Light and confocal microscopic studies of evolutionary changes in neurofilament proteins following cortical impact injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article						axons; confocal microscopy; dendrites; immunofluorescence; neurofilament proteins; traumatic brain injury	TRAUMATIC BRAIN INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; INDUCED AXONAL INJURY; LEVELS DECREASE; CALPAIN; NEURONS; HIPPOCAMPUS; SPECTRIN; PHOSPHORYLATION; PERMEABILITY	Previous studies have shown that traumatic brain injury (TBI) produces progressive degradation of cytoskeletal proteins including neurofilaments (e,g,, neurofilament 68 [NF68] and neurofilament 200 [NF2001]) within the first 24 h after injury. Thus, we employed immunofluorescence (light and confocal microscopy) to study the histopathological correlates of progressive neurofilament protein loss observed at 15 min, 3 h, and 24 h following unilateral cortical injury in rats, TBI produced significant alterations in NF68 and NF200 immunolabeling in dendrites and cell bodies at contusion sites ipsilateral to injury, as well as in the noncontused contralateral cortex, Changes in immunolabeling were associated with, but not exclusively restricted to, regions previously shown to contain dark shrunken neurons labeled by hematoxylin and eosin staining, a morphopathological response to injury suggesting impending cell death. Immunofluorescence microscopic studies of neurofilament proteins in the ipsilateral cerebral cortex detected prominent fragmentation of apical dendrites of pyramidal neurons in layers 3-5 and loss of fine dendritic arborization within layer 1, While modest changes were observed 15 min follow-injury, more pronounced loss of dendritic neurofilament immunofluorescence was detected 3 and 24 h following injury. Confocal microscopy also revealed progressive alterations in NF68 immunoreactivity in dendrites following TBI, While some evidence of structural alterations was observed 15 min following TBI, dendritic breaks were readily detected in confocal micrographs from 3 to 24 h following injury. However, disturbances in axonal NF68 by immunofluorescence microscopy in the corpus callosum were not detected until 24 h after injury. These studies confirmed that derangements in dendritic neurofilament cytoskeletal proteins are not exclusively restricted to sites of impact contusion. Moreover, changes in dendritic cytoskeletal proteins are progressive and not fully expressed within the first 15 min following impact injury, These progressive dendritic disruptions are characterized by disturbances in the morphology of neurofilament proteins, resulting in fragmentation and focal loss of NF68 immunofluorescence within apical dendrites. In contrast, alterations in axonal cytoskeletal proteins are more restricted and delayed with no pronounced changes until 24 h after injury, (C) 2000 Academic Press.	Bristol Myers Squibb Co, Neurosci Drug Discovery, Dept 405, Wallingford, CT 06492 USA; Univ Texas, Hlth Sci Ctr, Vivian L Smith Ctr Neurol Res, Dept Neurosurg, Houston, TX 77030 USA; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria; Univ Florida, Inst Brain, Dept Neurosci, Ctr Traumat Brain Injury Studies, Gainesville, FL 32610 USA	Posmantur, RM (corresponding author), Bristol Myers Squibb Co, Neurosci Drug Discovery, Dept 405, POB 5100,5 Res Pkwy, Wallingford, CT 06492 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 40182, R01-NS 21458] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040182, R01NS021458] Funding Source: NIH RePORTER		ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BARINAGA M, 1995, SCIENCE, V268, P200, DOI 10.1126/science.7536341; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; ISOKAWA M, 1991, NEUROSCI LETT, V132, P212, DOI 10.1016/0304-3940(91)90304-C; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; KARST H, 1993, NEUROSCI LETT, V164, P154, DOI 10.1016/0304-3940(93)90880-T; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MULTANI P, 1994, EPILEPSIA, V35, P728, DOI 10.1111/j.1528-1157.1994.tb02503.x; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; Nixon RA, 1998, CURR OPIN CELL BIOL, V10, P87, DOI 10.1016/S0955-0674(98)80090-2; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Posmantur RM, 1998, NEUROCHEM RES, V23, P1265, DOI 10.1023/A:1020792132629; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Regehr Wade G., 1994, Current Opinion in Neurobiology, V4, P373, DOI 10.1016/0959-4388(94)90099-X; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; SCHORMAIR C, 1993, BRAIN RES BULL, V32, P329, DOI 10.1016/0361-9230(93)90196-I; SHAW G, 1986, BIOESSAYS, V4, P161, DOI 10.1002/bies.950040406; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YUSTE R, 1994, NEURON, V13, P23, DOI 10.1016/0896-6273(94)90457-X; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	50	33	33	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2000	161	1					15	26		10.1006/exnr.1999.7244			12	Neurosciences	Neurosciences & Neurology	290FU	WOS:000085666300002	10683270				2021-06-18	
J	Reinvang, I; Nordby, H; Nielsen, CS				Reinvang, I; Nordby, H; Nielsen, CS			Information processing deficits in head injury assessed with ERPs reflecting early and late processing stages	NEUROPSYCHOLOGIA			English	Article						P3; Nl; attention; oddball paradigm	EVOKED-POTENTIAL FINDINGS; EVENT-RELATED POTENTIALS; TRAUMATIC BRAIN INJURY; AUDITORY ODDBALL TASK; ATTENTION; ATTENUATION; WAVE; EEG	ERPs provide informative measures of slowed information processing in head injury. While several studies have reported changes in long latency ERPs (N2, P3) in head injury, the data on early ERP components related to attention selection are inconclusive. The problem may be partly methodological because the standard oddball paradigm does not give an adequate basis for discriminating components contributing to the N1 and P2 waveforms. Following a suggestion by Garcia-Larrea et al. [10: Garcia-Larrea L, Lukasziewicz A-C, Maugiere F. Revisiting the oddball paradigm. Non-target vs neutral stimuli and the evaluation of ERP attention effects. Neuropsychologia 1992;30:723-741] we used an extended oddball paradigm to study measures of early processing (N1-average, P250) as well as conventional cognitive ERPs (N1, P2, N2, P3) in a group of head injured patients and controls. We found evidence of deficits in early processing of neutral and non-target stimuli in the patient group, and interpret the findings as an indication that the patients are less efficient in terminating processing of irrelevant stimuli. The results further indicate that processing deviations affect both target and non-target stimuli in the oddball paradigm and thus the allocation of attention in the task as a whole. (C) 2000 Elsevier Science Ltd. All rights reserved.	Univ Oslo, Dept Psychol, N-0317 Oslo, Norway; Univ Bergen, Dept Med & Biol Psychol, Bergen, Norway	Reinvang, I (corresponding author), Univ Oslo, Dept Psychol, Box 1094 Blindern, N-0317 Oslo, Norway.						ALHO K, 1992, PSYCHOPHYSIOLOGY, V29, P247, DOI 10.1111/j.1469-8986.1992.tb01695.x; BARIBEAU J, 1990, PSYCHOPHYSIOLOGICAL, P161; CAMPBELL KB, 1995, EVENT RELATED POTENT, V10, P269; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199606000-00004; Ford MR, 1996, J HEAD TRAUMA REHAB, V11, P16, DOI 10.1097/00001199-199606000-00005; GARCIALARREA L, 1992, NEUROPSYCHOLOGIA, V30, P723, DOI 10.1016/0028-3932(92)90042-K; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; KNIGHT RT, 1989, BRAIN RES, V502, P109, DOI 10.1016/0006-8993(89)90466-6; KNIGHT RT, 1984, ELECTROENCEPHALOGRAP, V50, P112; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; NAATANEN R, 1987, PSYCHOPHYSIOLOGY, V24, P375, DOI 10.1111/j.1469-8986.1987.tb00311.x; NAATANEN R, 1986, CEREBRAL PSYCHOPHYSI, P169; NIELSEN CS, 1997, READPEAK DATA PROGRA; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Reinvang I, 1998, J CLIN EXP NEUROPSYC, V20, P885, DOI 10.1076/jcen.20.6.885.1106; REINVANG I, 1995, J INT NEUROPSYCH SOC, V1, P357; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1992, HDB NEUROPSYCHOLOGIC, P393; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P696; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; UNSAL A, 1995, PSYCHOPHYSIOLOGY, V32, P249, DOI 10.1111/j.1469-8986.1995.tb02953.x; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6	30	33	36	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2000	38	7					995	1005		10.1016/S0028-3932(99)00153-0			11	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	316HC	WOS:000087160700010	10775710				2021-06-18	
J	Cirak, B; Rousan, N; Kocak, A; Palaoglu, O; Palaoglu, S; Kilic, K				Cirak, B; Rousan, N; Kocak, A; Palaoglu, O; Palaoglu, S; Kilic, K			Melatonin as a free radical scavenger in experimental head trauma	PEDIATRIC NEUROSURGERY			English	Article; Proceedings Paper	European Congress on Neurotrauma	OCT, 1998	MAGDEBURG, GERMANY	Bundesministerium Fur Bild Forsch		experimental head trauma; free radical; lipid peroxidation; malondealdehyde; melatonin	CENTRAL-NERVOUS-SYSTEM; OXYGEN FREE-RADICALS; SPINAL-CORD INJURY; BRAIN INJURY; PINEAL-GLAND; EDEMA; RATS; ACID	Head trauma causes two kinds of injury in the neural tissue. One is the primary injury which occurs at the time of impact. The other one is a secondary injury and is a progressive process. Free radicals are produced during oxidative reactions formed after trauma. They have been thought to be responsible in the mechanism of the secondary injury. Some studies have been conducted to demonstrate the role of free oxygen radicals in neuronal injury. The alterations in the free radical level during the early posttraumatic period and the effect of a free radical scavenger on these alterations have not been studied as a whole. We aimed to demonstrate the free oxygen radical level changes in the early posttraumatic period and the effect of melatonin, which is a potent free radical scavenger, on the early posttraumatic free radical level. A two-staged experimental head trauma study was designed. In stage one, post-traumatic free radical level changes were determined. In the second stage, the effect of melatonin on the free radical level changes in the post-traumatic period was studied. Two main groups of rats each divided into four subgroups were studied. Rats in one of the main groups underwent severe head trauma, and malondealdehyde (MDA) levels were measured in the contused cerebral tissue at different time points. Rats in the other main group also underwent the same type of trauma, and melatonin was injected intraperitoneally at different time points after trauma. The MDA level alteration in the tissue was determined after the injection of melatonin. The MDA level increased rapidly in the early posttraumatic period. But in time, it decreased in the groups with only trauma. In the melatonin-treated group, the MDA level decreased after the injection of melatonin, when injected in the early posttraumatic period, compared to the control and trauma groups. However, melatonin increased MDA to a higher level than in the groups with only trauma and the control group when injected later than 2 h after trauma. The MDA level increases in the very early posttraumatic period of cerebral trauma and decreases in time. Melatonin, which is the most potent endogenous free radical scavenger, when injected intraperitoneally to the cerebral traumatized rats in the very early posttraumatic period, causes a significant decrease in the MDA level. But, melatonin, when injected more than 2 h after trauma, increases the MDA level in experimental cerebral trauma in rats. Copyright (C) 2000 S. Karger AG, Basel.	100 Yil Univ, Tip Fak Arastirma Hastanesi, Sch Med, Dept Neurosurg, TR-65300 Van, Turkey; Ankara Univ, Sch Med, Dept Pharmacol, TR-06100 Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Neurosurg, Ankara, Turkey; Hacettepe Univ, Sch Med, Dept Biochem, Ankara, Turkey; Inonu Univ, Sch Med, Dept Neurosurg, Malatya, Turkey	Cirak, B (corresponding author), 100 Yil Univ, Tip Fak Arastirma Hastanesi, Sch Med, Dept Neurosurg, Beyin Cerrahisi, TR-65300 Van, Turkey.						ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; AVOLIO AEC, 1992, NEUROSURGERY, V31, P557, DOI 10.1227/00006123-199209000-00019; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BULLOCK R, 1993, SCHWEIZ MED WSCHR, V123, P449; CADET JL, 1988, INT J NEUROSCI, V40, P13, DOI 10.3109/00207458808985722; ERLICH SS, 1985, J NEUROSURG, V63, P321, DOI 10.3171/jns.1985.63.3.0321; FADEN AI, 1987, CLIN NEUROPHARMACOL, V10, P193, DOI 10.1097/00002826-198706000-00001; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HINDER RA, 1991, ARCH SURG-CHICAGO, V126, P104; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; IKEDA Y, 1990, NEUROSURGERY, V27, P1; IKEDA Y, 1989, NEUROSURGERY, V24, P679, DOI 10.1227/00006123-198905000-00004; KALSBEEK WD, 1980, J NEUROSURGERY S, V53, P19; KAPPERS JA, 1976, ACTA NEUROCHIR, V34, P109, DOI 10.1007/BF01405867; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; LERNER AB, 1960, J BIOL CHEM, V235, P1992; MAESTRONI GJM, 1993, J PINEAL RES, V14, P1, DOI 10.1111/j.1600-079X.1993.tb00478.x; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; OLESEN SP, 1987, ACTA PHYSIOL SCAND, V129, P181, DOI 10.1111/j.1748-1716.1987.tb08057.x; PALAOGLU S, 1994, ACTA NEUROCHIR, V128, P8, DOI 10.1007/BF01400646; PIERREFICHE G, 1993, RES COMMUN CHEM PATH, V80, P211; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; PRYOR WA, 1986, ANN NY ACAD SCI, V393, P1; REITER RJ, 1993, NEUROENDOCRINOL LETT, V15, P103; REITER RJ, 1994, ANN NY ACAD SCI, V12, P1; Tan D-X, 1993, ENDOCR J, V1, P57; TAN DX, 1993, CANCER LETT, V70, P65, DOI 10.1016/0304-3835(93)90076-L; UCHIYAMA M, 1978, ANAL BIOCHEM, V86, P271, DOI 10.1016/0003-2697(78)90342-1	33	33	33	1	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291			PEDIATR NEUROSURG	Pediatr. Neurosurg.	DEC	1999	31	6					298	301		10.1159/000028879			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	292NV	WOS:000085802600003	10702729				2021-06-18	
J	Schmidt, RH; Scholten, KJ; Maughan, PH				Schmidt, RH; Scholten, KJ; Maughan, PH			Time course for recovery of water maze performance and central cholinergic innervation after fluid percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						cholinergic; fluid percussion injury; neural plasticity; traumatic brain injury; water maze	TRAUMATIC BRAIN INJURY; CONTROLLED CORTICAL IMPACT; REDUCED EVOKED RELEASE; CLOSED-HEAD INJURY; COGNITIVE IMPAIRMENT; ACETYLCHOLINE; HIPPOCAMPAL; RATS; DEFICITS; MEMORY	This study further investigates the possible connection between postconcussive cognitive impairment and damage to forebrain cholinergic innervation. Moderate parasagittal fluid percussion injury was delivered to adult male rats. Water maze performance and synaptosomal choline uptake was measured at various times following injury. Water maze learning was severely impaired between 1 and 5 weeks, but recovered to normal by 10 weeks. Synaptosomal choline uptake was significantly decreased by 15-27% in the ipsilateral hippocampus and parietal cortex 3 and 7 days following injury, but not by 3 weeks or thereafter. Choline acetyltransferase was also significantly decreased in the ipsilateral cortex at 3 and 7 days with subsequent recovery. This study shoes that parasagittal fluid percussion injury causes significant impairment in water maze learning and ipsilateral forebrain cholinergic innervation. Both of these parameters recover spontaneously, but with different time courses.	Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA	Schmidt, RH (corresponding author), Univ Utah, Dept Neurosurg, 50 N Med Dr, Salt Lake City, UT 84132 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001866] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 01866] Funding Source: Medline		BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; DACY RG, 1993, HEAD INJURY, P159; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DESNER RP, 1988, NEUROBIOL AGING, V9, P609; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1995, NEUROSCI LETT, V198, P111, DOI 10.1016/0304-3940(95)11979-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; FONNUM F, 1975, J NEUROCHEM, V24, P407, DOI 10.1111/j.1471-4159.1975.tb11895.x; GAGE FH, 1986, J NEUROSCI, V6, P2837; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; GRAFDY MS, 1999, J NEUROTRAUM, V16, P13; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; JOPE RS, 1979, BRAIN RES REV, V1, P313, DOI 10.1016/0165-0173(79)90009-2; LAPCHAK PA, 1988, J NEUROCHEM, V50, P68; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCNAMARA RK, 1993, BRAIN RES REV, V18, P33, DOI 10.1016/0165-0173(93)90006-L; Muir JL, 1997, PHARMACOL BIOCHEM BE, V56, P687, DOI 10.1016/S0091-3057(96)00431-5; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Pike BR, 1997, J NEUROTRAUM, V14, P897, DOI 10.1089/neu.1997.14.897; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SHAPIRO SM, 1993, MINOR HEAD TRAUMA, P1; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259	41	33	39	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1999	16	12					1139	1147		10.1089/neu.1999.16.1139			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266WC	WOS:000084322400002	10619193				2021-06-18	
J	Connolly, JF; Mate-Kole, CC; Joyce, BM				Connolly, JF; Mate-Kole, CC; Joyce, BM			Global aphasia: An innovative assessment approach	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							RECEPTIVE VOCABULARY; BRAIN POTENTIALS; SPOKEN SENTENCES; COMPREHENSION; STROKE; WORDS	Objective: To provide an alternative language comprehension assessment strategy for patients unable to be tested with traditional verbally/behaviorally based methods. Design: Event-related brain potentials were recorded from three midline scalp locations to visually and aurally computer-presented sentences, 50% of which were semantically appropriate and 50% semantically incongruous. Setting: A rehabilitation hospital. Patient: A 21-year-old man with a traumatic brain injury. Results: The patient exhibited brain response patterns to aurally presented congruous and incongruous sentences indicative of intact semantic processing capabilities. These findings resulted in reinstatement of individualized rehabilitative intervention, with a successful outcome. Conclusions: This innovative technique provides new opportunities for assessing intellectual function in noncommunicative patients who were patients previously unable to be tested. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Dalhousie Univ, Life Sci Ctr, Dept Psychol, Cognit Clin Neurosci Unit, Halifax, NS B3H 4J1, Canada; Dalhousie Univ, Dept Med, Div Psychiat, Halifax, NS B3H 4J1, Canada; Dalhousie Univ, Div Phys Med & Rehabil, Halifax, NS B3H 4J1, Canada; Cent Connecticut State Univ, Dept Psychol, New Britain, CT 06050 USA	Connolly, JF (corresponding author), Dalhousie Univ, Life Sci Ctr, Dept Psychol, Cognit Clin Neurosci Unit, Halifax, NS B3H 4J1, Canada.			Connolly, John/0000-0001-8869-5369			ANDERSON JE, 1995, PSYCHOPHYSIOLOGY, V32, P177, DOI 10.1111/j.1469-8986.1995.tb03310.x; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BESSON M, 1992, J COGNITIVE NEUROSCI, V4, P132, DOI 10.1162/jocn.1992.4.2.132; Byrne JM, 1995, CHILD NEUROPSYCHOL, V1, P211, DOI 10.1080/09297049508400226; BYRNE JM, 1995, J CLIN EXP NEUROPSYC, V17, P9, DOI 10.1080/13803399508406576; CHIAPPA K, 1997, EVOKED POTENTIALS CL; COLTHEART M, 1985, ATTENTION PERFORM, V11, P3; CONNOLLY JF, 1992, BRAIN LANG, V43, P1, DOI 10.1016/0093-934X(92)90018-A; CONNOLLY JF, 1995, J CLIN EXP NEUROPSYC, V17, P548, DOI 10.1080/01688639508405145; CONNOLLY JF, 1990, BRAIN LANG, V39, P302, DOI 10.1016/0093-934X(90)90016-A; CONNOLLY JF, 1995, ELECTROEN CLIN NEURO, V94, P276, DOI 10.1016/0013-4694(95)98479-R; CONNOLLY JF, 1994, J COGNITIVE NEUROSCI, V6, P256, DOI 10.1162/jocn.1994.6.3.256; CONNOLLY JF, IN PRESS INT J PSYCH; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; Dunn L., 1981, PEABODY PICTURE VOCA; Enderby P, 1987, Int Rehabil Med, V8, P162; ENDERBY P, 1986, BRIT J DISORD COMMUN, V21, P151; Goodglass H., 1972, ASSESSMENT APHASIA R; Helenius P, 1998, BRAIN, V121, P1133, DOI 10.1093/brain/121.6.1133; Ingles JL, 1996, CORTEX, V32, P199, DOI 10.1016/S0010-9452(96)80047-5; JOHNSON R, 1986, PSYCHOPHYSIOLOGY, V23, P367, DOI 10.1111/j.1469-8986.1986.tb00649.x; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; KIMURA D, 1986, NEUROPSYCHOLOGY TEST; Kutas M., 1988, ADV PSYCHOPHYSIOLOGY, V3, P139; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MARQUARDSEN J, 1969, ACTA NEUROL SCAND  S, V38, P67; MATARAZZO JD, 1992, AM PSYCHOL, V47, P1007, DOI 10.1037/0003-066X.47.8.1007; MATEKOLE CC, 1994, ARCH PHYS MED REHAB, V75, P867; MCFIE J, 1952, J MENT SCI, V98, P299; MCFIE J, 1975, ASSESSMENT ORGANIC I; MICHELL PF, 1993, PSYCHOPHYSIOLOGY, V30, P496; MORSE PA, 1992, CLIN SYNDROMES ADULT, P86; NAATANEN R, 1995, EAR HEARING, V16, P6; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Osterhout L, 1996, J COGNITIVE NEUROSCI, V8, P507, DOI 10.1162/jocn.1996.8.6.507; Patterson K., 1982, NORMALITY PATHOLOGY, P77; PEDERSEN PM, 1995, ANN NEUROL, V38, P659, DOI 10.1002/ana.410380416; Picton T., 1995, HDB NEUROPHYSIOLOGY, P3; Polich J., 1993, CURRENT DIRECTIONS P, V2, P175, DOI DOI 10.1111/1467-8721.EP10769728; Rugg Michael D., 1995, P789; Shallice T., 1988, NEUROPSYCHOLOGY MENT; Swaab T, 1997, J COGNITIVE NEUROSCI, V9, P39, DOI 10.1162/jocn.1997.9.1.39; WADE DT, 1986, J NEUROL NEUROSUR PS, V49, P11, DOI 10.1136/jnnp.49.1.11; Warrington EK., 1984, RECOGNITION MEMORY T; WECHSLER D, 1991, WECHSLER INTELLIGENC, V3; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	47	33	34	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1999	80	10					1309	1315		10.1016/S0003-9993(99)90035-7			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	244AW	WOS:000083030500018	10527093				2021-06-18	
J	Leder, SB				Leder, SB			Fiberoptic endoscopic evaluation of swallowing in patients with acute traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aspiration; deglutition; deglutition disorders; dysphagia; fiberoptic endoscopic evaluation of swallowing; silent aspiration; traumatic brain injury	ASPIRATION; DYSPHAGIA	Dysphagia and aspiration in intensive care unit patients with acute traumatic brain injury (TBI) is a frequent and potentially life-threatening problem. Any diagnostic technique used with this population, therefore, must be able to be performed in a timely and efficient manner while providing objective information on the nature of the swallowing problem. The purpose of the present study was to investigate the utility of using the fiberoptic endoscopic evaluation of swallowing (FEES) technique to diagnosis pharyngeal stage dysphagia and determine aspiration status in patients who presented with acute TBI. A total of 47 subjects were assessed with FEES. Thirty of 47 (64%) subjects swallowed successfully and were able to take an oral diet: 2 of 30 (7%) thickened liquids and puree consistencies, 8 of 30 (27%) a soft diet, and 20 of 30 (67%) a regular diet. Seventeen of 47 (36%) subjects exhibited pharyngeal stage dysphagia with aspiration and were not permitted an oral diet based on objective results provided by FEES. Of the 17 subjects who aspirated, 9 of 17 (53%) exhibited silent aspiration. Younger subjects (mean age 34 years, 3 months) aspirated significantly less often than older subjects (mean age 51 years, 8 months). No significant age difference was observed for gender or between overt and silent aspirators. It was concluded that FEES is an objective and sensitive tool that can be used successfully to diagnose pharyngeal stage dysphagia, determine aspiration status. and make recommendations for oral or nonoral feeding in patients with acute TBI.	Yale Univ, Sch Med, Dept Surg, Otolaryngol Sect, New Haven, CT 06510 USA	Leder, SB (corresponding author), Yale New Haven Hosp, Otolaryngol Sect, Commun Disorders Ctr, 20 York St,YPB-468, New Haven, CT 06514 USA.						Bastian Robert W., 1993, Dysphagia, V8, P359, DOI 10.1007/BF01321780; BASTIAN RW, 1991, OTOLARYNG HEAD NECK, V104, P339, DOI 10.1177/019459989110400309; ELPERN EH, 1994, CHEST, V105, P563, DOI 10.1378/chest.105.2.563; Kidder Thomas M., 1994, Dysphagia, V9, P256, DOI 10.1007/BF00301919; Langmore S E, 1988, Dysphagia, V2, P216, DOI 10.1007/BF02414429; LANGMORE SE, 1991, ANN OTO RHINOL LARYN, V100, P678; LANGMORE SE, 1996, DEGLUTITION ITS DISO; Leder SB, 1998, DYSPHAGIA, V13, P19, DOI 10.1007/PL00009544; Leder SB, 1998, DYSPHAGIA, V13, P208, DOI 10.1007/PL00009573; Leder SB, 1997, J SPEECH LANG HEAR R, V40, P1352, DOI 10.1044/jslhr.4006.1352; Leder SB, 1998, ARCH PHYS MED REHAB, V79, P1264, DOI 10.1016/S0003-9993(98)90273-8; LINDEN P, 1983, ARCH PHYS MED REHAB, V64, P281; Logemann J. A., 1983, EVALUATION TREATMENT; Murray J, 1996, DYSPHAGIA, V11, P99, DOI 10.1007/BF00417898; SPLAINGARD ML, 1988, ARCH PHYS MED REHAB, V69, P637; TEASDALE G, 1974, LANCET, V2, P81; YLVISAKER M, 1986, MANAGEMENT HEAD INJU	17	33	35	0	8	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					448	453		10.1097/00001199-199910000-00005			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600005	10653940				2021-06-18	
J	Sleigh, JW; Havill, JH; Frith, R; Kersel, D; Marsh, NV; Ulyatt, D				Sleigh, JW; Havill, JH; Frith, R; Kersel, D; Marsh, NV; Ulyatt, D			Somatosensory evoked potentials in severe traumatic brain injury: a blinded study	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; evoked potential; coma; outcome prediction	HEAD-INJURY; PREDICTION; CHILDREN	Object. Beginning in 1979, the results of somatosensory evoked potential (SSEP) monitoring have been used to predict outcome in patients who have suffered severe brain trauma. The data indicate that if the cortical components of the SSEPs were bilaterally absent, the outcome was always death or a vegetative state, but previous studies have not been blinded. The aims of this study were to correlate the results of SSEP recordings with the outcome in a prospectively blinded manner and to assess whether monitoring of SSEPs was a useful adjunct to clinical judgment in the prediction of outcome. Methods. The authors studied 105 severely head injured patients (median Glasgow Coma Scale score of 6) who were admitted to the Waikato Intensive Care Unit. The upper limb SSEPs were classified according to the central conduction time (CCT) as normal, of increased latency, or absent. The outcome as assessed using the Glasgow Outcome Scale (GOS) score was evaluated 12 months after the injury. Conclusions. Of 51 patients with a bilaterally normal CCT, 29 (57%) had a good outcome (GOS Score 5). Any delay in CCT was associated with a decreased incidence of good outcome (30%). Unilateral absence of the cortical component of the SSEP was usually associated with a poor outcome (death or severe disability), and bilateral absence was always associated with a poor outcome. The authors conclude that SSEPs correlate well with outcome and that this is not the result of investigator bias.	Waikato Hosp, Intens Care Unit, Dept Intens Care, Hamilton, New Zealand; Waikato Hosp, Dept Crit Care, Hamilton, New Zealand; Waikato Hosp, Dept Neuropsychol, Hamilton, New Zealand; Auckland Hosp, Dept Neurol, Auckland, New Zealand; Mercy Hosp, Intens Care Unit, Brisbane, Qld, Australia	Sleigh, JW (corresponding author), Waikato Hosp, Intens Care Unit, Dept Intens Care, Hamilton, New Zealand.	sleighj@hwl.co.nz	Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			Adams E, 1996, J PEDIATR-US, V128, P438, DOI 10.1016/S0022-3476(96)70305-0; BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; CHIAPPA KH, 1997, EVOKED POTENTIALS CL, P389; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; Havill JH, 1998, ANAESTH INTENS CARE, V26, P642, DOI 10.1177/0310057X9802600605; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KEREN O, 1994, BRAIN INJURY, V8, P239, DOI 10.3109/02699059409150976; MARKAND ON, 1990, ELECTROEN CLIN NEURO, V77, P416, DOI 10.1016/0168-5597(90)90002-U; MOULTON RJ, 1994, CLIN INVEST MED, V17, P187; PETERSON PL, 1995, CURR OPIN CRIT CARE, V1, P98; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; 1996, J NEUROTRAUMA, V13, P643	13	33	35	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	1999	91	4					577	580		10.3171/jns.1999.91.4.0577			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	239HV	WOS:000082763400007	10507377				2021-06-18	
J	Aibiki, M; Maekawa, S; Nishiyama, T; Seki, K; Yokono, S				Aibiki, M; Maekawa, S; Nishiyama, T; Seki, K; Yokono, S			Activated cytokine production in patients with accidental hypothermia	RESUSCITATION			English	Article						accidental hypothermia; interleukin-6; interleukin-8; rewarming rate; surface rewarming; systemic inflammatory response		We have demonstrated recently that therapeutic moderate hypothermia of 32-33 degrees C, induced by surface cooling under the administration of narcotics, sedatives and muscle relaxant, suppresses cytokine production after traumatic brain injury. We present here the first documented case report of augmented cytokine production in two accidental hypothermia patients, unconscious 84- (acute immersion) and 87- (non-immersion) year-old women, whose rectal temperatures were below 28 degrees C. The victims were artificially ventilated after sedation with midazolam and buprenorphine in accordance with our protocol. Rewarming at the rate of approximately 1 degrees C/h was done by blowing forced-air with appropriate fluid resuscitation. Plasma interleukin(IL)-6 and/or IL-8 levels were measured using ELISA in the patients. In both patients, plasma IL-6 levels on admission were already elevated and the cytokine levels further increased during and after the rewarming period. In the patient with the poorer prognosis, the plasma IL-8 level on admission was not elevated remarkably but after rewarming the level rose significantly. Augmented IL-6 production in accidental hypothermia was sustained for 6 days in the patient with the poorer prognosis but not in the subject with good recovery, who was treated with anti-thrombin III in the early phase. Since the mechanisms for developing accidental hypothermia were different, simple comparisons between the two cases should be limited. But, these findings may suggest a need for testing a hypothesis whether cytokine modulation could be a therapeutic approach worthy of consideration. The results presented here also suggest that in hypothermia, changes in cytokine release may vary depending on procedures such as the anesthetic drugs used, the duration of the therapy, or the rate of rewarming from hypothermia. (C) 1999 Elsevier Science Ireland Ltd.. All rights reserved.	Kagawa Med Univ Hosp, Intens Care Unit, Miki, Kagawa 7610793, Japan	Aibiki, M (corresponding author), Kagawa Med Univ Hosp, Intens Care Unit, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.						Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; AIBIKI M, 1997, IMMUNE CONSEQUENCES, P139; BIGGAR WD, 1986, J APPL PHYSIOL, V60, P1186; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BONE RC, 1992, CRIT CARE MED, V20, P864, DOI 10.1097/00003246-199206000-00025; DANZL DF, 1994, NEW ENGL J MED, V331, P1756, DOI 10.1056/NEJM199412293312607; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; Dinarello C A, 1992, Eur Cytokine Netw, V3, P7; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Kornberger E, 1996, J NEUROSURG ANESTH, V8, P83, DOI 10.1097/00008506-199601000-00027; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATEN J, 1996, NETHERLANDS J MED, V49, P160; MILLER JW, 1980, ANN EMERG MED, V9, P456, DOI 10.1016/S0196-0644(80)80304-0; Tveita T, 1996, J APPL PHYSIOL, V80, P291; VRETENAR DF, 1994, ANN THORAC SURG, V58, P895, DOI 10.1016/0003-4975(94)90784-6; Walpoth BH, 1997, NEW ENGL J MED, V337, P1500, DOI 10.1056/NEJM199711203372103; WONG KC, 1983, WESTERN J MED, V138, P227	17	33	35	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-9572			RESUSCITATION	Resuscitation	AUG	1999	41	3					263	268		10.1016/S0300-9572(99)00052-0			6	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	239MP	WOS:000082772200007	10507712				2021-06-18	
J	Snow, PC; Douglas, JM; Ponsford, JL				Snow, PC; Douglas, JM; Ponsford, JL			Narrative discourse following severe traumatic brain injury: a longitudinal follow-up	APHASIOLOGY			English	Article							SEVERE HEAD-INJURY; PROCEDURAL DISCOURSE; ADULTS; LANGUAGE; CHILDREN; COMPREHENSION; ABILITIES; DEFICITS; COHESION; SKILLS	This paper describes the narrative discourse abilities of a group of severely traumatically brain injured (TBI) speakers at two intervals post-injury. At initial assessment (between 3 and 6 months post-injury) a group of 26 TBI speakers were assessed using a picture description task. The performance of two control groups was also examined. The first control group was comprised of 26 non-TBI orthopaedically injured speakers and the second control group comprised 26 university students. These control groups were selected in order to examine the possibility that premorbid demographic factors can influence the discourse skills of TBI speakers. Measures of interest included content (number and type of story grammar elements present), communicative efficiency (syllables per story grammar element) and pragmatic performance (errors on a modified version of Damico's Clinical Discourse Analysis-the CDA-M). The measure which most clearly separated the performance of the TBI speakers from that of the controls on an initial assessment was the CDA-M. At follow-up, a mean of 2 years 10 months post-injury, 24 of the TBI speakers were seen for review. Results at follow-up revealed significant improvement over time and the performance of the TBI speakers could no longer be differentiated from that of the orthopaedic patients included in the initial study. The findings are discussed with respect to the implications for narrative discourse sampling and measurement, in relation to severity and chronicity of brain injury.	La Trobe Univ, Melbourne, Vic, Australia	Snow, PC (corresponding author), Deakin Univ, Sch Psychol, Burwood Highway, Burwood, Vic 3125, Australia.		Douglas, Jacinta M/C-2380-2009	Snow, Pamela/0000-0002-2426-8349; Douglas, Jacinta/0000-0003-0940-6624			ASHA (American Speech-Language-Hearing Association), 1990, ASHA S2, V32, P17; BAMBERG MGW, 1987, NEW BABYLON STUDIES, V49; Barrie-Blackey S, 1978, CLIN ORAL LANGUAGE S; BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; COELHO CA, 1990, J PSYCHOLINGUIST RES, V19, P405, DOI 10.1007/BF01068887; COPPENS P, 1995, BRAIN INJURY, V9, P195, DOI 10.3109/02699059509008192; Damico JS, 1985, COMMUNICATION SKILLS, P165; DAMICO JS, 1991, COMMUNICATION SKILLS, P125; Davis GA, 1997, BRAIN LANG, V56, P183; DICKER BG, 1989, J HEAD TRAUMA REHAB, V4, P73; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; DIKMEN S, 1987, NEUROBEHAVIORAL RECO, P73; DOLLAGHAN CA, 1990, J SPEECH HEAR DISORD, V55, P582, DOI 10.1044/jshd.5503.582; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Goodglass H., 1972, ASSESSMENT APHASIA R; Grice H., 1975, SYNTAX SEMANTICS, P41, DOI DOI 10.1111/J.1365-2664.2006.01229.X; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HEDBERG NL, 1986, TOP LANG DISORD, V7, P58, DOI 10.1097/00011363-198612000-00008; HUDSON RA, 1980, SOCIOLINGUISTICS; KEPPELL G, 1991, DESIGN ANAL RES HDB; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; PARSONS CL, 1989, AUSTR J HUMAN COMMUN, V17, P37; Prigatano GP, 1995, PSYCHOL ASSESSMENT, V7, P396; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Rimel RW, 1990, REHABILITATION ADULT, P8; Roth F. P., 1994, DISCOURSE ANAL APPL, P131; Ruff R, 1991, COGNITIVE REHABILITA, P23; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Stein N. L., 1979, NEW DIRECTIONS DISCO, V2, P53; THORNDYKE PW, 1977, COGNITIVE PSYCHOL, V9, P77, DOI 10.1016/0010-0285(77)90005-6; ULATOWSKA HK, 1983, BRAIN LANG, V18, P315, DOI 10.1016/0093-934X(83)90023-8; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Westby C, 1982, COMMUNICATION DISORD, V7, P1; WINOGRAD T., 1977, COGNITIVE PROCESS, P63; WOLFOLK WB, 1992, B PSYCHONOMIC SOC, V30, P226	55	33	33	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0268-7038			APHASIOLOGY	Aphasiology	JUL	1999	13	7					529	551		10.1080/026870399401993			23	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	220QW	WOS:000081679800002					2021-06-18	
J	Oehmichen, M; Theuerkauf, I; Meissner, C				Oehmichen, M; Theuerkauf, I; Meissner, C			Is traumatic axonal injury (AI) associated with an early microglial activation? Application of a double-labeling technique for simultaneous detection of microglia and AI	ACTA NEUROPATHOLOGICA			English	Article						trauma; axonal injury; microglia; immunohistochemical double labeling	AMYLOID PRECURSOR PROTEIN; CLOSED-HEAD INJURY; BRAIN INJURY; DIAGNOSIS; MILD	The aim of the present study was to determine whether axonal injury (AI) induces a microglial reaction within 15 days after brain trauma. In 40 selected cases of confirmed Al, the topographical relation of Al and microglial reaction was assessed using an immunohistochemical double-labeling technique for simultaneous demonstration of AI using beta-amyloid precursor protein (beta-APP) antibody and of microglia using CD68 antibody. Although traumatic injury was usually followed by a moderate early diffuse rise in the number of CD68-reactive cells in the white matter, increases in macrophages in areas of Al accumulation were only sporadic and did not occur until after 4 days. At survival intervals of 5-15 days a moderate microglial reaction in regions of beta-APP-positive injured axons was detected, at maximum, in half of the case material. During this interval AI-associated satellitosis-like clusters or stars described by other authors after a survival time of more than 7 weeks were an isolated phenomenon. The prolonged microglial reaction as well as the reduction of beta-APP-positive Al during longer survival periods supports the hypothesis that AI is not primarily chemotactically attractive and that the damage to a portion of beta-APP-stained axons may be partly reversible. Most cases clearly require a prolonged interval of more than 15 days before initiation of the final scavenger reaction. For forensic purposes the increase in the number of microglial cells within the region of AI accumulation after a survival time of more than 5 days and the multiple and distinct demonstration of star-like microglial reactions within the white matter after survival times exceeding 7 weeks may provide valuable postmortem information on the timing of a traumatic event.	Univ Lubeck, Inst Forens Med, D-23562 Lubeck, Germany	Oehmichen, M (corresponding author), Univ Lubeck, Inst Forens Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.	tychsenl@rmed.mu-luebeck.de					ADAMS H, 1988, INTRO NEUROPATHOLOGY; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BAZZAZ AA, 1995, NEUROPATHOL APPL NEU, V21, P447; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; Geddes JF, 1997, J CLIN PATHOL, V50, P271, DOI 10.1136/jcp.50.4.271; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Graeber MB, 1997, RES LEG MED, V17, P239; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; Lassmann H, 1997, RES LEG MED, V17, P253; MAZWELL WL, 1997, J NEUROTRAUM, V7, P419; McLellan D, 1986, COMA TRAUMATIQUE, P165; MERZ H, 1995, LAB INVEST, V73, P149; Meyermann R, 1997, RES LEG MED, V17, P261; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Oehmichen M, 1997, RES LEG MED, V17, P19; Oehmichen M., 1996, WOUND HEALING PROCES; OEHMICHEN M, 1999, IN PRESS INT J LEGAL; OEHMICHEN M, 1978, MONONUCLEAR PHAGOCYT; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Povlishock JT, 1997, RES LEG MED, V17, P175; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55	29	33	34	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAY	1999	97	5					491	494		10.1007/s004010051018			4	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	189TU	WOS:000079922900008	10334486				2021-06-18	
J	Guluma, KZ; Saatman, KE; Brown, A; Raghupathi, R; McIntosh, TK				Guluma, KZ; Saatman, KE; Brown, A; Raghupathi, R; McIntosh, TK			Sequential pharmacotherapy with magnesium chloride and basic fibroblast growth factor after fluid percussion brain injury results in less neuromotor efficacy than that achieved with magnesium alone	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; fluid percussion; motor dysfunction; neuroprotection; rat	SPINAL-CORD INJURY; FOCAL CEREBRAL-ISCHEMIA; CALCIUM-BINDING PROTEIN; CENTRAL-NERVOUS-SYSTEM; HIPPOCAMPAL-NEURONS; PHARMACOLOGICAL STRATEGIES; NEUROTROPHIC FACTORS; CORTICAL-NEURONS; CHANNEL BLOCKER; MESSENGER-RNA	Combinational pharmacotherapy with individually efficacious agents is a potential strategy for the treatment of traumatic central nervous system (CNS) injury. Basic fibroblast growth factor (bFGF) has been shown to be neuroprotective against excitotoxic, ischemic, and traumatic injury to the CNS, while acute posttraumatic treatment with magnesium (Mg2+) has been shown to decrease the motor and cognitive deficits following experimental brain injury. In this study, bFGF and Mg2+ were evaluated separately and in combination to assess their potential additive effects on posttraumatic neurological recovery and histological cell loss (lesion volume). Twenty minutes after fluid percussion (FP) brain injury of moderate severity (2.2-2.4 atm), anesthetized rats received a 15-min intravenous infusion of either 125 mu mol of MgCl2 or vehicle, followed 5 min later by a 24-h constant intravenous infusion of either bFGF (16 mu g/h) or vehicle. Injured animals had a significant motor deficit when compared to sham (uninjured) animals at both 48 h and 7 days postinjury. At 48 h postinjury, there were no significant differences among injured animals when compared by treatment, By 7 days postinjury, injured animals treated with MgCl2 alone displayed significantly improved motor function when compared to brain-injured, vehicle-treated animals (p < 0.05). Animals treated with either bFGF alone or a combination of MgCl2 and bFGF displayed no significant neurological improvement relative to vehicle-treated injured animals at 7 days. No effect of any drug treatment or combination was observed on the extent of the postinjury lesion volume in the injured cortex. These results suggest that caution must be exercised when combining "cocktails" of potentially neuroprotective compounds in the setting of traumatic brain injury.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 3320 Smith Walk,105 Hyden Hall, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline		ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BAFFOUR R, 1995, J NEUROSURG, V83, P105, DOI 10.3171/jns.1995.83.1.0105; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ENDOH M, 1994, MOL BRAIN RES, V22, P76, DOI 10.1016/0169-328X(94)90034-5; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FINKLESTEIN SP, 1993, STROKE S1, V24, P141; FISHER M, 1995, J CEREBR BLOOD F MET, V15, P953, DOI 10.1038/jcbfm.1995.121; FREESE A, 1992, BRAIN RES, V575, P351, DOI 10.1016/0006-8993(92)90104-H; FRIM DM, 1993, NEUROREPORT, V4, P367, DOI 10.1097/00001756-199304000-00006; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Himmelseher S, 1996, BRAIN RES, V707, P54, DOI 10.1016/0006-8993(95)01220-6; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; INGERSOLL RJ, 1971, J BIOL CHEM, V246, P2808; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; Kawamata T, 1996, J CEREBR BLOOD F MET, V16, P542, DOI 10.1097/00004647-199607000-00003; KIRSCHNER PB, 1995, J CEREBR BLOOD F MET, V15, P619, DOI 10.1038/jcbfm.1995.76; KOHMURA E, 1994, RESTOR NEUROL NEUROS, V6, P309, DOI 10.3233/RNN-1994-6407; KOKETSU N, 1994, ANN NEUROL, V35, P451, DOI 10.1002/ana.410350413; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MATTSON MP, 1993, J NEUROSCI, V13, P4575; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MATTSON MP, 1989, J NEUROSCI, V9, P3728; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; NAKATA N, 1993, BRAIN RES, V605, P354, DOI 10.1016/0006-8993(93)91766-L; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; Ohki SY, 1997, BIOCHEMISTRY-US, V36, P4309, DOI 10.1021/bi962759m; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OTTO D, 1989, J NEUROSCI RES, V22, P83, DOI 10.1002/jnr.490220111; Pappas IS, 1997, EXP NEUROL, V144, P302, DOI 10.1006/exnr.1997.6411; PETTMANN B, 1986, NEUROSCI LETT, V68, P175, DOI 10.1016/0304-3940(86)90137-0; REGLI L, 1994, BRAIN RES, V665, P155, DOI 10.1016/0006-8993(94)91167-3; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROSENBLATT S, 1994, J CEREBR BLOOD F MET, V14, P70, DOI 10.1038/jcbfm.1994.11; SEELIG JM, 1983, AM J PHYSIOL, V202, pH22; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; SUSSMAN F, 1989, P NATL ACAD SCI USA, V86, P7880, DOI 10.1073/pnas.86.20.7880; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WOLF G, 1991, NEUROSCIENCE, V43, P31, DOI 10.1016/0306-4522(91)90413-I; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YUGUCHI T, 1994, MOL BRAIN RES, V25, P50, DOI 10.1016/0169-328X(94)90277-1; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	72	33	33	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	1999	16	4					311	321		10.1089/neu.1999.16.311			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	190AM	WOS:000079939400004	10225217				2021-06-18	
J	Fenwick, T; Anderson, V				Fenwick, T; Anderson, V			Impairments of attention following childhood traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; DEFICITS	Attentional deficits are commonly reported following traumatic brain injury (TBI) in adults, although the occurrence of such problems is less well documented in young children. This study aimed to investigate residual attentional abilities associated with TBI during childhood, by examining a number of aspects of attention including sustained, focussed, and divided attention, attentional shift, and response inhibition. Eighteen children with a history of TBI, aged between 8 and 14 years and 18 non-injured matched controls participated in the study. Results show that attentional skills may be differentially impaired after TBI, with children who have sustained moderate-to-severe TBI exhibiting significant deficits on the following attentional domains: sustain, focus, and response inhibition. These findings support the view that attentional impairments following pediatric TBI, while not global, may be more generalized than those reported for adult samples, perhaps reflecting the relative immaturity of attentional skills at the time of injury.	Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia	Anderson, V (corresponding author), Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Barkley R. A., 1988, ASSESSMENT ISSUES CH, P145; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Daniel A. E., 1983, POWER PRIVILEGE PRES; DENNIS M, 1995, TRAUMATIC HEAD INJUR, P156; Dennis M., 1989, CLIN NEUROPSYCHOLOGY, P89; Fuster J M, 1993, Curr Opin Neurobiol, V3, P160, DOI 10.1016/0959-4388(93)90204-C; Garth J, 1997, Pediatr Rehabil, V1, P99; Golden C., 1978, STROOP COLOR WORD TE; HEILMAN KM, 1979, NEUROPSYCHOLOGIA, V17, P315, DOI 10.1016/0028-3932(79)90077-0; HUDSPETH WJ, 1990, J EDUC PSYCHOL, V82, P881, DOI 10.1037/0022-0663.82.4.881; KAGAN J, 1964, PSYCHOL MONOGR, V78, P578; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MCKAY KE, 1994, DEV NEUROPSYCHOL, V10, P121, DOI 10.1080/87565649409540572; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Posner M.I., 1994, IMAGES MIND; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; ROURKE BP, 1987, CLIN NEUROPSYCHOL, V1, P209, DOI DOI 10.1080/13854048708520056; ROWE KS, 1993, RBRI USERS MANUAL PA; Sattler JM, 1988, ASSESSMENT CHILDREN; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; STAUDT M, 1993, PEDIATR RADIOL, V23, P169, DOI 10.1007/BF02013824; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Tabachnick B.G., 1989, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; Wechsler D., 1991, WECHSLER INTELLIGENC	35	33	33	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.		1999	5	4					213	223		10.1076/0929-7049(199912)05:04;1-R;FT213			11	Clinical Neurology	Neurosciences & Neurology	324XA	WOS:000087645600001	10925705				2021-06-18	
J	Strauss, E; Hultsch, DF; Hunter, M; Slick, DJ; Patry, B; Levy-Bencheton, J				Strauss, E; Hultsch, DF; Hunter, M; Slick, DJ; Patry, B; Levy-Bencheton, J			Using intraindividual variability to detect malingering in cognitive performance	CLINICAL NEUROPSYCHOLOGIST			English	Article							NEUROPSYCHOLOGICAL TEST-SCORES; TRAUMATIC BRAIN INJURY; VERBAL-LEARNING TEST; HEAD-INJURY; REACTION-TIME; MEMORY; CONSISTENCY; MMPI-2; ATTENTION; VALIDITY	The utility of measures for detecting malingering was evaluated using a simulation design in which half the participants were encouraged to do their best and half were asked to feign head injury. Particular attention was focused on the utility of repeated assessment (intraindividual variability) in discriminating the groups. Participants were tested on three occasions on measures commonly used to detect malingering including a specific symptom validity test (SVT). The results indicated that multiple measures of malingering obtained in single assessment (occasion one) discriminated the groups effectively. In addition, however, intraindividual variability in performance, particularly of indicators from the SVT, provided unique information beyond level of performance. The results suggest that response inconsistency across testing sessions may be a clinically useful measure for the detection of malingering.	Univ Victoria, Dept Psychol, Victoria, BC V8W 3P5, Canada; Riverview Hosp, Vancouver, BC, Canada	Strauss, E (corresponding author), Univ Victoria, Dept Psychol, POB 3050, Victoria, BC V8W 3P5, Canada.						ABRISI PA, 1995, PSYCHOL ASSESSMENT, V7, P424; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bernard L C, 1991, Arch Clin Neuropsychol, V6, P81, DOI 10.1016/0887-6177(91)90024-4; Bernard LC, 1996, ARCH CLIN NEUROPSYCH, V11, P231, DOI 10.1016/0887-6177(95)00025-9; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1993, ARCH CLIN NEUROPSYCH, V8, P137, DOI 10.1016/0887-6177(93)90031-U; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Coleman RD, 1998, J CLIN EXP NEUROPSYC, V20, P201, DOI 10.1076/jcen.20.2.201.1164; Cullum C, 1991, FORENSIC NEUROPSYCHO, P141; Davis HP, 1997, ARCH CLIN NEUROPSYCH, V12, P191; DAVIS HP, 1995, COLORADO MALINGERING; Ekstrom R.B., 1976, MANUAL KIT FACTOR RE; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEZAK MD, 1976, NEUROPSYCHOLOGICAL A; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Mittenberg W., 1995, PROFESSIONAL PSYCHOL, V11, P271; MITTENBERG W, 1993, PSYCHOL ASSESSMENT, V5, P34, DOI DOI 10.1037/1040-3590.5.1.34; Price J R, 1997, Appl Neuropsychol, V4, P75, DOI 10.1207/s15324826an0401_10; Rapport LJ, 1998, J CLIN EXP NEUROPSYC, V20, P89, DOI 10.1076/jcen.20.1.89.1488; Reitan R M, 1995, Appl Neuropsychol, V2, P67, DOI 10.1207/s15324826an0202_3; Reitan RM, 1997, CLIN NEUROPSYCHOL, V11, P69, DOI 10.1080/13854049708407031; Reitan RM, 1996, ARCH CLIN NEUROPSYCH, V11, P573, DOI 10.1016/0887-6177(95)00037-2; REYNOLDS C, 1998, DETECTION MALINGERIN; Rogers R., 1997, CLIN ASSESSMENT MALI, V2nd; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; SLICK D, IN PRESS CLIN NEUROP; Slick D., 1997, VICTORIA SYMPTOM VAL; Spreen O., 1998, COMPENDIUM NEUROPSYC; STRAUSS E, 1994, ARCH CLIN NEUROPSYCH, V9, P483, DOI 10.1016/0887-6177(94)90039-6; Stuss D.T., 1999, J INT NEUROPSYCH SOC, V5, P123; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Tenhula WN, 1996, CLIN NEUROPSYCHOL, V10, P104, DOI 10.1080/13854049608406669; Tombaugh TN, 1996, TEST MEMORY MALINGER; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wetter MW, 1996, PSYCHOL ASSESSMENT, V8, P39; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	47	33	33	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		1999	13	4					420	432		10.1076/1385-4046(199911)13:04;1-Y;FT420			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	310PP	WOS:000086836800005	10806454				2021-06-18	
J	Thiagarajan, A; Goverdhan, PD; Chari, P; Somasunderam, K				Thiagarajan, A; Goverdhan, PD; Chari, P; Somasunderam, K			The effect of hyperventilation and hyperoxia on cerebral venous oxygen saturation in patients with traumatic brain injury	ANESTHESIA AND ANALGESIA			English	Article							ACUTE HEAD-INJURY; COMATOSE PATIENTS; BLOOD-FLOW	Eighteen head-injured patients undergoing hyperventilation were studied for changes in jugular venous oxygen saturation (Sjvo(2)) and arteriovenous oxygen content difference (AVDo(2)) in response to changes in Pao(2) and Paco(2). Sjvo(2) decreased significantly from 66% +/- 3% to 56% +/- 3% (mean +/- SD) when Paco(2) decreased from 30 to 25 mm Hg at a Pao(2) of 100-150 mm Hg. Sjvo(2) values returned to baseline (66% +/- 2%) when Paco(2) was restored to 30 mm Hg. Repetition of the study at a Pao(2) of 200-250 mm Hg produced a similar pattern. However, Sjvo(2) values were significantly greater with Pao, within the range of 200-250 mm Hg (77% +/- 4% and 64% +/- 3%) than Sjvo(2) measured at a Pao(2) of 100-150 mm Hg at Paco(2) values of both 30 and 25 mm Hg. AVDo(2) also improved with a Pao(2) of 200-250 mm Hg at each Paco(2) (P < 0.001). In conclusion, decreases in Sjvo(2) associated with decreases in Paco(2) map be offset by increasing Pao(2). Implications: The adequacy of cerebral oxygenation can be estimated in head-injured patients by monitoring jugular bulb oxygen saturation and the arteriovenous oxygenation content difference. Increasing the partial pressure of arterial oxygen above normal offset deleterious effects of hyperventilation on jugular bulb oxygen saturation and arteriovenous oxygenation content difference in head-injured patients.	Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India	Goverdhan, PD (corresponding author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India.						ALBERT JW, 1961, J CLIN INVEST, V40, P1297; BUSIJA DW, 1980, J APPL PHYSIOL, V48, P10; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; ELIASJONES AC, 1992, ARCH DIS CHILD, V67, P1430, DOI 10.1136/adc.67.12.1430; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; KENNEALY JA, 1980, AM REV RESPIR DIS, V122, P407; LEAHY FAN, 1980, J APPL PHYSIOL, V48, P468; MATTA BF, 1994, CAN J ANAESTH, V41, P1041, DOI 10.1007/BF03015651; MATTA BF, 1994, ANESTH ANALG, V79, P745; MORI K, 1994, ANESTHESIA, P2565; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SHINIJ N, 1983, ARCH NEUROL-CHICAGO, V40, P271; VOLDBY B, 1985, J NEUROSURG, V62, P59, DOI 10.3171/jns.1985.62.1.0059	16	33	38	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	1998	87	4					850	853		10.1097/00000539-199810000-00019			4	Anesthesiology	Anesthesiology	125JK	WOS:000076234300019	9768781				2021-06-18	
J	Hux, D; Bond, V; Skinner, S; Belau, D; Sanger, D				Hux, D; Bond, V; Skinner, S; Belau, D; Sanger, D			Parental report of occurrences and consequences of traumatic brain injury among delinquent and non-delinquent youth	BRAIN INJURY			English	Article							FLUID-PERCUSSION INJURY; MINOR HEAD-INJURY; EPIDEMIOLOGY; POPULATION; ATTENTION; CHILDREN; SEQUELAE; COUNTY	Completed questionnaires from parents of youths attending a public middle school or high school and parents of youths admitted to an institution for juvenile delinquents provided information about incidents of traumatic brain injury (TBI) in their children. Results revealed that approximately 40% of the non-delinquent youth and 50% of the delinquent youth had sustained one or more TBIs during their childhood or youth. The majority of injuries appeared to be mild and had no permanent consequences. However, the parents of more than one-third of the delinquent youth with TBI histories reported long-term effects on academic performance, behaviour and emotional control, activity level, and/or interactions with friends and family members; parental reports of long-term effects occurred significantly less frequently among the non-delinquent youth. The most common causes of TBI differed between the two adolescent populations. Non-delinquent youth sustained TBIs most frequently from blows to the head during; sporting events, and delinquent youth sustained TBIs with approximately equal frequency from sporting events, falls, motor vehicle accidents, and fights.	Univ Nebraska, Barkley Mem Ctr 318E, Dept Special Educ & Commun Disorders, Lincoln, NE 68588 USA; Youth Rehabil & Treatment Ctr, Geneva, NE USA	Hux, D (corresponding author), Univ Nebraska, Barkley Mem Ctr 318E, Dept Special Educ & Commun Disorders, Lincoln, NE 68588 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BARNES J, 1978, J IRISH MED ASSOC, V71, P19; Bond M. R., 1990, REHABILITATION ADULT, P179; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROOKS N, 1990, REHABILITATION ADULT, P163; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Caveness W F, 1979, Adv Neurol, V22, P1; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; CULLUM CM, 1990, TRAUMATIC BRAIN INJU, P129; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; GORDON N, 1993, BRAIN DEV-JPN, V15, P169, DOI 10.1016/0387-7604(93)90060-L; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; Hartley L. L., 1995, COGNITIVE COMMUNICAT; HENGGELER SW, 1989, DELINQUENCY ADOLESCE; HURT J, 1992, J CLIN PSYCHOL, V48, P120, DOI 10.1002/1097-4679(199201)48:1<120::AID-JCLP2270480117>3.0.CO;2-5; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KANDEL E, 1991, CRIMINOLOGY, V29, P519, DOI 10.1111/j.1745-9125.1991.tb01077.x; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MILLER JD, 1985, LANCET, V1, P1141; OSTROV E, 1972, J YOUTH ADOLESCENCE, V1, P179, DOI 10.1007/BF01537072; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rosen CD, 1986, HEAD TRAUMA ED REINT; ROSENBAUM JL, 1989, CRIME DELINQUENCY, V35, P31, DOI 10.1177/0011128789035001003; Sanger D. D., 1997, AM J SPEECH-LANG PAT, V6, P70; STRICKER LJ, 1988, J APPL SOC PSYCHOL, V18, P423, DOI 10.1111/j.1559-1816.1988.tb00026.x; Szekeres S. F., 1987, COMMUNITY REENTRY HE, P87; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; VIRKKUNEN M, 1977, DIS NERV SYST, V38, P907; VIRKKUNEN M, 1976, ACTA PSYCHIAT SCAND, V53, P168, DOI 10.1111/j.1600-0447.1976.tb00072.x; 1992, FED REG, V57, P44794	41	33	33	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1998	12	8					667	681					15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	108AN	WOS:000075243800004	9724838				2021-06-18	
J	Fabian, RH; DeWitt, DS; Kent, TA				Fabian, RH; DeWitt, DS; Kent, TA			The 21-aminosteroid U-74389G reduces cerebral superoxide anion concentration following fluid percussion injury of the brain	JOURNAL OF NEUROTRAUMA			English	Article						21-aminosteroids; cerebral blood flow; oxygen radicals; rat; traumatic brain injury	NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; TIRILAZAD MESYLATE; SPREADING DEPRESSION; RADICAL PRODUCTION; CYTOCHROME-C; RAT; U74389G; ISCHEMIA; MODEL	We examined the effects of the 21-aminosteroid antioxidant U-74389G (16-desmethyl-tirilazad) on the concentration of extracellular superoxide anion following fluid percussion traumatic brain injury (TBI) measured by a cytochrome c-coated electrode and on local cerebral perfusion (CBFld) measured by laser Doppler flowmetry (LDF). U-74389G in a dose of 3 mg/kg reduced superoxide anion concentrations 60 min after TBI significantly but had no significant effect on CBFld. These results indicate that reduction of CBF after TBI can be dissociated from superoxide anion production. Persistent ischemia may limit neuroprotection efficacy and may contribute to divergent outcome results in clinical and animal trials using agents to modify reactive oxygen species.	Univ Texas, Med Branch, Sch Med, Dept Neurol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sch Med, Dept Anesthesiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sch Med, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sch Med, Dept Psychiat & Behav Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Inst Marine Biomed, Galveston, TX 77555 USA	Fabian, RH (corresponding author), Univ Texas, Med Branch, Sch Med, Dept Neurol, Galveston, TX 77555 USA.			Kent, Thomas/0000-0002-9877-7584	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 19355] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019355] Funding Source: NIH RePORTER		ANTONINI JM, 1995, INFLAMMATION, V19, P9, DOI 10.1007/BF01534376; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Buatti JM, 1996, INT J RADIAT ONCOL, V34, P591, DOI 10.1016/0360-3016(95)02113-2; Bukoski RD, 1997, AM J PHYSIOL-HEART C, V272, pH1406; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCKROW RB, 1992, BRAIN RES, V572, P296, DOI 10.1016/0006-8993(92)90488-U; Duguay P, 1996, TRANSPLANTATION, V61, P1023, DOI 10.1097/00007890-199604150-00007; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; FABIAN RH, 1995, J CEREBR BLOOD F MET, V15, P242, DOI 10.1038/jcbfm.1995.30; HABERL RL, 1989, AM J PHYSIOL, V256, pH1255; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1988, STROKE, V19, P340, DOI 10.1161/01.STR.19.3.340; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALL ED, 1991, BRAIN RES, V553, P243, DOI 10.1016/0006-8993(91)90832-G; HALL ED, 1991, STROKE, V22, P361, DOI 10.1161/01.STR.22.3.361; HOBALLAH JJ, 1995, TRANSPL P, V27, P2836; KONTOS CD, 1992, AM J PHYSIOL, V263, pH1234; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; MARUKI Y, 1995, J CEREBR BLOOD F MET, V15, P88, DOI 10.1038/jcbfm.1995.10; MCNEIL CJ, 1992, FREE RADICAL RES COM, V17, P399, DOI 10.3109/10715769209083144; MCNEIL CJ, 1989, FREE RADICAL RES COM, V7, P89, DOI 10.3109/10715768909087928; MUIR JK, 1995, J NEUROTRAUM, V12, P87, DOI 10.1089/neu.1995.12.87; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; MULLER TB, 1995, STROKE, V26, P1453, DOI 10.1161/01.STR.26.8.1453; MUROHARA T, 1993, J CARDIOVASC PHARM, V21, P760, DOI 10.1097/00005344-199305000-00011; NELSON CW, 1992, AM J PHYSIOL, V263, pH1356; Povlishock J T, 1992, Hum Cell, V5, P345; Remmers D, 1996, J SURG RES, V62, P278, DOI 10.1006/jsre.1996.0208; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SHI FL, 1995, FREE RADICAL BIO MED, V19, P349, DOI 10.1016/0891-5849(95)00049-4; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; WATSON BD, 1988, OXYGEN RADICALS TISS, P81; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZALESKA MM, 1985, NEUROCHEM RES, V10, P397, DOI 10.1007/BF00964608	43	33	33	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1998	15	6					433	440		10.1089/neu.1998.15.433			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	ZR931	WOS:000074030700005	9624628				2021-06-18	
J	Yeates, KO; Taylor, HG				Yeates, KO; Taylor, HG			Predicting premorbid neuropsychological functioning following pediatric traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	24th Annual Meeting of the International-Neuropsychological-Society	FEB 14-17, 1996	CHICAGO, ILLINOIS	Int Neuropsychol Soc, US PHS, Natl Inst Aging, Alzheimers Dis Cooperat Study			DEMOGRAPHIC-VARIABLES; HEAD-INJURY; WAIS-R; INTELLIGENCE; IQ; VALIDATION; SEVERITY; INDEX; SCALE	This study examined the prediction of premorbid neuropsychological functioning using data from an ongoing prospective study of traumatic brain injuries (TBI) in children ages 6 to 12 years. Prediction equations were derived based on 80 children with orthopedic injuries (OI), who served as a comparison group for the children with TBI. Collectively, parent ratings of premorbid school performance, maternal ethnicity, family socioeconomic status, and children's word recognition skill predicted from 13% to 45% of the variance in three measures of neuropsychological functioning. The regression equations were used to compute predicted scores among 109 children with TBI. Actual scores fell significantly below predicted scores among children with TBI, and the magnitude of the deficits was correlated with injury severity. Premorbid neuropsychological functioning can be predicted in children with TBI, but with less precision than would be desirable for clinical purposes.	Childrens Hosp, Dept Psychol, Columbus, OH 43205 USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA	Yeates, KO (corresponding author), Childrens Hosp, Dept Psychol, 700 Childrens Dr, Columbus, OH 43205 USA.		Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BEERY KE, 1989, REVISED ADM SCORING; Blair JR., 1989, CLIN NEUROPSYCHOL, V3, P129; BRYAN J, 1992, J CLIN EXPT NEUROPSY, V14, P64; Christensen H., 1991, PSYCHOL ASSESS J CON, V3, P147; Delis D, 1994, MANUAL CALIFORNIA VE; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FINKELSTEIN NW, 1980, AM J MENT DEF, V84, P546; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P933, DOI 10.1080/01688639108405109; HART S, 1986, BRIT J CLIN PSYCHOL, V25, P119, DOI 10.1111/j.2044-8260.1986.tb00680.x; JENNETT B, 1975, LANCET, V1, P480; KAREKEN DA, 1995, ARCH CLIN NEUROPSYCH, V10, P147, DOI 10.1016/0887-6177(94)E0012-E; KARZMARK P, 1985, J CLIN EXP NEUROPSYC, V7, P412, DOI 10.1080/01688638508401273; KLESGES RC, 1987, INT J CLIN NEUROPSYC, V9, P1; KLESGES RC, 1980, J CONSULT CLIN PSYCH, V49, P141; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; Psychological Corporation, 1992, WECHSL IND ACH TEST; RAMEY CT, 1978, AM J MENT DEF, V82, P525; REYNOLDS CR, 1979, CLIN NEUROPSYCHOLOGY, V1, P36; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; Sattler J. M., 1992, ASSESSMENT CHILDREN; SILVERSTEIN AB, 1987, J CLIN PSYCHOL, V43, P493, DOI 10.1002/1097-4679(198709)43:5<493::AID-JCLP2270430511>3.0.CO;2-V; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P18, DOI 10.1080/13854049008401493; Stebbins Glenn T, 1990, Clin Neuropsychol, V4, P64, DOI 10.1080/13854049008401497; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; THOMPSON NM, 1994, NEUROPSYCHOLOGY, V8, P333, DOI DOI 10.1037/0894-4105.8.3.333; Wechsler D., 1991, MANUAL WECHSLER INTE; WILLSHIRE D, 1991, J CLIN EXP NEUROPSYC, V13, P204, DOI 10.1080/01688639108401038; WOODCOCK RW, 1989, WOODCOCKJOHNSON TEST; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	38	33	34	0	1	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	DEC	1997	19	6					825	837		10.1080/01688639708403763			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	ZA276	WOS:000072347100004	9524877				2021-06-18	
J	Kita, T; Liu, L; Tanaka, N; Kinoshita, Y				Kita, T; Liu, L; Tanaka, N; Kinoshita, Y			The expression of tumor necrosis factor-alpha in the rat brain after fluid percussive injury	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						traumatic head injury; tumor necrosis factor-alpha; blood-brain barrier; fluid percussion device; microglial cell	SEVERE HEAD-INJURY; IMMUNOCYTOCHEMICAL LOCALIZATION; PENETRATING GUNSHOTS; TNF-ALPHA; LIPOPOLYSACCHARIDE; BARRIER; INCAPACITATION; PERMEABILITY; MACROPHAGES; LEUKOTRIENE	To investigate the role of tumor necrosis factor-alpha (TNF alpha) after traumatic head injury in rats, moderate brain injury of 1000 mmHg was generated by an original fluid percussion injury device, TNF alpha levels in cerebrospinal fluid (CSF) gradually increased during the first 1 h, rose to a maximal elevation at 3 h and 6 h and returned to basal values by 24 h. Horseradish peroxidase tracer experiments revealed that primary microvascular damage appeared as early as 15 min after impact, but rapidly recovered and 1 h after impact secondary microvascular damage occurred in the hippocampus and parasagittal cortex. By immunoelectron microscopy, TNF alpha reactions were detected in the lysosomes of microglia accumulated at the impact site of the cortex 30 min after impact, and 1 h after impact these reactions were mainly detected at the glial cells (such as microglia and astrocytes) in the hippocampus and parasagittal cortex. Therefore the delayed microvascular damage observed in sites remote from the impact may be induced by TNF alpha which is synthesized mainly by glial cells, The present study suggests that TNF alpha conveyed from the microglial cells is one cofactor contributing to the fluid percussive brain edema formation after moderate brain injury.	UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT NEUROSURG,KITAKYUSHU,FUKUOKA 807,JAPAN	Kita, T (corresponding author), UNIV OCCUPAT & ENVIRONM HLTH,SCH MED,DEPT FORENS MED,KITAKYUSHU,FUKUOKA 807,JAPAN.						AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; CHAO CC, 1995, CLIN IMMUNOL IMMUNOP, V77, P358, DOI 10.1006/clin.1995.1163; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FUKUDA K, 1993, NEUROTRAUMA, V16, P19; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; KAHN MA, 1995, BRAIN RES, V685, P55, DOI 10.1016/0006-8993(95)00411-I; KARGER B, 1995, INT J LEGAL MED, V108, P117, DOI 10.1007/BF01844822; KARGER B, 1995, INT J LEGAL MED, V108, P53, DOI 10.1007/BF01369905; KARNOVASKY MORRIS J., 1967, J CELL BIOL, V35, P213, DOI 10.1083/jcb.35.1.213; KITA T, 1993, INT J EXP PATHOL, V74, P471; Liu L, 1996, INT J EXP PATHOL, V77, P37, DOI 10.1046/j.1365-2613.1996.961099.x; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; MERRICK B A, 1992, Applied and Theoretical Electrophoresis, V2, P177; NAGANO T, 1992, INT J EXP PATHOL, V73, P675; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; OZAWA Y, 1991, Neurologia Medico-Chirurgica, V31, P685, DOI 10.2176/nmc.31.685; PIZARRO TT, 1993, TRANSPLANTATION, V56, P399, DOI 10.1097/00007890-199308000-00029; PLATASALAMAN CR, 1988, BRAIN RES, V448, P106, DOI 10.1016/0006-8993(88)91106-7; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHSTEIN JL, 1992, TUMOR NECROSIS FACTO, P453; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; STOLPEN AH, 1986, AM J PATHOL, V123, P16; STREIT WJ, 1995, SCI AM           NOV, P38; Sunami K, 1989, Neurol Med Chir (Tokyo), V29, P975, DOI 10.2176/nmc.29.975; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; TERADA LS, 1992, INFLAMMATION, V16, P13, DOI 10.1007/BF00917511; TRACEY KJ, 1990, J CLIN INVEST, V86, P2014, DOI 10.1172/JCI114937; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613	39	33	33	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0937-9827			INT J LEGAL MED	Int. J. Legal Med.	NOV	1997	110	6					305	311		10.1007/s004140050093			7	Medicine, Legal	Legal Medicine	YF831	WOS:A1997YF83100003	9387012				2021-06-18	
J	McCrory, PR				McCrory, PR			Were you knocked out? A team physician's approach to initial concussion management	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						concussion; mild head injury	CEREBRAL CONCUSSION; HEAD-INJURIES; CONTACT-SPORTS; 2ND IMPACT; GUIDELINES; PREVENTION; RECOVERY; MEMORY	To present an evidence-based approach reviewing the acute management of concussive brain injury in sport. All published articles on the acute management of sport-related brain injury were extracted using searches of computerised databases (Medline, Embase, Spelt Discus) as well as detailed literature reviews based upon the published bibliographies in this area. The review details the aspects where prospective scientific data is available upon which to base clinical management strategies. The first few minutes after an athlete receives a concussive injury provides a window of opportunity during which time the initial medical management forms a crucial and potentially lifesaving treatment. All clinicians involved in care of the concussed athlete need to have an understanding of the early management of the concussed athlete and a strategy by which they may manage such problems. An efficient and appropriate response to the immediate concussion management will help minimise the potential sequelae which may impact upon the athletes ability to return to sport.	AUSTIN & REPATRIAT MED CTR,DEPT NEUROL,HEIDELBERG,GERMANY	McCrory, PR (corresponding author), OLYMPIC PK SPORTS MED CTR,MELBOURNE,VIC,AUSTRALIA.		McCrory, Paul/Q-8688-2019				ALVES WM, 1987, CLIN SPORT MED, V6, P211; Barth JT., 1989, MILD HEAD INJURY, P257; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; GASTAUT H, 1957, LANCET, V2, P1018; GERSOFF W, 1991, SPORTS MED SCH AGE A, P45; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENNETT B, 1975, LANCET, V1, P480; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KOBRINE AI, 1977, J NEUROSURG, V46, P256, DOI 10.3171/jns.1977.46.2.0256; KULUND D, 1982, INJURED ATHLETE, P225; LEMPERT T, 1994, ANN NEUROL, V36, P233, DOI 10.1002/ana.410360217; LENINGER B, 1990, J NEUROL NEUROSUR PS, V53, P293; LEVIN H, 1982, NEUROBEHAVIOURAL CON, P88; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MADDOCKS DL, 1995, THESIS U MELBOURNE M; Maroon J C, 1980, Clin Neurosurg, V27, P414; McCrory P, 1997, PHYSICIAN SPORTSMED, V25, P33, DOI 10.3810/psm.1997.02.1133; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; NARAYAN R, 1996, NEUROTRAUMA, P913; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; OMMAYA A, 1990, SPORTS NEUROLOGY, P84; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PATEL MN, 1994, PHYSICIAN SPORTSMED, V22, P57, DOI 10.1080/00913847.1994.11947694; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; Russell WR, 1935, LANCET, V2, P762; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SAAL JA, 1991, SPORTS MED, V12, P132, DOI 10.2165/00007256-199112020-00005; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SNOEK J, 1990, TRAUMATIC BRAIN INJU, P9; *SOC COL MED, 1991, REP SPORTS MED COMM; TORG JF, 1991, ATHLETIC INJURIES HE, P694; VANZOMEREN AH, 1981, REACTION TIME ATTENT, P15; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863	55	33	32	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JUL	1997	29	7		S			S207	S212					6	Sport Sciences	Sport Sciences	XM280	WOS:A1997XM28000001	9247917				2021-06-18	
J	Pieter, W; Zemper, ED				Pieter, W; Zemper, ED			Injury rates in children participating in taekwondo competition	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						taekwondo; boys; girls; martial sports; Junior Olympic; injuries	CONCUSSION; PREVENTION; ATHLETE; SPORTS	Objective: To report rates of injuries sustained during Junior taekwondo competitions. Design: Prospective, Materials and Methods: Data were collected with simple check-off forms that describe the athlete, nature, site, circumstances, and severity of the injury at three major taekwondo tournaments involving a total of 3,341 boys and 917 girls, Main Results: No difference was found between boys (58.34/1,000 athlete-exposures) and girls (56.57/1,000 athlete-exposures) in total injury rate (p > 0.05), Collapsed over gender, significant differences (p = 0.013) in injury rates of body parts were found with the lower extremities (21.83/1,000 athlete-exposures) ranked first, Unblocked attacks are the major cause of injury in both boys and girls. Conclusions: Coaches are advised to work on the blocking skills of their Junior taekwondo athletes, No head contact for children in taekwondo competition should also be considered.	EXERCISE RES ASSOCIATES OREGON,EUGENE,OR	Pieter, W (corresponding author), UNIV N LONDON,SCH HLTH & SPORTS SCI,166-220 HOLLOWAY RD,LONDON N7 8DB,ENGLAND.						BROEKHOFF J, 1995, P 1992 OLYMP SCI C, V5, P258; Caine D., 1990, PEDIAT EXERC SCI, V2, P209, DOI [10.1123/pes.2.3.209, DOI 10.1123/PES.2.3.209]; CAINE D, 1990, CAHPER J, V56, P24; CAINE DJ, 1987, PHYSICIAN SPORTSMED, V15, P67, DOI 10.1080/00913847.1987.11709303; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CHAPMAN PJ, 1989, AM J SPORT MED, V17, P690, DOI 10.1177/036354658901700518; GOLDBERG B, 1989, PHYSICIAN SPORTSMED, V17, P174, DOI 10.1080/00913847.1989.11709740; GOLDBERG B, 1984, PHYSICIAN SPORTSMED, V12, P122; JORRITSMA LSM, 1987, RAPPORT COMMISSIE VE; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; KOZAR B, 1988, CHILDREN SPORT, P119; Kurland Harvey L, 1980, Phys Sportsmed, V8, P80, DOI 10.1080/00913847.1980.11948652; LORISH TR, 1992, AM J SPORT MED, V20, P199, DOI 10.1177/036354659202000218; MAFFULLI N, 1990, SPORTS MED, V9, P229, DOI 10.2165/00007256-199009040-00004; Malina RM., 1991, GROWTH MATURATION PH; MARTIN RK, 1987, AM J SPORT MED, V15, P603, DOI 10.1177/036354658701500614; McCarroll JR, 1984, PHYSICIAN SPORTSMED, V12, P113; MCLATCHIE GR, 1994, CLIN PRACTICE SPORTS, V5, P609; MICHELI LJ, 1986, EXERCISE SPORTS SCI, P359; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Pappas A M, 1983, Phys Sportsmed, V11, P140, DOI 10.1080/00913847.1983.11708566; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; PIETER W, 1995, ICHPER SD 38 WORLD C; Pieter W, 1995, J HUM MOVEMENT STUD, V28, P1; PIETER W, 1995, TAEKWONDO TECHNIK TR; POIRIER T, 1990, THESIS U PARIS VAL M; RETTIG AC, 1989, AM J SPORT MED, V17, P567, DOI 10.1177/036354658901700420; Ryan A J, 1983, Phys Sportsmed, V11, P49, DOI 10.1080/00913847.1983.11708702; SCHWARTZ ML, 1986, J NEUROSURG, V64, P248, DOI 10.3171/jns.1986.64.2.0248; TANNER JM, 1990, FETUS MAN PHYSICAL G; WESTERHOF B, 1995, 1995 ICHPER SD 38 WO, pP23; WILKINS KE, 1980, AM J SPORT MED, V8, P377, DOI 10.1177/036354658000800517; Zemper E D, 1989, Br J Sports Med, V23, P161; Zemper E. D., 1991, INT C EXP SPORTS MED; ZEMPER ED, 1993, PRIMARY CARE SPORTS, P63	35	33	34	0	7	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	1997	43	1					89	95		10.1097/00005373-199707000-00020			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	XN917	WOS:A1997XN91700025	9253914				2021-06-18	
J	Deshpande, AA; Millis, SR; Zafonte, RD; Hammond, FM; Wood, DL				Deshpande, AA; Millis, SR; Zafonte, RD; Hammond, FM; Wood, DL			Risk factors for acute care transfer among traumatic brain injury patients	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; YATES CONTINUITY CORRECTION; 2X2 CONTINGENCY-TABLES; REHABILITATION; MANAGEMENT; COMPLICATIONS; HYPONATREMIA; REASONS	Objective: Acute inpatient traumatic brain injury (TBI) rehabilitation has seen a jump in complexity of medical patient care over the past several years, often necessitating transfer back to an acute care facility. The purpose of this study was to determine the association between selected clinical variables and transfer from inpatient rehabilitation to an acute care facility. Design: A retrospective review of cases from 1992 to 1994. Setting: A TBI unit in a freestanding rehabilitation hospital. Patients: Twenty-two patients were identified as having received acute care transfer. This group was compared with 78 patients, admitted in the same interval, who did not require acute care transfer. The variables evaluated included recent surgery, pneumonia, fracture, intracranial blood, tracheostomy use, percutaneous feeding tube use, deep venous thrombosis, focal neurological examination, following simple commands, serum sodium level of <135mmol/L, serum white blood cell count of >11,000 cells/mu L, and serum hemoglobin level of <10.0g/dL. Analysis: Chi-square analysis was performed on the association between acute care transfer and the noted variables. Results: History of pneumonia (p<.03) and history of recent surgery (p<.02) were both associated with acute care transfer, and serum hemoglobin of <10.0g/dL had a trend towards association (p<.10). Conclusion: Physiatrists caring for the TBI patient may warrant more acute observation of individuals with these parameters to prevent the problems necessitating acute care transfer. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	REHABIL INST MICHIGAN,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48202							Atchison James W., 1993, Brain Injury, V7, P347, DOI 10.3109/02699059309034961; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; Bryant ET, 1993, J HEAD TRAUMA REHAB, V8, P15; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CITTAPIETROLUNGO TJ, 1993, ARCH PHYS MED REHAB, V74, P905; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CONOVER WJ, 1974, J AM STAT ASSOC, V69, P374, DOI 10.2307/2285661; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; FLEMING MC, 1994, PRINCIPLES APPL STAT; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; HAIG AJ, 1990, J OCCUP ENVIRON MED, V32, P241, DOI 10.1097/00043764-199003000-00011; KALISKY Z, 1985, ARCH PHYS MED REHAB, V66, P25; KEIL MK, 1994, ARCH PHYS MED REHAB, V75, P116; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; MANTEL N, 1974, J AM STAT ASSOC, V69, P378, DOI 10.2307/2285663; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NORUSIS MJ, 1993, SPSS WINDOWS 6 0; POWELL JN, 1994, J HEAD TRAUMA REHABI, V9, P57; SEIGLER EL, 1994, ARCH INTERN MED, V154, P2185; SIVAKUMAR V, 1994, NEUROSURGERY, V34, P269, DOI 10.1227/00006123-199402000-00010; WOO P, 1989, LARYNGOSCOPE, V99, P725	25	33	33	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	1997	78	4					350	352		10.1016/S0003-9993(97)90224-0			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	WT595	WOS:A1997WT59500004	9111452				2021-06-18	
J	Junque, C; Bruna, O; Mataro, M				Junque, C; Bruna, O; Mataro, M			Information needs of the traumatic brain injury patient's family members regarding the consequences of the injury and associated perception of physical, cognitive, emotional and quality of life changes	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; RELATIVES VIEW; REHABILITATION; PERSONALITY; RECOVERY; IMPACT	We studied physical, cognitive, emotional and quality-of-life changes noted by relatives in a sample of 65 severely traumatic brain-injured (TBI) patients several years after injury. The purpose of the present study waste evaluate the families' perception of these changes and their need for information concerning the consequences of TBI. Our results indicated that the perceived changes in behavioural and affective symptoms and in the patient's quality of life were most closely associated with the need expressed by family members for information concerning TBI. We also found that family relationships were especially affected by problems in the behavioural and affective domain, and the decrease in patient quality of life, as reported by relatives. These findings underline the importance of providing the relatives of TBI patients with information about the consequences of the injury with particular emphasis on behavioural and emotional disturbances, in order that they might cope better with these problems.		Junque, C (corresponding author), UNIV BARCELONA, FAC PSICOL, DEPT PSIQUIAT & PSICOBIOL CLIN, PASEO VALL HEBRON 171, BARCELONA, SPAIN.		Mataro, Maria/B-4524-2011; Junque, Carme/B-4400-2011; Bruna, Olga/ABG-7936-2020	Mataro, Maria/0000-0002-9946-2656; Junque, Carme/0000-0002-6381-3063; Bruna, Olga/0000-0002-7851-2909			BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Eisner J, 1989, Brain Inj, V3, P79, DOI 10.3109/02699058909008078; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; GLOAG D, 1985, BRIT MED J, V290, P913, DOI 10.1136/bmj.290.6472.913; KAY T, 1991, HEAD INJURY FAMILY M, P121; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEAF LE, 1993, BRAIN INJURY, V7, P543, DOI 10.3109/02699059309008182; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1986, BRIT MED J, V293, P742, DOI 10.1136/bmj.293.6549.742; Livingston MG., 1990, REHABILITATION ADULT, P225; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; MCMORDIE W R, 1991, Brain Injury, V5, P43, DOI 10.3109/02699059108998510; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; NORUSIS MJ, 1986, SPSS PC PLUS IBM PC; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODER W, 1992, J NEUROL NEUROSUR PS, V55, P475, DOI 10.1136/jnnp.55.6.475; Panting A., 1972, REHABILITATION, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; PONSFORD J, 1995, TRAUMATIC BRAIN INJU, P265; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SOLOMON JS, 1991, BRAIN INJURY, V5, P253; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; TZIDKIAHU T, 1994, BRAIN INJURY, V8, P159, DOI 10.3109/02699059409150967; Walker A E, 1972, Scand J Rehabil Med, V4, P5; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	40	33	35	1	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	1997	11	4					251	258		10.1080/026990597123557			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WQ736	WOS:A1997WQ73600002	9134199				2021-06-18	
J	Schmitt, U; Sabel, BA				Schmitt, U; Sabel, BA			MK-801 reduces retinal ganglion cell survival but improves visual performance after controlled optic nerve crush	JOURNAL OF NEUROTRAUMA			English	Article						behavior; functional recovery; MK-801; optic nerve crush; rat; retinal ganglion cells	SEVERE FOREBRAIN ISCHEMIA; D-ASPARTATE ANTAGONIST; ADULT-RAT RETINA; NMDA RECEPTOR; GLUTAMATE NEUROTOXICITY; HORSERADISH-PEROXIDASE; CEREBRAL-ISCHEMIA; BRAIN INJURY; BLOOD-FLOW; RECOVERY	Excitotoxicity is implicated in secondary cell death after ischemic or traumatic brain injury. We therefore evaluated the role of excitotoxicity mediated by the NMDA glutamate receptor subtype on retinal ganglion cell (RGC) survival and visual performance after optic nerve injury in adult rats, To monitor visual deficits after mild optic nerve crush, rats were trained in a two-choice pattern discrimination task. Immediately after the crush and on postoperative day 1, MK-801 (1 nmol), a noncompetitive open channel blocker of the NMDA-receptor, was injected intraocularly. Within the first few days after crush, all rats showed a loss of their discrimination ability that was followed by a significant recovery within a 3-week testing period, Although animals treated with MK-801 had a significantly smaller initial deficit compared with PBS-injected controls, anatomic investigations using retrograde HRP tracing revealed a significant retrograde loss of RGC in lesioned rats that was significantly exacerbated by MK-801. These results confirm our earlier studies suggesting that neuronal damage does not uniformly match behavioral defects in CNS injury paradigms and that near-normal visual performance occurs in rats with only about 10% of RGC being connected to their target. The observation that after traumatic injury MK-801 is neuroprotective functionally while being neurotoxic anatomically is a structural-functional paradox that needs to be explored further.	UNIV MAGDEBURG, SCH MED, INST MED PSYCHOL, D-39120 MAGDEBURG, GERMANY			Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543			ABUELASRAR AM, 1992, INVEST OPHTH VIS SCI, V33, P3463; ALLCUTT D, 1984, DEV BRAIN RES, V16, P219, DOI 10.1016/0165-3806(84)90027-0; AUER RN, 1994, ACTA NEUROPATHOL, V87, P1; BALAZS R, 1990, INT J DEV NEUROSCI, V8, P347, DOI 10.1016/0736-5748(90)90068-D; BARRON KD, 1986, J NEUROCYTOL, V15, P345, DOI 10.1007/BF01611437; BARTH TM, 1990, STROKE, V21, P153; BEATTIE MS, 1988, PHARM APPROACHES TRE, P43; BUCHAN A, 1991, J NEUROSCI, V11, P1049; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; DEZSI L, 1992, J CEREBR BLOOD F MET, V12, P390, DOI 10.1038/jcbfm.1992.56; DREYER EB, 1994, NEUROREPORT, V5, P629, DOI 10.1097/00001756-199401000-00024; GALAMBOS R, 1967, EXP NEUROL, V18, P8, DOI 10.1016/0014-4886(67)90084-2; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GILL R, 1989, NEUROSCI LETT, V105, P101, DOI 10.1016/0304-3940(89)90019-0; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; GOULD E, 1994, J COMP NEUROL, V340, P551, DOI 10.1002/cne.903400408; HANKER JS, 1977, HISTOCHEM J, V9, P789, DOI 10.1007/BF01003075; HAO JX, 1992, EXP NEUROL, V118, P143, DOI 10.1016/0014-4886(92)90031-K; HOLTZ A, 1991, ACTA NEUROL SCAND, V84, P334, DOI 10.1111/j.1600-0404.1991.tb04964.x; LEVY DI, 1990, NEUROLOGY, V40, P852, DOI 10.1212/WNL.40.5.852; LEVY DI, 1991, NEUROREPORT, V2, P345, DOI 10.1097/00001756-199106000-00011; MARTINEZARIZALA A, 1990, EXP NEUROL, V108, P232, DOI 10.1016/0014-4886(90)90128-F; MAXWELL WL, 1994, J NEUROCYTOL, V23, P379, DOI 10.1007/BF01666527; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MICHAELS RL, 1990, J NEUROSCI, V10, P283; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; NELLGARD B, 1991, ANESTHESIOLOGY, V75, P279, DOI 10.1097/00000542-199108000-00016; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; OLNEY JW, 1986, NEUROSCI LETT, V65, P65, DOI 10.1016/0304-3940(86)90121-7; OLUCHA F, 1985, J NEUROSCI METH, V13, P131, DOI 10.1016/0165-0270(85)90025-1; PERRY VH, 1979, PROC R SOC SER B-BIO, V204, P363, DOI 10.1098/rspb.1979.0033; PERRY VH, 1982, NEUROSCIENCE, V7, P583, DOI 10.1016/0306-4522(82)90065-3; RAMIREZ JJ, 1990, ACTA NEUROBIOL EXP, V50, P415; ROGERS BC, 1989, TOXICOL APPL PHARM, V99, P445, DOI 10.1016/0041-008X(89)90152-X; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SABEL BA, 1995, EXP BRAIN RES, V106, P93; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; Schmitt U, 1996, EXP NEUROL, V139, P17, DOI 10.1006/exnr.1996.0076; Schmitt U, 1996, RESTOR NEUROL NEUROS, V10, P61, DOI 10.3233/RNN-1996-10201; SCHWARCZ R, 1977, INVEST OPHTH VIS SCI, V16, P141; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759, DOI 10.1038/jcbfm.1992.107; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; THANOS S, 1995, J NEUROSCI, V15, P1057, DOI 10.1523/jneurosci.15-02-01057.1995; THANOS S, 1988, CELL TISSUE RES, V254, P599; VONLUBITZ DKJE, 1993, EUR J PHARMACOL, V233, P95, DOI 10.1016/0014-2999(93)90353-J; ZIGMOND MJ, 1984, ARCH NEUROL-CHICAGO, V41, P856, DOI 10.1001/archneur.1984.04050190062015	50	33	34	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1996	13	12					791	800		10.1089/neu.1996.13.791			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	WC105	WOS:A1996WC10500006	9002064				2021-06-18	
J	Wilson, SL; Powell, GE; Brock, D; Thwaites, H				Wilson, SL; Powell, GE; Brock, D; Thwaites, H			Vegetative state and responses to sensory stimulation: An analysis of 24 cases	BRAIN INJURY			English	Article							COMA	A meta-analysis was performed on data from 24 single-case experimental studies evaluating the immediate effects of sensory stimulation treatment on patients in vegetative state following traumatic brain injury. Response to treatment was evaluated by time sampling behaviour pre- and posttreatment, and examining for changes in behaviour that suggested increased arousal. In this analysis the relative effectiveness of different treatment protocols was examined. The effects of variables such as age, gender and time since injury on magnitude of behaviour change was examined; also whether there was a relationship between response to treatment and outcome in terms of whether patients emerged from vegetative state or not. Analyses showed that multimodal stimulation produced greater behavioural changes than unimodal stimulation, and the use of personally salient stimuli in multimodal stimulation the greatest changes of all. Age and gender both showed effects on the magnitude of the behaviour change, but time since injury did not. Patients who did not emerge from the vegetative state were no less likely that those who did to produce statistically significant changes in behaviour in response to treatment. The paper includes a discussion of general issues concerning vegetative state.	PSYCHOL SERV,LONDON,ENGLAND; WOLFSON MED REHAB CTR,DEPT CLIN NEUROPSYCHOL,LONDON,ENGLAND; ROYAL HOSP NEURODISABIL,OCCUPAT THERAPY DEPT,LONDON,ENGLAND	Wilson, SL (corresponding author), UNIV SURREY,DEPT PSYCHOL,GUILDFORD GU2 5XH,SURREY,ENGLAND.			Wilson, Sarah L./0000-0001-8347-5156			CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; JENNETT B, 1981, MANAGEMENT HEAD INJU, P85; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; Wilson S. L., 1992, CLIN REHABIL, V6, P181, DOI [10.1177/026921559200600301, DOI 10.1177/026921559200600301]; Wilson SL, 1996, BRAIN INJURY, V10, P509, DOI 10.1080/026990596124223; Wilson SL, 1993, NEUROPSYCHOL REHABIL, V3, P191, DOI 10.1080/09602019308401435; WILSON SL, 1993, NEUROPSYCHOL REHABIL, V3, P149; WOOD R L, 1991, Brain Injury, V5, P401, DOI 10.3109/02699059109008113; 1994, NEW ENGL J MED, V330, P1499	9	33	35	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1996	10	11					807	818		10.1080/026990596123927			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VM779	WOS:A1996VM77900003	8905159				2021-06-18	
J	High, WM; Hall, KM; Rosenthal, M; Mann, N; Zafonte, R; Cifu, DX; Boake, C; Bartha, M; Ivanhoe, C; Yablon, S; Newton, CN; Sherer, M; Silver, B; Lehmkuhl, LD				High, WM; Hall, KM; Rosenthal, M; Mann, N; Zafonte, R; Cifu, DX; Boake, C; Bartha, M; Ivanhoe, C; Yablon, S; Newton, CN; Sherer, M; Silver, B; Lehmkuhl, LD			Factors affecting hospital length of stay and charges following traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						closed head injury; duration of impaired consciousness; Functional Independence Measure; length of stay	FUNCTIONAL INDEPENDENCE MEASURE; HEAD-INJURY; INPATIENT REHABILITATION; MILD; PREDICTION; COMA	Objective: To examine the effect of initial severity of traumatic brain injury (TBI), level of functional independence at admission to rehabilitation, medical complications, mechanism of injury, and payer source on hospital length of stay (LOS) and charges. Design: Cohort analysis. Setting: Inpatient rehabilitation. Patients: 525 subjects from the National Institute on Disability and Rehabilitation Research TBI Model Systems National Data Base with relatively mild to severe TBI, an average Glasgow Coma Scale (GCS) score of 8.5 (SD=3.9), and average duration of impaired consciousness (DIC) of 15.1 days (SD=40.6). Intervention: Inpatient rehabilitation. Main Outcome Measures: Hospital LOS, hospital charges. Results: Persons with lower initial GCS scores generally reached the rehabilitation setting later and stayed longer than persons with higher initial GCS scores. Within each GCS level, lower initial Functional independence Measure (FIM) scores were associated with longer acute care and rehabilitation LOS. For persons admitted to rehabilitation with relatively high or medium FIM scores, greater severity of injury resulted in relatively modest increases in rehabilitation LOS. In contrast, low admission FIM scores were associated with much longer rehabilitation LOS for patients with severe injuries, compared with those with relatively mild injuries. Initial GCS score, DIC, admission FIM, and acute LOS accounted for 48% (adjusted R(2)) of the variance in rehabilitation LOS and 42% of the variance in rehabilitation hospital charges. Of the medical complications examined, only neurologic complications and intracranial operations added significantly to the model, explaining an additional 2% of the variance In rehabilitation LOS. The effect of payer source on LOS is complicated by age as well as by severity and mechanism of injury. Conclusions: Age, severity of injury, and medical complications are powerful predictors of rehabilitation LOS and hospital charges. Other factors, such as functional independence at rehabilitation admission and length of acute hospitalization, explain additional variance. None of these factors in isolation is able to sufficiently predict rehabilitation LOS or charges. Multidimensional analysis of these factors is necessary to plan or administer the delivery of brain injury services.	BAYLOR COLL MED,HOUSTON,TX 77030; SANTA CLARA VALLEY MED CTR,SAN JOSE,CA 95128; WAYNE STATE UNIV,DETROIT,MI; REHABIL INST MICHIGAN,DETROIT,MI; VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,RICHMOND,VA				Cifu, David/0000-0003-1600-9387			Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; CIFU DX, IN PRESS ARCH PHYS M; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Heinemann AW, 1990, J NEUROL REHABIL, V4, P27; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; KEPPEL G, 1973, DESIGN ANAL; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; LONG WB, 1994, ARCH PHYS MED REHAB, V75, P144; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; SAHGAL V, 1989, SCAND J REHABIL MED, V21, P71; SEIGEL JH, 1991, CRIT CARE MED, V19, P1252; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; TEASDALE G, 1974, LANCET, V2, P81; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILLIAMS RJL, 1994, J ROY SOC MED, V87, P83	24	33	33	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21701	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1996	11	5					85	96		10.1097/00001199-199610000-00008			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VP053	WOS:A1996VP05300008					2021-06-18	
J	Petty, MA; Poulet, P; Haas, A; Namer, IJ; Wagner, J				Petty, MA; Poulet, P; Haas, A; Namer, IJ; Wagner, J			Reduction of traumatic brain injury-induced cerebral oedema by a free radical scavenger	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						head injury; edema; antioxidant free radical scavenger; magnetic resonance imaging	ARACHIDONIC-ACID METABOLISM; EXPERIMENTAL HEAD-INJURY; SUPEROXIDE-DISMUTASE; 21-AMINOSTEROID U74006F; LIPID-PEROXIDATION; ALPHA-TOCOPHEROL; EDEMA; RAT; TISSUE; MICE	Oxygen derived free radicals have been proposed to be in part responsible for the cerebral oedema resulting from head injury. In the present study the effects of free radical suppression with MDL 74,180 (2,3-dihydro-2,2,4,6,7-pentamethyl-3 -(4-methylpiperazino)-methyl-1-benzofuran-5-ol dihydrochloride), an alpha-tocopherol analogue free radical scavenger, on the development of cerebral oedema resulting from head injury has been assessed. Fluid percussion head injury in rats caused a regional oedema 48 h after injury. Infusion of MDL 74,180 for 2 h after the injury significantly attenuated oedema development in a dose-related manner, Using magnetic resonance imaging, cerebral oedema development was monitored in head injured mice, Oedema was apparent 4 h after head injury and was greatest in the vicinity of the olfactory bulb and surrounding the ventricles. Treatment with MDL 74,180 (1-10 mu g/kg intravenously, administered 3-5 min after the injury) significantly reduced the oedema development. MDL 74,180 is a potential treatment for the oedema caused as a result of head injury.	FAC MED,INST BIOL PHYS,STRASBOURG,FRANCE	Petty, MA (corresponding author), MARION MERRELL,16 RUE ANKARA,F-67080 STRASBOURG,FRANCE.		Poulet, Patrick/AAG-7783-2021; Poulet, Patrick/AAD-1438-2020; NAMER, Izzie-Jacques/AAS-7224-2020; Poulet, Patrick/A-2001-2012	NAMER, Izzie-Jacques/0000-0003-1822-7759; Poulet, Patrick/0000-0001-7998-9672			Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; Bolkenius FN, 1996, EUR J PHARMACOL, V298, P37, DOI 10.1016/0014-2999(95)00768-7; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1991, J NEUROSURG, V75, P774, DOI 10.3171/jns.1991.75.5.0774; GRISAR JM, 1995, J MED CHEM, V38, P453, DOI 10.1021/jm00003a008; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HALL ED, 1989, J NEUROTRAUM, V6, P144; IKEDA Y, 1989, Neurological Research, V11, P213; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MILLER JD, 1993, 2 INT NEUR S; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1993, ANN EMERG MED, V22, P1014, DOI 10.1016/S0196-0644(05)82744-1; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Stein DG, 1991, J NEUROTRAUM, V8, P281, DOI 10.1089/neu.1991.8.281; WEI E, 1981, CIRC RES, V49, P95; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166	29	33	35	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	JUN 27	1996	307	2					149	155		10.1016/0014-2999(96)00235-X			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	UY106	WOS:A1996UY10600004	8832216				2021-06-18	
J	Baskaya, MFK; Rao, AM; Prasad, MR; Dempsey, RJ				Baskaya, MFK; Rao, AM; Prasad, MR; Dempsey, RJ			Regional activity of ornithine decarboxylase and edema formation after traumatic brain injury	NEUROSURGERY			English	Article						brain injury; edema; ornithine decarboxylase; polyamines; trauma	REVERSIBLE CEREBRAL-ISCHEMIA; RAT-BRAIN; POLYAMINE METABOLISM; POSTISCHEMIC BRAIN; BARRIER BREAKDOWN; HEAD-INJURY	THIS STUDY EXAMINED ornithine decarboxylase (ODC) activity and edema formation bilaterally in brain cortices and hippocampi after lateral controlled cortical-impact injury in rats. To measure the activity of ODC, the brains of injured and control rats were frozen in situ at 30 minutes and at 6, 24, and 72 hours after controlled cortical-impact injury of moderate severity. The specific gravity of these regions was examined in decapitated animals at corresponding time points as an indicator of edema formation. Thirty minutes after injury, ODC activity did not increase in the injury-site cortex and ipsilateral hippocampus. At 6 hours after injury, ODC activity had increased by nine times that of the control in the injury-site cortex, by five times in the adjacent cortex, and by five and one-half times in the ipsilateral hippocampus. Twenty-four hours after injury, ODC activity had increased by three times that of the control in the injury-site cortex and two times in the ipsilateral hippocampus. Seventy-two hours after injury, activity had returned to control levels. ODC activity increased significantly in the contralateral cortex and hippocampus only at 6 and 24 hours. The injury-site and adjacent cortices and the ipsilateral hippocampus showed significant edema at 6, 24, and 72 hours but not at 30 minutes after injury. These findings indicate that polyamine metabolism is significantly altered in traumatic brain injury. The temporal association between ODC activity and edema formation indicates that polyamines might be a contributing factor in edema formation after traumatic brain injury. The delayed induction of ODC after brain injury suggests a potential therapeutic window for future pharmacological intervention to decrease posttraumatic secondary cerebral injury.	UNIV KENTUCKY,MED CTR,DIV NEUROSURG,LEXINGTON,KY; UNIV KENTUCKY,MED CTR,DEPT SURG,LEXINGTON,KY 40536; VET ADM MED CTR,LEXINGTON,KY					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS 31220] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER		BAETHMAN A, 1978, NEUROSURG REV, V1, P85; CHAN PH, 1984, FED PROC, V43, P210; CHAN PH, 1983, BRAIN RES, V277, P329, DOI 10.1016/0006-8993(83)90941-1; DEMPSEY R J, 1988, Neurological Research, V10, P175; DEMPSEY RJ, 1990, ACT NEUR S, V51, P189; DEMPSEY RJ, 1985, NEUROSURGERY, V17, P635, DOI 10.1227/00006123-198510000-00017; DEMPSEY RJ, 1991, J CEREBR BLOOD F MET, V11, P979, DOI 10.1038/jcbfm.1991.164; DEMPSEY RJ, 1988, J CEREBR BLOOD F MET, V8, P843, DOI 10.1038/jcbfm.1988.141; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DIENEL GA, 1984, J NEUROCHEM, V42, P1053, DOI 10.1111/j.1471-4159.1984.tb12710.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GARDINER IM, 1990, STROKE, V21, P93; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JOO F, 1989, Neurological Research, V11, P67; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; KOENIG H, 1983, BIOCHEM BIOPH RES CO, V116, P1039, DOI 10.1016/S0006-291X(83)80247-2; KOENIG H, 1983, NATURE, V305, P530, DOI 10.1038/305530a0; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MARTINEZ E, 1991, LIFE SCI, V48, P77, DOI 10.1016/0024-3205(91)90427-D; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; PAJUNEN AEI, 1979, J NEUROCHEM, V32, P1401, DOI 10.1111/j.1471-4159.1979.tb11077.x; PASCHEN W, 1991, BRAIN RES, V566, P354, DOI 10.1016/0006-8993(91)91726-H; PASCHEN W, 1987, NEUROCHEM PATHOL, V7, P143, DOI 10.1007/BF02834214; PASCHEN W, 1987, J NEUROCHEM, V49, P35, DOI 10.1111/j.1471-4159.1987.tb03390.x; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1982, AM J PHYSIOL, V243, pC212; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; SCHMITZ MP, 1993, NEUROSURGERY, V33, P882; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TORNHEIM PA, 1975, EXPT MODEL HEAD INJU, P123; TZIGARET C, 1993, J NEUROCHEM, V60, P827, DOI 10.1111/j.1471-4159.1993.tb03226.x; UNTERBERG A, 1984, J CEREBR BLOOD F MET, V4, P574, DOI 10.1038/jcbfm.1984.82; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617	42	33	33	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JAN	1996	38	1					140	145					6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TK455	WOS:A1996TK45500056	8747962				2021-06-18	
J	DeWitt, DS; Prough, DS; Deal, DD; Vines, SM; Hoen, H				DeWitt, DS; Prough, DS; Deal, DD; Vines, SM; Hoen, H			Hypertonic saline does not improve cerebral oxygen delivery after head injury and mild hemorrhage in cats	CRITICAL CARE MEDICINE			English	Article						hemorrhagic shock; trauma, central nervous system; intravenous fluid therapy; hypertonic saline; hydroxyethyl starch; resuscitation; oxygenation; brain injury; neurologic emergencies	FLUID-PERCUSSION INJURY; CONCUSSIVE BRAIN INJURY; INTRACRANIAL-PRESSURE; BLOOD-FLOW; HORSERADISH-PEROXIDASE; ACUTE HYPERTENSION; 3-PERCENT SALINE; AUTO-REGULATION; RESUSCITATION; SHOCK	Objectives: To investigate the effects of hypertonic saline for resuscitation after mild hemorrhagic hypotension combined with fluid percussion traumatic brain injury. Specifically, the effects of hypertonic saline on intracranial pressure, cerebral blood flow (radioactive microsphere method), cerebral oxygen delivery (cerebral oxygen delivery = cerebral blood flow x arterial oxygen content), and electroencephalographic activity were studied. Design: Randomized, controlled, intervention trial. Setting: University laboratory. Subjects: Thirty four mongrel cats of either sex, anesthetized with 1.0% to 1.5% isoflurane in nitrous oxide/oxygen (70:30). Interventions: Anesthetized (isoflurane) cats were prepared for traumatic brain injury, and then randomly assigned to the following groups: moderate traumatic brain injury only (2.7 +/- 0.2 atmospheres [atm], group 1); mild hemorrhage (18 mL/kg) only, followed immediately by resuscitation with 10% hydroxyethyl starch in 0.9% saline in a volume equal to shed blood (group 2); or both traumatic brain injury (2.7 +/- 0.1 atm) and mild hemorrhage, followed immediately by replacement of a volume equal to shed blood of 10% hydroxyethyl starch in 0.9% saline (group 3); or 3.0% saline (group 4). Measurements and Main Results: Data were collected at baseline, at the end of hemorrhage, and at 0, 60, and 120 mins after resuscitation (or at comparable time points in group 1). Intracranial pressure in group 1 was significantly increased by traumatic brain injury at the end of hemorrhage, immediately after resuscitation, and 60 mins after resuscitation (p < .02 vs. baseline). In group 2, intracranial pressure increased significantly only immediately after resuscitation (p < .0001 vs. baseline). Groups 3 and 4 exhibited higher, although statistically insignificant, intracranial pressure increases at 60 and 120 mins after resuscitation. During resuscitation, cerebral blood flow increased significantly (p < .02 vs, baseline) in the uninjured cats. In contrast, cerebral blood flow failed to increase during resuscitation in the cats subjected to traumatic brain injury before hemorrhage and resuscitation. Although cerebral oxygen delivery in group 2 decreased significantly immediately, 60 mins, and 120 mins after resuscitation (p < .001 vs. baseline) both groups 3 and 4 had significantly lower cerebral oxygen delivery at 60 and 120 mins after resuscitation (p < .01 and p < .005, respectively, vs. group 1 at 60 mins after resuscitation, and p < .01 and p < .01, respectively, vs. group 1 at 120 mins after resuscitation). Conclusions: After a combination of hemorrhage and traumatic brain injury, neither 10% hydroxyethyl starch nor 3.0% hypertonic saline restored cerebral oxygen delivery. Although neither trauma alone nor hemorrhage alone altered electroencephalographic activity, the combination produced significant decreases in electroencephalographic activity at 60 and 120 mins after resuscitation in groups 3 and 4, suggesting that cerebral oxygen delivery is inadequately restored by either resuscitation fluid. Therefore, traumatic brain injury abolished compensatory cerebral blood flow increases to hemodilution, and neither hydroxyethyl starch nor 3.0% hypertonic saline restored cerebral blood flow, cerebral oxygen delivery, or electroencephalographic activity after hemorrhagic hypotension after traumatic brain injury.	WAKE FOREST UNIV, MED CTR, DEPT ANESTHESIA, WINSTON SALEM, NC 27103 USA; WAKE FOREST UNIV, MED CTR, DEPT PUBL HLTH SCI, WINSTON SALEM, NC USA	DeWitt, DS (corresponding author), UNIV TEXAS, MED BRANCH, DEPT ANESTHESIOL, GALVESTON, TX 77555 USA.		Prough, Donald S/G-5793-2013	Prough, Donald S/0000-0001-7994-532X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [19355] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COLE JWL, 1966, BIOMETRICS, V22, P810, DOI 10.2307/2528076; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; DUCEY JP, 1989, J TRAUMA, V29, P1510, DOI 10.1097/00005373-198911000-00010; ELLISON MD, 1986, J CEREBR BLOOD F MET, V6, P471, DOI 10.1038/jcbfm.1986.81; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; GUNNAR W, 1988, SURGERY, V103, P398; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOFFBRAND BI, 1969, CARDIOVASC RES, V3, P426, DOI 10.1093/cvr/3.4.426; HOLM S, 1979, SCAND J STAT, V6, P65; HUDAK ML, 1989, AM J PHYSIOL, V257, pH912; HURN PD, 1993, AM J PHYSIOL, V264, pH2131; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1992, AM J PHYSIOL, V262, pH949; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; PRIOR PF, 1978, BRIT J ANAESTH, V50, P993, DOI 10.1093/bja/50.10.993; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1991, ANESTHESIOLOGY, V75, P319, DOI 10.1097/00000542-199108000-00021; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; ROSENBLUM WI, 1971, CIRC RES, V29, P96, DOI 10.1161/01.RES.29.1.96; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; RUDOLPH AM, 1967, CIRC RES, V21, P163, DOI 10.1161/01.RES.21.2.163; SILVA MRF, 1987, AM J PHYSIOL, V253, pH751; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TEASDALE G, 1974, LANCET, V2, P81; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TRAVERSO LW, 1987, J TRAUMA, V27, P32, DOI 10.1097/00005373-198701000-00006; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781; WHITLEY JM, 1991, SURGERY, V110, P514; YOSHIDA K, 1991, J NEUROSURG, V74, P87, DOI 10.3171/jns.1991.74.1.0087; ZORAN DL, 1992, AM J VET RES, V53, P1791	48	33	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	1996	24	1					109	117		10.1097/00003246-199601000-00019			9	Critical Care Medicine	General & Internal Medicine	TT354	WOS:A1996TT35400019	8565515				2021-06-18	
J	Kronisch, RL; Chow, TK; Simon, LM; Wong, PF				Kronisch, RL; Chow, TK; Simon, LM; Wong, PF			Acute injuries in off-road bicycle racing	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							SEVERITY SCORE; CARE	A descriptive study was conducted to investigate injuries sustained at a major off-road bicycling race at Mammoth Mountain, California, July 6 to 10, 1994. A total of 4027 individual starts in five events during the race were reported. Overall, the total number of competitors in the 5 events was 3624, with some cyclists participating in multiple events. Injuries were considered significant if they occurred during competition and prevented the rider from completing the event. Sixteen cyclists had injuries that met these criteria for an overall injury rate of 0.40%. These 16 cyclists had 44 injuries. Abrasions were the most common injury, followed by contusions, lacerations, fractures, and concussions. The mean injury severity score was 3.0 (range, 1 to 5) with 81.2% of the injuries resulting from cyclists going downhill. Injuries were more severe when the riders were thrown from the bicycles (P = 0.03). We observed different mechanisms of injury in various events, suggesting that the risk factors for sustaining a traumatic injury may vary according to the type of competition involved.	LOMA LINDA UNIV,MED CTR,LOMA LINDA,CA	Kronisch, RL (corresponding author), SAN JOSE STATE UNIV,1 WASHINGTON SQ,SAN JOSE,CA 95192, USA.						[Anonymous], 1990, ABBREVIATED INJURY S; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brogger-Jensen T, 1990, Br J Sports Med, V24, P269; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHOW TK, 1993, WESTERN J MED, V159, P145; KRONISCH RL, 1994, CLIN J SPORT MED, V4, P240; Maslanka Alex M., 1993, Emergency Medicine Clinics of North America, V11, P15; MCLENNAN JG, 1988, AM J SPORT MED, V16, P266, DOI 10.1177/036354658801600312; PFEIFFER RP, 1994, CLIN SPORT MED, V13, P207; PFEIFFER RP, 1993, CYCLING SCI, V5, P21; Withers B F, 1984, Emerg Med Clin North Am, V2, P701	12	33	35	0	2	AMER ORTHOPAEDIC SOC SPORT MED	WALTHAM	230 CALVARY STREET, WALTHAM, MA 02154	0363-5465			AM J SPORT MED	Am. J. Sports Med.	JAN-FEB	1996	24	1					88	93		10.1177/036354659602400116			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	TR338	WOS:A1996TR33800016	8638760				2021-06-18	
J	Lindsberg, PJ; Frerichs, KU; Siren, AL; Hallenbeck, JM; Nowak, TS				Lindsberg, PJ; Frerichs, KU; Siren, AL; Hallenbeck, JM; Nowak, TS			Heat-shock protein and c-fos expression in focal microvascular brain damage	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						c-fos; heat-shock proteins; hsp72; brain edema; focal brain injury	HSP70 MESSENGER-RNA; CEREBRAL-ISCHEMIA; RAT-BRAIN; INSITU HYBRIDIZATION; TRANSIENT ISCHEMIA; GENE-EXPRESSION; GLOBAL-ISCHEMIA; GERBIL BRAIN; INDUCTION; STRESS	Cortical brain damage was produced in rats by a focal pulse from a Nd-YAG laser, and evolution of the lesion was evaluated at 30 min, and 2, 8, and 24 h with respect to microvascular perfusion, blood-brain barrier (BBB) permeability, and expression of both the heat-shock/stress protein, hsp72, and the c-fos proto-oncogene transcription factor. A double-labeling fluorescence technique employing intravenously injected Evans blue albumin (EBA) and fluorescein-labeled dextran was used to map and measure BBB damage and microvascular perfusion in fresh frozen brain sections. Hsp72 and c-fos mRNAs were localized by in situ hybridization, and the respective proteins were identified by immunocytochemistry. Parallel sections were stained for glial fibrillary acidic protein and for routine histologic examination. Striking hsp72 mRNA expression was evident by 2 h in an similar to 300 mu m wide rim surrounding an area of expanding BBB damage. Increased hsp72 mRNA was observed only in regions of preserved microcirculation, where the hsp72 protein was subsequently localized exclusively in the vasculature at 24 h after the insult. Hsp72-positive endothelial cells spanned the narrow margin between the lesion and histologically normal, glial fibrillary acidic protein (GFAP)-positive cortical tissue. There was no hsp72 expression in the area of subcortically migrating edema fluid. Inductions of c-fos mRNA and Fos protein were not strikingly evident around the focal brain lesion, but were observed transiently throughout the injured hemisphere at 30 min and 2.5 h, respectively, indicating that spreading depression was triggered by the focal injury. These results are in striking contrast to those previously obtained from studies of models of focal ischemic or traumatic brain injury, which are characterized by a complex pattern of glial and neuronal hsp72 expression in the periphery of an infarct, and which suggest that the tightly demarcated lesion produced by the Nd-YAG laser lacks these components of graded injury that are evident following other types of focal brain damage.	UNIFORMED SERV UNIV HLTH SCI,F EDWARD HEBERT SCH MED,DEPT NEUROL,BETHESDA,MD 20814; NINCDS,STROKE BRANCH,BETHESDA,MD 20892; UNIV TENNESSEE,DEPT NEUROL,MEMPHIS,TN	Lindsberg, PJ (corresponding author), HELSINKI UNIV,DEPT NEUROL,HAARTMANINKATU 4,SF-00290 HELSINKI,FINLAND.		Lindsberg, Perttu J/F-1271-2010; Siren, Anna-Leena/AAE-1374-2019	Siren, Anna-Leena/0000-0002-2217-0081; Lindsberg, Perttu/0000-0001-7690-811X			AN G, 1993, ANN NEUROL, V33, P457, DOI 10.1002/ana.410330508; BLAKE MJ, 1990, MOL BRAIN RES, V8, P89, DOI 10.1016/0169-328X(90)90014-5; BROWN IR, 1989, NEURON, V2, P1559, DOI 10.1016/0896-6273(89)90044-5; DRAGUNOW M, 1988, BRAIN RES, V455, P295, DOI 10.1016/0006-8993(88)90088-1; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRERICHS KU, 1990, J NEUROSURG, V73, P223, DOI 10.3171/jns.1990.73.2.0223; GASS P, 1992, ACTA NEUROPATHOL, V84, P545, DOI 10.1007/BF00304474; GONZALEZ MF, 1989, MOL BRAIN RES, V6, P93, DOI 10.1016/0169-328X(89)90033-8; HERRERA DG, 1989, BRAIN RES, V503, P205, DOI 10.1016/0006-8993(89)91665-X; HERRERA DG, 1990, BRAIN RES, V510, P166, DOI 10.1016/0006-8993(90)90747-Y; JACEWICZ M, 1986, J CEREBR BLOOD F MET, V6, P263, DOI 10.1038/jcbfm.1986.48; JACEWICZ M, 1992, J CEREBR BLOOD F MET, V12, P359, DOI 10.1038/jcbfm.1992.53; JORGENSEN MB, 1989, BRAIN RES, V484, P393, DOI 10.1016/0006-8993(89)90388-0; KAWAGOE J, 1992, BRAIN RES, V587, P195, DOI 10.1016/0006-8993(92)90997-N; KIESSLING M, 1990, J NEUROSURG, V73, P909, DOI 10.3171/jns.1990.73.6.0909; KIESSLING M, 1993, J CEREBR BLOOD F MET, V13, P914, DOI 10.1038/jcbfm.1993.114; KINOUCHI H, 1993, J CEREBR BLOOD F MET, V13, P105, DOI 10.1038/jcbfm.1993.13; KLATZO I, 1985, BRIT J ANAESTH, V57, P18, DOI 10.1093/bja/57.1.18; LI Y, 1992, STROKE, V23, P1293; LINDSBERG PJ, 1991, J CEREBR BLOOD F MET, V11, P88, DOI 10.1038/jcbfm.1991.10; LINDSBERG PL, 1991, SOC NEUROSCI, V16, P55; MARINI AM, 1990, J NEUROCHEM, V54, P1509, DOI 10.1111/j.1471-4159.1990.tb01198.x; MILLER AD, 1984, CELL, V36, P51; MILLER EK, 1991, J NEUROCHEM, V56, P2060, DOI 10.1111/j.1471-4159.1991.tb03467.x; NOWAK TS, 1990, STROKE, V21, P107; NOWAK TS, 1990, J NEUROCHEM, V54, P451, DOI 10.1111/j.1471-4159.1990.tb01893.x; NOWAK TS, 1991, J CEREBR BLOOD F MET, V11, P432, DOI 10.1038/jcbfm.1991.84; PARDUE S, 1992, NEUROBIOL AGING, V13, P661, DOI 10.1016/0197-4580(92)90088-F; Roychoudhury R, 1980, Methods Enzymol, V65, P43; SCHINDLER M, 1987, METHOD ENZYMOL, V141, P439; SCHINDLER M, 1989, METHOD CELL BIOL, V32, P1; SHARP FR, 1991, J CEREBR BLOOD F MET, V11, P621, DOI 10.1038/jcbfm.1991.113; SIMON RP, 1991, J NEUROSCI, V11, P881; SLOVITER RS, 1992, J NEUROSCI, V12, P3004; SPRANG GK, 1987, MOL BRAIN RES, V3, P89, DOI 10.1016/0169-328X(87)90049-0; TAKEDA Y, 1993, J CEREB BLOOD FLO S1, V13, pS450; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; UEMURA Y, 1991, BRAIN RES, V552, P99, DOI 10.1016/0006-8993(91)90665-I; VASS K, 1988, ACTA NEUROPATHOL, V77, P128; VASS K, 1989, NEUROSCI LETT, V100, P259, DOI 10.1016/0304-3940(89)90695-2; WELSH FA, 1992, J CEREBR BLOOD F MET, V12, P204, DOI 10.1038/jcbfm.1992.30; WESSEL TC, 1991, BRAIN RES, V567, P231, DOI 10.1016/0006-8993(91)90800-B; WILLIAMS JL, 1993, AM J PHYSIOL, V264, pH1740	43	33	34	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	1996	16	1					82	91		10.1097/00004647-199601000-00010			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	TM214	WOS:A1996TM21400010	8530560	Bronze			2021-06-18	
J	Suuronen, P; Lehtonen, E; Tschernij, V; Larsson, PO				Suuronen, P; Lehtonen, E; Tschernij, V; Larsson, PO			Skin injury and mortality of Baltic cod escaping from trawl codends equipped with exit windows	ARCHIVE OF FISHERY AND MARINE RESEARCH			English	Article								Skin injury and mortality of Baltic cod (Gadus morhua L.) escaping from trawl codends equipped with two different types of 95 mm exit window were investigated between May and June 1994 in the southern Baltic Sea (ICES Subdivision 25). Fish escaping through the end of an open codend extension (i.e. the trawl was towed without the codend) were also studied. Escaping fish were collected in a small mesh cage that was released from the codend cover, closed and then slowly towed to the cage site. In total, nine valid hauls were completed, and 261 cod (24 to 50 cm long) were held in cages for a period of 10 to 14 days. Only two escapees (34 and 36 cm) died during the experiment; both fish died during the first caging day. The degree of skin injury of fish was examined after cagings. Scale loss was the predominant visible skin injury; the main area of injury for most specimens was the posterior half of the body. Other skin injuries included lesions around the flank and snout, and dark 'net marks' behind the head. Scale loss was observed in 29 of 109 (27 %) cod that had escaped through exit windows codends. The average injured area was 2.5 % of the total skin area. For the open codend escapees, 48 of 139 (35 %) fish examined exhibited scale loss, and the average injured area was 2.3 % of the total skin area. No clear relationship existed between the degree of skin injury and fish size. Most of the observed skin injuries were probably caused by mechanical abrasion while fish were inside the trawl.	SWEDISH BOARD FISHERIES,BALT SEA RES STN,S-37137 KARLSKRONA,SWEDEN; INST MARINE RES,LYSEKIL,SWEDEN	Suuronen, P (corresponding author), FINNISH GAME & FISHERIES RES INST,POB 202,FIN-00151 HELSINKI,FINLAND.						CHAMBERS J, 1992, STAT MODELS S PACIFI, V15; CHOPIN FS, 1995, FISH RES, V21, P315, DOI 10.1016/0165-7836(94)00301-C; Hastie T.J., 1990, GEN ADDITIVE MODELS; HAY DE, 1986, FISH RES, V4, P191, DOI 10.1016/0165-7836(86)90002-0; HILDEN M, 1996, IN PRESS ECOL EC; JACOBSEN JA, 1992, INT COUNC EXPLOR SEA, V29; JONSSON E, 1994, INT COUNC EXPLOR SEA, V16; LARSSON PO, 1988, INT COUNC EXPLOR SEA, V57; LOCKWOOD SJ, 1983, FISH RES, V2, P129, DOI 10.1016/0165-7836(83)90114-5; LOWRY N, 1994, INT COUNC EXPLOR SEA, V29; LOWRY N, 1995, INT COUNC EXPLOR SEA, V5; MAIN J, 1990, 46 SCOTT FISH; MAIN J, 1991, 1891 SCOTT FISH; MAIN J, 1981, 23 SCOTT FISH; MARTEINSSON JE, 1991, SKADER PA FISK SOM S; NETZEL J, 1989, INT COUNC EXPLOR SEA, V54; OTTERLIND G, 1960, INT COUNC EXPLOR SEA, V204; ROALD SV, 1980, INT COUNC EXPLOR SEA, V34; Robinson W. E., 1993, NA26FD003901 NOAA; Sangster GI, 1996, FISH RES, V25, P323, DOI 10.1016/0165-7836(95)00430-0; SANGSTER GI, 1992, INT COUNC EXPLOR SEA, V30; SOLDAL A, 1994, TEMA NORD, V521, P37; SOLDAL AV, 1993, ICES MAR SC, V196, P122; SOLDAL AV, 1993, INT COUNC EXPL SEA W; SOLDAL AV, 1991, INT COUNC EXPLOR SEA, V44; SPARHOLD H, 1995, P C BALT FISH WARN G, P43; Suuronen P, 1996, ICES J MAR SCI, V53, P691, DOI 10.1006/jmsc.1996.0088; Thurow F., 1993, International Council for the Exploration of the Sea Cooperative Research Report, V186, P20; THUROW F, 1976, INT COUNC EXPLOR SEA, V4; ZAFERMAN ML, 1989, INT COUNC EXPLOR SEA, V18; 1991, INT COUNC EXPLOR SEA, V16; 1994, INT COUNC EXPLOR SEA, V17; 1995, INT COUNC EXPLOR SEA, V18	33	33	34	0	5	GUSTAV FISCHER VERLAG	JENA	VILLENGANG 2, D-07745 JENA, GERMANY	0944-1921			ARCH FISH MAR RES	Arch. Fish. Mar. Res.		1996	44	3					165	178					14	Fisheries	Fisheries	WG934	WOS:A1996WG93400001					2021-06-18	
J	ODELL, DM; HAMM, RJ				ODELL, DM; HAMM, RJ			CHRONIC POSTINJURY ADMINISTRATION OF MDL-26,479 (SURITOZALE), A NEGATIVE MODULATOR AT THE GABA(A) RECEPTOR, AND COGNITIVE IMPAIRMENT IN RATS FOLLOWING TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; NEGATIVE MODULATOR; MDL26,479; GAMMA-AMINOBUTYRIC ACID; CHOLINERGIC FUNCTION; RAT	AFFINITY CHOLINE UPTAKE; CLOSED HEAD-INJURY; LONG-TERM POTENTIATION; HIPPOCAMPAL SYNAPTOSOMES; FOREBRAIN ISCHEMIA; NUCLEUS BASALIS; BETA-CARBOLINES; UPTAKE INVITRO; MEMORY; ACETYLCHOLINE	The present experiment examined the efficacy of postinjury administration of MDL 26,479 (Suritozole), a negative modulator at the gamma-aminobutyric acid(A) (GABA(A)) receptor that enhances cholinergic function, in attenuating spatial memory deficits after traumatic brain injury in the rat. Two experiments were performed. In the delayed-dosing experiment, rats received a moderate level (2.1 arm) of fluid-percussion brain injury and were tested in the Morris water maze 11 to 15 days following injury. These rats were injected with either 5 mg/kg (eight rats) or 10 mg/kg (eight rats) of MDL 26,479 60 minutes before each water maze test. Additional rats were injured and treated with saline (eight rats) or were surgically prepared but not injured (eight rats). In the second experiment, an early postinjury dosing procedure was followed. Rats were injured in the same manner but drug treatment began 24 hours after injury and continued daily through Day 15. Results indicated that the rats in the delayed chronic dosing regimen did not differ from the injured, saline-treated rats in their latency to reach the goal platform (p > 0.05). However, those treated chronically beginning 24 hours after injury had significantly shorter latencies than the injured, saline-treated rats (p < 0.05). These results suggest that administration of agents that enhance cholinergic function may be an appropriate strategy for promoting cognitive recovery when given after traumatic brain injury. Furthermore, prolonged treatment may be necessary to elicit beneficial effects.	VIRGINIA COMMONWEALTH UNIV,DEPT PSYCHOL,RICHMOND,VA 23284					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587] Funding Source: Medline		BIANCHI C, 1982, N-S ARCH PHARMACOL, V318, P253, DOI 10.1007/BF00501162; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRIONI JD, 1990, BRAIN RES, V522, P227, DOI 10.1016/0006-8993(90)91465-S; BROOKS D N, 1975, Cortex, V11, P329; DEANGELIS MM, 1994, BRAIN RES, V653, P39, DOI 10.1016/0006-8993(94)90369-7; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DRACHMAN DA, 1974, ARCH NEUROL-CHICAGO, V30, P113, DOI 10.1001/archneur.1974.00490320001001; DUNNETT SB, 1985, PSYCHOPHARMACOLOGY, V87, P357, DOI 10.1007/BF00432721; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HAMM RJ, 1994, J NEUROSURG, V81, P267, DOI 10.3171/jns.1994.81.2.0267; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOLLEY LA, 1993, BRAIN RES, V610, P181, DOI 10.1016/0006-8993(93)91399-D; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LI H, 1993, J CEREBR BLOOD F MET, V13, P933, DOI 10.1038/jcbfm.1993.116; Liu S. J., 1993, Society for Neuroscience Abstracts, V19, P1881; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAYO W, 1992, BRAIN RES, V589, P109, DOI 10.1016/0006-8993(92)91168-E; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MILLER JA, 1990, NEUROSCI LETT, V114, P351, DOI 10.1016/0304-3940(90)90589-2; MILLER JA, 1986, J NEUROCHEM, V47, P1916, DOI 10.1111/j.1471-4159.1986.tb13107.x; MILLER JA, 1992, BRIT J PHARMACOL, V107, P78, DOI 10.1111/j.1476-5381.1992.tb14466.x; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; MORAN PM, 1992, BRAIN RES, V569, P156, DOI 10.1016/0006-8993(92)90383-K; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; SARTER M, 1990, PSYCHOPHARMACOLOGY, V101, P1, DOI 10.1007/BF02253710; SARTER M, 1988, TRENDS NEUROSCI, V11, P13, DOI 10.1016/0166-2236(88)90042-2; SARTER M, 1988, BENZODIAZEPINE RECEP, P230; SIMON JR, 1976, J NEUROCHEM, V26, P909, DOI 10.1111/j.1471-4159.1976.tb06472.x; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; STOOF JC, 1979, EUR J PHARMACOL, V57, P35, DOI 10.1016/0014-2999(79)90101-8; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; WEHMAN P, 1989, J HEAD TRAUMA REHAB, V4, P66; WOOD PL, 1979, NEUROSCIENCE, V4, P1479, DOI 10.1016/0306-4522(79)90052-6	48	33	33	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1995	83	5					878	883		10.3171/jns.1995.83.5.0878			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TA725	WOS:A1995TA72500018	7472558				2021-06-18	
J	MCDONALD, S; PEARCE, S				MCDONALD, S; PEARCE, S			THE DICE GAME - A NEW TEST OF PRAGMATIC LANGUAGE-SKILLS AFTER CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							NARRATIVE DISCOURSE; VERBAL IMPAIRMENT; COHESION; ADULTS	There are few clinical tools available to assess communication skills following dosed-head injury. This paper describes one such task in which the subject is required to explain a board game to a naive listener. The explanation is taped, transcribed and the content is quantified. Reliability studies demonstrated that the test can be consistently scored. A group of 43 normal subjects was investigated, and some variation in peformance according to age and educational background was revealed. A group of 20 brain-injured male adults with executive-type deficits were then compared to a matched subgroup of the controls. The clinical group produced less essential information and relatively more unnecessary information than their non-brain-damaged counterparts. Qualitative features of discourse disorganization were also revealed.	LIDCOMBE HOSP, LIDCOMBE, NSW, AUSTRALIA	MCDONALD, S (corresponding author), UNIV NEW S WALES, SCH PSYCHOL, KENSINGTON, NSW 2052, AUSTRALIA.		McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ARMSTRONG E, 1987, CLIN APHASIOLOGY, V17, P210; ARMSTRONG EM, 1991, CLIN LINGUIST PHONET, V5, P39, DOI 10.3109/02699209108985501; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DEANE A, 1987, THESIS MACQUARIE U S; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; FLAVELL JH, 1987, DEV ROLE TAKING COMM; Goodglass H., 1983, ASSESSMENT APHASIA R; HAGAN C, 1981, TOP LANG DISORD, V1, P73; HAGAN C, LANGUAGE DISORDERS A, P245; Halliday MAK, 1985, LANGUAGE CONTEXT TEX; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Holland A, 1980, COMMUNICATIVE ABILIT; HOLLAND AL, 1984, CLIN APHASIOLOGY, V14, P345; KERTESZ A, 1981, W APHASIA BATTERY; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Milton S. B., 1984, CLIN APHASIOLOGY, V14, P114; MILTON SB, 1986, CLIN NEUROPSCHOLOGY; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; Porch B. E., 1971, PORCH INDEX COMMUNIC; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; ROLLINS J, 1987, ANN C AUSTR ASS SPEE; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1988, SCAND J REHABIL MED, P55; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SNOW P, 1986, BRAIN IMPAIRMENT; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; WYKOFF LH, 1984, THESIS U FLORIDA	36	33	34	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	1995	9	3					255	271		10.3109/02699059509008197			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QR499	WOS:A1995QR49900004	7541680				2021-06-18	
